-DOCSTART- -X- O O

Randomized VBN N
controlled JJ N
trial NN N
: : N
Multimodal NNP 4_i
Anxiety NNP 4_i
and CC 4_i
Social NNP 5_i
Skill NNP 5_i
Intervention NNP 5_i
for IN N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

Anxiety NN N
is VBZ N
common JJ N
among IN N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
and CC N
may MD N
amplify VB N
the DT N
core NN N
social JJ N
disability NN N
, , N
thus RB N
necessitating VBG N
combined VBN N
treatment NN N
approaches NNS N
. . N

This DT N
pilot NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
evaluated VBD N
the DT N
feasibility NN N
and CC N
preliminary JJ N
outcomes NNS N
of IN N
the DT N
Multimodal NNP 4_i
Anxiety NNP 4_i
and CC 4_i
Social NNP 5_i
Skills NNP 5_i
Intervention NNP 5_i
( ( 5_i
MASSI NNP 5_i
) ) 5_i
program NN 5_i
in IN N
a DT N
sample NN N
of IN N
30 CD N
adolescents NNS N
with IN N
ASD NNP N
and CC N
anxiety NN N
symptoms NNS N
of IN N
moderate JJ N
or CC N
greater JJR N
severity NN N
. . N

The DT N
treatment NN N
was VBD N
acceptable JJ N
to TO N
families NNS N
, , N
subject JJ N
adherence NN N
was VBD N
high JJ N
, , N
and CC N
therapist JJ N
fidelity NN N
was VBD N
high JJ N
. . N

A DT N
16 CD N
% NN N
improvement NN N
in IN N
ASD NNP N
social JJ N
impairment NN N
( ( N
within-group JJ N
effect NN N
size NN N
= NNP N
1.18 CD N
) ) N
was VBD N
observed VBN N
on IN N
a DT N
parent-reported JJ N
scale NN N
. . N

Although IN N
anxiety NN N
symptoms NNS N
declined VBD N
by IN N
26 CD N
% NN N
, , N
the DT N
change NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

These DT N
findings NNS N
suggest VBP N
MASSI NNP 5_i
is VBZ N
a DT N
feasible JJ N
treatment NN N
program NN N
and CC N
further JJ N
evaluation NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Phase NNP N
III NNP N
trial NN N
of IN N
gemcitabine NN 3_i
plus CC N
tipifarnib NN 3_i
compared VBN N
with IN N
gemcitabine JJ 3_i
plus CC N
placebo NN 7_i
in IN N
advanced JJ N
pancreatic JJ N
cancer NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
whether IN N
addition NN N
of IN N
the DT N
farnesyltransferase NN N
inhibitor NN N
tipifarnib NN 3_i
( ( N
Zarnestra NNP N
, , N
R115777 NNP N
; : N
Johnson NNP N
and CC N
Johnson NNP N
Pharmaceutical NNP N
Research NNP N
and CC N
Development NNP N
, , N
Beerse NNP N
, , N
Belgium NNP N
) ) N
to TO N
standard VB N
gemcitabine NN N
therapy NN N
improves VBZ N
overall JJ N
survival NN N
in IN N
advanced JJ N
pancreatic JJ N
cancer NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
compared VBN N
gemcitabine JJ 3_i
+ NNP 3_i
tipifarnib NN 3_i
versus NN N
gemcitabine NN N
+ NNP N
placebo NN N
in IN N
patients NNS N
with IN N
advanced JJ N
pancreatic JJ N
adenocarcinoma NN N
previously RB N
untreated VBN N
with IN N
systemic JJ N
therapy NN N
. . N

Tipifarnib NNP 3_i
was VBD 3_i
given VBN 3_i
at IN 3_i
200 CD 3_i
mg NNS 3_i
bid VBD 3_i
orally RB 3_i
continuously RB 3_i
; : 3_i
gemcitabine NN 3_i
was VBD 3_i
given VBN 3_i
at IN 3_i
1,000 CD 3_i
mg/m NN 3_i
( ( 3_i
2 CD 3_i
) ) 3_i
intravenously RB 3_i
weekly JJ 3_i
x NN 3_i
7 CD 3_i
for IN 3_i
8 CD 3_i
weeks NNS 3_i
, , 3_i
then RB 3_i
weekly JJ 3_i
x NN 3_i
3 CD 3_i
every DT 3_i
4 CD 3_i
weeks NNS 3_i
. . 3_i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ N
survival NN N
; : N
secondary JJ N
end NN N
points NNS N
included VBD N
6-month JJ N
and CC N
1-year JJ N
survival NN N
rates NNS N
, , N
progression-free JJ N
survival NN N
, , N
response NN N
rate NN N
, , N
safety NN N
, , N
and CC N
quality NN N
of IN N
life NN N
. . N

RESULTS NNP N
Six NNP N
hundred VBD N
eighty-eight JJ N
patients NNS N
were VBD N
enrolled VBN N
. . N

Baseline JJ N
characteristics NNS N
were VBD N
well RB N
balanced VBN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
survival JJ N
parameters NNS N
were VBD N
observed VBN N
. . N

The DT N
median JJ N
overall JJ N
survival NN N
for IN N
the DT N
experimental JJ N
arm NN N
was VBD N
193 CD N
v JJ N
182 CD N
days NNS N
for IN N
the DT N
control NN N
arm NN N
( ( N
P NNP N
=.75 NNP N
) ) N
; : N
6-month JJ N
and CC N
1-year JJ N
survival NN N
rates NNS N
were VBD N
53 CD N
% NN N
and CC N
27 CD N
% NN N
v JJ N
49 CD N
% NN N
and CC N
24 CD N
% NN N
for IN N
the DT N
control NN N
arm NN N
, , N
respectively RB N
; : N
median JJ N
progression-free JJ N
survival NN N
was VBD N
112 CD N
v JJ N
109 CD N
days NNS N
for IN N
the DT N
control NN N
arm NN N
. . N

Ten CD N
drug-related JJ N
deaths NNS N
were VBD N
reported VBN N
for IN N
the DT N
experimental JJ N
arm NN N
and CC N
seven CD N
for IN N
the DT N
control NN N
arm NN N
. . N

Neutropenia NNP N
and CC N
thrombocytopenia NN N
grade NN N
> NN N
or CC N
= $ N
3 CD N
were VBD N
observed VBN N
in IN N
40 CD N
% NN N
and CC N
15 CD N
% NN N
in IN N
the DT N
experimental JJ N
arm NN N
versus NN N
30 CD N
% NN N
and CC N
12 CD N
% NN N
in IN N
the DT N
control NN N
arm NN N
. . N

Incidences NNS N
of IN N
nonhematologic JJ N
adverse JJ N
events NNS N
were VBD N
similar JJ N
in IN N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
combination NN N
of IN N
gemcitabine NN 3_i
and CC 3_i
tipifarnib NN 3_i
has VBZ N
an DT N
acceptable JJ N
toxicity NN N
profile NN N
but CC N
does VBZ N
not RB N
prolong VB N
overall JJ N
survival NN N
in IN N
advanced JJ N
pancreatic JJ N
cancer NN N
compared VBN N
with IN N
single-agent JJ N
gemcitabine NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Hemostatic NNP N
balance NN N
during IN N
treatment NN N
with IN N
the DT N
newest JJS N
contraceptives NNS N
] RB N
. . N

Thirty-four CD N
healthy JJ N
young JJ N
women NNS N
were VBD N
allocated VBN N
to TO N
12 CD N
consecutive JJ N
cycles NNS N
of IN N
treatment NN N
with IN N
monophasic JJ 3_i
combinations NNS 3_i
of IN 3_i
: : 3_i
20 CD 3_i
micrograms NNS 3_i
ethinyl VBP 3_i
estradiol NN 3_i
and CC N
150 CD 3_i
micrograms NNS 3_i
desogestrel NN 3_i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
30 CD 3_i
micrograms NNS 3_i
ethinyl VBP 3_i
estradiol NN 3_i
and CC N
75 CD 3_i
micrograms NNS 3_i
gestodene NN 3_i
( ( N
n JJ N
= NNP N
19 CD N
) ) N
. . N

In IN N
both DT N
groups NNS N
plasma VBP N
levels NNS N
of IN N
fibrinogen NN N
and CC N
factor NN N
VII NNP N
increased VBD N
while IN N
the DT N
capacity NN N
of IN N
coagulation NN N
inhibition NN N
was VBD N
affected VBN N
by IN N
increased JJ N
protein NN N
C NNP N
and CC N
decreased VBN N
protein NN N
S NNP N
levels NNS N
. . N

Increased VBN N
fibrinolytic JJ N
capacity NN N
was VBD N
indicated VBN N
by IN N
elevated JJ N
activity NN N
and CC N
reduced JJ N
antigen NN N
levels NNS N
of IN N
tissue NN N
plasminogen NN N
activator NN N
and CC N
reduced JJ N
activity NN N
and CC N
concentration NN N
of IN N
tissue NN N
plasminogen NN N
activator NN N
inhibitor NN N
. . N

The DT N
ratio NN N
between IN N
thrombin-antithrombin-III-complexes NNS N
and CC N
fibrin JJ N
degradation NN N
products NNS N
were VBD N
unchanged JJ N
signifying VBG N
no DT N
effect NN N
of IN N
hormonal JJ N
intake NN N
on IN N
the DT N
balance NN N
between IN N
thrombin JJ N
formation NN N
and CC N
fibrin JJ N
resolution NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
dynamic JJ N
balance NN N
between IN N
generation NN N
and CC N
resolution NN N
of IN N
fibrin NN N
was VBD N
undisturbed JJ N
during IN N
treatment NN N
with IN N
both DT N
hormonal JJ N
compounds NNS N
and CC N
our PRP$ N
findings NNS N
do VBP N
not RB N
provide VB N
evidence NN N
for IN N
increased VBN N
risk NN N
of IN N
thrombosis NN N
in IN N
normal JJ N
women NNS N
. . N

-DOCSTART- -X- O O

Overexpression NN N
of IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
and CC N
its PRP$ N
cellular JJ N
receptor NN N
KDR NNP N
( ( N
VEGFR-2 NNP N
) ) N
in IN N
the DT N
bone NN N
marrow NN N
of IN N
patients NNS N
with IN N
acute JJ N
myeloid NN N
leukemia NN N
. . N

Vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
and CC N
its PRP$ N
cellular JJ N
receptor NN N
VEGFR-2 NNP N
have VBP N
been VBN N
implicated VBN N
as IN N
the DT N
main JJ N
endothelial JJ N
pathway NN N
required VBN N
for IN N
tumor NN N
neovascularization NN N
. . N

However RB N
, , N
the DT N
importance NN N
of IN N
the DT N
VEGF/VEGFR-2 NNP N
system NN N
for IN N
angiogenesis NN N
in IN N
hematologic JJ N
malignancies NNS N
such JJ N
as IN N
AML NNP N
remains VBZ N
to TO N
be VB N
elucidated VBN N
. . N

In IN N
32 CD N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
untreated JJ N
AML NNP N
, , N
we PRP N
observed VBD N
by IN N
immunohistochemical JJ 2_i
analysis NN 2_i
of IN 2_i
bone NN 2_i
marrow NN 2_i
biopsies NNS 2_i
significantly RB N
higher JJR N
levels NNS N
of IN N
VEGF NNP N
and CC N
VEGFR-2 NNP N
expression NN N
than IN N
in IN N
10 CD N
control NN N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
VEGFR-1 NNP N
staining NN N
levels NNS N
in IN N
AML NNP N
patients NNS N
were VBD N
in IN N
the DT N
same JJ N
range NN N
as IN N
in IN N
the DT N
controls NNS N
. . N

Expression NN N
of IN N
VEGF NNP N
and CC N
VEGFR-2 NNP N
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS N
with IN N
a DT N
high JJ N
degree NN N
of IN N
microvessel NN N
density NN N
compared VBN N
to TO N
those DT N
with IN N
a DT N
low JJ N
degree NN N
( ( N
VEGF NNP N
: : N
P NNP N
=0.024 NNP N
; : N
VEGFR-2 JJ N
: : N
P NNP N
=0.040 NNP N
) ) N
and CC N
correlated VBN N
well RB N
with IN N
bone NN N
marrow NN N
microvessel NN N
density NN N
( ( N
r NN N
( ( N
s PRP N
) ) N
=0.566 NN N
and CC N
0.609 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Furthermore UH N
, , N
in IN N
patients NNS N
who WP N
achieved VBD N
a DT N
complete JJ N
remission NN N
following VBG N
induction NN 3_i
chemotherapy VBD 3_i
VEGFR-2 NNP N
staining NN N
levels NNS N
decreased VBN N
into IN N
the DT N
normal JJ N
range NN N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
results NNS N
provide VBP N
evidence NN N
for IN N
increased JJ N
expression NN N
of IN N
VEGF/VEGFR-2 NNP N
of IN N
leukemic JJ N
blasts NNS N
and CC N
correlation NN N
with IN N
angiogenesis NN N
in IN N
the DT N
bone NN N
marrow NN N
of IN N
AML NNP N
patients NNS N
. . N

Thus RB N
, , N
VEGF/VEGFR-2 NNP N
might MD N
constitute VB N
promising VBG N
targets NNS N
for IN N
antiangiogenic JJ 6_i
and CC N
antileukemic JJ N
treatment NN N
strategies NNS N
in IN N
AML NNP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
halothane NN 3_i
and CC N
isoflurane NN 3_i
on IN N
plasma JJ N
cytokine NN N
levels NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
halothane NN 3_i
vs. FW N
isoflurane NN 3_i
on IN N
cytokine JJ N
production NN N
during IN N
minor JJ N
elective JJ N
surgery NN N
. . N

Forty NNP N
adult NN N
patients NNS N
, , N
ASA NNP N
I-II NNP N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
halothane NN 3_i
or CC N
isoflurane NN 3_i
. . N

Venous JJ N
samples NNS N
for IN N
interleukin NN N
( ( N
IL NNP N
) ) N
-1beta NN N
, , N
IL-2 NNP N
, , N
IL-6 NNP N
, , N
tumour JJ N
necrosis NN N
factor-alpha NN N
( ( N
TNF-alpha NNP N
) ) N
and CC N
interferon-gamma JJ N
( ( N
IFN-gamma NNP N
) ) N
were VBD N
taken VBN N
before RB N
anaesthesia JJ N
, , N
before IN N
incision NN N
, , N
at IN N
the DT N
end NN N
of IN N
anaesthesia NN N
and CC N
24 CD N
h NN N
postoperatively RB N
. . N

In IN N
both DT N
groups NNS N
, , N
IL-6 NNP N
and CC N
TNF-alpha NNP N
levels NNS N
remained VBD N
low JJ N
throughout IN N
the DT N
study NN N
period NN N
. . N

Before IN N
incision NN N
, , N
in IN N
both DT N
groups NNS N
IL-1beta NNP N
and CC N
IFN-gamma NNP N
showed VBD N
a DT N
decrease NN N
( ( N
p JJ N
< VBP N
0.01 CD N
for IN N
IL-1beta NNP N
in IN N
isoflurane NN N
group NN N
and CC N
p NN N
< VBP N
0.05 CD N
for IN N
the DT N
others NNS N
) ) N
compared VBN N
with IN N
pre-induction NN N
. . N

By IN N
the DT N
end NN N
of IN N
anaesthesia NN N
and CC N
surgery NN N
, , N
IL-1beta NNP N
had VBD N
increased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
IFN-gamma NNP N
had VBD N
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
both DT N
groups NNS N
compared VBN N
with IN N
pre-incisional JJ N
levels NNS N
. . N

By IN N
24 CD N
h NNS N
postoperatively RB N
in IN N
both DT N
groups NNS N
, , N
IL-1beta NNP N
had VBD N
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
whereas JJ N
IFN-gamma NNP N
had VBD N
increased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
compared VBN N
with IN N
the DT N
end NN N
of IN N
anaesthesia NN N
and CC N
surgery NN N
level NN N
. . N

Pre-incisionally RB N
, , N
IL-2 NNP N
increased VBD N
in IN N
the DT N
halothane NN 3_i
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
whereas IN N
it PRP N
decreased VBD N
significantly RB N
in IN N
the DT N
isoflurane NN 3_i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
compared VBN N
with IN N
the DT N
pre-induction NN N
level NN N
. . N

By IN N
the DT N
end NN N
of IN N
anaesthesia NN N
and CC N
surgery NN N
and CC N
by IN N
24 CD N
h NN N
postoperatively RB N
, , N
IL-2 NNP N
had VBD N
decreased VBN N
significantly RB N
in IN N
the DT N
halothane NN 3_i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
whereas IN N
it PRP N
increased VBD N
significantly RB N
in IN N
the DT N
isoflurane NN 3_i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
compared VBN N
with IN N
pre-incision NN N
and CC N
end NN N
of IN N
anaesthesia NN N
and CC N
surgery NN N
levels NNS N
, , N
respectively RB N
. . N

-DOCSTART- -X- O O

Combined VBN N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
improves VBZ N
peers NNS N
' POS N
perceptions NNS N
of IN N
autism NN N
. . N

Authors NNS N
examined VBD N
the DT N
combined JJ N
effects NNS N
of IN N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
on IN N
peers NNS N
' POS N
perceptions NNS N
and CC N
behavioral JJ N
intentions NNS N
toward IN N
an DT N
unfamiliar JJ N
child NN N
with IN N
autism NN N
. . N

Children NNP N
( ( N
N NNP N
= NNP N
576 CD N
; : N
M NNP N
age NN N
= VBD N
10.06 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB N
two CD 4_i
videotapes NNS 4_i
of IN 4_i
a DT 4_i
boy NN 4_i
engaging VBG 4_i
in IN 4_i
typical JJ 4_i
and CC 4_i
autistic JJ 4_i
behaviors NNS 4_i
receiving VBG 4_i
either RB 4_i
descriptive JJ 4_i
( ( 4_i
AUT-D NNP 4_i
) ) 4_i
or CC 4_i
descriptive JJ 4_i
and CC 4_i
explanatory JJ 4_i
information NN 4_i
( ( 4_i
AUT-D NNP 4_i
+ NNP 4_i
E NNP 4_i
) ) 4_i
. . 4_i

Children NNP N
responded VBD N
to TO N
measures NNS N
of IN N
attitudes NNS N
( ( N
Adjective NNP N
Checklist NNP N
) ) N
and CC N
behavioral JJ N
intentions NNS N
( ( N
Shared NNP N
Activities NNP N
Questionnaire NNP N
) ) N
. . N

Children NNP N
rated VBD N
the DT N
typical JJ N
boy NN N
more RBR N
favorably RB N
than IN N
the DT N
boy NN N
showing VBG N
autistic JJ N
symptoms NNS N
. . N

When WRB N
compared VBN N
to TO N
descriptive VB N
information NN N
alone RB N
, , N
the DT N
combination NN N
of IN N
descriptive JJ N
and CC N
explanatory JJ N
information NN N
resulted VBD N
in IN N
improved JJ N
third- JJ N
and CC N
fourth-graders NNS N
' '' N
but CC N
not RB N
fifth-graders NNS N
' POS N
attitudes NNS N
toward IN N
the DT N
child NN N
with IN N
autism NN N
. . N

Combined VBN N
information NN N
improved VBN N
behavioral JJ N
intentions NNS N
across IN N
grades NNS N
; : N
however RB N
, , N
girls NNS N
( ( N
vs. FW N
boys NNS N
) ) N
were VBD N
more RBR N
responsive JJ N
to TO N
information NN N
as IN N
evidenced VBN N
by IN N
differences NNS N
in IN N
academic JJ N
intentions NNS N
. . N

The DT N
combination NN N
of IN N
descriptive JJ 4_i
and CC 4_i
explanatory JJ 4_i
information NN 4_i
about IN N
autism NN N
appears VBZ N
to TO N
have VB N
a DT N
positive JJ N
effect NN N
on IN N
children NNS N
's POS N
attitudes NNS N
and CC N
behavioral JJ N
intentions NNS N
. . N

Implications NNS N
of IN N
the DT N
findings NNS N
are VBP N
briefly RB N
discussed VBN N
as RB N
well RB N
as IN N
study NN N
limitations NNS N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
. . N

-DOCSTART- -X- O O

An DT N
evaluation NN N
of IN N
chemical JJ N
arthrodesis NN N
of IN N
the DT N
proximal JJ N
interphalangeal NN N
joint NN N
in IN N
the DT N
horse NN N
by IN N
using VBG N
monoiodoacetate NN 3_i
. . N

The DT N
use NN N
of IN N
monoiodoacetate NN 3_i
( ( 3_i
MIA NNP 3_i
) ) 3_i
for IN N
arthrodesis NN N
of IN N
the DT N
proximal JJ N
interphalangeal NN N
joint NN N
( ( N
PIJ NNP N
) ) N
and CC N
the DT N
effect NN N
of IN N
exercise NN N
on IN N
the DT N
degree NN N
of IN N
fusion NN N
were VBD N
investigated VBN N
. . N

Eight JJ N
horses NNS N
received VBD N
3 CD N
injections NNS N
( ( N
Weeks NNP N
0 CD N
, , N
3 CD N
, , N
6 CD N
) ) N
of IN N
MIA NNP 3_i
( ( N
2 CD N
mL NN N
; : N
60 CD N
mg/mL NN N
) ) N
into IN N
the DT N
right NN N
or CC N
left VBD N
front JJ N
PIJ NNP N
. . N

Peri-operatively RB N
, , N
the DT N
horses NNS N
received VBD N
phenylbutazone NN 3_i
, , N
butorphanol NN 3_i
, , N
and CC N
abaxial JJ 3_i
sesamoidean NN 3_i
nerve NN 2_i
blocks NNS 2_i
to TO N
relieve VB N
pain NN N
. . N

During IN N
the DT N
study NN N
, , N
the DT N
horses NNS N
were VBD N
monitored VBN N
for IN N
general JJ N
health NN N
, , N
lameness NN N
, , N
and CC N
swelling VBG N
around IN N
the DT N
injection NN N
area NN N
. . N

Radiographs NNP N
were VBD N
taken VBN N
biweekly RB N
to TO N
evaluate VB N
bony NN N
fusion NN N
. . N

Horses NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
non-exercised JJ N
and CC N
exercised JJ N
groups NNS N
. . N

Exercise NNP 2_i
consisted VBD N
of IN N
20 CD N
minutes NNS N
of IN N
trotting VBG N
on IN N
a DT N
treadmill NN N
( ( N
4 CD N
m/s NN N
) ) N
, , N
3 CD N
days NNS N
per IN N
week NN N
for IN N
13 CD N
weeks NNS N
. . N

The DT N
horses NNS N
were VBD N
euthanized VBN N
at IN N
24 CD N
weeks NNS N
. . N

Slab NNP N
sections NNS N
of IN N
the DT N
PIJ NNP N
were VBD N
evaluated VBN N
grossly RB N
and CC N
radiographically RB N
for IN N
bony NN N
fusion NN N
. . N

Histologic JJ N
examinations NNS N
were VBD N
performed VBN N
to TO N
evaluate VB N
articular JJ N
cartilage NN N
. . N

Three CD N
horses NNS N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
after IN N
developing VBG N
soft JJ N
tissue NN N
necrosis NN N
around IN N
the DT N
injection NN N
site NN N
, , N
septic JJ N
arthritis NN N
, , N
and CC N
necrotic JJ N
tendinitis NN N
. . N

The DT N
remaining VBG N
horses NNS N
remained VBD N
healthy JJ N
, , N
developed VBD N
a DT N
grade NN N
1 CD N
to TO N
4 CD N
lameness NN N
with IN N
minimal JJ N
to TO N
severe VB N
swelling VBG N
in IN N
the DT N
PIJ NNP N
region NN N
. . N

All DT N
5 CD N
horses NNS N
showed VBD N
radiographic JJ N
evidence NN N
of IN N
bony NN N
fusion NN N
, , N
however RB N
, , N
no DT N
fusion NN N
was VBD N
present JJ N
when WRB N
injected JJ N
joints NNS N
were VBD N
examined VBN N
on IN N
postmortem NN N
examination NN N
. . N

Histologic NNP N
examination NN N
revealed VBD N
thinning NN N
of IN N
the DT N
cartilage NN N
, , N
diffuse VBP N
necrosis NN N
of IN N
chondrocytes NNS N
, , N
with IN N
the DT N
calcified JJ N
zone NN N
intact JJ N
. . N

Subjectively RB N
, , N
exercise NN N
did VBD N
not RB N
influence VB N
the DT N
degree NN N
of IN N
cartilage NN N
destruction NN N
. . N

Based VBN N
on IN N
this DT N
study NN N
, , N
chemical JJ 3_i
arthrodesis NN 3_i
can MD N
not RB N
be VB N
advocated VBN N
in IN N
clinical JJ N
cases NNS N
because IN N
of IN N
the DT N
high JJ N
complication NN N
rate NN N
and CC N
lack NN N
of IN N
bony NN N
fusion NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Physical NNP N
performance NN N
and CC N
sedation NN N
: : N
comparative JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
a DT N
benzodiazepine NN 3_i
( ( 3_i
temazepam NN 3_i
) ) 3_i
and CC N
of IN N
a DT 3_i
non-benzodiazepine JJ 3_i
hypnotic NN 3_i
( ( 3_i
zolpidem NN 3_i
) ) 3_i
] NN N
. . N

It PRP N
is VBZ N
well-known JJ N
that IN N
many JJ N
athletes NNS N
experience VBP N
some DT N
form NN N
of IN N
precompetition NN N
stress NN N
that WDT N
may MD N
result VB N
in IN N
insomnia NN N
during IN N
the DT N
night NN N
before IN N
their PRP$ N
competition NN N
. . N

Yet CC N
, , N
sleep VBP N
withdrawal NN N
even RB N
if IN N
only RB N
partial JJ N
, , N
has VBZ N
a DT N
negative JJ N
influence NN N
on IN N
performance NN N
, , N
particularly RB N
when WRB N
the DT N
type NN N
of IN N
exercise NN N
requires VBZ N
good JJ N
psychomotor NN N
performance NN N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
intake NN N
of IN N
a DT N
hypnotic JJ N
drug NN N
would MD N
have VB N
negative JJ N
effects NNS N
on IN N
physical JJ N
performance NN N
capacity NN N
. . N

The DT N
authors NNS N
have VBP N
compared VBN N
the DT N
effects NNS N
of IN N
oral JJ 3_i
temazepam NN 3_i
, , N
a DT N
medium NN 3_i
half-life JJ 3_i
benzodiazepine NN 3_i
vs IN N
oral JJ 3_i
zolpidem NN 3_i
, , N
a DT 3_i
short JJ 3_i
half-life JJ 3_i
non-benzodiazepine JJ 3_i
drug NN 3_i
, , N
vs NN N
placebo NN 7_i
. . N

A DT N
randomized JJ N
double-blind JJ N
trial NN N
was VBD N
used VBN N
to TO N
assess VB N
endurance NN N
, , N
resistance NN N
, , N
strength NN N
and CC N
coordination NN N
in IN N
26 CD N
athletes NNS N
. . N

The DT N
results NNS N
did VBD N
not RB N
show VB N
any DT N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
, , N
neither CC N
in IN N
physical JJ N
performance NN N
characteristic JJ N
nor CC N
in IN N
coordination NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
as IN N
regards NNS N
the DT N
performance NN N
capacity NN N
, , N
there EX N
is VBZ N
no DT N
risk NN N
for IN N
stressed JJ N
athletes NNS N
to TO N
use VB N
sleep JJ N
inducers NNS N
the DT N
night NN N
before IN N
their PRP$ N
competition NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
topical JJ N
pimecrolimus NN 3_i
for IN N
cetuximab-associated JJ N
acnelike JJ N
eruption NN N
. . N

BACKGROUND NNP N
Clinical NNP N
trials NNS N
addressing VBG N
the DT N
acneiform NN N
rash NN N
associated VBN N
with IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
inhibitors NNS N
are VBP N
lacking VBG N
. . N

OBJECTIVE IN N
We PRP N
evaluated VBD N
the DT N
ability NN N
of IN N
topical JJ N
pimecrolimus NN 3_i
to TO N
reduce VB N
the DT N
severity NN N
of IN N
cetuximab-related JJ N
facial JJ N
rash NN N
. . N

METHODS NNP N
In IN N
all DT N
, , N
24 CD N
patients NNS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
with IN N
cetuximab JJ N
facial JJ N
rash NN N
received VBD N
twice RB N
daily JJ N
pimecrolimus NNS 3_i
application NN N
for IN N
5 CD N
weeks NNS N
to TO N
half NN N
of IN N
the DT N
face NN N
. . N

At IN N
baseline NN N
, , N
week NN N
2 CD N
, , N
and CC N
week NN N
5 CD N
, , N
a DT N
dermatologist NN N
performed VBN N
facial JJ N
lesion NN N
counts NNS N
, , N
patients NNS N
reported VBD N
perceived JJ N
severity NN N
of IN N
rash-related JJ N
symptoms NNS N
, , N
and CC N
standardized VBD N
facial JJ N
photographs NN N
were VBD N
obtained VBN N
for IN N
blinded JJ N
evaluation NN N
of IN N
global JJ N
rash NN N
severity NN N
. . N

RESULTS NNP N
Treatment NNP N
sides NNS N
had VBD N
greater JJR N
decrease NN N
in IN N
lesion NN N
counts NNS N
than IN N
observation NN N
sides NNS N
of IN N
face NN N
at IN N
weeks NNS N
2 CD N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
5 CD N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
patients NNS N
' POS N
assessment NN N
of IN N
symptoms NNS N
and CC N
in IN N
review NN N
of IN N
facial JJ N
photographs NN N
for IN N
rash NN N
severity NN N
between IN N
treatment NN N
and CC N
observation NN N
sides NNS N
. . N

LIMITATIONS VB N
This DT N
study NN N
was VBD N
not RB N
placebo JJ N
controlled VBN N
. . N

CONCLUSIONS NNP N
Pimecrolimus NNP 3_i
application NN N
did VBD N
not RB N
translate VB N
into IN N
clinically RB N
meaningful JJ N
benefit NN N
for IN N
patients NNS N
with IN N
cetuximab-related JJ N
facial JJ N
rash NN N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
antioxidants NNS 3_i
, , N
zinc NN 3_i
, , N
and CC N
copper NN 3_i
on IN N
cognition NN N
in IN N
the DT N
elderly JJ N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

Participants NNS N
in IN N
the DT N
Age-Related JJ N
Eye NNP N
Disease NNP N
Study NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
daily JJ N
antioxidants NNS 3_i
( ( 3_i
vitamin JJ 3_i
C NNP 3_i
, , 3_i
500 CD 3_i
mg NN 3_i
; : 3_i
vitamin CC 3_i
E NNP 3_i
, , 3_i
400 CD 3_i
IU NNP 3_i
; : 3_i
beta NN 3_i
carotene NN 3_i
, , 3_i
15 CD 3_i
mg NN 3_i
) ) 3_i
, , 3_i
zinc NN 3_i
and CC 3_i
copper NN 3_i
( ( 3_i
zinc NN 3_i
, , 3_i
80 CD 3_i
mg NN 3_i
; : 3_i
cupric JJ 3_i
oxide NN 3_i
, , 3_i
2 CD 3_i
mg NN 3_i
) ) 3_i
, , 3_i
antioxidants NNS 3_i
plus CC 3_i
zinc NN 3_i
and CC 3_i
copper NN 3_i
, , N
or CC N
placebo NN 7_i
. . N

A DT N
cognitive JJ N
battery NN N
was VBD N
administered VBN N
to TO N
2,166 CD N
elderly JJ N
persons NNS N
after IN N
a DT N
median NN N
of IN N
6.9 CD N
years NNS N
of IN N
treatment NN N
. . N

Treatment NNP N
groups NNS N
did VBD N
not RB N
differ VB N
on IN N
any DT N
of IN N
the DT N
six CD N
cognitive JJ N
tests NNS N
( ( N
p JJ N
> VBP N
0.05 CD N
for IN N
all DT N
) ) N
. . N

These DT N
results NNS N
do VBP N
not RB N
support VB N
a DT N
beneficial JJ N
or CC N
harmful JJ N
effect NN N
of IN N
antioxidants NNS 3_i
or CC 3_i
zinc NN 3_i
and CC N
copper NN 3_i
on IN N
cognition NN N
in IN N
older JJR N
adults NNS N
. . N

-DOCSTART- -X- O O

Components NNS N
of IN N
working VBG N
memory NN N
and CC N
visual JJ N
selective JJ N
attention NN N
. . N

Load NNP N
theory NN N
( ( N
Lavie NNP N
, , N
N. NNP N
, , N
Hirst NNP N
, , N
A. NNP N
, , N
De NNP N
Fockert NNP N
, , N
J. NNP N
W. NNP N
, , N
& CC N
Viding NNP N
, , N
E. NNP N
[ NNP N
2004 CD N
] NNP N
. . N

Load NNP N
theory NN N
of IN N
selective JJ N
attention NN N
and CC N
cognitive JJ N
control NN N
. . N

Journal NNP N
of IN N
Experimental NNP N
Psychology NNP N
: : N
General NNP N
, , N
133 CD N
, , N
339-354 JJ N
. . N

) ) N
proposes VBZ N
that IN N
control NN N
of IN N
attention NN N
depends VBZ N
on IN N
the DT N
amount NN N
and CC N
type NN N
of IN N
load NN N
that WDT N
is VBZ N
imposed VBN N
by IN N
current JJ N
processing NN N
. . N

Specifically RB N
, , N
perceptual JJ N
load NN N
should MD N
lead VB N
to TO N
efficient JJ N
distractor NN N
rejection NN N
, , N
whereas IN N
working VBG N
memory NN N
load NN N
( ( N
dual-task JJ N
coordination NN N
) ) N
should MD N
hinder VB N
distractor NN N
rejection NN N
. . N

Studies NNPS N
support VBP N
load NN N
theory NN N
's POS N
prediction NN N
that IN N
working VBG N
memory NN N
load NN N
will MD N
lead VB N
to TO N
larger JJR N
distractor NN N
effects NNS N
; : N
however RB N
, , N
these DT N
studies NNS N
used VBD N
secondary JJ N
tasks NNS N
that WDT N
required VBD N
only RB N
verbal JJ N
working VBG N
memory NN N
and CC N
the DT N
central JJ N
executive NN N
. . N

The DT N
present JJ N
study NN N
examined VBD N
which WDT N
other JJ N
working VBG N
memory NN N
components NNS N
( ( N
visual JJ N
, , N
spatial JJ N
, , N
and CC N
phonological JJ N
) ) N
influence NN N
visual JJ N
selective JJ N
attention NN N
. . N

Subjects NNS N
completed VBD N
an DT N
attentional JJ 4_i
capture NN 4_i
task NN 4_i
alone RB 4_i
( ( 4_i
single-task JJ 4_i
) ) 4_i
or CC N
while IN N
engaged VBN N
in IN N
a DT N
working JJ 4_i
memory NN 4_i
task NN 4_i
( ( 4_i
dual-task JJ 4_i
) ) 4_i
. . N

Results CC N
showed VBD N
that IN N
along IN N
with IN N
the DT N
central JJ N
executive NN N
, , N
visual JJ N
and CC N
spatial JJ N
working VBG N
memory NN N
influenced VBD N
selective JJ N
attention NN N
, , N
but CC N
phonological JJ N
working VBG N
memory NN N
did VBD N
not RB N
. . N

Specifically RB N
, , N
attentional JJ N
capture NN N
was VBD N
larger JJR N
when WRB N
visual JJ N
or CC N
spatial JJ N
working VBG N
memory NN N
was VBD N
loaded VBN N
, , N
but CC N
phonological JJ N
working VBG N
memory NN N
load NN N
did VBD N
not RB N
affect VB N
attentional JJ N
capture NN N
. . N

The DT N
results NNS N
are VBP N
consistent JJ N
with IN N
load NN N
theory NN N
and CC N
suggest VBP N
specific JJ N
components NNS N
of IN N
working VBG N
memory NN N
influence NN N
visual JJ N
selective JJ N
attention NN N
. . N

-DOCSTART- -X- O O

Direct JJ N
and CC N
indirect JJ N
effects NNS N
of IN N
interdental JJ 4_i
hygiene NN 4_i
in IN N
a DT N
clinical JJ N
trial NN N
. . N

Many JJ N
randomized VBD N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
in IN N
dental JJ N
research NN N
test NN N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
more JJR N
than IN N
one CD N
outcome NN N
variable NN N
. . N

Univariate NNP N
methods NNS N
, , N
such JJ N
as IN N
the DT N
t JJ N
test NN N
or CC N
analysis NN N
of IN N
covariance NN N
, , N
can MD N
not RB N
evaluate VB N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
multiple JJ N
outcomes NNS N
simultaneously RB N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
structural JJ 4_i
equation NN 4_i
modeling NN 4_i
( ( N
SEM NNP N
) ) N
to TO N
re-analyze VB N
a DT N
RCT NNP N
, , N
comparing VBG N
the DT N
effects NNS N
of IN N
pre-curved JJ 4_i
interdental JJ 4_i
brushes NNS 4_i
and CC 4_i
flossing VBG 4_i
on IN N
probing VBG N
pocket NN N
depth NN N
( ( N
PPD NNP N
) ) N
, , N
plaque JJ N
indices NNS N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
measured VBD N
at IN N
baseline NN N
, , N
intermediate NN N
, , N
and CC N
final JJ N
examinations NNS N
. . N

Results NNS N
of IN N
SEM NNP N
showed VBD N
that IN N
the DT N
observed JJ N
greater JJR N
reduction NN N
in IN N
PPD NNP N
and CC N
BOP NNP N
in IN N
persons NNS N
using VBG N
interdental JJ N
brushing NN N
than IN N
in IN N
those DT N
flossing NN N
is VBZ N
due JJ N
mainly RB N
to TO N
the DT N
greater JJR N
efficiency NN N
in IN N
plaque NN N
removal NN N
with IN N
the DT N
interdental JJ N
brushes NNS N
( ( N
indirect JJ N
effect NN N
) ) N
rather RB N
than IN N
to TO N
the DT N
compression NN N
of IN N
the DT N
interdental JJ N
papillae NN N
( ( N
direct JJ N
effect NN N
) ) N
. . N

In IN N
contrast NN N
, , N
smokers NNS N
showed VBD N
less JJR N
BOP NNP N
at IN N
baseline NN N
but CC N
also RB N
less RBR N
improvement NN N
in IN N
BOP NNP N
through IN N
direct JJ N
effects NNS N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
the DT N
electrothermal JJ 1_i
bipolar JJ 1_i
vessel NN 1_i
system NN 1_i
( ( 1_i
EBVS NNP 1_i
) ) 1_i
in IN N
laparoscopic JJ N
adrenalectomy NN N
: : N
a DT N
prospective JJ N
study NN N
. . N

BACKGROUND NNP N
Since IN N
laparoscopic NN N
adrenalectomy NN N
( ( N
LA NNP N
) ) N
has VBZ N
been VBN N
adopted VBN N
as IN N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
treatment NN N
of IN N
adrenal JJ N
diseases NNS N
, , N
the DT N
development NN N
of IN N
technology NN N
for IN N
vascular JJ N
control NN N
and CC N
dissection NN N
manoeuvres NNS N
, , N
amongst VBZ N
other JJ N
things NNS N
, , N
may MD N
play VB N
a DT N
pivotal JJ N
role NN N
in IN N
its PRP$ N
further JJ N
improvement NN N
. . N

We PRP N
report VBP N
our PRP$ N
experience NN N
with IN N
the DT N
electrothermal JJ 1_i
bipolar JJ 1_i
vessel NN 1_i
sealing NN 1_i
( ( 1_i
EBVS NNP 1_i
) ) 1_i
device NN N
for IN N
LA NNP N
. . N

METHODS NNP N
From IN N
January NNP N
2004 CD N
to TO N
January NNP N
2006 CD N
, , N
50 CD N
patients NNS N
( ( N
pts NNS N
) ) N
undergoing VBG N
LA NNP N
were VBD N
selected VBN N
and CC N
randomized VBN N
for IN N
use NN N
of IN N
the DT N
EBVS NNP 1_i
( ( 2_i
25 CD 2_i
pts NNS 2_i
, , 2_i
group NN 2_i
A NNP 2_i
) ) 2_i
versus IN 2_i
the DT 2_i
UltraSonic NNP 2_i
Shears NNP 2_i
( ( 2_i
USS NNP 2_i
) ) 2_i
device NN 2_i
( ( N
25 CD N
pts NNS N
, , N
group NN N
B NNP N
) ) N
. . N

Age NNP N
, , N
sex NN N
, , N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
previous JJ N
surgery NN N
and CC N
associated VBN N
diseases NNS N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
main JJ N
surgical JJ N
parameters NNS N
collected VBN N
for IN N
each DT N
patient NN N
( ( N
pt NN N
) ) N
concerned VBD N
operative JJ N
time NN N
, , N
major JJ N
and CC N
minor JJ N
complications NNS N
, , N
conversion NN N
rate NN N
, , N
blood NN N
loss NN N
, , N
hospital JJ N
stay NN N
and CC N
histology NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
mortality NN N
in IN N
either DT N
group NN N
. . N

The DT N
right JJ N
adrenalectomy NN N
mean VB N
operative JJ N
time NN N
( ( N
OpT NNP N
) ) N
was VBD N
51.8 CD N
mins NNS N
( ( N
range VB N
40-90 JJ N
mins NNS N
) ) N
and CC N
68.6 CD N
mins NNS N
( ( N
range VB N
50-130 NNP N
mins NNS N
) ) N
in IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P NNP N
not RB N
significant JJ N
) ) N
. . N

The DT N
left JJ N
adrenalectomy JJ N
mean JJ N
OpT NNP N
was VBD N
72.2 CD N
mins NNS N
( ( N
range VB N
55-100 NNP N
mins NNS N
) ) N
and CC N
94 CD N
mins NNS N
( ( N
range VB N
65-140 NNP N
mins NNS N
) ) N
for IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
mean JJ N
blood NN N
loss NN N
was VBD N
83 CD N
ml NN N
( ( N
group NN N
A NNP N
) ) N
and CC N
210 CD N
ml NN N
( ( N
group NN N
B NNP N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Complications NNS N
were VBD N
not RB N
different JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
mean JJ N
hospital NN N
stay NN N
was VBD N
2.9 CD N
and CC N
3.1 CD N
days NNS N
in IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P NNP N
not RB N
significant JJ N
) ) N
. . N

CONCLUSIONS NNP N
EBVS NNP N
in IN N
LA NNP N
may MD N
provide VB N
a DT N
significantly RB N
short JJ N
operating NN N
time NN N
and CC N
blood NN N
loss NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
cooking NN 3_i
plant NN 3_i
oils NNS 3_i
on IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

OBJECTIVE NNP N
One-third NNP N
of IN N
the DT N
total JJ N
population NN N
seems VBZ N
to TO N
develop VB N
minor JJ N
recurrent NN N
aphthous JJ N
stomatitis NN N
( ( N
RAS NNP N
) ) N
during IN N
their PRP$ N
lifetime NN N
. . N

However RB N
, , N
well-controlled JJ N
dietary JJ N
intervention NN N
studies NNS N
to TO N
prevent VB N
minor JJ N
RAS NNP N
are VBP N
very RB N
rare JJ N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
prevalence NN N
of IN N
RAS NNP N
decreased VBD N
with IN N
perilla NN 3_i
oil NN 3_i
( ( N
rich JJ N
in IN N
alpha-linolenic JJ N
acid NN N
) ) N
. . N

METHODS NNP N
Thirty NNP N
subjects NNS N
( ( N
8 CD N
men NNS N
and CC N
22 CD N
women NNS N
) ) N
who WP N
had VBD N
minor JJ N
RAS NNP N
at IN N
least JJS N
once RB N
a DT N
month NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
soybean JJ 3_i
oil NN 3_i
group NN N
or CC N
a DT N
perilla JJ 3_i
oil NN 3_i
group NN N
in IN N
a DT N
double-blind JJ N
manner NN N
( ( N
experimental JJ N
phase NN N
) ) N
after IN N
a DT N
run-in JJ N
phase NN N
of IN N
4 CD N
mo NN N
during IN N
which WDT N
subjects NNS N
used VBD N
a DT N
reference NN N
oil NN N
, , N
the DT N
most RBS N
popular JJ N
cooking NN N
oil NN N
in IN N
Japan NNP N
, , N
or CC N
a DT N
50/50 CD N
mixture NN N
of IN N
soybean JJ N
oil NN N
and CC N
rapeseed NN N
oil NN N
. . N

During IN N
the DT N
experimental JJ N
phase NN N
, , N
subjects NNS N
were VBD N
asked VBN N
to TO N
use VB N
soybean JJ N
oil NN N
or CC N
perilla NN N
oil NN N
as IN N
the DT N
sole JJ N
cooking NN N
oil NN N
for IN N
8 CD N
mo NN N
. . N

Blood NN N
samples NNS N
were VBD N
collected VBN N
at IN N
the DT N
start NN N
and CC N
end NN N
of IN N
the DT N
experimental JJ N
phase NN N
for IN N
fatty JJ N
acid JJ N
analysis NN N
of IN N
total JJ N
plasma NN N
phospholipid JJ N
fraction NN N
. . N

Occurrence NN N
and CC N
needed VBN N
days NNS N
for IN N
healing NN N
of IN N
minor JJ N
RAS NNP N
were VBD N
recorded VBN N
during IN N
the DT N
two CD N
phases NNS N
and CC N
compared VBN N
. . N

RESULTS NNP N
alpha-Linolenic JJ N
acid JJ N
concentrations NNS N
in IN N
the DT N
plasma NN N
phospholipid JJ N
fraction NN N
increased VBD N
significantly RB N
in IN N
both DT N
groups NNS N
during IN N
the DT N
experimental JJ N
phase NN N
to TO N
a DT N
similar JJ N
extent NN N
. . N

The DT N
prevalence NN N
of IN N
minor JJ N
RAS NNP N
in IN N
the DT N
experimental JJ N
phase NN N
decreased VBD N
significantly RB N
in IN N
both DT N
groups NNS N
compared VBN N
with IN N
the DT N
run-in JJ N
phase NN N
to TO N
a DT N
similar JJ N
extent NN N
, , N
without IN N
intergroup JJ N
differences NNS N
. . N

CONCLUSION NNP N
Perilla NNP N
oil NN N
, , N
which WDT N
is VBZ N
rich JJ N
in IN N
alpha-linolenic JJ N
acid NN N
, , N
was VBD N
not RB N
superior JJ N
to TO N
soybean VB N
oil NN N
in IN N
preventing VBG N
minor JJ N
RAS NNP N
. . N

There EX N
was VBD N
a DT N
possibility NN N
that IN N
avoiding VBG N
rapeseed VB N
oil NN N
might MD N
be VB N
beneficial JJ N
for IN N
prevention NN N
of IN N
minor JJ N
RAS NNP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
fasting VBG 2_i
on IN N
total JJ N
serum NN N
bilirubin NN N
concentrations NNS N
. . N

Thirty-seven NNP N
healthy JJ N
volunteers NNS N
, , N
19 CD N
of IN N
whom WP N
had VBD N
consistently RB N
elevated VBN N
total JJ N
serum NN N
bilirubin NN N
( ( N
TSB NNP N
) ) N
concentrations NNS N
, , N
took VBD N
part NN N
in IN N
an DT N
open JJ N
, , N
randomised VBD N
cross-over NN N
study NN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
fasting VBG 6_i
on IN N
TSB NNP N
concentrations NNS N
. . N

The DT N
study NN N
comprised VBD N
of IN N
two CD N
treatments NNS N
. . N

During IN N
one CD N
treatment NN N
period NN N
volunteers NNS N
ate VBP 2_i
a DT 2_i
standard JJ 2_i
supper NN 2_i
but CC 2_i
fasted VBD 2_i
for IN 2_i
24 CD 2_i
h NN 2_i
thereafter RB 2_i
. . N

During IN N
the DT N
other JJ N
treatment NN N
period NN N
volunteers NNS N
ate VBP N
a DT N
standard JJ 2_i
supper NN 2_i
, , 2_i
snacks NNS 2_i
, , 2_i
breakfast NN 2_i
and CC 2_i
lunch NN 2_i
. . N

TSB NNP N
concentrations NNS N
were VBD N
measured VBN N
at IN N
regular JJ N
intervals NNS N
. . N

In IN N
both DT N
the DT N
normal JJ N
and CC N
high JJ N
bilirubin NN N
groups NNS N
, , N
minimum JJ N
TSB NNP N
values NNS N
were VBD N
recorded VBN N
4 CD N
h NN N
after IN N
the DT N
supper NN N
. . N

A DT N
24 CD N
h NN N
fast RB N
more RBR N
than IN N
doubled VBD N
TSB NNP N
concentration NN N
from IN N
baseline NN N
values NNS N
in IN N
both DT N
the DT N
normal JJ N
and CC N
high JJ N
bilirubin NN N
groups NNS N
. . N

A DT N
clinically RB N
relevant JJ N
rise NN N
in IN N
TSB NNP N
took VBD N
place NN N
after IN N
12 CD N
h NN N
into IN N
the DT N
fasting JJ N
period NN N
( ( N
TSB NNP N
of IN N
17.3 CD N
mumol JJ N
l-1 NN N
in IN N
the DT N
fasted JJ N
group NN N
vs VBD N
14.0 CD N
mumol JJ N
l-1 NN N
in IN N
the DT N
non-fasted JJ N
group NN N
) ) N
. . N

When WRB N
designing VBG N
a DT N
clinical JJ N
trial NN N
, , N
selecting VBG N
volunteers NNS N
, , N
or CC N
judging VBG N
the DT N
tolerance NN N
of IN N
a DT N
new JJ N
drug NN N
, , N
the DT N
rise NN N
in IN N
TSB NNP N
caused VBN N
by IN N
fasting VBG N
must MD N
therefore RB N
be VB N
taken VBN N
into IN N
account NN N
, , N
particularly RB N
in IN N
trials NNS N
where WRB N
volunteers NNS N
or CC N
patients NNS N
fast JJ N
before IN N
entering VBG N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
multicenter JJ N
trial NN N
comparing VBG N
two CD N
doses NNS N
of IN N
arzoxifene NN 3_i
( ( 3_i
LY353381 NNP 3_i
) ) 3_i
in IN N
hormone-sensitive JJ N
advanced JJ N
or CC N
metastatic JJ N
breast NN N
cancer NN N
patients NNS N
. . N

BACKGROUND NNP N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
assessed VBD N
two CD N
doses NNS N
of IN N
the DT N
selective JJ 3_i
estrogen NN 3_i
receptor NN 3_i
modulator NN 3_i
arzoxifene NN 3_i
in IN N
women NNS N
with IN N
advanced JJ N
breast NN N
cancer NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
to TO N
choose VB N
the DT N
best JJS N
of IN N
two CD N
doses NNS N
of IN N
arzoxifene NN 3_i
based VBN N
on IN N
the DT N
response NN N
rate NN N
or CC N
the DT N
clinical JJ N
benefit NN N
rate NN N
( ( N
CBR NNP N
) ) N
. . N

Pharmacokinetics NNPS N
and CC N
toxicities NNS N
were VBD N
also RB N
assessed VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Ninety-two NNP N
patients NNS N
with IN N
advanced JJ N
breast NN N
cancer NN N
received VBD N
arzoxifene JJ 3_i
20 CD 3_i
or CC 3_i
50 CD 3_i
mg/day NN 3_i
. . N

Tumor NNP N
response NN N
was VBD N
assessed VBN N
using VBG N
World NNP 2_i
Health NNP 2_i
Organization NNP 2_i
criteria NNS 2_i
. . N

Toxicities NNS N
were VBD N
graded VBN N
according VBG N
to TO N
the DT N
National NNP 2_i
Cancer NNP 2_i
Institute NNP 2_i
Common NNP 2_i
Toxicity NNP 2_i
Criteria NNP 2_i
( ( 2_i
NCI-CTC NNP 2_i
) ) 2_i
system NN 2_i
. . N

Pharmacokinetic JJ N
data NNS N
were VBD N
analyzed VBN N
using VBG N
the DT N
NONMEM NNP N
software NN N
program NN N
( ( N
GloboMax NNP N
, , N
Hanover NNP N
, , N
MD NNP N
, , N
USA NNP N
) ) N
. . N

RESULTS JJ N
Response JJ N
rates NNS N
in IN N
the DT N
20 CD N
mg NN N
arm NN N
were VBD N
numerically RB N
higher JJR N
than IN N
the DT N
50-mg JJ N
arm NN N
according VBG N
to TO N
the DT N
investigator NN N
( ( N
40.5 CD N
% NN N
versus IN N
36.4 CD N
% NN N
) ) N
and CC N
the DT N
independent JJ N
review NN N
panel NN N
( ( N
42.9 CD N
% NN N
versus IN N
27.3 CD N
% NN N
) ) N
. . N

CBR NNP N
was VBD N
higher RBR N
in IN N
the DT N
20 CD N
mg NN N
arm NN N
according VBG N
to TO N
the DT N
investigator NN N
( ( N
64.3 CD N
% NN N
versus IN N
61.4 CD N
% NN N
) ) N
and CC N
the DT N
independent JJ N
review NN N
panel NN N
( ( N
59.5 CD N
% NN N
versus IN N
47.7 CD N
% NN N
) ) N
. . N

Arzoxifene NNP 3_i
was VBD N
well RB N
tolerated VBN N
. . N

There EX N
were VBD N
no DT N
study NN N
drug-related JJ N
deaths NNS N
. . N

Mean NNP N
observed VBD N
steady-state JJ N
plasma JJ N
concentrations NNS N
of IN N
arzoxifene NN 3_i
were VBD N
3.62 CD N
and CC N
7.48 CD N
ng/ml NN N
for IN N
the DT N
20 CD N
and CC N
50 CD N
mg NN N
doses NNS N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
efficacy NN N
or CC N
safety NN N
between IN N
20 CD N
and CC N
50 CD N
mg NN N
of IN N
arzoxifene NN 3_i
. . N

Accordingly RB N
, , N
arzoxifene VBZ 3_i
20 CD N
mg/day NN N
was VBD N
selected VBN N
for IN N
further JJ N
study NN N
in IN N
patients NNS N
with IN N
breast JJ N
cancer NN N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
venous JJ N
thromboembolism NN N
after IN N
knee NN N
arthroplasty NN N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
comparing VBG N
enoxaparin NN 3_i
with IN N
warfarin NN 3_i
. . 3_i

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
fixed-dose JJ 3_i
enoxaparin NN 3_i
and CC N
adjusted VBD 3_i
dose JJ 3_i
warfarin NN 3_i
in IN N
preventing VBG N
venous JJ N
thromboembolism NN N
after IN N
knee NN N
arthroplasty NN N
. . N

DESIGN VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
controlled VBN N
trial NN N
. . N

SETTING NN N
8 CD N
university NN N
hospitals NNS N
. . N

PATIENTS VB N
670 CD N
consecutive JJ N
patients NNS N
who WP N
had VBD N
knee VBN N
arthroplasty RB N
. . N

INTERVENTION NN N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
enoxaparin NN 3_i
( ( 3_i
30 CD 3_i
mg NN 3_i
subcutaneously RB 3_i
every DT 3_i
12 CD 3_i
hours NNS 3_i
) ) 3_i
or CC 3_i
adjusted-dose JJ 3_i
warfarin NN 3_i
( ( 3_i
international JJ 3_i
normalized VBN 3_i
ratio NN 3_i
, , 3_i
2.0 CD 3_i
to TO 3_i
3.0 CD 3_i
) ) 3_i
. . N

Both DT N
regimens NNS N
were VBD N
started VBN N
after IN N
surgery NN N
. . N

MEASUREMENTS PDT N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
incidence NN N
of IN N
deep JJ N
venous JJ N
thrombosis NN N
in IN N
patients NNS N
with IN N
adequate JJ N
bilateral JJ N
venograms NNS N
; : N
the DT N
secondary JJ N
end NN N
point NN N
was VBD N
hemorrhage NN N
. . N

RESULTS NNP N
Among IN N
the DT N
417 CD N
patients NNS N
with IN N
adequate JJ N
venograms NNS N
, , N
109 CD N
of IN N
211 CD N
warfarin NN 3_i
recipients NNS N
( ( N
51.7 CD N
% NN N
) ) N
had VBD N
deep JJ N
venous JJ N
thrombosis NN N
compared VBN N
with IN N
76 CD N
of IN N
206 CD N
enoxaparin NN 3_i
recipients NNS N
( ( N
36.9 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
absolute NN N
risk NN N
difference NN N
was VBD N
14.8 CD N
% NN N
in IN N
favor NN N
of IN N
enoxaparin NN 3_i
( ( N
95 CD N
% NN N
Cl NNP N
, , N
5.3 CD N
% NN N
to TO N
24.1 CD N
% NN N
) ) N
Twenty-two NNP N
warfarin NN 3_i
recipients NNS N
( ( N
10.4 CD N
% NN N
) ) N
and CC N
24 CD N
enoxaparin NN 3_i
recipients NNS N
( ( N
11.7 CD N
% NN N
) ) N
had VBD N
proximal JJ N
venous JJ N
thrombosis NN N
( ( N
P NNP N
> NNP N
0.2 CD N
) ) N
. . N

The DT N
absolute NN N
risk NN N
difference NN N
was VBD N
1.2 CD N
% NN N
in IN N
favor NN N
of IN N
warfarin NN 3_i
( ( N
Cl NNP N
, , N
-7.2 NNP N
% NN N
to TO N
4.8 CD N
% NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
major JJ N
bleeding NN N
was VBD N
1.8 CD N
% NN N
( ( N
6 CD N
of IN N
334 CD N
patients NNS N
) ) N
in IN N
the DT N
warfarin NN N
group NN N
and CC N
2.1 CD N
% NN N
( ( N
7 CD N
of IN N
336 CD N
patients NNS N
) ) N
in IN N
the DT N
enoxaparin NN N
group NN N
( ( N
P NNP N
> NNP N
0.2 CD N
) ) N
. . N

The DT N
absolute NN N
risk NN N
difference NN N
was VBD N
0.3 CD N
% NN N
in IN N
favor NN N
of IN N
warfarin NN N
( ( N
Cl NNP N
, , N
-2.4 NNP N
% NN N
to TO N
1.8 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
A DT N
postoperative JJ N
, , N
fixed-dose JJ N
enoxaparin NN 3_i
regimen NNS N
is VBZ N
more RBR N
effective JJ N
than IN N
adjusted-dose JJ N
warfarin NN 3_i
in IN N
preventing VBG N
deep JJ N
venous JJ N
thrombosis NN N
after IN N
knee NN N
arthroplasty NN N
. . N

No DT N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
incidence NN N
of IN N
proximal JJ N
venous JJ N
thrombosis NN N
or CC N
clinically RB N
overt JJ N
hemorrhage NN N
. . N

-DOCSTART- -X- O O

Moclobemide NNP N
, , N
imipramine NN N
and CC N
placebo NN N
in IN N
the DT N
treatment NN N
of IN N
major JJ N
depression NN N
. . N

Moclobemide NNP 3_i
was VBD N
compared VBN N
with IN N
imipramine NN 3_i
and CC N
placebo NN 7_i
in IN N
the DT N
treatment NN N
of IN N
major JJ N
depressive JJ N
episodes NNS N
in IN N
75 CD N
outpatients NNS N
. . N

The DT N
dosage NN N
of IN N
moclobemide NN 3_i
( ( 3_i
25 CD 3_i
patients NNS 3_i
) ) 3_i
was VBD 3_i
300 CD 3_i
mg JJ 3_i
daily RB 3_i
for IN 3_i
the DT 3_i
first JJ 3_i
5 CD 3_i
days NNS 3_i
, , 3_i
after IN 3_i
which WDT 3_i
it PRP 3_i
could MD 3_i
be VB 3_i
increased VBN 3_i
to TO 3_i
600 CD 3_i
mg. NNS 3_i
Imipramine NNP 3_i
( ( 3_i
25 CD 3_i
patients NNS 3_i
) ) 3_i
was VBD 3_i
given VBN 3_i
in IN 3_i
a DT 3_i
dosage NN 3_i
starting VBG 3_i
with IN 3_i
33 CD 3_i
mg NNS 3_i
and CC 3_i
gradually RB 3_i
increased VBD 3_i
to TO 3_i
100 CD 3_i
mg/day NN 3_i
in IN 3_i
the DT 3_i
first JJ 3_i
5 CD 3_i
days NNS 3_i
, , N
after IN N
which WDT N
it PRP N
could MD N
be VB N
further RB N
increased VBN N
; : N
25 CD N
patients NNS N
received VBD N
placebo NN 7_i
. . 7_i

Both DT N
drugs NNS N
were VBD N
equally RB N
effective JJ N
as IN N
measured VBN N
by IN N
the DT N
Hamilton NNP N
Rating NNP N
Scale NNP N
for IN N
Depression NNP N
, , N
the DT N
overall JJ N
assessment NN N
of IN N
efficacy NN N
and CC N
the DT N
Zung NNP N
Self-rating NNP N
Scale NNP N
, , N
and CC N
clearly RB N
superior JJ N
to TO N
placebo VB N
; : N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
active JJ N
drugs NNS N
. . N

Moclobemide NNP 3_i
was VBD N
better RBR N
tolerated VBN N
than IN N
imipramine NN 3_i
, , N
and CC N
was VBD N
almost RB N
comparable JJ N
to TO N
placebo VB N
in IN N
this DT N
respect NN N
. . N

-DOCSTART- -X- O O

Cardiovascular JJ N
risk NN N
markers NNS N
during IN N
treatment NN N
with IN N
estradiol NN 3_i
and CC N
trimegestone NN 3_i
or CC N
dydrogesterone NN 3_i
. . N

OBJECTIVE UH N
To TO N
study VB N
cardiovascular JJ N
risk NN N
markers NNS N
in IN N
women NNS N
taking VBG N
estradiol/trimegestone NN N
or CC N
estradiol/dydrogesterone NN N
. . N

DESIGN NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
prospective JJ N
, , N
double-blind JJ N
study NN N
of IN N
184 CD N
healthy JJ N
post-menopausal JJ N
women NNS N
randomized VBD N
to TO N
6 CD 3_i
cycles NNS 3_i
of IN 3_i
either DT 3_i
estradiol NN 3_i
( ( 3_i
2mg CD 3_i
) ) 3_i
+trimegestone NN 3_i
( ( 3_i
0.5mg CD 3_i
) ) 3_i
( ( 3_i
T-group NNP 3_i
) ) 3_i
or CC N
estradiol NN 3_i
( ( 3_i
2mg CD 3_i
) ) 3_i
+dydrogesterone NN 3_i
( ( 3_i
10mg CD 3_i
) ) 3_i
( ( 3_i
DYDR NNP 3_i
group NN 3_i
) ) 3_i
. . N

Cardiovascular JJ 2_i
risk NN 2_i
markers NNS 2_i
were VBD N
measured VBN N
before IN N
, , N
after IN N
cycle NN N
1 CD N
, , N
3 CD N
and CC N
6 CD N
and CC N
at IN N
4 CD N
weeks NNS N
post-treatment JJ N
. . N

RESULTS NNP N
Fibrinogen NNP N
was VBD N
reduced VBN N
in IN N
both DT N
groups NNS N
but CC N
more JJR N
markedly RB N
in IN N
the DT N
DYDR NNP N
group NN N
. . N

Factor NNP N
VIIc NNP N
activity NN N
levels NNS N
decreased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
change NN N
in IN N
the DT N
T-group NNP N
. . N

Factor NNP N
VII NNP N
antigen NN N
was VBD N
increased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
increase NN N
in IN N
the DT N
DYDR NNP N
group NN N
. . N

Factor NNP N
VIIa NNP N
was VBD N
increased VBN N
in IN N
the DT N
DYDR NNP N
group NN N
only RB N
. . N

Plasminogen NN N
levels NNS N
were VBD N
also RB N
increased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
increase NN N
in IN N
the DT N
T-group NNP N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
in IN N
lipid JJ N
variables NNS N
between IN N
the DT N
different JJ N
regimens NNS N
. . N

Changes NNS N
in IN N
total JJ N
cholesterol NN N
and CC N
LDL NNP N
cholesterol NN N
were VBD N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
factor NN N
VIIc NNP N
in IN N
the DT N
DYDR NNP N
group NN N
and CC N
negatively RB N
with IN N
changes NNS N
in IN N
factor NN N
VIIc NNP N
in IN N
the DT N
T-group NNP N
. . N

Trigemestone NN N
was VBD N
associated VBN N
with IN N
a DT N
better JJR N
bleeding NN N
pattern NN N
. . N

CONCLUSIONS NNP N
Trimegestone NNP N
was VBD N
associated VBN N
with IN N
less RBR N
procoagulant JJ N
changes NNS N
in IN N
factor NN N
VIIa NNP N
and CC N
factor NN N
VIIc NNP N
activity NN N
and CC N
larger JJR N
decrease NN N
in IN N
PAI-1 NNP N
activity NN N
compared VBN N
with IN N
the DT N
dydrogesterone NN N
preparation NN N
. . N

These DT N
results NNS N
reflect VBP N
less JJR N
androgenic JJ N
properties NNS N
of IN N
the DT N
trimegestone NN N
preparation NN N
. . N

The DT N
fibrinogen NN N
level NN N
and CC N
Lp NNP N
( ( N
a DT N
) ) N
were VBD N
more JJR N
decreased JJ N
during IN N
dydrogesterone NN N
treatment NN N
. . N

Further JJ N
investigation NN N
is VBZ N
required VBN N
to TO N
clarify VB N
the DT N
relative JJ N
importance NN N
of IN N
beneficial JJ N
effects NNS N
with IN N
respect NN N
to TO N
cardiovascular JJ N
risk NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
effects NNS N
of IN N
terazosin NN 3_i
and CC N
enalapril NN 3_i
on IN N
laboratory NN N
stress NN N
testing VBG N
blood NN N
pressure NN N
in IN N
patients NNS N
with IN N
essential JJ N
hypertension NN N
. . N

It PRP N
is VBZ N
the DT N
current JJ N
opinion NN N
that IN N
an DT N
ideal JJ N
antihypertensive JJ 3_i
drug NN 3_i
should MD N
reduce VB N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
not RB N
only RB N
at IN N
rest NN N
but CC N
also RB N
during IN N
stressful JJ N
situations NNS N
. . N

The DT N
current JJ N
study NN N
was VBD N
aimed VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
selective JJ 3_i
alpha NN 3_i
1-adrenergic JJ 3_i
blocker NN 3_i
terazosin NN 3_i
( ( N
5 CD N
mg NN N
once RB N
daily JJ N
) ) N
and CC N
of IN N
the DT N
angiotensin-converting JJ 3_i
enzyme NN 3_i
inhibitor NN 3_i
enalapril NN 3_i
( ( N
20 CD N
mg NN N
once RB N
daily RB N
) ) N
on IN N
cardiovascular JJ N
response NN N
to TO N
a DT N
set NN N
of IN N
standardized JJ N
laboratory NN N
stressors NNS N
, , N
such JJ N
as IN N
mental JJ N
arithmetic JJ N
, , N
handgrip JJ N
test NN N
and CC N
cycle NN N
ergometry NN N
, , N
in IN N
a DT N
group NN N
of IN N
16 CD N
essential JJ N
hypertensive JJ N
patients NNS N
. . N

The DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
trial NN N
preceded VBN N
by IN N
a DT N
placebo JJ 7_i
run-in JJ N
period NN N
. . N

Terazosin NNP 3_i
and CC N
enalapril VB 3_i
had VBD N
a DT N
comparable JJ N
effect NN N
on IN N
resting VBG N
BP NNP N
, , N
reducing VBG N
systolic JJ N
( ( N
SBP NNP N
) ) N
and CC N
diastolic JJ N
( ( N
DBP NNP N
) ) N
blood NN N
pressure NN N
from IN N
159.5 CD N
+/- JJ N
13.9/101.6 CD N
+/- JJ N
8.8 CD N
mm NN N
Hg NNP N
during IN N
placebo NN N
by IN N
7.8 CD N
% NN N
/6.7 CC N
% NN N
and CC N
by IN N
11.3 CD N
% NN N
/10.2 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
response NN N
rate NN N
to TO N
the DT N
two CD N
treatments NNS N
was VBD N
approximately RB N
the DT N
same JJ N
, , N
being VBG N
69 CD N
% NN N
and CC N
75 CD N
% NN N
after IN N
terazosin NN 3_i
and CC N
enalapril NN 3_i
, , N
respectively RB N
. . N

During IN N
mental JJ N
arithmetic JJ N
, , N
from IN N
an DT N
average NN N
of IN N
181.6 CD N
+/- JJ N
17.8/118.6 CD N
+/- JJ N
11.5 CD N
mm NN N
Hg NNP N
during IN N
placebo NN 7_i
, , N
BP NNP N
was VBD N
reduced VBN N
by IN N
11.5 CD N
% NN N
/7.9 CD N
% NN N
after IN N
terazosin NN 3_i
and CC N
by IN N
13.6 CD N
% NN N
/8.5 CD N
% NN N
after IN N
enalapril NN 3_i
; : N
during IN N
handgrip NN N
test NN N
, , N
BP NNP N
decreased VBD N
from IN N
207.2 CD N
+/- JJ N
22.2/142.2 CD N
+/- JJ N
13.6 CD N
mm NN N
Hg NNP N
by IN N
7.3 CD N
% NN N
/8.4 CD N
% NN N
after IN N
terazosin NN 3_i
and CC N
by IN N
7.7 CD N
% NN N
/7.1 CD N
% NN N
after IN N
enalapril NN 3_i
; : N
finally RB N
, , N
during IN N
cycle NN N
ergometry NN N
, , N
terazosin NN N
and CC N
enalapril NN N
lowered VBN N
BP NNP N
by IN N
5.4 CD N
% NN N
/6.7 CC N
% NN N
and CC N
7 CD N
% NN N
/3.1 CD N
% NN N
, , N
respectively RB N
, , N
from IN N
a DT N
placebo NN 7_i
value NN N
of IN N
215.5 CD N
+/- JJ N
17.3/127.6 CD N
+/- JJ N
11.2 CD N
. . N

No DT N
significant JJ N
difference NN N
in IN N
antihypertensive JJ N
efficacy NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
drugs NNS N
, , N
either RB N
at IN N
rest NN N
and CC N
during IN N
stress JJ N
testing VBG N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Randomized NNP N
clinical JJ N
study NN N
comparing VBG N
Compeed NNP 3_i
cold VBD 3_i
sore RB 3_i
patch NN 3_i
to TO N
acyclovir VB 3_i
cream RB 3_i
5 CD 3_i
% NN 3_i
in IN N
the DT N
treatment NN N
of IN N
herpes NNS N
simplex JJ N
labialis NN N
. . N

BACKGROUND NNP N
Hydrocolloid NNP N
technology NN N
has VBZ N
been VBN N
proven RB N
effective JJ N
in IN N
treating VBG N
dermal JJ N
wounds NNS N
. . N

A DT N
previous JJ N
study NN N
showed VBD N
that IN N
a DT N
newly RB N
developed VBN N
thin JJ 3_i
hydrocolloid NN 3_i
patch NN 3_i
[ NNP 3_i
Compeed NNP 3_i
cold VBD 3_i
sore RB 3_i
patch NN 3_i
( ( 3_i
CSP NNP 3_i
) ) 3_i
] NN 3_i
provided VBD N
multiple JJ N
wound-healing JJ N
benefits NNS N
across IN N
all DT N
stages NNS N
of IN N
a DT N
herpes NNS N
simplex JJ N
labialis NN N
( ( N
HSL NNP N
) ) N
outbreak NN N
. . N

METHODS NNP N
An DT N
assessment NN N
of IN N
CSP NNP N
efficacy NN N
and CC N
safety NN N
was VBD N
conducted VBN N
in IN N
an DT N
international JJ N
, , N
multicentre JJ N
, , N
assessor-blinded JJ N
study NN N
, , N
which WDT N
enrolled VBD N
728 CD N
subjects NNS N
with IN N
a DT N
history NN N
of IN N
recurrent NN N
HSL NNP N
. . N

Of IN N
these DT N
, , N
351 CD N
experienced VBD N
an DT N
HSL NNP N
outbreak NN N
and CC N
were VBD N
randomized VBN N
to TO N
use VB N
CSP NNP N
( ( N
n JJ N
= NNP N
179 CD N
) ) N
or CC N
acyclovir JJ 3_i
cream NN 3_i
5 CD 3_i
% NN 3_i
( ( N
n JJ N
= NNP N
172 CD N
) ) N
at IN N
the DT N
onset NN N
of IN N
symptoms NNS N
until IN N
the DT N
lesion NN N
healed VBD N
, , N
for IN N
a DT N
maximum NN N
of IN N
10 CD N
days NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
subject NN N
's POS N
global JJ N
assessment NN N
of IN N
therapy NN N
( ( N
SGAT NNP N
; : N
0-10 JJ N
scale NN N
; : N
0 CD N
= IN N
no DT N
response NN N
, , N
10 CD N
= JJ N
excellent JJ N
response NN N
) ) N
. . N

Multiple NNP N
secondary JJ N
end NN N
points NNS N
included VBD N
clinician-assessed JJ N
healing NN N
time NN N
and CC N
subject JJ N
assessment NN N
of IN N
lesion NN N
protection NN N
, , N
noticeability NN N
and CC N
social JJ N
embarrassment NN N
. . N

RESULTS NNP N
CSP NNP 3_i
and CC N
acyclovir NNS 3_i
were VBD N
highly RB N
effective JJ N
( ( N
mean JJ N
SGAT NNP N
= NNP N
7.89 CD N
and CC N
8.00 CD N
, , N
respectively RB N
) ) N
, , N
with IN N
no DT N
significant JJ N
difference NN N
observed VBD N
( ( N
P NNP N
= NNP N
0.65 CD N
) ) N
. . N

The DT N
difference NN N
in IN N
healing VBG N
times NNS N
between IN N
products NNS N
was VBD N
not RB N
significant JJ N
( ( N
median JJ N
, , N
7.57 CD N
days NNS N
with IN N
CSP NNP N
vs. FW N
7.03 CD N
days NNS N
with IN N
acyclovir NN N
, , N
P NNP N
= NNP N
0.37 CD N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
. . N

CONCLUSION NNP N
CSP NNP 3_i
using VBG 3_i
hydrocolloid JJ 3_i
technology NN 3_i
provides VBZ N
an DT N
efficacious JJ N
and CC N
safe JJ N
alternative NN N
to TO N
topical JJ N
antivirals NNS N
in IN N
treating VBG N
HSL NNP N
as IN N
a DT N
wound NN N
while IN N
affording VBG N
additional JJ N
immediate JJ N
benefits NNS N
of IN N
wound NN N
protection NN N
, , N
discretion NN N
and CC N
relief NN N
of IN N
social JJ N
embarrassment NN N
. . N

-DOCSTART- -X- O O

New NNP 1_i
mini-extracorporeal JJ 1_i
circulation NN 1_i
system NN 1_i
( ( 1_i
ECC.O NNP 1_i
) ) 1_i
is VBZ N
a DT N
safe JJ N
technique NN N
in IN N
coronary JJ N
surgery NN N
. . N

OBJECTIVES NNP N
Cardiopulmonary NNP 1_i
bypass NN 1_i
( ( 1_i
CPB NNP 1_i
) ) 1_i
is VBZ N
known VBN N
to TO N
cause VB N
the DT N
systemic JJ N
inflammatory NN N
reaction NN N
after IN N
cardiac JJ N
surgery NN N
. . N

New NNP N
coated VBD N
and CC N
closed VBD N
loop NN N
circuit NN N
systems NNS N
may MD N
reduce VB N
this DT N
inflammation NN N
response NN N
and CC N
improve VB N
the DT N
surgical JJ N
outcome NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
mini-extracorporeal JJ 1_i
circulation NN 1_i
system NN 1_i
( ( 1_i
ECC.O NNP 1_i
) ) 1_i
in IN N
CABG NNP N
patients NNS N
. . N

DESIGN NNP N
Forty NNP N
patients NNS N
undergoing VBG N
elective JJ N
coronary JJ N
surgery NN N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
ECC.O NNP 2_i
group NN 2_i
and CC 2_i
the DT 2_i
standard JJ 7_i
CPB NNP 7_i
group NN 7_i
. . N

Routine NNP N
hemodynamic JJ N
monitoring NN N
and CC N
biochemical JJ N
measurements NNS N
were VBD N
registered VBN N
according VBG N
to TO N
the DT N
hospital NN N
practice NN N
. . N

RESULTS VB N
The DT N
clinical JJ N
outcome NN N
of IN N
the DT N
patients NNS N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
the DT N
duration NN N
of IN N
intubation NN N
following VBG N
surgery NN N
, , N
the DT N
length NN N
of IN N
intensive JJ N
care NN N
unit-stay JJ N
or CC N
the DT N
total JJ N
hospital NN N
stay NN N
. . N

The DT N
haemoglobin JJ N
level NN N
was VBD N
significantly RB N
higher JJR N
( ( N
p=0.0069 NN N
) ) N
during IN N
and CC N
after IN N
the DT N
perfusion NN N
in IN N
the DT N
ECC.O NNP 2_i
group NN N
. . N

CONCLUSIONS VB N
The DT N
ECC.O NNP 2_i
system NN N
can MD N
be VB N
safely RB N
used VBN N
in IN N
CABG NNP N
patients NNS N
and CC N
it PRP N
maintains VBZ N
haemoglobin JJ N
level NN N
better RBR N
than IN N
conventional JJ N
CPB NNP 2_i
. . N

-DOCSTART- -X- O O

Does VBZ N
short-term JJ N
treatment NN N
with IN N
proton NN 3_i
pump NN 3_i
inhibitors NNS 3_i
cause VBP N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
? . N
BACKGROUND NNP N
Rebound NNP N
acid VBZ N
hypersecretion NN N
might MD N
occur VB N
after IN N
treatment NN N
with IN N
proton NN 3_i
pump NN 3_i
inhibitors NNS 3_i
. . N

This DT N
study NN N
looks VBZ N
for IN N
a DT N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
after IN N
short-term JJ N
treatment NN N
with IN N
lansoprazole NN 3_i
. . 3_i

STUDY NNP N
Sixty-two JJ N
patients NNS N
( ( N
19 CD N
men NNS N
and CC N
43 CD N
women NNS N
; : N
mean JJ N
age NN N
, , N
54 CD N
years NNS N
; : N
range NN N
, , N
32-77 CD N
years NNS N
) ) N
with IN N
heartburn NN N
and CC N
regurgitation NN N
and CC N
normal JJ N
upper JJ N
endoscopy NN N
findings NNS N
were VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
trial NN N
with IN N
a DT N
crossover NN N
design NN N
. . N

There EX N
were VBD N
two CD N
5-day JJ N
treatment NN N
periods NNS N
with IN N
lansoprazole JJ 3_i
60 CD 3_i
mg NN 3_i
once RB 3_i
daily JJ 3_i
or CC N
placebo NN 7_i
in IN N
random JJ N
order NN N
, , N
separated VBN N
by IN N
a DT N
9-day JJ N
washout NN N
period NN N
. . N

Reflux NNP N
, , N
total JJ N
, , N
and CC N
antacid JJ N
scores NNS N
were VBD N
calculated VBN N
for IN N
each DT N
of IN N
the DT N
treatment NN N
periods NNS N
. . N

Higher JJR N
scores NNS N
during IN N
the DT N
placebo JJ 7_i
period NN N
in IN N
the DT N
group NN N
given VBN N
lansoprazole VBZ 3_i
first RB N
than IN N
in IN N
the DT N
group NN N
given VBN N
placebo VBP N
first RB N
indicated VBN N
a DT N
rebound NN N
aggravation NN N
of IN N
symptoms NNS N
. . N

RESULTS VB N
The DT N
mean JJ N
symptom NN N
scores NNS N
during IN N
the DT N
placebo JJ 7_i
period NN N
in IN N
the DT N
groups NNS N
given VBN N
lansoprazole VBP N
first JJ N
and CC N
placebo NN N
first RB N
were VBD N
as IN N
follows VBZ N
: : N
reflux NN N
score NN N
, , N
21.5 CD N
and CC N
17.6 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
; : N
total JJ N
score NN N
, , N
11.2 CD N
and CC N
10.3 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
; : N
and CC N
antacid VB N
score NN N
, , N
8.2 CD N
and CC N
7.2 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
no DT N
indication NN N
of IN N
a DT N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
12 CD N
to TO N
14 CD N
days NNS N
after IN N
a DT N
5-day JJ N
treatment NN N
with IN N
lansoprazole JJ 3_i
60 CD N
mg NN N
once RB N
daily JJ N
in IN N
patients NNS N
with IN N
reflux NN N
symptoms NNS N
. . N

-DOCSTART- -X- O O

Bronchodilatory JJ N
responses NNS N
to TO N
formoterol VB 3_i
, , N
ipratropium NN 3_i
, , N
and CC N
their PRP$ N
combination NN 3_i
in IN N
patients NNS N
with IN N
stable JJ N
COPD NNP N
. . N

We PRP N
studied VBD N
27 CD N
patients NNS N
with IN N
stable JJ N
chronic JJ N
obstuctive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
in IN N
a DT N
randomised JJ N
, , N
single-blind JJ N
, , N
within-patient JJ N
, , N
placebo-controlled JJ 7_i
clinical JJ N
study NN N
. . N

Each DT N
patient NN N
was VBD N
assigned VBN N
on IN N
six CD N
separate JJ N
days NNS N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
drug NN N
regimens NNS N
in IN N
random JJ N
order NN N
: : N
A DT N
. . N

40 CD N
micrograms JJ N
ipratropium NN 3_i
bromide NN 3_i
( ( 3_i
Atrovent NNP 3_i
MDI NNP 3_i
, , 3_i
20 CD 3_i
micrograms/puff NN 3_i
) ) 3_i
plus CC N
2 CD 7_i
puffs NNS 7_i
placebo NN 7_i
; : N
B NNP N
. . N

12 CD N
micrograms NNS N
formoterol JJ 3_i
fumarate NN 3_i
( ( 3_i
Foradil NNP 3_i
MDI NNP 3_i
, , 3_i
12 CD 3_i
micrograms/puff NN 3_i
) ) 3_i
plus CC N
3 CD 7_i
puffs NNS 7_i
placebo VBP 7_i
; : N
C. NNP N
80 CD 3_i
micrograms NNS 3_i
ipratropium NN 3_i
; : N
D. NNP N
24 CD 3_i
micrograms NNS 3_i
formoterol JJ 3_i
plus CC 3_i
2 CD 3_i
puffs NNS 3_i
placebo VBP 3_i
; : N
E. NNP N
12 CD 3_i
micrograms NNS 3_i
formoterol JJ 3_i
plus CC N
40 CD 3_i
micrograms NNS 3_i
ipratropium JJ 3_i
plus CC N
1 CD 7_i
puff NN 7_i
placebo NN 7_i
; : N
F. NNP N
4 CD 7_i
puffs NNS 7_i
placebo NN 7_i
. . N

On IN N
each DT N
study NN N
day NN N
, , N
spirometric JJ N
indices NNS N
and CC N
vital JJ N
signs NNS N
were VBD N
measured VBN N
at IN N
5 CD N
, , N
10 CD N
, , N
15 CD N
and CC N
60 CD N
minutes NNS N
, , N
and CC N
hourly RB N
thereafter RB N
up IN N
to TO N
and CC N
including VBG N
12 CD N
hours NNS N
after IN N
study JJ N
drug NN N
administration NN N
. . N

Mean NNP N
peak JJ N
FEV1 NNP N
change NN N
( ( N
primary JJ N
endpoint NN N
) ) N
was VBD N
maximum JJ N
with IN N
the DT N
administration NN N
of IN N
the DT N
combination NN N
of IN N
ipratropium NN 3_i
and CC N
formoterol NN 3_i
( ( N
335.2 CD N
ml NN N
, , N
SE NNP N
24.6 CD N
) ) N
, , N
and CC N
it PRP N
differed VBD N
significantly RB N
from IN N
the DT N
observed JJ N
peak NN N
changes NNS N
following VBG N
single JJ N
administration NN N
of IN N
the DT N
two CD N
tested VBD N
doses NNS N
of IN N
ipratropium NN 3_i
( ( N
p JJ N
< NN N
0.05 CD N
and CC N
p VB N
< JJ N
0.05 CD N
respectively RB N
) ) N
. . N

Safety NN N
and CC N
tolerability NN N
were VBD N
satisfactory JJ N
throughout IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

Immediately RB N
restored VBN N
, , N
single-tapered JJ N
implants NNS 2_i
in IN N
the DT N
anterior JJ N
maxilla NN N
: : N
prosthodontic JJ N
and CC N
aesthetic JJ N
outcomes NNS N
after IN N
1 CD N
year NN N
. . N

BACKGROUND NNP N
Conventional NNP N
implant JJ N
protocols NNS N
advocate VBP N
a DT N
two-stage NN N
technique NN N
with IN N
a DT N
load-free JJ N
, , N
submerged VBD N
healing JJ N
period NN N
. . N

Recent JJ N
studies NNS N
suggest VBP N
that IN N
immediate JJ N
restoration NN N
of IN N
single JJ N
implants NNS N
may MD N
be VB N
a DT N
viable JJ N
treatment NN N
option NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
prosthodontic JJ N
and CC N
aesthetic JJ N
peri-implant JJ N
mucosal NN N
outcomes NNS N
of IN N
immediately RB N
restored VBN N
, , N
Southern JJ N
single-tapered JJ N
implants NNS 2_i
in IN N
the DT N
anterior JJ N
maxilla NN N
after IN N
1 CD N
year NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Participants NNP N
( ( N
mean JJ N
age NN N
: : N
43.25 CD N
years NNS N
; : N
range NN N
: : N
23-71 JJ N
years NNS N
) ) N
satisfying VBG N
specified VBN N
inclusion NN N
criteria NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
conventional JJ N
two-stage JJ 2_i
restoration NN 2_i
( ( N
control NN N
group NN N
; : N
n=14 CC N
) ) N
and CC N
immediate JJ N
restoration NN N
groups NNS N
( ( N
test NN N
group NN N
; : N
n CC N
=14 NN N
) ) N
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

Tapered VBN N
, , N
roughened-surface JJ N
Southern JJ N
implants NNS N
were VBD N
placed VBN N
using VBG N
a DT N
standardized JJ N
technique NN N
, , N
and CC N
implant JJ N
level NN N
bone NN N
impressions NNS N
were VBD N
made VBN N
. . N

Provisional JJ N
screw-retained JJ N
crowns NNS N
, , N
out IN N
of IN N
occlusion NN N
, , N
were VBD N
placed VBN N
at IN N
second-stage NN N
surgery NN N
after IN N
26 CD N
weeks NNS N
for IN N
the DT N
conventional JJ N
restoration NN N
group NN N
, , N
and CC N
within IN N
4 CD N
hours NNS N
of IN N
implant JJ N
placement NN N
for IN N
the DT N
immediate JJ N
restoration NN N
group NN N
. . N

Both DT N
groups NNS N
had VBD N
definitive JJ N
screw-retained JJ N
metal-ceramic JJ N
crowns NNS N
placed VBN N
in IN N
occlusion NN N
8 CD N
weeks NNS N
later RB N
. . N

Peri-implant JJ N
mucosal NN N
response NN N
and CC N
papilla NN N
index NN N
were VBD N
recorded VBN N
4 CD N
weeks NNS N
after IN N
definitive JJ N
crown JJ N
placement NN N
to TO N
allow VB N
for IN N
mucosal JJ N
maturation NN N
and CC N
at IN N
1 CD N
year NN N
. . N

Prosthodontic NNP N
and CC N
aesthetic JJ N
outcomes NNS N
were VBD N
assessed VBN N
using VBG N
established VBN N
criteria NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
within IN N
, , N
or CC N
between IN N
, , N
the DT N
control NN N
and CC N
test NN N
groups NNS N
for IN N
age NN N
, , N
gender NN N
, , N
bone NN N
quality NN N
or CC N
quantity NN N
, , N
implant JJ N
stability NN N
measurements NNS N
at IN N
surgery NN N
, , N
or CC N
implant JJ N
length NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
implant JJ N
success NN N
rate NN N
as IN N
determined VBN N
by IN N
radiographic JJ N
bone NN N
loss NN N
and CC N
stability NN N
tests NNS N
after IN N
1 CD N
year NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
prosthodontic JJ N
maintenance NN N
, , N
peri-implant JJ N
mucosal NN N
response NN N
, , N
and CC N
papilla NN N
index NN N
between IN N
the DT N
two CD N
groups NNS N
over IN N
1 CD N
year NN N
. . N

CONCLUSIONS NNP N
Tapered NNP N
, , N
roughened-surface JJ N
implants NNS N
immediately RB N
restored VBN N
with IN N
single JJ N
provisional JJ N
crowns NNS N
at IN N
surgery NN N
and CC N
definitive JJ N
crowns NNS N
8 CD N
weeks NNS N
later RB N
were VBD N
as IN N
prosthodontically RB N
and CC N
aesthetically RB N
successful JJ N
as IN N
conventionally RB N
restored VBN N
two-stage JJ N
implants NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
service NN N
. . N

Restoring VBG 2_i
single JJ N
implants NNS N
immediately RB N
with IN N
screw-retained JJ N
crowns NNS N
is VBZ N
an DT N
efficient JJ N
procedure NN N
, , N
but CC N
the DT N
short-term JJ N
outcome NN N
is VBZ N
by IN N
no DT N
means NNS N
superior VBP N
to TO N
a DT N
conventional JJ N
two-stage JJ N
approach NN N
. . N

-DOCSTART- -X- O O

Adjuvant NNP N
goserelin NN N
and CC N
ovarian JJ N
preservation NN N
in IN N
chemotherapy NN N
treated VBD N
patients NNS N
with IN N
early JJ N
breast NN N
cancer NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
study NN N
was VBD N
to TO N
examine VB N
if IN N
goserelin JJ N
concomitant NN N
to TO N
CMF-chemotherapy NNP N
as IN N
adjuvant JJ N
treatment NN N
for IN N
premenopausal NN N
breast NN N
cancer NN N
, , N
protects VBZ N
the DT N
ovaries NNS N
from IN N
premature JJ N
failure NN N
. . N

A DT N
total NN N
of IN N
285 CD N
premenopausal NN N
breast NN N
cancer NN N
patients NNS N
, , N
in IN N
a DT N
randomized JJ N
adjuvant JJ N
trial NN N
( ( N
Zoladex NNP 3_i
in IN N
premenopausal NN N
patients NNS N
( ( N
ZIPP NNP N
) ) N
) ) N
, , N
were VBD N
assigned VBN N
to TO N
a DT N
study NN N
on IN N
ovarian JJ N
function NN N
. . N

Node NNP N
positive JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
CMF- NNP 3_i
( ( 3_i
cyclophosphamide NN 3_i
, , 3_i
methotrexate NN 3_i
and CC 3_i
5-fluorouracil NN 3_i
) ) 3_i
chemotherapy NN 3_i
in IN N
addition NN N
to TO N
endocrine VB 3_i
therapy NN 3_i
. . N

All DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
2 CD N
years NNS N
of IN N
goserelin NN 3_i
, , 3_i
goserelin NN 3_i
plus CC 3_i
tamoxifen NN 3_i
, , 3_i
tamoxifen VB 3_i
alone RB 3_i
or CC N
no DT 7_i
endocrine JJ 7_i
treatment NN 7_i
. . N

We PRP N
studied VBD N
, , N
if IN N
menses NNS N
were VBD N
affected VBN N
in IN N
the DT N
treatment NN N
groups NNS N
, , N
up RB N
to TO N
36 CD N
months NNS N
after IN N
randomization NN N
. . N

One CD N
year NN N
after IN N
completed VBN N
CMF- NNP N
and CC N
endocrine JJ N
therapy NN N
, , N
36 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
goserelin NN N
group NN N
reported VBD N
menses NNS N
, , N
compared VBN N
to TO N
7 CD N
% NN N
in IN N
the DT N
goserelin NN N
plus CC N
tamoxifen JJ N
group NN N
, , N
13 CD N
% NN N
in IN N
the DT N
tamoxifen NN N
group NN N
and CC N
10 CD N
% NN N
of IN N
the DT N
controls NNS N
. . N

Among IN N
women NNS N
treated VBN N
with IN N
goserelin NN N
, , N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
the DT N
proportion NN N
of IN N
menstruating VBG N
women NNS N
, , N
1 CD N
year NN N
after IN N
completed VBN N
treatment NN N
compared VBN N
to TO N
at IN N
24 CD N
months NNS N
of IN N
treatment NN N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
in IN N
contrast NN N
to TO N
all DT N
other JJ N
treatment NN N
groups NNS N
, , N
who WP N
were VBD N
unchanged JJ N
or CC N
more RBR N
often RB N
amenorrheic JJ N
. . N

In IN N
our PRP$ N
study NN N
, , N
there EX N
is VBZ N
some DT N
evidence NN N
of IN N
protective JJ N
effect NN N
of IN N
goserelin NN N
on IN N
ovarian JJ N
function NN N
in IN N
CMF NNP N
treated VBD N
women NNS N
. . N

This DT N
effect NN N
was VBD N
not RB N
observed VBN N
in IN N
the DT N
combined JJ N
tamoxifen NN N
and CC N
goserelin NN N
treatment NN N
. . N

-DOCSTART- -X- O O

Ipratropium NNP 3_i
bromide NN 3_i
nasal NN 3_i
spray NN 3_i
for IN N
treatment NN N
of IN N
rhinorrhea NN N
in IN N
the DT N
laryngectomized JJ N
patient NN N
: : N
a DT N
pilot NN N
study NN N
. . N

Many NNP N
who WP N
have VBP N
had VBD N
a DT N
total JJ N
laryngectomy NN N
complain NN N
of IN N
unrelenting VBG N
rhinorrhea NN N
that WDT N
is VBZ N
often RB N
very RB N
difficult JJ N
to TO N
control VB N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
ipratropium NN 3_i
bromide NN 3_i
( ( 3_i
IB NNP 3_i
) ) 3_i
, , N
an DT N
anticholinergic JJ N
nasal NN N
spray NN N
, , N
on IN N
rhinorrhea NN N
in IN N
these DT N
patients NNS N
. . N

This DT N
was VBD N
designed VBN N
as IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
, , N
crossover NN N
pilot NN N
study NN N
. . N

Participants NNS N
were VBD N
selected VBN N
if IN N
they PRP N
had VBD N
a DT N
total JJ N
laryngectomy NN N
and CC N
complained VBD N
of IN N
rhinorrhea NN N
. . N

They PRP N
were VBD N
asked VBN N
to TO N
rate NN N
the DT N
severity NN N
and CC N
duration NN N
of IN N
their PRP$ N
rhinorrhea JJ N
each DT N
day NN N
throughout IN N
the DT N
study NN N
on IN N
a DT N
scale NN N
from IN N
zero CD N
to TO N
six CD N
. . N

Each DT N
participant NN N
was VBD N
initially RB N
given VBN N
a DT N
saline NN 7_i
nasal NN 7_i
spray NN 7_i
for IN N
one CD N
week NN N
. . N

They PRP N
were VBD N
then RB N
randomized VBN N
to TO N
use VB N
either DT N
IB NNP 3_i
or CC N
saline NN 7_i
for IN N
the DT N
double-blinded JJ N
portion NN N
of IN N
the DT N
study NN N
. . N

Two CD N
sprays NNS N
of IN N
IB NNP 3_i
at IN N
a DT N
dose NN N
of IN N
42 CD N
micrograms/spray NN N
( ( N
0.06 CD N
% NN N
) ) N
, , N
or CC N
saline NN 7_i
, , N
were VBD N
administered VBN N
intranasally RB N
twice JJ N
daily RB N
for IN N
two CD N
weeks NNS N
, , N
after IN N
which WDT N
time NN N
the DT N
participants NNS N
were VBD N
given VBN N
another DT N
nasal NN N
spray NN N
( ( N
either CC N
IB NNP 3_i
or CC N
saline NN 7_i
) ) N
for IN N
the DT N
crossover NN N
portion NN N
of IN N
the DT N
study NN N
. . N

Six CD N
patients NNS N
entered VBD N
and CC N
completed VBD N
the DT N
study NN N
. . N

Those DT N
patients NNS N
using VBG N
the DT N
IB NNP N
recorded VBD N
a DT N
mean JJ N
55 CD N
% NN N
decline NN N
in IN N
severity NN N
and CC N
a DT N
mean JJ N
51 CD N
% NN N
decline NN N
in IN N
duration NN N
of IN N
the DT N
rhinorrhea NN N
as IN N
compared VBN N
to TO N
placebo VB N
. . N

The DT N
relief NN N
in IN N
both DT N
severity NN N
and CC N
duration NN N
of IN N
rhinorrhea NN N
obtained VBN N
by IN N
patients NNS N
was VBD N
analyzed VBN N
using VBG N
the DT N
Wilcoxon NNP N
signed-rank JJ N
test NN N
and CC N
found VBN N
to TO N
be VB N
highly RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Despite IN N
the DT N
limitations NNS N
of IN N
a DT N
small JJ N
sample NN N
size NN N
in IN N
this DT N
study NN N
, , N
ipratropium NN N
bromide NN N
nasal NN N
spray NN N
significantly RB N
reduced VBD N
both DT N
the DT N
severity NN N
and CC N
duration NN N
of IN N
rhinorrhea NN N
in IN N
laryngectomized JJ N
patients NNS N
. . N

We PRP N
suggest VBP N
ipratropium JJ N
nasal NN N
spray NN N
as IN N
a DT N
safe JJ N
, , N
effective JJ N
way NN N
to TO N
treat VB N
chronic JJ N
rhinorrhea NN N
in IN N
laryngectomized JJ N
patients NNS N
, , N
improving VBG N
their PRP$ N
quality NN N
of IN N
life NN N
. . N

-DOCSTART- -X- O O

Do VBP N
readers NNS N
with IN N
autism NN N
make VBP N
bridging VBG N
inferences NNS N
from IN N
world NN N
knowledge NN N
? . N
Individuals NNS N
with IN N
autism NN N
frequently RB N
show VBP N
impairments NNS N
in IN N
text JJ N
reading NN N
comprehension NN N
. . N

This DT N
often RB N
is VBZ N
attributed VBN N
to TO N
poor JJ N
ability NN N
to TO N
draw VB N
inferences NNS N
during IN N
reading NN N
and CC N
to TO N
inadequate VB N
access NN N
to TO N
relevant VB N
knowledge NN N
. . N

The DT N
current JJ N
study NN N
tested VBD N
this DT N
hypothesis NN N
by IN N
measuring VBG N
the DT N
time NN N
taken VBN N
to TO N
read VB 4_i
the DT 4_i
same JJ 4_i
question NN 4_i
, , 4_i
relating VBG 4_i
to TO 4_i
either DT 4_i
physical JJ 4_i
or CC 4_i
social JJ 4_i
world NN 4_i
knowledge NN 4_i
, , 4_i
when WRB 4_i
it PRP 4_i
was VBD 4_i
either CC 4_i
relevant JJ 4_i
or CC 4_i
irrelevant JJ 4_i
to TO 4_i
the DT 4_i
bridging NN 4_i
inference NN 4_i
evoked VBN 4_i
by IN 4_i
a DT 4_i
preceding VBG 4_i
two-sentence NN 4_i
vignette NN 4_i
. . N

In IN N
the DT N
study NN N
, , N
16 CD N
normally RB N
developing VBG N
adolescents NNS N
and CC N
16 CD N
adolescents NNS N
with IN N
autism NN N
were VBD N
matched VBN N
on IN N
word NN N
reading NN N
accuracy NN N
, , N
chronological JJ N
age NN N
, , N
and CC N
vocabulary JJ N
but CC N
differed VBD N
significantly RB N
in IN N
text JJ N
comprehension NN N
. . N

A DT N
strong JJ N
priming NN N
effect NN N
was VBD N
found VBN N
, , N
robust VBZ N
over IN N
participants NNS N
and CC N
over IN N
items NNS N
; : N
participants NNS N
read VBP N
those DT N
questions NNS N
that WDT N
were VBD N
relevant JJ N
to TO N
the DT N
inference NN N
evoked VBN N
by IN N
the DT N
vignette NN N
faster RBR N
than IN N
they PRP N
read VBP N
those DT N
questions NNS N
that WDT N
were VBD N
irrelevant JJ N
, , N
and CC N
no DT N
interaction NN N
with IN N
group NN N
membership NN N
or CC N
type NN N
of IN N
knowledge NN N
was VBD N
found VBN N
. . N

This DT N
indicates VBZ N
that IN N
readers NNS N
with IN N
autism NN N
, , N
just RB N
like IN N
controls NNS N
, , N
were VBD N
activating VBG N
appropriate JJ N
world NN N
knowledge NN N
primed VBN N
by IN N
implicit JJ N
inferences NNS N
while IN N
reading VBG N
the DT N
vignettes NNS N
. . N

Thus RB N
, , N
the DT N
comprehension NN N
problems NNS N
in IN N
these DT N
readers NNS N
can MD N
not RB N
be VB N
attributed VBN N
to TO N
an DT N
inability NN N
to TO N
make VB N
implicit JJ N
inferences NNS N
or CC N
to TO N
draw VB N
on IN N
relevant JJ N
world NN N
knowledge NN N
. . N

Instead RB N
, , N
we PRP N
suggest VBP N
that IN N
these DT N
problems NNS N
must MD N
be VB N
sought VBN N
at IN N
a DT N
higher JJR N
level NN N
of IN N
text JJ N
processing NN N
. . N

-DOCSTART- -X- O O

Palliative JJ 2_i
brachytherapy NN 2_i
with IN 1_i
or CC 1_i
without IN 1_i
primary JJ 1_i
stent JJ 1_i
placement NN 1_i
in IN N
patients NNS N
with IN N
oesophageal JJ N
cancer NN N
, , N
a DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
whether IN N
a DT N
combination NN 2_i
of IN 2_i
self-expanding JJ 1_i
metal NN 1_i
stent NN 1_i
( ( 1_i
SEMS NNP 1_i
) ) 1_i
and CC 2_i
brachytherapy NN 2_i
provided VBD N
more RBR N
rapid JJ N
and CC N
prolonged JJ N
effect NN N
on IN N
dysphagia NN N
without IN N
increased VBN N
pain NN N
compared VBN N
to TO N
brachytherapy VB N
alone RB N
in IN N
patients NNS N
with IN N
incurable JJ N
oesophageal JJ N
cancer NN N
. . N

METHODS NNP N
41 CD N
Patients NNPS N
were VBD N
randomised VBN N
to TO N
SEMS NNP N
followed VBN N
by IN N
brachytherapy NN N
, , N
8 CD N
Gy?3 NNP N
( ( N
n=21 NN N
) ) N
or CC N
brachytherapy VB N
alone RB N
, , N
8 CD N
Gy?3 NNP N
( ( N
n=20 NN N
) ) N
. . N

Change NN N
in IN N
dysphagia NN N
and CC N
pain NN N
three CD N
and CC N
seven CD N
weeks NNS N
after IN N
randomisation NN N
( ( N
FU1 NNP N
and CC N
FU2 NNP N
) ) N
was VBD N
assessed VBN N
by IN N
patient-reported JJ N
outcome NN N
. . N

Dysphagia NNP N
, , N
other JJ N
symptoms NNS N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
were VBD N
assessed VBN N
every DT N
four CD N
weeks NNS N
thereafter RB N
. . N

The DT N
study NN N
was VBD N
closed VBN N
before IN N
the DT N
estimated VBN N
patient-number NN N
was VBD N
reached VBN N
due JJ N
to TO N
slow VB N
recruitment NN N
. . N

RESULTS JJ N
Patients NNPS N
receiving VBG N
SEMS NNP N
followed VBN N
by IN N
brachytherapy NN N
had VBD N
significantly RB N
improved VBN N
dysphagia NN N
at IN N
FU1 NNP N
compared VBN N
to TO N
patients NNS N
receiving VBG N
brachytherapy NN N
alone RB N
( ( N
n=35 JJ N
) ) N
. . N

Difference NN N
in IN N
pain NN N
was VBD N
not RB N
observed VBN N
. . N

At IN N
FU2 NNP N
, , N
patients NNS N
in IN N
both DT N
arms NNS N
( ( N
n=21 NN N
) ) N
had VBD N
less JJR N
dysphagia JJ N
. . N

Four CD N
patients NNS N
in IN N
the DT N
combined JJ N
treatment NN N
arm NN N
experienced VBD N
manageable JJ N
complications NNS N
, , N
no DT N
complications NNS N
occurred VBD N
after IN N
brachytherapy NN N
alone RB N
. . N

CONCLUSION NNP N
For IN N
the DT N
relief NN N
of IN N
dysphagia NN N
, , N
SEMS NNP N
followed VBN N
by IN N
brachytherapy NN N
is VBZ N
preferable JJ N
and CC N
safe JJ N
for IN N
patients NNS N
in IN N
need NN N
of IN N
immediate JJ N
alleviation NN N
, , N
while IN N
brachytherapy NN N
with IN N
or CC N
without IN N
preceding VBG N
SEMS NNP N
provides VBZ N
relief NN N
within IN N
a DT N
few JJ N
weeks NNS N
after IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
HIV NNP N
infection NN N
on IN N
tolerability NN N
and CC N
bacteriologic JJ N
outcomes NNS N
of IN N
tuberculosis NN N
treatment NN N
. . N

SETTING NN N
Two CD N
international JJ N
, , N
multicenter JJ N
Phase NNP N
2 CD N
clinical JJ N
trials NNS N
examining VBG N
fluoroquinolone-containing JJ 3_i
regimens NNS 3_i
in IN N
adults NNS N
with IN N
smear-positive JJ N
pulmonary JJ N
tuberculosis NN N
( ( N
TB NNP N
) ) N
, , N
conducted VBN N
from IN N
July NNP N
2003 CD N
to TO N
March NNP N
2007 CD N
. . N

Both DT N
trials NNS N
enrolled VBD N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
infected VBD N
participants NNS N
who WP N
were VBD N
not RB N
receiving VBG N
antiretroviral JJ N
therapy NN N
( ( N
ART NNP N
) ) N
at IN N
TB NNP N
treatment NN N
initiation NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
impact NN N
of IN N
HIV NNP N
infection NN N
on IN N
TB NNP N
treatment NN N
outcomes NNS N
in IN N
Phase NNP N
2 CD N
clinical JJ N
trials NNS N
. . N

DESIGN NNP N
Cross-protocol JJ N
analysis NN N
comparing VBG N
the DT N
safety NN N
, , N
tolerability NN N
and CC N
outcomes NNS N
of IN N
anti-tuberculosis NN 3_i
treatment NN 3_i
by IN N
HIV NNP N
status NN N
. . N

RESULTS NNP N
Of IN N
750 CD N
participants NNS N
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
study NN N
treatment NN N
, , N
123 CD N
( ( N
16 CD N
% NN N
) ) N
were VBD N
HIV-infected JJ N
. . N

Treatment JJ N
completion NN N
rates NNS N
were VBD N
similar JJ N
by IN N
HIV NNP N
status NN N
( ( N
81 CD N
% NN N
infected VBN N
vs. IN N
85 CD N
% NN N
non-infected JJ N
) ) N
, , N
as IN N
were VBD N
rates NNS N
of IN N
week NN N
8 CD N
culture NN N
conversion NN N
( ( N
66 CD N
% NN N
infected VBN N
vs. IN N
63 CD N
% NN N
non-infected JJ N
) ) N
, , N
and CC N
treatment NN N
failure NN N
( ( N
5 CD N
% NN N
infected VBN N
vs. IN N
3 CD N
% NN N
non-infected JJ N
) ) N
. . N

Among IN N
HIV-infected JJ N
participants NNS N
, , N
treatment NN N
failure NN N
detected VBD N
using VBG N
liquid JJ N
media NNS N
was VBD N
more RBR N
frequent JJ N
in IN N
those DT N
treated JJ N
thrice JJ N
weekly JJ N
( ( N
14 CD N
% NN N
thrice JJ N
weekly JJ N
vs. FW N
2 CD N
% NN N
daily RB N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

HIV-infected JJ N
participants NNS N
more RBR N
frequently RB N
experienced VBD N
an DT N
adverse JJ N
event NN N
during IN N
the DT N
intensive JJ N
phase NN N
treatment NN N
than IN N
non-HIV-infected JJ N
participants NNS N
( ( N
30 CD N
% NN N
vs. FW N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
HIV-infected JJ N
persons NNS N
not RB N
receiving VBG N
ART NNP N
had VBD N
more RBR N
adverse JJ N
events NNS N
during IN N
the DT N
intensive JJ N
phase NN N
of IN N
anti-tuberculosis NN N
treatment NN N
, , N
but CC N
tolerated VBD N
treatment NN N
well RB N
. . N

Failure NN N
rates NNS N
were VBD N
higher JJR N
among IN N
HIV-infected JJ N
persons NNS N
treated VBN N
with IN N
thrice-weekly JJ N
intensive JJ N
phase NN N
therapy NN N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
renal JJ N
failure NN N
associated VBN N
with IN N
multiple JJ N
myeloma NN N
. . N

Plasmapheresis NN N
, , N
hemodialysis NN N
, , N
and CC N
chemotherapy NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
the DT N
efficacy NN N
of IN N
plasmapheresis NN N
in IN N
preventing VBG N
irreversible JJ N
renal JJ N
failure NN N
in IN N
patients NNS N
with IN N
multiple JJ N
myeloma NN N
and CC N
to TO N
study VB N
the DT N
renal JJ N
biopsy NN N
tissues NNS N
from IN N
such JJ N
patients NNS N
. . N

Twenty-one CD N
patients NNS N
with IN N
active JJ N
myeloma NN N
and CC N
progressive JJ N
renal JJ N
failure NN N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
: : N
group NN N
1 CD N
, , N
forced VBN 3_i
diuresis NN 3_i
and CC N
chemotherapy NN 3_i
( ( N
10 CD N
patients NNS N
) ) N
, , N
and CC N
group NN N
2 CD N
, , N
forced VBN 3_i
diuresis NN 3_i
, , N
chemotherapy NN 3_i
, , N
and CC N
plasmapheresis NN 2_i
( ( N
11 CD N
patients NNS N
) ) N
. . N

Plasmapheresis NN N
and CC N
chemotherapy NN N
lowered VBD N
the DT N
serum NN N
myeloma NN N
protein IN N
value NN N
much RB N
more RBR N
rapidly RB N
than IN N
chemotherapy VB N
alone JJ N
. . N

Of IN N
5 CD N
patients NNS N
who WP N
were VBD N
oliguric JJ N
and CC N
undergoing JJ N
dialysis NN N
at IN N
presentation NN N
, , N
only RB N
3 CD N
who WP N
were VBD N
treated VBN N
by IN N
plasmapheresis NN N
recovered VBN N
. . N

Of IN N
16 CD N
polyuric JJ N
patients NNS N
, , N
5 CD N
in IN N
group NN N
1 CD N
and CC N
7 CD N
in IN N
group NN N
2 CD N
showed VBD N
improvement NN N
in IN N
renal JJ N
function NN N
. . N

The DT N
main JJ N
factor NN N
that WDT N
determined VBD N
irreversibility NN N
of IN N
renal JJ N
failure NN N
was VBD N
the DT N
severity NN N
of IN N
myeloma NN N
cast NN N
formation NN N
. . N

-DOCSTART- -X- O O

The DT N
Social NNP N
Communication NNP N
Intervention NNP N
Project NNP N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
the DT N
effectiveness NN N
of IN N
speech NN N
and CC N
language NN N
therapy NN N
for IN N
school-age JJ N
children NNS N
who WP N
have VBP N
pragmatic JJ N
and CC N
social JJ N
communication NN N
problems NNS N
with IN N
or CC N
without IN N
autism NN N
spectrum NN N
disorder NN N
. . N

BACKGROUND NNP N
Children NNPS N
who WP N
show VBP N
disproportionate JJ N
difficulty NN N
with IN N
the DT N
pragmatic JJ N
as IN N
compared VBN N
with IN N
the DT N
structural JJ N
aspects NNS N
of IN N
language NN N
are VBP N
described VBN N
as IN N
having VBG N
pragmatic JJ N
language NN N
impairment NN N
( ( N
PLI NNP N
) ) N
or CC N
social JJ N
communication NN N
disorder NN N
( ( N
SCD NNP N
) ) N
. . N

Some DT N
children NNS N
who WP N
have VBP N
PLI NNP N
also RB N
show VBP N
mild JJ N
social JJ N
impairments NNS N
associated VBN N
with IN N
high-functioning JJ N
autism NN N
or CC N
autism NN N
spectrum JJ N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

There EX N
is VBZ N
little JJ N
robust JJ N
evidence NN N
of IN N
effectiveness NN N
of IN N
speech-language NN N
interventions NNS N
which WDT N
target VBP N
the DT N
language NN N
, , N
pragmatic JJ N
or CC N
social JJ N
communication NN N
needs NNS N
of IN N
these DT N
children NNS N
. . N

AIMS NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
an DT N
intensive JJ 4_i
manualized VBN 4_i
social JJ 4_i
communication NN 4_i
intervention NN 4_i
( ( 4_i
SCIP NNP 4_i
) ) 4_i
for IN N
children NNS N
who WP N
have VBP N
PLI VBN N
with IN N
or CC N
without IN N
features NNS N
of IN N
ASD NNP N
. . N

METHODS NNP N
& CC N
PROCEDURES NNP N
In IN N
a DT N
single-blind JJ N
RCT NNP N
design NN N
, , N
88 CD N
children NNS N
with IN N
pragmatic JJ N
and CC N
social JJ N
communication NN N
needs NNS N
aged VBD N
5 CD N
; : N
11-10 JJ N
; : N
8 CD N
, , N
recruited VBN N
from IN N
UK NNP N
speech NN N
and CC N
language NN N
therapy NN N
services NNS N
, , N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
2:1 CD N
ratio NN N
to TO N
SCIP NNP 4_i
or CC N
to TO N
treatment-as-usual JJ 6_i
. . N

Children NNP N
in IN N
the DT N
SCIP NNP 4_i
condition NN N
received VBD N
up RB N
to TO N
20 CD 4_i
sessions NNS 4_i
of IN 4_i
direct JJ 4_i
intervention NN 4_i
from IN 4_i
a DT 4_i
specialist JJ 4_i
research NN 4_i
speech NN 4_i
and CC 4_i
language NN 4_i
therapist NN 4_i
working VBG 4_i
with IN 4_i
supervised JJ 4_i
assistants NNS 4_i
. . N

All DT N
therapy NN N
content NN N
and CC N
methodology NN N
was VBD N
derived VBN N
from IN N
an DT N
intervention NN N
manual NN N
. . N

A DT N
primary JJ N
outcome JJ N
measure NN N
of IN N
structural JJ N
language NN N
and CC N
secondary JJ N
outcome NN N
measures NNS N
of IN N
narrative JJ N
, , N
parent-reported JJ N
pragmatic JJ N
functioning NN N
and CC N
social JJ N
communication NN N
, , N
blind-rated JJ N
perceptions NNS N
of IN N
conversational JJ N
competence NN N
and CC N
teacher-reported JJ N
ratings NNS N
of IN N
classroom NN N
learning VBG N
skills NNS N
were VBD N
taken VBN N
pre-intervention NN N
, , N
immediately RB N
post-intervention NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

OUTCOMES NNP N
& CC N
RESULTS NNP N
No NNP N
significant JJ N
treatment NN N
effect NN N
was VBD N
found VBN N
for IN N
the DT N
primary JJ N
outcome JJ N
measure NN N
of IN N
structural JJ N
language NN N
ability NN N
or CC N
for IN N
a DT N
measure NN N
of IN N
narrative JJ N
ability NN N
. . N

Significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
blind-rated JJ N
perceptions NNS N
of IN N
conversational JJ N
competence NN N
, , N
for IN N
parent-reported JJ N
measures NNS N
of IN N
pragmatic JJ N
functioning NN N
and CC N
social JJ N
communication NN N
, , N
and CC N
for IN N
teacher-reported JJ N
ratings NNS N
of IN N
classroom NN N
learning NN N
skills NNS N
. . N

CONCLUSIONS NNP N
& CC N
IMPLICATIONS NNP N
There EX N
is VBZ N
some DT N
evidence NN N
of IN N
an DT N
intervention NN N
effect NN N
on IN N
blind NN N
and CC N
parent/teacher-reported JJ N
communication NN N
outcomes NNS N
, , N
but CC N
not RB N
standardized JJ N
language NN N
assessment NN N
outcomes NNS N
, , N
for IN N
6-11-year-old JJ N
children NNS N
who WP N
have VBP N
pragmatic JJ N
and CC N
social JJ N
communication NN N
needs NNS N
. . N

These DT N
findings NNS N
are VBP N
discussed VBN N
in IN N
the DT N
context NN N
of IN N
the DT N
increasingly RB N
central JJ N
role NN N
of IN N
service NN N
user NN N
outcomes NNS N
in IN N
providing VBG N
evidence NN N
for IN N
an DT N
intervention NN N
. . N

The DT N
substantial JJ N
overlap NN N
between IN N
the DT N
presence NN N
of IN N
PLI NNP N
and CC N
ASD NNP N
( ( N
75 CD N
% NN N
) ) N
across IN N
the DT N
whole JJ N
cohort NN N
suggests VBZ N
that IN N
the DT N
intervention NN N
may MD N
also RB N
be VB N
applicable JJ N
to TO N
some DT N
verbally RB N
able JJ N
children NNS N
with IN N
ASD NNP N
who WP N
have VBP N
pragmatic JJ N
communication NN N
needs NNS N
. . N

-DOCSTART- -X- O O

Heart NNP N
rate NN N
variability NN N
and CC N
QT NNP N
dispersion NN N
in IN N
patients NNS N
with IN N
subclinical JJ N
hypothyroidism NN N
. . N

UNLABELLED IN N
The DT N
effect NN N
of IN N
subclinical JJ N
hypothyroidism NN N
( ( N
SH NNP N
) ) N
on IN N
cardiovascular JJ N
autonomic JJ N
function NN N
and CC N
ventricular JJ N
repolarization NN N
has VBZ N
not RB N
been VBN N
yet RB N
elucidated VBN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
dispersion NN N
of IN N
QT NNP N
interval NN N
, , N
i.e NN N
. . N

an DT N
index NN N
of IN N
inhomogeneity NN N
of IN N
repolarization NN N
, , N
and CC N
heart NN N
rate NN N
variability NN N
( ( N
HRV NNP N
) ) N
, , N
i.e RB N
. . N

a DT N
measure NN N
of IN N
cardiac JJ N
autonomic JJ N
modulation NN N
, , N
in IN N
SH NNP N
patients NNS N
. . N

METHODS NNP N
The DT N
study NN N
included VBD N
42 CD N
patients NNS N
( ( N
29 CD N
women NNS N
and CC N
13 CD N
men NNS N
; : N
mean JJ N
age NN N
53.2+/-14.2 JJ N
years NNS N
; : N
body NN N
surface JJ N
area NN N
1.76+/-0.14 JJ N
m2 NN N
) ) N
with IN N
SH NNP N
, , N
as IN N
judged VBN N
by IN N
elevated JJ N
serum NN N
TSH NNP N
levels NNS N
( ( N
> $ N
3.6 CD N
mIU/l NN N
; : N
range NN N
, , N
3.8-12.0 JJ N
) ) N
and CC N
normal JJ N
free JJ N
thyroid NN N
hormones NNS N
( ( N
FT4 NNP N
and CC N
FT3 NNP N
) ) N
and CC N
30 CD N
euthyroid JJ N
volunteer NN N
. . N

Subjects NNS N
with IN N
cardiac JJ N
, , N
metabolic JJ N
, , N
neurological JJ N
disease NN N
or CC N
any DT N
other JJ N
systemic JJ N
disease NN N
that WDT N
could MD N
affect VB N
autonomic JJ N
activity NN N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
. . N

Patients NNS N
with IN N
SH NNP N
and CC N
control VB N
subjects NNS N
underwent VB N
a DT N
full JJ N
history NN N
, , N
physical JJ N
examination NN N
, , N
standard JJ N
12-lead JJ 2_i
ECG NNP 2_i
, , 2_i
and CC 2_i
24-h JJ 2_i
ambulatory NN 2_i
ECG NNP 2_i
monitoring NN 2_i
. . N

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
L-thyroxine NNP 3_i
on IN N
QT NNP N
dispersion NN N
and CC N
HRV NNP N
, , N
15 CD N
patients NNS N
with IN N
SH NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
therapy NN N
with IN N
L-thyroxine NNP 3_i
. . N

All PDT N
the DT N
subjects NNS N
were VBD N
evaluated VBN N
at IN N
enrolment NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Patients NNPS N
with IN N
SH NNP N
showed VBD N
higher JJR N
QT NNP N
dispersion NN N
and CC N
lower JJR N
HRV NNP N
measures NNS N
than IN N
healthy JJ N
controls NNS N
( ( N
P NNP N
< VBZ N
0.01 CD N
for IN N
all DT N
) ) N
. . N

In IN N
SH NNP N
patients NNS N
, , N
the DT N
standard JJ N
deviation NN N
of IN N
N-Ns NNP N
( ( N
SDNN NNP N
) ) N
was VBD N
negatively RB N
related VBN N
to TO N
TSH NNP N
( ( N
r=-0.42 JJ N
, , N
P=0.006 NNP N
) ) N
, , N
while IN N
low JJ N
frequency NN N
( ( N
LF NNP N
) ) N
/high VBP N
frequency NN N
( ( N
HF NNP N
) ) N
ratio NN N
was VBD N
positively RB N
related VBN N
to TO N
TSH NNP N
( ( N
r=0.42 NN N
, , N
P=0.006 NNP N
) ) N
. . N

Moreover RB N
, , N
in IN N
SH NNP N
patients NNS N
both DT N
QT NNP N
dispersion NN N
and CC N
QTc NNP N
dispersion NN N
were VBD N
positively RB N
related VBN N
to TO N
TSH NNP N
( ( N
r=0.64 NN N
and CC N
r=0.63 NN N
, , N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
patients NNS N
treated VBN N
with IN N
L-tiroxine NNP 3_i
exhibited VBD N
a DT N
reduction NN N
of IN N
QT NNP N
dispersion NN N
and CC N
an DT N
increase NN N
of IN N
HRV NNP N
parameters NNS N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
SH NNP N
can MD N
alter VB N
autonomic JJ N
modulation NN N
of IN N
heart NN N
rate NN N
and CC N
cause NN N
increased VBD N
inhomogeneity NN N
of IN N
ventricular JJ N
recovery NN N
times NNS N
. . N

Accordingly RB N
, , N
early JJ N
L-thyroxine JJ 3_i
treatment NN N
may MD N
be VB N
advised VBN N
not RB N
only RB N
to TO N
prevent VB N
progression NN N
to TO N
overt VB N
hypothyroidism NN N
but CC N
also RB N
to TO N
improve VB N
abnormal JJ N
cardiac JJ N
autonomic JJ N
function NN N
and CC N
ventricular JJ N
repolarization NN N
inhomogeneity NN N
. . N

-DOCSTART- -X- O O

High-intensity NNP 2_i
physical JJ 2_i
training NN 2_i
in IN N
adults NNS N
with IN N
asthma NN N
. . N

A DT N
comparison NN N
between IN N
training VBG 2_i
on IN 2_i
land NN 2_i
and CC 2_i
in IN 2_i
water NN 2_i
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
inactive JJ N
asthmatic JJ N
patients NNS N
could MD N
perform VB N
high-intensity JJ 2_i
physical JJ 2_i
training NN 2_i
equally RB N
well RB N
on IN 2_i
land NN 2_i
as IN 2_i
in IN 2_i
water NN 2_i
, , N
and CC N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
these DT N
training NN N
forms NNS N
. . N

Thirty-two JJ N
adults NNS N
with IN N
asthma NN N
, , N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
underwent VBD N
a DT N
10-week JJ 2_i
supervised JJ 2_i
rehabilitation NN 2_i
program NN 2_i
with IN 2_i
emphasis NN 2_i
on IN 2_i
physical JJ 2_i
training NN 2_i
. . N

All DT N
patients NNS N
, , N
irrespective JJ N
of IN N
training VBG N
form NN N
, , N
were VBD N
able JJ N
to TO N
exercise VB N
to TO N
maximal VB N
intensity NN N
( ( N
80-90 CD N
% NN N
of IN N
estimated VBN N
maximal JJ N
heart NN N
rate NN N
) ) N
. . N

No UH N
asthmatic JJ N
attacks NNS N
occurred VBD N
in IN N
connection NN N
with IN N
the DT N
training NN N
sessions NNS N
. . N

Respiratory NNP N
variables NNS N
remained VBD N
almost RB N
unchanged JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
asthma NN N
symptoms NNS N
declined VBD N
during IN N
the DT N
rehabilitation NN N
period NN N
, , N
and CC N
the DT N
subjects NNS N
needed VBN N
less JJR N
acute JJ N
asthma NN N
care NN N
after IN N
the DT N
rehabilitation NN N
. . N

The DT N
cardiovascular JJ N
condition NN N
improved VBN N
significantly RB N
and CC N
similarly RB N
in IN N
the DT N
two CD N
groups NNS N
. . N

Ten CD N
patients NNS N
, , N
5 CD N
in IN N
each DT N
group NN N
, , N
had VBD N
exercise-induced JJ N
asthma NN N
at IN N
the DT N
start NN N
of IN N
the DT N
rehabilitation NN N
. . N

Only RB N
3 CD N
patients NNS N
, , N
2 CD N
from IN N
the DT N
water NN N
group NN N
and CC N
1 CD N
from IN N
the DT N
land NN N
group NN N
, , N
had VBD N
exercise-induced VBN N
asthma NNS N
after IN N
10 CD N
weeks NNS N
. . N

We PRP N
conclude VBP N
that IN N
indoor JJ N
training NN N
, , N
either CC N
on IN N
land NN N
or CC N
in IN N
water NN N
, , N
is VBZ N
beneficial JJ N
. . N

The DT N
effects NNS N
of IN N
these DT N
two CD N
training NN N
forms NNS N
are VBP N
almost RB N
equivalent JJ N
. . N

-DOCSTART- -X- O O

Behavioral NNP N
and CC N
physiological JJ N
effects NNS N
of IN N
remifentanil NN 3_i
and CC N
alfentanil NN 3_i
in IN N
healthy JJ N
volunteers NNS N
. . N

BACKGROUND IN N
The DT N
subjective JJ N
and CC N
psychomotor JJ N
effects NNS N
of IN N
remifentanil NNS 3_i
have VBP N
not RB N
been VBN N
evaluated VBN N
. . N

Accordingly RB N
, , N
the DT N
authors NNS N
used VBD N
mood NN N
inventories NNS N
and CC N
psychomotor NN N
tests NNS N
to TO N
characterize VB N
the DT N
effects NNS N
of IN N
remifentanil NN 3_i
in IN N
healthy JJ N
, , N
non-drug-abusing JJ N
volunteers NNS N
. . N

Alfentanil NNP N
was VBD N
used VBN N
as IN N
a DT N
comparator NN N
drug NN N
. . N

METHODS NNP N
Ten NNP N
healthy JJ N
volunteers NNS N
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ 7_i
, , N
crossover JJ N
trial NN N
in IN N
which WDT N
they PRP N
received VBD N
an DT N
infusion NN N
of IN N
saline NN 3_i
, , N
remifentanil NN 3_i
, , N
or CC N
alfentanil NN 3_i
for IN N
120 CD N
min NN N
. . N

The DT N
age- JJ N
and CC N
weight-adjusted JJ N
infusions NNS N
( ( N
determined VBN N
with IN N
STANPUMP NNP 3_i
, , N
a DT N
computer NN 3_i
modeling VBG 3_i
software NN 3_i
package NN 3_i
) ) N
were VBD N
given VBN N
to TO N
achieve VB N
three CD N
predicted VBN N
constant JJ N
plasma NN N
levels NNS N
for IN N
40 CD N
min NNS N
each DT N
of IN N
remifentanil NN 3_i
( ( N
0.75 CD N
, , N
1.5 CD N
, , N
and CC N
3 CD N
ng/ml NN N
) ) N
and CC N
alfentanil NN N
( ( N
16 CD N
, , N
32 CD N
, , N
and CC N
64 CD N
ng/ml NN N
) ) N
. . N

Mood NN N
forms NNS N
and CC N
psychomotor NN N
tests NNS N
were VBD N
completed VBN N
, , N
and CC N
miosis NN N
was VBD N
assessed VBN N
, , N
during IN N
and CC N
after IN N
the DT N
infusions NNS N
. . N

In IN N
addition NN N
, , N
analgesia NN N
was VBD N
tested VBN N
at IN N
each DT N
dose JJ N
level NN N
using VBG N
a DT N
cold-pressor JJ N
test NN N
. . N

RESULTS NNP N
Remifentanil NNP 3_i
had VBD N
prototypic VBN N
micro-like JJ N
opioid JJ N
subjective JJ N
effects NNS N
, , N
impaired JJ N
psychomotor NN N
performance NN N
, , N
and CC N
produced VBD N
analgesia NN N
. . N

Alfentanil NNP N
at IN N
the DT N
dose JJ N
range NN N
tested VBD N
had VBD N
more RBR N
mild JJ N
effects NNS N
on IN N
these DT N
measures NNS N
, , N
and CC N
the DT N
analgesia NN N
data NNS N
indicated VBD N
that IN N
a DT N
40:1 CD N
potency NN N
ratio NN N
, , N
rather RB N
than IN N
the DT N
20:1 CD N
ratio NN N
we PRP N
used VBD N
, , N
may MD N
exist VB N
between IN N
remifentanil NN N
and CC N
alfentanil NN N
. . N

A DT N
psychomotor NN N
test NN N
administered VBD N
60 CD N
min NN N
after IN N
the DT N
remifentanil NN N
infusion NN N
was VBD N
discontinued VBN N
showed VBD N
that IN N
the DT N
volunteers NNS N
were VBD N
still RB N
impaired VBN N
, , N
although IN N
they PRP N
reported VBD N
feeling VBG N
no DT N
drug NN N
effects NNS N
. . N

CONCLUSIONS VB N
The DT N
notion NN N
that IN N
the DT N
pharmacodynamic JJ N
effects NNS N
of IN N
remifentanil NN 3_i
are VBP N
extremely RB N
short-lived JJ N
after IN N
the DT N
drug NN N
is VBZ N
no DT N
longer RB N
administered VBN N
must MD N
be VB N
questioned VBN N
given VBN N
our PRP$ N
findings NNS N
that IN N
psychomotor NN N
effects NNS N
were VBD N
still RB N
apparent JJ N
1 CD N
h NN N
after IN N
the DT N
infusion NN N
was VBD N
discontinued VBN N
. . N

-DOCSTART- -X- O O

Safety NN N
of IN N
intravitreous JJ N
fomivirsen NN 3_i
for IN N
treatment NN N
of IN N
cytomegalovirus NN N
retinitis NN N
in IN N
patients NNS N
with IN N
AIDS NNP N
. . N

PURPOSE NNP N
To TO N
report VB N
data NNS N
regarding VBG N
the DT N
safety NN N
of IN N
intravitreous JJ N
fomivirsen NN 3_i
for IN N
treatment NN N
of IN N
cytomegalovirus NN N
( ( N
CMV NNP N
) ) N
retinitis NN N
in IN N
patients NNS N
with IN N
acquired JJ N
immunodeficiency NN N
syndrome NN N
( ( N
AIDS NNP N
) ) N
. . N

DESIGN NNP N
Critical NNP N
review NN N
of IN N
safety NN N
data NNS N
from IN N
three CD N
randomized NNS N
controlled VBD N
clinical JJ N
trials NNS N
with IN N
supplemental JJ N
information NN N
from IN N
an DT N
expanded VBN N
drug NN N
access NN N
program NN N
. . N

METHODS NNP N
Adverse NNP N
ocular JJ N
events NNS N
reported VBN N
by IN N
clinician JJ N
investigators NNS N
were VBD N
listed VBN N
using VBG N
terms NNS N
modified VBN N
from IN N
the DT N
COSTART NNP N
dictionary NN N
. . N

Data NNP N
for IN N
two CD N
doses NNS N
( ( N
165-microg/injection JJ N
[ NN N
35 CD N
eyes NNS N
, , N
30 CD N
patients NNS N
] JJ N
and CC N
330-microg/injection JJ N
[ NN N
153 CD N
eyes NNS N
, , N
120 CD N
patients NNS N
] JJ N
) ) N
and CC N
two CD N
330-microg/injection JJ N
dose JJ N
schedules NNS N
of IN N
different JJ N
intensity NN N
were VBD N
pooled VBN N
to TO N
calculate VB N
incidence NN N
rates NNS N
for IN N
each DT N
event NN N
. . N

Rates NNS N
were VBD N
calculated VBN N
as IN N
events/patient-year JJ N
( ( N
based VBN N
on IN N
total JJ N
cumulative JJ N
reported VBD N
events NNS N
and CC N
duration NN N
of IN N
treatment NN N
) ) N
for IN N
events NNS N
that WDT N
could MD N
recur VB N
during IN N
treatment NN N
. . N

Rates NNS N
were VBD N
calculated VBN N
as IN N
patients NNS N
with IN N
events/person-year JJ N
for IN N
the DT N
following JJ N
events NNS N
: : N
retinal JJ N
detachment NN N
, , N
cataract NN N
, , N
visual JJ N
field NN N
disturbance NN N
, , N
and CC N
retinal JJ N
pigment NN N
epitheliopathy NN N
. . N

To TO N
assess VB N
the DT N
ability NN N
to TO N
manage VB N
events NNS N
, , N
we PRP N
reviewed VBD N
treatments NNS N
given VBN N
for IN N
two CD N
events NNS N
( ( N
anterior JJ N
chamber NN N
inflammation NN N
, , N
increased VBD N
intraocular JJ N
pressure NN N
) ) N
in IN N
one CD N
trial NN N
. . N

We PRP N
also RB N
report VBP N
an DT N
analysis NN N
comparing VBG N
the DT N
proportion NN N
of IN N
eyes NNS N
that WDT N
developed VBD N
one CD N
or CC N
more JJR N
key JJ N
events NNS N
to TO N
the DT N
cumulative JJ N
number NN N
of IN N
injections NNS N
. . N

RESULTS JJ N
Incidence NN N
rates NNS N
were VBD N
dose JJ N
and CC N
schedule JJ N
dependent NN N
( ( N
165 CD N
microg/injection NN N
, , N
4.06 CD N
events/patient-year JJ N
; : N
330 CD N
microg/injection NN N
, , N
6.58 CD N
events/patient-year JJ N
[ NNP N
less JJR N
intense JJ N
regimen NNS N
] VBP N
and CC N
8.35 CD N
events/patient-year JJ N
[ NNP N
more JJR N
intense JJ N
regimen NNS N
] VBP N
) ) N
. . N

The DT N
most RBS N
frequently RB N
reported VBN N
events NNS N
were VBD N
anterior JJ N
chamber NN N
inflammation NN N
and CC N
increased VBD N
intraocular JJ N
pressure NN N
. . N

We PRP N
found VBD N
no DT N
evidence NN N
that IN N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
events NNS N
increased VBN N
as IN N
the DT N
number NN N
of IN N
injections NNS N
increased VBN N
. . N

CONCLUSIONS NNP N
Intravitreous NNP N
fomivirsen NN N
is VBZ N
well RB N
tolerated VBN N
with IN N
an DT N
acceptable JJ N
safety NN N
profile NN N
. . N

Adverse JJ N
ocular JJ N
events NNS N
associated VBN N
with IN N
doses NNS N
and CC N
schedules NNS N
used VBN N
clinically RB N
can MD N
be VB N
managed VBN N
successfully RB N
with IN N
medical JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
betamethasone NN 3_i
on IN N
neuromuscular JJ N
blockade NN N
induced VBN N
by IN N
vecuronium NN 3_i
in IN N
continuous JJ N
infusion NN N
] NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
a DT N
possible JJ N
interaction NN N
between IN N
a DT N
corticosteroid NN 3_i
( ( 3_i
betamethasone NN 3_i
) ) 3_i
and CC 3_i
vecuronium NN 3_i
, , N
a DT N
nondepolarizing JJ 3_i
muscle NN 3_i
relaxant NN 3_i
. . N

The DT N
authors NNS N
studied VBD N
20 CD N
patients NNS N
, , N
ASA NNP N
I-II NNP N
, , N
aged VBD N
20-54 JJ N
, , N
both DT N
sexes NNS N
, , N
scheduled VBN N
for IN N
abdominal JJ 1_i
surgery NN 1_i
. . 1_i

Mechanomyographic NNP N
and CC N
clinical JJ N
evaluation NN N
by IN N
single JJ N
twitch NN N
and CC N
TOF NNP N
stimulation NN N
of IN N
the DT N
ulnar JJ N
nerve NN N
at IN N
the DT N
wrist NN N
and CC N
measurement NN N
of IN N
the DT N
concomitant JJ N
abductor NN N
pollicis NN N
muscle NN N
was VBD N
applied VBN N
. . N

The DT N
onset JJ N
time NN N
of IN N
vecuronium NN 3_i
after IN N
a DT N
single JJ N
bolus NN N
dose NN N
of IN N
0.08 CD N
mg/kg NN N
, , N
duration NN N
of IN N
action NN N
to TO N
10 CD N
% NN N
single JJ N
twitch NN N
recovery NN N
, , N
duration NN N
of IN N
continuous JJ N
infusion NN N
of IN N
0.4-0.5 JJ N
micrograms/kg/min NN N
of IN N
vecuronium NN 3_i
started VBN N
at IN N
10 CD N
% NN N
single JJ N
twitch NN N
recovery NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
0.1 CD N
mg/kg NNS N
betamethasone CD 3_i
administration NN N
10 CD N
min NN N
after IN N
continuous JJ N
infusion NN N
were VBD N
evaluated VBN N
. . N

The DT N
recovery NN N
rate NN N
of IN N
vecuronium NN 3_i
after IN N
stopping VBG N
infusion NN N
at IN N
10 CD N
% NN N
recovery NN N
was VBD N
also RB N
evaluated VBN N
. . N

Corticosteroids NNS 3_i
may MD N
interact VB N
with IN N
non-depolarizing JJ N
muscle NN N
relaxants NNS N
both DT N
in IN N
prejunctional NN N
and CC N
postjunctional JJ N
acetylcholine NN N
receptors NNS N
by IN N
several JJ N
mechanisms NNS N
of IN N
action NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
leisure NN 4_i
programme NN 4_i
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
individuals NNS N
with IN N
ASD NNP N
. . N

BACKGROUND NNP N
Even RB N
though IN N
there EX N
is VBZ N
research NN N
demonstrating VBG N
a DT N
positive JJ N
relationship NN N
between IN N
leisure NN N
participation NN N
and CC N
the DT N
two CD N
constructs NNS N
of IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
reduction NN N
, , N
current JJ N
conceptualisation NN N
of IN N
leisure NN N
as IN N
a DT N
contributor NN N
to TO N
quality NN N
of IN N
life NN N
is VBZ N
limited VBN N
. . N

In IN N
addition NN N
, , N
in IN N
spite NN N
of IN N
improvements NNS N
in IN N
accurate JJ N
diagnosis NN N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
at IN N
increasingly RB N
earlier JJR N
ages NNS N
and CC N
proliferation NN N
of IN N
interventions NNS N
, , N
research NN N
associated VBN N
with IN N
leisure NN N
and CC N
quality NN N
of IN N
life NN N
for IN N
people NNS N
with IN N
ASD NNP N
is VBZ N
lacking VBG N
. . N

METHODS NNP N
Therefore NNP N
, , N
a DT N
study NN N
using VBG N
a DT N
repeated JJ N
measures NNS N
design NN N
was VBD N
used VBN N
to TO N
measure VB N
effects NNS N
of IN N
a DT N
1-year JJ 4_i
group NN 4_i
leisure NN 4_i
programme NN 4_i
intended VBN N
to TO N
facilitate VB N
interaction NN 4_i
with IN 4_i
media NNS 4_i
, , N
engagement NN 4_i
in IN 4_i
exercise NN 4_i
, , N
playing VBG 4_i
games NNS 4_i
and CC 4_i
doing VBG 4_i
crafts NNS 4_i
, , N
attending VBG 4_i
events NNS 4_i
, , N
and CC N
participating VBG 4_i
in IN 4_i
other JJ 4_i
recreation NN 4_i
activities NNS 4_i
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
37 CD N
participants NNS N
( ( N
22 CD N
male NN N
, , N
15 CD N
female NN N
) ) N
, , N
ages VBZ N
17-39 JJ N
( ( N
M NNP N
= NNP N
31.49 CD N
) ) N
years NNS N
at IN N
the DT N
beginning NN N
of IN N
the DT N
programme NN N
) ) N
diagnosed VBD N
with IN N
an DT N
ASD NNP N
and CC N
a DT N
group NN N
of IN N
34 CD N
adults NNS N
with IN N
ASD NNP N
as IN N
control NN N
group NN N
( ( N
waiting VBG N
list NN N
) ) N
( ( N
19 CD N
male NN N
, , N
15 CD N
female NN N
) ) N
, , N
ages VBZ N
24-38 JJ N
( ( N
M NNP N
= VBZ N
30 CD N
at IN N
programme JJ N
initiation NN N
) ) N
years NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
overall JJ N
scores NNS N
of IN N
stress NN N
levels NNS N
for IN N
participants NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
and CC N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
four CD N
factors NNS N
of IN N
quality NN N
of IN N
life NN N
that WDT N
were VBD N
measured VBN N
( ( N
satisfaction NN N
, , N
independence NN N
, , N
competence NN N
and CC N
social JJ N
interaction NN N
) ) N
as RB N
well RB N
as IN N
the DT N
total JJ N
score NN N
for IN N
quality NN N
of IN N
life NN N
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
the DT N
intervention NN N
12 CD N
months NNS N
later RB N
. . N

In IN N
contrast NN N
, , N
the DT N
control NN N
group NN N
demonstrated VBD N
no DT N
significant JJ N
improvements NNS N
related VBN N
to TO N
stress VB N
or CC N
quality NN N
of IN N
life NN N
. . N

Implications NNS N
of IN N
these DT N
findings NNS N
to TO N
leisure VB N
services NNS N
and CC N
the DT N
quality NN N
of IN N
life NN N
of IN N
individuals NNS N
with IN N
ASD NNP N
are VBP N
discussed VBN N
. . N

CONCLUSION NNP N
Findings NNP N
support NN N
the DT N
contention NN N
that WDT N
participation NN N
in IN N
recreation NN N
activities NNS N
positively RB N
influenced VBD N
the DT N
stress NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
adults NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O

A DT N
simplified JJ N
4-site JJ N
economical JJ N
intradermal JJ N
post-exposure NN N
rabies NNS 3_i
vaccine VBP 3_i
regimen NNS N
: : N
a DT N
randomised JJ N
controlled VBN N
comparison NN N
with IN N
standard JJ N
methods NNS N
. . N

BACKGROUND IN N
The DT N
need NN N
for IN N
economical JJ N
rabies NNS N
post-exposure JJ N
prophylaxis NN N
( ( N
PEP NNP N
) ) N
is VBZ N
increasing VBG N
in IN N
developing VBG N
countries NNS N
. . N

Implementation NN N
of IN N
the DT N
two CD N
currently RB N
approved VBN N
economical JJ N
intradermal NN N
( ( N
ID NNP N
) ) N
vaccine NN N
regimens VBZ N
is VBZ N
restricted VBN N
due JJ N
to TO N
confusion NN N
over IN N
different JJ N
vaccines NNS N
, , N
regimens NNS N
and CC N
dosages NNS N
, , N
lack NN N
of IN N
confidence NN N
in IN N
intradermal JJ N
technique NN N
, , N
and CC N
pharmaceutical JJ N
regulations NNS N
. . N

We PRP N
therefore RB N
compared VBN N
a DT N
simplified JJ N
4-site JJ N
economical JJ N
PEP NNP N
regimen NNS N
with IN N
standard JJ N
methods NNS N
. . N

METHODS NNP N
Two CD N
hundred VBD N
and CC N
fifty-four JJ N
volunteers NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
single JJ N
blind NN N
controlled VBD N
trial NN N
. . N

Each DT N
received VBD N
purified JJ 3_i
vero NN 3_i
cell NN 3_i
rabies NNS 3_i
vaccine VBP 3_i
by IN N
one CD N
of IN N
four CD N
PEP NNP N
regimens NNS N
: : N
the DT N
currently RB N
accepted VBN N
2-site JJ N
ID NNP N
; : N
the DT N
8-site JJ N
regimen NNS N
using VBG N
0.05 CD N
ml JJ N
per IN N
ID NNP N
site NN N
; : N
a DT N
new JJ N
4-site JJ N
ID NNP N
regimen NNS N
( ( N
on IN N
day NN N
0 CD N
, , N
approximately RB N
0.1 CD N
ml NNS N
at IN N
4 CD N
ID NNP N
sites NNS N
, , N
using VBG N
the DT N
whole JJ N
0.5 CD N
ml JJ N
ampoule NN N
of IN N
vaccine NN N
; : N
on IN N
day NN N
7 CD N
, , N
0.1 CD N
ml NN N
ID NNP N
at IN N
2 CD N
sites NNS N
and CC N
at IN N
one CD N
site NN N
on IN N
days NNS N
28 CD N
and CC N
90 CD N
) ) N
; : N
or CC N
the DT N
standard JJ 3_i
5-dose JJ 3_i
intramuscular JJ N
regimen NNS N
. . N

All DT N
ID NNP N
regimens NNS N
required VBD N
the DT N
same JJ N
total JJ N
amount NN N
of IN N
vaccine NN N
, , N
60 CD N
% NN N
less JJR N
than IN N
the DT N
intramuscular JJ N
method NN N
. . N

Neutralising VBG N
antibody NN N
responses NNS N
were VBD N
measured VBN N
five CD N
times NNS N
over IN N
a DT N
year NN N
in IN N
229 CD N
people NNS N
, , N
for IN N
whom WP N
complete JJ N
data NNS N
were VBD N
available JJ N
. . N

FINDINGS NNP N
All NNP N
ID NNP N
regimens VBZ N
showed VBD N
similar JJ N
immunogenicity NN N
. . N

The DT N
intramuscular JJ N
regimen NNS N
gave VBD N
the DT N
lowest JJS N
geometric JJ N
mean NN N
antibody NN N
titres NNS N
. . N

Using VBG N
the DT N
rapid JJ N
fluorescent JJ N
focus NN N
inhibition NN N
test NN N
, , N
some DT N
sera NN N
had VBD N
unexpectedly RB N
high JJ N
antibody NN N
levels NNS N
that WDT N
were VBD N
not RB N
attributable JJ N
to TO N
previous JJ N
vaccination NN N
. . N

The DT N
results NNS N
were VBD N
confirmed VBN N
using VBG N
the DT N
fluorescent NN N
antibody NN N
virus JJ N
neutralisation NN N
method NN N
. . N

CONCLUSIONS VB N
This DT N
4-site JJ N
PEP NNP N
regimen NNS N
proved VBD N
as RB N
immunogenic JJ N
as IN N
current JJ N
regimens NNS N
, , N
and CC N
has VBZ N
the DT N
advantages NNS N
of IN N
requiring VBG N
fewer JJR N
clinic JJ N
visits NNS N
, , N
being VBG N
more RBR N
practicable JJ N
, , N
and CC N
having VBG N
a DT N
wider JJR N
margin NN N
of IN N
safety NN N
, , N
especially RB N
in IN N
inexperienced JJ N
hands NNS N
, , N
than IN N
the DT N
2-site JJ N
regimen NNS N
. . N

It PRP N
is VBZ N
more RBR N
convenient JJ N
than IN N
the DT N
8-site JJ N
method NN N
, , N
and CC N
can MD N
be VB N
used VBN N
economically RB N
with IN N
vaccines NNS N
formulated VBN N
in IN N
1.0 CD N
or CC N
0.5 CD N
ml NN N
ampoules NNS N
. . N

The DT N
4-site JJ N
regimen NNS N
now RB N
meets VBZ N
all DT N
requirements NNS N
of IN N
immunogenicity NN N
for IN N
PEP NNP N
and CC N
can MD N
be VB N
introduced VBN N
without IN N
further JJ N
studies NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Controlled-Trials.com NNP N
ISRCTN NNP N
30087513 CD N
. . N

-DOCSTART- -X- O O

Azelnidipine NNP 3_i
and CC N
amlodipine VB 3_i
anti-coronary JJ N
atherosclerosis NN N
trial NN N
in IN N
hypertensive JJ N
patients NNS N
undergoing VBG N
coronary JJ N
intervention NN N
by IN N
serial JJ N
volumetric JJ N
intravascular NN N
ultrasound NN N
analysis NN N
in IN N
Juntendo NNP N
university NN N
( ( N
ALPS-J NNP N
) ) N
. . N

PURPOSE NNP N
Many JJ N
trials NNS N
have VBP N
shown VBN N
that IN N
calcium NN N
channel NN N
blockers NNS N
( ( N
CCBs NNP N
) ) N
can MD N
reduce VB N
the DT N
cardiovascular NN N
( ( N
CV NNP N
) ) N
events NNS N
in IN N
patients NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
( ( N
CAD NNP N
) ) N
. . N

The DT N
mechanisms NN N
of IN N
this DT N
effect NN N
could MD N
be VB N
associated VBN N
with IN N
plaque JJ N
regression NN N
due JJ N
to TO N
the DT N
anti-atherosclerotic JJ N
properties NNS N
of IN N
CCBs NNP N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
CCB NNP N
on IN N
volumetric JJ N
quantitative JJ N
changes NNS N
of IN N
coronary JJ N
plaques NNS N
accessed VBN N
by IN N
intravascular JJ N
ultrasound NN N
( ( N
IVUS NNP N
) ) N
. . N

To TO N
confirm VB N
this DT N
hypothesis NN N
, , N
a DT N
multicenter NN N
randomized VBN N
trial NN N
of IN N
CCBs NNP N
treatment NN N
with IN N
azelnidipine NN 3_i
or CC N
amlodipine NN 3_i
will MD N
be VB N
conducted VBN N
in IN N
hypertensive JJ N
CAD NNP N
patients NNS N
undergoing VBG N
elective JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNPS N
who WP N
have VBP N
hypertension NN N
and CC N
are VBP N
scheduled VBN N
for IN N
PCI NNP N
will MD N
be VB N
enrolled VBN N
. . N

Subjects NNS N
will MD N
be VB N
randomized VBN N
to TO N
azelnidipine VB 3_i
or CC N
amlodipine VB 3_i
and CC N
observed VB N
for IN N
48 CD N
weeks NNS N
. . N

The DT N
primary JJ N
endpoint NN N
will MD N
be VB N
the DT N
percent NN N
change NN N
of IN N
coronary JJ N
plaque NN N
volume NN N
. . N

The DT N
secondary JJ N
endpoint NN N
will MD N
include VB N
inflammatory JJ N
markers NNS N
, , N
antioxidant JJ N
activity NN N
, , N
and CC N
incidence NN N
of IN N
composite JJ N
cardiovascular JJ N
events NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
we PRP N
will MD N
investigate VB N
the DT N
improvement NN N
of IN N
coronary JJ N
plaque NN N
with IN N
IVUS NNP N
by IN N
treatment NN N
with IN N
two CD N
dihydropyridine NN N
CCBs NNP N
in IN N
hypertensive JJ N
patients NNS N
undergoing VBG N
elective JJ N
PCI NNP N
. . N

This DT N
result NN N
will MD N
lead VB N
to TO N
the DT N
discovery NN N
of IN N
more RBR N
effective JJ N
drug NN N
therapy NN N
for IN N
inhibition NN N
of IN N
coronary JJ N
events NNS N
. . N

-DOCSTART- -X- O O

Differential JJ N
response NN N
of IN N
seven CD N
subjects NNS N
with IN N
autistic JJ N
disorder NN N
to TO N
clomipramine VB 3_i
and CC N
desipramine VB 3_i
. . N

OBJECTIVE NNP N
Clomipramine NNP N
, , N
a DT N
serotonin JJ N
reuptake NN N
blocker NN N
that WDT N
has VBZ N
unique JJ N
antiobsessional JJ N
properties NNS N
, , N
was VBD N
hypothesized VBN N
to TO N
have VB N
a DT N
different JJ N
effect NN N
from IN N
that DT N
of IN N
desipramine NN N
, , N
a DT N
tricyclic JJ N
antidepressant NN N
with IN N
selective JJ N
adrenergic JJ N
effects NNS N
, , N
for IN N
the DT N
stereotyped NN N
, , N
repetitive JJ N
behaviors NNS N
in IN N
autism NN N
. . N

METHOD NNP N
Seven NNP N
subjects NNS N
, , N
ages VBZ N
6-18 CD N
years NNS N
, , N
with IN N
autistic JJ N
disorder NN N
completed VBD N
a DT N
10-week JJ N
double-blind NN N
, , N
crossover JJ N
trial NN N
of IN N
clomipramine NN 3_i
and CC N
desipramine NN 3_i
following VBG N
a DT N
2-week JJ N
single-blind NN N
, , N
placebo JJ 7_i
phase NN N
. . N

RESULTS NNP N
Clomipramine NNP N
was VBD N
superior JJ N
to TO N
desipramine VB N
and CC N
placebo VB N
, , N
as IN N
indicated VBN N
by IN N
standardized JJ N
ratings NNS N
of IN N
autism NN N
and CC N
anger NN N
as RB N
well RB N
as IN N
ratings NNS N
of IN N
repetitive JJ N
and CC N
compulsive JJ N
behaviors NNS N
. . N

Clomipramine NNP N
and CC N
desipramine NN N
were VBD N
equally RB N
superior JJ N
to TO N
placebo VB N
for IN N
ratings NNS N
of IN N
hyperactivity NN N
. . N

Parents NNS N
of IN N
all DT N
seven CD N
subjects NNS N
elected VBN N
to TO N
have VB N
their PRP$ N
children NNS N
continue VBP N
to TO N
take VB N
clomipramine NN N
after IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
Clomipramine NNP N
and CC N
desipramine NN N
are VBP N
differentially RB N
effective JJ N
in IN N
treating VBG N
the DT N
obsessive-compulsive JJ N
and CC N
core NN N
symptoms NNS N
in IN N
autistic JJ N
disorder NN N
. . N

Biological JJ N
links NNS N
between IN N
compulsions NNS N
and CC N
stereotyped VBD N
, , N
repetitive JJ N
behaviors NNS N
in IN N
autistic JJ N
disorder NN N
should MD N
be VB N
explored VBN N
. . N

-DOCSTART- -X- O O

Thermal JJ 1_i
welding VBG 1_i
versus NN N
bipolar JJ 1_i
tonsillectomy NN 1_i
: : N
a DT N
comparative JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
thermal JJ 2_i
welding VBG 2_i
tonsillectomy NN 2_i
( ( 2_i
TWT NNP 2_i
) ) 2_i
with IN N
bipolar JJ 2_i
electrocautery NN 2_i
tonsillectomy NN 2_i
( ( 2_i
BET NNP 2_i
) ) 2_i
procedure NN 1_i
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
on IN N
150 CD N
consecutive JJ N
adult NN N
patients NNS N
undergoing VBG N
tonsillectomy NN 1_i
. . N

Indications NNS N
included VBD N
chronic JJ N
tonsillitis NN N
and CC N
obstructive JJ N
sleep NN N
apnea NN N
syndrome NN N
. . N

Exclusion NN N
criteria NNS N
included VBD N
peritonsillar JJ N
abscess NN N
history NN N
, , N
bleeding VBG N
disorders NNS N
, , N
and CC N
any DT N
other JJ N
procedure NN N
together RB N
with IN N
tonsillectomy NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
TWT NNP 2_i
or CC N
BET NNP 2_i
groups NNS N
. . N

Intraoperative JJ N
bleeding NN N
, , N
operative JJ N
time NN N
, , N
postoperative JJ N
pain NN N
, , N
complication NN N
rates NNS N
, , N
and CC N
return VB N
to TO N
normal JJ N
diet JJ N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
In IN N
the DT N
TWT NNP 2_i
group NN N
there EX N
was VBD N
no DT N
measurable JJ N
intraoperative JJ N
bleeding NN N
, , N
while IN N
mean JJ N
bleeding NN N
for IN N
BET NNP 2_i
group NN N
was VBD N
16 CD N
mL NN N
. . N

No DT N
significant JJ N
difference NN N
regarding VBG N
mean JJ N
operative JJ N
time NN N
was VBD N
noticed VBN N
. . N

Mean NNP N
postoperative JJ N
pain NN N
score NN N
and CC N
mean JJ N
time NN N
for IN N
return NN N
to TO N
normal JJ N
diet JJ N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
TWT NNP 2_i
group NN N
. . N

Primary JJ N
hemorrhage NN N
occurred VBD N
in IN N
1 CD N
subject NN N
of IN N
the DT N
BET NNP 2_i
group NN N
. . N

Secondary JJ N
postoperative JJ N
hemorrhage NN N
was VBD N
noticed VBN N
in IN N
1 CD N
subject NN N
of IN N
the DT N
TWT NNP 2_i
group NN N
and CC N
3 CD N
subjects NNS N
of IN N
the DT N
BET NNP 2_i
group NN N
. . N

CONCLUSION NNP N
Thermal NNP 1_i
welding VBG 1_i
tonsillectomy JJ 1_i
procedure NN 1_i
provides VBZ N
sufficient JJ N
hemostasis NN N
, , N
lower JJR N
postoperative NN N
pain NN N
, , N
and CC N
quick JJ N
return NN N
to TO N
normal JJ N
diet JJ N
. . N

EBM JJ N
RATING NNP N
A-1b NNP N
. . N

-DOCSTART- -X- O O

Science NN N
to TO N
practice NN N
in IN N
underserved JJ N
communities NNS N
: : N
the DT N
effectiveness NN N
of IN N
school NN 4_i
mental JJ 4_i
health NN 4_i
programming NN 4_i
. . N

This DT N
study NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
treatment NN 4_i
program NN 4_i
comprised VBN N
of IN N
several JJ N
components NNS N
based VBN N
on IN N
evidence-based JJ 4_i
treatments NNS 4_i
( ( 4_i
EBTs NNP 4_i
) ) 4_i
for IN 4_i
disruptive JJ 4_i
behavior NN 4_i
problems NNS 4_i
delivered VBN N
to TO N
youth VB N
participating VBG N
in IN N
a DT N
school NN N
mental JJ N
health NN N
program NN N
in IN N
an DT N
underserved JJ N
community NN N
in IN N
the DT N
Appalachian JJ N
region NN N
. . N

Participants NNS N
were VBD N
117 CD N
children NNS N
in IN N
kindergarten VBN N
through IN N
6th CD N
grade NN N
including VBG N
91 CD N
children NNS N
( ( N
78 CD N
% NN N
male NN N
) ) N
from IN N
5 CD N
schools NNS N
who WP N
were VBD N
consecutively RB N
referred VBN N
to TO N
the DT N
intervention NN 4_i
program NN 4_i
and CC N
26 CD N
children NNS N
( ( N
73 CD N
% NN N
male NN N
) ) N
from IN N
3 CD N
schools NNS N
in IN N
which WDT N
program NN N
implementation NN N
was VBD N
delayed VBN N
for IN N
1 CD N
year NN N
. . N

Treatment NNP N
outcome NN N
was VBD N
measured VBN N
via IN N
parent NN N
and CC N
teacher JJ N
ratings NNS N
of IN N
child NN N
symptoms NNS N
and CC N
functioning VBG N
. . N

The DT N
treatment NN N
condition NN N
resulted VBD N
in IN N
significant JJ N
reduction NN N
in IN N
hyperactivity/impulsivity NN N
and CC N
early JJ N
aggressive JJ N
and CC N
delinquent JJ N
behavior NN N
, , N
as RB N
well RB N
as IN N
significant JJ N
improvement NN N
in IN N
several JJ N
other JJ N
functional JJ N
domains NNS N
. . N

Results VB N
suggest JJS N
that IN N
EBTs NNP 4_i
can MD N
retain VB N
their PRP$ N
effectiveness NN N
when WRB N
transported VBN N
to TO N
a DT N
community NN N
context NN N
. . N

-DOCSTART- -X- O O

A DT N
controlled VBN N
study NN N
of IN N
early JJ 4_i
discharge NN 4_i
after IN N
uncomplicated JJ N
myocardial JJ N
infarction NN N
. . N

Out IN N
of IN N
383 CD N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
patients NNS N
aged VBN N
below IN N
70 CD N
years NNS N
, , N
252 CD N
( ( N
66 CD N
% NN N
) ) N
were VBD N
judged VBN N
after IN N
the DT N
third JJ N
day NN N
in IN N
hospital NN N
to TO N
have VB N
had VBN N
uncomplicated VBN N
infarctions NNS N
. . N

These DT N
patients NNS N
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
two CD N
groups NNS N
, , N
one CD 4_i
of IN 4_i
which WDT 4_i
was VBD 4_i
given VBN 4_i
treatment NN 4_i
for IN 4_i
8 CD 4_i
days NNS 4_i
and CC 4_i
the DT 4_i
other JJ 4_i
for IN 4_i
15 CD 4_i
days NNS 4_i
. . N

No DT N
significant JJ N
differences NNS N
in IN N
mortality NN N
, , N
morbidity NN N
or CC N
incapacity NN N
for IN N
work NN N
could MD N
be VB N
detected VBN N
during IN N
the DT N
three-month JJ N
period NN N
of IN N
follow-up NN N
. . N

The DT N
findings NNS N
thus RB N
support VBP N
previous JJ N
conclusions NNS N
that WDT N
early RB 4_i
discharge VBP 4_i
from IN N
hospital NN N
after IN N
uncomplicated JJ N
MI NNP N
is VBZ N
not RB N
associated VBN N
with IN N
greater JJR N
risk NN N
for IN N
the DT N
patient NN N
than IN N
later RB N
discharge NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
performance NN N
of IN N
the DT N
Reichert NNP 3_i
AT550 NNP 3_i
: : 3_i
a DT N
new JJ N
non-contact JJ 3_i
tonometer NN 3_i
. . 3_i

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
level NN N
of IN N
accuracy NN N
for IN N
measurements NNS N
of IN N
intra-ocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
obtained VBD N
with IN N
a DT N
new JJ N
non-contact JJ 6_i
tonometer NN 6_i
( ( 3_i
NCT NNP 3_i
) ) 3_i
the DT 3_i
Reichert NNP 3_i
AT550 NNP 3_i
. . 3_i

Measurements NNS N
were VBD N
compared VBN N
against IN N
those DT N
obtained VBN N
with IN N
the DT N
Reichert NNP 2_i
Xpert NNP 2_i
Plus NNP 2_i
, , N
Goldmann NNP 6_i
applanation NN 6_i
tonometer NN 6_i
and CC N
Perkins NNP 6_i
tonometer NN 6_i
. . N

Thirty-five JJ N
university NN N
students NNS N
were VBD N
assessed VBN N
with IN N
the DT N
four CD N
tonometers NNS N
in IN N
a DT N
randomised JJ N
order NN N
, , N
with IN N
non-contact JJ N
tonometry NN N
performed VBD N
first RB N
. . N

Each DT N
of IN N
the DT N
four CD N
measurement NN N
devices NNS N
had VBD N
its PRP$ N
own JJ N
trained JJ N
clinical JJ N
observer NN N
. . N

Plots NNP N
of IN N
differences NNS N
of IN N
IOP NNP N
as IN N
a DT N
function NN N
of IN N
the DT N
mean NN N
for IN N
each DT N
pair NN N
of IN N
instruments NNS N
were VBD N
obtained VBN N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
when WRB N
comparing VBG N
the DT N
AT550 NNP 2_i
NCT NNP 2_i
with IN N
contact JJ 3_i
applanation NN 3_i
tonometry NN 3_i
( ( 3_i
AT NNP 3_i
) ) 3_i
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
, , N
displaying VBG N
the DT N
closest JJS N
level NN N
of IN N
agreement NN N
( ( N
as IN N
represented VBN N
by IN N
the DT N
lowest JJS N
mean JJ N
difference NN N
and CC N
the DT N
narrowest JJS N
confidence NN N
interval NN N
) ) N
with IN N
the DT N
Goldmann NNP 3_i
tonometer NN 3_i
( ( N
limits NNS N
of IN N
agreement NN N
, , N
0.12+/-2.17 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
readings NNS N
of IN N
IOP NNP N
with IN N
the DT N
AT550 NNP 2_i
NCT NNP 2_i
are VBP N
clinically RB N
comparable JJ N
with IN N
those DT N
obtained VBN N
with IN N
Goldmann NNP 3_i
tonometry NN 3_i
in IN N
a DT N
population NN N
with IN N
IOP NNP N
within IN N
the DT N
normal JJ N
range NN N
. . N

-DOCSTART- -X- O O

Chemoradiation NN N
comparing VBG N
cisplatin JJ 3_i
versus NN N
carboplatin NN 3_i
in IN N
locally RB N
advanced JJ N
nasopharyngeal JJ N
cancer NN N
: : N
randomised VBN N
, , N
non-inferiority NN N
, , N
open JJ N
trial NN N
. . N

PURPOSE VB N
This DT N
single JJ N
centre NN N
, , N
open JJ N
labelled VBD N
, , N
randomised VBD N
non-inferiority JJ N
trial NN N
compared VBN N
concurrent JJ N
chemoradiotherapy NN 3_i
with IN 3_i
carboplatin JJ 3_i
versus JJ N
standard NN 3_i
concurrent NN 3_i
chemoradiotherapy NN 3_i
with IN 3_i
cisplatin NN 3_i
in IN N
patients NNS N
with IN N
locoregionally RB N
advanced JJ N
nasopharyngeal JJ N
cancer NN N
( ( N
NPC NNP N
) ) N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP N
August NNP N
1999 CD N
to TO N
December NNP N
2004 CD N
, , N
206 CD N
patients NNS N
with IN N
locally RB N
advanced JJ N
NPC NNP N
were VBD N
randomised VBN N
with IN N
101 CD N
to TO N
cisplatin VB 3_i
arm NN N
and CC N
105 CD N
to TO N
carboplatin VB 3_i
arm NN N
. . N

Planned VBD 3_i
radiotherapy NN 3_i
was VBD N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
. . N

All PDT N
the DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
toxicity NN N
and CC N
survival NN N
according VBG N
to TO N
the DT N
as-treated JJ N
principle NN N
. . N

RESULTS NNP N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
26.3 CD N
months NNS N
( ( N
range VB N
3-74.6 JJ N
months NNS N
) ) N
, , N
59 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
cisplatin NN N
arm NN N
completed VBD N
the DT N
planned VBN N
concurrent NN N
chemoradiation NN N
treatment NN N
, , N
compared VBN N
to TO N
73 CD N
% NN N
in IN N
the DT N
carboplatin NN N
arm NN N
. . N

Forty-two JJ N
percent NN N
of IN N
cisplatin NN N
patients NNS N
completed VBD N
the DT N
3 CD N
cycles NNS N
of IN N
adjuvant JJ N
therapy NN N
compared VBN N
to TO N
70 CD N
% NN N
in IN N
the DT N
carboplatin NN N
group NN N
. . N

There EX N
were VBD N
more JJR N
renal JJ N
toxicity NN N
, , N
leucopenia NN N
, , N
and CC N
anaemia NN N
in IN N
the DT N
cisplatin NN N
group NN N
, , N
and CC N
more JJR N
thrombocytopenia NN N
in IN N
the DT N
carboplatin NN N
arm NN N
. . N

The DT N
3 CD N
year NN N
disease NN N
free JJ N
survival NN N
rates NNS N
were VBD N
63.4 CD N
% NN N
for IN N
the DT N
cisplatin NN N
group NN N
and CC N
60.9 CD N
% NN N
for IN N
the DT N
carboplatin NN N
group NN N
( ( N
p=0.9613 NN N
) ) N
( ( N
HR $ N
0.70 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
0.50-0.98 JJ N
) ) N
. . N

The DT N
3 CD N
year NN N
overall JJ N
survival NN N
rates NNS N
were VBD N
77.7 CD N
% NN N
and CC N
79.2 CD N
% NN N
for IN N
cisplatin NN N
and CC N
carboplatin NN N
groups NNS N
, , N
respectively RB N
( ( N
p=0.9884 NN N
) ) N
( ( N
HR $ N
0.83 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.63-1.010 NN N
) ) N
. . N

CONCLUSION NNP N
We PRP N
concluded VBD N
that IN N
the DT N
tolerability NN N
of IN N
carboplatin NN 3_i
based VBN N
regimen NNS N
is VBZ N
better JJR N
than IN N
that DT N
of IN N
the DT N
cisplatin NN 3_i
regimen NN N
. . N

Moreover RB N
, , N
the DT N
treatment NN N
efficacy NN N
of IN N
carboplatin NN N
arm NN N
is VBZ N
not RB N
different JJ N
from IN N
the DT N
standard JJ N
regimen NNS N
in IN N
the DT N
treatment NN N
of IN N
locoregional JJ N
advanced JJ N
stage NN N
NPC NNP N
. . N

-DOCSTART- -X- O O

Inhaled VBN N
fluticasone NN 3_i
reduces NNS N
sputum VBP N
inflammatory JJ N
indices NNS N
in IN N
severe JJ N
bronchiectasis NN N
. . N

Although IN N
corticosteroid JJ 3_i
therapy NN 3_i
might MD N
be VB N
clinically RB N
beneficial JJ N
for IN N
bronchiectasis NN N
, , N
very RB N
little JJ N
is VBZ N
known VBN N
of IN N
its PRP$ N
effects NNS N
on IN N
the DT N
inflammatory NN N
and CC N
infective JJ N
markers NNS N
in IN N
bronchiectasis NN N
. . N

We PRP N
have VBP N
therefore RB N
performed VBN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
study NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
4-wk JJ N
administration NN N
of IN N
inhaled JJ N
fluticasone NN 3_i
in IN N
bronchiectasis NN N
. . N

Twenty-four CD N
patients NNS N
( ( N
12 CD N
female NN N
; : N
mean JJ N
age NN N
51 CD N
yr NN N
) ) N
were VBD N
randomized VBN N
into IN N
receiving VBG N
either CC N
inhaled JJ 3_i
fluticasone NN 3_i
( ( N
500 CD N
microgram NN N
twice RB N
daily RB N
) ) N
via IN N
the DT N
Accuhaler NNP N
device NN N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
or CC N
placebo NN 7_i
. . N

At IN N
each DT N
visit NN N
, , N
spirometry NN N
, , N
24-h JJ N
sputum NN N
volume NN N
, , N
sputum NN N
leukocyte NN N
density NN N
, , N
bacterial JJ N
densities NNS N
, , N
and CC N
concentrations NNS N
of IN N
interleukin NN N
( ( N
IL NNP N
) ) N
-1beta NN N
, , N
IL-8 NNP N
, , N
tumor NN N
necrosis NN N
factor-alpha JJ N
( ( N
TNF-alpha NNP N
) ) N
, , N
and CC N
leukotriene JJ N
B4 NNP N
( ( N
LTB4 NNP N
) ) N
were VBD N
determined VBN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
decrease NN N
in IN N
sputum NN N
leukocyte NN N
density NN N
and CC N
IL-1beta NNP N
, , N
IL-8 NNP N
, , N
and CC N
LTB4 NNP N
after IN N
fluticasone NN 3_i
treatment NN N
. . N

The DT N
fluticasone NN 3_i
group NN N
had VBD N
one CD N
and CC N
the DT N
placebo NN 7_i
group NN N
three CD N
episodes NNS N
of IN N
exacerbation NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
spirometry NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
or CC N
any DT N
reported JJ N
adverse JJ N
reactions NNS N
in IN N
either DT N
group NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
show VB N
that IN N
high-dose JJ N
fluticasone NN N
is VBZ N
effective JJ N
in IN N
reducing VBG N
the DT N
sputum NN N
inflammatory NN N
indices NNS N
in IN N
bronchiectasis NN N
. . N

Large-scale JJ N
and CC N
long-term JJ N
studies NNS N
are VBP N
indicated VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
inhaled JJ N
steroid JJ N
therapy NN N
on IN N
the DT N
inflammatory JJ N
components NNS N
in IN N
bronchiectasis NN N
. . N

-DOCSTART- -X- O O

Reduction NN N
of IN N
isoflurane NN N
MAC NNP N
by IN N
fentanyl NN 3_i
or CC N
remifentanil NN 3_i
in IN N
rats NNS N
. . N

OBJECTIVE IN N
The DT N
main JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
three CD N
different JJ N
infusion NN N
rates NNS N
of IN N
fentanyl NN 3_i
and CC N
remifentanil NN 3_i
on IN N
the DT N
minimum JJ N
alveolar JJ N
concentration NN N
( ( N
MAC NNP N
) ) N
of IN N
isoflurane NN N
in IN N
the DT N
rat NN N
. . N

A DT N
secondary JJ N
objective NN N
was VBD N
to TO N
assess VB N
the DT N
cardiovascular NN N
and CC N
respiratory JJ N
effects NNS N
of IN N
the DT N
two CD N
opioid JJ N
drugs NNS N
. . N

ANIMAL NNP N
POPULATION NNP N
Thirty-seven NNP N
male NN N
Wistar NNP N
rats NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
six CD N
treatment NN N
groups NNS N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
For IN N
all DT N
treatment NN N
groups NNS N
anaesthesia NN N
was VBD N
induced VBN N
with IN N
5 CD N
% NN N
isoflurane NN 3_i
in IN 3_i
oxygen NN 3_i
using VBG N
an DT N
induction NN N
chamber NN N
. . N

A DT N
14-gauge JJ N
catheter NN N
was VBD N
used VBN N
for IN N
endotracheal JJ N
intubation NN N
, , N
and CC N
anaesthesia NN N
was VBD N
maintained VBN N
with IN N
isoflurane NN N
delivered VBN N
in IN N
oxygen NN N
via IN N
a DT N
T-piece NNP N
breathing NN N
system NN N
. . N

A DT N
baseline JJ N
determination NN N
of IN N
the DT N
minimum JJ N
alveolar JJ N
concentration NN N
of IN N
isoflurane NN N
( ( N
MACISO NNP N
) ) N
was VBD N
made VBN N
for IN N
each DT N
animal NN N
. . N

Fentanyl NNP 3_i
( ( N
15 CD N
, , N
30 CD N
, , N
60 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
or CC N
remifentanil NN 3_i
( ( N
60 CD N
, , N
120 CD N
, , N
240 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
were VBD N
infused VBN N
intravenously RB N
into IN N
a DT N
previously RB N
cannulated VBN N
tail NN N
vein NN N
. . N

Thirty NNP N
minutes NNS N
after IN N
the DT N
infusion NN N
started VBD N
, , N
a DT N
second JJ N
MACISO NNP N
( ( N
MACISO+drug NNP N
) ) N
was VBD N
determined VBN N
. . N

The DT N
carotid NN N
artery NN N
was VBD N
cannulated VBN N
to TO N
monitor VB N
the DT N
arterial JJ N
pressure NN N
and CC N
to TO N
take VB N
samples NNS N
for IN N
arterial JJ N
gas NN N
measurements NNS N
. . N

Cardiovascular NNP N
( ( N
heart NN N
rate NN N
and CC N
arterial JJ N
pressure NN N
) ) N
and CC N
respiratory NN N
( ( N
respiratory JJ N
rate NN N
and CC N
presence/absence NN N
of IN N
apnoea NN N
) ) N
effects NNS N
after IN N
opioid JJ N
infusion NN N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS NNP N
Fentanyl NNP 3_i
( ( N
15 CD N
, , N
30 CD N
, , N
60 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
and CC N
remifentanil NN 3_i
( ( N
60 CD N
, , N
120 CD N
, , N
240 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
similarly RB N
reduced VBN N
isoflurane NN N
MAC NNP N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
: : N
by IN N
10 CD N
% NN N
at IN N
lower JJR N
doses NNS N
, , N
25 CD N
% NN N
at IN N
medium NN N
doses NNS N
and CC N
by IN N
60 CD N
% NN N
at IN N
higher JJR N
doses NNS N
of IN N
both DT N
the DT N
drugs NNS N
. . N

Both DT N
opioids NNS N
reduced VBD N
the DT N
respiratory NN N
rate NN N
in IN N
a DT N
similar JJ N
way NN N
for IN N
all DT N
doses NNS N
tested VBN N
. . N

No DT N
episodes NNS N
of IN N
apnoea NN N
were VBD N
recorded VBN N
in IN N
the DT N
remifentanil NN 3_i
groups NNS N
, , N
while IN N
administration NN N
of IN N
fentanyl NN N
resulted VBN N
in IN N
apnoea NN N
in IN N
three CD N
animals NNS N
( ( N
one CD N
at IN N
each DT N
dose JJ N
level NN N
) ) N
. . N

The DT N
effects NNS N
on IN N
the DT N
cardiovascular JJ N
system NN N
were VBD N
similar JJ N
with IN N
both DT N
drugs NNS N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
the DT N
intraoperative JJ N
use NN N
of IN N
remifentanil NN 3_i
in IN N
the DT N
rat NN N
reduces VBZ N
the DT N
MAC NNP N
of IN N
isoflurane NN N
, , N
and CC N
that IN N
this DT N
anaesthetic JJ N
sparing NN N
effect NN N
is VBZ N
dose-dependent JJ N
and CC N
similar JJ N
to TO N
that DT N
produced VBN N
by IN N
fentanyl NN N
at IN N
the DT N
doses NNS N
tested VBN N
. . N

CLINICAL JJ N
RELEVANCE NNP N
The DT N
use NN N
of IN N
remifentanil NN 3_i
during IN N
inhalant JJ N
anaesthesia NN N
in IN N
the DT N
rat NN N
can MD N
be VB N
considered VBN N
an DT N
intravenous JJ N
alternative NN N
to TO N
fentanyl VB 3_i
, , N
providing VBG N
similar JJ N
reduction NN N
in IN N
isoflurane NN N
requirements NNS N
. . N

Due NNP N
to TO N
its PRP$ N
rapid JJ N
offset NN N
, , N
it PRP N
is VBZ N
recommended VBN N
that IN N
alternative JJ N
pain NN N
relief NN N
be VB N
instituted VBN N
before IN N
it PRP N
is VBZ N
discontinued VBN N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
and CC N
experimental JJ N
research NN N
of IN N
Epimedium NNP 3_i
brevicornum NN 3_i
in IN N
relieving VBG N
neuroendocrino-immunological JJ N
effect NN N
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
protective JJ N
effect NN N
of IN N
Epimedium NNP 3_i
brevicornum NN 3_i
( ( 3_i
EB NNP 3_i
) ) 3_i
on IN N
hypothalamus-pituitary-adrenal-thymus NN N
( ( N
HPAT NNP N
) ) N
axis NN N
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
. . N

METHODS NNP N
In IN N
clinical JJ N
research NN N
, , N
variation NN N
of IN N
cortisol NN N
, , N
adrenocorticotrophin NN N
( ( N
ACTH NNP N
) ) N
, , N
lymphocyte JJ N
proliferative JJ N
reaction NN N
were VBD N
observed VBN N
before IN N
and CC N
after IN N
medication NN N
in IN N
65 CD N
patients NNS N
took VBD N
prednisone NN 3_i
, , N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
Fufang NNP 3_i
prednisone NN 3_i
group NN 3_i
( ( 3_i
mixture NN 3_i
of IN 3_i
prednisone NN 3_i
and CC 3_i
EB NNP 3_i
) ) 3_i
and CC N
prednisone NN 3_i
group NN 3_i
. . N

An DT N
experimental JJ N
model NN N
of IN N
HPAT NNP N
axis NN N
inhibited VBN N
by IN N
corticosterone NN N
( ( N
CORT NNP N
) ) N
was VBD N
established VBN N
to TO N
observe VB N
the DT N
effect NN N
of IN N
EB NNP N
on IN N
relevant JJ N
indices NNS N
of IN N
HPAT NNP N
axis NN N
. . N

RESULTS VB N
The DT N
level NN N
of IN N
ACTH NNP N
and CC N
CORT NNP N
in IN N
plasma NN N
decreased VBN N
and CC N
lymphocyte JJ N
proliferative JJ N
reaction NN N
reduced VBN N
in IN N
patients NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
experimental JJ N
study NN N
, , N
monoaminic JJ N
transmitters NNS N
activated VBN N
in IN N
hypothalamus NN N
; : N
weight NN N
of IN N
pituitary JJ N
, , N
adrenal JJ N
and CC N
thymus NN N
decreased VBN N
; : N
number NN N
of IN N
CRH NNP N
positive JJ N
neurons NNS N
in IN N
hypothalamic JJ N
paraventricular JJ N
nucleus NN N
, , N
CRH NNP N
positive JJ N
neurofibrilin NN N
median JJ N
eminence NN N
and CC N
anterior JJ N
pituitary JJ N
ACTH NNP N
positive JJ N
secretory NN N
cells NNS N
decreased VBD N
; : N
adrenal JJ N
fasciculate NN N
zone NN N
and CC N
thymus NN N
cortex NN N
atrophies NNS N
; : N
NK NNP N
cell VBP N
cytotoxicity NN N
and CC N
the DT N
level NN N
of IN N
IL-2 NNP N
and CC N
gamma-IFN NN N
which WDT N
were VBD N
produced VBN N
by IN N
lymphocytes NNS N
reduced VBN N
in IN N
CORT-rats NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
significant JJ N
difference NN N
between IN N
Fufang NNP N
prednisone NN N
group NN N
( ( N
clinical JJ N
research NN N
) ) N
or CC N
EB NNP N
group NN N
( ( N
experimental JJ N
research NN N
) ) N
and CC N
CORT NNP N
control NN N
groups NNS N
, , N
P NNP N
< VBZ N
0.05 CD N
. . N

CONCLUSION NNP N
EB NNP N
could MD N
relieve VB N
neuroendocrino-immunological JJ N
effect NN N
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
. . N

-DOCSTART- -X- O O

Erythema JJ N
migrans NNS N
: : N
comparison NN N
of IN N
treatment NN N
with IN N
azithromycin NN 3_i
, , N
doxycycline NN 3_i
and CC N
phenoxymethylpenicillin NN 3_i
. . N

Azithromycin NNP 3_i
, , N
doxycycline NN 3_i
and CC N
phenoxymethylpenicillin NN 3_i
were VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
study NN N
of IN N
64 CD N
patients NNS N
with IN N
typical JJ N
erythema NN N
migrans NNS N
. . N

Twenty CD N
patients NNS N
were VBD N
treated VBN N
with IN N
oral JJ 3_i
azithromycin NN 3_i
, , N
250 CD N
mg NN N
bd NN N
for IN N
two CD N
days NNS N
followed VBN N
by IN N
250 CD N
mg NNS N
od NN N
for IN N
eight CD N
days NNS N
, , N
21 CD N
patients NNS N
were VBD N
given VBN N
phenoxymethylpenicillin $ 3_i
1 CD N
million CD N
IU NNP N
tds NN N
for IN N
14 CD N
days NNS N
and CC N
23 CD N
patients NNS N
received JJ N
doxycycline NN 3_i
, , N
100 CD N
mg NN N
bd NN N
for IN N
14 CD N
days NNS N
. . N

All DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
24 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
with IN N
respect NN N
to TO N
the DT N
persistence NN N
of IN N
cutaneous JJ N
lesions NNS N
after IN N
starting VBG N
treatment NN N
; : N
the DT N
mean JJ N
durations NNS N
were VBD N
10.5 CD N
days NNS N
in IN N
the DT N
penicillin NN 3_i
group NN N
, , N
8.8 CD N
days NNS N
in IN N
the DT N
doxycycline NN 3_i
group NN N
and CC N
8.6 CD N
days NNS N
in IN N
the DT N
azithromycin NN 3_i
group NN N
. . N

There EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
the DT N
resolution NN N
of IN N
associated JJ N
local JJ N
and/or NN N
systemic NN N
symptoms NNS N
. . N

The DT N
response NN N
time NN N
was VBD N
shortest VBN N
in IN N
patients NNS N
treated VBN N
with IN N
azithromycin NN 3_i
. . N

Two CD N
patients NNS N
who WP N
received VBD N
phenoxymethylpenicillin NN 3_i
and CC N
two CD N
given VBN N
doxycycline VBP 3_i
subsequently RB N
developed VBN N
major JJ N
manifestations NNS N
of IN N
Lyme NNP N
borreliosis NN N
; : N
these DT N
did VBD N
not RB N
occur VB N
in IN N
patients NNS N
receiving VBG N
azithromycin RB 3_i
. . N

Although IN N
azithromycin NN 3_i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
erythema NN N
migrans NNS N
, , N
further JJ N
studies NNS N
will MD N
be VB N
needed VBN N
to TO N
determine VB N
the DT N
optimal JJ N
dosage NN N
and CC N
duration NN N
of IN N
therapy NN N
. . N

-DOCSTART- -X- O O

Inhibin NNP N
A NNP N
is VBZ N
down-regulated JJ N
during IN N
chemotherapy NN 3_i
in IN N
patients NNS N
with IN N
breast JJ N
cancer NN N
. . N

BACKGROUND NNP N
Inhibins NNP N
are VBP N
dimeric JJ N
glycoproteins NNS N
, , N
composed VBN N
of IN N
an DT N
alpha-subunit JJ N
( ( N
INH-? NNP N
) ) N
and CC N
one CD N
of IN N
two CD N
possible JJ N
beta-subunits NNS N
( ( N
?A CD N
or CC N
?B NNP N
) ) N
, , N
with IN N
substantial JJ N
roles NNS N
in IN N
human JJ N
reproduction NN N
and CC N
in IN N
endocrine-responsive JJ N
tumours NNS N
. . N

Aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
serological JJ N
measurement NN N
of IN N
inhibin NN N
A NNP N
( ( N
?-?A JJ N
) ) N
in IN N
breast NN N
cancer NN N
patients NNS N
during IN N
chemotherapy NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
series NN N
of IN N
30 CD N
breast NN N
cancer NN N
patients NNS N
who WP N
underwent VBP N
standardised VBN N
chemotherapy NN N
were VBD N
prospectively RB N
evaluated VBN N
before IN N
chemotherapeutic JJ N
treatment NN N
as RB N
well RB N
as IN N
four CD N
weeks NNS N
after IN N
chemotherapy NN N
and CC N
two CD N
years NNS N
after IN N
chemotherapy NN N
for IN N
the DT N
serological JJ N
expression NN N
of IN N
inhibin NN N
A NNP N
. . N

For IN N
statistical JJ N
analysis NN N
the DT N
Wilcoxon NNP N
rank NN N
sum NN N
test NN N
was VBD N
used VBN N
for IN N
paired JJ N
samples NNS N
. . N

Statistical JJ N
significance NN N
was VBD N
assumed VBN N
at IN N
p NN N
< $ N
0.05 CD N
. . N

RESULTS VB N
The DT N
concentration NN N
of IN N
inhibin NN N
A NNP N
showed VBD N
a DT N
significant JJ N
decrease NN N
between IN N
data NNS N
obtained VBN N
before IN N
chemotherapy NN N
and CC N
after IN N
chemotherapy NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
and CC N
two-year JJ N
follow-up NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Interestingly RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
inhibin NN N
A NNP N
concentrations NNS N
between IN N
the DT N
four-week JJ N
and CC N
two-year JJ N
follow-up NN N
( ( N
p=0.744 NN N
) ) N
. . N

DISCUSSION NNP N
Chemotherapy NNP N
significantly RB N
decreases VBZ N
inhibin VB N
A DT N
concentration NN N
during IN N
chemotherapy NN N
. . N

This DT N
might MD N
reflect VB N
a DT N
suppression NN N
of IN N
ovarian JJ N
function NN N
, , N
being VBG N
also RB N
a DT N
marker NN N
for IN N
chemotherapy-induced JJ N
amenorrhoea NN N
. . N

Moreover RB N
, , N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
inhibin VBZ N
A DT N
might MD N
be VB N
a DT N
tumour JJ N
marker NN N
for IN N
breast NN N
cancer NN N
, , N
and CC N
therefore RB N
a DT N
sudden JJ N
increase NN N
in IN N
its PRP$ N
concentration NN N
might MD N
be VB N
indicative JJ N
of IN N
breast NN N
cancer NN N
recurrence NN N
. . N

-DOCSTART- -X- O O

Veterans NNS N
Affairs VBP N
congestive JJ N
heart NN N
failure NN N
antiarrhythmic JJ N
trial NN N
. . N

CHF NNP N
STAT NNP N
Investigators NNP N
. . N

This DT N
is VBZ N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
antiarrhythmic JJ N
drug NN N
therapy NN N
on IN N
mortality NN N
in IN N
patients NNS N
with IN N
congestive JJ N
heart NN N
failure NN N
and CC N
ventricular JJ N
arrhythmia NN N
. . N

Patients NNS N
will MD N
be VB N
assigned VBN N
to TO N
receive VB N
either CC N
amiodarone VB 3_i
or CC N
placebo VB 7_i
. . N

Eligible JJ N
patients NNS N
include VBP N
those DT N
with IN N
ischemic JJ N
and CC N
nonischemic JJ N
congestive JJ N
heart NN N
failure NN N
and CC N
with IN N
> NNP N
or CC N
= $ N
10 CD N
ventricular JJ N
premature NN N
beats NNS N
per IN N
hour NN N
. . N

All DT N
patients NNS N
must MD N
have VB N
shortness NN N
of IN N
breath NN N
with IN N
minimal JJ N
exertion NN N
or CC N
paroxysmal JJ N
nocturnal JJ N
dyspnea NN N
, , N
a DT N
left JJ N
ventricular JJ N
internal JJ N
dimension NN N
( ( N
LVIDd NNP N
) ) N
by IN N
echocardiogram NN N
of IN N
> NN N
or CC N
= $ N
55 CD N
mm NN N
or CC N
a DT N
cardiothoracic JJ N
ratio NN N
of IN N
> $ N
0.5 CD N
and CC N
an DT N
ejection NN N
fraction NN N
of IN N
< NN N
or CC N
= VB N
40 CD N
% NN N
. . N

All DT N
patients NNS N
will MD N
receive VB N
vasodilator NN N
therapy NN N
, , N
unless IN N
they PRP N
find VBP N
it PRP N
intolerable JJ N
. . N

Patients NNS N
will MD N
be VB N
entered VBN N
into IN N
the DT N
study NN N
for IN N
2.5 CD N
years NNS N
and CC N
followed VBD N
for IN N
an DT N
additional JJ N
2 CD N
years NNS N
. . N

Drug NNP N
therapy NN N
will MD N
be VB N
continued VBN N
for IN N
all DT N
patients NNS N
throughout IN N
the DT N
entire JJ N
study NN N
unless IN N
adverse JJ N
reactions NNS N
occur VBP N
that IN N
necessitate JJ N
individualized JJ N
treatment NN N
. . N

The DT N
expectation NN N
is VBZ N
that IN N
674 CD N
patients NNS N
will MD N
be VB N
entered VBN N
into IN N
the DT N
study NN N
from IN N
25 CD N
participating VBG N
centers NNS N
. . N

This DT N
sample JJ N
size NN N
will MD N
allow VB N
for IN N
the DT N
detection NN N
of IN N
a DT N
33 CD N
% NN N
decrease NN N
in IN N
2-year JJ N
mortality NN N
( ( N
20 CD N
% NN N
vs JJ N
30 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
patients NNS N
compared VBN N
with IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
with IN N
a DT N
power NN N
of IN N
0.90 CD N
and CC N
a DT N
2-sided JJ N
alpha JJ N
level NN N
of IN N
0.05 CD N
. . N

Intermittent JJ N
Holter NNP N
monitoring NN N
, , N
radionuclide JJ N
ventriculograms NN N
, , N
pulmonary JJ N
function NN N
tests NNS N
, , N
echocardiograms NNS N
, , N
and CC N
blood NN N
tests NNS N
, , N
including VBG N
arterial JJ N
blood NN N
gases NNS N
, , N
will MD N
be VB N
required VBN N
for IN N
each DT N
patient NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Tissue NN N
microarray NN N
in IN N
a DT N
subset NN N
of IN N
South JJ N
African JJ N
patients NNS N
with IN N
DLBCL NNP N
. . N

Tissue NN N
samples NNS N
from IN N
93 CD N
de NNS N
novo FW N
diffuse RB N
large JJ N
B-cell NNP N
lymphoma NN N
patients NNS N
seen VBN N
between IN N
1995 CD N
and CC N
2009 CD N
randomly NN N
receiving VBG N
either CC N
standard JJ 3_i
combination NN 3_i
chemotherapy NN 3_i
( ( N
CHOP NNP N
, , N
n=48 NN N
) ) N
or CC N
the DT N
identical JJ 3_i
program NN 3_i
with IN 3_i
rituximab NN 3_i
( ( N
n=45 JJ N
) ) N
were VBD N
subtyped VBN N
using VBG N
an DT N
investigational JJ N
immunohistochemical NN N
( ( N
IHC NNP N
) ) N
based VBN N
tissue NN N
microarray NN N
( ( N
TMA NNP N
) ) N
and CC N
contrasted VBN N
to TO N
the DT N
approximately RB N
corresponding JJ N
categories NNS N
as IN N
defined VBN N
either CC N
by IN N
Hans NNPS N
and CC N
associates NNS N
using VBG N
a DT N
three CD N
marker NN N
panel NN N
into IN N
germinal JJ N
or CC N
non-germinal JJ N
centre NN N
subtypes NNS N
or CC N
by IN N
Choi NNP N
and CC N
colleagues NNS N
with IN N
two CD N
additional JJ N
antibodies NNS N
into IN N
germinal JJ N
centre NN N
( ( N
GCB NNP N
) ) N
or CC N
activated VBN N
B-cells NNP N
( ( N
ABC NNP N
) ) N
. . N

Each DT N
of IN N
these DT N
primary JJ N
subdivisions NNS N
was VBD N
further RBR N
evaluated VBN N
for IN N
expression NN N
of IN N
BCL2 NNP N
and CC N
LMO2 NNP N
both DT N
of IN N
which WDT N
are VBP N
recognised VBN N
to TO N
predicate VB N
response NN N
. . N

The DT N
addition NN N
of IN N
rituximab NN N
to TO N
the DT N
uniform JJ N
drug NN N
regimen NNS N
did VBD N
not RB N
show VB N
any DT N
significant JJ N
improvement NN N
in IN N
5 CD N
years NNS N
overall JJ N
( ( N
63 CD N
% NN N
versus IN N
59 CD N
% NN N
, , N
p RB N
0.68 CD N
) ) N
or CC N
event-free JJ N
survival NN N
( ( N
42 CD N
% NN N
versus IN N
39 CD N
% NN N
, , N
p RB N
0.94 CD N
) ) N
, , N
for IN N
CHOP NNP N
versus NN N
R-CHOP NNP N
comparisons NNS N
. . N

Similarly RB N
no DT N
differences NNS N
were VBD N
evident JJ N
in IN N
subtype JJ N
analysis NN N
. . N

Interestingly RB N
however RB N
, , N
when WRB N
segregated VBN N
on IN N
the DT N
Choi NNP N
criteria NNS N
, , N
cytotoxic NN N
drugs NNS N
alone RB N
showed VBD N
a DT N
non-significant JJ N
trend NN N
in IN N
improved JJ N
survival NN N
( ( N
74 CD N
% NN N
versus IN N
55 CD N
% NN N
, , N
p RB N
0.32 CD N
) ) N
as RB N
well RB N
as IN N
event-free JJ N
survival NN N
( ( N
44 CD N
% NN N
versus IN N
40 CD N
% NN N
, , N
p RB N
0.42 CD N
) ) N
for IN N
the DT N
germinal JJ N
centre NN N
as IN N
opposed VBN N
to TO N
the DT N
activated VBN N
B-cell NNP N
subtype NN N
. . N

Nevertheless NNP N
not RB N
even RB N
a DT N
small JJ N
difference NN N
could MD N
be VB N
demonstrated VBN N
in IN N
the DT N
presence NN N
of IN N
the DT N
anti JJ N
CD NN N
20 CD N
monoclonal JJ N
antibody NN N
. . N

According VBG N
to TO N
Choi NNP N
, , N
both DT N
regimens NNS N
( ( N
chemotherapy NN N
or CC N
immunotherapy VB N
antibody NN N
) ) N
revealed VBD N
similar JJ N
results NNS N
to TO N
the DT N
Hans NNPS N
algorithm VBP N
on IN N
5 CD N
years NNS N
OS NNP N
as RB N
well RB N
as IN N
3 CD N
year NN N
EFS NNP N
when WRB N
comparing VBG N
GCB NNP N
versus NN N
ABC NNP N
or CC N
non-GCB JJ N
subgroups NNS N
. . N

BCL2 NNP N
and CC N
LMO2 NNP N
marker NNP N
expression NN N
of IN N
the DT N
respective JJ N
immunohistochemical JJ N
( ( N
IHC NNP N
) ) N
subtype NN N
, , N
despite IN N
small JJ N
sample NN N
size NN N
, , N
revealed VBD N
the DT N
following NN N
. . N

Analysis NN N
by IN N
Choi NNP N
criteria NNS N
on IN N
survival NN N
for IN N
BCL2 NNP N
, , N
no DT N
matter NN N
for IN N
which WDT N
subsets NNS N
( ( N
GCB NNP N
or CC N
ABC NNP N
) ) N
or CC N
treatment NN N
modality NN N
( ( N
chemotherapy NN N
with IN N
or CC N
without IN N
the DT N
addition NN N
of IN N
rituximab NN N
) ) N
showed VBD N
no DT N
difference NN N
in IN N
5 CD N
years NNS N
OS NNP N
or CC N
EFS NNP N
. . N

In IN N
contrast NN N
, , N
a DT N
significant JJ N
difference NN N
for IN N
better JJR N
EFS NNP N
( ( N
p=0.0015 NN N
) ) N
in IN N
the DT N
BCL2 NNP N
positive JJ N
group NN N
of IN N
the DT N
ABC NNP N
subgroups NNS N
subtypes NNS N
treated VBN N
with IN N
rituximab NN N
containing VBG N
chemotherapy NN N
. . N

For IN N
LMO2 NNP N
similar JJ N
results NNS N
on IN N
survival JJ N
outcome NN N
were VBD N
seen VBN N
thus RB N
showing VBG N
no DT N
difference NN N
in IN N
5 CD N
years NNS N
OS NNP N
or CC N
EFS NNP N
- : N
regardless NN N
of IN N
subtype NN N
or CC N
treatment NN N
modality NN N
. . N

Also RB N
here RB N
, , N
this DT N
was VBD N
contrasted VBN N
by IN N
better JJR N
EFS NNP N
( ( N
p=0.039 NN N
) ) N
in IN N
the DT N
LMO2 NNP N
positive JJ N
group NN N
of IN N
ABC NNP N
subtypes NNS N
when WRB N
treated VBN N
with IN N
the DT N
rituximab NN N
containing VBG N
regimen NNS N
. . N

The DT N
use NN N
of IN N
the DT N
IHC NNP N
based VBN N
TMA NNP N
methodology NN N
has VBZ N
shown VBN N
to TO N
be VB N
a DT N
simple JJ N
, , N
cost NN N
effective JJ N
and CC N
a DT N
robust JJ N
alternative NN N
to TO N
gene NN N
expression NN N
profiling VBG N
( ( N
GEP NNP N
) ) N
which WDT N
is VBZ N
currently RB N
regarded VBN N
as IN N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
classification NN N
in IN N
lymphomas NN N
. . N

It PRP N
provides VBZ N
a DT N
useful JJ N
prognostic JJ N
tool NN N
in IN N
stratifying VBG N
DLBCL NNP N
or CC N
other JJ N
entities NNS N
in IN N
future JJ N
, , N
even RB N
when WRB N
frozen JJ N
tissue NN N
samples NNS N
are VBP N
not RB N
available JJ N
for IN N
GEP NNP N
analysis NN N
. . N

With IN N
the DT N
current JJ N
budgetary JJ N
limitations NNS N
in IN N
South JJ N
African JJ N
public JJ N
hospitals NNS N
chemotherapy VBP N
protocols NNS N
for IN N
lymphoproliferative JJ N
disorders NNS N
exclude VBP N
agents NNS N
such JJ N
as IN N
rituximab NN N
. . N

Local JJ N
therapeutic JJ N
drug NN N
committees NNS N
consider VBP N
the DT N
approximately RB N
15 CD N
% NN N
overall JJ N
survival NN N
benefit NN N
seen VBN N
at IN N
5 CD N
years NNS N
for IN N
DLBCL NNP N
when WRB N
rituximab NN N
is VBZ N
added VBN N
to TO N
combination VB N
chemotherapy NN N
as IN N
too RB N
marginal JJ N
for IN N
justifying VBG N
the DT N
arising VBG N
additional JJ N
expenses NNS N
. . N

Accordingly RB N
, , N
demonstration NN N
that IN N
a DT N
specific JJ N
molecular JJ N
subtype NN N
accounts NNS N
for IN N
superior JJ N
outcome NN N
, , N
when WRB N
using VBG N
these DT N
regimens NNS N
, , N
is VBZ N
needed VBN N
. . N

Such JJ N
an DT N
option NN N
would MD N
provide VB N
convincing VBG N
evidence NN N
for IN N
the DT N
use NN N
of IN N
immunochemotherapy NN N
in IN N
a DT N
resource NN N
constrained VBD N
setting NN N
. . N

-DOCSTART- -X- O O

Utilization NN N
patterns NNS N
of IN N
conventional JJ 7_i
and CC N
complementary/alternative JJ 6_i
treatments NNS 6_i
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
and CC N
developmental JJ N
disabilities NNS N
in IN N
a DT N
population-based JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
utilization NN N
of IN N
conventional JJ 7_i
treatments NNS 7_i
and CC N
utilization NN N
of IN N
complementary JJ 3_i
and CC 3_i
alternative JJ 3_i
medicine NN 3_i
in IN N
preschoolers NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
and CC N
other JJ N
developmental JJ N
disabilities NNS N
( ( N
DD NNP N
) ) N
. . N

METHODS JJ N
Participants NNS N
were VBD N
578 CD N
children NNS N
who WP N
were VBD N
part NN N
of IN N
an DT N
ongoing JJ N
population-based JJ N
, , N
case-control JJ N
study NN N
of IN N
2- JJ N
to TO N
5-year JJ N
olds NNS N
with IN N
ASD NNP N
, , N
DD NNP N
, , N
and CC N
the DT N
general JJ N
population NN N
. . N

Parents NNS N
completed VBD N
an DT N
interview NN N
on IN N
past JJ N
and CC N
current JJ N
services NNS N
. . N

RESULTS NNP N
Four CD N
hundred VBD N
fifty-three JJ N
children NNS N
with IN N
ASD NNP N
and CC N
125 CD N
DD NNP N
children NNS N
were VBD N
included VBN N
. . N

ASD NNP N
families NNS N
received VBD N
more RBR N
hours NNS N
of IN N
conventional JJ 2_i
services NNS 2_i
compared VBN N
with IN N
DD NNP N
families NNS N
( ( N
17.8 CD N
vs RB N
11 CD N
; : N
p NN N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
use NN N
of IN N
psychotropic NN N
medications NNS N
was VBD N
low JJ N
in IN N
both DT N
groups NNS N
( ( N
approximately RB N
3 CD N
% NN N
) ) N
. . N

Overall JJ N
, , N
complementary JJ 3_i
and CC 3_i
alternative JJ 3_i
medicine NN 3_i
( ( 3_i
CAM NNP 3_i
) ) 3_i
use NN N
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
ASD NNP N
( ( N
39 CD N
% NN N
) ) N
versus NN N
DD NNP N
( ( N
30 CD N
% NN N
) ) N
. . N

Hispanic JJ N
families NNS N
in IN N
both DT N
groups NNS N
used VBD N
CAM NNP 3_i
less RBR N
often RB N
than IN N
non-Hispanic JJ N
families NNS N
. . N

Variables NNS N
such JJ N
as IN N
level NN N
of IN N
function NN N
, , N
immunization NN N
status NN N
, , N
and CC N
the DT N
presence NN N
of IN N
an DT N
identified VBN N
neurogenetic JJ N
disorder NN N
were VBD N
not RB N
predictive JJ N
of IN N
CAM NNP 3_i
use NN N
. . N

A DT N
higher JJR N
level NN N
of IN N
parental JJ N
education NN N
was VBD N
associated VBN N
with IN N
an DT N
increased VBN N
CAM NNP 3_i
use NN N
in IN N
ASD NNP N
and CC N
DD NNP N
. . N

Families NNS N
who WP N
used VBD N
> $ N
20 CD N
hours NNS N
per IN N
week NN N
of IN N
conventional JJ 2_i
services NNS 2_i
were VBD N
more RBR N
likely JJ N
to TO N
use VB N
CAM NNP 3_i
, , N
including VBG N
potentially RB N
unsafe JJ N
or CC N
disproven JJ N
CAM NNP 3_i
. . N

Underimmunized VBN N
children NNS N
were VBD N
marginally RB N
more RBR N
likely JJ N
to TO N
use VB N
CAM NNP 3_i
but CC N
not RB N
more RBR N
likely JJ N
to TO N
have VB N
received VBN N
potentially RB N
unsafe JJ N
or CC N
disproven JJ N
CAM NNP 3_i
. . N

CONCLUSION NNP N
Use NNP N
of IN N
CAM NNP 3_i
is VBZ N
common JJ N
in IN N
families NNS N
of IN N
young JJ N
children NNS N
with IN N
neurodevelopmental JJ N
disorders NNS N
, , N
and CC N
it PRP N
is VBZ N
predicted VBN N
by IN N
higher JJR N
parental JJ N
education NN N
and CC N
non-Hispanic JJ N
ethnicity NN N
but CC N
not RB N
developmental JJ N
characteristics NNS N
. . N

Further NNP N
research NN N
should MD N
address VB N
how WRB N
health NN N
care NN N
providers NNS N
can MD N
support VB N
families NNS N
in IN N
making VBG N
decisions NNS N
about IN N
CAM NNP 3_i
use NN N
. . N

-DOCSTART- -X- O O

Galactomannan NNP 3_i
and CC N
PCR NNP 3_i
versus NN N
culture NN N
and CC N
histology NN N
for IN N
directing VBG N
use NN N
of IN N
antifungal JJ N
treatment NN N
for IN N
invasive JJ N
aspergillosis NN N
in IN N
high-risk JJ N
haematology NN N
patients NNS N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Empirical NNP N
treatment NN N
with IN N
antifungal JJ N
drugs NNS N
is VBZ N
often RB N
used VBN N
in IN N
haematology NN N
patients NNS N
at IN N
high JJ N
risk NN N
of IN N
invasive JJ N
aspergillosis NN N
. . N

We PRP N
compared VBN N
a DT N
standard JJ N
diagnostic JJ N
strategy NN N
( ( N
culture NN N
and CC N
histology NN N
) ) N
with IN N
a DT N
rapid JJ N
biomarker-based JJ N
diagnostic JJ N
strategy NN N
( ( N
aspergillus JJ N
galactomannan NN N
and CC N
PCR NNP N
) ) N
for IN N
directing VBG N
the DT N
use NN N
of IN N
antifungal JJ N
treatment NN N
in IN N
this DT N
group NN N
of IN N
patients NNS N
. . N

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
parallel-group JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
, , N
eligible JJ N
patients NNS N
were VBD N
adults NNS N
undergoing VBG N
allogeneic JJ N
stem-cell JJ N
transplantation NN N
or CC N
chemotherapy NN 3_i
for IN N
acute JJ N
leukaemia NN N
, , N
with IN N
no DT N
history NN N
of IN N
invasive JJ N
fungal JJ N
disease NN N
. . N

Enrolled JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1 CD N
) ) N
by IN N
a DT N
computer-generated JJ N
schedule NN N
to TO N
follow VB N
either RB N
a DT N
standard JJ 5_i
diagnostic JJ 5_i
strategy NN 5_i
( ( N
based VBN N
on IN N
culture NN N
and CC N
histology NN N
) ) N
or CC N
a DT N
biomarker-based JJ 3_i
diagnostic JJ 3_i
strategy NN 3_i
( ( 3_i
aspergillus JJ 3_i
galactomannan NN 3_i
and CC 3_i
PCR NNP 3_i
) ) 3_i
to TO N
direct VB N
treatment NN N
with IN N
antifungal JJ N
drugs NNS N
. . N

Patients NNS N
, , N
were VBD N
followed VBN N
up RP N
for IN N
26 CD N
weeks NNS N
or CC N
until IN N
death NN N
. . N

Masking NNP N
of IN N
the DT N
use NN N
of IN N
different JJ N
diagnostic JJ N
tests NNS N
was VBD N
not RB N
possible JJ N
for IN N
patients NNS N
, , N
treating VBG N
physicians NNS N
, , N
or CC N
investigators NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
empirical JJ N
treatment NN N
with IN N
antifungal JJ N
drugs NNS N
in IN N
the DT N
26 CD N
weeks NNS N
after IN N
enrolment NN N
( ( N
for IN N
the DT N
biomarker-based JJ N
diagnostic JJ N
strategy NN N
, , N
a DT N
single JJ N
postive JJ N
galactomannan NN N
or CC N
PCR NNP N
result NN N
was VBD N
deemed VBN N
insufficient JJ N
to TO N
confirm VB N
invasive JJ N
aspergillosis NN N
, , N
so RB N
treatment NN N
in IN N
this DT N
context NN N
was VBD N
classified VBN N
as IN N
empirical JJ N
) ) N
. . N

This DT N
outcome NN N
was VBD N
assessed VBN N
by IN N
an DT N
independent JJ N
data NN N
review NN N
committee NN N
from IN N
which WDT N
the DT N
study NN N
allocations NNS N
were VBD N
masked VBN N
. . N

Analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
and CC N
included VB N
all DT N
enrolled JJ N
patients NNS N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrial.gov NNP N
, , N
number NN N
NCT00163722 NNP N
. . N

FINDINGS NNP N
240 CD N
eligible JJ N
patients NNS N
were VBD N
recruited VBN N
from IN N
six CD N
Australian JJ N
centres NNS N
between IN N
Sept NNP N
30 CD N
, , N
2005 CD N
, , N
and CC N
Nov NNP N
19 CD N
, , N
2009 CD N
. . N

122 CD N
were VBD N
assigned VBN N
the DT N
standard JJ N
diagnostic JJ N
strategy NN N
and CC N
118 CD N
the DT N
biomarker-based JJ N
diagnostic JJ N
strategy NN N
. . N

39 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
in IN N
the DT N
standard JJ N
diagnosis NN N
group NN N
and CC N
18 CD N
( ( N
15 CD N
% NN N
) ) N
in IN N
the DT N
biomarker NN N
diagnosis NN N
group NN N
received VBD N
empirical JJ N
antifungal JJ N
treatment NN N
( ( N
difference NN N
17 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
4-26 CD N
; : N
p=0?002 NN N
) ) N
. . N

The DT N
numbers NNS N
of IN N
patients NNS N
who WP N
had VBD N
hepatotoxic NN N
and CC N
nephrotoxic JJ N
effects NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
standard JJ N
diagnosis NN N
and CC N
biomarker NN N
diagnosis NN N
groups NNS N
( ( N
hepatotoxic JJ N
effects NNS N
: : N
21 CD N
[ $ N
17 CD N
% NN N
] NNP N
vs NN N
12 CD N
[ JJ N
10 CD N
% NN N
] NN N
, , N
p=0?11 NN N
; : N
nephrotoxic JJ N
effects NNS N
: : N
52 CD N
[ $ N
43 CD N
% NN N
] NNP N
vs NN N
60 CD N
[ JJ N
51 CD N
% NN N
] NN N
, , N
p=0?20 NN N
) ) N
. . N

INTERPRETATION NNP N
Use NNP N
of IN N
aspergillus JJ N
galactomannan NN N
and CC N
PCR NNP N
to TO N
direct VB N
treatment NN N
reduced VBN N
use NN N
of IN N
empirical JJ N
antifungal JJ N
treatment NN N
. . N

This DT N
approach NN N
is VBZ N
an DT N
effective JJ N
strategy NN N
for IN N
the DT N
management NN N
of IN N
invasive JJ N
aspergillosis NN N
in IN N
high-risk JJ N
haematology NN N
patients NNS N
. . N

FUNDING NNP N
Australian JJ N
National NNP N
Health NNP N
and CC N
Medical NNP N
Research NNP N
Council NNP N
, , N
Cancer NNP N
Council NNP N
New NNP N
South NNP N
Wales NNP N
, , N
Pfizer NNP N
, , N
Merck NNP N
, , N
Gilead NNP N
Sciences NNPS N
. . N

-DOCSTART- -X- O O

Standard NNP 2_i
versus NN N
extended VBD 1_i
lymphadenectomy NN 1_i
in IN N
radical JJ N
pancreatoduodenectomy NN N
for IN N
ductal JJ N
adenocarcinoma NN N
of IN N
the DT N
head NN N
of IN N
the DT N
pancreas NNS N
: : N
long-term JJ N
results NNS N
of IN N
a DT N
Japanese JJ N
multicenter NN N
randomized VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND IN N
The DT N
value NN N
of IN N
pancreatoduodenectomy NN N
( ( N
PD NNP N
) ) N
with IN N
extended VBN N
lymphadenectomy NN N
for IN N
pancreatic JJ N
cancer NN N
has VBZ N
been VBN N
evaluated VBN N
by IN N
many JJ N
retrospective JJ N
studies NNS N
and CC N
3 CD N
randomized VBN N
controlled VBN N
trials NNS N
( ( N
RCT NNP N
) ) N
. . N

However RB N
, , N
the DT N
protocols NNS N
used VBN N
and CC N
the DT N
results NNS N
found VBD N
in IN N
the DT N
3 CD N
RCTs NNP N
were VBD N
diverse JJ N
. . N

Therefore RB N
, , N
a DT N
multicenter NN N
RCT NNP N
was VBD N
proposed VBN N
in IN N
1998 CD N
to TO N
evaluate VB N
the DT N
primary JJ N
end NN N
point NN N
of IN N
long-term JJ N
survival NN N
and CC N
the DT N
secondary JJ N
end NN N
points NNS N
of IN N
morbidity NN N
, , N
mortality NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
patients NNS N
undergoing VBG N
standard JJ N
versus NN N
extended VBD 1_i
lymphadenectomy NN 1_i
in IN N
radical JJ N
PD NNP N
for IN N
pancreatic JJ N
cancer NN N
. . N

METHODS NNP N
From IN N
March NNP N
2000 CD N
to TO N
May NNP N
2003 CD N
, , N
112 CD N
patients NNS N
with IN N
potentially RB N
curable JJ N
pancreatic JJ N
head NN N
cancer NN N
were VBD N
enrolled VBN N
and CC N
intraoperatively RB N
randomized VBN N
to TO N
a DT N
standard NN 1_i
or CC 1_i
extended JJ 1_i
lymphadenectomy NN 1_i
group NN N
. . N

No RB N
resected JJ N
patients NNS N
received VBD N
any DT N
adjuvant JJ N
treatments NNS N
. . N

RESULTS VB N
A DT N
hundred CD N
and CC N
one CD N
eligible JJ N
patients NNS N
were VBD N
analyzed VBN N
. . N

Demographic NNP N
and CC N
histopathological JJ N
characteristics NNS N
of IN N
the DT N
two CD N
groups NNS N
were VBD N
similar JJ N
. . N

The DT N
mean NN N
operating NN N
time NN N
, , N
intraoperative JJ N
blood NN N
loss NN N
and CC N
number NN N
of IN N
retrieved JJ N
lymph NN N
nodes NNS N
were VBD N
greater JJR N
in IN N
the DT N
extended JJ N
group NN N
, , N
but CC N
the DT N
other JJ N
operative JJ N
results NNS N
were VBD N
comparable JJ N
. . N

CONCLUSIONS NNP N
Although IN N
this DT N
multicenter NN N
RCT NNP N
was VBD N
conducted VBN N
in IN N
a DT N
strict JJ N
setting NN N
, , N
extended VBD 1_i
lymphadenectomy NN 1_i
in IN N
radical JJ N
PD NNP N
did VBD N
not RB N
benefit VB N
long-term JJ N
survival NN N
in IN N
patients NNS N
with IN N
resectable JJ N
pancreatic JJ N
head NN N
cancer NN N
and CC N
led VBD N
to TO N
levels NNS N
of IN N
morbidity NN N
, , N
mortality NN N
and CC N
quality NN N
of IN N
life NN N
comparable JJ N
to TO N
those DT N
found VBN N
after IN N
standard JJ 1_i
lymphadenectomy NN 1_i
. . 1_i

-DOCSTART- -X- O O

Cone NN N
biopsy NN N
: : N
has VBZ N
endocervical JJ 2_i
sampling VBG 2_i
a DT N
role NN N
? . N
OBJECTIVE UH N
To TO N
investigate VB N
the DT N
sensitivity NN N
, , N
specificity NN N
and CC N
predictive JJ N
value NN N
of IN N
endocervical JJ 2_i
sampling NN 2_i
in IN N
women NNS N
with IN N
abnormal JJ N
cervical JJ N
smears NNS N
. . N

DESIGN VB N
A DT N
randomized JJ N
study NN N
of IN N
two CD N
methods NNS N
of IN N
endocervical JJ 2_i
sampling NN 2_i
. . N

SETTING NN N
Colposcopy NNP N
clinic NN N
at IN N
Aberdeen NNP N
Royal NNP N
Infirmary NNP N
. . N

SUBJECTS NNP N
100 CD N
women NNS N
with IN N
abnormal JJ N
cervical JJ N
smears NNS N
selected VBN N
for IN N
cone NN N
biopsy NN N
according VBG N
to TO N
current JJ N
colposcopy NN N
criteria NNS N
. . N

INTERVENTIONS NNP N
53 CD N
women NNS N
were VBD N
randomized VBN N
to TO N
have VB N
endocervical JJ 2_i
sampling VBG 2_i
with IN 2_i
the DT 2_i
Kevorkian NNP 2_i
curette NN 2_i
and CC N
47 CD N
to TO N
have VB N
sampling VBG 2_i
with IN 2_i
the DT 2_i
Medscand NNP 2_i
endocervical JJ 2_i
brush NN 2_i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Cytology NNP N
and CC N
histology NN N
results NNS N
from IN N
endocervical JJ 2_i
sampling NN 2_i
compared VBN N
with IN N
cone NN N
biopsy NN N
histology NN N
. . N

RESULTS VB N
The DT N
overall JJ N
sensitivity NN N
of IN N
endocervical JJ 2_i
sampling NN 2_i
was VBD N
56 CD N
% NN N
, , N
with IN N
a DT N
false JJ N
negative JJ N
rate NN N
of IN N
44 CD N
% NN N
and CC N
a DT N
negative JJ N
predictive JJ N
value NN N
of IN N
26 CD N
% NN N
. . N

CONCLUSIONS NNP N
Endocervical NNP 2_i
sampling VBG 2_i
should MD N
not RB N
influence VB N
management NN N
when WRB N
colposcopy NN N
is VBZ N
unsatisfactory JJ N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
Positive NNP 4_i
Action NNP 4_i
on IN N
the DT N
emotional JJ N
health NN N
of IN N
urban JJ N
youth NN N
: : N
a DT N
cluster-randomized JJ N
trial NN N
. . N

PURPOSE NNP N
We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
Positive JJ 4_i
Action NNP 4_i
( ( 4_i
PA NNP 4_i
) ) 4_i
, , N
a DT N
school-based JJ 4_i
social-emotional JJ 4_i
learning NN 4_i
and CC 4_i
health NN 4_i
promotion NN 4_i
program NN 4_i
, , N
on IN N
the DT N
emotional JJ N
health NN N
of IN N
predominately RB N
low-income JJ N
and CC N
ethnic JJ N
minority NN N
urban JJ N
youth NN N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
matched-pair JJ N
, , N
cluster-randomized JJ N
controlled VBN N
trial NN N
involving VBG N
14 CD N
Chicago NNP N
public JJ N
schools NNS N
. . N

Outcomes NNS N
were VBD N
assessed VBN N
over IN N
a DT N
6-year JJ N
period NN N
of IN N
program NN N
implementation NN N
for IN N
a DT N
cohort NN N
of IN N
youth NN N
in IN N
each DT N
school NN N
, , N
followed VBD N
from IN N
grades NNS N
3 CD N
to TO N
8 CD N
. . N

Youth NN N
reported VBD N
on IN N
their PRP$ N
emotional JJ N
health NN N
( ( N
positive JJ N
affect NN N
, , N
life NN N
satisfaction NN N
, , N
depression NN N
, , N
anxiety NN N
) ) N
and CC N
social-emotional JJ N
and CC N
character NN N
development NN N
. . N

Growth-curve NNP N
and CC N
structural-equation NN N
modeling NN N
analyses NNS N
assessed VBD N
overall JJ N
program NN N
effects NNS N
on IN N
the DT N
emotional JJ N
health NN N
outcomes NNS N
as RB N
well RB N
as IN N
mediation NN N
of IN N
these DT N
effects NNS N
via IN N
the DT N
program NN N
's POS N
impact NN N
on IN N
youths NNS N
' POS N
social-emotional JJ N
and CC N
character NN N
development NN N
. . N

RESULTS JJ N
Students NNS N
in IN N
PA NNP 4_i
schools NNS N
, , N
compared VBN N
with IN N
those DT N
in IN N
control NN N
schools NNS N
, , N
had VBD N
more RBR N
favorable JJ N
change NN N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
in IN N
positive JJ N
affect NN N
( ( N
standardized JJ N
mean NN N
difference NN N
effect NN N
size NN N
[ NNP N
ES NNP N
] NNP N
= NNP N
.17 NNP N
) ) N
and CC N
life NN N
satisfaction NN N
( ( N
ES NNP N
= NNP N
.13 NNP N
) ) N
as RB N
well RB N
as IN N
significantly RB N
lower JJR N
depression NN N
( ( N
ES NNP N
= NNP N
-.14 NNP N
) ) N
and CC N
anxiety NN N
( ( N
ES NNP N
= NNP N
-.26 NNP N
) ) N
at IN N
study JJ N
end NN N
point NN N
. . N

Program NNP N
effects NNS N
for IN N
positive JJ N
affect NN N
, , N
depression NN N
, , N
and CC N
anxiety NN N
were VBD N
mediated VBN N
by IN N
more RBR N
favorable JJ N
change NN N
over IN N
time NN N
in IN N
social-emotional JJ N
and CC N
character NN N
development NN N
for IN N
students NNS N
in IN N
PA NNP N
schools NNS N
. . N

CONCLUSIONS NNP N
Results NNP N
suggest VBP N
that IN N
universal JJ N
, , N
school-based JJ N
programs NNS N
can MD N
benefit VB N
the DT N
emotional JJ N
health NN N
of IN N
youth NN N
in IN N
low-income JJ N
, , N
urban JJ N
settings NNS N
. . N

The DT N
modest JJ N
magnitude NN N
of IN N
effects NNS N
over IN N
an DT N
extended JJ N
period NN N
of IN N
program NN N
implementation NN N
, , N
however RB N
, , N
reflects VBZ N
the DT N
challenges NNS N
of IN N
both DT N
mounting VBG N
interventions NNS N
and CC N
offsetting VBG N
formidable JJ N
risks NNS N
for IN N
mental JJ N
health NN N
problems NNS N
in IN N
such JJ N
environments NNS N
. . N

-DOCSTART- -X- O O

Antipyrine NNP N
clearance NN N
and CC N
response NN N
to TO N
interferon VB 3_i
treatment NN N
in IN N
patients NNS N
with IN N
chronic JJ N
active JJ N
hepatitis NN N
C. NNP N
To TO N
determine VB N
whether IN N
hepatic JJ N
metabolic JJ N
function NN N
affects VBZ N
the DT N
response NN N
to TO N
interferon VB 3_i
treatment NN N
, , N
we PRP N
measured VBD N
antipyrine JJ N
clearance NN N
( ( N
APC NNP N
) ) N
in IN N
85 CD N
patients NNS N
with IN N
chronic JJ N
active JJ N
hepatitis NN N
C NNP N
and CC N
compared VBN N
the DT N
results NNS N
with IN N
treatment NN N
outcome NN N
. . N

Among IN N
55 CD N
patients NNS N
who WP N
responded VBD N
to TO N
interferon VB 2_i
by IN N
normalization NN N
of IN N
alanine JJ N
transaminase NN N
( ( N
ALT NNP N
) ) N
, , N
median JJ N
APC NNP N
before IN N
treatment NN N
was VBD N
0.47 CD N
( ( N
range NN N
, , N
0.12 CD N
to TO N
0.98 CD N
; : N
normal JJ N
range NN N
, , N
0.34 CD N
to TO N
1.02 CD N
mL/min/kg NNS N
body NN N
wt NN N
) ) N
, , N
a DT N
value NN N
that WDT N
was VBD N
significantly RB N
greater JJR N
than IN N
in IN N
30 CD N
nonresponders NNS N
( ( N
0.23 CD N
; : N
0.08 CD N
to TO N
0.67 CD N
mL/min/kg NNS N
body NN N
wt NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

APC NNP N
was VBD N
closely RB N
associated VBN N
with IN N
response NN N
to TO N
interferon VB 2_i
. . N

The DT N
response NN N
rate NN N
among IN N
cases NNS N
with IN N
values NNS N
> VBP N
0.25 CD N
mL/min/kg NN N
body NN N
weight NN N
was VBD N
79 CD N
% NN N
, , N
the DT N
same JJ N
as IN N
in IN N
cases NNS N
without IN N
cirrhosis NN N
. . N

Cases NNS N
without IN N
cirrhosis NN N
and CC N
with IN N
APC NNP N
of IN N
> NNP N
0.25 CD N
mL/min/kg NN N
body NN N
weight NN N
had VBD N
an DT N
85 CD N
% NN N
chance NN N
of IN N
responding VBG N
to TO N
interferon VB 2_i
; : N
this DT N
was VBD N
unlikely JJ N
a DT N
simple JJ N
reflection NN N
of IN N
histological JJ N
activity NN N
, , N
because IN N
the DT N
correlation NN N
with IN N
Scheuer NNP N
score NN N
was VBD N
poor JJ N
in IN N
this DT N
subgroup NN N
( ( N
r JJ N
= NNP N
-.31 NNP N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

A DT N
second JJ N
, , N
independent JJ N
group NN N
of IN N
43 CD N
patients NNS N
was VBD N
used VBN N
to TO N
test VB N
the DT N
predictive JJ N
value NN N
of IN N
APC NNP N
( ( N
using VBG N
0.25 CD N
mL/min/kg NN N
body NN N
wt VBD N
as IN N
a DT N
cut-off NN N
) ) N
for IN N
response NN N
to TO N
interferon VB 3_i
treatment NN N
. . N

In IN N
this DT N
group NN N
, , N
APC NNP N
correctly RB N
predicted VBD N
positive JJ N
response NN N
to TO N
interferon VB 3_i
in IN N
75 CD N
% NN N
of IN N
cases NNS N
. . N

APC NNP N
was VBD N
also RB N
used VBN N
to TO N
measure VB N
the DT N
effects NNS N
of IN N
treatment NN N
on IN N
hepatic JJ N
metabolic JJ N
function NN N
. . N

Regardless NNP N
of IN N
outcome NN N
, , N
there EX N
was VBD N
no DT N
change NN N
in IN N
APC NNP N
at IN N
the DT N
end NN N
of IN N
a DT N
6-month JJ N
course NN N
of IN N
interferon NN 3_i
treatment NN N
. . N

Six CD N
months NNS N
later RB N
, , N
however RB N
, , N
improvement NN N
in IN N
APC NNP N
( ( N
14 CD N
% NN N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
was VBD N
evident JJ N
among IN N
responders NNS N
but CC N
not RB N
in IN N
those DT N
who WP N
had VBD N
failed VBN N
to TO N
respond VB N
to TO N
interferon VB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Etomidate NN 3_i
with IN 3_i
or CC 3_i
without IN 3_i
flumazenil JJ 3_i
anesthesia NN 3_i
for IN N
stem NN N
cell NN N
transplantation NN N
in IN N
autistic JJ N
children NNS N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
etomidate JJ 3_i
administration NN 3_i
with IN 3_i
or CC 3_i
without IN 3_i
flumazenil NNS 3_i
in IN N
autistic JJ N
children NNS N
who WP N
underwent VBP N
intrathecal JJ N
transplantation NN N
of IN N
stem NN N
cells NNS N
by IN N
lumbar NN N
puncture NN N
. . N

METHODS NNP N
Forty NNP N
autistic JJ N
children NNS N
aged VBN N
2-12 CD N
, , N
who WP N
were VBD N
scheduled VBN N
for IN N
stem NN N
cell NN N
transplantation NN N
via IN N
lumbar NN N
puncture NN N
under IN N
anesthesia NN N
, , N
were VBD N
randomized VBN N
for IN N
a DT N
double-blind JJ N
study NN N
. . N

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
: : N
the DT 3_i
flumazenil NN 3_i
group NN 3_i
( ( N
group NN N
F NNP N
, , N
n=20 NN N
) ) N
and CC N
the DT 3_i
etomidate NN 3_i
group NN 3_i
( ( N
group NN N
E NNP N
, , N
n=20 NN N
) ) N
. . N

All DT N
children NNS N
received VBD N
0.2 CD N
mg/kg NN N
of IN N
etomidate NN 3_i
. . N

In IN N
the DT N
case NN N
of IN N
inadequate JJ N
anesthesia NN N
, , N
patients NNS N
received VBD N
repeated JJ N
doses NNS N
of IN N
0.1 CD N
mg/kg NN N
of IN N
etomidate NN 3_i
until IN N
reaching VBG N
deep JJ N
sedation NN N
. . N

After IN N
operation NN N
, , N
children NNS N
in IN N
group NN N
F NNP N
were VBD N
given VBN N
flumazenil NNS 3_i
( ( N
0.01 CD N
mg/kg NN N
) ) N
and CC N
children NNS N
in IN N
group NN N
E NNP N
received VBD N
placebo NN 7_i
. . N

Heart NNP N
rate NN N
( ( N
HR NNP N
) ) N
, , N
mean JJ N
arterial JJ N
pressure NN N
, , N
oxygen NN N
saturation NN N
, , N
respiratory NN N
rate NN N
, , N
the DT N
Ramsay NNP N
sedation NN N
score NN N
( ( N
RSS NNP N
) ) N
, , N
and CC N
recovery NN N
time NN N
of IN N
all DT N
children NNS N
were VBD N
continuously RB N
monitored VBN N
and CC N
recorded VBN N
during IN N
the DT N
entire JJ N
procedure NN N
. . N

RESULTS NNP N
After IN N
anesthesia NN N
, , N
blood NN N
pressure NN N
and CC N
HR NNP N
measurements NNS N
were VBD N
not RB N
significantly RB N
changed VBN N
in IN N
both DT N
groups NNS N
compared VBN N
with IN N
the DT N
baseline NN N
. . N

There EX N
were VBD N
no DT N
respiratory JJ N
depression NN N
, , N
bradycardia NN N
, , N
hypotension NN N
, , N
nausea NN N
, , N
and CC N
vomiting VBG N
. . N

Five CD N
patients NNS N
complained VBN N
of IN N
pain NN N
on IN N
the DT N
site NN N
of IN N
injection NN N
. . N

Myoclonus NNP N
occurred VBD N
in IN N
seven CD N
patients NNS N
. . N

Recovery JJ N
time NN N
in IN N
group NN N
F NNP N
was VBD N
significantly RB N
shorter JJR N
than IN N
in IN N
group NN N
E NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
after IN N
the DT N
injection NN N
of IN N
flumazenil NN 3_i
, , N
RSS NNP N
in IN N
group NN N
F NNP N
significantly RB N
decreased VBD N
than IN N
in IN N
group NN N
E. NNP N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
operation NN N
time NN N
. . N

Physician JJ N
satisfaction NN N
in IN N
both DT N
groups NNS N
was VBD N
similar JJ N
. . N

CONCLUSIONS NNP N
Etomidate NNP 3_i
resulted VBD N
in IN N
stable JJ N
hemodynamic JJ N
responses NNS N
and CC N
relatively RB N
less JJ N
adverse JJ N
effects NNS N
, , N
and CC N
flumazenil RB 3_i
antagonized VBD N
the DT N
anesthetic JJ N
effect NN N
of IN N
etomidate NN N
; : N
thus RB N
, , N
etomidate NN N
with IN N
flumazenil NN N
is VBZ N
suitable JJ N
for IN N
performing VBG N
stem NN N
cell NN N
transplantation NN N
in IN N
autistic JJ N
children NNS N
. . N

-DOCSTART- -X- O O

Large-dose JJ N
intravenous JJ N
ferric NNS 3_i
carboxymaltose VBP 3_i
injection NN 3_i
for IN N
iron NN N
deficiency NN N
anemia NN N
in IN N
heavy JJ N
uterine JJ N
bleeding NN N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
objective NN N
was VBD N
to TO N
evaluate VB N
efficacy NN N
and CC N
safety NN N
of IN N
rapid JJ N
, , N
large-dose JJ 3_i
intravenous JJ 3_i
( ( 3_i
IV NNP 3_i
) ) 3_i
administration NN 3_i
of IN 3_i
ferric JJ 3_i
carboxymaltose NN 3_i
compared VBN N
to TO N
oral JJ 3_i
iron NN 3_i
in IN N
correcting VBG N
iron NN N
deficiency NN N
anemia NN N
due JJ N
to TO N
heavy JJ N
uterine JJ N
bleeding NN N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
, , N
477 CD N
women NNS N
with IN N
anemia NN N
, , N
iron NN N
deficiency NN N
, , N
and CC N
heavy JJ N
uterine JJ N
bleeding NN N
were VBD N
assigned VBN N
to TO N
receive VB N
either DT N
IV NNP 3_i
ferric NN 3_i
carboxymaltose NN 3_i
( ( N
< JJ N
or=1000 NN N
mg NN N
over IN N
15 CD N
min NNS N
, , N
repeated VBD N
weekly JJ N
to TO N
achieve VB N
a DT N
total JJ N
calculated JJ N
replacement NN N
dose NN N
) ) N
or CC N
325 CD N
mg NN N
of IN 3_i
ferrous JJ 3_i
sulfate NN 3_i
( ( N
65 CD N
mg NN N
elemental JJ N
iron NN N
) ) N
prescribed VBD N
orally RB N
thrice JJ N
daily RB N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
Compared VBD N
to TO N
those DT N
assigned VBN N
to TO N
ferrous JJ 3_i
sulfate NN 3_i
, , N
more JJR N
patients NNS N
assigned VBD N
to TO N
ferric VB 3_i
carboxymaltose NN 3_i
responded VBN N
with IN N
a DT N
hemoglobin NN N
( ( N
Hb NNP N
) ) N
increase NN N
of IN N
2.0 CD N
g/dL NN N
or CC N
more JJR N
( ( N
82 CD N
% NN N
vs. FW N
62 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
treatment NN N
difference NN N
12.2-28.3 CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
, , N
more JJR N
achieved VBD N
a DT N
3.0 CD N
g/dL NN N
or CC N
more JJR N
increase NN N
( ( N
53 CD N
% NN N
vs. FW N
36 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
more JJR N
achieved JJ N
correction NN N
( ( N
Hb NNP N
> NNP N
or= VBD N
12 CD N
g/dL NN N
) ) N
of IN N
anemia NN N
( ( N
73 CD N
% NN N
vs. FW N
50 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Patients NNS N
treated VBD N
with IN N
ferric JJ 3_i
carboxymaltose NN 3_i
compared VBN N
to TO N
those DT N
prescribed VBN N
ferrous JJ 3_i
sulfate NN 3_i
reported VBD N
greater JJR N
gains NNS N
in IN N
vitality NN N
and CC N
physical JJ N
function NN N
and CC N
experienced JJ N
greater JJR N
improvement NN N
in IN N
symptoms NNS N
of IN N
fatigue NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ N
drug NN N
events NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
with IN N
iron NN N
deficiency NN N
anemia NN N
due JJ N
to TO N
heavy JJ N
uterine JJ N
bleeding NN N
, , N
rapid JJ N
IV NNP N
administration NN N
of IN N
large JJ N
doses NNS N
of IN N
a DT N
new JJ 3_i
iron NN 3_i
agent NN 3_i
, , 3_i
ferric JJ 3_i
carboxymaltose NN 3_i
, , N
is VBZ N
more RBR N
effective JJ N
than IN N
oral JJ 3_i
iron NN 3_i
therapy NN 3_i
in IN N
correcting VBG N
anemia NN N
, , N
replenishing VBG N
iron NN N
stores NNS N
, , N
and CC N
improving VBG N
quality NN N
of IN N
life NN N
. . N

-DOCSTART- -X- O O

Skin NNP N
manifestations NNS N
of IN N
inhaled JJ N
corticosteroids NNS 3_i
in IN N
COPD NNP N
patients NNS N
: : N
results NNS N
from IN N
Lung NNP N
Health NNP N
Study NNP N
II NNP N
. . N

OBJECTIVE NNP N
To TO N
define VB N
the DT N
relationship NN N
between IN N
skin NN N
bruising NN N
( ( N
as RB N
well RB N
as IN N
other JJ N
cutaneous JJ N
manifestations NNS N
) ) N
and CC N
inhaled VBN N
corticosteroid NN 3_i
( ( 3_i
ICS NNP 3_i
) ) 3_i
therapy NN N
vs NN N
placebo NN N
in IN N
subjects NNS N
with IN N
COPD NNP N
who WP N
were VBD N
participating VBG N
in IN N
a DT N
clinical JJ N
trial NN N
. . N

To TO N
explore VB N
the DT N
relationship NN N
between IN N
easy JJ N
skin NN N
bruising NN N
and CC N
other JJ N
systemic JJ N
effects NNS N
of IN N
ICS NNP N
therapy NN N
, , N
including VBG N
adrenal JJ N
suppression NN N
and CC N
loss NN N
of IN N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
. . N

DESIGN NNP N
Double-blind NNP N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
triamcinolone NN 3_i
acetonide NN 3_i
( ( N
1200 CD N
microg FW N
daily RB N
) ) N
vs NN N
placebo NN 7_i
in IN N
participants NNS N
with IN N
mild-to-moderate JJ N
COPD NNP N
. . N

SETTING NNP N
Lung NNP N
Health NNP N
Study NNP N
II NNP N
, , N
a DT N
clinical JJ N
trial NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
ICS NNP 3_i
compared VBN N
to TO N
placebo VB N
in IN N
1,116 CD N
participants NNS N
in IN N
10 CD N
centers NNS N
over IN N
> $ N
3.5 CD N
to TO N
4.5 CD N
years NNS N
. . N

PARTICIPANTS VB N
A DT N
total NN N
of IN N
1,116 CD N
smokers NNS N
or CC N
recent JJ N
ex-smokers NNS N
with IN N
mild-to-moderate JJ N
COPD NNP N
( ( N
age NN N
range NN N
, , N
40 CD N
to TO N
69 CD N
years NNS N
; : N
mean JJ N
age NN N
, , N
56.3 CD N
years NNS N
; : N
37.2 CD N
% NN N
female NN N
) ) N
. . N

MEASUREMENTS NNP N
AND CC N
RESULTS NNP N
Every NNP N
6 CD N
months NNS N
, , N
a DT N
structured JJ N
questionnaire NN N
was VBD N
administered VBN N
to TO N
elicit VB N
reports NNS N
of IN N
any DT N
bruising NN N
and/or NN N
skin NN N
rashes NNS N
, , N
slow JJ N
healing NN N
of IN N
cuts NNS N
or CC N
sores NNS N
, , N
or CC N
other JJ N
skin JJ N
changes NNS N
. . N

Compliance NN N
with IN N
inhaler NN N
use NN N
was VBD N
assessed VBN N
by IN N
canister NN N
weighing VBG N
. . N

A DT N
significantly RB N
higher JJR N
proportion NN N
of IN N
ICS NNP 3_i
than IN N
placebo NN N
participants NNS N
who WP N
complied VBD N
with IN N
using VBG N
their PRP$ N
inhaler NN N
reported VBD N
easy JJ N
bruising NN N
( ( N
11.2 CD N
% NN N
vs JJ N
3.5 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
the DT N
slow JJ N
healing NN N
of IN N
skin NN N
cuts NNS N
or CC N
sores NNS N
( ( N
2.4 CD N
% NN N
vs JJ N
0.5 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Older JJR N
men NNS N
in IN N
the DT N
ICS NNP 3_i
group NN N
with IN N
good JJ N
inhaler NN N
compliance NN N
appeared VBD N
to TO N
be VB N
at IN N
the DT N
greatest JJS N
risk NN N
of IN N
bruising VBG N
. . N

In IN N
those DT N
participants NNS N
undergoing VBG N
serial JJ N
measurements NNS N
of IN N
adrenal JJ N
function NN N
and CC N
BMD NNP N
, , N
no DT N
association NN N
was VBD N
noted VBN N
between IN N
skin JJ N
bruising NN N
and CC N
either CC N
the DT N
suppression NN N
of IN N
adrenal JJ N
function NN N
or CC N
the DT N
loss NN N
of IN N
BMD NNP N
as IN N
systemic JJ N
complications NNS N
of IN N
ICS NNP N
use NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
moderate-to-high JJ N
doses NNS N
of IN N
ICSs NNP N
result NN N
in IN N
an DT N
increased JJ N
incidence NN N
of IN N
easy JJ N
bruising NN N
and CC N
impairment NN N
in IN N
skin NN N
healing NN N
in IN N
middle-aged JJ N
to TO N
elderly JJ N
persons NNS N
with IN N
COPD NNP N
. . N

No DT N
association NN N
was VBD N
noted VBN N
between IN N
skin JJ N
bruising NN N
and CC N
other JJ N
markers NNS N
of IN N
systemic JJ N
toxicity NN N
from IN N
the DT N
use NN N
of IN N
ICSs NNP N
. . N

-DOCSTART- -X- O O

Topiramate NNP 3_i
improves VBZ N
health-related JJ N
quality NN N
of IN N
life NN N
when WRB N
used VBN N
to TO N
prevent VB N
migraine NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
changes NNS N
in IN N
health-related JJ N
quality NN N
of IN N
life NN N
( ( N
HRQoL NNP N
) ) N
measures VBZ N
among IN N
patients NNS N
receiving VBG N
topiramate NN 3_i
( ( 3_i
TPM NNP 3_i
) ) 3_i
100 CD N
mg/d NN N
in IN N
two CD N
divided JJ N
doses NNS N
for IN N
migraine JJ N
prevention NN N
in IN N
three CD N
randomized NNS N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
26-week JJ N
trials NNS N
with IN N
similar JJ N
protocols NNS N
and CC N
study NN N
populations NNS N
. . N

BACKGROUND NNP N
Migraine NNP N
substantially RB N
impairs VBZ N
HRQoL NNP N
and CC N
work NN N
productivity NN N
before IN N
, , N
during IN N
, , N
and CC N
after IN N
attacks NNS N
. . N

Approximately RB N
50 CD N
% NN N
of IN N
patients NNS N
with IN N
migraine NN N
could MD N
be VB N
recommended VBN N
for IN N
preventive JJ N
therapies NNS N
, , N
yet RB N
only RB N
3 CD N
% NN N
to TO N
5 CD N
% NN N
of IN N
patients NNS N
receive VBP N
them PRP N
. . N

TPM NNP 3_i
is VBZ N
an DT N
effective JJ N
and CC N
generally RB N
well-tolerated JJ N
migraine NN N
prophylactic NN N
( ( N
preventive JJ N
) ) N
therapy NN N
for IN N
adults NNS N
, , N
as IN N
demonstrated VBN N
in IN N
several JJ N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trials NNS N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
in IN N
double-blind NN N
, , N
placebo-controlled JJ N
studies NNS N
of IN N
TPM NNP 3_i
in IN N
migraine JJ N
prevention NN N
are VBP N
paresthesia NN N
, , N
fatigue NN N
, , N
anorexia NN N
, , N
nausea NN N
, , N
taste NN N
alteration NN N
, , N
and CC N
diarrhea NN N
. . N

DESIGN NNP N
AND CC N
METHODS NNP N
The DT N
Migraine-Specific NNP N
Questionnaire NNP N
( ( N
MSQ NNP N
, , N
version NN N
2.1 CD N
) ) N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
TPM NNP 3_i
100 CD N
mg/d NN N
on IN N
the DT N
functionality NN N
and CC N
HRQoL NNP N
of IN N
randomized VBN N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
and CC N
study-completer JJ N
populations NNS N
pooled VBD N
from IN N
three CD N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trials NNS N
. . N

MSQ NNP N
scores NNS N
( ( N
0 CD N
to TO N
100 CD N
, , N
higher JJR N
score NN N
indicates VBZ N
better RBR N
functioning VBG N
) ) N
were VBD N
assessed VBN N
for IN N
the DT N
following JJ N
three CD N
domains NNS N
: : N
role NN N
restriction NN N
( ( N
examines VBZ N
the DT N
degree NN N
to TO N
which WDT N
performance NN N
of IN N
daily JJ N
activities NNS N
is VBZ N
limited VBN N
by IN N
migraine NN N
) ) N
, , N
role NN N
prevention NN N
( ( N
examines VBZ N
the DT N
degree NN N
to TO N
which WDT N
performance NN N
of IN N
daily JJ N
activities NNS N
is VBZ N
interrupted VBN N
by IN N
migraine NN N
) ) N
, , N
and CC N
emotional JJ N
function NN N
( ( N
examines JJ N
feelings NNS N
of IN N
frustration NN N
and CC N
helplessness NN N
due JJ N
to TO N
migraine VB N
) ) N
. . N

Between-group JJ N
differences NNS N
from IN N
baseline NN N
in IN N
mean JJ N
MSQ NNP N
domain NN N
scores NNS N
for IN N
TPM NNP 3_i
100 CD N
mg/d NN N
and CC N
placebo NN 7_i
were VBD N
compared VBN N
using VBG N
a DT N
mixed-effects NNS N
model NN N
with IN N
piecewise NN N
linear JJ N
regression NN N
. . N

Effect JJ N
sizes NNS N
were VBD N
calculated VBN N
to TO N
estimate VB N
the DT N
magnitude NN N
of IN N
change NN N
in IN N
HRQoL NNP N
that WDT N
can MD N
be VB N
associated VBN N
with IN N
TPM NNP 3_i
therapy NN 3_i
. . N

RESULTS NNP N
TPM NNP 3_i
100 CD N
mg/d NN N
significantly RB N
improved VBN N
all DT N
three CD N
MSQ NNP N
domains NNS N
compared VBN N
with IN N
placebo NN 3_i
for IN N
both DT N
the DT N
ITT NNP N
( ( N
TPM NNP 3_i
, , N
n JJ N
= VBP N
372 CD N
; : N
placebo NN 3_i
, , N
n JJ N
= NNP N
362 CD N
) ) N
and CC N
study-completer NN N
( ( N
TPM NNP N
, , N
n JJ N
= VBP N
220 CD N
; : N
placebo NN N
, , N
n JJ N
= NNP N
216 CD N
) ) N
populations NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
for IN N
all DT N
three CD N
domains NNS N
, , N
both DT N
populations NNS N
) ) N
. . N

Effect JJ N
sizes NN N
for IN N
TPM NNP 3_i
100 CD N
mg/d NN N
varied VBD N
from IN N
0.40 CD N
to TO N
0.78 CD N
, , N
indicating VBG N
that IN N
the DT N
changes NNS N
in IN N
MSQ NNP N
scores NNS N
for IN N
TPM NNP 3_i
100 CD N
mg/d NN N
were VBD N
moderate JJ N
and CC N
may MD N
be VB N
clinically RB N
significant JJ N
. . N

CONCLUSION NNP N
TPM NNP 3_i
100 CD N
mg/d NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
the DT N
prevention NN N
of IN N
migraine NN N
headache NN N
in IN N
adults NNS N
. . N

As IN N
the DT N
MSQ NNP N
results NNS N
from IN N
the DT N
three CD N
randomized VBN N
, , N
placebo-controlled JJ N
trials NNS N
indicate VBP N
, , N
HRQoL NNP N
is VBZ N
significantly RB N
improved VBN N
for IN N
up RB N
to TO N
6 CD N
months NNS N
following VBG N
initiation NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
beta-carotene NN N
levels NNS N
by IN N
long-term JJ N
administration NN N
of IN N
natural JJ 3_i
beta-carotene JJ 3_i
derived VBN N
from IN N
Dunaliella NNP N
bardawil NN N
in IN N
humans NNS N
. . N

Long-term JJ N
administration NN N
of IN N
a DT N
beta-carotene JJ 3_i
preparation NN 3_i
derived VBN N
from IN N
Dunaliella NNP N
bardawil NN N
, , N
a DT N
beta-carotene-rich JJ 3_i
algae NN 3_i
, , N
was VBD N
studied VBN N
in IN N
healthy JJ N
young JJ N
male NN N
volunteers NNS N
. . N

The DT N
daily JJ N
administration NN N
of IN N
60 CD 3_i
mg NN 3_i
of IN 3_i
the DT 3_i
beta-carotene JJ 3_i
preparation NN 3_i
( ( N
30 CD N
mg NN N
of IN N
all-trans JJ N
beta-carotene NN N
and CC N
30 CD N
mg NN N
of IN N
9-cis JJ N
beta-carotene NN N
) ) N
was VBD N
performed VBN N
and CC N
beta-carotene JJ N
concentrations NNS N
were VBD N
determined VBN N
in IN N
the DT N
plasma NN N
, , N
red JJ N
blood NN N
cells NNS N
( ( N
RBC NNP N
) ) N
, , N
platelets NNS N
( ( N
PLT NNP N
) ) N
, , N
and CC N
mononuclear JJ N
cells NNS N
( ( N
MN NNP N
) ) N
. . N

The DT N
all-trans JJ N
beta-carotene JJ N
level NN N
increased VBD N
four- JJ N
, , N
two- JJ N
, , N
and CC N
threefold VBD N
the DT N
baseline NN N
in IN N
plasma NN N
, , N
PLT NNP N
, , N
and CC N
MN NNP N
, , N
respectively RB N
. . N

Basal NNP N
levels NNS N
of IN N
9-cis CD N
beta-carotene NN N
in IN N
plasma NN N
, , N
PLT NNP N
, , N
and CC N
MN NNP N
were VBD N
low JJ N
and CC N
found VBN N
as IN N
one-tenth JJ N
, , N
one-fifth JJ N
, , N
and CC N
one-fifth JJ N
of IN N
all-trans JJ N
beta-carotene NN N
, , N
which WDT N
increased VBD N
three- NN N
, , N
two- JJ N
, , N
and CC N
1.5-fold JJ N
the DT N
baseline NN N
, , N
respectively RB N
. . N

Plasma NNP N
and CC N
RBC NNP N
alpha-tocopherol NN N
levels NNS N
were VBD N
not RB N
changed VBN N
by IN N
the DT N
intake NN N
of IN N
beta-carotene NN N
. . N

No DT N
side NN N
effects NNS N
or CC N
toxicities NNS N
were VBD N
documented VBN N
in IN N
any DT N
of IN N
the DT N
subjects NNS N
during IN N
the DT N
administration NN N
period NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
bioavailability NN N
of IN N
beta-carotene JJ N
derived VBN N
from IN N
Dunaliella NNP N
bardawil NN N
was VBD N
preferential JJ N
for IN N
all-trans JJ N
beta-carotene NN N
, , N
although IN N
a DT N
small JJ N
amount NN N
of IN N
the DT N
9-cis JJ N
form NN N
was VBD N
detected VBN N
in IN N
the DT N
plasma NN N
and CC N
blood NN N
cells NNS N
. . N

-DOCSTART- -X- O O

Randomised VBN N
placebo-controlled JJ 7_i
trial NN N
of IN N
rhesus-human JJ 3_i
reassortant JJ 3_i
rotavirus NN 3_i
vaccine NN 3_i
for IN N
prevention NN N
of IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
. . N

BACKGROUND NNP N
Rotavirus NNP N
is VBZ N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
acute JJ N
childhood NN N
gastroenteritis NN N
. . N

Vaccination NN N
with IN N
live JJ N
oral JJ N
heterologous JJ N
rotavirus NN N
vaccines NNS N
may MD N
prevent VB N
rotavirus NN N
gastroenteritis NN N
. . N

We PRP N
assessed VBD N
the DT N
efficacy NN N
of IN N
rhesus-human JJ 3_i
reassortant JJ 3_i
rotavirus NN 3_i
tetravalent NN 3_i
vaccine NN 3_i
( ( 3_i
RRV-TV NNP 3_i
) ) 3_i
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
in IN N
Finnish JJ N
children NNS N
in IN N
a DT N
randomised JJ N
placebo-controlled JJ 7_i
double-blind JJ N
trial NN N
. . N

METHODS NNP N
Placebo NNP 7_i
or CC N
RRV-TV NNP 3_i
( ( N
titre JJ N
4x10 CD N
( ( N
5 CD N
) ) N
plaque-forming JJ N
units NNS N
) ) N
was VBD N
given VBN N
to TO N
infants NNS N
at IN N
ages NNS N
2 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
months NNS N
. . N

The DT N
children NNS N
were VBD N
followed VBN N
up RP N
for IN N
one CD N
or CC N
two CD N
rotavirus JJ N
epidemic JJ N
seasons NNS N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
protection NN N
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
( ( N
score JJ N
> NN N
or CC N
=11 NN N
on IN N
a DT N
20-point JJ N
severity NN N
scale NN N
) ) N
. . N

2398 CD N
children NNS N
were VBD N
enrolled VBN N
and CC N
received VBN N
at IN N
least JJS N
one CD N
dose NN N
of IN N
RRV-TV NNP N
( ( N
n=1191 NN N
) ) N
or CC N
placebo NN 7_i
( ( N
n=1207 JJ N
) ) N
. . N

The DT N
primary JJ N
efficacy NN N
analysis NN N
was VBD N
based VBN N
on IN N
children NNS N
who WP N
received VBD N
three CD N
doses NNS N
of IN N
RRV-TV NNP N
( ( N
n=1128 NN N
) ) N
or CC N
placebo NN N
( ( N
n=1145 JJ N
) ) N
. . N

FINDINGS $ N
256 CD N
episodes NNS N
of IN N
rotavirus NN N
gastroenteritis NN N
occurred VBD N
at IN N
any DT N
time NN N
during IN N
the DT N
study NN N
; : N
65 CD N
were VBD N
among IN N
1191 CD N
RRV-TV JJ 3_i
recipients NNS N
, , N
and CC N
191 CD N
among IN N
1207 CD N
placebo NN 7_i
recipients NNS N
( ( N
vaccine JJ N
efficacy NN N
66 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
55-74 JJ N
] NN N
; : N
intention-to-treat JJ N
analysis NN N
) ) N
. . N

226 CD N
episodes NNS N
were VBD N
included VBN N
in IN N
the DT N
primary JJ N
efficacy NN N
analysis NN N
of IN N
fully RB N
vaccinated VBN N
children NNS N
( ( N
54 CD N
among IN N
1128 CD N
RRV-TV JJ N
recipients NNS N
, , N
172 CD N
among IN N
1145 CD N
placebo NN N
recipients NNS N
; : N
vaccine VB N
efficacy NN N
68 CD N
% NN N
[ JJ N
57-76 JJ N
] NN N
) ) N
. . N

100 CD N
episodes NNS N
were VBD N
severe JJ N
, , N
eight CD N
in IN N
RRV-TV NNP 3_i
recipients NNS N
and CC N
92 CD N
in IN N
placebo NN N
recipients NNS N
( ( N
vaccine JJ N
efficacy NN N
91 CD N
% NN N
[ JJ N
82-96 JJ N
] NN N
) ) N
. . N

INTERPRETATION NNP N
RRV-TV NNP 3_i
vaccine NN 3_i
was VBD N
highly RB N
effective JJ N
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
in IN N
young JJ N
children NNS N
. . N

Incorporation NN N
of IN N
this DT N
vaccine NN N
into IN N
routine JJ N
immunisation NN N
schedules NNS N
of IN N
infants NNS N
could MD N
reduce VB N
severe JJ N
rotavirus NN N
gastroenteritis NN N
by IN N
90 CD N
% NN N
and CC N
severe JJ N
gastroenteritis NN N
of IN N
all DT N
causes NNS N
in IN N
young JJ N
children NNS N
by IN N
60 CD N
% NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
Saccharomyces NNP 3_i
boulardii NN 3_i
in IN N
children NNS N
with IN N
acute JJ N
diarrhoea NN N
. . N

AIM NNP N
Certain NNP N
probiotic JJ N
agents NNS N
, , N
e.g NN N
. . N

Lactobacillus CC N
GG NNP N
, , N
have VBP N
shown VBN N
efficacy NN N
in IN N
clinical JJ N
trials NNS N
for IN N
the DT N
treatment NN N
of IN N
acute JJ N
childhood NN N
diarrhoea NN N
, , N
but CC N
few JJ N
studies NNS N
have VBP N
examined VBN N
the DT N
effect NN N
of IN N
Saccharomyces NNP 3_i
boulardii NN 3_i
. . N

We PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
S. NNP N
boulardii NN N
in IN N
children NNS N
with IN N
acute JJ N
diarrhoea NN N
. . N

METHODS NNP N
Two CD N
hundred VBD N
children NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
S. NNP N
boulardii NN N
in IN N
a DT N
granulated JJ N
form NN N
in IN N
a DT N
daily JJ N
dose NN N
of IN N
250 CD N
mg NN N
( ( 3_i
S. NNP 3_i
boulardii NNP 3_i
group NN N
) ) N
or CC N
placebo NN 7_i
( ( 7_i
placebo JJ 7_i
group NN N
) ) N
for IN N
5 CD N
d. JJ N
Clinical NNP N
and CC N
demographic JJ N
characteristics NNS N
on IN N
admission NN N
were VBD N
similar JJ N
between IN N
the DT N
study NN N
groups NNS N
. . N

RESULTS VB N
The DT N
medians NNS N
of IN N
the DT N
average JJ N
stool NN N
frequency NN N
after IN N
the DT N
second JJ N
day NN N
of IN N
the DT N
treatment NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
S. NNP N
boulardii NN N
group NN N
than IN N
in IN N
the DT N
placebo NN 7_i
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
duration NN N
of IN N
diarrhoea NN N
significantly RB N
reduced VBN N
in IN N
the DT N
S. NNP N
boulardii NN N
group NN N
compared VBN N
with IN N
the DT N
placebo NN 7_i
group NN N
( ( N
4.7 CD N
vs RB N
5.5 CD N
d NN N
, , N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

The DT N
effect NN N
of IN N
S. NNP N
boulardii NN N
on IN N
watery NN N
diarrhoea NN N
became VBD N
apparent JJ N
after IN N
the DT N
second JJ N
day NN N
of IN N
the DT N
treatment NN N
. . N

The DT N
duration NN N
of IN N
hospital NN N
stay NN N
was VBD N
shorter JJR N
in IN N
the DT N
S. NNP N
boulardii NN N
group NN N
than IN N
in IN N
the DT N
placebo NN 7_i
group NN N
( ( N
2.9 CD N
vs RB N
3.9 CD N
d NN N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Four CD N
children NNS N
from IN N
the DT N
placebo NN 7_i
group NN N
versus VBD N
only RB N
one CD N
child NN N
from IN N
the DT N
S. NNP N
boulardii NN N
group NN N
had VBD N
persisting VBG N
diarrhoea NN N
. . N

CONCLUSION VB N
The DT N
placebo-controlled JJ 7_i
study NN N
suggested VBD N
that IN N
S. NNP N
boulardii VBP N
significantly RB N
reduced VBN N
the DT N
duration NN N
of IN N
acute JJ N
diarrhoea NN N
and CC N
the DT N
duration NN N
of IN N
hospital NN N
stay NN N
. . N

S. NNP N
boulardii NN N
seems VBZ N
to TO N
be VB N
a DT N
promising JJ N
agent NN N
for IN N
the DT N
amelioration NN N
of IN N
the DT N
course NN N
of IN N
acute JJ N
diarrhoea NN N
in IN N
children NNS N
when WRB N
used VBN N
therapeutically RB N
. . N

-DOCSTART- -X- O O

Clinical JJ N
trial NN N
: : N
marine NN 3_i
lipid JJ 3_i
suppositories NNS 3_i
as IN N
laxatives NNS N
. . N

UNLABELLED JJ N
Cod-liver JJ N
oil NN N
and CC N
other JJ N
marine NN N
products NNS N
containing VBG N
polyunsaturated JJ N
fatty JJ N
acids NNS N
have VBP N
anti-inflammatory JJ N
, , N
anti-bacterial JJ N
and CC N
anti-viral JJ N
effects NNS N
and CC N
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
various JJ N
inflammatory NN N
and CC N
infectious JJ N
diseases NNS N
. . N

We PRP N
developed VBD N
suppositories NNS 3_i
and CC 3_i
ointment NN 3_i
with IN 3_i
30 CD 3_i
% NN 3_i
free JJ 3_i
fatty JJ 3_i
acid NN 3_i
( ( 3_i
FFA NNP 3_i
) ) 3_i
extract NN 3_i
from IN 3_i
omega-3 JJ 3_i
fish JJ 3_i
oil NN 3_i
. . N

Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN N
of IN N
marine JJ N
lipid JJ N
suppositories NNS N
and CC N
ointment NN N
in IN N
healthy JJ N
volunteers NNS N
and CC N
to TO N
explore VB N
the DT N
laxative JJ N
effect NN N
of IN N
the DT N
suppositories NNS N
. . N

Thirty NNP N
healthy JJ N
volunteers NNS N
were VBD N
randomized VBN N
either RB N
to TO N
a DT N
study NN N
group NN N
administrating VBG N
30 CD N
% NN N
FFA NNP 3_i
suppositories NNS 3_i
and CC N
applying VBG N
30 CD N
% NN N
FFA NNP 3_i
ointment NN 3_i
to TO N
the DT N
perianal JJ N
region NN N
twice RB N
per IN N
day NN N
for IN N
two CD N
weeks NNS N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
using VBG N
placebo NN 7_i
suppositories NNS 7_i
and CC N
ointment NN N
in IN N
a DT N
double JJ N
blinded JJ N
manner NN N
. . N

RESULTS NNP N
No NNP N
serious JJ N
toxic NN N
effects NNS N
or CC N
irritation NN N
were VBD N
observed VBN N
. . N

In IN N
the DT N
study NN N
group NN N
93 CD N
% NN N
felt VBD N
the DT N
urge NN N
to TO N
defecate VB N
after IN N
administration NN N
of IN N
the DT N
suppositories NNS N
as IN N
compared VBN N
to TO N
37 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Subsequently RB N
90 CD N
% NN N
in IN N
the DT N
study NN N
group NN N
defecated VBD N
, , N
compared VBN N
to TO N
33 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
marine JJ N
lipid JJ N
suppositories NNS N
and CC N
ointment NN N
were VBD N
well RB N
tolerated VBN N
with IN N
no DT N
significant JJ N
toxic JJ N
side NN N
effects NNS N
observed VBD N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
suppositories NNS N
have VBP N
a DT N
distinct JJ N
laxative JJ N
effect NN N
and CC N
we PRP N
aim VBP N
to TO N
explore VB N
this DT N
effect NN N
in IN N
further JJ N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
Interceed NNP 2_i
( ( 2_i
TC7 NNP 2_i
) ) 2_i
absorbable JJ 2_i
adhesion NN 2_i
barrier NN 2_i
to TO N
reduce VB N
postoperative JJ N
adhesion NN N
reformation NN N
in IN N
infertility NN N
and CC N
endometriosis NN N
surgery NN N
. . N

The DT N
Obstetrics NNPS N
and CC N
Gynecology NNP N
Adhesion NNP N
Prevention NNP N
Committee NNP N
. . N

Interceed NNP 2_i
( ( 2_i
TC7 NNP 2_i
) ) 2_i
is VBZ N
a DT N
fabric NN N
composed VBN N
of IN N
oxidized JJ N
, , N
regenerated VBD N
cellulose NN N
that WDT N
was VBD N
designed VBN N
to TO N
reduce VB N
the DT N
formation NN N
of IN N
postsurgical JJ N
adhesions NNS N
. . N

We PRP N
evaluated VBD N
Interceed NNP 2_i
( ( 2_i
TC7 NNP 2_i
) ) 3_i
in IN N
a DT N
randomized JJ N
, , N
multicenter RB N
clinical JJ N
study NN N
. . N

Sixty-three JJ N
infertility NN N
patients NNS N
had VBD N
bilateral JJ N
pelvic JJ N
sidewall NN N
adhesions NNS N
removed VBD N
at IN N
laparotomy NN N
. . N

One CD N
pelvic NN N
sidewall NN N
was VBD N
covered VBN N
by IN N
Interceed NNP 2_i
( ( 2_i
TC7 NNP 2_i
) ) N
and CC N
the DT N
other JJ 4_i
was VBD 4_i
left VBN 4_i
uncovered JJ 4_i
. . N

The DT N
deperitonealized JJ N
areas NNS N
( ( N
N NNP N
= NNP N
205 CD N
) ) N
of IN N
all DT N
sidewalls NNS N
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
less JJR N
than IN N
100 CD N
mm2 NN N
, , N
N NNP N
= NNP N
72 CD N
; : N
100-1000 CD N
mm2 NN N
, , N
N NNP N
= NNP N
95 CD N
; : N
and CC N
more JJR N
than IN N
1000 CD N
mm2 NN N
, , N
N NNP N
= VBZ N
38 CD N
. . N

The DT N
effectiveness NN N
of IN N
Interceed NNP 2_i
( ( 2_i
TC7 NNP 2_i
) ) 2_i
was VBD N
evaluated VBN N
at IN N
laparoscopy JJ N
10-98 JJ N
days NNS N
after IN N
laparotomy NN 2_i
. . N

Significantly RB N
more JJR N
adhesions NNS N
were VBD N
observed VBN N
at IN N
laparoscopy NN N
on IN N
the DT N
control NN N
pelvic JJ N
sidewalls NNS N
( ( N
48 CD N
of IN N
63 CD N
, , N
76 CD N
% NN N
) ) N
than IN N
on IN N
the DT N
treated VBN N
sides NNS N
( ( N
26 CD N
of IN N
63 CD N
, , N
41 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
.0001 NN N
) ) N
. . N

The DT N
Interceed NNP 3_i
( ( 3_i
TC7 NNP 3_i
) ) 3_i
-treated VBD 3_i
sidewalls NNS N
also RB N
had VBD N
significantly RB N
less RBR N
area NN N
involved VBN N
with IN N
adhesions NNS N
at IN N
laparoscopy NN N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
, , N
P NNP N
less JJR N
than IN N
.001 NN N
, , N
and CC N
P NNP N
less JJR N
than IN N
.001 NN N
in IN N
the DT N
three CD N
groups NNS N
, , N
respectively RB N
) ) N
. . N

Twenty-eight JJ N
women NNS N
with IN N
severe JJ N
endometriosis NN N
also RB N
had VBD N
significantly RB N
more JJR N
adhesions NNS N
on IN N
the DT N
control NN N
side NN N
( ( N
23 CD N
of IN N
28 CD N
, , N
82 CD N
% NN N
) ) N
than IN N
on IN N
the DT N
treated JJ N
side NN N
( ( N
14 CD N
of IN N
28 CD N
, , N
50 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
Interceed NNP 3_i
( ( 3_i
TC7 NNP 3_i
) ) 3_i
effectively RB N
reduced VBD N
the DT N
incidence NN N
and CC N
extent NN N
of IN N
postoperative JJ N
adhesions NNS N
, , N
even RB N
in IN N
patients NNS N
with IN N
severe JJ N
endometriosis NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
on IN N
pressure NN N
after IN N
instillation NN N
of IN N
a DT N
drop NN N
of IN N
depot-pilocarpine NN 3_i
. . N

Clinical JJ N
results NNS N
of IN N
its PRP$ N
medium-term JJ N
action NN N
] NNP N
. . N

A NNP N
clinical JJ N
comparison NN N
of IN N
an DT N
emulsion NN N
containing VBG N
a DT N
new JJ 3_i
pilocarpine NN 3_i
polymer NN 3_i
( ( 3_i
Polym NNP 3_i
) ) 3_i
compound NN N
to TO N
that DT N
of IN N
a DT N
traditional JJ 3_i
pilocarpine NN 3_i
salt NN 3_i
solution NN 3_i
( ( 3_i
Plc NNP 3_i
) ) 3_i
on IN N
the DT N
intraocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
has VBZ N
been VBN N
performed VBN N
in IN N
40 CD N
open-angle JJ N
patients NNS N
treated VBN N
with IN N
the DT N
long JJ N
acting JJ N
pilocarpine-complex NN N
for IN N
120 CD N
days NNS N
. . N

The DT N
treatment NN N
protocol NN N
was VBD N
divided VBN N
into IN N
3 CD N
stages NNS N
: : N
Stage NN N
1 CD N
is VBZ N
a DT N
single JJ N
dose NN N
treatment NN N
where WRB N
12 CD N
patients NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
groups NNS N
of IN N
6 CD N
each DT N
. . N

The DT N
patients NNS N
of IN N
each DT N
group NN N
were VBD N
given VBN N
1 CD N
drop NN N
into IN N
each DT N
eye NN N
: : N
1 CD N
drop NN N
every DT N
12 CD N
hours NNS N
for IN N
Polym NNP N
, , N
1 CD N
drop NN N
every DT N
6 CD N
hours NNS N
for IN N
Plc NNP N
. . N

The DT N
patients NNS N
were VBD N
observed VBN N
for IN N
a DT N
period NN N
of IN N
24 CD N
hours NNS N
. . N

After IN N
24 CD N
hours NNS N
without IN N
medication NN N
, , N
the DT N
treatments NNS N
were VBD N
crossed VBN N
over IN N
and CC N
nycthemeral JJ N
graph NN N
curves NNS N
were VBD N
registered VBN N
for IN N
both DT N
groups NNS N
. . N

Stage NN N
2 CD N
is VBZ N
a DT N
medium JJ N
term NN N
study NN N
were VBD N
the DT N
12 CD N
patients NNS N
used VBN N
in IN N
Stage NNP N
1 CD N
were VBD N
added VBN N
to TO N
another DT N
28 CD N
patients NNS N
. . N

All DT N
40 CD N
were VBD N
then RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
treatment NN N
groups NNS N
( ( N
2 CD N
groups NNS N
of IN N
20 CD N
patients NNS N
each DT N
) ) N
according VBG N
to TO N
a DT N
table NN N
of IN N
random NN N
numbers NNS N
. . N

Treatments NNS N
were VBD N
administered VBN N
during IN N
one CD N
month NN N
, , N
then RB N
cross-overed JJ N
again RB N
during IN N
4 CD N
weeks NNS N
. . N

Stage NN N
3 CD N
: : N
finally RB N
, , N
every DT N
patient NN N
could MD N
choose VB N
his PRP$ N
treatment NN N
( ( N
either CC N
Polym NNP 3_i
or CC N
Plc NNP 3_i
) ) N
for IN N
the DT N
rest NN N
of IN N
the DT N
period NN N
( ( N
2 CD N
months NNS N
) ) N
. . N

The DT N
clinical JJ N
study NN N
shows VBZ N
that IN N
the DT N
polymer NN N
complex NN N
( ( N
Polym NNP N
) ) N
produced VBD N
a DT N
prolonged JJ N
therapeutic JJ N
effect NN N
, , N
this DT N
being VBG N
consistant JJ N
with IN N
a DT N
slow JJ N
release NN N
pattern NN N
and CC N
maintained VBD N
a DT N
more RBR N
effective JJ N
around-the-clock NN N
control NN N
than IN N
pilocarpine JJ 3_i
solution NN N
. . N

These DT N
results NNS N
were VBD N
accomplished VBN N
by IN N
two CD N
applications NNS N
per IN N
day NN N
as IN N
compared VBN N
to TO N
the DT N
four CD N
necessary JJ N
applications NNS N
of IN N
Plc NNP 3_i
, , N
on IN N
a DT N
half JJ N
daily JJ N
pilocarpine NN 3_i
dose NN N
with IN N
Polym NNP 3_i
. . N

The DT N
medium JJ N
term NN N
results NNS N
confirmed VBD N
the DT N
efficacity NN N
noted VBD N
in IN N
the DT N
short JJ N
term NN N
survey NN N
. . N

Most JJS N
patients NNS N
preferred JJ N
Polym NNP 3_i
to TO N
Plc VB 3_i
when WRB N
they PRP N
were VBD N
asked VBN N
. . N

Throughout IN N
the DT N
4 CD N
months NNS N
study JJ N
period NN N
, , N
no DT N
adverse JJ N
side NN N
effects NNS N
were VBD N
reported VBN N
. . N

Visual JJ N
disturbances NNS N
characteristic NN N
of IN N
pilocarpine JJ 3_i
eye-drops NNS N
were VBD N
reduced VBN N
from IN N
3 CD N
times NNS N
a DT N
day NN N
on IN N
pilocarpine NN 3_i
salt NN 3_i
solution NN N
to TO N
once VB N
a DT N
day NN N
on IN N
pilocarpine JJ 3_i
polymer NN 3_i
complex NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
chelation NN 3_i
therapy NN 3_i
on IN N
progressive JJ N
diabetic JJ N
nephropathy NN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
and CC N
high-normal JJ N
body NN N
lead JJ N
burdens NNS N
. . N

BACKGROUND VB N
A DT N
previous JJ N
study NN N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
with IN N
high-normal JJ N
body NN N
lead NN N
burdens VBZ N
showed VBD N
that IN N
EDTA NNP 3_i
chelation NN 3_i
therapy NN 3_i
for IN N
3 CD N
months NNS N
slows VBZ N
progressive JJ N
diabetic JJ N
nephropathy NN N
during IN N
a DT N
12-month JJ N
follow-up NN N
. . N

The DT N
effect NN N
of IN N
a DT N
longer JJR N
course NN N
of IN N
therapy NN N
on IN N
kidney NN N
function NN N
decrease NN N
over IN N
a DT N
longer JJR N
follow-up NN N
is VBZ N
not RB N
known VBN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
12-month JJ N
run-in JJ N
phase NN N
, , N
then RB N
a DT N
randomized VBN N
single-blind NN N
study NN N
with IN N
a DT N
27-month JJ N
intervention NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP N
University NNP N
medical JJ N
center NN N
; : N
50 CD N
patients NNS N
( ( N
serum JJ N
creatinine NN N
, , N
1.5-3.9 JJ N
mg/dL NN N
) ) N
with IN N
high-normal JJ N
body NN N
lead JJ N
burden NN N
( ( N
?80- JJ N
< NN N
600 CD N
?g NN N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
. . N

INTERVENTION NNP N
The DT N
treatment NN N
group NN N
received VBD N
weekly JJ N
chelation NN N
therapy NN N
for IN N
3 CD N
months NNS N
to TO N
reduce VB N
their PRP$ N
body NN N
lead JJ N
burden NN N
to TO N
< VB N
60 CD N
?g NNS N
and CC N
then RB N
as IN N
needed VBN N
for IN N
24 CD N
months NNS N
to TO N
maintain VB N
this DT N
level NN N
. . N

The DT N
control NN N
group NN N
received VBD N
placebo NN N
for IN N
3 CD N
months NNS N
and CC N
then RB N
weekly VB N
for IN N
5 CD N
weeks NNS N
at IN N
6-month JJ N
intervals NNS N
for IN N
24 CD N
months NNS N
. . N

OUTCOMES IN N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
change NN N
in IN N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
eGFR NN N
) ) N
over IN N
time NN N
. . N

A DT N
secondary JJ N
end NN N
point NN N
was VBD N
a DT N
2-fold JJ N
increase NN N
in IN N
baseline JJ N
serum NN N
creatinine NN N
level NN N
or CC N
the DT N
requirement NN N
for IN N
renal JJ N
replacement NN N
therapy NN N
. . N

MEASUREMENTS NNP N
Body NNP N
lead JJ N
burdens NNS N
were VBD N
assessed VBN N
by IN N
EDTA NNP N
mobilization NN N
tests NNS N
and CC N
eGFR NN N
was VBD N
calculated VBN N
using VBG N
the DT N
equation NN N
for IN N
Chinese JJ N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
. . N

RESULTS NNP N
Mean NNP N
baseline NN N
eGFRs NN N
in IN N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
were VBD N
similar JJ N
. . N

After IN N
3 CD N
months NNS N
of IN N
chelation NN N
therapy NN N
, , N
the DT N
change NN N
in IN N
eGFR NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
+1.0 NNP N
? . N
4.8 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
) ) N
differed VBN N
significantly RB N
from IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
-1.5 NNP N
? . N
4.8 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

In IN N
the DT N
subsequent JJ N
24-month JJ N
intervention NN N
, , N
the DT N
yearly JJ N
rate NN N
of IN N
decrease NN N
in IN N
eGFR NN N
( ( N
5.6 CD N
? . N
5.0 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
per IN N
year NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
slower JJR N
than IN N
that DT N
( ( N
9.2 CD N
? . N
3.6 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
per IN N
year NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

17 CD N
( ( N
68 CD N
% NN N
) ) N
control-group NN N
patients NNS N
and CC N
9 CD N
( ( N
36 CD N
% NN N
) ) N
treatment-group NN N
patients NNS N
achieved VBD N
the DT N
secondary JJ N
end NN N
point NN N
. . N

LIMITATIONS NNP N
Small NNP N
sample NN N
size NN N
, , N
not RB N
double JJ N
blind NN N
. . N

CONCLUSIONS VB N
A DT N
27-month JJ N
course NN N
of IN N
EDTA NNP N
chelation NN N
therapy NN N
retards VBZ N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
with IN N
high-normal JJ N
body NN N
lead JJ N
burdens NNS N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
oral JJ N
misoprostol NN 3_i
and CC N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ N
stage NN N
of IN N
labor NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ N
misoprostol NN N
400 CD N
mug NN N
with IN N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ N
stage NN N
of IN N
labor NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
conducted VBN N
in IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
. . N

Three CD N
hundred VBD N
and CC N
fifty-five JJ N
women NNS N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ 3_i
misoprostol NN 3_i
400 CD 3_i
mug NN 3_i
or CC 3_i
intramuscular JJ 3_i
syntometrine NN 3_i
in IN N
the DT N
third JJ N
stage NN N
of IN N
labor NN N
were VBD N
studied VBN N
. . N

The DT N
change NN N
in IN N
hemoglobin JJ N
level NN N
from IN N
before IN N
to TO N
48 CD N
h NN N
after IN N
delivery NN N
, , N
use NN N
of IN N
additional JJ N
oxytocics NNS N
and CC N
treatment NN N
related JJ N
side NN N
effects NNS N
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
the DT N
change NN N
in IN N
hemoglobin JJ N
level NN N
and CC N
mean JJ N
blood NN N
loss NN N
. . N

The DT N
incidence NN N
of IN N
shivering NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
misoprostol NN 3_i
group NN N
whilst VBD N
that IN N
of IN N
vomiting NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
syntometrine NN 3_i
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
nausea NN N
, , N
headache NN N
, , N
diarrhea NN N
and CC N
pyrexia NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Orally RB N
administered VBD N
misoprostol NN 3_i
at IN N
a DT N
dose NN N
of IN N
400 CD N
mug NN N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
in IN N
preventing VBG N
post-partum JJ N
blood NN N
loss NN N
, , N
as IN N
measured VBN N
by IN N
the DT N
peri-partum JJ N
change NN N
in IN N
hemoglobin JJ N
level NN N
and CC N
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O

Competitive JJ 5_i
memory NN 5_i
training NN 5_i
( ( 5_i
COMET NNP 5_i
) ) 5_i
for IN N
treating VBG N
low JJ N
self-esteem NNS N
in IN N
patients NNS N
with IN N
depressive JJ N
disorders NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Self-esteem NNP N
is VBZ N
a DT N
major JJ N
concern NN N
in IN N
mood NN N
disorders NNS N
. . N

Low JJ N
self-esteem NN N
is VBZ N
a DT N
symptom NN N
of IN N
depressive JJ N
disorders NNS N
and CC N
is VBZ N
considered VBN N
by IN N
some DT N
to TO N
be VB N
a DT N
predictor NN N
for IN N
relapse NN N
, , N
whereas JJ N
high JJ N
self-esteem NN N
seems VBZ N
to TO N
buffer VB N
against IN N
depression NN N
. . N

Recently RB N
, , N
Competitive NNP 5_i
Memory NNP 5_i
Training NNP 5_i
( ( 5_i
COMET NNP 5_i
) ) 5_i
has VBZ N
shown VBN N
to TO N
be VB N
effective JJ N
for IN N
the DT N
enhancement NN N
of IN N
self-esteem NN N
in IN N
several JJ N
psychopathological JJ N
conditions NNS N
. . N

The DT N
current JJ N
study NN N
assesses VBZ N
whether IN N
COMET NNP 5_i
is VBZ N
also RB N
an DT N
effective JJ N
intervention NN N
for IN N
patients NNS N
with IN N
depressive JJ N
disorders NNS N
. . N

METHODS NNP N
Sixty-one JJ N
patients NNS N
with IN N
depressive JJ N
disorders NNS N
who WP N
were VBD N
already RB N
in IN N
therapy NN N
in IN N
an DT N
outpatient JJ N
mental JJ N
health NN N
institution NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
eight CD N
group NN N
sessions NNS N
of IN N
COMET NNP 5_i
in IN 2_i
addition NN 2_i
to TO 2_i
their PRP$ 2_i
regular JJ 5_i
therapy NN 5_i
( ( 2_i
COMET NNP 5_i
+ NNP 2_i
therapy NN 5_i
as IN 5_i
usual JJ 5_i
[ NNP 5_i
TAU NNP 5_i
] NN 5_i
: : N
the DT N
experimental JJ N
group NN N
) ) N
or CC N
to TO N
8 CD N
weeks NNS N
of IN N
ongoing VBG 7_i
regular JJ 7_i
therapy NN 7_i
( ( 7_i
TAU NNP 7_i
only RB 7_i
: : N
the DT N
control NN N
group NN N
) ) N
. . N

These DT N
latter JJ N
( ( N
control NN N
) ) N
patients NNS N
received VBD N
COMET NNP 5_i
after IN N
their PRP$ N
TAU NNP 5_i
only RB N
period NN N
. . N

All DT N
patients NNS N
in IN N
both DT N
groups NNS N
that WDT N
completed VBD N
COMET NNP 5_i
were VBD N
contacted VBN N
3 CD N
and CC N
6 CD N
months NNS N
later RB N
to TO N
assess VB N
whether IN N
the DT N
effects NNS N
of IN N
COMET NNP 5_i
had VBD N
remained VBN N
stable JJ N
. . N

RESULTS NNP N
Compared VBD N
to TO N
the DT N
patients NNS N
who WP N
received VBD N
TAU NNP 2_i
only RB N
, , N
patients NNS N
in IN N
the DT N
COMET NNP 5_i
+ NNP N
TAU NNP 5_i
condition NN N
showed VBD N
significant JJ N
improvement NN N
with IN N
large JJ N
effect NN N
sizes VBZ N
on IN N
indices NNS N
of IN N
self-esteem JJ N
, , N
depression NN N
, , N
and CC N
depressive JJ N
rumination NN N
. . N

The DT N
therapeutic JJ N
effects NNS N
of IN N
COMET NNP 5_i
+ NNP N
TAU NNP 5_i
remained VBD N
stable JJ N
after IN N
3 CD N
and CC N
6 CD N
months NNS N
on IN N
all DT N
outcome NN N
measures NNS N
or CC N
improved VBN N
even RB N
further RBR N
. . N

CONCLUSION NNP N
COMET NNP 5_i
for IN N
low JJ N
self-esteem JJ N
seems VBZ N
to TO N
be VB N
an DT N
efficacious JJ N
trans-diagnostic JJ N
intervention NN N
that WDT N
can MD N
relatively RB N
easily RB N
be VB N
added VBN N
to TO N
the DT N
regular JJ N
treatment NN N
of IN N
patients NNS N
with IN N
depressive JJ N
disorders NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
remifentanil NN 3_i
with IN N
fentanyl NN 3_i
for IN N
deep JJ N
sedation NN N
in IN N
oral JJ N
surgery NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
recovery NN N
for IN N
oral JJ N
surgery NN N
patients NNS N
given VBN N
a DT N
deep JJ N
sedation NN N
regimen NNS N
of IN N
midazolam NN 3_i
, , 3_i
propofol NN 3_i
, , N
and CC N
remifentanil NN 3_i
with IN N
a DT N
standard JJ N
control NN N
of IN N
fentanyl NN N
in IN N
place NN N
of IN N
remifentanil NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
investigation NN N
was VBD N
designed VBN N
as IN N
a DT N
randomized NN N
, , N
prospective JJ N
, , N
single-blinded JJ N
controlled VBD N
study NN N
. . N

Group NNP N
1 CD N
, , N
the DT N
control NN N
, , N
received VBD N
midazolam JJ 3_i
0.03 CD 3_i
mg/kg NN 3_i
, , 3_i
fentanyl VBP 3_i
1 CD 3_i
microg/kg NN 3_i
, , 3_i
and CC 3_i
propofol VB 3_i
initially RB 3_i
at IN 3_i
140 CD 3_i
microg/kg/min NN 3_i
. . 3_i

Group NNP N
2 CD N
received VBD N
midazolam RB 3_i
0.03 CD 3_i
mg/kg NN 3_i
, , 3_i
remifentanil NN 3_i
: : 3_i
propofol NN 3_i
( ( 3_i
1:500 CD 3_i
) ) 3_i
given VBN 3_i
at IN 3_i
an DT 3_i
initial JJ 3_i
propofol JJ 3_i
infusion NN 3_i
rate NN 3_i
of IN 3_i
40 CD 3_i
microg/kg/min NN 3_i
. . 3_i

Outcome NNP N
measures NNS N
included VBD N
time NN N
to TO N
response NN N
to TO N
verbal JJ N
command NN N
, , N
Aldrete NNP N
score VBD N
= JJ N
9 CD N
, , N
Postanesthesia NNP N
Discharge NNP N
Scoring NNP N
System NNP N
= VBD N
7 CD N
, , N
and CC N
assessment NN N
by IN N
the DT N
Digit NNP N
Symbol NNP N
Substitution NNP N
Test NNP N
. . N

RESULTS NNP N
Forty-seven JJ N
subjects NNS N
were VBD N
entered VBN N
in IN N
the DT N
study NN N
. . N

Baseline NNP N
findings NNS N
were VBD N
homogenous JJ N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Subjects NNS N
in IN N
group NN N
2 CD N
recovered VBN N
earlier JJR N
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
and CC N
required VBN N
less JJR N
propofol NN 3_i
for IN N
both DT N
the DT N
induction NN N
( ( N
0.8 CD N
+/- JJ N
0.4 CD N
versus NN N
1.2 CD N
+/- JJ N
0.6 CD N
mg/kg NN N
; : N
mean JJ N
+/- JJ N
SD NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
maintenance NN N
of IN N
deep JJ N
sedation NN N
( ( N
46 CD N
+/- JJ N
9 CD N
versus NN N
131 CD N
+/- JJ N
17 CD N
microg/kg/min NN N
; : N
P NNP N
< NNP N
.005 NNP N
) ) N
. . N

There EX N
were VBD N
minor JJ N
differences NNS N
in IN N
vital JJ N
signs NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
demonstrated VBD N
that IN N
this DT N
remifentanil JJ N
regimen NNS N
provided VBD N
significantly RB N
more RBR N
rapid JJ N
recovery NN N
and CC N
used VBD N
significantly RB N
less JJR N
propofol JJ 3_i
compared VBN N
with IN N
the DT N
fentanyl JJ 3_i
regimen NNS N
. . N

-DOCSTART- -X- O O

High-dose JJ 3_i
pyridoxine NN 3_i
and CC 3_i
magnesium NN 3_i
administration NN 3_i
in IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
: : N
an DT N
absence NN N
of IN N
salutary JJ N
effects NNS N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

Several JJ N
reports NNS N
have VBP N
described VBN N
salutary JJ N
effects NNS N
such JJ N
as IN N
decreased JJ N
physical JJ N
aggression NN N
and CC N
improved VBN N
social JJ N
responsiveness NN N
being VBG N
associated VBN N
with IN N
the DT N
administration NN N
of IN N
high JJ N
doses NNS N
of IN N
pyridoxine NN 3_i
and CC 3_i
magnesium NN 3_i
( ( 3_i
HDPM NNP 3_i
) ) 3_i
in IN N
open-labeled JJ N
and CC N
controlled JJ N
studies NNS N
of IN N
patients NNS N
with IN N
autism NN N
. . N

Despite IN N
this DT N
fact NN N
, , N
this DT N
intervention NN N
remains VBZ N
controversial JJ N
. . N

A DT N
10-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
examine VB N
both DT N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
HDPM NNP 3_i
in IN N
autism NN N
. . N

Twelve CD N
patients NNS N
were VBD N
enrolled VBN N
, , N
and CC N
10 CD N
patients NNS N
( ( N
mean JJ N
age NN N
6 CD N
years NNS N
3 CD N
months NNS N
) ) N
were VBD N
able JJ N
to TO N
complete VB N
the DT N
study NN N
. . N

HDPM NNP 3_i
at IN N
an DT N
average JJ N
dose NN N
of IN N
638.9 CD N
mg NN N
of IN N
pyridoxine NN 3_i
and CC N
216.3 CD N
mg NN N
of IN N
magnesium NN 3_i
oxide NN 3_i
was VBD N
ineffective JJ N
in IN N
ameliorating VBG N
autistic JJ N
behaviors NNS N
as IN N
assessed VBN N
by IN N
the DT N
Children NNP N
's POS N
Psychiatric NNP N
Rating NNP N
Scale NNP N
( ( N
CPRS NNP N
) ) N
, , N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
Scale NNP N
, , N
and CC N
the DT N
NIMH NNP N
Global NNP N
Obsessive NNP N
Compulsive NNP N
Scale NNP N
. . N

Furthermore NNP N
, , N
no DT N
clinically RB N
significant JJ N
side NN N
effects NNS N
were VBD N
noted VBN N
during IN N
HDPM NNP 3_i
administration NN N
. . N

A DT N
trend NN N
for IN N
a DT N
transient JJ N
change NN N
on IN N
the DT N
CPRS NNP N
was VBD N
found VBN N
that IN N
was VBD N
possibly RB N
due JJ N
to TO N
a DT N
placebo NN N
response NN N
. . N

This DT N
study NN N
raises VBZ N
doubts NNS N
about IN N
the DT N
clinical JJ N
effectiveness NN N
of IN N
HDPM NNP 3_i
in IN N
autistic JJ N
disorder NN N
. . N

-DOCSTART- -X- O O

Unopposed VBN 3_i
estrogen NN 3_i
increases NNS N
total JJ N
plasma JJ N
factor NN N
VII NNP N
, , N
but CC N
not RB N
active JJ N
factor NN N
VII NNP N
-- : N
a DT N
short-term JJ N
placebo-controlled JJ 7_i
study NN N
in IN N
healthy JJ N
postmenopausal NN N
women NNS N
. . N

Estrogen NNP 3_i
therapy NN 3_i
may MD N
increase VB N
the DT N
risk NN N
of IN N
arterial JJ N
thromboembolism NN N
, , N
at IN N
least JJS N
in IN N
the DT N
short JJ N
term NN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
and CC N
placebo-controlled JJ N
study NN N
in IN N
25 CD N
healthy JJ N
postmenopausal NN N
women NNS N
( ( N
52.5 CD N
+/- JJ N
2.8 CD N
years NNS N
) ) N
, , N
we PRP N
therefore VBP N
examined VBD N
the DT N
short-term JJ N
effect NN N
of IN N
unopposed JJ 3_i
estrogen NN 3_i
on IN N
the DT N
fasting NN N
and CC N
fat-load-stimulated JJ N
plasma NN N
levels NNS N
of IN N
total JJ N
factor NN N
VII NNP N
versus NN N
active JJ N
factor NN N
VII NNP N
. . N

Plasma NNP N
total JJ N
factor NN N
VII NNP N
was VBD N
measured VBN N
by IN N
use NN N
of IN N
a DT N
chromogenic JJ N
assay NN N
; : N
plasma CC N
active JJ N
FVII NNP N
by IN N
a DT N
recently RB N
developed VBN N
method NN N
using VBG N
truncated JJ N
tissue NN N
factor NN N
. . N

As IN N
compared VBN N
to TO N
placebo VB 7_i
, , N
8 CD N
weeks NNS N
of IN N
oral JJ 3_i
17beta-estradiol JJ 3_i
( ( N
2 CD N
mg NNS N
daily RB N
) ) N
increased VBD N
the DT N
mean NN N
fasting NN N
and CC N
postprandial JJ N
plasma NN N
levels NNS N
of IN N
total JJ N
factor NN N
VII NNP N
by IN N
17 CD N
and CC N
21 CD N
% NN N
points NNS N
, , N
respectively RB N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
the DT N
fasting NN N
and/or JJ N
postprandial JJ N
plasma NN N
levels NNS N
of IN N
active JJ N
factor NN N
VII NNP N
( ( N
mean JJ N
change NN N
both DT N
0.05 CD N
ng/mL NN N
; : N
P NNP N
> NNP N
0.35 CD N
) ) N
. . N

Furthermore UH N
, , N
the DT N
change NN N
in IN N
the DT N
fasting JJ N
level NN N
of IN N
total JJ N
factor NN N
VII NNP N
after IN N
therapy NN N
was VBD N
not RB N
associated VBN N
with IN N
the DT N
change NN N
in IN N
the DT N
fasting JJ N
level NN N
of IN N
active JJ N
factor NN N
VII NNP N
( ( N
r VB N
= RB N
0.27 CD N
; : N
P NNP N
= NNP N
0.21 CD N
) ) N
. . N

These DT N
findings NNS N
argue VBP N
against IN N
the DT N
idea NN N
that WDT N
elevated VBD N
levels NNS N
of IN N
total JJ N
factor NN N
VII NNP N
underlie VBZ N
an DT N
increased VBN N
risk NN N
of IN N
arterial JJ N
thromboembolism NN N
in IN N
postmenopausal JJ N
women NNS N
using VBG N
unopposed JJ 3_i
estrogen NN 3_i
replacement NN 3_i
. . 3_i

-DOCSTART- -X- O O

Atrioventricular JJ N
conduction NN N
during IN N
long-term JJ N
follow-up NN N
of IN N
patients NNS N
with IN N
sick JJ N
sinus NN N
syndrome NN N
. . N

BACKGROUND NNP N
It PRP N
has VBZ N
been VBN N
claimed VBN N
that IN N
patients NNS N
with IN N
sick JJ N
sinus NN N
syndrome NN N
have VBP N
an DT N
increased VBN N
risk NN N
of IN N
developing VBG N
AV NNP N
block NN N
, , N
but CC N
this DT N
has VBZ N
never RB N
been VBN N
assessed VBN N
prospectively RB N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
in IN N
a DT N
prospective JJ N
trial NN N
AV NNP N
conduction NN N
during IN N
the DT N
long-term JJ N
follow-up NN N
of IN N
patients NNS N
with IN N
sick JJ N
sinus NN N
syndrome NN N
. . N

METHODS NNP N
Two CD N
hundred VBD N
twenty-five JJ N
consecutive JJ N
patients NNS N
with IN N
sick JJ N
sinus NN N
syndrome NN N
and CC N
intact JJ N
AV NNP N
conduction NN N
were VBD N
randomized VBN N
to TO N
undergo VB N
single-chamber JJ 1_i
atrial JJ 1_i
pacing NN 1_i
( ( N
110 CD N
patients NNS N
) ) N
or CC N
single-chamber JJ 1_i
ventricular JJ 1_i
pacing NN 1_i
( ( N
115 CD N
patients NNS N
) ) N
. . N

Follow-up NN N
after IN N
3 CD N
months NNS N
and CC N
then RB N
yearly RB N
included VBN N
measurement NN N
of IN N
the DT N
PQ NNP N
interval NN N
and CC N
, , N
in IN N
patients NNS N
with IN N
atrial JJ N
pacemakers NNS N
, , N
determination NN N
of IN N
the DT N
atrial JJ N
stimulus-Q JJ N
intervals NNS N
at IN N
pacing VBG N
rates NNS N
of IN N
100 CD N
and CC N
120 CD N
bpm NN N
. . N

The DT N
occurrence NN N
of IN N
AV NNP N
block NN N
in IN N
the DT N
atrial JJ N
group NN N
was VBD N
recorded VBN N
. . N

During IN N
follow-up JJ N
( ( N
mean JJ N
, , N
5.5+/-2.4 JJ N
years NNS N
) ) N
, , N
there EX N
was VBD N
no DT N
change NN N
in IN N
PQ NNP N
interval NN N
in IN N
either DT N
group NN N
and CC N
no DT N
change NN N
in IN N
atrial JJ N
stimulus-Q JJ N
intervals NNS N
or CC N
Wenckebach NNP N
block NN N
point NN N
in IN N
the DT N
atrial JJ N
group NN N
. . N

Four CD N
of IN N
110 CD N
patients NNS N
in IN N
the DT N
atrial JJ N
group NN N
developed VBD N
grade $ N
2 CD N
to TO N
3 CD N
AV NNP N
block NN N
that WDT N
required VBD N
upgrading NN N
of IN N
the DT N
pacemaker NN N
( ( N
0.6 CD N
% NN N
per IN N
year NN N
) ) N
. . N

Two CD N
of IN N
these DT N
4 CD N
patients NNS N
had VBD N
right JJ N
bundle-branch JJ N
block NN N
at IN N
pacemaker NN N
implantation NN N
. . N

CONCLUSIONS NNP N
AV NNP N
conduction NN N
, , N
estimated VBN N
as IN N
PQ NNP N
interval NN N
and CC N
atrial JJ N
stimulus-Q JJ N
interval NN N
at IN N
atrial JJ N
pacing VBG N
rates NNS N
of IN N
100 CD N
and CC N
120 CD N
bpm NN N
and CC N
the DT N
Wenckebach NNP N
block NN N
point NN N
, , N
remains VBZ N
stable JJ N
during IN N
long-term JJ N
follow-up JJ N
. . N

Thus RB N
, , N
treatment NN N
with IN N
single-chamber JJ 1_i
atrial JJ 1_i
pacing NN 1_i
is VBZ N
safe JJ N
and CC N
can MD N
be VB N
recommended VBN N
to TO N
patients NNS N
with IN N
sick JJ N
sinus NN N
syndrome NN N
without IN N
bundle-branch JJ N
block NN N
. . N

-DOCSTART- -X- O O

A DT N
controlled VBN N
study NN N
of IN N
psychiatric JJ 4_i
hospital NN 4_i
versus NN N
community NN 4_i
treatment NN 4_i
- : N
the DT N
effect NN N
on IN N
relatives NNS N
. . N

One CD N
hundred CD N
and CC N
twenty JJ N
patients NNS N
presenting VBG N
at IN N
Macquarie NNP N
Hospital NNP N
for IN N
admission NN N
were VBD N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
. . N

The DT N
control NN N
group NN N
patients NNS N
received VBD N
standard JJ 4_i
hospital NN 4_i
care NN 4_i
and CC 4_i
follow-up NN 4_i
. . N

The DT N
project NN N
group NN N
patients NNS N
were VBD N
not RB N
admitted VBN N
if IN N
this DT N
could MD N
be VB N
avoided VBN N
; : N
instead RB N
they PRP N
were VBD N
taken VBN N
back RB 4_i
to TO 4_i
the DT 4_i
community NN 4_i
by IN 4_i
the DT 4_i
project NN 4_i
team NN 4_i
who WP 4_i
provided VBD 4_i
them PRP 4_i
and CC 4_i
their PRP$ 4_i
relatives NNS 4_i
with IN 4_i
comprehensive JJ 4_i
, , 4_i
assertive JJ 4_i
and CC 4_i
prolonged JJ 4_i
follow-up JJ 4_i
treatment NN 4_i
backed VBN 4_i
by IN 4_i
a DT 4_i
24-hour JJ 4_i
crisis NN 4_i
service NN 4_i
. . N

The DT N
majority NN N
( ( N
63 CD N
% NN N
) ) N
of IN N
the DT N
project NN N
group NN N
had VBD N
no DT N
admission NN N
during IN N
the DT N
10 CD N
month NN N
study NN N
period NN N
. . N

Initially RB N
, , N
the DT N
burden NN N
on IN N
the DT N
relatives NNS N
of IN N
the DT N
project NN N
group NN N
was VBD N
higher JJR N
, , N
but CC N
by IN N
one CD N
month NN N
it PRP N
was VBD N
somewhat RB N
lower JJR N
and CC N
by IN N
four CD N
months NNS N
it PRP N
was VBD N
significantly RB N
lower JJR N
than IN N
the DT N
burden NN N
on IN N
the DT N
control NN N
group NN N
relatives VBZ N
. . N

Relatives NNS N
of IN N
the DT N
project NN N
group NN N
patients NNS N
were VBD N
significantly RB N
more RBR N
satisfied JJ N
with IN N
the DT N
treatment NN N
than IN N
control NN N
group NN N
relatives VBZ N
. . N

It PRP N
is VBZ N
clearly RB N
feasible JJ N
to TO N
treat VB N
most JJS N
psychiatric JJ N
patients NNS N
in IN N
the DT N
community NN N
without IN N
increasing VBG N
the DT N
burden NN N
on IN N
their PRP$ N
relatives NNS N
. . N

-DOCSTART- -X- O O

EEG NNP N
mapping NN N
and CC N
psychopharmacological JJ N
studies NNS N
with IN N
denbufylline NN 3_i
in IN N
SDAT NNP N
and CC N
MID NNP N
. . N

Computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
, , N
electroencephalograms FW N
( ( N
EEG NNP N
) ) N
, , N
clinical JJ N
and CC N
psychometric JJ N
data NNS N
were VBD N
obtained VBN N
in IN N
96 CD N
mildly RB N
to TO N
moderately RB N
demented JJ N
patients NNS N
( ( N
72 CD N
women NNS N
, , N
24 CD N
men NNS N
) ) N
, , N
aged VBN N
61-96 CD N
years NNS N
( ( N
mean VB N
82 CD N
) ) N
, , N
diagnosed VBD N
according VBG N
to TO N
DSM-III NNP N
criteria NNS N
. . N

Patients NNS N
were VBD N
off RP N
drugs NNS N
for IN N
at IN N
least JJS N
2 CD N
weeks NNS N
and CC N
subdiagnosed VBD N
according VBG N
to TO N
the DT N
modified VBN N
Marshall-Hachinski NNP N
ischemic JJ N
score NN N
and CC N
CT NNP N
in IN N
45 CD N
senile JJ N
dementia NN N
of IN N
the DT N
Alzheimer NNP N
type NN N
( ( N
SDAT NNP N
) ) N
and CC N
51 CD N
multiinfarct NN N
dementia NN N
( ( N
MID NNP N
) ) N
patients NNS N
. . N

Evaluations NNS N
were VBD N
carried VBN N
out RP N
before IN N
and CC N
12 CD N
weeks NNS N
after IN N
treatment NN N
with IN N
either DT N
100 CD N
mg NNS N
denbufylline JJ 3_i
BID NNP N
or CC N
placebo NN 7_i
and CC N
included VBD N
EEG NNP N
mapping NN N
, , N
the DT N
Sandoz NNP N
Clinical NNP N
Assessment NNP N
Geriatric NNP N
( ( N
SCAG NNP N
) ) N
score/factors NNS N
, , N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
CGI NNP N
) ) N
, , N
the DT N
Digit NNP N
Symbol NNP N
Substitution NNP N
Test NNP N
( ( N
DSST NNP N
) ) N
, , N
the DT N
Trail-Making JJ N
Test NNP N
( ( N
TMT NNP N
) ) N
and CC N
the DT N
Digit NNP N
Span NNP N
Test NNP N
( ( N
DS NNP N
) ) N
. . N

Descriptive NNP N
data NNS N
analysis NN N
including VBG N
confirmatory JJ N
statements NNS N
found VBN N
delta/theta JJ N
activity NN N
enhanced VBD N
, , N
alpha NN N
and CC N
beta NN N
activity NN N
reduced VBN N
, , N
total JJ N
power NN N
augmented VBN N
, , N
and CC N
the DT N
centroid NN N
slowed VBD N
down RB N
over RB N
various JJ N
brain NN N
regions NNS N
in IN N
patients NNS N
as IN N
compared VBN N
with IN N
controls NNS N
. . N

The DT N
two CD N
subtypes NNS N
of IN N
dementia NN N
could MD N
be VB N
differentiated VBN N
in IN N
some DT N
conventional JJ N
EEG NNP N
variables NNS N
but CC N
mostly RB N
by IN N
means NNS N
of IN N
power NN N
asymmetry NN N
indices NNS N
. . N

Denbufylline NNP 3_i
induced VBD N
a DT N
statistically RB N
significant JJ N
and CC N
clinically RB N
relevant JJ N
improvement NN N
in IN N
both DT N
SDAT NNP N
and CC N
MID NNP N
patients NNS N
, , N
whereas NNS N
after IN N
placebo NN 7_i
this DT N
was VBD N
not RB N
the DT N
case NN N
in IN N
CGI NNP N
, , N
the DT N
TMT NNP N
, , N
and CC N
the DT N
DS NNP N
, , N
with IN N
interdrug JJ N
differences NNS N
being VBG N
significant JJ N
in IN N
all DT N
primary JJ N
target NN N
variables NNS N
such JJ N
as IN N
the DT N
CGI NNP N
, , N
MMS NNP N
, , N
SCAG NNP N
, , N
and CC N
DSST NNP N
. . N

Thus RB N
, , N
both DT N
the DT N
degenerative NN N
and CC N
vascular JJ N
type NN N
of IN N
dementia NN N
exhibited VBD N
a DT N
therapeutic JJ N
benefit NN N
that WDT N
could MD N
be VB N
objectified VBN N
at IN N
the DT N
neurophysiological JJ N
level NN N
by IN N
EEG NNP N
mapping NN N
in IN N
an DT N
improvement NN N
of IN N
vigilance NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
benefit NN N
with IN N
docetaxel JJ 3_i
plus CC 3_i
fluorouracil JJ 3_i
and CC N
cisplatin NNS 3_i
compared VBN N
with IN N
cisplatin NN 3_i
and CC N
fluorouracil NN 3_i
in IN N
a DT N
phase NN N
III NNP N
trial NN N
of IN N
advanced JJ N
gastric NN N
or CC N
gastroesophageal NN N
cancer NN N
adenocarcinoma NN N
: : N
the DT N
V-325 NNP N
Study NNP N
Group NNP N
. . N

PURPOSE NNP N
For IN N
patients NNS N
with IN N
advanced JJ N
gastric NN N
or CC N
gastroesophageal NN N
cancer NN N
( ( N
AGGEC NNP N
) ) N
providing VBG N
clinical JJ N
benefit NN N
with IN N
improved JJ N
palliation NN N
is VBZ N
highly RB N
desirable JJ N
. . N

However RB N
, , N
a DT N
prospective JJ N
evaluation NN N
of IN N
clinical JJ N
benefit NN N
in IN N
AGGEC NNP N
patients NNS N
has VBZ N
never RB N
before RB N
been VBN N
reported VBN N
in IN N
a DT N
phase NN N
III NNP N
setting NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
multinational JJ N
trial NN N
( ( N
V325 NNP N
) ) N
, , N
445 CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
and CC N
treated VBN N
with IN N
either DT N
docetaxel JJ 3_i
plus CC 3_i
cisplatin JJ 3_i
and CC 3_i
fluorouracil NN 3_i
( ( 3_i
DCF NNP 3_i
) ) 3_i
or CC N
cisplatin NN 3_i
and CC 3_i
fluorouracil NN 3_i
( ( 3_i
CF NNP 3_i
) ) 3_i
. . 3_i

Clinical JJ N
benefit NN N
was VBD N
prospectively RB N
evaluated VBN N
in IN N
this DT N
trial NN N
as IN N
a DT N
secondary JJ N
end NN N
point NN N
. . N

The DT N
primary JJ N
measure NN N
for IN N
clinical JJ N
benefit NN N
analysis NN N
was VBD N
time NN N
to TO N
definitive VB N
worsening NN N
by IN N
one CD N
or CC N
more JJR N
categories NNS N
of IN N
Karnofsky NNP N
performance NN N
status NN N
( ( N
KPS NNP N
) ) N
. . N

Secondary JJ N
clinical JJ N
benefit NN N
end NN N
points NNS N
included VBD N
time NN N
to TO N
5 CD N
% NN N
definitive JJ N
weight NN N
loss NN N
, , N
time NN N
to TO N
definitive JJ N
worsening NN N
of IN N
appetite NN N
by IN N
one CD N
grade NN N
, , N
pain-free JJ N
survival NN N
( ( N
defined VBN N
as IN N
time NN N
to TO N
first JJ N
appearance NN N
of IN N
pain NN N
) ) N
, , N
and CC N
time NN N
to TO N
first JJ N
cancer NN N
pain-related JJ N
opioid JJ N
intake NN N
. . N

Clinical JJ N
benefit NN N
assessments NNS N
were VBD N
recorded VBN N
at IN N
each DT N
clinic JJ N
visit NN N
. . N

RESULTS NNP N
Clinical JJ N
benefit NN N
assessments NNS N
were VBD N
performed VBN N
in IN N
more JJR N
than IN N
75 CD N
% NN N
of IN N
patients NNS N
throughout IN N
V325 NNP N
. . N

DCF NNP N
significantly RB N
prolonged VBD N
time NN N
to TO N
definitive JJ N
worsening NN N
of IN N
KPS NNP N
compared VBN N
with IN N
CF NNP 3_i
( ( N
median JJ N
, , N
6.1 CD N
v NN N
4.8 CD N
months NNS N
; : N
hazard RB N
ratio NN N
, , N
1.38 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.08 CD N
to TO N
1.76 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
.009 NNP N
) ) N
. . N

Although IN N
time NN N
to TO N
definitive JJ N
weight NN N
loss NN N
and CC N
time NN N
to TO N
definitive JJ N
worsening NN N
of IN N
appetite NN N
favored VBN N
DCF NNP 3_i
, , N
the DT N
results NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Pain-free JJ N
survival NN N
and CC N
time NN N
to TO N
first JJ N
cancer NN N
pain-related JJ N
opioid JJ N
intake NN N
were VBD N
comparable JJ N
. . N

CONCLUSION NN N
To TO N
our PRP$ N
knowledge NN N
, , N
V325 NNP N
is VBZ N
the DT N
first JJ N
phase NN N
III NNP N
trial NN N
to TO N
report VB N
clinical JJ N
benefit NN N
in IN N
AGGEC NNP N
patients NNS N
. . N

Clinical JJ N
benefit NN N
was VBD N
assessed VBN N
beyond IN N
protocol-specific JJ 2_i
chemotherapy NN 2_i
. . N

The DT N
addition NN N
of IN N
D NNP 3_i
to TO N
CF NNP 3_i
not RB N
only RB N
significantly RB N
improved VBN N
clinical JJ N
benefit NN N
but CC N
also RB N
improved JJ N
quality NN N
of IN N
life NN N
, , N
time NN N
to TO N
progression NN N
, , N
and CC N
overall JJ N
survival NN N
compared VBN N
with IN N
CF NNP 3_i
. . N

-DOCSTART- -X- O O

Short-term JJ N
effects NNS N
of IN N
prednisolone NN 3_i
and CC N
dexamethasone NN 3_i
on IN N
circulating VBG N
concentrations NNS N
of IN N
leptin NN N
and CC N
sex NN N
hormone-binding JJ N
globulin NN N
in IN N
children NNS N
being VBG N
treated VBN N
for IN N
acute JJ N
lymphoblastic JJ N
leukaemia NN N
. . N

OBJECTIVE NNP N
Disturbances NNPS N
in IN N
body NN N
weight JJ N
regulation NN N
are VBP N
often RB N
encountered VBN N
during IN N
glucocorticoid JJ 3_i
treatment NN N
and CC N
are VBP N
associated VBN N
with IN N
increased JJ N
insulin NN N
resistance NN N
and CC N
truncal JJ N
fat NN N
accumulation NN N
. . N

Children NNP N
were VBD N
investigated VBN N
who WP N
were VBD N
receiving VBG N
glucocorticoid JJ 3_i
treatment NN N
for IN N
acute JJ N
lymphoblastic JJ N
leukaemia NN N
( ( N
ALL DT N
) ) N
. . N

They PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
prednisolone VB 3_i
or CC N
dexamethasone VB 3_i
as IN N
part NN N
of IN N
induction NN N
of IN N
remission NN N
. . N

This DT N
randomization NN N
process NN N
provided VBD N
a DT N
suitable JJ N
opportunity NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
these DT N
two CD N
administered VBD N
steroid NN N
on IN N
surrogate JJ N
markers NNS N
of IN N
adipocyte NN N
activity NN N
( ( N
leptin NN N
) ) N
and CC N
hyperinsulinaemia/insulin JJ N
resistance NN N
( ( N
SHBG NNP N
) ) N
. . N

DESIGN NNP N
AND CC N
PATIENTS NNP N
Prospective NNP N
study NN N
over IN N
16 CD N
weeks NNS N
of IN N
children NNS N
randomized VBN N
to TO N
receive VB N
prednisolone NN 3_i
( ( N
40 CD N
mg/m2 NN N
) ) N
or CC N
dexamethasone NN 3_i
( ( N
6.5 CD N
mg/m2 NN N
) ) N
as IN N
part NN N
of IN N
the DT N
MRC-ALL97/99 NNP N
induction NN 3_i
chemotherapy NN 3_i
for IN N
ALL NNP N
. . N

Nineteen NNP N
children NNS N
( ( N
8 CD N
male NN N
, , N
11 CD N
female NN N
) ) N
with IN N
a DT N
median JJ N
age NN N
5.9 CD N
years NNS N
( ( N
range VB N
2.6-13 CD N
years NNS N
) ) N
were VBD N
recruited VBN N
into IN N
the DT N
study NN N
. . N

Main NNP N
outcome JJ N
measures NNS N
were VBD N
body JJ N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
serum JJ N
leptin NN N
and CC N
sex NN N
hormone NN N
binding VBG N
globulin NN N
( ( N
SHBG NNP N
) ) N
. . N

RESULTS NNP N
Glucocorticoid NNP N
administration NN N
for IN N
5 CD N
weeks NNS N
resulted VBD N
in IN N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
increases NNS N
in IN N
BMI NNP N
, , N
leptin NN N
( ( N
corrected VBN N
for IN N
BMI NNP N
) ) N
and CC N
the DT N
leptin NN N
: : N
SHBG NNP N
ratio NN N
and CC N
lowering NN N
of IN N
SHBG NNP N
. . N

Dose NNP N
for IN N
dose NN N
, , N
dexamethasone NN 3_i
was VBD N
significantly RB N
more RBR N
potent JJ N
than IN N
prednisolone NN 3_i
in IN N
altering VBG N
these DT N
parameters NNS N
. . N

CONCLUSIONS NNP N
Short-term JJ N
glucocorticoid NN N
treatment NN N
has VBZ N
significant JJ N
effects NNS N
on IN N
BMI NNP N
, , N
leptin NN N
and CC N
SHBG NNP N
. . N

The DT N
leptin NN N
: : N
SHBG NNP N
ratio NN N
increase NN N
indicates VBZ N
that IN N
this DT N
may MD N
be VB N
a DT N
novel JJ N
and CC N
sensitive JJ N
biochemical JJ N
marker NN N
of IN N
metabolic JJ N
change NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
glucocorticoid JJ 3_i
treatment NN N
regimens NNS N
should MD N
be VB N
kept VBN N
as RB N
short JJ N
as IN N
possible JJ N
to TO N
avoid VB N
possible JJ N
detrimental JJ N
effects NNS N
associated VBN N
with IN N
increased JJ N
adiposity NN N
and CC N
insulin NN N
resistance NN N
. . N

-DOCSTART- -X- O O

Cardiovascular JJ N
safety NN N
and CC N
gastrointestinal JJ N
tolerability NN N
of IN N
etoricoxib JJ N
vs NN N
diclofenac NN N
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
( ( N
The DT N
MEDAL NNP N
study NN N
) ) N
. . N

OBJECTIVE UH N
To TO N
compare VB N
cardiovascular JJ N
( ( N
CV NNP N
) ) N
and CC N
other JJ N
safety NN N
and CC N
efficacy NN N
parameters NNS N
of IN N
etoricoxib JJ 3_i
60 CD N
and CC N
90 CD N
mg NN N
, , N
and CC N
diclofenac VBZ 3_i
150 CD N
mg. NN N
METHODS NNP N
This DT N
double-blind NN N
study NN N
randomized VBD N
OA NNP N
patients NNS N
to TO N
etoricoxib VB 3_i
90 CD N
mg NN N
, , N
then RB N
to TO N
60 CD N
mg NNS N
once RB N
daily JJ N
vs NNS N
diclofenac VBP 3_i
75 CD N
mg JJ N
twice RB N
daily RB N
; : N
RA NNP N
patients NNS N
were VBD N
randomized VBN N
to TO N
etoricoxib VB 3_i
90 CD N
mg NNS N
once RB N
daily JJ N
or CC N
diclofenac JJ 3_i
75 CD N
mg JJ N
twice RB N
daily RB N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
non-inferiority NN N
of IN N
etoricoxib JJ 3_i
vs NN N
diclofenac NN 3_i
for IN N
thrombotic JJ N
CV NNP N
events NNS N
( ( N
95 CD N
% NN N
CI NNP N
upper JJ N
bound NN N
of IN N
hazard NN N
ratio NN N
< NNP N
1.30 CD N
) ) N
. . N

Other JJ N
safety NN N
and CC N
efficacy NN N
parameters NNS N
were VBD N
evaluated VBN N
in IN N
cohorts NNS N
of IN N
patients NNS N
based VBN N
on IN N
etoricoxib NN 3_i
dose NN N
and CC N
disease NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
23 CD N
504 CD N
patients NNS N
were VBD N
randomized VBN N
with IN N
mean JJ N
treatment NN N
duration NN N
from IN N
19.4 CD N
to TO N
20.8 CD N
months NNS N
. . N

The DT N
thrombotic JJ N
CV NNP N
risk NN N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
( ( N
etoricoxib UH 3_i
to TO N
diclofenac VB N
) ) N
was VBD N
0.96 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.81 CD N
, , N
1.15 CD N
) ) N
, , N
consistent JJ N
with IN N
non-inferiority NN N
of IN N
etoricoxib NN 3_i
to TO N
diclofenac VB 3_i
. . N

The DT N
cumulative JJ N
gastrointestinal NN N
( ( N
GI NNP N
) ) N
/liver VBP N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
discontinuation NN N
rate NN N
was VBD N
significantly RB N
lower JJR N
for IN N
etoricoxib JJR 3_i
than IN N
diclofenac NN 3_i
in IN N
each DT N
patient NN N
cohort NN N
; : N
HR NNP N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
of IN N
0.46 CD N
( ( N
0.39 CD N
, , N
0.54 CD N
) ) N
, , N
0.52 CD N
( ( N
0.42 CD N
, , N
0.63 CD N
) ) N
and CC N
0.49 CD N
( ( N
0.39 CD N
, , N
0.62 CD N
) ) N
for IN N
the DT N
60 CD N
mg NN N
OA NNP N
, , N
90 CD N
mg NN N
OA NNP N
and CC N
RA NNP N
cohorts NNS N
. . N

The DT N
maximum JJ N
average JJ N
change NN N
in IN N
systolic JJ N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
with IN N
etoricoxib NN 3_i
was VBD N
3.4-3.6 JJ N
mmHg NN N
( ( N
diastolic JJ N
BP NNP N
: : N
1.0-1.5 JJ N
mmHg NN N
) ) N
, , N
while IN N
diclofenac NN N
produced VBD N
a DT N
maximum JJ N
average JJ N
change NN N
of IN N
0.9-1.9 JJ N
mmHg NN N
( ( N
diastolic JJ N
BP NNP N
: : N
0.0-0.5 JJ N
mmHg NN N
) ) N
. . N

Both DT N
agents NNS N
resulted VBD N
in IN N
similar JJ N
efficacy NN N
regardless NN N
of IN N
etoricoxib NN N
dose NN N
. . N

CONCLUSION NNP N
Long-term NNP N
etoricoxib NN 3_i
use NN N
is VBZ N
associated VBN N
with IN N
a DT N
risk NN N
of IN N
thrombotic JJ N
CV NNP N
events NNS N
comparable JJ N
with IN N
that DT N
of IN N
diclofenac NN 3_i
. . N

Compared VBN N
with IN N
diclofenac NN 3_i
, , N
etoricoxib RB 3_i
demonstrated VBD N
a DT N
greater JJR N
risk NN N
of IN N
renovascular JJ N
AEs NNP N
, , N
but CC N
a DT N
more RBR N
favourable JJ N
GI/liver NNP N
tolerability NN N
profile NN N
. . N

-DOCSTART- -X- O O

Prediction NN N
of IN N
creatinine JJ N
clearance NN N
from IN N
serum JJ N
creatinine NN N
in IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
: : N
comparison NN N
of IN N
six CD 6_i
formulae NNS 6_i
and CC N
one CD 6_i
nomogram NN 6_i
. . N

The DT N
estimation NN N
of IN N
glomerular JJ N
filtration NN N
rate NN N
is VBZ N
important JJ N
for IN N
the DT N
medical JJ N
treatment NN N
of IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

However RB N
, , N
the DT N
determination NN N
of IN N
endogenous JJ N
creatinine JJ N
clearance NN N
( ( N
Clcr NNP N
) ) N
from IN N
a DT N
24-h JJ N
urine JJ N
collection NN N
is VBZ N
an DT N
unreliable JJ N
and CC N
time-consuming JJ N
procedure NN N
. . N

We PRP N
therefore RB N
tested VBD N
the DT N
accuracy NN N
of IN N
six CD 6_i
equations NNS 6_i
and CC N
one CD 6_i
nomogram NN 6_i
for IN N
the DT N
prediction NN N
of IN N
Clcr NNP N
from IN N
serum JJ N
creatinine NN N
( ( N
Scr NNP N
) ) N
in IN N
38 CD N
patients NNS N
with IN N
RA NNP N
and CC N
20 CD N
controls NNS N
. . N

A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
for IN N
all DT N
methods NNS N
in IN N
the DT N
controls NNS N
( ( N
r VB N
= NNP N
0.83-0.94 NN N
) ) N
and CC N
RA NNP N
patients NNS N
( ( N
r JJ N
= NNP N
0.51-0.69 NN N
) ) N
. . N

The DT N
methods NNS N
did VBD N
not RB N
overestimate VB N
Clcr NNP N
in IN N
RA NNP N
. . N

In IN N
the DT N
RA NNP N
group NN N
the DT N
simple JJ N
formula NN N
published VBN N
by IN N
Cockcroft NNP 4_i
[ NNP N
Clcr NNP N
= NNP N
( ( N
( ( N
140 CD N
- : N
age NN N
) ) N
x VBZ N
body NN N
weight NN N
) ) N
/ NN N
( ( N
72 CD N
x NNP N
Scr NNP N
) ) N
, , N
x $ N
0.85 CD N
for IN N
females NNS N
] VBP N
showed VBD N
the DT N
best JJS N
correlation NN N
with IN N
the DT N
measured VBN N
Clcr NNP N
. . N

In IN N
RA NNP N
the DT N
Cockroft NNP 6_i
formula NN 6_i
can MD N
reliably RB N
be VB N
used VBN N
to TO N
predict VB N
Clcr NNP N
from IN N
Scr NNP N
. . N

-DOCSTART- -X- O O

Noradrenergic NNP N
response NN N
to TO N
intravenous JJ 3_i
yohimbine NN 3_i
in IN N
patients NNS N
with IN N
depression NN N
and CC N
comorbidity NN N
of IN N
depression NN N
and CC N
panic NN N
. . N

Adrenergic NNP N
response NN N
following VBG N
infusions NNS N
of IN N
yohimbine NN 3_i
or CC N
normal JJ 3_i
saline NN 3_i
was VBD N
evaluated VBN N
in IN N
9 CD N
control NN N
subjects NNS N
, , N
8 CD N
patients NNS N
suffering VBG N
from IN N
a DT N
major JJ N
depressive JJ N
episode NN N
( ( N
MDE NNP N
) ) N
, , N
and CC N
12 CD N
patients NNS N
suffering VBG N
from IN N
concurrent JJ N
MDE NNP N
and CC N
panic JJ N
disorder NN N
( ( N
MDE NNP N
+ NNP N
P NNP N
) ) N
. . N

Blood NN N
was VBD N
drawn VBN N
at IN N
-20 NNP N
, , N
0 CD N
, , N
5 CD N
, , N
10 CD N
, , N
20 CD N
, , N
45 CD N
, , N
and CC N
90 CD N
min NN N
following VBG N
the DT N
infusions NNS N
, , N
and CC N
assayed VBD N
for IN N
norepinephrine NN N
( ( N
NE NNP N
) ) N
and CC N
3-methoxy-4-hydroxy-phenyl JJ N
glycol NN N
( ( N
MHPG NNP N
) ) N
. . N

Although IN N
the DT N
patient NN N
groups NNS N
exhibited VBD N
higher JJR N
baseline NN N
NE NNP N
concentrations NNS N
, , N
and CC N
a DT N
greater JJR N
NE NNP N
area NN N
under IN N
the DT N
plasma JJ N
concentration NN N
versus NN N
time NN N
curve NN N
( ( N
AUC0-90 NNP N
) ) N
during IN N
the DT N
yohimbine JJ 3_i
infusion NN N
, , N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Baseline NNP N
NE NNP N
was VBD N
significantly RB N
correlated VBN N
with IN N
the DT N
NE NNP N
AUC0-90 NNP N
in IN N
all DT N
three CD N
groups NNS N
, , N
suggesting VBG N
that IN N
, , N
although IN N
the DT N
NE NNP N
system NN N
may MD N
be VB N
dysregulated VBN N
in IN N
the DT N
MDE NNP N
and CC N
MDE NNP N
+ NNP N
P NNP N
patients NNS N
, , N
the DT N
NE NNP N
system NN N
still RB N
appears VBZ N
to TO N
respond VB N
somewhat RB N
predictably RB N
following VBG N
a DT N
challenge NN N
, , N
even RB N
though IN N
the DT N
actual JJ N
magnitude NN N
of IN N
response NN N
may MD N
vary VB N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
Duraflo NNP 3_i
II NNP 3_i
heparin-coated JJ 3_i
circuits NNS 3_i
in IN N
cardiac JJ N
reoperations NNS N
. . N

BACKGROUND NNP N
Heparin-coated JJ 3_i
circuits NNS 3_i
in IN N
cardiopulmonary JJ N
bypass NN N
have VBP N
been VBN N
shown VBN N
to TO N
decrease VB N
the DT N
systemic JJ N
inflammatory NN N
responses NNS N
associated VBN N
with IN N
cardiopulmonary JJ N
bypass NN N
. . N

Previous JJ N
clinical JJ N
studies NNS N
on IN N
low-risk JJ N
patients NNS N
who WP N
had VBD N
coronary JJ 2_i
artery NN 2_i
bypass NN 2_i
grafting NN 2_i
( ( N
CABG NNP N
) ) N
and CC N
received VBN N
full-dose JJ N
systemic JJ N
heparin NN 3_i
did VBD N
not RB N
have VB N
clearly RB N
improved VBN N
clinical JJ N
outcomes NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
beneficial JJ N
effects NNS N
of IN N
heparin-coated JJ 3_i
circuits NNS 3_i
might MD N
be VB N
seen VBN N
in IN N
patients NNS N
who WP N
had VBD N
cardiac JJ N
reoperations NNS N
. . N

METHODS NNP N
Three CD N
hundred VBD N
fifty JJ N
patients NNS N
who WP N
had VBD N
reoperation NN N
with IN N
CABG NNP N
only RB N
( ( N
58 CD N
% NN N
) ) N
, , N
or CC N
with IN N
valve JJ N
operations NNS N
( ( N
42 CD N
% NN N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
a DT N
heparin-coated JJ 3_i
( ( 3_i
Duraflo NNP 3_i
II NNP 3_i
; : N
study VB N
group NN N
) ) N
or CC N
uncoated JJ 7_i
( ( N
control VB N
group NN N
) ) N
circuit NN N
. . N

Clinical JJ N
outcomes NNS N
were VBD N
compared VBN N
and CC N
the DT N
variables NNS N
were VBD N
analyzed VBN N
using VBG N
the DT N
following JJ N
three CD N
groups NNS N
: : N
entire JJ N
populations NNS N
of IN N
study NN N
group NN N
and CC N
control NN N
group NN N
, , N
subgroup NN N
of IN N
patients NNS N
who WP N
had VBD N
CABG NNP N
reoperation NN N
only RB N
, , N
and CC N
a DT N
subgroup NN N
who WP N
had VBD N
valve VBN N
reoperation NN N
or CC N
combined VBN N
valve NNS N
and CC N
CABG NNP N
reoperation NN N
. . N

RESULTS NNP N
Preoperative JJ N
variables NNS N
were VBD N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
. . N

No DT N
difference NN N
in IN N
clinical JJ N
outcomes NNS N
could MD N
be VB N
demonstrated VBN N
except IN N
that IN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
major JJ N
bleeding VBG N
episodes NNS N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
study NN N
group NN N
( ( N
1.2 CD N
% NN N
versus IN N
5.4 CD N
% NN N
, , N
p NN N
= NNP N
0.035 CD N
) ) N
. . N

In IN N
the DT N
subgroup NN N
analysis NN N
of IN N
patients NNS N
who WP N
had VBD N
valve NN N
reoperations NNS N
, , N
lower JJR N
blood NN N
transfusion NN N
requirements NNS N
in IN N
the DT N
intensive JJ N
care NN N
unit NN N
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
were VBD N
found VBN N
in IN N
the DT N
study NN N
group NN N
. . N

When WRB N
the DT N
subgroup NN N
of IN N
patients NNS N
who WP N
had VBD N
CABG NNP N
reoperations NNS N
was VBD N
analyzed VBN N
separately RB N
, , N
there EX N
was VBD N
a DT N
trend NN N
toward IN N
less JJR N
reoperation NN N
for IN N
bleeding VBG N
in IN N
the DT N
study NN N
group NN N
( ( N
0 CD N
% NN N
versus IN N
4.0 CD N
% NN N
, , N
p NN N
= NNP N
0.058 CD N
) ) N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
the DT N
use NN N
of IN N
heparin-coated JJ N
circuits NNS N
was VBD N
safe JJ N
and CC N
imparted JJ N
protection NN N
from IN N
reoperations NNS N
for IN N
bleeding NN N
and CC N
major JJ N
bleeding VBG N
episodes NNS N
. . N

Material-independent JJ N
blood NN N
activation NN N
( ( N
eg JJ N
, , N
blood-air JJ N
interface NN N
and CC N
cardiotomy JJ N
suction NN N
) ) N
blunted VBD N
the DT N
total JJ N
effect NN N
of IN N
the DT N
heparin-coated JJ N
surface NN N
. . N

-DOCSTART- -X- O O

PSK NNP 3_i
may MD N
suppress VB N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
to TO N
improve VB N
survival NN N
of IN N
advanced JJ N
gastric JJ N
cancer NN N
patients NNS N
. . N

BACKGROUND NNP N
A NNP N
recent JJ N
report NN N
showed VBD N
that IN N
oral JJ 3_i
adjuvant JJ 3_i
immunochemotherapy NN 3_i
with IN N
protein-bound JJ 3_i
polysaccharide NN 3_i
K NNP 3_i
( ( 3_i
PSK NNP 3_i
) ) 3_i
and CC N
tegafur/uracil NN 3_i
( ( 3_i
UFT NNP 3_i
) ) 3_i
for IN N
stage NN N
II NNP N
and CC N
III NNP N
colorectal JJ N
cancer NN N
improves VBZ N
overall JJ N
survival NN N
compared VBN N
with IN N
UFT NNP 3_i
alone RB N
. . N

PSK NNP 3_i
has VBZ N
been VBN N
supposed VBN N
to TO N
improve VB N
survival NN N
through IN N
immunological JJ N
mechanisms NNS N
such JJ N
as IN N
induction NN N
of IN N
cytokines NNS N
, , N
regulation NN N
of IN N
Th1/Th2 NNP N
balance NN N
, , N
and CC N
inhibition NN N
of IN N
immunosuppressive JJ N
molecules NNS N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
mechanisms NNS N
by IN N
which WDT N
PSK NNP 3_i
influences VBZ N
immunological JJ N
parameters NNS N
such JJ N
as IN N
Th1 NNP N
cells NNS N
( ( N
IFN-gamma-positive JJ N
CD4 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
) ) N
, , N
Th2 NNP N
cells NNS N
( ( N
IL-4-positive JJ N
CD4 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
) ) N
, , N
Th1/Th2 NNP N
ratio NN N
, , N
NKT NNP N
cells NNS N
( ( N
CD56 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
and CC N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
) ) N
, , N
NK NNP N
cells NNS N
, , N
and CC N
CD25 NNP N
( ( N
+ NNP N
) ) N
CD4 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
in IN N
stage NN N
III NNP N
gastric JJ N
cancer NN N
patients NNS N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
3 CD N
g NN N
PSK NNP 3_i
plus CC 3_i
300 CD 3_i
mg NN 3_i
UFT NNP 3_i
( ( 3_i
PSK NNP 3_i
group NN 3_i
) ) 3_i
or CC N
300 CD N
mg JJ N
UFT NNP 3_i
alone RB 3_i
( ( N
control NN N
) ) N
orally RB N
each DT N
day NN N
for IN N
at IN N
least JJS N
1 CD N
year NN N
following VBG N
their PRP$ N
operation NN N
. . N

RESULTS NNP N
Twenty-one CD N
registered VBD N
patients NNS N
with IN N
stage NN N
III NNP N
gastric JJ N
cancer NN N
were VBD N
analyzed VBN N
. . N

The DT N
3-year JJ N
overall JJ N
survival NN N
was VBD N
62.2 CD N
% NN N
in IN N
the DT N
PSK NNP 3_i
group NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
and CC N
12.5 CD N
% NN N
in IN N
the DT N
control NN 7_i
group NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

Before IN N
operation NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
proportions NNS N
of IN N
Th1 NNP N
cells NNS N
, , N
Th2 NNP N
cells NNS N
, , N
Th1/Th2 NNP N
ratio NN N
, , N
CD56 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
, , N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
, , N
NK NNP N
cells NNS N
, , N
and CC N
CD4 NNP N
( ( N
+ NNP N
) ) N
CD25 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
between IN N
PSK NNP N
and CC N
control NN N
groups NNS N
. . N

However RB N
, , N
after IN N
operation NN N
, , N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
decreased VBD N
significantly RB N
in IN N
the DT N
PSK NNP 3_i
group NN N
compared VBN N
to TO N
the DT N
control NN N
( ( N
P NNP N
= NNP N
0.0486 CD N
) ) N
. . N

When WRB N
all DT N
patients NNS N
were VBD N
analyzed VBN N
, , N
patients NNS N
with IN N
increased JJ N
proportion NN N
( ( N
> JJ N
18 CD N
% NN N
) ) N
of IN N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
showed VBD N
worse JJR N
survival NN N
than IN N
those DT N
with IN N
lower JJR N
( ( N
< CD N
or CC N
= VB N
18 CD N
% NN N
) ) N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
( ( N
3-year JJ N
survival NN N
, , N
25.0 CD N
and CC N
45.7 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.046 CD N
) ) N
, , N
consistent JJ N
with IN N
our PRP$ N
previous JJ N
report NN N
that WDT N
high JJ N
CD57 NNP N
( ( N
+ NNP N
) ) N
is VBZ N
an DT N
indicator NN N
of IN N
poor JJ N
prognosis NN N
in IN N
patients NNS N
with IN N
advanced JJ N
gastric JJ N
cancer NN N
. . N

However RB N
, , N
in IN N
the DT N
group NN N
treated VBD N
with IN N
PSK NNP 3_i
+ NNP 3_i
UFT NNP 3_i
, , N
3-year JJ N
survival NN N
of IN N
CD57-high JJ N
patients NNS N
was VBD N
as RB N
great JJ N
as IN N
that DT N
of IN N
CD57-low JJ N
patients NNS N
( ( N
66.7 CD N
and CC N
51.4 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.67 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
PSK NNP 3_i
improves VBZ N
overall JJ N
survival NN N
of IN N
stage NN N
III NNP N
gastric JJ N
cancer NN N
patients NNS N
partly RB N
by IN N
inhibiting VBG N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
, , N
a DT N
proven JJ N
poor JJ N
prognostic JJ N
factor NN N
in IN N
advanced JJ N
gastric JJ N
cancer NN N
. . N

-DOCSTART- -X- O O

[ VB N
A DT N
randomized JJ N
comparative NN N
study NN N
of IN N
surgical JJ 1_i
adjuvant NN 1_i
chemotherapy NN 1_i
using VBG N
5-fluorouracil JJ 3_i
and CC 3_i
dl-leucovorin JJ 3_i
with IN 3_i
CDDP NNP 3_i
5-FU JJ 3_i
and CC 3_i
dl-leucovorin JJ 3_i
for IN N
colorectal JJ N
cancer NN N
] NNP N
. . N

A NNP N
randomized JJ N
comparative NN N
study NN N
of IN N
surgical JJ 1_i
adjuvant NN 1_i
chemotherapy NN 1_i
using VBG N
dl-leucovorin JJ 3_i
( ( 3_i
dl-LV JJ 3_i
) ) 3_i
and CC 3_i
5-fluorouracil JJ 3_i
( ( 3_i
5-FU JJ 3_i
) ) 3_i
( ( 3_i
FL-therapy NNP 3_i
) ) 3_i
with IN 3_i
CDDP NNP 3_i
, , 3_i
5-FU JJ 3_i
, , 3_i
and CC 3_i
dl-LV JJ 3_i
( ( 3_i
PFL-therapy NNP 3_i
) ) 3_i
was VBD N
conducted VBN N
. . N

The DT N
following VBG N
were VBD N
the DT N
administration NN N
schedules NNS N
: : N
Arm VB N
A DT N
was VBD N
13 CD N
mg/m2 NN N
of IN N
CDDP NNP 3_i
, , N
300 CD N
mg/m2 NN N
of IN N
5-FU JJ 3_i
, , N
and CC N
30 CD N
mg/body NN N
of IN N
dl-LV NN 3_i
for IN N
5 CD N
consecutive JJ N
days NNS N
and CC N
arm NN N
B NNP N
was VBD N
300 CD N
mg/m2 NN N
of IN N
5-FU JJ 3_i
and CC N
30 CD N
mg/body NN N
of IN N
dl-LV NN 3_i
for IN N
5 CD N
consecutive JJ N
days NNS N
. . N

Both DT N
regimens NNS N
were VBD N
followed VBN N
by IN N
biweekly JJ N
administration NN N
of IN N
the DT N
same JJ N
dose NN N
of IN N
dl-LV JJ 3_i
and CC N
5-FU JJ 3_i
in IN N
outpatients NNS N
. . N

Arm VB N
A DT N
was VBD N
started VBN N
at IN N
the DT N
26th CD N
postoperative JJ N
day NN N
and CC N
arm NN N
B NNP N
at IN N
the DT N
21st CD N
day NN N
on IN N
average NN N
. . N

Some DT N
26 CD N
cases NNS N
composed VBN N
of IN N
11 CD N
cases NNS N
of IN N
arm NN N
A NNP N
and CC N
15 CD N
cases NNS N
of IN N
arm NN N
B NNP N
completed VBD N
the DT N
administration NN N
schedules NNS N
. . N

Only RB N
one CD N
case NN N
in IN N
arm NN N
A NN N
was VBD N
complicated VBN N
by IN N
local JJ N
recurrence NN N
around IN N
35 CD N
months NNS N
after IN N
operation NN N
. . N

Major JJ N
toxicities NNS N
were VBD N
anorexia JJ N
and CC N
neutropenia NN N
. . N

Both CC N
toxicities NNS N
were VBD N
seen VBN N
more RBR N
in IN N
arm NN N
A NN N
than IN N
in IN N
arm NN N
B NNP N
, , N
showing VBG N
complete JJ N
recovery NN N
in IN N
all DT N
cases NNS N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
PFL-therapy NNP N
and CC N
FL-therapy NNP N
seem VBP N
to TO N
be VB N
possible JJ N
and CC N
promising JJ N
surgical JJ 1_i
adjuvant NN 1_i
therapies NNS 1_i
for IN N
advanced JJ N
colorectal JJ N
carcinoma NN N
. . N

-DOCSTART- -X- O O

Analgesic JJ N
efficacy NN N
of IN N
low-dose JJ N
diclofenac NN 3_i
versus NN N
paracetamol NN 3_i
and CC N
placebo NN 7_i
in IN N
postoperative JJ N
dental NN N
pain NN N
. . N

AIMS NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
diclofenac-K NN 3_i
( ( N
12.5 CD N
mg NN N
) ) N
vs NN N
paracetamol NN 3_i
( ( N
500 CD N
mg NN N
) ) N
and CC N
placebo VB 7_i
given VBN N
in IN N
a DT N
flexible JJ N
dosage NN N
regimen NNS N
to TO N
treat VB N
pain NN N
resulting VBG N
from IN N
extraction NN N
of IN N
impacted JJ N
third JJ N
molar JJ N
teeth NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
2-day JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ 7_i
study NN N
of IN N
diclofenac-K NN 3_i
( ( 3_i
12.5 CD 3_i
mg NN 3_i
) ) 3_i
tablets VBZ 3_i
vs JJ 3_i
paracetamol NN 3_i
( ( N
500 CD N
mg NN N
) ) N
tablets NNS N
and CC N
placebo NN 7_i
in IN N
patients NNS N
with IN N
moderate JJ N
or CC N
severe JJ N
pain NN N
within IN N
8 CD N
hours NNS N
of IN N
extraction NN N
of IN N
impacted JJ N
third JJ N
molars NNS N
. . N

RESULTS NNP N
After IN N
the DT N
first JJ N
2-tablet JJ N
dose NN N
, , N
patients NNS N
took VBD N
on IN N
average JJ N
2.5 CD N
additional JJ N
tablets NNS N
of IN N
diclofenac-K NN 3_i
or CC N
2.4 CD N
tablets NNS N
of IN N
paracetamol NN 3_i
, , N
almost RB N
all DT N
as IN N
1-tablet JJ N
doses NNS N
. . N

Most JJS N
placebo JJ 7_i
patients NNS N
discontinued VBN N
by IN N
taking VBG N
rescue JJ N
medication NN N
( ( N
ibuprofen JJ N
200 CD N
mg NN N
) ) N
on IN N
the DT N
first JJ N
day NN N
. . N

Pain NNP N
relief NN N
after IN N
the DT N
initial JJ N
dose NN N
of IN N
diclofenac-K NN 3_i
( ( N
2 CD N
x RB N
12.5 CD N
mg NN N
) ) N
was VBD N
superior JJ N
to TO N
placebo VB 7_i
( ( N
P NNP N
< NNP N
.01 NNP N
for IN N
all DT N
efficacy NN N
outcomes NNS N
) ) N
and CC N
comparable JJ N
to TO N
paracetamol VB 3_i
( ( N
2 CD N
x RB N
500 CD N
mg NN N
) ) N
. . N

About IN N
30 CD N
% NN N
of IN N
patients NNS N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
took VBD N
rescue NN N
medication NN N
during IN N
the DT N
study NN N
, , N
compared VBN N
to TO N
78 CD N
% NN N
on IN N
placebo NN 7_i
. . N

About IN N
70 CD N
% NN N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
considered VBD N
the DT N
overall JJ N
pain NN N
relief NN N
to TO N
be VB N
some DT N
, , N
a DT N
lot NN N
, , N
or CC N
complete JJ N
compared VBN N
to TO N
only RB N
15 CD N
% NN N
on IN N
placebo NN 7_i
. . N

The DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
was VBD N
low JJ N
and CC N
comparable JJ N
between IN N
the DT N
treatments NNS N
. . N

CONCLUSION NNP N
An DT N
initial JJ N
double-dose NN N
of IN N
diclofenac-K NN 3_i
( ( N
2 CD N
x RB N
12.5 CD N
mg NN N
) ) N
or CC N
paracetamol NN 3_i
( ( N
2 CD N
x RB N
500 CD N
mg NNS N
) ) N
adequately RB N
relieved VBD N
the DT N
most RBS N
intense JJ N
postoperative NN N
pain NN N
, , N
and CC N
the DT N
flexible JJ N
multiple NN N
dose JJ N
regimen NNS N
( ( N
1 CD N
or CC N
2 CD N
tablets NNS N
) ) N
maintained VBD N
adequate JJ N
pain NN N
relief NN N
thereafter RB N
. . N

Most JJS N
patients NNS N
needed VBN N
only RB N
1-tablet JJ N
doses NNS N
following VBG N
the DT N
initial JJ N
2-tablet JJ N
dose NN N
. . N

-DOCSTART- -X- O O

Intraoperative JJ 6_i
microscopy NN 6_i
of IN N
bile NN N
-- : N
is VBZ N
it PRP N
useful JJ N
? . N
Direct JJ 2_i
microscopy NN 2_i
of IN 2_i
the DT 2_i
bile NN 2_i
was VBD N
performed VBN N
during IN N
cholecystectomy NN 1_i
in IN N
111 CD N
patients NNS N
in IN N
an DT N
attempt NN N
to TO N
identify VB N
those DT N
with IN N
a DT N
high JJ N
risk NN N
of IN N
wound JJ N
infection NN N
. . N

Bacteria NNP N
were VBD N
identified VBN N
in IN N
23 CD N
patients NNS N
, , N
11 CD N
of IN N
83 CD N
undergoing JJ N
cholecystectomy NN 1_i
alone RB N
and CC N
12 CD N
of IN N
28 CD N
undergoing JJ N
exploration NN N
of IN N
the DT N
common JJ N
bile NN N
duct NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

These DT N
23 CD N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
an DT N
antibiotic JJ 3_i
group NN 3_i
or CC N
a DT N
control NN N
group NN N
; : N
there EX N
was VBD N
one CD N
wound NN N
infection NN N
in IN N
the DT N
antibiotic JJ 3_i
group NN 3_i
and CC N
two CD N
in IN N
the DT N
control NN 7_i
group NN 7_i
. . N

A DT N
total NN N
of IN N
14 CD N
patients NNS N
developed VBD N
wound JJ N
sepsis NN N
. . N

Infection NN N
was VBD N
more RBR N
likely JJ N
if IN N
the DT N
common JJ N
bile NN N
duct NN N
was VBD N
explored VBN N
( ( N
6 CD N
of IN N
28 CD N
) ) N
rather RB N
than IN N
cholecystectomy VB 1_i
alone JJ N
( ( N
8 CD N
of IN N
83 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
poor JJ N
correlation NN N
between IN N
microscopy NN N
and CC N
culture NN N
of IN N
the DT N
bile NN N
for IN N
bacteria NNS N
and CC N
there EX N
was VBD N
no DT N
increase NN N
in IN N
sepsis NN N
when WRB N
bacteria NNS N
were VBD N
observed VBN N
on IN N
microscopy NN N
. . N

We PRP N
were VBD N
not RB N
able JJ N
to TO N
identify VB N
a DT N
high JJ N
risk NN N
group NN N
of IN N
patients NNS N
by IN N
intraoperative JJ N
microscopy NN N
of IN N
bile NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
autologous JJ N
bone NN N
marrow NN N
transplantation NN N
with IN N
sequential JJ N
chemotherapy NN N
for IN N
intermediate-grade JJ N
and CC N
high-grade JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
in IN N
first JJ N
complete JJ N
remission NN N
: : N
a DT N
study NN N
of IN N
464 CD N
patients NNS N
. . N

Groupe NNP N
d'Etude NN N
des NNS N
Lymphomes NNP N
de IN N
l'Adulte FW N
. . N

PURPOSE NNP N
Intensive NNP N
chemotherapy NN N
followed VBN N
by IN N
autotransplantation NN N
has VBZ N
given VBN N
promising VBG N
results NNS N
in IN N
partially RB N
responding VBG N
or CC N
sensitive JJ N
relapsed JJ N
patients NNS N
with IN N
aggressive JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
. . N

In IN N
1987 CD N
, , N
we PRP N
designed VBD N
a DT N
randomized VBN N
study NN N
to TO N
evaluate VB N
the DT N
potential JJ N
benefit NN N
of IN N
a DT N
high-dose JJ 3_i
regimen NN 3_i
containing VBG 3_i
cyclophosphamide NN 3_i
, , N
carmustine NN 3_i
, , N
and CC N
etoposide RB 3_i
( ( 3_i
CBV NNP 3_i
) ) 3_i
followed VBN N
by IN N
autotransplantation NN 3_i
over IN 3_i
a DT 3_i
consolidative JJ 3_i
sequential JJ 3_i
chemotherapy NN 3_i
( ( N
ifosfamide JJ 3_i
, , N
etoposide RB 3_i
, , N
asparaginase NN 3_i
, , N
and CC N
cytarabine NN 3_i
) ) N
in IN N
patients NNS N
in IN N
first JJ N
complete JJ N
remission NN N
with IN N
intermediate- JJ N
and CC N
high-grade JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
younger JJR N
than IN N
55 CD N
years NNS N
and CC N
had VBD N
at IN N
least JJS N
one CD N
adverse JJ N
prognostic JJ N
factor NN N
. . N

Induction NNP N
treatment NN N
was VBD N
that IN N
of IN N
the DT N
LNH84 NNP N
protocol NN N
with IN N
an DT N
open JJ N
randomization NN N
on IN N
the DT N
anthracycline NN 3_i
. . 3_i

Patients NNS N
in IN N
complete JJ N
remission NN N
were VBD N
further JJ N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
consolidation NN N
procedure NN N
. . N

RESULTS NNP N
After IN N
induction NN N
treatment NN N
, , N
464 CD N
patients NNS N
were VBD N
assessable JJ N
for IN N
the DT N
consolidation NN N
phase NN N
. . N

With IN N
a DT N
median JJ N
follow-up JJ N
duration NN N
of IN N
28 CD N
months NNS N
, , N
the DT N
3-year JJ N
disease-free JJ N
survival NN N
rate NN N
was VBD N
52 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
45 CD N
% NN N
to TO N
59 CD N
% NN N
) ) N
in IN N
the DT N
sequential JJ N
chemotherapy NN N
arm NN N
and CC N
59 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
52 CD N
% NN N
to TO N
66 CD N
% NN N
) ) N
in IN N
the DT N
autologous JJ N
transplant NN N
arm NN N
( ( N
P NNP N
= NNP N
.46 NNP N
, , N
relative JJ N
risk NN N
= NNP N
0.90 CD N
) ) N
. . N

The DT N
3-year JJ N
survival NN N
rate NN N
did VBD N
not RB N
differ VB N
between IN N
sequential JJ N
chemotherapy NN N
and CC N
autotransplantation NN N
, , N
at IN N
71 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
64 CD N
% NN N
to TO N
78 CD N
% NN N
) ) N
and CC N
69 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
62 CD N
% NN N
to TO N
76 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.60 NNP N
, , N
relative JJ N
risk NN N
= NNP N
1.11 CD N
) ) N
. . N

CONCLUSION NNP N
For IN N
such JJ N
a DT N
subset NN N
of IN N
patients NNS N
, , N
consolidation NN N
with IN N
the DT N
CBV NNP N
regimen NNS N
followed VBN N
by IN N
autologous JJ N
bone NN N
marrow NN N
transplantation NN N
is VBZ N
not RB N
superior JJ N
to TO N
sequential JJ N
chemotherapy NN N
. . N

-DOCSTART- -X- O O

Role NNP N
of IN N
diltiazem NN 3_i
in IN N
the DT N
treatment NN N
of IN N
silent JJ N
myocardial JJ N
ischemia NN N
. . N

Silent JJ N
myocardial JJ N
ischemia NN N
is VBZ N
a DT N
frequent JJ N
finding NN N
when WRB N
Holter NNP N
monitoring NN N
is VBZ N
done VBN N
in IN N
patients NNS N
with IN N
advanced JJ N
coronary JJ N
disease NN N
. . N

Silent JJ N
ischemia NN N
is VBZ N
associated VBN N
with IN N
a DT N
worse JJR N
prognosis NN N
in IN N
patients NNS N
with IN N
stable JJ N
or CC N
unstable JJ N
angina NN N
, , N
survivors NNS N
of IN N
myocardial JJ N
infarction NN N
, , N
and CC N
populations NNS N
at IN N
risk NN N
for IN N
coronary JJ N
disease NN N
. . N

Whether NNP N
medical JJ N
therapy NN N
for IN N
silent JJ N
ischemia NN N
improves VBZ N
prognosis NN N
is VBZ N
not RB N
known VBN N
. . N

In IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 7_i
, , N
multicenter JJ N
trial NN N
of IN N
60 CD N
patients NNS N
with IN N
documented JJ N
coronary JJ N
disease NN N
, , N
positive JJ N
exercise NN N
tests NNS N
, , N
and CC N
ischemic JJ N
episodes NNS N
on IN N
Holter NNP N
monitoring NN N
, , N
long-acting JJ N
diltiazem NN 3_i
reduced VBD N
ischemic JJ N
episodes NNS N
by IN N
50 CD N
% NN N
compared VBN N
to TO N
placebo VB 7_i
, , N
from IN N
a DT N
mean NN N
of IN N
5.6 CD N
to TO N
2.8 CD N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

Efficacy NN N
was VBD N
maintained VBN N
over IN N
24 CD N
h NNS N
and CC N
diltiazem NN 3_i
also RB N
significantly RB N
improved VBN N
exercise NN N
test NN N
parameters NNS N
. . N

Three CD N
smaller JJR N
studies NNS N
also RB N
demonstrated VBD N
that IN N
diltiazem NN 3_i
effectively RB N
reduces VBZ N
ambulatory JJ N
ischemia NN N
; : N
however RB N
, , N
results NNS N
with IN N
nifedipine JJ N
are VBP N
conflicting VBG N
, , N
with IN N
several JJ N
studies NNS N
showing VBG N
no DT N
benefit NN N
. . N

In IN N
contrast NN N
, , N
beta-blockers NNS N
reliably RB N
reduce VB N
ischemic JJ N
episodes NNS N
. . N

The DT N
role NN N
of IN N
medical JJ N
therapy NN N
for IN N
silent JJ N
ischemia NN N
will MD N
be VB N
clarified VBN N
only RB N
when WRB N
its PRP$ N
effect NN N
upon IN N
morbidity NN N
and CC N
mortality NN N
are VBP N
determined VBN N
. . N

-DOCSTART- -X- O O

Inhibition NN N
of IN N
epidural JJ N
morphine-induced JJ N
pruritus NN N
by IN N
intravenous JJ N
droperidol NN 3_i
. . 3_i

The DT N
effect NN N
of IN N
increasing VBG N
the DT N
doses NNS N
of IN N
morphine NN 3_i
and CC N
of IN N
droperidol NN 3_i
. . 3_i

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Because IN N
the DT N
mechanism NN N
of IN N
inhibition NN N
of IN N
epidural JJ N
morphine-induced JJ N
pruritus NN N
by IN N
droperidol NN N
is VBZ N
not RB N
clear JJ N
, , N
this DT N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
larger JJR N
doses NNS N
of IN N
droperidol NN 3_i
or CC N
morphine NN 3_i
, , N
or CC N
both DT N
. . N

METHODS VB N
A DT N
double-blind NN N
study NN N
was VBD N
performed VBN N
in IN N
210 CD N
ASA NNP N
I PRP N
or CC N
II NNP N
patients NNS N
undergoing VBG N
cesarean JJ N
delivery NN N
, , N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
six CD N
groups NNS N
. . N

All DT N
patients NNS N
received VBD N
epidural JJ 3_i
anesthesia NN 3_i
with IN N
0.5 CD N
% NN N
bupivacaine NN 3_i
containing VBG N
1:200,000 CD N
epinephrine NN 3_i
, , N
to TO N
which WDT N
2 CD N
mg NN N
( ( N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
or CC N
4 CD N
mg NN N
( ( N
groups NNS N
4 CD N
, , N
5 CD N
, , N
and CC N
6 CD N
) ) N
morphine NN 3_i
sulfate NN 3_i
was VBD N
added VBN N
. . N

Just RB N
after IN N
delivery NN N
, , N
2.5 CD N
mg NN N
droperidol NN 3_i
was VBD N
given VBN N
intravenously RB N
to TO N
groups NNS N
2 CD N
and CC N
5 CD N
, , N
and CC N
5 CD N
mg NN N
was VBD N
given VBN N
to TO N
groups NNS N
3 CD N
and CC N
6 CD N
. . N

During IN N
the DT N
postoperative JJ N
period NN N
, , N
the DT N
patients NNS N
were VBD N
assessed VBN N
for IN N
the DT N
occurrence NN N
and CC N
severity NN N
of IN N
pruritus NN N
( ( N
classified VBN N
as IN N
absent NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
or CC N
severe RB N
) ) N
or CC N
other JJ N
untoward JJ N
symptoms NNS N
. . N

The DT N
groups NNS N
were VBD N
compared VBN N
for IN N
the DT N
incidence NN N
of IN N
pruritus NN N
by IN N
the DT N
Mann-Whitney NNP N
nonparametric JJ N
test NN N
. . N

RESULTS VB N
The DT N
incidence NN N
of IN N
pruritus NN N
was VBD N
significantly RB N
reduced VBN N
only RB N
when WRB N
the DT N
control NN N
group NN N
. . N

( ( N
no DT N
droperidol NN 3_i
) ) 3_i
was VBD N
compared VBN N
with IN N
the DT N
group NN N
that WDT N
received VBD N
2.5 CD N
mg NN N
droperidol NN 3_i
, , N
both DT N
when WRB N
2 CD N
mg NN N
and CC N
when WRB N
4 CD N
mg NN N
morphine NN 3_i
was VBD N
used VBN N
. . N

A DT N
5-mg JJ N
dose NN N
of IN N
droperidol NN N
had VBD N
no DT N
inhibitory JJ N
effect NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
pruritus NN N
between IN N
use NN N
of IN N
2 CD N
mg NNS N
and CC N
4 CD N
mg NN N
morphine NN 3_i
. . 3_i

Other JJ N
untoward JJ N
effects NNS N
of IN N
morphine NN 3_i
either DT N
could MD N
not RB N
be VB N
observed VBN N
or CC N
occurred VBN N
with IN N
an DT N
incidence NN N
unaffected VBN N
by IN N
either DT N
dose NN N
of IN N
droperidol NN 3_i
. . 3_i

CONCLUSION NNP N
Pruritus NNP N
caused VBN N
by IN N
epidural JJ N
use NN N
of IN N
2 CD N
or CC N
4 CD N
mg NN N
of IN N
morphine NN N
is VBZ N
inhibited VBN N
by IN N
the DT N
intravenous JJ N
use NN N
of IN N
2.5 CD N
mg NNS N
droperidol RB 3_i
but CC N
not RB N
by IN N
a DT N
larger JJR N
dose NN N
. . N

-DOCSTART- -X- O O

Multicenter NNP N
trial NN N
of IN N
cryotherapy NN 2_i
for IN N
retinopathy NN N
of IN N
prematurity NN N
: : N
preliminary JJ N
results NNS N
. . N

Cryotherapy NNP 2_i
for IN N
Retinopathy NNP N
of IN N
Prematurity NNP N
Cooperative NNP N
Group NNP N
. . N

We PRP N
report VBP N
the DT N
preliminary JJ N
3-month JJ N
outcome NN N
of IN N
a DT N
multicenter NN N
randomized VBN N
trial NN N
of IN N
cryotherapy NN 2_i
for IN N
treatment NN N
of IN N
retinopathy NN N
of IN N
prematurity NN N
( ( N
ROP NNP N
) ) N
. . N

Transscleral JJ 2_i
cryotherapy NN 2_i
to TO N
the DT N
avascular JJ N
retina NN N
was VBD N
applied VBN N
to TO N
one CD N
randomly NN N
selected VBN N
eye NN N
when WRB N
there EX N
was VBD N
threshold JJ N
disease NN N
( ( N
defined VBN N
as IN N
five CD N
or CC N
more JJR N
contiguous JJ N
or CC N
eight CD N
cumulative JJ N
30 CD N
degree JJ N
sectors NNS N
[ VBP N
clock NN N
hours NNS N
] CD N
of IN N
stage NN N
3 CD N
ROP NNP N
in IN N
zone CD N
1 CD N
or CC N
2 CD N
in IN N
the DT N
presence NN N
of IN N
plus JJ N
disease NN N
) ) N
. . N

An DT N
unfavorable JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
posterior JJ N
retinal JJ N
detachment NN N
, , N
retinal JJ N
fold NN N
involving VBG N
the DT N
macula NN N
, , N
or CC N
retrolental JJ N
tissue NN N
. . N

At IN N
this DT N
writing NN N
, , N
172 CD N
infants NNS N
had VBD N
been VBN N
examined VBN N
3 CD N
months NNS N
after IN N
randomization NN N
. . N

An DT N
unfavorable JJ N
outcome NN N
was VBD N
significantly RB N
less JJR N
frequent JJ N
in IN N
the DT N
eyes NNS N
undergoing VBG N
cryotherapy NN 2_i
( ( N
21.8 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
untreated JJ N
eyes NNS N
( ( N
43 CD N
% NN N
) ) N
. . N

While IN N
the DT N
surgery NN N
was VBD N
stressful JJ N
, , N
no DT N
unexpected JJ N
complications NNS N
occurred VBD N
during IN N
or CC N
following VBG N
treatment NN N
. . N

These DT N
data NNS N
support NN N
the DT N
efficacy NN N
of IN N
cryotherapy NN 2_i
in IN N
reducing VBG N
by IN N
approximately RB N
one CD N
half PDT N
the DT N
risk NN N
of IN N
unfavorable JJ N
retinal JJ N
outcome NN N
from IN N
threshold JJ N
ROP NNP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
Cys NNP 2_i
LT1 NNP 2_i
receptor NN 2_i
blockade NN 2_i
on IN N
airway NN N
responses NNS N
to TO N
allergen VB N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
potent JJ N
experimental JJ N
leukotriene NN 3_i
receptor NN 3_i
antagonist NN 3_i
, , 3_i
MK-571 NNP 3_i
, , N
on IN N
airway NN N
responses NNS N
to TO N
inhaled VB N
allergen NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ 7_i
, , N
crossover JJ N
trial NN N
. . N

SETTING NNP N
Clinical NNP N
research NN N
center NN N
. . N

SUBJECTS NNP N
Eight NNP N
male NN N
volunteers NNS N
with IN N
allergic JJ N
asthma NN N
. . N

INTERVENTIONS NNP N
An DT N
intravenous JJ N
loading NN N
dose NN N
was VBD N
followed VBN N
by IN N
an DT N
8-hour JJ 3_i
infusion NN 3_i
of IN 3_i
MK-571 NNP 3_i
or CC N
placebo NN 3_i
, , N
with IN N
a DT N
7- JJ N
to TO N
14-day JJ N
washout NN N
between IN N
treatments NNS N
. . N

Allergen NNP N
challenge NN N
was VBD N
performed VBN N
after IN N
the DT N
loading NN N
dose NN N
and CC N
a DT N
histamine NN 3_i
challenge NN N
was VBD N
performed VBN N
before IN N
and CC N
24 CD N
hours NNS N
after IN N
allergen NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Forced NNP N
expiratory JJ N
volume NN N
in IN N
1 CD N
second NN N
was VBD N
measured VBN N
serially RB N
. . N

MK-571 NNP 3_i
provided VBD N
about IN N
50 CD N
% NN N
protection NN N
during IN N
maximum JJ N
early JJ N
and CC N
late JJ N
responses NNS N
compared VBN N
with IN N
placebo NN 7_i
( ( N
p=0.005 NN N
) ) N
, , N
but CC N
airway RB N
obstruction NN N
persisted VBD N
8-24 CD N
hours NNS N
after IN N
allergen NN N
on IN N
both DT N
treatment NN N
days NNS N
. . N

Airway NNP N
responsiveness NN N
to TO N
histamine VB N
was VBD N
not RB N
significantly RB N
attenuated VBN N
at IN N
24 CD N
hours NNS N
. . N

CONCLUSION NNP N
Blocking NNP N
Cys NNP N
LT1 NNP N
receptors NNS N
for IN N
8 CD N
hours NNS N
attenuated VBD N
the DT N
early JJ N
and CC N
late JJ N
responses NNS N
but CC N
did VBD N
not RB N
interrupt VB N
the DT N
cascade NN N
of IN N
events NNS N
leading VBG N
to TO N
subsequent JJ N
allergen-induced JJ N
airway NN N
obstruction NN N
and CC N
hyperreactivity NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
chlorhexidine NN 3_i
gluconate NN 3_i
use NN N
in IN N
the DT N
prevention NN N
of IN N
perirectal JJ N
infections NNS N
in IN N
patients NNS N
with IN N
acute JJ N
leukemia NN N
. . N

The DT N
frequency NN N
of IN N
rectal JJ N
infections NNS N
is VBZ N
increased VBN N
in IN N
patients NNS N
with IN N
acute JJ N
leukemia NN N
. . N

Complications NNS N
associated VBN N
with IN N
rectal JJ N
lesions NNS N
may MD N
be VB N
severe JJ N
enough RB N
to TO N
cause VB N
life-threatening JJ N
septicemia NN N
. . N

Clinical JJ N
research NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
preventive JJ N
perirectal NN N
skin NN N
care NN N
is VBZ N
scarce JJ N
. . N

This DT N
study NN N
's POS N
purpose NN N
was VBD N
to TO N
determine VB N
whether IN N
using VBG N
chlorhexidine JJ 3_i
gluconate NN 3_i
( ( 3_i
CHG NNP 3_i
) ) 3_i
in IN N
a DT N
prophylactic JJ N
perirectal JJ N
skin-care JJ N
regimen NNS N
decreases VBZ N
perirectal JJ N
infections NNS N
and CC N
whether IN N
it PRP N
produces VBZ N
more JJR N
skin JJ N
irritation NN N
than IN N
a DT N
nonmedicated JJ N
skin NN N
cleanser NN N
. . N

The DT N
sample NN N
consisted VBD N
of IN N
40 CD N
patients NNS N
, , N
16 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
use VB N
chlorhexidine NN 3_i
and CC N
24 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
use VB N
nonmedicated JJ 2_i
skin NN 2_i
cleanser NN 2_i
. . N

Chi-square JJ N
and CC N
t-tests NNS N
were VBD N
used VBN N
to TO N
analyze VB N
the DT N
incidence NN N
of IN N
skin JJ N
breakdown NN N
and CC N
rectal JJ N
infections NNS N
; : N
the DT N
correlation NN N
between IN N
the DT N
two CD N
factors NNS N
; : N
a DT N
positive JJ N
history NN N
of IN N
rectal JJ N
infections NNS N
, , N
fissures NNS N
, , N
or CC N
hemorrhoids NNS N
; : N
presence NN N
of IN N
hemorrhoids NNS N
; : N
severity NN N
of IN N
diarrhea NN N
; : N
and CC N
duration NN N
and CC N
severity NN N
of IN N
granulocytopenia NN N
. . N

A DT N
positive JJ N
relationship NN N
was VBD N
found VBN N
between IN N
the DT N
severity NN N
of IN N
granulocytopenia NN N
and CC N
the DT N
incidence NN N
of IN N
rectal JJ N
infections NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
in IN N
the DT N
occurrence NN N
of IN N
perirectal JJ N
infections NNS N
( ( N
p JJ N
= NNP N
0.35 CD N
) ) N
or CC N
skin JJ N
breakdown NN N
( ( N
p JJ N
= NNP N
0.18 CD N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
data NN N
suggest NN N
that IN N
CHG NNP N
does VBZ N
not RB N
offer VB N
increased JJ N
protection NN N
against IN N
perirectal JJ N
infections NNS N
in IN N
patients NNS N
undergoing VBG N
intensive JJ N
chemotherapy NN N
, , N
nor CC N
is VBZ N
it PRP N
more RBR N
irritating JJ N
than IN N
a DT N
nonmedicated JJ N
skin NN N
cleanser NN N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
hygienic JJ N
measures NNS N
such JJ N
as IN N
using VBG N
skin JJ N
disinfectants NNS N
to TO N
prevent VB N
infections NNS N
in IN N
patients NNS N
who WP N
are VBP N
immunocompromised VBN N
. . N

-DOCSTART- -X- O O

Children NNP N
with IN N
autistic JJ N
spectrum NN N
disorders NNS N
. . N

II NN N
: : N
parents NNS N
are VBP N
unable JJ N
to TO N
distinguish VB N
secretin NN N
from IN N
placebo NN N
under IN N
double-blind JJ N
conditions NNS N
. . N

BACKGROUND NNP N
Standardised VBD N
measures NNS N
of IN N
behaviour NNS N
have VBP N
failed VBN N
to TO N
detect VB N
short JJ N
term NN N
improvement NN N
in IN N
children NNS N
with IN N
autism NN N
following VBG N
treatment NN N
with IN N
secretin NN 3_i
. . N

However RB N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
standardised JJ N
measures NNS N
are VBP N
insensitive JJ N
to TO N
dimensions NNS N
of IN N
child NN N
behaviour NN N
that WDT N
are VBP N
nonetheless RB N
detectable JJ N
by IN N
parents NNS N
. . N

AIM NNP N
To TO N
determine VB N
the DT N
ability NN N
of IN N
parents NNS N
of IN N
children NNS N
with IN N
autism NN N
to TO N
guess VB N
, , N
under IN N
double JJ N
blind NN N
conditions NNS N
, , N
whether IN N
their PRP$ N
child NN N
had VBD N
received VBN N
secretin NN 3_i
or CC N
placebo NN 7_i
. . N

METHODS NNP N
2x2 CD N
crossover NN N
randomised VBD N
blinded VBN N
study NN N
, , N
comparing VBG N
the DT N
effect NN N
of IN N
synthetic JJ N
human JJ N
secretin NN N
2 CD N
U/kg NNP N
to TO N
placebo VB 7_i
( ( 7_i
saline NN 7_i
) ) 7_i
. . N

Sixty CD N
two CD N
children NNS N
with IN N
autism NN N
( ( N
aged VBN N
43-103 CD N
months NNS N
) ) N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
group NN N
1 CD N
received VBD N
placebo NN 3_i
, , 3_i
followed VBD 3_i
six CD 3_i
weeks NNS 3_i
later RB 3_i
by IN 3_i
secretin NN 3_i
, , N
and CC N
group NN N
2 CD N
received VBD N
secretin NN 3_i
followed VBN 3_i
by IN 3_i
placebo NN 3_i
. . N

At IN N
the DT N
conclusion NN N
of IN N
the DT N
study NN N
, , N
parents NNS N
were VBD N
asked VBN N
to TO N
guess VB N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
. . N

RESULTS NNP N
Twenty NNP N
seven CD N
families NNS N
guessed VBD N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
correctly RB N
and CC N
27 CD N
guessed VBN N
incorrectly RB N
. . N

In IN N
48 CD N
instances NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
improvement NN N
; : N
in IN N
six CD N
cases NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
deterioration NN N
. . N

Six NNP N
families NNS N
saw VBD N
no DT N
difference NN N
after IN N
either DT N
infusion NN N
, , N
and CC N
offered VBD N
no DT N
guess NN N
. . N

One CD N
family NN N
dropped VBD N
out RP N
after IN N
the DT N
first JJ N
infusion NN N
, , N
and CC N
one CD N
family NN N
was VBD N
lost VBN N
to TO N
follow VB N
up RP N
after IN N
the DT N
second JJ N
infusion NN N
. . N

CONCLUSION NNP N
In IN N
a DT N
controlled JJ N
setting NN N
, , N
parents NNS N
of IN N
young JJ N
children NNS N
with IN N
autism NN N
are VBP N
unable JJ N
to TO N
distinguish VB N
the DT N
short JJ N
term NN N
behavioural JJ N
effects NNS N
of IN N
secretin NN 3_i
from IN N
placebo NN 7_i
. . N

-DOCSTART- -X- O O

Individual JJ N
differences NNS N
in IN N
the DT N
efficacy NN N
of IN N
a DT N
short JJ 4_i
theory NN 4_i
of IN 4_i
mind NN 4_i
intervention NN 4_i
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Having VBG N
a DT N
'theory NN N
of IN N
mind NN N
' '' N
, , N
or CC N
having VBG N
the DT N
ability NN N
to TO N
attribute VB N
mental JJ N
states NNS N
to TO N
oneself VB N
or CC N
others NNS N
, , N
is VBZ N
considered VBN N
one CD N
of IN N
the DT N
most RBS N
central JJ N
domains NNS N
of IN N
impairment NN N
among IN N
children NNS N
with IN N
an DT N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

Many JJ N
interventions NNS N
focus VBP N
on IN N
improving VBG N
theory NN 4_i
of IN 4_i
mind NN 4_i
skills NNS 4_i
in IN N
children NNS N
with IN N
ASD NNP N
. . N

Nonetheless NNP N
, , N
the DT N
empirical JJ N
evidence NN N
for IN N
the DT N
effect NN N
of IN N
these DT N
interventions NNS N
is VBZ N
limited JJ N
. . N

The DT N
main JJ N
goal NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
a DT N
short JJ 4_i
theory NN 4_i
of IN 4_i
mind NN 4_i
intervention NN 4_i
for IN N
children NNS N
with IN N
ASD NNP N
. . N

A DT N
second JJ N
objective NN N
is VBZ N
to TO N
determine VB N
which WDT N
subgroups NNS N
within IN N
the DT N
autism NN N
spectrum JJ N
profit NN N
most JJS N
from IN N
the DT N
intervention NN N
. . N

METHODS NNP N
This DT N
study NN N
is VBZ N
a DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

One CD N
hundred VBD N
children NNS N
with IN N
ASD NNP N
, , N
aged VBD N
7 CD N
to TO N
12 CD N
years NNS N
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
or CC N
a DT N
waiting JJ N
list NN N
control NN 7_i
group NN N
. . N

Outcome NNP N
measures VBZ N
include VBP N
the DT N
completion NN 4_i
of IN 4_i
theory NN 4_i
of IN 4_i
mind NN 4_i
and CC 4_i
emotion NN 4_i
understanding NN 4_i
tasks NNS 4_i
, , 4_i
and CC 4_i
parent NN 4_i
and CC 4_i
teacher NN 4_i
questionnaires NNS 4_i
on IN N
children NNS N
's POS N
social JJ N
skills NNS N
. . N

Follow-up NNP N
data NN N
for IN N
the DT N
intervention NN N
group NN N
will MD N
be VB N
collected VBN N
6 CD N
months NNS N
after IN N
the DT N
interventions NNS N
. . N

DISCUSSION NNP N
This DT N
study NN N
evaluates VBZ N
the DT N
efficacy NN N
of IN N
a DT N
theory NN N
of IN N
mind NN 4_i
intervention NN 4_i
for IN N
children NNS N
with IN N
ASD NNP N
. . N

Hypotheses NNP N
, , N
strengths NNS N
, , N
and CC N
limitations NNS N
of IN N
the DT N
study NN N
are VBP N
discussed VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Netherlands NNP N
Trial NNP N
Register NNP N
NTR2327 NNP N
. . N

-DOCSTART- -X- O O

Topical JJ N
adrenaline NN 3_i
in IN N
the DT N
control NN N
of IN N
intraoperative JJ N
bleeding NN N
in IN N
adenoidectomy NN N
: : N
a DT N
randomised JJ N
, , N
controlled JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
topical JJ N
racemic JJ 3_i
adrenaline NN 3_i
( ( 3_i
RA NNP 3_i
) ) 3_i
( ( N
Micronefrin NNP N
; : N
Bird NNP N
Products NNPS N
, , N
Palm NNP N
Springs NNP N
, , N
CA NNP N
, , N
USA NNP N
) ) N
in IN N
the DT N
control NN N
of IN N
intraoperative JJ N
bleeding NN N
and CC N
the DT N
prevention NN N
of IN N
postoperative JJ N
bleeding NN N
, , N
laryngeal JJ N
spasm NN N
and CC N
postoperative JJ N
pain NN N
in IN N
adenoidectomy NN N
among IN N
children NNS N
< VBP N
6 CD N
years NNS N
of IN N
age NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomised VBD N
, , N
blinded VBD N
and CC N
placebo-controlled JJ N
trial NN N
. . N

SETTING CC N
Kanta-Hame JJ N
Central NNP N
Hospital NNP N
, , N
a DT N
district NN N
referral NN N
center NN N
in IN N
Finland NNP N
. . N

PATIENTS VB N
A DT N
consecutive JJ N
sample NN N
of IN N
93 CD N
children NNS N
undergoing JJ N
outpatient JJ N
adenoidectomy NN N
. . N

INTERVENTION NN N
Patients NNPS N
were VBD N
randomised VBN N
to TO N
receive VB N
topical JJ 3_i
gauze NN 3_i
sponges NNS 3_i
soaked VBN 3_i
in IN 3_i
either DT 3_i
1:500 CD 3_i
RA NNP 3_i
or CC N
0.9 CD 7_i
% NN 7_i
sodium NN 3_i
chloride NN 3_i
( ( 3_i
physiological JJ 3_i
saline NN 3_i
) ) 3_i
for IN N
3 CD N
min NN N
after IN N
adenoidectomy NN 1_i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Amount NNP N
of IN N
intraoperative JJ N
bleeding NN N
( ( N
surgeons NNS N
' POS N
subjective JJ N
estimate NN N
) ) N
, , N
need VBP N
for IN N
additional JJ N
packings NNS N
, , N
need VBP N
for IN N
electrocautery NN N
, , N
laryngeal JJ N
spasm NN N
, , N
postoperative JJ N
bleeding NN N
and CC N
pain NN N
, , N
duration NN N
of IN N
procedure NN N
and CC N
duration NN N
of IN N
patients NNS N
' POS N
stay NN N
in IN N
the DT N
operation NN N
room NN N
( ( N
OR NNP N
) ) N
. . N

RESULTS NNP N
Adrenaline NNP 3_i
significantly RB N
decreased VBD N
surgeons NNS N
' POS N
subjective JJ N
estimate NN N
of IN N
the DT N
amount NN N
of IN N
intraoperative JJ N
bleeding NN N
( ( N
proportion NN N
of IN N
patients NNS N
with IN N
significant JJ N
decrease NN N
67 CD N
versus NN N
21 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
reduced VBD N
the DT N
mean JJ N
number NN N
of IN N
packings NNS N
needed VBN N
( ( N
0.6 CD N
versus NN N
1.2 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
use NN N
of IN N
electrocautery NN N
( ( N
22 CD N
versus RB N
45 CD N
% NN N
, , N
P NNP N
= NNP N
0.015 CD N
) ) N
, , N
and CC N
shortened VBD N
the DT N
mean JJ N
duration NN N
of IN N
the DT N
procedure NN N
( ( N
13 CD N
versus NN N
18 CD N
min NN N
, , N
P NNP N
= NNP N
0.043 CD N
) ) N
and CC N
the DT N
mean JJ N
stay NN N
in IN N
the DT N
OR NNP N
( ( N
31 CD N
versus NN N
35 CD N
min NN N
, , N
P NNP N
= NNP N
0.058 CD N
) ) N
. . N

The DT N
impact NN N
of IN N
adrenaline NN 3_i
was VBD N
even RB N
more RBR N
pronounced JJ N
among IN N
patients NNS N
with IN N
extensive JJ N
adenoids NNS N
and/or VBP N
profuse RB N
intraoperative JJ N
bleeding NN N
. . N

A DT N
slight JJ N
elevation NN N
of IN N
heart NN N
rate NN N
was VBD N
observed VBN N
more RBR N
often RB N
in IN N
the DT N
adrenaline NN 3_i
group NN N
( ( N
P NNP N
= NNP N
0.043 CD N
) ) N
. . N

CONCLUSIONS NNP N
Use NNP N
of IN N
topical JJ N
adrenaline NN 3_i
can MD N
be VB N
recommended VBN N
in IN N
adenoidectomy NN N
among IN N
children NNS N
. . N

It PRP N
helps VBZ N
control VB N
the DT N
intraoperative JJ N
bleeding NN N
, , N
reduces VBZ N
the DT N
use NN N
of IN N
electrocautery NN N
and CC N
shortens VBZ N
the DT N
durations NNS N
of IN N
procedure NN N
and CC N
stay VB N
in IN N
the DT N
OR NNP N
. . N

-DOCSTART- -X- O O

Altered NNP N
growth NN N
hormone NN N
response NN N
after IN N
growth NN 3_i
hormone NN 3_i
releasing VBG 3_i
hormone CD 3_i
administration NN N
in IN N
chronic JJ N
renal JJ N
failure NN N
. . N

Eleven NNP N
chronic JJ N
renal JJ N
failure NN N
patients NNS N
and CC N
11 CD N
matched JJ N
controls NNS N
, , N
received VBD N
growth NN 3_i
hormone NN 3_i
GHRH NNP 3_i
( ( N
1 CD N
microgram/kg RB N
iv NN N
) ) N
or CC N
TRH NNP 3_i
( ( N
400 CD N
microgram RB N
iv NN N
) ) N
on IN N
separate JJ N
occasions NNS N
, , N
immediately RB N
before IN N
undergoing JJ N
hemodialysis NN N
. . N

GHRH-induced JJ 3_i
GH NNP N
peak NN N
in IN N
uremics NNS N
( ( N
22.7 CD N
+/- JJ N
5.2 CD N
micrograms/l NN N
) ) N
was VBD N
not RB N
different JJ N
from IN N
that DT N
obtained VBN N
in IN N
control NN N
subjects NNS N
( ( N
16.0 CD N
+/- JJ N
4.3 CD N
micrograms/l NN N
) ) N
. . N

However RB N
, , N
the DT N
uremic JJ N
patients NNS N
did VBD N
not RB N
show VB N
the DT N
habitual JJ N
post-peak JJ N
fall NN N
, , N
remaining VBG N
GH NNP N
levels NNS N
over IN N
10 CD N
micrograms/l NNS N
till IN N
the DT N
end NN N
of IN N
the DT N
test NN N
. . N

Differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Uremic JJ N
patients NNS N
showed VBD N
PRL NNP N
values VBZ N
higher JJR N
than IN N
in IN N
controls NNS N
, , N
however RB N
their PRP$ N
TRH-induced JJ 3_i
PRL NNP N
peak NN N
( ( N
20.6 CD N
+/- JJ N
6.6 CD N
micrograms/l NN N
) ) N
was VBD N
not RB N
different JJ N
from IN N
that DT N
of IN N
controls NNS N
( ( N
26.5 CD N
+/- JJ N
3.0 CD N
micrograms/l NN N
) ) N
. . N

Again NNP N
chronic JJ N
renal JJ N
failure NN N
patients NNS N
showed VBD N
PRL NNP N
plasma NN N
values NNS N
abnormally RB N
elevated VBD N
till IN N
the DT N
end NN N
of IN N
the DT N
test NN N
. . N

Differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Administration NN N
of IN N
placebo NN 7_i
to TO N
a DT N
different JJ N
group NN N
of IN N
seven CD N
uremic JJ N
patients NNS N
did VBD N
not RB N
alter VB N
GH NNP N
and CC N
PRL NNP N
plasma NN N
levels NNS N
. . N

This DT N
sustained JJ N
secretion NN N
of IN N
both DT N
GH NNP N
and CC N
PRL NNP N
in IN N
uremia NN N
could MD N
be VB N
attributed VBN N
to TO N
reduced VB N
kidney NN N
clearance NN N
. . N

However RB N
, , N
when WRB N
subjects NNS N
were VBD N
examined VBN N
individually RB N
both DT N
the DT N
GHRH- NNP 3_i
and CC N
the DT N
TRH-induced NNP 3_i
hormonal JJ N
peaks NNS N
and CC N
the DT N
subsequent JJ N
fall NN N
were VBD N
not RB N
different JJ N
in IN N
both DT N
groups NNS N
. . N

Unlike IN N
with IN N
controls NNS N
, , N
in IN N
uremic JJ N
patients NNS N
GHRH-stimulated JJ 3_i
GH NNP N
and CC N
TRH-stimulated NNP 3_i
PRL/GH NNP N
peaks NNS N
were VBD N
dispersed VBN N
throughout IN N
the DT N
120 CD N
min JJ N
period NN N
. . N

In IN N
controls NNS N
GH NNP N
and CC N
PRL NNP N
peaks NNS N
clustered VBD N
around IN N
15-30 JJ N
min NN N
. . N

The DT N
peak JJ N
dispersion NN N
created VBD N
a DT N
false JJ N
impression NN N
of IN N
flattened JJ N
curves NNS N
or CC N
sustained VBN N
hypersecretion NN N
in IN N
uremia NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Results NNS N
of IN N
the DT N
EICESS-92 NNP N
Study NNP N
: : N
two CD N
randomized JJ N
trials NNS N
of IN N
Ewing NNP N
's POS N
sarcoma NN N
treatment NN N
-- : N
cyclophosphamide NN 3_i
compared VBN N
with IN N
ifosfamide NN 3_i
in IN N
standard-risk JJ N
patients NNS N
and CC N
assessment NN N
of IN N
benefit NN N
of IN N
etoposide NN 3_i
added VBD N
to TO N
standard VB N
treatment NN N
in IN N
high-risk JJ N
patients NNS N
. . N

PURPOSE VB N
The DT N
European NNP N
Intergroup NNP N
Cooperative NNP N
Ewing NNP N
's POS N
Sarcoma NNP N
Study NNP N
investigated VBD N
whether IN N
cyclophosphamide NN 3_i
has VBZ N
a DT N
similar JJ N
efficacy NN N
as IN N
ifosfamide NN 3_i
in IN N
standard-risk JJ N
( ( N
SR NNP N
) ) N
patients NNS N
and CC N
whether IN N
the DT N
addition NN N
of IN N
etoposide JJ 3_i
improves NNS N
survival VBP N
in IN N
high-risk NN N
( ( N
HR NNP N
) ) N
patients NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
SR NNP N
patients NNS N
( ( N
localized JJ N
tumors NNS N
, , N
volume NN N
< VBD N
100 CD N
mL NN N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
four CD N
courses NNS N
of IN N
vincristine NN 3_i
, , 3_i
dactinomycin NN 3_i
, , 3_i
ifosfamide NN 3_i
, , 3_i
and CC 3_i
doxorubicin NN 3_i
( ( 3_i
VAIA NNP 3_i
) ) 3_i
induction NN 3_i
therapy NN 3_i
followed VBN N
by IN N
10 CD N
courses NNS N
of IN N
either DT N
VAIA NNP 3_i
or CC 3_i
vincristine NN 3_i
, , 3_i
dactinomycin NN 3_i
, , 3_i
cyclophosphamide NN 3_i
, , 3_i
and CC 3_i
doxorubicin NN 3_i
( ( N
VACA NNP N
; : N
cyclophosphamide NN N
replacing VBG N
ifosfamide NN N
) ) N
. . N

HR $ N
patients NNS N
( ( N
volume NN N
> NNP N
or=100 VBZ N
mL NN N
or CC N
metastases NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
14 CD N
courses NNS N
of IN N
either DT N
VAIA NNP 3_i
or CC N
VAIA NNP 3_i
plus CC N
etoposide NN 3_i
( ( 3_i
EVAIA NNP 3_i
) ) 3_i
. . N

Outcome JJ N
measures NNS N
were VBD N
event-free JJ N
survival NN N
( ( N
EFS NNP N
; : N
defined VBD N
as IN N
the DT N
time NN N
to TO N
first JJ N
recurrence NN N
, , N
progression NN N
, , N
second JJ N
malignancy NN N
, , N
or CC N
death NN N
) ) N
and CC N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
647 CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
: : N
79 CD N
SR NNP N
patients NNS N
were VBD N
assigned VBN N
to TO N
VAIA NNP 3_i
, , N
76 CD N
SR NN N
patients NNS N
were VBD N
assigned VBN N
to TO N
VACA NNP 3_i
, , N
240 CD N
HR NNP N
were VBD N
assigned VBN N
to TO N
VAIA NNP 3_i
, , N
and CC N
252 CD N
HR NNP N
patients NNS N
were VBD N
assigned VBN N
to TO N
EVAIA NNP 3_i
. . N

The DT N
median JJ N
follow-up NN N
was VBD N
8.5 CD N
years NNS N
. . N

In IN N
the DT N
SR NNP N
group NN N
, , N
the DT N
hazard NN N
ratios NNS N
( ( N
VACA NNP N
v NNP N
VAIA NNP N
) ) N
for IN N
EFS NNP N
and CC N
OS NNP N
were VBD N
0.91 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.55 CD N
to TO N
1.53 CD N
) ) N
and CC N
1.08 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.58 CD N
to TO N
2.03 CD N
) ) N
, , N
respectively RB N
. . N

There EX N
was VBD N
a DT N
higher JJR N
incidence NN N
of IN N
hematologic JJ N
toxicities NNS N
in IN N
the DT N
VACA NNP N
arm NN N
. . N

In IN N
the DT N
HR NNP N
group NN N
, , N
the DT N
EFS NNP N
and CC N
OS NNP N
hazard NN N
ratios NNS N
( ( N
EVAIA NNP N
v NNP N
VAIA NNP N
) ) N
indicated VBD N
a DT N
17 CD N
% NN N
reduction NN N
in IN N
the DT N
risk NN N
of IN N
an DT N
event NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-35 NNP N
% NN N
to TO N
5 CD N
% NN N
; : N
P NNP N
= NNP N
.12 NNP N
) ) N
and CC N
15 CD N
% NN N
reduction NN N
in IN N
dying VBG N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-34 NNP N
% NN N
to TO N
10 CD N
% NN N
) ) N
, , N
respectively RB N
. . N

The DT N
effect NN N
seemed VBD N
greater JJR N
among IN N
patients NNS N
without IN N
metastases NNS N
( ( N
hazard NN N
ratio NN N
= VBZ N
0.79 CD N
; : N
P NNP N
= NNP N
.16 NNP N
) ) N
than IN N
among IN N
those DT N
with IN N
metastases NNS N
( ( N
hazard NN N
ratio NN N
= VBZ N
0.96 CD N
; : N
P NNP N
= NNP N
.84 NNP N
) ) N
. . N

CONCLUSION NNP N
Cyclophosphamide NNP N
seemed VBD N
to TO N
have VB N
a DT N
similar JJ N
effect NN N
on IN N
EFS NNP N
and CC N
OS NNP N
as IN N
ifosfamide NN N
in IN N
SR NNP N
patients NNS N
but CC N
was VBD N
associated VBN N
with IN N
increased JJ N
toxicity NN N
. . N

In IN N
HR NNP N
patients NNS N
, , N
the DT N
addition NN N
of IN N
etoposide NN N
seemed VBD N
to TO N
be VB N
beneficial JJ N
. . N

-DOCSTART- -X- O O

Intensive JJ 3_i
insulin NN 3_i
therapy NN 3_i
on IN N
infection NN N
rate NN N
, , N
days NNS N
in IN N
NICU NNP N
, , N
in-hospital JJ N
mortality NN N
and CC N
neurological JJ N
outcome NN N
in IN N
severe JJ N
traumatic JJ N
brain NN N
injury NN N
patients NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVES NNP N
Evaluate NNP N
the DT N
impact NN N
of IN N
an DT N
intensive JJ 3_i
insulin NN 3_i
therapy NN 3_i
and CC N
conventional JJ 3_i
glucose NN 3_i
control NN 3_i
protocol NN 3_i
during IN N
staying VBG N
in IN N
neurological JJ N
intensive JJ N
care NN N
unit NN N
( ( N
NICU NNP N
) ) N
on IN N
infection NN N
rate NN N
, , N
days NNS N
in IN N
NICU NNP N
, , N
in-hospital JJ N
mortality NN N
and CC N
long-term JJ N
neurological JJ N
outcome NN N
in IN N
severe JJ N
traumatic JJ N
brain NN N
injury NN N
( ( N
TBI NNP N
) ) N
patients NNS N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
240 CD N
patients NNS N
with IN N
severe JJ N
TBI NNP N
( ( N
GCS NNP N
score RB N
3-8 JJ N
) ) N
admitted VBD N
to TO N
NICU NNP N
were VBD N
prospectively RB N
enrolled VBN N
and CC N
randomly RB N
assigned VBD N
either DT N
to TO N
conventional JJ 3_i
insulin NN 3_i
therapy NN 3_i
or CC N
to TO N
intensive JJ 3_i
insulin NN 3_i
therapy NN 3_i
. . N

Patients NNS N
in IN N
intensive JJ 3_i
glucose NNS 3_i
control NN 3_i
group NN 3_i
( ( N
n=121 NN N
) ) N
received VBD N
continuous JJ 3_i
insulin NN 3_i
infusion NN 3_i
to TO N
maintain VB N
glucose JJ N
levels NNS N
between IN N
4.4 CD N
m NNS N
mol/l NN N
( ( N
80 CD N
mg/dl NN N
) ) N
and CC N
6.1 CD N
m NN N
mol/l NN N
( ( N
110 CD N
mg/dl NN N
) ) N
. . N

Patients NNS N
in IN N
the DT N
conventional JJ 3_i
treatment NN 3_i
group NN 3_i
( ( N
n=119 RB N
) ) N
were VBD N
not RB N
given VBN N
insulin NN 3_i
unless IN N
glucose JJ N
levels NNS N
were VBD N
greater JJR N
than IN N
11.1 CD N
m JJ N
mol/l NN N
( ( N
200mg/dl CD N
) ) N
. . N

Both DT N
groups NNS N
were VBD N
treated VBN N
with IN N
insulin JJ 3_i
infusion NN N
to TO N
maintain VB N
normoglycemia RB N
after IN N
leaving VBG N
NICU NNP N
. . N

Comparison NNP N
was VBD N
made VBN N
against IN N
conventional JJ 3_i
insulin NN 3_i
therapy NN 3_i
using VBG N
a DT N
randomized JJ N
trial NN N
design NN N
. . N

The DT N
primary JJ N
outcomes NNS N
is VBZ N
the DT N
mortality NN N
rate NN N
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

The DT N
second JJ N
outcomes NNS N
including VBG N
ICU NNP N
infection NN N
rate NN N
, , N
duration NN N
of IN N
ICU NNP N
stay NN N
, , N
in-hospital JJ N
mortality NN N
rate NN N
and CC N
neurologic JJ N
outcome NN N
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
gender NN N
( ( N
66 CD N
% NN N
vs. FW N
67 CD N
% NN N
male NN N
) ) N
, , N
age NN N
( ( N
46+/-11 CD N
years NNS N
vs. IN N
45+/-10 CD N
years NNS N
) ) N
, , N
APACHE NNP N
II NNP N
score NN N
( ( N
30 CD N
vs. FW N
29 CD N
) ) N
, , N
TISS-28 NNP N
score NN N
( ( N
47 CD N
vs. FW N
46 CD N
) ) N
, , N
and CC N
Glasgow NNP N
Coma NNP N
Score NNP N
( ( N
GCS NNP N
, , N
5.3 CD N
vs. FW N
5.3 CD N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

Overall JJ N
mortality NN N
rates NNS N
at IN N
6 CD N
months NNS N
follow-up JJ N
were VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
61 CD N
of IN N
117 CD N
, , N
52.1 CD N
% NN N
vs. FW N
62 CD N
of IN N
116 CD N
, , N
53.4 CD N
% NN N
; : N
P=0.8 NNP N
) ) N
. . N

The DT N
infection NN N
rate NN N
during IN N
the DT N
study NN N
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS N
who WP N
received VBD N
conventional JJ 3_i
insulin NN 3_i
therapy NN 3_i
than IN N
that DT N
in IN N
patients NNS N
who WP N
received VBD N
intensive JJ 3_i
insulin NN 3_i
therapy NN 3_i
( ( N
46.2 CD N
% NN N
vs. FW N
31.4 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
days NNS N
stay VBP N
in IN N
NICU NNP N
was VBD N
shorter RBR N
in IN N
intensive JJ 3_i
insulin NN 3_i
control NN N
group NN N
than IN N
that DT N
in IN N
conventional JJ 3_i
therapy NN 3_i
group NN N
[ VBD N
4.2 CD N
days NNS N
vs. FW N
5.6 CD N
days NNS N
( ( N
medians NNS N
) ) N
P NNP N
< $ N
0.05 CD N
] NNP N
. . N

The DT N
in-hospital JJ N
mortality NN N
during IN N
the DT N
study NN N
was VBD N
similar JJ N
in IN N
conventional JJ 3_i
and CC N
intensive JJ 3_i
therapy NN 3_i
groups NNS N
( ( N
34 CD N
of IN N
119 CD N
, , N
28.6 CD N
% NN N
vs. FW N
35 CD N
of IN N
121 CD N
, , N
28.9 CD N
% NN N
in IN N
the DT N
conventional JJ 3_i
and CC N
intensive JJ 3_i
insulin NN 3_i
therapy NN 3_i
groups NNS N
; : N
P=0.85 NNP N
) ) N
. . N

The DT N
neurologic JJ N
outcome NN N
according VBG N
to TO N
Glasgow NNP N
Outcome NNP N
Score NNP N
( ( N
GOS NNP N
) ) N
at IN N
6 CD N
months NNS N
( ( N
GOS NNP N
5 CD N
and CC N
4 CD N
) ) N
was VBD N
better RBR N
in IN N
the DT N
intensive JJ N
insulin NN N
therapy NN N
group NN N
( ( N
34 CD N
of IN N
117 CD N
, , N
29.1 CD N
% NN N
) ) N
than IN N
that DT N
in IN N
the DT N
conventional JJ 3_i
therapy NN 3_i
group NN N
( ( N
26 CD N
of IN N
116 CD N
, , N
22.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Mortality NNP N
rates NNS N
at IN N
6 CD N
months NNS N
follow-up NNS N
are VBP N
not RB N
affected VBN N
by IN N
intensive JJ N
glucose NNS N
control NN N
in IN N
patients NNS N
with IN N
severe JJ N
TBI NNP N
. . N

Intensive JJ 3_i
insulin NN 3_i
therapy NN 3_i
decreases VBZ N
infection NN N
rate NN N
and CC N
days NNS N
in IN N
NICU NNP N
and CC N
improves VBZ N
the DT N
neurological JJ N
outcome NN N
at IN N
6 CD N
months NNS N
follow-up RB N
, , N
while IN N
has VBZ N
no DT N
obvious JJ N
influence NN N
on IN N
in-hospital JJ N
mortality NN N
of IN N
severe JJ N
TBI NNP N
patients NNS N
. . N

-DOCSTART- -X- O O

Comparative JJ N
evaluation NN N
of IN N
calcium NN 3_i
hydroxide NN 3_i
and CC N
zinc NN 3_i
oxide RB 3_i
eugenol RB 3_i
as IN N
root JJ 2_i
canal JJ 2_i
filling NN 2_i
materials NNS N
for IN N
primary JJ N
molars NNS N
: : N
a DT N
clinical JJ N
and CC N
radiographic JJ N
study NN N
. . N

Calcium NNP 3_i
hydroxide NN 3_i
, , N
a DT N
material NN N
widely RB N
used VBN N
for IN N
the DT N
treatment NN N
of IN N
permanent JJ N
teeth NN N
has VBZ N
not RB N
been VBN N
used VBN N
frequently RB N
for IN N
pulpectomy NN N
in IN N
primary JJ N
teeth NNS N
. . N

A DT N
comparative JJ N
evaluation NN N
of IN N
calcium NN 3_i
hydroxide NN 3_i
and CC N
zinc NN 3_i
oxide NN 3_i
eugenol NN 3_i
used VBN N
as IN N
root JJ 2_i
canal JJ 2_i
filling NN 2_i
materials NNS 2_i
in IN N
primary JJ N
molars NNS N
is VBZ N
presented VBN N
. . N

-DOCSTART- -X- O O

Service NNP N
variation NN N
in IN N
baseline NN N
variables NNS N
and CC N
prediction NN N
of IN N
risk NN N
in IN N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
psychological JJ 5_i
treatment NN 5_i
in IN N
repeated JJ N
parasuicide NN N
: : N
the DT N
POPMACT NNP N
Study NNP N
. . N

The DT N
treatment NN N
protocol NN N
and CC N
baseline NN N
characteristics NNS N
of IN N
480 CD N
subjects NNS N
with IN N
a DT N
history NN N
of IN N
repeated VBN N
parasuicide NN N
recruited VBN N
in IN N
five CD N
centres NNS N
to TO N
a DT N
randomised VBN N
therapeutic JJ N
trial NN N
of IN N
manual JJ 5_i
assisted VBN 5_i
cognitive-behaviour JJ 5_i
therapy NN 5_i
( ( 5_i
MACT NNP 5_i
) ) 5_i
and CC N
treatment NN 2_i
as IN 2_i
usual JJ 2_i
( ( 2_i
TAU NNP 2_i
) ) 2_i
are VBP N
described VBN N
. . N

Most JJS N
patients NNS N
had VBD N
significant JJ N
anxiety NN N
and CC N
depressive JJ N
disturbance NN N
with IN N
42 CD N
% NN N
having VBG N
a DT N
personality NN N
disorder NN N
. . N

Variation NNP N
in IN N
service NN N
policies NNS N
influenced VBD N
recruitment NN N
, , N
with IN N
earlier RBR N
assessment JJ N
centres NNS N
seeing VBG N
people NNS N
with IN N
more RBR N
frequent JJ N
episodes NNS N
of IN N
self-harm NN N
and CC N
greater JJR N
parasuicide NN N
risk NN N
than IN N
later JJR N
ones NNS N
. . N

Parasuicide NNP N
risk NN N
was VBD N
also RB N
significantly RB N
greater JJR N
in IN N
those DT N
with IN N
their PRP$ N
first JJ N
parasuicide NN N
episode NN N
at IN N
an DT N
earlier JJR N
age NN N
and CC N
in IN N
those DT N
with IN N
a DT N
more RBR N
recent JJ N
latest JJS N
episode NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
venlafaxine NN 3_i
on IN N
ongoing VBG N
and CC N
experimentally RB N
induced JJ N
pain NN N
in IN N
neuropathic JJ N
pain NN N
patients NNS N
: : N
a DT N
double JJ N
blind NN N
, , N
placebo NN 7_i
controlled VBD N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIM NNP N
The DT N
aim NN N
of IN N
this DT N
randomized VBN N
double JJ N
blind NN N
placebo NN 7_i
controlled VBD N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effectiveness NN N
and CC N
the DT N
safety NN N
of IN N
venlafaxine JJ 3_i
XR NNP 3_i
75 CD 3_i
and CC 3_i
150 CD 3_i
mg NN 3_i
on IN N
ongoing VBG N
pain NN N
and CC N
on IN N
quantitative JJ N
sensory NN N
tests NNS N
in IN N
60 CD N
patients NNS N
with IN N
neuropathic JJ N
pain NN N
for IN N
8 CD N
weeks NNS N
. . N

METHODS NNP N
Evaluation NNP N
parameters NNS N
consisted VBD N
of IN N
ongoing VBG N
pain NN N
intensity NN N
( ( N
VAS NNP N
) ) N
, , N
patient JJ N
satisfaction NN N
, , N
side NN N
effects NNS N
, , N
global JJ N
efficacy NN N
and CC N
tolerance NN N
. . N

Quantitative JJ N
sensory NN N
measurements NNS N
taken VBN N
from IN N
the DT N
affected JJ N
area NN N
before IN N
and CC N
after IN N
the DT N
drug NN N
treatment NN N
included VBD N
pin-prick JJ N
hyperalgesia NN N
, , N
allodynia NN N
, , N
detection NN N
and CC N
pain NN N
thresholds NNS N
to TO N
electrical JJ N
and CC N
heat NN N
stimuli NNS N
, , N
temporal JJ N
summation NN N
of IN N
repetitive JJ N
electrical JJ N
and CC N
heat NN N
stimuli NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
55 CD N
patients NNS N
completed VBD N
the DT N
study NN N
. . N

VAS NNP N
scores NNS N
decreased VBD N
significantly RB N
compared VBN N
to TO N
the DT N
baseline NN N
measurements NNS N
in IN N
all DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
regarding VBG N
pain NN N
intensity NN N
and CC N
escape NN N
medication NN N
. . N

The DT N
areas NNS N
of IN N
allodynia NN N
and CC N
pin-prick JJ N
hyperalgesia NN N
decreased VBN N
significantly RB N
in IN N
venlafaxine NN N
groups NNS N
compared VBN N
to TO N
the DT N
placebo NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
regarding VBG N
the DT N
detection NN N
thresholds NNS N
( ( N
electrical JJ N
and CC N
heat NN N
) ) N
. . N

The DT N
pain NN N
threshold NN N
and CC N
the DT N
summation NN N
threshold NN N
to TO N
electrical JJ N
stimuli NNS N
and CC N
the DT N
summation NN N
threshold NN N
to TO N
heat VB N
stimuli NNS N
increased VBN N
significantly RB N
following VBG N
treatment NN N
in IN N
both DT N
venlafaxine JJ 3_i
groups NNS N
. . N

In IN N
addition NN N
, , N
the DT N
degree NN N
of IN N
the DT N
temporal JJ N
summation NN N
to TO N
electrical JJ N
and CC N
heat NN N
stimuli NNS N
decreased VBN N
significantly RB N
following VBG N
treatment NN N
in IN N
both DT N
venlafaxine NN 3_i
groups NNS N
compared VBN N
to TO N
the DT N
placebo NN N
. . N

CONCLUSION VB N
The DT N
study NN N
showed VBD N
significant JJ N
effect NN N
of IN N
venlafaxine NN 3_i
in IN N
the DT N
manifestations NNS N
of IN N
hyperalgesia NN N
and CC N
temporal JJ N
summation NN N
, , N
but CC N
not RB N
on IN N
the DT N
ongoing JJ N
pain NN N
intensity NN N
. . N

Furthermore RB N
, , N
the DT N
quantitative JJ N
sensory NN N
tests NNS N
provided VBD N
complementing VBG N
information NN N
to TO N
the DT N
clinical JJ N
measures NNS N
. . N

-DOCSTART- -X- O O

A DT N
comparative JJ N
trial NN N
of IN N
fixed JJ N
ratio NN N
beta-adrenoceptor NN 2_i
blocker NN 2_i
and CC N
diuretic JJ 2_i
combination NN 2_i
products NNS 2_i
in IN N
moderate JJ N
hypertension NN N
. . N

Two CD N
fixed JJ N
ratio NN N
combination NN N
tablets NNS N
, , N
10 CD N
mg NN N
pindolol NN 3_i
combined VBN 3_i
with IN 3_i
5 CD 3_i
mg NNS 3_i
clopamide NN 3_i
and CC N
100 CD N
mg NN N
metoprolol NN 3_i
combined VBN 3_i
with IN 3_i
12.5 CD 3_i
mg NNS 3_i
hydrochlorothiazide RB 3_i
, , N
were VBD N
compared VBN N
at IN N
two CD N
dose JJ N
levels NNS N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
in IN N
10 CD N
previously RB N
untreated JJ 4_i
hypertensive JJ N
patients NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
resting VBG N
blood NN N
pressure NN N
on IN N
the DT N
two CD N
combinations NNS N
at IN N
either DT N
dose JJ N
level NN N
. . N

Exercise NNP N
systolic JJ N
pressure NN N
was VBD N
lower JJR N
after IN N
the DT N
pindolol/clopamide JJ 3_i
combination NN N
at IN N
low JJ N
dose NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
side-effects NNS N
in IN N
this DT N
trial NN N
was VBD N
high JJ N
but CC N
proper JJ N
comparison NN N
of IN N
the DT N
two CD N
products NNS N
could MD N
not RB N
be VB N
made VBN N
because IN N
of IN N
the DT N
small JJ N
number NN N
of IN N
patients NNS N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
combination NN N
products NNS N
should MD N
be VB N
used VBN N
only RB N
after IN N
patients NNS N
have VBP N
failed VBN N
to TO N
respond VB N
adequately RB N
to TO N
a DT N
single JJ N
agent NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
intensive JJ 4_i
early JJ 4_i
intervention NN 4_i
for IN N
children NNS N
with IN N
pervasive JJ N
developmental JJ N
disorder NN N
. . N

Young NNP N
children NNS N
with IN N
pervasive JJ N
developmental JJ N
disorder NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
intensive VB 7_i
treatment NN 7_i
or CC N
parent NN 4_i
training NN 4_i
. . N

The DT N
intensive JJ N
treatment NN N
group NN N
( ( N
7 CD N
with IN N
autism NN N
, , N
8 CD N
with IN N
pervasive JJ N
developmental JJ N
disorder NN N
not RB N
otherwise RB N
specified VBN N
-- : N
NOS NNP N
) ) N
averaged VBD N
24.52 CD N
hours NNS N
per IN N
week NN N
of IN N
individual JJ N
treatment NN N
for IN N
one CD N
year NN N
, , N
gradually RB N
reducing VBG N
hours NNS N
over IN N
the DT N
next JJ N
1 CD N
to TO N
2 CD N
years NNS N
. . N

The DT N
parent NN 4_i
training NN 4_i
group NN N
( ( N
7 CD N
with IN N
autism NN N
, , N
6 CD N
with IN N
pervasive JJ N
developmental JJ N
disorder NN N
NOS NNP N
) ) N
received VBD N
3 CD N
to TO N
9 CD N
months NNS N
of IN N
parent NN 4_i
training NN 4_i
. . N

The DT N
groups NNS N
appeared VBD N
similar JJ N
at IN N
intake NN N
on IN N
all DT N
measures NNS N
; : N
however RB N
, , N
at IN N
follow-up JJ N
the DT N
intensive JJ N
treatment NN N
group NN N
outperformed VBD N
the DT N
parent NN 4_i
training VBG 4_i
group NN N
on IN N
measures NNS N
of IN N
intelligence NN N
, , N
visual-spatial JJ N
skills NNS N
, , N
language NN N
, , N
and CC N
academics NNS N
, , N
though IN N
not RB N
adaptive JJ N
functioning NN N
or CC N
behavior NN N
problems NNS N
. . N

Children NNP N
with IN N
pervasive JJ N
developmental JJ N
disorder NN N
NOS NNP N
may MD N
have VB N
gained VBN N
more JJR N
than IN N
those DT N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O

Simulating VBG N
a DT N
memory NN N
impairment NN N
: : N
can MD N
amnesics VB N
implicitly RB N
outperform JJ N
simulators NNS N
? . N
OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
a DT N
variety NN N
of IN N
tests NNS N
in IN N
differentiating VBG N
simulating VBG N
test NN N
performances NNS N
from IN N
genuine JJ N
memory-impaired JJ N
and CC N
normal JJ N
( ( N
control NN N
) ) N
test NN N
performances NNS N
. . N

DESIGN VB N
A DT N
simulation NN 4_i
design NN 4_i
was VBD N
implemented VBN N
, , N
based VBN N
on IN N
an DT N
analogue NN N
design NN N
in IN N
which WDT N
normal JJ N
participants NNS N
were VBD N
given VBN N
experimental JJ N
instructions NNS N
to TO N
feign VB N
a DT N
mental JJ N
impairment NN N
and CC N
are VBP N
compared VBN N
to TO N
( ( N
a DT N
) ) N
other JJ N
normal JJ N
participants NNS N
with IN N
instructions NNS N
to TO N
perform VB N
honestly RB N
, , N
and CC N
( ( N
b NN N
) ) N
a DT N
comparison NN N
group NN N
, , N
for IN N
example NN N
, , N
acquired VBD N
brain-injured JJ N
persons NNS N
, , N
with IN N
similar JJ N
instructions NNS N
. . N

METHOD NNP N
Forty NNP N
individuals NNS N
comprised VBD N
the DT N
simulating NN N
and CC N
control NN N
group NN N
and CC N
all DT N
participants NNS N
were VBD N
randomly RB N
assigned VBN 4_i
to TO 4_i
the DT 4_i
simulating NN 4_i
and CC N
control NN 7_i
groups NNS 7_i
. . N

Twenty CD N
memory-impaired JJ N
patients NNS N
, , N
all DT N
of IN N
whom WP N
had VBD N
been VBN N
diagnosed VBN N
as IN N
suffering VBG N
from IN N
a DT N
memory NN N
impairment NN N
following VBG N
acquired VBD N
brain NN N
damage NN N
, , N
participated VBD N
as IN N
the DT N
memory-impaired JJ N
control NN N
group NN N
. . N

The DT N
simulation NN N
group NN N
was VBD N
directed VBN 4_i
to TO 4_i
imitate VB 4_i
a DT 4_i
person NN 4_i
with IN 4_i
a DT 4_i
memory NN 4_i
impairment NN 4_i
. . N

The DT N
primary JJ N
outcome JJ N
measure NN N
involved VBN N
identifying VBG N
those DT N
tests NNS N
, , N
if IN N
any DT N
, , N
where WRB N
simulators NNS N
were VBD N
significantly RB N
different JJ N
from IN N
normal JJ N
and CC N
memory-impaired JJ N
participants NNS N
. . N

RESULTS VB N
On IN N
5 CD N
of IN N
the DT N
15 CD N
tasks NNS N
administered VBN N
, , N
simulators NNS 4_i
performed VBD N
significantly RB N
differently RB N
from IN N
normal JJ N
and CC N
memory-impaired JJ N
participants NNS N
. . N

Of IN N
these DT N
5 CD N
tasks NNS N
, , N
the DT N
coin-in-the-hand NN N
, , N
when WRB N
administered VBN N
in IN N
conjunction NN N
with IN N
the DT N
autobiographical JJ N
interview NN N
, , N
identified VBD N
95 CD N
per IN N
cent NN N
of IN N
the DT N
simulators NNS N
without IN N
misclassifying VBG N
any DT N
of IN N
the DT N
memory-impaired JJ N
or CC N
normal JJ N
participants NNS N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
suggested VBN N
that IN N
these DT N
two CD N
tests NNS N
, , N
when WRB N
administered VBN N
jointly RB N
, , N
might MD N
be VB N
of IN N
use NN N
in IN N
clinical JJ N
settings NNS N
to TO N
assist VB N
in IN N
the DT N
detection NN N
of IN N
malingerers NNS N
. . N

-DOCSTART- -X- O O

Preventive JJ N
treatment NN N
of IN N
serotonin-migraine JJ N
with IN N
1,3,4,14b-tetrahydro-2,7-dimethyl-2H-dibenzo JJ 3_i
( ( 3_i
b NN 3_i
, , 3_i
f NN 3_i
) ) 3_i
pyrazino- NN 3_i
( ( 3_i
1,2 CD 3_i
-- : 3_i
d NN 3_i
) ) 3_i
- : 3_i
( ( 3_i
1,4 CD 3_i
) ) 3_i
-oxazepine NN 3_i
hydrogen NN 3_i
maleate NN 3_i
( ( 3_i
Org NNP 3_i
GC NNP 3_i
94 CD 3_i
) ) 3_i
. . 3_i

A DT N
double-blind JJ N
study NN N
. . N

1,3,4,14b-Tetrahydro-2,7-dimethyl-2H-dibenzo JJ 3_i
( ( 3_i
b NN 3_i
, , 3_i
f NN 3_i
) ) 3_i
pyrazino- NN 3_i
( ( 3_i
1,2-d CD 3_i
) ) 3_i
- : 3_i
( ( 3_i
1,4 CD 3_i
) ) 3_i
-oxazepine NN 3_i
hydrogen NN 3_i
maleate NN 3_i
( ( 3_i
Org NNP 3_i
GC NNP 3_i
94 CD 3_i
) ) 3_i
is VBZ N
an DT N
oral JJ N
antamine NN N
preparation NN N
with IN N
anti-serotoninergic JJ N
and CC N
anti-histaminic JJ N
effects NNS N
. . N

Its PRP$ N
lack NN N
of IN N
unpleasant JJ N
side-effects NNS N
permits NNS N
protracted VBN N
use NN N
for IN N
the DT N
preventive JJ N
treatment NN N
of IN N
serotonin-migraine NN N
. . N

Its PRP$ N
chemical NN N
structure NN N
-- : N
tetracyclic JJ N
ring NN N
, , N
C-beta NNP N
, , N
C-alpha NNP N
, , N
amine NN N
in IN N
a DT N
secondary JJ N
position NN N
-- : N
allows VBZ N
block NN N
of IN N
the DT N
receptors NNS N
for IN N
serotonin NN N
and CC N
histamine NN N
. . N

Preventive JJ N
treatment NN N
with IN N
3 CD N
x NNS N
5 CD N
mg/day NN N
of IN N
Org NNP 3_i
GC NNP 3_i
94 CD 3_i
for IN N
a DT N
period NN N
of IN N
3 CD N
months NNS N
can MD N
almost RB N
completely RB N
eliminate JJ N
migraine NN N
attacks NNS N
. . N

21 CD N
out IN N
of IN N
30 CD N
patients NNS N
( ( N
70 CD N
% NN N
) ) N
profited VBN N
from IN N
such JJ N
a DT N
treatment NN N
, , N
showing VBG N
a DT N
drop NN N
from IN N
5 CD N
-- : N
30 CD N
attacks NNS N
to TO N
0 CD N
-- : N
1 CD N
attack NN N
per IN N
month NN N
and CC N
normalization NN N
of IN N
high JJ N
urinary JJ N
serotonin NN N
, , N
5-HIAA JJ N
or CC N
histamine JJ N
levels NNS N
. . N

However RB N
, , N
30 CD N
patients NNS N
receiving VBG N
3 CD N
x JJ N
0.5 CD N
mg NN N
or CC N
placebo JJ 7_i
daily RB N
reacted VBD N
only RB N
rarely RB N
. . N

The DT N
typical JJ N
side-effects NNS N
of IN N
anti-serotonin JJ N
drugs NNS N
, , N
especially RB N
sedation NN N
or CC N
dizziness NN N
and CC N
hyperorexia NN N
were VBD N
hardly RB N
observed VBN N
. . N

Randomization NN N
of IN N
the DT N
serotonin-migraine JJ N
cases NNS N
and CC N
double-blind JJ N
methodology NN N
were VBD N
applied VBN N
throughout IN N
the DT N
trial NN N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
sleep JJ N
quality NN N
, , N
but CC N
not RB N
hormones VB N
predict JJ N
time NN N
to TO N
postpartum VB N
depression NN N
recurrence NN N
. . N

BACKGROUND NNP N
Poor NNP N
sleep JJ N
quality NN N
, , N
dysregulation NN N
of IN N
hormones NNS N
and CC N
increased VBD N
inflammatory JJ N
cytokines NNS N
are VBP N
all DT N
associated VBN N
with IN N
the DT N
risk NN N
for IN N
postpartum NN N
major JJ N
depression NN N
( ( N
PPMD NNP N
) ) N
. . N

We PRP N
evaluated VBD N
change NN N
over IN N
time NN N
in IN N
sleep JJ N
quality NN N
and CC N
hormones NNS N
during IN N
the DT N
first JJ N
17 CD N
weeks NNS N
postpartum RB N
, , N
as RB N
well RB N
as IN N
a DT N
single JJ N
cytokine NN N
measure NN N
, , N
and CC N
their PRP$ N
association NN N
with IN N
PPMD NNP N
recurrence NN N
. . N

METHODS JJ N
Participants NNS N
were VBD N
pregnant JJ N
women NNS N
( ( N
N=56 NNP N
) ) N
, , N
with IN N
past JJ N
histories NNS N
of IN N
MDD/PPMD NNP N
but CC N
not RB N
depressed VBN N
in IN N
their PRP$ N
current JJ N
pregnancy NN N
. . N

The DT N
Pittsburgh NNP 4_i
Sleep NNP 4_i
Quality NNP 4_i
Index NNP 4_i
( ( 4_i
PSQI NNP 4_i
) ) 4_i
and CC N
blood NN 3_i
samples NNS 3_i
were VBD N
collected VBN N
8 CD N
times NNS N
during IN N
the DT N
first JJ N
17 CD N
weeks NNS N
postpartum NN N
. . N

Estradiol NNP N
, , N
prolactin NN N
and CC N
cortisol NN N
, , N
and CC N
a DT N
single JJ N
measure NN N
of IN N
IL-6 NNP N
were VBD N
assayed VBN N
. . N

Recurrence NN N
was VBD N
determined VBN N
by IN N
two CD N
consecutive JJ N
21-item JJ N
Hamilton NNP N
Rating NNP N
Scale NNP N
for IN N
Depression NNP N
( ( N
HRSD NNP N
) ) N
scores?15 NN N
and CC N
clinician JJ N
interview NN N
. . N

RESULTS NNP N
In IN N
the DT N
analyses NNS N
of IN N
time NN N
to TO N
PPMD NNP N
recurrence NN N
, , N
poor JJ N
sleep JJ N
quality NN N
, , N
but CC N
none NN N
of IN N
the DT N
hormones NNS N
, , N
was VBD N
associated VBN N
with IN N
PPMD NNP N
recurrence NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
after IN N
controlling VBG N
for IN N
medication NN N
assignment NN N
. . N

With IN N
every DT N
one CD N
point NN N
increase NN N
in IN N
PSQI NNP N
scores NNS N
across IN N
time NN N
, , N
a DT N
woman NN N
's POS N
risk NN N
for IN N
recurrence NN N
increased VBN N
by IN N
approximately RB N
25 CD N
% NN N
There EX N
was VBD N
no DT N
significant JJ N
association NN N
between IN N
PSQI NNP N
scores NNS N
and CC N
IL-6 NNP N
concentrations NNS N
in IN N
early JJ N
postpartum NN N
( ( N
? . N
( ( N
2 CD N
) ) N
=0.98 NN N
, , N
p=.32 NN N
) ) N
. . N

CONCLUSIONS NNP N
Poor NNP N
sleep VBP N
quality NN N
across IN N
the DT N
first JJ N
17 CD N
weeks NNS N
post-delivery JJ N
increases NNS N
the DT N
risk NN N
for IN N
recurrent JJ N
PPMD NNP N
among IN N
women NNS N
with IN N
a DT N
history NN N
of IN N
MDD NNP N
. . N

Changes NNS N
in IN N
the DT N
hormonal JJ N
milieu NN N
were VBD N
not RB N
associated VBN N
with IN N
recurrence NN N
. . N

Further JJ N
exploration NN N
of IN N
the DT N
degree NN N
to TO N
which WDT N
poor JJ N
sleep NN N
contributes NNS N
to TO N
hormonal JJ N
and CC N
cytokine JJ N
dysregulation NN N
and CC N
how WRB N
they PRP N
are VBP N
involved VBN N
in IN N
the DT N
pathophysiology NN N
of IN N
PPMD NNP N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Absolute NNP N
bioavailability NN N
of IN N
a DT N
new JJ N
high JJ N
dose NN N
methylprednisolone NN 3_i
tablet NN N
formulation NN N
. . N

This DT N
was VBD N
a DT N
single-blind JJ N
, , N
single-dose JJ N
, , N
randomized VBN N
crossover NN N
study NN N
to TO N
determine VB N
the DT N
absolute JJ N
bioavailability NN N
of IN N
Medrol NNP 3_i
, , N
a DT N
new JJ N
high JJ N
dose NN N
( ( N
100 CD N
mg NN N
) ) N
methylprednisolone NN 3_i
tablet NN N
product NN N
, , N
by IN N
comparing VBG N
it PRP N
with IN N
100 CD N
mg NNS N
methylprednisolone NN 3_i
from IN N
an DT N
intravenous JJ N
formulation NN N
, , N
Solu-Medrol NNP 3_i
. . N

Fourteen NNP N
healthy JJ N
, , N
non-smoking JJ N
, , N
Caucasian JJ N
male NN N
volunteers NNS N
took VBD N
part NN N
. . N

On IN N
treatment NN N
days NNS N
volunteers NNS N
remained VBD N
recumbent NN N
for IN N
4 CD N
hours NNS N
after IN N
drug NN N
administration NN N
, , N
with IN N
food NN N
and CC N
fluid NN N
intake VBP N
standardized VBN N
over IN N
this DT N
period NN N
. . N

Serial JJ N
blood NN N
samples NNS N
were VBD N
drawn VBN N
over IN N
a DT N
14-hour JJ N
period NN N
after IN N
drug NN N
administration NN N
. . N

Plasma NNP N
methylprednisolone NN 3_i
concentrations NNS N
were VBD N
determined VBN N
by IN N
high JJ N
performance NN N
liquid NN N
chromatography NN N
. . N

The DT N
geometric JJ N
means NNS N
of IN N
AUCi.v NNP N
. . N

and CC N
AUCtablet NNP N
were VBD N
4,049 CD N
and CC N
3,334 CD N
ng.h/ml NN N
, , N
respectively RB N
. . N

The DT N
absolute JJ N
bioavailability NN N
of IN N
the DT N
tablet NN N
product NN N
was VBD N
82 CD N
% NN N
, , N
which WDT N
is VBZ N
in IN N
agreement NN N
with IN N
published VBN N
data NNS N
for IN N
other JJ N
oral JJ N
dosage NN N
forms NNS N
of IN N
methylprednisolone NN 3_i
. . N

Volunteers NNS N
displayed VBD N
the DT N
expected VBN N
rise NN N
in IN N
peripheral JJ N
blood NN N
neutrophil NN N
count NN N
, , N
but CC N
no DT N
other JJ N
clinically RB N
relevant JJ N
changes NNS N
in IN N
hematology NN N
or CC N
clinical JJ N
chemistry NN N
were VBD N
observed VBN N
. . N

No DT N
adverse JJ N
drug NN N
reactions NNS N
were VBD N
recorded VBN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
tablet NN N
product NN N
can MD N
be VB N
used VBN N
as IN N
a DT N
substitute NN N
for IN N
parenteral JJ N
methylprednisolone NN 3_i
in IN N
situations NNS N
requiring VBG N
high-dose JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

[ IN N
The DT N
effects NNS N
of IN N
early JJ 3_i
enteral JJ 3_i
nutrition NN 3_i
with IN 3_i
addition NN 3_i
of IN 3_i
probiotics NNS 3_i
on IN N
the DT N
prognosis NN N
of IN N
patients NNS N
suffering VBG N
from IN N
severe JJ N
acute NN N
pancreatitis NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
curative JJ N
effect NN N
of IN N
early JJ 3_i
enteral JJ 3_i
nutrition NN 3_i
( ( 3_i
EN NNP 3_i
) ) 3_i
supplemented VBD 3_i
with IN 3_i
probiotics NNS 3_i
( ( 3_i
bifidobacterium NN 3_i
) ) 3_i
in IN N
patients NNS N
with IN N
severe JJ N
acute NN N
pancreatitis NN N
( ( N
ASP NNP N
) ) N
. . N

METHODS NNP N
Seventy NNP N
SAP NNP N
cases NNS N
admitted VBD N
from IN N
January NNP N
2005 CD N
to TO N
October NNP N
2012 CD N
were VBD N
randomly RB N
assigned VBN N
into IN N
parenteral JJ 3_i
nutrition NN 3_i
( ( 3_i
PN NNP 3_i
) ) 3_i
group NN N
( ( N
n=22 NN N
) ) N
, , N
EN NNP 3_i
group NN N
( ( N
n=25 CC N
) ) N
and CC N
bifidobacterium NN 3_i
added VBD 3_i
EN NNP 3_i
( ( 3_i
P+EN NNP 3_i
) ) 3_i
group NN N
( ( N
n=23 RB N
) ) N
. . N

In IN N
P+EN NNP 3_i
group NN N
, , N
patients NNS N
were VBD N
given VBN N
their PRP$ N
nutrition NN N
the DT N
same JJ N
as IN N
that DT N
of IN N
EN NNP 3_i
, , N
and CC N
also RB N
probiotics NNS 3_i
( ( 3_i
bifidobacterium NN 3_i
, , N
4 CD N
capsules NNS N
every DT N
12 CD N
hours NNS N
, , N
given VBN N
through IN N
nasal JJ N
gastric JJ N
tube NN N
, , N
each DT N
capsule NN N
weighing VBG N
210 CD N
mg NN N
) ) N
. . N

The DT N
routine JJ N
treatment NN N
including VBG N
anti-infection NN 3_i
and CC 3_i
anti-acid JJ 3_i
agents NNS 3_i
, , N
and CC N
that IN N
of IN N
inhibition NN N
of IN N
pancreatic JJ N
secretion NN N
were VBD N
given VBN N
, , N
except IN N
for IN N
the DT N
different JJ N
nutritional JJ N
interventions NNS N
in IN N
all DT N
groups NNS N
. . N

The DT N
blood NN N
samples NNS N
were VBD N
collected VBN N
for IN N
e NN N
same JJ N
measurements NNS N
of IN N
interleukin-8 JJ N
( ( N
IL-8 NNP N
) ) N
and CC N
tumor JJ N
necrosis NN N
factor NN N
( ( N
TNF-? NNP N
) ) N
by IN N
enzyme NN N
linked VBN N
immunosorbent JJ N
assay NN N
( ( N
ELISA NNP N
) ) N
, , N
and CC N
for IN N
the DT N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
lactic JJ N
acid NN N
dehydrogenase NN N
( ( N
LDH NNP N
) ) N
, , N
white JJ N
blood NN N
cell NN N
( ( N
WBC NNP N
) ) N
count NN N
, , N
amylase NN N
and CC N
lipase NN N
by IN N
biochemistry NN N
assay VBP N
1 CD N
day NN N
before IN N
intervention NN N
of IN N
nutrition NN N
, , N
and CC N
7 CD N
days NNS N
and CC N
14 CD N
days NNS N
after IN N
intervention NN N
. . N

Changes NNS N
in IN N
organ JJ N
function NN N
and CC N
outcome NN N
were VBD N
also RB N
recorded VBN N
at IN N
the DT N
same JJ N
time NN N
points NNS N
. . N

RESULTS VB N
The DT N
plasma JJ N
levels NNS N
of IN N
IL-8 NNP N
, , N
TNF-? NNP N
, , N
CRP NNP N
, , N
LDH NNP N
, , N
WBC NNP N
count NN N
, , N
amylase NN N
and CC N
lipase NN N
were VBD N
significantly RB N
reduced VBN N
after IN N
nutritional JJ N
intervention NN N
compared VBN N
with IN N
their PRP$ N
levels NNS N
on IN N
day NN N
1 CD N
before IN N
intervention NN N
in IN N
all DT N
three CD N
groups NNS N
. . N

The DT N
plasma JJ N
IL-8 NNP N
, , N
TNF-? NNP N
, , N
CRP NNP N
, , N
lipase NN N
, , N
LDH NNP N
at IN N
14 CD N
days NNS N
after IN N
intervention NN N
of IN N
nutrition NN N
in IN N
P+EN NNP N
group NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
PN NNP N
group NN N
and CC N
EN NNP N
group NN N
( ( N
IL-8 NNP N
: : N
21.00 CD N
? . N
7.07 CD N
?g/L NN N
vs. FW N
48.00 CD N
? . N
10.32 CD N
?g/L NN N
, , N
32.00 CD N
? . N
9.30 CD N
?g/L NN N
; : N
TNF-? JJ N
: : N
44.3 CD N
? . N
10.9 CD N
ng/L JJ N
vs. FW N
132.1 CD N
? . N
34.1 CD N
ng/L NN N
, , N
67.8 CD N
? . N
22.3 CD N
ng/L NN N
; : N
CRP NNP N
: : N
35.0 CD N
? . N
12.4 CD N
mg/L NN N
vs. FW N
103.2 CD N
? . N
49.2 CD N
mg/L NN N
, , N
63.0 CD N
? . N
29.2 CD N
mg/L NN N
; : N
lipase NN N
: : N
269 CD N
? . N
79 CD N
U/L NNP N
vs. FW N
670 CD N
? . N
145 CD N
U/L NNP N
, , N
310 CD N
? . N
78 CD N
U/L NNP N
; : N
LDH NNP N
: : N
21.8 CD N
? . N
10.3 CD N
U/L NNP N
vs. FW N
78.1 CD N
? . N
37.4 CD N
U/L NNP N
, , N
37.9 CD N
? . N
25.1 CD N
U/L NNP N
, , N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
WBC NNP N
count NN N
in IN N
P+EN NNP N
group NN N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
PN NNP N
group NN N
( ( N
5.9 CD N
? . N
3.0 CD N
? . N
10?/L CD N
, , N
6.3 CD N
? . N
3.2 CD N
? . N
10?/L CD N
vs. IN N
9.6 CD N
? . N
3.0 CD N
?10?/L NN N
, , N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
amylase NN N
between IN N
P+EN NNP N
group NN N
and CC N
PN NNP N
group NN N
( ( N
211 CD N
? . N
49 CD N
U/L NNP N
, , N
236 CD N
? . N
52 CD N
U/L NNP N
vs. FW N
298 CD N
? . N
71 CD N
U/L NNP N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
gastrointestinal JJ N
dysfunction NN N
score NN N
in IN N
P+EN NNP N
, , N
EN NNP N
, , N
PN NNP N
groups NNS N
14 CD N
days NNS N
after IN N
nutritional JJ N
intervention NN N
was VBD N
0.28 CD N
? . N
0.05 CD N
, , N
0.43 CD N
? . N
0.09 CD N
, , N
0.71 CD N
? . N
0.11 CD N
, , N
respectively RB N
, , N
with IN N
statistically RB N
significant JJ N
differences NNS N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Compared VBN N
with IN N
PN NNP N
and CC N
EN NNP N
groups NNS N
, , N
the DT N
incidence NN N
of IN N
upper JJ N
gastrointestinal JJ N
bleeding NN N
( ( N
1 CD N
vs. FW N
9 CD N
, , N
2 CD N
) ) N
, , N
infection NN N
and CC N
abscess NN N
( ( N
2 CD N
vs. FW N
12 CD N
, , N
5 CD N
) ) N
was VBD N
lower JJR N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
hospital JJ N
day NN N
was VBD N
significantly RB N
shortened VBN N
in IN N
P+EN NNP N
group NN N
( ( N
10.4 CD N
? . N
3.9 CD N
days NNS N
vs. FW N
25.8 CD N
? . N
6.4 CD N
days NNS N
, , N
13.4 CD N
? . N
5.2 CD N
days NNS N
, , N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
statistical JJ N
difference NN N
in IN N
mortality NN N
rate NN N
among IN N
three CD N
groups NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicated VBD N
that IN N
early JJ N
EN NNP N
with IN N
addition NN N
of IN N
probiotics NNS N
( ( N
bifidobacterium NN N
) ) N
resulted VBD N
in IN N
significant JJ N
lowering NN N
of IN N
the DT N
level NN N
of IN N
pro-inflammatory JJ N
cytokines NNS N
, , N
earlier JJR N
restoration NN N
of IN N
gastrointestinal JJ N
function NN N
, , N
decrease NN N
of IN N
complications NNS N
such JJ N
as IN N
infection NN N
, , N
and CC N
shortening NN N
of IN N
hospital JJ N
day NN N
in IN N
patients NNS N
with IN N
SAP NNP N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
heat NN 2_i
and CC 2_i
cold NN 2_i
on IN N
the DT N
perineum NN N
after IN N
episiotomy/laceration NN N
. . N

The DT N
Redness NNP N
Edema NNP N
Ecchymosis NNP N
Discharge NNP N
Approximation NNP N
( ( N
REEDA NNP N
) ) N
tool NN N
, , N
devised VBN N
to TO N
evaluate VB N
postpartum NN N
healing NN N
of IN N
the DT N
perineum NN N
following VBG N
an DT N
episiotomy/laceration NN 2_i
, , N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
heat NN 2_i
and CC 2_i
cold NN 2_i
on IN N
the DT N
perineum NN N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
after IN N
delivery NN N
. . N

Ninety NN N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
groups NNS N
. . N

Treatment NNP N
consisted VBD N
of IN N
30 CD N
subjects NNS N
applying VBG N
a DT N
warm JJ 2_i
perineal NN 2_i
pack NN 2_i
, , N
30 CD N
applying VBG N
a DT N
cold JJ 2_i
perineal NN 2_i
pack NN 2_i
, , N
and CC N
30 CD N
taking VBG N
a DT N
warm JJ 2_i
sitz NN 2_i
bath NN 2_i
. . N

Analysis NN N
of IN N
variance NN N
indicated VBD N
no DT N
difference NN N
in IN N
the DT N
REEDA NNP N
score NN N
before IN N
or CC N
two CD N
hours NNS N
after IN N
treatment NN N
. . N

A DT N
Pearson NNP N
r NN N
correlation NN N
indicated VBD N
the DT N
REEDA NNP N
score NN N
was VBD N
associated VBN N
with IN N
a DT N
laceration NN N
and CC N
not RB N
with IN N
infant JJ N
weight NN N
. . N

Although IN N
these DT N
findings NNS N
do VBP N
not RB N
support VB N
assumptions NNS N
from IN N
the DT N
literature NN N
, , N
this DT N
study NN N
provides VBZ N
baseline JJ N
data NNS N
and CC N
trends NNS N
for IN N
future JJ N
study NN N
. . N

-DOCSTART- -X- O O

Acute NNP N
prolactin NN 3_i
and CC N
oxytocin JJ 3_i
responses NNS N
and CC N
milk NN N
yield NN N
to TO N
infant VB N
suckling NN N
and CC N
artificial JJ N
methods NNS N
of IN N
expression NN N
in IN N
lactating VBG N
women NNS N
. . N

Breast-feeding NN N
is VBZ N
today NN N
the DT N
major JJ N
form NN N
of IN N
infant JJ N
nutrition NN N
in IN N
the DT N
immediate JJ N
postpartum NN N
period NN N
. . N

Despite IN N
this DT N
, , N
recent JJ N
trends NNS N
in IN N
modern JJ N
life-styles NNS N
have VBP N
raised VBN N
obstacles NNS N
to TO N
successful JJ N
lactation NN N
. . N

These DT N
include VBP N
infant NN N
illness NN N
and CC N
maternal JJ N
responsibilities NNS N
outside IN N
the DT N
home NN N
, , N
both DT N
requiring VBG N
separation NN N
from IN N
the DT N
mother NN N
. . N

While IN N
the DT N
hormonal JJ N
dynamics NNS N
of IN N
infant JJ N
suckling NN N
are VBP N
understood JJ N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
artificial JJ N
methods NNS N
of IN N
milk NN N
expression NN N
. . N

A DT N
variety NN N
of IN N
breast NN N
pumps NNS N
exist VBP N
in IN N
the DT N
current JJ N
US NNP N
market NN N
which WDT N
vary VBP N
considerably RB N
in IN N
price NN N
and CC N
effectiveness NN N
. . N

To TO N
understand VB N
better JJR N
the DT N
ability NN N
of IN N
these DT N
pumps NNS N
to TO N
assist VB N
women NNS N
in IN N
the DT N
maintenance NN N
of IN N
lactation NN N
, , N
the DT N
current JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
their PRP$ N
effects NNS N
on IN N
milk NN N
yield NN N
and CC N
prolactin NN N
and CC N
oxytocin NN N
release NN N
when WRB N
compared VBN N
to TO N
natural JJ N
infant NN N
suckling NN N
. . N

Twenty-three JJ N
women NNS N
who WP N
were VBD N
exclusively RB N
breast-feeding VBG N
their PRP$ N
infants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
serially RB N
use VB N
several JJ N
pumping VBG N
methods NNS N
, , N
as RB N
well RB N
as IN N
infant NN N
suckling NN N
, , N
with IN N
blood NN N
being VBG N
taken VBN N
at IN N
10-minute JJ N
intervals NNS N
to TO N
determine VB N
the DT N
hormonal JJ N
responses NNS N
. . N

The DT N
results NNS N
reveal VBP N
variability NN N
in IN N
the DT N
prolactin NN N
responses VBZ N
to TO N
the DT N
artificial JJ N
pumping NN N
methods NNS N
, , N
with IN N
the DT N
greatest JJS N
responses NNS N
found VBN N
with IN N
an DT N
electric JJ N
pulsatile NN N
pump NN N
; : N
these DT N
responses NNS N
compare VBP N
favorably RB N
with IN N
those DT N
of IN N
natural JJ N
infant NN N
suckling NN N
. . N

Other JJ N
methods NNS N
were VBD N
less RBR N
successful JJ N
in IN N
causing VBG N
prolactin JJ N
elevations NNS N
. . N

No DT N
differences NNS N
were VBD N
seen VBN N
among IN N
the DT N
methods NNS N
in IN N
the DT N
oxytocin JJ N
response NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
demonstrate VB N
striking JJ N
differences NNS N
in IN N
the DT N
ability NN N
of IN N
breast-pumping JJ N
methods NNS N
to TO N
produce VB N
an DT N
acute NN N
and CC N
sustained VBD N
prolactin NNS N
rise NN N
in IN N
breast-feeding JJ N
mothers NNS N
. . N

The DT N
large JJ N
discrepancies NNS N
found VBD N
suggest VBP N
the DT N
need NN N
for IN N
further JJ N
studies NNS N
in IN N
to TO N
enable JJ N
women NNS N
and CC N
health NN N
care NN N
providers NNS N
to TO N
choose VB N
the DT N
most RBS N
appropriate JJ N
method NN N
for IN N
milk NN N
expression NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Effects NNS N
of IN N
enalapril NN 3_i
and CC N
eprosartan NN 3_i
on IN N
the DT N
renal JJ N
vascular NN N
nitric JJ N
oxide NN N
system NN N
in IN N
human JJ N
essential JJ N
hypertension NN N
. . N

BACKGROUND NNP N
Experimental NNP N
data NNS N
in IN N
humans NNS N
on IN N
the DT N
contribution NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
and CC N
angiotensin NN N
II NNP N
type NN N
1 CD N
receptor NN N
blockers NNS N
to TO N
the DT N
nitric JJ N
oxide NN N
system NN N
of IN N
the DT N
renal JJ N
vasculature NN N
are VBP N
inconsistent JJ N
. . N

Enalapril NNP 3_i
and CC N
eprosartan RB 3_i
, , N
alone RB N
and CC N
in IN N
combination NN N
, , N
were VBD N
used VBN N
to TO N
determine VB N
their PRP$ N
short-term JJ N
effects NNS N
on IN N
the DT N
renal JJ N
nitric JJ N
oxide NN N
system NN N
and CC N
renal JJ N
hemodynamics NNS N
of IN N
human JJ N
subjects NNS N
with IN N
essential JJ N
hypertension NN N
. . N

METHODS NNP N
Twenty NNP N
male NN N
, , N
white JJ N
patients NNS N
( ( N
27 CD N
+/- JJ N
1 CD N
years NNS N
) ) N
with IN N
mild JJ N
essential JJ N
hypertension NN N
( ( N
143 CD N
+/- JJ N
11/95 CD N
+/- JJ N
6 CD N
mm NN N
Hg NNP N
) ) N
were VBD N
included VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ 7_i
, , N
fourfold JJ N
cross-over NN N
study NN N
with IN N
placebo NN 7_i
, , N
enalapril NN 3_i
( ( 3_i
20 CD 3_i
mg/day NN 3_i
) ) 3_i
, , N
eprosartan FW 3_i
( ( 3_i
600 CD 3_i
mg/day NN 3_i
) ) 3_i
, , N
or CC N
combination NN 3_i
of IN 3_i
both DT 3_i
drugs NNS 3_i
( ( N
10 CD N
and CC N
300 CD N
mg/day NN N
, , N
respectively RB N
) ) N
each DT N
over IN N
a DT N
one CD N
week NN N
period NN N
followed VBN N
by IN N
a DT N
two-week JJ N
washout NN N
phase NN N
. . N

After IN N
each DT N
study NN N
phase VBD N
the DT N
glomerular JJ N
filtration NN N
rate NN N
( ( N
GFR NNP N
) ) N
and CC N
renal JJ N
plasma NN N
flow NN N
( ( N
RPF NNP N
) ) N
were VBD N
determined VBN N
. . N

Basal NNP N
nitric JJ N
oxide JJ N
synthesis NN N
of IN N
the DT N
renal JJ N
vasculature NN N
was VBD N
assessed VBN N
by IN N
the DT N
decrease NN N
in IN N
RPF NNP N
after IN N
inhibition NN N
of IN N
nitric JJ N
oxide JJ N
synthase NN N
with IN N
NG-monomethyl-L-arginine NNP N
( ( N
L-NMMA NNP N
; : N
4.25 CD N
mg/kg NN N
) ) N
. . N

RESULTS CC N
After IN N
one CD N
week NN N
of IN N
therapy NN N
, , N
the DT N
combination NN 3_i
therapy NN 3_i
decreased VBD N
casual JJ N
blood NN N
pressure NN N
by IN N
5 CD N
+/- JJ N
2/3 CD N
+/- JJ N
1 CD N
mm NN N
Hg NNP N
versus NN N
placebo NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Neither CC N
enalapril JJ N
alone RB N
( ( N
-2 JJ N
+/- JJ N
2/1 CD N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
, , N
NS NNP N
vs. FW N
placebo NN N
) ) N
nor CC N
eprosartan JJ N
alone NN N
( ( N
-1 JJ N
+/- JJ N
1/0 CD N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
, , N
NS NNP N
vs. FW N
placebo NN N
) ) N
had VBD N
a DT N
clear-cut JJ N
significant JJ N
effect NN N
on IN N
casual JJ N
blood NN N
pressure NN N
. . N

In IN N
the DT N
combination NN N
phase NN N
, , N
RPF NNP N
increased VBN N
by IN N
123 CD N
+/- JJ N
36 CD N
mL/min NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Neither CC N
enalapril JJ 3_i
alone RB N
( ( N
+59 JJ N
+/- JJ N
46 CD N
mL/min NN N
, , N
P NNP N
= NNP N
0.21 CD N
) ) N
nor CC N
eprosartan JJ 3_i
alone NN N
( ( N
+113 JJ N
+/- JJ N
51 CD N
mL/min NN N
, , N
P NNP N
= NNP N
0.06 CD N
) ) N
had VBD N
a DT N
clear-cut JJ N
significant JJ N
effect NN N
on IN N
RPF NNP N
. . N

Changes NNS N
of IN N
RPF NNP N
induced VBN N
by IN N
treatment NN N
correlated VBN N
with IN N
the DT N
L-NMMA NNP N
induced JJ N
decrease NN N
in IN N
RPF NNP N
in IN N
the DT N
combination NN N
( ( N
r JJ N
= NN N
0.70 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
eprosartan JJ N
phase NN N
( ( N
r JJ N
= NN N
0.86 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
in IN N
the DT N
enalapril JJ N
phase NN N
( ( N
r JJ N
= NNP N
-0.44 NNP N
, , N
P NNP N
= NNP N
0.10 CD N
) ) N
. . N

Renal JJ N
vascular JJ N
resistance NN N
was VBD N
reduced VBN N
by IN N
each DT N
active JJ N
treatment NN N
with IN N
the DT N
most RBS N
prominent JJ N
reduction NN N
in IN N
the DT N
combination NN N
phase NN N
. . N

GFR NNP N
was VBD N
unaffected VBN N
by IN N
any DT N
treatment NN N
. . N

CONCLUSIONS NNP N
In IN N
contrast NN N
to TO N
the DT N
effects NNS N
of IN N
either DT N
substance NN N
alone RB N
, , N
a DT N
combination NN N
of IN N
half PDT N
the DT N
dose NN N
of IN N
eprosartan NN 3_i
with IN N
half PDT N
the DT N
dose NN N
of IN N
enalapril NN 3_i
had VBD N
a DT N
prominent JJ N
effect NN N
on IN N
renal JJ N
perfusion NN N
. . N

The DT N
effects NNS N
of IN N
eprosartan NN 3_i
on IN N
RPF NNP N
are VBP N
mediated VBN N
, , N
at IN N
least JJS N
in IN N
part NN N
, , N
by IN N
an DT N
increased JJ N
bioavailability NN N
of IN N
nitric JJ N
oxide NN N
in IN N
the DT N
renal JJ N
vasculature NN N
. . N

-DOCSTART- -X- O O

Twenty-four CD N
vs. IN N
forty-eight JJ N
weeks NNS N
of IN N
re-therapy NN N
with IN N
interferon NN 3_i
alpha NN 3_i
2b CD 3_i
and CC N
ribavirin VB 3_i
in IN N
interferon NN N
alpha NN N
monotherapy NN N
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
BACKGROUND/AIM NNP N
Roughly NNP N
50 CD N
% NN N
of IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
, , N
who WP N
relapsed VBD N
after IN N
a DT N
previous JJ N
monotherapy NN N
with IN N
interferon NN N
alpha NN N
, , N
will MD N
respond VB N
in IN N
a DT N
sustained JJ N
fashion NN N
to TO N
24 CD N
weeks NNS N
of IN N
re-therapy NN N
with IN N
the DT N
combination NN 3_i
of IN 3_i
interferon NN 3_i
alpha NN 3_i
plus CC 3_i
ribavirin NN 3_i
. . N

Whether CC N
prolonging VBG N
treatment NN N
duration NN N
to TO N
48 CD N
weeks NNS N
will MD N
further RB N
increase VB N
sustained JJ N
response NN N
rates NNS N
remains VBZ N
ill JJ N
defined VBN N
. . N

In IN N
this DT N
randomised VBN N
controlled VBD N
pilot JJ N
trial NN N
we PRP N
compared VBN N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
a DT N
24 CD N
week NN N
with IN N
that DT N
of IN N
a DT N
48 CD N
week NN N
course NN N
of IN N
combination NN N
therapy NN N
with IN N
interferon NN N
alpha NN N
and CC N
ribavirin NN N
in IN N
interferon NN N
monotherapy NN N
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
METHODS NNP N
Interferon NNP N
alpha NN N
monotherapy NN N
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
were VBD N
randomised VBN N
to TO N
receive VB N
interferon NN 3_i
alpha NN 3_i
2b CD 3_i
( ( N
3 CD N
x RB N
3 CD N
MIU NNP N
sc JJ N
weekly RB N
) ) N
and CC N
oral JJ 3_i
ribavirin NN 3_i
( ( N
1000/1200 CD N
mg NNS N
po JJ N
daily RB N
) ) N
for IN N
either DT N
24 CD N
weeks NNS N
or CC N
48 CD N
weeks NNS N
. . N

Virological JJ N
response NN N
was VBD N
evaluated VBN N
by IN N
HCV NNP N
RNA NNP N
PCR NNP N
at IN N
week NN N
10 CD N
( ( N
initial JJ N
response NN N
) ) N
, , N
at IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
end JJ N
of- JJ N
treatment NN N
response NN N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
24 CD N
weeks NNS N
follow-up JJ N
( ( N
sustained JJ N
response NN N
) ) N
. . N

Only JJ N
patients NNS N
with IN N
negative JJ N
HCV NNP N
RNA NNP N
at IN N
week NN N
10 CD N
continued VBD N
treatment NN N
. . N

Adverse JJ N
events NNS N
were VBD N
recorded VBN N
at IN N
regular JJ N
intervals NNS N
. . N

RESULTS NNP N
Thirty-seven JJ N
patients NNS N
were VBD N
enrolled VBN N
, , N
19 CD N
( ( N
6 CD N
females NNS N
, , N
median JJ N
age NN N
43 CD N
) ) N
in IN N
the DT N
24 CD N
week NN N
and CC N
18 CD N
( ( N
5 CD N
females NNS N
, , N
median JJ N
age NN N
40 CD N
) ) N
in IN N
the DT N
48 CD N
week NN N
treatment NN N
arm NN N
. . N

Baseline JJ N
characteristics NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

At IN N
treatment NN N
week NN N
10 CD N
, , N
12/19 CD N
( ( N
63 CD N
% NN N
) ) N
in IN N
the DT N
24 CD N
week NN N
group NN N
and CC N
14/18 CD N
( ( N
78 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
48 CD N
week NN N
group NN N
had VBD N
lost VBN N
HCV NNP N
RNA NNP N
in IN N
serum NN N
( ( N
p JJ N
= NNP N
0.33 CD N
) ) N
. . N

All DT N
initial JJ N
responders NNS N
remained VBD N
HCV NNP N
RNA NNP N
negative JJ N
throughout IN N
the DT N
treatment NN N
period NN N
. . N

Sustained VBN N
response NN N
rates NNS N
were VBD N
10/19 CD N
( ( N
53 CD N
% NN N
) ) N
in IN N
the DT N
24 CD N
week NN N
group NN N
and CC N
13/18 CD N
( ( N
72 CD N
% NN N
) ) N
in IN N
the DT N
48 CD N
week NN N
group NN N
( ( N
p JJ N
= NNP N
0.31 CD N
) ) N
. . N

Three CD N
patients NNS N
discontinued VBN N
treatment NN N
early JJ N
( ( N
two CD N
due JJ N
to TO N
moderate VB N
adverse JJ N
events NNS N
, , N
one CD N
due JJ N
to TO N
non-compliance NN N
) ) N
. . N

Dose JJ N
modifications NNS N
were VBD N
necessary JJ N
in IN N
9 CD N
patients NNS N
, , N
4 CD N
in IN N
the DT N
24 CD N
week NN N
and CC N
5 CD N
in IN N
the DT N
48 CD N
week NN N
group NN N
for IN N
anaemia NN N
, , N
neutropenia NN N
, , N
nausea NN N
and CC N
depression NN N
, , N
respectively RB N
. . N

CONCLUSION NNP N
Prolonging NNP N
interferon NN N
/ NNP N
ribavirin NN N
combination NN N
therapy NN N
in IN N
interferon NN N
alpha NN N
monotherapy NN N
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
from IN N
24 CD N
to TO N
48 CD N
weeks NNS N
may MD N
increase VB N
sustained JJ N
response NN N
rates NNS N
. . N

Larger NNP N
controlled VBD N
trials NNS N
using VBG N
pegylated JJ N
interferon NN N
alpha NN N
and CC N
ribavirin NN N
in IN N
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
seem VBP N
warranted VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
diet JJ 6_i
and CC N
Aspergillus NNP 6_i
oryzae VBP 6_i
extract NN 6_i
or CC N
Saccharomyces NNS 6_i
cervisiae VBP 6_i
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
of IN N
lambs NNS N
and CC N
steers NNS N
fed VBP N
to TO N
meet VB N
requirements NNS N
of IN N
natural JJ N
markets NNS N
. . N

Two CD N
studies NNS N
were VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
diet JJ 2_i
and CC 2_i
feed JJ 2_i
additive NN 2_i
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
of IN N
lambs NNS N
and CC N
cattle NNS N
destined VBD N
for IN N
all DT N
natural JJ N
markets NNS N
. . N

In IN N
Exp NNP N
. . N

1 CD N
, , N
48 CD N
Dorset NNP N
? . N
Hampshire NNP N
lambs NN N
( ( N
initial JJ N
BW NNP N
29.4 CD N
? . N
0.1 CD N
kg NN N
) ) N
were VBD N
used VBN N
in IN N
a DT N
randomized JJ N
complete JJ N
block NN N
experiment NN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
Aspergillus NNP N
oryzae NNP N
extract NN N
, , N
Amaferm NNP N
( ( N
AMF NNP N
) ) N
supplementation NN N
( ( N
1 CD N
g/d NN N
) ) N
in IN N
an DT N
85 CD N
% NN N
concentrate NN N
diet NN N
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
. . N

Lambs NNP N
were VBD N
allotted VBN N
to TO N
12 CD N
pens NNS N
( ( N
4 CD N
lambs NNS N
per IN N
pen NN N
) ) N
, , N
and CC N
blocked VBN N
by IN N
sex NN N
and CC N
BW NNP N
. . N

Lambs NNP N
were VBD N
fed VBN N
until IN N
the DT N
average JJ N
BW NNP N
of IN N
each DT N
pen NN N
reached VBD N
a DT N
target NN N
BW NNP N
( ( N
55.4 CD N
kg NN N
for IN N
wethers NNS N
and CC N
50.0 CD N
kg NN N
for IN N
ewes NN N
) ) N
, , N
at IN N
which WDT N
time NN N
the DT N
entire JJ N
pen NN N
of IN N
lambs NN N
was VBD N
slaughtered VBN N
. . N

Amaferm NNP N
resulted VBD N
in IN N
a DT N
greater JJR N
( ( N
P=0.07 NNP N
) ) N
G NNP N
: : N
F. NNP N
In IN N
Exp NNP N
. . N

2 CD N
, , N
168 CD N
crossbred VBD N
steers NNS N
( ( N
initial JJ N
BW NNP N
300 CD N
? . N
0.7 CD N
kg NN N
) ) N
were VBD N
used VBN N
in IN N
a DT N
trial NN N
with IN N
a DT N
3 CD N
? . N
2 CD N
factorial JJ N
arrangement NN N
of IN N
treatments NNS N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
0.5 CD N
g/d NN N
of IN N
Saccaromyces NNP N
cervisiae NN N
boulardii NN N
CNCM NNP N
1079-Levucell CD N
SB NNP N
( ( N
LEV NNP N
) ) N
, , N
or CC N
3 CD N
g/d NN N
of IN N
AMF NNP N
with IN N
2 CD N
corn NN N
sources NNS N
, , N
dry JJ N
whole-shelled JJ N
corn NN N
or CC N
high JJ N
moisture NN N
corn NN N
, , N
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
. . N

Neither CC N
LEV NNP N
nor CC N
AMF NNP N
improved VBD N
( ( N
P NNP N
> NNP N
0.10 CD N
) ) N
carcass NN N
characteristics NNS N
compared VBN N
with IN N
control NN N
or CC N
non-feed-supplemented JJ N
steers NNS N
. . N

Addition NN N
of IN N
LEV NNP N
to TO N
high-concentrate NN N
, , N
corn-based JJ N
diets NNS N
did VBD N
not RB N
improve VB N
( ( N
P NNP N
> NNP N
0.10 CD N
) ) N
growth NN N
performance NN N
of IN N
feedlot NN N
steers NNS N
. . N

However RB N
, , N
addition NN N
of IN N
AMF NNP N
to TO N
a DT N
diet JJ N
composed VBN N
of IN N
dry JJ N
whole-shelled JJ N
corn NN N
resulted VBD N
in IN N
an DT N
improvement NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
G NNP N
: : N
F NNP N
( ( N
0.208 CD N
vs. FW N
0.194 CD N
) ) N
. . N

Results VB N
indicate JJ N
that WDT N
at IN N
the DT N
amounts NNS N
fed VBN N
, , N
AMF NNP N
may MD N
improve VB N
G NNP N
: : N
F NNP N
for IN N
lambs NN N
and CC N
steers NNS N
fed VBP N
dry JJ N
corn-based JJ N
finishing VBG N
diets NNS N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
electrofunctional JJ N
data NNS N
following VBG N
argon-laser NN 1_i
trabeculoplasty NN 1_i
in IN N
primary JJ N
open-angle JJ N
glaucoma NN N
. . N

To TO N
establish VB N
whether IN N
or CC N
not RB N
glaucomatous JJ N
damage NN N
is VBZ N
reversible JJ N
, , N
we PRP N
obtained VBD N
pattern-reversal JJ N
electroretinograms NNS N
( ( N
PERGs NNP N
) ) N
and CC N
visual JJ N
evoked VBN N
potentials NNS N
( ( N
VEPs NNP N
) ) N
in IN N
25 CD N
eyes NNS N
of IN N
25 CD N
patients NNS N
suffering VBG N
from IN N
bilateral JJ N
primary JJ N
open-angle JJ N
glaucoma NN N
( ( N
POAG NNP N
) ) N
before IN N
and CC N
after IN N
argon-laser JJ 1_i
trabeculoplasty NN 1_i
. . N

The DT N
laser NN N
treatment NN N
was VBD N
carried VBN N
out RP N
in IN N
only RB N
one CD N
eye NN N
chosen VBN N
at IN N
random NN N
, , N
and CC N
the DT N
fellow JJ N
eye NN N
was VBD N
used VBN N
as IN N
a DT N
control NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
intended VBD N
to TO N
verify VB N
the DT N
possibility NN N
of IN N
using VBG N
electrofunctional JJ N
techniques NNS N
to TO N
determine VB N
the DT N
two CD N
distinct NN N
and CC N
, , N
probably RB N
, , N
consecutive JJ N
glaucomatous JJ N
alterations NNS N
occurring VBG N
in IN N
ganglion NN N
cells NNS N
: : N
functional JJ N
( ( N
reversible JJ N
) ) N
and CC N
anatomical JJ N
( ( N
irreversible JJ N
) ) N
. . N

The DT N
results NNS N
obtained VBD N
indicate VBP N
that IN N
glaucomatous JJ N
damage NN N
is VBZ N
irreversible JJ N
. . N

We PRP N
propose VBP N
that IN N
such JJ N
alterations NNS N
differ VBP N
very RB N
slightly RB N
and CC N
that IN N
the DT N
current JJ N
electrofunctional JJ N
techniques NNS N
may MD N
not RB N
be VB N
sufficiently RB N
sophisticated JJ N
to TO N
distinguish VB N
between IN N
them PRP N
. . N

-DOCSTART- -X- O O

Using VBG N
personalized VBN 4_i
feedback NN 4_i
to TO N
reduce VB N
alcohol NN N
use NN N
among IN N
hazardous JJ N
drinking VBG N
college NN N
students NNS N
: : N
the DT N
moderating VBG N
effect NN N
of IN N
alcohol-related JJ N
negative JJ N
consequences NNS N
. . N

UNLABELLED JJ N
Web-based JJ 4_i
screening NN 4_i
and CC N
brief JJ 4_i
interventions NNS 4_i
that WDT N
include VBP N
personalized VBN N
feedback NN N
about IN N
their PRP$ N
alcohol NN N
use NN N
have VBP N
proven VBN N
to TO N
be VB N
particularly RB N
promising VBG N
for IN N
reducing VBG N
hazardous JJ N
drinking NN N
among IN N
university JJ N
students NNS N
. . N

Despite IN N
the DT N
increasing VBG N
use NN N
of IN N
these DT N
approaches NNS N
, , N
there EX N
is VBZ N
still RB N
relatively RB N
little JJ N
known VBN N
about IN N
how WRB N
the DT N
content NN N
of IN N
these DT N
interventions NNS N
may MD N
influence VB N
outcomes NNS N
and CC N
who WP N
may MD N
benefit VB N
most JJS N
from IN N
these DT N
approaches NNS N
. . N

The DT N
current JJ N
study NN N
sought VBD N
to TO N
address VB N
these DT N
issues NNS N
by IN N
examining VBG N
how WRB N
individual JJ N
differences NNS N
in IN N
alcohol NN N
consequences NNS N
influence NN N
outcomes NNS N
of IN N
a DT N
laboratory-based JJ 4_i
computerized JJ 4_i
intervention NN 4_i
. . 4_i

METHODS NNP N
One-hundred JJ N
and CC N
nineteen JJ N
introductory NN N
psychology NN N
students NNS N
who WP N
either DT N
had VBD N
two CD N
episodes NNS N
of IN N
heavy JJ N
episodic JJ N
drinking NN N
in IN N
the DT N
past JJ N
month NN N
or CC N
scored VBN N
?8 NNS N
on IN N
the DT N
AUDIT NNP N
participated VBD N
in IN N
this DT N
randomized VBN N
controlled VBD N
trial NN N
for IN N
course NN N
credit NN N
. . N

Participants NNS N
were VBD N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
conditions NNS N
in IN N
this DT N
2 CD N
Intervention NNP N
( ( N
Alcohol NNP N
Feedback NNP N
vs. IN N
Control NNP N
) ) N
?2 FW N
Assessment NNP N
( ( N
Motivational NNP N
Assessment NNP N
vs. IN N
No NNP N
Motivational NNP N
Assessment NNP N
) ) N
between-subjects NNS N
design NN N
. . N

Quantity NN N
of IN N
alcohol NN N
consumed VBN N
per IN N
week NN N
and CC N
heavy JJ N
episodic JJ N
drinking VBG N
one CD N
month NN N
later RBR N
were VBD N
the DT N
primary JJ N
dependent JJ N
variables NNS N
. . N

RESULTS NNP N
Controlling VBG N
for IN N
corresponding VBG N
baseline NN N
alcohol NN N
measures NNS N
, , N
hierarchical JJ N
linear JJ N
regression NN N
analyses NNS N
showed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
intervention NN N
condition NN N
and CC N
baseline VB N
alcohol-related JJ N
consequences NNS N
. . N

For IN N
those DT N
who WP N
reported VBD N
more JJR N
alcohol NN N
consequences NNS N
at IN N
baseline NN N
, , N
the DT N
alcohol NN N
intervention NN N
resulted VBD N
in IN N
significantly RB N
less JJR N
alcohol NN N
use NN N
and CC N
fewer JJR N
heavy JJ N
drinking NN N
episodes NNS N
at IN N
follow-up JJ N
, , N
while IN N
no DT N
difference NN N
was VBD N
observed VBN N
between IN N
intervention NN N
conditions NNS N
for IN N
those DT N
with IN N
few JJ N
baseline NN N
consequences NNS N
. . N

Assessment NN N
did VBD N
not RB N
moderate VB N
intervention NN N
effects NNS N
. . N

DISCUSSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
a DT N
feedback-based JJ N
computerized JJ N
intervention NN N
that WDT N
includes VBZ N
normative JJ N
information NN N
about IN N
alcohol NN N
use NN N
and CC N
consequences NNS N
may MD N
be VB N
more RBR N
effective JJ N
for IN N
hazardous JJ N
drinking NN N
students NNS N
who WP N
are VBP N
experiencing VBG N
higher JJR N
levels NNS N
of IN N
alcohol-related JJ N
consequences NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
10 CD N
Hz NNP N
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
( ( 1_i
rTMS NN 1_i
) ) 1_i
on IN N
clinical JJ N
global JJ N
impression NN N
in IN N
chronic JJ N
schizophrenia NN N
. . N

UNLABELLED IN N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
sham-controlled JJ N
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
( ( 1_i
rTMS NN 1_i
) ) N
study NN N
in IN N
chronic JJ N
schizophrenia NN N
in-patients NNS N
( ( N
n=35 NN N
) ) N
to TO N
evaluate VB N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
10 CD 1_i
Hz NNP 1_i
stimulation NN N
. . N

Patients NNS N
, , N
who WP N
were VBD N
on IN N
stable JJ N
antipsychotic JJ N
treatment NN N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
active JJ N
or CC N
sham JJ N
condition NN N
. . N

In IN N
the DT N
active JJ N
rTMS NN 1_i
group NN N
, , N
ten JJ N
sessions NNS N
with IN N
a DT N
total NN N
of IN N
10,000 CD N
stimuli NNS N
were VBD N
applied VBN N
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
at IN N
110 CD N
% NN N
of IN N
motor NN N
threshold NN N
. . N

The DT N
sham NN N
group NN N
received VBD N
corresponding VBG N
sham JJ 7_i
stimulation NN 7_i
. . N

Clinical JJ N
improvement NN N
was VBD N
measured VBN N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
scale NN N
( ( N
primary JJ N
outcome NN N
measure NN N
) ) N
, , N
the DT N
Global NNP N
Assessment NNP N
of IN N
Functioning NNP N
Scale NNP N
( ( N
GAF NNP N
) ) N
and CC N
the DT N
Positive NNP N
and CC N
Negative NNP N
Symptom NNP N
Scale NNP N
( ( N
PANSS NNP N
; : N
secondary JJ N
outcome NN N
measures NNS N
) ) N
. . N

Between-group JJ N
comparisons NNS N
revealed VBD N
no DT N
significant JJ N
differences NNS N
in IN N
clinical JJ N
outcome NN N
variables NNS N
. . N

Only RB N
a DT N
subgroup NN N
of IN N
patients NNS N
with IN N
pronounced JJ N
negative JJ N
symptoms NNS N
developed VBD N
some DT N
clinical JJ N
improvement NN N
as IN N
indicated VBN N
by IN N
significant JJ N
changes NNS N
in IN N
the DT N
GAF-scale NNP N
. . N

Besides IN N
there EX N
is VBZ N
some DT N
evidence NN N
for IN N
a DT N
more RBR N
favourable JJ N
clinical JJ N
outcome NN N
within IN N
this DT N
subgroup NN N
after IN N
rTMS NN 1_i
in IN N
the DT N
CGI-S NNP N
and CC N
PANSS NNP N
negative JJ N
scale NN N
, , N
too RB N
. . N

In IN N
line NN N
with IN N
earlier JJR N
investigations NNS N
, , N
our PRP$ N
results NNS N
suggest VBP N
a DT N
moderate JJ N
- : N
potentially RB N
clinically RB N
relevant JJ N
- : N
treatment NN N
effect NN N
of IN N
prefrontal JJ 1_i
10 CD 1_i
Hz NNP 1_i
rTMS NN 1_i
stimulation NN N
in IN N
chronic JJ N
patients NNS N
. . N

However RB N
, , N
in IN N
our PRP$ N
study NN N
this DT N
beneficial JJ N
effect NN N
was VBD N
restricted VBN N
to TO N
subjects NNS N
with IN N
pronounced JJ N
negative JJ N
symptoms NNS N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
INFORMATION NNP N
ClinicalTrial.gov NNP N
Identifier NNP N
: : N
NCT00169689 NNP N
, , N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Comparison NNP N
of IN N
complications NNS N
after IN N
intra- JJ 2_i
and CC 2_i
extracapsular JJ 2_i
cataract NN 2_i
extraction NN 2_i
with IN 2_i
lens JJ 2_i
implantation NN 2_i
. . N

Results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
clinical JJ N
study NN N
] NNP N
. . N

BACKGROUND NNP N
The DT N
postoperative JJ N
complications NNS N
of IN N
ICCE NNP 2_i
with IN 2_i
ACL NNP 2_i
implantation NN 2_i
are VBP N
compared VBN N
with IN N
those DT N
of IN N
ECCE NNP 2_i
and CC 2_i
PCL NNP 2_i
. . 2_i

Our PRP$ N
clinical JJ N
experience NN N
with IN N
ICCE NNP 2_i
and CC 2_i
ACL NNP 2_i
implantation NN 2_i
can MD N
not RB N
confirm VB N
the DT N
widespread JJ N
rejection NN N
of IN N
this DT N
method NN N
. . N

PATIENTS NNP N
AND CC N
METHOD NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
, , N
clinical JJ N
study NN N
with IN N
participation NN N
of IN N
medical JJ N
statisticians NNS N
was VBD N
performed VBN N
. . N

A DT N
total NN N
of IN N
190 CD N
patients NNS N
with IN N
ICCE NNP 2_i
and CC 2_i
ACL NNP 2_i
and CC N
170 CD N
patients NNS N
with IN N
ECCE NNP 2_i
and CC 2_i
PCL NNP 2_i
were VBD N
followed VBN N
up RP N
for IN N
2 CD N
years NNS N
. . N

The DT N
follow-up JJ N
examinations NNS N
were VBD N
performed VBN N
upon IN N
dismission NN N
from IN N
the DT N
hospital NN N
, , N
after IN N
6 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
. . N

The DT N
data NNS N
were VBD N
compiled VBN N
in IN N
a DT N
computer NN N
program NN N
designed VBN N
for IN N
this DT N
study NN N
and CC N
evaluated VBN N
by IN N
the DT N
statisticians NNS N
. . N

The DT N
surgical JJ N
procedures NNS N
and CC N
the DT N
surgeons NNS N
were VBD N
defined VBN N
prior RB N
to TO N
the DT N
beginning NN N
of IN N
patient JJ N
recruitment NN N
. . N

RESULTS NNP N
ICCE NNP 2_i
with IN 2_i
ACL NNP 2_i
shows NNS N
much RB N
less RBR N
postoperative JJ N
complications NNS N
as IN N
usually RB N
emphasized VBN N
. . N

There EX N
were VBD N
only RB N
2 CD N
( ( N
1.2 CD N
% NN N
) ) N
of IN N
retinal JJ N
detachment NN N
and CC N
no DT N
case NN N
of IN N
corneal NN N
decompensation NN N
. . N

Cystoid NNP N
macular JJ N
edema NN N
8 CD N
( ( N
4.7 CD N
% NN N
) ) N
, , N
postoperative JJ N
vitreous JJ N
prolaps NNS N
into IN N
the DT N
anterior JJ N
chamber NN N
4 CD N
( ( N
2.3 CD N
% NN N
) ) N
and CC N
spontaneous JJ N
complaints NNS N
of IN N
pain NN N
16 CD N
( ( N
9.4 CD N
% NN N
) ) N
occurred VBD N
in IN N
a DT N
low JJ N
percentage NN N
after IN N
ICCE NNP 2_i
with IN 2_i
ACL NNP 2_i
. . N

These DT N
complications NNS N
did VBD N
not RB N
occur VB N
after IN N
ECCE NNP 2_i
with IN 2_i
PCL NNP 2_i
. . N

The DT N
patients NNS N
with IN N
ECCE NNP 2_i
and CC 2_i
PCL NNP 2_i
showed VBD N
capsular JJ N
fibrosis NN N
in IN N
48 CD N
( ( N
28 CD N
% NN N
) ) N
making VBG N
it PRP N
the DT N
most RBS N
frequent JJ N
complication NN N
of IN N
the DT N
whole JJ N
study NN N
. . N

33 CD N
% NN N
of IN N
these DT N
patients NNS N
required VBD N
YAG-laser NNP 1_i
capsulotomy NN 1_i
. . N

Since IN N
retinal JJ N
detachment NN N
occurs VBZ N
in IN N
2.5 CD N
% NN N
after IN N
YAG-laser NNP 1_i
capsulotomy NN 1_i
we PRP N
can MD N
not RB N
regard VB N
capsular JJ N
fibrosis NN N
as IN N
a DT N
totally RB N
harmless JJ N
complication NN N
. . N

It PRP N
is VBZ N
noteworthy JJ N
that IN N
visual JJ N
acuity NN N
is VBZ N
almost RB N
identical JJ N
1 CD N
year NN N
after IN N
surgery NN N
in IN N
both DT N
methods NNS N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
the DT N
evaluation NN N
of IN N
ICCE NNP 2_i
with IN 2_i
ACL NNP 2_i
is VBZ N
too RB N
negative JJ N
. . N

The DT N
elimination NN N
of IN N
postoperative JJ N
complications NNS N
in IN N
this DT N
method NN N
is VBZ N
more RBR N
difficult JJ N
. . N

ECCE VB 1_i
with IN 1_i
PCL NNP 1_i
is VBZ N
burdened VBN N
by IN N
frequent JJ N
capsular JJ N
fibrosis NN N
. . N

Visual JJ N
acuity NN N
is VBZ N
almost RB N
the DT N
same JJ N
in IN N
both DT N
methods NNS N
1 CD N
years NNS N
after IN N
the DT N
operation NN N
. . N

ACL-implantation NN 1_i
remains VBZ N
our PRP$ N
method NN N
of IN N
choice NN N
for IN N
secondary JJ N
implantation NN N
in IN N
patients NNS N
with IN N
an DT N
intact JJ N
iris JJ N
diaphragm NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
tryptophan JJ N
depletion NN N
in IN N
drug-free JJ N
adults NNS N
with IN N
autistic JJ N
disorder NN N
. . N

BACKGROUND IN N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
behavioral JJ N
and CC N
biochemical JJ N
responses NNS N
to TO N
acute VB N
tryptophan JJ N
depletion NN N
in IN N
drug-free JJ N
adult NN N
patients NNS N
with IN N
autistic JJ N
disorder NN N
. . N

METHODS NNP N
Twenty NNP N
drug-free JJ N
adults NNS N
with IN N
autistic JJ N
disorder NN N
( ( N
16 CD N
men NNS N
and CC N
4 CD N
women NNS N
) ) N
( ( N
mean JJ N
[ NNP N
+/- NN N
SD NNP N
] NNP N
age NN N
, , N
30.5 CD N
+/- JJ N
8.5 CD N
years NNS N
) ) N
underwent JJ N
short-term JJ N
tryptophan NN 3_i
depletion NN 3_i
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
, , N
randomized JJ N
crossover NN N
design NN N
. . N

Patients NNS N
received VBD N
a DT N
24-hour JJ N
, , N
low-tryptophan JJ 3_i
diet NN 3_i
followed VBD 3_i
the DT 3_i
next JJ 3_i
morning NN 3_i
by IN 3_i
an DT 3_i
amino NN 3_i
acid NN 3_i
drink NN 3_i
. . 3_i

Behavioral JJ N
ratings NNS N
were VBD N
obtained VBN N
on IN N
the DT N
morning NN N
of IN N
the DT N
amino NN 3_i
acid NN 3_i
drink NN 3_i
( ( N
baseline NN N
) ) N
and CC N
180 CD N
, , N
300 CD N
, , N
and CC N
420 CD N
minutes NNS N
after IN N
the DT N
drink NN N
. . N

Plasma NNP N
free JJ N
and CC N
total JJ N
tryptophan NN N
levels NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
5 CD N
hours NNS N
after IN N
the DT N
drink NN N
. . N

The DT N
active JJ N
and CC N
sham JJ N
testing NN N
sessions NNS N
were VBD N
separated VBN N
by IN N
7 CD N
days NNS N
. . N

RESULTS NNP N
Eleven NNP N
( ( N
65 CD N
% NN N
) ) N
of IN N
the DT N
17 CD N
patients NNS N
who WP N
completed VBD N
both DT N
test NN N
days NNS N
showed VBD N
a DT N
significant JJ N
global JJ N
worsening NN N
of IN N
behavioral JJ N
symptoms NNS N
with IN N
short-term JJ N
tryptophan NN N
depletion NN N
, , N
but CC N
none NN N
of IN N
the DT N
17 CD N
patients NNS N
showed VBD N
any DT N
significant JJ N
change NN N
in IN N
clinical JJ N
status NN N
from IN N
baseline NN N
after IN N
sham JJ N
depletion NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Tryptophan NNP N
depletion NN N
led VBD N
to TO N
a DT N
significant JJ N
increase NN N
in IN N
behaviors NNS N
such JJ N
as IN N
whirling NN N
, , N
flapping NN N
, , N
pacing NN N
, , N
banging NN N
and CC N
hitting VBG N
self NN N
, , N
rocking NN N
, , N
and CC N
toe NN N
walking NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
patients NNS N
were VBD N
significantly RB N
less JJR N
calm JJ N
and CC N
happy JJ N
and CC N
more RBR N
anxious JJ N
. . N

No DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
social JJ N
relatedness NN N
or CC N
repetitive JJ N
thoughts NNS N
and CC N
behavior NN N
. . N

Plasma NNP N
total JJ N
and CC N
free JJ N
tryptophan NN N
levels NNS N
were VBD N
reduced VBN N
86 CD N
% NN N
and CC N
69 CD N
% NN N
, , N
respectively RB N
, , N
5 CD N
hours NNS N
after IN N
the DT N
tryptophan-deficient JJ N
amino NN N
acid NN N
drink NN N
. . N

Patients NNS N
who WP N
had VBD N
a DT N
significant JJ N
global JJ N
exacerbation NN N
of IN N
symptoms NNS N
had VBD N
significantly RB N
higher JJR N
baseline NN N
plasma IN N
total JJ N
tryptophan NN N
levels NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
Autism NNP N
Behavior NNP N
Checklist NNP N
scores NNS N
( ( N
P NNP N
= NNP N
.005 NNP N
) ) N
than IN N
did VBD N
patients NNS N
who WP N
showed VBD N
no DT N
significant JJ N
change NN N
in IN N
symptoms NNS N
after IN N
tryptophan JJ N
depletion NN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
that WDT N
has VBZ N
implicated VBN N
a DT N
dysregulation NN N
in IN N
serotonin JJ N
function NN N
in IN N
some DT N
patients NNS N
with IN N
autism NN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
short-term JJ N
reduction NN N
of IN N
serotonin NN N
precursor NN N
availability NN N
may MD N
exacerbate VB N
some DT N
symptoms NNS N
characteristic JJ N
of IN N
autism NN N
in IN N
some DT N
patients NNS N
. . N

Continued JJ N
investigation NN N
into IN N
the DT N
role NN N
of IN N
serotonin NN N
in IN N
the DT N
pathogenesis NN N
and CC N
treatment NN N
of IN N
autistic JJ N
disorder NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Bevacizumab-augmented JJ 3_i
retinal JJ 2_i
laser NN 2_i
photocoagulation NN 2_i
in IN N
proliferative JJ N
diabetic JJ N
retinopathy NN N
: : N
a DT N
randomized JJ N
double-masked JJ N
clinical JJ N
trial NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
additional JJ N
therapeutic JJ N
effect NN N
of IN N
single JJ N
intravitreal NN 3_i
bevacizumab NN 3_i
injection NN 3_i
on IN N
standard JJ 2_i
laser NN 2_i
treatment NN 2_i
in IN N
the DT N
management NN N
of IN N
proliferative JJ N
diabetic JJ N
retinopathy NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
, , N
fellow-eye JJ N
sham NN N
controlled VBD N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
80 CD N
eyes NNS N
of IN N
40 CD N
high-risk JJ N
characteristic JJ N
proliferative JJ N
diabetic JJ N
retinopathy NN N
type NN N
II NNP N
diabetics NNS N
. . N

All DT N
cases NNS N
received VBN N
standard JJ N
laser NN 2_i
treatment NN 2_i
according VBG N
to TO N
Early NNP N
Treatment NNP N
Diabetic NNP N
Retinopathy NNP N
Study NNP N
protocol NN N
. . N

Avastin-assigned JJ N
eyes NNS N
received VBD N
1.25 CD 3_i
mg NNS 3_i
intravitreal JJ 3_i
bevacizumab NN 3_i
( ( N
Genentech NNP N
Inc. NNP N
, , N
San NNP N
Francisco NNP N
, , N
CA NNP N
) ) N
on IN N
the DT N
first JJ N
session NN N
of IN N
their PRP$ N
laser NN N
treatments NNS N
. . N

Fluorescein NNP 2_i
angiography NN 2_i
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
weeks NNS N
6 CD N
and CC N
16 CD N
, , N
and CC N
proliferative JJ N
diabetic JJ N
retinopathy NN N
regression NN N
was VBD N
evaluated VBN N
in IN N
a DT N
masked JJ N
fashion NN N
. . N

RESULTS VB N
The DT N
median JJ N
age NN N
was VBD N
52 CD N
years NNS N
( ( N
range NN N
: : N
39-68 JJ N
) ) N
and CC N
30 CD N
% NN N
of IN N
the DT N
participants NNS N
were VBD N
male JJ N
. . N

All DT N
patients NNS N
were VBD N
followed VBN N
for IN N
16 CD N
weeks NNS N
. . N

A DT N
total NN N
of IN N
87.5 CD N
% NN N
of IN N
Avastin-injected JJ N
eyes NNS N
and CC N
25 CD N
% NN N
of IN N
sham NN N
group NN N
showed VBD N
complete JJ N
regression NN N
at IN N
week NN N
6 CD N
of IN N
follow-up NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

However RB N
, , N
at IN N
week NN N
16 CD N
, , N
PDR NNP N
recurred VBD N
in IN N
a DT N
sizable JJ N
number NN N
of IN N
the DT N
Avastin-treated JJ N
eyes NNS N
, , N
and CC N
the DT N
complete JJ N
regression NN N
rate NN N
in IN N
the DT N
two CD N
groups NNS N
became VBD N
identical JJ N
( ( N
25 CD N
% NN N
; : N
p=1.000 NN N
) ) N
; : N
partial JJ N
regression NN N
rates NNS N
were VBD N
70 CD N
% NN N
vs JJ N
65 CD N
% NN N
. . N

In IN N
the DT N
subgroup NN N
of IN N
Avastin-treated JJ 3_i
eyes NNS N
, , N
multivariate NN N
analysis NN N
identified VBN N
hemoglobin JJ N
A1c NNP N
as IN N
the DT N
strongest JJS N
predictor NN N
of IN N
proliferative JJ N
diabetic JJ N
retinopathy NN N
recurrence NN N
( ( N
p=0.033 NN N
) ) N
. . N

CONCLUSIONS NNP N
Intravitreal NNP N
bevacizumab NN 3_i
remarkably RB N
augmented VBD N
the DT N
short-term JJ N
response NN N
to TO N
scatter VB N
panretinal JJ N
laser NN N
photocoagulation NN N
in IN N
high-risk JJ N
characteristic JJ N
proliferative JJ N
diabetic JJ N
retinopathy NN N
but CC N
the DT N
effect NN N
was VBD N
short-lived JJ N
, , N
as IN N
many JJ N
of IN N
the DT N
eyes NNS N
showed VBD N
rapid JJ N
recurrence NN N
. . N

Alternative JJ N
dosing NN N
( ( N
multiple JJ N
and/or NN N
periodic JJ N
intravitreal NN N
Avastin NNP 3_i
injections NNS N
) ) N
is VBZ N
recommended VBN N
for IN N
further JJ N
evaluation NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
propranolol NN 3_i
on IN N
bone NN N
metabolism NN N
in IN N
the DT N
rat NN N
. . N

Propranolol NNP 3_i
, , N
a DT N
nonspecific JJ N
beta-blocker NN N
has VBZ N
many JJ N
physiologic JJ N
effects NNS N
. . N

Its PRP$ N
effects NNS N
on IN N
bone NN N
in IN N
vivo NN N
are VBP N
unknown JJ N
, , N
although IN N
beta NN N
receptor NN N
sites NNS N
have VBP N
been VBN N
found VBN N
on IN N
osteoblasts NNS N
. . N

In IN N
this DT N
study NN N
, , N
the DT N
hypothesis NN N
tested VBD N
was VBD N
that IN N
low JJ N
doses NNS N
of IN N
propranolol NN 3_i
could MD N
alter VB N
bone NN N
properties NNS N
and CC N
enhance NN N
orthotopic RB N
endochondral JJ N
bone NN N
formation NN N
. . N

In IN N
a DT N
group NN N
of IN N
nonsurgical JJ N
rats NNS N
, , N
propranolol JJ 3_i
treatment NN N
increased VBD N
femoral JJ N
torsional JJ N
strength NN N
on IN N
biomechanical JJ N
testing NN N
. . N

In IN N
the DT N
rat NN N
surgical JJ N
model NN N
used VBN N
, , N
right JJ N
femora NNS N
were VBD N
fixed VBN N
to TO N
a DT N
polyethylene NN N
plate NN N
and CC N
then RB N
defects NNS N
were VBD N
created VBN N
mid-diaphysis NN N
and CC N
subsequently RB N
filled VBN N
with IN N
demineralized JJ N
bone NN N
matrix NN N
. . N

These DT N
rats NNS N
( ( N
defect JJ N
rats NNS N
) ) N
were VBD N
randomly RB N
divided VBN N
into IN N
groups NNS N
that WDT N
were VBD N
given VBN N
propranolol NNS 3_i
or CC N
a DT N
saline NN 3_i
carrier NN N
for IN N
19 CD N
consecutive JJ N
days NNS N
. . N

In IN N
the DT N
defect NN N
rats NNS N
, , N
increased VBD N
trabecular JJ N
femoral JJ N
metaphyseal JJ N
mineral JJ N
apposition NN N
rates NNS N
were VBD N
observed VBN N
in IN N
propranolol-treated JJ N
groups NNS N
. . N

Densitometry NNP N
and CC N
roentgenographic JJ N
scoring NN N
of IN N
callus NN N
formation NN N
after IN N
12 CD N
weeks NNS N
in IN N
propranolol-treated JJ N
rats NNS N
revealed VBD N
increased JJ N
callus NN N
and CC N
bone NN N
union NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
propranolol NN 3_i
treatment NN N
can MD N
significantly RB N
affect VB N
bone NN N
properties NNS N
. . N

-DOCSTART- -X- O O

Hepatorenal JJ N
syndrome NN N
. . N

Studies NNS N
of IN N
the DT N
effect NN N
of IN N
vascular JJ N
volume NN N
and CC N
intraperitoneal JJ N
pressure NN N
on IN N
renal JJ N
and CC N
hepatic JJ N
function NN N
. . N

Eleven JJ N
patients NNS N
with IN N
well-documented JJ N
hepatorenal JJ N
syndrome NN N
were VBD N
studied VBN N
by IN N
measurement NN N
of IN N
blood NN N
volume NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
plasma VBP N
aldosterone JJ N
concentration NN N
, , N
renin JJ N
substrate NN N
concentration NN N
, , N
and CC N
plasma JJ N
renin NN N
activity NN N
. . N

They PRP N
were VBD N
then RB N
given VBN N
750 CD 3_i
ml NN 3_i
of IN 3_i
stored JJ 3_i
plasma NN 3_i
, , N
750 CD 3_i
ml NN 3_i
of IN 3_i
fresh JJ 3_i
frozen JJ 3_i
plasma NN 3_i
, , N
and CC N
then RB N
an DT N
infusion NN 3_i
of IN 3_i
angiotensin NN 3_i
II NNP 3_i
, , N
in IN N
random JJ N
order NN N
on IN N
successive JJ N
days NNS N
. . N

Infusion NN 3_i
of IN 3_i
fresh JJ 3_i
frozen JJ 3_i
plasma NN 3_i
improved VBD N
function NN N
more RBR N
than IN N
did VBD N
stored VBN N
plasma NN N
and CC N
in IN N
addition NN N
returned VBD N
a DT N
very RB N
low JJ N
filtration NN N
fraction NN N
toward IN N
normal JJ N
. . N

Angiotensin NNP 3_i
II NNP 3_i
infusion NN 3_i
increased VBD N
filtration NN N
fraction NN N
, , N
but CC N
decreased VBD N
glomerular JJ N
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
and CC N
urine JJ N
flow NN N
sharply RB N
. . N

Patients NNS N
were VBD N
then RB N
given VBN N
a DT N
daily JJ N
infusion NN N
of IN N
1,000 CD 3_i
ml NNS 3_i
of IN 3_i
fresh JJ 3_i
frozen JJ 3_i
plasma NN 3_i
for IN N
seven CD N
to TO N
18 CD N
days NNS N
to TO N
expand VB N
the DT N
blood NN N
volume NN N
to TO N
supranormal JJ N
levels NNS N
as IN N
assayed VBN N
by IN N
serial JJ N
measurement NN N
of IN N
blood NN N
volume NN N
. . N

Plasma NNP N
aldosterone NN N
levels NNS N
decreased VBN N
to TO N
a DT N
normal JJ N
range NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
and CC N
renal JJ N
plasma NN N
flow NN N
both DT N
increased VBN N
, , N
and CC N
urinary JJ N
excretion NN N
of IN N
sodium NN N
and CC N
potassium NN N
both DT N
returned VBN N
toward IN N
normal JJ N
. . N

The DT N
effect NN N
of IN N
intraperitoneal JJ N
pressure NN N
was VBD N
then RB N
studied VBN N
by IN N
measuring VBG N
glomerular JJ N
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
pressure NN N
in IN N
the DT N
vena NN N
cava NN N
, , N
hepatic JJ N
vein NN N
free JJ N
flow NN N
, , N
and CC N
hepatic JJ N
vein NNS N
wedged VBD N
pressure NN N
before IN N
, , N
during IN N
, , N
and CC N
after IN N
paracentesis NN N
to TO N
reduce VB N
the DT N
intraperitoneal JJ N
pressure NN N
from IN N
30 CD N
to TO N
40 CD N
cm NNS N
H2O NNP N
to TO N
12 CD N
to TO N
17 CD N
cm NN N
H2O NNP N
. . N

Venous JJ N
pressures NNS N
moved VBD N
parallel RB N
to TO N
ascitic JJ N
fluid NN N
pressures NNS N
, , N
and CC N
glomerular JJ N
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
and CC N
urine JJ N
flow NN N
all DT N
improved VBD N
sharply RB N
; : N
then RB N
, , N
as IN N
ascitic JJ N
fluid NN N
continued VBD N
to TO N
form VB N
, , N
reducing VBG N
vascular JJ N
volume NN N
, , N
urine JJ N
flow NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
, , N
and CC N
renal JJ N
plasma NN N
flow NN N
all DT N
decreased VBD N
slowly RB N
. . N

Six CD N
patients NNS N
then RB N
underwent JJ N
placement NN N
of IN N
a DT N
LeVeen NNP N
shunt NN N
. . N

Improvement NN N
in IN N
glomerular JJ N
filtration NN N
rate NN N
and CC N
renal JJ N
plasma NN N
flow NN N
and CC N
clinical JJ N
condition NN N
was VBD N
dramatic JJ N
. . N

During IN N
postoperative JJ N
observation NN N
of IN N
up IN N
to TO N
two CD N
years NNS N
, , N
progressive JJ N
improvement NN N
in IN N
hepatic JJ N
function NN N
has VBZ N
occurred VBN N
. . N

-DOCSTART- -X- O O

Prediction NN N
of IN N
metabolic JJ N
and CC N
cardiopulmonary JJ N
responses NNS N
to TO N
maximum JJ 2_i
cycle NN 2_i
ergometry NN 2_i
: : 2_i
a DT N
randomised JJ N
study NN N
. . N

All DT N
of IN N
the DT N
most RBS N
widely-cited JJ N
studies NNS N
for IN N
the DT N
prediction NN N
of IN N
maximum JJ N
exercise NN N
responses NNS N
have VBP N
utilized VBN N
either CC N
volunteers NNS N
or CC N
referred JJ N
subjects NNS N
. . N

Therefore RB N
, , N
selection NN N
bias NN N
, , N
with IN N
overestimation NN N
of IN N
the DT N
reference NN N
values NNS N
, , N
is VBZ N
a DT N
likely JJ N
consequence NN N
. . N

In IN N
order NN N
to TO N
establish VB N
a DT N
set NN N
of IN N
predictive JJ N
equations NNS N
for IN N
the DT N
gas NN N
exchange NN N
, , N
ventilatory NN N
and CC N
cardiovascular JJ N
responses NNS N
to TO N
maximum VB 2_i
ramp-incremental JJ 2_i
cycle NN 2_i
ergometry NN 2_i
, , N
this DT N
study NN N
prospectively RB N
evaluated VBD N
120 CD N
sedentary JJ N
individuals NNS N
( ( N
60 CD N
males NNS N
, , N
60 CD N
females NNS N
, , N
aged VBD N
20-80 CD N
) ) N
, , N
randomly-selected JJ N
from IN N
> JJ N
8,000 CD N
subjects NNS N
. . N

Regular JJ N
physical JJ N
activity NN N
pattern NN N
by IN N
questionnaire NN N
, , N
body NN N
composition NN N
by IN N
anthropometry NN N
and CC N
dual JJ 2_i
energy NN 2_i
X-ray JJ 2_i
absorptiometry NN 2_i
( ( N
n JJ N
= NNP N
75 CD N
) ) N
and CC N
knee JJ N
strength NN N
by IN N
isokinetic JJ N
dynamometry NN N
were VBD N
also RB N
assessed VBN N
. . N

Previously RB N
reported VBD N
equations NNS N
typically RB N
overestimated VBD N
the DT N
subjects NNS N
' POS N
peak NN N
oxygen NN N
uptake NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Prediction NN N
linear JJ N
equations NNS N
for IN N
the DT N
main JJ N
variables NNS N
of IN N
clinical JJ N
interest NN N
were VBD N
established VBN N
by IN N
backward NN N
stepwise NN N
regression NN N
analysis NN N
including VBG N
: : N
sex NN N
, , N
age NN N
, , N
knee NN N
extensor NN N
peak NN N
torque NN N
, , N
bone-free JJ N
lean JJ N
leg NN N
mass NN N
, , N
total JJ N
and CC N
lean JJ N
body NN N
mass NN N
, , N
height NN N
, , N
and CC N
physical JJ N
activity NN N
scores NNS N
. . N

Reference NN N
intervals NNS N
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
) ) N
were VBD N
calculated VBN N
: : N
some DT N
of IN N
these DT N
values NNS N
differed VBD N
markedly RB N
from IN N
those DT N
formerly RB N
recommended VBN N
. . N

The DT N
results NNS N
therefore RB N
might MD N
provide VB N
a DT N
more RBR N
appropriate JJ N
frame NN N
of IN N
reference NN N
for IN N
interpretation NN N
of IN N
the DT N
responses NNS N
to TO N
symptom-limited JJ N
ramp JJ 2_i
incremental JJ 2_i
cycle NN 2_i
ergometry NN 2_i
in IN N
sedentary JJ N
subjects NNS N
; : N
i.e NN N
. . N

those DT N
usually RB N
referred VBN N
for IN N
clinical JJ N
cardiopulmonary JJ N
exercise NN N
tests NNS N
. . N

-DOCSTART- -X- O O

Controlled-release NNP N
melatonin NN 3_i
, , N
singly RB 5_i
and CC 5_i
combined VBN 5_i
with IN 5_i
cognitive JJ 5_i
behavioural JJ 5_i
therapy NN 5_i
, , N
for IN N
persistent JJ N
insomnia NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
: : N
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
. . N

Although IN N
melatonin NN 3_i
and CC N
cognitive-behavioural JJ 5_i
therapy NN 5_i
have VBP N
shown VBN N
efficacy NN N
in IN N
treating VBG N
sleep JJ N
disorders NNS N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
their PRP$ N
relative NN N
or CC N
combined VBN N
efficacy NN N
. . N

One CD N
hundred CD N
and CC N
sixty JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
, , N
aged VBN N
4-10 CD N
years NNS N
, , N
suffering VBG N
from IN N
sleep JJ N
onset NN N
insomnia NN N
and CC N
impaired JJ N
sleep JJ N
maintenance NN N
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
either DT N
( ( N
1 CD N
) ) N
combination NN N
of IN N
controlled-release JJ 3_i
melatonin NN 3_i
and CC N
cognitive-behavioural JJ 4_i
therapy NN 4_i
; : N
( ( N
2 CD N
) ) N
controlled-release NN 3_i
melatonin NN 3_i
; : N
( ( N
3 CD N
) ) N
four CD 4_i
sessions NNS 4_i
of IN 4_i
cognitive-behavioural JJ 4_i
therapy NN 4_i
; : N
or CC N
( ( N
4 CD N
) ) N
placebo FW 7_i
drug NN N
treatment NN N
condition NN N
for IN N
12 CD N
weeks NNS N
in IN N
a DT N
1 CD N
: : N
1 CD N
: : N
1 CD N
: : N
1 CD N
ratio NN N
. . N

Children NNP N
were VBD N
studied VBN N
at IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Treatment NNP N
response NN N
was VBD N
assessed VBN N
with IN N
1-week JJ N
actigraphic JJ N
monitoring NN N
, , N
sleep JJ N
diary NN N
and CC N
sleep JJ N
questionnaire NN N
. . N

Main NNP N
outcome NN N
measures NNS N
, , N
derived VBN N
actigraphically RB N
, , N
were VBD N
sleep JJ N
latency NN N
, , N
total JJ N
sleep JJ N
time NN N
, , N
wake VBP N
after IN N
sleep JJ N
onset NN N
and CC N
number NN N
of IN N
awakenings NNS N
. . N

The DT N
active JJ N
treatment NN N
groups NNS N
all DT N
resulted VBD N
in IN N
improvements NNS N
across IN N
all DT N
outcome NN N
measures NNS N
, , N
with IN N
moderate-to-large JJ N
effect NN N
sizes VBZ N
from IN N
baseline NN N
to TO N
a DT N
12-week JJ N
assessment NN N
. . N

Melatonin NNP 3_i
treatment NN N
was VBD N
mainly RB N
effective JJ N
in IN N
reducing VBG N
insomnia NN N
symptoms NNS N
, , N
while IN N
cognitive-behavioural JJ 5_i
therapy NN 5_i
had VBD N
a DT N
light JJ N
positive JJ N
impact NN N
mainly RB N
on IN N
sleep JJ N
latency NN N
, , N
suggesting VBG N
that IN N
some DT N
behavioural JJ N
aspects NNS N
might MD N
play VB N
a DT N
role NN N
in IN N
determining VBG N
initial JJ N
insomnia NN N
. . N

The DT N
combination NN N
treatment NN N
group NN N
showed VBD N
a DT N
trend NN N
to TO N
outperform VB N
other JJ N
active JJ N
treatment NN N
groups NNS N
, , N
with IN N
fewer JJR N
dropouts NNS N
and CC N
a DT N
greater JJR N
proportion NN N
of IN N
treatment NN N
responders NNS N
achieving VBG N
clinically RB N
significant JJ N
changes NNS N
( ( N
63.38 CD N
% NN N
normative JJ N
sleep JJ N
efficiency NN N
criterion NN N
of IN N
> $ N
85 CD N
% NN N
and CC N
84.62 CD N
% NN N
, , N
sleep JJ N
onset NN N
latency NN N
< VBD N
30 CD N
min NN N
) ) N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
adding VBG N
behavioural JJ 4_i
intervention NN 4_i
to TO N
melatonin VB 3_i
treatment NN N
seems VBZ N
to TO N
result VB N
in IN N
a DT N
better JJR N
treatment NN N
response NN N
, , N
at IN N
least JJS N
in IN N
the DT N
short JJ N
term NN N
. . N

-DOCSTART- -X- O O

Plasma NNP N
pH NN N
does VBZ N
not RB N
influence VB N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
during IN N
maximal JJ N
whole JJ N
body NN N
exercise NN N
. . N

Exercise NN N
lowers VBZ N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
of IN N
O2 NNP N
to TO N
carbohydrate VB N
( ( N
glucose+1/2 JJ N
lactate NN N
) ) N
and CC N
metabolic JJ N
acidosis NN N
appears VBZ N
to TO N
promote VB N
cerebral JJ N
lactate JJ N
uptake NN N
. . N

However RB N
, , N
the DT N
influence NN N
of IN N
pH NN N
on IN N
cerebral JJ N
lactate JJ N
uptake NN N
and CC N
, , N
in IN N
turn NN N
, , N
on IN N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
during IN N
exercise NN N
is VBZ N
not RB N
known VBN N
. . N

Sodium NN 3_i
bicarbonate NN 3_i
( ( N
Bicarb NNP N
, , N
1 CD N
M NNP N
; : N
350-500 CD N
ml NN N
) ) N
or CC N
an DT N
equal JJ N
volume NN N
of IN N
normal JJ 3_i
saline NN 3_i
( ( N
Sal NNP N
) ) N
was VBD N
infused VBN N
intravenously RB N
at IN N
a DT N
constant JJ N
rate NN N
during IN N
a DT N
'2000 CD N
m NN N
' '' N
maximal JJ N
ergometer NN 3_i
row NN 3_i
in IN N
six CD N
male JJ N
oarsmen NNS N
( ( N
23?2 CD N
years NNS N
; : N
mean?S.D. NN N
) ) N
. . N

During IN N
the DT N
Sal NNP N
trial NN N
, , N
pH NN N
decreased VBD N
from IN N
7.41?0.01 CD N
at IN N
rest NN N
to TO N
7.02?0.02 CD N
but CC N
only RB N
to TO N
7.36?0.02 CD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
during IN N
the DT N
Bicarb NNP N
trial NN N
. . N

Arterial JJ N
lactate NN N
increased VBD N
to TO N
21.4?0.8 CD N
and CC N
32.7?2.3 CD N
mM NN N
during IN N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Also RB N
, , N
the DT N
arterial-jugular JJ N
venous JJ N
lactate NN N
difference NN N
increased VBD N
from-0.03?0.01 JJ N
mM NN N
at IN N
rest NN N
to TO N
3.2?0.9 CD N
mM NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
3.4?1.4 CD N
mM NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
following VBG N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
, , N
respectively RB N
. . N

Accordingly RB N
, , N
the DT N
cerebral JJ N
metabolic NN N
ratio NN N
decreased VBD N
equally RB N
during IN N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
: : N
from IN N
5.8?0.6 CD N
at IN N
rest NN N
to TO N
1.7?0.1 CD N
and CC N
1.8?0.2 CD N
, , N
respectively RB N
. . N

The DT N
enlarged JJ N
blood-buffering NN N
capacity NN N
after IN N
infusion NN N
of IN N
Bicarb NNP N
eliminated VBD N
metabolic JJ N
acidosis NN N
during IN N
maximal JJ N
exercise NN N
but CC N
that DT N
did VBD N
not RB N
affect VB N
the DT N
cerebral JJ N
lactate NN N
uptake NN N
and CC N
, , N
therefore RB N
, , N
the DT N
decrease NN N
in IN N
the DT N
cerebral JJ N
metabolic NN N
ratio NN N
. . N

-DOCSTART- -X- O O

Longterm NNP N
safety NN N
, , N
efficacy NN N
, , N
and CC N
radiographic JJ N
outcome NN N
with IN N
etanercept JJ 3_i
treatment NN N
in IN N
patients NNS N
with IN N
early JJ N
rheumatoid NN N
arthritis NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
safety NN N
, , N
efficacy NN N
, , N
and CC N
radiographic JJ N
progression NN N
in IN N
patients NNS N
with IN N
early JJ N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
undergoing VBG N
longterm JJ N
treatment NN N
with IN N
etanercept NN 3_i
. . N

METHODS NNP N
Patients NNPS N
with IN N
early JJ N
RA NNP N
( ( N
disease JJ N
duration NN N
of IN N
3 CD N
years NNS N
or CC N
less JJR N
) ) N
who WP N
had VBD N
completed VBN N
a DT N
2-year JJ N
efficacy NN N
study NN N
comparing VBG N
etanercept NNS 3_i
and CC N
methotrexate NN 3_i
( ( N
MTX NNP N
) ) N
were VBD N
followed VBN N
in IN N
an DT N
extension NN N
where WRB N
they PRP N
received VBD N
25 CD N
mg NNS N
etanercept JJ 3_i
twice RB N
weekly RB N
. . N

Safety NNP N
was VBD N
summarized VBN N
descriptively RB N
and CC N
compared VBN N
with IN N
data NNS N
from IN N
the DT N
efficacy NN N
study NN N
. . N

Efficacy NNP N
and CC N
radiographic JJ N
progression NN N
were VBD N
assessed VBN N
using VBG N
American JJ N
College NNP N
of IN N
Rheumatology NNP N
response NN N
criteria NNS N
, , N
disease NN N
activity NN N
scores VBZ N
, , N
and CC N
Total NNP N
Sharp NNP N
Score NNP N
( ( N
TSS NNP N
) ) N
. . N

RESULTS JJ N
Rates NNS N
of IN N
serious JJ N
adverse JJ N
events NNS N
and CC N
serious JJ N
infections NNS N
did VBD N
not RB N
increase VB N
with IN N
longterm JJ N
exposure NN N
to TO N
etanercept VB N
, , N
and CC N
were VBD N
similar JJ N
to TO N
rates NNS N
reported VBN N
for IN N
the DT N
blinded JJ N
portion NN N
of IN N
the DT N
efficacy NN N
study NN N
. . N

Efficacy NNP N
was VBD N
sustained VBN N
in IN N
patients NNS N
who WP N
completed VBD N
5 CD N
years NNS N
of IN N
etanercept JJ 3_i
treatment NN N
at IN N
the DT N
time NN N
of IN N
this DT N
report NN N
( ( N
N NNP N
= NNP N
201 CD N
) ) N
, , N
even RB N
in IN N
those DT N
who WP N
decreased VBD N
or CC N
discontinued VBN N
use NN N
of IN N
MTX NNP N
or CC N
corticosteroids NNS N
. . N

No DT N
radiographic JJ N
progression NN N
( ( N
change NN N
in IN N
TSS NNP N
< NNP N
or CC N
= VB N
0 CD N
) ) N
was VBD N
seen VBN N
in IN N
55 CD N
% NN N
of IN N
patients NNS N
with IN N
5-year JJ N
radiographs NN N
; : N
negative JJ N
change NN N
( ( N
TSS NNP N
< NNP N
0 CD N
) ) N
was VBD N
seen VBN N
in IN N
11 CD N
% NN N
. . N

CONCLUSION NNP N
Etanercept NNP 3_i
treatment NN N
in IN N
patients NNS N
with IN N
early JJ N
RA NNP N
was VBD N
generally RB N
well RB N
tolerated VBN N
for IN N
up RB N
to TO N
5 CD N
years NNS N
. . N

The DT N
results NNS N
indicate VBP N
sustained VBN N
efficacy NN N
and CC N
decreased JJ N
rate NN N
of IN N
radiographic JJ N
progression NN N
. . N

The DT N
rate NN N
of IN N
radiographic JJ N
progression NN N
was VBD N
low JJ N
compared VBN N
with IN N
other JJ N
studies NNS N
, , N
emphasizing VBG N
the DT N
benefit NN N
gained VBN N
in IN N
patients NNS N
with IN N
early JJ N
aggressive JJ N
RA NNP N
who WP N
undergo VBP N
longterm JJ N
treatment NN N
with IN N
etanercept NN 3_i
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
human JJ N
leukocyte JJ 3_i
IFN-alpha NN 3_i
on IN N
the DT N
immune JJ N
response NN N
to TO N
the DT N
HBV NNP 3_i
vaccine NN 3_i
in IN N
healthy JJ N
unvaccinated JJ N
individuals NNS N
. . N

HBV NNP 3_i
vaccine NN 3_i
needs VBZ N
3 CD N
injections NNS N
over IN N
6 CD N
months NNS N
to TO N
induce VB N
immunity NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
adjuvants NNS N
capable JJ N
of IN N
inducing VBG N
earlier JJR N
immune JJ N
protection NN N
would MD N
be VB N
highly RB N
desirable JJ N
. . N

Most JJS N
adjuvants NNS N
may MD N
act VB N
by IN N
inducing VBG N
cytokines NNS N
, , N
and CC N
among IN N
them PRP N
, , N
type NN N
I PRP N
interferons NNS N
( ( N
IFNs NNP N
) ) N
, , N
deserve VB N
a DT N
special JJ N
attention NN N
in IN N
view NN N
of IN N
the DT N
potent JJ N
immunomostimulatory NN N
activity NN N
observed VBN N
in IN N
mouse NN N
models NNS N
and CC N
on IN N
dendritic JJ N
cell NN N
functions NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
IFN-alpha NNP 3_i
administered VBD N
as IN N
an DT N
adjuvant NN 3_i
of IN 3_i
HBV NNP 3_i
vaccine NN 3_i
in IN N
healthy JJ N
unvaccinated JJ N
individuals NNS N
. . N

No DT N
significant JJ N
enhancing VBG N
effect NN N
on IN N
the DT N
antibody NN N
response NN N
was VBD N
observed VBN N
, , N
in IN N
spite NN N
of IN N
an DT N
early JJ N
and CC N
transient JJ N
upregulation NN N
of IN N
costimulatory NN N
molecule NN N
expression NN N
on IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
, , N
which WDT N
may MD N
be VB N
suggestive JJ N
of IN N
an DT N
IFN-mediated JJ N
activation NN N
of IN N
antigen NN N
presenting VBG N
cells NNS N
. . N

We PRP N
conclude VBP N
that IN N
, , N
under IN N
the DT N
conditions NNS N
used VBN N
in IN N
this DT N
trial NN N
, , N
natural JJ N
IFN-alpha NNP 3_i
does VBZ N
not RB N
act VB N
as IN N
an DT N
adjuvant NN N
of IN N
the DT N
HBV NNP N
vaccine NN N
in IN N
healthy JJ N
unvaccinated JJ N
individuals NNS N
. . N

-DOCSTART- -X- O O

Recombinant JJ 3_i
human JJ 3_i
granulocyte NN 3_i
and CC 3_i
granulocyte-macrophage JJ 3_i
colony-stimulating JJ 3_i
factor NN 3_i
( ( 3_i
G-CSF NNP 3_i
and CC 3_i
GM-CSF NNP 3_i
) ) 3_i
administered VBD N
following VBG N
cytotoxic NN 3_i
chemotherapy NNS 3_i
have VBP N
a DT N
similar JJ N
ability NN N
to TO N
mobilize VB N
peripheral JJ N
blood NN N
stem NN N
cells NNS N
. . N

The DT N
availability NN N
of IN N
hematopoietic JJ N
growth NN N
factors NNS N
has VBZ N
greatly RB N
facilitated VBN N
the DT N
mobilization NN N
and CC N
collection NN N
of IN N
peripheral JJ N
blood NN N
stem NN N
cells NNS N
( ( N
PBSC NNP N
) ) N
. . N

It PRP N
was VBD N
the DT N
aim NN N
of IN N
this DT N
double-blind NN N
study NN N
to TO N
compare VB N
the DT N
PBSC-mobilizing NNP N
efficacy NN N
of IN N
recombinant JJ 3_i
human JJ 3_i
G-CSF NNP 3_i
and CC N
GM-CSF NNP 3_i
when WRB N
administered VBN N
post-chemotherapy NN 3_i
. . N

Twenty-six JJ N
patients NNS N
with IN N
relapsed JJ N
Hodgkin NNP N
's POS N
disease NN N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Their PRP$ N
median JJ N
age NN N
was VBD N
31 CD N
years NNS N
( ( N
range NN N
, , N
22-59 JJ N
) ) N
and CC N
14 CD N
patients NNS N
were VBD N
males NNS N
and CC N
12 CD N
were VBD N
females NNS N
. . N

Patients NNS N
were VBD N
pretreated VBN N
with IN N
a DT N
median NN N
of IN N
eight CD N
cycles NNS N
of IN N
cytotoxic NN 3_i
chemotherapy NN 3_i
, , N
while IN N
18 CD N
patients NNS N
had VBD N
undergone JJ N
extended JJ N
field NN N
irradiation NN N
. . N

The DT N
patients NNS N
received VBD N
dexamethasone RB 3_i
24 CD 3_i
mg JJ 3_i
days NNS 3_i
1-7 CD 3_i
, , 3_i
melphalan FW 3_i
30 CD 3_i
mg/m2 NNS 3_i
day NN 3_i
3 CD 3_i
, , 3_i
BCNU NNP 3_i
60 CD 3_i
mg/m2 NN 3_i
day NN 3_i
3 CD 3_i
, , 3_i
etoposide RB 3_i
75 CD 3_i
mg/m2 JJ 3_i
days NNS 3_i
4-7 CD 3_i
, , 3_i
Ara-C NNP 3_i
100 CD 3_i
mg/m2 NN 3_i
twice RB 3_i
daily JJ 3_i
days NNS 3_i
4-7 JJ 3_i
( ( 3_i
Dexa-BEAM NNP 3_i
) ) 3_i
. . N

Twelve CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB 3_i
5/microg/kg/day CD 3_i
G-CSF NNP 3_i
and CC N
14 CD N
patients NNS N
to TO N
receive VB N
5 CD 3_i
microg/kg/day JJ 3_i
GM-CSF NNP 3_i
, , N
both DT N
administered VBN N
subcutaneously RB N
starting VBG N
on IN N
day NN N
1 CD N
after IN N
the DT N
end NN N
of IN N
Dexa-BEAM NNP 3_i
. . N

Primary JJ N
endpoints NNS N
of IN N
the DT N
study NN N
were VBD N
the DT N
number NN N
of IN N
CD34+ NNP N
cells NNS N
harvested VBD N
per IN N
kg NN N
body NN N
weight VBD N
on IN N
the DT N
occasion NN N
of IN N
six CD N
consecutive JJ N
leukaphereses NNS N
and CC N
the DT N
time NN N
needed VBN N
for IN N
hematological JJ N
reconstitution NN N
following VBG N
autografting VBG N
. . N

Twenty-one CD N
patients NNS N
completed VBN N
PBSC NNP N
collection NN N
, , N
and CC N
six CD N
patients NNS N
of IN N
the DT N
G-CSF NNP N
group NN N
and CC N
nine CD N
of IN N
the DT N
GM-CSF NNP N
group NN N
were VBD N
autografted VBN N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
with IN N
respect NN N
to TO N
the DT N
median JJ N
yield NN N
of IN N
CFU-GM NNP N
and CC N
CD34+ NNP N
cells NNS N
: : N
32.5 CD N
x $ N
10 CD N
( ( N
4 CD N
) ) N
/kg NN N
vs $ N
31.3 CD N
x $ N
10 CD N
( ( N
4 CD N
) ) N
/kg CD N
CFU-GM NNP N
, , N
and CC N
7.6 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
vs $ N
5.6 CD N
x $ N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
CD34+ NNP N
cells NNS N
, , N
for IN N
G-CSF NNP 3_i
and CC N
GM-CSF NNP 3_i
, , N
respectively RB N
( ( N
U NNP N
test NN N
, , N
P= NNP N
0.837 CD N
and CC N
0.696 CD N
) ) N
. . N

High-dose JJ N
chemotherapy NN N
consisted VBN N
of IN N
cyclophosphamide NN 3_i
1.7 CD N
g/m2 JJ N
days NNS N
1-4 CD N
, , N
BCNU NNP 3_i
150 CD N
mg/m2 NN N
days NNS N
1-4 CD N
, , N
etoposide RB 3_i
400 CD N
mg/m2 JJ N
days NNS N
1-4 JJ N
. . N

All DT N
patients NNS N
transplanted VBN N
with IN N
more JJR N
than IN N
5 CD N
x JJ N
10 CD N
( ( N
6 CD N
) ) N
CD34+ NNP N
cells/kg NN N
had VBD N
a DT N
rapid JJ N
platelet NN N
recovery NN N
( ( N
20 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
) ) N
between IN N
6 CD N
and CC N
11 CD N
days NNS N
and CC N
neutrophil JJ N
recovery NN N
( ( N
0.5 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
/1 NN N
) ) N
between IN N
9 CD N
and CC N
16 CD N
days NNS N
, , N
while IN N
patients NNS N
transplanted VBN N
with IN N
less JJR N
than IN N
5 CD N
x JJ N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
had VBD N
a DT N
delayed VBN N
reconstitution NN N
, , N
regardless RB N
of IN N
the DT N
kind NN N
of IN N
growth NN N
factor NN N
used VBN N
for IN N
PBSC NNP N
mobilization NN N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
data NNS N
indicate VBP N
that IN N
in IN N
patients NNS N
with IN N
Hodgkin NNP N
's POS N
disease NN N
G-CSF NNP N
and CC N
GM-CSF NNP N
given VBN N
after IN N
salvage NN N
chemotherapy NN N
appear VBP N
to TO N
be VB N
not RB N
different JJ N
in IN N
their PRP$ N
ability NN N
to TO N
mobilize VB N
PBSC NNP N
resulting VBG N
in IN N
a DT N
similar JJ N
time NN N
needed VBN N
for IN N
hematological JJ N
reconstitution NN N
when WRB N
autografted VBD N
following VBG N
high-dose JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

Comparative NNP N
in IN N
vitro JJ N
dissolution NN N
and CC N
in IN N
vivo JJ N
bioavailability NN N
of IN N
diflunisal/naproxen JJ N
fixed-dose JJ N
combination NN N
tablets NNS N
and CC N
concomitant JJ N
administration NN N
of IN N
diflunisal NN N
and CC N
naproxen NN N
in IN N
healthy JJ N
adult NN N
subjects NNS N
. . N

A DT N
simple JJ N
validated JJ N
high-performance NN N
liquid NN N
chromatography NN N
( ( N
HPLC NNP N
) ) N
assay NN N
was VBD N
developed VBN N
for IN N
determination NN N
of IN N
diflunisal NN N
and CC N
naproxen NN N
in IN N
human JJ N
plasma NN N
samples NNS N
. . N

This DT N
is VBZ N
to TO N
compare VB N
the DT N
bioavailability NN N
of IN N
diflunisal-naproxen JJ N
fixed-dose JJ N
combination NN N
( ( N
FDC NNP N
) ) N
with IN N
their PRP$ N
separate JJ N
dosage NN N
forms NNS N
. . N

The DT N
in IN N
vitro JJ N
dissolution NN N
study NN N
was VBD N
adopted VBN N
to TO N
compare VB N
the DT N
dissolution NN N
behavior NN N
of IN N
FDC NNP N
with IN N
respect NN N
to TO N
separate VB N
marketed VBN N
tablets NNS N
. . N

In IN N
vivo NN N
study NN N
was VBD N
conducted VBN N
according VBG N
to TO N
a DT N
single-center NN N
, , N
randomized VBN N
, , N
single-dose JJ N
, , N
laboratory-blinded JJ N
, , N
2 CD N
Way NNP N
, , N
Cross-Over NNP N
Study NNP N
with IN N
a DT N
washout JJ N
period NN N
of IN N
10 CD N
days NNS N
. . N

Under IN N
fasting VBG N
conditions NNS N
, , N
24 CD N
healthy JJ N
Egyptian JJ N
male NN N
volunteers NNS N
were VBD N
randomly RB 3_i
allocated VBN 3_i
to TO 3_i
receive VB 3_i
a DT 3_i
single JJ 3_i
oral JJ 3_i
dose NN 3_i
of IN 3_i
either DT 3_i
one CD 3_i
FDC NNP 3_i
tablet NN 3_i
or CC N
co-administration NN 3_i
of IN 3_i
two CD 3_i
separate JJ 3_i
diflunisal NN 3_i
and CC 3_i
naproxen RB 3_i
marketed VBN 3_i
tablets NNS 3_i
. . N

Plasma NNP N
samples NNS N
were VBD N
obtained VBN N
over IN N
a DT N
72-h JJ N
interval NN N
and CC N
analyzed VBN N
for IN N
diflunisal NN N
and CC N
naproxen NN N
by IN N
reversed JJ N
phase NN N
liquid NN N
chromatography NN N
with IN N
UV NNP N
detection NN N
. . N

The DT N
pharmacokinetic JJ N
parameters NNS N
Cmax NNP N
, , N
AUC0-t NNP N
, , N
AUC0-? NNP N
, , N
tmax NN N
, , N
and CC N
t1/2 NNS N
were VBD N
determined VBN N
from IN N
plasma JJ N
concentration-time JJ N
profiles NNS N
. . N

The DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
ratio NN N
of IN N
log NN N
transformed VBN N
values NNS N
of IN N
Cmax NNP N
, , N
AUC0-t NNP N
, , N
and CC N
AUCt-? NNP N
of IN N
the DT N
2 CD N
treatments NNS N
were VBD N
within IN N
the DT N
acceptable JJ N
range NN N
( ( N
0.8-1.25 JJ N
) ) N
for IN N
bioequivalence NN N
. . N

From IN N
pharmacokinetic JJ N
and CC N
in IN N
vitro JJ N
studies NNS N
perspectives NNS N
, , N
1 CD N
FDC NNP N
tablet NN N
demonstrated VBD N
similar JJ N
relative JJ N
bioavailability NN N
with IN N
the DT N
2 CD N
individual JJ N
-reference NN N
tablets NNS N
. . N

-DOCSTART- -X- O O

Long-term JJ N
treatment NN N
with IN N
atomoxetine NN 3_i
for IN N
attention-deficit/hyperactivity NN N
disorder NN N
symptoms NNS N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
: : N
an DT N
open-label JJ N
extension NN N
study NN N
. . N

OBJECTIVE CC N
The DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
long-term JJ N
treatment NN N
with IN N
atomoxetine NN 3_i
for IN N
symptoms NNS N
of IN N
attention-deficit/hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
has VBZ N
not RB N
been VBN N
established VBN N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
88 CD N
patients NNS N
6-17 JJ N
years NNS N
of IN N
age NN N
, , N
with IN N
ADHD NNP N
and CC N
ASD NNP N
, , N
were VBD N
treated VBN N
with IN N
1.2 CD N
mg/kg/day JJ N
atomoxetine NN 3_i
for IN N
20 CD N
weeks NNS N
as IN N
follow-up NN N
of IN N
an DT N
8 CD N
week NN N
double-blind JJ N
placebo-controlled JJ 7_i
period NN N
. . N

Primary JJ N
endpoint NN N
was VBD N
the DT N
ADHD NNP N
Rating NNP N
Scale NNP N
( ( N
ADHD-RS NNP N
) ) N
. . N

RESULTS NNP N
After IN N
8 CD N
weeks NNS N
of IN N
initial JJ N
treatment NN N
, , N
the DT N
mean JJ N
total NN N
, , N
inattention NN N
, , N
and CC N
hyperactivity-impulsivity NN N
ADHD-RS NNP N
further RB N
decreased VBD N
significantly RB N
from IN N
34.9 CD N
to TO N
27.0 CD N
for IN N
the DT N
total JJ N
ADHD-RS NNP N
, , N
from IN N
18.3 CD N
to TO N
14.5 CD N
for IN N
the DT N
ADHD-RS NNP N
inattention NN N
subscale NN N
, , N
and CC N
from IN N
16.5 CD N
to TO N
12.6 CD N
for IN N
the DT N
hyperactivity-impulsivity JJ N
subscale NN N
. . N

Adverse JJ N
events NNS N
were VBD N
mild JJ N
and CC N
tended VBD N
to TO N
diminish VB N
over IN N
time NN N
during IN N
continued JJ N
treatment NN N
, , N
especially RB N
regarding VBG N
nausea NN N
and CC N
fatigue NN N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ N
events NNS N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
the DT N
present JJ N
analysis NN N
suggest NN N
that WDT N
continued VBD N
treatment NN N
with IN N
atomoxetine NN 3_i
up RB N
to TO N
28 CD N
weeks NNS N
further RBR N
improve VB N
ADHD NNP N
symptoms NNS N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
ASD NNP N
, , N
while IN N
adverse JJ N
events NNS N
tend VBP N
to TO N
subside VB N
. . N

Future JJ N
studies NNS N
investigating VBG N
the DT N
long-term JJ N
efficacy NN N
of IN N
atomoxetine NN 3_i
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
ASD NNP N
should MD N
be VB N
randomized VBN N
and CC N
placebo VB N
controlled VBN N
. . N

This DT N
study NN N
has VBZ N
been VBN N
registered VBN N
in IN N
ClinicalTrials.gov NNP N
( ( N
www.clinicaltrials.gov NN N
) ) N
under IN N
registration NN N
number NN N
NCT00380692 NNP N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
norgestimate NN 3_i
and CC N
ethinyl NN 3_i
estradiol NN 3_i
in IN N
treating VBG N
moderate JJ N
acne NN N
vulgaris NN N
. . N

BACKGROUND NNP N
An DT N
excess NN N
of IN N
androgen NN N
is VBZ N
believed VBN N
to TO N
contribute VB N
to TO N
development NN N
of IN N
acne NN N
in IN N
some DT N
patients NNS N
. . N

Because IN N
oral JJ 3_i
contraceptives NNS 3_i
( ( N
OCs NNP N
) ) N
may MD N
reduce VB N
the DT N
active JJ N
androgen NN N
level NN N
, , N
hormonal JJ N
therapy NN N
with IN N
OCs NNP N
has VBZ N
been VBN N
used VBN N
successfully RB N
to TO N
treat VB N
patients NNS N
with IN N
acne NN N
, , N
although IN N
this DT N
treatment NN N
has VBZ N
previously RB N
not RB N
been VBN N
studied VBN N
in IN N
placebo-controlled JJ N
trials NNS N
. . N

OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
triphasic JJ 3_i
, , 3_i
combination NN 3_i
OC NNP 3_i
( ( 3_i
ORTHO NNP 3_i
TRI-CYCLEN NNP 3_i
[ NNP 3_i
Ortho-McNeil NNP 3_i
Pharmaceutical NNP 3_i
, , 3_i
Raritan NNP 3_i
, , 3_i
N.J. NNP 3_i
] NNP 3_i
, , 3_i
norgestimate/ethinyl RB 3_i
estradiol NN 3_i
) ) 3_i
compared VBN N
with IN N
placebo NN 7_i
in IN N
the DT N
treatment NN N
of IN N
moderate JJ N
acne NN N
vulgaris NN N
. . N

METHODS NNP N
Two CD N
hundred VBD N
fifty-seven RB N
healthy JJ N
female NN N
subjects NNS N
, , N
15 CD N
to TO N
49 CD N
years NNS N
of IN N
age NN N
with IN N
moderate JJ N
acne NNS N
vulgaris NN N
, , N
were VBD N
enrolled VBN N
in IN N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

Each DT N
month NN N
for IN N
6 CD N
months NNS N
, , N
subjects VBZ N
received VBN N
either RB N
3 CD N
consecutive JJ N
weeks NNS N
of IN N
the DT N
OC NNP 3_i
( ( N
i.e. FW N
, , N
tablets NNS N
containing VBG N
a DT N
fixed VBN N
dose NN N
of IN N
ethinyl JJ 3_i
estradiol NN 3_i
[ VBD N
0.035 CD N
mg NN N
] NN N
and CC N
increasing VBG N
doses NNS N
of IN N
norgestimate JJ 3_i
[ NNS N
0.180 CD N
mg NNS N
, , N
0.215 CD N
mg NN N
, , N
0.250 CD N
mg NN N
] NN N
) ) N
followed VBN N
by IN N
7 CD N
days NNS N
of IN N
inactive JJ 3_i
drug NN 3_i
or CC N
placebo NN 7_i
( ( N
color-matched JJ N
tablets NNS N
) ) N
. . N

Efficacy NN N
was VBD N
assessed VBN N
by IN N
facial JJ N
acne JJ N
lesion NN N
counts NNS N
, , N
an DT N
investigator NN N
's POS N
global JJ N
assessment NN N
, , N
a DT N
subject NN N
's POS N
self-assessment NN N
, , N
and CC N
an DT N
analysis NN N
of IN N
within-cycle JJ N
variation NN N
( ( N
cycle NN N
6 CD N
) ) N
in IN N
lesion NN N
counts NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
160 CD N
subjects NNS N
in IN N
whom WP N
efficacy NN N
could MD N
be VB N
evaluated VBN N
, , N
the DT N
OC NNP N
group NN N
showed VBD N
a DT N
statistically RB N
significantly RB N
greater JJR N
improvement NN N
than IN N
the DT N
placebo NN N
group NN N
for IN N
all DT N
primary JJ N
efficacy NN N
measures NNS N
. . N

The DT N
mean JJ N
decrease NN N
in IN N
inflammatory JJ N
lesion NN N
count NN N
from IN N
baseline NN N
to TO N
cycle NN N
6 CD N
was VBD N
11.8 CD N
( ( N
62.0 CD N
% NN N
) ) N
versus NN N
7.6 CD N
( ( N
38.6 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
, , N
and CC N
the DT N
mean JJ N
decrease NN N
in IN N
total JJ N
lesion NN N
count NN N
was VBD N
29.1 CD N
( ( N
53.1 CD N
% NN N
) ) N
versus NN N
14.1 CD N
( ( N
26.8 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
in IN N
the DT N
OC NNP N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
investigator NN N
's POS N
global JJ N
assessment NN N
, , N
93.7 CD N
% NN N
of IN N
the DT N
active JJ N
treatment NN N
group NN N
versus VBD N
65.4 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
were VBD N
rated VBN N
as IN N
improved VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Six CD N
of IN N
the DT N
seven CD N
secondary JJ N
efficacy NN N
measures NNS N
( ( N
total JJ N
comedones NNS N
, , N
open JJ N
comedones NNS N
, , N
closed VBD N
comedones NNS N
, , N
papules NNS N
, , N
pustules NNS N
, , N
and CC N
the DT N
subject NN N
's POS N
self-assessment NN N
of IN N
study NN N
treatment NN N
) ) N
were VBD N
also RB N
significantly RB N
more RBR N
favorable JJ N
in IN N
the DT N
OC NNP N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

CONCLUSION NNP N
An DT N
OC NNP N
containing VBG N
0.035 CD N
mg NN N
of IN N
ethinyl JJ 3_i
estradiol NN 3_i
combined VBN N
with IN N
the DT N
triphasic JJ N
regimen NNS N
of IN N
norgestimate NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
treatment NN N
of IN N
moderate JJ N
acne NNS N
vulgaris VBP N
in IN N
women NNS N
with IN N
no DT N
known VBN N
contraindication NN N
to TO N
OC NNP N
therapy NN N
. . N

-DOCSTART- -X- O O

Theory NN N
of IN N
Mind NNP 4_i
training NN 4_i
in IN N
children NNS N
with IN N
autism NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Many JJ N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorders NNP N
( ( N
ASD NNP N
) ) N
participate NN N
in IN N
social JJ N
skills NNS N
or CC N
Theory NN 4_i
of IN 4_i
Mind NNP 4_i
( ( 4_i
ToM NNP 4_i
) ) 4_i
treatments NNS 4_i
. . N

However RB N
, , N
few JJ N
studies NNS N
have VBP N
shown VBN N
evidence NN N
for IN N
their PRP$ N
effectiveness NN N
. . N

The DT N
current JJ N
study NN N
used VBD N
a DT N
randomized JJ N
controlled JJ N
design NN N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
a DT N
16-week JJ N
ToM NNP 4_i
treatment NN 4_i
in IN N
8-13 JJ N
year NN N
old JJ N
children NNS N
with IN N
ASD NNP N
and CC N
normal JJ N
IQs NNP N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
. . N

The DT N
results NNS N
showed VBD N
that IN N
, , N
compared VBN N
to TO N
controls NNS N
, , N
the DT N
treated JJ N
children NNS N
with IN N
ASD NNP N
improved VBN N
in IN N
their PRP$ N
conceptual JJ N
ToM NNP N
skills NNS N
, , N
but CC N
their PRP$ N
elementary JJ N
understanding NN N
, , N
self PRP N
reported VBD N
empathic JJ N
skills NNS N
or CC N
parent NN N
reported VBN N
social JJ N
behaviour NN N
did VBD N
not RB N
improve VB N
. . N

Despite IN N
the DT N
effects NNS N
on IN N
conceptual JJ N
understanding NN N
, , N
the DT N
current JJ N
study NN N
does VBZ N
not RB N
indicate VB N
strong JJ N
evidence NN N
for IN N
the DT N
effectiveness NN N
of IN N
a DT N
ToM NNP N
treatment NN N
on IN N
the DT N
daily JJ N
life NN N
mindreading VBG N
skills NNS N
. . N

-DOCSTART- -X- O O

Zinc NNP 3_i
supplementation NN 3_i
in IN N
alcoholic JJ N
cirrhosis NN N
. . N

A DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

A DT N
double-blind JJ N
clinical JJ N
trial NN N
with IN N
zinc NN 3_i
sulfate NN 3_i
, , N
0.2 CD N
g NN N
three CD N
times NNS N
daily RB N
, , N
and CC N
a DT N
placebo NN 7_i
was VBD N
performed VBN N
in IN N
30 CD N
patients NNS N
with IN N
biopsy-proven JJ N
alcoholic JJ N
liver NN N
cirrhosis NN N
. . N

The DT N
disease NN N
was VBD N
in IN N
a DT N
stable JJ N
phase NN N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
showed VBD N
evidence NN N
of IN N
a DT N
decompensated VBN N
liver NN N
function NN N
. . N

Parameters NNS N
of IN N
liver NN N
function NN N
, , N
taste NN N
acuity NN N
, , N
dark JJ N
adaptation NN N
and CC N
of IN N
zinc NN 3_i
and CC N
vitamin VB 3_i
A DT 3_i
metabolism NN 3_i
were VBD N
followed VBN N
for IN N
six CD N
weeks NNS N
. . N

In IN N
the DT N
zinc-treated JJ N
group NN N
of IN N
16 CD N
patients NNS N
, , N
serum JJ N
zinc NN N
rose VBD N
from IN N
a DT N
normal JJ N
mean JJ N
value NN N
of IN N
13.3 CD N
to TO N
17.4 CD N
mumol/l NNS N
, , N
whereas IN N
the DT N
mean JJ N
serum NN N
vitamin VBZ N
A DT N
level NN N
remained VBD N
practically RB N
unaltered JJ N
within IN N
the DT N
normal JJ N
range NN N
, , N
1.89 CD N
at IN N
the DT N
entry NN N
and CC N
1.83 CD N
mumol/l NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Plasma NNP N
prothrombin NN N
and CC N
serum JJ N
alkaline JJ N
phosphatase NN N
levels NNS N
of IN N
the DT N
zinc NNP N
group NN N
increased VBD N
and CC N
serum JJ N
bilirubin NN N
and CC N
serum JJ N
carotene NN N
decreased VBN N
significantly RB N
. . N

The DT N
dark JJ N
adaptation NN N
did VBD N
not RB N
change NN N
, , N
but CC N
the DT N
taste NN N
function NN N
was VBD N
significantly RB N
improved VBN N
during IN N
zinc NN N
treatment NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
zinc NN 3_i
supplementation NN 3_i
causes VBZ N
alleviation NN N
of IN N
certain JJ N
abnormalities NNS N
of IN N
cirrhotics NNS N
, , N
which WDT N
deserves VBZ N
further JJ N
attention NN N
. . N

-DOCSTART- -X- O O

Early JJ N
reperfusion NN N
and CC N
late JJ N
clinical JJ N
outcomes NNS N
in IN N
patients NNS N
presenting VBG N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
randomly RB N
assigned VBN N
to TO N
primary VB 2_i
percutaneous JJ 2_i
coronary JJ 2_i
intervention NN 2_i
or CC N
streptokinase NN 3_i
. . N

BACKGROUND NNP N
Primary NNP 2_i
percutaneous JJ 2_i
coronary JJ 2_i
intervention NN 2_i
( ( 2_i
PCI NNP 2_i
) ) 2_i
has VBZ N
become VBN N
an DT N
alternative JJ N
to TO N
thrombolytic JJ 3_i
therapy NN 3_i
as IN N
a DT N
reperfusion NN N
strategy NN N
for IN N
ST-elevation NNP N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
. . N

METHODS PDT N
The DT N
main JJ N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
PCI NNP 2_i
and CC N
thrombolytic JJ 3_i
therapy NN 3_i
achieve VBP N
comparable JJ N
reperfusion NN N
rates NNS N
, , N
as IN N
evidenced VBN N
by IN N
ST-segment JJ N
resolution NN N
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
infarct JJ N
vessel NN N
patency NN N
rates NNS N
before IN N
hospital JJ N
discharge NN N
and CC N
short- JJ N
and CC N
long-term JJ N
outcomes NNS N
. . N

Patients NNS N
with IN N
ischemic JJ N
chest NN N
pain NN N
with IN N
duration NN N
< NN N
or CC N
=12 NN N
hours NNS N
and CC N
no DT N
contraindication NN N
for IN N
thrombolytic JJ N
therapy NN N
were VBD N
included VBN N
. . N

RESULTS NNP N
Between NNP N
October NNP N
1993 CD N
and CC N
August NNP N
1995 CD N
, , N
58 CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
streptokinase VB 3_i
( ( 3_i
SK NNP 3_i
) ) 3_i
and CC N
54 CD N
patients NNS N
to TO N
primary JJ 2_i
PCI NNP 2_i
. . N

Baseline NNP N
clinical JJ N
characteristics NNS N
and CC N
infarct JJ N
location NN N
were VBD N
well RB N
balanced VBN N
in IN N
both DT N
groups NNS N
. . N

Median JJ N
age NN N
( ( N
interquartile JJ N
range NN N
) ) N
was VBD N
68 CD N
( ( N
58 CD N
, , N
75 CD N
) ) N
years NNS N
, , N
29 CD N
% NN N
were VBD N
women NNS N
, , N
and CC N
78 CD N
% NN N
of IN N
the DT N
patients NNS N
met VBD N
at IN N
least JJS N
one CD N
criterion NN N
for IN N
not RB N
low JJ N
risk NN N
AMI NNP N
( ( N
anterior JJ N
location NN N
, , N
age NN N
> VBD N
70 CD N
years NNS N
old JJ N
, , N
previous JJ N
MI NNP N
, , N
systolic JJ N
blood NN N
pressure NN N
< VBZ N
100 CD N
mm NN N
Hg NNP N
, , N
and/or JJ N
heart NN N
rate NN N
> VBD N
100 CD N
bpm NN N
) ) N
. . N

The DT N
median JJ N
time NN N
from IN N
symptom JJ N
onset VBN N
to TO N
random VB N
assignment NN N
was VBD N
217 CD N
( ( N
139 CD N
, , N
335 CD N
) ) N
minutes NNS N
in IN N
the DT N
PCI NNP 2_i
group NN N
and CC N
210 CD N
( ( N
145 CD N
, , N
334 CD N
) ) N
minutes NNS N
in IN N
the DT N
SK NNP 3_i
group NN N
. . N

Median JJ N
random JJ N
assignment NN N
to TO N
balloon VB N
time NN N
was VBD N
82 CD N
( ( N
55 CD N
, , N
100 CD N
) ) N
minutes NNS N
, , N
and CC N
median JJ N
random NN N
assignment NN N
to TO N
needle JJ N
time NN N
was VBD N
15 CD N
( ( N
10 CD N
, , N
26 CD N
) ) N
minutes NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

TIMI NNP N
grade VBD N
3 CD N
flow NN N
after IN N
primary JJ N
PCI NNP N
was VBD N
obtained VBN N
in IN N
85 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
with IN N
ST-segment JJ N
resolution NN N
> NN N
or CC N
=50 VB N
% NN N
at IN N
120 CD N
minutes NNS N
was VBD N
80 CD N
% NN N
in IN N
the DT N
PCI NNP N
group NN N
and CC N
50 CD N
% NN N
in IN N
the DT N
SK NNP N
group NN N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
predischarge NN N
angiogram NN N
showed VBD N
the DT N
presence NN N
of IN N
TIMI NNP N
3 CD N
flow NN N
in IN N
96 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
PCI NNP N
and CC N
65 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
SK NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

A DT N
composite JJ N
of IN N
in-hospital JJ N
death NN N
, , N
reinfarction NN N
, , N
severe JJ N
heart NN N
failure NN N
, , N
stroke NN N
, , N
and CC N
major JJ N
bleeding NN N
occurred VBD N
in IN N
15 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
PCI NNP N
and CC N
21 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
SK NNP N
( ( N
P NNP N
=.4 NNP N
) ) N
. . N

At IN N
3 CD N
years NNS N
, , N
freedom NN N
from IN N
the DT N
composite JJ N
end NN N
point NN N
of IN N
AMI NNP N
, , N
postdischarge NN N
revascularization NN N
, , N
and CC N
death NN N
was VBD N
61 CD N
% NN N
in IN N
the DT N
PCI NNP N
group NN N
and CC N
40 CD N
% NN N
in IN N
the DT N
SK NNP N
group NN N
( ( N
P NNP N
=.025 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
shows VBZ N
that IN N
primary JJ N
PCI NNP N
, , N
as IN N
compared VBN N
with IN N
SK NNP N
, , N
is VBZ N
associated VBN N
with IN N
more RBR N
effective JJ N
ST-segment JJ N
resolution NN N
, , N
higher JJR N
patency NN N
rates NNS N
in IN N
the DT N
infarct JJ N
vessel NN N
at IN N
7 CD N
days NNS N
, , N
and CC N
more RBR N
favorable JJ N
clinical JJ N
outcomes NNS N
at IN N
3 CD N
years NNS N
of IN N
follow-up NN N
. . N

-DOCSTART- -X- O O

Placebo-controlled JJ N
pilot NN N
trial NN N
of IN N
mecamylamine NN 3_i
for IN N
treatment NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

OBJECTIVE NNP N
To TO N
explore VB N
possible JJ N
benefits NNS N
of IN N
a DT N
nicotinic JJ 3_i
acetylcholine NN 3_i
receptor NN 3_i
( ( 3_i
nAChR JJ 3_i
) ) 3_i
agent NN 3_i
for IN N
autistic JJ N
symptoms NNS N
based VBN N
on IN N
postmortem NN N
observation NN N
of IN N
nAChR JJ N
abnormalities NNS N
( ( N
deficient JJ N
?4?2 NN N
nAChRs NN N
, , N
excess JJ N
?7 NNP N
nAChRs NN N
) ) N
in IN N
brains NNS N
of IN N
patients NNS N
with IN N
autism NN N
. . N

METHOD NNP N
Mecamylamine NNP N
, , N
because IN N
of IN N
its PRP$ N
safety NN N
record NN N
in IN N
children NNS N
with IN N
other JJ N
disorders NNS N
, , N
was VBD N
chosen VBN N
for IN N
this DT N
first JJ N
exploration NN N
. . N

Twenty NNP N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
age NN N
4-12 CD N
years NNS N
were VBD N
randomly RB N
assigned VBN N
for IN N
14 CD N
weeks NNS N
to TO N
placebo VB N
( ( N
n=8 NN N
) ) N
or CC N
mecamylamine NN N
( ( N
n=12 JJ N
) ) N
in IN N
ascending VBG N
fixed JJ N
doses NNS N
: : N
0.5 CD N
mg/day NN N
for IN N
6 CD N
weeks NNS N
, , N
2.5 CD N
mg NN N
for IN N
2 CD N
weeks NNS N
, , N
then RB N
5 CD N
mg/day NN N
for IN N
6 CD N
weeks NNS N
. . N

Improvement NNP N
was VBD N
rated VBN N
by IN N
a DT N
blinded JJ N
independent JJ N
evaluator NN N
. . N

Because IN N
of IN N
small JJ N
sample NN N
, , N
data NNS N
analysis NN N
was VBD N
descriptive JJ N
. . N

RESULTS NNP N
Eighteen JJ N
participants NNS N
( ( N
10 CD N
mecamylamine NN N
, , N
8 CD N
placebo NN N
) ) N
completed VBD N
the DT N
study NN N
. . N

All DT N
doses NNS N
were VBD N
well RB N
tolerated VBN N
; : N
the DT N
only JJ N
side NN N
effect NN N
of IN N
note NN N
was VBD N
constipation NN N
( ( N
50 CD N
% NN N
compared VBN N
with IN N
25 CD N
% NN N
of IN N
placebo NN N
group NN N
) ) N
. . N

Three CD N
children NNS N
had VBD N
clinically RB N
nonsignificant JJ N
electrocardiographic JJ N
QT NNP N
prolongation NN N
. . N

Both DT N
groups NNS N
showed VBD N
modest JJ N
to TO N
moderate VB N
improvement NN N
, , N
but CC N
differences NNS N
between IN N
groups NNS N
were VBD N
negligible JJ N
. . N

On IN N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
the DT N
Ohio NNP N
Autism NNP N
Clinical NNP N
Impressions NNP N
Scale NNP N
, , N
90 CD N
% NN N
of IN N
the DT N
active JJ N
treatment NN N
group NN N
showed VBD N
improvement NN N
at IN N
some DT N
point NN N
( ( N
but CC N
only RB N
40 CD N
% NN N
sustained VBD N
it PRP N
) ) N
, , N
compared VBN N
with IN N
62 CD N
% NN N
on IN N
placebo NN N
. . N

Of IN N
the DT N
four CD N
in IN N
active JJ N
treatment NN N
that WDT N
sustained VBD N
improvement NN N
, , N
three CD N
had VBD N
a DT N
maximum JJ N
dose NN N
of IN N
0.13-0.15 JJ N
mg/kg/day NN N
, , N
while IN N
those DT N
who WP N
regressed VBD N
had VBD N
doses NNS N
?0.18 JJ N
mg/kg/day NN N
. . N

Graphed VBN N
means NNS N
suggested VBD N
better RBR N
outcome NN N
with IN N
lower JJR N
mg/kg NN N
and CC N
longer JJR N
medication NN N
duration NN N
. . N

Four CD N
parents NNS N
spontaneously RB N
reported VBD N
reduced JJ N
hyperactivity NN N
and CC N
irritability NN N
and CC N
better JJR N
verbalization NN N
and CC N
continued JJ N
mecamylamine NN N
at IN N
their PRP$ N
own JJ N
expense NN N
. . N

CONCLUSION NNP N
Mecamylamine NNP N
appeared VBD N
to TO N
be VB N
safe JJ N
, , N
but CC N
not RB N
very RB N
effective JJ N
in IN N
autism NN N
. . N

The DT N
suggestion NN N
of IN N
better JJR N
results NNS N
at IN N
lower JJR N
doses NNS N
and CC N
longer JJR N
exposure NN N
warrants NNS N
consideration NN N
for IN N
future JJ N
trials NNS N
. . N

The DT N
next JJ N
step NN N
would MD N
be VB N
exploration NN N
of IN N
a DT N
more RBR N
specific JJ N
?4?2 NNP N
nAChR JJ N
agonist NN N
, , N
such JJ N
as IN N
varenicline NN N
. . N

-DOCSTART- -X- O O

Safety NN N
and CC N
immunogenicity NN N
of IN N
an DT N
oral JJ 3_i
, , 3_i
inactivated JJ 3_i
, , 3_i
whole-cell JJ 3_i
vaccine NN 3_i
for IN 3_i
Shigella NNP 3_i
sonnei NN 3_i
: : N
preclinical JJ N
studies NNS N
and CC N
a DT N
Phase NNP N
I PRP N
trial NN N
. . N

Orally RB N
delivered VBN N
, , N
inactivated VBN N
whole-cell NN N
vaccines NNS 3_i
are VBP N
safe JJ N
methods NNS N
of IN N
inducing VBG N
local JJ N
and CC N
systemic JJ N
immunity NN N
. . N

To TO N
increase VB N
surface NN N
proteins NNS N
associated VBN N
with IN N
adherence NN N
and CC N
invasion NN N
, , N
Shigella NNP N
sonnei NN N
were VBD N
grown VBN N
in IN N
BHI NNP N
broth CC N
containing VBG N
deoxycholate NN N
. . N

A DT N
whole-cell JJ 3_i
vaccine NN 3_i
( ( 3_i
SsWC NNP 3_i
) ) 3_i
was VBD N
then RB N
produced VBN N
by IN N
formalin JJ N
inactivation NN N
. . N

In IN N
pre-clinical JJ N
studies NNS N
, , N
the DT N
SsWC NNP 3_i
vaccine NN 3_i
was VBD N
immunogenic JJ N
and CC N
protected VBN N
against IN N
S. NNP N
sonnei-induced JJ N
keratoconjunctivitis NN N
in IN N
the DT N
guinea NN N
pig NN N
model NN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
, , N
Phase NNP N
I PRP N
study VBP N
, , N
10 CD N
evaluable JJ N
subjects NNS N
received VBD N
either DT N
three CD N
doses NNS N
of IN N
SsWC NNP 3_i
on IN N
Days NNP N
0 CD N
, , N
14 CD N
, , N
and CC N
28 CD N
( ( N
N NNP N
= NNP N
3 CD N
) ) N
; : N
five CD N
doses NNS N
of IN N
SsWC NNP 3_i
on IN N
Days NNP N
0 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
28 CD N
( ( N
N NNP N
= NNP N
4 CD N
) ) N
; : N
or CC N
placebo VB 7_i
( ( N
N NNP N
= NNP N
3 CD N
) ) N
. . N

Each DT N
dose NN N
contained VBD N
2.0 CD N
x JJ N
10 CD N
( ( N
10 CD N
) ) N
inactivated VBN N
cells NNS N
. . N

Serum NNP N
and CC N
fecal JJ N
antibodies NNS N
against IN N
SsWC NNP N
, , N
LPS NNP N
, , N
and CC N
IpaC NNP N
were VBD N
measured VBN N
by IN N
ELISA NNP N
. . N

A NNP N
> NN N
or CC N
= VB N
4-fold JJ N
increase NN N
in IN N
titer NN N
was VBD N
considered VBN N
significant JJ N
. . N

Both DT N
SsWC NNP 3_i
dosing NN N
regimens NNS N
were VBD N
well RB N
tolerated VBN N
. . N

No DT N
fever NN N
or CC N
severe JJ N
gastrointestinal JJ N
symptoms NNS N
were VBD N
noted VBN N
by IN N
any DT N
of IN N
the DT N
vaccinated JJ N
subjects NNS N
. . N

Antibody NN N
responses NNS N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
dosing VBG N
groups NNS N
. . N

Serum NNP N
IgG NNP N
or CC N
IgA NNP N
responses NNS N
to TO N
SsWC NNP 3_i
were VBD N
seen VBN N
in IN N
six CD N
of IN N
seven CD N
vaccinees NNS N
( ( N
86 CD N
% NN N
) ) N
, , N
to TO N
LPS NNP N
in IN N
four CD N
of IN N
seven CD N
( ( N
57 CD N
% NN N
) ) N
, , N
and CC N
to TO N
IpaC NNP N
in IN N
five CD N
of IN N
seven CD N
( ( N
61 CD N
% NN N
) ) N
. . N

Fecal JJ N
IgA NNP N
responses NNS N
to TO N
these DT N
three CD N
antigens NNS N
developed VBN N
in IN N
five CD N
of IN N
five CD N
, , N
three CD N
of IN N
five CD N
, , N
and CC N
three CD N
of IN N
five CD N
subjects NNS N
, , N
respectively RB N
. . N

Among IN N
the DT N
seven CD N
vaccinees NNS N
, , N
geometric JJ N
mean NN N
rises NNS N
in IN N
serum JJ N
IgA NNP N
levels NNS N
to TO N
all DT N
three CD N
immunogens NNS N
were VBD N
significant JJ N
; : N
IgG NNP N
increases VBZ N
trended VBD N
toward IN N
significance NN N
( ( N
paired JJ N
one-tailed JJ N
t-test NN N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
SsWC NNP 3_i
was VBD N
immunogenic JJ N
and CC N
protective JJ N
in IN N
animal JJ N
studies NNS N
and CC N
well RB N
tolerated VBN N
and CC N
immunogenic JJ N
in IN N
a DT N
Phase NNP N
I PRP N
trial NN N
. . N

-DOCSTART- -X- O O

Lung NNP N
function NN N
measurement NN N
in IN N
general JJ N
practice NN N
: : N
a DT N
comparison NN N
of IN N
the DT N
Escort NNP 3_i
spirometer NN 3_i
with IN N
the DT N
Micromed NNP 3_i
turbine NN 3_i
spirometer NN 3_i
and CC N
the DT N
mini-Wright JJ 3_i
peak NN 3_i
flow NN 3_i
meter NN 3_i
. . 3_i

It PRP N
is VBZ N
important JJ N
that IN N
new JJ N
types NNS N
of IN N
spirometer NN 3_i
for IN N
widespread JJ N
clinical JJ N
use NN N
are VBP N
pragmatically RB N
evaluated VBN N
in IN N
primary JJ N
care NN N
. . N

This DT N
study NN N
compared VBN N
measurements NNS N
taken VBN N
by IN N
a DT N
new JJ 2_i
portable JJ 2_i
Fleisch NNP 2_i
pneumotachograph NN 3_i
spirometer NN 3_i
( ( N
known VBN N
as IN N
the DT N
Escort NNP N
) ) N
with IN N
those DT N
of IN N
the DT N
commonly NN N
used VBN N
mini-Wright JJ 3_i
peak NN 3_i
flow NN 3_i
meter NN 3_i
and CC N
the DT N
Micromed NNP 3_i
Pocket NNP 3_i
turbine NN 3_i
spirometer NN 3_i
. . 3_i

A NNP N
pragmatic JJ N
study NN N
was VBD N
conducted VBN N
in IN N
two CD N
phases NNS N
during IN N
routine JJ N
surgeries NNS N
at IN N
Aldermoor NNP N
Health NNP N
Centre NNP N
, , N
Southampton NNP N
. . N

Phase NNP N
I PRP N
compared VBN N
the DT N
new JJ 3_i
spirometer NN 3_i
with IN N
the DT N
mini-Wright JJ 2_i
peak NN 2_i
flow NN 2_i
meter NN 2_i
and CC N
Phase NNP N
2 CD N
compared VBN N
the DT N
new JJ 3_i
spirometer NN 3_i
and CC N
the DT N
turbine NN 3_i
spirometer NN 3_i
. . 3_i

One CD N
hundred VBD N
patients NNS N
aged VBN N
5-88 CD N
years NNS N
( ( N
56 CD N
patients NNS N
with IN N
a DT N
history NN N
of IN N
chronic JJ N
respiratory NN N
complaints NNS N
and CC N
44 CD N
patients NNS N
without IN N
) ) N
entered VBD N
Phase NNP N
1 CD N
, , N
and CC N
100 CD N
patients NNS N
aged VBN N
6-82 JJ N
years NNS N
( ( N
62 CD N
patients NNS N
with IN N
a DT N
history NN N
of IN N
chronic JJ N
respiratory NN N
complaints NNS N
and CC N
38 CD N
patients NNS N
without IN N
) ) N
entered VBD N
Phase NNP N
2 CD N
. . N

Each DT N
patient NN N
contributed VBD N
only RB N
once RB N
to TO N
each DT N
phase NN N
, , N
but CC N
some DT N
entered VBD N
both DT N
phases NNS N
on IN N
separate JJ N
occasions NNS N
. . N

Ninety-five JJ N
percent NN N
limits NNS N
of IN N
agreement NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
were VBD N
wide JJ N
for IN N
all DT N
comparisons NNS N
. . N

Graphical JJ N
plots NNS N
revealed VBD N
trends NNS N
towards IN N
higher JJR N
Escort NN N
values NNS N
as IN N
mean NN N
values NNS N
rose VBD N
compared VBN N
with IN N
both DT N
mini-Wright JJ N
and CC N
turbine JJ N
readings NNS N
for IN N
peak JJ N
expiratory JJ N
flow NN N
rate NN N
and CC N
forced VBD N
expiratory JJ N
volume NN N
in IN N
one CD N
second NN N
. . N

Possible JJ N
over-reading NN N
of IN N
peak JJ N
expiratory JJ N
flow NN N
rate NN N
with IN N
the DT N
mini-Wright JJ 2_i
meter NN 2_i
at IN N
low JJ N
mean NN N
values NNS N
was VBD N
also RB N
seen VBN N
. . N

Readings NNS N
taken VBN N
with IN N
these DT N
different JJ N
types NNS N
of IN N
meter NN N
can MD N
not RB N
be VB N
interchanged VBN N
with IN N
confidence NN N
in IN N
clinical JJ N
practice NN N
. . N

The DT N
clinical JJ N
significance NN N
of IN N
the DT N
theoretically RB N
more RBR N
accurate JJ N
measures NNS N
of IN N
lung NN N
function NN N
produced VBN N
with IN N
the DT N
new JJ N
meter NN N
, , N
and CC N
indeed RB N
of IN N
spirometry NN N
itself PRP N
, , N
needs VBZ N
further JJ N
investigation NN N
. . N

-DOCSTART- -X- O O

Older JJR N
patients NNS N
with IN N
chronic JJ N
myeloid NN N
leukemia NN N
( ( N
?65 CD N
years NNS N
) ) N
profit NN N
more RBR N
from IN N
higher JJR N
imatinib NN 3_i
doses NNS N
than IN N
younger JJR N
patients NNS N
: : N
a DT N
subanalysis NN N
of IN N
the DT N
randomized JJ N
CML-Study NNP N
IV NNP N
. . N

The DT N
impact NN N
of IN N
imatinib NN 3_i
dose NN N
on IN N
response NN N
rates NNS N
and CC N
survival NN N
in IN N
older JJR N
patients NNS N
with IN N
chronic JJ N
myeloid NN N
leukemia NN N
in IN N
chronic JJ N
phase NN N
has VBZ N
not RB N
been VBN N
studied VBN N
well RB N
. . N

We PRP N
analyzed VBD N
data NNS N
from IN N
the DT N
German JJ N
CML-Study NNP N
IV NNP N
, , N
a DT N
randomized JJ N
five-arm JJ N
treatment NN N
optimization NN N
study NN N
in IN N
newly RB N
diagnosed VBN N
BCR-ABL-positive JJ N
chronic JJ N
myeloid NN N
leukemia NN N
in IN N
chronic JJ N
phase NN N
. . N

Patients NNS N
randomized VBD N
to TO N
imatinib VB 3_i
400 CD N
mg/day NN N
( ( N
IM400 NNP N
) ) N
or CC N
imatinib $ 3_i
800 CD N
mg/day NN N
( ( N
IM800 NNP N
) ) N
and CC N
stratified VBD N
according VBG N
to TO N
age NN N
( ( N
?65 CD N
years NNS N
vs. FW N
< RB N
65 CD N
years NNS N
) ) N
were VBD N
compared VBN N
regarding VBG N
dose RB N
, , N
response NN N
, , N
adverse JJ N
events NNS N
, , N
rates NNS N
of IN N
progression NN N
, , N
and CC N
survival NN N
. . N

The DT N
full JJ N
800 CD N
mg NN N
dose NN N
was VBD N
given VBN N
after IN N
a DT N
6-week JJ N
run-in JJ N
period NN N
with IN N
imatinib JJ 3_i
400 CD 3_i
mg/day NN N
. . N

The DT N
dose NN N
could MD N
then RB N
be VB N
reduced VBN N
according VBG N
to TO N
tolerability NN N
. . N

A DT N
total NN N
of IN N
828 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
IM400 NNP N
or CC N
IM800 NNP N
. . N

Seven NNP N
hundred VBD N
eighty-four JJ N
patients NNS N
were VBD N
evaluable JJ N
( ( N
IM400 NNP N
, , N
382 CD N
; : N
IM800 NNP N
, , N
402 CD N
) ) N
. . N

One CD N
hundred VBD N
ten JJ N
patients NNS N
( ( N
29 CD N
% NN N
) ) N
on IN N
IM400 NNP N
and CC N
83 CD N
( ( N
21 CD N
% NN N
) ) N
on IN N
IM800 NNP N
were VBD N
?65 JJ N
years NNS N
. . N

The DT N
median JJ N
dose JJ N
per IN N
day NN N
was VBD N
lower JJR N
for IN N
patients NNS N
?65 CD N
years NNS N
on IN N
IM800 NNP N
, , N
with IN N
the DT N
highest JJS N
median JJ N
dose NN N
in IN N
the DT N
first JJ N
year NN N
( ( N
466 CD N
mg/day NN N
for IN N
patients NNS N
?65 CD N
years NNS N
vs. FW N
630 CD N
mg/day NN N
for IN N
patients NNS N
< JJ N
65 CD N
years NNS N
) ) N
. . N

Older JJR N
patients NNS N
on IN N
IM800 NNP N
achieved VBD N
major JJ N
molecular JJ N
remission NN N
and CC N
deep JJ N
molecular JJ N
remission NN N
as IN N
fast NN N
as IN N
younger JJR N
patients NNS N
, , N
in IN N
contrast NN N
to TO N
standard VB N
dose JJ N
imatinib NN N
with IN N
which WDT N
older JJR N
patients NNS N
achieved VBD N
remissions NNS N
much RB N
later RBR N
than IN N
younger JJR N
patients NNS N
. . N

Grades NNP N
3 CD N
and CC N
4 CD N
adverse JJ N
events NNS N
were VBD N
similar JJ N
in IN N
both DT N
age NN N
groups NNS N
. . N

Five-year JJ N
relative JJ N
survival NN N
for IN N
older JJR N
patients NNS N
was VBD N
comparable JJ N
to TO N
that DT N
of IN N
younger JJR N
patients NNS N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
optimal JJ N
dose NN N
for IN N
older JJR N
patients NNS N
is VBZ N
higher JJR N
than IN N
400 CD N
mg/day NN N
. . N

ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00055874 NN N
-DOCSTART- -X- O O

Subcutaneous JJ N
low-molecular-weight JJ 3_i
heparin NN 3_i
compared VBN N
with IN N
continuous JJ N
intravenous JJ N
unfractionated JJ 3_i
heparin NN 3_i
in IN N
the DT N
treatment NN N
of IN N
proximal JJ N
deep JJ N
vein NN N
thrombosis NN N
. . N

BACKGROUND VB N
A DT N
low-molecular-weight JJ 3_i
heparin NN 3_i
, , N
enoxaparin JJ 3_i
sodium NN 3_i
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
in IN N
preventing VBG N
deep JJ N
vein NN N
thrombosis NN N
both DT N
in IN N
general JJ N
surgery NN N
and CC N
in IN N
high-risk JJ N
orthopedic JJ N
surgery NN N
. . N

We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
randomized VBN N
trial NN N
with IN N
enoxaparin NN N
in IN N
the DT N
treatment NN N
of IN N
established VBN N
deep JJ N
vein NN N
thrombosis NN N
. . N

METHODS NNP N
In IN N
a DT N
multicenter NN N
trial NN N
, , N
we PRP N
compared VBN N
fixed-dose RB N
subcutaneous JJ N
enoxaparin NN 3_i
, , N
given VBN N
twice RB N
daily RB N
, , N
with IN N
adjusted-dose JJ N
intravenous JJ N
unfractionated JJ 3_i
heparin NN 3_i
( ( 3_i
UFH NNP 3_i
) ) 3_i
given VBN N
by IN N
continuous JJ N
intravenous JJ N
infusion NN N
for IN N
the DT N
initial JJ N
10 CD N
days NNS N
of IN N
treatment NN N
of IN N
patients NNS N
with IN N
proximal JJ N
vein NN N
thrombosis NN N
. . N

The DT N
primary JJ N
efficacy NN N
outcome NN N
was VBD N
the DT N
change NN N
of IN N
the DT N
size NN N
of IN N
the DT N
thrombus NN N
assessed VBN N
by IN N
repeated JJ N
venograms NNS N
between IN N
day NN N
0 CD N
and CC N
day NN N
10 CD N
. . N

The DT N
primary JJ N
analysis NN N
of IN N
safety NN N
was VBD N
based VBN N
on IN N
the DT N
incidence NN N
of IN N
major JJ N
bleeding VBG N
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
. . N

RESULTS CC N
There EX N
were VBD N
67 CD N
patients NNS N
in IN N
each DT N
group NN N
. . N

Venographic NNP N
assessment NN N
of IN N
clot NN N
size NN N
evolution NN N
between IN N
day NN N
0 CD N
and CC N
day NN N
10 CD N
showed VBD N
a DT N
statistically RB N
significant JJ N
superiority NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
of IN N
enoxaparin NN 3_i
over IN N
the DT N
reference NN N
treatment NN N
with IN N
UFH NNP 3_i
. . N

Moreover RB N
, , N
the DT N
incidence NN N
of IN N
overall JJ N
recurrent JJ N
thromboembolic JJ N
events NNS N
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
in IN N
the DT N
UFH NNP 3_i
group NN N
( ( N
seven CD N
of IN N
67 CD N
) ) N
than IN N
in IN N
the DT N
enoxaparin NN 3_i
group NN N
( ( N
one CD N
of IN N
67 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ N
bleeding VBG N
complications NNS N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS NNP N
Enoxaparin NNP 3_i
is VBZ N
at IN N
least JJS N
as IN N
effective JJ N
and CC N
safe JJ N
as IN N
UFH NNP 3_i
under IN N
the DT N
conditions NNS N
of IN N
this DT N
study NN N
. . N

Moreover RB N
, , N
it PRP N
is VBZ N
more RBR N
comfortable JJ N
for IN N
patients NNS N
and CC N
less JJR N
time-consuming NN N
for IN N
nurses NNS N
and CC N
laboratories NNS N
. . N

Thus RB N
, , N
our PRP$ N
study NN N
confirmed VBD N
, , N
with IN N
the DT N
use NN N
of IN N
enoxaparin NN 3_i
, , N
other JJ N
observations NNS N
that IN N
low-molecular-weight JJ 3_i
heparin NN 3_i
provides VBZ N
a DT N
real JJ N
therapeutic JJ N
advance NN N
in IN N
the DT N
treatment NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
total JJ N
enteral JJ N
nutrition NN N
on IN N
the DT N
short-term JJ N
outcome NN N
of IN N
severely RB N
malnourished VBN N
cirrhotics NNS N
. . N

A DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

Thirty-five JJ N
severely RB N
malnourished VBN N
cirrhotic JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
enteral-tube JJ 3_i
feeding NN 3_i
as IN 3_i
the DT 3_i
sole JJ 3_i
nutritional JJ 3_i
support NN 3_i
( ( N
n JJ N
= NNP N
16 CD N
) ) N
or CC N
an DT N
isocaloric JJ 3_i
, , N
isonitrogenous JJ 3_i
, , N
low-sodium JJ 3_i
standard JJ 3_i
oral JJ 3_i
diet NN 3_i
( ( N
n JJ N
= NNP N
19 CD N
) ) N
. . N

Both DT N
groups NNS N
were VBD N
homogeneous JJ N
regarding VBG N
age NN N
, , N
sex NN N
distribution NN N
, , N
etiology NN N
of IN N
liver JJ N
cirrhosis NN N
, , N
history NN N
of IN N
previous JJ N
complications NNS N
, , N
clinical JJ N
status NN N
, , N
liver RB N
and CC N
renal JJ N
function NN N
, , N
modified VBD N
Child NNP N
's POS N
score NN N
, , N
and CC N
nutritional JJ N
status NN N
at IN N
admission NN N
. . N

The DT N
enteral JJ N
formula NN N
diet NN N
was VBD N
energy NN N
dense NN N
, , N
containing VBG N
40 CD N
mmol NN N
Na/day NNP N
, , N
whole JJ 3_i
protein NN 3_i
plus CC 3_i
branched-chain JJ 3_i
amino NN 3_i
acids NNS 3_i
, , N
medium- JJ 3_i
and CC 3_i
long-chain JJ 3_i
triglycerides NNS 3_i
, , N
and CC N
maltodextrin NN 3_i
. . N

It PRP 2_i
supplied VBD 2_i
2115 CD 2_i
kcal/day NN 2_i
. . N

The DT N
amount NN N
of IN N
vitamins NNS N
and CC N
trace NN N
elements NNS N
was VBD N
at IN N
the DT N
upper JJ N
limit NN N
of IN N
the DT N
recommended JJ N
dietary JJ N
allowances NNS N
. . N

The DT 4_i
orally RB 4_i
fed JJ 4_i
patients NNS 4_i
were VBD 4_i
encouraged VBN 4_i
to TO 4_i
eat VB 4_i
all DT 4_i
meals NNS 4_i
served VBD 4_i
. . N

Total JJ N
enteral JJ N
nutrition NN N
was VBD N
well RB N
tolerated VBN N
without IN N
major JJ N
complications NNS N
. . N

Serum NNP N
albumin NN N
and CC N
Child NNP N
's POS N
score NN N
improved VBD N
in IN N
the DT N
enterally RB N
fed JJ N
patients NNS N
but CC N
not RB N
in IN N
controls NNS N
. . N

Mortality NNP N
rate NN N
while IN N
in IN N
the DT N
hospital NN N
was VBD N
lower JJR N
in IN N
patients NNS N
on IN N
enteral JJ N
feeding NN N
than IN N
in IN N
controls NNS N
( ( N
12 CD N
% NN N
vs JJ N
47 CD N
% NN N
) ) N
. . N

These DT N
results NNS N
show VBP N
that IN N
total JJ N
enteral JJ N
nutrition NN N
is VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
improving VBG N
the DT N
short-term JJ N
clinical JJ N
outcome NN N
in IN N
severely RB N
malnourished JJ N
cirrhotics NNS N
. . N

-DOCSTART- -X- O O

The DT N
preparation NN N
of IN N
patients NNS N
for IN N
cardiac JJ N
surgery NN N
. . N

This DT N
study NN N
examines VBZ N
the DT N
impact NN N
of IN N
a DT N
preadmission NN 4_i
telephone NN 4_i
intervention NN 4_i
on IN N
anxiety NN N
, , N
knowledge NN N
, , N
and CC N
readiness NN N
for IN N
discharge NN N
for IN N
patients NNS N
attending VBG N
a DT N
preadmission NN N
teaching VBG N
program NN N
prior RB N
to TO N
cardiac VB N
surgery NN N
. . N

The DT N
primary JJ N
goal NN N
of IN N
the DT N
telephone NN 4_i
intervention NN 4_i
was VBD N
to TO N
provide VB N
support NN N
by IN N
giving VBG N
additional JJ N
information NN N
about IN N
individual JJ N
concerns NNS N
. . N

The DT N
telephone NN N
intervention NN N
did VBD N
not RB N
have VB N
an DT N
effect NN N
on IN N
anxiety NN N
and CC N
knowledge NN N
. . N

A DT N
significantly RB N
higher JJR N
level NN N
of IN N
anxiety NN N
was VBD N
found VBN N
in IN N
the DT N
experimental JJ N
group NN N
on IN N
admission NN N
, , N
but CC N
this DT N
difference NN N
became VBD N
nonsignificant JJ N
when WRB N
baseline NN N
level NN N
and CC N
length NN N
of IN N
waiting VBG N
time NN N
were VBD N
entered VBN N
as IN N
covariates NNS N
. . N

The DT N
more RBR N
anxious JJ N
group NN N
rated VBD N
their PRP$ N
perceived JJ N
knowledge NN N
level NN N
lower RBR N
, , N
despite IN N
the DT N
fact NN N
that IN N
both DT N
groups NNS N
had VBD N
similar JJ N
scores NNS N
in IN N
actual JJ N
knowledge NN N
. . N

Given VBN N
the DT N
potential JJ N
barrier NN N
that IN N
anxiety NN N
can MD N
pose VB N
for IN N
patient NN N
learning NN N
, , N
nurses NNS N
need VBP N
to TO N
adapt VB N
their PRP$ N
interventions NNS N
to TO N
deal VB N
with IN N
the DT N
patients NNS N
' POS N
feelings NNS N
of IN N
anxiety NN N
that IN N
accompany JJ N
cardiac JJ N
surgery NN N
to TO N
make VB N
the DT N
learning NN N
process NN N
effective JJ N
. . N

-DOCSTART- -X- O O

Theta NNP 2_i
burst JJS 2_i
stimulation NN 2_i
in IN N
the DT N
rehabilitation NN N
of IN N
the DT N
upper JJ N
limb NN N
: : N
a DT N
semirandomized JJ N
, , N
placebo-controlled JJ N
trial NN N
in IN N
chronic JJ N
stroke NN N
patients NNS N
. . N

BACKGROUND NNP N
Noninvasive NNP N
cortical JJ 2_i
stimulation NN 2_i
could MD N
represent VB N
an DT N
add-on JJ N
treatment NN N
to TO N
enhance VB N
motor NN N
recovery NN N
after IN N
stroke NN N
. . N

However RB N
, , N
its PRP$ N
clinical JJ N
value NN N
, , N
including VBG N
anticipated VBN N
size NN N
and CC N
duration NN N
of IN N
the DT N
treatment NN N
effects NNS N
, , N
remains VBZ N
largely RB N
unknown JJ N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
designed VBD N
a DT N
small JJ N
semi-randomized JJ N
clinical JJ N
trial NN N
to TO N
explore VB N
whether IN N
long-lasting JJ N
clinically RB N
important JJ N
gains NNS N
can MD N
be VB N
achieved VBN N
by IN N
adding VBG N
theta JJ 2_i
burst JJ 2_i
stimulation NN 2_i
( ( 2_i
TBS NNP 2_i
) ) 2_i
, , N
a DT N
form NN N
of IN N
repetitive JJ N
transcranial JJ 2_i
magnetic JJ 2_i
stimulation NN 2_i
( ( 2_i
TMS NNP 2_i
) ) 2_i
, , N
to TO N
a DT N
rehabilitation NN N
program NN N
for IN N
the DT N
hand NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
41 CD N
chronic JJ N
stroke NN N
patients NNS N
received VBD N
excitatory JJ N
TBS NNP 2_i
to TO N
the DT N
ipsilesional NN N
hemisphere NN N
or CC N
inhibitory NN 2_i
TBS NNP 2_i
to TO N
the DT N
contralesional NN N
hemisphere NN N
in IN N
2 CD N
centers NNS N
; : N
each DT N
active JJ N
group NN N
was VBD N
compared VBN N
with IN N
a DT N
group NN N
receiving VBG N
sham NN 2_i
TBS NNP 2_i
. . 7_i

TBS NNP 2_i
was VBD N
followed VBN N
by IN N
physical JJ N
therapy NN N
for IN N
10 CD N
working JJ N
days NNS N
. . N

Patients NNS N
and CC N
therapists NNS N
were VBD N
blinded VBN N
to TO N
the DT N
type NN N
of IN N
TBS NNP 2_i
. . N

Primary NNP N
outcome JJ N
measures NNS N
( ( N
9-hole CD N
Peg NNP N
Test NNP N
[ VBD N
9HPT CD N
] NN N
, , N
Jebsen NNP N
Taylor NNP N
Test NNP N
[ NNP N
JTT NNP N
] NNP N
, , N
and CC N
grip NN N
and CC N
pinch-grip JJ N
dynamometry NN N
) ) N
were VBD N
assessed VBN N
4 CD N
, , N
30 CD N
, , N
and CC N
90 CD N
days NNS N
post RB N
treatment NN N
. . N

The DT N
clinically RB N
important JJ N
difference NN N
was VBD N
defined VBN N
as IN N
10 CD N
% NN N
of IN N
the DT N
maximum JJ N
score NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
active JJ N
treatment NN N
and CC N
sham NN N
groups NNS N
in IN N
any DT N
of IN N
the DT N
outcome NN N
measures NNS N
. . N

All DT N
patients NNS N
achieved VBN N
small JJ N
sustainable JJ N
improvements NNS N
-- : N
9HPT CD N
, , N
5 CD N
% NN N
of IN N
maximum NN N
( ( N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= VBD N
3 CD N
% NN N
-7 NNP N
% NN N
) ) N
; : N
JTT NNP N
, , N
5.7 CD N
% NN N
( ( N
CI NNP N
= RB N
3 CD N
% NN N
-8 NNP N
% NN N
) ) N
; : N
and CC N
grip VB N
strength NN N
, , N
6 CD N
% NN N
( ( N
CI NNP N
= RB N
2 CD N
% NN N
-10 NNP N
% NN N
) ) N
-- : N
all DT N
below IN N
the DT N
defined VBN N
clinically RB N
important JJ N
level NN N
. . N

CONCLUSIONS NNP N
Cortical NNP N
stimulation NN N
did VBD N
not RB N
augment VB N
the DT N
gains NNS N
from IN N
a DT N
late JJ N
rehabilitation NN N
program NN N
. . N

The DT N
effect NN N
size NN N
anticipated VBN N
by IN N
the DT N
authors NNS N
was VBD N
overestimated VBN N
. . N

These DT N
results NNS N
can MD N
improve VB N
the DT N
design NN N
of IN N
future JJ N
work NN N
on IN N
therapeutic JJ N
uses NNS N
of IN N
TMS NNP N
. . N

-DOCSTART- -X- O O

Gemcitabine NNP 3_i
and CC N
split-dose JJ N
paclitaxel NN 3_i
or CC N
docetaxel NN 3_i
in IN N
metastatic JJ N
breast NN N
cancer NN N
: : N
a DT N
randomised JJ N
phase NN N
II NNP N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
activity NN N
and CC N
toxicity NN N
of IN N
split-dose JJ 3_i
paclitaxel NN 3_i
or CC N
docetaxel NN 3_i
in IN N
combination NN 3_i
with IN 3_i
gemcitabine NN 3_i
in IN N
patients NNS N
with IN N
metastatic JJ N
breast NN N
cancer NN N
( ( N
MBC NNP N
) ) N
who WP N
had VBD N
previously RB N
received VBN N
anthracyclines NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
total NN N
of IN N
210 CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
arms NNS N
: : N
gemcitabine NN 3_i
1,250 CD 3_i
mg/m NN 3_i
( ( 3_i
2 CD 3_i
) ) 3_i
Days VBZ 3_i
1 CD 3_i
and CC 3_i
8 CD 3_i
and CC 3_i
paclitaxel VB 3_i
175 CD 3_i
mg/m NN 3_i
( ( 3_i
2 CD 3_i
) ) 3_i
as IN 3_i
a DT 3_i
3-h JJ 3_i
infusion NN 3_i
on IN 3_i
Day NNP 3_i
1 CD 3_i
( ( 3_i
GP1 NNP 3_i
) ) 3_i
; : N
gemcitabine $ 3_i
1,000 CD 3_i
mg/m NN 3_i
( ( 3_i
2 CD 3_i
) ) 3_i
Days VBZ 3_i
1 CD 3_i
and CC 3_i
8 CD 3_i
and CC 3_i
paclitaxel VB 3_i
100 CD 3_i
mg/m NN 3_i
( ( 3_i
2 CD 3_i
) ) 3_i
as IN 3_i
a DT 3_i
1-h JJ 3_i
infusion NN 3_i
on IN 3_i
Days NNP 3_i
1 CD 3_i
and CC 3_i
8 CD 3_i
( ( 3_i
GP2 NNP 3_i
) ) 3_i
; : N
gemcitabine $ 3_i
1,000 CD 3_i
mg/m NN 3_i
( ( 3_i
2 CD 3_i
) ) 3_i
Days VBZ 3_i
1 CD 3_i
and CC 3_i
8 CD 3_i
and CC 3_i
docetaxel VB 3_i
40 CD 3_i
mg/m NN 3_i
( ( 3_i
2 CD 3_i
) ) 3_i
as IN 3_i
a DT 3_i
1-h JJ 3_i
infusion NN 3_i
on IN 3_i
Days NNP 3_i
1 CD 3_i
and CC 3_i
8 CD 3_i
( ( 3_i
GD NNP 3_i
) ) N
. . N

Cycles NNS N
were VBD N
repeated VBN N
every DT N
3 CD N
weeks NNS N
. . N

RESULTS NNP N
For IN N
the DT N
204 CD N
patients NNS N
evaluable JJ N
for IN N
response NN N
assessment NN N
, , N
the DT N
response NN N
rates NNS N
were VBD N
48.6 CD N
% NN N
for IN N
GP1 NNP N
, , N
52.2 CD N
% NN N
for IN N
GP2 NNP N
, , N
and CC N
52.3 CD N
% NN N
for IN N
GD NNP N
. . N

Median JJ N
response NN N
duration NN N
, , N
time NN N
to TO N
treatment NN N
failure NN N
, , N
and CC N
time NN N
to TO N
progression NN N
( ( N
TTP NNP N
) ) N
were VBD N
similar JJ N
in IN N
each DT N
arm NN N
. . N

Median JJ N
TTP NNP N
for IN N
GP1 NNP N
, , N
GP2 NNP N
and CC N
GD NNP N
was VBD N
7.5 CD N
, , N
7.0 CD N
and CC N
7.4 CD N
months NNS N
, , N
respectively RB N
. . N

For IN N
the DT N
208 CD N
patients NNS N
evaluable JJ N
for IN N
safety NN N
, , N
the DT N
most RBS N
common JJ N
grade NN N
3/4 CD N
toxicity NN N
for IN N
each DT N
regimen NN N
was VBD N
neutropaenia RB N
, , N
with IN N
64 CD N
% NN N
, , N
57 CD N
% NN N
, , N
and CC N
68 CD N
% NN N
for IN N
GP1 NNP N
, , N
GP2 NNP N
, , N
and CC N
GD NNP N
, , N
respectively RB N
. . N

Grade VB N
4 CD N
neutropaenia NN N
, , N
grade VBD N
3/4 CD N
anaemia NN N
, , N
febrile JJ N
neutropaenia NN N
, , N
and CC N
diarrhoea NNS N
were VBD N
more JJR N
common JJ N
in IN N
the DT N
docetaxel NN N
arm NN N
, , N
as IN N
was VBD N
the DT N
use NN N
of IN N
intravenous JJ N
antibiotics NNS N
and CC N
blood NN N
transfusions NNS N
. . N

CONCLUSION VB N
The DT N
study NN N
confirmed VBD N
the DT N
high JJ N
activity NN N
of IN N
gemcitabine-taxane JJ 3_i
combinations NNS 3_i
in IN N
MBC NNP N
. . N

Split-dose JJ N
paclitaxel NN 3_i
had VBD N
similar JJ N
activity NN N
and CC N
toxicity NN N
to TO N
the DT N
3-weekly JJ N
administration NN N
. . N

The DT N
split-dose JJ N
docetaxel NN 3_i
regimen NNS N
had VBD N
similar JJ N
activity NN N
to TO N
the DT N
paclitaxel NN 3_i
combinations NNS 3_i
though IN N
associated VBN N
with IN N
higher JJR N
toxicity NN N
. . N

-DOCSTART- -X- O O

Determination NN N
of IN N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
DIG NNP N
trial NN N
. . N

The DT N
Digitalis NNP N
Investigation NNP N
Group NNP N
( ( N
DIG NNP N
) ) N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
placebo-controlled JJ 7_i
trial NN N
whose WP$ N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
digoxin NN 3_i
had VBD N
beneficial JJ N
, , N
harmful JJ N
, , N
or CC N
no DT N
effect NN N
on IN N
total JJ N
mortality NN N
in IN N
patients NNS N
with IN N
heart NN N
failure NN N
who WP N
were VBD N
in IN N
sinus NN N
rhythm NN N
and CC N
whose WP$ N
ejection NN N
fraction NN N
was VBD N
< JJ N
/=0.45 NNP N
. . N

The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
large JJ N
simple JJ N
trial NN N
with IN N
a DT N
large JJ N
number NN N
of IN N
centers NNS N
( ( N
302 CD N
) ) N
in IN N
the DT N
United NNP N
States NNPS N
and CC N
Canada NNP N
, , N
many JJ N
of IN N
which WDT N
were VBD N
inexperienced VBN N
in IN N
research NN N
. . N

To TO N
ensure VB N
that IN N
the DT N
results NNS N
of IN N
the DT N
trial NN N
would MD N
be VB N
reported VBN N
accurately RB N
without IN N
possible JJ N
bias NN N
due JJ N
to TO N
missing VBG N
data NNS N
, , N
the DT N
study NN N
leadership NN N
decided VBD N
that IN N
no DT N
outcome NN N
results NNS N
would MD N
be VB N
reported VBN N
until IN N
the DT N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
known VBN N
for IN N
at IN N
least JJS N
97 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
. . N

Planning VBG N
for IN N
closeout NN N
of IN N
the DT N
study NN N
began VBD N
a DT N
year NN N
prior RB N
to TO N
the DT N
common JJ N
end NN N
date NN N
of IN N
December NNP N
31 CD N
, , N
1995 CD N
and CC N
included VBD N
plans NNS N
for IN N
obtaining VBG N
vital JJ N
status NN N
on IN N
December NNP N
31 CD N
, , N
1995 CD N
. . N

Participants NNS N
were VBD N
given VBN 4_i
postcards NNS 4_i
at IN 4_i
their PRP$ 4_i
final JJ 4_i
study NN 4_i
visit NN 4_i
to TO 4_i
be VB 4_i
completed VBN 4_i
and CC 4_i
mailed VBN 4_i
on IN 4_i
or CC 4_i
after IN 4_i
January NNP 4_i
1 CD 4_i
, , 4_i
1996 CD 4_i
. . N

Of IN N
5602 CD N
postcards NNS N
distributed VBN N
, , N
5070 CD N
( ( N
90.5 CD N
% NN N
) ) N
were VBD N
completed VBN N
and CC N
returned VBN N
. . N

A DT N
contract NN N
search NN N
agency NN N
was VBD N
hired VBN N
to TO N
locate VB N
the DT N
remaining VBG N
participants NNS N
. . N

Of IN N
the DT N
total JJ N
7788 CD N
participants NNS N
entered VBD N
into IN N
the DT N
DIG NNP N
trial NN N
, , N
only RB N
97 CD N
participants NNS N
( ( N
1.2 CD N
% NN N
) ) N
could MD N
not RB N
have VB N
their PRP$ N
vital JJ N
status NN N
as IN N
of IN N
December NNP N
31 CD N
, , N
1995 CD N
determined VBD N
. . N

It PRP N
is VBZ N
recommended VBN N
that IN N
investigators NNS N
having VBG N
an DT N
outcome NN N
measure NN N
with IN N
a DT N
common JJ N
end NN N
date NN N
include VBP N
plans NNS N
in IN N
their PRP$ N
protocols NNS N
for IN N
obtaining VBG N
their PRP$ N
measures NNS N
and CC N
activate VBP N
those DT N
plans NNS N
as RB N
early RB N
as IN N
possible JJ N
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

Pain NN N
and CC N
fatigue JJ N
management NN N
: : N
results NNS N
of IN N
a DT N
nursing NN N
randomized VBN N
clinical JJ N
trial NN N
. . N

PURPOSE/OBJECTIVES NNP N
Through IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
to TO N
compare VB N
patients NNS N
undergoing VBG N
an DT N
initial JJ N
course NN N
of IN N
chemotherapy NN 2_i
who WP N
report VBP N
pain NN N
and CC N
fatigue NN N
at IN N
baseline NN N
and CC N
who WP N
are VBP N
receiving VBG N
conventional JJ 4_i
care NN 4_i
alone RB 4_i
with IN N
those DT N
receiving VBG N
conventional JJ 4_i
care NN 4_i
plus CC 4_i
a DT 4_i
nursing NN 4_i
intervention NN 4_i
on IN N
outcomes NNS N
reported VBN N
at IN N
20 CD N
weeks NNS N
. . N

SETTING NN N
Chemotherapy NNP N
clinics NNS N
of IN N
two CD N
comprehensive JJ N
and CC N
two CD N
community NN N
cancer NN N
centers NNS N
. . N

METHODS NNP N
Interviews NNP N
were VBD N
conducted VBN N
at IN N
baseline NN N
and CC N
10 CD N
and CC N
20 CD N
weeks NNS N
. . N

An DT N
18-week JJ N
, , N
10-contact JJ N
nursing NN 5_i
intervention NN 5_i
utilizing VBG 5_i
problem-solving JJ 5_i
approaches NNS 5_i
to TO 5_i
symptom VB 5_i
management NN 5_i
and CC 5_i
improving VBG 5_i
physical JJ 5_i
functioning NN 5_i
and CC 5_i
emotional JJ 5_i
health NN 5_i
was VBD N
implemented VBN N
. . N

SAMPLE VB N
The DT N
sample NN N
consisted VBD N
of IN N
53 CD N
patients NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
60 CD N
in IN N
the DT N
control NN N
arm NN N
who WP N
reported VBD N
pain NN N
and CC N
fatigue NN N
at IN N
baseline NN N
. . N

VARIABLES NNP N
Pain NNP N
and CC N
fatigue NN N
, , N
numbers NNS N
of IN N
other JJ N
symptoms NNS N
, , N
and CC N
physical JJ N
role NN N
impact NN N
and CC N
social-functioning JJ N
subscales NNS N
from IN N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
36 CD N
Short NNP N
Form NNP N
. . N

FINDINGS NNP N
Patients NNPS N
who WP N
received VBD N
the DT N
intervention NN 4_i
reported VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN N
of IN N
symptoms NNS N
experienced VBN N
and CC N
improved VBN N
physical JJ N
and CC N
social JJ N
functioning NN N
. . N

Fewer JJR N
patients NNS N
in IN N
the DT N
experimental JJ N
arm NN N
reported VBD N
both DT N
pain NN N
and CC N
fatigue NN N
at IN N
20 CD N
weeks NNS N
. . N

CONCLUSIONS NNP N
Behavioral NNP 4_i
interventions NNS 4_i
targeted VBD N
to TO N
patients NNS N
with IN N
pain NN N
and CC N
fatigue NN N
can MD N
reduce VB N
symptom JJ N
burden NN N
, , N
improve VB N
the DT N
quality NN N
of IN N
the DT N
daily JJ N
life NN N
of IN N
patients NNS N
, , N
and CC N
demonstrate VB N
the DT N
value-added JJ N
role NN N
of IN N
nursing VBG 4_i
care NN 4_i
for IN N
patients NNS N
undergoing JJ N
chemotherapy NN N
. . N

IMPLICATIONS NNP N
FOR IN N
NURSING NNP N
These DT N
data NNS N
support VBD N
the DT N
value-added JJ N
role NN N
of IN N
nursing NN 4_i
interventions NNS 4_i
for IN N
symptom JJ N
management NN N
and CC N
improved JJ N
quality NN N
of IN N
life NN N
during IN N
the DT N
course NN N
of IN N
cancer NN N
treatment NN N
. . N

-DOCSTART- -X- O O

Recurrent JJ N
epithelial JJ N
ovarian JJ N
carcinoma NN N
: : N
a DT N
randomized JJ N
phase NN N
III NNP N
study NN N
of IN N
pegylated VBN 3_i
liposomal JJ 3_i
doxorubicin NN 3_i
versus NN N
topotecan JJ 3_i
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
pegylated JJ 3_i
liposomal JJ 3_i
doxorubicin NN 3_i
( ( 3_i
PLD NNP 3_i
) ) 3_i
and CC N
topotecan JJ 3_i
in IN N
patients NNS N
with IN N
epithelial JJ N
ovarian JJ N
carcinoma NN N
that WDT N
recurred VBD N
after IN N
or CC N
did VBD N
n't RB N
respond VB N
to TO N
first-line JJ N
, , N
platinum-based JJ 3_i
chemotherapy NN 3_i
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
measurable JJ N
and CC N
assessable JJ N
disease NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
PLD NNP 3_i
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
as IN N
a DT N
1-hour JJ N
infusion NN N
every DT N
4 CD N
weeks NNS N
or CC N
topotecan JJ 3_i
1.5 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
3 CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
stratified VBN N
prospectively RB N
for IN N
platinum NN N
sensitivity NN N
and CC N
for IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
bulky JJ N
disease NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
474 CD N
patients NNS N
were VBD N
treated VBN N
( ( N
239 CD N
PLD NNP 3_i
and CC N
235 CD N
topotecan JJ 3_i
) ) N
. . N

They PRP N
comprised VBD N
the DT N
intent-to-treat JJ N
population NN N
. . N

The DT N
overall JJ N
progression-free JJ N
survival NN N
rates NNS N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
arms NNS N
( ( N
P NNP N
=.095 NNP N
) ) N
. . N

The DT N
overall JJ N
response NN N
rates NNS N
for IN N
PLD NNP 3_i
and CC N
topotecan JJ 3_i
were VBD N
19.7 CD N
% NN N
and CC N
17.0 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
=.390 NNP N
) ) N
. . N

Median JJ N
overall JJ N
survival NN N
times NNS N
were VBD N
60 CD N
weeks NNS N
for IN N
PLD NNP 3_i
and CC N
56.7 CD N
weeks NNS N
for IN N
topotecan JJ 3_i
. . N

Data NNP N
analyzed VBD N
in IN N
platinum-sensitive JJ N
patients NNS N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
benefit NN N
from IN N
PLD NNP 3_i
for IN N
progression-free JJ N
survival NN N
( ( N
P NNP N
=.037 NNP N
) ) N
, , N
with IN N
medians NNS N
of IN N
28.9 CD N
for IN N
PLD NNP 3_i
versus FW N
23.3 CD N
weeks NNS N
for IN N
topotecan JJ 3_i
. . N

For IN N
overall JJ N
survival NN N
, , N
PLD NNP 3_i
was VBD N
significantly RB N
superior JJ N
to TO N
topotecan VB 3_i
( ( N
P NNP N
=.008 NNP N
) ) N
, , N
with IN N
a DT N
median NN N
of IN N
108 CD N
weeks NNS N
versus RB N
71.1 CD N
weeks NNS N
. . N

The DT N
platinum-refractory JJ N
subgroup NN N
demonstrated VBD N
a DT N
nonstatistically RB N
significant JJ N
survival JJ N
trend NN N
in IN N
favor NN N
of IN N
topotecan JJ 3_i
( ( N
P NNP N
=.455 NNP N
) ) N
. . N

Severe JJ N
hematologic JJ N
toxicity NN N
was VBD N
more RBR N
common JJ N
with IN N
topotecan JJ 3_i
and CC N
was VBD N
more RBR N
likely JJ N
to TO N
be VB N
associated VBN N
with IN N
dosage NN N
modification NN N
, , N
or CC N
growth NN N
factor NN N
or CC N
blood NN N
product NN N
utilization NN N
. . N

CONCLUSION VB N
The DT N
comparable JJ N
efficacy NN N
, , N
favorable JJ N
safety NN N
profile NN N
, , N
and CC N
convenient NN N
dosing VBG N
support NN N
the DT N
role NN N
of IN N
PLD NNP 3_i
as IN N
a DT N
valuable JJ N
treatment NN N
option NN N
in IN N
this DT N
patient JJ N
population NN N
. . N

-DOCSTART- -X- O O

Kata NNP 2_i
techniques NNS 2_i
training VBG 2_i
consistently RB N
decreases VBZ N
stereotypy NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

The DT N
effects NNS N
of IN N
14 CD N
weeks NNS N
of IN N
Kata NNP 2_i
techniques NNS 2_i
training VBG 2_i
on IN N
stereotypic JJ N
behaviors NNS N
of IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
were VBD N
investigated VBN N
. . N

The DT N
study NN N
included VBD N
30 CD N
eligible JJ N
( ( N
diagnosed JJ N
ASD NNP N
, , N
school NN N
age NN N
) ) N
children NNS N
with IN N
ages NNS N
ranging VBG N
from IN N
5 CD N
to TO N
16 CD N
years NNS N
whom WP N
they PRP N
assigned VBD N
to TO N
an DT N
exercise NN N
( ( N
n=15 JJ N
) ) N
or CC N
a DT N
no-exercise JJ 7_i
control NN 7_i
group NN 7_i
( ( N
n=15 RB N
) ) N
. . N

Participants NNS N
of IN N
the DT N
exercise NN N
group NN N
received VBD N
Kata NNP 2_i
techniques NNS 2_i
instruction VBP 2_i
four CD N
times NNS N
per IN N
week NN N
for IN N
14 CD N
weeks NNS N
( ( N
56 CD N
sessions NNS N
) ) N
. . N

Stereotypy NNP 2_i
was VBD N
assessed VBN N
at IN N
baseline NN N
( ( N
pre-intervention NN N
) ) N
, , N
week NN N
14 CD N
( ( N
post-intervention NN N
) ) N
, , N
and CC N
at IN N
one CD N
month NN N
follow VB N
up RP N
in IN N
both DT N
groups NNS N
. . N

Results NNS N
showed VBD N
that IN N
Kata NNP N
techniques NNS N
training VBG N
significantly RB N
reduced VBN N
stereotypy NN N
in IN N
the DT N
exercise NN N
group NN N
. . N

Following VBG N
participation NN N
in IN N
Kata NNP N
techniques NNS N
training NN N
, , N
stereotypy NN N
decreased VBN N
from IN N
baseline NN N
levels NNS N
by IN N
a DT N
M NNP N
of IN N
42.54 CD N
% NN N
across IN N
participants NNS N
. . N

Interestingly NNP N
, , N
after IN N
30 CD N
days NNS N
of IN N
no DT N
practice NN N
, , N
stereotypy NN N
in IN N
the DT N
exercise NN N
group NN N
remained VBD N
significantly RB N
decreased VBN N
compared VBN N
to TO N
pre-intervention NN N
time NN N
. . N

The DT N
participants NNS N
of IN N
the DT N
control NN N
group NN N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
in IN N
the DT N
stereotypy NN N
. . N

Teaching VBG N
martial JJ N
arts NNS N
techniques NNS N
to TO N
children NNS N
with IN N
ASD NNP N
for IN N
a DT N
long JJ N
period NN N
of IN N
time NN N
consistently RB N
decreased VBN N
their PRP$ N
stereotypic NN N
behaviors NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Hepatoprotective NNP N
activity NN N
of IN N
remaxol NN 3_i
in IN N
patients NNS N
with IN N
chronic JJ N
hepatic JJ N
disorders NNS N
] VBP N
. . N

This DT N
milticentre NN N
randomized VBD N
clinical JJ N
study NN N
of IN N
the DT N
efficiency NN N
of IN N
remaxol JJ 3_i
infusion NN 3_i
solution NN 3_i
( ( N
hepatoprotective JJ N
medicine NN N
for IN N
chronic JJ N
liver NN N
dysfunction NN N
) ) N
included VBD N
494 CD N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
B NNP N
and CC N
C. NNP N
294 CD N
of IN N
them PRP N
staying VBG N
in IN N
7 CD N
clinics NNS N
were VBD N
given VBN N
remaxol NNS 3_i
and CC N
200 CD N
ones NNS N
received VBD N
placebo NN 7_i
. . N

Randomization NN N
was VBD N
achieved VBN N
by IN N
the DT N
envelope NN N
method NN N
. . N

A DT N
detailed JJ N
description NN N
of IN N
clinical JJ N
and CC N
laboratory JJ N
characteristics NNS N
of IN N
the DT N
diseases NNS N
is VBZ N
presented VBN N
. . N

Effects NNS N
of IN N
remaxol NN 3_i
vs NN N
placebo NN 7_i
on IN N
the DT N
functional JJ N
activity NN N
of IN N
affected VBN N
liver NN N
are VBP N
discussed VBN N
. . N

Results NNS N
of IN N
laboratory NN N
and CC N
clinical JJ N
analysis NN N
indicate VBP N
that IN N
mechanism NN N
of IN N
remaxol JJ 3_i
action NN N
is VBZ N
based VBN N
on IN N
hepatoprotective JJ N
, , N
antioxidative JJ N
, , N
and CC N
anticholestatic JJ N
activities NNS N
of IN N
the DT N
drug NN N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
placebo-controlled JJ 7_i
pilot NN N
study NN N
of IN N
olanzapine NN 3_i
in IN N
childhood/adolescent JJ N
pervasive JJ N
developmental NN N
disorder NN N
. . N

Atypical JJ N
antipsychotics NNS N
have VBP N
been VBN N
shown VBN N
to TO N
improve VB N
disruptive NN N
and CC N
repetitive JJ N
behaviors NNS N
in IN N
pervasive JJ N
developmental NN N
disorders NNS N
( ( N
PDDs NNP N
) ) N
, , N
but CC N
they PRP N
require VBP N
assessment NN N
of IN N
potential JJ N
side NN N
effects NNS N
. . N

This DT N
is VBZ N
the DT N
first JJ N
placebo-controlled JJ 7_i
trial NN N
of IN N
olanzapine NN 3_i
in IN N
the DT N
treatment NN N
of IN N
children NNS N
and CC N
adolescents NNS N
with IN N
PDD NNP N
. . N

Eleven NNP N
patients NNS N
with IN N
a DT N
diagnosis NN N
of IN N
either DT N
autism NN N
, , N
Asperger NNP N
's POS N
syndrome NN N
, , N
or CC N
PDD NNP N
not RB N
otherwise RB N
specified VBN N
( ( N
PDD-NOS NNP N
) ) N
and CC N
aged VBN N
6-14 CD N
years NNS N
were VBD N
randomized VBN N
into IN N
an DT N
8-week JJ N
double-blind NN N
, , N
placebo-controlled JJ 7_i
, , N
parallel JJ N
treatment NN N
study NN N
with IN N
olanzapine NN 3_i
. . 3_i

There EX N
was VBD N
a DT N
significant JJ N
linear JJ N
trend NN N
x NNP N
group NN N
interaction NN N
on IN N
the DT N
Clinical JJ N
Global NNP N
Impressions- NNP N
Improvement NNP N
( ( N
CGI-I NNP N
) ) N
and CC N
50 CD N
% NN N
on IN N
olanzapine JJ N
versus NN N
20 CD N
% NN N
on IN N
placebo NN N
were VBD N
responders NNS N
. . N

Olanzapine NNP N
was VBD N
associated VBN N
with IN N
significant JJ N
weight JJ N
gain NN N
( ( N
7.5 CD N
+/- JJ N
4.8 CD N
lbs NN N
vs. FW N
1.5 CD N
+/- JJ N
1.5 CD N
lbs NN N
on IN N
placebo NN N
) ) N
. . N

Olanzapine NN N
may MD N
be VB N
a DT N
promising JJ N
treatment NN N
for IN N
improving VBG N
global JJ N
functioning NN N
of IN N
PDDs NNP N
, , N
but CC N
the DT N
risk NN N
of IN N
significant JJ N
weight JJ N
gain NN N
remains VBZ N
a DT N
concern NN N
. . N

Additional JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
olanzapine NN N
in IN N
the DT N
treatment NN N
of IN N
children NNS N
with IN N
PDD NNP N
. . N

-DOCSTART- -X- O O

Helicobacter NNP N
pylori NN N
and CC N
gastric JJ N
cancer NN N
: : N
current JJ N
status NN N
of IN N
the DT N
Austrain NNP N
Czech JJ N
German NNP N
gastric NN N
cancer NN N
prevention NN N
trial NN N
( ( N
PRISMA NNP N
Study NNP N
) ) N
. . N

AIM UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
Helicobacter NNP N
pylori VBZ N
eradication NN N
alone RB N
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
gastric JJ N
cancer NN N
in IN N
a DT N
subgroup NN N
of IN N
individuals NNS N
with IN N
an DT N
increased VBN N
risk NN N
for IN N
this DT N
fatal JJ N
disease NN N
. . N

METHODS NNP N
It PRP N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN 7_i
controlled VBD N
multinational JJ N
multicenter NN N
trial NN N
. . N

Men NN N
between IN N
55 CD N
and CC N
65 CD N
years NNS N
of IN N
age NN N
with IN N
a DT N
gastric JJ N
cancer NN N
phenotype NN N
of IN N
Helicobacter NNP N
pylori FW N
gastritis NN N
are VBP N
randomized VBN N
to TO N
receive VB N
a DT N
7 CD N
day NN N
course NN N
of IN N
omeprazole JJ 3_i
2 CD 3_i
X NN 3_i
20mg CD 3_i
, , N
clarithromycin VBD 3_i
2 CD 3_i
X NNP 3_i
500mg CD 3_i
, , N
and CC N
amoxicillin RB 3_i
2 CD 3_i
X NNS 3_i
1g CD 3_i
for IN N
7 CD N
days NNS N
, , N
or CC N
omeprazole JJ 7_i
2 CD 7_i
X NN 7_i
20mg CD 7_i
plus CC N
placebo NN 7_i
. . N

Follow-up JJ N
endoscopy NN N
is VBZ N
scheduled VBN N
3 CD N
months NNS N
after IN N
therapy NN N
, , N
and CC N
thereafter RB N
in IN N
one-year JJ N
intervals NNS N
. . N

Predefined VBN N
study NN N
endpoints NNS N
are VBP N
gastric JJ N
cancer NN N
, , N
precancerous JJ N
lesions NNS N
( ( N
dysplasia NN N
, , N
adenoma NN N
) ) N
, , N
other JJ N
cancers NNS N
, , N
and CC N
death NN N
. . N

RESULTS NNP N
Since IN N
March NNP N
1998 CD N
, , N
1524 CD N
target NN N
patients NNS N
have VBP N
been VBN N
screened VBN N
, , N
279 CD N
patients NNS N
( ( N
18.3 CD N
% NN N
) ) N
had VBD N
a DT N
corpus NN N
dominant JJ N
type NN N
of IN N
H. NNP N
pylori FW N
gastritis NN N
, , N
and CC N
167 CD N
of IN N
those DT N
were VBD N
randomized VBN N
( ( N
58.8 CD N
% NN N
) ) N
. . N

In IN N
the DT N
active JJ N
treatment NN N
group NN N
( ( N
r NN N
= RB N
86 CD N
) ) N
, , N
H. NNP N
pylori VBZ N
infection NN N
infection NN N
was VBD N
cured VBN N
in IN N
88.9 CD N
% NN N
of IN N
patients NNS N
. . N

Currently RB N
, , N
the DT N
cumulative JJ N
follow-up JJ N
time NN N
is VBZ N
3046 CD N
months NNS N
( ( N
253.38 CD N
patient NN N
years NNS N
, , N
median NN N
follow VBP N
up RB N
16 CD N
months NNS N
) ) N
. . N

So RB N
far RB N
, , N
none NN N
of IN N
the DT N
patients NNS N
developed VBD N
gastric JJ N
cancer NN N
or CC N
any DT N
precancerous JJ N
lesion NN N
. . N

Three NNP N
( ( N
1.8 CD N
% NN N
) ) N
patients NNS N
reached VBD N
study NN N
endpoints NNS N
other JJ N
than IN N
gastric JJ N
cancer NN N
. . N

CONCLUSION NNP N
Among IN N
men NNS N
between IN N
55 CD N
and CC N
65 CD N
years NNS N
of IN N
age NN N
, , N
the DT N
gastric JJ N
cancer NN N
phenotype NN N
of IN N
H. NNP N
pylori FW N
gastritis NN N
appears VBZ N
to TO N
be VB N
more JJR N
common JJ N
than IN N
expected VBN N
. . N

Further RBR N
follow VB N
up RB N
and CC N
continuing VBG N
recruitment NN N
are VBP N
necessary JJ N
to TO N
fulfil VB N
the DT N
main JJ N
aim NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

Prognostic JJ N
significance NN N
and CC N
beneficial JJ N
effect NN N
of IN N
diltiazem NN 3_i
on IN N
the DT N
incidence NN N
of IN N
early JJ N
recurrent NN N
ischemia NN N
after IN N
non-Q-wave JJ N
myocardial JJ N
infarction NN N
: : N
results NNS N
from IN N
the DT N
Multicenter NNP N
Diltiazem NNP N
Reinfarction NNP N
Study NNP N
. . N

Of IN N
576 CD N
patients NNS N
with IN N
non-Q-wave JJ N
acute JJ N
myocardial JJ N
infarction NN N
enrolled VBN N
in IN N
the DT N
Diltiazem NNP N
Reinfarction NNP N
Study NNP N
, , N
246 CD N
( ( N
43 CD N
% NN N
) ) N
had VBD N
1 CD N
or CC N
more JJR N
episodes NNS N
of IN N
angina NN N
at IN N
rest NN N
or CC N
with IN N
minimal JJ N
effort NN N
during IN N
10.5 CD N
days NNS N
of IN N
treatment NN N
with IN N
either DT N
diltiazem NN 3_i
( ( N
90 CD N
mg NN N
every DT N
6 CD N
hours NNS N
) ) N
or CC N
placebo NN 7_i
. . N

Reinfarction NNP N
( ( N
12.2 CD N
% NN N
vs JJ N
3.6 CD N
% NN N
, , N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
or CC N
death NN N
( ( N
6.1 CD N
% NN N
vs JJ N
1.5 CD N
% NN N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
was VBD N
more RBR N
likely JJ N
to TO N
occur VB N
within IN N
2 CD N
weeks NNS N
of IN N
randomization NN N
in IN N
patients NNS N
with IN N
postinfarction NN N
angina NNS N
than IN N
in IN N
those DT N
without IN N
angina NNS N
. . N

Based VBN N
on IN N
serial JJ N
electrocardiographic JJ N
data NNS N
, , N
115 CD N
of IN N
the DT N
246 CD N
patients NNS N
with IN N
angina NNS N
had VBD N
transient JJ N
ST-T JJ N
changes NNS N
and CC N
131 CD N
did VBD N
not RB N
. . N

Comparison NNP N
of IN N
the DT N
14-day JJ N
event NN N
rates NNS N
in IN N
these DT N
2 CD N
groups NNS N
showed VBD N
that IN N
the DT N
115 CD N
patients NNS N
with IN N
electrocardiographic JJ N
evidence NN N
of IN N
ischemia NN N
had VBD N
a DT N
higher JJR N
frequency NN N
of IN N
reinfarction NN N
( ( N
20 CD N
% NN N
vs JJ N
5.3 CD N
% NN N
, , N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
more RBR N
extensive JJ N
damage NN N
as IN N
assessed VBN N
by IN N
peak JJ N
MB-creatine JJ N
kinase NN N
levels NNS N
( ( N
91 CD N
+/- JJ N
76 CD N
vs JJ N
37 CD N
+/- JJ N
19 CD N
IU/liter NNP N
, , N
p NN N
= VBD N
0.059 CD N
[ NNP N
Wilcoxon NNP N
rank NN N
sum NN N
] NN N
) ) N
and CC N
a DT N
higher JJR N
mortality NN N
rate NN N
( ( N
11.3 CD N
% NN N
vs JJ N
1.5 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
. . N

Angina NNP N
associated VBD N
with IN N
transient JJ N
ST-T JJ N
changes NNS N
occurred VBD N
in IN N
70 CD N
of IN N
the DT N
289 CD N
patients NNS N
in IN N
the DT N
placebo NN 7_i
group NN N
but CC N
in IN N
only RB N
45 CD N
of IN N
the DT N
287 CD N
patients NNS N
in IN N
the DT N
diltiazem NN N
group NN N
-- : N
a DT N
28 CD N
% NN N
reduction NN N
in IN N
cumulative JJ N
life-table JJ N
incidence NN N
( ( N
p JJ N
= $ N
0.0103 CD N
[ NNP N
2-tail JJ N
, , N
log JJ N
rank NN N
] NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
9.3 CD N
to TO N
53.8 CD N
% NN N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
patients NNS N
with IN N
early JJ N
postinfarction NN N
angina NN N
are VBP N
at IN N
increased JJ N
risk NN N
of IN N
reinfarction NN N
and CC N
death NN N
, , N
and CC N
angina RB N
associated VBN N
with IN N
transient JJ N
electrocardiographic JJ N
changes NNS N
identified VBD N
a DT N
very RB N
high JJ N
risk NN N
subset NN N
. . N

This DT N
subset NN N
appeared VBD N
to TO N
have VB N
a DT N
larger JJR N
area NN N
of IN N
viable JJ N
but CC N
jeopardized JJ N
myocardium NN N
and CC N
benefited VBD N
from IN N
prophylactic JJ N
therapy NN N
with IN N
diltiazem NN 3_i
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
premature JJ N
labor NN N
by IN N
17 CD 3_i
alpha-hydroxyprogesterone JJ 3_i
caproate NN 3_i
. . N

Eighty NNP N
pregnant JJ N
women NNS N
at IN N
high JJ N
risk NN N
of IN N
giving VBG N
birth NN N
prematurely RB N
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

Treatment NN N
with IN N
either DT N
17 CD 3_i
alpha-hydroxyprogesterone NN 3_i
caproate NN 3_i
, , N
250 CD N
mg NN N
by IN N
intramuscular JJ N
injection NN N
once RB N
a DT N
week NN N
, , N
or CC N
a DT N
placebo NN 7_i
was VBD N
given VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
. . N

Imminent JJ N
premature NN N
labor NN N
occurred VBD N
in IN N
29.0 CD N
% NN N
of IN N
the DT N
treated VBN N
group NN N
and CC N
in IN N
59.4 CD N
% NN N
of IN N
the DT N
control NN 7_i
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.025 CD N
) ) N
. . N

The DT N
rate NN N
of IN N
premature NN N
deliveries NNS N
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
treated JJ N
group NN N
( ( N
16.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
37.82 CD N
% NN N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
cases NNS N
of IN N
perinatal JJ N
death NN N
or CC N
fetal JJ N
malformations NNS N
in IN N
either DT N
group NN N
. . N

The DT N
mean JJ N
birth NN N
weight NN N
of IN N
all DT N
infants NNS N
of IN N
the DT N
treated JJ N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
those DT N
of IN N
the DT N
control NN N
group NN N
( ( N
3111.9 CD N
+/- JJ N
905 CD N
gm NN N
versus NN N
2680 CD N
+/- JJ N
813.4 CD N
gm NN N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
results NNS N
support VB N
treatment NN N
with IN N
progesterone NN 3_i
caproate NN 3_i
for IN N
the DT N
prevention NN N
of IN N
premature JJ N
labor NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
dietary JJ 3_i
pyridoxine NN 3_i
on IN N
haemato-immunological JJ N
responses NNS N
of IN N
Labeo NNP N
rohita JJ N
fingerlings NNS N
reared VBD N
at IN N
higher JJR N
water NN N
temperature NN N
. . N

A DT N
sixty-day JJ N
feeding NN N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
dietary JJ 3_i
pyridoxine NN 3_i
( ( 3_i
PN NNP 3_i
) ) 3_i
on IN N
hemato-immunological JJ N
parameters NNS N
in IN N
Labeo NNP N
rohita VBP N
fingerlings NNS N
exposed VBN N
to TO N
an DT N
elevated JJ N
temperature NN N
( ( N
ET NNP N
) ) N
of IN N
33 CD N
?C NNS N
. . N

Two CD N
hundred VBD N
and CC N
seventy JJ N
fingerlings NNS N
( ( N
6.71 CD N
? . N
0.32 CD N
g NN N
) ) N
were VBD N
randomly RB N
distributed VBN N
into IN N
six CD N
treatments NNS N
in IN N
triplicates NNS N
( ( N
15 CD N
fish/tank NN N
) ) N
. . N

Five CD N
iso-nitrogenous JJ N
( ( N
356.3 CD N
? . N
2.7 CD N
g/kg JJ N
crude NN N
protein NN N
) ) N
purified VBD N
diets NNS N
were VBD N
prepared VBN N
with IN N
graded JJ N
levels NNS N
( ( N
0 CD N
, , N
10 CD N
, , N
50 CD N
, , N
100 CD N
and CC N
200 CD N
mg/kg NNS N
diet JJ N
) ) N
of IN N
PN NNP N
. . N

Six NNP N
treatment NN N
groups NNS N
were VBD N
P10T26 NNP N
( ( N
10 CD N
mg NN N
PN NNP N
+ NNP N
ambient JJ N
temperature NN N
( ( N
26 CD N
?C NN N
) ) N
, , N
P0T33 NNP N
( ( N
0 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P10T33 NNP N
( ( N
10 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P50T33 NNP N
( ( N
50 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P100T33 NNP N
( ( N
100 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
and CC N
P200T33 NNP N
( ( N
200 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
. . N

The DT N
responses NNS N
of IN N
L. NNP N
rohita JJ N
fingerlings NNS N
to TO N
dietary JJ N
PN NNP N
were VBD N
assessed VBN N
in IN N
terms NNS N
of IN N
growth NN N
and CC N
by IN N
analysing VBG N
some DT N
hemato-immunological JJ N
parameters NNS N
. . N

When WRB N
PN NNP N
supplementation NN N
increased VBD N
from IN N
10 CD N
to TO N
200 CD N
mg/kg NNS N
diet JJ N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
weight JJ N
gain NN N
percentage NN N
was VBD N
observed VBN N
. . N

Erythrocyte NNP N
( ( N
RBC NNP N
) ) N
count NN N
, , N
leucocyte NN N
( ( N
WBC NNP N
) ) N
count NN N
, , N
haemoglobin NN N
content NN N
and CC N
respiratory JJ N
burst NN N
activity NN N
were VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
100 CD N
mg JJ N
PN/kg NNP N
diet-fed NN N
group NN N
than IN N
their PRP$ N
non-PN-fed JJ N
counterpart NN N
. . N

Also RB N
, , N
serum JJ N
albumin NN N
, , N
globulin NN N
and CC N
lysozyme JJ N
activity NN N
were VBD N
found VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
PN-fed NNP N
groups NNS N
. . N

The DT N
overall JJ N
results NNS N
indicated VBD N
that IN N
dietary JJ N
PN NNP N
supplementation NN N
at IN N
100 CD N
mg/kg NNS N
diet JJ N
may MD N
reverse VB N
the DT N
negative JJ N
effects NNS N
caused VBN N
by IN N
ET NNP N
and CC N
may MD N
protect VB N
the DT N
haemato-immunological JJ N
status NN N
of IN N
L. NNP N
rohita JJ N
fingerlings NNS N
reared VBD N
at IN N
higher JJR N
water NN N
temperature NN N
. . N

-DOCSTART- -X- O O

Oral JJ N
desensitization NN N
in IN N
papular JJ N
urticaria NN N
in IN N
children NNS N
. . N

Papular JJ N
urticaria NN N
( ( N
PU NNP N
) ) N
is VBZ N
among IN N
the DT N
commonest JJS N
skin NN N
ailments NNS N
in IN N
children NNS N
. . N

Induced NNP N
specific JJ N
desensitization NN N
to TO N
insect VB N
bites NNS N
is VBZ N
theoretically RB N
an DT N
effective JJ N
means NNS N
of IN N
prevention NN N
of IN N
PU NNP N
. . N

In IN N
this DT N
double JJ N
blind NN N
placebo NN 7_i
controlled VBD N
study NN N
, , N
an DT N
oral JJ 3_i
vaccine NN 3_i
prepared VBN 3_i
from IN 3_i
insect JJ 3_i
saliva NN 3_i
was VBD N
compared VBN N
with IN N
placebo NN 7_i
( ( 7_i
stable JJ 7_i
vaccine NN 7_i
solvent NN 7_i
) ) 7_i
. . 7_i

Vaccine NNP 3_i
and CC N
placebo NN 7_i
effectiveness NN N
were VBD N
tested VBN N
by IN N
counting VBG N
active JJ N
PU NNP N
lesions NNS N
, , N
serum NN N
eosinophils NNS N
, , N
and CC N
IgE NNP N
, , N
before IN N
and CC N
after IN N
4 CD N
months NNS N
of IN N
treatment NN N
. . N

Statistically NNP N
significant JJ N
differences NNS N
between IN N
oral JJ N
vaccine NN N
and CC N
placebo NN N
were VBD N
not RB N
found VBN N
in IN N
the DT N
clinical JJ N
or CC N
the DT N
immunological JJ N
variables NNS N
tested VBN N
. . N

We PRP N
conclude VBP N
that IN N
, , N
although IN N
a DT N
lack NN N
of IN N
oral JJ N
vaccine NN N
efficacy NN N
was VBD N
suspected VBN N
, , N
larger JJR N
study NN N
samples NNS N
are VBP N
needed VBN N
to TO N
strengthen VB N
our PRP$ N
conclusion NN N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
erythromycin NN 3_i
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
bronchitis NN N
. . N

BACKGROUND NNP N
Clinical NNP N
trials NNS N
have VBP N
not RB N
shown VBN N
a DT N
consistent JJ N
benefit NN N
of IN N
treating VBG N
bronchitis NN N
with IN N
antibiotics NNS N
. . N

Many JJ N
physicians NNS N
, , N
however RB N
, , N
treat VB N
acute JJ N
bronchitis NN N
with IN N
antibiotics NNS N
because IN N
of IN N
the DT N
possibility NN N
of IN N
Mycoplasma NNP N
pneumoniae NN N
or CC N
other JJ N
pathogens NNS N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
erythromycin JJ 3_i
treatment NN N
in IN N
patients NNS N
with IN N
acute JJ N
bronchitis NN N
and CC N
to TO N
determine VB N
whether IN N
a DT N
newly RB N
developed VBN N
rapid JJ N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
is VBZ N
useful JJ N
in IN N
predicting VBG N
which WDT N
patients NNS N
will MD N
respond VB N
to TO N
therapy VB N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
at IN N
three CD N
primary JJ N
care NN N
centers NNS N
in IN N
North NNP N
Carolina NNP N
. . N

A DT N
convenience NN N
sample NN N
of IN N
140 CD N
patients NNS N
presenting VBG N
with IN N
acute JJ N
bronchitis NN N
were VBD N
tested VBN N
for IN N
M NNP N
pneumoniae NN N
, , N
91 CD N
of IN N
whom WP N
were VBD N
treated VBN N
with IN N
either DT N
erythromycin JJ 3_i
250 CD N
mg RB N
four CD N
times NNS N
daily RB N
for IN N
10 CD N
days NNS N
or CC N
an DT N
identical-appearing JJ N
placebo NN N
. . N

RESULTS JJ N
Patients NNS N
treated VBN N
with IN N
erythromycin NN 3_i
missed VBD N
an DT N
average NN N
of IN N
only JJ N
0.81 CD N
+/- JJ N
1.1 CD N
days NNS N
of IN N
work NN N
compared VBN N
with IN N
2.16 CD N
+/- JJ N
3.2 CD N
days NNS N
for IN N
placebo-treated JJ 7_i
patients NNS N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
cough NN N
, , N
use NN N
of IN N
cough JJ N
medicine NN N
, , N
general JJ N
feeling NN N
of IN N
well-being NN N
, , N
or CC N
chest JJS N
congestion NN N
between IN N
the DT N
erythromycin NN 3_i
and CC N
placebo NN 7_i
groups NNS N
. . N

Twenty-five JJ N
percent NN N
of IN N
the DT N
patients NNS N
tested VBD N
positive JJ N
for IN N
M NNP N
pneumoniae NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
response NN N
to TO N
erythromycin VB 3_i
based VBN N
on IN N
whether IN N
the DT N
patient NN N
had VBD N
a DT N
positive JJ N
test NN N
for IN N
M NNP N
pneumoniae NN N
. . N

CONCLUSIONS NNP N
Erythromycin NNP 3_i
is VBZ N
effective JJ N
in IN N
significantly RB N
reducing VBG N
lost VBN N
time NN N
from IN N
work NN N
, , N
but CC N
it PRP N
is VBZ N
not RB N
effective JJ N
in IN N
reducing VBG N
cough NN N
or CC N
other JJ N
symptoms NNS N
in IN N
patients NNS N
with IN N
acute JJ N
bronchitis NN N
, , N
regardless RB N
of IN N
the DT N
outcome NN N
of IN N
the DT N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
. . N

-DOCSTART- -X- O O

Antibiotic JJ N
elimination NN N
of IN N
group-B JJ N
streptococci NN N
in IN N
urine NN N
in IN N
prevention NN N
of IN N
preterm JJ N
labour NN N
. . N

The DT N
presence NN N
of IN N
group-B JJ N
streptococci NN N
in IN N
the DT N
urine NN N
of IN N
pregnant JJ N
women NNS N
seems VBZ N
to TO N
be VB N
associated VBN N
with IN N
preterm JJ N
labour NN N
. . N

Urine JJ N
samples NNS N
from IN N
4122 CD N
women NNS N
at IN N
27-31 JJ N
weeks NNS N
' POS N
gestation NN N
were VBD N
examined VBN N
for IN N
bacteria NNS N
. . N

Group-B JJ N
streptococci NN N
were VBD N
found VBN N
in IN N
the DT N
urine NN N
of IN N
69 CD N
women NNS N
. . N

In IN N
a DT N
double-blind NN N
, , N
controlled VBD N
study NN N
these DT N
patients NNS N
were VBD N
given VBN N
either CC N
penicillin NN 3_i
( ( N
10 CD N
( ( N
6 CD N
) ) N
IU NNP N
three CD N
times NNS N
daily RB N
for IN N
6 CD N
days NNS N
; : N
37 CD N
patients NNS N
) ) N
or CC N
placebo NN 7_i
( ( N
32 CD N
patients NNS N
) ) N
. . N

The DT N
rates NNS N
of IN N
primary JJ N
rupture NN N
of IN N
the DT N
membranes NNS N
( ( N
11 CD N
% NN N
v JJ N
53 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
preterm VB N
labour NN N
( ( N
5.4 CD N
% NN N
v JJ N
38 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.002 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
penicillin NN 3_i
group NN N
than IN N
in IN N
the DT N
placebo NN 7_i
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
treatment NN N
and CC N
follow-up NN N
to TO N
prevent VB N
recolonisation NN N
in IN N
pregnant JJ N
women NNS N
with IN N
group-B JJ N
streptococci NN N
in IN N
the DT N
urine NN N
may MD N
reduce VB N
the DT N
frequency NN N
of IN N
preterm JJ N
labour NN N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Post NNP N
hoc NN N
analysis NN N
of IN N
a DT N
single JJ N
IV NNP N
infusion NN N
of IN N
zoledronic JJ 3_i
acid NNS 3_i
versus VBP N
daily JJ N
oral JJ N
risedronate NN 3_i
on IN N
lumbar NN N
spine NN N
bone NN N
mineral JJ N
density NN N
in IN N
different JJ N
subgroups NNS N
with IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

This DT N
study NN N
summarizes VBZ N
the DT N
treatment NN N
effect NN N
of IN N
zoledronic JJ 3_i
acid JJ 3_i
infusion NN N
on IN N
lumbar NN N
spine NN N
bone NN N
mineral JJ N
density NN N
in IN N
different JJ N
subgroups NNS N
with IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

Zoledronic JJ 3_i
acid NN 3_i
is VBZ N
significantly RB N
more RBR N
effective JJ N
than IN N
risedronate NN 3_i
in IN N
increasing VBG N
lumbar NN N
spine NN N
( ( N
LS NNP N
) ) N
bone NN N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
in IN N
both DT N
prevention NN N
and CC N
treatment NN N
of IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

Introduction NN N
In IN N
patients NNS N
on IN N
glucocorticoids NNS 3_i
, , N
a DT N
single JJ N
zoledronic NN 3_i
acid NN 3_i
infusion NN N
significantly RB N
increased VBD N
BMD NNP N
versus IN N
daily JJ N
oral JJ N
risedronate NN 3_i
. . N

We PRP N
assessed VBD N
treatment NN N
effect NN N
on IN N
LS NNP N
BMD NNP N
in IN N
different JJ N
patient NN N
subgroups NNS N
at IN N
month NN N
12 CD N
that WDT N
contributed VBD N
to TO N
the DT N
risk NN N
of IN N
osteoporosis NN N
in IN N
addition NN N
to TO N
glucocorticoids NNS N
. . N

Methods NNS N
Patients NNPS N
randomized VBN N
to TO N
a DT N
single JJ N
IV NNP N
infusion NN N
of IN N
zoledronic JJ 3_i
acid NN 3_i
5 CD N
mg NN N
or CC N
risedronate NN 3_i
( ( N
5 CD N
mg/day NN N
) ) N
and CC N
stratified VBN N
based VBN N
on IN N
glucocorticoids NNS 3_i
duration NN N
[ FW N
treatment NN N
( ( N
> JJ N
3 CD N
months NNS N
) ) N
and CC N
prevention NN N
( ( N
? . N
3 CD N
months NNS N
) ) N
subpopulations NNS N
] VBP N
were VBD N
subgrouped VBN N
by IN N
age NN N
; : N
gender NN N
; : N
menopausal NN N
status NN N
in IN N
women NNS N
; : N
dose VB N
and CC N
duration NN N
of IN N
prednisone NN N
during IN N
the DT N
trial NN N
; : N
and CC N
baseline VB N
serum JJ N
25-OH JJ N
vitamin NN N
D NNP N
, , N
LS NNP N
BMD NNP N
T-score NNP N
, , N
creatinine JJ N
clearance NN N
, , N
and CC N
concomitant JJ N
medication NN N
use NN N
. . N

Results NNS N
At IN N
month NN N
12 CD N
, , N
zoledronic JJ N
acid NN N
significantly RB N
increased VBD N
LS NNP N
BMD NNP N
versus NN N
risedronate NN N
in IN N
patients NNS N
? . N
74 CD N
years NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
treatment NN N
and CC N
65-74 JJ N
years NNS N
( ( N
P NNP N
= NNP N
0.0008 CD N
) ) N
in IN N
the DT N
prevention NN N
subpopulation NN N
. . N

At IN N
month NN N
12 CD N
, , N
zoledronic JJ N
acid NN N
significantly RB N
increased VBD N
LS NNP N
BMD NNP N
versus NN N
risedronate NN N
in IN N
both DT N
subpopulations NNS N
irrespective VBP N
of IN N
gender NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
cumulative JJ N
prednisone NN N
dose NN N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
postmenopausal NN N
status NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
premenopausal JJ N
women NNS N
, , N
in IN N
both DT N
subpopulations NNS N
, , N
zoledronic JJ 3_i
acid NN 3_i
significantly RB N
increased VBD N
total JJ N
hip NN N
BMD NNP N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
versus NN N
risedronate NN 3_i
at IN N
month NN N
12 CD N
but CC N
not RB N
LS NNP N
BMD NNP N
. . N

Osteoporotic JJ N
patients NNS N
in IN N
the DT N
prevention NN N
( ( N
P=0.0189 NNP N
) ) N
and CC N
osteopenic JJ N
patients NNS N
in IN N
the DT N
treatment NN N
subpopulation NN N
( ( N
P=0.0305 NNP N
) ) N
showed VBD N
significant JJ N
LS NNP N
BMD NNP N
increases VBZ N
with IN N
zoledronic JJ N
acid NNS N
versus NN N
risedronate NN N
at IN N
month NN N
12 CD N
. . N

Conclusions NNS N
This DT N
post NN N
hoc NN N
analysis NN N
suggests VBZ N
that IN N
zoledronic JJ N
acid NN N
is VBZ N
significantly RB N
more RBR N
effective JJ N
than IN N
risedronate NN N
in IN N
increasing VBG N
LS NNP N
BMD NNP N
in IN N
prevention NN N
and CC N
treatment NN N
of IN N
glucocorticoid-induced JJ N
osteoporosis NN N
across IN N
a DT N
wide JJ N
range NN N
of IN N
patients NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
phenylephrine NN 3_i
on IN N
the DT N
haemodynamic JJ N
state NN N
and CC N
cerebral JJ N
oxygen NN N
saturation NN N
during IN N
anaesthesia NN N
in IN N
the DT N
upright JJ N
position NN N
. . N

BACKGROUND IN N
The DT N
upright JJ N
sitting NN N
or CC N
beachchair NN N
position NN N
is VBZ N
associated VBN N
with IN N
hypotension NN N
, , N
risk NN N
of IN N
cerebral JJ N
hypoperfusion NN N
, , N
and CC N
cerebral JJ N
injury NN N
. . N

We PRP N
hypothesized VBD N
that IN N
by IN N
increasing VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine JJ 3_i
administration NN N
, , N
cerebral JJ N
perfusion NN N
, , N
and CC N
postoperative JJ N
recovery NN N
would MD N
be VB N
improved VBN N
. . N

METHODS NNP N
Thirty-four JJ N
patients NNS N
undergoing VBG N
elective JJ N
shoulder NN N
surgery NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
saline NN 3_i
or CC 3_i
phenylephrine NN 3_i
infusion NN 3_i
( ( 3_i
PE NNP 3_i
) ) 3_i
5 CD N
min NN N
before IN N
being VBG N
placed VBN N
in IN N
the DT N
upright JJ N
position NN N
. . N

Simultaneous JJ N
measurements NNS N
of IN N
mean JJ N
arterial JJ N
pressure NN N
, , N
cerebral JJ N
oxygen NN N
saturation NN N
, , N
middle JJ N
cerebral JJ N
artery NN N
velocity NN N
, , N
and CC N
cardiac JJ N
function NN N
using VBG N
transthoracic JJ N
echocardiography NN N
were VBD N
made VBN N
. . N

Postoperative JJ N
neurocognitive JJ N
function NN N
was VBD N
assessed VBN N
. . N

RESULTS NNP N
At IN N
the DT N
commencement NN N
of IN N
PE NNP N
, , N
mean NN N
( ( N
SD NNP N
) ) N
cerebral JJ N
oxygen NN N
saturation NN N
significantly RB N
decreased VBN N
from IN N
77 CD N
( ( N
10 CD N
) ) N
to TO N
67 CD N
( ( N
13 CD N
) ) N
% NN N
( ( N
P=0.02 NNP N
) ) N
, , N
and CC N
further RB N
to TO N
59 CD N
( ( N
11 CD N
) ) N
% NN N
on IN N
upright JJ N
positioning NN N
. . N

The DT N
level NN N
of IN N
cerebral JJ N
saturation NN N
upright NN N
was VBD N
not RB N
significantly RB N
different JJ N
to TO N
patients NNS N
receiving VBG N
saline NN N
( ( N
P=0.07 NNP N
) ) N
, , N
with IN N
values NNS N
remaining VBG N
at IN N
room-air JJ N
levels NNS N
. . N

Middle NNP N
cerebral JJ N
artery RB N
blood NN N
velocity NN N
increased VBN N
by IN N
20 CD N
% NN N
( ( N
P=0.04 NNP N
) ) N
. . N

Phenylephrine NNP N
prevented VBD N
hypotension NN N
in IN N
the DT N
upright JJ N
position NN N
primarily RB N
by IN N
maintaining VBG N
preload NN N
and CC N
increasing VBG N
systemic JJ N
vascular NN N
resistance NN N
( ( N
P=0.01 NNP N
) ) N
, , N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
cardiac JJ N
output NN N
. . N

No DT N
postoperative JJ N
neurocognitive JJ N
dysfunction NN N
was VBD N
identified VBN N
. . N

CONCLUSIONS NNP N
Despite IN N
maintaining VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine NN 3_i
, , N
cerebral JJ N
desaturation NN N
occurred VBD N
with IN N
upright JJ N
positioning VBG N
. . N

Cerebral NNP N
oxygen IN N
saturation NN N
can MD N
provide VB N
a DT N
valuable JJ N
endpoint NN N
when WRB N
evaluating VBG N
the DT N
effect NN N
of IN N
vasopressor NN N
therapy NN N
on IN N
cerebral JJ N
perfusion NN N
. . N

-DOCSTART- -X- O O

Resistance NNP 2_i
training NN 2_i
increases NNS N
basal VBP N
limb JJ N
blood NN N
flow NN N
and CC N
vascular JJ N
conductance NN N
in IN N
aging VBG N
humans NNS N
. . N

Age-related JJ N
reductions NNS N
in IN N
basal NN N
limb NN N
blood NN N
flow NN N
and CC N
vascular JJ N
conductance NN N
are VBP N
associated VBN N
with IN N
the DT N
metabolic JJ N
syndrome NN N
, , N
functional JJ N
impairments NNS N
, , N
and CC N
osteoporosis NN N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that IN N
a DT N
strength NN 2_i
training NN 2_i
program NN 2_i
would MD N
increase VB N
basal JJ N
femoral JJ N
blood NN N
flow NN N
in IN N
aging VBG N
adults NNS N
. . N

Twenty-six JJ N
sedentary JJ N
but CC N
healthy JJ N
middle-aged JJ N
and CC N
older JJR N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
a DT N
whole JJ 2_i
body NN 2_i
strength NN 2_i
training VBG 2_i
intervention NN N
group NN N
( ( N
52 CD N
+/- JJ N
2 CD N
yr NN N
, , N
3 CD N
men NNS N
, , N
10 CD N
women NNS N
) ) N
who WP N
underwent VBD N
three CD N
supervised VBN N
resistance NN 2_i
training NN 2_i
sessions NNS N
per IN N
week NN N
for IN N
13 CD N
wk NN N
or CC N
a DT N
control NN N
group NN N
( ( N
53 CD N
+/- JJ N
2 CD N
yr NN N
, , N
4 CD N
men NNS N
, , N
9 CD N
women NNS N
) ) N
who WP N
participated VBD N
in IN N
a DT N
supervised JJ N
stretching NN N
program NN N
. . N

At IN N
baseline NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
blood NN N
pressure NN N
, , N
cardiac JJ N
output NN N
, , N
basal JJ N
femoral JJ N
blood NN N
flow NN N
( ( N
via IN N
Doppler NNP N
ultrasound NN N
) ) N
, , N
vascular JJ N
conductance NN N
, , N
and CC N
vascular JJ N
resistance NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
strength NN 2_i
training VBG 2_i
group NN 2_i
increased VBD N
maximal JJ N
strength NN N
in IN N
all PDT N
the DT N
major JJ N
muscle NN N
groups NNS N
tested VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Whole JJ N
body NN N
lean JJ N
body NN N
mass NN N
increased VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
strength NN N
training NN N
, , N
but CC N
leg VBZ N
fat-free JJ N
mass NN N
did VBD N
not RB N
. . N

Basal NNP N
femoral JJ N
blood NN N
flow NN N
and CC N
vascular JJ N
conductance NN N
increased VBN N
by IN N
55-60 CD N
% NN N
after IN N
strength NN 2_i
training NN 2_i
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
such JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
both DT N
groups NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
brachial JJ N
blood NN N
pressure NN N
, , N
plasma JJ N
endothelin-1 NN N
and CC N
angiotensin NN N
II NNP N
concentrations NNS N
, , N
femoral JJ N
artery NN N
wall NN N
thickness NN N
, , N
cardiac JJ N
output NN N
, , N
and CC N
systemic JJ N
vascular JJ N
resistance NN N
. . N

Our PRP$ N
results NNS N
indicate VBP N
that IN N
short-term JJ 2_i
strength NN 2_i
training NN 2_i
increases NNS N
basal VBP N
femoral JJ N
blood NN N
flow NN N
and CC N
vascular JJ N
conductance NN N
in IN N
healthy JJ N
middle-aged JJ N
and CC N
older JJR N
adults NNS N
. . N

-DOCSTART- -X- O O

Eltrombopag NNP 3_i
for IN N
management NN N
of IN N
chronic JJ N
immune NN N
thrombocytopenia NN N
( ( N
RAISE NNP N
) ) N
: : N
a DT N
6-month JJ N
, , N
randomised VBN N
, , N
phase VB N
3 CD N
study NN N
. . N

BACKGROUND NNP N
Eltrombopag NNP 3_i
is VBZ N
an DT N
oral JJ 3_i
thrombopoietin NN 3_i
receptor NN 3_i
agonist NN 3_i
for IN N
the DT N
treatment NN N
of IN N
thrombocytopenia NN N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
response NN N
to TO N
once RB N
daily JJ N
eltrombopag NNS 3_i
versus VBP N
placebo NN 7_i
in IN N
patients NNS N
with IN N
chronic JJ N
immune JJ N
thrombocytopenia NN N
during IN N
a DT N
6-month JJ N
period NN N
. . N

METHODS NNP N
We PRP N
undertook VBD N
a DT N
phase NN N
3 CD N
, , N
double-blind NN N
, , N
placebo-controlled JJ 7_i
study NN N
in IN N
adults NNS N
with IN N
previously RB N
treated VBN N
immune JJ N
thrombocytopenia NN N
of IN N
more JJR N
than IN N
6 CD N
months NNS N
' POS N
duration NN N
who WP N
had VBD N
baseline NN N
platelet NN N
counts VBZ N
lower JJR N
than IN N
30,000 CD N
per IN N
?L NN N
. . N

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
( ( N
in IN N
a DT N
2:1 CD N
ratio NN N
) ) N
treatment NN N
with IN N
local JJ N
standard NN N
of IN N
care NN N
plus CC N
50 CD N
mg NN N
eltrombopag NN N
or CC N
matching VBG N
placebo JJ N
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
. . N

Randomisation NN N
was VBD N
done VBN N
centrally RB N
with IN N
a DT N
computer-generated JJ N
randomisation NN N
schedule NN N
and CC N
was VBD N
stratified VBN N
by IN N
baseline JJ N
platelet NN N
count NN N
( ( N
? . N
15,000 CD N
per IN N
?L NN N
) ) N
, , N
use NN N
of IN N
treatment NN N
for IN N
immune JJ N
thrombocytopenia NN N
, , N
and CC N
splenectomy JJ N
status NN N
. . N

Patients NNS N
, , N
investigators NNS N
, , N
and CC N
those DT N
assessing VBG N
data NNS N
were VBD N
masked VBN N
to TO N
allocation NN N
. . N

Dose JJ N
modifications NNS N
were VBD N
made VBN N
on IN N
the DT N
basis NN N
of IN N
platelet NN N
response NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
for IN N
response NN N
to TO N
treatment NN N
( ( N
defined VBN N
as IN N
a DT N
platelet NN N
count NN N
of IN N
50,000-400,000 CD N
per IN N
?L NN N
) ) N
weekly NN N
during IN N
the DT N
first JJ N
6 CD N
weeks NNS N
and CC N
at IN N
least JJS N
once RB N
every DT N
4 CD N
weeks NNS N
thereafter RB N
; : N
the DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
odds NNS N
of IN N
response NN N
to TO N
eltrombopag VB N
versus NN N
placebo NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00370331 NNP N
. . N

FINDINGS NNP N
Between NNP N
Nov NNP N
22 CD N
, , N
2006 CD N
, , N
and CC N
July NNP N
31 CD N
, , N
2007 CD N
, , N
197 CD N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
groups NNS N
and CC N
were VBD N
included VBN N
in IN N
the DT N
intention-to-treat JJ N
analysis NN N
( ( N
135 CD N
eltrombopag NN N
, , N
62 CD N
placebo NN N
) ) N
. . N

106 CD N
( ( N
79 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
eltrombopag NN N
group NN N
responded VBD N
to TO N
treatment NN N
at IN N
least JJS N
once RB N
during IN N
the DT N
study NN N
, , N
compared VBN N
with IN N
17 CD N
( ( N
28 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
odds NNS N
of IN N
responding VBG N
were VBD N
greater JJR N
in IN N
patients NNS N
in IN N
the DT N
eltrombopag NN N
group NN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
throughout IN N
the DT N
6-month JJ N
treatment NN N
period NN N
( ( N
odds NNS N
ratio VBP N
8?2 CD N
, , N
99 CD N
% NN N
CI NNP N
3?59-18?73 CD N
; : N
p CC N
< VB N
0?0001 CD N
) ) N
. . N

37 CD N
( ( N
59 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
eltrombopag NN N
reduced VBD N
concomitant JJ N
treatment NN N
versus NN N
ten NN N
( ( N
32 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
placebo NN N
( ( N
p=0?016 NN N
) ) N
. . N

24 CD N
( ( N
18 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
eltrombopag NN N
needed VBN N
rescue NN N
treatment NN N
compared VBN N
with IN N
25 CD N
( ( N
40 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
placebo NN N
( ( N
p=0?001 NN N
) ) N
. . N

Three NNP N
( ( N
2 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
eltrombopag NN N
had VBD N
thromboembolic JJ N
events NNS N
compared VBN N
with IN N
none NN N
in IN N
patients NNS N
on IN N
placebo NN N
. . N

Nine NNP N
( ( N
7 CD N
% NN N
) ) N
eltrombopag-treated JJ N
patients NNS N
and CC N
two CD N
( ( N
3 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
had VBD N
mild VBN N
increases NNS N
in IN N
alanine JJ N
aminotransferase NN N
concentration NN N
, , N
and CC N
five CD N
( ( N
4 CD N
% NN N
) ) N
eltrombopag-treated JJ N
patients NNS N
( ( N
vs IN N
none NN N
allocated VBN N
to TO N
placebo VB N
) ) N
had VBD N
increases NNS N
in IN N
total JJ N
bilirubin NN N
. . N

Four CD N
( ( N
7 CD N
% NN N
) ) N
patients NNS N
taking VBG N
placebo NN N
had VBD N
serious JJ N
bleeding VBG N
events NNS N
, , N
compared VBN N
with IN N
one CD N
( ( N
< VB N
1 CD N
% NN N
) ) N
patient NN N
treated VBN N
with IN N
eltrombopag NN N
. . N

INTERPRETATION NNP N
Eltrombopag NNP N
is VBZ N
effective JJ N
for IN N
management NN N
of IN N
chronic JJ N
immune NN N
thrombocytopenia NN N
, , N
and CC N
could MD N
be VB N
particularly RB N
beneficial JJ N
for IN N
patients NNS N
who WP N
have VBP N
not RB N
responded VBN N
to TO N
splenectomy VB N
or CC N
previous JJ N
treatment NN N
. . N

These DT N
benefits NNS N
should MD N
be VB N
balanced VBN N
with IN N
the DT N
potential JJ N
risks NNS N
associated VBN N
with IN N
eltrombopag JJ N
treatment NN N
. . N

FUNDING NN N
GlaxoSmithKline NNP N
. . N

-DOCSTART- -X- O O

Does VBZ N
3-day JJ N
course NN N
of IN N
oral JJ 3_i
amoxycillin NN 3_i
benefit NN N
children NNS N
of IN N
non-severe JJ N
pneumonia NN N
with IN N
wheeze NN N
: : N
a DT N
multicentric NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
WHO-defined JJ N
pneumonias NN N
, , N
treated VBN N
with IN N
antibiotics NNS N
, , N
are VBP N
responsible JJ N
for IN N
a DT N
significant JJ N
proportion NN N
of IN N
childhood NN N
morbidity NN N
and CC N
mortality NN N
in IN N
the DT N
developing NN N
countries NNS N
. . N

Since IN N
substantial JJ N
proportion NN N
pneumonias NNS N
have VBP N
a DT N
viral JJ N
etiology NN N
, , N
where WRB N
children NNS N
are VBP N
more RBR N
likely JJ N
to TO N
present VB N
with IN N
wheeze NN N
, , N
there EX N
is VBZ N
a DT N
concern NN N
that WDT N
currently RB N
antibiotics NNS N
are VBP N
being VBG N
over-prescribed JJ N
for IN N
it PRP N
. . N

Hence VB N
the DT N
current JJ N
trial NN N
was VBD N
conducted VBN N
with IN N
the DT N
objective NN N
to TO N
show VB N
the DT N
therapeutic JJ N
equivalence NN N
of IN N
two CD N
treatments NNS N
( ( N
placebo NN 7_i
and CC N
amoxycillin NN 3_i
) ) N
for IN N
children NNS N
presenting VBG N
with IN N
non-severe JJ N
pneumonia NN N
with IN N
wheeze NN N
, , N
who WP N
have VBP N
persistent VBN N
fast RB N
breathing NN N
after IN N
nebulisation NN N
with IN N
salbutamol NN N
, , N
and CC N
have VBP N
normal JJ N
chest NN N
radiograph NN N
. . N

METHODOLOGY NNP N
This DT N
multi-centric JJ N
, , N
randomised VBD N
placebo NN N
controlled VBN N
double JJ N
blind NN N
clinical JJ N
trial NN N
intended VBN N
to TO N
investigate VB N
equivalent JJ N
efficacy NN N
of IN N
placebo NN 7_i
and CC N
amoxicillin NN 3_i
and CC N
was VBD N
conducted VBN N
in IN N
ambulatory NN N
care NN N
settings NNS N
in IN N
eight CD N
government NN N
hospitals NNS N
in IN N
India NNP N
. . N

Participants NNS N
were VBD N
children NNS N
aged VBN N
2-59 JJ N
months NNS N
of IN N
age NN N
, , N
who WP N
received VBD N
either DT N
oral JJ N
amoxycillin NN 3_i
( ( N
31-54 JJ N
mg/Kg/day NN N
, , N
in IN N
three CD N
divided JJ N
doses NNS N
for IN N
three CD N
days NNS N
) ) N
or CC N
placebo NN N
, , N
and CC N
standard JJ 3_i
bronchodilator NN 3_i
therapy NN 3_i
. . N

Primary JJ N
outcome NN N
was VBD N
clinical JJ N
failure NN N
on IN N
or CC N
before IN N
day- JJ N
4 CD N
. . N

PRINCIPAL JJ N
FINDINGS NNP N
We PRP N
randomized VBD N
836 CD N
cases NNS N
in IN N
placebo NN N
and CC N
835 CD N
in IN N
amoxycillin NN N
group NN N
. . N

Clinical JJ N
failures NNS N
occurred VBD N
in IN N
201 CD N
( ( N
24.0 CD N
% NN N
) ) N
on IN N
placebo NN N
and CC N
166 CD N
( ( N
19.9 CD N
% NN N
) ) N
on IN N
amoxycillin NN 3_i
( ( N
risk NN N
difference NN N
4.2 CD N
% NN N
in IN N
favour NN N
of IN N
antibiotic JJ N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.2 CD N
to TO N
8.1 CD N
) ) N
. . N

Adherence NN N
for IN N
both DT N
placebo NN N
and CC N
amoxycillin NN 3_i
was VBD N
> JJ N
96 CD N
% NN N
and CC N
98.9 CD N
% NN N
subjects NNS N
were VBD N
followed VBN N
up RP N
on IN N
day- JJ N
4 CD N
. . N

Clinical JJ N
failure NN N
was VBD N
associated VBN N
with IN N
( ( N
i NN N
) ) N
placebo NN N
treatment NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.28 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01 CD N
to1.62 NN N
) ) N
, , N
( ( N
ii NN N
) ) N
excess JJ N
respiratory JJ N
rate NN N
of IN N
> $ N
10 CD N
breaths NNS N
per IN N
minute NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.51 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.19 CD N
, , N
1.92 CD N
) ) N
, , N
( ( N
iii NN N
) ) N
vomiting VBG N
at IN N
enrolment NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.49 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.13 CD N
, , N
1.96 CD N
) ) N
, , N
( ( N
iv NN N
) ) N
history NN N
of IN N
use NN N
of IN N
broncho-dilators NNS N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.71 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.30 CD N
, , N
2.24 CD N
) ) N
and CC N
( ( N
v NN N
) ) N
non-adherence NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
8.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
4.36 CD N
, , N
14.92 CD N
) ) N
. . N

CONCLUSIONS NNP N
Treating NNP N
children NNS N
with IN N
non-severe JJ N
pneumonia NN N
and CC N
wheeze NN N
with IN N
a DT N
placebo NN N
is VBZ N
not RB N
equivalent JJ N
to TO N
treatment NN N
with IN N
oral JJ N
amoxycillin NN 3_i
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00407394 NNP N
. . N

-DOCSTART- -X- O O

The DT N
gluten-free JJ 2_i
, , 2_i
casein-free JJ 2_i
diet NN 2_i
in IN N
autism NN N
: : N
results NNS N
of IN N
a DT N
preliminary JJ N
double NN N
blind VB N
clinical JJ N
trial NN N
. . N

This DT N
study NN N
tested VBD N
the DT N
efficacy NN N
of IN N
a DT N
gluten-free JJ 6_i
and CC 6_i
casein-free JJ 6_i
( ( 6_i
GFCF NNP 6_i
) ) 6_i
diet NN 6_i
in IN N
treating VBG N
autism NN N
using VBG N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
repeated VBD N
measures NNS N
crossover RB N
design NN N
. . N

The DT N
sample NN N
included VBD N
15 CD N
children NNS N
aged VBN N
2-16 CD N
years NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

Data NNP N
on IN N
autistic JJ N
symptoms NNS N
and CC N
urinary JJ N
peptide NN N
levels NNS N
were VBD N
collected VBN N
in IN N
the DT N
subjects NNS N
' POS N
homes NNS N
over IN N
the DT N
12 CD N
weeks NNS N
that IN N
they PRP N
were VBD N
on IN N
the DT N
diet JJ N
. . N

Group NNP N
data VBD N
indicated VBD N
no DT N
statistically RB N
significant JJ N
findings NNS N
even RB N
though IN N
several JJ N
parents NNS N
reported VBD N
improvement NN N
in IN N
their PRP$ N
children NNS N
. . N

Although IN N
preliminary JJ N
, , N
this DT N
study NN N
demonstrates VBZ N
how WRB N
a DT N
controlled JJ N
clinical JJ N
trial NN N
of IN N
the DT N
GFCF NNP 2_i
diet NN 2_i
can MD N
be VB N
conducted VBN N
, , N
and CC N
suggests VBZ N
directions NNS N
for IN N
future JJ N
research NN N
. . N

-DOCSTART- -X- O O

Assessment NN N
of IN N
response NN N
to TO N
induction NN N
therapy NN N
and CC N
its PRP$ N
influence NN N
on IN N
5-year JJ N
failure-free JJ N
survival NN N
in IN N
group NN N
III NNP N
rhabdomyosarcoma NN N
: : N
the DT N
Intergroup NNP N
Rhabdomyosarcoma NNP N
Study-IV NNP N
experience NN N
-- : N
a DT N
report NN N
from IN N
the DT N
Soft NNP N
Tissue NNP N
Sarcoma NNP N
Committee NNP N
of IN N
the DT N
Children NNP N
's POS N
Oncology NNP N
Group NNP N
. . N

PURPOSE NNP N
Initial NNP N
response NN N
to TO N
induction NN 3_i
chemotherapy NN 3_i
predicts VBZ N
failure-free JJ N
survival NN N
( ( N
FFS NNP N
) ) N
in IN N
osteosarcoma NN N
and CC N
Ewing NNP N
's POS N
sarcoma NN N
. . N

For IN N
Intergroup NNP N
Rhabdomyosarcoma NNP N
Study NNP N
( ( N
IRS NNP N
) ) N
IV VBZ N
patients NNS N
with IN N
group NN N
III NNP N
rhabdomyosarcoma NN N
, , N
we PRP N
assessed VBD N
whether IN N
reported VBN N
response NN N
assessed VBN N
by IN N
anatomic JJ N
imaging NN N
at IN N
week NN N
8 CD N
predicted VBD N
FFS NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP N
studied VBD N
444 CD N
group NN N
III NNP N
patients NNS N
who WP N
received VBD N
induction NN 3_i
therapy NN 3_i
, , N
had VBD N
response NN N
assessed VBN N
at IN N
week NN N
8 CD N
by IN N
anatomic JJ 2_i
imaging NN 2_i
, , N
and CC N
continued VBD 2_i
with IN 2_i
protocol NN 2_i
therapy NN 2_i
. . N

Induction NNP 3_i
chemotherapy NN 3_i
was VBD N
generally RB N
followed VBN N
by IN N
radiation NN 2_i
therapy NN 2_i
( ( 2_i
RT NNP 2_i
) ) 2_i
starting VBG N
after IN N
week NN N
9 CD N
. . N

Response NN N
to TO N
induction NN N
therapy NN N
was VBD N
determined VBN N
at IN N
weeks NNS N
0 CD N
and CC N
8 CD N
. . N

Local JJ N
institutions NNS N
coded VBD N
response NN N
. . N

RESULTS JJ N
Response JJ N
rate NN N
for IN N
the DT N
entire JJ N
cohort NN N
at IN N
week NN N
8 CD N
was VBD N
77 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
73 CD N
% NN N
to TO N
81 CD N
% NN N
; : N
complete JJ N
response NN N
[ NNP N
CR NNP N
] NNP N
, , N
21 CD N
% NN N
; : N
partial JJ N
response NN N
[ NNP N
PR NNP N
] NNP N
, , N
56 CD N
% NN N
) ) N
but CC N
response NN N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP N
( ( N
P NNP N
= NNP N
.57 NNP N
) ) N
. . N

Two CD N
hundred VBD N
seventy-two JJ N
patients NNS N
received VBD N
standard-timing JJ N
RT NNP N
at IN N
week NN N
9 CD N
and CC N
thus RB N
only RB N
chemotherapy NN N
during IN N
induction NN N
. . N

Response NNP N
rate NN N
was VBD N
81 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
76 CD N
% NN N
to TO N
86 CD N
% NN N
; : N
CR NNP N
, , N
22 CD N
% NN N
; : N
PR NNP N
, , N
59 CD N
% NN N
) ) N
. . N

In IN N
these DT N
patients NNS N
, , N
response NN N
did VBD N
not RB N
influence VB N
FFS NNP N
except IN N
for IN N
those DT N
with IN N
alveolar JJ N
histology NN N
. . N

One CD N
hundred VBD N
thirty-two NN N
other JJ N
patients NNS N
received VBN N
chemotherapy NN N
and CC N
RT NNP N
during IN N
induction NN N
( ( N
up-front JJ N
RT NNP N
) ) N
. . N

Response JJ N
rate NN N
was VBD N
65 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
57 CD N
% NN N
to TO N
73 CD N
% NN N
; : N
CR NNP N
, , N
12 CD N
% NN N
; : N
PR NNP N
, , N
53 CD N
% NN N
) ) N
, , N
but CC N
response NN N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP N
( ( N
P NNP N
= NNP N
.69 NNP N
) ) N
. . N

Forty JJ N
patients NNS N
received VBD N
no DT N
RT NNP N
at IN N
all DT N
( ( N
protocol JJ N
violation NN N
) ) N
and CC N
response NN N
to TO N
induction NN N
therapy NN N
had VBD N
no DT N
effect NN N
on IN N
FFS NNP N
. . N

CONCLUSION NNP N
In IN N
IRS-IV NNP N
, , N
response NN N
rate NN N
to TO N
induction NN N
therapy NN N
was VBD N
77 CD N
% NN N
in IN N
group NN N
III NNP N
patients NNS N
, , N
was VBD N
independent JJ N
of IN N
histology NN N
, , N
and CC N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP N
overall JJ N
. . N

-DOCSTART- -X- O O

Medication NN N
and CC N
parent NN N
training NN N
in IN N
children NNS N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
and CC N
serious JJ N
behavior NN N
problems NNS N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE NNP N
Many JJ N
children NNS N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
( ( N
PDDs NNP N
) ) N
have VBP N
serious JJ N
, , N
functionally RB N
impairing VBG N
behavioral JJ N
problems NNS N
. . N

We PRP N
tested VBD N
whether IN N
combined VBN 4_i
treatment NN 4_i
( ( 4_i
COMB NNP 4_i
) ) 4_i
with IN N
risperidone NN 3_i
and CC 3_i
parent NN 3_i
training NN 3_i
( ( 3_i
PT NNP 3_i
) ) 3_i
in IN N
behavior JJ N
management NN N
is VBZ N
superior JJ N
to TO N
medication VB N
alone RB N
( ( N
MED NNP N
) ) N
in IN N
improving VBG N
severe JJ N
behavioral JJ N
problems NNS N
in IN N
children NNS N
with IN N
PDDs NNP N
. . N

METHOD NNP N
This DT N
24-week JJ N
, , N
three-site JJ N
, , N
randomized VBN N
, , N
parallel-groups JJ N
clinical JJ N
trial NN N
enrolled VBD N
124 CD N
children NNS N
, , N
aged VBD N
4 CD N
through IN N
13 CD N
years NNS N
, , N
with IN N
PDDs NNP N
, , N
accompanied VBN N
by IN N
frequent JJ N
tantrums NNS N
, , N
self-injury NN N
, , N
and CC N
aggression NN N
. . N

The DT N
children NNS N
were VBD N
randomized VBN N
3:2 CD N
to TO N
COMB NNP N
( ( N
n JJ N
= NNP N
75 CD N
) ) N
or CC N
MED NNP N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
. . N

The DT N
participants NNS N
received VBD N
risperidone JJ 3_i
monotherapy NN 3_i
from IN N
0.5 CD N
to TO N
3.5 CD N
mg/day NN N
( ( N
with IN N
switch NN N
to TO N
aripiprazole VB 3_i
if IN N
risperidone NN 3_i
was VBD N
ineffective JJ N
) ) N
. . N

Parents NNS N
in IN N
the DT N
COMB NNP N
group NN N
( ( N
n JJ N
= VBZ N
75 CD N
; : N
60.5 CD N
% NN N
) ) N
received VBD N
a DT N
mean NN N
of IN N
10.9 CD N
PT NNP N
sessions NNS N
. . N

The DT N
primary JJ N
measure NN N
of IN N
compliance NN N
was VBD N
the DT N
Home NNP N
Situations NNP N
Questionnaire NNP N
( ( N
HSQ NNP N
) ) N
score NN N
. . N

RESULTS NNP N
Primary JJ N
: : N
intent-to-treat JJ N
random NN N
effects NNS N
regression NN N
showed VBD N
that IN N
COMB NNP 4_i
was VBD N
superior JJ N
to TO N
MED NNP N
on IN N
HSQ NNP N
( ( N
p JJ N
= NNP N
.006 NNP N
) ) N
[ VBP N
effect NN N
size NN N
at IN N
week NN N
24 CD N
( ( N
d NN N
) ) N
= VBZ N
0.34 CD N
] NN N
. . N

The DT N
HSQ NNP N
score NN N
declined VBD N
from IN N
4.31 CD N
( ( N
? . N
1.67 CD N
) ) N
to TO N
1.23 CD N
( ( N
? . N
1.36 CD N
) ) N
for IN N
COMB NNP N
compared VBN N
with IN N
4.16 CD N
( ( N
? . N
1.47 CD N
) ) N
to TO N
1.68 CD N
( ( N
? . N
1.36 CD N
) ) N
for IN N
MED NNP N
. . N

Secondary JJ N
: : N
groups NNS N
did VBD N
not RB N
differ VB N
on IN N
Clinical JJ N
Global NNP N
Impressions-Improvement NN N
scores NNS N
at IN N
endpoint NN N
; : N
compared VBN N
with IN N
MED NNP N
, , N
COMB NNP N
showed VBD N
significant JJ N
reductions NNS N
on IN N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
Irritability NNP N
( ( N
d JJ N
= VBZ N
0.48 CD N
; : N
p NN N
= NNP N
.01 NNP N
) ) N
, , N
Stereotypic NNP N
Behavior NNP N
( ( N
d JJ N
= VBZ N
0.23 CD N
; : N
p NN N
= NNP N
.04 NNP N
) ) N
, , N
and CC N
Hyperactivity/Noncompliance NNP N
subscales NNS N
( ( N
d VB N
= RB N
0.55 CD N
; : N
p NN N
= NNP N
.04 NNP N
) ) N
. . N

Final NNP N
risperidone NN N
mean NN N
dose NN N
for IN N
MED NNP N
was VBD N
2.26 CD N
mg/day NN N
( ( N
0.071 CD N
mg/kg NN N
) ) N
, , N
compared VBN N
with IN N
1.98 CD N
mg/day NN N
for IN N
COMB NNP N
( ( N
0.066 CD N
mg/kg NN N
) ) N
( ( N
p JJ N
= NNP N
.04 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Medication NNP N
plus CC N
PT NNP N
resulted VBD N
in IN N
greater JJR N
reduction NN N
of IN N
serious JJ N
maladaptive JJ N
behavior NN N
than IN N
MED NNP N
in IN N
children NNS N
with IN N
PDDs NNP N
, , N
with IN N
a DT N
lower JJR N
risperidone NN N
dose NN N
. . N

-DOCSTART- -X- O O

The DT N
NORwegian JJ N
study NN N
on IN N
DIstrict NNP N
treatment NN N
of IN N
ST-elevation NNP N
myocardial JJ N
infarction NN N
( ( N
NORDISTEMI NNP N
) ) N
. . N

OBJECTIVES NNP N
Thrombolysis NNP N
is VBZ N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
patients NNS N
with IN N
ST-elevation NNP N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
living NN N
in IN N
rural JJ N
areas NNS N
with IN N
long JJ N
transfer NN N
delays NNS N
to TO N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

This DT N
trial NN N
compares VBZ N
two CD N
different JJ N
strategies NNS N
following VBG N
thrombolysis NN N
: : N
to TO N
transfer VB N
all DT N
patients NNS N
for IN N
immediate JJ N
coronary JJ N
angiography NN N
and CC N
intervention NN N
, , N
or CC N
to TO N
manage VB N
the DT N
patients NNS N
more RBR N
conservatively RB N
. . N

DESIGN VB N
The DT N
NORwegian JJ N
study NN N
on IN N
DIstrict NNP N
treatment NN N
of IN N
STEMI NNP N
( ( N
NORDISTEMI NNP N
) ) N
is VBZ N
an DT N
open JJ N
, , N
prospective JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
in IN N
patients NNS N
with IN N
STEMI NNP N
of IN N
less JJR N
than IN N
6 CD N
hours NNS N
of IN N
duration NN N
and CC N
more JJR N
than IN N
90 CD N
minutes NNS N
expected VBD N
time NN N
delay NN N
to TO N
PCI NNP 1_i
. . N

A NNP N
total NN N
of IN N
266 CD N
patients NNS N
will MD N
receive VB 2_i
full-dose JJ 3_i
thrombolysis NN 3_i
, , N
preferably RB N
pre-hospital JJ N
, , N
and CC N
then RB N
be VB N
randomized VBN N
to TO N
either DT N
strategy NN N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
is VBZ N
the DT N
one CD N
year NN N
combined VBN N
incidence NN N
of IN N
death NN N
, , N
reinfarction NN N
, , N
stroke VBD N
or CC N
new JJ N
myocardial JJ N
ischaemia NN N
. . N

The DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00161005 NNP N
. . N

RESULTS VBN N
By IN N
April NNP N
2006 CD N
, , N
109 CD N
patients NNS N
have VBP N
been VBN N
randomized VBN N
. . N

Thrombolysis NN N
has VBZ N
been VBN N
given VBN N
pre-hospital JJ N
to TO N
52 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
median JJ N
transport NN N
distance NN N
from IN N
first JJ N
medical JJ N
contact NN N
to TO N
catheterization NN N
laboratory NN N
was VBD N
155 CD N
km NN N
( ( N
range JJ N
90-396 CD N
km NN N
) ) N
. . N

Results NNS N
of IN N
the DT N
study NN N
are VBP N
expected VBN N
in IN N
2008 CD N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
bepotastine NN 3_i
besilate NN 3_i
ophthalmic JJ 3_i
solution NN 3_i
1.5 CD N
% NN N
for IN N
seasonal JJ N
allergic JJ N
conjunctivitis NN N
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 7_i
, , N
natural JJ N
exposure NN N
, , N
clinical JJ N
trial NN N
. . N

Allergic NNP N
conjunctivitis NN N
( ( N
AC NNP N
) ) N
affects VBZ N
an DT N
estimated JJ N
20 CD N
% NN N
of IN N
the DT N
population NN N
in IN N
the DT N
Western JJ N
world NN N
, , N
with IN N
a DT N
large JJ N
fraction NN N
suffering VBG N
due JJ N
to TO N
seasonal JJ N
or CC N
perennial JJ N
allergen NN N
exposures NNS N
. . N

Bepotastine NNP 3_i
besilate NN 3_i
ophthalmic JJ 3_i
solution NN 3_i
( ( 3_i
BBOS NNP 3_i
) ) 3_i
1.5 CD N
% NN N
, , N
a DT N
dual-acting JJ 3_i
histamine NN 3_i
( ( N
H NNP N
( ( N
1 CD N
) ) N
) ) N
receptor NN N
antagonist NN N
and CC N
mast NN N
cell NN N
stabilizer NN N
, , N
is VBZ N
indicated VBN N
for IN N
itching VBG N
associated VBN N
with IN N
AC NNP N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
BBOS NNP N
1.5 CD N
% NN N
for IN N
reducing VBG N
ocular JJ N
itching NN N
associated VBN N
with IN N
AC NNP N
in IN N
subjects NNS N
enrolled VBN N
in IN N
a DT N
natural JJ N
exposure NN N
trial NN N
. . N

Eligible JJ N
subjects NNS N
in IN N
a DT N
multicenter NN N
, , N
double-masked JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ 7_i
, , N
natural JJ N
exposure NN N
clinical JJ N
trial NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
BBOS NNP 3_i
1.5 CD N
% NN N
or CC N
placebo NN 7_i
eyedrops NNS 7_i
on IN N
a DT N
1:1 CD N
basis NN N
and CC N
instilled VBD N
1 CD N
drop NN N
of IN N
the DT N
test NN N
agent NN N
into IN N
both DT N
eyes NNS N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
instantaneous JJ N
and CC N
reflective JJ N
ocular JJ N
itching NN N
scores NNS N
at IN N
the DT N
end NN N
of IN N
2 CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
based VBN N
on IN N
subject-assessed JJ N
severity NN N
of IN N
instantaneous JJ N
and CC N
reflective JJ N
itching NN N
. . N

Subject-reported JJ N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
were VBD N
also RB N
recorded VBN N
for IN N
safety NN N
. . N

Treatment NN N
with IN N
BBOS NNP N
1.5 CD N
% NN N
significantly RB N
reduced VBN N
instantaneous JJ N
and CC N
reflective JJ N
ocular JJ N
itching NN N
scores NNS N
from IN N
baseline NN N
compared VBN N
with IN N
placebo NN N
over IN N
the DT N
2-week JJ N
study NN N
period NN N
( ( N
p JJ N
= NN N
0.007 CD N
and CC N
p VB N
= JJ N
0.005 CD N
, , N
respectively RB N
) ) N
. . N

BBOS $ N
1.5 CD N
% NN N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
AEs NNP N
were VBD N
generally RB N
transient JJ N
and CC N
mild JJ N
. . N

This DT N
clinical JJ N
study NN N
indicates VBZ N
BBOS NNP N
1.5 CD N
% NN N
effectively RB N
and CC N
safely RB N
treated VBD N
ocular JJ N
itching NN N
in IN N
a DT N
natural JJ N
exposure NN N
allergy NN N
study NN N
and CC N
is VBZ N
a DT N
useful JJ N
treatment NN N
option NN N
for IN N
the DT N
management NN N
of IN N
ocular JJ N
itching NN N
associated VBN N
with IN N
AC NNP N
. . N

( ( N
ClinicalTrials.gov NNP N
identifier VBZ N
number NN N
: : N
NCT01174823 NNP N
. . N

) ) N
-DOCSTART- -X- O O

Is VBZ N
the DT N
orientation NN N
of IN N
the DT N
apical JJ N
defibrillation NN N
paddle NN N
of IN N
importance NN N
during IN N
manual JJ 2_i
external JJ 2_i
defibrillation NN 2_i
? . N
OBJECTIVE NNP N
Transthoracic NNP N
impedance NN N
( ( N
TTI NNP N
) ) N
is VBZ N
a DT N
factor NN N
determining VBG N
the DT N
magnitude NN N
of IN N
the DT N
transmyocardial JJ N
current JJ N
during IN N
external JJ 2_i
defibrillation NN 2_i
. . N

Minimising VBG N
TTI NNP N
increases VBZ N
the DT N
chances NNS N
of IN N
successful JJ N
defibrillation NN N
. . N

Most JJS N
external JJ N
defibrillation NN N
paddles NNS N
are VBP N
rectangular JJ N
in IN N
shape NN N
and CC N
can MD N
, , N
therefore RB N
, , N
be VB N
placed VBN N
in IN N
a DT N
transverse NN N
or CC N
longitudinal JJ N
orientation NN N
. . N

The DT N
apical JJ N
paddle NN N
is VBZ N
often RB N
placed VBN N
in IN N
a DT N
transverse JJ N
orientation NN N
. . N

This DT N
may MD N
theoretically RB N
result VB N
in IN N
a DT N
higher JJR N
TTI NNP N
than IN N
a DT N
longitudinal JJ N
orientation NN N
because IN N
of IN N
poorer NN N
contact NN N
at IN N
the DT N
lateral JJ N
paddle NN N
edges NNS N
. . N

We PRP N
compared VBN N
TTI NNP N
with IN N
the DT N
apical JJ N
paddle NN N
in IN N
both DT N
a DT N
transverse NN N
and CC N
longitudinal JJ N
orientation NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty NNP N
sequential NN N
anaesthetised VBD N
patients NNS N
were VBD N
studied VBN N
. . N

A DT N
pair NN N
of IN N
defibrillator NN 2_i
paddles NNS 2_i
were VBD N
instrumented VBN N
to TO N
measure VB N
paddle JJ N
force NN N
. . N

TTI NNP N
was VBD N
recorded VBN N
pre-operatively RB N
at IN N
end-expiration NN N
with IN N
the DT N
apical JJ N
paddle NN N
in IN N
both DT N
longitudinal JJ N
and CC N
transverse JJ N
orientations NNS N
. . N

The DT N
sternal JJ N
paddle NN N
was VBD N
placed VBN N
in IN N
a DT N
longitudinal JJ N
orientation NN N
for IN N
all DT N
measurements NNS N
. . N

RESULTS NNP N
TTI NNP N
decreased VBD N
in IN N
both DT N
transverse NN N
and CC N
longitudinal JJ N
orientations NNS N
as IN N
paddle JJ N
force NN N
increased VBD N
. . N

Transverse NNP 2_i
paddle JJ 2_i
orientation NN 2_i
resulted VBD N
in IN N
a DT N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
higher JJR N
TTI NNP N
than IN N
longitudinal JJ N
orientation NN N
at IN N
all DT N
paddle JJ N
forces NNS N
below IN N
12 CD N
kg NNS N
force NN N
. . N

CONCLUSION VB N
The DT N
longitudinal JJ N
orientation NN N
of IN N
a DT N
rectangular JJ N
defibrillation NN N
paddle NN N
provides VBZ N
a DT N
lower JJR N
TTI NNP N
than IN N
orientation NN N
horizontally RB N
. . N

-DOCSTART- -X- O O

Relief NN N
of IN N
periorbital JJ N
pain NN N
after IN N
acute JJ N
angle JJ N
closure NN N
glaucoma NN N
attack NN N
by IN N
botulinum NN 3_i
toxin NN 3_i
type NN 3_i
A NNP 3_i
. . 3_i

PURPOSE NNP N
To TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
botulinum NN 3_i
toxin NN 3_i
type NN 3_i
A NNP 3_i
( ( 3_i
BoNT-A NNP 3_i
) ) 3_i
injection NN N
in IN N
patients NNS N
suffering VBG N
from IN N
intractable JJ N
periorbital NN N
pain NN N
after IN N
acute JJ N
angle JJ N
closure NN N
glaucoma NN N
( ( N
AACG NNP N
) ) N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
prospective JJ N
randomized VBN N
intervention NN N
study NN N
, , N
19 CD N
patients NNS N
suffering VBG N
from IN N
periorbital JJ N
pain NN N
after IN N
an DT N
AACG NNP N
attack NN N
were VBD N
injected VBN 3_i
with IN 3_i
BoNT-A NNP 3_i
or CC N
placebo NN 7_i
for IN N
pain NN N
relief NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
on IN N
days NNS N
1 CD N
, , N
2 CD N
, , N
7 CD N
, , N
14 CD N
, , N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
. . N

The DT N
main JJ N
outcomes NNS N
were VBD N
mean JJ N
change NN N
of IN N
visual JJ N
analog NN N
rating NN N
scale NN N
( ( N
VARS NNP N
) ) N
and CC N
index NN N
scores NNS N
measured VBN N
through IN N
a DT N
quality-of-life JJ N
questionnaire NN N
( ( N
EQ-5D NNP N
) ) N
, , N
and CC N
changes NNS N
in IN N
the DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
, , N
all DT N
of IN N
which WDT N
were VBD N
assessed VBN N
at IN N
each DT N
visit NN N
. . N

A DT N
secondary JJ N
outcome NN N
was VBD N
the DT N
frequency NN N
and CC N
nature NN N
of IN N
adverse JJ N
events NNS N
and CC N
the DT N
number NN N
of IN N
patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
study NN N
as IN N
a DT N
result NN N
. . N

RESULTS NN N
In IN N
the DT N
treatment NN N
group NN N
( ( N
n=10 NN N
) ) N
, , N
the DT N
mean JJ N
index NN N
score NN N
of IN N
EQ-5D NNP N
and CC N
VAS NNP N
changed VBD N
significantly RB N
from IN N
the DT N
placebo NN 7_i
group NN N
( ( N
by IN N
0.299 CD N
and CC N
2.61 CD N
, , N
respectively RB N
) ) N
from IN N
day NN N
2 CD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
VARS NNP N
of IN N
EQ-5D NNP N
also RB N
disclosed VBD N
significant JJ N
changes NNS N
from IN N
day NN N
2 CD N
( ( N
17 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
addition NN N
, , N
efficacy NN N
was VBD N
maintained VBN N
mainly RB N
between IN N
days NNS N
2 CD N
and CC N
60 CD N
but CC N
declined VBD N
slightly RB N
by IN N
day NN N
90 CD N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
treatment-related JJ N
adverse JJ N
events NNS N
in IN N
the DT N
treatment NN N
and CC N
placebo NN N
groups NNS N
were VBD N
local JJ N
tenderness NN N
( ( N
21 CD N
% NN N
) ) N
, , N
subcutaneous JJ N
hemorrhage NN N
( ( N
10.5 CD N
% NN N
) ) N
, , N
and CC N
conjunctivitis NN N
( ( N
10.5 CD N
% NN N
) ) N
. . N

No UH N
severe JJ N
adverse JJ N
events NNS N
were VBD N
reported VBN N
during IN N
the DT N
study NN N
or CC N
follow-up JJ N
period NN N
. . N

CONCLUSIONS NNP N
BoNT-A NNP 3_i
is VBZ N
effective JJ N
and CC N
well RB N
tolerated VBN N
for IN N
the DT N
treatment NN N
of IN N
periorbital JJ N
pain NN N
after IN N
an DT N
AACG NNP N
attack NN N
. . N

Its PRP$ N
effects NNS N
may MD N
be VB N
maintained VBN N
for IN N
3 CD N
months NNS N
. . N

-DOCSTART- -X- O O

Fine NNP 1_i
needle JJ 1_i
aspiration NN 1_i
coupled VBN 1_i
with IN 1_i
real-time JJ 2_i
PCR NNP 2_i
: : N
a DT N
painless JJ N
methodology NN N
to TO N
study VB N
adaptive JJ N
functional JJ N
changes NNS N
in IN N
skeletal JJ N
muscle NN N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
In IN N
this DT N
study NN N
we PRP N
developed VBD N
a DT N
new JJ N
methodology NN 2_i
for IN N
obtaining VBG N
human JJ N
skeletal JJ N
muscle NN N
samples NNS N
to TO N
evaluate VB N
gene NN N
expression NN N
. . N

This DT N
approach NN N
is VBZ N
based VBN N
on IN N
a DT N
fine JJ 2_i
needle JJ 2_i
aspiration NN 2_i
technique NN 2_i
, , N
which WDT N
allows VBZ N
us PRP N
to TO N
extract VB N
a DT N
small JJ N
tissue NN N
sample NN N
in IN N
a DT N
significantly RB N
less RBR N
invasive JJ N
manner NN N
than IN N
with IN N
classic JJ N
biopsy NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Multiplex NNP 2_i
tandem VBD 2_i
RT-PCR NNP 2_i
was VBD N
used VBN N
to TO N
determine VB N
the DT N
mRNA NN N
levels NNS N
of IN N
genes NNS N
involved VBN N
in IN N
ATP NNP N
production NN N
and CC N
mitochondrial JJ N
biogenesis NN N
in IN N
muscle NN N
tissue NN N
. . N

Samples NNS N
of IN N
vastus NN N
lateralis NNS N
muscle NN N
were VBD N
obtained VBN N
from IN N
21 CD N
healthy JJ N
subjects NNS N
with IN N
different JJ N
fitness NN N
levels NNS N
. . N

The DT N
principal JJ N
findings NNS N
in IN N
our PRP$ N
study NN N
show VB N
a DT N
strong JJ N
correlation NN N
between IN N
PGC-1alpha NNP N
and CC N
COX5B NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
between IN N
PGC-1alpha NNP N
and CC N
MT-CO2 NNP N
( ( N
p=0.017 NN N
) ) N
expression NN N
. . N

Furthermore NNP N
, , N
a DT N
significant JJ N
positive JJ N
correlation NN N
between IN N
mtDNA NN N
content NN N
and CC N
the DT N
percentage NN N
of IN N
MHCI NNP N
present NN N
in IN N
the DT N
aspired JJ N
samples NNS N
were VBD N
found VBN N
( ( N
p=0.028 NN N
) ) N
. . N

These DT N
data NNS N
are VBP N
in IN N
agreement NN N
with IN N
current JJ N
knowledge NN N
on IN N
skeletal JJ N
muscle NN N
physiology NN N
and CC N
show VB N
the DT N
reliability NN N
of IN N
the DT N
proposed VBN N
method NN N
. . N

CONCLUSION VB N
This DT N
painless JJ 2_i
methodology NN 2_i
can MD N
be VB N
used VBN N
to TO N
investigate VB N
, , N
in IN N
vivo NN N
, , N
human JJ N
muscle NN N
RNA NNP N
and CC N
DNA NNP N
adaptations NNS N
in IN N
response NN N
to TO N
either DT N
physiological JJ N
and/or NN N
pharmacological JJ N
stimuli NN N
. . N

This DT N
method NN N
has VBZ N
major JJ N
clinical JJ N
relevance NN N
, , N
such JJ N
as IN N
its PRP$ N
application NN N
in IN N
clarifying VBG N
the DT N
mechanisms NN N
underling VBG N
metabolic JJ N
and CC N
systemic JJ N
disorders NNS N
. . N

-DOCSTART- -X- O O

Dopamine NNP 3_i
transporter NN 3_i
gene NN 3_i
moderates VBZ N
response NN N
to TO N
behavioral JJ N
parent NN N
training NN N
in IN N
children NNS N
with IN N
ADHD NNP N
: : N
a DT N
pilot NN N
study NN N
. . N

There EX N
is VBZ N
great JJ N
variability NN N
in IN N
the DT N
degree NN N
to TO N
which WDT N
children NNS N
with IN N
attention NN N
deficit/hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
improve VBP N
through IN N
behavioral JJ N
treatments NNS N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
influence NN N
of IN N
the DT N
dopamine NN 3_i
transporter NN 3_i
gene NN 3_i
( ( 3_i
SCL6A3/DAT1 NNP 3_i
) ) 3_i
on IN N
outcome NN N
of IN N
behavioral JJ 4_i
parent NN 4_i
training NN 4_i
( ( 4_i
BPT NNP 4_i
) ) 4_i
. . 4_i

Study NNP N
subjects NNS N
were VBD N
a DT N
subsample NN N
( ( N
n JJ N
= NN N
50 CD N
, , N
for IN N
whom WP N
DAT1 NNP N
genotypes NNS N
were VBD N
available JJ N
) ) N
of IN N
a DT N
randomized VBN N
controlled VBN N
BPT NNP N
effectiveness NN N
study NN N
( ( N
N NNP N
= NNP N
94 CD N
) ) N
comparing VBG N
BPT NNP 4_i
plus CC 4_i
ongoing JJ 4_i
routine JJ 4_i
clinical JJ 4_i
care NN 4_i
( ( 4_i
RCC NNP 4_i
) ) 4_i
versus NN N
RCC NNP 4_i
alone RB 4_i
in IN N
referred JJ N
children NNS N
( ( N
4-12 CD N
years NNS N
old JJ N
) ) N
with IN N
ADHD NNP N
. . N

Treatment NNP N
outcome NN N
was VBD N
based VBN N
on IN N
parent-reported JJ N
ADHD NNP N
symptoms NNS N
and CC N
behavioral JJ N
problems NNS N
. . N

Presence NNP N
of IN N
2 CD N
versus NN N
no DT N
or CC N
1 CD N
DAT1 NNP N
10-repeat JJ N
allele NN N
served VBD N
as IN N
moderator NN N
variable NN N
. . N

Time NNP N
? . N
Treatment NNP N
? . N
Genotype NNP N
effect NN N
was VBD N
analyzed VBN N
with IN N
repeated-measures JJ N
analysis NN N
of IN N
variance NN N
, , N
controlling VBG N
for IN N
baseline JJ N
medication NN N
status NN N
. . N

Results VB N
indicate JJ N
that IN N
DAT1 NNP N
moderated VBD N
treatment NN N
response NN N
( ( N
p JJ N
= NNP N
.009 NNP N
) ) N
. . N

In IN N
children NNS N
with IN N
no DT N
or CC N
1 CD N
DAT1 NNP N
10-repeat JJ N
allele NN N
, , N
superior JJ N
treatment NN N
effects NNS N
of IN N
BPT NNP N
+ NNP N
RCC NNP N
compared VBN N
with IN N
RCC NNP N
alone RB N
were VBD N
present JJ N
( ( N
p JJ N
= NNP N
.005 NNP N
) ) N
, , N
which WDT N
was VBD N
not RB N
the DT N
case NN N
in IN N
children NNS N
with IN N
2 CD N
DAT1 NNP N
10-repeat JJ N
alleles NNS N
( ( N
p JJ N
= NNP N
.57 NNP N
) ) N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
genetic JJ N
differences NNS N
in IN N
DAT1 NNP N
in IN N
children NNS N
with IN N
ADHD NNP N
influence VBP N
their PRP$ N
susceptibility NN N
to TO N
a DT N
behavioral JJ N
intervention NN N
directed VBD N
at IN N
shaping VBG N
their PRP$ N
environment NN N
through IN N
their PRP$ N
parents NNS N
. . N

The DT N
role NN N
of IN N
the DT N
dopamine NN N
system NN N
in IN N
motivation NN N
and CC N
learning NN N
and CC N
in IN N
the DT N
aberrant JJ N
sensitivity NN N
to TO N
reinforcement VB N
in IN N
children NNS N
with IN N
ADHD NNP N
may MD N
explain VB N
this DT N
moderating NN N
effect NN N
, , N
given VBN N
that IN N
the DT N
management NN N
of IN N
contingencies NNS N
is VBZ N
typically RB N
addressed VBN N
in IN N
BPT NNP N
. . N

-DOCSTART- -X- O O

International NNP N
Czech NNP 6_i
and CC 6_i
Slovak NNP 6_i
cooperation NN 6_i
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancer NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
paper NN N
is VBZ N
to TO N
present VB N
our PRP$ N
experience NN N
concerning VBG N
cooperation NN N
in IN N
the DT N
treatment NN N
of IN N
Slovak NNP N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancer NN N
in IN N
Slovak NNP N
and CC N
Czech NNP N
hospitals NNS N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
demonstrate VB N
the DT N
means NNS N
of IN N
this DT N
cooperation NN 6_i
and CC N
the DT N
results NNS N
of IN N
therapy NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
From NNP N
September NNP N
1991 CD N
to TO N
October NNP N
2005 CD N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Ostrava NNP N
357 CD N
patients NNS N
from IN N
the DT N
Slovak NNP N
Republic NNP N
with IN N
differentiated VBN N
thyroid NN N
cancers NNS N
( ( N
follicular JJ N
and CC N
papillary JJ N
) ) N
underwent NN N
complex JJ 2_i
therapy NN 2_i
. . N

They PRP N
were VBD N
diagnosed VBN N
and CC N
operated VBN N
due JJ N
to TO N
the DT N
cancer NN N
( ( N
near-total JJ N
thyroidectomy NN N
and CC N
removal NN N
of IN N
lymph JJ N
node JJ N
metastases NNS N
) ) N
in IN N
Slovak NNP N
hospitals NNS N
. . N

Then RB N
they PRP N
were VBD N
sent VBN N
to TO N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Ostrava NNP N
in IN N
the DT N
Czech NNP N
Republic NNP N
. . N

In IN N
this DT N
department NN N
a DT N
radioiodine JJ 3_i
ablation NN N
of IN N
thyroid JJ N
remnants NNS N
, , N
by IN N
means NNS N
of IN N
the DT N
treatment NN N
amount NN N
of IN N
radioiodine NN 3_i
of IN N
a DT N
standard JJ N
activity NN N
of IN N
3.7 CD N
GBq NNP N
, , N
was VBD N
performed VBN N
, , N
and CC N
then RB N
a DT N
suppression NN N
and CC N
substitution NN N
therapy NN N
of IN N
thyroid JJ N
hormones NNS N
was VBD N
started VBN N
. . N

After IN N
3-6 JJ N
months NNS N
some DT N
patients NNS N
were VBD N
examined VBN N
by IN N
means NNS N
of IN N
diagnostic JJ N
whole JJ N
body NN N
scintigraphy NN N
after IN N
application NN N
of IN N
300 CD N
MBq NNP N
131I CD N
. . N

Some DT N
patients NNS N
were VBD N
treated VBN N
by IN N
means NNS N
of IN N
a DT N
standard JJ N
activity NN N
of IN N
7.4 CD N
GBq NNP N
131I CD N
and CC N
after IN N
5 CD N
days NNS N
whole JJ N
body NN N
scintigraphy NN N
( ( N
WBS NNP N
) ) N
was VBD N
performed VBN N
. . N

In IN N
both DT N
of IN N
these DT N
groups NNS N
of IN N
patients NNS N
the DT N
diagnostic JJ N
or CC N
therapeutic JJ N
radioiodine NN 3_i
application NN N
was VBD N
done VBN N
after IN N
withdrawal NN N
of IN N
thyroid JJ N
hormone NN N
treatment NN N
. . N

If IN N
thyroglobulin JJ N
levels NNS N
were VBD N
low JJ N
and CC N
WBSs NNP N
were VBD N
negative JJ N
, , N
patients NNS N
were VBD N
followed VBN N
up RP N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Martin NNP N
. . N

Patients NNS N
with IN N
radioiodine NN N
accumulated VBN N
metastases NNS N
were VBD N
again RB N
treated VBN N
with IN N
radioiodine NN 3_i
in IN N
Ostrava NNP N
. . N

If IN N
indicated VBN N
, , N
external JJ N
radiation NN 2_i
therapy NN 2_i
targeted VBN N
on IN N
the DT N
neck NN N
and CC N
upper JJ N
mediastinum NN N
was VBD N
performed VBN N
in IN N
the DT N
Slovak NNP N
Republic NNP N
, , N
in IN N
the DT N
University NNP N
Hospital NNP N
in IN N
Martin NNP N
. . N

Newly RB N
formed VBN N
lymph JJ N
node NN N
metastases NNS N
were VBD N
surgically RB N
treated VBN N
in IN N
Slovakia NNP N
, , N
too RB N
. . N

Generally RB N
we PRP N
have VBP N
very RB N
good JJ N
treatment NN N
results NNS N
. . N

Also RB N
, , N
economically RB N
our PRP$ N
partnership NN N
is VBZ N
cost VBN N
effective JJ N
. . N

Our PRP$ N
collaboration NN N
also RB N
successfully RB N
continues VBZ N
after IN N
entrance NN N
of IN N
the DT N
Slovak NNP N
Republic NNP N
and CC N
the DT N
Czech NNP N
Republic NNP N
to TO N
the DT N
European NNP N
Union NNP N
in IN N
2004 CD N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
multi-centre JJ N
study NN N
show NN N
that IN N
international JJ N
Czech NNP N
and CC N
Slovak NNP N
cooperation NN 6_i
in IN N
the DT N
complex JJ N
therapy NN N
of IN N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancers NNS N
is VBZ N
successful JJ N
, , N
with IN N
high JJ N
efficacy NN N
. . N

The DT N
treatment NN N
results NNS N
were VBD N
very RB N
similar JJ N
to TO N
therapeutic JJ N
results NNS N
in IN N
our PRP$ N
patients NNS N
from IN N
the DT N
Czech NNP N
Republic NNP N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
of IN N
a DT N
low-tilt JJ N
biphasic JJ N
waveform NN N
for IN N
transvenous JJ N
cardioversion NN N
of IN N
atrial JJ N
fibrillation NN N
: : N
improved VBN N
efficacy NN N
compared VBN N
with IN N
conventional JJ N
capacitor-based JJ N
waveforms NNS N
in IN N
patients NNS N
. . N

BACKGROUND NNP N
The DT N
optimal JJ N
waveform NN N
tilt NN N
for IN N
defibrillation NN N
is VBZ N
not RB N
known VBN N
. . N

Most JJS N
modern JJ N
defibrillators NNS N
used VBN N
for IN N
the DT N
cardioversion NN N
of IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
employ VBD N
high-tilt JJ N
, , N
capacitor-based JJ N
biphasic JJ N
waveforms NNS N
. . N

METHODS NNP N
We PRP N
have VBP N
developed VBN N
a DT N
low-tilt JJ 2_i
biphasic JJ 2_i
waveform NN 2_i
for IN N
defibrillation NN N
. . N

This DT N
low-tilt JJ 3_i
waveform NN 3_i
was VBD N
compared VBN N
with IN N
a DT N
conventional JJ 3_i
waveform NN 3_i
of IN N
equivalent JJ N
duration NN N
and CC N
voltage NN N
in IN N
patients NNS N
with IN N
AF NNP N
. . N

Patients NNS N
with IN N
persistent JJ N
AF NNP N
or CC N
AF NNP N
induced VBD N
during IN N
a DT N
routine JJ N
electrophysiology NN N
study NN N
( ( N
EPS NNP N
) ) N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
the DT N
low-tilt JJ 2_i
waveform NN 2_i
or CC N
a DT N
conventional JJ 2_i
waveform NN 2_i
. . N

Defibrillation NNP N
electrodes NNS N
were VBD N
positioned VBN N
in IN N
the DT N
right JJ N
atrial JJ N
appendage NN N
and CC N
distal JJ N
coronary JJ N
sinus NN N
. . N

Phase VB N
1 CD N
peak JJ N
voltage NN N
was VBD N
increased VBN N
in IN N
a DT N
stepwise NN N
progression NN N
from IN N
50 CD N
V NNP N
to TO N
300V CD N
. . N

Shock NNP N
success NN N
was VBD N
defined VBN N
as IN N
return NN N
of IN N
sinus NN N
rhythm NN N
for IN N
> NNP N
/=30 NNP N
seconds NNS N
. . N

RESULTS VB N
The DT N
low-tilt JJ 2_i
waveform NN 2_i
produced VBN N
successful JJ N
termination NN N
of IN N
persistent JJ N
AF NNP N
at IN N
a DT N
mean JJ N
voltage NN N
of IN N
223 CD N
V NNP N
( ( N
8.2 CD N
J NNP N
) ) N
versus VBD N
270 CD N
V NNP N
( ( N
6.7 CD N
J NNP N
) ) N
with IN N
the DT N
conventional JJ 3_i
waveform NN 3_i
( ( N
P NNP N
= VBZ N
0.002 CD N
for IN N
voltage NN N
, , N
P NNP N
= NNP N
ns NN N
for IN N
energy NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
induced JJ N
AF NNP N
the DT N
mean JJ N
voltage NN N
for IN N
the DT N
low-tilt JJ N
waveform NN N
was VBD N
91V CD N
( ( N
1.6 CD N
J NNP N
) ) N
and CC N
for IN N
the DT N
conventional JJ N
waveform NN N
was VBD N
158 CD N
V NNP N
( ( N
2.0 CD N
J NNP N
) ) N
( ( N
P NNP N
= VBZ N
0.005 CD N
for IN N
voltage NN N
, , N
P NNP N
= NNP N
ns NN N
for IN N
energy NN N
) ) N
. . N

The DT N
waveform NN N
was VBD N
much RB N
more RBR N
successful JJ N
at IN N
very RB N
low JJ N
voltages NNS N
( ( N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
100 CD N
V NNP N
) ) N
compared VBN N
with IN N
the DT N
conventional JJ N
waveform NN N
( ( N
Novel NNP N
: : N
82 CD N
% NN N
vs JJ N
Conventional NNP N
22 CD N
% NN N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
low-tilt JJ 3_i
biphasic JJ 3_i
waveform NN 3_i
was VBD N
more RBR N
successful JJ N
for IN N
the DT N
internal JJ N
cardioversion NN N
of IN N
both DT N
persistent JJ N
and CC N
induced JJ N
AF NNP N
in IN N
patients NNS N
( ( N
in IN N
terms NNS N
of IN N
leading VBG N
edge NN N
voltage NN N
) ) N
. . N

-DOCSTART- -X- O O

[ JJ N
Prevention NNP N
of IN N
migraine NN N
with IN N
flunarizine NN 3_i
and CC N
acetylsalicylic JJ 3_i
acid NN 3_i
. . N

A DT N
double-blind JJ N
study NN N
] NNP N
. . N

UNLABELLED CC N
30 CD N
children NNS N
between IN N
7 CD N
and CC N
17 CD N
years NNS N
suffering VBG N
from IN N
at IN N
least JJS N
2 CD N
attacks/month NN N
of IN N
common JJ N
or CC N
classical JJ N
migraine NN N
since IN N
more JJR N
than IN N
1 CD N
year NN N
were VBD N
studied VBN N
. . N

After IN N
clinical JJ N
exclusion NN N
of IN N
symptomatic JJ N
headache NN N
4 CD N
weeks NNS N
were VBD N
documented VBN N
by IN N
means NNS N
of IN N
a DT N
migraine NN N
diary NN N
. . N

Prophylaxis NNP N
with IN N
Calcium NNP N
entry NN N
blocker NN 3_i
Flunarizine NNP 3_i
( ( 3_i
Sibelium NNP 3_i
) ) 3_i
or CC N
Thromboxane VB N
A DT N
inhibitor NN N
Acetylsalicylic NNP 3_i
acid NN 3_i
( ( 3_i
ASS NNP 3_i
) ) 3_i
was VBD N
carried VBN N
out RP N
in IN N
a DT N
double JJ N
blind NN N
design NN N
for IN N
3 CD N
months NNS N
. . N

Medication NNP N
was VBD N
given VBN N
as IN N
one CD N
dosage NN N
in IN N
the DT N
evening NN N
: : N
2-5 JJ N
mg/kg NN N
KG NNP N
ASS NNP 3_i
or CC N
5-10 JJ N
mg NN N
Flunarizine NNP 3_i
. . N

Documented NNP N
attack NN N
frequency NN N
and CC N
duration NN N
were VBD N
controlled VBN N
at IN N
monthly JJ N
physical JJ N
examinations NNS N
. . N

Final JJ N
results NNS N
showed VBD N
no DT N
differences NNS N
in IN N
significant JJ N
reduction NN N
of IN N
attack NN N
frequency NN N
or CC N
symptoms NNS N
between IN N
both DT N
different JJ N
therapeutic JJ N
principals NNS N
. . N

72.4 CD N
% NN N
( ( N
ASS NNP N
73.3 CD N
% NN N
; : N
Flunarizine NNP 3_i
71.4 CD N
% NN N
) ) N
of IN N
patients NNS N
were VBD N
attack-free JJ N
or CC N
had VBD N
at IN N
least JJS N
a DT N
50 CD N
% NN N
reduction NN N
. . N

Migraine NNP N
frequency NN N
of IN N
initially RB N
7-8 NNP N
was VBD N
reduced VBN N
to TO N
1-2 JJ N
attacks/month NN N
. . N

Duration NN N
remained VBD N
constant JJ N
in IN N
both DT N
groups NNS N
( ( N
1-3 JJ N
h NN N
) ) N
. . N

Side JJ N
effects NNS N
were VBD N
slight JJ N
body NN N
weight VBD N
gain NN N
or CC N
abdominal JJ N
pain NN N
after IN N
intake NN N
, , N
prophylaxis NN N
had VBD N
not RB N
to TO N
be VB N
interrupted VBN N
therefore RB N
. . N

Longtime JJ N
prognosis NN N
is VBZ N
not RB N
yet RB N
possible JJ N
because IN N
the DT N
time NN N
of IN N
observation NN N
is VBZ N
too RB N
short JJ N
so RB N
far RB N
. . N

CONCLUSION NNP N
Both NNP N
substances NNS N
are VBP N
definitely RB N
useful JJ N
and CC N
have VBP N
few JJ N
side NN N
effects NNS N
in IN N
childhood NN N
migraine NN N
. . N

If IN N
the DT N
response NN N
to TO N
one CD N
is VBZ N
insufficient JJ N
the DT N
other JJ N
substance NN N
should MD N
be VB N
tried VBN N
. . N

-DOCSTART- -X- O O

[ NN N
Study NNP N
on IN N
treatment NN N
of IN N
iron-deficiency NN N
anemia NN N
by IN N
shengxuening VBG 3_i
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
therapeutic JJ N
effect NN N
of IN N
shengxuening VBG 3_i
( ( 3_i
SXN NNP 3_i
) ) 3_i
in IN N
treating VBG N
iron-deficiency NN N
anemia NN N
( ( N
IDA NNP N
) ) N
and CC N
to TO N
explore VB N
its PRP$ N
molecular JJ N
mechanism NN N
on IN N
iron NN N
metabolism NN N
balance NN N
regulation NN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
IDA NNP N
were VBD N
randomly RB N
divided VBN N
into IN N
the DT N
treated VBN N
group NN N
and CC N
the DT N
control NN 7_i
group NN N
, , N
50 CD N
in IN N
each DT N
group NN N
. . N

They PRP N
were VBD N
treated VBN N
with IN N
SXN NNP 3_i
( ( 3_i
0.1 CD 3_i
g NN 3_i
, , 3_i
three CD 3_i
times NNS 3_i
per IN 3_i
day NN 3_i
) ) 3_i
and CC N
ferrous JJ 3_i
gluconate NN 3_i
( ( 3_i
0.1 CD 3_i
g NN 3_i
, , 3_i
three CD 3_i
times NNS 3_i
per IN 3_i
day NN 3_i
) ) 3_i
respectively RB N
, , N
for IN N
30 CD N
days NNS N
. . N

Levels NNS N
of IN N
serum NN N
iron NN N
( ( N
Fe NNP N
) ) N
, , N
total JJ N
iron NN N
binding NN N
capacity NN N
( ( N
TIBC NNP N
) ) N
, , N
transferrin JJ N
saturation NN N
( ( N
TS NNP N
) ) N
, , N
serum JJ N
ferritin NN N
( ( N
SF NNP N
) ) N
, , N
transferrin NN N
( ( N
Tf NNP N
) ) N
, , N
soluble JJ N
transferrin NN N
receptor NN N
( ( N
sTfR NN N
) ) N
and CC N
blood NN N
routine JJ N
test NN N
, , N
as RB N
well RB N
as IN N
scoring NN N
of IN N
TCM NNP N
qi-blood JJ N
deficiency NN N
Syndrome NNP N
were VBD N
conducted VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
in IN N
the DT N
treated JJ N
group NN N
reached VBD N
92 CD N
% NN N
, , N
it PRP N
was VBD N
shown VBN N
that IN N
SXN NNP N
could MD N
improve VB N
the DT N
iron NN N
metabolism NN N
, , N
increase NN N
levels NNS N
of IN N
Fe NNP N
, , N
TS NNP N
, , N
SF NNP N
and CC N
reduce VB N
levels NNS N
of IN N
TIBC NNP N
, , N
Tf NNP N
, , N
sTfR NN N
, , N
it PRP N
has VBZ N
obvious JJ N
effect NN N
in IN N
promoting VBG N
erythrocyte JJ N
generation NN N
and CC N
could MD N
promote VB N
formation NN N
of IN N
leucocytes NNS N
and CC N
platelets NNS N
. . N

The DT N
total JJ N
effective JJ N
rate NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
32 CD N
% NN N
, , N
which WDT N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
treated JJ N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
effect NN N
of IN N
SXN NNP 3_i
in IN N
treating VBG N
IDA NNP N
and CC N
qi-blood JJ N
deficiency NN N
Syndrome NNP N
is VBZ N
evident JJ N
, , N
it PRP N
could MD N
improve VB N
the DT N
iron NN N
metabolism NN N
, , N
increase NN N
levels NNS N
of IN N
Fe NNP N
, , N
TS NNP N
, , N
SF NNP N
and CC N
lower JJR N
levels NNS N
of IN N
TIBC NNP N
, , N
Tf NNP N
, , N
sTfR NN N
. . N

-DOCSTART- -X- O O

Calcium NN 3_i
and CC 3_i
fibre JJ 3_i
supplementation NN 3_i
in IN N
prevention NN N
of IN N
colorectal JJ N
adenoma JJ N
recurrence NN N
: : N
a DT N
randomised JJ N
intervention NN N
trial NN N
. . N

European JJ N
Cancer NNP N
Prevention NNP N
Organisation NNP N
Study NNP N
Group NNP N
. . N

BACKGROUND NNP N
Some DT N
epidemiological JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
high JJ N
dietary JJ N
intake NN N
of IN N
calcium NN 3_i
and CC N
fibre JJ 3_i
reduces NNS N
colorectal JJ N
carcinogenesis NN N
. . N

Available JJ N
data NNS N
are VBP N
not RB N
sufficient JJ N
to TO N
serve VB N
as IN N
a DT N
basis NN N
for IN N
firm NN N
dietary JJ N
advice NN N
. . N

We PRP N
undertook VBD N
a DT N
multicentre NN N
randomised VBN N
trial NN N
to TO N
test VB N
the DT N
effect NN N
of IN N
diet JJ 3_i
supplementation NN 3_i
with IN 3_i
calcium NN 3_i
and CC 3_i
fibre NN 3_i
on IN N
adenoma NN N
recurrence NN N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
665 CD N
patients NNS N
with IN N
a DT N
history NN N
of IN N
colorectal JJ N
adenomas NN N
to TO N
three CD N
treatment NN N
groups NNS N
, , N
in IN N
a DT N
parallel JJ N
design NN N
: : N
calcium NN 6_i
gluconolactate NN 6_i
and CC 6_i
carbonate NN 6_i
( ( 6_i
2 CD 6_i
g NN 6_i
elemental JJ 6_i
calcium NN 6_i
daily RB 6_i
) ) 6_i
, , N
fibre JJ 6_i
( ( 6_i
3.5 CD 6_i
g NN 6_i
ispaghula NN 6_i
husk NN 6_i
) ) 6_i
, , N
or CC N
placebo NN 7_i
. . N

Participants NNS N
had VBD N
colonoscopy NN N
after IN N
3 CD N
years NNS N
of IN N
follow-up NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
adenoma JJ N
recurrence NN N
. . N

Analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
23 CD N
patients NNS N
died VBD N
, , N
15 CD N
were VBD N
lost VBN N
to TO N
follow-up NN N
, , N
45 CD N
refused VBD N
repeat NN N
colonoscopy NN N
, , N
and CC N
five CD N
developed NNS N
severe JJ N
contraindications NNS N
to TO N
colonoscopy VB N
. . N

Among IN N
the DT N
552 CD N
participants NNS N
who WP N
completed VBD N
the DT N
follow-up JJ N
examination NN N
, , N
94 CD N
stopped VBD N
treatment NN N
early RB N
. . N

At IN N
least JJS N
one CD N
adenoma NN N
developed VBD N
in IN N
28 CD N
( ( N
15.9 CD N
% NN N
) ) N
of IN N
176 CD N
patients NNS N
in IN N
the DT N
calcium NN N
group NN N
, , N
58 CD N
( ( N
29.3 CD N
% NN N
) ) N
of IN N
198 CD N
in IN N
the DT N
fibre NN N
group NN N
, , N
and CC N
36 CD N
( ( N
20.2 CD N
% NN N
) ) N
of IN N
178 CD N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
adjusted JJ N
odds NNS N
ratio NN N
for IN N
recurrence NN N
was VBD N
0.66 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.38-1.17 CD N
; : N
p=0.16 NN N
) ) N
for IN N
calcium NN N
treatment NN N
and CC N
1.67 CD N
( ( N
1.01-2.76 CD N
, , N
p=0.042 NN N
) ) N
for IN N
the DT N
fibre JJ N
treatment NN N
. . N

The DT N
odds NNS N
ratio NN N
associated VBN N
with IN N
the DT N
fibre NN N
treatment NN N
was VBD N
significantly RB N
higher JJR N
in IN N
participants NNS N
with IN N
baseline NN N
dietary JJ N
calcium NN N
intake NN N
above IN N
the DT N
median JJ N
than IN N
in IN N
those DT N
with IN N
intake JJ N
below IN N
the DT N
median NN N
( ( N
interaction JJ N
test NN N
, , N
p=0.028 NN N
) ) N
INTERPRETATION NNP N
Supplementation NNP N
with IN N
fibre NN N
as IN N
ispaghula JJ N
husk NN N
may MD N
have VB N
adverse JJ N
effects NNS N
on IN N
colorectal JJ N
adenoma NN N
recurrence NN N
, , N
especially RB N
in IN N
patients NNS N
with IN N
high JJ N
dietary JJ N
calcium NN N
intake NN N
. . N

Calcium NNP N
supplementation NN N
was VBD N
associated VBN N
with IN N
a DT N
modest JJ N
but CC N
not RB N
significant JJ N
reduction NN N
in IN N
the DT N
risk NN N
of IN N
adenoma JJ N
recurrence NN N
. . N

-DOCSTART- -X- O O

Braced NNP N
for IN N
impact NN N
: : N
reducing VBG N
military JJ N
paratroopers NNS N
' POS N
ankle NN N
sprains NNS N
using VBG N
outside-the-boot JJ 2_i
braces NNS 2_i
. . N

BACKGROUND NNP N
Ankle NNP N
injuries VBZ N
account NN N
for IN N
30 CD N
to TO N
60 CD N
% NN N
of IN N
all DT N
parachuting VBG N
injuries NNS N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
if IN N
outside-the-boot JJ N
ankle NN N
braces NNS N
could MD N
reduce VB N
ankle JJ N
sprains NNS N
during IN N
Army NNP N
paratrooper IN N
training NN N
. . N

METHODS NNP N
The DT N
randomized JJ N
trial NN N
involved VBD N
777 CD N
volunteers NNS N
from IN N
the DT N
U.S. NNP N
Army NNP N
Airborne NNP N
School NNP N
, , N
Fort NNP N
Benning NNP N
, , N
Ga. NNP N
Of IN N
this DT N
group NN N
, , N
745 CD N
completed VBD N
all DT N
study NN N
requirements NNS N
( ( N
369 CD N
brace-wearers NNS 6_i
and CC N
376 CD N
non-brace-wearers NNS 4_i
) ) 4_i
. . N

Each DT N
volunteer NN N
made VBD N
five CD N
parachute NN N
jumps NNS N
, , N
for IN N
a DT N
total NN N
of IN N
3,674 CD N
jumps NNS N
. . N

RESULTS VB N
The DT N
incidence NN N
of IN N
inversion NN N
ankle NN N
sprains NNS N
was VBD N
1.9 CD N
% NN N
in IN N
non-brace-wearers NNS N
and CC N
0.3 CD N
% NN N
in IN N
brace-wearers NNS N
( ( N
risk NN N
ratio NN N
, , N
6.9 CD N
; : N
p NN N
= VBZ N
0.04 CD N
) ) N
. . N

Other JJ N
injuries NNS N
appeared VBD N
unaffected JJ N
by IN N
the DT N
brace NN N
. . N

Overall NNP N
, , N
5.3 CD N
% NN N
of IN N
the DT N
non-brace JJ N
group NN N
and CC N
4.6 CD N
% NN N
of IN N
the DT N
brace NN N
group NN N
experienced VBD N
at IN N
least JJS N
one CD N
injury NN N
. . N

The DT N
risk NN N
ratio NN N
for IN N
injured JJ N
individuals NNS N
was VBD N
1.2:1 CD N
( ( N
non-brace NN N
to TO N
brace VB N
groups NNS N
; : N
p CC N
= VB N
0.65 CD N
) ) N
. . N

CONCLUSION NNP N
Inversion NNP N
ankle NN N
sprains NNS N
during IN N
parachute JJ N
training NN N
can MD N
be VB N
significantly RB N
reduced VBN N
by IN N
using VBG N
an DT N
outside-the-boot JJ N
ankle NN N
brace NN N
, , N
with IN N
no DT N
increase NN N
in IN N
risk NN N
for IN N
other JJ N
injuries NNS N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
prethrombolytic JJ 3_i
cyclosporine-A JJ 3_i
injection NN 3_i
on IN N
clinical JJ N
outcome NN N
of IN N
acute JJ N
anterior JJ N
ST-elevation NNP N
myocardial JJ N
infarction NN N
. . N

INTRODUCTION NNP N
Reperfusion NNP N
injury NN N
reduces VBZ N
the DT N
benefits NNS N
of IN N
early JJ N
reperfusion NN N
therapies NNS N
after IN N
acute JJ N
ST-elevation NNP N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
. . N

Cyclosporine-A NNP 3_i
( ( 3_i
CsA NNP 3_i
) ) 3_i
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
opening NN N
of IN N
the DT N
mitochondrial JJ N
permeability NN N
transition NN N
pore NN N
, , N
which WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
play VB N
a DT N
key JJ N
role NN N
in IN N
myocardial JJ N
reperfusion NN N
injury NN N
. . N

The DT N
impact NN N
of IN N
this DT N
treatment NN N
on IN N
clinical JJ N
outcomes NNS N
of IN N
acute JJ N
STEMI NNP N
remains VBZ N
unknown JJ N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
investigate VB N
the DT N
clinical JJ N
outcomes NNS N
of IN N
using VBG N
this DT N
drug NN N
in IN N
patients NNS N
with IN N
acute JJ N
anterior JJ N
STEMI NNP N
receiving VBG N
thrombolytic JJ N
treatment NN N
( ( N
TLT NNP N
) ) N
. . N

METHODS NNP N
In IN N
this DT N
double-blinded JJ N
randomized JJ N
clinical JJ N
trial NN N
, , N
101 CD N
patients NNS N
with IN N
acute JJ N
anterior JJ N
STEMI NNP N
who WP N
were VBD N
candidate NN N
for IN N
TLT NNP N
, , N
were VBD N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
into IN N
treatment NN N
or CC N
control NN N
groups NNS N
. . N

Patients NNS N
in IN N
the DT N
treatment NN N
group NN N
received VBD N
an DT N
intravenous JJ N
bolus NN N
injection NN N
of IN N
2.5 CD N
mg/kg NN N
of IN N
CsA NNP 3_i
immediately RB N
before IN N
TLT NNP N
. . N

The DT N
patients NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
an DT N
equivalent JJ N
volume NN N
of IN N
normal JJ 7_i
saline NN 7_i
. . N

Infarct NNP N
size NN N
, , N
occurrence NN N
of IN N
major JJ N
arrhythmias NNS N
, , N
heart NN N
failure NN N
, , N
left VBD N
ventricular JJ N
ejection NN N
fraction NN N
( ( N
LVEF NNP N
) ) N
, , N
TLT-related JJ N
complications NNS N
, , N
in-hospital JJ N
and CC N
6-month JJ N
mortality NN N
rates NNS N
were VBD N
investigated VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
the DT N
demographics NNS N
, , N
myocardial JJ N
enzyme NN N
release NN N
, , N
occurrence NN N
of IN N
major JJ N
arrhythmias NNS N
[ VBP N
9 CD N
( ( N
18 CD N
% NN N
) ) N
vs. FW N
12 CD N
( ( N
23.5 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.80 CD N
] NN N
, , N
heart NN N
failure NN N
[ VBZ N
18 CD N
( ( N
36 CD N
% NN N
) ) N
vs. FW N
19 CD N
( ( N
38.3 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.83 CD N
] NN N
, , N
LVEF NNP N
at IN N
first JJ N
day NN N
[ VB N
34.7 CD N
? . N
9.9 CD N
% NN N
vs. FW N
33.5 CD N
? . N
8.1 CD N
% NN N
, , N
P NNP N
= VBZ N
0.50 CD N
] NN N
or CC N
at IN N
discharge NN N
[ $ N
37.7 CD N
? . N
10 CD N
% NN N
vs. FW N
36.1 CD N
? . N
8.2 CD N
% NN N
, , N
P NNP N
= VBZ N
0.43 CD N
] NN N
, , N
and CC N
in-hospital JJ N
[ NN N
4 CD N
( ( N
8 CD N
% NN N
) ) N
vs. FW N
6 CD N
( ( N
11.8 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.74 CD N
] NN N
or CC N
6-month JJ N
mortality NN N
rates NNS N
[ VBP N
9 CD N
( ( N
18 CD N
% NN N
) ) N
vs. FW N
10 CD N
( ( N
19.6 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.99 CD N
] NN N
between IN N
the DT N
CsA NNP N
vs. IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
the DT N
prethrombolytic JJ N
administration NN N
of IN N
CsA NNP N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
infarct JJ N
size NN N
or CC N
any DT N
improvement NN N
in IN N
clinical JJ N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Sodium-potassium JJ 3_i
pump NN 3_i
activity NN 3_i
in IN N
white JJ N
blood NN N
cells NNS N
from IN N
children NNS N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
developing VBG N
hypertension NN N
-- : N
The DT N
Odense NNP N
Schoolchild NNP N
Study NNP N
. . N

We PRP N
have VBP N
measured VBN N
the DT N
capacity NN N
of IN N
the DT N
sodium-potassium JJ 3_i
pump NN 3_i
, , N
as IN N
assessed VBN N
by IN N
86rubidium CD N
uptake NN N
and CC N
the DT N
number NN N
of IN N
[ $ N
3H CD N
] NNP N
-ouabain NN N
binding VBG N
sites NNS N
on IN N
white JJ N
blood NN N
cells NNS N
, , N
in IN N
children NNS N
aged VBN N
9-11 CD N
years NNS N
, , N
partly RB N
cross-sectionally RB N
and CC N
partly RB N
longitudinally RB N
after IN N
a DT N
physical JJ 2_i
training NN 2_i
programme NN 2_i
. . 4_i

Children NNP N
from IN N
a DT N
hypertensive JJ N
subgroup NN N
comprising VBG N
the DT N
upper JJ N
5 CD N
% NN N
of IN N
the DT N
blood NN N
pressure NN N
distribution NN N
and CC N
children NNS N
from IN N
a DT N
randomly RB N
selected VBN N
normotensive JJ N
subgroup NN N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
. . N

In IN N
the DT N
cross-sectional JJ N
study NN N
40 CD N
children NNS N
from IN N
the DT N
hypertensive JJ N
subgroup NN N
and CC N
40 CD N
children NNS N
from IN N
the DT N
normotensive JJ N
subgroup NN N
were VBD N
evaluated VBN N
. . N

A DT N
significant JJ N
increase NN N
in IN N
86rubidium CD N
uptake NN N
was VBD N
present JJ N
in IN N
boys NN N
as IN N
compared VBN N
to TO N
girls NNS N
. . N

After IN N
adjustment NN N
for IN N
differences NNS N
in IN N
sexual JJ N
maturation NN N
the DT N
observed JJ N
significant JJ N
difference NN N
disappeared VBD N
. . N

Important NNP N
correlates NNS N
of IN N
pump NN 2_i
activity NN 2_i
were VBD N
height VBN N
, , N
plasma FW N
glucose NN N
, , N
and CC N
physical JJ N
fitness NN N
. . N

In IN N
the DT N
training NN N
study NN N
10 CD N
boys NNS N
from IN N
the DT N
hypertensive JJ N
subgroup NN N
and CC N
10 CD N
boys NNS N
from IN N
the DT N
normotensive JJ N
subgroup NN N
were VBD N
also RB N
evaluated VBN N
after IN N
eight CD N
months NNS N
of IN N
physical JJ N
training NN N
. . N

A DT N
significant JJ N
fall NN N
in IN N
86rubidium CD N
uptake NN N
was VBD N
observed VBN N
. . N

No DT N
control NN N
group NN N
was VBD N
examined VBN N
and CC N
probably RB N
the DT N
changes NNS N
reflect VBP N
some DT N
effects NNS N
of IN N
sexual JJ N
maturation NN N
on IN N
cation NN N
handling NN N
of IN N
cells NNS N
. . N

These DT N
results NNS N
indicate VBP N
a DT N
significant JJ N
effect NN N
of IN N
sexual JJ N
maturation NN N
in IN N
capacity NN N
of IN N
sodium-potassium JJ 3_i
pump NN 3_i
in IN N
children NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
shearing VBG 2_i
on IN N
water NN N
turnover NN N
and CC N
thermobiological JJ N
variables NNS N
in IN N
German JJ N
Blackhead NNP N
mutton NN N
sheep NN N
. . N

Current JJ N
equations NNS N
for IN N
estimating VBG N
water NN N
requirements NNS N
in IN N
sheep JJ N
do VBP N
not RB N
differentiate VB N
between IN N
shorn JJ N
and CC N
unshorn JJ N
sheep NN N
. . N

Furthermore RB N
, , N
the DT N
effect NN N
of IN N
shearing VBG N
on IN N
thermoregulative JJ N
responses NNS N
in IN N
sheep NN N
has VBZ N
not RB N
been VBN N
adequately RB N
studied VBN N
under IN N
temperate JJ N
environmental JJ N
conditions NNS N
. . N

Therefore RB N
, , N
the DT N
present JJ N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
wool NN N
coverage NN N
on IN N
water NN N
turnover NN N
in IN N
relation NN N
to TO N
thermoregulation NN N
in IN N
sheep NN N
by IN N
using VBG N
the DT N
deuterium NN N
dilution NN N
technique NN N
to TO N
predict VB N
total JJ N
water NN N
intake NN N
before IN N
and CC N
after IN N
shearing VBG 2_i
. . N

Physiological JJ N
responses NNS N
, , N
such JJ N
as IN N
water NN N
turnover NN N
, , N
surface NN N
temperature NN N
, , N
and CC N
rectal JJ N
temperature NN N
, , N
as RB N
well RB N
as IN N
drinking VBG N
behavior NN N
of IN N
sheep NN N
were VBD N
also RB N
evaluated VBN N
. . N

Fourteen NNP N
nonlactating JJ N
German JJ N
Blackhead NNP N
mutton NN N
ewes NN N
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
groups NNS N
: : N
a DT 7_i
control NN 7_i
group NN 7_i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
that WDT N
was VBD N
already RB 2_i
shorn VBN 2_i
, , N
and CC N
a DT N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
that WDT N
was VBD N
left VBN 7_i
unshorn JJ 7_i
( ( N
wool JJ N
length NN N
: : N
10.6 CD N
? . N
1.2 CD N
cm NN N
) ) N
. . N

Individual NNP N
feed NN N
and CC N
water NN N
intakes NNS N
were VBD N
recorded VBN N
throughout IN N
the DT N
experiment NN N
( ( N
d JJ N
1 CD N
to TO N
71 CD N
) ) N
. . N

Two CD N
weeks NNS N
after IN N
measurements NNS N
commenced VBD N
( ( N
d JJ N
15 CD N
) ) N
, , N
treatment NN N
sheep NN N
were VBD N
shorn VBN N
. . N

Water NNP N
intake NN N
was VBD N
estimated VBN N
twice RB N
for IN N
2 CD N
consecutive JJ N
weeks NNS N
by IN N
using VBG N
deuterium JJ N
dilution NN N
techniques NNS N
( ( N
d VB N
1 CD N
to TO N
15 CD N
and CC N
d VB N
57 CD N
to TO N
71 CD N
) ) N
. . N

Ambient JJ N
temperature NN N
( ( N
T NNP N
( ( N
a DT N
) ) N
) ) N
, , N
relative JJ N
humidity NN N
, , N
and CC N
respiratory JJ N
rate NN N
were VBD N
measured VBN N
daily RB N
, , N
whereas JJ N
BW NNP N
, , N
rectal NN N
and CC N
animal JJ N
surface NN N
temperatures NNS N
( ( N
using VBG N
infrared VBN N
thermography NN N
) ) N
, , N
and CC N
wool JJ N
length NN N
were VBD N
measured VBN N
weekly RB N
. . N

In IN N
the DT N
first JJ N
2 CD N
wk NN N
, , N
when WRB N
treatment NN N
sheep NN N
were VBD N
unshorn JJ N
, , N
treatment NN N
and CC N
control NN N
ewes NN N
differed VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
DMI NNP N
( ( N
52 CD N
? . N
4 CD N
vs. IN N
59 CD N
? . N
4 CD N
g?kg NN N
( ( N
-0.75 NNP N
) ) N
?d NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
water NN N
intake NN N
( ( N
165 CD N
? . N
17 CD N
vs. IN N
134 CD N
? . N
18 CD N
g?kg NN N
( ( N
-0.75 NNP N
) ) N
?d NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
respiratory JJ N
rate NN N
( ( N
66 CD N
? . N
5 CD N
vs. IN N
31 CD N
? . N
4 CD N
breath/min NN N
) ) N
, , N
rectal JJ N
temperature NN N
( ( N
39.3 CD N
? . N
0.2 CD N
vs. IN N
38.8 CD N
? . N
0.1?C CD N
) ) N
, , N
and CC N
surface NN N
temperatures NNS N
( ( N
body JJ N
side NN N
: : N
19.3 CD N
? . N
0.3 CD N
vs. IN N
24.5 CD N
? . N
0.6?C CD N
; : N
leg NN N
: : N
25.8 CD N
? . N
2.4 CD N
vs. IN N
27.4 CD N
? . N
1.6?C CD N
) ) N
. . N

However RB N
, , N
after IN N
shearing VBG N
, , N
these DT N
differences NNS N
partly RB N
disappeared VBD N
. . N

The DT N
same JJ N
trend NN N
in IN N
water NN N
intake NN N
between IN N
groups NNS N
was VBD N
confirmed VBN N
using VBG N
the DT N
isotope NN N
dilution NN N
technique NN N
. . N

We PRP N
found VBD N
a DT N
significant JJ N
relationship NN N
between IN N
T NNP N
( ( N
a DT N
) ) N
and CC N
water NN N
intake NN N
, , N
respiratory NN N
rate NN N
, , N
and CC N
body NN N
surface NN N
temperatures NNS N
. . N

Even RB N
under IN N
temperate NN N
conditions NNS N
( ( N
T NNP N
( ( N
a DT N
) ) N
< $ N
28?C CD N
) ) N
, , N
shearing VBG N
significantly RB N
reduced VBN N
core NN N
body NN N
temperature NN N
, , N
water NN N
intake NN N
, , N
and CC N
respiratory NN N
rate NN N
in IN N
German JJ N
Blackhead NNP N
mutton NN N
sheep NN N
, , N
thus RB N
indicating VBG N
heat NN N
stress NN N
in IN N
fleeced JJ N
animals NNS N
, , N
which WDT N
should MD N
be VB N
considered VBN N
when WRB N
determining VBG N
the DT N
optimal JJ N
shearing NN N
time NN N
in IN N
sheep NN N
as RB N
well RB N
as IN N
when WRB N
estimating VBG N
water NN N
requirements NNS N
. . N

-DOCSTART- -X- O O

Around-the-clock NNP N
intraocular JJ N
pressure NN N
reduction NN N
with IN N
once-daily JJ N
application NN N
of IN N
latanoprost NN 3_i
by IN N
itself PRP N
or CC N
in IN N
combination NN 3_i
with IN 3_i
timolol NN 3_i
. . N

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
once-daily RB N
, , N
in IN N
the DT N
morning NN N
, , N
topical JJ N
application NN N
of IN N
the DT N
new JJ N
ocular JJ N
hypotensive JJ N
prostaglandin NN N
analogue NN N
, , N
latanoprost NN 3_i
, , N
yields NNS N
nocturnal JJ N
intraocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
reduction NN N
similar JJ N
to TO N
its PRP$ N
diurnal JJ N
IOP NNP N
reducing VBG N
efficacy NN N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
PATIENTS NNP N
Placebo- NNP N
controlled VBD N
, , N
randomized VBN N
, , N
and CC N
double-masked JJ N
study NN N
on IN N
hospitalized JJ N
patients NNS N
with IN N
ocular JJ N
hypertension NN N
or CC N
glaucoma NN N
. . N

Patients NNS N
in IN N
group NN N
1 CD N
( ( N
n=9 NN N
) ) N
were VBD N
maintained VBN N
on IN N
twice-daily JJ N
applications NNS N
of IN N
0.5 CD N
% NN N
timolol JJ 3_i
maleate NN 3_i
. . N

Patients NNS N
in IN N
group NN N
2 CD N
( ( N
n=10 NN N
) ) N
terminated VBD N
their PRP$ N
timolol NN 3_i
treatment NN N
3 CD N
weeks NNS N
before IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
. . N

In IN N
both DT N
groups NNS N
the DT N
test NN N
drug NN N
( ( N
0.005 CD N
% NN N
latanoprost NN 3_i
) ) N
and CC N
its PRP$ N
vehicle NN N
( ( N
placebo NN 7_i
) ) N
was VBD N
applied VBN N
by IN N
hospital JJ N
staff NN N
every DT N
morning NN N
for IN N
9 CD N
days NNS N
. . N

MEASUREMENTS NNS N
After IN N
4 CD N
days NNS N
of IN N
ambulatory JJ N
treatment NN N
, , N
patients NNS N
were VBD N
hospitalized VBN N
, , N
and CC N
IOP NNP N
values NNS N
were VBD N
obtained VBN N
in IN N
the DT N
supine NN N
and CC N
sitting VBG N
positions NNS N
with IN N
a DT N
handheld NN N
electronic JJ N
tonometer NN N
( ( N
Tono-Pen NNP N
XL NNP N
, , N
Bio-Rad NNP N
, , N
Glendale NNP N
, , N
Calif NNP N
) ) N
and CC N
a DT N
Goldmann NNP N
's POS N
applanation NN N
tonometer NN N
, , N
covering VBG N
every DT N
2-hour CD N
interval NN N
, , N
around IN N
the DT N
clock NN N
, , N
but CC N
not RB N
more JJR N
than IN N
at IN N
four CD N
time NN N
points NNS N
per IN N
day NN N
during IN N
a DT N
5-day JJ N
period NN N
. . N

RESULTS VB N
The DT N
mean JJ N
nocturnal JJ N
IOPs NNP N
( ( N
Goldmann NNP N
's POS N
applanation NN N
tonometer NN N
) ) N
collected VBD N
for IN N
5 CD N
days NNS N
were VBD N
mean JJ N
+/-SEM JJ N
17.9+/-0.6 JJ N
vs NN N
20.2+/-0.6 JJ N
mm NN N
Hg NNP N
and CC N
16.8+/-0.3 JJ N
vs NN N
20.6+/-0.5 JJ N
mm NN N
Hg NNP N
for IN N
the DT N
study NN N
vs IN N
the DT N
control NN N
eyes NNS N
in IN N
group NN N
1 CD N
and CC N
group NN N
2 CD N
, , N
respectively RB N
. . N

These DT N
nocturnal JJ N
IOP NNP N
reductions NNS N
were VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
, , N
two-tailed JJ N
paired VBD N
Student NNP N
's POS N
t JJ N
test NN N
) ) N
. . N

The DT N
differences NNS N
between IN N
diurnal JJ N
and CC N
nocturnal JJ N
IOP NNP N
reductions NNS N
( ( N
handheld JJ N
electronic JJ N
or CC N
Goldmann NNP N
's POS N
applanation NN N
tonometer NN N
) ) N
were VBD N
minimal JJ N
( ( N
> JJ N
0.3 CD N
mm NN N
Hg NNP N
) ) N
and CC N
statistically RB N
not RB N
significant JJ N
( ( N
P NNP N
> NNP N
.31 NNP N
, , N
two-tailed JJ N
paired VBD N
Student NNP N
's POS N
t JJ N
test NN N
) ) N
. . N

CONCLUSION NNP N
Once-daily JJ N
latanoprost NN 3_i
treatment NN N
provides VBZ N
uniform JJ N
circadian JJ N
( ( N
around-the-clock NN N
) ) N
IOP NNP N
reduction NN N
by IN N
itself PRP N
, , N
or CC N
in IN N
combination NN N
with IN N
timolol NN 3_i
. . N

-DOCSTART- -X- O O

[ NN N
Limbal NNP 1_i
epithelial NN 1_i
autograft NN 1_i
transplantation NN 1_i
in IN N
treatment NN N
of IN N
pterygium NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
therapeutic JJ N
effects NNS N
of IN N
limbal JJ 1_i
epithelial JJ 1_i
autograft NN 1_i
transplantation NN 1_i
and CC N
pterygium NN 1_i
excision NN 1_i
in IN N
the DT N
treatment NN N
of IN N
pterygium NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
paired-eye JJ N
trial NN N
was VBD N
studied VBN N
. . N

There EX N
were VBD N
208 CD N
patients NNS N
( ( N
229 CD N
eyes NNS N
) ) N
with IN N
initial JJ N
pterygium NN N
, , N
and CC N
they PRP N
were VBD N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
excision NN 1_i
of IN 1_i
pterygium NN 1_i
with IN 1_i
limbal JJ 1_i
epithelial JJ 1_i
autograft NN 1_i
transplantation NN 1_i
surgery NN 1_i
( ( N
A NNP N
group NN N
, , N
106 CD N
cases NNS N
and CC N
124 CD N
eyes NNS N
) ) N
and CC N
simple JJ 1_i
pterygium NN 1_i
excision NN 1_i
( ( N
B NNP N
group NN N
, , N
102 CD N
cases NNS N
and CC N
105 CD N
eyes NNS N
) ) N
. . N

The DT N
criteria NN N
for IN N
recovery NN N
were VBD N
corneal JJ N
transparency NN N
with IN N
stable JJ N
epithelial JJ N
healing NN N
and CC N
no DT N
abnormal JJ N
proliferation NN N
of IN N
pterygium-like JJ N
tissue NN N
. . N

The DT N
post-operative JJ N
follow-up JJ N
periods NNS N
ranged VBD N
from IN N
18 CD N
approximately RB N
28 CD N
( ( N
22.4 CD N
+/- JJ N
4.9 CD N
) ) N
months NNS N
. . N

RESULTS NNP N
Some DT N
of IN N
the DT N
patients NNS N
lost VBD N
follow-up JJ N
. . N

In IN N
the DT N
eyes NNS N
followed VBD N
up RB N
, , N
5 CD N
of IN N
11 CD N
2 CD N
eyes NNS N
( ( N
4.5 CD N
% NN N
) ) N
in IN N
A NNP N
group NN N
and CC N
41 CD N
of IN N
96 CD N
eyes NNS N
( ( N
42.7 CD N
% NN N
) ) N
in IN N
B NNP N
group NN N
were VBD N
recurred VBN N
, , N
the DT N
difference NN N
being VBG N
very RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
To TO N
provide VB N
a DT N
new JJ N
stem NN N
cell NN N
source NN N
, , N
limbal JJ 1_i
epithelial JJ 1_i
autograft NN 1_i
transplantation NN 1_i
, , N
for IN N
an DT N
injured JJ N
limb NN N
us PRP N
is VBZ N
a DT N
reasonable JJ N
therapeutic JJ N
method NN N
for IN N
the DT N
treatment NN N
of IN N
pterygium NN N
. . N

-DOCSTART- -X- O O

Language NN N
, , N
speech NN N
sound NN N
production NN N
, , N
and CC N
cognition NN N
in IN N
three-year-old JJ N
children NNS N
in IN N
relation NN N
to TO N
otitis VB N
media NNS N
in IN N
their PRP$ N
first JJ N
three CD N
years NNS N
of IN N
life NN N
. . N

OBJECTIVE CC N
As IN N
part NN N
of IN N
a DT N
prospective JJ N
study NN N
of IN N
possible JJ N
effects NNS N
of IN N
early-life JJ N
otitis NN N
media NNS N
on IN N
speech NN N
, , N
language NN N
, , N
cognitive JJ N
, , N
and CC N
psychosocial JJ N
development NN N
, , N
we PRP N
tested VBD N
relationships NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
duration NN N
of IN N
middle JJ N
ear JJ N
effusion NN N
( ( N
MEE NNP N
) ) N
in IN N
their PRP$ N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
and CC N
their PRP$ N
scores NNS N
on IN N
measures NNS N
of IN N
language NN N
, , N
speech NN N
sound NN N
production NN N
, , N
and CC N
cognition NN N
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

METHODS NNP N
We PRP N
enrolled VBD N
6350 CD N
healthy JJ N
infants NNS N
by IN N
2 CD N
months NNS N
of IN N
age NN N
who WP N
presented VBD N
for IN N
primary JJ N
care NN N
at IN N
1 CD N
of IN N
2 CD N
urban JJ N
hospitals NNS N
or CC N
1 CD N
of IN N
2 CD N
small JJ N
town/rural JJ N
and CC N
4 CD N
suburban JJ N
private JJ N
pediatric JJ N
practices NNS N
. . N

We PRP N
intensively RB N
monitored VBD N
the DT N
children NNS N
's POS N
middle JJ N
ear NN N
status NN N
by IN N
pneumatic JJ 2_i
otoscopy NN 2_i
, , N
supplemented VBN 2_i
by IN 2_i
tympanometry NN 2_i
, , N
throughout IN N
their PRP$ N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
; : N
we PRP N
monitored VBD N
the DT N
validity NN N
of IN N
the DT N
otoscopic JJ N
observations NNS N
on IN N
an DT N
ongoing JJ N
basis NN N
; : N
and CC N
we PRP N
treated VBD N
children NNS N
for IN N
otitis NN 2_i
media NNS 2_i
according VBG N
to TO N
specified VBN N
guidelines NNS N
. . N

Children NNP N
who WP N
met VBD N
specified VBN N
minimum JJ N
criteria NNS N
regarding VBG N
the DT N
persistence NN N
of IN N
MEE NNP N
became VBD N
eligible JJ N
for IN N
a DT N
clinical JJ N
trial NN N
in IN N
which WDT N
they PRP N
were VBD N
assigned VBN N
randomly RB N
to TO N
undergo VB N
tympanostomy JJ 1_i
tube NN 1_i
placement NN 1_i
either CC N
promptly RB N
or CC N
after IN N
a DT N
defined JJ N
extended JJ N
period NN N
if IN N
MEE NNP N
remained VBD N
present JJ N
. . N

From IN N
among IN N
those DT N
remaining VBG N
, , N
we PRP N
selected VBD N
randomly RB N
, , N
within IN N
sociodemographic JJ N
strata NNS N
, , N
a DT N
sample NN N
of IN N
241 CD N
children NNS N
who WP N
represented VBD N
a DT N
spectrum NN N
of IN N
MEE NNP N
experience NN N
from IN N
having VBG N
no DT N
MEE NNP N
to TO N
having VBG N
MEE NNP N
whose WP$ N
cumulative JJ N
duration NN N
fell VBD N
just RB N
short RB N
of IN N
meeting VBG N
randomization NN N
criteria NNS N
. . N

In IN N
subjects NNS N
so RB N
selected VBN N
, , N
the DT N
estimated JJ N
duration NN N
of IN N
MEE NNP N
ranged VBD N
from IN N
none NN N
to TO N
65.6 CD N
% NN N
of IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
and CC N
44.8 CD N
% NN N
of IN N
the DT N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
. . N

In IN N
these DT N
241 CD N
children NNS N
we PRP N
assessed VBD N
language NN N
development NN N
, , N
speech NN N
sound NN N
production NN N
, , N
and CC N
cognition NN N
at IN N
3 CD N
years NNS N
of IN N
age NN N
, , N
using VBG N
both DT N
formal JJ N
tests NNS N
and CC N
conversational JJ N
samples NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
weak JJ N
to TO N
moderate VB N
, , N
statistically RB N
significant JJ N
negative JJ N
correlations NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
durations NNS N
of IN N
MEE NNP N
in IN N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
or CC N
in IN N
age NN N
periods NNS N
that WDT N
included VBD N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
, , N
and CC N
their PRP$ N
scores NNS N
on IN N
formal JJ N
tests NNS N
of IN N
receptive JJ N
vocabulary NN N
and CC N
verbal JJ N
aspects NNS N
of IN N
cognition NN N
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

However RB N
, , N
the DT N
percent NN N
of IN N
variance NN N
in IN N
these DT N
scores NNS N
explained VBN N
by IN N
time NN N
with IN N
MEE NNP N
in IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
beyond IN N
that DT N
explained VBN N
by IN N
sociodemographic JJ N
variables NNS N
ranged VBD N
only RB N
from IN N
1.2 CD N
% NN N
to TO N
2.9 CD N
% NN N
, , N
and CC N
the DT N
negative JJ N
correlations NNS N
were VBD N
concentrated VBN N
in IN N
the DT N
subgroup NN N
of IN N
children NNS N
whose WP$ N
families NNS N
had VBD N
private JJ N
health NN N
insurance NN N
( ( N
rather RB N
than IN N
Medicaid NNP N
) ) N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
correlations NNS N
in IN N
the DT N
study NN N
population NN N
as IN N
a DT N
whole NN N
or CC N
in IN N
any DT N
subgroup NN N
between IN N
time NN N
with IN N
MEE NNP N
during IN N
antecedent JJ N
periods NNS N
and CC N
children NNS N
's POS N
scores NNS N
on IN N
measures NNS N
of IN N
spontaneous JJ N
expressive JJ N
language NN N
, , N
speech NN N
sound NN N
production NN N
, , N
or CC N
other JJ N
measured JJ N
aspects NNS N
of IN N
cognition NN N
. . N

In IN N
contrast NN N
, , N
by IN N
wide JJ N
margins NNS N
, , N
scores NNS N
on IN N
all DT N
measures NNS N
were VBD N
consistently RB N
highest JJS N
among IN N
the DT N
most RBS N
socioeconomically RB N
advantaged JJ N
children NNS N
and CC N
lowest JJS N
among IN N
the DT N
most RBS N
socioeconomically RB N
disadvantaged JJ N
children NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
either RB N
that DT N
persistent JJ N
early-life JJ N
MEE NNP N
actually RB N
causes VBZ N
later RB N
small JJ N
, , N
circumscribed JJ N
impairments NNS N
of IN N
receptive JJ N
language NN N
and CC N
verbal JJ N
aspects NNS N
of IN N
cognition NN N
in IN N
certain JJ N
groups NNS N
of IN N
children NNS N
or CC N
that DT N
unidentified JJ N
, , N
confounding VBG N
factors NNS N
predispose JJ N
children NNS N
both DT N
to TO N
early-life NN N
otitis NN N
media NNS N
and CC N
to TO N
certain JJ N
types NNS N
of IN N
developmental JJ N
impairment NN N
. . N

Findings NNS N
in IN N
the DT N
randomized JJ N
clinical JJ N
trial NN N
component NN N
of IN N
the DT N
larger JJR N
study NN N
should MD N
help VB N
distinguish VB N
between IN N
causality NN N
and CC N
confounding NN N
as IN N
explanations NNS N
for IN N
our PRP$ N
findings.language NN N
, , N
speech NN N
, , N
cognition NN N
, , N
development NN N
, , N
otitis NN N
media NNS N
, , N
middle JJ N
ear JJ N
effusion NN N
. . N

-DOCSTART- -X- O O

A DT N
double-blind NN N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
multicenter NN N
study NN N
to TO N
assess VB N
the DT N
safety NN N
and CC N
cardiovascular JJ N
effects NNS N
of IN N
skeletal JJ 2_i
myoblast NN 2_i
implantation NN 2_i
by IN 2_i
catheter NN 2_i
delivery NN 2_i
in IN N
patients NNS N
with IN N
chronic JJ N
heart NN N
failure NN N
after IN N
myocardial JJ N
infarction NN N
. . N

BACKGROUND NNP N
We PRP N
sought VBD N
to TO N
determine VB N
the DT N
safety NN N
and CC N
preliminary JJ N
efficacy NN N
of IN N
transcatheter NN 2_i
intramyocardial JJ 2_i
administration NN 2_i
of IN 2_i
myoblasts NNS 2_i
in IN N
patients NNS N
with IN N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
. . N

METHODS NNP N
MARVEL NNP N
is VBZ N
a DT N
randomized JJ N
placebo-controlled JJ 7_i
trial NN N
of IN N
image-guided JJ N
, , N
catheter-based JJ N
intramyocardial JJ N
injection NN N
of IN N
placebo NN 7_i
or CC N
myoblasts NNS 3_i
( ( N
400 CD N
or CC N
800 CD N
million CD N
) ) N
in IN N
patients NNS N
with IN N
class NN N
II NNP N
to TO N
IV NNP N
HF NNP N
and CC N
ejection NN N
fraction NN N
< VBD N
35 CD N
% NN N
. . N

Primary JJ N
end NN N
points NNS N
were VBD N
frequency NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
( ( N
safety NN N
) ) N
and CC N
changes NNS N
in IN N
6-minute JJ N
walk NN N
test NN N
and CC N
Minnesota NNP N
Living NNP N
With IN N
HF NNP N
score NN N
( ( N
efficacy NN N
) ) N
. . N

Of IN N
330 CD N
patients NNS N
intended VBN N
for IN N
enrollment NN N
, , N
23 CD N
were VBD N
randomized VBN N
( ( N
MARVEL-1 NNP N
) ) N
before IN N
stopping VBG N
the DT N
study NN N
for IN N
financial JJ N
reasons NNS N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
similar JJ N
numbers NNS N
of IN N
events NNS N
occurred VBN N
in IN N
each DT N
group NN N
: : N
8 CD N
( ( N
placebo NN 7_i
) ) N
, , N
7 CD N
( ( N
low JJ N
dose NN N
) ) N
, , N
and CC N
8 CD N
( ( N
high JJ N
dose NN N
) ) N
, , N
without IN N
deaths NNS N
. . N

Ventricular JJ N
tachycardia NN N
responsive NN N
to TO N
amiodarone VB N
was VBD N
more RBR N
frequent JJ N
in IN N
myoblast-treated JJ 3_i
patients NNS N
: : N
1 CD N
( ( N
placebo NN 7_i
) ) N
, , N
3 CD N
( ( N
low JJ N
dose NN N
) ) N
, , N
and CC N
4 CD N
( ( N
high JJ N
dose NN N
) ) N
. . N

A DT N
trend NN N
toward IN N
improvement NN N
in IN N
functional JJ N
capacity NN N
was VBD N
noted VBN N
in IN N
myoblast-treated JJ 3_i
groups NNS N
( ( N
?6-minute JJ N
walk NN N
test NN N
of IN N
-3.6 NNP N
vs FW N
+95.6 NNP N
vs FW N
+85.5 NNP N
m FW N
[ NNP N
placebo NN N
vs NN N
low JJ N
dose NN N
vs NN N
high JJ N
dose NN N
; : N
P NNP N
= NNP N
.50 NNP N
] NNP N
) ) N
without IN N
significant JJ N
changes NNS N
in IN N
Minnesota NNP N
Living NNP N
With IN N
HF NNP N
scores NNS N
. . N

CONCLUSIONS NNP N
In IN N
HF NNP N
patients NNS N
with IN N
chronic JJ N
postinfarction NN N
cardiomyopathy NN N
, , N
transcatheter JJ N
administration NN N
of IN N
myoblasts NNS N
in IN N
doses NNS N
of IN N
400 CD N
to TO N
800 CD N
million CD N
cells NNS N
is VBZ N
feasible JJ N
and CC N
may MD N
lead VB N
to TO N
important JJ N
clinical JJ N
benefits NNS N
. . N

Ventricular JJ N
tachycardia NN N
may MD N
be VB N
provoked VBN N
by IN N
myoblast JJ N
injection NN N
but CC N
appears VBZ N
to TO N
be VB N
a DT N
transient NN N
and CC N
treatable JJ N
problem NN N
. . N

A DT N
large-scale JJ N
outcome JJ N
trial NN N
of IN N
myoblast JJ N
administration NN N
in IN N
HF NNP N
patients NNS N
with IN N
postinfarction NN N
cardiomyopathy NN N
is VBZ N
feasible JJ N
and CC N
warranted VBD N
. . N

-DOCSTART- -X- O O

Analgesic JJ N
efficacy NN N
of IN N
caudal JJ 2_i
block NN 2_i
versus NN N
diclofenac NN 3_i
suppository NN 3_i
and CC N
local JJ N
anesthetic JJ N
infiltration NN N
following VBG N
pediatric JJ N
laparoscopy NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
caudal JJ 3_i
block NN 3_i
with IN N
diclofenac JJ 3_i
suppository NN 3_i
and CC N
local JJ 3_i
anesthetic JJ 3_i
infiltration NN 3_i
in IN N
children NNS N
undergoing VBG N
laparoscopy NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
50 CD N
children NNS N
undergoing JJ N
laparoscopy NN N
for IN N
diagnostic JJ N
and CC N
therapeutic JJ N
purposes NNS N
. . N

Their PRP$ N
ages NNS N
ranged VBN N
from IN N
3 CD N
to TO N
13 CD N
years NNS N
, , N
and CC N
all DT N
belonged VBD N
to TO N
American NNP N
Society NNP N
of IN N
Anesthesiologists NNP N
( ( N
ASA NNP N
) ) N
class NN N
I PRP N
or CC N
II NNP N
. . N

Anesthesia NNP 3_i
was VBD N
carried VBN N
out RP N
using VBG N
the DT N
standard JJ N
procedure NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Group NNP N
1 CD N
received VBD N
caudal JJ 3_i
block NN 3_i
with IN 3_i
bupivacaine NN 3_i
1 CD 3_i
mL/kg NN 3_i
after IN 3_i
anesthetic JJ 3_i
induction NN 3_i
. . N

Group NNP N
2 CD N
received VBD N
diclofenac JJ 3_i
suppository JJ 3_i
3 CD 3_i
mg/kg JJ 3_i
postinduction NN 3_i
and CC 3_i
local JJ 3_i
anesthetic JJ 3_i
infiltration NN 3_i
at IN 3_i
the DT 3_i
port NN 3_i
sites VBZ 3_i
at IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
. . N

Pain NN N
was VBD N
assessed VBN N
using VBG N
the DT N
Hannallah NNP N
objective JJ N
pain NN N
scale NN N
at IN N
15 CD N
, , N
30 CD N
, , N
60 CD N
, , N
120 CD N
, , N
and CC N
360 CD N
minutes NNS N
postextubation NN N
. . N

RESULTS VB N
The DT N
pain NN N
scores NNS N
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
at IN N
all DT N
times NNS N
. . N

Twelve NNP N
percent NN N
of IN N
caudal JJ N
block NN N
patients NNS N
and CC N
20 CD N
% NN N
of IN N
diclofenac NN N
patients NNS N
needed VBN N
rescue NN N
analgesic NN N
, , N
a DT N
statistically RB N
insignificant JJ N
difference NN N
. . N

In IN N
2 CD N
patients NNS N
, , N
caudal JJ N
block NN N
was VBD N
technically RB N
difficult JJ N
and CC N
they PRP N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
. . N

The DT N
incidence NN N
of IN N
side NN N
effects NNS N
was VBD N
low JJ N
in IN N
our PRP$ N
study NN N
. . N

CONCLUSION NNP N
We PRP N
find VBP N
the DT N
analgesic JJ N
efficacy NN N
of IN N
diclofenac JJ 3_i
suppository NN 3_i
combined VBN N
with IN N
local JJ N
anesthetic JJ 3_i
infiltration NN 3_i
at IN N
port NN N
sites NNS N
comparable JJ N
to TO N
caudal VB N
block NN N
. . N

Given VBN N
the DT N
necessarily RB N
invasive JJ N
nature NN N
of IN N
caudal NN N
block NN N
, , N
we PRP N
suggest VBP N
the DT N
combined JJ N
use NN N
of IN N
diclofenac JJ 3_i
suppository NN 3_i
with IN N
local JJ N
anesthetic JJ N
infiltration NN N
at IN N
port NN N
sites NNS N
as IN N
a DT N
useful JJ N
and CC N
more RBR N
economical JJ N
alternative NN N
for IN N
analgesia NN N
following VBG N
pediatric JJ N
laparoscopy NN N
. . N

-DOCSTART- -X- O O

Perceptual JJ N
wind-up NN N
in IN N
the DT N
human JJ N
oesophagus NN N
is VBZ N
enhanced VBN N
by IN N
central JJ N
sensitisation NN N
. . N

BACKGROUND NNP N
Oesophageal NNP N
acid JJ N
infusion NN N
induces NNS N
enhanced VBD N
pain NN N
hypersensitivity NN N
in IN N
non-acid JJ N
exposed JJ N
upper JJ N
oesophagus NN N
( ( N
secondary JJ N
hyperalgesia NN N
) ) N
in IN N
patients NNS N
with IN N
non-cardiac JJ N
chest NN N
pain NN N
, , N
thus RB N
suggesting VBG N
central JJ N
sensitisation NN N
contributes NNS N
to TO N
visceral JJ N
pain NN N
hypersensitivity NN N
in IN N
functional JJ N
gut NN N
disorders NNS N
( ( N
FGD NNP N
) ) N
. . N

Perceptual JJ N
wind-up JJ N
( ( N
increased JJ N
pain NN N
perception NN N
to TO N
constant JJ N
intensity NN N
sensory NN N
stimuli NN N
at IN N
frequencies NNS N
> VBP N
or=0.3 JJ N
Hz NNP N
) ) N
is VBZ N
used VBN N
as IN N
a DT N
proxy NN N
for IN N
central JJ N
sensitisation NN N
to TO N
investigate VB N
pain NN N
syndromes NNS N
where WRB N
pain NN N
hypersensitivity NN N
is VBZ N
important JJ N
( ( N
for IN N
example NN N
, , N
fibromyalgia NN N
) ) N
. . N

AIMS $ N
Wind-up JJ N
in IN N
central JJ N
sensitisation NN N
induced VBD N
human JJ N
visceral JJ N
pain NN N
hypersensitivity NN N
has VBZ N
not RB N
been VBN N
explored VBN N
. . N

We PRP N
hypothesised VBD N
that IN N
if IN N
wind-up NN N
is VBZ N
a DT N
proxy NN N
for IN N
central JJ N
sensitisation NN N
induced VBD N
human JJ N
visceral JJ N
pain NN N
hypersensitivity NN N
, , N
then RB N
oesophageal JJ N
wind-up NN N
should MD N
be VB N
enhanced VBN N
by IN N
secondary JJ N
hyperalgesia NN N
. . N

METHODS NNP N
In IN N
eight CD N
healthy JJ N
volunteers NNS N
( ( N
seven CD N
males NNS N
; : N
mean JJ N
age NN N
32 CD N
years NNS N
) ) N
, , N
perception NN N
at IN N
pain NN N
threshold NN N
to TO N
a DT N
train NN N
of IN N
20 CD N
electrical JJ 2_i
stimuli NNS 2_i
applied VBN N
to TO N
the DT N
hand NN N
and CC N
upper JJ N
oesophagus NN N
( ( N
UO NNP N
) ) N
at IN N
either DT N
0.1 CD 2_i
Hz NNP 2_i
( ( N
control NN N
) ) N
or CC N
2 CD 2_i
Hz NNP 2_i
was VBD N
determined VBN N
before IN N
and CC N
one CD N
hour NN N
after IN N
a DT N
30 CD N
minute NN N
lower JJR N
oesophageal NN N
acid JJ N
infusion NN N
. . N

RESULTS NNP N
Wind-up JJ N
occurred VBD N
only RB N
with IN N
the DT N
2 CD 2_i
Hz NNP 2_i
train NN N
in IN N
the DT N
UO NNP N
and CC N
hand NN N
( ( N
both DT N
p=0.01 NN N
) ) N
. . N

Following VBG N
acid JJ N
infusion NN N
, , N
pain VBP N
threshold JJ N
decreased VBN N
( ( N
17 CD N
( ( N
4 CD N
) ) N
% NN N
; : N
p=0.01 NN N
) ) N
in IN N
the DT N
UO NNP N
, , N
suggesting VBG N
the DT N
presence NN N
of IN N
secondary JJ N
hyperalgesia NN N
. . N

Wind-up UH N
to TO N
the DT N
2 CD 2_i
Hz NNP 2_i
train NN N
increased VBD N
in IN N
the DT N
UO NNP N
( ( N
wind-up JJ N
ratio NN N
1.4 CD N
( ( N
0.1 CD N
) ) N
to TO N
1.6 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.03 NN N
) ) N
but CC N
not RB N
in IN N
the DT N
hand NN N
( ( N
wind-up JJ N
ratio NN N
1.3 CD N
( ( N
0.1 CD N
) ) N
and CC N
1.3 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.3 NN N
) ) N
CONCLUSION NNP N
Enhanced NNP N
wind-up NN N
after IN N
secondary JJ N
oesophageal NN N
hyperalgesia NN N
suggests VBZ N
that IN N
visceral JJ N
pain NN N
hypersensitivity NN N
induced VBN N
by IN N
central JJ N
sensitisation NN N
results NNS N
from IN N
increased JJ N
central JJ N
neuronal JJ N
excitability NN N
. . N

Wind-up JJ N
may MD N
offer VB N
new JJ N
opportunities NNS N
to TO N
investigate VB N
the DT N
contribution NN N
of IN N
central JJ N
neuronal JJ N
changes NNS N
to TO N
symptoms NNS N
in IN N
FGD NNP N
. . N

-DOCSTART- -X- O O

Pre-operative JJ 2_i
radiochemotherapy NN 2_i
for IN N
rectal JJ N
cancer NN N
. . N

A DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
pre-operative JJ 2_i
vs. FW N
postoperative JJ 2_i
radiochemotherapy NN 2_i
in IN N
rectal JJ N
cancer NN N
patients NNS N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
find VB N
out RP N
whether IN N
pre-operative JJ 2_i
radiochemotherapy NN 2_i
had VBD N
any DT N
survival JJ N
advantage NN N
over IN N
postoperative JJ 2_i
radiochemotherapy NN 2_i
for IN N
rectal JJ N
carcinoma NN N
patients NNS N
without IN N
distant JJ N
metastasis NN N
or CC N
peritoneal JJ N
carcinomatosis NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
Between NNP N
January NNP N
1998 CD N
and CC N
December NNP N
2003 CD N
, , N
51 CD N
rectal JJ N
carcinoma NN N
patients NNS N
without IN N
distant JJ N
metastasis NN N
or CC N
peritoneal JJ N
carcinomatosis NN N
were VBD N
randomly RB N
divided VBN N
into IN N
pre-operative JJ 2_i
( ( 2_i
PRE NNP 2_i
) ) 2_i
and CC N
postoperative JJ 2_i
( ( 2_i
POST NNP 2_i
) ) 2_i
radiochemotherapy NN 2_i
groups NNS N
. . N

Twenty-six CD N
were VBD N
assigned VBN N
to TO N
the DT N
PRE NNP N
group NN N
and CC N
were VBD N
operated VBN N
on IN N
5 CD N
to TO N
8 CD N
weeks NNS N
after IN N
the DT N
completion NN N
of IN N
radiotherapy NN 2_i
. . N

The DT N
other JJ N
25 CD N
patients NNS N
were VBD N
operated VBN N
on IN N
immediately RB N
and CC N
received VBD N
radiotherapy NN N
postoperatively RB N
2 CD N
to TO N
4 CD N
weeks NNS N
after IN N
surgery NN N
. . N

The DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
between IN N
4 CD N
to TO N
51 CD N
months NNS N
. . N

RESULTS NNP N
In IN N
the DT N
PRE NNP N
group NN N
the DT N
rates NNS N
of IN N
disease-free JJ N
survival NN N
were VBD N
92 CD N
% NN N
, , N
70 CD N
% NN N
, , N
56 CD N
% NN N
and CC N
56 CD N
% NN N
at IN N
the DT N
end NN N
of IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
3rd CD N
and CC N
4th CD N
years NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
POST NNP N
group NN N
those DT N
percentages NNS N
were VBD N
83 CD N
% NN N
, , N
68 CD N
% NN N
, , N
51 CD N
% NN N
and CC N
51 CD N
% NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
3rd CD N
and CC N
4th CD N
years NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.707 CD N
) ) N
. . N

One-year JJ N
and CC N
4-year JJ N
overall JJ N
survival NN N
rates NNS N
in IN N
the DT N
PRE NNP N
group NN N
were VBD N
100 CD N
% NN N
and CC N
86 CD N
% NN N
respectively RB N
and CC N
100 CD N
% NN N
and CC N
60 CD N
% NN N
in IN N
the DT N
POST NNP N
group NN N
( ( N
p JJ N
= NNP N
0.520 CD N
) ) N
. . N

CONCLUSION NNP N
No NNP N
statistical JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
survival JJ N
rates NNS N
of IN N
the DT N
rectal JJ N
carcinoma NN N
patients NNS N
receiving VBG N
radiotherapy NN N
either CC N
pre-operatively RB N
or CC N
postoperatively RB N
. . N

However RB N
, , N
the DT N
disease-free JJ N
survival NN N
rates NNS N
of IN N
the DT N
PRE NNP 2_i
group NN N
were VBD N
higher JJR N
than IN N
the DT N
POST NNP 2_i
group NN N
's POS N
during IN N
each DT N
year NN N
and CC N
overall JJ N
survival NN N
rates NNS N
were VBD N
higher JJR N
after IN N
the DT N
third JJ N
and CC N
fourth JJ N
years NNS N
. . N

We PRP N
conclude VBP N
that IN N
pre-operative JJ 2_i
radiotherapy NN 2_i
is VBZ N
at IN N
least JJS N
as RB N
effective JJ N
as IN N
postoperative JJ 2_i
radiotherapy NN 2_i
. . N

-DOCSTART- -X- O O

Is VBZ N
psychotherapy VBN 5_i
more RBR N
effective JJ N
when WRB N
therapists NNS N
disclose VB N
information NN N
about IN N
themselves PRP N
? . N
Theorists NNS N
have VBP N
long RB N
debated VBN N
the DT N
wisdom NN N
of IN N
therapists NNS N
disclosing VBG N
personal JJ N
information NN N
during IN N
psychotherapy NN 5_i
. . N

Some DT N
observers NNS N
have VBP N
argued VBN N
that IN N
such JJ N
therapist JJ N
self-disclosure NN N
impedes NNS N
treatment NN N
, , N
whereas IN N
others NNS N
have VBP N
suggested VBN N
that IN N
it PRP N
enhances VBZ N
the DT N
effectiveness NN N
of IN N
therapy NN N
. . N

To TO N
test VB N
these DT N
competing VBG N
positions NNS N
, , N
therapists NNS N
at IN N
a DT N
university NN N
counseling NN N
center NN N
were VBD N
instructed VBN N
to TO N
increase VB 5_i
the DT 5_i
number NN 5_i
of IN 5_i
self-disclosures NNS 5_i
they PRP N
made VBD N
during IN N
treatment NN 5_i
of IN N
one CD N
client NN N
and CC N
refrain NN 5_i
from IN 5_i
making VBG 5_i
self-disclosures NNS 5_i
during IN 5_i
treatment NN 5_i
of IN N
another DT N
client NN N
. . N

Analyses NNS N
revealed VBD N
that IN N
clients NNS N
receiving VBG N
psychotherapy NN 5_i
under IN N
conditions NNS N
of IN N
heightened VBN N
therapist NN 5_i
disclosure NN 5_i
not RB N
only RB N
reported VBD N
lower JJR N
levels NNS N
of IN N
symptom NN N
distress NN N
but CC N
also RB N
liked VBD N
their PRP$ N
therapist NN N
more RBR N
. . N

Such JJ N
findings NNS N
suggest VBP N
that IN N
self-disclosure NN N
by IN N
the DT N
therapist NN N
may MD N
improve VB N
both PDT N
the DT N
quality NN N
of IN N
the DT N
therapeutic JJ N
relationship NN N
and CC N
the DT N
outcome NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Combination NN N
of IN N
arteriovenous JJ 2_i
extracorporeal NN 2_i
lung NN 2_i
assist NN 2_i
and CC N
high-frequency NN 2_i
oscillatory NN 2_i
ventilation NN 2_i
in IN N
a DT N
porcine JJ N
model NN N
of IN N
lavage-induced JJ N
acute NN N
lung NN N
injury NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
To TO N
compare VB N
the DT N
combined JJ N
effects NNS N
of IN N
arteriovenous JJ 2_i
extracorporeal NN 2_i
lung NN 2_i
assist NN 2_i
( ( 2_i
AV-ECLA NNP 2_i
) ) 2_i
and CC N
high-frequency JJ 2_i
oscillatory NN 2_i
ventilation NN 2_i
( ( 2_i
HFOV NNP 2_i
) ) 2_i
on IN N
pulmonary NN N
gas NN N
exchange NN N
, , N
hemodynamics NNS N
, , N
and CC N
respiratory NN N
parameters NNS N
in IN N
a DT N
lavage-induced JJ N
porcine NN N
lung NN N
injury NN N
model NN N
. . N

METHODS CC N
A DT N
prospective JJ N
, , N
randomized VBN N
animal NN N
study NN N
. . N

Saline NNP 2_i
lung NN 2_i
lavage NN 2_i
was VBD N
performed VBN N
in IN N
33 CD N
healthy JJ N
female NN N
pigs NNS N
, , N
weighing VBG N
52 CD N
+/- JJ N
4.1 CD N
kg NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
, , N
until IN N
the DT N
Pao2 NNP N
decreased VBD N
to TO N
53 CD N
+/- JJ N
8 CD N
mm NN N
Hg NNP N
. . N

After IN N
a DT N
stabilization NN N
period NN N
of IN N
60 CD N
minutes NNS N
, , N
the DT N
animals NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
: : N
group NN N
1 CD N
, , N
pressure-controlled JJ 2_i
ventilation NN 2_i
( ( 2_i
PCV NNP 2_i
) ) 2_i
with IN N
a DT N
tidal JJ N
volume NN N
of IN N
6 CD N
mL/kg NNS N
; : N
group NN N
2 CD N
, , N
PCV NNP 2_i
with IN N
a DT N
tidal JJ N
volume NN N
of IN N
6 CD N
mL/kg NNS N
and CC N
AV-ECLA NNP 2_i
; : 1_i
group NN N
3 CD N
, , N
HFOV NNP 2_i
; : N
group NN N
4 CD N
, , N
HFOV NNP 2_i
and CC 2_i
AV-ECLA NNP 2_i
. . N

In IN N
groups NNS N
2 CD N
and CC N
4 CD N
, , N
the DT N
femoral JJ N
artery NN N
and CC N
vein NN N
were VBD N
cannulated VBN N
and CC N
a DT N
low-resistance NN N
membrane NN N
lung NN N
was VBD N
interposed VBN N
. . N

After IN N
isolated JJ N
evaluation NN N
of IN N
AV-ECLA NNP 2_i
, , N
the DT N
mean JJ N
airway NN N
pressure NN N
was VBD N
increased VBN N
by IN N
3 CD N
cm NNS N
H2O NNP N
from IN N
16 CD N
to TO N
34 CD N
cm NNS N
H2O NNP N
every DT N
20 CD N
minutes NNS N
, , N
accompanied VBN N
by IN N
blood NN N
gas NN N
analyses NNS N
and CC N
measurements NNS N
of IN N
respiratory NN N
and CC N
hemodynamic JJ N
variables NNS N
. . N

RESULTS NNP N
Only RB N
in IN N
AV-ECLA-treated JJ 2_i
animals NNS N
was VBD N
normocapnia RB N
achieved VBN N
. . N

No DT N
significant JJ N
increase NN N
of IN N
Pao2 NNP N
attributable JJ N
to TO N
AV-ECLA NNP 2_i
alone RB N
was VBD N
detected VBN N
. . N

Mean NNP N
airway JJ N
pressure NN N
augmentation NN N
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
Pao2 NNP N
in IN N
all DT N
groups NNS N
. . N

Peak NNP N
inspiratory JJ N
pressure NN N
was VBD N
significantly RB N
lower JJR N
in IN N
HFOV-treated JJ N
animals NNS N
. . N

CONCLUSIONS VB N
The DT N
combination NN N
of IN N
AV-ECLA NNP 2_i
and CC N
HFOV NNP 2_i
resulted VBD N
in IN N
normocapnia NN N
and CC N
comparable JJ N
Pao2 NNP N
, , N
although IN N
a DT N
smaller JJR N
ventilator NN N
pressure NN N
amplitude NN N
was VBD N
applied VBN N
. . N

Long-term JJ N
animal JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
assess VB N
whether IN N
this DT N
approach NN N
results NNS N
in IN N
further JJ N
lung NN N
protection NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
sport-tinted JJ 2_i
contact NN 2_i
lenses NNS 2_i
for IN N
contrast NN N
enhancement NN N
on IN N
retinal JJ N
straylight NN N
measurements NNS N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
two CD N
tinted JJ 2_i
contact NN 2_i
lenses NNS 2_i
( ( 2_i
CL NNP 2_i
) ) 2_i
designed VBN N
for IN N
outdoor JJ N
sports NNS N
activity NN N
on IN N
the DT N
psychometric JJ N
determination NN N
of IN N
retinal JJ N
straylight NN N
using VBG N
the DT N
compensation NN N
comparison NN N
method NN N
. . N

METHODS NNP N
Thirteen NNP N
emmetropic JJ N
subjects NNS N
were VBD N
randomly RB N
fitted VBN N
with IN N
two CD 2_i
different JJ 2_i
tinted VBN 2_i
Nike NNP 2_i
Maxsight NNP 2_i
( ( 2_i
Bausch NNP 2_i
& CC 2_i
Lomb NNP 2_i
, , 2_i
Rochester NNP 2_i
, , 2_i
NY NNP 2_i
, , 2_i
USA NNP 2_i
) ) 2_i
CL NNP 2_i
in IN 2_i
one CD 2_i
eye NN 2_i
, , N
while IN N
the DT N
contralateral JJ 7_i
eye NN 7_i
was VBD 7_i
fitted VBN 7_i
with IN 7_i
a DT 7_i
clear JJ 7_i
lens NNS 7_i
made VBN 7_i
of IN 7_i
the DT 7_i
same JJ 7_i
material NN 7_i
( ( N
Optima NNP N
38 CD N
, , N
Bausch NNP N
& CC N
Lomb NNP N
) ) N
. . N

Three CD N
valid JJ N
straylight NN N
measurements NNS N
were VBD N
taken VBN N
on IN N
each DT N
eye NN N
before IN N
and CC N
a DT N
few JJ N
minutes NNS N
after IN N
lens JJ N
insertion NN N
, , N
when WRB N
lens VBZ N
stabilization NN N
had VBD N
occurred VBN N
. . N

RESULTS VB N
The DT N
subjects NNS N
' POS N
mean NN N
straylight NN N
values NNS N
were VBD N
0.90 CD N
+/- JJ N
0.09 CD N
at IN N
baseline NN N
and CC N
0.95 CD N
+/- JJ N
0.10 CD N
with IN N
the DT N
clear JJ N
Optima NNP N
38 CD N
CL NNP N
. . N

Straylight NNP N
values NNS N
were VBD N
0.97 CD N
+/- JJ N
0.10 CD N
and CC N
1.0 CD N
+/- JJ N
0.10 CD N
log JJ N
units NNS N
with IN N
the DT N
amber NN N
and CC N
grey-green JJ N
tinted JJ N
CL NNP N
, , N
respectively RB N
. . N

Differences NNS N
in IN N
straylight NN N
between IN N
baseline NN N
( ( N
without IN N
CL NNP N
) ) N
and CC N
with IN N
the DT N
clear JJ N
CL NNP N
in IN N
place NN N
were VBD N
neither RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.066 CD N
) ) N
nor CC N
was VBD N
there EX N
a DT N
significant JJ N
difference NN N
between IN N
baseline NN N
and CC N
the DT N
amber NN N
CL NNP N
( ( N
p JJ N
= NNP N
0.052 CD N
) ) N
. . N

However RB N
, , N
the DT N
grey-green JJ N
CL NNP N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
from IN N
baseline NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
. . N

Differences NNS N
in IN N
straylight NN N
with IN N
the DT N
clear JJ N
CL NNP N
compared VBN N
with IN N
the DT N
grey-green JJ N
CL NNP N
were VBD N
also RB N
statistically RB N
different JJ N
from IN N
zero NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
showing VBG N
an DT N
increased VBN N
straylight NN N
value NN N
for IN N
the DT N
tinted JJ N
CL NNP N
. . N

These DT N
differences NNS N
were VBD N
variable JJ N
, , N
but CC N
consistent JJ N
for IN N
each DT N
subject NN N
, , N
thus RB N
those DT N
showing VBG N
higher JJR N
or CC N
lower JJR N
changes NNS N
with IN N
one CD N
tinted JJ N
lens VBZ N
tended VBN N
to TO N
show VB N
the DT N
same JJ N
trend NN N
with IN N
the DT N
second JJ N
lens NNS N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.736 CD N
) ) N
. . N

CONCLUSIONS NNP N
Despite IN N
increases NNS N
having VBG N
been VBN N
found VBN N
in IN N
straylight JJ N
values NNS N
with IN N
tinted VBN N
contact NN N
lenses NNS N
, , N
those DT N
changes NNS N
are VBP N
not RB N
likely JJ N
to TO N
induce VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
visual JJ N
function NN N
under IN N
photopic NN N
conditions NNS N
, , N
even RB N
for IN N
the DT N
grey-green JJ N
CL NNP N
, , N
which WDT N
seems VBZ N
to TO N
increase VB N
straylight JJ N
values NNS N
more RBR N
significantly RB N
than IN N
the DT N
amber JJ N
CL NNP N
. . N

This DT N
difference NN N
between IN N
the DT N
tinted JJ N
CL NNP N
could MD N
suggest VB N
a DT N
wavelength JJ N
dependence NN N
of IN N
straylight NN N
values NNS N
, , N
although IN N
this DT N
should MD N
be VB N
investigated VBN N
further JJ N
by IN N
controlling VBG N
for IN N
pupil NN N
size NN N
and CC N
subjects NNS N
' POS N
pigmentation NN N
, , N
as RB N
well RB N
as IN N
by IN N
using VBG N
neutral JJ N
density NN N
filters NNS N
. . N

-DOCSTART- -X- O O

Evolution NN N
of IN N
neuropathy JJ N
and CC N
myopathy JJ N
during IN N
intensive JJ N
vincristine/corticosteroid NNS 2_i
chemotherapy NN 2_i
for IN N
non-Hodgkin NN N
's POS N
lymphoma NN N
. . N

Neuropathy NNP N
and CC N
myopathy NN N
are VBP N
common JJ N
sequelae NN N
of IN N
intensive JJ 2_i
chemotherapy NN 2_i
protocols NNS 2_i
that WDT 2_i
contain VBP 2_i
vincristine JJ 2_i
and CC 2_i
corticosteroids NNS 2_i
. . N

The DT N
authors NNS N
prospectively RB N
monitored VBD N
the DT N
evolution NN N
of IN N
neuropathy JJ N
and CC N
myopathy JJ N
during IN N
an DT N
intensive JJ N
12-week JJ N
chemotherapy NN 2_i
program NN N
for IN N
patients NNS N
with IN N
intermediate JJ N
and CC N
high-grade JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
. . N

In IN N
this DT N
study NN N
, , N
vincristine NN 3_i
was VBD N
administered VBN N
by IN N
bolus NN 3_i
injection NN N
followed VBN N
by IN N
a DT N
3-day JJ N
continuous JJ N
intravenous JJ N
( ( N
IV NNP N
) ) N
infusion NN N
( ( N
total JJ N
dose NN N
of IN N
2.0 CD N
mg/m2 NNS N
every DT N
other JJ N
week NN N
) ) N
; : N
the DT N
maximum JJ N
dose NN N
of IN N
vincristine NN 3_i
was VBD N
not RB N
arbitrarily RB N
limited VBN N
. . N

Cronassial NNP 3_i
, , 3_i
a DT 3_i
mixture NN 3_i
of IN 3_i
four CD 3_i
naturally RB 3_i
occurring VBG 3_i
gangliosides NNS 3_i
, , N
was VBD N
administered VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
test NN N
to TO N
evaluate VB N
whether IN N
this DT N
agent NN N
could MD N
prevent VB N
vincristine-induced JJ 3_i
neuropathy NN N
. . N

High JJ N
doses NNS N
of IN N
dexamethasone NN 3_i
( ( N
50 CD N
mg/d NN N
for IN N
3 CD N
days NNS N
weekly RB N
or CC N
every DT N
other JJ N
week NN N
) ) N
were VBD N
also RB N
prescribed VBN N
. . N

Patients NNS N
were VBD N
monitored VBN N
every DT N
4 CD N
weeks NNS N
with IN N
comprehensive JJ N
physical JJ N
and CC N
neurologic JJ N
examinations NNS N
and CC N
electrophysiologic JJ N
studies NNS N
of IN N
peripheral JJ N
nerve NN N
function NN N
. . N

Twenty-seven JJ N
patients NNS N
were VBD N
fully RB N
evaluable JJ N
. . N

Weakness NNP N
was VBD N
a DT N
prominent JJ N
adverse JJ N
reaction NN N
in IN N
this DT N
study NN N
, , N
and CC N
all DT N
patients NNS N
had VBD N
moderate JJ N
to TO N
severe VB N
signs NNS N
and CC N
symptoms NNS N
of IN N
neuropathy JJ N
and CC N
myopathy JJ N
. . N

Cronassial NNP 3_i
( ( N
100 CD N
mg NN N
) ) N
administered VBN N
by IN N
intramuscular NN N
( ( N
IM NNP N
) ) N
injection NN N
daily RB N
provided VBD N
no DT N
protection NN N
against IN N
the DT N
development NN N
of IN N
neuropathic JJ N
symptoms NNS N
. . N

Vincristine NNP 3_i
typically RB N
impaired VBD N
fine-motor JJ N
coordination NN N
initially RB N
, , N
whereas JJ N
corticosteroids NNS 3_i
were VBD N
associated VBN N
with IN N
delayed JJ N
development NN N
of IN N
proximal JJ N
muscle NN N
weakness NN N
. . N

Results NNS N
of IN N
electrodiagnostic JJ N
studies NNS N
did VBD N
not RB N
add VB N
to TO N
the DT N
clinical JJ N
examination NN N
results NNS N
. . N

The DT N
authors NNS N
conclude VBP N
that IN N
symptomatic JJ N
weakness NN N
due JJ N
to TO N
neuropathy JJ N
or CC N
myopathy JJ N
appears VBZ N
in IN N
a DT N
predictable JJ N
manner NN N
during IN N
intensive JJ N
vincristine/corticosteroid-based JJ 2_i
treatment NN 2_i
protocols NNS N
. . N

Simple JJ N
clinical JJ N
tests NNS N
can MD N
be VB N
used VBN N
to TO N
rapidly RB N
distinguish VB N
between IN N
toxic JJ N
effects NNS N
due JJ N
either RB N
to TO N
vincristine VB 3_i
or CC 3_i
corticosteroids NNS 3_i
, , N
and CC N
routine JJ N
implementation NN N
of IN N
these DT N
tests NNS N
can MD N
prevent VB N
inappropriate JJ N
dose JJ N
attenuation NN N
of IN N
these DT N
agents NNS N
. . N

-DOCSTART- -X- O O

Oesophageal JJ N
intubation NN N
can MD N
be VB N
undetected VBN N
by IN N
auscultation NN 2_i
of IN N
the DT N
chest NN N
. . N

Prompt NNP N
detection NN N
of IN N
oesophageal JJ 1_i
intubation NN 1_i
is VBZ N
a DT N
primary JJ N
concern NN N
in IN N
anaesthetic JJ N
practice NN N
. . N

This DT N
blind NN N
, , N
randomised VBD N
study NN N
evaluates NNS N
three CD N
widely RB N
used JJ N
tests NNS N
of IN N
intubation NN 1_i
. . N

Forty NNP N
patients NNS N
had VBD N
both DT N
their PRP$ N
trachea NN N
and CC N
oesophagus NN N
intubated VBN 1_i
, , N
each DT N
patient NN N
was VBD N
studied VBN N
twice RB N
. . N

Auscultation NN N
of IN N
the DT N
epigastrium NN N
, , N
right NN N
and CC N
left VBD N
axilla NN N
is VBZ N
more RBR N
reliable JJ N
than IN N
auscultation NN N
of IN N
the DT N
chest NN N
, , N
and CC N
the DT N
anaesthetist NN N
's POS N
feeling NN N
when WRB N
he PRP N
squeezes VBZ N
the DT N
bag NN N
. . N

P NNP N
= VBD N
0.001 CD N
and CC N
P NNP N
= NNP N
0.048 CD N
, , N
respectively RB N
. . N

The DT N
tests NNS N
were VBD N
carried VBN N
out RP N
after IN N
gastric JJ N
distension NN N
with IN N
gas NN N
had VBD N
occurred VBN N
. . N

We PRP N
conclude VBP N
that DT N
auscultation NN N
of IN N
epigastrium NN N
, , N
right NN N
and CC N
left VBD N
axilla NN N
, , N
are VBP N
recommended VBN N
. . N

-DOCSTART- -X- O O

Neurophysiological JJ N
responses NNS N
to TO N
faces VBZ N
and CC N
gaze JJ N
direction NN N
differentiate NN N
children NNS N
with IN N
ASD NNP N
, , N
ADHD NNP N
and CC N
ASD+ADHD NNP N
. . N

Children NNP N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
and CC N
attention NN N
deficit NN N
hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
demonstrate VBP N
face NN N
processing NN N
abnormalities NNS N
that WDT N
may MD N
underlie VB N
social JJ N
impairment NN N
. . N

Despite IN N
substantial JJ N
overlap NN N
between IN N
ASD NNP N
and CC N
ADHD NNP N
, , N
ERP NNP N
markers NNS N
of IN N
face NN N
and CC N
gaze NN N
processing NN N
have VBP N
not RB N
been VBN N
directly RB N
compared VBN N
across IN N
pure NN N
and CC N
comorbid NN N
cases NNS N
. . N

Children NNP N
with IN N
ASD NNP N
( ( N
n=19 NN N
) ) N
, , N
ADHD NNP N
( ( N
n=18 NN N
) ) N
, , N
comorbid JJ N
ASD+ADHD NNP N
( ( N
n=29 NN N
) ) N
and CC N
typically RB N
developing VBG N
( ( N
TD NNP N
) ) N
controls NNS N
( ( N
n=26 NN N
) ) N
were VBD N
presented VBN N
with IN N
upright/inverted JJ 5_i
faces VBZ 5_i
with IN 5_i
direct/averted VBN 5_i
gaze NN 5_i
, , N
with IN N
concurrent JJ N
recording NN N
of IN N
the DT N
P1 NNP N
and CC N
N170 NNP N
components NNS N
. . N

While IN N
the DT N
N170 NNP N
was VBD N
predominant VBN N
in IN N
the DT N
right NN N
hemisphere NN N
in IN N
TD NNP N
and CC N
ADHD NNP N
, , N
children NNS N
with IN N
ASD NNP N
( ( N
ASD/ASD+ADHD NNP N
) ) N
showed VBD N
a DT N
bilateral JJ N
distribution NN N
. . N

In IN N
addition NN N
, , N
children NNS N
with IN N
ASD NNP N
demonstrated VBD N
altered JJ N
response NN N
to TO N
gaze VB N
direction NN N
on IN N
P1 NNP N
latency NN N
and CC N
no DT N
sensitivity NN N
to TO N
gaze VB N
direction NN N
on IN N
midline-N170 JJ N
amplitude NN N
compared VBN N
to TO N
TD NNP N
and CC N
ADHD NNP N
. . N

In IN N
contrast NN N
, , N
children NNS N
with IN N
ADHD NNP N
( ( N
ADHD/ASD+ADHD NNP N
) ) N
exhibited VBD N
a DT N
reduced JJ N
face NN N
inversion NN N
effect NN N
on IN N
P1 NNP N
latency NN N
compared VBN N
to TO N
TD NNP N
and CC N
ASD NNP N
. . N

These DT N
findings NNS N
suggest VBP N
children NNS N
with IN N
ASD NNP N
have VBP N
specific JJ N
abnormalities NNS N
in IN N
gaze NN N
processing NN N
and CC N
altered JJ N
neural JJ N
specialisation NN N
, , N
whereas JJ N
children NNS N
with IN N
ADHD NNP N
show NN N
abnormalities NNS N
at IN N
early JJ N
visual JJ N
attention NN N
stages NNS N
. . N

Children NNP N
with IN N
ASD+ADHD NNP N
are VBP N
an DT N
additive JJ N
co-occurrence NN N
with IN N
deficits NNS N
of IN N
both DT N
disorders NNS N
. . N

Elucidating VBG N
the DT N
neural JJ N
basis NN N
of IN N
the DT N
overlap NN N
between IN N
ASD NNP N
and CC N
ADHD NNP N
is VBZ N
likely JJ N
to TO N
inform VB N
aetiological JJ N
investigation NN N
and CC N
clinical JJ N
assessment NN N
. . N

-DOCSTART- -X- O O

Pharmacokinetic JJ N
interaction NN N
between IN N
proton NN 3_i
pump NN 3_i
inhibitors NNS 3_i
and CC N
roxithromycin NN 3_i
in IN N
volunteers NNS N
. . N

BACKGROUND NNP N
Triple NNP N
therapy NN N
including VBG N
two CD N
antibiotics NNS N
and CC N
a DT N
proton NN N
pump NN N
inhibitor NN N
is VBZ N
a DT N
rational JJ N
approach NN N
to TO N
the DT N
treatment NN N
of IN N
Helicobacter NNP N
pylori NN N
induced VBD N
peptic JJ N
ulcer JJ N
disease NN N
. . N

The DT N
interaction NN N
of IN N
antimicrobial JJ N
therapy NN N
and CC N
acid JJ N
suppression NN N
is VBZ N
not RB N
yet RB N
well RB N
elucidated VBN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
proton NN 3_i
pump NN 3_i
inhibitors NNS 3_i
on IN N
roxithromycin NN 3_i
levels NNS N
in IN N
plasma NN N
and CC N
gastric JJ N
tissue NN N
under IN N
steady-state JJ N
conditions NNS N
in IN N
volunteers NNS N
. . N

METHODS NNP N
In IN N
two CD N
crossover NN N
studies NNS N
omeprazole VBP 3_i
20 CD 3_i
mg NN 3_i
b.d. NN 3_i
, , N
lansoprazole JJ 3_i
30 CD 3_i
mg NN 3_i
b.d. NN 3_i
, , N
roxithromycin VBZ 3_i
300 CD 3_i
mg NN 3_i
b.d. NN 3_i
, , N
and CC N
the DT N
combination NN N
of IN N
roxithromycin NN 3_i
with IN N
either DT N
omeprazole NN 3_i
or CC 3_i
lansoprazole NN 3_i
were VBD N
administered VBN N
to TO N
12 CD N
healthy JJ N
volunteers NNS N
over IN N
6 CD N
days NNS N
. . N

Blood NNP N
plasma NN N
levels NNS N
of IN N
the DT N
drugs NNS N
were VBD N
measured VBN N
. . N

In IN N
addition NN N
, , N
roxithromycin JJ N
concentrations NNS N
were VBD N
also RB N
determined VBN N
in IN N
gastric JJ N
juice NN N
and CC N
gastric JJ N
tissue NN N
obtained VBN N
during IN N
endoscopy NN N
. . N

RESULTS VB N
The DT N
proton NN 3_i
pump NN 3_i
inhibitors NNS 3_i
and CC N
roxithromycin NN 3_i
did VBD N
not RB N
alter VB N
the DT N
blood NN N
plasma NN N
pharmacokinetics NNS N
of IN N
each DT N
other JJ N
. . N

When WRB N
compared VBN N
to TO N
roxithromycin VB 3_i
administered JJ N
alone RB N
, , N
its PRP$ N
combination NN N
with IN N
a DT N
proton NN N
pump NN N
inhibitor NN N
significantly RB N
increased VBD N
the DT N
roxithromycin NN N
concentrations NNS N
in IN N
gastric JJ N
juice NN N
( ( N
3.0-5.0 JJ N
microg/mL NN N
vs. IN N
0.3-0.4 NNP N
microg/mL NN N
) ) N
and CC N
gastric JJ N
tissue NN N
( ( N
antrum NN N
: : N
3.8-4.0 JJ N
vs. FW N
2.8 CD N
microg/g NN N
, , N
fundus NN N
: : N
5.9-7.4 JJ N
vs. IN N
4.2-4.4 JJ N
microg/g NN N
) ) N
. . N

CONCLUSIONS NNP N
Proton NNP 3_i
pump NN 3_i
inhibitors NNS 3_i
and CC N
roxithromycin VB 3_i
do VBP N
not RB N
alter VB N
the DT N
systemic JJ N
bioavailability NN N
of IN N
each DT N
other JJ N
. . N

However RB N
, , N
proton VBP 3_i
pump NN 3_i
inhibitors NNS 3_i
increase VBP N
the DT N
local JJ N
concentration NN N
of IN N
roxithromycin NN N
in IN N
the DT N
stomach NN N
which WDT N
may MD N
contribute VB N
to TO N
the DT N
clinically RB N
proven JJ N
synergic JJ N
beneficial JJ N
action NN N
in IN N
eradication NN N
therapy NN N
of IN N
H. NNP N
pylori NN N
. . N

-DOCSTART- -X- O O

Stapled VBN 1_i
hemorrhoidopexy JJ 1_i
versus NN N
milligan-morgan JJ 1_i
hemorrhoidectomy NN 1_i
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
with IN N
2-year JJ N
postoperative NN N
follow VB N
up RP N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
outcome NN N
of IN N
stapled JJ 1_i
hemorrhoidopexy NN 1_i
( ( 1_i
SH NNP 1_i
group NN 1_i
) ) 1_i
performed VBD N
using VBG N
a DT N
circular JJ N
stapler NN N
with IN N
that DT N
of IN N
the DT N
Milligan-Morgan NNP 1_i
technique NN 1_i
( ( 1_i
MM NNP 1_i
group NN 1_i
) ) 1_i
. . N

The DT N
goals NNS N
of IN N
the DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
reproducibility NN N
of IN N
stapled JJ 1_i
hemorrhoidopexy NN 1_i
and CC N
define VB N
its PRP$ N
place NN N
among IN N
conventional JJ N
techniques NNS N
. . N

METHODS VB N
A NNP N
series NN N
of IN N
134 CD N
patients NNS N
were VBD N
included VBN N
at IN N
7 CD N
hospital NN N
centers NNS N
. . N

They PRP N
were VBD N
randomized VBN N
according VBG N
to TO N
a DT N
single-masked JJ N
design NN N
and CC N
stratified VBN N
by IN N
center NN N
( ( N
with IN N
balancing VBG N
every DT N
4 CD N
patients NNS N
) ) N
. . N

Patients NNS N
were VBD N
clinically RB N
evaluated VBN N
preoperatively RB N
and CC N
at IN N
6 CD N
weeks NNS N
, , N
1 CD N
year NN N
, , N
and CC N
a DT N
minimum NN N
of IN N
2 CD N
years NNS N
after IN N
treatment NN N
. . N

Patients NNS N
completed VBD N
a DT N
questionnaire NN 4_i
before IN N
and CC N
1 CD N
year NN N
after IN N
surgery NN N
to TO N
evaluate VB N
symptoms NNS N
, , N
function NN N
, , N
and CC N
overall JJ N
satisfaction NN N
. . N

RESULTS VB N
The DT N
mean JJ N
follow-up JJ N
period NN N
was VBD N
2.21 CD N
years NNS N
+/- JJ N
0.26 CD N
( ( N
1.89-3.07 JJ N
) ) N
. . N

Nine JJ N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
could MD N
not RB N
be VB N
monitored VBN N
at IN N
1 CD N
or CC N
2 CD N
years NNS N
, , N
but CC N
4 CD N
of IN N
these DT N
9 CD N
nevertheless RB N
filled VBN N
in IN N
the DT N
1-year JJ N
questionnaire NN N
. . N

The DT N
patients NNS N
in IN N
the DT N
SH NNP 1_i
group NN N
experienced VBD N
less RBR N
postoperative JJ N
pain/discomfort NN N
as IN N
scored VBN N
by IN N
pain NN N
during IN N
bowel NN N
movement NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
total JJ N
analgesic JJ N
requirement NN N
over IN N
the DT N
first JJ N
3 CD N
days NNS N
( ( N
according VBG N
to TO N
the DT N
World NNP N
Health NNP N
Organization NNP N
[ NNP N
WHO NNP N
] NNP N
class NN N
II NNP N
analgesics NNS N
[ VBP N
P NNP N
= NNP N
0.002 CD N
] NNP N
; : N
class NN N
III NNP N
[ NNP N
P NNP N
= VBD N
0.066 CD N
] NN N
) ) N
, , N
and CC N
per-patient JJ N
consumption NN N
frequency NN N
of IN N
class NN N
III NNP N
analgesics NNS N
( ( N
P NNP N
= NNP N
0.089 CD N
) ) N
. . N

A DT N
clear JJ N
difference NN N
in IN N
morphine JJ N
requirement NN N
became VBD N
evident JJ N
after IN N
24 CD N
hours NNS N
( ( N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

Hospital NNP N
stay NN N
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
SH NNP 1_i
group NN N
( ( N
SH NNP N
2.2 CD N
+/- JJ N
1.2 CD N
[ JJ N
0 CD N
; : N
5.0 CD N
] NNP N
versus NN N
MM NNP 1_i
3.1 CD N
+/- JJ N
1.7 CD N
[ JJ N
1 CD N
; : N
8.0 CD N
] NN N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

At IN N
1 CD N
year NN N
, , N
no DT N
differences NNS N
in IN N
the DT N
resolution NN N
of IN N
symptoms NNS N
were VBD N
observed VBN N
between IN N
the DT N
2 CD N
groups NNS N
, , N
and CC N
over IN N
2 CD N
years NNS N
, , N
the DT N
overall JJ N
incidence NN N
of IN N
complications NNS N
was VBD N
the DT N
same JJ N
, , N
specifically RB N
fecaloma JJ N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
in IN N
the DT N
MM NNP 1_i
group NN N
and CC N
external JJ N
hemorrhoidal NN N
thrombosis NN N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
in IN N
the DT N
SH NNP 1_i
group NN N
. . N

Impaired NNP N
sphincter NN N
function NN N
was VBD N
observed VBN N
at IN N
1 CD N
year NN N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
for IN N
urgency NN N
( ( N
12 CD N
% NN N
) ) N
, , N
continence NN N
problems NNS N
( ( N
10 CD N
% NN N
) ) N
, , N
or CC N
tenesmus NN N
( ( N
3 CD N
% NN N
) ) N
. . N

No DT N
patient NN N
needed VBD N
a DT N
second JJ N
procedure NN N
for IN N
recurrence NN N
within IN N
2 CD N
years NNS N
, , N
although IN N
partial JJ N
residual JJ N
prolapse NN N
was VBD N
detected VBN N
in IN N
4 CD N
SH JJ 1_i
patients NNS N
( ( N
7.5 CD N
% NN N
) ) N
versus NN N
1 CD N
MM NNP 1_i
patient NN N
( ( N
1.8 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.194 CD N
) ) N
. . N

CONCLUSION NNP N
Stapled VBD 1_i
hemorrhoidopexy JJ 1_i
causes NNS N
significantly RB N
less RBR N
postoperative JJ N
pain NN N
. . N

The DT N
technique NN N
is VBZ N
reproducible JJ N
and CC N
can MD N
achieve VB N
comparable JJ N
outcomes NNS N
as IN N
those DT N
of IN N
the DT N
MM NNP 1_i
technique NN N
as RB N
long RB N
as IN N
the DT N
well-described JJ N
steps NNS N
of IN N
the DT N
technique NN N
are VBP N
followed VBN N
. . N

Like IN N
with IN N
conventional JJ N
surgery NN 1_i
, , N
anorectal JJ N
dysfunction NN N
can MD N
occur VB N
after IN N
stapled JJ 1_i
hemorrhoidopexy NN 1_i
in IN N
some DT N
patients NNS N
. . N

Its PRP$ N
effectiveness NN N
in IN N
relieving VBG N
symptoms NNS N
is VBZ N
equivalent JJ N
to TO N
conventional JJ N
surgery NN N
, , N
and CC N
the DT N
number NN N
of IN N
hemorrhoidal JJ N
prolapse NN N
recurrences NNS N
at IN N
2 CD N
years NNS N
is VBZ N
not RB N
significantly RB N
different JJ N
. . N

Hemorroidopexy NNP 1_i
is VBZ N
applicable JJ N
for IN N
treating VBG N
reducible JJ N
hemorrhoidal JJ N
prolapse NN N
. . N

-DOCSTART- -X- O O

Further JJ N
validation NN N
of IN N
the DT N
alcohol NN N
dependence NN N
scale NN N
as IN N
an DT N
index NN N
of IN N
severity NN N
. . N

OBJECTIVE CC N
The DT N
Alcohol NNP 4_i
Dependence NNP 4_i
Scale NNP 4_i
( ( N
ADS NNP N
) ) N
yields VBZ N
continuous JJ N
scores NNS N
purported VBN N
to TO N
reflect VB N
the DT N
severity NN N
of IN N
the DT N
dependence NN N
syndrome NN N
. . N

We PRP N
evaluated VBD N
the DT N
concurrent JJ N
validity NN N
of IN N
the DT N
ADS NNP N
as IN N
a DT N
general JJ N
measure NN N
of IN N
severity NN N
and CC N
the DT N
screening VBG N
accuracy NN N
of IN N
the DT N
total JJ N
score NN N
and CC N
subscales NNS N
to TO N
detect VB N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
( ( N
DSM-IV NNP N
) ) N
, , N
physiological JJ N
dependence NN N
. . N

METHOD NNP N
Treatment-seeking JJ N
, , N
alcohol-dependent JJ N
individuals NNS N
entering VBG N
the DT N
Combining NNP N
Pharmacotherapies NNPS N
and CC N
Behavioral NNP N
Interventions NNP N
for IN N
Alcohol NNP N
Dependence NNP N
( ( N
COMBINE NNP N
) ) N
Study NNP N
( ( N
N NNP N
= NNP N
1,372 CD N
; : N
69 CD N
% NN N
men NNS N
) ) N
completed VBD N
the DT N
ADS NNP N
, , N
diagnostic JJ N
interviews NNS N
, , N
and CC N
other JJ N
measures NNS N
before IN N
randomization NN N
. . N

Analyses NNS N
of IN N
variance NN N
tested VBN N
differences NNS N
between IN N
ADS NNP 4_i
quartiles NNS N
on IN N
alcohol- JJ N
related JJ N
measures NNS N
. . N

Areas NNP N
under IN N
the DT N
receiver NN N
operating VBG N
characteristic JJ N
( ( N
AUROC NNP N
) ) N
curve NN N
assessed VBD N
screening VBG N
accuracy NN N
for IN N
DSM-IV NNP N
physiological JJ N
dependence NN N
( ( N
tolerance NN N
or CC N
withdrawal NN N
) ) N
or CC N
withdrawal VB N
alone RB N
. . N

RESULTS NNP N
ADS NNP N
quartiles VBZ N
differed VBN N
on IN N
age NN N
, , N
other JJ N
demographics NNS N
, , N
and CC N
prior RB N
treatment NN N
episodes NNS N
. . N

Linear JJ N
correlation NN N
showed VBD N
moderate JJ N
to TO N
large JJ N
magnitude NN N
associations NNS N
with IN N
alcohol-related JJ N
self-report JJ N
measures NNS N
and CC N
most JJS N
indices NNS N
of IN N
consumption NN N
. . N

ADS NNP N
quartiles NNS N
differed VBD N
significantly RB N
on IN N
proportion NN N
with IN N
DSM-IV NNP N
physiological JJ N
dependence NN N
, , N
but CC N
AUROC NNP N
curves NNS N
indicated VBD N
that IN N
the DT N
ADS NNP N
had VBD N
limited VBN N
accuracy NN N
as IN N
a DT N
continuous JJ N
measure NN N
to TO N
detect VB N
DSMIV NNP N
physiological JJ N
dependence NN N
( ( N
AUROC NNP N
= NNP N
.75 NNP N
[ VBD N
95 CD N
% NN N
confidence NN N
interval NN N
{ ( N
CI NNP N
} ) N
: : N
.70-.79 JJ N
] NN N
and CC N
.67 NNP N
[ VBP N
95 CD N
% NN N
CI NNP N
: : N
.60-.74 JJ N
] NN N
for IN N
men NNS N
and CC N
women NNS N
, , N
respectively RB N
; : N
p CC N
= NNP N
.08 NNP N
) ) N
or CC N
withdrawal VB N
alone RB N
( ( N
AUROC NNP N
= NNP N
.77 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
: : N
.74-.80 JJ N
] NN N
and CC N
.74 NNP N
[ VBP N
95 CD N
% NN N
CI NNP N
: : N
.69-.79 JJ N
] NN N
for IN N
men NNS N
and CC N
women NNS N
, , N
respectively RB N
; : N
p CC N
= NNP N
.30 NNP N
) ) N
. . N

Screening VBG N
accuracy NN N
was VBD N
comparably RB N
limited VBN N
based VBN N
on IN N
ADS NNP N
subscales NNS N
reflecting VBG N
psychoperceptual JJ N
or CC N
psychophysical JJ N
withdrawal NN N
. . N

CONCLUSIONS VB N
The DT N
ADS NNP N
reflected VBD N
variation NN N
in IN N
symptom JJ N
severity NN N
but CC N
did VBD N
not RB N
adequately RB N
identify VB N
physiological JJ N
dependence NN N
or CC N
withdrawal NN N
in IN N
treatment-seeking JJ N
individuals NNS N
with IN N
DSM-IV NNP N
alcohol NN N
dependence NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
sclerotherapy NN 1_i
with IN N
staple JJ 1_i
transection NN 1_i
of IN 1_i
the DT 1_i
esophagus NN 1_i
for IN N
the DT N
emergency NN N
control NN N
of IN N
bleeding VBG N
from IN N
esophageal JJ N
varices NNS N
. . N

We PRP N
compared VBN N
two CD N
procedures NNS N
for IN N
the DT N
emergency NN N
treatment NN N
of IN N
bleeding VBG N
esophageal JJ N
varices NNS N
in IN N
patients NNS N
who WP N
did VBD N
not RB N
respond VB N
to TO N
blood VB N
transfusion NN N
and CC N
vasoactive JJ N
drugs NNS N
. . N

We PRP N
randomly VBP N
assigned VBD N
101 CD N
patients NNS N
with IN N
cirrhosis NN N
of IN N
the DT N
liver NN N
and CC N
bleeding VBG N
esophageal JJ N
varices NNS N
to TO N
undergo VB 1_i
either DT 1_i
emergency NN 1_i
sclerotherapy NN 1_i
( ( N
n JJ N
= NNP N
50 CD N
) ) N
or CC N
staple JJ 1_i
transection NN 1_i
of IN 1_i
the DT 1_i
esophagus NN 1_i
( ( N
n JJ N
= NNP N
51 CD N
) ) N
. . N

Four CD N
patients NNS N
assigned VBN N
to TO N
sclerotherapy VB 1_i
and CC N
12 CD N
assigned VBN N
to TO N
staple VB N
transection NN N
did VBD N
not RB N
actually RB N
undergo VBP N
those DT N
procedures NNS N
, , N
but CC N
all DT N
analyses NNS N
were VBD N
made VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

Total JJ N
mortality NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
; : N
the DT N
relative JJ N
risk NN N
of IN N
death NN N
for IN N
staple JJ N
transection NN N
as IN N
compared VBN N
with IN N
sclerotherapy NN N
was VBD N
0.88 CD N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.51 CD N
to TO N
1.54 CD N
) ) N
. . N

Mortality NN N
at IN N
six CD N
weeks NNS N
was VBD N
44 CD N
percent NN N
among IN N
those DT N
assigned VBN N
to TO N
sclerotherapy VB 1_i
and CC N
35 CD N
percent NN N
among IN N
those DT N
assigned VBN N
to TO N
staple VB N
transection NN N
. . N

Complication NN N
rates NNS N
were VBD N
similar JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

An DT N
interval NN N
of IN N
five CD N
days NNS N
without IN N
bleeding NN N
was VBD N
achieved VBN N
in IN N
88 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
staple VB N
transection NN N
and CC N
in IN N
62 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
sclerotherapy VB 1_i
after IN N
a DT N
single JJ N
injection NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
82 CD N
percent NN N
after IN N
three CD N
injections NNS N
. . N

In IN N
only RB N
2 CD N
of IN N
the DT N
11 CD N
patients NNS N
who WP N
received VBD N
a DT N
third JJ N
sclerotherapy NN 1_i
injection NN N
was VBD N
bleeding VBG N
controlled VBN N
for IN N
more JJR N
than IN N
five CD N
days NNS N
, , N
and CC N
9 CD N
died VBD N
. . N

We PRP N
conclude VBP N
that IN N
staple JJ N
transection NN N
of IN N
the DT N
esophagus NN N
is VBZ N
as RB N
safe JJ N
as IN N
sclerotherapy NN N
for IN N
the DT N
emergency NN N
treatment NN N
of IN N
bleeding VBG N
esophageal JJ N
varices NNS N
and CC N
that IN N
it PRP N
is VBZ N
more RBR N
effective JJ N
than IN N
a DT N
single JJ N
sclerotherapy NN 1_i
procedure NN N
. . N

We PRP N
currently RB N
recommend VBP N
surgery NN N
after IN N
two CD N
injection NN N
treatments NNS N
have VBP N
failed VBN N
. . N

-DOCSTART- -X- O O

A DT N
double-blind NN N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
multicenter NN N
safety NN N
and CC N
immunogenicity NN N
study NN N
of IN N
a DT N
refrigerator-stable JJ 3_i
formulation NN 3_i
of IN 3_i
Zostavax NNP 3_i
. . N

The DT N
vaccine NN 3_i
Zostavax NNP 3_i
has VBZ N
been VBN N
shown VBN N
to TO N
prevent VB N
herpes NNS N
zoster NNP N
( ( N
HZ NNP N
) ) N
and CC N
postherpetic JJ N
neuralgia NN N
and CC N
is VBZ N
recommended VBN N
for IN N
individuals NNS N
> CD N
or CC N
=60 CD N
years NNS N
of IN N
age NN N
. . N

This DT N
study NN N
compared VBN N
the DT N
safety NN N
and CC N
the DT N
immunogenicity NN N
of IN N
a DT N
refrigerator-stable JJ 3_i
formulation NN 3_i
( ( 3_i
Zostavax NNP 3_i
refrigerated VBD 3_i
) ) 3_i
with IN N
those DT N
of IN N
the DT N
current JJ 3_i
formulation NN 3_i
( ( 3_i
Zostavax NNP 3_i
frozen RB 3_i
) ) 3_i
in IN N
subjects NNS N
> VBP N
or CC N
=50 CD N
years NNS N
of IN N
age NN N
. . N

Subjects VBZ N
with IN N
a DT N
negative JJ N
history NN N
for IN N
HZ NNP N
were VBD N
randomized VBN N
1:1 CD N
to TO N
receive VB N
one CD N
dose NN N
of IN N
either DT N
formulation NN N
. . N

Enrollment NN N
was VBD N
stratified VBN N
1:2 CD N
by IN N
age NN N
( ( N
50 CD N
to TO N
59 CD N
years NNS N
and CC N
> NN N
or CC N
=60 CD N
years NNS N
) ) N
. . N

Safety NN N
was VBD N
evaluated VBN N
for IN N
28 CD N
days NNS N
postvaccination NN N
. . N

Varicella-zoster JJ N
virus NN N
( ( N
VZV NNP N
) ) N
antibody NN N
responses NNS N
were VBD N
measured VBN N
by IN N
a DT N
glycoprotein JJ N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
gpELISA NN N
) ) N
. . N

The DT N
primary JJ N
endpoints NNS N
were VBD N
the DT N
VZV NNP N
antibody NN N
geometric JJ N
mean NN N
titer NN N
( ( N
GMT NNP N
; : N
day NN N
28 CD N
) ) N
, , N
the DT N
VZV NNP N
antibody NN N
geometric JJ N
mean NN N
rise NN N
( ( N
GMR NNP N
; : N
days NNS N
1 CD N
to TO N
28 CD N
) ) N
, , N
and CC N
the DT N
incidence NN N
of IN N
vaccine-related JJ N
serious JJ N
adverse JJ N
experiences NNS N
( ( N
AEs NNP N
) ) N
over IN N
28 CD N
days NNS N
. . N

The DT N
refrigerated JJ 3_i
( ( N
n JJ N
= NNP N
182 CD N
) ) N
and CC N
frozen JJ 3_i
( ( N
n JJ N
= NNP N
185 CD N
) ) N
formulations NNS N
induced VBD N
similar JJ N
GMTs NNP N
( ( N
727.4 CD N
and CC N
834.4 CD N
gpELISA NN N
units/ml NN N
, , N
respectively RB N
) ) N
; : N
the DT N
estimated VBN N
GMT NNP N
ratio NN N
( ( N
refrigerated VBN 3_i
formulation/frozen RB 3_i
formulation NN 3_i
) ) N
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.71 CD N
to TO N
1.07 CD N
) ) N
. . N

The DT N
GMRs NNPS N
were VBD N
2.6- JJ N
and CC N
2.9-fold JJ N
, , N
respectively RB N
. . N

No DT N
vaccine-related JJ N
serious JJ N
AEs NNP N
were VBD N
reported VBN N
in IN N
either DT N
group NN N
, , N
and CC N
the DT N
safety NN N
profiles NNS N
of IN N
the DT N
formulations NNS N
were VBD N
generally RB N
similar JJ N
. . N

The DT N
frequencies NNS N
of IN N
injection-site JJ N
AEs NNP N
during IN N
follow-up JJ N
were VBD N
35.6 CD N
% NN N
and CC N
46.4 CD N
% NN N
in IN N
the DT N
refrigerated JJ 3_i
and CC 2_i
the DT 2_i
frozen JJ 3_i
formulation NN 3_i
groups NNS N
, , N
respectively RB N
, , N
and CC N
were VBD N
generally RB N
mild VBN N
. . N

The DT N
frequencies NNS N
of IN N
systemic JJ N
AEs NNP N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
, , N
and CC N
those DT N
of IN N
vaccine-related JJ N
AEs NNP N
were VBD N
approximately RB N
6 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
refrigerator-stable JJ 3_i
formulation NN 3_i
of IN 3_i
Zostavax NNP 3_i
has VBZ N
an DT N
acceptable JJ N
safety NN N
profile NN N
and CC N
is VBZ N
as RB N
immunogenic JJ N
as IN N
the DT N
frozen JJ 3_i
formulation NN 3_i
; : N
thus RB N
, , N
the DT N
vaccine NN N
may MD N
be VB N
used VBN N
in IN N
clinical JJ N
settings NNS N
where WRB N
freezer NN N
availability NN N
is VBZ N
limited VBN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
topical JJ N
azithromycin NN 3_i
ophthalmic JJ N
solution NN N
1 CD N
% NN N
in IN N
the DT N
treatment NN N
of IN N
posterior JJ N
blepharitis NN N
. . N

INTRODUCTION NNP N
Azithromycin NNP 3_i
, , N
a DT N
broad-spectrum JJ N
antibiotic JJ N
with IN N
potent JJ N
anti-inflammatory JJ N
activities NNS N
, , N
has VBZ N
the DT N
potential JJ N
to TO N
effectively RB N
treat VB N
blepharitis NN N
, , N
an DT N
inflammatory JJ N
disease NN N
of IN N
the DT N
eyelid JJ N
with IN N
abnormal JJ N
eyelid JJ N
flora NN N
as IN N
an DT N
etiologic JJ N
determinant NN N
. . N

The DT N
present JJ N
study NN N
compared VBN N
the DT N
efficacy NN N
of IN N
topical JJ N
azithromycin NN 3_i
ophthalmic JJ N
solution NN N
1 CD N
% NN N
( ( N
AzaSite NNP N
; : N
Inspire NNP N
Pharmaceuticals NNP N
, , N
Inc NNP N
, , N
NC NNP N
, , N
USA NNP N
) ) N
combined VBD N
with IN N
warm JJ N
compresses NNS N
( ( N
azithromycin JJ N
group NN N
) ) N
to TO N
warm JJ N
compresses NNS N
alone RB N
( ( N
compress JJ N
group NN N
) ) N
in IN N
patients NNS N
with IN N
posterior JJ N
blepharitis NN N
. . N

METHODS NNP N
Twenty-one CD N
patients NNS N
diagnosed VBN N
with IN N
posterior JJ N
blepharitis NN N
were VBD N
randomized VBN N
in IN N
an DT N
open-label JJ N
study NN N
to TO N
receive VB N
either DT N
azithromycin NN 3_i
plus CC N
warm JJ 3_i
compresses NNS 3_i
( ( N
10 CD N
patients NNS N
) ) N
, , N
or CC N
compresses VBZ N
alone RB N
( ( N
11 CD N
patients NNS N
) ) N
. . N

All DT N
patients NNS N
were VBD N
instructed VBN N
to TO N
apply VB N
compresses NNS N
to TO N
each DT N
eye NN N
for IN N
5-10 JJ N
minutes NNS N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Each DT N
eye NN N
in IN N
the DT N
azithromycin NN 3_i
group NN N
also RB N
received VBD N
azithromycin JJ N
solution NN N
( ( N
1 CD N
drop NN N
) ) N
twice RB N
daily RB N
for IN N
the DT N
first JJ N
2 CD N
days NNS N
followed VBN N
by IN N
once RB N
daily JJ N
for IN N
the DT N
next JJ N
12 CD N
days NNS N
. . N

Patients NNS N
were VBD N
evaluated VBN N
at IN N
study NN N
initiation NN N
( ( N
visit IN N
1 CD N
) ) N
and CC N
at IN N
end NN N
of IN N
treatment NN N
( ( N
visit IN N
2 CD N
) ) N
for IN N
the DT N
severity NN N
of IN N
five CD N
clinical JJ N
signs NNS N
: : N
eyelid JJ N
debris NN N
, , N
eyelid JJ N
redness NN N
, , N
eyelid JJ N
swelling NN N
, , N
meibomian JJ N
gland NN N
( ( N
MG NNP N
) ) N
plugging NN N
, , N
and CC N
the DT N
quality NN N
of IN N
MG NNP N
secretion NN N
. . N

At IN N
visit NN N
2 CD N
, , N
patients NNS N
also RB N
rated VBD N
their PRP$ N
degree NN N
of IN N
overall JJ N
symptomatic JJ N
relief NN N
. . N

RESULTS NNP N
Twenty NNP N
patients NNS N
completed VBD N
the DT N
study NN N
. . N

At IN N
visit NN N
2 CD N
, , N
patients NNS N
in IN N
the DT N
azithromycin NN 3_i
group NN N
demonstrated VBD N
significant JJ N
improvements NNS N
in IN N
MG NNP N
plugging NN N
, , N
MG NNP N
secretions NNS N
, , N
and CC N
eyelid JJ N
redness NN N
as IN N
compared VBN N
with IN N
the DT N
compress NN N
group NN N
. . N

In IN N
the DT N
azithromycin NN 3_i
group NN N
, , N
MG NNP N
plugging VBG N
resolved VBN N
completely RB N
in IN N
three CD N
patients NNS N
and CC N
MG NNP N
secretion NN N
returned VBD N
to TO N
normal JJ N
in IN N
two CD N
patients NNS N
; : N
no DT N
such JJ N
results NNS N
were VBD N
seen VBN N
in IN N
the DT N
compress NN N
group NN N
. . N

Furthermore RB N
, , N
a DT N
higher JJR N
percentage NN N
of IN N
patients NNS N
in IN N
the DT N
azithromycin NN N
group NN N
rated VBD N
overall JJ N
symptomatic JJ N
relief NN N
as IN N
excellent NN N
or CC N
good JJ N
. . N

Visual JJ N
acuity NN N
measurements NNS N
and CC N
biomicroscopic JJ N
evaluation NN N
revealed VBD N
no DT N
ocular JJ N
safety NN N
issues NNS N
. . N

CONCLUSION NNP N
Azithromycin NNP 3_i
ophthalmic JJ N
solution NN N
in IN N
combination NN N
with IN N
warm JJ N
compresses NNS N
provided VBD N
a DT N
significantly RB N
greater JJR N
clinical JJ N
benefit NN N
than IN N
warm JJ N
compresses NNS N
alone RB N
in IN N
treating VBG N
the DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
posterior JJ N
blepharitis NN N
. . N

-DOCSTART- -X- O O

A DT N
first-in-man JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ 7_i
study NN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
feasibility NN N
of IN N
autologous JJ 2_i
delipidated VBN 2_i
high-density NN 2_i
lipoprotein NN 2_i
plasma NN 2_i
infusions NNS 2_i
in IN N
patients NNS N
with IN N
acute JJ N
coronary JJ N
syndrome NN N
. . N

OBJECTIVES CC N
This DT N
study NN N
aimed VBD N
to TO N
determine VB N
whether IN N
serial JJ 3_i
autologous JJ 3_i
infusions NNS 3_i
of IN 3_i
selective JJ 3_i
high-density NN 3_i
lipoprotein NN 3_i
( ( 3_i
HDL NNP 3_i
) ) 3_i
delipidated VBD 2_i
plasma NN 2_i
are VBP N
feasible JJ N
and CC N
well RB N
tolerated VBN N
in IN N
patients NNS N
with IN N
acute JJ N
coronary JJ N
syndrome NN N
( ( N
ACS NNP N
) ) N
. . N

BACKGROUND NNP N
Low NNP N
HDL NNP N
is VBZ N
associated VBN N
with IN N
increased JJ N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

Plasma NNP N
selective JJ N
delipidation NN N
converts NNS N
alphaHDL VBP N
to TO N
prebeta-like JJ N
HDL NNP N
, , N
the DT N
most RBS N
effective JJ N
form NN N
of IN N
HDL NNP N
for IN N
lipid JJ N
removal NN N
from IN N
arterial JJ N
plaques NNS N
. . N

METHODS NNP N
ACS NNP N
patients NNS N
undergoing VBG N
cardiac JJ N
catheterization NN N
with IN N
> NNP N
or=1 VBP N
nonobstructive JJ N
native JJ N
coronary JJ N
artery NN N
atheroma NN N
were VBD N
randomized VBN N
to TO N
either DT N
7 CD N
weekly JJ N
HDL NNP 2_i
selective NN 2_i
delipidated VBD 2_i
or CC N
control VB 7_i
plasma JJ 7_i
apheresis/reinfusions NNS 7_i
. . N

Patients NNS N
underwent JJ N
intravascular JJ 2_i
ultrasound NN 2_i
( ( N
IVUS NNP N
) ) N
evaluation NN N
of IN N
the DT N
target NN N
vessel NN N
during IN N
the DT N
catheterization NN N
for IN N
ACS NNP N
and CC N
up RB N
to TO N
14 CD N
days NNS N
following VBG N
the DT N
final JJ N
apheresis/reinfusion NN 3_i
session NN N
. . N

2-D JJ N
gel JJ N
electrophoresis NN N
of IN N
delipidated JJ N
plasmas NN N
established VBN N
successful JJ N
conversion NN N
of IN N
alphaHDL NN N
to TO N
prebeta-like JJ N
HDL NNP N
. . N

The DT N
trial NN N
was VBD N
complete JJ N
with IN N
28 CD N
patients NNS N
randomized VBN N
. . N

RESULTS NNP N
All DT N
reinfusion NN N
sessions NNS N
were VBD N
tolerated VBN N
well RB N
by IN N
all DT N
patients NNS N
. . N

The DT N
levels NNS N
of IN N
prebeta-like JJ N
HDL NNP N
and CC N
alphaHDL NN N
in IN N
the DT N
delipidated JJ N
plasma NN N
converted VBD N
from IN N
5.6 CD N
% NN N
to TO N
79.1 CD N
% NN N
and CC N
92.8 CD N
% NN N
to TO N
20.9 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
IVUS NNP N
data NNS N
demonstrated VBD N
a DT N
numeric JJ N
trend NN N
toward IN N
regression NN N
in IN N
the DT N
total JJ N
atheroma NN N
volume NN N
of IN N
-12.18 JJ N
+/- JJ N
36.75 CD N
mm NN N
( ( N
3 CD N
) ) N
in IN N
the DT N
delipidated JJ N
group NN N
versus VBD N
an DT N
increase NN N
of IN N
total JJ N
atheroma JJ N
volume NN N
of IN N
2.80 CD N
+/- JJ N
21.25 CD N
mm NN N
( ( N
3 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.268 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
ACS NNP N
patients NNS N
, , N
serial JJ N
autologous JJ N
infusions NNS N
of IN N
selective JJ 3_i
HDL NNP 3_i
delipidated VBD 3_i
plasma NNS 3_i
are VBP N
clinically RB N
feasible JJ N
and CC N
well RB N
tolerated VBN N
. . N

This DT N
therapy NN N
may MD N
offer VB N
a DT N
novel JJ N
adjunct JJ N
treatment NN N
for IN N
patients NNS N
presenting VBG N
with IN N
ACS NNP N
. . N

Further NNP N
study NN N
will MD N
be VB N
needed VBN N
to TO N
determine VB N
its PRP$ N
ability NN N
to TO N
reduce VB N
clinical JJ N
cardiovascular JJ N
events NNS N
. . N

-DOCSTART- -X- O O

Strength NN N
of IN N
vital JJ N
force NN N
in IN N
classical JJ N
homeopathy NN N
: : N
bio-psycho-social-spiritual JJ N
correlates NNS N
within IN N
a DT N
complex JJ N
systems NNS N
context NN N
. . N

OBJECTIVE UH N
To TO N
explore VB N
associations NNS N
between IN N
a DT N
global JJ N
rating NN N
for IN N
the DT N
classical JJ N
homeopathic JJ N
construct NN N
of IN N
vital JJ N
force NN N
and CC N
clinician JJ N
and CC N
patient JJ N
ratings NNS N
on IN N
previously RB N
validated VBN N
bio-psycho-social-spiritual JJ N
questionnaires NNS N
. . N

METHODS NNP N
Sixty-two NNP N
( ( N
62 CD N
) ) N
community-recruited JJ N
patients NNS N
with IN N
fibromyalgia NN N
( ( N
FM NNP N
) ) N
were VBD N
assessed VBN N
at IN N
baseline NN N
prior RB N
to TO N
a DT N
clinical JJ N
trial NN N
of IN N
individualized JJ N
homeopathy NN N
. . N

Two CD N
homeopaths NNS N
jointly RB N
performed VBD N
case-taking JJ 5_i
interviews NNS 5_i
. . N

A DT N
conventional JJ N
medical JJ N
provider NN N
independently RB N
evaluated VBD N
patients NNS N
with IN N
a DT N
standardized JJ N
history NN N
and CC N
physical JJ N
examination NN N
. . N

Homeopaths NNP N
rated VBD N
each DT N
patient NN N
's POS N
vital JJ N
force NN N
( ( N
five-point JJ N
Likert NNP N
scale NN N
, , N
with IN N
1 CD N
= JJ N
very RB N
weak JJ N
to TO N
5 CD N
= NNS N
very RB N
strong JJ N
) ) N
. . N

Homeopaths NNP N
and CC N
the DT N
conventional JJ N
medical JJ N
provider NN N
rated VBN N
their PRP$ N
Clinical JJ N
Global NNP N
Impression NNP N
( ( N
CGI NNP N
) ) N
of IN N
the DT N
severity NN N
of IN N
illness NN N
( ( N
1 CD N
= NNP N
normal JJ N
; : N
7 CD N
= NN N
among IN N
the DT N
most RBS N
extremely RB N
ill JJ N
) ) N
. . N

Patients NNS N
completed VBD N
self-rating JJ 4_i
scales NNS 4_i
on IN N
pain NN N
, , N
global JJ N
health NN N
, , N
mood NN N
, , N
quality NN N
of IN N
life NN N
, , N
coping VBG N
style NN N
, , N
health NN N
locus NN N
of IN N
control NN N
, , N
multidimensional JJ N
well-being NN N
, , N
spirituality NN N
, , N
sense NN N
of IN N
coherence NN N
, , N
positive JJ N
states NNS N
of IN N
mind NN N
, , N
and CC N
social JJ N
desirability NN N
. . N

RESULTS NNP N
Greater NNP N
vital JJ N
force NN N
ratings NNS N
( ( N
mean VB N
2.9 CD N
standard JJ N
deviation NN N
[ NNP N
SD NNP N
] NNP N
0.6 CD N
) ) N
correlated VBN N
moderately RB N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.005 CD N
) ) N
with IN N
less JJR N
severe JJ N
CGI NNP N
illness NN N
ratings NNS N
by IN N
the DT N
homeopaths NNS N
( ( N
r VB N
=-0.59 NN N
) ) N
, , N
decreased VBD N
patient-rated JJ N
mental JJ N
confusion NN N
( ( N
r VB N
=-0.43 NN N
) ) N
, , N
higher JJR N
vigor NN N
( ( N
r JJ N
= NNP N
0.38 CD N
) ) N
, , N
and CC N
greater JJR N
positive JJ N
states NNS N
of IN N
mind NN N
( ( N
r JJ N
= NNP N
0.36 CD N
) ) N
. . N

Vital NNP N
force NN N
also RB N
showed VBD N
correlations NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
lower JJR N
CGI NNP N
ratings NNS N
by IN N
the DT N
conventional JJ N
medical JJ N
provider NN N
( ( N
r VB N
=-0.32 NN N
) ) N
, , N
better RB N
selfrated VBN N
quality NN N
of IN N
life NN N
( ( N
r JJ N
= NNP N
0.33 CD N
) ) N
, , N
lesser JJR N
fatigue NN N
( ( N
r VB N
=-0.31 NN N
) ) N
, , N
better JJR N
global JJ N
health NN N
( ( N
r VB N
= RB N
0.29 CD N
) ) N
, , N
greater JJR N
sense NN N
of IN N
coherence NN N
( ( N
r JJ N
= NNP N
0.28 CD N
) ) N
, , N
powerful-others JJ N
health NN N
locus NN N
of IN N
control NN N
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
increased VBD N
emotional JJ N
well-being NN N
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
and CC N
higher JJR N
social JJ N
desirability NN N
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
but CC N
not RB N
with IN N
age NN N
, , N
pain NN N
, , N
or CC N
illness JJ N
duration NN N
. . N

CONCLUSION NNP N
Homeopathic NNP N
vital JJ N
force NN N
ratings NNS N
reflect VBP N
better JJR N
perceived VBN N
mental JJ N
function NN N
, , N
energy NN N
, , N
and CC N
positive JJ N
dimensions NNS N
of IN N
the DT N
individual NN N
, , N
beyond IN N
absence NN N
of IN N
disease NN N
. . N

-DOCSTART- -X- O O

TENS NNP 2_i
for IN N
the DT N
treatment NN N
of IN N
writer NN N
's POS N
cramp NN N
dystonia NN N
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 7_i
study NN N
. . N

Manipulation NNP N
of IN N
afferent NN N
inputs NNS N
may MD N
temporarily RB N
modulate VB N
dystonic JJ N
spasms NNS N
. . N

Ten CD N
patients NNS N
with IN N
writer NN N
's POS N
cramp NN N
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
in IN N
which WDT N
the DT N
effects NNS N
of IN N
transcutaneous JJ 2_i
electrical JJ 2_i
stimulation NN 2_i
( ( 2_i
TENS NNP 2_i
) ) 2_i
and CC N
placebo JJ 7_i
treatment NN N
were VBD N
compared VBN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
using VBG N
four CD N
measures NNS N
of IN N
dystonic JJ N
impairment NN N
. . N

The DT N
TENS NNP 2_i
group NN N
showed VBD N
a DT N
significant JJ N
improvement NN N
that WDT N
persisted VBD N
for IN N
3 CD N
weeks NNS N
in IN N
three CD N
of IN N
the DT N
four CD N
measures NNS N
. . N

-DOCSTART- -X- O O

Placebo-controlled JJ 7_i
trial NN N
evaluating VBG N
safety NN N
with IN N
12-months JJ N
continuous JJ N
use NN N
of IN N
6 CD 3_i
% NN 3_i
hydrogen NN 3_i
peroxide IN 3_i
whitening VBG 3_i
strips NNS 3_i
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
6 CD 3_i
% NN 3_i
hydrogen NN 3_i
peroxide IN 3_i
whitening VBG 3_i
strips NNS 3_i
over IN N
12 CD N
months NNS N
. . N

METHODS NNP N
80 CD N
adults NNS N
were VBD N
randomly RB N
assigned VBN N
equally RB N
to TO N
one CD N
of IN N
two CD N
treatments NNS N
: : N
6 CD 3_i
% NN 3_i
hydrogen NN 3_i
peroxide JJ 3_i
strips NNS 3_i
or CC 3_i
placebo VB 3_i
strips NNS 3_i
. . 3_i

Strips NNS N
were VBD N
worn JJ N
5 CD N
min JJ N
daily RB N
for IN N
12 CD N
months NNS N
. . N

Safety NNP N
and CC N
tolerability NN N
were VBD N
assessed VBN N
via IN N
oral JJ N
status NN N
interviews NNS N
and CC N
oral JJ N
examinations NNS N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
of IN N
use NN N
. . N

RESULTS NNP N
Tooth NNP N
sensitivity NN N
and CC N
oral JJ N
irritation NN N
were VBD N
the DT N
two CD N
most JJS N
common JJ N
adverse JJ N
events NNS N
. . N

After IN N
12 CD N
months NNS N
use RB N
, , N
tooth DT N
sensitivity NN N
was VBD N
reported VBN N
by IN N
10 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
6 CD 3_i
% NN 3_i
strip NN 3_i
group NN N
with IN N
a DT N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
( ( N
2.8 CD N
% NN N
, , N
23.7 CD N
% NN N
) ) N
and CC N
5 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
placebo NN 7_i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.6 CD N
% NN N
, , N
16.9 CD N
% NN N
) ) N
. . N

The DT N
occurrence NN N
of IN N
reported VBN N
oral JJ N
irritation NN N
was VBD N
0 CD N
% NN N
in IN N
the DT N
6 CD 3_i
% NN 3_i
strip NN 3_i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0 CD N
% NN N
, , N
8.8 CD N
% NN N
) ) N
and CC N
2.5 CD N
% NN N
in IN N
the DT N
placebo NN 7_i
strip NN 7_i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.1 CD N
% NN N
, , N
13.2 CD N
% NN N
) ) N
. . N

The DT N
occurrence NN N
of IN N
observed JJ N
oral JJ N
irritation NN N
was VBD N
also RB N
similar JJ N
between IN N
groups NNS N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.67 CD N
) ) N
for IN N
the DT N
percent NN N
of IN N
subjects NNS N
with IN N
each DT N
type NN N
of IN N
adverse JJ N
event NN N
. . N

In IN N
the DT N
6 CD 3_i
% NN 3_i
strip NN 3_i
group NN N
, , N
two CD N
subjects NNS N
discontinued VBN N
product NN N
use NN N
due JJ N
to TO N
an DT N
adverse JJ N
event NN N
( ( N
tooth JJ N
sensitivity NN N
) ) N
compared VBN N
to TO N
no DT N
subjects NNS N
in IN N
the DT N
placebo NN 7_i
group NN N
. . N

Groups NNP N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.49 CD N
) ) N
with IN N
respect NN N
to TO N
this DT N
outcome NN N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
6 CD 3_i
% NN 3_i
hydrogen NN 3_i
peroxide IN 3_i
whitening VBG 3_i
strips NNS 3_i
over IN N
12 CD N
months NNS N
resulted VBN N
in IN N
a DT N
safety NN N
profile NN N
similar JJ N
to TO N
that DT N
seen VBN N
with IN N
placebo JJ 7_i
strips NNS 7_i
. . N

-DOCSTART- -X- O O

Tailored NNP 4_i
, , 4_i
iterative JJ 4_i
, , 4_i
printed JJ 4_i
dietary JJ 4_i
feedback NN 4_i
is VBZ N
as RB N
effective JJ N
as IN N
group NN N
education NN N
in IN N
improving VBG N
dietary JJ N
behaviours NNS N
: : N
results NNS N
from IN N
a DT N
randomised VBN N
control NN N
trial NN N
in IN N
middle-aged JJ N
adults NNS N
with IN N
cardiovascular JJ N
risk NN N
factors NNS N
. . N

BACKGROUND NNP N
Tailored NNP N
nutrition NN N
interventions NNS N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
non-tailored JJ N
materials NNS N
in IN N
changing VBG N
dietary JJ N
behaviours NNS N
, , N
particularly RB N
fat JJ N
intake NN N
and CC N
fruit NN N
and CC N
vegetable JJ N
intake NN N
. . N

But CC N
further JJ N
research NN N
examining VBG N
efficacy NN N
of IN N
tailored JJ N
nutrition NN N
education NN N
in IN N
comparison NN N
to TO N
other JJ N
nutrition JJ N
education NN N
methods NNS N
and CC N
across IN N
a DT N
wider NN N
range NN N
of IN N
dietary JJ N
behaviours NNS N
is VBZ N
needed VBN N
. . N

The DT N
Stages NNPS N
to TO N
Healthy NNP N
Eating NNP N
Patterns NNP N
Study NNP N
( ( N
STEPs NNP N
) ) N
was VBD N
an DT N
intervention NN N
study NN N
, , N
in IN N
middle-aged JJ N
adults NNS N
with IN N
cardiovascular JJ N
risk NN N
factors NNS N
, , N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
delivered VBN N
by IN N
mail NN N
in IN N
improving VBG N
short-term JJ N
dietary JJ N
behaviour NN N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ N
fat NN N
, , N
fruit NN N
, , N
vegetable JJ N
and CC N
grain NN N
and CC N
cereal NN N
intake NN N
. . N

METHODS NNP N
STEPs NNP N
was VBD N
a DT N
3-month JJ N
randomised VBN N
controlled VBN N
trial NN N
with IN N
a DT N
pre NN N
and CC N
post-test JJ N
design NN N
. . N

There EX N
were VBD N
three CD N
experimental JJ N
conditions NNS N
: : N
1 CD N
) ) N
tailored VBN 4_i
, , 4_i
iterative JJ 4_i
, , 4_i
printed JJ 4_i
dietary JJ 4_i
feedback NN 4_i
( ( 4_i
TF NNP 4_i
) ) 4_i
with IN N
three CD N
instalments NNS N
mail-delivered JJ N
over IN N
a DT N
3-month JJ N
period NN N
that WDT N
were VBD N
re-tailored VBN N
to TO N
most RBS N
recent JJ N
assessment NN N
of IN N
dietary JJ N
intake NN N
, , N
intention NN N
to TO N
change VB N
and CC N
assessment NN N
of IN N
self-adequacy NN N
of IN N
dietary JJ N
intake NN N
. . N

Tailoring VBG N
for IN N
dietary JJ N
intake NN N
was VBD N
performed VBN N
on IN N
data NNS N
from IN N
a DT N
validated JJ N
63-item JJ N
combination NN N
FFQ NNP N
designed VBN N
for IN N
the DT N
purpose JJ N
2 CD N
) ) N
small JJ N
group NN N
nutrition NN 4_i
education NN 4_i
sessions NNS 4_i
( ( N
GE NNP N
) ) N
: : N
consisting NN N
of IN N
two CD N
90-minute JJ N
dietitian-led JJ N
small JJ N
group NN N
nutrition NN N
education NN N
sessions NNS N
and CC N
3 CD N
) ) N
and CC N
a DT N
wait-listed JJ N
control NN N
( ( N
C NNP N
) ) N
group NN N
who WP N
completed VBD N
the DT N
dietary JJ 4_i
measures NNS 4_i
and CC 4_i
socio-demographic JJ 4_i
questionnaires NNS 4_i
at IN N
baseline NN N
and CC N
3-months JJ N
later NN N
. . N

Dietary NNP N
outcome NN N
measures NNS N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ N
fat JJ N
intake NN N
( ( N
g NN N
) ) N
, , N
and CC N
the DT N
intake NN N
of IN N
fruit NN N
( ( N
serves NNS N
) ) N
, , N
vegetables NNS N
( ( N
serves NNS N
) ) N
, , N
grain NN N
and CC N
cereals NNS N
as IN N
total JJ N
and CC N
wholegrain NN N
( ( N
serves NNS N
) ) N
were VBD N
collected VBN N
using VBG N
7-day JJ N
estimated VBN N
dietary JJ N
records NNS N
. . N

Descriptive JJ N
statistics NNS N
, , N
paired VBD N
t-tests NNS N
and CC N
general JJ N
linear JJ N
models NNS N
adjusted VBN N
for IN N
baseline NN N
dietary JJ N
intake NN N
, , N
age NN N
and CC N
gender NN N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
different JJ N
nutrition NN N
interventions NNS N
. . N

RESULTS VB N
The DT N
TF NNP 4_i
group NN N
reported VBD N
a DT N
significantly RB N
greater JJR N
increase NN N
in IN N
fruit JJ N
intake NN N
( ( N
0.3 CD N
serves/d NN N
P NNP N
= NNP N
0.031 CD N
) ) N
in IN N
comparison NN N
to TO N
GE NNP N
and CC N
the DT N
C NNP N
group NN N
. . N

All DT N
three CD N
intervention NN N
groups NNS N
showed VBD N
a DT N
reduction NN N
in IN N
total JJ N
saturated JJ N
fat JJ N
intake NN N
. . N

GE NNP N
also RB N
had VBD N
a DT N
within-group JJ N
increase NN N
in IN N
mean JJ N
vegetable JJ N
intake NN N
after IN N
3 CD N
months NNS N
, , N
but CC N
this DT N
increase NN N
was VBD N
not RB N
different JJ N
from IN N
changes NNS N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
was VBD N
more RBR N
effective JJ N
than IN N
small JJ N
group NN N
nutrition NN N
education NN N
in IN N
improving VBG N
the DT N
short-term JJ N
fruit NN N
intake VB N
behaviour NN N
, , N
and CC N
as IN N
effective JJ N
in IN N
improving VBG N
saturated VBN N
fat JJ N
intake NN N
of IN N
middle-aged JJ N
adults NNS N
with IN N
cardiovascular JJ N
risk NN N
factors NNS N
. . N

This DT N
showed VBD N
that IN N
a DT N
low-level JJ N
dietary JJ N
intervention NN N
could MD N
achieve VB N
modest JJ N
dietary JJ N
behaviour NN N
changes NNS N
that WDT N
are VBP N
of IN N
public JJ N
health NN N
significance NN N
. . N

-DOCSTART- -X- O O

Study NNP N
design NN N
and CC N
rationale NN N
of IN N
a DT N
dose-ranging JJ N
trial NN N
of IN N
LX4211 NNP 3_i
, , N
a DT N
dual JJ N
inhibitor NN N
of IN N
SGLT1 NNP N
and CC N
SGLT2 NNP N
, , N
in IN N
type JJ N
2 CD N
diabetes NNS N
inadequately RB N
controlled VBN N
on IN N
metformin NN N
monotherapy NN N
. . N

Sodium-glucose JJ N
cotransporters NNS N
1 CD N
( ( N
SGLT1 NNP N
) ) N
and CC N
2 CD N
( ( N
SGLT2 NNP N
) ) N
are VBP N
the DT N
major JJ N
cellular JJ N
transporters NNS N
responsible JJ N
for IN N
gastrointestinal JJ N
( ( N
GI NNP N
) ) N
glucose VBP N
absorption NN N
and CC N
renal JJ N
glucose NN N
reabsorption NN N
, , N
respectively RB N
. . N

LX4211 NNP 3_i
, , N
a DT N
dual JJ N
inhibitor NN N
of IN N
SGLT1 NNP N
and CC N
SGLT2 NNP N
, , N
reduces VBZ N
glucose JJ N
absorption NN N
from IN N
the DT N
GI NNP N
tract NN N
and CC N
enhances NNS N
urinary JJ N
glucose JJ N
excretion NN N
. . N

Although IN N
several JJ N
SGLT2-selective JJ N
inhibitors NNS N
have VBP N
been VBN N
tested VBN N
in IN N
large JJ N
phase NN N
2 CD N
studies NNS N
, , N
dual JJ N
inhibition NN N
of IN N
SGLT1 NNP N
and CC N
SGLT2 NNP N
is VBZ N
novel JJ N
at IN N
this DT N
stage NN N
of IN N
drug NN N
development NN N
, , N
and CC N
it PRP N
has VBZ N
implications NNS N
for IN N
clinical-trial JJ N
design NN N
. . N

In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
the DT N
design NN N
and CC N
rationale NN N
of IN N
a DT N
phase NN N
2 CD N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
, , N
parallel JJ N
group NN N
study NN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
LX4211 NNP 3_i
in IN N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus NN N
who WP N
have VBP N
inadequate JJ N
glycemic NNS N
control NN N
on IN N
metformin NN N
monotherapy NN N
. . N

The DT N
primary JJ N
endpoint NN N
is VBZ N
the DT N
change NN N
in IN N
glycated JJ N
hemoglobin NN N
A1c NNP N
from IN N
baseline NN N
to TO N
week NN N
12 CD N
. . N

Secondary JJ N
endpoints NNS N
include VBP N
the DT N
proportion NN N
of IN N
subjects NNS N
achieving VBG N
a DT N
glycated JJ N
hemoglobin NN N
A1c NNP N
value NN N
of IN N
< $ N
7 CD N
% NN N
, , N
change NN N
from IN N
baseline NN N
in IN N
fasting VBG N
plasma NN N
glucose NN N
and CC N
postprandial JJ N
glucose NN N
( ( N
as IN N
part NN N
of IN N
an DT N
oral JJ N
glucose NN N
tolerance NN N
test NN N
) ) N
, , N
body NN N
weight NN N
, , N
and CC N
blood NN N
pressure NN N
. . N

Safety NN N
is VBZ N
evaluated VBN N
with IN N
particular JJ N
focus NN N
on IN N
hypoglycemia NN N
, , N
GI NNP N
symptoms NNS N
, , N
and CC N
incidence NN N
of IN N
genitourinary JJ N
tract NN N
infections NNS N
. . N

-DOCSTART- -X- O O

Albumin-glutaraldehyde JJ 3_i
bioadhesive NN 3_i
( ( 3_i
Bioglue NNP 3_i
) ) 3_i
for IN N
prevention NN N
of IN N
postoperative JJ N
complications NNS N
after IN N
stapled VBN N
hemorrhoidopexy NN N
: : N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Hemorrhoidopexy NNP N
using VBG N
the DT N
circumferential JJ N
stapler NN N
is VBZ N
an DT N
established JJ N
method NN N
for IN N
surgical JJ N
treatment NN N
of IN N
patients NNS N
with IN N
prolapsing JJ N
hemorrhoids NNS N
. . N

Despite IN N
its PRP$ N
advantages NNS N
, , N
complications NNS N
such JJ N
as IN N
anal JJ N
canal JJ N
stenosis NN N
, , N
hemorrhage NN N
and CC N
anastomosis NN N
leak NN N
with IN N
eventual JJ N
intrapelvic JJ N
sepsis NN N
can MD N
cause VB N
serious JJ N
postoperative JJ N
problems NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
utility NN N
of IN N
a DT N
surgical JJ N
adhesive NN N
, , N
the DT N
biological JJ 3_i
albumin-glutaraldehyde JJ 3_i
glue NN 3_i
Bioglue NNP 3_i
, , N
in IN N
reduction NN N
of IN N
these DT N
postoperative JJ N
complications NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP N
January NNP N
2002 CD N
and CC N
November NNP N
2004 CD N
, , N
200 CD N
patients NNS N
undergoing VBG N
stapled JJ 1_i
hemorrhoidopexy NN 1_i
were VBD N
enrolled VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
. . N

One CD N
hundred VBD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
control NN 7_i
group NN 7_i
; : 4_i
the DT N
study NN N
group NN N
consisted VBD N
of IN N
100 CD N
patients NNS N
who WP N
received VBD N
Bioglue NNP 3_i
in IN 3_i
the DT 3_i
mucosa NN 3_i
anastomosis NN 3_i
area NN 3_i
. . N

All DT N
patients NNS N
received VBD N
standardized JJ 3_i
postoperative JJ 3_i
analgesic NN 3_i
, , 3_i
laxative JJ 3_i
and CC 3_i
antibiotic JJ 3_i
treatment NN 3_i
. . N

We PRP N
then RB N
evaluated VBD N
the DT N
two CD N
groups NNS N
for IN N
postoperative JJ N
complications NNS N
( ( N
after IN N
surgery NN N
and CC N
6 CD N
months NNS N
postoperatively RB N
) ) N
. . N

RESULTS CC N
From IN N
the DT N
control NN N
group NN N
( ( N
no DT N
Bioglue NNP N
application NN N
) ) N
, , N
two CD N
patients NNS N
presented VBN N
with IN N
anal JJ N
stenosis NN N
, , N
two CD N
with IN N
hemorrhage NN N
, , N
three CD N
had VBD N
anastomosis VBN N
leak NN N
and CC N
one CD N
had VBD N
thrombosis NN N
, , N
whereas IN N
none NN N
of IN N
the DT N
patients NNS N
from IN N
the DT N
Bioglue NNP N
group NN N
had VBD N
any DT N
of IN N
these DT N
complications NNS N
. . N

Both DT N
groups NNS N
had VBD N
patients NNS N
with IN N
severe JJ N
postoperative JJ N
pain NN N
( ( N
3 CD N
each DT N
) ) N
and CC N
fecal JJ N
incontinence NN N
( ( N
1 CD N
patient NN N
each DT N
) ) N
. . N

The DT N
overall JJ N
difference NN N
in IN N
the DT N
number NN N
of IN N
complications NNS N
in IN N
the DT N
two CD N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
first JJ N
study NN N
using VBG N
Bioglue NNP N
in IN N
patients NNS N
undergoing VBG N
circumferential JJ N
stapled JJ N
hemorrhoidopexy NN N
we PRP N
have VBP N
shown VBN N
that IN N
application NN N
of IN N
the DT N
glue NN N
is VBZ N
effective JJ N
in IN N
reducing VBG N
postoperative JJ N
complications NNS N
. . N

-DOCSTART- -X- O O

Outcomes NNS N
of IN N
Japanese JJ N
breast NN N
cancer NN N
patients NNS N
treated VBN N
with IN N
pre-operative JJ 3_i
and CC 3_i
post-operative JJ 3_i
anastrozole NN 3_i
or CC 3_i
tamoxifen NN 3_i
. . N

The DT N
present JJ N
study NN N
examined VBD N
long-term JJ N
efficacy NN N
outcomes NNS N
in IN N
a DT N
subgroup NN N
of IN N
postmenopausal NN N
, , N
estrogen VBP N
receptor-positive JJ N
Japanese JJ N
breast NN N
cancer NN N
patients NNS N
from IN N
the DT N
Pre-Operative JJ N
Arimidex NNP 3_i
Compared NNP N
with IN N
Tamoxifen NNP 3_i
trial NN N
, , N
following VBG N
pre-operative JJ 3_i
( ( 3_i
3 CD 3_i
months NNS 3_i
) ) 3_i
and CC 3_i
post-operative JJ 3_i
( ( 3_i
5 CD 3_i
years NNS 3_i
) ) 3_i
adjuvant VBP 3_i
treatment NN 3_i
with IN N
either DT N
anastrozole NN 3_i
or CC N
tamoxifen NN 3_i
. . N

Patients NNS N
with IN N
large JJ N
, , N
potentially RB N
operable JJ N
, , N
locally-advanced JJ N
breast NN N
cancer NN N
were VBD N
randomized VBN N
to TO N
receive VB N
anastrozole NN 3_i
( ( N
1 CD N
mg/day NN N
) ) N
plus CC N
tamoxifen JJ 7_i
placebo NN 7_i
or CC N
tamoxifen NN 3_i
( ( N
20 CD N
mg/day NN N
) ) N
plus CC N
anastrozole JJ 7_i
placebo NN 7_i
pre-operatively RB N
. . N

After IN N
surgery NN N
at IN N
3 CD N
months NNS N
, , N
patients NNS N
continued VBD N
on IN N
the DT N
same JJ N
study NN N
medication NN N
as IN N
adjuvant JJ 3_i
therapy NN 3_i
for IN N
up IN N
to TO N
5 CD N
years NNS N
or CC N
until IN N
recurrence NN N
, , N
intolerable JJ N
toxicity NN N
or CC N
withdrawal NN N
of IN N
patient JJ N
consent NN N
. . N

Recurrence-free JJ N
survival NN N
and CC N
overall JJ N
survival NN N
were VBD N
measured VBN N
from IN N
the DT N
date NN N
of IN N
randomization NN N
to TO N
the DT N
date NN N
of IN N
recurrence NN N
or CC N
death NN N
, , N
whichever WDT N
occurred VBD N
first RB N
. . N

Patients NNS N
were VBD N
monitored VBN N
for IN N
adverse JJ N
events NNS N
throughout IN N
the DT N
study NN N
period NN N
and CC N
up RB N
to TO N
30 CD N
days NNS N
following VBG N
administration NN N
of IN N
the DT N
last JJ N
study NN N
medication NN N
. . N

During IN N
post-operative JJ N
adjuvant JJ N
therapy NN N
, , N
4/48 CD N
( ( N
8 CD N
% NN N
) ) N
anastrozole NN 3_i
and CC N
25/49 CD N
( ( N
51 CD N
% NN N
) ) N
tamoxifen NN 3_i
patients NNS N
experienced VBD N
recurrence NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
recurrence-free JJ N
survival NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
hazard JJ N
ratio NN N
0.14 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
0.05-0.41 NN N
; : N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
overall JJ N
survival NN N
with IN N
anastrozole NN 3_i
( ( N
0.21 CD N
; : N
0.05-0.96 CD N
; : N
P NNP N
= NNP N
0.0436 CD N
) ) N
and CC N
there EX N
were VBD N
2/48 CD N
( ( N
4 CD N
% NN N
) ) N
and CC N
10/49 CD N
( ( N
20 CD N
% NN N
) ) N
deaths NNS N
with IN N
anastrozole JJ 3_i
and CC N
tamoxifen NN 3_i
, , N
respectively RB N
. . N

Most JJS N
patients NNS N
responding VBG N
to TO N
pre-operative JJ N
therapy NN N
remained VBD N
recurrence-free JJ N
. . N

Sequential JJ N
pre-operative/post-operative JJ N
treatment NN N
with IN N
anastrozole JJ 3_i
resulted VBN N
in IN N
lower JJR N
recurrence NN N
and CC N
death NN N
rates NNS N
, , N
compared VBN N
with IN N
tamoxifen NN 3_i
. . N

-DOCSTART- -X- O O

[ JJ N
Comparison NNP N
of IN N
fracture NN N
resistance NN N
of IN N
pulpless NN 2_i
teeth NNS 2_i
restored VBD 2_i
with IN 2_i
fiber NN 2_i
reinforced VBN 2_i
composite JJ 2_i
posts NNS 2_i
and CC N
three CD N
kinds NNS N
of IN N
resin NN N
core NN N
material NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
fracture NN N
resistances NNS N
of IN N
pulpless NN N
teeth NNS N
restored VBD N
with IN N
FRC NNP 2_i
( ( 2_i
Fiber NNP 2_i
Reinforced NNP 2_i
Composite NNP 2_i
) ) 2_i
posts NNS 2_i
and CC N
three CD 2_i
kinds NNS 2_i
of IN 2_i
resin NN 2_i
core NN 2_i
material NN 2_i
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
42 CD N
recently RB N
extracted VBN N
upper JJ N
incisors NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
. . N

Group NNP N
A NNP N
was VBD N
restored VBN N
with IN N
prefabricated JJ 2_i
glass-fiber JJ 2_i
posts NNS 2_i
and CC 2_i
Artglass NNP 2_i
polymer NN 2_i
core NN 2_i
; : N
group NN N
B NNP N
with IN N
prefabricated JJ 2_i
glass-fiber JJ 2_i
posts NNS 2_i
and CC 2_i
Charisma NNP 2_i
composite JJ 2_i
resin NN 2_i
core NN 2_i
; : N
and CC N
group NN N
C NNP N
with IN N
prefabricated JJ 2_i
glass-fiber JJ 2_i
posts NNS 2_i
and CC 2_i
AB NNP 2_i
composite JJ 2_i
resin NN 2_i
core NN 2_i
. . N

In IN N
every DT N
group NN N
, , N
the DT N
core NN N
material NN N
was VBD N
processed VBN N
by IN N
hot-press NN N
and CC N
non JJ N
hot-press NN N
respectively RB N
. . N

The DT N
posts NNS N
size NN N
and CC N
shape NN N
were VBD N
identical JJ N
in IN N
the DT N
3 CD N
groups NNS N
. . N

All DT N
teeth NNS N
were VBD N
fully RB N
covered VBN N
with IN N
polycarbonate JJ N
resin NN N
crowns NNS N
. . N

Fracture NN N
resistance NN N
was VBD N
measured VBN N
by IN N
applying VBG N
point NN N
force NN N
at IN N
130 CD N
degrees NNS N
to TO N
the DT N
long JJ N
axis NN N
of IN N
the DT N
teeth NN N
on IN N
an DT N
universal JJ N
testing NN N
machine NN N
. . N

RESULTS JJ N
Mean JJ N
fracture NN N
threshold NN N
was VBD N
505.4 CD N
N NNP N
+/- JJ N
42.0 CD N
N NNP N
and CC N
564.1 CD N
N NNP N
+/- JJ N
41.7 CD N
N NNP N
in IN N
group NN N
A NNP N
, , N
411.3 CD N
N NNP N
+/- JJ N
23.3 CD N
N NNP N
and CC N
315.3 CD N
N NNP N
+/- JJ N
19.1 CD N
N NNP N
in IN N
group NN N
B NNP N
and CC N
358.4 CD N
N NNP N
+/- JJ N
36.1 CD N
N NNP N
and CC N
423.4 CD N
N NNP N
+/- JJ N
47.5 CD N
N NNP N
in IN N
group NN N
C. NNP N
In IN N
all DT N
groups NNS N
, , N
there EX N
was VBD N
no DT N
posts NNS N
fracture NN N
and CC N
polycarbonate NN N
resin NN N
crowns NNS N
fragmentation NN N
. . N

CONCLUSION VB N
The DT N
composite JJ N
restoration NN N
of IN N
FRC NNP 2_i
posts NNS 2_i
combined VBD 2_i
with IN 2_i
resin NN 2_i
core NN 2_i
and CC 2_i
resin VB 2_i
crown NN 2_i
can MD N
improve VB N
the DT N
fracture NN N
resistance NN N
of IN N
the DT N
pulpless JJ N
roots NNS N
. . N

The DT N
strength NN N
of IN N
resin NN N
core NN N
material NN N
can MD N
be VB N
increased VBN N
by IN N
hot-press JJ 2_i
methods NNS 2_i
. . N

-DOCSTART- -X- O O

Helping VBG N
women NNS N
make VBP N
choices NNS N
about IN N
mammography NN N
screening NN N
: : N
an DT N
online NN N
randomized VBN N
trial NN N
of IN N
a DT N
decision NN N
aid NN N
for IN N
40-year-old JJ N
women NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
decision NN 4_i
aid NN 4_i
( ( 4_i
DA NNP 4_i
) ) 4_i
on IN N
women NNS N
's POS N
knowledge NN N
of IN N
the DT N
benefits NNS N
and CC N
harms NNS N
of IN N
screening VBG N
and CC N
on IN N
their PRP$ N
ability NN N
to TO N
make VB N
an DT N
informed JJ N
decision NN N
. . N

METHODS NNP N
An DT N
online NN N
randomized VBN N
controlled VBN N
trial NN N
among IN N
321 CD N
women NNS N
aged VBN N
38-45 CD N
years NNS N
was VBD N
conducted VBN N
. . N

Participants NNS N
were VBD N
randomized VBN N
to TO N
either DT N
immediate JJ 4_i
or CC 4_i
delayed JJ 4_i
access NN 4_i
to TO 4_i
the DT 4_i
online NN 4_i
DA NNP 4_i
which WDT N
( ( N
i NN N
) ) N
explained VBD N
the DT N
benefits NNS N
and CC N
harms NNS N
, , N
( ( N
ii NN N
) ) N
included VBD N
a DT N
values NNS N
clarification NN N
exercise NN N
and CC N
a DT N
worksheet NN N
to TO N
support VB N
decision NN N
making NN N
. . N

The DT N
primary JJ N
outcome NN N
, , N
knowledge NN N
of IN N
benefits NNS N
and CC N
harms NNS N
of IN N
screening NN N
, , N
and CC N
secondary JJ N
outcomes NNS N
, , N
informed VBN N
choice NN N
( ( N
composite JJ N
of IN N
knowledge NN N
, , N
values NNS N
and CC N
intention NN N
) ) N
, , N
anxiety NN N
and CC N
acceptability NN N
of IN N
the DT N
DA NNP N
were VBD N
measured VBN N
using VBG N
online JJ N
questionnaires NNS N
. . N

RESULTS NNP N
Women NNP N
in IN N
the DT N
intervention NN N
group NN N
were VBD N
more RBR N
knowledgeable JJ N
( ( N
mean VB N
score NN N
out IN N
of IN N
10 CD N
, , N
7.35 CD N
vs NN N
6.27 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
made VBN N
a DT N
decision NN N
( ( N
82 CD N
% NN N
vs JJ N
61 CD N
% NN N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Of IN N
those DT N
who WP N
made VBD N
a DT N
decision NN N
, , N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
were VBD N
less RBR N
likely JJ N
to TO N
start VB N
screening VBG N
now RB N
( ( N
52 CD N
% NN N
vs JJ N
65 CD N
% NN N
p=0.05 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
proportion NN N
of IN N
women NNS N
who WP N
made VBD N
an DT N
informed JJ N
choice NN N
( ( N
71 CD N
% NN N
intervention NN N
group NN N
vs VBD N
64 CD N
% NN N
control NN 7_i
group NN N
, , N
p=0.24 NN N
) ) N
. . N

The DT N
DA NNP N
was VBD N
helpful JJ N
, , N
balanced JJ N
and CC N
clear JJ N
, , N
and CC N
did VBD N
not RB N
make VB N
women NNS N
anxious JJ N
. . N

CONCLUSIONS VB N
The DT N
DA NNP N
increased VBD N
knowledge NN N
and CC N
reduced JJ N
indecision NN N
, , N
without IN N
increasing VBG N
feelings NNS N
of IN N
anxiety NN N
. . N

PRACTICE NNP N
IMPLICATIONS NNP N
This DT N
decision NN N
aid NN N
is VBZ N
easy JJ N
to TO N
access NN N
online NN N
and CC N
could MD N
be VB N
an DT N
inexpensive JJ N
way NN N
of IN N
supporting VBG N
women NNS N
aged VBN N
40 CD N
who WP N
are VBP N
considering VBG N
whether IN N
to TO N
start VB N
screening VBG N
now RB N
, , N
or CC N
wait VBP N
until IN N
they PRP N
are VBP N
50 CD N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
demonstrate VB N
the DT N
potential NN N
of IN N
DAs NNP N
to TO N
help VB N
inform VB N
women NNS N
about IN N
both DT N
the DT N
benefits NNS N
and CC N
risks NNS N
of IN N
screening VBG N
at IN N
this DT N
age NN N
and CC N
to TO N
support VB N
women NNS N
and CC N
clinicians NNS N
in IN N
this DT N
decision NN N
making VBG N
process NN N
. . N

-DOCSTART- -X- O O

Diet NNP N
and CC N
vitamin NNP N
D NNP N
status NN N
among IN N
pregnant JJ N
Pakistani NNP N
women NNS N
in IN N
Oslo NNP N
. . N

OBJECTIVES NNP N
In IN N
the DT N
present JJ N
study NN N
the DT N
diet NN N
and CC N
the DT N
nutritional JJ N
status NN N
of IN N
pregnant JJ N
Pakistani NNP N
immigrant NN N
women NNS N
have VBP N
been VBN N
compared VBN N
with IN N
a DT N
group NN N
of IN N
Norwegian JJ N
women NNS N
. . N

DESIGN VB N
A DT N
cross-sectional JJ N
survey NN N
of IN N
women NNS N
in IN N
the DT N
18th CD N
week NN N
of IN N
pregnancy NN N
. . N

SETTING NNP N
Women NNP N
referred VBD N
to TO N
routine VB N
ultrasound JJ N
examination NN N
at IN N
Aker NNP N
and CC N
Ullev?l NNP N
Hospitals NNP N
in IN N
Norway NNP N
. . N

SUBJECTS NNP N
All NNP N
( ( N
58 CD N
) ) N
healthy JJ N
women NNS N
of IN N
Pakistani NNP N
origin NN N
referred VBD N
from IN N
October NNP N
of IN N
1991 CD N
to TO N
January NNP N
of IN N
1992 CD N
were VBD N
included VBN N
, , N
of IN N
whom WP N
38 CD N
( ( N
66 CD N
% NN N
) ) N
participated VBD N
. . N

Forty-five JJ N
Norwegian JJ N
women NNS N
were VBD N
randomly RB N
included VBN N
in IN N
the DT N
same JJ N
period NN N
and CC N
38 CD N
( ( N
84 CD N
% NN N
) ) N
of IN N
these DT N
women NNS N
participated VBD N
. . N

RESULTS VB N
The DT N
serum NN N
levels NNS N
of IN N
25-hydroxyvitamin JJ N
D3 NNP N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
Pakistanis NNP N
compared VBN N
with IN N
the DT N
Norwegians NNPS N
( ( N
median JJ N
19 CD N
nmol/l JJ N
vs NN N
55 CD N
nmol/l NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
83 CD N
% NN N
of IN N
the DT N
Pakistani NNP N
women NNS N
had VBD N
25-hydroxyvitamin JJ N
D3 NNP N
levels NNS N
below IN N
the DT N
reference NN N
value NN N
( ( N
< JJ N
30 CD N
nmol/l NN N
) ) N
. . N

The DT N
Pakistanis NNP N
had VBD N
higher JJR N
levels NNS N
of IN N
serum NN N
parathyroid NN N
hormone NN N
( ( N
median JJ N
2.6 CD N
vs NN N
1.6 CD N
pmol/l NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
Pakistanis NNP N
also RB N
had VBD N
a DT N
lower JJR N
dietary JJ N
intake NN N
of IN N
vitamin NN N
D NNP N
than IN N
that DT N
of IN N
the DT N
Norwegians NNPS N
( ( N
median JJ N
2.2 CD N
vs NN N
3.3 CD N
micrograms/day NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
a DT N
lower JJR N
total JJ N
intake NN N
, , N
including VBG N
supplements NNS N
( ( N
median JJ N
2.9 CD N
vs NN N
7.0 CD N
micrograms/day NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Among IN N
the DT N
Pakistanis NNP N
a DT N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
dietary JJ N
intake NN N
of IN N
margarine NN N
, , N
the DT N
main JJ N
source NN N
of IN N
vitamin NN N
D NNP N
in IN N
the DT N
diet NN N
, , N
and CC N
the DT N
concentration NN N
of IN N
25-hydroxyvitamin JJ N
D3 NNP N
in IN N
serum NN N
, , N
r NN N
= NN N
0.48 CD N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

In IN N
general JJ N
, , N
the DT N
Pakistanis NNP N
avoided VBD N
any DT N
direct JJ N
sunshine NN N
exposure NN N
, , N
and CC N
no DT N
relation NN N
between IN N
outdoor JJ N
activity NN N
and CC N
serum JJ N
level NN N
of IN N
25-hydroxyvitamin JJ N
D3 NNP N
was VBD N
found VBN N
. . N

The DT N
Pakistani NNP N
women NNS N
had VBD N
a DT N
lower JJR N
intake NN N
of IN N
calcium NN N
than IN N
the DT N
Norwegians NNPS N
( ( N
median JJ N
793 CD N
vs NN N
1134 CD N
mg/day NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
This DT N
study NN N
has VBZ N
shown VBN N
that IN N
Pakistani NNP N
women NNS N
living VBG N
in IN N
Oslo NNP N
are VBP N
at IN N
great JJ N
risk NN N
of IN N
developing VBG N
vitamin JJ N
D NNP N
deficiency NN N
during IN N
pregnancy NN N
. . N

The DT N
main JJ N
reasons NNS N
for IN N
this DT N
are VBP N
avoidance NN N
of IN N
sun NN N
exposure NN N
, , N
a DT N
low JJ N
dietary JJ N
intake NN N
of IN N
vitamin NN N
D NNP N
, , N
and CC N
no DT N
or CC N
little JJ N
use NN N
of IN N
supplementation NN N
. . N

-DOCSTART- -X- O O

Teriparatide NNP N
improves VBZ N
early JJ N
callus NN N
formation NN N
in IN N
distal JJ N
radial JJ N
fractures NNS N
. . N

BACKGROUND NNP N
Teriparatide NNP N
( ( N
parathyreoid JJ N
hormone NN N
; : N
PTH NNP N
1-34 CD N
) ) N
increases VBZ N
skeletal JJ N
mass NN N
in IN N
humans NNS N
and CC N
improves VBZ N
fracture NN N
healing VBG N
in IN N
animals NNS N
. . N

A DT N
recent JJ N
randomized JJ N
multicenter NN N
trial NN N
of IN N
nonoperated JJ N
distal JJ N
radial NN N
fractures NNS N
showed VBD N
a DT N
moderate JJ N
shortening NN N
of IN N
the DT N
time NN N
to TO N
restoration NN N
of IN N
cortical JJ N
continuity NN N
by IN N
treatment NN N
with IN N
20 CD 3_i
microg NNS 3_i
( ( 3_i
low-dose JJ 3_i
) ) 3_i
teriparatide NN 3_i
per IN N
day NN N
, , N
but CC N
not RB 7_i
with IN 7_i
40 CD 7_i
microg NNS 7_i
( ( 7_i
high-dose JJ 7_i
) ) 7_i
. . N

As IN N
radiographic JJ N
cortical JJ N
continuity NN N
appears VBZ N
late RB N
in IN N
the DT N
healing NN N
process NN N
, , N
perhaps RB N
too RB N
late JJ N
for IN N
clinical JJ N
relevance NN N
, , N
we PRP N
studied VBD N
the DT N
qualitative JJ N
appearance NN N
of IN N
the DT N
callus JJ N
5 CD N
weeks NNS N
after IN N
fracture NN N
. . N

METHODS NNP N
One CD N
third NN N
of IN N
the DT N
patients NNS N
of IN N
the DT N
international JJ N
trial NN N
were VBD N
treated VBN N
at IN N
Link?ping NNP N
University NNP N
Hospital NNP N
. . N

The DT N
multicenter NN N
trial NN N
did VBD N
not RB N
evaluate VB N
early JJ N
callus NN N
formation NN N
. . N

We PRP N
therefore RB N
made VBD N
a DT N
blinded JJ N
qualitative JJ N
scoring NN N
of IN N
the DT N
callus NN N
at IN N
5 CD N
weeks NNS N
in IN N
our PRP$ N
27 CD N
patients NNS N
. . N

Callus NNP N
formation NN N
was VBD N
arbitrarily RB N
classified VBN N
as IN N
rich JJ N
, , N
intermediate JJ N
, , N
or CC N
poor JJ N
. . N

RESULTS NNP N
9 CD N
patients NNS N
were VBD N
classified VBN N
as IN N
rich JJ N
( ( N
none NN N
had VBD N
received VBN N
placebo RB N
, , N
3 CD N
low-dose JJ N
teriparatide NN N
, , N
and CC N
6 CD N
high-dose JJ N
teriparatide NN N
) ) N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN N
intermediate NN N
( ( N
1 CD N
had VBD N
received VBN N
placebo RB N
, , N
5 CD N
low-dose JJ N
, , N
and CC N
3 CD N
high-dose JJ N
) ) N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN N
poor JJ N
( ( N
7 CD N
had VBD N
received VBN N
placebo RB N
, , N
1 CD N
low-dose JJ N
, , N
and CC N
1 CD N
high-dose NN N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

INTERPRETATION NN N
This DT N
is VBZ N
a DT N
post NN N
hoc NN N
subgroup NN N
analysis NN N
of IN N
an DT N
outcome NN N
variable NN N
, , N
which WDT N
was VBD N
not RB N
in IN N
the DT N
official JJ N
protocol NN N
. . N

The DT N
results NNS N
must MD N
therefore RB N
be VB N
interpreted VBN N
with IN N
caution NN N
. . N

However RB N
, , N
in IN N
combination NN N
with IN N
the DT N
results NNS N
of IN N
the DT N
larger JJR N
trial NN N
, , N
the DT N
data NN N
suggest NN N
that IN N
radiographic JJ N
quality NN N
at IN N
an DT N
early JJ N
time NN N
point NN N
might MD N
be VB N
a DT N
sensitive JJ N
variable NN N
, , N
perhaps RB N
better JJR N
than IN N
time NN N
to TO N
cortical JJ N
continuity NN N
. . N

Moreover RB N
, , N
teriparatide RB N
appeared VBD N
to TO N
improve VB N
early JJ N
callus NN N
formation NN N
in IN N
distal JJ N
radial JJ N
fractures NNS N
. . N

-DOCSTART- -X- O O

Exposure NN N
to TO N
the DT N
self-face NN 2_i
facilitates VBZ 2_i
identification NN N
of IN N
dynamic JJ N
facial JJ N
expressions NNS N
: : N
influences NNS N
on IN N
individual JJ N
differences NNS N
. . N

A DT N
growing VBG N
literature NN N
suggests VBZ N
that IN N
the DT N
self-face NN 2_i
is VBZ N
involved VBN N
in IN N
processing VBG N
the DT N
facial JJ N
expressions NNS N
of IN N
others NNS N
. . N

The DT N
authors NNS N
experimentally RB N
activated VBD N
self-face JJ 2_i
representations NNS 2_i
to TO N
assess VB N
its PRP$ N
effects NNS N
on IN N
the DT N
recognition NN N
of IN N
dynamically RB N
emerging VBG N
facial JJ N
expressions NNS N
of IN N
others NNS N
. . N

They PRP N
exposed VBD N
participants NNS N
to TO N
videos NNS N
of IN N
either DT N
their PRP$ N
own JJ N
faces VBZ N
( ( N
self-face JJ 2_i
prime NN 2_i
) ) 2_i
or CC 2_i
faces VBZ 2_i
of IN 2_i
others NNS 2_i
( ( 2_i
nonself-face JJ 2_i
prime NN 2_i
) ) N
prior RB N
to TO N
a DT N
facial JJ N
expression NN N
judgment NN N
task NN N
. . N

Their PRP$ N
results NNS N
show VBP N
that IN N
experimentally RB N
activating VBG N
self-face JJ N
representations NNS N
results NNS N
in IN N
earlier JJR N
recognition NN N
of IN N
dynamically RB N
emerging VBG N
facial JJ N
expression NN N
. . N

As IN N
a DT N
group NN N
, , N
participants NNS N
in IN N
the DT N
self-face JJ N
prime JJ N
condition NN N
recognized VBD N
expressions NNS N
earlier RBR N
( ( N
when WRB N
less RBR N
affective JJ N
perceptual JJ N
information NN N
was VBD N
available JJ N
) ) N
compared VBN N
to TO N
participants NNS N
in IN N
the DT N
nonself-face JJ N
prime JJ N
condition NN N
. . N

There EX N
were VBD N
individual JJ N
differences NNS N
in IN N
performance NN N
, , N
such JJ N
that IN N
poorer JJR N
expression NN N
identification NN N
was VBD N
associated VBN N
with IN N
higher JJR N
autism NN N
traits NNS N
( ( N
in IN N
this DT N
neurocognitively RB N
healthy JJ N
sample NN N
) ) N
. . N

However RB N
, , N
when WRB N
randomized VBN N
into IN N
the DT N
self-face JJ N
prime JJ N
condition NN N
, , N
participants NNS N
with IN N
high JJ N
autism NN N
traits NNS N
performed VBN N
as RB N
well RB N
as IN N
those DT N
with IN N
low JJ N
autism NN N
traits NNS N
. . N

Taken VB N
together RB N
, , N
these DT N
data NNS N
suggest VBP N
that IN N
the DT N
ability NN N
to TO N
recognize VB N
facial JJ N
expressions NNS N
in IN N
others NNS N
is VBZ N
linked VBN N
with IN N
the DT N
internal JJ N
representations NNS N
of IN N
our PRP$ N
own JJ N
faces VBZ N
. . N

-DOCSTART- -X- O O

Face NNP 6_i
composite JJ 6_i
effects NNS N
reveal VBP N
abnormal JJ N
face NN N
processing NN N
in IN N
Autism NNP N
spectrum NN N
disorders NNS N
. . N

Although IN N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
individuals NNS N
with IN N
an DT N
Autism NNP N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
process NN N
faces VBZ N
less RBR N
holistically RB N
than IN N
typically RB N
developing VBG N
controls NNS N
, , N
there EX N
are VBP N
few JJ N
direct JJ N
investigations NNS N
of IN N
this DT N
hypothesis NN N
. . N

This DT N
question NN N
was VBD N
addressed VBN N
before IN N
using VBG N
the DT N
composite JJ N
paradigm NN N
( ( N
Teunisse NNP N
, , N
J. NNP N
P. NNP N
, , N
& CC N
de FW N
Gelder NNP N
, , N
B NNP N
. . N

( ( N
2003 CD N
) ) N
. . N

Face NN N
processing NN N
in IN N
adolescents NNS N
with IN N
autistic JJ N
disorder NN N
: : N
The DT N
inversion NN N
and CC N
composite JJ N
effects NNS N
. . N

Brain NNP N
Cognition NNP N
, , N
52 CD N
( ( N
3 CD N
) ) N
, , N
285-294. JJ N
) ) N
. . N

The DT N
results NNS N
had VBD N
revealed VBN N
that IN N
adolescents NNS N
with IN N
ASDs NNP N
were VBD N
less RBR N
sensitive JJ N
than IN N
controls NNS N
to TO N
the DT N
misalignment NN N
of IN N
face NN N
parts NNS N
and CC N
it PRP N
was VBD N
concluded VBN N
their PRP$ N
face NN N
processing NN N
was VBD N
less RBR N
holistic JJ N
. . N

However RB N
, , N
because IN N
of IN N
shortcomings NNS N
of IN N
the DT N
design NN N
, , N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
distinguish VB N
whether IN N
individuals NNS N
with IN N
Autism NNP N
processed VBD N
both DT N
aligned VBN N
and CC N
misaligned VBN N
composites NNS N
in IN N
a DT N
part-based JJ N
fashion NN N
, , N
or CC N
both DT N
in IN N
a DT N
holistic JJ N
fashion NN N
. . N

We PRP N
compared VBN N
adolescents NNS 4_i
with IN 4_i
ASDs NNP 4_i
to TO N
controls VB 7_i
matched VBN N
on IN N
sex NN N
, , N
age NN N
and CC N
IQ NNP N
on IN N
a DT N
more RBR N
complete JJ N
version NN N
of IN N
the DT N
composite JJ 4_i
paradigm NN 4_i
. . N

The DT N
results NNS N
indicate VBP N
that IN N
individuals NNS N
with IN N
ASDs NNP N
, , N
like IN N
controls NNS N
, , N
experience NN N
interference NN N
from IN N
facial JJ N
features NNS N
that IN N
they PRP N
are VBP N
told VBN N
to TO N
ignore VB N
. . N

However RB N
, , N
while IN N
such JJ N
interference NN N
is VBZ N
released VBN N
for IN N
controls NNS N
if IN N
parts NNS N
of IN N
face NN N
composites NNS N
are VBP N
misaligned VBN N
, , N
individuals NNS N
with IN N
ASDs NNP N
show VBP N
comparable JJ N
interference NN N
from IN N
irrelevant JJ N
parts NNS N
regardless RB N
of IN N
alignment NN N
. . N

Two CD N
different JJ N
interpretations NNS N
are VBP N
discussed VBN N
, , N
both DT N
compatible JJ N
with IN N
the DT N
idea NN N
that WDT N
perceptual JJ N
and CC N
or CC N
attentional JJ N
abnormalities NNS N
in IN N
ASDs NNP N
result NN N
in IN N
a DT N
diminished JJ N
level NN N
of IN N
expertise NN N
for IN N
faces VBZ N
. . N

-DOCSTART- -X- O O

Hexetidine NNP 3_i
( ( 3_i
'Oraldene NNP 3_i
' POS 3_i
) ) 3_i
: : N
a DT N
report NN N
on IN N
its PRP$ N
antibacterial JJ N
and CC N
antifungal JJ N
properties NNS N
on IN N
the DT N
oral JJ N
flora NNS N
in IN N
healthy JJ N
subjects NNS N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
crossover NN N
trial NN N
, , N
in IN N
10 CD N
adult NN N
healthy JJ N
subjects NNS N
, , N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
the DT N
antibacterial JJ N
and CC N
antifungal JJ N
activity NN N
of IN N
a DT N
0.1 CD 3_i
% NN 3_i
solution NN 3_i
of IN 3_i
hexetidine NN 3_i
with IN N
that DT N
of IN N
placebo NN 7_i
. . N

The DT N
pre-dosing JJ N
oral JJ N
flora NN N
of IN N
the DT N
subjects NNS N
was VBD N
assessed VBN N
from IN N
saliva NN N
samples NNS N
cultured VBD N
for IN N
aerobic JJ N
and CC N
anaerobic JJ N
bacteria NNS N
, , N
as RB N
well RB N
as IN N
Candida NNP N
albicans NNS N
. . N

Subjects NNS N
then RB N
rinsed VBD N
their PRP$ N
mouths NNS N
for IN N
1 CD N
minute JJ N
3-times NNS N
a DT N
day NN N
with IN N
15 CD N
ml NNS N
0.1 CD N
% NN N
hexetidine NN 3_i
or CC N
placebo NN 7_i
, , N
saliva NN N
samples NNS N
being VBG N
collected VBN N
at IN N
2 CD N
minutes NNS N
, , N
30 CD N
minutes NNS N
, , N
1 CD N
hour NN N
, , N
3 CD N
hours NNS N
and CC N
5 CD N
hours NNS N
post-dosing JJ N
. . N

Dosing NN N
was VBD N
continued VBN N
for IN N
8 CD N
consecutive JJ N
days NNS N
on IN N
each DT N
treatment NN N
with IN N
an DT N
intervening VBG N
wash-out JJ N
period NN N
of IN N
1 CD N
week NN N
. . N

Hexetidine NNP 3_i
reduced VBD N
aerobic JJ N
bacterial JJ N
counts NNS N
on IN N
Day NNP N
1 CD N
and CC N
Day NNP N
8 CD N
by IN N
a DT N
maximum NN N
of IN N
83 CD N
% NN N
and CC N
86 CD N
% NN N
, , N
respectively RB N
, , N
at IN N
2 CD N
minutes NNS N
post-dosing JJ N
. . N

The DT N
reductions NNS N
were VBD N
statistically RB N
significantly RB N
lower JJR N
than IN N
placebo VB 7_i
up IN N
to TO N
1 CD N
hour NN N
post-dose JJ N
on IN N
Day NNP N
1 CD N
and CC N
up RB N
to TO N
3 CD N
hours NNS N
post-dose JJ N
on IN N
Day NNP N
8 CD N
. . N

Similarly RB N
for IN N
anaerobic JJ N
bacterial JJ N
counts NNS N
, , N
92 CD N
% NN N
and CC N
88 CD N
% NN N
maximum JJ N
reductions NNS N
were VBD N
recorded VBN N
on IN N
Day NNP N
1 CD N
and CC N
Day NNP N
8 CD N
, , N
which WDT N
again RB N
were VBD N
significantly RB N
lower JJR N
than IN N
placebo NN N
for IN N
up IN N
to TO N
3 CD N
hours NNS N
post-dose JJ N
. . N

For IN N
Candida NNP N
albicans NNS N
, , N
however RB N
, , N
the DT N
maximum JJ N
reduction NN N
was VBD N
91 CD N
% NN N
on IN N
the DT N
first JJ N
day NN N
and CC N
67 CD N
% NN N
on IN N
Day NNP N
8 CD N
, , N
maintained VBD N
for IN N
30 CD N
minutes NNS N
post-dosing JJ N
. . N

Although IN N
not RB N
eradicating VBG N
completely RB N
aerobic JJ N
and CC N
anaerobic JJ N
bacteria NNS N
, , N
it PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
substantial JJ N
reduction NN N
in IN N
their PRP$ N
numbers NNS N
should MD N
prove VB N
clinically RB N
useful JJ N
. . N

-DOCSTART- -X- O O

Clinical JJ N
application NN N
of IN N
C-reactive JJ 2_i
protein NN 2_i
across IN N
the DT N
spectrum NN N
of IN N
acute JJ N
coronary JJ N
syndromes NNS N
. . N

BACKGROUND NNP N
High-sensitivity NNP 3_i
C-reactive JJ 3_i
protein NN 3_i
( ( 3_i
hsCRP NN 3_i
) ) 3_i
is VBZ N
associated VBN N
with IN N
adverse JJ N
cardiovascular JJ N
outcomes NNS N
in IN N
acute JJ N
coronary JJ N
syndromes NNS N
( ( N
ACS NNP N
) ) N
. . N

The DT N
ability NN N
to TO N
formulate VB N
recommendations NNS N
regarding VBG N
clinical JJ N
use NN N
of IN N
hsCRP NN 3_i
is VBZ N
limited VBN N
by IN N
a DT N
paucity NN N
of IN N
data NNS N
regarding VBG N
several JJ N
key JJ N
issues NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
hsCRP NN 3_i
across IN N
the DT N
spectrum NN N
of IN N
ACS NNP N
. . N

METHODS NNP N
hsCRP NN 3_i
was VBD N
measured VBN N
on IN N
admission NN N
in IN N
3225 CD N
patients NNS N
with IN N
ACS NNP N
. . N

hsCRP NN N
concentrations NNS N
were VBD N
compared VBN N
in IN N
patients NNS N
who WP N
suffered VBD N
an DT N
adverse JJ N
cardiac NN N
outcome NN N
within IN N
10 CD N
months NNS N
of IN N
study NN N
entry NN N
and CC N
in IN N
patients NNS N
who WP N
had VBD N
no DT N
adverse JJ N
event NN N
. . N

Because IN N
of IN N
heterogeneity NN N
in IN N
the DT N
relationship NN N
between IN N
hsCRP NN 3_i
and CC N
clinical JJ N
outcomes NNS N
, , N
evaluation NN N
was VBD N
limited VBN N
to TO N
patients NNS N
from IN N
whom WP N
samples NNS N
were VBD N
collected VBN N
within IN N
48 CD N
h NN N
of IN N
symptom JJ N
onset NN N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
highest JJS N
quartile NN N
of IN N
hsCRP NN 3_i
compared VBN N
to TO N
those DT N
in IN N
the DT N
lowest JJS N
quartile NN N
were VBD N
at IN N
increased VBN N
risk NN N
of IN N
death NN N
at IN N
30 CD N
days NNS N
[ RB N
adjusted VBN N
hazard NN N
ratio NN N
( ( N
adjHR NN N
) ) N
4.6 CD N
, , N
P NNP N
< VBZ N
0.001 CD N
] NN N
and CC N
10 CD N
months NNS N
( ( N
adjHR JJ N
3.9 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
unstable JJ N
angina/non-ST-elevation JJ N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
, , N
hsCRP JJ 3_i
> FW N
3 CD N
mg/L NN N
was VBD N
associated VBN N
with IN N
increased JJ N
10-month JJ N
mortality NN N
( ( N
adjHR JJ N
2.3 CD N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
whereas RB N
in IN N
STEMI NNP N
a DT N
relationship NN N
with IN N
mortality NN N
was VBD N
seen VBN N
at IN N
hsCRP JJ N
> $ N
10 CD N
mg/L NN N
( ( N
adjHR JJ N
3.0 CD N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

Increased VBN N
concentrations NNS N
of IN N
hsCRP NN 3_i
were VBD N
strongly RB N
associated VBN N
with IN N
the DT N
development NN N
of IN N
heart NN N
failure NN N
at IN N
30 CD N
days NNS N
( ( N
adjHR JJ N
8.2 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
10 CD N
months NNS N
( ( N
adjHR JJ N
2.6 CD N
, , N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

CONCLUSION NNP N
Increased VBD N
baseline JJ N
concentrations NNS N
of IN N
hsCRP NN 3_i
are VBP N
strongly RB N
associated VBN N
with IN N
mortality NN N
and CC N
heart NN N
failure NN N
across IN N
the DT N
ACS NNP N
spectrum NN N
. . N

hsCRP JJ 3_i
measurement NN N
should MD N
be VB N
performed VBN N
early RB N
after IN N
presentation NN N
and CC N
index NN N
diagnosis-specific JJ N
cutpoints NNS N
should MD N
be VB N
used VBN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
case NN 4_i
management NN 4_i
on IN N
the DT N
costs NNS N
of IN N
health NN N
care NN N
for IN N
enrollees NNS N
in IN N
Medicare NNP N
Plus NNP N
Choice NNP N
plans VBZ N
: : N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
measure VB N
the DT N
effects NNS N
of IN N
case NN N
management NN N
on IN N
an DT N
older JJR N
population NN N
's POS N
costs NNS N
of IN N
health NN N
care NN N
. . N

DESIGN VB N
A DT N
1-year JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

SETTING NN N
Multiple NNP N
sites NNS N
of IN N
care NN N
in IN N
San NNP N
Francisco NNP N
, , N
California NNP N
. . N

PARTICIPANTS NN N
Patients NNPS N
aged VBD N
65 CD N
or CC N
older JJR N
of IN N
primary JJ N
care NN N
physicians NNS N
in IN N
a DT N
large JJ N
provider NN N
organization NN N
bearing VBG N
financial JJ N
risk NN N
for IN N
their PRP$ N
care NN N
( ( N
n JJ N
= NN N
6409 CD N
) ) N
. . N

INTERVENTION NNP N
Screening VBG 4_i
for IN 4_i
high JJ 4_i
risk NN 4_i
and CC 4_i
provision NN 4_i
of IN 4_i
social JJ 4_i
work-based JJ 4_i
case NN 4_i
management NN 4_i
. . 4_i

OUTCOME NNP N
MEASURES NNP N
Volume NN N
and CC N
cost NN N
of IN N
hospital NN N
, , N
physician NN N
, , N
case NN N
management NN N
, , N
and CC N
other JJ N
health-related JJ N
services NNS N
. . N

RESULTS VB N
The DT N
experimental JJ N
group NN N
used VBD N
more JJR N
case NN N
management NN N
services NNS N
than IN N
the DT N
control NN N
group NN N
( ( N
0.09 CD N
vs. FW N
0.02 CD N
months NNS N
per IN N
person NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
experimental JJ N
group NN N
's POS N
average JJ N
total JJ N
payments NNS N
for IN N
health NN N
care NN N
were VBD N
slightly RB N
lower JJR N
( ( N
$ $ N
3148 CD N
vs IN N
$ $ N
3277 CD N
, , N
P NNP N
= NNP N
.40 NNP N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
no DT N
statistically RB N
significant JJ N
evidence NN N
that IN N
social JJ N
work-oriented JJ N
case NN N
management NN N
reduces VBZ N
the DT N
use NN N
or CC N
the DT N
cost NN N
of IN N
health NN N
care NN N
for IN N
high-risk JJ N
older JJR N
people NNS N
. . N

Other JJ N
potentially RB N
favorable JJ N
effects NNS N
of IN N
this DT N
type NN N
of IN N
case NN N
management NN N
need NN N
to TO N
be VB N
evaluated VBN N
, , N
as IN N
do VBP N
the DT N
effects NNS N
of IN N
other JJ N
types NNS N
of IN N
case NN N
management NN N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
incident NN N
depression NN N
after IN N
hip NN N
fracture NN N
surgery NN N
. . N

OBJECTIVE NNP N
Depression NNP N
after IN N
hip NN 1_i
fracture NN 1_i
surgery NN 1_i
is VBZ N
prevalent JJ N
and CC N
associated VBN N
with IN N
increased JJ N
mortality NN N
rates NNS N
and CC N
impaired JJ N
functional JJ N
recovery NN N
. . N

The DT N
incidence NN N
of IN N
new-onset JJ N
depressive NN N
symptoms NNS N
in IN N
patients NNS N
initially RB N
not RB N
depressed VBN N
after IN N
hip NN 1_i
fracture NN 1_i
surgery NN 1_i
and CC N
their PRP$ N
relationship NN N
with IN N
functional JJ N
recovery NN N
is VBZ N
unknown JJ N
. . N

METHODS VB N
A DT N
cohort NN N
of IN N
139 CD N
nondepressed JJ N
elderly JJ N
patients NNS N
( ( N
> JJ N
60 CD N
years NNS N
) ) N
hospitalized VBD N
for IN N
hip NN 1_i
fracture NN 1_i
surgery NN 1_i
were VBD N
followed VBN N
up RP N
for IN N
six CD N
months NNS N
. . N

Clinically NNP N
significant JJ N
depressive NN N
symptoms NNS N
were VBD N
defined VBN N
as IN N
a DT N
score NN N
of IN N
7 CD N
or CC N
more JJR N
on IN N
the DT N
15-item JJ N
Geriatric NNP N
Depression NNP N
Scale NNP N
. . N

RESULTS VB N
The DT N
authors NNS N
found VBD N
a DT N
cumulative JJ N
incidence NN N
rate NN N
of IN N
20.5 CD N
% NN N
adjusted VBN N
for IN N
dropouts NNS N
. . N

Multiple JJ N
Cox-regression JJ N
analyses NNS N
yielded VBD N
the DT N
presence NN N
of IN N
subthreshold JJ N
symptoms NNS N
of IN N
depression NN N
, , N
anxiety NN N
, , N
pain NN N
, , N
and CC N
cognitive JJ N
impairment NN N
at IN N
baseline NN N
, , N
the DT N
premorbid NN N
level NN N
of IN N
mobility NN N
, , N
and CC N
a DT N
history NN N
of IN N
( ( N
treated VBN N
) ) N
depression NN N
as IN N
risk NN N
factors NNS N
for IN N
incident JJ N
depression NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

A DT N
forward NN N
, , N
conditional JJ N
procedure NN N
identified VBN N
postoperative JJ N
pain NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
= NNP N
1.32 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
1.14-1.53 JJ N
, , N
Wald NNP N
chi NN N
( ( N
2 CD N
) ) N
= NN N
13.57 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
baseline JJ N
anxiety NN N
( ( N
HR NNP N
= NNP N
1.25 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.08-1.44 JJ N
, , N
Wald NNP N
chi NN N
( ( N
2 CD N
) ) N
= NN N
8.86 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
as IN N
the DT N
strongest JJS N
independent JJ N
risk NN N
factors NNS N
. . N

Incident NNP N
depression NN N
was VBD N
associated VBN N
with IN N
a DT N
less RBR N
favorable JJ N
outcome NN N
at IN N
3 CD N
months NNS N
follow-up RB N
. . N

CONCLUSION VB N
This DT N
exploratory NN N
study NN N
identified VBD N
two CD N
treatable JJ N
baseline NN N
characteristics NNS N
that WDT N
predicted VBD N
incident JJ N
depression NN N
in IN N
nondepressed JJ N
patients NNS N
after IN N
hip-fracture JJ N
surgery NN N
. . N

-DOCSTART- -X- O O

Long-term JJ N
effects NNS N
of IN N
risperidone NN 3_i
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
: : N
a DT N
placebo NN 7_i
discontinuation NN N
study NN N
. . N

OBJECTIVE IN N
The DT N
short-term JJ N
benefit NN N
of IN N
risperidone NN N
in IN N
ameliorating VBG N
severe JJ N
disruptive JJ N
behavior NN N
in IN N
pediatric JJ N
patients NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
is VBZ N
well RB N
established VBN N
; : N
however RB N
, , N
only RB N
one CD N
placebo-controlled JJ N
, , N
long-term JJ N
study NN N
of IN N
efficacy NN N
is VBZ N
available JJ N
. . N

METHOD NNP N
Thirty-six JJ N
children NNS N
with IN N
an DT N
autism NN N
spectrum NN N
disorder NN N
( ( N
5-17 JJ N
years NNS N
old JJ N
) ) N
accompanied VBN N
by IN N
severe JJ N
tantrums NNS N
, , N
aggression NN N
, , N
or CC N
self-injurious JJ N
behavior NN N
, , N
started VBD N
8-week JJ N
open-label JJ N
treatment NN N
with IN N
risperidone NN N
. . N

Responders NNP N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
continued VBD N
treatment NN N
for IN N
another DT N
16 CD N
weeks NNS N
, , N
followed VBN N
by IN N
a DT N
double-blind JJ N
discontinuation NN N
( ( N
n JJ N
= VBZ N
24 CD N
; : N
two CD N
patients NNS N
discontinued VBN N
treatment NN N
because IN N
of IN N
weight JJ N
gain NN N
) ) N
consisting NN N
of IN N
either CC N
3 CD N
weeks NNS N
of IN N
taper NN N
and CC N
5 CD N
weeks NNS N
of IN N
placebo NN N
only RB N
or CC N
continuing VBG N
use NN N
of IN N
risperidone NN N
. . N

Relapse NNP N
was VBD N
defined VBN N
as IN N
a DT N
significant JJ N
deterioration NN N
of IN N
symptoms NNS N
based VBN N
on IN N
clinical JJ N
judgment NN N
and CC N
a DT N
parent NN N
questionnaire NN N
. . N

RESULTS NNP N
Risperidone NNP N
was VBD N
superior JJ N
to TO N
placebo VB N
in IN N
preventing VBG N
relapse NN N
: : N
this DT N
occurred VBD N
in IN N
3 CD N
of IN N
12 CD N
patients NNS N
continuing VBG N
on IN N
risperidone NN N
versus NN N
8 CD N
of IN N
12 CD N
who WP N
switched VBD N
to TO N
placebo VB N
( ( N
p JJ N
= NNP N
.049 NNP N
) ) N
. . N

Weight NNP N
gain NN N
, , N
increased VBD N
appetite RB N
, , N
anxiety NN N
, , N
and CC N
fatigue NN N
were VBD N
the DT N
most RBS N
frequently RB N
reported VBN N
side NN N
effects NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
indicates VBZ N
the DT N
effectiveness NN N
of IN N
risperidone NN N
during IN N
a DT N
period NN N
of IN N
several JJ N
months NNS N
, , N
reducing VBG N
disruptive JJ N
behavior NN N
in IN N
about IN N
half NN N
of IN N
the DT N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

The DT N
results NNS N
provide VBP N
a DT N
rationale NN N
for IN N
the DT N
continuing VBG N
use NN N
of IN N
risperidone NN N
beyond IN N
6 CD N
months NNS N
, , N
although IN N
considerable JJ N
weight JJ N
gain NN N
can MD N
limit VB N
the DT N
use NN N
of IN N
this DT N
agent NN N
. . N

-DOCSTART- -X- O O

Partial-area JJ N
method NN N
in IN N
bioequivalence NN N
assessment NN N
: : N
naproxen NN 3_i
. . N

Regulatory NNP N
authorities NNS N
require VBP N
demonstration NN N
of IN N
bioequivalence NN N
through IN N
comparisons NNS N
of IN N
different JJ N
pharmacokinetic JJ N
parameters NNS N
, , N
the DT N
area NN N
under IN N
the DT N
plasma JJ N
concentration-time JJ N
curve NN N
( ( N
AUC NNP N
) ) N
, , N
the DT N
maximum JJ N
plasma JJ N
concentration NN N
( ( N
Cmax NNP N
) ) N
, , N
and CC N
the DT N
time NN N
to TO N
reach VB N
peak JJ N
concentration NN N
( ( N
Tmax NNP N
) ) N
. . N

The DT N
applicability NN N
and CC N
validity NN N
of IN N
regulatory JJ N
requirements NNS N
have VBP N
been VBN N
widely RB N
criticized VBN N
on IN N
statistical JJ N
and CC N
clinical JJ N
relevance NN N
grounds NNS N
. . N

For IN N
most JJS N
noncomplicated JJ N
absorption NN N
models NNS N
, , N
the DT N
AUC NNP N
correlates VBZ N
well RB N
with IN N
the DT N
extent NN N
of IN N
absorption NN N
. . N

However RB N
, , N
in IN N
nonlinear JJ N
models NNS N
of IN N
absorption NN N
, , N
in IN N
mechanisms NN N
involving VBG N
recycling NN N
of IN N
drugs NNS N
, , N
and CC N
for IN N
drugs NNS N
with IN N
long JJ N
half-life NN N
, , N
the DT N
use NN N
of IN N
total JJ N
AUC NNP N
( ( N
from IN N
zero CD N
to TO N
infinity NN N
) ) N
can MD N
give VB N
erroneous JJ N
and CC N
clinically RB N
irrelevant JJ N
results NNS N
since IN N
the DT N
area NN N
is VBZ N
mostly RB N
determined VBN N
by IN N
elimination NN N
phase NN N
or CC N
by IN N
recycling VBG N
. . N

The DT N
calculation NN N
of IN N
total JJ N
AUC NNP N
also RB N
involves VBZ N
prolonged JJ N
sampling NN N
, , N
adding VBG N
to TO N
the DT N
cost NN N
and CC N
risks NNS N
associated VBN N
with IN N
bioequivalence NN N
studies NNS N
. . N

The DT N
use NN N
of IN N
Cmax NNP N
or CC N
Tmax NNP N
as IN N
a DT N
measure NN N
of IN N
rate NN N
of IN N
absorption NN N
, , N
to TO N
correlate VB N
with IN N
clinical JJ N
relevance NN N
, , N
is VBZ N
widely RB N
criticized VBN N
on IN N
logical JJ N
, , N
technical JJ N
, , N
and CC N
statistical JJ N
grounds NNS N
. . N

For IN N
drugs NNS N
used VBN N
on IN N
a DT N
multiple-dose JJ N
basis NN N
, , N
Cmax NNP N
and CC N
Tmax NNP N
evaluations NNS N
become VBP N
redundant JJ N
since IN N
the DT N
average JJ N
plateau NN N
concentration NN N
is VBZ N
not RB N
affected VBN N
by IN N
these DT N
parameters NNS N
. . N

To TO N
resolve VB N
the DT N
drawbacks NNS N
in IN N
the DT N
traditional JJ N
methodology NN N
of IN N
bioequivalence NN N
evaluation NN N
, , N
the DT N
use NN N
of IN N
partial JJ N
areas NNS N
in IN N
lieu NN N
of IN N
total JJ N
AUC NNP N
, , N
Tmax NNP N
, , N
and CC N
Cmax NNP N
is VBZ N
suggested VBN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
logic NN N
and CC N
robustness NN N
of IN N
the DT N
partial-area JJ N
method NN N
in IN N
establishing VBG N
bioequivalence NN N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
5h CD N
AUC NNP N
is VBZ N
a DT N
more RBR N
relevant JJ N
parameter NN N
to TO N
establish VB N
naproxen NNS 3_i
bioequivalence NN N
than IN N
AUCinf NNP N
. . N

We PRP N
recommend VBP N
against IN N
using VBG N
symmetrical JJ N
confidence NN N
intervals NNS N
and CC N
report NN N
excellent JJ N
agreement NN N
among IN N
several JJ N
methods NNS N
of IN N
calculating VBG N
confidence NN N
intervals NNS N
, , N
probability NN N
values NNS N
, , N
and CC N
nonparametric JJ N
tests NNS N
. . N

We PRP N
suggest VBP N
that IN N
a DT N
single-point JJ N
short-term JJ N
AUC NNP N
is VBZ N
a DT N
better JJR N
indicator NN N
of IN N
the DT N
bioequivalence NN N
of IN N
generic JJ N
products NNS N
than IN N
the DT N
total JJ N
AUC NNP N
, , N
Cmax NNP N
, , N
and CC N
Tmax NNP N
as IN N
required VBN N
currently RB N
by IN N
the DT N
regulatory JJ N
authorities NNS N
. . N

-DOCSTART- -X- O O

Analgesia NN N
after IN N
caesarean JJ N
section NN N
with IN N
intramuscular JJ N
ketorolac NN 3_i
or CC N
pethidine NN 3_i
. . N

We PRP N
compared VBN N
, , N
in IN N
a DT N
double-blind NN N
randomised VBN N
study NN N
, , N
intramuscular JJ 3_i
ketorolac NN 3_i
30 CD N
mg NN N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
and CC N
intramuscular JJ 3_i
pethidine NN 3_i
75 CD N
mg NN N
( ( N
n JJ N
= NNP N
51 CD N
) ) N
for IN N
analgesia NN 3_i
after IN N
elective JJ N
caesarean JJ N
section NN N
under IN N
general JJ N
anaesthesia NN N
. . N

Anaesthesia NNP N
was VBD N
induced VBN N
with IN N
thiopentone NN 3_i
and CC 3_i
suxamethonium NN 3_i
and CC 3_i
maintained VBD 3_i
with IN 3_i
atracurium NN 3_i
, , 3_i
nitrous JJ 3_i
oxide NN 3_i
and CC 3_i
isoflurane NN 3_i
. . N

Intravenous JJ 3_i
fentanyl JJ 3_i
100 CD N
micrograms NN N
was VBD N
given VBN N
after IN N
delivery NN N
of IN N
the DT N
neonate NN N
. . N

In IN N
the DT N
recovery NN N
ward NN N
, , N
patients NNS N
who WP N
requested VBD N
analgesia NN N
were VBD N
allocated VBN N
randomly RB N
to TO N
receive VB N
ketorolac NN 3_i
30 CD N
mg NN N
or CC N
pethidine VB N
75 CD N
mg NNS N
intramuscularly RB N
. . N

Analgesia NNP N
was VBD N
assessed VBN N
at IN N
intervals NNS N
up RB N
to TO N
six CD N
hours NNS N
, , N
using VBG N
a DT N
visual JJ N
analogue NN N
scale NN N
and CC N
a DT N
four-point JJ N
verbal JJ N
scale NN N
, , N
while IN N
duration NN N
of IN N
analgesia NN N
was VBD N
taken VBN N
as IN N
the DT N
time NN N
until IN N
the DT N
patient NN N
requested VBD N
additional JJ N
analgesia NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
duration NN N
of IN N
analgesia NN N
between IN N
groups NNS N
( ( N
Mann-Whitney NNP N
test NN N
P NNP N
= NNP N
0.27 CD N
, , N
Mantel-Haentszel NNP N
test NN N
P NNP N
= NNP N
0.17 CD N
) ) N
. . N

Twenty-six JJ N
patients NNS N
in IN N
the DT N
ketorolac NN N
group NN N
and CC N
17 CD N
patients NNS N
in IN N
the DT N
pethidine NN N
group NN N
requested VBD N
further RBR N
analgesia NN N
by IN N
90 CD N
minutes NNS N
. . N

However RB N
, , N
four CD N
patients NNS N
in IN N
the DT N
ketorolac NN N
group NN N
and CC N
six CD N
patients NNS N
in IN N
the DT N
pethidine NN N
group NN N
requested VBD N
no DT N
further JJ N
analgesia NN N
within IN N
24 CD N
hours NNS N
. . N

Pain NNP N
VAS NNP N
and CC N
overall JJ N
assessment NN N
of IN N
analgesia NN N
was VBD N
similar JJ N
between IN N
groups NNS N
, , N
although IN N
more JJR N
side-effects NNS N
( ( N
nausea NN N
, , N
dizziness NN N
) ) N
were VBD N
noted VBN N
in IN N
the DT N
pethidine NN N
group NN N
. . N

Ketorolac NNP N
30 CD N
mg NN N
and CC N
pethidine NN N
75 CD N
mg NN N
provided VBD N
similar JJ N
but CC N
variable JJ N
quality NN N
of IN N
analgesia NN N
after IN N
caesarean JJ N
section NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Validity NNP N
of IN N
cardiotocography NN 2_i
in IN N
the DT N
detection NN N
of IN N
umbilical JJ N
cord NN N
complications NNS N
] VBP N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
validity NN N
of IN N
cardiotocography NN 2_i
for IN N
the DT N
detection NN N
of IN N
cord NN N
complications NNS N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP N
low-risk JJ N
population NN N
of IN N
4196 CD N
cases NNS N
was VBD N
selected VBN N
in IN N
which WDT N
cord NN N
complications NNS N
have VBP N
been VBN N
recognized VBN N
in IN N
34.3 CD N
% NN N
. . N

Cases VBZ N
with IN N
cord NN N
complications NNS N
and CC N
controls NNS N
were VBD N
paired VBN N
by IN N
parity NN N
, , N
gestational JJ N
age NN N
, , N
maternal JJ N
age NN N
and CC N
mode NN N
of IN N
delivery NN N
. . N

25 CD N
pairs NNS N
were VBD N
randomly RB N
selected VBN N
. . N

50 CD N
tracings NNS N
were VBD N
presented VBN N
twice RB N
to TO N
4 CD N
obstetricians NNS N
in IN N
a DT N
double-blind JJ N
manner NN N
. . N

As IN N
parameters NNS N
for IN N
the DT N
determination NN N
of IN N
the DT N
validity NN N
of IN N
fetal JJ N
monitoring VBG N
the DT N
reliability NN N
, , N
positive JJ N
( ( N
ppv NN N
) ) N
and CC N
negative JJ N
predictive JJ N
value NN N
( ( N
npv JJ N
) ) N
, , N
sensitivity NN N
and CC N
specificity NN N
were VBD N
used VBN N
. . N

Inter- JJ N
and CC N
intra-observer JJ N
variability NN N
were VBD N
also RB N
examined VBN N
. . N

RESULTS NNP N
Reliability NNP N
52 CD N
% NN N
, , N
ppv RB N
52 CD N
% NN N
, , N
npv RB N
52 CD N
% NN N
, , N
sensitivity NN N
46 CD N
% NN N
, , N
specificity NN N
58 CD N
% NN N
. . N

Interobserver NNP N
variability NN N
: : N
All DT N
4 CD N
obstetricians NNS N
agreed VBD N
in IN N
47 CD N
of IN N
100 CD N
evaluations NNS N
. . N

The DT N
level NN N
of IN N
agreement NN N
was VBD N
higher RBR N
in IN N
the DT N
controls NNS N
( ( N
63 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
cord NN N
complication NN N
group NN N
( ( N
56 CD N
% NN N
) ) N
. . N

The DT N
intraobserver NN N
variability NN N
was VBD N
25 CD N
% NN N
. . N

CONCLUSIONS NNP N
Cardiotocography NNP 2_i
is VBZ N
not RB N
useful JJ N
for IN N
the DT N
detection NN N
of IN N
cord NN N
complications NNS N
. . N

The DT N
range NN N
of IN N
possibilities NNS N
has VBZ N
not RB N
been VBN N
exploited VBN N
yet RB N
, , N
even RB N
for IN N
the DT N
evaluation NN N
of IN N
the DT N
fetal JJ N
state NN N
. . N

-DOCSTART- -X- O O

Modest NNP N
antihypertensive JJ N
effect NN N
of IN N
epanolol NN 3_i
, , N
a DT N
beta NN N
1-selective JJ N
receptor NN N
blocker NN N
with IN N
beta NN N
1 CD N
agonist NN N
activity NN N
: : N
an DT N
acute NN N
and CC N
long-term JJ N
hemodynamic NN N
study NN N
at IN N
rest NN N
and CC N
during IN N
exercise NN N
and CC N
double JJ N
crossover NN N
comparison NN N
with IN N
atenolol NN N
on IN N
ambulatory JJ N
blood NN N
pressure NN N
. . N

Beta-blockers NNS N
with IN N
less JJR N
cardiodepressive JJ N
effect NN N
than IN N
traditional JJ N
nonselective JJ N
beta NN N
( ( N
1+2 CD N
) ) N
-blocking VBG N
agents NNS N
could MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
, , N
provided VBD N
the DT N
reduction NN N
in IN N
blood NN N
pressure NN N
was VBD N
satisfactory JJ N
. . N

Epanolol NNP 3_i
, , N
a DT N
selective JJ N
beta NN N
1-receptor JJ N
blocker NN N
with IN N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
, , N
induced VBD N
a DT N
fall NN N
in IN N
intraarterial JJ N
pressure NN N
of IN N
8 CD N
% NN N
at IN N
rest NN N
sitting VBG N
and CC N
11 CD N
% NN N
during IN N
100 CD N
W NNP N
bicycle NN N
exercise NN N
after IN N
the DT N
first JJ N
dose NN N
of IN N
200 CD N
mg NNS N
in IN N
12 CD N
patients NNS N
with IN N
essential JJ N
hypertension NN N
. . N

Heart NNP N
rate NN N
, , N
stroke VBD N
index NN N
, , N
and CC N
cardiac JJ N
index NN N
initially RB N
fell VBD N
by IN N
14 CD N
% NN N
, , N
11 CD N
% NN N
, , N
and CC N
23 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
total JJ N
peripheral JJ N
resistance NN N
index NN N
increased VBD N
by IN N
21 CD N
% NN N
after IN N
2 CD N
hours NNS N
, , N
and CC N
then RB N
reverted VBD N
towards IN N
the DT N
pretreatment NN N
level NN N
. . N

After IN N
10 CD N
months NNS N
of IN N
epanolol JJ 3_i
treatment NN N
( ( N
mean JJ N
300 CD N
mg/day NN N
) ) N
, , N
the DT N
reduction NN N
in IN N
arterial JJ N
pressure NN N
was VBD N
5 CD N
% NN N
at IN N
rest NN N
and CC N
10 CD N
% NN N
during IN N
exercise NN N
. . N

Cardiac NNP N
index NN N
and CC N
heart NN N
rate NN N
were VBD N
still RB N
reduced VBN N
14-21 CD N
% NN N
, , N
while IN N
total JJ N
peripheral JJ N
resistance NN N
was VBD N
unchanged JJ N
or CC N
slightly RB N
increased VBN N
( ( N
2-10 CD N
% NN N
) ) N
. . N

Twenty-four JJ N
hour NN N
ambulatory NN N
blood NN N
pressure NN N
was VBD N
higher JJR N
on IN N
epanolol NN 3_i
( ( N
300 CD N
mg/day NN N
) ) N
than IN N
on IN N
atenolol NN 3_i
( ( N
150 CD N
mg/day NN N
) ) N
treatment NN N
( ( N
137/97 CD N
vs. FW N
128/91 CD N
mmHg NN N
) ) N
. . N

Thus RB N
, , N
the DT N
achieved VBN N
blood NN N
pressure NN N
reduction NN N
induced VBN N
by IN N
epanolol NN 3_i
was VBD N
moderate JJ N
, , N
while IN N
other JJ N
characteristics NNS N
of IN N
beta-receptor NN N
blockade NN N
, , N
in IN N
particular JJ N
, , N
the DT N
reduction NN N
of IN N
heart NN N
rate NN N
and CC N
cardiac JJ N
output NN N
, , N
were VBD N
maintained VBN N
. . N

This DT N
suggests VBZ N
that IN N
the DT N
compound NN N
may MD N
be VB N
useful JJ N
for IN N
other JJ N
cardiovascular JJ N
disorders NNS N
, , N
e.g. NN N
, , N
angina JJ N
pectoris NN N
in IN N
patients NNS N
without IN N
hypertension NN N
or CC N
cardiac JJ N
arrhythmia NN N
. . N

-DOCSTART- -X- O O

Hypotensive JJ N
effects NNS N
and CC N
influence NN N
on IN N
serum NN N
lipids NNS N
of IN N
SQ29,852 NNP 3_i
, , 3_i
a DT 3_i
new JJ 3_i
angiotensin NN 3_i
converting VBG 3_i
enzyme JJ 3_i
inhibitor NN 3_i
, , N
in IN N
patients NNS N
with IN N
essential JJ N
hypertension NN N
: : N
a DT N
comparison NN N
with IN N
atenolol NN 3_i
. . N

The DT N
effects NNS N
of IN N
SQ29,852 NNP 3_i
( ( N
n JJ N
= NNP N
24 CD N
) ) N
, , N
a DT N
new JJ N
angiotensin NN 3_i
converting VBG 3_i
enzyme JJ 3_i
inhibitor NN 3_i
, , N
and CC N
atenolol NN 3_i
( ( N
n JJ N
= NNP N
22 CD N
) ) N
, , N
monotherapies NNS N
were VBD N
compared VBN N
in IN N
46 CD N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
essential JJ N
hypertension NN N
. . N

Both DT N
SQ29,852 NNP 3_i
( ( N
mean VBP N
dose RB N
15.0 CD N
+/- JJ N
5.1 CD N
mg/day NN N
) ) N
and CC N
atenolol $ 3_i
( ( N
mean VB N
dose RB N
37.5 CD N
+/- JJ N
18.5 CD N
mg/day NN N
) ) N
significantly RB N
decreased VBN N
both DT N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressures NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
serum NN N
lipids NNS N
, , N
apolipoproteins NNS N
, , N
lipoproteins VBZ N
or CC N
atherosclerotic JJ N
indices NNS N
after IN N
both DT N
SQ29,852 NNP 3_i
and CC N
atenolol RB 3_i
. . N

There EX N
were VBD N
also RB N
no DT N
significant JJ N
inter-group JJ N
differences NNS N
. . N

There EX N
were VBD N
no DT N
serious JJ N
side NN N
effects NNS N
or CC N
abnormal JJ N
laboratory NN N
tests NNS N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
SQ29,852 NNP 3_i
is VBZ N
an DT N
effective JJ N
antihypertensive JJ N
drug NN N
without IN N
adverse JJ N
effect NN N
on IN N
lipid JJ N
metabolism NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
standardized JJ 4_i
pamphlet NN 4_i
on IN N
insomnia NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

OBJECTIVE NNP N
Sleep NNP N
difficulties NNS N
are VBP N
common JJ N
reasons NNS N
why WRB N
parents NNS N
seek VBP N
medical JJ N
intervention NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
. . N

We PRP N
determined VBD N
whether IN N
a DT N
pamphlet NN 4_i
alone RB N
could MD N
be VB N
used VBN N
by IN N
parents NNS N
to TO N
help VB N
their PRP$ N
child NN N
's POS N
insomnia NN N
. . N

METHODS NNP N
Thirty-six JJ N
children NNS N
with IN N
ASD NNP N
, , N
ages VBZ N
2 CD N
to TO N
10 CD N
years NNS N
, , N
were VBD N
enrolled VBN N
. . N

All DT N
had VBD N
prolonged VBN N
sleep JJ N
latency NN N
confirmed VBN N
by IN N
actigraphy NN N
showing VBG N
a DT N
mean JJ N
sleep JJ N
latency NN N
of IN N
30 CD N
minutes NNS N
or CC N
more JJR N
. . N

Parents NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
the DT N
sleep JJ 4_i
education NN 4_i
pamphlet NN 4_i
or CC 4_i
no DT 4_i
intervention NN 7_i
. . N

Children NNP N
wore VBD N
an DT N
actigraphy NN 6_i
device NN 6_i
to TO N
record VB N
baseline NN N
sleep JJ N
parameters NNS N
, , N
with IN N
the DT N
primary JJ N
outcome NN N
variable JJ N
being VBG N
change NN N
in IN N
sleep JJ N
latency NN N
. . N

Actigraphy NNP N
data NNS N
were VBD N
collected VBN N
a DT N
second JJ N
time NN N
2 CD N
weeks NNS N
after IN N
the DT N
parent NN N
received VBD N
the DT N
randomization NN N
assignment NN N
and CC N
analyzed VBN N
by IN N
using VBG N
Student NNP N
's POS N
t JJ N
test NN N
. . N

Parents NNS N
were VBD N
also RB N
asked VBN N
a DT N
series NN N
of IN N
questions NNS N
to TO N
gather VB N
information NN N
about IN N
the DT N
pamphlet NN 4_i
and CC N
its PRP$ N
usefulness NN N
. . N

RESULTS NNP N
Although IN N
participants NNS N
randomized VBN N
to TO N
the DT N
2 CD N
arms NNS N
did VBD N
not RB N
differ VB N
statistically RB N
in IN N
age NN N
, , N
gender NN N
, , N
socioeconomic JJ N
status NN N
, , N
total JJ N
Children NNP N
's POS N
Sleep NNP N
Habits NNP N
Questionnaire NNP N
score NN N
, , N
or CC N
actigraphy NN N
parameters NNS N
, , N
some DT N
differences NNS N
may MD N
be VB N
large JJ N
enough RB N
to TO N
affect VB N
results NNS N
. . N

Mean JJ N
change NN N
in IN N
sleep-onset JJ N
latency NN N
did VBD N
not RB N
differ VB N
between IN N
the DT N
randomized VBN N
groups NNS N
( ( N
pamphlet VB 4_i
versus NN 4_i
no DT 7_i
pamphlet NN 7_i
) ) N
. . N

Parents NNS N
commented VBD N
that IN N
the DT N
pamphlet NN 4_i
contained VBD N
good JJ N
information NN N
, , N
but CC N
indicated VBD N
that IN N
it PRP N
would MD N
have VB N
been VBN N
more RBR N
useful JJ N
to TO N
be VB N
given VBN N
specific JJ N
examples NNS N
of IN N
how WRB N
to TO N
take VB N
the DT N
information NN N
and CC N
put VB N
it PRP N
into IN N
practice NN N
. . N

CONCLUSIONS VB N
A DT N
sleep JJ 4_i
education NN 4_i
pamphlet NN 4_i
did VBD N
not RB N
appear VB N
to TO N
improve VB N
sleep JJ N
latency NN N
in IN N
children NNS N
with IN N
ASDs NNP N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
duodenal JJ N
ulcer NN N
with IN N
low-dose JJ 3_i
antacids NNS 3_i
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
investigation NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
a DT N
low-dose JJ 3_i
antacid NN 3_i
( ( 3_i
Maalox NNP 3_i
70 CD 3_i
, , N
280 CD N
mmol/day NN N
) ) N
with IN N
that DT N
of IN N
the DT N
H2-receptor NNP 3_i
antagonist NN 3_i
cimetidine NN 3_i
( ( 3_i
Tagamet NNP 3_i
, , N
200 CD N
mg NN N
three CD N
times NNS N
daily RB N
and CC N
400 CD N
mg/day NN N
) ) N
after IN N
14 CD N
and CC N
28 CD N
days NNS N
in IN N
the DT N
treatment NN N
of IN N
duodenal JJ N
ulcer NN N
. . N

The DT N
prospective JJ N
multicentre NN N
study NN N
included VBD N
171 CD N
patients NNS N
with IN N
endoscopically RB N
confirmed VBN N
duodenal JJ N
ulcers NNS N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
groups NNS N
with IN N
antacid JJ 3_i
containing VBG 3_i
Mg NNP 3_i
and CC 3_i
Al NNP 3_i
hydroxide NN 3_i
( ( 3_i
M NNP 3_i
) ) 3_i
( ( 3_i
4 CD 3_i
X RB N
70 CD N
mmol/day NN N
; : N
n CC N
= VB N
86 CD N
) ) N
or CC N
to TO N
the DT N
group NN N
receiving VBG N
cimetidine NN 3_i
( ( N
T NNP N
) ) N
( ( N
1000 CD N
mg/day NN N
; : N
n CC N
= VB N
85 CD N
) ) N
. . N

The DT N
two CD N
treatment NN N
groups NNS N
were VBD N
matched VBN N
for IN N
age NN N
, , N
sex NN N
, , N
drinking NN N
and CC N
smoking NN N
habits NNS N
, , N
and CC N
drug NN N
use NN N
. . N

Endoscopic JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
14 CD N
days NNS N
later RB N
. . N

If IN N
the DT N
ulcer NN N
was VBD N
still RB N
present JJ N
at IN N
this DT N
time NN N
, , N
the DT N
second JJ N
endoscopic NN N
examination NN N
was VBD N
done VBN N
after IN N
a DT N
further JJ N
14 CD N
days NNS N
. . N

Endoscopically RB N
, , N
the DT N
ulcer NN N
had VBD N
healed VBN N
at IN N
14 CD N
days NNS N
in IN N
38.8 CD N
% NN N
( ( N
M NNP N
) ) N
and CC N
in IN N
34.9 CD N
% NN N
( ( N
T NNP N
) ) N
and CC N
at IN N
28 CD N
days NNS N
in IN N
80.0 CD N
% NN N
( ( N
M NNP N
) ) N
and CC N
74.7 CD N
% NN N
( ( N
T NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
healing VBG N
rate NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Complaints NNS N
, , N
measured VBN N
as IN N
percentage NN N
of IN N
days NNS N
per IN N
week NN N
with IN N
upper JJ N
abdominal JJ N
pain NN N
, , N
were VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
pain VB N
relief NN N
or CC N
side NN N
effects NNS N
. . N

Treatment NN N
had VBD N
to TO N
be VB N
abandoned VBN N
in IN N
one CD N
patient NN N
receiving VBG N
antacid NN N
because IN N
of IN N
diarrhoea NN N
and CC N
in IN N
one CD N
patient NN N
receiving VBG N
cimetidine NN N
because IN N
of IN N
the DT N
absence NN N
of IN N
any DT N
response NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Use NNP N
of IN N
high-dose JJ N
cytarabine NN 3_i
to TO N
enhance VB N
cisplatin JJ 3_i
cytotoxicity-effects NNS N
on IN N
the DT N
response NN N
and CC N
overall JJ N
survival NN N
rates NNS N
of IN N
advanced JJ N
head NN N
and CC N
neck NN N
cancer NN N
patients NNS N
. . N

UNLABELLED IN N
It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
cytarabine NN 3_i
, , N
acting VBG N
by IN N
at IN N
least JJS N
two CD N
different JJ N
mechanisms NNS N
, , N
enhances VBZ N
the DT N
cytotoxic JJ N
effect NN N
of IN N
cisplatin NN 3_i
in IN N
in IN N
vitro JJ N
systems NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
open JJ N
, , N
prospective JJ N
, , N
randomised VBD N
study NN N
was VBD N
to TO N
estimate VB N
the DT N
eventual JJ N
benefits NNS N
from IN N
the DT N
inclusion NN N
of IN N
high-dose JJ N
cytarabine NN 3_i
in IN N
the DT N
cisplatin-5-fluorouracil NN 3_i
( ( 3_i
5-FU JJ 3_i
) ) 3_i
regimen NNS N
as IN N
first-line JJ N
treatment NN N
of IN N
patients NNS N
with IN N
advanced JJ N
head NN N
and CC N
neck NN N
cancer NN N
. . N

The DT N
study NN N
recruited VBD N
successive JJ N
patients NNS N
with IN N
unresectable JJ N
grade NN N
I/II NNP N
head NN N
and CC N
neck NN N
cancer NN N
who WP N
were VBD N
not RB N
suitable JJ N
for IN N
irradiation NN 2_i
treatment NN 2_i
( ( N
T NNP N
any DT N
N3 NNP N
or CC N
T4 NNP N
N2C NNP N
) ) N
, , N
metastatic JJ N
or CC N
previously RB N
irradiated VBN N
. . N

All DT N
patients NNS N
gave VBD N
their PRP$ N
informed JJ N
consent NN N
. . N

A DT N
joint JJ N
ear NN N
, , N
nose JJ N
and CC N
throat NN N
( ( N
ENT NNP N
) ) N
oncological JJ N
committee NN N
performed VBD N
the DT N
selection NN N
. . N

A DT N
total NN N
of IN N
170 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Patients NNS N
randomised VBD N
to TO N
arm VB N
A NNP N
were VBD N
given VBN N
1000 CD 3_i
mg/m NN 3_i
( ( 3_i
2 CD 3_i
) ) 3_i
cytarabine NN 3_i
on IN N
day NN N
1 CD N
preceding NN N
for IN N
6 CD N
h NN N
cisplatin NN 3_i
infusion NN 3_i
, , N
30 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/24 NN N
h NN N
cisplatin NN 3_i
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
bolus JJ N
days NNS N
1-4 CD N
and CC N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/24 NN N
h JJ N
5-FU JJ N
in IN N
a DT N
4-h JJ N
infusion NN N
on IN N
days NNS N
1-4 JJ N
. . N

Patients NNS N
in IN N
arm NN N
B NNP N
were VBD N
given VBN N
cisplatin NNS 3_i
and CC 3_i
5-FU JJ 3_i
in IN N
the DT N
same JJ N
dosage NN N
and CC N
schedule NN N
as IN N
in IN N
arm NN N
A NNP N
. . N

Additional NNP N
irradiation+/-surgery NN 1_i
was VBD N
performed VBN N
if IN N
and CC N
when WRB N
feasible JJ N
. . N

Patients NNS N
in IN N
both DT N
arms NNS N
were VBD N
well RB N
balanced VBN N
with IN N
regard NN N
to TO N
clinical JJ N
variables NNS N
. . N

The DT N
following JJ N
results NNS N
were VBD N
obtained VBN N
: : N
Arm NN N
A NN N
: : N
84 CD N
patients NNS N
were VBD N
included VBN N
, , N
74 CD N
were VBD N
evaluable JJ N
for IN N
activity NN N
; : N
RESPONSE NNP N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
8 CD N
( ( N
11 CD N
% NN N
) ) N
, , N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
40 CD N
( ( N
54 CD N
% NN N
) ) N
, , N
stable JJ N
disease NN N
( ( N
SD NNP N
) ) N
11 CD N
( ( N
15 CD N
% NN N
) ) N
, , N
progressive JJ N
disease NN N
( ( N
PD NNP N
) ) N
15 CD N
( ( N
20 CD N
% NN N
) ) N
. . N

The DT N
overall JJ N
response NN N
rate NN N
( ( N
RR NNP N
) ) N
based VBN N
on IN N
the DT N
evaluable JJ N
patients NNS N
was VBD N
48/74 CD N
( ( N
65 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
54-75 CD N
% NN N
) ) N
; : N
The DT N
RR NNP N
based VBN N
on IN N
an DT N
intent-to-treat JJ N
analysis NN N
was VBD N
57 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
47-67 CD N
% NN N
; : N
Median JJ N
survival NN N
was VBD N
13 CD N
months NNS N
; : N
There EX N
were VBD N
50 CD N
episodes NNS N
of IN N
granulocytopenia NN N
grade NN N
IV NNP N
and CC N
15 CD N
of IN N
febrile JJ N
neutropenia NNS N
per IN N
316 CD N
cycles NNS N
. . N

Arm NN N
B NN N
: : N
86 CD N
patients NNS N
were VBD N
included VBN N
, , N
80 CD N
were VBD N
evaluable JJ N
for IN N
activity NN N
; : N
RESPONSE NNP N
CR NNP N
7 CD N
( ( N
9 CD N
% NN N
) ) N
, , N
PR NNP N
29 CD N
( ( N
36 CD N
% NN N
) ) N
, , N
SD NNP N
10 CD N
( ( N
12.5 CD N
% NN N
) ) N
, , N
PD NNP N
34 CD N
( ( N
42.5 CD N
% NN N
) ) N
; : N
The DT N
overall JJ N
RR NNP N
based VBN N
on IN N
the DT N
evaluable JJ N
patients NNS N
was VBD N
36/80 CD N
( ( N
45 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
35-56 CD N
% NN N
) ) N
; : N
The DT N
RR NNP N
based VBN N
on IN N
an DT N
intent-to-treat JJ N
analysis NN N
was VBD N
42 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
32-52 CD N
% NN N
; : N
Median JJ N
survival NN N
was VBD N
8 CD N
months NNS N
; : N
There EX N
were VBD N
14 CD N
episodes NNS N
of IN N
granulocytopenia NN N
grade NN N
IV NNP N
and CC N
7 CD N
febrile NN N
neutropenias NNS N
per IN N
324 CD N
cycles NNS N
. . N

The DT N
RR NNP N
was VBD N
significantly RB N
higher JJR N
in IN N
arm NN N
A NNP N
( ( N
P=0.013 NNP N
) ) N
, , N
power NN N
( ( N
one-sided JJ N
) ) N
80 CD N
% NN N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
from IN N
the DT N
appropriate JJ N
subset NN N
who WP N
achieved VBD N
a DT N
clinical JJ N
response NN N
making VBG N
additional JJ N
treatment NN N
feasible NN N
was VBD N
higher RBR N
in IN N
arm NN N
A NNP N
( ( N
P=0.00015 NNP N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
a DT N
performance NN N
status NN N
2+3 CD N
achieving VBG N
a DT N
response NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Using VBG N
the DT N
Log-rank JJ N
test NN N
, , N
patients NNS N
from IN N
arm NN N
A NNP N
achieved VBD N
a DT N
significantly RB N
longer RBR N
survival JJ N
( ( N
P=0.009 NNP N
) ) N
, , N
with IN N
the DT N
probability NN N
of IN N
survival NN N
at IN N
12 CD N
months NNS N
of IN N
0.58 CD N
for IN N
patients NNS N
in IN N
arm NN N
A NN N
and CC N
0.28 CD N
for IN N
patients NNS N
in IN N
arm NN N
B. NNP N
Grade NNP N
IV NNP N
granulocytopenia NN N
and CC N
thrombocytopenia NN N
were VBD N
more RBR N
frequent JJ N
in IN N
arm NN N
A NN N
. . N

Due JJ N
to TO N
its PRP$ N
haematological JJ N
side-effects NNS N
, , N
cytarabine NN 3_i
might MD N
not RB N
be VB N
the DT N
ideal JJ N
drug NN N
to TO N
modulate VB N
the DT N
cytotoxicity NN N
of IN N
cisplatin NN 3_i
. . N

However RB N
, , N
other JJ N
modulators NNS N
of IN N
its PRP$ N
activity NN N
could MD N
be VB N
of IN N
interest NN N
for IN N
further JJ N
studies NNS N
in IN N
head NN N
and CC N
neck NN N
cancer NN N
patients NNS N
. . N

-DOCSTART- -X- O O

Sequential JJ N
alternate JJ N
administration NN N
of IN N
tamoxifen NN 3_i
and CC N
medroxyprogesterone NN 3_i
acetate NN 3_i
in IN N
advanced JJ N
breast NN N
cancer NN N
: : N
clinical-biological JJ N
randomized NN N
study NN N
. . N

From IN N
January NNP N
1985 CD N
to TO N
September NNP N
1988 CD N
, , N
60 CD N
women NNS N
with IN N
advanced JJ N
breast NN N
cancer NN N
were VBD N
randomized VBN N
in IN N
two CD 3_i
arms NNS 3_i
to TO 3_i
receive VB 3_i
: : 3_i
A DT 3_i
) ) 3_i
tamoxifen NN 3_i
( ( 3_i
TAM NNP 3_i
) ) 3_i
( ( 3_i
20 CD 3_i
mg/die NN 3_i
) ) 3_i
until IN 3_i
progression NN 3_i
or CC 3_i
B NNP 3_i
) ) 3_i
TAM NNP 3_i
( ( 3_i
20 CD 3_i
mg/die NN 3_i
for IN 3_i
14 CD 3_i
days NNS 3_i
) ) 3_i
then RB 3_i
medroxyprogesterone NN 3_i
acetate NN 3_i
( ( 3_i
MPA NNP 3_i
) ) 3_i
( ( 3_i
1500 CD 3_i
mg/die NN 3_i
p.o NN 3_i
. . 3_i

for IN 7_i
14 CD 7_i
days NNS 7_i
) ) 7_i
followed VBN 7_i
by IN 7_i
7 CD 7_i
days NNS 7_i
of IN 7_i
wash-out NN 7_i
before IN 7_i
repeating VBG 7_i
the DT 7_i
TAM/MPA NNP 7_i
treatment NN 7_i
. . 7_i

All DT N
patients NNS N
were VBD N
post-menopausal JJ N
, , N
previously RB N
untreated VBN N
with IN N
hormone NN N
therapy NN N
, , N
and CC N
with IN N
tumor NN N
receptor NN N
status NN N
determined VBD N
immediately RB N
before IN N
randomization NN N
; : N
all DT N
had VBD N
objectively RB N
evaluable JJ N
lesions NNS N
. . N

In IN N
order NN N
to TO N
verify VB N
hormone NN N
receptor NN N
variations NNS N
due JJ N
to TO N
the DT N
antiestrogen NN N
, , N
when WRB 4_i
possible JJ 4_i
a DT 4_i
second JJ 4_i
biopsy NN 4_i
was VBD 4_i
performed VBN 4_i
after IN 4_i
the DT 4_i
initial JJ 4_i
14 CD 4_i
day NN 4_i
cycle NN 4_i
of IN 4_i
TAM NNP 4_i
. . 4_i

Thirty-one NN N
and CC N
29 CD N
patients NNS N
were VBD N
included VBN N
respectively RB N
in IN N
arms NNS N
A NNP N
and CC N
B NNP N
. . N

Objective JJ N
regression NN N
( ( N
CR NNP N
+ NNP N
PR NNP N
) ) N
was VBD N
observed VBN N
in IN N
58 CD N
% NN N
of IN N
group NN N
A NNP N
and CC N
75 CD N
% NN N
of IN N
group NN N
B NNP N
, , N
with IN N
CR NNP N
in IN N
11 CD N
% NN N
and CC N
23 CD N
% NN N
, , N
respectively RB N
. . N

Differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Median JJ N
time NN N
to TO N
progression NN N
was VBD N
12 CD N
months NNS N
for IN N
group NN N
A NNP N
and CC N
9 CD N
for IN N
group NN N
B NNP N
. . N

Overall NNP N
survival NN N
has VBZ N
not RB N
yet RB N
been VBN N
reached VBN N
in IN N
group NN N
A NNP N
while IN N
it PRP N
was VBD N
34 CD N
months NNS N
for IN N
patients NNS N
of IN N
group NN N
B. NNP N
Metrorrhagia NNP N
was VBD N
observed VBN N
in IN N
two CD N
cases NNS N
of IN N
group NN N
A NNP N
and CC N
in IN N
6 CD N
of IN N
group NN N
B NNP N
, , N
and CC N
thrombophlebitis NN N
in IN N
1 CD N
and CC N
3 CD N
cases NNS N
, , N
respectively RB N
. . N

The DT N
second JJ N
biopsy NN N
confirmed VBD N
a DT N
clear JJ N
increase NN N
of IN N
PgR NNP N
content NN N
in IN N
8/11 CD N
cases NNS N
( ( N
75 CD N
% NN N
) ) N
. . N

Plasma NNP N
level JJ N
variations NNS N
of IN N
TAM NNP N
, , N
N-desmethyl NNP N
TAM NNP N
and CC N
MPA NNP N
were VBD N
checked VBN N
at IN N
various JJ N
intervals NNS N
on IN N
3 CD N
patients NNS N
of IN N
group NN N
B NNP N
, , N
and CC N
confirmed VBD N
that IN N
our PRP$ N
schedule NN N
is VBZ N
able JJ N
to TO N
produce VB N
a DT N
drug NN N
wash-out NN N
period NN N
for IN N
tumor NN N
cells NNS N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
study NN N
demonstrated VBD N
that IN N
while IN N
the DT N
manipulation NN N
of IN N
hormone NN N
receptors NNS N
seems VBZ N
possible JJ N
, , N
results NNS N
indicating VBG N
better JJR N
overall JJ N
survival NN N
and CC N
time NN N
to TO N
progression NN N
were VBD N
not RB N
obtained VBN N
with IN N
alternate JJ N
sequential JJ N
TAM-MPA NNP N
therapy NN N
. . N

-DOCSTART- -X- O O

Lack NN N
of IN N
interaction NN N
between IN N
pantoprazole NN 3_i
and CC 3_i
digoxin NN 3_i
at IN N
therapeutic JJ N
doses NNS N
in IN N
man NN N
. . N

Substituted JJ 3_i
benzimidazole JJ 3_i
inhibitors NNS 3_i
of IN N
the DT N
gastric JJ N
H+/K+ATPase NNP N
may MD N
interact VB N
with IN N
the DT N
cytochrome NN N
P450 NNP N
enzyme NN N
system NN N
and CC N
alter VB N
the DT N
pharmacokinetics NNS N
of IN N
coadministered JJ N
drugs NNS N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
changes NNS N
in IN N
intragastric JJ N
pH NN N
might MD N
alter VB N
the DT N
absorption NN N
of IN N
other JJ N
drugs NNS N
. . N

The DT N
primary JJ N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
pantoprazole JJ 3_i
modifies NNS N
the DT N
steady-state JJ N
serum NN N
concentrations NNS N
of IN N
orally RB N
administered VBN N
digoxin NN 3_i
. . N

Secondary JJ N
aims NNS N
were VBD N
the DT N
influence NN N
of IN N
digoxin NN 3_i
on IN N
the DT N
pharmacokinetics NNS N
of IN N
pantoprazole NN 3_i
as RB N
well RB N
as IN N
safety NN N
and CC N
tolerability NN N
. . N

Eighteen NNP N
healthy JJ N
volunteers NNS N
received VBD N
a DT N
single JJ N
oral JJ 3_i
dose NN 3_i
of IN 3_i
pantoprazole NN 3_i
( ( 3_i
40 CD 3_i
mg NN 3_i
) ) 3_i
and CC N
serum JJ N
concentrations NNS N
were VBD N
determined VBN N
. . N

Three CD N
to TO N
10 CD N
days NNS N
later RB N
, , N
subjects NNS N
received VBD N
in IN N
a DT N
single-blind NN N
, , N
randomized VBN N
, , N
crossover JJ N
fashion NN N
oral JJ N
beta-acetyldigoxin NN 3_i
( ( N
0.2 CD N
mg NN N
) ) N
twice RB N
daily RB N
and CC N
concomitant JJ 3_i
oral JJ 3_i
pantoprazole NN 3_i
( ( N
40 CD N
mg NN N
) ) N
or CC N
placebo JJ 7_i
once RB N
daily JJ N
for IN N
5 CD N
days NNS N
. . N

Serum NNP N
concentrations NNS N
of IN N
pantoprazole NN 3_i
and CC N
digoxin NN 3_i
were VBD N
determined VBN N
on IN N
day NN N
5 CD N
. . N

Primary JJ N
characteristics NNS N
for IN N
confirmative JJ N
assessment NN N
of IN N
no DT N
interaction NN N
were VBD N
AUC NNP N
and CC N
Cmax NNP N
of IN N
digoxin NN 3_i
. . N

Lack NNP N
of IN N
interaction NN N
in IN N
the DT N
sense NN N
of IN N
equivalence NN N
was VBD N
concluded VBN N
for IN N
both DT N
digoxin NN N
( ( N
with IN N
and CC N
without IN N
pantoprazole NN 3_i
) ) N
and CC N
pantoprazole JJ 3_i
( ( N
with IN N
and CC N
without IN N
digoxin NN 3_i
) ) N
as IN N
the DT N
90 CD N
% NN N
-confidence NN N
intervals NNS N
of IN N
the DT N
respective JJ N
AUC- NNP N
and CC N
Cmax-ratios NNP N
were VBD N
within IN N
the DT N
equivalence NN N
range NN N
of IN N
0.8-1.25 NNP N
. . N

Pantoprazole NNP 3_i
did VBD N
not RB N
influence VB N
the DT N
characteristic JJ N
ECG NNP N
modifications NNS N
( ( N
T-wave NNP N
) ) N
caused VBN N
by IN N
digoxin NN N
. . N

Both DT N
drugs NNS N
were VBD N
well RB N
tolerated VBN N
and CC N
no DT N
adverse JJ N
events NNS N
or CC N
clinically RB N
relevant JJ N
alterations NNS N
in IN N
vital JJ N
signs NNS N
or CC N
clinical JJ N
laboratory NN N
parameters NNS N
were VBD N
observed VBN N
during IN N
treatment NN N
. . N

In IN N
conclusion NN N
, , N
pantoprazole NN 3_i
and CC N
digoxin NN 3_i
may MD N
be VB N
administered VBN N
concomitantly RB N
without IN N
the DT N
need NN N
for IN N
dose JJ N
adjustment NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
Behavioral NNP 5_i
Family NNP 5_i
Systems NNP 5_i
Therapy NNP 5_i
for IN N
Diabetes NNPS N
: : N
maintenance NN N
and CC N
generalization NN N
of IN N
effects NNS N
on IN N
parent-adolescent JJ N
communication NN N
. . N

We PRP N
report VBP N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
revised JJ N
Behavioral NNP 5_i
Family NNP 5_i
Systems NNP 5_i
Therapy NNP 5_i
for IN 5_i
Diabetes NNP 5_i
( ( 5_i
BFST-D NNP 5_i
) ) 5_i
intervention NN 5_i
. . N

Families NNS N
of IN N
104 CD N
adolescents NNS N
with IN N
diabetes NNS N
were VBD N
randomized VBN N
to TO N
standard VB 4_i
care NN 4_i
( ( 4_i
SC NNP 4_i
) ) 4_i
or CC 4_i
to TO 4_i
6 CD 4_i
months NNS 4_i
of IN 4_i
an DT 4_i
educational JJ 4_i
support NN 4_i
group NN 4_i
( ( 4_i
ES NNP 4_i
) ) 4_i
or CC 4_i
BFST-D. JJ 4_i
Family NNP N
communication NN N
and CC N
problem-solving JJ N
skills NNS N
were VBD N
assessed VBN N
at IN N
0 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
months NNS N
by IN N
independent JJ N
rating NN N
of IN N
videotaped JJ N
family NN N
problem-solving JJ N
discussions NNS N
. . N

BFST-D NNP 5_i
improved VBD N
individual JJ N
communication NN N
of IN N
adolescents NNS N
and CC N
mothers NNS N
, , N
but CC N
not RB N
fathers NNS N
. . N

BFST-D NNP 4_i
significantly RB N
improved VBD N
quality NN N
of IN N
family NN N
interaction NN N
compared VBN N
to TO N
SC NNP N
( ( N
10 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
and CC N
ES NNP N
( ( N
6 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
. . N

Changes NNS N
in IN N
family NN N
communication NN N
were VBD N
differentially RB N
associated VBN N
with IN N
changes NNS N
in IN N
glycemic JJ N
control NN N
, , N
adherence NN N
, , N
and CC N
family NN N
conflict NN N
. . N

BFST-D NNP 4_i
improved VBD N
family NN N
communication NN N
and CC N
problem NN N
solving VBG N
relative JJ N
to TO N
SC NNP N
and CC N
modestly RB N
relative JJ N
to TO N
ES NNP N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
Selaginella NNP 3_i
combined VBD N
with IN N
radiotherapy NN 2_i
on IN N
nasopharyngeal JJ N
carcinoma NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
Chinese JJ N
herbal JJ N
medicine NN N
Selaginella-induced NNP N
radiosensitization NN N
of IN N
terminal JJ N
nasopharyngeal JJ N
carcinoma NN N
( ( N
NPC NNP N
) ) N
. . N

METHODS NNP N
Totally RB N
180 CD N
patients NNS N
with IN N
NPC NNP N
were VBD N
divided VBN N
equally RB N
into IN N
3 CD N
groups NNS N
with IN N
the DT N
same JJ N
radiotherapeutic JJ N
protocols NNS N
. . N

The DT N
patients NNS N
in IN N
group NN N
A NNP N
received VBD N
radiotherapy NN 2_i
alone RB 2_i
, , N
those DT N
in IN N
group NN N
B NNP N
were VBD N
given VBN N
daily JJ 3_i
Selaginella NNP 3_i
( ( 3_i
30 CD 3_i
g NN 3_i
) ) 3_i
prepared VBD 3_i
into IN 3_i
50 CD 3_i
ml JJ 3_i
decoction NN 3_i
during IN 3_i
the DT 3_i
entire JJ 3_i
course NN 3_i
of IN 3_i
radiotherapy NN 3_i
, , N
and CC N
those DT N
in IN N
group NN 3_i
C NNP 3_i
had VBD 3_i
Selaginella NNP 3_i
30 CD 3_i
g JJ 3_i
daily RB 3_i
in IN N
the DT N
late JJ N
course NN N
of IN N
radiotherapy NN 3_i
. . N

RESULTS VB N
The DT N
complete JJ N
remission NN N
rate NN N
of IN N
nasopharyngeal JJ N
primary JJ N
lesions NNS N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
group NN N
A NNP N
, , N
with IN N
also RB N
significantly RB N
higher JJR N
complete JJ N
remission NN N
rates NNS N
of IN N
the DT N
cervical JJ N
lymph NN N
nodes NNS N
. . N

The DT N
acute JJ N
toxicity NN N
of IN N
the DT N
skin NN N
and CC N
mucous JJ N
membrane NN N
was VBD N
milder RBR N
in IN N
the DT N
latter JJ N
two CD N
groups NNS N
, , N
but CC N
the DT N
differences NNS N
were VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Selaginella NNP 3_i
may MD N
induce VB N
radiosensitization NN N
for IN N
terminal JJ N
NPC NNP N
and CC N
does VBZ N
not RB N
increase VB N
the DT N
acute JJ N
toxicity NN N
of IN N
radiotherapy NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
treatment NN N
of IN N
non-nephrotic JJ N
syndrome JJ N
IgA NNP N
nephropathy NN N
with IN N
Shenyanning NNP 3_i
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
curative JJ N
effect NN N
of IN N
Shenyanning NNP 3_i
( ( 3_i
SYN NNP 3_i
) ) 3_i
on IN N
non-nephrotic JJ N
syndrome NN N
IgA NNP N
nephropathy NN N
( ( N
IgAN NNP N
) ) N
. . N

METHODS NNP N
Seventy NNP N
primary JJ N
IgAN NNP N
patients NNS N
were VBD N
equally RB N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
treatment NN N
group NN N
and CC N
the DT N
control NN N
group NN N
, , N
they PRP N
were VBD N
orally RB N
treated VBN N
with IN N
SYN NNP 3_i
Decoction NNP 3_i
( ( N
one CD N
dose NN N
per IN N
day NN N
) ) N
and CC N
Losartan NNP 3_i
( ( N
50 CD N
mg NNS N
per IN N
day NN N
) ) N
respectively RB N
for IN N
1 CD N
year NN N
. . N

Efficacy NNP N
of IN N
treatment NN N
, , N
Chinese JJ N
medicine JJ N
syndrome NN N
scores NNS N
, , N
end-point JJ N
events NNS N
occurrence NN N
as RB N
well RB N
as IN N
changes NNS N
of IN N
related JJ N
laboratory NN N
indices NNS N
were VBD N
observed VBN N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
obviously RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
77.1 CD N
% NN N
vs. FW N
54.3 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
the DT N
Chinese JJ N
medicine JJ N
syndrome NN N
scores NNS N
, , N
urinary JJ N
protein NN N
and CC N
urinary JJ N
red-cell NN N
count NN N
reduced VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
showed VBD N
significant JJ N
difference NN N
as IN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
while IN N
the DT N
endogenous JJ N
creatinine NN N
clearance NN N
was VBD N
changed VBN N
insignificantly RB N
in IN N
both DT N
groups NNS N
. . N

Beside NNP N
, , N
the DT N
occurrence NN N
of IN N
end-point JJ N
events NNS N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
slightly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
, , N
though IN N
showed VBN N
no DT N
statistical JJ N
difference NN N
between IN N
them PRP N
. . N

CONCLUSION VB N
The DT N
curative JJ N
effect NN N
of IN N
SYN NNP 3_i
in IN N
treating VBG N
IgAN NNP N
was VBD N
obviously RB N
better JJR N
than IN N
that DT N
of IN N
simple JJ N
Western JJ N
medicine NN N
. . N

-DOCSTART- -X- O O

Margarines NNS N
fortified VBN N
with IN N
?-linolenic JJ N
acid NN N
, , N
eicosapentaenoic JJ 3_i
acid NN 3_i
, , N
or CC N
docosahexaenoic JJ 3_i
acid NN 3_i
alter IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
erythrocytes NNS N
but CC N
do VBP N
not RB N
affect VB N
the DT N
antioxidant JJ N
status NN N
of IN N
healthy JJ N
adults NNS N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
increased JJ N
intake NN N
of IN N
?-linolenic JJ N
acid NN N
( ( N
ALA NNP N
) ) N
, , N
EPA NNP N
, , N
or CC N
DHA NNP N
incorporated VBN N
into IN N
a DT N
food NN N
matrix NN N
on IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
erythrocytes NNS N
and CC N
on IN N
biomarkers NNS N
of IN N
oxidant/antioxidant JJ N
status NN N
. . N

To TO N
this DT N
end NN N
, , N
a DT N
controlled VBN N
dietary NN N
study NN N
was VBD N
conducted VBN N
in IN N
74 CD N
healthy JJ N
men NNS N
and CC N
women NNS N
. . N

The DT N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
interventions NNS N
in IN N
which WDT N
margarines NNS N
fortified VBD N
with IN N
either DT N
10 CD N
weight NN N
percent NN N
ALA NNP N
, , N
EPA NNP N
, , N
or CC N
DHA NNP N
ethyl VBP N
esters NNS N
replaced VBD N
their PRP$ N
normal JJ N
spread NN N
for IN N
6 CD N
wk NN N
. . N

The DT N
total JJ N
intakes NNS N
of IN N
ALA NNP N
, , N
EPA NNP N
, , N
and CC N
DHA NNP N
were VBD N
4.4 CD N
, , N
2.2 CD N
, , N
and CC N
2.3 CD N
g/d NN N
, , N
respectively RB N
. . N

Consuming VBG N
EPA NNP N
increased VBD N
the DT N
erythrocyte JJ N
proportion NN N
of IN N
EPA NNP N
( ( N
394 CD N
% NN N
) ) N
and CC N
the DT N
omega-3 JJ N
index NN N
( ( N
sum NN N
of IN N
EPA NNP N
and CC N
DHA NNP N
, , N
38 CD N
% NN N
) ) N
. . N

Consumption NN N
of IN N
DHA NNP N
increased VBD N
erythrocyte JJ N
DHA NNP N
( ( N
91 CD N
% NN N
) ) N
, , N
the DT N
omega-3 JJ N
index NN N
( ( N
98 CD N
% NN N
) ) N
, , N
and CC N
EPA NNP N
( ( N
137 CD N
% NN N
) ) N
. . N

The DT N
omega-3 JJ N
index NN N
increased VBD N
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
in IN N
the DT N
DHA NNP N
group NN N
than IN N
in IN N
the DT N
EPA NNP N
group NN N
. . N

ALA NNP N
did VBD N
not RB N
increase VB N
erythrocyte NN N
EPA NNP N
or CC N
the DT N
omega-3 JJ N
index NN N
. . N

We PRP N
found VBD N
no DT N
change NN N
in IN N
plasma NN N
uric JJ N
acid NN N
or CC N
antioxidant JJ N
capacity NN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

Plasma NNP N
malondialdehyde NN N
( ( N
MDA NNP N
) ) N
increased VBD N
with IN N
the DT N
EPA NNP N
and CC N
DHA NNP N
interventions NNS N
. . N

All DT N
3 CD N
interventions NNS N
decreased VBD N
erythrocyte JJ N
linoleic NN N
acid NN N
hydroperoxides NNS N
but CC N
did VBD N
not RB N
affect VB N
their PRP$ N
MDA NNP N
concentrations NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
intake NN N
of IN N
both DT N
isolated JJ N
EPA NNP N
and CC N
DHA NNP N
incorporated VBD N
into IN N
margarine NN N
resulted VBN N
in IN N
an DT N
enhanced JJ N
incorporation NN N
of IN N
EPA NNP N
and CC N
DHA NNP N
into IN N
erythrocytes NNS N
. . N

Our PRP$ N
findings NNS N
indicate VBP N
that IN N
DHA NNP N
is VBZ N
quantitatively RB N
superior JJ N
to TO N
EPA NNP N
in IN N
view NN N
of IN N
the DT N
EPA+DHA NNP N
tissue NN N
incorporation NN N
and CC N
also RB N
that IN N
4 CD N
g/d NN N
ALA NNP N
is VBZ N
not RB N
sufficient JJ N
to TO N
increase VB N
the DT N
omega-3 JJ N
index NN N
over IN N
a DT N
6-wk JJ N
period NN N
. . N

-DOCSTART- -X- O O

Exemestane NN 3_i
for IN N
breast-cancer JJ N
prevention NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

BACKGROUND NNP N
Tamoxifen NNP N
and CC N
raloxifene NN N
have VBP N
limited VBN N
patient JJ N
acceptance NN N
for IN N
primary JJ N
prevention NN N
of IN N
breast NN N
cancer NN N
. . N

Aromatase NNP N
inhibitors NNS N
prevent VBP N
more JJR N
contralateral JJ N
breast NN N
cancers NNS N
and CC N
cause NN N
fewer JJR N
side NN N
effects NNS N
than IN N
tamoxifen NN N
in IN N
patients NNS N
with IN N
early-stage JJ N
breast NN N
cancer NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 7_i
, , N
double-blind JJ N
trial NN N
of IN N
exemestane NN 3_i
designed VBN N
to TO N
detect VB N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN N
in IN N
invasive JJ N
breast NN N
cancer NN N
, , N
eligible JJ N
postmenopausal NN N
women NNS N
35 CD N
years NNS N
of IN N
age NN N
or CC N
older JJR N
had VBD N
at IN N
least JJS N
one CD N
of IN N
the DT N
following JJ N
risk NN N
factors NNS N
: : N
60 CD N
years NNS N
of IN N
age NN N
or CC N
older JJR N
; : N
Gail NNP N
5-year JJ N
risk NN N
score NN N
greater JJR N
than IN N
1.66 CD N
% NN N
( ( N
chances NNS N
in IN N
100 CD N
of IN N
invasive JJ N
breast NN N
cancer NN N
developing VBG N
within IN N
5 CD N
years NNS N
) ) N
; : N
prior JJ N
atypical JJ N
ductal NN N
or CC N
lobular JJ N
hyperplasia NN N
or CC N
lobular JJ N
carcinoma NN N
in IN N
situ NN N
; : N
or CC N
ductal JJ N
carcinoma NN N
in IN N
situ NN N
with IN N
mastectomy NN N
. . N

Toxic NNP N
effects NNS N
and CC N
health-related JJ N
and CC N
menopause-specific JJ N
qualities NNS N
of IN N
life NN N
were VBD N
measured VBN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
4560 CD N
women NNS N
for IN N
whom WP N
the DT N
median JJ N
age NN N
was VBD N
62.5 CD N
years NNS N
and CC N
the DT N
median JJ N
Gail NNP N
risk NN N
score NN N
was VBD N
2.3 CD N
% NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
exemestane NN 3_i
or CC N
placebo NN 7_i
. . N

At IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
11 CD N
invasive JJ N
breast NN N
cancers NNS N
were VBD N
detected VBN N
in IN N
those DT N
given VBN N
exemestane NN 3_i
and CC N
in IN N
32 CD N
of IN N
those DT N
given VBN N
placebo NNS 7_i
, , N
with IN N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN N
in IN N
the DT N
annual JJ N
incidence NN N
of IN N
invasive JJ N
breast NN N
cancer NN N
( ( N
0.19 CD N
% NN N
vs. FW N
0.55 CD N
% NN N
; : N
hazard CC N
ratio NN N
, , N
0.35 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.18 CD N
to TO N
0.70 CD N
; : N
P=0.002 NNP N
) ) N
. . N

The DT N
annual JJ N
incidence NN N
of IN N
invasive JJ N
plus CC N
noninvasive JJ N
( ( N
ductal JJ N
carcinoma NN N
in IN N
situ NN N
) ) N
breast NN N
cancers NNS N
was VBD N
0.35 CD N
% NN N
on IN N
exemestane NN N
and CC N
0.77 CD N
% NN N
on IN N
placebo NN 7_i
( ( N
hazard JJ N
ratio NN N
, , N
0.47 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.79 CD N
; : N
P=0.004 NNP N
) ) N
. . N

Adverse JJ N
events NNS N
occurred VBD N
in IN N
88 CD N
% NN N
of IN N
the DT N
exemestane NN N
group NN N
and CC N
85 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
( ( N
P=0.003 NNP N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
skeletal JJ N
fractures NNS N
, , N
cardiovascular JJ N
events NNS N
, , N
other JJ N
cancers NNS N
, , N
or CC N
treatment-related JJ N
deaths NNS N
. . N

Minimal JJ N
quality-of-life JJ N
differences NNS N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Exemestane NNP 3_i
significantly RB N
reduced VBD N
invasive JJ N
breast NN N
cancers NNS N
in IN N
postmenopausal JJ N
women NNS N
who WP N
were VBD N
at IN N
moderately RB N
increased VBN N
risk NN N
for IN N
breast NN N
cancer NN N
. . N

During IN N
a DT N
median JJ N
follow-up JJ N
period NN N
of IN N
3 CD N
years NNS N
, , N
exemestane NN N
was VBD N
associated VBN N
with IN N
no DT N
serious JJ N
toxic NN N
effects NNS N
and CC N
only RB N
minimal JJ N
changes NNS N
in IN N
health-related JJ N
quality NN N
of IN N
life NN N
. . N

( ( N
Funded VBN N
by IN N
Pfizer NNP N
and CC N
others NNS N
; : N
NCIC NNP N
CTG NNP N
MAP.3 NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00083174 NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
a DT N
CBT NNP 4_i
intervention NN 4_i
for IN N
anxiety NN N
in IN N
children NNS N
with IN N
Asperger NNP N
syndrome NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
brief JJ 4_i
CBT NNP 4_i
intervention NN 4_i
for IN 4_i
anxiety NN 4_i
with IN N
children NNS N
diagnosed VBN N
with IN N
Asperger NNP N
syndrome NN N
( ( N
AS IN N
) ) N
. . N

A DT N
second JJ N
interest NN N
was VBD N
to TO N
evaluate VB N
whether IN N
more RBR N
intensive JJ N
parent NN N
involvement NN N
would MD N
increase VB N
the DT N
child NN N
's POS N
ability NN N
to TO N
manage VB N
anxiety NN N
outside IN N
of IN N
the DT N
clinic JJ N
setting NN N
. . N

METHODS NNP N
Seventy-one JJ N
children NNS N
aged VBN N
ten NNS N
to TO N
twelve VB N
years NNS N
were VBD N
recruited VBN N
to TO N
participate VB N
in IN N
the DT N
anxiety NN N
programme NN N
. . N

All DT N
children NNS N
were VBD N
diagnosed VBN N
with IN N
AS NNP N
and CC N
the DT N
presence NN N
of IN N
anxiety NN N
symptoms NNS N
was VBD N
accepted VBN N
on IN N
parent NN N
report NN N
via IN N
brief JJ N
interview NN N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
: : N
intervention NN 4_i
for IN 4_i
child NN 4_i
only RB 4_i
, , 4_i
intervention NN 4_i
for IN 4_i
child NN 4_i
and CC 4_i
parent NN 4_i
, , 4_i
wait-list JJ 4_i
control NN 4_i
. . 4_i

RESULTS VB N
The DT N
two CD N
intervention NN N
groups NNS N
demonstrated VBD N
significant JJ N
decreases NNS N
in IN N
parent-reported JJ N
anxiety NN N
symptoms NNS N
at IN N
follow-up JJ N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
child NN N
's POS N
ability NN N
to TO N
generate VB N
positive JJ N
strategies NNS N
in IN N
an DT N
anxiety-provoking JJ N
situation NN N
. . N

There EX N
were VBD N
a DT N
number NN N
of IN N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
interventions NNS N
to TO N
suggest VB N
parent NN N
involvement NN N
as IN N
beneficial JJ N
. . N

CONCLUSIONS VB N
The DT N
sample NN N
of IN N
children NNS N
with IN N
AS NNP N
in IN N
this DT N
study NN N
presented VBD N
with IN N
a DT N
profile NN N
of IN N
anxiety NN N
similar JJ N
to TO N
a DT N
sample NN N
of IN N
clinically RB N
diagnosed VBN N
anxious JJ N
children NNS N
. . N

The DT N
intervention NN N
was VBD N
endorsed VBN N
by IN N
parents NNS N
as IN N
a DT N
useful JJ N
programme NN N
for IN N
children NNS N
diagnosed VBN N
with IN N
Asperger NNP N
syndrome NN N
and CC N
exhibiting VBG N
anxiety NN N
symptoms NNS N
, , N
and CC N
active JJ N
parent NN N
involvement NN N
enhanced VBD N
the DT N
usefulness NN N
of IN N
the DT N
programme NN N
. . N

Limitations NNS N
of IN N
the DT N
study NN N
and CC N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
age NN N
and CC N
radiation NN 2_i
dose NN N
on IN N
local JJ N
control NN N
after IN N
breast NN 7_i
conserving NN 7_i
treatment NN 7_i
: : N
EORTC JJ N
trial NN N
22881-10882 JJ N
. . N

PURPOSE NN N
To TO N
determine VB N
whether IN N
the DT N
effect NN N
of IN N
an DT N
additional JJ N
boost NN 2_i
radiation NN 2_i
after IN N
breast NN 2_i
conservative JJ 2_i
therapy NN 2_i
( ( 2_i
BCT NNP 2_i
) ) 2_i
on IN N
local JJ N
control NN N
depends VBZ N
on IN N
age NN N
and CC N
evaluate VB N
the DT N
impact NN N
of IN N
a DT N
treatment NN N
policy NN N
with IN N
a DT N
threshold NN N
for IN N
age NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP N
used VBD N
data NNS N
from IN N
EORTC NNP N
22881-10882 JJ N
trial NN N
, , N
with IN N
median JJ N
follow-up NN N
of IN N
77.4 CD N
months NNS N
. . N

Patients NNS N
receiving VBG N
BCT NNP 2_i
and CC 2_i
50Gy CD 2_i
whole JJ 2_i
breast NN 2_i
irradiation NN 2_i
were VBD N
randomized VBN N
to TO N
no DT 2_i
boost NN 2_i
and CC 2_i
16Gy CD 2_i
boost NN 2_i
( ( N
N=5318 NNP N
) ) N
. . N

RESULTS NNP N
In IN N
univariate JJ N
analysis NN N
, , N
a DT N
boost NN 2_i
reduced VBN N
local JJ N
failure NN N
by IN N
a DT N
factor NN N
of IN N
2 CD N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Multivariate NNP N
analysis NN N
showed VBD N
local JJ N
control NN N
increased VBD N
with IN N
age NN N
( ( N
P=0.0003 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
the DT N
relative JJ N
effect NN N
of IN N
a DT N
boost NN 2_i
on IN N
local JJ N
control NN N
depends VBZ N
on IN N
age NN N
( ( N
P=0.97 NNP N
) ) N
However RB N
in IN N
younger JJR N
patients NNS N
the DT N
5-year JJ N
local JJ N
failure NN N
was VBD N
higher JJR N
, , N
therefore IN N
the DT N
absolute JJ N
reduction NN N
was VBD N
greater JJR N
. . N

If IN N
the DT N
threshold-age NN N
for IN N
boost NN N
treatment NN N
were VBD N
set VBN N
at IN N
40 CD N
years NNS N
, , N
8.4 CD N
% NN N
of IN N
the DT N
study NN N
population NN N
would MD N
receive VB N
a DT N
boost NN 2_i
, , N
resulting VBG N
in IN N
a DT N
5-year JJ N
local JJ N
failure NN N
of IN N
6.1 CD N
% NN N
in IN N
the DT N
study NN N
population NN N
. . N

Changing VBG N
the DT N
threshold-age NN N
to TO N
60 CD N
years NNS N
, , N
67 CD N
% NN N
of IN N
the DT N
study NN N
population NN N
would MD N
receive VB N
a DT N
boost NN 2_i
and CC N
the DT N
5-year JJ N
local JJ N
failure NN N
would MD N
be VB N
reduced VBN N
to TO N
4.4 CD N
% NN N
. . N

CONCLUSIONS NNP N
In IN N
younger JJR N
patients NNS N
a DT N
boost NN N
dose NN N
resulted VBD N
in IN N
a DT N
greater JJR N
absolute JJ N
reduction NN N
of IN N
local JJ N
failure NN N
. . N

The DT N
relative JJ N
risk NN N
reduction NN N
was VBD N
however RB N
similar JJ N
for IN N
all DT N
ages NNS N
. . N

Applying VBG N
a DT N
treatment NN N
policy NN N
with IN N
a DT N
threshold-age NN N
of IN N
60 CD N
would MD N
result VB N
in IN N
0.6 CD N
% NN N
increase NN N
in IN N
local JJ N
failure NN N
in IN N
the DT N
total NN N
study NN N
population NN N
, , N
while IN N
sparing VBG N
the DT N
boost NN N
to TO N
1/3 CD N
of IN N
the DT N
patients NNS N
. . N

-DOCSTART- -X- O O

A DT N
selective JJ 2_i
angiotensin NN 2_i
receptor NN 2_i
antagonist NN 2_i
, , N
Valsartan NNP 3_i
, , N
produced VBD N
regression NN N
of IN N
left JJ N
ventricular JJ N
hypertrophy NN N
associated VBN N
with IN N
a DT N
reduction NN N
of IN N
arterial JJ N
stiffness NN N
. . N

We PRP N
investigated VBD N
whether IN N
a DT N
selective JJ 3_i
angiotensin NN 3_i
II NNP 3_i
receptor NN 3_i
blocker NN 3_i
( ( 3_i
ARB NNP 3_i
) ) 3_i
would MD N
have VB N
a DT N
regressive JJ N
effect NN N
on IN N
left NN N
ventricular JJ N
hypertrophy NN N
( ( N
LVH NNP N
) ) N
in IN N
patients NNS N
on IN N
continuous JJ N
ambulatory JJ N
peritoneal JJ N
dialysis NN N
( ( N
CAPD NNP N
) ) N
. . N

In IN N
a DT N
double-blind NN N
study NN N
, , N
24 CD N
CAPD NNP N
patients NNS N
with IN N
LVH NNP N
[ NNP N
left VBD N
ventricular JJ N
mass NN N
index NN N
( ( N
LVMi NNP N
) ) N
> VBD N
110 CD N
g/m2 NN N
for IN N
women NNS N
and CC N
LVMi NNP N
> NNP N
137 CD N
g/m2 NN N
for IN N
men NNS N
] NNS N
were VBD N
randomized VBN N
to TO N
12 CD N
months NNS N
' POS N
administration NN N
of IN N
either CC N
the DT N
ARB NNP 3_i
valsartan NN 3_i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
or CC 7_i
a DT 7_i
placebo NN 7_i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
. . N

The DT N
target NN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
was VBD N
140/90 CD N
mmHg NN N
or CC N
lower JJR N
in IN N
both DT N
groups NNS N
. . N

The DT N
following JJ N
parameters NNS N
were VBD N
measured VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
: : N
aortic JJ N
and CC N
large-artery JJ N
compliance NN N
and CC N
arterial JJ N
wave NN N
reflections NNS N
[ VBP N
pulse JJ N
wave VBP N
velocity NN N
( ( N
PWV NNP N
) ) N
and CC N
augmentation NN N
index NN N
( ( N
AI NNP N
) ) N
application NN N
tonometry NN N
] NNP N
and CC N
cardiac JJ N
echocardiography NN N
. . N

Periodically RB N
recorded VBN N
were VBD N
body JJ N
weight NN N
, , N
BP NNP N
( ( N
mercury NN N
sphygmomanometer NN N
) ) N
, , N
serum JJ N
creatinine NN N
, , N
electrolytes VBZ N
, , N
complete JJ N
blood NN N
cell NN N
counts NNS N
, , N
urine JJ N
volume NN N
, , N
drainage NN N
volume NN N
, , N
and CC N
weekly JJ N
creatinine NN N
clearance NN N
. . N

Two-way JJ N
analysis NN N
of IN N
variance NN N
for IN N
repeated JJ N
measurements NNS N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

Systolic NNP N
and CC N
diastolic JJ N
BP NNP N
were VBD N
both DT N
reduced VBN N
in IN N
patients NNS N
treated VBN N
with IN N
ARB NNP N
. . N

The DT N
LVMi NNP N
was VBD N
significantly RB N
reduced VBN N
in IN N
patients NNS N
treated VBN N
with IN N
ARB NNP N
( ( N
to TO N
121 CD N
+/- JJ N
4 CD N
from IN N
145 CD N
+/- JJ N
5 CD N
) ) N
but CC N
not RB N
in IN N
those DT N
receiving VBG N
placebo NN N
( ( N
to TO N
137 CD N
+/- JJ N
3 CD N
from IN N
152 CD N
+/- JJ N
3 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
decrease NN N
in IN N
LVMi NNP N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
PWV NNP N
and CC N
AI NNP N
. . N

In IN N
CAPD NNP N
patients NNS N
with IN N
LVH NNP N
, , N
ARB NNP N
reduced VBD N
LVMi NNP N
in IN N
association NN N
with IN N
alterations NNS N
in IN N
arterial JJ N
hemodynamics NNS N
. . N

-DOCSTART- -X- O O

RESPECT-PTSD JJ N
: : N
re-engineering JJ N
systems NNS N
for IN N
the DT N
primary JJ N
care NN N
treatment NN N
of IN N
PTSD NNP N
, , N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
collaborative JJ N
care NN N
is VBZ N
effective JJ N
for IN N
treating VBG N
depression NN N
and CC N
other JJ N
mental JJ N
disorders NNS N
in IN N
primary JJ N
care NN N
, , N
there EX N
have VBP N
been VBN N
no DT N
randomized JJ N
trials NNS N
of IN N
collaborative JJ N
care NN N
specifically RB N
for IN N
patients NNS N
with IN N
Posttraumatic NNP N
stress NN N
disorder NN N
( ( N
PTSD NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
compare VB N
a DT N
collaborative JJ N
approach NN N
, , N
the DT N
Three NNP 5_i
Component NNP 5_i
Model NNP 5_i
( ( 5_i
3CM CD 5_i
) ) 5_i
, , N
with IN N
usual JJ 7_i
care NN 7_i
for IN N
treating VBG N
PTSD NNP N
in IN N
primary JJ N
care NN N
. . N

DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
two-arm JJ N
, , N
parallel JJ N
randomized VBD N
clinical JJ N
trial NN N
. . N

PTSD JJ N
patients NNS N
were VBD N
recruited VBN N
from IN N
five CD N
primary JJ N
care NN N
clinics NNS N
at IN N
four CD N
Veterans NNS N
Affairs NNP N
healthcare NN N
facilities NNS N
and CC N
randomized VBN N
to TO N
receive VB N
usual JJ 7_i
care NN 7_i
or CC 4_i
usual JJ 4_i
care NN 4_i
plus CC 4_i
3CM CD 4_i
. . N

Blinded VBN N
assessors NNS N
collected VBD N
data NNS N
at IN N
baseline NN N
and CC N
3-month JJ N
and CC N
6-month JJ N
follow-up NN N
. . N

PARTICIPANTS JJ N
Participants NNS N
were VBD N
195 CD N
Veterans NNPS N
. . N

Their PRP$ N
average JJ N
age NN N
was VBD N
45 CD N
years NNS N
, , N
91 CD N
% NN N
were VBD N
male JJ N
, , N
58 CD N
% NN N
were VBD N
white JJ N
, , N
40 CD N
% NN N
served VBN N
in IN N
Iraq NNP N
or CC N
Afghanistan NNP N
, , N
and CC N
42 CD N
% NN N
served VBD N
in IN N
Vietnam NNP N
. . N

INTERVENTION NNP N
All NNP N
participants NNS N
received VBD N
usual JJ 7_i
care NN 7_i
. . N

Participants NNS N
assigned VBD N
to TO N
3CM CD 5_i
also RB N
received VBD N
telephone NN 4_i
care NN 4_i
management NN 4_i
. . N

Care NN N
managers NNS N
received VBD N
supervision NN 4_i
from IN 4_i
a DT 4_i
psychiatrist NN 4_i
. . N

MAIN NNP N
MEASURES NNP N
PTSD NNP N
symptom NN N
severity NN N
was VBD N
the DT N
primary JJ N
outcome NN N
. . N

Depression NNP N
, , N
functioning NN N
, , N
perceived VBD N
quality NN N
of IN N
care NN N
, , N
utilization NN N
, , N
and CC N
costs NNS N
were VBD N
secondary JJ N
outcomes NNS N
. . N

KEY JJ N
RESULTS NNP N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
3CM CD N
and CC N
usual JJ N
care NN N
in IN N
symptoms NNS N
or CC N
functioning VBG N
. . N

Participants NNS N
assigned VBD N
to TO N
3CM CD 4_i
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
mental JJ N
health NN N
visit NN N
, , N
fill VB N
an DT N
antidepressant JJ N
prescription NN N
, , N
and CC N
have VBP N
adequate VBN N
antidepressant JJ N
refills NNS N
. . N

3CM CD 4_i
participants NNS N
also RB N
had VBD N
more RBR N
mental JJ N
health NN N
visits NNS N
and CC N
higher JJR N
outpatient NN N
pharmacy NN N
costs NNS N
. . N

CONCLUSIONS NNP N
Results NNP N
suggest VBP N
the DT N
need NN N
for IN N
careful JJ N
examination NN N
of IN N
the DT N
way NN N
that IN N
collaborative JJ N
care NN N
models NNS N
are VBP N
implemented VBN N
for IN N
treating VBG N
PTSD NNP N
, , N
and CC N
for IN N
additional JJ N
supports NNS N
to TO N
encourage VB N
primary JJ N
care NN N
providers NNS N
to TO N
manage VB N
PTSD NNP N
. . N

-DOCSTART- -X- O O

Esophageal JJ N
damage NN N
during IN N
radiofrequency NN 2_i
ablation NN 2_i
of IN N
atrial JJ N
fibrillation NN N
: : N
impact NN N
of IN N
energy NN N
settings NNS N
, , N
lesion NN N
sets NNS N
, , N
and CC N
esophageal JJ N
visualization NN N
. . N

INTRODUCTION NNP N
Atrioesophageal NNP N
fistula NN N
is VBZ N
an DT N
uncommon JJ N
but CC N
often RB N
lethal JJ N
complication NN N
of IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
ablation NN N
. . N

The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
prospectively RB N
investigate VB N
the DT N
incidence NN N
of IN N
esophageal JJ N
ulcerations NNS N
( ( N
ESUL NNP N
) ) N
as RB N
well RB N
as IN N
the DT N
impact NN N
of IN N
energy NN N
settings NNS N
, , N
radiofrequency NN N
lesion NN N
sets NNS N
, , N
and CC N
direct JJ N
visualization NN N
of IN N
the DT N
esophagus NN N
on IN N
esophageal NN N
wall JJ N
injury NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
One CD N
hundred VBD N
seventy-five JJ N
patients NNS N
, , N
57.1 CD N
% NN N
paroxysmal JJ N
AF NNP N
, , N
78.5 CD N
% NN N
male NN N
, , N
underwent JJ N
AF NNP 2_i
ablation NN 2_i
and CC N
esophagoscopy $ 2_i
24 CD N
hours NNS N
thereafter RB N
. . N

We PRP N
performed VBD N
a DT N
2:1:1-randomization JJ N
as IN N
follows VBZ N
: : N
CONTROL NNP N
GROUP NNP N
Ablation NNP 2_i
without IN 2_i
visualization NN 2_i
of IN 2_i
the DT 2_i
esophagus NN 2_i
using VBG N
25 CD N
Watt NNP N
( ( N
W NNP N
) ) N
power NN N
limit NN N
on IN N
the DT N
posterior NN N
wall NN N
, , N
n JJ N
= NN N
70 CD N
. . N

Visualization NN N
and CC N
15 CD N
W NNP N
maximum NN N
: : N
Ablation NN 1_i
guided VBN 1_i
by IN 1_i
barium NN 1_i
visualization NN 1_i
of IN N
the DT N
esophageal JJ N
course NN N
using VBG N
a DT N
limit NN N
of IN N
15 CD N
W NNP N
, , N
n JJ N
= NN N
35 CD N
. . N

Visualization NN N
and CC N
25 CD N
W NNP N
short JJ N
burns NNS N
: : N
Ablation NN 2_i
guided VBN 2_i
by IN 2_i
barium NN 2_i
visualization NN 2_i
using VBG 2_i
25 CD 2_i
W NNP 2_i
and CC 2_i
short JJ 2_i
burns NNS 2_i
( ( N
max NN N
. . N

5 CD N
sec NN N
) ) N
, , N
n JJ N
= NN N
35 CD N
. . N

Patients NNS N
performed VBN N
under IN N
general JJ N
anesthesia NN N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
were VBD N
separated VBN N
as IN N
a DT N
nasogastric JJ N
tube NN N
for IN N
visualization NN N
of IN N
the DT N
esophagus NN N
was VBD N
used VBN N
. . N

In IN N
total JJ N
, , N
we PRP N
found VBD N
2.9 CD N
% NN N
of IN N
patients NNS N
( ( N
5/175 CD N
) ) N
presenting NN N
ESUL NNP N
. . N

Parameters NNS N
discriminating VBG N
the DT N
development NN N
of IN N
ESUL NNP N
in IN N
a DT N
specific JJ N
patient NN N
were VBD N
type NN N
of IN N
AF NNP N
, , N
maximum JJ N
energy NN N
delivered VBN N
, , N
usage NN N
of IN N
a DT N
nasogastric JJ N
tube NN N
, , N
and CC N
additional JJ N
left NN N
atrial JJ N
lines NNS N
. . N

Visualization NN N
of IN N
the DT N
esophageal JJ N
course NN N
by IN N
barium NN N
contrast NN N
was VBD N
not RB N
able JJ N
to TO N
prevent VB N
ESUL NNP N
. . N

CONCLUSION NNP N
ESUL NNP N
is VBZ N
a DT N
rare JJ N
finding NN N
when WRB N
using VBG N
a DT N
reasonable JJ N
energy NN N
maximum NN N
of IN N
25 CD N
W NNP N
with IN N
open-irrigated JJ N
tip NN N
catheters NNS N
at IN N
the DT N
posterior JJ N
wall NN N
. . N

Lower NNP N
energy NN N
settings NNS N
may MD N
increase VB N
safety NN N
without IN N
losing VBG N
efficacy NN N
. . N

Additional JJ N
linear JJ N
radiofrequency NN N
lesions NNS N
increase VBP N
the DT N
risk NN N
of IN N
ESUL NNP N
development NN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ 3_i
enzyme NN 3_i
inhibitor NN 3_i
imidapril NN 3_i
on IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

This DT N
study NN N
sought VBD N
to TO N
determine VB N
whether IN N
early JJ N
treatment NN N
with IN N
angiotensin-converting JJ 3_i
enzyme NN 3_i
( ( 3_i
ACE NNP 3_i
) ) 3_i
inhibitors NNS 3_i
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
is VBZ N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ N
function NN N
, , N
as RB N
well RB N
as IN N
left VBN N
ventricular JJ N
function NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
levels NNS N
of IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
( ( N
PAI NNP N
) ) N
activity NN N
and CC N
serum JJ N
ACE NNP N
activity NN N
during IN N
the DT N
course NN N
of IN N
2 CD N
weeks NNS N
in IN N
40 CD N
patients NNS N
with IN N
AMI NNP N
within IN N
12 CD N
hours NNS N
after IN N
the DT N
onset NN N
of IN N
the DT N
symptom NN N
and CC N
who WP N
randomly VBP N
received VBN N
early JJ N
treatment NN N
with IN N
either CC N
the DT N
ACE NNP 3_i
inhibitor NN 3_i
imidapril NN 3_i
or CC N
a DT N
placebo NN 7_i
( ( N
20 CD N
patients NNS N
in IN N
the DT N
imidapril NN N
group NN N
and CC N
20 CD N
in IN N
the DT N
placebo NN N
group NN N
) ) N
. . N

The DT N
levels NNS N
of IN N
serum JJ N
ACE NNP N
activity NN N
in IN N
the DT N
imidapril NN 3_i
group NN N
decreased VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
8 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN 3_i
, , N
and CC N
the DT N
levels NNS N
24 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN 7_i
group NN N
( ( N
3.6 CD N
+/- JJ N
0.6 CD N
IU/L NNP N
vs VBD N
7.4 CD N
+/- JJ N
0.8 CD N
IU/L NNP N
; : N
p VBZ N
< $ N
0.001 CD N
) ) N
. . N

The DT N
plasma JJ N
PAI NNP N
activity NN N
increased VBD N
gradually RB N
to TO N
peak VB N
levels NNS N
16 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN N
and CC N
placebo NN N
. . N

The DT N
levels NNS N
in IN N
the DT N
placebo NN N
group NN N
decreased VBD N
gradually RB N
but CC N
remained VBD N
high JJ N
during IN N
the DT N
study NN N
period NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
levels NNS N
of IN N
PAI NNP N
activity NN N
in IN N
the DT N
imidapril NN 3_i
group NN N
decreased VBD N
rapidly RB N
and CC N
those DT N
48 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN 7_i
group NN N
( ( N
7.9 CD N
+/- JJ N
1.9 CD N
IU/ml NNP N
vs VBD N
18.4 CD N
+/- JJ N
3.5 CD N
IU/ml NNP N
; : N
p VBZ N
< $ N
0.01 CD N
) ) N
. . N

The DT N
levels NNS N
of IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
about IN N
2 CD N
weeks NNS N
after IN N
admission NN N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
imidapril NN N
group NN N
than IN N
in IN N
the DT N
placebo NN 7_i
group NN N
( ( N
65.9 CD N
% NN N
+/- JJ N
2.5 CD N
% NN N
vs JJ N
49.1 CD N
% NN N
+/- JJ N
4.4 CD N
% NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

This DT N
study NN N
showed VBD N
that IN N
imidapril NN 3_i
, , N
an DT N
ACE NNP N
inhibitor NN N
, , N
might MD N
be VB N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ N
function NN N
and CC N
left VBD N
ventricular JJ N
function NN N
in IN N
the DT N
acute JJ N
phase NN N
of IN N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
single JJ N
dose NN N
intranasal NN N
oxytocin NN 3_i
on IN N
social JJ N
cognition NN N
in IN N
schizophrenia NN N
. . N

Deficits NNS N
in IN N
social JJ N
cognition NN N
are VBP N
common JJ N
in IN N
schizophrenia NN N
and CC N
predict JJ N
poor JJ N
community NN N
functioning NN N
. . N

Given VBN N
the DT N
current JJ N
limitations NNS N
of IN N
psychosocial JJ N
treatments NNS N
and CC N
the DT N
lack NN N
of IN N
pharmacological JJ N
treatments NNS N
for IN N
social JJ N
cognitive JJ N
deficits NNS N
, , N
the DT N
development NN N
of IN N
novel JJ N
therapeutic JJ N
agents NNS N
could MD N
greatly RB N
enhance VB N
functional JJ N
recovery NN N
in IN N
schizophrenia NN N
. . N

This DT N
study NN N
evaluated VBD N
whether IN N
a DT N
single JJ N
dose NN N
of IN N
intranasal JJ N
oxytocin FW 3_i
acutely RB N
improves VBZ N
social JJ N
cognitive JJ N
functioning NN N
in IN N
schizophrenia NN N
. . N

Twenty-three JJ N
male JJ N
veterans NNS N
with IN N
schizophrenia NN N
completed VBN N
baseline JJ N
assessments NNS N
of IN N
social JJ N
cognition NN N
that WDT N
were VBD N
divided VBN N
into IN N
lower-level JJ N
( ( N
facial JJ N
affect NN N
perception NN N
, , N
social JJ N
perception NN N
, , N
detection NN N
of IN N
lies NNS N
) ) N
and CC N
higher-level JJ N
( ( N
detection NN N
of IN N
sarcasm NN N
and CC N
deception NN N
, , N
empathy NN N
) ) N
processes VBZ N
. . N

One CD N
week NN N
later RB N
, , N
patients NNS N
received VBD N
the DT N
same JJ N
battery NN N
after IN N
being VBG N
randomized VBN N
to TO N
a DT N
single JJ N
dose NN N
of IN N
40 CD N
IU NNP N
intranasal NN 3_i
oxytocin NN 3_i
or CC N
placebo NN 7_i
. . N

Though IN N
the DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
on IN N
the DT N
social JJ N
cognition NN N
composite JJ N
score NN N
, , N
oxytocin RB N
improved VBN N
performance NN N
for IN N
the DT N
higher-level JJ N
social JJ N
cognitive NN N
tasks NNS N
( ( N
Cohen NNP N
's POS N
d=1.0 NN N
, , N
p=0.045 NN N
) ) N
. . N

Subjects NNS N
were VBD N
unable JJ N
to TO N
accurately RB N
guess VB N
which WDT N
treatment NN N
they PRP N
had VBD N
received VBN N
. . N

The DT N
improvements NNS N
found VBN N
in IN N
higher-level JJ N
social JJ N
cognition NN N
encourage VB N
further JJ N
studies NNS N
into IN N
the DT N
therapeutic JJ N
potential NN N
of IN N
oxytocin NN N
in IN N
schizophrenia NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
to TO N
assess VB N
5 CD N
% NN N
imiquimod JJ 3_i
cream NN 3_i
for IN N
the DT N
treatment NN N
of IN N
multiple JJ N
actinic JJ N
keratoses NNS N
. . N

BACKGROUND NNP N
Actinic NNP N
keratoses NNS N
( ( N
AKs NNP N
) ) N
are VBP N
precancerous JJ N
epidermal JJ N
lesions NNS N
found VBD N
most JJS N
frequently RB N
on IN N
areas NNS N
of IN N
the DT N
skin NN N
exposed VBD N
to TO N
the DT N
sun NN N
. . N

Several JJ N
case NN N
studies NNS N
published VBN N
recently RB N
have VBP N
indicated VBN N
that IN N
5 CD N
% NN N
imiquimod JJ N
cream NN N
, , N
currently RB N
licensed VBN N
for IN N
the DT N
treatment NN N
of IN N
genital JJ N
warts NNS N
, , N
may MD N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
AK NNP N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
imiquimod NN N
for IN N
the DT N
treatment NN N
of IN N
AK NNP N
. . N

DESIGN NNP N
Patients NNPS N
in IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
applied VBD N
5 CD N
% NN N
imiquimod JJ 3_i
cream NN 3_i
or CC N
vehicle NN N
to TO N
AK NNP N
lesions NNS N
3 CD N
times NNS N
per IN N
week NN N
for IN N
a DT N
maximum NN N
of IN N
12 CD N
weeks NNS N
or CC N
until IN N
lesions NNS N
had VBD N
resolved VBN N
. . N

In IN N
the DT N
event NN N
of IN N
an DT N
adverse JJ N
reaction NN N
, , N
application NN N
of IN N
imiquimod NN 3_i
was VBD N
reduced VBN N
to TO N
1 CD N
or CC N
2 CD N
times NNS N
per IN N
week NN N
. . N

Rest JJS N
periods NNS N
were VBD N
also RB N
allowed VBN N
if IN N
necessary JJ N
. . N

SETTING VB N
A DT N
specialized JJ N
outpatient NN N
dermatology NN N
clinic NN N
within IN N
a DT N
state-funded JJ N
hospital NN N
in IN N
Germany NNP N
. . N

PATIENTS VB N
The DT N
study NN N
population NN N
was VBD N
aged VBN N
45 CD N
to TO N
85 CD N
years NNS N
. . N

Of IN N
52 CD N
patients NNS N
screened VBD N
, , N
36 CD N
men NNS N
and CC N
women NNS N
with IN N
AK NNP N
confirmed VBN N
by IN N
histological JJ N
diagnosis NN N
were VBD N
enrolled VBN N
. . N

Patients NNS N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
if IN N
they PRP N
did VBD N
not RB N
have VB N
a DT N
histological JJ N
diagnosis NN N
for IN N
AK NNP N
, , N
if IN N
they PRP N
were VBD N
older JJR N
than IN N
85 CD N
years NNS N
, , N
or CC N
if IN N
they PRP N
did VBD N
not RB N
comply VB N
with IN N
the DT N
protocol NN N
. . N

All DT N
patients NNS N
had VBD N
responded VBN N
to TO N
a DT N
notice NN N
asking VBG N
for IN N
volunteers NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
number NN N
and CC N
appearance NN N
of IN N
lesions NNS N
were VBD N
evaluated VBN N
before RB N
, , N
during IN N
, , N
and CC N
after IN N
treatment NN N
. . N

All DT N
adverse JJ N
effects NNS N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Lesions NNP N
treated VBD N
with IN N
5 CD N
% NN N
imiquimod JJ 3_i
cream NN 3_i
were VBD N
clinically RB N
cleared VBN N
in IN N
21 CD N
( ( N
84 CD N
% NN N
) ) N
of IN N
25 CD N
patients NNS N
and CC N
partially RB N
cleared VBN N
in IN N
2 CD N
( ( N
8 CD N
% NN N
) ) N
. . N

Clearance NN N
was VBD N
histologically RB N
confirmed VBN N
2 CD N
weeks NNS N
after IN N
the DT N
last JJ N
application NN N
of IN N
imiquimod NN 3_i
in IN N
all DT N
patients NNS N
clinically RB N
diagnosed VBN N
as IN N
lesion NN N
free NN N
. . N

Only RB N
10 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
imiquimod NN N
were VBD N
clinically RB N
diagnosed VBN N
with IN N
recurrence NN N
1 CD N
year NN N
after IN N
treatment NN N
. . N

No DT N
reduction NN N
in IN N
the DT N
size NN N
or CC N
number NN N
of IN N
AK NNP N
lesions NNS N
was VBD N
observed VBN N
in IN N
vehicle-treated JJ N
patients NNS N
. . N

Adverse JJ N
effects NNS N
reported VBN N
by IN N
patients NNS N
treated VBN N
with IN N
imiquimod NN 3_i
included VBD N
erythema NN N
, , N
edema NN N
, , N
induration NN N
, , N
vesicles NNS N
, , N
erosion NN N
, , N
ulceration NN N
, , N
excoriation NN N
, , N
and CC N
scabbing VBG N
. . N

However RB N
, , N
imiquimod NN 3_i
was VBD N
well RB N
tolerated VBN N
since IN N
all DT N
patients NNS N
completed VBD N
the DT N
12-week JJ N
treatment NN N
. . N

Only RB N
a DT N
few JJ N
, , N
mild JJ N
adverse JJ N
reactions NNS N
to TO N
the DT N
vehicle NN N
cream NN N
were VBD N
reported VBN N
. . N

CONCLUSION NNP N
Application NNP N
of IN N
5 CD N
% NN N
imiquimod JJ 3_i
cream NN 3_i
for IN N
12 CD N
weeks NNS N
is VBZ N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
AK NNP N
. . N

-DOCSTART- -X- O O

Faux NNP 4_i
pas CC 4_i
detection NN 4_i
and CC N
intentional JJ N
action NN N
in IN N
Asperger NNP N
Syndrome NNP N
. . N

A DT N
replication NN N
on IN N
a DT N
French JJ N
sample NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
investigated VBD N
mind NN N
reading NN N
abilities NNS N
in IN N
a DT N
group NN N
of IN N
adults NNS N
with IN N
Asperger NNP N
Syndrome NNP N
( ( N
AS IN N
) ) N
by IN N
using VBG N
the DT N
faux JJ 4_i
pas NN 4_i
task NN 4_i
, , 4_i
an DT 4_i
advanced JJ 4_i
test NN 4_i
of IN 4_i
theory NN 4_i
of IN 4_i
mind NN 4_i
( ( N
Baron-Cohen NNP N
et RB N
al RB N
. . N

( ( N
1999 CD N
) ) N
. . N

Journal NNP N
of IN N
Autism NNP N
and CC N
Developmental NNP N
Disorders NNP N
, , N
29 CD N
, , N
407-418 JJ N
) ) N
. . N

The DT N
faux JJ 4_i
pas NN 4_i
is VBZ N
a DT N
particular JJ N
case NN N
of IN N
a DT N
non-intentional JJ N
action NN N
reflecting VBG N
an DT N
involuntary JJ N
socially RB N
inappropriate JJ N
behavior NN N
. . N

Here RB N
, , N
individuals NNS N
with IN N
AS NNP N
over-detected JJ N
faux NN 4_i
pas NN 4_i
stories NNS N
, , N
failed VBD N
to TO N
provide VB N
correct JJ N
justifications NNS N
of IN N
the DT N
speaker NN N
's POS N
behavior NN N
and CC N
were VBD N
unaware NN N
of IN N
the DT N
mistaken JJ N
belief NN N
and CC N
of IN N
the DT N
resulting JJ N
emotional JJ N
impact NN N
, , N
whereas IN N
they PRP N
appeared VBD N
to TO N
be VB N
responsive JJ N
to TO N
social JJ N
rule NN N
violations NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
because IN N
of IN N
an DT N
impaired JJ N
theory-of-mind NN N
, , N
individuals NNS N
with IN N
AS NNP N
may MD N
develop VB N
compensatory JJ N
cognitive JJ N
strategies NNS N
based VBN N
on IN N
overlearned JJ N
abstract JJ N
knowledge NN N
about IN N
normative JJ N
rules NNS N
. . N

-DOCSTART- -X- O O

Short-term JJ N
metabolic NN N
and CC N
cardiovascular JJ N
effects NNS N
of IN N
metformin NN 3_i
in IN N
markedly RB N
obese JJ N
adolescents NNS N
with IN N
normal JJ N
glucose JJ N
tolerance NN N
. . N

OBJECTIVE CC N
Although IN N
metformin NN 3_i
( ( N
MET NNP N
) ) N
is VBZ N
an DT N
insulin JJ N
sensitizer NN N
currently RB N
used VBN N
as IN N
an DT N
adjunct NN N
to TO N
the DT N
treatment NN N
of IN N
some DT N
of IN N
the DT N
complications NNS N
of IN N
childhood NN N
obesity NN N
besides IN N
type JJ N
2 CD N
diabetes NNS N
mellitus NN N
, , N
few JJ N
studies NNS N
have VBP N
comprehensively RB N
examined VBN N
its PRP$ N
metabolic NN N
and CC N
clinical JJ N
effects NNS N
in IN N
obese JJ N
children NNS N
with IN N
normal JJ N
glucose JJ N
tolerance NN N
( ( N
NGT NNP N
) ) N
. . N

METHODS NNP N
We PRP N
therefore RB N
conducted VBD N
a DT N
4-month JJ N
double-blind JJ N
clinical JJ N
trial NN N
in IN N
28 CD N
obese JJ N
[ JJ N
mean NN N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
: : N
40.3 CD N
+/- JJ N
5.7 CD N
kg/m NN N
( ( N
2 CD N
) ) N
] NN N
, , N
insulin-resistant JJ N
[ JJ N
homeostasis NN N
model NN N
assessment JJ N
- : N
insulin NN N
resistance NN N
: : N
7.6 CD N
+/- JJ N
2.8 CD N
and CC N
whole JJ N
body NN N
insulin JJ N
sensitivity NN N
index NN N
( ( N
WBISI NNP N
) ) N
: : N
1.5 CD N
+/- JJ N
0.7 CD N
] JJ N
adolescents NNS N
( ( N
age NN N
15.0 CD N
+/- JJ N
1.3 CD N
yr NN N
) ) N
randomized VBD N
to TO N
MET NNP N
( ( N
n JJ N
= NN N
15 CD N
, , N
dose JJ N
1500 CD N
mg JJ N
daily JJ N
) ) N
or CC N
placebo NN 7_i
( ( N
n JJ N
= NNP N
13 CD N
) ) N
. . N

RESULTS VB N
The DT N
treatment NN N
with IN N
MET NNP N
was VBD N
well RB N
tolerated VBN N
. . N

MET NNP N
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
BMI NNP N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
as RB N
well RB N
as IN N
with IN N
a DT N
reduction NN N
in IN N
subcutaneous JJ N
fat NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
, , N
particularly RB N
the DT N
deep JJ N
subcutaneous JJ N
fat NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
as IN N
assessed VBN N
by IN N
magnetic JJ N
resonance NN N
imaging NN N
. . N

Postintervention NN N
, , N
the DT N
MET NNP N
group NN N
had VBD N
a DT N
35 CD N
% NN N
improvement NN N
in IN N
insulin NN N
sensitivity NN N
( ( N
WBISI NNP N
) ) N
compared VBN N
with IN N
the DT N
placebo NN 7_i
group NN N
( ( N
p JJ N
= NNP N
0.008 CD N
) ) N
. . N

However RB N
, , N
significance NN N
was VBD N
lost VBN N
with IN N
adjustments NNS N
for IN N
differences NNS N
in IN N
baseline JJ N
insulin NN N
sensitivity NN N
( ( N
p JJ N
= NNP N
0.09 CD N
) ) N
. . N

While IN N
there EX N
was VBD N
no DT N
change NN N
in IN N
inflammatory JJ N
cytokines NNS N
or CC N
lipid JJ N
parameters NNS N
, , N
cardiovascular JJ N
function NN N
as IN N
assessed VBN N
by IN N
heart NN N
rate NN N
recovery NN N
after IN N
exercise NN N
improved VBN N
with IN N
MET NNP N
and CC N
worsened VBN N
in IN N
placebo NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSION NNP N
Short-term NNP N
use NN N
of IN N
MET NNP N
is VBZ N
well RB N
tolerated VBN N
by IN N
obese JJ N
children NNS N
with IN N
NGT NNP N
and CC N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
BMI NNP N
and CC N
autonomic JJ N
control NN N
of IN N
the DT N
heart NN N
as RB N
well RB N
as IN N
a DT N
trend NN N
toward IN N
improved JJ N
insulin NN N
sensitivity NN N
. . N

Thus RB N
, , N
long-term JJ N
treatment NN N
with IN N
MET NNP N
may MD N
provide VB N
a DT N
means NN N
to TO N
ameliorate VB N
the DT N
cardio-metabolic JJ N
consequences NNS N
of IN N
adolescent JJ N
obesity NN N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
placebo-controlled JJ 7_i
study NN N
to TO N
evaluate VB N
valacyclovir NN 3_i
alone RB 3_i
and CC N
with IN N
aspirin NN 3_i
for IN N
asymptomatic JJ N
HSV-1 NNP N
DNA NNP N
shedding VBG N
in IN N
human JJ N
tears NNS N
and CC N
saliva NN N
. . N

PURPOSE NNP N
To TO N
test VB N
the DT N
effect NN N
of IN N
valacyclovir NN 3_i
alone RB 3_i
and CC N
with IN N
aspirin NN 3_i
on IN N
the DT N
asymptomatic JJ N
shedding NN N
of IN N
HSV-1 NNP N
DNA NNP N
in IN N
tears NNS N
and CC N
saliva NN N
of IN N
healthy JJ N
individuals NNS N
. . N

METHOD NNP N
. . N

The DT N
subjects NNS N
( ( N
n JJ N
= NNP N
45 CD N
) ) N
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
without IN N
regard NN N
to TO N
age NN N
, , N
sex NN N
, , N
or CC N
race NN N
. . N

Group NNP N
1 CD N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
received VBD N
the DT N
placebo NN 7_i
, , N
group NN N
2 CD N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
received VBD N
a DT N
dose NN N
of IN N
500 CD 3_i
mg NNS 3_i
valacyclovir JJ 3_i
once RB 3_i
daily JJ 3_i
, , N
and CC N
group NN N
3 CD N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
received VBD N
a DT N
dose NN N
of IN N
500 CD 3_i
mg NNS 3_i
valacyclovir JJ 3_i
once RB 3_i
daily JJ 3_i
and CC N
350 CD 3_i
mg NN 3_i
aspirin JJ 3_i
twice RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

Ocular JJ N
and CC N
oral JJ N
swabs NNS N
were VBD N
collected VBN N
twice RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

DNA NN N
was VBD N
extracted VBN N
from IN N
all DT N
swabs NNS N
and CC N
HSV-1 NNP N
DNA NNP N
copy NN N
numbers NNS N
were VBD N
determined VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
to TO N
compare VB N
the DT N
DNA NNP N
copy NN N
numbers NNS N
of IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
HSV-1 NNP N
DNA NNP N
copy NN N
numbers NNS N
in IN N
the DT N
tears NNS N
or CC N
saliva NN N
among IN N
any DT N
of IN N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
mean JJ N
copy NN N
numbers NNS N
+/- JJ N
SE NNP N
of IN N
mean NN N
( ( N
SEM NNP N
) ) N
of IN N
HSV-1 NNP N
DNA NNP N
in IN N
tears NNS N
were VBD N
340 CD N
+/- JJ N
35 CD N
, , N
1074 CD N
+/- JJ N
320 CD N
, , N
and CC N
630 CD N
+/- JJ N
51 CD N
for IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
and CC N
in IN N
saliva NN N
were VBD N
238 CD N
+/- JJ N
35 CD N
, , N
963 CD N
+/- JJ N
462 CD N
, , N
and CC N
493 CD N
+/- JJ N
25 CD N
, , N
respectively RB N
, , N
for IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
. . N

CONCLUSIONS NNP N
No NNP N
correlation NN N
was VBD N
found VBN N
between IN N
HSV-1 NNP N
shedding VBG N
and CC N
valacyclovir NNS 3_i
and CC N
valacyclovir NN 3_i
with IN 3_i
aspirin JJ 3_i
treatment NN N
. . N

The DT N
HSV-1 NNP N
DNA NNP N
copy NN N
number NN N
was VBD N
not RB N
reduced VBN N
by IN N
treatment NN N
with IN N
500 CD N
mg NNS N
of IN N
valacyclovir JJ 3_i
daily JJ N
or CC N
with IN N
a DT N
combination NN N
of IN N
daily JJ N
valacyclovir NN 3_i
( ( N
500 CD N
mg NN N
) ) N
plus CC N
twice-daily JJ N
doses NNS N
of IN N
aspirin NN 3_i
( ( N
350 CD N
mg NN N
) ) N
over IN N
30 CD N
days NNS N
. . N

-DOCSTART- -X- O O

[ RB N
Intravenous JJ N
treatment NN N
of IN N
postpartum NN N
anemia NN N
with IN N
trivalent JJ 3_i
ferrum NN 3_i
preparation NN 3_i
] NNP N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
assess VB N
the DT N
effectivity NN N
and CC N
safeness NN N
of IN N
intravenous JJ N
treatment NN N
of IN N
pospartal JJ N
anemia NN N
with IN N
trivalent JJ 3_i
ferrum NN 3_i
preparation NN 3_i
. . N

TYPE NNP N
OF IN N
THE NNP N
STUDY NNP N
Prospective NNP N
randomized VBD N
study NN N
. . N

SETTING NNP N
Department NNP N
of IN N
Obstetric NNP N
and CC N
Gynecology NNP N
2nd CD N
Medical NNP N
Faculty NNP N
Charles NNP N
University NNP N
and CC N
Teaching NNP N
Hospital NNP N
Motol NNP N
, , N
Prague NNP N
, , N
and CC N
Department NNP N
of IN N
Obstetric NNP N
and CC N
Gynecology NNP N
1st CD N
Medical NNP N
Faculty NNP N
and CC N
Teaching NNP N
Hospital NNP N
Bulovka NNP N
, , N
Prague NNP N
. . N

METHODS NNP N
500 CD 3_i
mg NN 3_i
of IN 3_i
sacharose JJ 3_i
ferric JJ 3_i
oxide NN 3_i
( ( 3_i
Venofer NNP 3_i
) ) 3_i
was VBD N
intravenously RB N
administered VBN N
in IN N
two CD N
days NNS N
regimen NNS N
to TO N
50 CD N
women NNS N
with IN N
clinical JJ N
and CC N
lab JJ N
signs NNS N
of IN N
postpartal JJ N
anemia NN N
. . N

The DT N
effect NN N
of IN N
administered JJ N
drug NN N
was VBD N
determined VBN N
by IN N
comparsion NN N
of IN N
values NNS N
of IN N
red JJ N
blood NN N
count NN N
recovered VBD N
before IN N
the DT N
treatment NN N
, , N
2nd CD N
or CC N
3rd CD N
day NN N
post NN N
administration NN N
and CC N
two CD N
weeks NNS N
later RB N
. . N

The DT N
serum NN N
values NNS N
of IN N
soluble JJ N
transferrin NN N
receptors NNS N
and CC N
ferritin NNS N
were VBD N
observed VBN N
as IN N
markers NNS N
of IN N
iron NN N
cell NN N
saturation NN N
and CC N
body NN N
iron NN N
reserves NNS N
, , N
too RB N
. . N

Integral JJ N
part NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
monitoring NN N
of IN N
adverse JJ N
events NNS N
during IN N
the DT N
treatment NN N
. . N

RESULTS NNP N
Venofer NNP 3_i
came VBD N
in IN N
sight NN N
as IN N
effective JJ N
drug NN N
in IN N
the DT N
treatment NN N
of IN N
pospartal JJ N
anemia NN N
and CC N
could MD N
become VB N
as IN N
the DT N
alternative NN N
to TO N
blood VB N
transfusion NN N
in IN N
mid-severe JJ N
cases NNS N
. . N

It PRP N
should MD N
be VB N
emphasized VBN N
that IN N
we PRP N
have VBP N
not RB N
encountered VBN N
any DT N
serious JJ N
adverse JJ N
event NN N
with IN N
intravenous JJ N
trivalent NN 3_i
saccharose VBD 3_i
ferric JJ 3_i
oxide JJ 3_i
treatment NN 3_i
. . N

-DOCSTART- -X- O O

[ NN N
Study NNP N
on IN N
safety NN N
and CC N
immunogenicity NN N
of IN N
oral JJ 3_i
poliomyelitis NN 3_i
attenuated VBD 3_i
live JJ 3_i
vaccine NN 3_i
( ( N
human JJ N
diploid NN N
cell NN N
) ) N
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN N
and CC N
Immunogenicity NNP N
of IN N
the DT N
Poliomyelitis NNP 3_i
vaccine NN 3_i
( ( N
Human NNP N
Diploid NNP N
Cell NNP N
) ) N
in IN N
> NN N
or CC N
=2 VB N
month-old JJ N
children NNS N
. . N

METHODS NNP N
A NNP N
random NN N
, , N
blind NN N
and CC N
control NN N
trial NN N
, , N
1200 CD N
healthy JJ N
children NNS N
of IN N
2-5 JJ N
months NNS N
old JJ N
in IN N
Jiangsu NNP N
province NN N
were VBD N
administered VBN N
OPV NNP 3_i
( ( 3_i
HDC NNP 3_i
) ) 3_i
vaccine NN 3_i
and CC N
control NN 3_i
vaccines NNS 3_i
. . N

The DT N
antibody NN N
was VBD N
tested VBN N
by IN N
neutralization NN N
test NN N
. . N

RESULTS NNP N
After IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP 3_i
( ( 3_i
HDC NNP 3_i
) ) 3_i
vaccine NN 3_i
, , N
the DT N
systemic JJ N
reactions NNS N
were VBD N
mild JJ N
. . N

After IN N
1 CD N
month NN N
of IN N
vaccination NN N
with IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP 3_i
( ( 3_i
HDC NNP 3_i
) ) 3_i
vaccine NN 3_i
, , N
the DT N
immune JJ N
success NN N
rates NNS N
of IN N
I PRP N
, , N
II NNP N
, , N
III NNP N
type NN N
were VBD N
98.28 CD N
% NN N
, , N
99.45 CD N
% NN N
, , N
and CC N
95.71 CD N
% NN N
respectively RB N
, , N
the DT N
GMTs NNP N
of IN N
I PRP N
, , N
II NNP N
, , N
III NNP N
type NN N
in IN N
susceptible JJ N
children NNS N
were VBD N
1:1243.72 CD N
, , N
1:234.38 CD N
and CC N
1:273.10 CD N
respectively RB N
. . N

CONCLUSIONS VB N
The DT N
OPV NNP 3_i
( ( 3_i
HDC NNP 3_i
) ) 3_i
vaccine NN 3_i
was VBD N
safe JJ N
and CC N
immunogenicity NN N
for IN N
the DT N
children NNS N
> VBP N
or CC N
=2 JJ N
months NNS N
old JJ N
. . N

-DOCSTART- -X- O O

Pain NN N
relief NN N
can MD N
reduce VB N
hypoxemia NN N
in IN N
distressed JJ N
neonates NNS N
during IN N
routine JJ N
treatment NN N
procedures NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
opioids NNS 3_i
could MD N
reduce VB N
the DT N
hypoxemia NN N
and CC N
hemodynamic JJ N
instability NN N
associated VBN N
with IN N
routine JJ N
intensive JJ N
care NN N
procedures NNS N
in IN N
neonates NNS N
with IN N
respiratory JJ N
distress NN N
. . N

DESIGN NNP N
Randomized NNP N
and CC N
placebo-controlled JJ 7_i
study NN N
. . N

METHODS NNP N
Physiological NNP N
, , N
plasma JJ N
beta-endorphin NN N
, , N
cortisol NN N
, , N
and CC N
glucose JJ N
responses NNS N
to TO N
routine VB N
treatment NN N
procedures NNS N
were VBD N
studied VBN N
in IN N
84 CD N
mechanically RB N
ventilated VBN N
distressed JJ N
neonates NNS N
randomized VBN N
into IN N
groups NNS N
receiving VBG N
1 CD 3_i
mg/kg JJ 3_i
meperidine NN 3_i
or CC N
0.9 CD 7_i
% NN 7_i
saline NN 7_i
15 CD N
minutes NNS N
before IN N
tracheal JJ 2_i
suction NN 2_i
or CC N
routine JJ 2_i
nursing NN 2_i
care NN 2_i
. . N

RESULTS VB N
The DT N
duration NN N
of IN N
hypoxemia NN N
( ( N
transcutaneous JJ N
partial JJ N
pressure NN N
of IN N
O2 NNP N
< NNP N
6.6 CD N
kPa NN N
( ( N
< JJ N
50 CD N
mm NN N
Hg NNP N
) ) N
and/or VBP N
arterial JJ N
blood NN N
oxygen NN N
saturation NN N
< VBD N
80 CD N
% NN N
) ) N
during IN N
treatment NN N
procedures NNS N
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
saline NN N
group NN N
( ( N
mean JJ N
82 CD N
vs NN N
36 CD N
seconds NNS N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
and CC N
distress JJ N
quantified VBN N
by IN N
a DT N
novel JJ N
behavioral JJ N
scoring VBG N
method NN N
was VBD N
much RB N
higher JJR N
. . N

Changes NNS N
in IN N
arterial JJ N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
or CC N
plasma VB N
beta-endorphin JJ N
, , N
cortisol NN N
, , N
and CC N
glucose JJ N
concentration NN N
did VBD N
not RB N
show VB N
any DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
Newborns NNP N
with IN N
respiratory JJ N
difficulties NNS N
often RB N
suffer VBP N
from IN N
hypoxemia NN N
during IN N
essential JJ N
treatment NN N
procedures NNS N
. . N

The DT N
use NN N
of IN N
opioid JJ 3_i
analgesia NN 3_i
may MD N
reduce VB N
the DT N
duration NN N
of IN N
hypoxemia NN N
and CC N
the DT N
associated JJ N
distress NN N
and CC N
, , N
therefore RB N
, , N
may MD N
improve VB N
the DT N
long-term JJ N
results NNS N
of IN N
neonatal JJ N
intensive JJ N
care NN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
nonpharmacologic JJ 4_i
methods NNS 4_i
of IN N
pain NN 2_i
and CC 2_i
anxiety NN 2_i
management NN 2_i
for IN N
laceration NN N
repair NN N
in IN N
the DT N
pediatric JJ N
emergency NN N
department NN N
. . N

BACKGROUND NNP N
Nonpharmacologic NNP 4_i
interventions NNS 4_i
, , 4_i
such JJ 4_i
as IN 4_i
distraction NN 4_i
, , N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
powerful JJ N
adjuncts NNS N
in IN N
reducing VBG N
pain NN N
and CC N
anxiety NN N
in IN N
children NNS N
with IN N
both DT N
acute NN N
and CC N
chronic JJ N
painful JJ N
conditions NNS N
. . N

There EX N
are VBP N
no DT N
controlled JJ N
studies NNS N
evaluating VBG N
these DT N
interventions NNS N
as IN N
adjuncts NNS N
to TO N
facilitate VB N
completion NN N
of IN N
painful JJ N
procedures NNS N
in IN N
the DT N
pediatric JJ N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
. . N

OBJECTIVE IN N
We PRP N
assessed VBD N
the DT N
effectiveness NN N
of IN N
distraction NN 5_i
techniques NNS 5_i
in IN N
reducing VBG N
the DT N
sensory NN N
and CC N
affective JJ N
components NNS N
of IN N
pain NN N
among IN N
pediatric JJ N
patients NNS N
undergoing JJ N
laceration NN N
repair NN N
in IN N
the DT N
ED NNP N
. . N

METHODS NNP N
Eligible JJ N
children NNS N
between IN N
6 CD N
and CC N
18 CD N
years NNS N
of IN N
age NN N
( ( N
N NNP N
= NNP N
240 CD N
) ) N
presenting NN N
to TO N
the DT N
ED NNP N
for IN N
laceration NN N
repair NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
or CC N
control NN N
arm NN N
. . N

Those DT N
assigned VBN N
to TO N
the DT N
intervention NN N
arm NN N
were VBD N
given VBN N
a DT N
choice NN N
of IN N
age-appropriate JJ 4_i
distracters NNS 4_i
during IN N
laceration NN N
repair NN N
. . N

Quantitative JJ N
measures NNS N
of IN N
pain NN N
intensity NN N
, , N
situational JJ N
anxiety NN N
, , N
and CC N
pain NN N
distress NN N
( ( N
as IN N
perceived VBN N
by IN N
the DT N
parent NN N
) ) N
were VBD N
assessed VBN N
by IN N
using VBG N
the DT N
7-point JJ N
Facial NNP N
Pain NNP N
Scale NNP N
, , N
State NNP N
Trait NNP N
Anxiety NNP N
Inventory NNP N
for IN N
Children NNP N
, , N
and CC N
a DT N
visual JJ N
analog NN N
scale NN N
, , N
respectively RB N
, , N
before IN N
and CC N
after IN N
laceration NN N
repair NN N
. . N

The DT N
State NNP N
Trait NNP N
Anxiety NNP N
Inventory NNP N
for IN N
Children NNP N
was VBD N
performed VBN N
in IN N
children NNS N
> VBP N
or CC N
= VBP N
10 CD N
years NNS N
of IN N
age NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
mean JJ N
change NN N
in IN N
Facial NNP N
Pain NNP N
Scale NNP N
scores VBZ N
between IN N
the DT N
control NN N
and CC N
the DT N
intervention NN N
groups NNS N
in IN N
children NNS N
< VBP N
10 CD N
years NNS N
of IN N
age NN N
. . N

Multivariate NNP N
analysis NN N
in IN N
this DT N
same JJ N
age NN N
group NN N
showed VBD N
that IN N
the DT N
intervention NN N
was VBD N
independently RB N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
pain NN N
distress NN N
as IN N
perceived VBN N
by IN N
parents NNS N
based VBN N
on IN N
the DT N
mean JJ N
change NN N
in IN N
visual JJ N
analog NN N
scale NN N
scores NNS N
. . N

In IN N
older JJR N
children NNS N
, , N
the DT N
intervention NN N
was VBD N
independently RB N
associated VBN N
with IN N
reduction NN N
in IN N
situational JJ N
anxiety NN N
but CC N
not RB N
in IN N
pain NN N
intensity NN N
or CC N
in IN N
parental JJ N
perception NN N
of IN N
pain NN N
distress NN N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
distraction NN 4_i
techniques NNS 4_i
is VBZ N
effective JJ N
in IN N
reducing VBG N
situational JJ N
anxiety NN N
in IN N
older JJR N
children NNS N
and CC N
lowering VBG N
parental JJ N
perception NN N
of IN N
pain NN N
distress NN N
in IN N
younger JJR N
children NNS N
. . N

This DT N
technique NN N
may MD N
have VB N
a DT N
role NN N
in IN N
improving VBG N
the DT N
quality NN N
of IN N
management NN N
of IN N
procedural JJ N
pain NN N
in IN N
a DT N
pediatric JJ N
ED NNP N
setting NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Comparison NNP N
of IN N
two CD N
methods NNS N
of IN N
local JJ 3_i
anaesthesia NN 3_i
prior RB N
to TO N
transrectal VB N
ultrasound-guided JJ N
prostate NN N
biopsies NNS N
] VBP N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
rectal JJ N
administration NN N
of IN N
Lidoca?ne NNP N
gel NN N
with IN N
Lidoca?ne NNP N
periprostatic JJ N
infiltration NN N
prior RB N
to TO N
transrectal VB N
ultrasound-guided JJ N
prostate NN N
biopsies NNS N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
Between NNP N
July NNP N
2002 CD N
and CC N
July NNP N
2003 CD N
, , N
candidates NNS N
to TO N
prostate VB N
biopsies NNS N
were VBD N
randomised VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
group NN N
1 CD N
, , N
15 CD N
ml VBD N
2 CD N
% NN N
Lidoca?ne NNP N
gel NN N
was VBD N
administered VBN N
intra-rectally RB N
10 CD N
minutes NNS N
prior RB N
to TO N
biopsies NNS N
and CC N
patients NNS N
included VBD N
in IN N
group NN N
2 CD N
received VBD N
10 CD N
ml NN N
of IN N
1 CD N
% NN N
Lidoca?ne NNP N
in IN N
two CD N
p?riprostatique JJ N
equivalent JJ N
injections NNS N
, , N
4 CD N
minutes NNS N
prior RB N
to TO N
prostate VB N
biopsies NNS N
. . N

Pain NN N
was VBD N
assessed VBN N
with IN N
a DT N
Visual JJ N
Analog NNP N
Scale NNP N
, , N
during IN N
anaesthesia NN N
( ( N
VAS NNP N
1 CD N
) ) N
, , N
during IN N
the DT N
biopsies NNS N
procedure NN N
( ( N
VAS NNP N
2 CD N
) ) N
and CC N
30 CD N
minutes NNS N
after IN N
them PRP N
( ( N
VAS NNP N
3 CD N
) ) N
. . N

RESULTS $ N
308 CD N
patients NNS N
were VBD N
included VBN N
in IN N
this DT N
trial NN N
with IN N
156 CD N
patients NNS N
in IN N
group NN N
1 CD N
and CC N
152 CD N
in IN N
group NN N
2 CD N
. . N

Group NNP N
1 CD N
experienced VBD N
statistically RB N
less JJR N
pain NN N
for IN N
VAS NNP N
1 CD N
( ( N
0.1 CD N
versus NN N
1.4 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
and CC N
VAS $ N
3 CD N
( ( N
0.8 CD N
versus NN N
1.4 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
but CC N
no DT N
significative JJ N
difference NN N
could MD N
be VB N
demonstrated VBN N
for IN N
VAS NNP N
2 CD N
( ( N
1.8 CD N
versus IN N
2.0 CD N
) ) N
. . N

No DT N
major JJ N
complication NN N
was VBD N
noted VBN N
. . N

CONCLUSION NNP N
Rectal NNP N
administration NN N
of IN N
Lidoca?ne NNP N
gel NN N
and CC N
infiltration NN N
of IN N
Lidoca?ne NNP N
lead NN N
to TO N
a DT N
comparable JJ N
level NN N
of IN N
anaesthesia NN N
during IN N
prostatic JJ N
biopsies NNS N
procedure NN N
. . N

However RB N
, , N
the DT N
Lidoca?ne NNP N
gel NN N
, , N
being VBG N
both DT N
safe JJ N
and CC N
simple JJ N
, , N
tends VBZ N
to TO N
maintain VB N
a DT N
better JJR N
comfort NN N
of IN N
the DT N
patient NN N
30 CD N
minutes NNS N
after IN N
the DT N
end NN N
of IN N
the DT N
biopsies NNS N
. . N

-DOCSTART- -X- O O

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
intravenous JJ N
diltiazem NNS 3_i
in IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
or CC N
atrial JJ N
flutter NN N
. . N

BACKGROUND NNP N
Diltiazem NNP 3_i
, , N
a DT N
calcium NN N
channel NN N
blocker NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
in IN N
atrial JJ N
fibrillation NN N
and/or IN N
atrial JJ N
flutter NN N
. . N

However RB N
, , N
there EX N
have VBP N
been VBN N
no DT N
pharmacokinetic/pharmacodynamic JJ N
studies NNS N
of IN N
diltiazem NN N
in IN N
these DT N
patients NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
intravenous JJ 3_i
diltiazem NNS 3_i
were VBD N
determined VBN N
in IN N
32 CD N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
or CC N
atrial JJ N
flutter NN N
( ( N
mean JJ N
+/- NN N
SD NNP N
age NN N
, , N
66 CD N
+/- JJ N
7 CD N
years NNS N
; : N
mean VB N
baseline JJ N
heart NN N
rate NN N
, , N
131 CD N
+/- JJ N
10 CD N
beats NNS N
per IN N
minute NN N
) ) N
after IN N
20 CD N
mg NN N
or CC N
20 CD N
mg NN N
followed VBN N
by IN N
25-mg JJ N
bolus NN N
doses NNS N
and CC N
a DT N
10 CD N
and CC N
15 CD N
mg/hr NN N
infusion NN N
for IN N
24 CD N
hours NNS N
. . N

After IN N
the DT N
10 CD N
and CC N
15 CD N
mg/hr JJ N
infusions NNS N
of IN N
diltiazem NN 3_i
, , N
mean JJ N
+/- JJ N
SD NNP N
elimination NN N
half-life NN N
was VBD N
6.8 CD N
+/- JJ N
1.8 CD N
and CC N
6.9 CD N
+/- JJ N
1.5 CD N
hours NNS N
, , N
volume NN N
of IN N
distribution NN N
was VBD N
411 CD N
+/- JJ N
151.8 CD N
and CC N
299 CD N
+/- JJ N
70.8 CD N
I PRP N
, , N
and CC N
systemic JJ N
clearance NN N
was VBD N
42 CD N
+/- JJ N
12.4 CD N
and CC N
31 CD N
+/- JJ N
8.3 CD N
l/hr NN N
, , N
respectively RB N
. . N

Percentages NNS N
of IN N
the DT N
plasma JJ N
concentrations NNS N
of IN N
the DT N
principal JJ N
metabolites NNS N
desacetyldiltiazem NNS N
and CC N
N-desmethyldiltiazem NNP N
to TO N
diltiazem VB N
were VBD N
< JJ N
15 CD N
% NN N
and CC N
< $ N
10 CD N
% NN N
, , N
respectively RB N
. . N

Thirty NNP N
of IN N
32 CD N
patients NNS N
maintained VBD N
response NN N
throughout IN N
the DT N
24-hour JJ N
infusion NN N
of IN N
diltiazem NN N
. . N

Using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
pharmacodynamic JJ N
model NN N
, , N
a DT N
strong JJ N
relation NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
r2 NN N
, , N
0.78 CD N
+/- JJ N
0.2 CD N
) ) N
was VBD N
observed VBN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent JJ N
heart NN N
rate NN N
reduction NN N
. . N

Mean JJ N
+/- JJ N
SD NNP N
Emax NNP N
( ( N
maximum JJ N
percent NN N
reduction NN N
in IN N
heart NN N
rate NN N
from IN N
baseline NN N
) ) N
and CC N
EC50 NNP N
( ( N
plasma JJ N
diltiazem NN N
concentration NN N
that WDT N
achieves VBZ N
half DT N
Emax NNP N
) ) N
were VBD N
52 CD N
+/- JJ N
17 CD N
% NN N
and CC N
110 CD N
+/- JJ N
84 CD N
ng/ml NN N
, , N
respectively RB N
. . N

The DT N
model NN N
predicts VBZ N
that IN N
mean JJ N
plasma NN N
diltiazem NN N
concentration NN N
of IN N
79 CD N
, , N
172 CD N
, , N
and CC N
294 CD N
ng/ml NNS N
are VBP N
required VBN N
to TO N
produce VB N
a DT N
20 CD N
% NN N
, , N
30 CD N
% NN N
, , N
and CC N
40 CD N
% NN N
reduction NN N
in IN N
heart NN N
rate NN N
, , N
respectively RB N
. . N

A DT N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent NN N
change NN N
in IN N
systolic JJ N
blood NN N
pressure NN N
( ( N
SBP NNP N
) ) N
or CC N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
from IN N
baseline NN N
was VBD N
not RB N
observed VBN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
r2 NN N
, , N
SBP/DBP NNP N
: : N
0.35 CD N
+/- JJ N
0.24/0.36 CD N
+/- JJ N
0.2 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
untoward JJ N
side NN N
effects NNS N
observed VBN N
. . N

CONCLUSIONS NNP N
First NNP N
, , N
the DT N
pharmacokinetics NNS N
of IN N
diltiazem NN 3_i
in IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
or CC N
atrial JJ N
flutter NN N
is VBZ N
nonlinear JJ N
with IN N
an DT N
apparent JJ N
dose-dependent JJ N
decrease NN N
in IN N
systemic JJ N
clearance NN N
with IN N
increasing VBG N
infusion NN N
rate NN N
. . N

Second NNP N
, , N
using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
model NN N
, , N
there EX N
is VBZ N
a DT N
strong JJ N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent JJ N
heart NN N
rate NN N
reduction NN N
. . N

Third NNP N
, , N
the DT N
plasma JJ N
concentrations NNS N
of IN N
the DT N
principal JJ N
metabolites NNS N
desacetyldiltiazem NNS N
and CC N
N-desmethyldiltiazem NNP N
are VBP N
low JJ N
and CC N
are VBP N
not RB N
expected VBN N
to TO N
contribute VB N
significantly RB N
to TO N
the DT N
pharmacodynamics NNS N
of IN N
intravenous JJ N
diltiazem NNS N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
acupuncture NN 2_i
combined VBN N
with IN N
Yizhi NNP 3_i
Jiannao NNP 3_i
granules NNS 3_i
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
clinical JJ N
therapeutic JJ N
effect NN N
of IN N
acupuncture NN 2_i
combined VBN N
with IN N
Yizhi NNP 3_i
Jiannao NNP 3_i
Granules NNP 3_i
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
and CC N
its PRP$ N
effects NNS N
on IN N
intelligence NN N
, , N
daily JJ N
life NN N
and CC N
social JJ N
activity NN N
ability NN N
. . N

METHODS NNP N
Eighty-four JJ N
cases NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
, , N
28 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

The DT N
combined JJ N
acupuncture NN 2_i
and CC N
medication NN N
group NN N
was VBD N
treated VBN N
with IN N
acupuncture NN 2_i
at IN N
Baihui NNP N
( ( N
GV NNP N
20 CD N
) ) N
, , N
Sishencong NNP N
( ( N
EX-HN NNP N
1 CD N
) ) N
, , N
Dazhui NNP N
( ( N
GV NNP N
14 CD N
) ) N
, , N
Guanyuan NNP N
( ( N
CV NNP N
4 CD N
) ) N
, , N
etc FW N
. . N

and CC N
oral JJ N
administration NN N
of IN N
Yizhi NNP 3_i
Jiannao NNP 3_i
Granules NNP 3_i
; : N
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
treated VBN N
with IN N
Yizhi NNP 3_i
Jiannao NNP 3_i
Granules NNP 3_i
, , N
and CC N
the DT N
western JJ 3_i
medicine NN 3_i
group NN 3_i
with IN N
oral JJ N
administration NN N
of IN N
Aricept NNP 3_i
. . N

The DT N
scores NNS N
for IN N
the DT N
Mini-Mental JJ N
State NNP N
Examination NNP N
( ( N
MMSE NNP N
) ) N
, , N
Ability NNP N
of IN N
Daily NNP N
Life NNP N
( ( N
ADL NNP N
) ) N
and CC N
the DT N
therapeutic JJ N
effects NNS N
were VBD N
assessed VBN N
and CC N
compared VBN N
before IN N
treatment NN N
and CC N
after IN N
treatment NN N
for IN N
12 CD N
weeks NNS N
among IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
scores NNS N
for IN N
MMSE NNP N
and CC N
ADL NNP N
were VBD N
improved VBN N
in IN N
the DT N
combined JJ 2_i
acupuncture NN 2_i
and CC 2_i
medication NN 2_i
group NN N
, , N
the DT N
Chinese JJ 3_i
herb NN 3_i
group NN N
and CC N
the DT N
western JJ 3_i
medicine NN 3_i
group NN N
, , N
which WDT N
were VBD N
better RBR N
in IN N
the DT N
combined JJ N
acupuncture NN 2_i
and CC 2_i
medication NN 2_i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
total JJ N
effective JJ N
rate NN N
of IN N
85.7 CD N
% NN N
in IN N
the DT N
combined JJ 2_i
acupuncture NN 2_i
and CC 2_i
medication NN 2_i
group NN N
was VBD N
better JJR N
than IN N
71.4 CD N
% NN N
in IN N
the DT N
Chinese JJ N
herb NN N
group NN N
and CC N
67.9 CD N
% NN N
in IN N
the DT N
western JJ N
medicine NN N
group NN N
. . N

CONCLUSION NNP N
Acupuncture NNP N
combined VBN N
with IN N
Yizhi NNP N
Jiannao NNP N
Granules NNP N
has VBZ N
a DT N
significant JJ N
therapeutic JJ N
effect NN N
on IN N
Alzheimer NNP N
's POS N
disease NN N
, , N
which WDT N
is VBZ N
better JJR N
than IN N
that DT N
of IN N
Yizhi NNP N
Jiannao NNP N
Granules NNP N
or CC N
Aricept NNP N
. . N

-DOCSTART- -X- O O

Extra JJ 4_i
prompts NNS 4_i
versus IN N
no DT 4_i
extra JJ 4_i
prompts NNS 4_i
in IN N
self-care JJ N
training NN N
of IN N
autistic JJ N
children NNS N
and CC N
adolescents NNS N
. . N

A DT N
color-coded JJ 4_i
extra JJ 4_i
prompt JJ 4_i
procedure NN 4_i
was VBD N
compared VBN 4_i
to TO 4_i
a DT 4_i
no DT 4_i
extra JJ 4_i
prompt JJ 4_i
procedure NN 4_i
in IN N
teaching VBG N
autistic JJ N
children NNS N
and CC N
adolescents VBZ N
how WRB N
to TO N
lace VB N
shoes NNS N
. . N

One CD N
randomly NN N
assigned VBN N
group NN N
of IN N
10 CD N
autistic JJ N
subjects NNS N
first RB N
learned VBD 4_i
to TO 4_i
lace VB 4_i
shoes NNS 4_i
whose WP$ 4_i
laces NNS 4_i
and CC 4_i
eyelets NNS 4_i
were VBD 4_i
color-coded JJ 4_i
red JJ 4_i
and CC 4_i
white JJ 4_i
, , N
and CC N
then RB N
encountered VBD 4_i
the DT 4_i
no DT 4_i
extra JJ 4_i
prompt JJ 4_i
condition NN 4_i
in IN 4_i
which WDT 4_i
color NN 4_i
codes NNS 4_i
could MD 4_i
no RB 4_i
longer RB 4_i
be VB 4_i
depended VBN 4_i
upon IN 4_i
to TO 4_i
solve VB 4_i
the DT 4_i
position NN 4_i
discriminations NNS 4_i
required VBN 4_i
to TO 4_i
lace VB 4_i
properly RB 4_i
. . N

In IN N
a DT N
counterbalanced JJ N
fashion NN N
, , N
the DT N
other JJ N
group NN N
of IN N
10 CD N
autistic JJ N
subjects NNS N
reached VBN N
criterion NN N
on IN N
the DT N
non-color-coded JJ N
, , N
naturalistic JJ N
shoe NN N
before IN N
experiencing VBG N
the DT N
extra JJ N
prompt JJ N
condition NN N
. . N

Analysis NN N
of IN N
variance NN N
and CC N
post-hoc JJ N
analyses NNS N
suggest VBP N
that IN N
subjects NNS N
who WP N
first RB N
learned VBN N
under IN N
the DT N
color-coded JJ N
, , N
extra JJ N
prompt JJ N
condition NN N
encountered VBD N
significant JJ N
difficulty NN N
in IN N
transferring VBG N
their PRP$ N
newly RB N
acquired VBN N
skill NN N
to TO N
the DT N
naturalistic JJ N
, , N
non-color-coded JJ N
condition NN N
, , N
whereas JJ N
subjects NNS N
who WP N
learned VBD N
initially RB N
without IN N
the DT N
extra JJ N
prompts NNS N
had VBD N
little JJ N
difficulty NN N
with IN N
the DT N
subsequent JJ N
color-coded JJ N
condition NN N
. . N

A DT N
follow-up JJ N
procedure NN N
requiring VBG N
all DT N
subjects NNS N
to TO N
choose VB N
between IN N
the DT N
color NN N
prompt NN N
and CC N
the DT N
position NN N
cue NN N
revealed VBD N
that IN N
11 CD N
of IN N
20 CD N
subjects NNS N
consistently RB N
chose VBD N
the DT N
color NN N
cue NN N
, , N
even RB N
though IN N
it PRP N
resulted VBD N
in IN N
improper JJ N
lacing NN N
. . N

It PRP N
is VBZ N
recommended VBN N
that IN N
clinicians NNS N
avoid VBP N
the DT N
use NN N
of IN N
highly RB N
salient JJ N
, , N
non-criterion-related JJ N
prompts NNS N
in IN N
teaching VBG N
certain JJ N
types NNS N
of IN N
adaptive JJ N
skills NNS N
to TO N
autistic JJ N
children NNS N
. . N

-DOCSTART- -X- O O

[ RB N
Clinical JJ N
benefits NNS N
of IN N
normothermic JJ 1_i
cardiopulmonary JJ 1_i
bypass NN 1_i
on IN N
postoperative JJ N
systemic JJ N
metabolism NN N
] NNP N
. . N

To TO N
evaluate VB N
the DT N
influence NN N
of IN N
body NN N
temperature NN N
during IN N
cardiopulmonary JJ 1_i
bypass NN 1_i
( ( 1_i
CPB NNP 1_i
) ) 1_i
on IN N
postoperative JJ N
systemic JJ N
metabolism NN N
, , N
32 CD N
patients NNS N
undergoing JJ N
elective JJ N
cardiac NN N
surgery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
hypothermia NN 1_i
( ( N
n JJ N
= NNP N
16 CD N
) ) N
or CC N
normothermia NN 1_i
( ( N
n JJ N
= NNP N
16 CD N
) ) N
. . N

Serial JJ N
hemodynamic JJ N
parameters NNS N
and CC N
blood NN N
samples NNS N
were VBD N
obtained VBN N
after IN N
surgery NN N
. . N

CPB NNP N
and CC N
operation NN N
times NNS N
were VBD N
significantly RB N
shorter JJR N
and CC N
the DT N
platelet NN N
reduction NN N
ratio NN N
during IN N
CPB NNP 1_i
[ NNP N
= NNP N
( ( N
platelets NNS N
before IN N
CPB-platelets NNS N
after IN N
CPB NNP N
) ) N
/platelets VBZ N
before IN N
CPB NNP N
] NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
normothermic JJ N
patients NNS N
than IN N
in IN N
hypothermic JJ N
patients NNS N
. . N

The DT N
platelet NN N
reduction NN N
ratio NN N
was VBD N
dependent JJ N
on IN N
the DT N
minimum JJ N
rectal JJ N
temperature NN N
during IN N
CPB NNP 1_i
, , N
the DT N
operation NN N
time NN N
, , N
and CC N
the DT N
CPB NNP N
time NN N
. . N

In IN N
the DT N
early JJ N
postoperative JJ N
period NN N
, , N
hypothermic JJ N
patients NNS N
had VBD N
abnormally RB N
high JJ N
systemic JJ N
vascular NN N
resistance NN N
and CC N
a DT N
reduced JJ N
cardiac JJ N
index NN N
compared VBN N
with IN N
the DT N
normothermic JJ N
patients NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
2 CD N
groups NNS N
in IN N
postoperative JJ N
hepatic JJ N
and CC N
renal JJ N
functions NNS N
, , N
changes NNS N
in IN N
oxygen NN N
consumption NN N
, , N
arterial-venous JJ N
PCO2 NNP N
or CC N
arterial-venous JJ N
pH JJ N
gradient NN N
. . N

This DT N
study NN N
suggested VBD N
a DT N
beneficial JJ N
influence NN N
of IN N
normothermic JJ 1_i
CPB NNP 1_i
on IN N
postoperative JJ N
hemodynamics NNS N
. . N

Normothermic NNP 1_i
CPB NNP 1_i
was VBD N
not RB N
associated VBN N
with IN N
adverse JJ N
effects NNS N
on IN N
postoperative JJ N
metabolic JJ N
recovery NN N
. . N

-DOCSTART- -X- O O

Phase NNP N
III NNP N
trial NN N
of IN N
gemcitabine NN 3_i
plus CC 3_i
docetaxel JJ 3_i
versus NN N
capecitabine NN 3_i
plus CC 3_i
docetaxel NN 3_i
with IN N
planned VBN N
crossover NN N
to TO N
the DT N
alternate NN N
single JJ N
agent NN N
in IN N
metastatic JJ N
breast NN N
cancer NN N
. . N

BACKGROUND NNP N
Safety NNP N
and CC N
efficacy NN N
of IN N
gemcitabine JJ 3_i
plus CC 3_i
docetaxel JJ 3_i
( ( 3_i
GD NNP 3_i
) ) 3_i
and CC N
capecitabine JJ 3_i
plus CC 3_i
docetaxel JJ 3_i
( ( 3_i
CD NN 3_i
) ) 3_i
were VBD N
compared VBN N
in IN N
patients NNS N
with IN N
metastatic JJ N
breast NN N
cancer NN N
, , N
where WRB N
the DT N
alternate NN N
crossover NN N
monotherapy NN N
( ( N
GD?C NNP N
or CC N
CD?G NNP N
) ) N
was VBD N
predetermined VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
3-week JJ N
cycles NNS N
of IN N
either DT N
gemcitabine NN N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
plus CC N
docetaxel JJ N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
or CC N
capecitabine VB N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
twice RB N
daily RB N
on IN N
days NNS N
1-14 JJ N
plus JJ N
docetaxel NN N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1 CD N
. . N

Upon IN N
progression NN N
, , N
patients NNS N
received VBD N
crossover JJ N
monotherapy NN N
. . N

Primary JJ N
end NN N
point NN N
was VBD N
time NN N
to TO N
progression NN N
( ( N
TtP NNP N
) ) N
. . N

Secondary JJ N
end NN N
points NNS N
evaluated VBD N
overall JJ N
response NN N
rate NN N
( ( N
ORR NNP N
) ) N
, , N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
, , N
and CC N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
. . N

RESULTS NNP N
Despite IN N
over-accrual JJ N
of IN N
475 CD N
patients NNS N
, , N
the DT N
trial NN N
matured VBD N
with IN N
only RB N
324 CD N
of IN N
385 CD N
planned JJ N
TtP NNP N
events NNS N
due JJ N
to TO N
patient JJ N
discontinuations NNS N
. . N

Human NNP N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
2 CD N
status NN N
was VBD N
not RB N
captured VBN N
in IN N
this DT N
study NN N
. . N

More JJR N
CD NN N
patients NNS N
( ( N
28 CD N
% NN N
) ) N
discontinued VBD N
due JJ N
to TO N
AEs NNP N
than IN N
GD NNP N
patients NNS N
( ( N
18.0 CD N
% NN N
, , N
P NNP N
= NNP N
0.009 CD N
) ) N
. . N

TtP NNP N
[ NNP N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
= VBD N
1.101 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.885-1.370 NN N
, , N
P NNP N
= VBZ N
0.387 CD N
] NN N
and CC N
OS NNP N
( ( N
HR NNP N
= NNP N
1.031 CD N
, , N
95 CD N
% NN N
CI NNP N
0.830-1.280 NN N
, , N
P NNP N
= NNP N
0.785 CD N
) ) N
were VBD N
not RB N
significantly RB N
different JJ N
comparing VBG N
GD NNP N
and CC N
CD NNP N
. . N

ORR NNP N
was VBD N
not RB N
statistically RB N
different JJ N
( ( N
P NNP N
= NNP N
0.239 CD N
) ) N
comparing VBG N
GD NNP N
( ( N
72 CD N
of IN N
207 CD N
, , N
34.8 CD N
% NN N
) ) N
and CC N
CD NNP N
( ( N
78 CD N
of IN N
191 CD N
, , N
40.8 CD N
% NN N
) ) N
. . N

TtP NNP N
, , N
OS NNP N
, , N
and CC N
ORR NNP N
were VBD N
not RB N
significantly RB N
different JJ N
comparing VBG N
crossover NN N
groups NNS N
. . N

GD NNP N
caused VBD N
greater JJR N
fatigue NN N
, , N
hepatotoxicity NN N
, , N
neutropenia NN N
, , N
and CC N
thrombocytopenia NNS N
but CC N
not RB N
febrile JJ N
neutropenia NN N
; : N
CD NN N
caused VBD N
more JJR N
hand-foot JJ N
syndrome NN N
, , N
gastrointestinal JJ N
toxicity NN N
, , N
and CC N
mucositis NN N
. . N

CONCLUSIONS NNP N
GD NNP N
and CC N
CD NNP N
produced VBD N
similar JJ N
efficacy NN N
and CC N
toxicity NN N
profiles NNS N
consistent JJ N
with IN N
prior JJ N
clinical JJ N
experience NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
rosuvastatin NN N
monotherapy NN N
or CC N
in IN N
combination NN N
with IN N
fenofibrate NN N
or CC N
?-3 JJ N
fatty JJ N
acids NNS N
on IN N
lipoprotein JJ N
subfraction NN N
profile NN N
in IN N
patients NNS N
with IN N
mixed JJ N
dyslipidaemia NN N
and CC N
metabolic JJ N
syndrome NN N
. . N

BACKGROUND NNP N
Raised VBD N
triglycerides NNS N
( ( N
TG NNP N
) ) N
, , N
decreased VBD N
high-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
levels NNS N
and CC N
a DT N
predominance NN N
of IN N
small JJ N
dense NN N
low JJ N
density NN N
lipoproteins NNS N
( ( N
sdLDL NN N
) ) N
are VBP N
characteristics NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
( ( N
MetS NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
high-dose JJ N
rosuvastatin NN N
monotherapy NN N
with IN N
moderate JJ N
dosing NN N
combined VBN N
with IN N
fenofibrate NN N
or CC N
?-3 JJ N
fatty JJ N
acids NNS N
on IN N
the DT N
lipoprotein JJ N
subfraction NN N
profile NN N
in IN N
patients NNS N
with IN N
mixed JJ N
dyslipidaemia NN N
and CC N
MetS NNP N
. . N

METHODS NNP N
We PRP N
previously RB N
randomised VBD N
patients NNS N
with IN N
low-density JJ N
lipoprotein NNS N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
> VBZ N
160 CD N
and CC N
TG NNP N
> NNP N
200 CD N
mg/dl NN N
to TO N
rosuvastatin VB N
monotherapy NN N
40 CD N
mg/day NN N
( ( N
R NNP N
group NN N
, , N
n RB N
= VBZ N
30 CD N
) ) N
or CC N
rosuvastatin $ N
10 CD N
mg/day NN N
combined VBN N
with IN N
fenofibrate JJ N
200 CD N
mg/day NN N
( ( N
RF NNP N
group NN N
, , N
n RB N
= VBZ N
30 CD N
) ) N
or CC N
?-3 JJ N
fatty JJ N
acids NNS N
2 CD N
g/day NN N
( ( N
R? NNP N
group NN N
, , N
n RB N
= VBZ N
30 CD N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
only RB N
patients NNS N
with IN N
MetS NNP N
were VBD N
included VBN N
( ( N
24 CD N
, , N
23 CD N
and CC N
24 CD N
in IN N
the DT N
R NNP N
, , N
RF NNP N
and CC N
R? NNP N
groups NNS N
respectively RB N
) ) N
. . N

At IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
lipoprotein JJ N
subfraction NN N
profile NN N
was VBD N
determined VBN N
by IN N
polyacrylamide JJ N
3 CD N
% NN N
gel JJ N
electrophoresis NN N
. . N

RESULTS VB N
The DT N
mean JJ N
LDL NNP N
size NN N
was VBD N
significantly RB N
increased VBN N
in IN N
all DT N
groups NNS N
. . N

This DT N
change NN N
was VBD N
more RBR N
prominent JJ N
with IN N
RF NNP N
than IN N
with IN N
other JJ N
treatments NNS N
in IN N
parallel JJ N
with IN N
its PRP$ N
greater JJR N
hypotriglyceridemic JJ N
capacity NN N
( ( N
p JJ N
< $ N
0.05 CD N
compared VBN N
with IN N
R NNP N
and CC N
R? NNP N
) ) N
. . N

A DT N
decrease NN N
in IN N
insulin NN N
resistance NN N
by IN N
RF NNP N
was VBD N
also RB N
noted VBN N
. . N

Only RB N
RF NNP N
significantly RB N
raised VBD N
HDL-C NNP N
levels NNS N
( ( N
by IN N
7.7 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
by IN N
increasing VBG N
the DT N
cholesterol NN N
of IN N
small JJ N
HDL NNP N
particles NNS N
. . N

The DT N
cholesterol NN N
of IN N
larger JJR N
HDL NNP N
subclasses NNS N
was VBD N
significantly RB N
increased VBN N
by IN N
R NNP N
and CC N
R? NNP N
. . N

CONCLUSIONS NNP N
All NNP N
regimens VBZ N
increased VBN N
mean JJ N
LDL NNP N
size NN N
; : N
RF NNP N
was VBD N
the DT N
most RBS N
effective JJ N
. . N

A DT N
differential JJ N
effect NN N
of IN N
treatments NNS N
was VBD N
noted VBN N
on IN N
the DT N
HDL NNP N
subfraction NN N
profile NN N
. . N

-DOCSTART- -X- O O

An DT N
analysis NN N
of IN N
the DT N
mortality NN N
effect NN N
in IN N
a DT N
breast NN 2_i
cancer NN 2_i
screening VBG 2_i
study NN N
. . N

In IN N
order NN N
to TO N
better JJR N
understand VB N
the DT N
effect NN N
of IN N
breast NN N
cancer NN N
screening VBG N
on IN N
mortality NN N
, , N
we PRP N
use VBP N
the DT N
theory NN N
of IN N
competing VBG N
risks NNS N
to TO N
analyse VB N
deaths NNS N
from IN N
the DT N
long-term JJ N
follow-up NN N
of IN N
the DT N
HIP NNP 2_i
breast NN 2_i
cancer NN 2_i
screening VBG 2_i
trial NN 2_i
. . N

We PRP N
conclude VBP N
that IN N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
of IN N
the DT N
breast NN N
cancer NN N
cases NNS N
detected VBD N
early RB N
as IN N
a DT N
result NN N
of IN N
screening VBG 2_i
realized VBN N
a DT N
benefit NN N
in IN N
terms NNS N
of IN N
elimination NN N
of IN N
the DT N
risk NN N
of IN N
breast NN N
cancer NN N
mortality NN N
. . N

Breast NNP 2_i
cancer NN 2_i
screening VBG 2_i
appears VBZ N
not RB N
to TO N
affect VB N
the DT N
rate NN N
of IN N
mortality NN N
from IN N
causes NNS N
of IN N
death NN N
other JJ N
than IN N
breast JJ N
cancer NN N
. . N

Methodologically RB N
, , N
we PRP N
demonstrate VBP N
the DT N
importance NN N
of IN N
analysing VBG N
mortality NN N
separately RB N
for IN N
the DT N
breast NN N
cancer NN N
cases NNS N
as RB N
well RB N
as IN N
for IN N
the DT N
entire JJ N
population NN N
in IN N
a DT N
trial NN N
. . N

-DOCSTART- -X- O O

Clarithromycin NNP 3_i
reduces VBZ N
the DT N
severity NN N
of IN N
bronchial JJ N
hyperresponsiveness NN N
in IN N
patients NNS N
with IN N
asthma NN N
. . N

A DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ 7_i
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
semisynthetic JJ 3_i
macrolide NN 3_i
antibiotic JJ 3_i
, , N
clarithromycin NN 3_i
, , N
on IN N
bronchial JJ 3_i
hyperresponsiveness NN 3_i
to TO N
methacholine VB 3_i
in IN N
patients NNS N
with IN N
a DT N
diagnosis NN N
of IN N
asthma NN N
. . N

Adult NNP N
asthma JJ N
patients NNS N
undergoing VBG N
treatment NN N
with IN N
budesonide JJ N
400 CD N
microg NN N
b.i.d NN N
. . N

and CC N
salbutamol JJ 3_i
200 CD N
microg NN N
p.r.n NN N
. . N

less JJR N
than IN N
twice RB N
weekly JJ N
were VBD N
studied VBN N
. . N

Arm VB N
A NNP N
( ( N
16 CD N
males/six NN N
females NNS N
, , N
aged VBD N
48 CD N
+/- JJ N
16 CD N
yrs NN N
) ) N
received VBD N
clarithromycin JJ N
250 CD N
mg NN N
b.i.d NN N
. . N

for IN N
8 CD N
weeks NNS N
, , N
arm NN N
B NNP N
( ( N
eight CD N
males/12 NN N
females NNS N
, , N
aged VBD N
42 CD N
+/- JJ N
12 CD N
yrs NN N
) ) N
clarithromycin VBZ 3_i
250 CD N
mg NN N
t.id NN N
. . N

and CC N
arm JJ N
C NNP N
( ( N
six CD N
males/15 NN N
females NNS N
, , N
aged VBD N
41 CD N
+/- JJ N
16 CD N
yrs NN N
) ) N
placebo NN 3_i
dextrose JJ 3_i
tablets NNS N
. . N

Bronchial NNP N
hyperresponsiveness NN N
was VBD N
quantified VBN N
by IN N
measurement NN N
of IN N
the DT N
provocative JJ N
dose NN N
of IN N
methacholine NN 3_i
causing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( N
PD20 NNP N
) ) N
. . N

Median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
PD20 NNP N
in IN N
the DT N
three CD N
groups NNS N
before IN N
and CC N
after IN N
treatment NN N
with IN N
clarithromycin NNS 3_i
were VBD N
: : N
arm NN N
A NN N
: : N
0.3 CD N
( ( N
0.1-1 NN N
) ) N
and CC N
1.3 CD N
( ( N
0.6-2 NN N
) ) N
mg NN N
; : N
arm NN N
B NN N
: : N
0.4 CD N
( ( N
0.1-0.9 NN N
) ) N
and CC N
2 CD N
( ( N
2-2 JJ N
) ) N
mg NN N
; : N
and CC N
arm JJ N
C NNP N
: : N
0.4 CD N
( ( N
0.1-0.9 NN N
) ) N
and CC N
0.3 CD N
( ( N
0.1-0.6 NN N
) ) N
mg NN N
, , N
respectively RB N
. . N

Serum NNP N
free JJ N
cortisol NN N
levels NNS N
were VBD N
determined VBN N
and CC N
remained VBN N
unchanged JJ N
from IN N
baseline NN N
in IN N
the DT N
clarithromycin-treated JJ 3_i
patients NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
clarithromycin NN 3_i
reduces VBZ N
the DT N
degree NN N
of IN N
bronchial JJ N
hyperresponsiveness NN N
in IN N
patients NNS N
with IN N
asthma NN N
. . N

-DOCSTART- -X- O O

Dose-response JJ N
relationship NN N
of IN N
complementary JJ N
radiotherapy NN 2_i
following VBG N
four CD N
cycles NNS N
of IN N
combination NN N
chemotherapy NN 2_i
in IN N
intermediate-stage JJ N
Hodgkin NNP N
's POS N
disease NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
the DT N
appropriate JJ N
irradiation NN N
dose NN N
after IN N
four CD N
cycles NNS N
of IN N
modern JJ 2_i
combination NN 2_i
chemotherapy NN 2_i
in IN N
nonbulky JJ N
involved JJ N
field NN N
( ( N
IF/BF NNP N
) ) N
and CC N
noninvolved VBN N
extended-field NN N
( ( N
EF/IF NNP N
) ) N
sites VBZ N
in IN N
patients NNS N
with IN N
intermediate-stage JJ N
Hodgkin NNP N
's POS N
disease NN N
( ( N
HD NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
HD NNP N
patients NNS N
in IN N
stage NN N
I PRP N
to TO N
IIIA NNP N
with IN N
a DT N
large JJ N
mediastinal JJ N
mass NN N
, , N
E NNP N
stage NN N
, , N
or CC N
massive JJ N
spleen JJ N
involvement NN N
were VBD N
treated VBN N
with IN N
two CD N
double JJ N
cycles NNS N
of IN N
alternating VBG N
cyclophosphamide NN 3_i
, , N
vincristine NN 3_i
, , N
procarbazine NN 3_i
, , N
and CC N
prednisone NN 3_i
( ( 3_i
COPP NNP 3_i
) ) 3_i
plus CC 3_i
doxorubicin JJ 3_i
, , N
bleomycin NN 3_i
, , N
vinblastine NN 3_i
, , N
and CC N
dacarbazine NN 3_i
( ( 3_i
ABVD NNP 3_i
) ) 3_i
followed VBN N
by IN N
EF NNP 2_i
irradiation NN 2_i
in IN N
two CD N
successive JJ N
trials NNS N
( ( N
HD1 NNP N
and CC N
HD5 NNP N
) ) N
. . N

In IN N
the DT N
HD1 NNP N
trial NN N
( ( N
1983 CD N
to TO N
1988 CD N
) ) N
, , N
146 CD N
patients NNS N
who WP N
responded VBD N
to TO N
chemotherapy VB N
were VBD N
randomized VBN N
to TO N
receive VB N
20 CD N
Gy NNP N
( ( N
70 CD N
patients NNS N
) ) N
or CC N
40 CD N
Gy NNP N
( ( N
76 CD N
patients NNS N
) ) N
of IN N
EF NNP N
irradiation NN N
in IN N
all DT N
fields NNS N
outside IN N
bulky JJ N
disease NN N
sites NNS N
. . N

A DT N
cohort NN N
of IN N
111 CD N
patients NNS N
who WP N
fulfilled VBD N
the DT N
same JJ N
inclusion NN N
criteria NNS N
in IN N
the DT N
subsequent JJ N
trial NN N
HD5 NNP N
( ( N
1988 CD N
to TO N
1993 CD N
) ) N
were VBD N
treated VBN N
with IN N
30 CD N
Gy NNP N
. . N

Bulky NNP N
disease NN N
always RB N
received VBD N
40 CD N
Gy NNP N
. . N

RESULTS NNP N
Freedom-from-treatment-failure NNP N
( ( N
FFTF NNP N
) ) N
and CC N
survival NN N
( ( N
SV NNP N
) ) N
curves VBZ N
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
20- JJ N
, , N
30- JJ N
, , N
and CC N
40-Gy JJ N
groups NNS N
. . N

However RB N
, , N
acute JJ N
toxicities NNS N
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
40-Gy JJ N
arm NN N
. . N

Analysis NN N
of IN N
relapse NN N
patterns NNS N
showed VBD N
that IN N
18 CD N
of IN N
26 CD N
relapsing VBG N
patients NNS N
either CC N
failed VBD N
to TO N
respond VB N
in IN N
initial JJ N
bulky NN N
sites NNS N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
had VBD N
an DT N
extranodal JJ N
relapse NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
or CC N
both DT N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
. . N

After IN N
5 CD N
years NNS N
, , N
the DT N
cumulative JJ N
risk NN N
for IN N
relapse NN N
in IN N
bulky NN N
sites NNS N
is VBZ N
10 CD N
% NN N
, , N
despite IN N
40 CD N
Gy NNP N
of IN N
radiation NN 2_i
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
strongly RB N
suggest VBP N
that IN N
there EX N
is VBZ N
no DT N
relevant JJ N
radiotherapy NN 2_i
dose JJ N
effect NN N
in IN N
the DT N
range NN N
between IN N
20 CD N
Gy NNP N
and CC N
40 CD N
Gy NNP N
in IN N
IF/BF NNP N
and CC N
EF/IF NNP N
after IN N
4 CD N
months NNS N
of IN N
modern JJ N
polychemotherapy NN 2_i
in IN N
patients NNS N
with IN N
intermediate-stage JJ N
HD NNP N
. . N

Relapse NNP N
patterns VBZ N
indicate VB N
that IN N
patients NNS N
destined VBD N
to TO N
relapse VB N
need VB N
more JJR N
systemic JJ N
, , N
rather RB N
than IN N
local JJ N
, , N
treatment NN N
. . N

Based VBN N
on IN N
our PRP$ N
data NNS N
, , N
we PRP N
conclude VBP N
that IN N
20 CD N
Gy NNP N
is VBZ N
sufficient JJ N
in IN N
EF/IF NNP N
of IN N
intermediate-stage JJ N
HD NNP N
following VBG N
four CD N
cycles NNS N
of IN N
modern JJ N
polychemotherapy NN 2_i
. . N

-DOCSTART- -X- O O

Peripheral NNP N
intravenous JJ N
line NN N
survival NN N
and CC N
phlebitis NN N
prevention NN N
in IN N
patients NNS N
receiving VBG N
intravenous JJ N
antibiotics NNS 3_i
: : N
heparin/hydrocortisone NN N
versus IN N
in-line JJ N
filters NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
use NN N
of IN N
in-line JJ N
filtration NN N
with IN N
the DT N
addition NN N
of IN N
heparin/hydrocortisone NN 3_i
( ( N
hep/hc NN N
) ) N
to TO N
the DT N
infusate NN N
for IN N
both DT N
phlebitis NN N
prevention NN N
and CC N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
line NN N
survival NN N
in IN N
peripheral JJ N
i.v NN N
. . N

catheters NNS N
. . N

This DT N
study NN N
was VBD N
specific JJ N
for IN N
a DT N
patient NN N
group NN N
receiving VBG N
prolonged JJ N
courses NNS N
of IN N
i.v NN N
. . N

antibiotics NNS N
. . N

Analysis NN N
of IN N
the DT N
two CD N
endpoints NNS N
for IN N
conventional JJ N
short JJ N
i.v NN 3_i
. . N

catheters NNS 3_i
( ( N
short JJ N
lines NNS N
) ) N
versus NN N
long RB N
( ( N
30 CD N
cm NN N
) ) N
i.v NN N
. . N

catheters NNS N
( ( N
long JJ N
lines NNS N
) ) N
was VBD N
also RB N
performed VBN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
cystic JJ N
fibrosis NN N
receiving VBG N
intermittent JJ N
i.v NN N
. . N

antibiotics NNS 3_i
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
their PRP$ N
drugs NNS N
either CC N
through IN N
an DT N
in-line JJ N
filter NN N
using VBG N
a DT N
drug-free JJ N
infusate NN N
or CC N
with IN N
no DT N
filter NN N
and CC N
an DT N
infusate NN N
containing VBG N
heparin JJ 3_i
500 CD N
units NNS N
and CC N
hydrocortisone NN 3_i
10 CD N
mg/L NN N
. . N

Infusion NN N
sites NNS N
were VBD N
assessed VBN N
daily RB N
. . N

RESULTS NNP N
Both NNP N
the DT N
hep/hc NN N
and CC N
filter NN N
groups NNS N
were VBD N
similar JJ N
in IN N
terms NNS N
of IN N
phlebitis NN N
incidence NN N
and CC N
i.v NN N
. . N

line NN N
survival NN N
when WRB N
analyzed VBN N
separately RB N
for IN N
both DT N
short JJ N
and CC N
long JJ N
lines NNS N
. . N

Long NNP N
lines NNS N
displayed VBD N
markedly RB N
prolonged JJ N
survival NN N
times NNS N
and CC N
reduced JJ N
phlebitis NN N
compared VBN N
with IN N
short JJ N
lines NNS N
. . N

CONCLUSIONS VB N
The DT N
effectiveness NN N
of IN N
i.v NN N
. . N

filters NNS N
in IN N
excluding VBG N
the DT N
large JJ N
particle NN N
load NN N
introduced VBN N
by IN N
i.v NN N
. . N

antibiotics NNS N
and CC N
hence NN N
in IN N
reducing VBG N
the DT N
subsequent JJ N
phlebitis NN N
makes VBZ N
them PRP N
a DT N
useful JJ N
alternative NN N
to TO N
the DT N
use NN N
of IN N
hep/hc NN N
. . N

The DT N
use NN N
of IN N
filters NNS N
in IN N
this DT N
patient JJ N
group NN N
may MD N
offer VB N
advantages NNS N
in IN N
terms NNS N
of IN N
ease NN N
of IN N
use NN N
and CC N
a DT N
possible JJ N
decrease NN N
in IN N
hep/hc-related JJ N
problems NNS N
. . N

Long JJ N
lines NNS N
offer VBP N
practical JJ N
advantages NNS N
over IN N
short JJ N
lines NNS N
for IN N
patients NNS N
requiring VBG N
longer JJR N
term NN N
i.v NN N
. . N

access NN N
. . N

-DOCSTART- -X- O O

Bridge NNP 1_i
plate NN 1_i
osteosynthesis NN 1_i
using VBG N
dynamic JJ 1_i
condylar JJ 1_i
screw NN 1_i
( ( 1_i
DCS NNP 1_i
) ) 1_i
or CC N
retrograde VBN 1_i
intramedullary JJ 1_i
supracondylar JJ 1_i
nail NN 1_i
( ( 1_i
RIMSN NNP 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
distal JJ N
femoral JJ N
fractures NNS N
: : N
comparison NN N
of IN N
two CD N
methods NNS N
in IN N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
The DT N
treatment NN N
of IN N
distal JJ N
femoral JJ N
fractures NNS N
remains VBZ N
a DT N
significant JJ N
surgical JJ N
challenge NN N
. . N

With IN N
the DT N
rigid JJ N
fixation NN N
of IN N
the DT N
distal JJ N
femoral JJ N
fractures NNS N
, , N
bone NN N
grafting NN N
is VBZ N
frequently RB N
needed VBN N
. . N

Biological JJ N
osteosynthesis NN N
using VBG N
dynamic JJ N
condylar JJ N
screw NN N
( ( N
DCS NNP N
) ) N
and CC N
retrograde JJ N
intramedullary JJ N
supracondylar NN N
nail NN N
( ( N
RIMSN NNP N
) ) N
preserve VBP N
the DT N
blood NN N
supply NN N
and CC N
limit NN N
the DT N
need NN N
for IN N
bone NN N
grafting NN N
. . N

METHODS NNP N
From IN N
September NNP N
2002 CD N
to TO N
December NNP N
2004 CD N
, , N
68 CD N
closed VBD N
fractures NNS N
of IN N
the DT N
distal JJ N
femur NN N
were VBD N
treated VBN N
by IN N
bridge NN 1_i
plate NN 1_i
osteosynthesis NN 1_i
using VBG N
DCS NNP 1_i
in IN N
31 CD N
and CC N
RIMSN NNP 1_i
in IN N
37 CD N
. . N

The DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
the DT N
two CD N
groups NNS N
randomly RB N
and CC N
followed VBD N
for IN N
24-36 JJ N
months NNS N
( ( N
average JJ N
: : N
30 CD N
months NNS N
) ) N
. . N

RESULTS VBN N
With IN N
respect NN N
to TO N
operation NN N
time NN N
, , N
the DT N
DCS NNP N
group NN N
presented VBD N
significantly RB N
better JJR N
results NNS N
than IN N
the DT N
RIMSN NNP N
group NN N
( ( N
p=0.000 NN N
) ) N
. . N

However RB N
, , N
the DT N
blood NN N
loss NN N
was VBD N
significantly RB N
more RBR N
in IN N
the DT N
DCS NNP N
group NN N
( ( N
p=0.000 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
cumulative JJ N
rate NN N
of IN N
union NN N
( ( N
p=0.855 NN N
) ) N
, , N
range NN N
of IN N
motion NN N
of IN N
the DT N
knee NN N
( ( N
p=0.727 NN N
) ) N
, , N
overall JJ N
results NNS N
( ( N
p=0.925 NN N
) ) N
and CC N
complications NNS N
( ( N
p=0.927 NN N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
No NNP N
implant NN N
or CC N
surgical JJ N
technique NN N
is VBZ N
superior JJ N
to TO N
any DT N
other JJ N
under IN N
all DT N
circumstances NNS N
for IN N
distal JJ N
femoral JJ N
fracture NN N
. . N

RIMSN NNP N
is VBZ N
standard JJ N
care NN N
, , N
yet RB N
the DT N
biological JJ N
osteosynthesis NN N
using VBG N
DCS NNP N
is VBZ N
a DT N
very RB N
good JJ N
alternative NN N
for IN N
the DT N
treatment NN N
of IN N
distal JJ N
femoral JJ N
fractures NNS N
. . N

-DOCSTART- -X- O O

Community-based JJ 4_i
treatment NN 4_i
for IN N
opioid JJ N
dependent JJ N
offenders NNS N
: : N
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Primary NNP 4_i
care NN 4_i
opioid JJ 4_i
substitution NN 4_i
treatment NN 4_i
( ( 4_i
OST NNP 4_i
) ) 4_i
has VBZ N
not RB N
been VBN N
compared VBN N
to TO N
program-based JJ N
OST NNP 3_i
for IN N
community-supervised JJ N
offenders NNS N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
project NN N
was VBD N
to TO N
compare VB N
primary JJ N
care NN N
to TO N
specialist VB N
supervised JJ N
OST NNP N
for IN N
opioid JJ N
dependent JJ N
offenders NNS N
in IN N
terms NNS N
of IN N
substance NN N
use NN N
and CC N
HIV NNP N
risk NN N
outcomes NNS N
. . N

METHODS NNP N
This DT N
project NN N
randomly RB N
assigned VBD N
15 CD N
jail NN N
diversion NN N
participants NNS N
to TO N
either DT N
: : N
( ( N
i NN N
) ) N
primary NN 4_i
care NN 4_i
buprenorphine NN 6_i
OST NNP 4_i
, , N
( ( N
ii NN N
) ) N
specialist NN 4_i
facility NN 4_i
buprenorphine NN 6_i
OST NNP 4_i
, , N
or CC N
( ( N
iii JJ N
) ) N
specialist NN 4_i
facility NN 4_i
methadone NN 6_i
OST NNP 4_i
. . N

Participation NNP N
lasted VBD N
13.5 CD N
months NNS N
( ( N
12-month JJ N
active JJ N
treatment NN N
plus CC N
a DT N
post-participation JJ N
visit NN N
) ) N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
endorsed VBN N
0 CD N
days NNS N
of IN N
opioid JJ N
use NN N
in IN N
the DT N
previous JJ N
14 CD N
at IN N
follow-up NN N
. . N

Specialty NNP N
care NN N
reduced VBD N
HIV NNP N
risk NN N
( ( N
Risk NNP N
Assessment NNP N
Battery NNP N
composite JJ N
score NN N
) ) N
over IN N
6 CD N
months NNS N
( ( N
-.24 VB N
? . N
.17 NN N
) ) N
compared VBN N
to TO N
primary VB N
care NN N
( ( N
.02 VB N
? . N
.14 NN N
; : N
p CC N
= NNP N
.032 NNP N
) ) N
. . N

CONCLUSION NNP N
Findings NNP N
support NN N
primary NN N
care NN N
OST NNP N
feasibility NN N
for IN N
a DT N
community-supervised JJ N
offender NN N
sample NN N
. . N

Specialist NNP N
care NN N
may MD N
facilitate VB N
improvements NNS N
in IN N
secondary JJ N
outcomes NNS N
, , N
such JJ N
as IN N
HIV NNP N
risk NN N
behaviors NNS N
. . N

SCIENTIFIC NNP N
SIGNIFICANCE NNP N
Further NNP N
research NN N
is VBZ N
needed VBN N
to TO N
clarify VB N
( ( N
i NN N
) ) N
the DT N
role NN N
of IN N
primary JJ N
care NN N
in IN N
addicted VBN N
offender NN N
management NN N
, , N
and CC N
( ( N
ii NN N
) ) N
the DT N
matching NN N
of IN N
offenders NNS N
, , N
based VBN N
upon IN N
history NN N
and CC N
co-morbidity NN N
, , N
to TO N
care VB N
coordination NN N
conditions NNS N
. . N

-DOCSTART- -X- O O

Human JJ N
achaete-scute JJ N
homologue NN N
( ( N
hASH1 NN N
) ) N
mRNA NN N
level NN N
as IN N
a DT N
diagnostic JJ N
marker NN N
to TO N
distinguish VB N
esthesioneuroblastoma NN N
from IN N
poorly RB N
differentiated VBN N
tumors NNS N
arising VBG N
in IN N
the DT N
sinonasal NN N
tract NN N
. . N

Distinction NN N
of IN N
high-grade JJ N
esthesioneuroblastomas NN N
from IN N
other JJ N
poorly RB N
differentiated VBN N
tumors NNS N
arising VBG N
in IN N
the DT N
nasal JJ N
cavity NN N
is VBZ N
an DT N
important JJ N
diagnostic JJ N
challenge NN N
because IN N
it PRP N
determines VBZ N
patient JJ N
management NN N
and CC N
prognosis NN N
. . N

The DT N
human JJ N
achaete-scute JJ N
homologue NN N
( ( N
hASH1 NN N
) ) N
gene NN N
is VBZ N
critical JJ N
in IN N
olfactory JJ N
neuronal JJ N
differentiation NN N
and CC N
is VBZ N
expressed VBN N
in IN N
immature NN N
olfactory NN N
cells NNS N
; : N
therefore RB N
, , N
it PRP N
could MD N
have VB N
potential JJ N
use NN N
as IN N
a DT N
diagnostic JJ N
marker NN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
value NN N
of IN N
hASH1 JJ N
messenger NN N
RNA NNP N
( ( N
mRNA NN N
) ) N
levels NNS N
in IN N
differentiating VBG N
esthesioneuroblastoma NN N
from IN N
other JJ N
poorly RB N
differentiated VBN N
tumors NNS N
. . N

A DT N
real-time JJ 2_i
polymerase NN 2_i
chain NN 2_i
reaction NN 2_i
assay NN 2_i
was VBD N
developed VBN N
, , N
permitting VBG N
the DT N
comparative JJ N
determination NN N
of IN N
hASH1 NN N
mRNA NN N
levels NNS N
in IN N
triplicate NN N
in IN N
a DT N
double-blind JJ N
pilot NN N
study NN N
including VBG N
24 CD N
frozen JJ N
cases NNS N
of IN N
esthesioneuroblastoma NN N
and CC N
poorly RB N
differentiated VBN N
tumors NNS N
. . N

All DT N
4 CD N
positive JJ N
cases NNS N
were VBD N
esthesioneuroblastomas JJ N
, , N
and CC N
all DT N
19 CD N
poorly RB N
differentiated VBN N
tumors NNS N
were VBD N
negative JJ N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
an DT N
inverse JJ N
association NN N
between IN N
the DT N
grade NN N
of IN N
esthesioneuroblastomas NN N
and CC N
hASH1 NN N
mRNA NN N
levels NNS N
. . N

The DT N
hASH1 NN N
mRNA FW N
level NN N
might MD N
represent VB N
a DT N
useful JJ N
tool NN N
for IN N
distinguishing VBG N
esthesioneuroblastoma NN N
from IN N
poorly RB N
differentiated VBN N
tumors NNS N
of IN N
the DT N
sinonasal JJ N
region NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
m-chlorophenylpiperazine NN 3_i
on IN N
plasma NN N
homovanillic JJ N
acid NN N
concentrations NNS N
in IN N
healthy JJ N
subjects NNS N
. . N

In IN N
view NN N
of IN N
the DT N
abundant JJ N
anatomical JJ N
and CC N
functional JJ N
interactions NNS N
between IN N
serotonin NN N
and CC N
dopamine NN N
systems NNS N
, , N
this DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
the DT N
serotonin JJ N
agonist NN N
, , N
m-chlorophenylpiperazine NN 3_i
( ( 3_i
mCPP NN 3_i
) ) 3_i
on IN N
plasma NN N
concentrations NNS N
of IN N
the DT N
dopamine NN N
metabolite NN N
, , N
homovanillic JJ N
acid NN N
. . N

Plasma NNP N
prolactin NN N
levels NNS N
, , N
body NN N
temperature NN N
, , N
and CC N
mCPP RB N
blood NN N
level NN N
were VBD N
also RB N
measured VBN N
. . N

mCPP NN 3_i
( ( N
0.35 CD N
mg/kg NN N
) ) N
and CC N
placebo $ 7_i
were VBD N
administered VBN N
orally RB N
to TO N
10 CD N
healthy JJ N
men NNS N
in IN N
a DT N
randomized JJ N
double-blind NN N
design NN N
. . N

Variables NNS N
were VBD N
measured VBN N
for IN N
210 CD N
min NNS N
after IN N
administration NN N
of IN N
capsules NNS N
. . N

mCPP NNS N
raised VBD N
prolactin NN N
and CC N
temperature NN N
as IN N
compared VBN N
to TO N
placebo VB N
, , N
but CC N
did VBD N
not RB N
affect VB N
plasma NN N
homovanillic JJ N
acid JJ N
concentrations NNS N
. . N

Results VB N
suggest JJS N
that IN N
mCPP NN N
does VBZ N
not RB N
alter VB N
dopamine NN N
function NN N
. . N

-DOCSTART- -X- O O

Preventing VBG N
paclitaxel-induced JJ N
peripheral JJ N
neuropathy NN N
: : N
a DT N
phase NN N
II NNP N
trial NN N
of IN N
vitamin NN 3_i
E NNP 3_i
supplementation NN 3_i
. . N

A DT N
randomized JJ N
, , N
controlled VBD N
trial NN N
was VBD N
performed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
vitamin NN 3_i
E NNP 3_i
supplementation NN 3_i
for IN N
prophylaxis NN N
against IN N
paclitaxel-induced JJ N
peripheral JJ N
neuropathy NN N
( ( N
PIPN NNP N
) ) N
. . N

Thirty-two JJ N
patients NNS N
undergoing VBG N
six CD N
courses NNS N
of IN N
paclitaxel-based JJ 3_i
chemotherapy NN 3_i
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
chemotherapy NN 3_i
with IN 3_i
vitamin NN 3_i
E NNP 3_i
( ( N
300 CD N
mg NN N
twice RB N
a DT N
day NN N
, , N
Group NNP N
I PRP N
) ) N
or CC N
chemotherapy NN 3_i
without IN 3_i
vitamin NN 3_i
E NNP 3_i
supplementation NN 3_i
( ( N
Group NNP N
II NNP N
) ) N
. . N

A DT N
detailed JJ N
neurological JJ N
examination NN N
and CC N
electrophysiological JJ N
study NN N
was VBD N
performed VBN N
during IN N
and CC N
3 CD N
months NNS N
after IN N
chemotherapy NN 3_i
. . N

The DT N
severity NN N
of IN N
PIPN NNP N
was VBD N
summarized VBN N
by IN N
means NNS N
of IN N
a DT N
modified JJ N
Peripheral NNP N
Neuropathy NNP N
( ( N
PNP NNP N
) ) N
score NN N
. . N

The DT N
incidence NN N
of IN N
neurotoxicity NN N
differed VBN N
significantly RB N
between IN N
groups NNS N
, , N
occurring VBG N
in IN N
3/16 CD N
( ( N
18.7 CD N
% NN N
) ) N
patients NNS N
assigned VBN N
to TO N
the DT N
vitamin NN 3_i
E NNP 3_i
supplementation NN 3_i
group NN N
and CC N
in IN N
10/16 CD N
( ( N
62.5 CD N
% NN N
) ) N
controls VBZ N
( ( N
P=0.03 NNP N
) ) N
. . N

The DT N
relative JJ N
risk NN N
( ( N
RR NNP N
) ) N
of IN N
developing VBG N
PIPN NNP N
was VBD N
significantly RB N
higher JJR N
in IN N
controls NNS N
than IN N
in IN N
vitamin JJ 3_i
E NNP 3_i
group NN N
patients NNS N
( ( N
RR=0.3 NNP N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
=0.1-0.9 NN N
) ) N
. . N

Mean JJ N
PNP NNP N
scores NNS N
were VBD N
2.25+/-5.1 CD N
( ( N
range VB N
0-15 NNP N
) ) N
for IN N
patients NNS N
in IN N
Group NNP N
I PRP N
and CC N
11+/-11.63 JJ N
( ( N
range VB N
0-32 NN N
) ) N
for IN N
those DT N
in IN N
Group NNP N
II NNP N
( ( N
P=0.01 NNP N
) ) N
. . N

Vitamin NNP 3_i
E NNP 3_i
supplementation NN 3_i
was VBD N
well RB N
tolerated VBN N
and CC N
showed VBD N
an DT N
excellent JJ N
safety NN N
profile NN N
. . N

This DT N
study NN N
shows VBZ N
that IN N
vitamin NN 3_i
E NNP 3_i
effectively RB N
and CC N
safely RB N
protects VBZ N
patients NNS N
with IN N
cancer NN N
from IN N
the DT N
occurrence NN N
of IN N
paclitaxel-induced JJ N
peripheral JJ N
nerve NN N
damage NN N
. . N

A DT N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
trial NN N
is VBZ N
needed VBN N
to TO N
confirm VB N
these DT N
results NNS N
. . N

-DOCSTART- -X- O O

[ VB N
The DT N
effect NN N
of IN N
indobufen NN 3_i
on IN N
aortocoronary JJ N
bypass NN N
patency NN N
after IN N
1 CD N
week NN N
and CC N
after IN N
1 CD N
year NN N
] NN N
. . N

A DT N
randomized JJ N
clinical JJ N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
effect NN N
of IN N
conventional JJ 3_i
antiaggregation NN 3_i
therapy NN 3_i
( ( 3_i
ASA NNP 3_i
plus CC 3_i
dipyridamole NN 3_i
) ) N
versus NN N
indobufen NN 3_i
in IN N
patients NNS N
after IN N
aortocoronary JJ N
bypass NN N
( ( N
ACB NNP N
) ) N
surgery NN N
. . N

The DT N
patency NN N
of IN N
venous JJ N
ACB NNP N
using VBG N
coronary JJ N
DSA NNP N
one CD N
week NN N
and CC N
one CD N
year NN N
after IN N
surgery NN N
was VBD N
evaluated VBN N
in IN N
52 CD N
patients NNS N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

The DT N
study NN N
included VBD N
only RB N
ACB NNP N
's POS N
with IN N
intraoperative JJ N
blood NN N
flow NN N
rates NNS N
< VBP N
or CC N
= VBP N
40 CD N
ml/min NN N
as IN N
it PRP N
is VBZ N
just RB N
these DT N
ACB NNP N
's POS N
which WDT N
are VBP N
at IN N
the DT N
highest JJS N
risk NN N
of IN N
early JJ N
and CC N
late JJ N
occlusions NNS N
. . N

While IN N
, , N
in IN N
the DT N
ASA NNP 3_i
plus CC 3_i
dipyridamole-treated JJ 3_i
group NN N
, , N
occlusions NNS N
were VBD N
found VBN N
in IN N
11 CD N
of IN N
the DT N
39 CD N
reconstructions NNS N
( ( N
28.2 CD N
% NN N
) ) N
, , N
the DT N
proportion NN N
was VBD N
nine CD N
out IN N
of IN N
37 CD N
procedures NNS N
( ( N
24.3 CD N
% NN N
) ) N
in IN N
the DT N
indobufen NN 3_i
group NN N
. . N

One CD N
year NN N
after IN N
surgery NN N
, , N
occlusion NN N
was VBD N
found VBN N
in IN N
14 CD N
out IN N
of IN N
32 CD N
ACB NNP N
's POS N
( ( N
43.7 CD N
% NN N
) ) N
in IN N
the DT N
ASA NNP N
plus CC N
dipyridamole JJ 3_i
group NN N
compared VBN N
to TO N
14 CD N
occlusions NNS N
in IN N
31 CD N
ACB NNP N
's POS N
( ( N
45.2 CD N
% NN N
) ) N
in IN N
the DT N
indobufen NN 3_i
group NN N
. . N

The DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
occlusions NNS N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Because IN N
of IN N
some DT N
benefits NNS N
of IN N
indobufen NN N
compared VBN N
to TO N
ASA NNP N
( ( N
shorter JJR N
time NN N
of IN N
effect NN N
, , N
superior JJ N
tolerance NN N
in IN N
patients NNS N
with IN N
ulceration NN N
) ) N
, , N
the DT N
former JJ N
drug NN N
can MD N
be VB N
recommended VBN N
for IN N
use NN N
in IN N
some DT N
indicated JJ N
cases NNS N
. . N

-DOCSTART- -X- O O

Safety NNP N
assessment NN N
of IN N
docosahexaenoic NN 3_i
acid NN 3_i
in IN N
X-linked JJ N
retinitis NN N
pigmentosa NN N
: : N
the DT N
4-year JJ N
DHAX NNP N
trial NN N
. . N

PURPOSE NNP N
Docosahexaenoic NNP N
acid NN N
( ( N
DHA NNP N
) ) N
continues VBZ N
to TO N
be VB N
evaluated VBN N
and CC N
recommended VBN N
as IN N
treatment NN N
and CC N
prophylaxis NN N
for IN N
various JJ N
diseases NNS N
. . N

We PRP N
recently RB N
assessed VBD N
efficacy NN N
of IN N
high-dose JJ N
DHA NNP N
supplementation NN N
to TO N
slow VB N
vision NN N
loss NN N
in IN N
patients NNS N
with IN N
X-linked JJ N
retinitis NN N
pigmentosa NN N
( ( N
XLRP NNP N
) ) N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

Because IN N
DHA NNP N
is VBZ N
a DT N
highly RB N
unsaturated JJ N
fatty JJ N
acid NN N
, , N
it PRP N
could MD N
serve VB N
as IN N
a DT N
target NN N
for IN N
free-radical JJ N
induced JJ N
oxidation NN N
, , N
resulting VBG N
in IN N
increased VBN N
oxidative JJ N
stress NN N
. . N

Biosafety NNP N
was VBD N
monitored VBN N
during IN N
the DT N
4-year JJ N
trial NN N
to TO N
determine VB N
whether IN N
DHA NNP N
supplementation NN N
was VBD N
associated VBN N
with IN N
identifiable JJ N
risks NNS N
. . N

METHODS NNP N
Males NNP N
( ( N
n JJ N
= VBZ N
78 CD N
; : N
7-31 CD N
years NNS N
) ) N
meeting NN N
entry NN N
criteria NNS N
were VBD N
enrolled VBN N
. . N

The DT N
modified JJ N
intent-to-treat JJ N
cohort NN N
( ( N
DHA NNP N
= NNP N
33 CD N
; : N
placebo NN 7_i
= VBZ N
27 CD N
) ) N
adhered VBD N
to TO N
the DT N
protocol NN N
? . N
1 CD N
year NN N
. . N

Participants NNS N
were VBD N
randomized VBN N
to TO N
an DT N
oral JJ N
dose NN N
of IN N
30 CD N
mg/kg/d NNS N
DHA NNP N
or CC N
placebo VB N
plus CC N
a DT N
daily JJ N
multivitamin NN N
. . N

Comprehensive NNP N
metabolic JJ N
analyses NNS N
were VBD N
assessed VBN N
for IN N
group NN N
differences NNS N
. . N

Treatment-emergent JJ N
adverse JJ N
events NNS N
including VBG N
blood NN N
chemistry NN N
metabolites NNS N
were VBD N
recorded VBN N
. . N

RESULTS VBN N
By IN N
year NN N
4 CD N
, , N
supplementation NN N
elevated VBD N
plasma NN N
and CC N
red JJ N
blood NN N
cell-DHA JJ N
4.4- JJ N
and CC N
3.6-fold JJ N
, , N
respectively RB N
, , N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
0.00001 CD N
) ) N
. . N

Over IN N
the DT N
trial NN N
duration NN N
, , N
no DT N
significant JJ N
differences NNS N
between IN N
DHA NNP N
and CC N
placebo NN N
groups NNS N
were VBD N
found VBN N
for IN N
vitamin NN N
A NNP N
, , N
vitamin NN N
E NNP N
, , N
platelet NN N
aggregation NN N
, , N
antioxidant JJ N
activity NN N
, , N
lipoprotein NN N
cholesterol NN N
, , N
or CC N
oxidized VBN N
LDL NNP N
levels NNS N
( ( N
all DT N
P NNP N
> NNP N
0.14 CD N
) ) N
. . N

Adverse JJ N
events NNS N
were VBD N
transient JJ N
and CC N
not RB N
considered VBN N
severe JJ N
( ( N
e.g. JJ N
, , N
gastrointestinal JJ N
[ NN N
GI NNP N
] NNP N
irritability NN N
, , N
blood NN N
chemistry NN N
alterations NNS N
) ) N
. . N

One CD N
participant NN N
was VBD N
unable JJ N
to TO N
tolerate VB N
persistent JJ N
GI NNP N
discomfort NN N
. . N

CONCLUSIONS NNP N
Long-term NNP N
, , N
high-dose JJ N
DHA NNP N
supplementation NN N
to TO N
patients NNS N
with IN N
XLRP NNP N
was VBD N
associated VBN N
with IN N
limited JJ N
safety NN N
risks NNS N
in IN N
this DT N
4-year JJ N
trial NN N
. . N

Nevertheless NNP N
, , N
GI NNP N
symptoms NNS N
should MD N
be VB N
monitored VBN N
in IN N
all DT N
patients NNS N
taking VBG N
high JJ N
dose JJ N
DHA NNP N
especially RB N
those DT N
with IN N
personal JJ N
or CC N
family NN N
history NN N
of IN N
GI NNP N
disturbances NNS N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00100230 NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double JJ N
dummy NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
oral JJ N
cefditoren NNS 3_i
pivoxil VBP 3_i
400mg CD N
once RB N
daily JJ N
as IN N
switch NN N
therapy NN N
after IN N
intravenous JJ N
ceftriaxone NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
pyelonephritis NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
clinical JJ N
and CC N
bacteriological JJ N
effectiveness NN N
of IN N
intravenous JJ N
( ( N
IV NNP N
) ) N
ceftriaxone NN 3_i
followed VBN N
by IN N
oral JJ N
cefditoren NNS 3_i
pivoxil VBP 3_i
or CC N
IV NNP 3_i
ceftriaxone NN 3_i
for IN N
acute JJ N
pyelonephritis NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
controlled JJ N
trial NN N
of IN N
patients NNS N
with IN N
a DT N
presumptive JJ N
diagnosis NN N
of IN N
acute JJ N
pyelonephritis NN N
was VBD N
performed VBN N
. . N

Daily JJ N
2g CD 3_i
IV NNP 3_i
ceftriaxone NN 3_i
was VBD N
initially RB N
given VBN N
to TO N
all DT N
patients NNS N
. . N

After IN N
day NN N
3 CD N
, , N
patients NNS N
who WP N
satisfied VBD N
the DT N
criteria NNS N
for IN N
switch NN N
therapy NN N
were VBD N
randomized VBN N
to TO N
either DT N
group NN N
A NNP N
( ( N
IV NNP 3_i
ceftriaxone NN 3_i
) ) N
or CC N
group NN N
B NNP N
( ( N
oral JJ 3_i
cefditoren NNS 3_i
pivoxil VBP 3_i
400mg CD 3_i
once RB N
daily JJ N
) ) N
. . N

RESULTS JJ N
Eighty-two JJ N
patients NNS N
were VBD N
enrolled VBN N
; : N
41 CD N
( ( N
50 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
41 CD N
( ( N
50 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
B NNP N
were VBD N
evaluated VBN N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
baseline NN N
characteristics NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

Clinical JJ N
cure NN N
was VBD N
observed VBN N
in IN N
39 CD N
of IN N
41 CD N
( ( N
95.1 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
41 CD N
of IN N
41 CD N
( ( N
100 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
B NNP N
( ( N
p=0.15 NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
-0.12 VBP N
to TO N
0.02 CD N
) ) N
. . N

Urine NNP N
bacteriological JJ N
eradication NN N
was VBD N
found VBN N
in IN N
63.4 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
60 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p=0.75 NN N
, , N
95 CD N
% NN N
CI NNP N
-0.18 NNP N
to TO N
0.25 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
adverse JJ N
effects NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
IV NNP N
ceftriaxone NN 3_i
followed VBN N
by IN N
oral JJ N
cefditoren NNS 3_i
pivoxil NN 3_i
is VBZ N
highly RB N
effective JJ N
and CC N
well-tolerated JJ N
for IN N
the DT N
treatment NN N
of IN N
acute JJ N
pyelonephritis NN N
, , N
even RB N
for IN N
uropathogens NNS N
with IN N
a DT N
high JJ N
proportion NN N
of IN N
quinolone-resistant JJ N
strains NNS N
. . N

-DOCSTART- -X- O O

Eye NNP N
movements NNS N
affirm NN N
: : N
automatic JJ N
overt NN N
gaze NN N
and CC N
arrow NN N
cueing NN N
for IN N
typical JJ N
adults NNS N
and CC N
adults NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

People NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
show NN N
reduced VBN N
interest NN N
towards NNS N
social JJ N
aspects NNS N
of IN N
the DT N
environment NN N
and CC N
a DT N
lesser JJR N
tendency NN N
to TO N
follow VB N
other JJ N
people NNS N
's POS N
gaze NN N
in IN N
the DT N
real JJ N
world NN N
. . N

However RB N
, , N
most JJS N
studies NNS N
have VBP N
shown VBN N
that IN N
people NNS N
with IN N
ASD NNP N
do VBP N
respond VB N
to TO N
eye-gaze JJ N
cues NNS N
in IN N
experimental JJ N
paradigms NN N
, , N
though IN N
it PRP N
is VBZ N
possible JJ N
that IN N
this DT N
behaviour NN N
is VBZ N
based VBN N
on IN N
an DT N
atypical JJ N
strategy NN N
. . N

We PRP N
tested VBD N
this DT N
possibility NN N
in IN N
adults NNS N
with IN N
ASD NNP N
using VBG N
a DT N
cueing NN 6_i
task NN 6_i
combined VBN 2_i
with IN 2_i
eye-movement JJ 2_i
recording NN 2_i
. . N

Both DT N
eye NN N
gaze NN N
and CC N
arrow VB N
pointing VBG N
distractors NNS N
resulted VBD N
in IN N
overt JJ N
cueing NN N
effects NNS N
, , N
both DT N
in IN N
terms NNS N
of IN N
increased VBN N
saccadic JJ N
reaction NN N
times NNS N
, , N
and CC N
in IN N
proportions NNS N
of IN N
saccades NNS N
executed VBN N
to TO N
the DT N
cued VBN N
direction NN N
instead RB N
of IN N
to TO N
the DT N
target NN N
, , N
for IN N
both DT N
participant JJ N
groups NNS N
. . N

Our PRP$ N
results NNS N
confirm VBP N
previous JJ N
reports NNS N
that IN N
eye NN N
gaze NN N
cues NNS N
as RB N
well RB N
as IN N
arrow NN N
cues NNS N
result VBP N
in IN N
automatic JJ N
orienting NN N
of IN N
overt JJ N
attention NN N
. . N

Moreover RB N
, , N
since IN N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
between IN N
arrow NN N
and CC N
eye NN N
gaze NN N
cues NNS N
, , N
we PRP N
conclude VBP N
that IN N
overt JJ N
attentional JJ N
orienting NN N
in IN N
ASD NNP N
, , N
at IN N
least JJS N
in IN N
response NN N
to TO N
centrally RB N
presented VBN N
schematic JJ N
directional JJ N
distractors NNS N
, , N
is VBZ N
typical JJ N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
prophylactic JJ 3_i
fentanyl NN 3_i
on IN N
shivering VBG N
in IN N
elective JJ N
caesarean JJ N
section NN N
under IN N
epidural JJ N
analgesia NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
randomised VBN N
double-blind NN N
study NN N
were VBD N
to TO N
investigate VB N
whether IN N
25 CD N
micrograms NNS N
of IN N
fentanyl NN 3_i
administered VBN N
prophylactically RB N
by IN N
the DT N
epidural JJ N
route NN N
would MD N
influence VB N
the DT N
incidence NN N
of IN N
shivering VBG N
in IN N
parturients NNS N
who WP N
underwent VBP N
elective JJ N
Caesarean JJ N
section NN N
under IN N
epidural JJ N
analgesia NN N
and CC N
whether IN N
it PRP N
would MD N
affect VB N
the DT N
axillary JJ N
and CC N
calf JJ N
temperatures NNS N
. . N

There EX N
was VBD N
a DT N
50 CD N
% NN N
reduction NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
in IN N
the DT N
overall JJ N
incidence NN N
of IN N
shivering VBG N
in IN N
patients NNS N
who WP N
received VBD N
fentanyl NN 3_i
and CC N
there EX N
was VBD N
some DT N
evidence NN N
to TO N
suggest VB N
that IN N
low-dose JJ N
epidural JJ N
fentanyl NN N
might MD N
reduce VB N
shivering VBG N
by IN N
an DT N
influence NN N
on IN N
thermoregulation NN N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
once-daily JJ 3_i
monotherapy NN 3_i
with IN N
a DT N
new JJ N
nifedipine NN N
sustained VBN N
release NN N
calcium NN N
antagonist NN N
. . N

Data NNS N
from IN N
2 CD N
separate JJ N
multicenter NN N
, , N
double-blind JJ N
clinical JJ N
studies NNS N
following VBG N
the DT N
same JJ N
protocol NN N
, , N
except IN N
for IN N
the DT N
selection NN N
of IN N
doses NNS N
, , N
were VBD N
pooled VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
fixed JJ N
doses NNS N
of IN N
a DT N
new JJ 3_i
sustained-release NN 3_i
( ( 3_i
SR NNP 3_i
) ) 3_i
formulation NN 3_i
of IN 3_i
nifedipine JJ 3_i
compared VBN N
with IN N
placebo NN 7_i
in IN N
388 CD N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
uncomplicated JJ N
essential JJ N
hypertension NN N
. . N

After IN N
a DT N
3-6 JJ N
week NN N
placebo NN N
washout IN N
period NN N
, , N
the DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
placebo NN 3_i
or CC 3_i
nifedipine JJ 3_i
SR-20 JJ N
mg NN N
( ( N
study NN N
I PRP N
only RB N
) ) N
, , N
50 CD N
mg NN N
, , N
100 CD N
mg NN N
, , N
or CC N
150 CD N
mg NN N
( ( N
study VB N
II NNP N
only RB N
) ) N
. . N

Among IN N
the DT N
278 CD N
patients NNS N
who WP N
completed VBD N
6 CD N
weeks NNS N
of IN N
active JJ N
therapy NN N
, , N
mean JJ N
supine VBP N
diastolic JJ N
blood NN N
pressure NN N
reductions NNS N
from IN N
pretreatment JJ N
baseline NN N
were VBD N
5.9 CD N
, , N
9.3 CD N
, , N
9.2 CD N
, , N
11.1 CD N
, , N
and CC N
13.2 CD N
mm NN N
Hg NNP N
in IN N
the DT N
placebo NN N
, , N
20- JJ N
, , N
50- JJ N
, , N
100- JJ N
, , N
and CC N
150-mg JJ N
groups NNS N
, , N
respectively RB N
. . N

The DT N
reductions NNS N
achieved VBN N
in IN N
each DT N
of IN N
the DT N
nifedipine JJ 3_i
SR NNP N
groups NNS N
were VBD N
statistically RB N
significant JJ N
versus NN N
baseline NN N
values NNS N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

All DT N
nifedipine-SR JJ N
doses NNS N
reduced VBN N
supine JJ N
systolic JJ N
blood NN N
pressure NN N
significantly RB N
more RBR N
than IN N
placebo NN 7_i
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
linear JJ N
relationship NN N
between IN N
the DT N
log NN N
of IN N
the DT N
dose NN N
and CC N
the DT N
blood NN N
pressure NN N
reduction NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Automated VBN N
ambulatory JJ N
blood NN N
pressure NN N
recordings NNS N
performed VBN N
in IN N
221 CD N
of IN N
the DT N
patients NNS N
showed VBD N
that IN N
the DT N
blood NN N
pressure NN N
was VBD N
lowered VBN N
evenly RB N
through IN N
the DT N
entire JJ N
24-hour JJ N
dosing NN N
period NN N
. . N

The DT N
doses NNS N
that WDT N
were VBD N
effective JJ N
and CC N
associated VBN N
with IN N
the DT N
fewest JJS N
adverse JJ N
reactions NNS N
were VBD N
20 CD N
mg NNS N
and CC N
50 CD N
mg NN N
once RB N
daily RB N
. . N

-DOCSTART- -X- O O

Dose-response NNP N
comparison NN N
of IN N
RRR-alpha-tocopherol NNP 3_i
and CC 3_i
all-racemic JJ 3_i
alpha-tocopherol NN 3_i
on IN N
LDL NNP N
oxidation NN N
. . N

Much JJ N
data NNS N
have VBP N
accrued VBN N
in IN N
support NN N
of IN N
the DT N
concept NN N
that IN N
oxidation NN N
of IN N
LDL NNP N
is VBZ N
a DT N
key JJ N
early JJ N
step NN N
in IN N
atherogenesis NN N
. . N

The DT N
most RBS N
consistent JJ N
data NNS N
with IN N
respect NN N
to TO N
micronutrient VB N
antioxidants NNS N
and CC N
atherosclerosis NN N
appear VBP N
to TO N
relate VB N
to TO N
alpha-tocopherol NN 3_i
( ( N
AT NNP N
) ) N
, , N
the DT N
predominant JJ N
lipid-soluble JJ N
antioxidant NN N
in IN N
LDL NNP N
. . N

There EX N
are VBP N
scant JJ N
data NNS N
on IN N
the DT N
direct JJ N
comparison NN N
of IN N
RRR-AT NNP N
and CC N
all-racemic JJ N
( ( N
rac NN N
) ) N
-AT NN N
on IN N
LDL NNP N
oxidizability NN N
. . N

Hence NNP N
, , N
the DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
relative JJ N
effects NNS N
of IN N
RRR-AT NNP N
and CC N
all-rac-AT NN N
on IN N
plasma NN N
antioxidant NN N
levels NNS N
and CC N
LDL NNP N
oxidation NN N
in IN N
healthy JJ N
persons NNS N
in IN N
a DT N
dose-response JJ N
study NN N
. . N

The DT N
effect NN N
of IN N
RRR-AT NNP 3_i
and CC 3_i
all-rac-AT NN 3_i
at IN N
doses NNS N
of IN N
100 CD N
, , N
200 CD N
, , N
400 CD N
, , N
and CC N
800 CD N
IU/d NNP N
on IN N
plasma NN N
and CC N
LDL NNP N
AT NNP N
levels NNS N
and CC N
LDL NNP N
oxidation NN N
was VBD N
tested VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
79 CD N
healthy JJ N
subjects NNS N
. . N

Copper-catalyzed JJ N
oxidation NN N
of IN N
LDL NNP N
was VBD N
monitored VBN N
by IN N
measuring VBG N
the DT N
formation NN N
of IN N
conjugated JJ N
dienes NNS N
and CC N
lipid JJ N
peroxides NNS N
over IN N
an DT N
8-hour JJ N
time NN N
course NN N
at IN N
baseline NN N
and CC N
again RB N
after IN N
8 CD N
weeks NNS N
. . N

Plasma NNP N
AT NNP N
, , N
lipid-standardized JJ N
AT NNP N
, , N
and CC N
LDL NNP N
AT NNP N
levels NNS N
rose VBD N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
in IN N
both DT N
the DT N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
groups NNS N
compared VBN N
with IN N
baseline NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
plasma NN N
, , N
lipid-standardized JJ N
, , N
and CC N
LDL NNP N
AT NNP N
levels NNS N
between IN N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
supplementation NN N
at IN N
any DT N
dose JJ N
comparison NN N
. . N

The DT N
lag NN N
phases NNS N
of IN N
oxidation NN N
were VBD N
significantly RB N
prolonged VBN N
with IN N
doses NNS N
> VBP N
or CC N
= VBP N
400 CD N
IU/d NNP N
of IN N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
, , N
as IN N
measured VBN N
by IN N
conjugated-dienes NNS N
assay NNS N
and CC N
at IN N
400 CD N
IU/d NNP N
of IN N
RRR-AT NNP N
and CC N
800 CD N
IU/d NNP N
of IN N
both DT N
forms NNS N
of IN N
AT NNP N
by IN N
lipid JJ N
peroxide NN N
assay NN N
. . N

Again NNP N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
lag NN N
phase NN N
of IN N
oxidation NN N
at IN N
each DT N
dose NN N
for IN N
RRR-AT NNP N
when WRB N
compared VBN N
with IN N
all-rac-AT NN N
. . N

Also RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
LDL NNP N
oxidation NN N
after IN N
in IN N
vitro JJ N
enrichment NN N
of IN N
LDL NNP N
with IN N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
. . N

Thus RB N
, , N
supplementation NN N
with IN N
either DT N
RRR-AT JJ N
or CC N
all-rac-AT JJ N
resulted VBN N
in IN N
similar JJ N
increases NNS N
in IN N
plasma NN N
and CC N
LDL NNP N
AT NNP N
levels NNS N
at IN N
equivalent JJ N
IU NNP N
doses NNS N
, , N
and CC N
the DT N
degree NN N
of IN N
protection NN N
against IN N
copper-catalyzed JJ N
LDL NNP N
oxidation NN N
was VBD N
only RB N
evident JJ N
at IN N
doses NNS N
> VBP N
or CC N
= VBP N
400 CD N
IU/d NNP N
for IN N
both DT N
forms NNS N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
prostaglandin NN N
inhibition NN N
by IN N
indomethacin NN 3_i
on IN N
blood NN N
pressure NN N
and CC N
renal JJ N
function NN N
in IN N
hypertensive JJ N
patients NNS N
treated VBN N
with IN N
cilazapril NN 3_i
. . N

1 CD N
. . N

In IN N
a DT N
placebo-controlled JJ 7_i
double-blind JJ N
cross-over NN N
study NN N
lasting VBG N
6 CD N
weeks NNS N
, , N
twenty JJ N
patients NNS N
with IN N
essential JJ N
hypertension NN N
were VBD N
treated VBN N
with IN N
placebo NN 7_i
for IN N
2 CD N
weeks NNS N
followed VBN N
by IN N
oral JJ 3_i
cilazapril NN 3_i
2.5 CD N
mg NN N
once RB N
a DT N
day NN N
or CC N
oral JJ 3_i
indomethacin NN 3_i
50 CD N
mg NN N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

Afterwards NNS N
they PRP N
received VBD N
the DT N
combination NN N
of IN N
both DT N
drugs NNS N
for IN N
a DT N
further JJ N
2 CD N
weeks NNS N
. . N

2 CD N
. . N

Cilazapril NNP 3_i
significantly RB N
lowered VBD N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
for IN N
a DT N
period NN N
of IN N
24 CD N
h NNS N
post JJ N
administration NN N
. . N

3 CD N
. . N

Indomethacin NNP 3_i
significantly RB N
attenuated VBD N
the DT N
antihypertensive JJ N
activity NN N
of IN N
cilazapril NN 3_i
. . N

This DT N
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
who WP N
were VBD N
treated VBN N
for IN N
the DT N
initial JJ N
2 CD N
weeks NNS N
with IN N
indomethacin JJ 7_i
plus CC 7_i
placebo NN 7_i
( ( N
and CC N
subsequently RB N
with IN N
cilazapril NN 3_i
in IN N
addition NN N
) ) N
than IN N
in IN N
the DT N
subjects NNS N
who WP N
first RB N
received VBD N
cilazapril JJ 7_i
plus CC 7_i
placebo NN 7_i
and CC N
then RB N
the DT N
combination NN N
. . N

4 CD N
. . N

Correspondingly VB N
the DT N
decrease NN N
of IN N
plasma JJ N
renin NN N
activity NN N
( ( N
PRA NNP N
) ) N
and CC N
urinary JJ N
prostaglandin NN N
excretion NN N
( ( N
PGE2 NNP N
) ) N
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
treated VBD N
initially RB N
with IN N
indomethacin NN 3_i
. . N

5 CD N
. . N

The DT N
effect NN N
of IN N
indomethacin NN 3_i
on IN N
the DT N
antihypertensive JJ N
effect NN N
of IN N
cilazapril NN 3_i
appears VBZ N
to TO N
depend VB N
upon IN N
the DT N
sequence NN N
of IN N
drug NN N
administration NN N
. . N

-DOCSTART- -X- O O

A DT N
placebo-controlled JJ 7_i
, , N
randomized JJ N
clinical JJ N
trial NN N
using VBG N
testosterone NN 3_i
undecanoate NN 3_i
with IN 3_i
injectable JJ 3_i
norethisterone JJ 3_i
enanthate NN 3_i
: : 3_i
effect NN N
on IN N
anthropometric NN N
, , N
metabolic JJ N
and CC N
biochemical JJ N
parameters NNS N
. . N

Testosterone CD N
administered VBD N
alone RB N
or CC N
in IN N
combination NN N
with IN N
progestogens NNS N
in IN N
male JJ N
contraception NN N
induces NNS N
reversible JJ N
oligo-azoospermia JJ N
, , N
but CC N
its PRP$ N
effects NNS N
on IN N
body NN N
composition NN N
and CC N
metabolism NN N
are VBP N
less RBR N
known JJ N
. . N

We PRP N
analysed VBD N
anthropometric JJ N
and CC N
metabolic JJ N
parameters NNS N
in IN N
five CD N
groups NNS N
of IN N
10 CD N
males NNS N
: : N
four CD N
receiving VBG N
testosterone NN 3_i
undecanoate NN 3_i
( ( N
TU NNP N
: : N
1000 CD N
mg NN N
) ) N
plus CC 3_i
norethisterone JJ 3_i
enanthate NN 3_i
( ( N
NETE NNP N
: : N
200 CD N
mg NN N
) ) N
at IN N
different JJ N
intervals NNS N
( ( N
every DT N
8 CD N
weeks NNS N
: : N
NETE-8 JJ N
; : N
every DT N
12 CD N
weeks NNS N
: : N
NETE-12 NN N
; : N
every DT N
6 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
and CC N
then RB N
every DT N
12 CD N
weeks NNS N
: : N
NETE-6/12 JJ N
; : N
every DT N
6 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
and CC N
then RB N
TU NNP 3_i
plus CC 3_i
placebo JJ 3_i
every DT N
12 CD N
weeks NNS N
: : N
NETE-6/12/0 NNP N
) ) N
and CC N
one CD N
placebo NN 7_i
( ( N
NETE-0/0 NNP N
) ) N
for IN N
a DT N
total NN N
of IN N
48 CD N
weeks NNS N
. . N

Body NNP N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
and CC N
waist JJ N
circumference NN N
did VBD N
not RB N
change VB N
in IN N
any DT N
groups NNS N
except IN N
for IN N
the DT N
NETE-8 NNP N
in IN N
which WDT N
BMI NNP N
increased VBD N
significantly RB N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
. . N

Lean JJ N
body NN N
mass NN N
( ( N
MAMC NNP N
or CC N
AMA NNP N
) ) N
increased VBD N
significantly RB N
in IN N
the DT N
highest JJS N
hormonal JJ N
dose NN N
groups NNS N
( ( N
p JJ N
= NN N
0.04 CD N
, , N
NETE-6/12 NNP N
; : N
p VBZ N
= $ N
0.004 CD N
, , N
NETE-8 NNP N
) ) N
. . N

No UH N
differences NNS N
were VBD N
observed VBN N
in IN N
glucose JJ N
levels NNS N
, , N
insulin NN N
sensitivity NN N
index NN N
and CC N
lipid JJ N
profile NN N
as RB N
well RB N
as IN N
in IN N
biochemical JJ N
and CC N
cell NN N
count NN N
parameters NNS N
in IN N
any DT N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
NETE NNP N
and CC N
TU NNP N
for IN N
48 CD N
weeks NNS N
were VBD N
not RB N
accompanied VBN N
by IN N
any DT N
metabolic JJ N
changes NNS N
and CC N
any DT N
adverse JJ N
effects NNS N
. . N

The DT N
weight JJ N
gain NN N
of IN N
the DT N
highest JJS N
NETE JJ N
plus CC N
TU JJ N
dosage NN N
was VBD N
mainly RB N
because IN N
of IN N
gain NN N
in IN N
muscle NN N
mass NN N
. . N

-DOCSTART- -X- O O

The DT N
Tiotropium NNP 3_i
Safety NNP N
and CC N
Performance NNP N
in IN N
Respimat NNP N
Trial NNP N
( ( N
TIOSPIR NNP N
) ) N
, , N
a DT N
large JJ N
scale NN N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
parallel-group JJ N
trial-design NN N
and CC N
rationale NN N
. . N

BACKGROUND NNP N
Tiotropium NNP 3_i
bromide NN 3_i
is VBZ N
an DT N
effective JJ N
therapy NN N
for IN N
COPD NNP N
patients NNS N
. . N

Comparing VBG N
across IN N
programs NNS N
tiotropium VBP 3_i
Respimat NNP 3_i
Soft NNP 3_i
Mist NNP 3_i
inhaler NN 3_i
was VBD N
at IN N
least JJS N
as RB N
efficacious JJ N
as IN N
tiotropium NN 3_i
HandiHaler NNP 3_i
, , N
however RB N
, , N
concerns NNS N
have VBP N
been VBN N
raised VBN N
about IN N
tiotropium NN 3_i
's POS 3_i
safety NN N
when WRB N
given VBN N
via IN N
Respimat NNP N
. . N

METHODS NNP N
The DT N
TIOSPIR NNP N
trial NN N
( ( N
NCT01126437 NNP N
) ) N
compares VBZ N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
tiotropium NN N
Respimat NNP N
5 CD N
?g NNP N
once RB N
daily RB N
( ( N
marketed VBN N
) ) N
and CC N
2.5 CD N
?g NNS N
once RB N
daily JJ N
( ( N
investigational JJ N
) ) N
with IN N
tiotropium NN N
HandiHaler NNP N
18 CD N
? . N
once RB N
daily JJ N
( ( N
marketed VBN N
) ) N
. . N

The DT N
hypotheses NNS N
to TO N
be VB N
tested VBN N
are VBP N
1 CD N
) ) N
. . N

that IN N
tiotropium NN N
Respimat NNP N
5 CD N
?g NNP N
once RB N
daily RB N
and CC N
Respimat NNP N
2.5 CD N
?g NNP N
once RB N
daily RB N
are VBP N
non-inferior JJ N
to TO N
HandiHaler NNP N
in IN N
terms NNS N
of IN N
all-cause NN N
mortality NN N
, , N
and CC N
2 CD N
) ) N
. . N

that IN N
tiotropium NN N
Respimat NNP N
5 CD N
?g NNP N
once RB N
daily RB N
is VBZ N
superior JJ N
to TO N
HandiHaler NNP N
in IN N
terms NNS N
of IN N
time NN N
to TO N
first JJ N
exacerbation NN N
. . N

A DT N
spirometry NN N
substudy NN N
evaluates VBZ N
the DT N
bronchodilator NN N
efficacy NN N
. . N

The DT N
trial NN N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double JJ N
dummy NN N
, , N
event-driven JJ N
, , N
parallel JJ N
group NN N
study NN N
. . N

Participants NNS N
can MD N
use VB N
any DT N
background NN N
treatment NN N
for IN N
COPD NNP N
except IN N
inhaled JJ N
anticholinergic JJ N
agents NNS N
. . N

The DT N
study NN N
encompasses VBZ N
a DT N
wide JJ N
range NN N
of IN N
COPD NNP N
patients NNS N
, , N
e.g FW N
. . N

patients NNS N
with IN N
stable JJ N
cardiac JJ N
diseases NNS N
including VBG N
arrhythmia NN N
can MD N
be VB N
included VBN N
. . N

Clinical JJ N
sites NNS N
are VBP N
international JJ N
and CC N
include VBP N
both DT N
primary JJ N
care NN N
as RB N
well RB N
as IN N
specialists NNS N
. . N

RESULTS NNP N
To TO N
date NN N
, , N
over IN N
17,000 CD N
participants NNS N
have VBP N
been VBN N
randomized VBN N
from IN N
over IN N
1200 CD N
sites NNS N
in IN N
50 CD N
countries NNS N
with IN N
an DT N
anticipated JJ N
treatment NN N
duration NN N
of IN N
2-3 JJ N
years NNS N
. . N

CONCLUSION NNP N
TIOSPIR NNP N
will MD N
provide VB N
precise JJ N
estimates NNS N
of IN N
the DT N
relative JJ N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
Respimat NNP N
and CC N
HandiHaler NNP N
formulations NNS N
of IN N
tiotropium NN N
, , N
assess JJ N
potential JJ N
dose-dependence NN N
of IN N
important JJ N
outcomes NNS N
and CC N
provide VB N
information NN N
on IN N
the DT N
clinical JJ N
epidemiology NN N
of IN N
COPD NNP N
in IN N
a DT N
large JJ N
international JJ N
patient NN N
cohort NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
cross-over NN N
study NN N
of IN N
inhalation NN N
of IN N
diesel NN N
exhaust NN N
, , N
hematological JJ N
indices NNS N
, , N
and CC N
endothelial JJ N
markers NNS N
in IN N
humans NNS N
. . N

BACKGROUND NNP N
Exposure NNP N
to TO N
traffic-related JJ N
air NN N
pollution NN N
( ( N
TRAP NNP N
) ) N
is VBZ N
considered VBN N
a DT N
trigger NN N
for IN N
acute JJ N
cardiovascular JJ N
events NNS N
. . N

Diesel NNP N
Exhaust NNP N
( ( N
DE NNP N
) ) N
is VBZ N
a DT N
major JJ N
contributor NN N
to TO N
TRAP NNP N
in IN N
the DT N
world NN N
. . N

We PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
DE NNP N
inhalation NN N
on IN N
circulating VBG N
blood NN N
cell NN N
populations NNS N
, , N
hematological JJ N
indices NNS N
, , N
and CC N
systemic JJ N
inflammatory NN N
cytokines NNS N
in IN N
humans NNS N
using VBG N
a DT N
specialized JJ N
facility NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
balanced VBD N
to TO N
order NN N
, , N
17 CD N
metabolic JJ N
syndrome NN N
( ( N
MetS NNP N
) ) N
and CC N
15 CD N
healthy JJ N
subjects NNS N
inhaled VBN 3_i
filtered JJ 3_i
air NN 3_i
( ( 3_i
FA NNP 3_i
) ) 3_i
or CC N
DE NNP 3_i
exposure NN 3_i
in IN N
two-hour JJ N
sessions NNS N
on IN N
different JJ N
days NNS N
with IN N
a DT N
minimum JJ N
2-week JJ N
washout NN N
period NN N
. . N

We PRP N
collected VBD N
blood NN N
pre-exposure NN N
, , N
7 CD N
, , N
and CC N
22 CD N
hours NNS N
after IN N
exposure NN N
initiation NN N
and CC N
measured VBD N
the DT N
complete JJ N
blood NN N
count NN N
and CC N
differential JJ N
. . N

We PRP N
performed VBD N
multiplex JJ N
cytokine NN N
assay NN N
to TO N
measure VB N
the DT N
changes NNS N
in IN N
the DT N
systemic JJ N
inflammatory NN N
cytokines NNS N
, , N
and CC N
endothelial JJ N
adhesion NN N
molecules NNS N
( ( N
n=15 NN N
) ) N
. . N

A DT N
paired JJ N
analysis NN N
compared VBN N
the DT N
effect NN N
of IN N
DE NNP N
and CC N
FA NNP N
exposures NNS N
for IN N
the DT N
change NN N
from IN N
pre-exposure NN N
to TO N
the DT N
subsequent JJ N
time NN N
points NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
increase NN N
in IN N
the DT N
hematocrit NN N
was VBD N
noted VBN N
7 CD N
hrs NNS N
after IN N
DE NNP N
[ FW N
1.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.9 CD N
to TO N
1.9 CD N
% NN N
) ) N
] NN N
compared VBN N
to TO N
FA NNP N
exposure NN N
[ VBZ N
0.5 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
-0.09 NN N
to TO N
1.0 CD N
% NN N
) ) N
; : N
p=0.008 NN N
. . N

The DT N
hemoglobin NN N
levels NNS N
increased VBD N
non-significantly RB N
at IN N
7 CD N
hrs JJ N
post NN N
DE NNP N
[ NNP N
0.3 CD N
gm/dL NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.2 CD N
to TO N
0.5 CD N
gm/dL NN N
) ) N
] VBZ N
versus JJ N
FA NNP N
exposure NN N
[ VBZ N
0.2 CD N
gm/dL NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0 CD N
to TO N
0.3 CD N
gm/dL NN N
) ) N
] NN N
; : N
p=0.06 NN N
. . N

Furthermore RB N
, , N
the DT N
platelet NN N
count NN N
increased VBD N
22 CD N
hrs NN N
after IN N
DE NNP N
exposure NN N
in IN N
healthy JJ N
, , N
but CC N
not RB N
in IN N
MetS NNP N
subjects NNS N
[ FW N
DE NNP N
: : N
16.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
10.2 CD N
to TO N
23 CD N
) ) N
thousand CD N
platelets/mL JJ N
versus NN N
[ NN N
FA NNP N
: : N
3.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
-9.5 NN N
to TO N
16.3 CD N
) ) N
thousand CD N
platelets/mL NN N
) ) N
] NN N
; : N
p=0.04 NN N
. . N

No DT N
DE NNP N
effect NN N
was VBD N
observed VBN N
for IN N
WBC NNP N
, , N
neutrophils RB N
, , N
lymphocytes VBZ N
or CC N
erythrocytes VBZ N
. . N

Using VBG N
the DT N
multiplex JJ N
assay NN N
, , N
small JJ N
borderline NN N
significant JJ N
increases NNS N
in IN N
matrix JJ N
metalloproteinase-9 NN N
, , N
interleukins NNS N
( ( N
IL NNP N
) ) N
-1 NNP N
beta NN N
, , N
6 CD N
and CC N
10 CD N
occurred VBD N
7 CD N
hrs NN N
post NN N
exposure NN N
initiation NN N
, , N
whereas IN N
E-selectin NNP N
, , N
intercellular JJ N
adhesion NN N
molecule-1 NN N
, , N
and CC N
vascular JJ N
cell NN N
adhesion NN N
molecule NN N
-1 NNP N
, , N
and CC N
myeloperoxidase VB N
22 CD N
hrs NN N
post NN N
exposure NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
short-term JJ N
DE NNP N
exposure NN N
results NNS N
in IN N
hemoconcentration NN N
and CC N
thrombocytosis NN N
, , N
which WDT N
are VBP N
important JJ N
determinants NNS N
of IN N
acute JJ N
cardiovascular JJ N
events NNS N
. . N

Multiplex NNP N
assay VBP N
showed VBD N
a DT N
non-significant JJ N
increase NN N
in IN N
IL-1? NNP N
and CC N
IL-6 NNP N
immediately RB N
post NN N
exposure NN N
followed VBN N
by IN N
myeloperoxidase NN N
and CC N
endothelial JJ N
activation NN N
molecules NNS N
. . N

Further NNP N
specific JJ N
assays NNS N
in IN N
a DT N
larger JJR N
population NN N
will MD N
improve VB N
our PRP$ N
understanding NN N
of IN N
the DT N
systemic JJ N
inflammatory JJ N
mechanisms NNS N
following VBG N
acute NN N
exposure NN N
to TO N
TRAP NNP N
. . N

-DOCSTART- -X- O O

Phosphate NNP 3_i
binder NN 3_i
impact NN N
on IN N
bone NN N
remodeling NN N
and CC N
coronary JJ N
calcification NN N
-- : N
results NNS N
from IN N
the DT N
BRiC NNP N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
Calcium-containing NNP 3_i
phosphate NN 3_i
binders NNS 3_i
have VBP N
been VBN N
shown VBN N
to TO N
increase VB N
the DT N
progression NN N
of IN N
vascular JJ N
calcification NN N
in IN N
hemodialysis NN N
patients NNS N
. . N

This DT N
is VBZ N
a DT N
prospective JJ N
study NN N
that WDT N
compares VBZ N
the DT N
effects NNS N
of IN N
calcium NN 3_i
acetate NN 3_i
and CC 3_i
sevelamer NN 3_i
on IN N
coronary JJ N
calcification NN N
( ( N
CAC NNP N
) ) N
and CC N
bone $ N
histology NN N
. . N

METHODS NNP N
101 CD N
hemodialysis NN N
patients NNS N
were VBD N
randomized VBN N
for IN N
each DT N
phosphate NN 3_i
binder NN 3_i
and CC N
submitted VBN N
to TO N
multislice VB 3_i
coronary JJ 3_i
tomographies NNS 3_i
and CC 3_i
bone NN 3_i
biopsies NNS 3_i
at IN N
entry NN N
and CC N
12 CD N
months NNS N
. . N

RESULTS VB N
The DT N
71 CD N
patients NNS N
who WP N
concluded VBD N
the DT N
study NN N
had VBD N
similar JJ N
baseline NN N
characteristics NNS N
. . N

On IN N
follow-up NN N
, , N
the DT N
sevelamer NN N
group NN N
had VBD N
higher JJR N
levels NNS N
of IN N
intact JJ N
parathyroid JJ N
hormone NN N
( ( N
498 CD N
+/- JJ N
352 CD N
vs. FW N
326 CD N
+/- JJ N
236 CD N
pg/ml NN N
, , N
p NN N
= NNP N
0.017 CD N
) ) N
, , N
bone JJ N
alkaline NN N
phosphatase NN N
( ( N
38 CD N
+/- JJ N
24 CD N
vs. FW N
28 CD N
+/- JJ N
15 CD N
U/l NNP N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
and CC N
deoxypyridinoline NN N
( ( N
135 CD N
+/- JJ N
107 CD N
vs. FW N
89 CD N
+/- JJ N
71 CD N
nmol/l NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
and CC N
lower JJR N
LDL NNP N
cholesterol NN N
( ( N
74 CD N
+/- JJ N
21 CD N
vs. FW N
91 CD N
+/- JJ N
28 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.015 CD N
) ) N
. . N

Phosphorus NNP N
( ( N
5.8 CD N
+/- JJ N
1.0 CD N
vs. FW N
6 CD N
+/- JJ N
1.0 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.47 CD N
) ) N
and CC N
calcium NN N
( ( N
1.27 CD N
+/- JJ N
0.07 CD N
vs. FW N
1.23 CD N
+/- JJ N
0.08 CD N
mmol/l NN N
, , N
p NN N
= NNP N
0.68 CD N
) ) N
levels NNS N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

CAC NNP N
progression NN N
( ( N
35 CD N
vs. FW N
24 CD N
% NN N
, , N
p NN N
= NNP N
0.94 CD N
) ) N
and CC N
bone $ N
histological JJ N
diagnosis NN N
at IN N
baseline NN N
and CC N
12 CD N
months NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Patients NNS N
of IN N
the DT N
sevelamer NN N
group NN N
with IN N
a DT N
high JJ N
turnover NN N
at IN N
baseline NN N
had VBD N
an DT N
increase NN N
in IN N
bone JJ N
resorption NN N
( ( N
eroded JJ N
surface NN N
, , N
ES/BS NNP N
= VBD N
9.0 CD N
+/- JJ N
5.9 CD N
vs. FW N
13.1 CD N
+/- JJ N
9.5 CD N
% NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
whereas JJ N
patients NNS N
of IN N
both DT N
groups NNS N
with IN N
low JJ N
turnover NN N
at IN N
baseline NN N
had VBD N
an DT N
improvement NN N
in IN N
bone NN N
formation NN N
rate NN N
( ( N
BFR/BS NNP N
= VBZ N
0.015 CD N
+/- JJ N
0.016 CD N
vs. FW N
0.062 CD N
+/- JJ N
0.078 CD N
, , N
p NN N
= VBD N
0.003 CD N
for IN N
calcium NN N
and CC N
0.017 CD N
+/- JJ N
0.016 CD N
vs. FW N
0.071 CD N
+/- JJ N
0.084 CD N
microm NN N
( ( N
3 CD N
) ) N
/microm NN N
( ( N
2 CD N
) ) N
/day NN N
, , N
p NN N
= VBD N
0.010 CD N
for IN N
sevelamer NN N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
CAC NNP N
progression NN N
or CC N
changes NNS N
in IN N
bone NN N
remodeling NN N
between IN N
the DT N
calcium NN N
and CC N
the DT N
sevelamer NN N
groups NNS N
. . N

-DOCSTART- -X- O O

Antihistamines NNS 3_i
do VBP N
not RB N
inhibit VB N
the DT N
wheal NN N
induced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
autologous JJ N
serum NN N
in IN N
resistant JJ N
chronic JJ N
idiopathic JJ N
urticaria NN N
. . N

Some DT N
patients NNS N
with IN N
chronic JJ N
idiopathic JJ N
urticaria NN N
( ( N
CIU NNP N
) ) N
are VBP N
resistant JJ N
to TO N
conventional JJ N
doses NNS N
of IN N
antihistamines NNS 3_i
( ( 3_i
AHs NNP 3_i
) ) 3_i
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
check VB N
whether IN N
the DT N
skin JJ N
wheal NN N
and CC N
flare JJ N
reaction NN N
produced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
autologous JJ 3_i
serum NN 3_i
( ( 3_i
AS IN 3_i
) ) 3_i
and CC N
by IN N
histamine NN 3_i
differs NNS N
in IN N
AH-resistant NNP N
and CC N
AH NNP N
responder VBP N
CIU NNP N
patients NNS N
. . N

CIU NNP N
patients NNS N
with IN N
treatment NN N
failure NN N
under IN N
fexofenadine NN 3_i
at IN N
180 CD N
mg NN N
q.d NN N
. . N

increased VBD N
their PRP$ N
daily JJ N
dose NN N
of IN N
AH NNP N
to TO N
4 CD N
tablets NNS N
daily RB N
. . N

Those DT N
with IN N
significant JJ N
improvement NN N
of IN N
urticaria JJ N
activity NN N
score NN N
under IN N
fexofenadine NN 3_i
at IN N
180 CD N
mg NNS N
were VBD N
included VBN N
in IN N
the DT N
CIU NNP N
group NN N
. . N

Subjects VBZ N
with IN N
treatment NN N
failure NN N
despite IN N
a DT N
full JJ N
8-week JJ N
fourfold JJ N
fexofenadine NN 3_i
treatment NN N
were VBD N
included VBN N
in IN N
the DT N
resistant JJ N
CIU NNP N
( ( N
R-CIU NNP N
group NN N
) ) N
. . N

The DT N
control NN N
group NN N
consisted VBD N
of IN N
sex- JJ N
and CC N
age-matched JJ N
patents NNS N
with IN N
allergic JJ N
rhinitis NN N
. . N

The DT N
AS NNP N
skin JJ N
test NN N
and CC N
intradermal JJ N
histamine-induced JJ 3_i
wheal NN N
and CC N
flare JJ N
reaction NN N
were VBD N
performed VBN N
at IN N
baseline NN N
( ( N
without IN N
AH NNP N
) ) N
, , N
after IN N
8 CD N
and CC N
16 CD N
weeks NNS N
( ( N
under IN N
AH NNP N
treatment NN N
) ) N
. . N

Forty-six JJ N
subjects NNS N
were VBD N
included VBN N
in IN N
the DT N
CIU NNP N
group NN N
, , N
21 CD N
were VBD N
in IN N
the DT N
R-CIU NNP N
group NN N
, , N
and CC N
44 CD N
were VBD N
in IN N
the DT N
control NN N
group NN N
. . N

Under IN N
AH NNP N
therapy NN N
, , N
the DT N
skin JJ N
reaction NN N
to TO N
intradermal VB N
histamine JJ N
injection NN N
was VBD N
significantly RB N
diminished VBN N
in IN N
all DT N
study NN N
groups NNS N
. . N

In IN N
the DT N
R-CIU NNP N
group NN N
, , N
fexofenadine NN 3_i
at IN N
180 CD N
mg NNS N
did VBD N
not RB N
suppress VB N
AS-induced NNP N
wheal JJ N
reaction NN N
( ( N
5.96 CD N
? . N
2.25 CD N
mm NN N
; : N
p CC N
= VB N
0.85 CD N
) ) N
, , N
and CC N
with IN N
a DT N
fourfold JJ N
AH NNP N
dose VB N
some DT N
reduction NN N
of IN N
AS-induced NNP N
wheal NN N
( ( N
3.79 CD N
? . N
1.74 CD N
mm NN N
; : N
p CC N
= VB N
0.008 CD N
) ) N
was VBD N
observed VBN N
but CC N
remained VBD N
larger JJR N
than IN N
in IN N
the DT N
CIU NNP N
( ( N
2.31 CD N
? . N
1.12 CD N
; : N
p NN N
= VBZ N
0.006 CD N
) ) N
and CC N
control NN N
groups NNS N
( ( N
2.52 CD N
? . N
1.36 CD N
; : N
p NN N
= VBZ N
0.037 CD N
) ) N
. . N

AHs NNP N
do VBP N
not RB N
inhibit VB N
the DT N
wheal NN N
induced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
AS NNP N
in IN N
R-CIU NNP N
. . N

-DOCSTART- -X- O O

Adjuvant NNP N
cyclophosphamide NN 3_i
, , N
doxorubicin NN 3_i
, , N
vincristine NN 3_i
, , N
and CC N
prednisone NN 2_i
chemotherapy NN 2_i
after IN N
radiation NN N
therapy NN N
in IN N
stage NN N
I PRP N
low-grade JJ N
and CC N
intermediate-grade JJ N
non-Hodgkin JJ N
lymphoma NN N
. . N

Results NNS N
of IN N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
In IN N
a DT N
prospective JJ N
randomized NN N
manner NN N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ 3_i
chemotherapy NN 3_i
( ( 3_i
cyclophosphamide NN 3_i
, , 3_i
doxorubicin NN 3_i
, , 3_i
vincristine NN 3_i
, , 3_i
and CC 3_i
prednisone NN 3_i
; : 3_i
CHOP NNP 3_i
) ) 3_i
in IN N
patients NNS N
with IN N
Stage NNP N
I PRP N
non-Hodgkin JJ N
lymphoma NN N
( ( N
NHL NNP N
) ) N
who WP N
have VBP N
achieved VBN N
a DT N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
after IN N
radiation NN N
therapy NN N
( ( N
RT NNP N
) ) N
. . N

METHODS NNP N
Forty-four JJ N
patients NNS N
with IN N
clinical JJ N
or CC N
pathologic JJ N
Stage NN N
I PRP N
intermediate-grade VBP N
or CC N
low-grade JJ N
NHL NNP N
were VBD N
randomized VBN N
to TO N
receive VB 7_i
regional JJ 7_i
RT NNP 7_i
alone RB 7_i
( ( 7_i
median JJ 7_i
dose NN 7_i
, , 7_i
40 CD 7_i
Gy NNP 7_i
) ) 7_i
or CC N
regional JJ 2_i
RT NNP 2_i
followed VBN 2_i
by IN 2_i
six CD 2_i
cycles NNS 2_i
of IN 2_i
CHOP NNP 2_i
chemotherapy NN 2_i
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
clinical JJ N
and CC N
pathologic JJ N
characteristics NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

RESULTS VB N
The DT N
median JJ N
follow-up NN N
was VBD N
7 CD N
years NNS N
( ( N
range NN N
, , N
2-10 JJ N
years NNS N
) ) N
. . N

The DT N
actuarial JJ N
relapse-free JJ N
survival NN N
( ( N
RFS NNP N
) ) N
rate NN N
for IN N
the DT N
RT NNP N
plus CC N
CHOP NNP N
group NN N
at IN N
7 CD N
years NNS N
was VBD N
83 CD N
% NN N
compared VBN N
with IN N
47 CD N
% NN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
for IN N
the DT N
RT-alone NNP N
group NN N
. . N

The DT N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
for IN N
the DT N
two CD N
groups NNS N
was VBD N
88 CD N
% NN N
and CC N
66 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.2 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
intermediate-grade JJ N
NHL NNP N
, , N
the DT N
7-year JJ N
actuarial JJ N
RFS NNP N
for IN N
RT NNP N
and CC N
CHOP NNP N
was VBD N
86 CD N
% NN N
compared VBN N
with IN N
20 CD N
% NN N
for IN N
RT NNP N
alone RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
corresponding JJ N
actuarial JJ N
survival NN N
rates NNS N
were VBD N
92 CD N
% NN N
and CC N
47 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.08 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
low-grade JJ N
histologic JJ N
findings NNS N
, , N
the DT N
addition NN N
of IN N
adjuvant JJ N
CHOP NNP 2_i
did VBD N
not RB N
improve VB N
RFS NNP N
( ( N
P NNP N
= NNP N
0.6 CD N
) ) N
or CC N
OS NNP N
. . N

All DT N
relapses VBZ N
in IN N
this DT N
study NN N
were VBD N
at IN N
sites NNS N
remote VBP N
from IN N
the DT N
initially RB N
involved JJ N
areas NNS N
, , N
and CC N
in IN N
5 CD N
of IN N
11 CD N
patients NNS N
( ( N
45 CD N
% NN N
) ) N
, , N
there EX N
were VBD N
recurrences NNS N
5 CD N
years NNS N
or CC N
longer JJR N
after IN N
initial JJ N
treatment NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
showed VBD N
that IN N
adjuvant JJ N
CHOP NNP 2_i
chemotherapy NN 2_i
significantly RB N
improves VBZ N
RFS NNP N
in IN N
patients NNS N
with IN N
Stage NNP N
I PRP N
intermediate-grade VBP N
NHL NNP N
who WP N
achieve VBP N
a DT N
CR NNP N
after IN N
regional-field JJ N
RT NNP N
. . N

The DT N
chemotherapeutic JJ N
regimen NNS N
favorably RB N
affected VBD N
their PRP$ N
probability NN N
of IN N
survival NN N
. . N

-DOCSTART- -X- O O

Accuracy NN N
and CC N
feasibility NN N
of IN N
contrast NN 2_i
echocardiography NN 2_i
for IN N
detection NN N
of IN N
perfusion NN N
defects NNS N
in IN N
routine JJ N
practice NN N
: : N
comparison NN N
with IN N
wall JJ 2_i
motion NN 2_i
and CC 2_i
technetium-99m JJ 2_i
sestamibi NN 2_i
single-photon JJ 2_i
emission NN 2_i
computed VBD 2_i
tomography NN 2_i
. . 2_i

The DT N
Nycomed NNP N
NC100100 NNP N
Investigators NNP N
. . N

OBJECTIVES NNP N
We PRP N
sought VBD N
to TO N
assess VB N
the DT N
feasibility NN N
and CC N
accuracy NN N
of IN N
myocardial JJ 2_i
contrast NN 2_i
echocardiography NN 2_i
( ( 2_i
MCE NNP 2_i
) ) 2_i
using VBG N
standard JJ N
imaging NN N
approaches NNS N
for IN N
the DT N
detection NN N
of IN N
perfusion NN N
defects NNS N
in IN N
patients NNS N
who WP N
had VBD N
a DT N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
. . N

BACKGROUND NNP N
Myocardial NNP 2_i
contrast NN 2_i
echocardiography NN 2_i
may MD N
be VB N
more JJR N
versatile JJ N
than IN N
perfusion NN 2_i
scintigraphy NN 2_i
for IN N
identifying VBG N
the DT N
presence NN N
and CC N
extent NN N
of IN N
perfusion NN N
defects NNS N
after IN N
MI NNP N
. . N

However RB N
, , N
its PRP$ N
reliability NN N
in IN N
routine JJ N
practice NN N
is VBZ N
unclear JJ N
. . N

METHODS NNP N
Fundamental NNP N
or CC N
harmonic JJ N
MCE NNP N
was VBD N
performed VBN N
with IN N
continuous JJ N
or CC N
triggered JJ N
imaging NN N
in IN N
203 CD N
patients NNS N
with IN N
a DT N
previous JJ N
MI NNP N
using VBG N
bolus JJ N
doses NNS N
of IN N
a DT N
perfluorocarbon-filled JJ 3_i
contrast NN 3_i
agent NN 3_i
( ( 3_i
NC100100 NNP 3_i
) ) 3_i
. . 2_i

All DT N
patients NNS N
underwent JJ N
single-photon JJ 2_i
emission NN 2_i
computed VBN 2_i
tomography NN 2_i
( ( 2_i
SPECT NNP 2_i
) ) 2_i
after IN N
the DT N
injection NN N
of IN N
technetium-99m JJ N
( ( N
Tc-99m NNP N
) ) N
sestamibi NN N
at IN N
rest NN N
. . N

Quantitative NNP N
and CC N
semiquantitative JJ N
SPECT NNP 2_i
, , N
wall NN N
motion NN N
and CC N
digitized JJ N
echocardiographic JJ N
data NNS N
were VBD N
interpreted VBN N
independently RB N
. . N

The DT N
accuracy NN N
of IN N
MCE NNP 2_i
was VBD N
assessed VBN N
for IN N
detection NN N
of IN N
segments NNS N
and CC N
patients NNS N
with IN N
moderate JJ N
and CC N
severe JJ N
sestamibi-SPECT JJ N
defects NNS N
, , N
as RB N
well RB N
as IN N
for IN N
detection NN N
of IN N
patients NNS N
with IN N
extensive JJ N
perfusion NN N
defects NNS N
( ( N
> VB N
12 CD N
% NN N
of IN N
left JJ N
ventricle NN N
) ) N
. . N

RESULTS NNP N
In IN N
segments NNS N
with IN N
diagnostic JJ N
MCE NNP N
, , N
the DT N
segmental JJ N
sensitivity NN N
ranged VBD N
from IN N
14 CD N
% NN N
to TO N
65 CD N
% NN N
, , N
and CC N
the DT N
specificity NN N
varied VBD N
from IN N
78 CD N
% NN N
to TO N
95 CD N
% NN N
, , N
depending VBG N
on IN N
the DT N
dose NN N
of IN N
contrast NN N
agent NN N
. . N

Using VBG N
both DT N
segment- JJ N
and CC N
patient-based JJ N
analysis NN N
, , N
the DT N
greatest JJS N
accuracy NN N
and CC N
proportion NN N
of IN N
interpretable JJ N
images NNS N
were VBD N
obtained VBN N
using VBG N
harmonic JJ N
imaging NN N
in IN N
the DT N
triggered JJ N
mode NN N
. . N

For IN N
the DT N
detection NN N
of IN N
extensive JJ N
defects NNS N
, , N
the DT N
sensitivity NN N
varied VBD N
from IN N
13 CD N
% NN N
to TO N
48 CD N
% NN N
, , N
with IN N
specificity NN N
from IN N
63 CD N
% NN N
to TO N
100 CD N
% NN N
. . N

Harmonic NNP N
imaging NN N
remained VBD N
the DT N
most RBS N
accurate JJ N
approach NN N
. . N

Time NNP N
since IN N
MI NNP N
and CC N
SPECT NNP N
defect VBP N
location NN N
and CC N
intensity NN N
were VBD N
all DT N
determinants NNS N
of IN N
the DT N
MCE NNP N
response NN N
. . N

The DT N
extent NN N
of IN N
defects NNS N
on IN N
MCE NNP N
was VBD N
less JJR N
than IN N
the DT N
extent NN N
of IN N
either DT N
abnormal JJ N
wall NN N
motion NN N
or CC N
SPECT NNP N
abnormalities NNS N
. . N

The DT N
combination NN N
of IN N
wall JJ N
motion NN N
and CC N
MCE NNP N
assessment NN N
gave VBD N
the DT N
best JJS N
balance NN N
of IN N
sensitivity NN N
( ( N
46 CD N
% NN N
to TO N
55 CD N
% NN N
) ) N
and CC N
specificity NN N
( ( N
82 CD N
% NN N
to TO N
83 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
MCE NNP N
is VBZ N
specific JJ N
, , N
it PRP N
has VBZ N
limited VBN N
sensitivity NN N
for IN N
detection NN N
of IN N
moderate JJ N
or CC N
severe JJ N
perfusion NN N
defects NNS N
, , N
and CC N
it PRP N
underestimates VBZ N
the DT N
extent NN N
of IN N
SPECT NNP N
defects NNS N
. . N

The DT N
best JJS N
results NNS N
are VBP N
obtained VBN N
by IN N
integration NN N
with IN N
wall DT N
motion NN N
. . N

More RBR N
sophisticated JJ N
methods NNS N
of IN N
acquisition NN N
and CC N
interpretation NN N
are VBP N
needed VBN N
to TO N
enhance VB N
the DT N
feasibility NN N
of IN N
this DT N
technique NN N
in IN N
routine JJ N
practice NN N
. . N

-DOCSTART- -X- O O

Multisensory JJ 2_i
temporal JJ 2_i
integration NN 2_i
in IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

The DT N
new JJ N
DSM-5 NNP 3_i
diagnostic JJ N
criteria NNS N
for IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
include VBP N
sensory JJ N
disturbances NNS N
in IN N
addition NN N
to TO N
the DT N
well-established JJ N
language NN N
, , N
communication NN N
, , N
and CC N
social JJ N
deficits NNS N
. . N

One CD N
sensory NN N
disturbance NN N
seen VBN N
in IN N
ASD NNP N
is VBZ N
an DT N
impaired JJ N
ability NN N
to TO N
integrate VB N
multisensory JJ N
information NN N
into IN N
a DT N
unified JJ N
percept NN N
. . N

This DT N
may MD N
arise VB N
from IN N
an DT N
underlying JJ N
impairment NN N
in IN N
which WDT N
individuals NNS N
with IN N
ASD NNP N
have VBP N
difficulty NN N
perceiving VBG N
the DT N
temporal JJ N
relationship NN N
between IN N
cross-modal JJ N
inputs NNS N
, , N
an DT N
important JJ N
cue NN N
for IN N
multisensory JJ N
integration NN N
. . N

Such JJ N
impairments NNS N
in IN N
multisensory NN N
processing NN N
may MD N
cascade VB N
into IN N
higher-level JJ N
deficits NNS N
, , N
impairing VBG N
day-to-day JJ N
functioning NN N
on IN N
tasks NNS N
, , N
such JJ N
as IN N
speech JJ N
perception NN N
. . N

To TO N
investigate VB N
multisensory JJ N
temporal JJ N
processing VBG N
deficits NNS N
in IN N
ASD NNP N
and CC N
their PRP$ N
links NNS N
to TO N
speech VB N
processing NN N
, , N
the DT N
current JJ N
study NN N
mapped VBD N
performance NN N
on IN N
a DT N
number NN N
of IN N
multisensory JJ 2_i
temporal JJ 2_i
tasks NNS 2_i
( ( N
with IN N
both DT N
simple JJ N
and CC N
complex JJ N
stimuli NN N
) ) N
onto IN N
the DT N
ability NN N
of IN N
individuals NNS N
with IN N
ASD NNP N
to TO N
perceptually RB N
bind VB N
audiovisual JJ N
speech NN N
signals NNS N
. . N

High-functioning JJ N
children NNS N
with IN N
ASD NNP N
were VBD N
compared VBN N
with IN N
a DT N
group NN N
of IN N
typically RB N
developing VBG N
children NNS N
. . N

Performance NN N
on IN N
the DT N
multisensory JJ 4_i
temporal JJ 4_i
tasks NNS 4_i
varied VBN N
with IN N
stimulus JJ N
complexity NN N
for IN N
both DT N
groups NNS N
; : N
less CC N
precise JJ N
temporal JJ N
processing NN N
was VBD N
observed VBN N
with IN N
increasing VBG N
stimulus JJ N
complexity NN N
. . N

Notably RB N
, , N
individuals NNS N
with IN N
ASD NNP N
showed VBD N
a DT N
speech-specific JJ N
deficit NN N
in IN N
multisensory JJ N
temporal JJ N
processing NN N
. . N

Most JJS N
importantly RB N
, , N
the DT N
strength NN N
of IN N
perceptual JJ N
binding NN N
of IN N
audiovisual JJ N
speech NN N
observed VBN N
in IN N
individuals NNS N
with IN N
ASD NNP N
was VBD N
strongly RB N
related VBN N
to TO N
their PRP$ N
low-level JJ N
multisensory JJ N
temporal JJ N
processing NN N
abilities NNS N
. . N

Collectively RB N
, , N
the DT N
results NNS N
represent VBP N
the DT N
first JJ N
to TO N
illustrate VB N
links NNS N
between IN N
multisensory JJ N
temporal JJ N
function NN N
and CC N
speech NN N
processing NN N
in IN N
ASD NNP N
, , N
strongly RB N
suggesting VBG N
that IN N
deficits NNS N
in IN N
low-level JJ N
sensory JJ N
processing NN N
may MD N
cascade VB N
into IN N
higher-order NN N
domains NNS N
, , N
such JJ N
as IN N
language NN N
and CC N
communication NN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
umbilical JJ 3_i
cord NN 3_i
serum NN 3_i
therapy NN 3_i
for IN N
persistent JJ N
corneal JJ N
epithelial JJ N
defects NNS N
. . N

AIMS NNP N
To TO N
evaluate VB N
umbilical JJ 3_i
cord NN 3_i
serum NN 3_i
therapy NN 3_i
as IN N
a DT N
means NN N
of IN N
promoting VBG N
the DT N
healing NN N
of IN N
persistent JJ N
corneal JJ N
epithelial JJ N
defects NNS N
. . N

METHODS NNP N
Umbilical NNP 3_i
cord NN 3_i
serum NN 3_i
or CC 3_i
autologous JJ 3_i
serum NN 3_i
drops NNS 3_i
were VBD N
used VBN N
to TO N
promote VB N
the DT N
healing NN N
of IN N
persistent JJ N
epithelial JJ N
defects NNS N
. . N

The DT N
study NN N
design NN N
was VBD N
a DT N
prospective JJ N
randomised VBN N
controlled VBD N
clinical JJ N
trial NN N
. . N

60 CD N
eyes NNS N
of IN N
59 CD N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
31 CD N
in IN N
the DT N
cord NN 3_i
serum NN 3_i
group NN N
and CC N
29 CD N
in IN N
the DT N
autologous JJ 7_i
serum NN 7_i
control NN 7_i
group NN 4_i
. . 4_i

Epithelial JJ N
defects NNS N
measuring VBG N
at IN N
least JJS N
2 CD N
mm NN N
in IN N
linear JJ N
dimension NN N
resistant NN N
to TO N
conventional JJ N
medical JJ N
management NN N
were VBD N
included VBN N
. . N

Serial JJ N
measurements NNS N
of IN N
the DT N
size NN N
of IN N
the DT N
epithelial JJ N
defects-namely RB N
, , N
two CD N
maximum JJ N
linear JJ N
dimensions NNS N
perpendicular VBP N
to TO N
each DT N
other JJ N
, , N
and CC N
the DT N
area NN N
and CC N
perimeter NN N
was VBD N
done VBN N
at IN N
start NN N
of IN N
therapy NN N
and CC N
follow VB N
up RP N
days NNS N
3 CD N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
. . N

Rate NN N
of IN N
healing NN N
of IN N
the DT N
epithelial JJ N
defects NNS N
were VBD N
measured VBN N
as IN N
percentage NN N
decrease NN N
from IN N
the DT N
baseline NN N
parameter NN N
at IN N
each DT N
subsequent NN N
follow VBP N
up RB N
. . N

The DT N
data NNS N
were VBD N
analysed VBN N
by IN N
the DT N
non-parametric JJ N
Wilcoxon NNP N
rank NN N
sum NN N
test NN N
using VBG N
STATA NNP N
7.0 CD N
. . N

RESULTS VB N
The DT N
median JJ N
percentage NN N
decrease NN N
in IN N
the DT N
size NN N
of IN N
the DT N
epithelial JJ N
defect NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
cord NN 3_i
serum NN 3_i
group NN N
at IN N
days NNS N
7 CD N
, , N
14 CD N
and CC N
21 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
when WRB N
measured VBN N
in IN N
terms NNS N
of IN N
the DT N
area NN N
and CC N
perimeter NN N
. . N

A DT N
greater JJR N
number NN N
of IN N
patients NNS N
showed VBD N
complete JJ N
re-epithelialisation NN N
with IN N
umbilical JJ N
cord NN 3_i
serum NN 3_i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
than IN N
with IN N
autologous JJ N
serum NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
( ( N
Pearson NNP N
chi VBZ N
= NNP N
0.19 CD N
) ) N
. . N

None NN N
of IN N
the DT N
patients NNS N
reported VBD N
any DT N
side NN N
effects NNS N
or CC N
discomfort NN N
with IN N
either DT N
treatment NN N
. . N

CONCLUSIONS NNP N
Umbilical NNP 3_i
cord NN 3_i
serum NN 3_i
leads VBZ N
to TO N
faster RBR N
healing NN N
of IN N
the DT N
persistent JJ N
corneal NN N
epithelial JJ N
defects NNS N
refractory NN N
to TO N
all DT N
medical JJ N
management NN N
compared VBN N
to TO N
autologous JJ 3_i
serum NN 3_i
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
of IN N
the DT N
Tele-Airway NNP 4_i
Management NNP 4_i
System NNP 4_i
in IN N
a DT N
hospital NN N
emergency NN N
department NN N
. . N

We PRP N
developed VBD N
a DT N
telemedicine NN N
system NN N
for IN N
remote JJ N
guidance NN N
of IN N
emergency NN N
airway NN N
management NN N
called VBD N
the DT N
Tele-Airway NNP 4_i
Management NNP 4_i
System NNP 4_i
( ( N
TAMS NNP N
) ) N
. . N

In IN N
a DT N
pilot NN N
study NN N
we PRP N
examined VBD N
the DT N
usefulness NN N
of IN N
the DT N
TAMS NNP 4_i
for IN N
intubations NNS N
of IN N
actual JJ N
patients NNS N
in IN N
a DT N
hospital NN N
emergency NN N
department NN N
. . N

Twenty-five JJ N
patients NNS N
were VBD N
allocated VBN N
randomly RB N
either DT N
to TO N
a DT N
TAMS NNP 4_i
group NN 4_i
or CC N
to TO N
an DT N
on-scene JJ 4_i
directed NN 4_i
( ( 4_i
OSD NNP 4_i
) ) 4_i
group NN 4_i
. . N

A DT N
total NN N
of IN N
12 CD N
were VBD N
intubated VBN N
using VBG N
the DT N
TAMS NNP 4_i
. . N

The DT N
mean JJ N
time NN N
to TO N
intubation NN N
( ( N
TAMS NNP 6_i
62 CD N
s NN N
vs. FW N
OSD NNP 4_i
56 CD N
s NN N
) ) N
and CC N
the DT N
success NN N
rate NN N
was VBD N
not RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
two CD N
oesophageal JJ N
intubations NNS N
in IN N
the DT N
TAMS NNP 4_i
group NN N
and CC N
four CD N
in IN N
the DT N
OSD NNP 6_i
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
P NNP N
= NNP N
0.36 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
mechanical JJ N
or CC N
technical JJ N
errors NNS N
such JJ N
as IN N
disconnection NN N
during IN N
use NN N
of IN N
the DT N
TAMS NNP 4_i
. . N

The DT N
pilot NN N
study NN N
demonstrated VBD N
the DT N
feasibility NN N
of IN N
the DT N
TAMS NNP N
as IN N
an DT N
alternative NN N
to TO N
OSD NNP 4_i
. . N

However RB N
, , N
a DT N
larger JJR N
study NN N
will MD N
be VB N
required VBN N
to TO N
determine VB N
non-superiority NN N
or CC N
equivalence NN N
. . N

-DOCSTART- -X- O O

Risperidone NN 3_i
in IN N
the DT N
treatment NN N
of IN N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN N
: : N
a DT N
meta-analysis NN N
. . N

Risperidone NN 3_i
has VBZ N
antiserotonergic VBN N
and CC N
antidopaminergic JJ N
properties NNS N
that WDT N
may MD N
make VB N
it PRP N
more RBR N
effective JJ N
than IN N
conventional JJ N
antipsychotic JJ N
agents NNS N
in IN N
the DT N
treatment NN N
of IN N
the DT N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN N
. . N

Clinical JJ N
trials NNS N
in IN N
chronic JJ N
schizophrenic JJ N
patients NNS N
have VBP N
shown VBN N
trends NNS N
in IN N
favor NN N
of IN N
risperidone NN 3_i
in IN N
the DT N
control NN N
of IN N
negative JJ N
symptoms NNS N
compared VBN N
with IN N
haloperidol NN 3_i
, , N
perphenazine NN 3_i
or CC N
zuclopenthixol NN 3_i
, , N
but CC N
the DT N
differences NNS N
were VBD N
not RB N
consistently RB N
statistically RB N
significant JJ N
. . N

A DT N
meta-analysis NN N
of IN N
the DT N
pooled JJ N
results NNS N
from IN N
six CD N
double-blind JJ N
trials NNS N
showed VBD N
that IN N
risperidone NN 3_i
at IN N
doses NNS N
ranging VBG N
from IN N
4 CD N
to TO N
8 CD N
mg/day NN N
had VBD N
a DT N
significantly RB N
( ( N
p JJ N
< NNP N
0.004 CD N
) ) N
higher JJR N
negative JJ N
symptom JJ N
response NN N
rate NN N
, , N
defined VBN N
as IN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
a DT N
20 CD N
% NN N
or CC N
more JJR N
reduction NN N
in IN N
scores NNS N
on IN N
the DT N
negative JJ N
subscale NN N
of IN N
the DT N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
, , N
than IN N
patients NNS N
receiving VBG N
active JJ N
controls NNS N
. . N

The DT N
combined JJ N
patient JJ N
population NN N
treated VBN N
with IN N
4-8 JJ N
mg/day NN N
of IN N
risperidone NN 3_i
was VBD N
1.43 CD N
times NNS N
more RBR N
likely JJ N
to TO N
have VB N
had VBN N
a DT N
clinical JJ N
response NN N
on IN N
the DT N
negative JJ N
symptom NN N
subscale NN N
than IN N
the DT N
combined JJ N
population NN N
treated VBN N
with IN N
haloperidol NN 3_i
, , N
perphenazine NN 3_i
or CC N
zuclopenthixol NN 3_i
. . N

-DOCSTART- -X- O O

Bedside IN N
ultrasound-guided JJ 1_i
celiac NN 1_i
plexus NN 1_i
neurolysis NN 1_i
in IN N
upper JJ N
abdominal JJ N
cancer NN N
patients NNS N
: : N
a DT N
randomized JJ N
, , N
prospective JJ N
study NN N
for IN N
comparison NN N
of IN N
percutaneous JJ N
bilateral JJ 1_i
paramedian JJ 1_i
vs. FW N
unilateral JJ 1_i
paramedian JJ 1_i
needle-insertion NN 1_i
technique NN 1_i
. . N

INTRODUCTION NNP N
Percutaneous NNP 1_i
anterior JJ 1_i
abdominal JJ 1_i
ultrasound NN 1_i
guidance NN 1_i
for IN N
performing VBG N
celiac JJ N
plexus NN N
neurolysis NN N
is VBZ N
a DT N
relatively RB N
new JJ N
but CC N
more RBR N
economical JJ N
, , N
less RBR N
time-consuming JJ N
, , N
more RBR N
comfortable JJ N
bedside NN N
technique NN N
for IN N
interventional JJ N
pain NN N
management NN N
. . N

Paucity NN N
of IN N
studies NNS N
evaluating VBG N
the DT N
efficacy NN N
of IN N
single-site JJ N
vs. FW N
double-site JJ N
injections NNS N
at IN N
celiac JJ N
trunk NN N
for IN N
ultrasound-guided JJ 1_i
celiac NN 1_i
plexus NN 1_i
neurolysis NN 1_i
( ( 1_i
USCPN NNP 1_i
) ) 1_i
prompted VBD N
us PRP N
to TO N
conduct VB N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
single-blind JJ N
clinical JJ N
trial NN N
to TO N
compare VB N
USCPN NNP 1_i
using VBG N
bilateral JJ 1_i
paramedian NN 1_i
( ( 1_i
double JJ 1_i
needle NN 1_i
) ) 1_i
technique NN 1_i
with IN N
unilateral JJ 1_i
paramedian NN 1_i
( ( 1_i
single JJ 1_i
needle NN 1_i
) ) 1_i
technique NN 1_i
. . N

METHODS NNP N
Sixty NNP N
patients NNS N
aged VBD N
18 CD N
years NNS N
or CC N
older JJR N
with IN N
unresectable JJ N
upper JJ N
abdominal JJ N
cancers NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
to TO N
receive VB N
USCPN NNP N
. . N

A DT N
20-mL JJ N
mixture NN N
of IN N
50 CD N
% NN N
ethanol NN 3_i
with IN N
0.25 CD N
% NN N
bupivacaine NN 3_i
was VBD N
injected VBN N
either RB N
unilaterally RB 2_i
( ( N
20 CD N
mL?1 RB N
site NN N
) ) N
or CC N
bilaterally RB N
( ( N
10 CD N
mL?2 NN N
sites NNS N
) ) N
depending VBG N
on IN N
the DT N
randomization NN N
group NN N
. . N

Subjects NNS N
were VBD N
assessed VBN N
for IN N
the DT N
pain NN N
relief NN N
using VBG N
Numerical NNP N
rating NN N
scale NN N
( ( N
NRS NNP N
) ) N
to TO N
assess VB N
their PRP$ N
pain NN N
relief NN N
. . N

RESULTS NNP N
Baseline NNP N
parameters NNS N
being VBG N
comparable JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
the DT N
site NN N
of IN N
drug NN N
injections NNS N
( ( N
single JJ N
or CC N
double JJ N
needle NN N
) ) N
had VBD N
no DT N
bearing NN N
on IN N
the DT N
onset NN N
of IN N
pain NN N
relief NN N
and CC N
patient JJ N
satisfaction NN N
scores NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Pain VB N
relief NN N
during IN N
follow-up JJ N
visits NNS N
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
discomfort NN N
score NN N
correlated VBD N
well RB N
with IN N
the DT N
pain NN N
relief NN N
scoring VBG N
without IN N
any DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
except IN N
in IN N
the DT N
last JJ N
visit NN N
( ( N
at IN N
3 CD N
month NN N
) ) N
. . N

Incidences NNS N
of IN N
the DT N
complications NNS N
were VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Ultrasound-guided JJ N
celiac NN N
plexus NN N
neurolysis NN N
using VBG N
unilateral JJ N
paramedian NN N
( ( N
single JJ N
needle NN N
) ) N
needle-insertion NN N
technique NN N
is VBZ N
comparable JJ N
with IN N
bilateral JJ N
paramedian NN N
( ( N
double JJ N
needle NN N
) ) N
needle-insertion NN N
technique NN N
with IN N
regard NN N
to TO N
pain VB N
relief NN N
and CC N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O

The DT N
relationship NN N
between IN N
the DT N
response NN N
of IN N
Plasmodium NNP N
falciparum NN N
malaria NN N
to TO N
mefloquine VB 3_i
in IN N
African JJ N
children NNS N
and CC N
its PRP$ N
sensitivity NN N
in IN N
vitro NN N
. . N

The DT N
clinical JJ N
efficacy NN N
of IN N
two CD N
doses NNS N
of IN N
mefloquine NN 3_i
( ( N
15 CD N
and CC N
25 CD N
mg/kg NN N
body NN N
weight VBD N
) ) N
was VBD N
evaluated VBN N
in IN N
85 CD N
children NNS N
suffering VBG N
from IN N
acute JJ N
symptomatic JJ N
falciparum NN N
malaria NN N
. . N

The DT N
cure NN N
rate NN N
on IN N
day NN N
28 CD N
was VBD N
100 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
in IN N
the DT N
mean JJ N
parasite NN N
and CC N
fever NN N
clearance NN N
times NNS N
in IN N
both DT N
groups NNS N
( ( N
48.5 CD N
+/- JJ N
14.6 CD N
and CC N
32.0 CD N
+/- JJ N
12.7 CD N
h NN N
respectively RB N
for IN N
the DT N
25 CD N
mg/kg NN N
group NN N
and CC N
49.0 CD N
+/- JJ N
15.1 CD N
and CC N
30.0 CD N
+/- JJ N
13.3 CD N
h NN N
respectively RB N
for IN N
the DT N
15 CD N
mg/kg NNS N
group NN N
) ) N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
in IN N
these DT N
values NNS N
between IN N
children NNS N
with IN N
hyperparasitaemia NN N
( ( N
53.6 CD N
+/- JJ N
11.1 CD N
and CC N
36.0 CD N
+/- JJ N
17.0 CD N
h NN N
respectively RB N
) ) N
and CC N
those DT N
without IN N
hyperparasitaemia NN N
( ( N
49.1 CD N
+/- JJ N
13.6 CD N
and CC N
31.8 CD N
+/- JJ N
14.6 CD N
h NN N
respectively RB N
) ) N
. . N

Recurrence NN N
of IN N
parasitaemia NN N
was VBD N
observed VBN N
after IN N
day NN N
30 CD N
in IN N
2 CD N
patients NNS N
in IN N
the DT N
15 CD N
mg/kg NN N
group NN N
and CC N
in IN N
1 CD N
patient NN N
in IN N
the DT N
25 CD N
mg/kg NN N
group NN N
. . N

In IN N
vitro NN N
, , N
3 CD N
of IN N
21 CD N
isolates NNS N
showed VBD N
reduced JJ N
susceptibility NN N
to TO N
mefloquine VB 3_i
, , N
with IN N
minimum JJ N
inhibitory JJ N
concentrations NNS N
( ( N
MIC NNP N
) ) N
> VBD N
67 CD N
nM/litre NN N
. . N

The DT N
MIC NNP N
and CC N
50 CD N
% NN N
, , N
90 CD N
% NN N
and CC N
99 CD N
% NN N
inhibitory JJ N
concentrations NNS N
were VBD N
200.8 CD N
, , N
6.27 CD N
, , N
31.7 CD N
and CC N
119.6 CD N
nM/litre NNS N
respectively RB N
. . N

Four CD N
of IN N
22 CD N
isolates NNS N
were VBD N
resistant JJ N
to TO N
chloroquine VB 3_i
( ( N
MIC NNP N
> NNP N
108 CD N
nM/litre NN N
) ) N
. . N

Isolates VBZ N
that IN N
showed VBD N
low JJ N
sensitivity NN N
to TO N
mefloquine VB 3_i
in IN N
vitro NN N
were VBD N
sensitive JJ N
to TO N
chloroquine VB N
in IN N
vitro NN N
, , N
and CC N
the DT N
4 CD N
that WDT N
were VBD N
resistant JJ N
to TO N
chloroquine VB N
were VBD N
sensitive JJ N
to TO N
mefloquine VB N
. . N

Irrespective NNP N
of IN N
MIC NNP N
and CC N
dose NN N
of IN N
mefloquine NN N
, , N
parasitaemia NN N
cleared VBN N
in IN N
all DT N
subjects NNS N
in IN N
96 CD N
h NN N
or CC N
less JJR N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

[ NN N
Statins VBZ 3_i
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
arterial JJ N
occlusive JJ N
disease NN N
of IN N
the DT N
lower JJR N
extremities NNS N
] VBP N
. . N

In IN N
patients NNS N
with IN N
advanced JJ N
atherosclerosis NN N
manifested VBN N
by IN N
arterial JJ N
occlusion NN N
in IN N
the DT N
lower JJR N
extremities NNS N
without IN N
a DT N
baseline NN N
blood NN N
lipid JJ N
disorder NN N
statin NN 3_i
treatment NN N
caused VBD N
improvement NN N
of IN N
the DT N
efficiency NN N
, , N
i.e NN N
. . N

prolongation NN N
of IN N
the DT N
claudication NN N
interval NN N
, , N
while IN N
in IN N
a DT N
comparable JJ N
control NN N
group NN N
without IN N
statins VBZ N
the DT N
efficiency NN N
deteriorated VBD N
further RBR N
. . N

In IN N
patients NNS N
with IN N
arterial JJ N
occlusion NN N
of IN N
the DT N
lower JJR N
extremities NNS N
with IN N
baseline NN N
dyslipidaemia NN N
statin NN 3_i
treatment NN N
proved VBD N
protective JJ N
, , N
i.e JJ N
. . N

at IN N
least JJS N
it PRP N
retarded VBD N
the DT N
patients NNS N
' POS N
complaints NNS N
. . N

The DT N
authors NNS N
recorded VBD N
improvement NN N
of IN N
the DT N
prooxidation NN N
state NN N
which WDT N
followed VBD N
after IN N
the DT N
dynamics NNS N
of IN N
improvement NN N
of IN N
the DT N
impaired JJ N
blood NN N
lipid JJ N
spectrum NN N
. . N

The DT N
results NNS N
admit VBP N
a DT N
possible JJ N
part NN N
played VBN N
by IN N
the DT N
pleiotropic NN N
effect NN N
of IN N
statins NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ 7_i
study NN N
of IN N
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
diethylpropion NN 3_i
in IN N
the DT N
treatment NN N
of IN N
obese JJ N
subjects NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
diethylpropion NN 3_i
on IN N
a DT N
long-term JJ N
basis NN N
, , N
with IN N
emphasis NN N
in IN N
cardiovascular JJ N
and CC N
psychiatric JJ N
safety NN N
aspects NNS N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
. . N

MEASUREMENTS NNP N
Following VBG N
a DT N
2-week JJ N
screening NN N
period NN N
, , N
69 CD N
obese JJ N
healthy JJ N
adults NNS N
received VBD N
a DT N
hypocaloric JJ 3_i
diet NN 3_i
and CC N
were VBD N
randomized VBN N
to TO N
diethylpropion VB 3_i
50 CD 3_i
mg NNS 3_i
BID NNP 3_i
( ( N
n=37 NN N
) ) N
or CC N
placebo NN 7_i
( ( N
n=32 JJ N
) ) N
for IN N
6 CD N
months NNS N
. . N

After IN N
this DT N
period NN N
, , N
all DT N
participants NNS N
received VBN N
diethylpropion NN 3_i
in IN N
an DT N
open-label JJ N
extension NN N
for IN N
an DT N
additional JJ N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
percentage NN N
change NN N
in IN N
body NN N
weight NN N
. . N

Electrocardiogram NNP N
( ( N
ECG NNP N
) ) N
, , N
echocardiography NN N
and CC N
clinical JJ N
chemistry NN N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
every DT N
6 CD N
months NNS N
. . N

Psychiatric NNP N
evaluation NN N
and CC N
application NN N
of IN N
Hamilton NNP N
rating NN N
scales NNS N
for IN N
depression NN N
and CC N
anxiety NN N
were VBD N
also RB N
performed VBN N
by IN N
experienced JJ N
psychiatrists NNS N
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
. . N

RESULTS NNP N
After IN N
6 CD N
months NNS N
, , N
the DT N
diethylpropion NN N
group NN N
lost VBD N
an DT N
average NN N
of IN N
9.8 CD N
% NN N
( ( N
s.d NN N
. . N

6.9 CD N
% NN N
) ) N
of IN N
initial JJ N
body NN N
weight VBD N
vs RB N
3.2 CD N
% NN N
( ( N
3.7 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN 7_i
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

From IN N
baseline NN N
to TO N
month NN N
12 CD N
, , N
the DT N
mean JJ N
weight NN N
loss NN N
produced VBN N
by IN N
diethylpropion NN N
was VBD N
10.6 CD N
% NN N
( ( N
8.3 CD N
% NN N
) ) N
. . N

Participants NNS N
in IN N
the DT N
placebo NN 7_i
group NN N
who WP N
were VBD N
switched VBN N
to TO N
diethylpropion NN 3_i
after IN N
6 CD N
months NNS N
lost VBN N
an DT N
average NN N
of IN N
7.0 CD N
% NN N
( ( N
7.7 CD N
% NN N
) ) N
of IN N
initial JJ N
body NN N
weight NN N
. . N

The DT N
difference NN N
between IN N
groups NNS N
at IN N
month NN N
12 CD N
was VBD N
not RB N
significant JJ N
( ( N
P=0.07 NNP N
) ) N
. . N

No DT N
differences NNS N
in IN N
blood NN N
pressure NN N
, , N
pulse JJ N
rate NN N
, , N
ECG NNP N
and CC N
psychiatric JJ N
evaluation NN N
were VBD N
observed VBN N
. . N

Dry NNP N
mouth NN N
and CC N
insomnia NN N
were VBD N
the DT N
most RBS N
frequent JJ N
adverse JJ N
events NNS N
. . N

CONCLUSION NNP N
Diethylpropion NNP 3_i
plus CC N
diet JJ N
produced VBN N
sustained VBN N
and CC N
clinically RB N
significant JJ N
weight JJ N
loss NN N
over IN N
1 CD N
year NN N
. . N

It PRP N
seems VBZ N
to TO N
be VB N
safe JJ N
in IN N
relation NN N
to TO N
cardiovascular VB N
and CC N
psychiatric JJ N
aspects NNS N
in IN N
a DT N
well-selected JJ N
population NN N
. . N

-DOCSTART- -X- O O

A DT N
controlled JJ N
trial NN N
of IN N
intravenous JJ N
immune JJ 3_i
globulin NN 3_i
to TO N
reduce VB N
nosocomial JJ N
infections NNS N
in IN N
very-low-birth-weight JJ N
infants NNS N
. . N

National NNP N
Institute NNP N
of IN N
Child NNP N
Health NNP N
and CC N
Human NNP N
Development NNP N
Neonatal NNP N
Research NNP N
Network NNP N
. . N

BACKGROUND NNP N
Nosocomial NNP N
infections NNS N
are VBP N
a DT N
major JJ N
cause NN N
of IN N
morbidity NN N
and CC N
mortality NN N
in IN N
premature JJ N
infants NNS N
. . N

As IN N
a DT N
rule NN N
, , N
their PRP$ N
low JJ N
serum NN N
gamma NN N
globulin NN N
levels NNS N
at IN N
birth NN N
subsequently RB N
decline VBZ N
to TO N
hypogammaglobulinemic VB N
values NNS N
; : N
hence NN N
, , N
prophylactic JJ N
administration NN N
of IN N
intravenous JJ N
immune NNS 3_i
globulin NN 3_i
may MD N
reduce VB N
the DT N
rate NN N
of IN N
hospital-acquired JJ N
infections NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
multicenter NN N
, , N
two-phase NN N
controlled VBD N
trial NN N
, , N
2416 CD N
infants NNS N
were VBD N
stratified VBN N
according VBG N
to TO N
birth NN N
weight NN N
( ( N
501 CD N
to TO N
1000 CD N
g NN N
and CC N
1001 CD N
to TO N
1500 CD N
g NN N
) ) N
and CC N
randomly RB N
assigned VBN N
to TO N
an DT N
intravenous JJ 3_i
immune JJ 3_i
globulin NN 3_i
group NN 3_i
( ( N
n IN N
= NNP N
1204 CD N
) ) N
or CC N
a DT N
control NN 7_i
group NN 7_i
( ( N
n IN N
= NNP N
1212 CD N
) ) N
. . N

Control NN N
infants NNS N
were VBD N
given VBN N
placebo JJ N
infusions NNS N
during IN N
phase NN N
1 CD N
of IN N
the DT N
study NN N
( ( N
n JJ N
= NNP N
623 CD N
) ) N
but CC N
were VBD N
not RB N
given VBN N
any DT N
infusions NNS N
during IN N
phase NN N
2 CD N
( ( N
n JJ N
= NNP N
589 CD N
) ) N
. . N

Infants NNS N
weighing VBG N
501 CD N
to TO N
1000 CD N
g NN N
at IN N
birth NN N
were VBD N
given VBN N
900 CD N
mg NN N
of IN N
immune JJ N
globulin NN N
per IN N
kilogram NN N
of IN N
body NN N
weight NN N
, , N
and CC N
infants NNS N
weighing VBG N
1001 CD N
to TO N
1500 CD N
g NN N
at IN N
birth NN N
were VBD N
given VBN N
a DT N
dose NN N
of IN N
700 CD N
mg NNS N
per IN N
kilogram NN N
. . N

The DT N
immune JJ 3_i
globulin NN 3_i
infusions NNS N
were VBD N
repeated VBN N
every DT N
14 CD N
days NNS N
until IN N
the DT N
infants NNS N
weighed VBD N
1800 CD N
g NN N
, , N
were VBD N
transferred VBN N
to TO N
another DT N
center NN N
, , N
died VBD N
, , N
or CC N
were VBD N
sent VBN N
home NN N
from IN N
the DT N
hospital NN N
. . N

RESULTS NNP N
Nosocomial JJ N
infections NNS N
of IN N
the DT N
blood NN N
, , N
meninges NNS N
, , N
or CC N
urinary JJ N
tract NN N
occurred VBD N
in IN N
439 CD N
of IN N
the DT N
2416 CD N
infants NNS N
( ( N
18.2 CD N
percent NN N
) ) N
: : N
208 CD N
( ( N
17.3 CD N
percent NN N
) ) N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
231 CD N
( ( N
19.1 CD N
percent NN N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
relative JJ N
risk NN N
, , N
0.91 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.77 CD N
to TO N
1.08 CD N
) ) N
. . N

Septicemia NNP N
occurred VBD N
in IN N
15.5 CD N
percent NN N
of IN N
the DT N
immune JJ N
globulin NN N
recipients NNS N
and CC N
17.2 CD N
percent NN N
of IN N
the DT N
controls NNS N
. . N

During IN N
phase NN N
1 CD N
the DT N
rate NN N
of IN N
nosocomial JJ N
infections NNS N
was VBD N
13.4 CD N
percent NN N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
17.8 CD N
percent NN N
in IN N
the DT N
control NN N
group NN N
; : N
the DT N
respective JJ N
rates NNS N
during IN N
phase NN N
2 CD N
were VBD N
21.0 CD N
percent NN N
and CC N
20.4 CD N
percent NN N
. . N

The DT N
predominant JJ N
organisms NNS N
included VBD N
gram-positive JJ N
cocci NN N
( ( N
53.0 CD N
percent NN N
) ) N
, , N
gram-negative JJ N
bacilli NN N
( ( N
22.4 CD N
percent NN N
) ) N
, , N
and CC N
candida NN N
species NNS N
( ( N
16.0 CD N
percent NN N
) ) N
. . N

Adverse JJ N
reactions NNS N
were VBD N
rarely RB N
observed VBN N
during IN N
the DT N
infusions NNS N
. . N

Immune NNP N
globulin NN N
therapy NN N
had VBD N
no DT N
effect NN N
on IN N
respiratory NN N
distress NN N
syndrome NN N
, , N
bronchopulmonary JJ N
dysplasia NN N
, , N
intracranial JJ N
hemorrhage NN N
, , N
the DT N
duration NN N
of IN N
hospitalization NN N
, , N
or CC N
mortality NN N
. . N

The DT N
incidence NN N
of IN N
necrotizing VBG N
enterocolitis NN N
was VBD N
12.0 CD N
percent NN N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
9.5 CD N
percent NN N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
Prophylactic NNP N
use NN N
of IN N
intravenous JJ N
immune JJ N
globulin NN N
failed VBD N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
hospital-acquired JJ N
infections NNS N
in IN N
very-low-birth-weight JJ N
infants NNS N
. . N

-DOCSTART- -X- O O

D-dimer JJ N
predicts NNS N
outcome VBP N
after IN N
aneurysmal JJ N
subarachnoid JJ N
hemorrhage NN N
: : N
no DT N
effect NN N
of IN N
thromboprophylaxis NN N
on IN N
coagulation NN N
activity NN N
. . N

OBJECTIVE NNP N
Approximately RB N
one-third NN N
of IN N
all DT N
patients NNS N
with IN N
acute JJ N
nontraumatic JJ N
subarachnoid NN N
hemorrhage NN N
( ( N
SAH NNP N
) ) N
experience NN N
complications NNS N
owing VBG N
to TO N
delayed VB N
ischemic JJ N
deficit NN N
. . N

We PRP N
reported VBD N
recently RB N
that IN N
enoxaparin VBZ 3_i
40 CD N
mg NN N
once RB N
daily JJ N
for IN N
10 CD N
days NNS N
seems VBZ N
safe JJ N
and CC N
demonstrates VBZ N
thromboprophylactic JJ N
efficacy NN N
, , N
but CC N
it PRP N
failed VBD N
to TO N
improve VB N
outcome NN N
in IN N
a DT N
randomized JJ N
SAH NNP N
trial NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
assessed VBD N
hemostatic JJ N
variables NNS N
associated VBN N
with IN N
clinical JJ N
status NN N
and CC N
outcome NN N
of IN N
SAH NNP N
. . N

We PRP N
also RB N
monitored VBD N
the DT N
effect NN N
of IN N
enoxaparin NN 3_i
on IN N
activation NN N
of IN N
coagulation NN N
and CC N
fibrinolysis NN N
after IN N
closure NN N
of IN N
the DT N
ruptured JJ N
aneurysm NN N
. . N

METHODS NNP N
Blood NNP N
samples NNS N
to TO N
measure VB N
activation NN N
of IN N
coagulation NN N
and CC N
fibrinolysis NN N
were VBD N
collected VBN N
from IN N
42 CD N
patients NNS N
participating VBG N
in IN N
the DT N
enoxaparin JJ 3_i
trial NN N
for IN N
acute NN N
aneurysmal JJ N
SAH NNP N
at IN N
four CD N
time NN N
points NNS N
: : N
1 CD N
) ) N
at IN N
hospital JJ N
admission NN N
; : N
2 CD N
) ) N
12 CD N
to TO N
24 CD N
hours NNS N
after IN N
aneurysm JJ N
surgery NN N
but CC N
before IN N
initiation NN N
of IN N
enoxaparin JJ 3_i
therapy NN N
; : N
3 CD N
) ) N
3 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
; : N
and CC N
4 CD N
) ) N
at IN N
the DT N
conclusion NN N
of IN N
treatment NN N
. . N

RESULTS NNP N
At IN N
admission NN N
, , N
several JJ N
variables NNS N
of IN N
coagulation NN N
and CC N
fibrinolysis NN N
were VBD N
elevated VBN N
and CC N
correlated VBN N
well RB N
with IN N
clinical JJ N
status NN N
. . N

Specifically RB N
, , N
D-dimer NNP N
levels NNS N
at IN N
all DT N
four CD N
time NN N
points NNS N
correlated VBN N
with IN N
patients NNS N
' POS N
long-term JJ N
outcomes NNS N
. . N

A DT N
single JJ N
dose NN N
of IN N
enoxaparin NN 3_i
suppressed VBD N
early JJ N
coagulation NN N
activity NN N
, , N
but CC N
thrombin JJ N
generation NN N
was VBD N
not RB N
inhibited VBN N
during IN N
thromboprophylaxis NN N
. . N

However RB N
, , N
PAI-1 NNP N
activity NN N
was VBD N
suppressed VBN N
. . N

CONCLUSION NNP N
D-dimer NNP N
offers VBZ N
a DT N
useful JJ N
laboratory NN N
tool NN N
for IN N
assessing VBG N
early JJ N
and CC N
late JJ N
clinical JJ N
severity NN N
of IN N
SAH NNP N
. . N

A NNP N
thromboprophylactic JJ N
dose NN N
of IN N
enoxaparin NN 3_i
inhibited VBN N
PAI-1 JJ N
activity NN N
but CC N
failed VBD N
to TO N
down-regulate JJ N
coagulation NN N
activity NN N
and CC N
D-dimer NNP N
. . N

These DT N
findings NNS N
are VBP N
compatible JJ N
with IN N
the DT N
lack NN N
of IN N
efficacy NN N
of IN N
enoxaparin NN 3_i
in IN N
reducing VBG N
ischemic JJ N
deficit NN N
after IN N
SAH NNP N
. . N

-DOCSTART- -X- O O

Design NN N
of IN N
a DT N
cost-effectiveness NN N
study NN N
within IN N
a DT N
randomized JJ N
trial NN N
: : N
the DT N
LIPID NNP N
Trial NNP N
for IN N
Secondary NNP N
Prevention NNP N
of IN N
IHD NNP N
. . N

Long-term JJ N
Intervention NN N
with IN N
Pravastatin NNP 3_i
in IN N
Ischemic NNP N
Heart NNP N
disease NN N
. . N

The DT N
Long-term JJ N
Intervention NN N
with IN N
Pravastatin NNP 3_i
in IN N
Ischemic NNP N
Heart NNP N
Disease NNP N
( ( N
LIPID NNP N
) ) N
trial NN N
is VBZ N
a DT N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ 7_i
trial NN N
evaluating VBG N
the DT N
long-term JJ N
effect NN N
of IN N
pravastatin NN 7_i
on IN N
coronary JJ N
mortality NN N
in IN N
patients NNS N
with IN N
a DT N
previous JJ N
myocardial JJ N
infarction NN N
or CC N
unstable JJ N
angina-ischemic JJ N
heart NN N
disease NN N
( ( N
IHD NNP N
) ) N
. . N

It PRP N
is VBZ N
planned VBN N
to TO N
run VB N
for IN N
at IN N
least JJS N
five CD N
years NNS N
with IN N
9014 CD N
patients NNS N
from IN N
85 CD N
centers NNS N
in IN N
Australia NNP N
and CC N
New NNP N
Zealand NNP N
. . N

The DT N
trial NN N
will MD N
monitor VB N
cause-specific JJ N
mortality NN N
and CC N
major JJ N
clinical JJ N
events NNS N
associated VBN N
with IN N
each DT N
treatment NN N
. . N

Running VBG N
in IN N
parallel NN N
with IN N
the DT N
main JJ N
study NN N
is VBZ N
a DT N
prospective JJ N
economic JJ N
analysis NN N
, , N
the DT N
objectives NNS N
of IN N
which WDT N
are VBP N
( ( N
1 CD N
) ) N
to TO N
estimate VB N
the DT N
effectiveness NN N
of IN N
pravastatin NN 3_i
compared VBN N
with IN N
placebo NN N
in IN N
terms NNS N
of IN N
survival NN N
, , N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
, , N
and CC N
quality-adjusted JJ N
life-years NNS N
( ( N
QALY NNP N
) ) N
; : N
( ( N
2 CD N
) ) N
to TO N
estimate VB N
the DT N
resource NN N
usage NN N
associated VBN N
with IN N
pravastatin NNS 3_i
compared VBN N
with IN N
placebo-in JJ 7_i
particular JJ N
, , N
to TO N
study VB N
whether IN N
it PRP N
alters VBZ N
resource JJ N
usage NN N
through IN N
prevention NN N
of IN N
disease NN N
progression NN N
; : N
and CC N
( ( N
3 CD N
) ) N
to TO N
use VB N
this DT N
information NN N
for IN N
a DT N
cost-utility JJ N
analysis NN N
with IN N
cost NN N
per IN N
quality-adjusted JJ N
life-year JJ N
as IN N
the DT N
unit NN N
of IN N
analysis NN N
. . N

A DT N
novel JJ N
aspect NN N
of IN N
the DT N
design NN N
is VBZ N
the DT N
use NN N
of IN N
a DT N
preliminary JJ N
cost-effectiveness NN N
analysis NN N
, , N
based VBN N
on IN N
best-guess JJ N
values NNS N
, , N
and CC N
a DT N
sensitivity NN N
analysis NN N
over IN N
plausible JJ N
ranges NNS N
to TO N
guide VB N
the DT N
choice NN N
of IN N
subsample JJ N
size NN N
. . N

Some DT N
data NNS N
, , N
such PDT N
a DT N
mortality NN N
, , N
days NNS N
spent VBD N
in IN N
hospital NN N
, , N
major JJ N
clinical JJ N
events NNS N
, , N
and CC N
drug NN N
use NN N
, , N
are VBP N
being VBG N
collected VBN N
within IN N
the DT N
main JJ N
LIPID NNP N
trial NN N
. . N

However RB N
, , N
additional JJ N
subsamples NNS N
for IN N
the DT N
cost-effectiveness NN N
study NN N
will MD N
include VB N
information NN N
on IN N
quality NN N
of IN N
life NN N
, , N
time NN N
off RP N
work NN N
, , N
and CC N
resources NNS N
used VBN N
, , N
such JJ N
as IN N
time NN N
in IN N
hospital NN N
, , N
procedures NNS N
, , N
and CC N
medications NNS N
taken VBN N
. . N

The DT N
methods NNS N
and CC N
sample NN N
sizes NNS N
for IN N
these DT N
substudies NNS N
have VBP N
been VBN N
a DT N
crucial JJ N
issue NN N
in IN N
validity NN N
and CC N
feasibility NN N
. . N

-DOCSTART- -X- O O

Irrigation NN N
with IN N
bupivacaine NN 3_i
at IN N
the DT N
surgical JJ N
bed NN N
for IN N
postoperative JJ N
pain NN N
relief NN N
after IN N
laparoscopic JJ N
cholecystectomy NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
bupivacaine NN 3_i
irrigated VBN N
at IN N
the DT N
surgical JJ N
bed NN N
on IN N
postoperative JJ N
pain NN N
relief NN N
in IN N
laparoscopic JJ N
cholecystectomy NN N
patients NNS N
. . N

METHODS NNP N
This DT N
study NN N
included VBD N
60 CD N
patients NNS N
undergoing JJ N
elective JJ N
laparoscopic NN N
cholecystectomy NN N
who WP N
were VBD N
prospectively RB N
randomized VBN N
into IN N
2 CD N
groups NNS N
. . N

The DT N
placebo NN 7_i
group NN N
( ( N
n=30 NN N
) ) N
received VBD N
20cc CD N
saline NN 7_i
without IN 7_i
bupivacaine NN 7_i
, , N
installed VBN N
into IN N
the DT N
gallbladder NN N
bed NN N
. . N

The DT N
bupivacaine NN 3_i
group NN N
( ( N
n=30 NN N
) ) N
received VBD N
20cc CD N
of IN N
0.5 CD N
% NN N
bupivacaine NN 3_i
in IN N
at IN N
the DT N
same JJ N
surgical JJ N
site NN N
. . N

Pain NNP N
was VBD N
assessed VBN N
at IN N
0 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
hours NNS N
by IN N
using VBG N
a DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
. . N

RESULTS VB N
A DT N
significant JJ N
difference NN N
( ( N
P=.018 NNP N
) ) N
was VBD N
observed VBN N
in IN N
pain NN N
levels NNS N
between IN N
both DT N
groups NNS N
at IN N
6 CD N
hours NNS N
postoperatively RB N
. . N

The DT N
average JJ N
analgesic JJ N
requirement NN N
was VBD N
lower JJR N
in IN N
the DT N
bupivacaine NN 3_i
group NN N
, , N
but CC N
this DT N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
In IN N
our PRP$ N
study NN N
, , N
the DT N
use NN N
of IN N
bupivacaine NN 3_i
irrigated VBN N
over IN N
the DT N
surgical JJ N
bed NN N
was VBD N
an DT N
effective JJ N
method NN N
for IN N
reducing VBG N
pain NN N
during IN N
the DT N
first JJ N
postoperative JJ N
hours NNS N
after IN N
laparoscopic JJ N
cholecystectomy NN N
. . N

-DOCSTART- -X- O O

Combination NNP 3_i
chemotherapy NN 3_i
and CC N
ALVAC-CEA/B7.1 NNP 3_i
vaccine NN 3_i
in IN N
patients NNS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
. . N

PURPOSE VB N
The DT N
combination NN N
of IN N
vaccines NNS 3_i
and CC N
chemotherapy NN 3_i
holds VBZ N
promise NN N
for IN N
cancer NN N
therapy NN N
, , N
but CC N
the DT N
effect NN N
of IN N
cytotoxic NN N
chemotherapy NN N
on IN N
vaccine-induced JJ N
antitumor NN N
immunity NN N
is VBZ N
unknown JJ N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
systemic JJ N
chemotherapy NN N
on IN N
ALVAC-CEA/B7.1-induced NNP N
T-cell NNP N
immunity NN N
in IN N
patients NNS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
Patients NNPS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
were VBD N
treated VBN N
with IN N
fluorouracil NN 3_i
, , N
leucovorin NN 3_i
, , N
and CC N
irinotecan JJ 3_i
and CC N
were VBD N
also RB N
given VBN N
ALVAC-CEA/B7.1 NNP 3_i
vaccine NN 3_i
with IN N
or CC N
without IN N
tetanus JJ 3_i
toxoid NN 3_i
adjuvant NN 3_i
. . N

Eligible JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
ALVAC NNP 3_i
followed VBN N
by IN N
chemotherapy NN 3_i
and CC N
booster NN 3_i
vaccination NN 3_i
( ( N
group NN N
1 CD N
) ) N
, , N
ALVAC NNP 3_i
and CC N
tetanus NN 3_i
toxoid NN 3_i
followed VBN N
by IN N
chemotherapy NN 3_i
( ( N
group NN N
2 CD N
) ) N
, , N
or CC N
chemotherapy VB 3_i
alone RB N
followed VBN N
by IN N
ALVAC NNP 3_i
in IN N
patients NNS N
without IN N
disease JJ N
progression NN N
( ( N
group NN N
3 CD N
) ) N
. . N

Humoral NNP N
immune JJ N
responses NNS N
were VBD N
measured VBN N
by IN N
standard JJ N
ELISA NNP 2_i
assay NN 2_i
, , N
and CC N
carcinoembryonic JJ N
antigen NN N
( ( N
CEA NNP N
) ) N
-specific VBD N
T-cell NNP N
responses NNS N
were VBD N
measured VBN N
by IN N
IFN-gamma NNP 2_i
enzyme-linked JJ 2_i
immunospot NN 2_i
assay NN 2_i
. . N

RESULTS NNP N
One CD N
hundred VBD N
eighteen JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
ALVAC NNP 3_i
before IN N
and CC N
concomitantly RB N
with IN N
chemotherapy NN 3_i
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
ALVAC NNP 3_i
with IN N
tetanus NN 3_i
adjuvant NN 3_i
before IN N
and CC N
concomitantly RB N
with IN N
chemotherapy NN 3_i
( ( N
n JJ N
= NNP N
40 CD N
) ) N
, , N
or CC N
chemotherapy NN 3_i
followed VBN N
by IN N
ALVAC NNP 3_i
( ( N
n JJ N
= NNP N
39 CD N
) ) N
. . N

Serious JJ N
adverse JJ N
events NNS N
were VBD N
largely RB N
gastrointestinal JJ N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
and CC N
hematologic $ N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
. . N

Overall JJ N
, , N
42 CD N
patients NNS N
( ( N
40.4 CD N
% NN N
) ) N
showed VBD N
objective JJ N
clinical JJ N
responses NNS N
. . N

All DT N
patients NNS N
developed VBD N
antibody JJ N
responses NNS N
against IN N
ALVAC NNP N
, , N
but CC N
increased VBD N
anti-CEA JJ N
antibody NN N
titers NNS N
were VBD N
detected VBN N
in IN N
only RB N
three CD N
patients NNS N
. . N

Increases NNS N
in IN N
CEA-specific NNP N
T NNP N
cells NNS N
were VBD N
detected VBN N
in IN N
50 CD N
% NN N
, , N
37 CD N
% NN N
, , N
and CC N
30 CD N
% NN N
of IN N
patients NNS N
in IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
clinical JJ N
or CC N
immune JJ N
responses NNS N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
combination NN N
of IN N
ALVAC-CEA/B7.1 NNP 3_i
vaccine NN 3_i
and CC N
systemic JJ N
chemotherapy NN 3_i
has VBZ N
an DT N
acceptable JJ N
safety NN N
profile NN N
in IN N
patients NNS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
. . N

Systemic NNP N
chemotherapy NN N
did VBD N
not RB N
affect VB N
the DT N
generation NN N
of IN N
CEA-specific NNP N
T-cell NNP N
responses NNS N
following VBG N
vaccination NN N
. . N

-DOCSTART- -X- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
tamoxifen JJ N
plus CC N
sequential JJ N
CMF NNP N
chemotherapy NN N
versus NN N
tamoxifen NN N
alone RB N
in IN N
postmenopausal JJ N
women NNS N
with IN N
advanced JJ N
breast NN N
cancer NN N
. . N

Eighty-eight JJ N
postmenopausal JJ N
women NNS N
with IN N
metastatic JJ N
breast NN N
cancer NN N
, , N
in IN N
whom WP N
estrogen NN N
receptors NNS N
( ( N
ER NNP N
) ) N
were VBD N
positive JJ N
or CC N
unknown JJ N
, , N
were VBD N
treated VBN N
on IN N
a DT N
controlled VBN N
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
tamoxifen NN 3_i
and CC N
to TO N
assess VB N
the DT N
therapeutic JJ N
advantage NN N
of IN N
sequentially RB N
adding VBG N
low-dose JJ 3_i
cyclophosphamide-methotrexate-5-fluorouracil NN 3_i
( ( 3_i
CMF NNP 3_i
) ) 3_i
chemotherapy NN 3_i
in IN 3_i
tamoxifen JJ 3_i
responders NNS 3_i
. . N

Patients NNS N
with IN N
known JJ N
ER NNP N
negative JJ N
status NN N
were VBD N
not RB N
studied VBN N
. . N

After IN N
the DT N
initial JJ N
12-week JJ N
treatment NN N
with IN N
tamoxifen NN 3_i
alone RB 3_i
, , N
60 CD N
% NN N
of IN N
ER NNP N
positive JJ N
patients NNS N
achieved VBD N
complete JJ N
or CC N
partial JJ N
response NN N
as IN N
did VBD N
35 CD N
% NN N
in IN N
whom WP N
ER NNP N
were VBD N
unknown JJ N
. . N

Response VB N
status NN N
further RB N
improved VBN N
in IN N
18 CD N
% NN N
randomized VBN N
to TO N
continue VB N
tamoxifen VB N
alone RB N
vs JJ N
31 CD N
% NN N
in IN N
whom WP N
CMF NNP N
was VBD N
added VBN N
to TO N
tamoxifen VB N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
time NN N
to TO N
the DT N
development NN N
of IN N
progressive JJ N
disease NN N
or CC N
survival NN N
between IN N
the DT N
ER NNP N
positive JJ N
and CC N
ER NNP N
unknown JJ N
patients NNS N
or CC N
between IN N
the DT N
tamoxifen NN N
and CC N
tamoxifen JJ N
plus CC N
CMF JJ N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
inability NN N
to TO N
determine VB N
ER NNP N
status NN N
should MD N
not RB N
prejudice VB N
against IN N
the DT N
use NN N
of IN N
tamoxifen NN N
in IN N
postmenopausal NN N
patients NNS N
with IN N
advanced JJ N
breast NN N
cancer NN N
. . N

No DT N
benefit NN N
has VBZ N
been VBN N
demonstrated VBN N
from IN N
the DT N
addition NN N
of IN N
CMF NNP N
chemotherapy NN N
in IN N
tamoxifen JJ N
responders NNS N
. . N

-DOCSTART- -X- O O

Gender NNP N
difference NN N
in IN N
the DT N
response NN N
to TO N
an DT N
angiotensin-converting JJ 3_i
enzyme NN 3_i
inhibitor NN 3_i
and CC N
a DT N
diuretic JJ 3_i
in IN N
hypertensive JJ N
patients NNS N
of IN N
African JJ N
descent NN N
. . N

BACKGROUND IN N
The DT N
efficacy NN N
of IN N
angiotensin-converting JJ 3_i
enzyme NN 3_i
( ( 3_i
ACE NNP 3_i
) ) 3_i
inhibitors NNS 3_i
in IN N
decreasing VBG N
blood NN N
pressure NN N
in IN N
African JJ N
patients NNS N
is VBZ N
controversial JJ N
. . N

OBJECTIVE IN N
We PRP N
examined VBD N
the DT N
ambulatory JJ N
blood NN N
pressure NN N
( ( N
ABP NNP N
) ) N
response NN N
to TO N
a DT N
diuretic JJ 3_i
and CC N
an DT N
ACE NNP 3_i
inhibitor NN 3_i
in IN N
hypertensive JJ N
patients NNS N
of IN N
East JJ N
African JJ N
descent NN N
and CC N
evaluated VBD N
the DT N
individual JJ N
characteristics NNS N
that WDT N
determined VBD N
treatment NN N
efficacy NN N
. . N

DESIGN VB N
A DT N
single-blind JJ N
randomized JJ N
AB/BA NNP N
crossover NN N
design NN N
. . N

SETTING NN N
Hypertensive JJ N
families NNS N
of IN N
East JJ N
African JJ N
descent NN N
from IN N
the DT N
general JJ N
population NN N
in IN N
the DT N
Seychelles NNP N
. . N

PARTICIPANTS NNP N
Fifty-two NNP N
( ( N
29 CD N
men NNS N
and CC N
23 CD N
women NNS N
) ) N
out IN N
of IN N
62 CD N
eligible JJ N
hypertensive JJ N
patients NNS N
were VBD N
included.Main JJ N
outcome JJ N
measures NNS N
ABP NNP N
response NN N
to TO N
20 CD N
mg NNS N
lisinopril NN 3_i
( ( 3_i
LIS NNP 3_i
) ) 3_i
daily RB N
and CC N
25 CD N
mg NNS N
hydrochlorothiazide RB 3_i
( ( 3_i
HCT NNP 3_i
) ) 3_i
daily RB N
given VBN N
for IN N
a DT N
4-week JJ N
period NN N
. . N

Results VB N
The DT N
daytime JJ N
systolic/diastolic JJ N
ABP NNP N
response NN N
to TO N
HCT NNP N
was VBD N
4.9 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
1.2-8.6 CD N
] JJ N
/3.6 NNP N
( ( N
1.0-6.2 JJ N
) ) N
mmHg NN N
for IN N
men NNS N
and CC N
12.9 CD N
( ( N
9.2-16.6 CD N
) ) N
/6.3 NN N
( ( N
3.7-8.8 JJ N
) ) N
mmHg NN N
for IN N
women NNS N
. . N

With IN N
LIS NNP N
the DT N
response NN N
was VBD N
18.8 CD N
( ( N
15.0-22.5 CD N
) ) N
/14.6 NN N
( ( N
12.0-17.1 JJ N
) ) N
mmHg NN N
for IN N
men NNS N
and CC N
12.4 CD N
( ( N
8.7-16.2 CD N
) ) N
/7.7 NN N
( ( N
5.1-10.2 JJ N
) ) N
mmHg NN N
for IN N
women NNS N
. . N

The DT N
night-time JJ N
systolic/diastolic JJ N
response NN N
to TO N
HCT NNP 3_i
was VBD N
5.0 CD N
( ( N
0.6-9.4 CD N
) ) N
/2.7 NN N
[ NNP N
( ( N
-0.4 NNP N
) ) N
-5.7 VBP N
] JJ N
mmHg NN N
for IN N
men NNS N
and CC N
11.5 CD N
( ( N
7.1-16.0 CD N
) ) N
/5.7 NN N
( ( N
2.6-8.8 JJ N
) ) N
mmHg NN N
for IN N
women NNS N
, , N
and CC N
to TO N
LIS NNP 3_i
was VBD N
18.7 CD N
( ( N
14.2-22.1 JJ N
) ) N
/15.4 NN N
( ( N
12.4-18.5 JJ N
) ) N
mmHg NN N
for IN N
men NNS N
and CC N
3.5 CD N
[ NN N
( ( N
-1.0 NNP N
) ) N
-7.9 VBP N
] JJ N
/2.3 NNP N
[ NNP N
( ( N
-0.8 NNP N
) ) N
-5.4 VBP N
] JJ N
mmHg NN N
for IN N
women NNS N
. . N

Linear JJ N
regression NN N
analyses NNS N
showed VBD N
that IN N
gender NN N
is VBZ N
an DT N
independent JJ N
predictor NN N
of IN N
the DT N
ABP NNP N
responses NNS N
to TO N
HCT NNP 3_i
and CC N
to TO N
LIS NNP 3_i
. . N

CONCLUSIONS NNP N
Hypertensive NNP N
patients NNS N
of IN N
African JJ N
descent NN N
responded VBD N
better JJR N
to TO N
LIS NNP 3_i
than IN N
to TO N
HCT NNP 3_i
. . N

Men NNP N
responded VBD N
better RBR N
to TO N
LIS NNP N
than IN N
to TO N
HCT NNP 3_i
and CC N
women NNS N
responded VBD N
similarly RB N
to TO N
both DT N
drugs NNS N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
delay NN N
in IN N
standard JJ N
treatment NN N
due JJ N
to TO N
induction VB N
chemotherapy NN N
in IN N
two CD N
randomized JJ N
prospective JJ N
studies NNS N
. . N

It PRP N
is VBZ N
often RB N
suggested VBN N
that IN N
tumors NNS N
will MD N
respond VB N
to TO N
induction VB 3_i
chemotherapy NN 3_i
and CC N
result NN N
in IN N
improved JJ N
survival NN N
for IN N
patients NNS N
with IN N
squamous JJ N
cell NN N
carcinoma NN N
of IN N
the DT N
head NN N
and CC N
neck NN N
. . N

Two CD N
regimens NNS N
of IN N
induction NN N
chemotherapy NN N
were VBD N
studied VBN N
in IN N
separate JJ N
randomized VBN N
, , N
prospective JJ N
trials NNS N
over IN N
the DT N
last JJ N
6 CD N
years NNS N
. . N

Eighty-three JJ N
patients NNS N
with IN N
advanced JJ N
disease NN N
were VBD N
entered VBN N
into IN N
the DT N
first JJ N
study NN N
( ( N
43/chemotherapy CD N
; : N
40/control CD N
) ) N
, , N
and CC N
60 CD N
into IN N
the DT N
second JJ N
( ( N
27/chemotherapy CD N
; : N
33/control CD N
) ) N
. . N

Patient JJ N
randomization NN N
was VBD N
stratified VBN N
by IN N
stage NN N
( ( N
III/IV NNP N
) ) N
and CC N
site NN N
( ( N
oral JJ N
cavity NN N
, , N
oropharynx NN N
, , N
nasopharynx RB N
, , N
hypopharynx NN N
, , N
larynx NN N
, , N
paranasal NN N
sinuses NNS N
) ) N
. . N

The DT N
first JJ N
study NN N
utilized JJ 3_i
bleomycin NN 3_i
, , N
Cytoxan NNP 3_i
, , N
methotrexate NN 3_i
and CC N
5-fluorouracil JJ 3_i
in IN N
two CD N
cycles NNS N
( ( N
one CD N
cycle NN N
if IN N
no DT N
tumor NN N
response NN N
) ) N
, , N
followed VBN 3_i
by IN 3_i
standard NN 3_i
treatment NN 3_i
which WDT 3_i
consisted VBD 3_i
of IN 3_i
combined JJ 3_i
irradiation NN 3_i
and CC 3_i
surgery NN 3_i
or CC 3_i
, , 3_i
in IN 3_i
some DT 3_i
instances NNS 3_i
, , 3_i
primary JJ 3_i
irradiation NN 3_i
alone RB N
. . N

The DT N
second JJ N
study NN N
utilized VBD N
cisplatin NN 3_i
and CC 3_i
5-fluorouracil NN 3_i
in IN 3_i
three CD N
cycles NNS N
prior RB 7_i
to TO 7_i
standard VB 7_i
treatment NN 7_i
. . N

An DT N
objective JJ N
tumor NN N
response NN N
to TO N
chemotherapy NN N
was VBD N
observed VBN N
in IN N
68 CD N
% NN N
in IN N
the DT N
first JJ N
study NN N
and CC N
85 CD N
% NN N
in IN N
the DT N
second JJ N
. . N

The DT N
patient NN N
survival NN N
in IN N
both DT N
studies NNS N
( ( N
at IN N
24 CD N
months NNS N
in IN N
the DT N
first JJ N
; : N
at IN N
19 CD N
in IN N
the DT N
second JJ N
) ) N
was VBD N
better RBR N
in IN N
the DT N
control NN N
than IN N
that DT N
in IN N
the DT N
experimental JJ N
groups NNS N
( ( N
43 CD N
% NN N
to TO N
31 CD N
% NN N
; : N
69 CD N
% NN N
to TO N
46 CD N
% NN N
) ) N
. . N

In IN N
the DT N
second JJ N
study NN N
, , N
the DT N
average JJ N
length NN N
of IN N
delay NN N
of IN N
standard JJ N
treatment NN N
was VBD N
longer JJR N
than IN N
in IN N
the DT N
first JJ N
study NN N
( ( N
95 CD N
days NNS N
vs. FW N
66 CD N
days NNS N
; : N
P NNP N
less JJR N
than IN N
.02 NN N
) ) N
. . N

Results CC N
combining VBG N
the DT N
P-values NNS N
of IN N
both DT N
studies NNS N
indicate VBP N
that IN N
the DT N
relative JJ N
risk NN N
of IN N
having VBG N
persistent JJ N
disease NN N
was VBD N
2.9 CD N
times NNS N
greater JJR N
for IN N
patients NNS N
who WP N
received VBD N
chemotherapy NN N
. . N

While IN N
toxicity NN N
to TO N
chemotherapy VB N
was VBD N
not RB N
a DT N
factor NN N
in IN N
survival NN N
, , N
the DT N
number NN N
of IN N
patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
studies NNS N
and CC N
those DT N
who WP N
did VBD N
not RB N
comply VB N
with IN N
treatment NN N
were VBD N
greater JJR N
in IN N
the DT N
chemotherapy NN N
groups NNS N
. . N

Except IN N
for IN N
new JJ N
drug NN N
regimens NNS N
of IN N
exceptional JJ N
promise NN N
, , N
it PRP N
is VBZ N
recommended VBN N
that IN N
future JJ N
studies NNS N
be VB N
designed VBN N
so RB N
that IN N
chemotherapy NN N
is VBZ N
given VBN N
concurrent NN N
with IN N
, , N
or CC N
following VBG N
the DT N
completion NN N
of IN N
standard JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
iron NN 3_i
on IN N
the DT N
pharmacokinetics NNS N
of IN N
paracetamol NN 3_i
in IN N
saliva NN N
. . N

Paracetamol NNP 3_i
has VBZ N
been VBN N
reported VBN N
to TO N
chelate VB N
with IN N
iron NN 3_i
. . N

It PRP N
was VBD N
found VBN N
that IN N
no DT N
in IN N
vitro JJ N
reaction NN N
between IN N
ferrous JJ N
ion NN N
and CC N
paracetamol NN N
. . N

Other JJ N
studies NNS N
found VBD N
that IN N
there EX N
is VBZ N
an DT N
aerobic JJ N
( ( N
in IN N
the DT N
gastrointestinal JJ N
tract NN N
) ) N
oxidation NN N
of IN N
ferrous JJ N
ion NN N
to TO N
ferric VB N
ion NN N
caused VBN N
in IN N
iron-paracetamol NN N
in IN N
vivo JJ N
reactions NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
iron NN N
interacts NNS N
with IN N
paracetamol NN N
and CC N
reduces NNS N
paracetamol JJ N
absorption NN N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
study NN N
design NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
in IN N
vivo JJ N
interaction NN N
of IN N
paracetamol NN 3_i
and CC N
ferrous JJ 3_i
ion NN 3_i
. . N

Paracetamol NNP 3_i
( ( N
1.0 CD N
g NN N
) ) N
was VBD N
co-ignested JJ N
alone RB N
or CC N
with IN N
( ( N
300 CD N
mg NN N
) ) N
ferrous JJ 3_i
sulphate NN 3_i
by IN N
ten JJ N
healthy JJ N
male NN N
volunteers NNS N
, , N
using VBG N
saliva JJ N
drug NN N
levels NNS N
as IN N
a DT N
parameter NN N
. . N

Concomitant NNP N
administration NN N
of IN N
ferrous JJ 3_i
sulphate NN 3_i
and CC N
paracetamol NN 3_i
, , N
decreased VBN N
AUC8 NNP N
from IN N
42.88 CD N
+/- JJ N
3.8-34.25 JJ N
+/- JJ N
2.8 CD N
microg NN N
h NN N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
and CC N
Cmax NNP N
from IN N
18.75 CD N
+/- JJ N
1.9 CD N
to TO N
15.9 CD N
+/- JJ N
1.7 CD N
microg NN N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
while IN N
no DT N
change NN N
in IN N
tmax NN N
( ( N
p JJ N
= NNP N
0.5 CD N
) ) N
was VBD N
originated VBN N
. . N

A DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
paracetamol NN N
pharmacokinetic JJ N
parameter NN N
oral JJ N
clearance NN N
( ( N
C1/F NNP N
) ) N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
and CC N
slightly RB N
increased VBN N
in IN N
volume NN N
of IN N
distribution NN N
( ( N
V NNP N
( ( N
d NN N
) ) N
/F NN N
) ) N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
. . N

Co-administration NN N
of IN N
iron NN 3_i
and CC N
paracetamol JJ 3_i
results NNS N
in IN N
decreased JJ N
paracetamol NN N
absorption NN N
due JJ N
to TO N
an DT N
interaction NN N
between IN N
iron NN N
and CC N
paracetamol NN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
the DT N
topical JJ N
hemostatic JJ N
efficacy NN N
and CC N
safety NN N
of IN N
TISSEEL NNP 3_i
VH NNP 3_i
S/D NNP 3_i
fibrin NN 3_i
sealant NN 3_i
compared VBN N
with IN N
currently RB 3_i
licensed VBN 3_i
TISSEEL NNP 3_i
VH NNP 3_i
in IN N
patients NNS N
undergoing JJ N
cardiac JJ N
surgery NN N
: : N
a DT N
phase NN N
3 CD N
, , N
randomized VBN N
, , N
double-blind JJ N
clinical JJ N
study NN N
. . N

AIM NNP N
TISSEEL NNP N
VH NNP N
is VBZ N
the DT N
only JJ N
commercially RB N
available JJ N
fibrin NN N
sealant NN N
indicated VBD N
as IN N
an DT N
adjunct NN N
to TO N
conventional JJ N
methods NNS N
of IN N
hemostasis NN N
during IN N
cardiac JJ N
surgery NN N
. . N

A DT N
next JJ N
generation NN N
fibrin NN 3_i
sealant NN 3_i
( ( 3_i
TISSEEL NNP 3_i
VH NNP 3_i
S/D NNP 3_i
) ) 3_i
has VBZ N
been VBN N
developed VBN N
in IN N
frozen JJ N
, , N
ready-to-use JJ N
form NN N
with IN N
an DT N
added JJ N
virus NN N
inactivation NN N
step NN N
( ( N
solvent/detergent JJ N
[ NNP N
S/D NNP N
] NNP N
treatment NN N
) ) N
to TO N
provide VB N
added JJ N
safety NN N
and CC N
convenience NN N
to TO N
the DT N
currently RB N
licensed VBN N
product NN N
. . N

This DT N
study NN N
was VBD N
performed VBN N
to TO N
compare VB N
efficacy NN N
and CC N
safety NN N
of IN N
the DT N
two CD N
products NNS N
. . N

METHODS NNP N
Phase NNP N
3 CD N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicenter NN N
study NN N
to TO N
compare VB N
TISSEEL NNP 3_i
VH NNP 3_i
S/D NNP 3_i
to TO 3_i
TISSEEL NNP 3_i
VH NNP 3_i
during IN N
cardiac JJ N
surgery NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
achieved VBD N
hemostasis NN N
at IN N
the DT N
primary JJ N
treatment NN N
site NN N
within IN N
5 CD N
min NN N
, , N
and CC N
maintained VBD N
hemostasis NN N
until IN N
surgical JJ N
closure NN N
. . N

RESULTS VB N
The DT N
proportion NN N
of IN N
patients NNS N
who WP N
achieved VBD N
hemostasis NN N
at IN N
the DT N
primary JJ N
treatment NN N
site NN N
within IN N
5 CD N
min NN N
, , N
and CC N
maintained VBD N
hemostasis NN N
until IN N
surgical JJ N
closure NN N
was VBD N
88.2 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
S/D NNP N
and CC N
89.6 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
in IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

The DT N
difference NN N
in IN N
proportions NNS N
, , N
TISSEEL NNP N
VH NNP N
S/D NNP N
minus CC N
TISSEEL NNP N
VH NNP N
, , N
was VBD N
1.4 CD N
% NN N
with IN N
a DT N
standard JJ N
error NN N
of IN N
3.70 CD N
% NN N
. . N

The DT N
lower JJR N
97.5 CD N
% NN N
confidence NN N
bound NN N
of IN N
this DT N
difference NN N
was VBD N
8.6 CD N
% NN N
, , N
which WDT N
is VBZ N
above IN N
the DT N
predefined JJ N
noninferiority NN N
margin NN N
of IN N
15 CD N
% NN N
. . N

Therefore RB N
, , N
TISSEEL NNP N
VH NNP N
S/D NNP N
is VBZ N
at IN N
least JJS N
as RB N
efficacious JJ N
as IN N
TISSEEL NNP N
VH NNP N
. . N

The DT N
safety NN N
profile NN N
of IN N
TISSEEL NNP N
VH NNP N
S/D NNP N
was VBD N
very RB N
similar JJ N
to TO N
that DT N
of IN N
currently RB N
licensed VBN N
TISSEEL NNP N
VH NNP N
as IN N
assessed VBN N
by IN N
the DT N
safety NN N
endpoints NNS N
. . N

CONCLUSION NNP N
TISSEEL NNP N
VH NNP N
S/D NNP N
is VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
use NN N
as IN N
an DT N
adjunct NN N
to TO N
hemostasis VB N
in IN N
patients NNS N
undergoing JJ N
cardiac JJ N
surgery NN N
. . N

-DOCSTART- -X- O O

Less NNP N
tachycardia NN N
in IN N
adults NNS N
when WRB N
using VBG N
atropine VBP 3_i
0.9 CD N
mg NNS N
compared VBN N
with IN N
1.2 CD N
mg NNS N
plus CC N
neostigmine JJ 3_i
2.5 CD N
mg NN N
. . N

OBJECTIVE CC N
Compare NNP N
the DT N
increase NN N
in IN N
heart NN N
rate NN N
in IN N
adults NNS N
after IN N
0.9 CD N
vs. FW N
1.2 CD N
mg NN N
of IN N
atropine JJ 3_i
plus CC 2_i
neostigmine JJ 3_i
2.5 CD N
mg NN N
as IN N
the DT N
non-depolarizing JJ N
muscle NN N
relaxant NN N
reversal NN N
agent NN N
. . N

MATERIAL NNP N
AND NNP N
METHOD NNP N
A NNP N
randomized NN N
, , N
double JJ N
blind NN N
, , N
controlled VBN N
trial NN N
on IN N
46 CD N
adults NNS N
ASA NNP N
I-II NNP N
, , N
undergoing VBG N
elective JJ N
gynecological NN N
or CC N
general JJ N
surgery NN N
with IN N
balanced JJ N
general JJ N
anesthesia NN N
was VBD N
performed VBN N
. . N

The DT N
subjects NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
After IN N
surgery NN N
, , N
the DT N
study NN N
group NN N
received VBD N
0.9 CD 3_i
mg NN 3_i
of IN 3_i
atropine NN 3_i
, , N
while IN N
the DT N
control NN 7_i
group NN N
received VBD N
1.2 CD 3_i
mg NN 3_i
of IN 3_i
atropine NN 3_i
. . N

Both DT N
groups NNS N
received VBD N
2.5 CD 3_i
mg NN 3_i
of IN 3_i
neostigmine JJ 3_i
simultaneously RB N
. . N

RESULTS VB N
The DT N
heart NN N
rate NN N
and CC N
blood NN N
pressure NN N
were VBD N
taken VBN N
at IN N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
6 CD N
, , N
7 CD N
, , N
8 CD N
, , N
9 CD N
, , N
10 CD N
, , N
15 CD N
, , N
20 CD N
, , N
25 CD N
, , N
and CC N
30 CD N
min NN N
after IN N
the DT N
injection NN N
. . N

The DT N
increase NN N
in IN N
heart NN N
rate NN N
and CC N
blood NN N
pressure NN N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

The DT N
heart NN N
rate NN N
( ( N
at IN N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
and CC N
6 CD N
min NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
study NN N
group NN N
increased VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
blood NN N
pressure NN N
between IN N
groups NNS N
and CC N
no DT N
side NN N
effects NNS N
occurred VBD N
. . N

CONCLUSION VB N
The DT N
authors NNS N
conclude VBP N
that IN N
0.9 CD N
mg NN N
of IN N
atropine NN 3_i
with IN N
2.5 CD N
mg NNS N
neostigmine JJ 3_i
can MD N
be VB N
safely RB N
used VBN N
as IN N
the DT N
reversal NN N
agent NN N
for IN N
a DT N
non-depolarizing JJ N
muscle NN N
relaxant NN N
, , N
particularly RB N
in IN N
patients NNS N
for IN N
whom WP N
any DT N
increase NN N
in IN N
heart NN N
rate NN N
would MD N
be VB N
harmful JJ N
. . N

-DOCSTART- -X- O O

Is VBZ N
the DT N
effect NN N
of IN N
mobile JJ 2_i
phone NN 2_i
radiofrequency NN 2_i
waves NNS 2_i
on IN N
human JJ N
skin JJ N
perfusion NN N
non-thermal JJ N
? . N
OBJECTIVE UH N
To TO N
establish VB N
whether IN N
SkBF NNP N
can MD N
be VB N
modified VBN N
by IN N
exposure NN N
to TO N
the DT N
radiofrequency NN 2_i
waves NNS 2_i
emitted VBN 2_i
by IN 2_i
a DT 2_i
mobile JJ 2_i
phone NN 2_i
when WRB N
the DT N
latter NN N
is VBZ N
held VBN N
against IN N
the DT N
jaw NN N
and CC N
ear NN N
. . N

METHODS NNP N
Variations NNP N
in IN N
SkBF NNP N
and CC N
Tsk NNP N
in IN N
adult NN N
volunteers NNS N
were VBD N
simultaneously RB N
recorded VBN 2_i
with IN 2_i
a DT 2_i
thermostatic JJ 2_i
laser NN 2_i
Doppler NNP 2_i
system NN 2_i
during IN 2_i
a DT 2_i
20-minute JJ 2_i
radiofrequency NN 2_i
exposure NN 2_i
session NN 2_i
and CC 2_i
a DT 2_i
20-minute JJ 2_i
sham NN 2_i
session NN 2_i
. . N

The DT N
skin JJ N
microvessels NNS N
' POS N
vasodilatory NN N
reserve NN N
was VBD N
assessed VBN N
with IN N
a DT N
heat NN N
challenge NN N
at IN N
the DT N
end NN N
of IN N
the DT N
protocol NN N
. . N

RESULTS NNP N
During IN N
the DT N
radiofrequency NN 2_i
exposure NN 2_i
session NN 2_i
, , N
SkBF NNP N
increased VBD N
( ( N
vs. FW N
baseline NN N
) ) N
more JJR N
than IN N
during IN N
the DT N
sham JJ 2_i
exposure NN 2_i
session NN 2_i
. . N

The DT N
sessions NNS N
did VBD N
not RB N
differ VB N
significant JJ N
in IN N
terms NNS N
of IN N
the DT N
Tsk NNP N
time-course JJ N
response NN N
. . N

The DT N
skin JJ N
microvessels NNS N
' POS N
vasodilatory NN N
ability NN N
was VBD N
found VBN N
to TO N
be VB N
greater JJR N
during IN N
radiofrequency NN N
exposure NN N
than IN N
during IN N
sham JJ N
exposure NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
reveal VBP N
the DT N
existence NN N
of IN N
a DT N
specific JJ N
vasodilatory JJ N
effect NN N
of IN N
mobile JJ 2_i
phone NN 2_i
radiofrequency NN 2_i
emission NN 2_i
on IN N
skin JJ N
perfusion NN N
. . N

-DOCSTART- -X- O O

Butorphanol NNP 3_i
and CC N
meperidine NN 3_i
compared VBN N
in IN N
patients NNS N
with IN N
acute JJ N
ureteral JJ N
colic NN N
. . N

Pain NNP N
relief NN N
was VBD N
evaluated VBN N
in IN N
81 CD N
patients NNS N
with IN N
acute JJ N
ureteral JJ N
colic NN N
and CC N
the DT N
confirmed JJ N
presence NN N
of IN N
a DT N
calculus NN N
. . N

A DT N
randomized JJ N
double-blind JJ N
comparison NN N
of IN N
intramuscular JJ N
2 CD N
and CC N
4 CD N
mg. NN N
butorphanol NN 3_i
and CC N
80 CD N
mg. NNS N
meperidine NN 3_i
was VBD N
used VBN N
. . N

Pain NNP N
intensity NN N
and CC N
pain NN N
relief NN N
were VBD N
evaluated VBN N
at IN N
half JJ N
hour NN N
and CC N
hourly JJ N
intervals NNS N
for IN N
4 CD N
hours NNS N
. . N

A DT N
2 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN 3_i
was VBD N
found VBN N
to TO N
be VB N
analgesically RB N
equivalent JJ N
to TO N
80 CD N
mg. NNS N
meperidine NN 3_i
, , N
while IN N
a DT N
4 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN 3_i
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
80 CD N
mg. JJ N
meperidine NN 3_i
and CC N
2 CD N
mg. NN N
butorphanol NN 3_i
. . N

Each DT N
patient NN N
received VBD N
up RB N
to TO N
2 CD N
doses NNS N
of IN N
analgesic JJ N
medication NN N
when WRB N
necessary JJ N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
side JJ N
effects NNS N
among IN N
treatments NNS N
. . N

One CD N
patient NN N
had VBD N
visual JJ N
hallucinations NNS N
after IN N
a DT N
2 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN 3_i
, , N
possibly RB N
owing VBG N
to TO N
its PRP$ N
antagonistic JJ N
activity NN N
to TO N
significant JJ N
narcotic JJ N
experience NN N
given VBN N
previously RB N
at IN N
another DT N
hospital NN N
. . N

There EX N
was VBD N
no DT N
other JJ N
evidence NN N
of IN N
toxicity NN N
with IN N
butorphanol NN 3_i
. . N

It PRP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ N
, , N
effective JJ N
and CC N
wall RB N
tolerated JJ N
drug NN N
for IN N
the DT N
treatment NN N
of IN N
ureteral JJ N
colic NN N
and CC N
is VBZ N
recommended VBN N
in IN N
place NN N
of IN N
narcotics NNS N
. . N

-DOCSTART- -X- O O

No DT N
pain NN N
relief NN N
with IN N
the DT N
rubber NN 4_i
hand NN 4_i
illusion NN 4_i
. . N

The DT N
sense NN N
of IN N
body NN N
ownership NN N
can MD N
be VB N
easily RB N
disrupted VBN N
during IN N
illusions NNS N
and CC N
the DT N
most RBS N
common JJ N
illusion NN N
is VBZ N
the DT N
rubber JJ 4_i
hand NN 4_i
illusion NN 4_i
. . N

An DT N
idea NN N
that WDT N
is VBZ N
rapidly RB N
gaining VBG N
popularity NN N
in IN N
clinical JJ N
pain NN N
medicine NN N
is VBZ N
that IN N
body NN 4_i
ownership NN 4_i
illusions NNS 4_i
can MD N
be VB N
used VBN N
to TO N
modify VB N
pathological JJ N
pain NN N
sensations NNS N
and CC N
induce VB N
analgesia NN N
. . N

However RB N
, , N
this DT N
idea NN N
has VBZ N
not RB N
been VBN N
empirically RB N
evaluated VBN N
. . N

Two CD N
separate JJ N
research NN N
laboratories NNS N
undertook VBP N
independent JJ N
randomized VBN N
repeated JJ N
measures NNS N
experiments NNS N
, , N
both DT N
designed VBN N
to TO N
detect VB N
an DT N
effect NN N
of IN N
the DT N
rubber NN 4_i
hand NN 4_i
illusion NN 4_i
on IN N
experimentally RB N
induced JJ N
hand NN N
pain NN N
. . N

In IN N
Experiment JJ N
1 CD N
, , N
16 CD N
healthy JJ N
volunteers NNS N
rated VBD N
the DT N
pain NN N
evoked VBN N
by IN N
noxious JJ 2_i
heat NN 2_i
stimuli NNS 2_i
( ( N
5 CD N
s NN N
duration NN N
; : N
interstimulus CC N
interval JJ N
25 CD N
s NN N
) ) N
of IN N
set NN N
temperatures NNS N
( ( N
47? CD N
, , N
48? CD N
and CC N
49?C CD N
) ) N
during IN N
the DT N
rubber NN N
hand NN N
illusion NN N
or CC N
during IN N
a DT N
control JJ N
condition NN N
. . N

There EX N
was VBD N
a DT N
main JJ N
effect NN N
of IN N
stimulus JJ N
temperature NN N
on IN N
pain NN N
ratings NNS N
, , N
but CC N
no DT N
main JJ N
effect NN N
of IN N
condition NN N
( ( N
p JJ N
= NNP N
0.32 CD N
) ) N
, , N
nor CC N
a DT N
condition NN N
x JJ N
temperature NN N
interaction NN N
( ( N
p JJ N
= NNP N
0.31 CD N
) ) N
. . N

In IN N
Experiment JJ N
2 CD N
, , N
20 CD N
healthy JJ N
volunteers NNS N
underwent JJ N
quantitative JJ N
sensory NN N
testing VBG N
to TO N
determine VB N
heat NN N
and CC N
cold JJ N
pain NN N
thresholds NNS N
during IN N
the DT N
rubber NN N
hand NN N
illusion NN N
or CC N
during IN N
a DT N
control JJ N
condition NN N
. . N

Secondary JJ N
analyses NNS N
involved VBN N
heat NN N
and CC N
cold JJ N
detection NN N
thresholds NNS N
and CC N
paradoxical JJ N
heat NN N
sensations NNS N
. . N

Again NNP N
, , N
there EX N
was VBD N
no DT N
main JJ N
effect NN N
of IN N
condition NN N
on IN N
heat NN N
pain NN N
threshold NN N
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
nor CC N
on IN N
cold JJ N
pain NN N
threshold NN N
( ( N
p JJ N
= NNP N
0.65 CD N
) ) N
, , N
nor CC N
on IN N
any DT N
of IN N
the DT N
secondary JJ N
measures NNS N
( ( N
p VB N
< $ N
0.56 CD N
for IN N
all DT N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
rubber NN N
hand NN N
illusion NN N
does VBZ N
not RB N
induce VB N
analgesia NN N
. . N

-DOCSTART- -X- O O

Closure NN N
of IN N
the DT N
femoral JJ N
artery NN N
after IN N
cardiac JJ N
catheterization NN N
: : N
a DT N
comparison NN N
of IN N
Angio-Seal NNP N
, , N
StarClose NNP N
, , N
and CC N
manual JJ N
compression NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
Angio-Seal NNP 2_i
( ( 2_i
AS NNP 2_i
) ) 2_i
and CC N
StarClose NNP 2_i
( ( 2_i
SC NNP 2_i
) ) 2_i
and CC N
manual JJ 2_i
compression NN 2_i
( ( 2_i
MC NNP 2_i
) ) 2_i
on IN N
efficacy NN N
of IN N
hemostasis NN N
, , N
complication NN N
rate NN N
, , N
safety NN N
of IN N
early JJ N
mobilization NN N
, , N
and CC N
patient JJ N
comfort NN N
. . N

BACKGROUND NNP N
Closure NNP N
of IN N
the DT N
femoral JJ N
artery NN N
after IN N
cardiac JJ N
catheterization NN N
can MD N
be VB N
obtained VBN N
through IN N
different JJ N
methods NNS N
. . N

Today NN N
, , N
physicians NNS N
can MD N
choose VB N
from IN N
a DT N
number NN N
of IN N
different JJ N
devices NNS N
to TO N
achieve VB N
arterial JJ N
closure NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
trial NN N
450 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
AS NNP 2_i
, , N
SC NNP 2_i
, , N
or CC N
MC NNP 2_i
. . N

Patients NNS N
were VBD N
mobilized VBN N
1 CD N
to TO N
2 CD N
hr NN N
after IN N
device NN N
placement NN N
, , N
and CC N
6 CD N
hr NN N
after IN N
MC NNP 2_i
. . N

Data NNP N
were VBD N
collected VBN N
during IN N
hospital JJ N
admission NN N
and CC N
by IN N
telephone NN N
at IN N
one CD N
month NN N
after IN N
hospital JJ N
discharge NN N
. . N

RESULTS JJ N
Devices NNPS N
were VBD N
used VBN N
in IN N
138/150 CD N
allocated JJ N
to TO N
AS NNP N
and CC N
124/150 CD N
allocated VBN N
to TO N
SC NNP N
patients NNS N
( ( N
92 CD N
% NN N
vs. FW N
83 CD N
% NN N
, , N
P NNP N
= NNP N
0.015 CD N
) ) N
Patients NNS N
with IN N
MC NNP N
experienced VBD N
more JJR N
pain NN N
during IN N
sheath NN N
removal NN N
than IN N
patients NNS N
receiving VBG N
a DT N
device NN N
, , N
and CC N
rated VBD N
their PRP$ N
period NN N
of IN N
bed NN N
rest NN N
as IN N
less RBR N
comfortable JJ N
. . N

Oozing VBG N
and CC N
need VB N
for IN N
pressure NN N
bandage NN N
at IN N
the DT N
puncture NN N
site NN N
were VBD N
observed VBN N
in IN N
37 CD N
AS IN N
patients NNS N
and CC N
57 CD N
SC NNP N
patients NNS N
( ( N
25 CD N
% NN N
vs. FW N
38 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Hematoma NNP N
occurred VBD N
in IN N
15 CD N
AS IN N
patients NNS N
, , N
in IN N
17 CD N
SC NNP N
patients NNS N
, , N
and CC N
in IN N
14 CD N
MC NNP N
patients NNS N
( ( N
11 CD N
vs. FW N
14 CD N
vs. FW N
9 CD N
% NN N
, , N
ns NN N
) ) N
. . N

CONCLUSION NNP N
There EX N
is VBZ N
no DT N
difference NN N
in IN N
safety NN N
between IN N
the DT N
three CD N
methods NNS N
of IN N
arterial JJ N
closure NN N
. . N

SC NNP N
was VBD N
more RBR N
often RB N
not RB N
used VBN N
or CC N
successfully RB N
deployed VBN N
. . N

SC JJ N
patients NNS N
more RBR N
often RB N
had VBD N
continuing VBG N
oozing VBG N
. . N

On IN N
patient JJ N
comfort NN N
, , N
closure NN N
devices NNS N
performed VBD N
better JJR N
than IN N
MC NNP N
. . N

Early JJ N
ambulation NN N
in IN N
patients NNS N
with IN N
a DT N
closure NN N
device NN N
is VBZ N
safe JJ N
. . N

AS NNP N
is VBZ N
the DT N
preferred JJ N
method NN N
of IN N
arterial JJ N
closure NN N
after IN N
cardiac JJ N
catheterization NN N
. . N

-DOCSTART- -X- O O

A DT N
single JJ N
infusion NN N
of IN N
intravenous JJ N
ketamine NN 3_i
improves VBZ N
pain VBP N
relief NN N
in IN N
patients NNS N
with IN N
critical JJ N
limb NN N
ischaemia NN N
: : N
results NNS N
of IN N
a DT N
double JJ N
blind NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

We PRP N
report VBP N
the DT N
first JJ N
double JJ N
blind NN N
randomised VBD N
controlled JJ N
trial NN N
of IN N
regular JJ N
opioids NNS 3_i
and CC N
an DT N
infusion NN N
of IN N
low JJ N
dose NN N
( ( N
0.6 CD N
mg/kg NN N
) ) N
intravenous JJ N
ketamine NN 3_i
compared VBN N
with IN N
opioids NNS 3_i
and CC N
placebo NN 3_i
in IN N
patients NNS N
with IN N
allodynia NN N
, , N
hyperalgesia NN N
and CC N
hyperpathia NN N
secondary JJ N
to TO N
critical JJ N
limb NN N
ischaemia NN N
. . N

Thirty-five JJ N
patients NNS N
completed VBD N
the DT N
study NN N
, , N
18 CD N
received VBD N
regular JJ N
opioids NNS 3_i
plus CC 3_i
ketamine NN 3_i
, , N
while IN N
17 CD N
received VBD N
regular JJ 3_i
opioids NNS 3_i
plus CC 3_i
placebo NN 3_i
. . 3_i

Using VBG N
the DT N
Brief NNP N
Pain NNP N
Inventory NNP N
, , N
the DT N
% NN N
pain NN N
relief NN N
that IN N
the DT N
patients NNS N
in IN N
the DT N
ketamine NN N
group NN N
attributed VBD N
to TO N
their PRP$ N
medication NN N
improved VBN N
significantly RB N
from IN N
50 CD N
% NN N
immediately RB N
pre-infusion NN N
to TO N
65 CD N
% NN N
24 CD N
h JJ N
post-infusion NN N
and CC N
69 CD N
% NN N
5 CD N
days NNS N
post VBN N
infusion NN N
. . N

Over IN N
the DT N
same JJ N
period NN N
, , N
the DT N
pain NN N
relief NN N
achieved VBN N
by IN N
the DT N
placebo NN N
group NN N
rose VBD N
from IN N
58 CD N
% NN N
pre-infusion NN N
to TO N
56 CD N
% NN N
24 CD N
h NN N
post NN N
infusion NN N
and CC N
then RB N
50 CD N
% NN N
relief NN N
5 CD N
days NNS N
later RB N
. . N

This DT N
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
using VBG N
both DT N
the DT N
t-test NN N
and CC N
the DT N
Wilcoxon NNP N
Rank NNP N
Sum NNP N
test NN N
. . N

The DT N
ketamine NN N
group NN N
also RB N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
24 CD N
h NN N
post NN N
infusion NN N
of IN N
the DT N
effect NN N
of IN N
pain NN N
on IN N
their PRP$ N
general JJ N
activity NN N
( ( N
P=0.03 NNP N
) ) N
and CC N
on IN N
their PRP$ N
enjoyment NN N
of IN N
life NN N
( ( N
P=0.004 NNP N
) ) N
. . N

This DT N
study NN N
shows VBZ N
that IN N
combining VBG N
a DT N
single JJ N
infusion NN N
of IN N
low JJ N
dose JJ N
ketamine NN N
with IN N
regular JJ N
opioid JJ 3_i
analgesia NN 3_i
can MD N
result VB N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
pain NN N
relief NN N
for IN N
this DT N
patient NN N
group NN N
. . N

-DOCSTART- -X- O O

Body NN N
size NN N
indexes NNS N
for IN N
optimizing VBG N
iodine NN 3_i
dose NN N
for IN N
aortic JJ N
and CC N
hepatic JJ N
enhancement NN N
at IN N
multidetector NN N
CT NNP N
: : N
comparison NN N
of IN N
total JJ N
body NN N
weight NN N
, , N
lean JJ N
body NN N
weight NN N
, , N
and CC N
blood NN N
volume NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
and CC N
compare VB N
total JJ N
body NN N
weight NN N
( ( N
TBW NNP N
) ) N
, , N
lean JJ N
body NN N
weight NN N
( ( N
LBW NNP N
) ) N
, , N
and CC N
estimated VBD N
blood NN N
volume NN N
( ( N
BV NNP N
) ) N
for IN N
the DT N
adjustment NN N
of IN N
the DT N
iodine NN 3_i
dose NN 3_i
required VBN N
for IN N
contrast NN N
material-enhanced JJ N
multidetector NN N
computed VBD N
tomography NN N
( ( N
CT NNP N
) ) N
of IN N
the DT N
aorta NN N
and CC N
liver NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Institutional NNP N
review NN N
committee NN N
approval NN N
and CC N
written VBN N
informed JJ N
consent NN N
were VBD N
obtained VBN N
. . N

One CD N
hundred VBD N
twenty NN N
patients NNS N
( ( N
54 CD N
men NNS N
, , N
66 CD N
women NNS N
; : N
mean JJ N
age NN N
, , N
64.1 CD N
years NNS N
; : N
range NN N
, , N
19-88 CD N
years NNS N
) ) N
who WP N
underwent JJ N
multidetector NN 2_i
CT NNP 2_i
of IN N
the DT N
upper JJ N
abdomen NNS N
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
of IN N
40 CD N
patients NNS N
each DT N
: : N
( ( N
a DT N
) ) N
TBW NNP N
group NN N
( ( N
0.6 CD N
g NN N
of IN N
iodine NN 3_i
per IN N
kilogram NN N
of IN N
TBW NNP N
) ) N
, , N
( ( N
b NN N
) ) N
LBW NNP N
group NN N
( ( N
0.821 CD N
g NN N
of IN N
iodine NN 3_i
per IN N
kilogram NN N
of IN N
LBW NNP N
) ) N
, , N
and CC N
( ( N
c NN N
) ) N
BV NNP N
group NN N
( ( N
men NNS N
, , N
8.6 CD N
g NN N
of IN N
iodine NN 3_i
per IN N
liter NN N
of IN N
BV NNP N
; : N
women NNS N
, , N
9.9 CD N
g NN N
of IN N
iodine NN N
per IN N
liter NN N
of IN N
BV NNP N
) ) N
. . N

Change NN N
in IN N
CT NNP N
number NN N
between IN N
unenhanced JJ N
and CC N
contrast-enhanced JJ N
images NNS N
per IN N
gram NN N
of IN N
iodine NN N
and CC N
maximum JJ N
hepatic JJ N
enhancement NN N
( ( N
MHE NNP N
) ) N
adjusted VBD N
for IN N
iodine NN 3_i
dose NN N
were VBD N
examined VBN N
for IN N
correlation NN N
with IN N
TBW NNP N
, , N
LBW NNP N
, , N
and CC N
BV NNP N
by IN N
using VBG N
linear JJ N
regression NN N
analysis NN N
. . N

RESULTS NNP N
In IN N
the DT N
portal JJ N
venous JJ N
phase NN N
, , N
correlation NN N
coefficients NNS N
for IN N
the DT N
correlation NN N
of IN N
change NN N
in IN N
CT NNP N
number NN N
per IN N
gram NN N
of IN N
iodine NN 3_i
with IN N
TBW NNP N
for IN N
the DT N
aorta NN N
and CC N
liver NN N
were VBD N
-0.71 NNP N
and CC N
-0.79 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
TBW NNP N
group NN N
; : N
-0.80 CC N
and CC N
-0.86 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
LBW NNP N
group NN N
; : N
and CC N
-0.68 VB N
and CC N
-0.66 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
BV NNP N
group NN N
. . N

In IN N
the DT N
liver NN N
, , N
they PRP N
were VBD N
marginally RB N
higher JJR N
in IN N
the DT N
LBW NNP N
group NN N
than IN N
in IN N
the DT N
BV NNP N
group NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Adjusted VBN N
MHE NNP N
remained VBD N
constant JJ N
at IN N
77.9 CD N
HU NNP N
+/- JJ N
10.2 CD N
( ( N
standard JJ N
deviation NN N
) ) N
in IN N
the DT N
LBW NNP N
group NN N
with IN N
respect NN N
to TO N
TBW NNP N
, , N
but CC N
it PRP N
increased VBD N
in IN N
the DT N
TBW NNP N
( ( N
r VB N
= RB N
0.80 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
BV NNP N
( ( N
r VB N
= RB N
0.70 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
groups NNS N
as IN N
TBW NNP N
increased VBD N
. . N

CONCLUSION NN N
When WRB N
LBW NNP N
, , N
rather RB N
than IN N
TBW NNP N
or CC N
BV NNP N
, , N
is VBZ N
used VBN N
, , N
the DT N
iodine NN 3_i
dose NN N
required VBN N
to TO N
achieve VB N
consistent JJ N
hepatic JJ N
enhancement NN N
may MD N
be VB N
estimated VBN N
more RBR N
precisely RB N
and CC N
with IN N
reduced JJ N
patient-to-patient JJ N
variability NN N
. . N

-DOCSTART- -X- O O

Working VBG N
well RB N
with IN N
a DT N
disability NN N
: : N
health NN 4_i
promotion NN 4_i
as IN N
a DT N
means NN N
to TO N
employment NN N
. . N

PURPOSE/OBJECTIVE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
utility NN N
of IN N
the DT N
Working NNP 4_i
Well NNP 4_i
with IN 4_i
a DT 4_i
Disability NNP 4_i
health-promotion NN 4_i
program NN 4_i
with IN N
vocational JJ 4_i
rehabilitation NN 4_i
( ( N
VR NNP N
) ) N
clients NNS N
. . N

Health-promotion NN 4_i
interventions NNS 4_i
have VBP N
been VBN N
shown VBN N
to TO N
reduce VB N
limitation NN N
from IN N
secondary JJ N
conditions NNS N
, , N
which WDT N
can MD N
be VB N
a DT N
significant JJ N
barrier NN N
to TO N
labor NN N
force NN N
participation NN N
among IN N
people NNS N
with IN N
disabilities NNS N
. . N

The DT N
state NN N
and CC N
federal JJ N
VR NNP N
system NN N
represents VBZ N
a DT N
potential JJ N
access NN N
point NN N
for IN N
delivery NN N
of IN N
health-promotion NN N
activities NNS N
. . N

RESEARCH NNP N
METHOD/DESIGN NNP N
A NNP N
total NN N
of IN N
297 CD N
VR NNP N
clients NNS N
participated VBD N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
the DT N
Working NNP 4_i
Well NNP 4_i
health NN 4_i
promotion NN 4_i
program NN 4_i
. . N

Control NNP N
and CC N
intervention NN N
participants NNS N
provided VBD N
baseline NN N
and CC N
four CD N
waves NNS N
of IN N
quarterly JJ N
follow-up JJ N
data NNS N
. . N

Data NNS N
were VBD N
analyzed VBN N
with IN N
repeated-measures NNS N
ANOVA NNP N
. . N

RESULTS NNP N
Intervention-group JJ 4_i
participants NNS N
who WP N
attended VBD N
over IN N
half NN N
of IN N
the DT N
Working NNP 4_i
Well NNP 4_i
sessions NNS N
reported VBD N
significantly RB N
lower JJR N
rates NNS N
of IN N
limitation NN N
from IN N
secondary JJ N
conditions NNS N
over IN N
the DT N
1-year JJ N
study NN N
span NN N
, , N
F NNP N
( ( N
1 CD N
, , N
124 CD N
) ) N
= NN N
4.11 CD N
, , N
p NN N
= NNP N
.004 NNP N
. . N

Control-group NN 7_i
participants NNS N
also RB N
experienced VBD N
significantly RB N
lower JJR N
rates NNS N
of IN N
limitation NN N
, , N
but CC N
pre- JJ N
to TO N
postdifferences NNS N
were VBD N
less RBR N
dramatic JJ N
, , N
F NNP N
( ( N
1 CD N
, , N
308 CD N
) ) N
= NN N
4.19 CD N
, , N
p NN N
= NNP N
.006 NNP N
. . N

CONCLUSIONS/IMPLICATIONS NNP N
Overall NNP N
, , N
health NN N
data NNS N
indicated VBD N
that IN N
the DT N
Working NNP 4_i
Well NNP 4_i
program NN 4_i
may MD N
be VB N
particularly RB N
helpful JJ N
to TO N
VR NNP N
clients NNS N
with IN N
higher JJR N
rates NNS N
of IN N
secondary JJ N
health NN N
conditions NNS N
and CC N
may MD N
represent VB N
one CD N
strategy NN N
for IN N
overcoming VBG N
barriers NNS N
to TO N
employment NN N
. . N

-DOCSTART- -X- O O

Abstinence NNP N
incentive NN N
effects NNS N
in IN N
a DT N
short-term JJ N
outpatient JJ N
detoxification NN N
program NN N
. . N

Despite IN N
being VBG N
widely RB N
available JJ N
, , N
outpatient JJ N
detoxification NN N
has VBZ N
limited VBN N
efficacy NN N
as IN N
a DT N
stand-alone JJ N
treatment NN N
. . N

This DT N
study NN N
examined VBD N
whether IN N
abstinence-contingent JJ 4_i
incentives NNS 4_i
would MD N
improve VB N
outcomes NNS N
for IN N
patients NNS N
entering VBG N
outpatient JJ N
opiate JJ N
detoxification NN N
. . N

Participants NNS N
( ( N
N NNP N
= NNP N
211 CD N
) ) N
received VBD N
a DT N
100 CD N
US NNP N
dollars NNS N
voucher RB N
on IN N
the DT N
last JJ N
day NN N
of IN N
detoxification NN N
either CC N
contingent NN N
on IN N
opiate NN N
and CC N
cocaine NN N
abstinence NN N
or CC N
noncontingently RB N
. . N

Urine JJ N
samples NNS N
were VBD N
collected VBN N
at IN N
intake NN N
, , N
on IN N
Wednesday NNP N
, , N
Friday NNP N
( ( N
the DT N
last JJ N
day NN N
of IN N
detoxification NN N
) ) N
, , N
and CC N
the DT N
following JJ N
Monday NNP N
. . N

Among IN N
contingent-voucher JJ 4_i
participants NNS N
, , N
31 CD N
% NN N
were VBD N
drug-free JJ N
on IN N
Friday NNP N
compared VBN N
with IN N
18 CD N
% NN N
of IN N
noncontingent NN N
controls NNS N
( ( N
Z NNP N
= NNP N
2.4 CD N
, , N
p NN N
< NNP N
.05 NNP N
) ) N
. . N

Few JJ N
( ( N
12-13 CD N
% NN N
) ) N
participants NNS N
tested VBN N
negative JJ N
on IN N
Monday NNP N
. . N

Results NNP N
support VBD N
the DT N
ability NN N
of IN N
vouchers NNS N
to TO N
produce VB N
modest JJ N
improvements NNS N
in IN N
abstinence NN N
initiation NN N
rates NNS N
during IN N
brief JJ N
detoxification NN N
but CC N
suggest VBP N
that IN N
additional JJ N
interventions NNS N
are VBP N
needed VBN N
to TO N
sustain VB N
improvements NNS N
. . N

-DOCSTART- -X- O O

Laryngeal JJ N
preservation NN N
with IN N
induction NN 3_i
chemotherapy NN 3_i
for IN N
hypopharyngeal NN N
squamous JJ N
cell NN N
carcinoma NN N
: : N
10-year JJ N
results NNS N
of IN N
EORTC NNP N
trial NN N
24891 CD N
. . N

BACKGROUND NNP N
We PRP N
report VBP N
the DT N
10-year JJ N
results NNS N
of IN N
the DT N
EORTC NNP N
trial NN N
24891 CD N
comparing VBG N
a DT N
larynx-preservation JJ 1_i
approach NN 1_i
to TO N
immediate VB 1_i
surgery NN 1_i
in IN N
hypopharynx NN N
and CC N
lateral JJ N
epilarynx NN N
squamous JJ N
cell NN N
carcinoma NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
Two CD N
hundred CD N
and CC N
two CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
surgical JJ N
approach NN N
( ( N
total JJ 1_i
laryngectomy NN 1_i
with IN 1_i
partial JJ 1_i
pharyngectomy NN 1_i
and CC 1_i
neck NN 1_i
dissection NN 1_i
, , 1_i
followed VBN N
by IN N
irradiation NN N
) ) N
or CC N
to TO N
the DT N
chemotherapy NN 3_i
arm NN 3_i
up IN 3_i
to TO 3_i
three CD 3_i
cycles NNS 3_i
of IN 3_i
induction NN 3_i
chemotherapy NN 3_i
( ( N
cisplatin JJ 3_i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1 CD N
+ CD N
5-FU JJ N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1-5 JJ N
) ) N
followed VBD N
for IN N
complete JJ N
responders NNS N
by IN N
irradiation NN 3_i
and CC N
otherwise RB N
by IN N
conventional JJ 7_i
treatment NN 7_i
. . N

The DT N
end NN N
points NNS N
were VBD N
overall JJ N
survival JJ N
[ NN N
OS NNP N
, , N
noninferiority NN N
: : N
hazard NN N
ratio NN N
( ( N
preservation/surgery NN N
) ) N
? . N
1.428 CD N
, , N
one-sided JJ N
? . N
= $ N
0.05 CD N
] NNP N
, , N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
and CC N
survival JJ N
with IN N
a DT N
functional JJ N
larynx NN N
( ( N
SFL NNP N
) ) N
. . N

RESULTS NNP N
At IN N
a DT N
median JJ N
follow-up NN N
of IN N
10.5 CD N
years NNS N
on IN N
194 CD N
eligible JJ N
patients NNS N
, , N
disease JJ N
evolution NN N
was VBD N
seen VBN N
in IN N
54 CD N
and CC N
49 CD N
patients NNS N
in IN N
the DT N
surgery NN N
and CC N
chemotherapy NN N
arm NN N
, , N
respectively RB N
, , N
and CC N
81 CD N
and CC N
83 CD N
patients NNS N
had VBD N
died VBN N
. . N

The DT N
10-year JJ N
OS NNP N
rate NN N
was VBD N
13.8 CD N
% NN N
in IN N
the DT N
surgery NN N
arm NN N
and CC N
13.1 CD N
% NN N
in IN N
the DT N
chemotherapy NN N
arm NN N
. . N

The DT N
10-year JJ N
PFS NNP N
rates NNS N
were VBD N
8.5 CD N
% NN N
and CC N
10.8 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
the DT N
chemotherapy NN N
arm NN N
, , N
the DT N
10-year JJ N
SFL NNP N
rate NN N
was VBD N
8.7 CD N
% NN N
. . N

CONCLUSION NNP N
This DT N
strategy NN N
did VBD N
not RB N
compromise VB N
disease NN N
control NN N
or CC N
survival NN N
( ( N
that IN N
remained VBD N
poor JJ N
) ) N
and CC N
allowed VBD N
more JJR N
than IN N
half NN N
of IN N
the DT N
survivors NNS N
to TO N
retain VB N
their PRP$ N
larynx NN N
. . N

-DOCSTART- -X- O O

Flow-cytometric JJ N
studies NNS N
with IN N
eleutherococcus JJ 4_i
senticosus NN 4_i
extract NN 4_i
as IN N
an DT N
immunomodulatory NN N
agent NN N
. . N

A DT N
placebo-controlled JJ 7_i
study NN N
of IN N
the DT N
effect NN N
of IN N
an DT N
Eleutherococcus NNP 4_i
senticosus NN 4_i
extract NN 4_i
( ( 4_i
Eleukokk NNP 4_i
) ) 4_i
on IN N
the DT N
immune NN N
system NN N
was VBD N
performed VBN N
with IN N
36 CD N
healthy JJ N
volunteers NNS N
utilising VBG N
quantitative JJ N
multi-parameter NN N
flow NN N
cytometry NN N
with IN N
monoclonal JJ N
antibodies NNS N
directed VBN N
against IN N
specific JJ N
surface NN N
markers NNS N
of IN N
human JJ N
lymphocyte JJ N
subsets NNS N
. . N

Volunteers NNS N
in IN N
the DT N
verum NN N
group NN N
received VBD N
10 CD N
ml NN N
of IN N
an DT N
ethanolic JJ 4_i
( ( 4_i
vincamine JJ 4_i
free JJ 4_i
) ) 4_i
eleutherococcus VBP 4_i
senticosus JJ 4_i
preparation NN 4_i
, , N
3 CD N
times NNS N
daily RB N
for IN N
4 CD N
weeks NNS N
. . N

In IN N
the DT N
placebo NN 7_i
, , 7_i
the DT 7_i
eleutherococcus NN 7_i
extract NN 7_i
was VBD 7_i
substituted VBN 7_i
by IN 7_i
additional JJ 7_i
wine NN 7_i
, , 7_i
resulting VBG 7_i
in IN 7_i
identical JJ 7_i
final JJ 7_i
concentrations NNS 7_i
of IN 7_i
ethanol NN 7_i
in IN 7_i
both DT 7_i
preparations NNS 7_i
. . N

The DT N
purpose NN N
of IN N
the DT N
double-blind NN N
study NN N
was VBD N
the DT N
demonstration NN N
of IN N
possible JJ N
effects NNS N
on IN N
the DT N
cellular JJ N
immune NN N
status NN N
, , N
as IN N
determined VBN N
by IN N
quantitative JJ N
flow NN N
cytometry NN N
. . N

The DT N
most RBS N
salient JJ N
feature NN N
in IN N
the DT N
verum NN N
group NN N
was VBD N
a DT N
drastic JJ N
increase NN N
in IN N
the DT N
absolute JJ N
number NN N
of IN N
immunocompetent JJ N
cells NNS N
, , N
with IN N
an DT N
especially RB N
pronounced JJ N
effect NN N
on IN N
T NNP N
lymphocytes NNS N
, , N
predominantly RB N
of IN N
the DT N
helper/inducer NN N
type NN N
, , N
but CC N
also RB N
on IN N
cytotoxic NN N
and CC N
natural JJ N
killer NN N
cells NNS N
. . N

In IN N
addition NN N
, , N
a DT N
general JJ N
enhancement NN N
of IN N
the DT N
activation NN N
state NN N
of IN N
T NNP N
lymphocytes NNS N
was VBD N
observed VBN N
. . N

No DT N
side NN N
effects NNS N
were VBD N
observed VBN N
during IN N
the DT N
trial NN N
or CC N
afterwards NNS N
( ( N
observation NN N
period NN N
6 CD N
months NNS N
) ) N
. . N

-DOCSTART- -X- O O

Short-term JJ N
fluoxetine NN 3_i
monotherapy NN 3_i
for IN N
bipolar JJ N
type NN N
II NNP N
or CC N
bipolar JJ N
NOS NNP N
major JJ N
depression NN N
- : N
low JJ N
manic JJ N
switch NN N
rate NN N
. . N

OBJECTIVES CC N
Current NNP N
guidelines NNS N
for IN N
the DT N
initial JJ N
treatment NN N
of IN N
bipolar JJ N
type NN N
II NNP N
( ( N
BP NNP N
II NNP N
) ) N
major JJ N
depressive JJ N
episode NN N
( ( N
MDE NNP N
) ) N
recommend VBP N
using VBG N
either CC N
a DT N
mood NN N
stabilizer NN N
alone RB N
or CC N
a DT N
combination NN N
of IN N
a DT N
mood NN N
stabilizer NN N
plus CC N
a DT N
selective JJ N
serotonin NN N
re-uptake NN N
inhibitor NN N
( ( N
SSRI NNP N
) ) N
. . N

This DT N
recommendation NN N
is VBZ N
the DT N
result NN N
of IN N
concern NN N
over IN N
antidepressant-induced JJ N
manic JJ N
switch NN N
episodes NNS N
. . N

However RB N
, , N
recent JJ N
evidence NN N
suggests VBZ N
that IN N
the DT N
manic JJ N
switch NN N
rate NN N
may MD N
be VB N
low JJ N
in IN N
BP NNP N
II NNP N
MDE NNP N
during IN N
SSRI NNP N
therapy NN N
. . N

METHODS NNP N
As IN N
part NN N
of IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
relapse-prevention NN N
study NN N
of IN N
fluoxetine JJ 2_i
monotherapy NN 2_i
in IN N
BP NNP N
II NNP N
MDE NNP N
, , N
37 CD N
patients NNS N
received VBD N
open-label JJ 3_i
fluoxetine NN 3_i
20 CD 3_i
mg NN 3_i
every DT 4_i
day NN 4_i
for IN 4_i
up IN 4_i
to TO 4_i
8 CD 4_i
weeks NNS 4_i
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
( ( N
HAM-D NNP N
17 CD N
) ) N
rating NN N
and CC N
the DT N
Young NNP N
Mania NNP N
Rating NNP N
( ( N
YMR NNP N
) ) N
scale NN N
. . N

RESULTS NNP N
Eleven NNP N
of IN N
23 CD N
patients NNS N
( ( N
48 CD N
% NN N
) ) N
who WP N
completed VBD N
8 CD N
weeks NNS N
of IN N
fluoxetine NN 3_i
treatment NN N
showed VBD N
a DT N
HAM-D JJ N
17 CD N
reduction NN N
of IN N
> NN N
or CC N
=50 CD N
% NN N
, , N
while IN N
14 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
all DT N
treated JJ N
patients NNS N
had VBD N
> VBN N
or CC N
=50 CD N
% NN N
reduction NN N
in IN N
baseline JJ N
HAM-D JJ N
17 CD N
score NN N
. . N

Using VBG N
a DT N
conservative JJ N
YMR NNP N
score NN N
of IN N
> NN N
or CC N
=8 VB N
to TO N
identify VB N
hypomanic JJ N
symptoms NNS N
, , N
the DT N
frequency NN N
of IN N
patients NNS N
with IN N
YMR NNP N
score NN N
> NN N
or CC N
=8 NN N
during IN N
fluoxetine NN N
did VBD N
not RB N
differ VB N
from IN N
that DT N
seen VBN N
during IN N
the DT N
screen NN N
and CC N
baseline JJ N
period NN N
. . N

Only RB N
three CD N
patients NNS N
( ( N
7.3 CD N
% NN N
) ) N
had VBD N
symptoms NNS N
suggestive JJ N
of IN N
hypomania NN N
, , N
and CC N
only RB N
one CD N
patient NN N
stopped VBD N
treatment NN N
because IN N
of IN N
a DT N
rapid JJ N
mood NN N
swing VBG N
into IN N
depression NN N
. . N

LIMITATIONS NNP N
Fluoxetine NNP 3_i
was VBD N
given VBN N
at IN N
a DT N
fixed JJ N
dose NN N
of IN N
20 CD N
mg NNS N
everyday JJ N
. . N

Fluoxetine NNP 3_i
was VBD N
prescribed VBN N
in IN N
an DT N
open-label JJ N
manner NN N
, , N
and CC N
the DT N
sample NN N
size NN N
was VBD N
limited VBN N
. . N

CONCLUSIONS NNP N
These DT N
observations NNS N
support VBP N
the DT N
findings NNS N
of IN N
a DT N
low JJ N
manic JJ N
switch NN N
rate NN N
during IN N
SSRI NNP N
monotherapy NN N
of IN N
BP NNP N
II NNP N
MDE NNP N
, , N
and CC N
suggest VBP N
that IN N
fluoxetine JJ 3_i
monotherapy NN 3_i
may MD N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
initial JJ N
treatment NN N
of IN N
BP NNP N
II NNP N
MDE NNP N
. . N

-DOCSTART- -X- O O

Levamisole NNP 5_i
versus NN N
placebo NN 7_i
as IN N
an DT N
adjunct NN N
to TO N
primary JJ N
therapy NN N
of IN N
laryngopharyngeal JJ N
epidermoid JJ N
carcinoma NN N
. . N

Evaluation NN N
of IN N
the DT N
immune JJ N
status NN N
. . N

Twenty-four CD N
patients NNS N
, , N
with IN N
a DT N
biopsy-proven JJ N
laryngeal NN N
or CC N
hypopharyngeal NN N
carcinoma NN N
, , N
received VBD N
as IN N
an DT N
adjunct NN N
to TO N
their PRP$ N
primary JJ N
treatment NN N
( ( N
surgery JJ N
and/or RB N
radiotherapy NN N
) ) N
, , N
levamisole JJ 3_i
( ( N
150 CD N
mg NNS N
daily RB N
during IN N
three CD N
consecutive JJ N
days NNS N
, , N
every DT N
fortnight NN N
) ) N
or CC N
placebo NN N
, , N
following VBG N
a DT N
single-blind JJ N
, , N
but CC N
randomized VBD N
method NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
follow-up NN N
, , N
an DT N
investigation NN N
of IN N
the DT N
immune NN N
status NN N
was VBD N
done VBN N
, , N
and CC N
compared VBN N
with IN N
that DT N
of IN N
a DT N
healthy JJ N
control-group NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
immunity NN N
is VBZ N
disturbed VBN N
in IN N
patients NNS N
with IN N
laryngo-pharyngeal JJ N
cancer NN N
, , N
but CC N
that IN N
this DT N
disturbance NN N
does VBZ N
not RB N
clearly RB N
correlate NN N
with IN N
the DT N
clinical JJ N
state NN N
of IN N
the DT N
disease NN N
. . N

Also RB N
, , N
the DT N
immunological JJ N
measures NNS N
did VBD N
not RB N
appear VB N
relevant JJ N
to TO N
the DT N
significantly RB N
favourable JJ N
effect NN N
of IN N
levamisole NN N
on IN N
the DT N
prognosis NN N
. . N

-DOCSTART- -X- O O

Sequential JJ 3_i
therapy NN 3_i
versus IN N
standard JJ 3_i
triple-drug JJ 3_i
therapy NN 3_i
for IN N
Helicobacter NNP N
pylori JJ N
eradication NN N
: : N
a DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
Antimicrobial NNP N
resistance NN N
has VBZ N
decreased VBN N
eradication NN N
rates NNS N
for IN N
Helicobacter NNP N
pylori JJ N
infection NN N
worldwide NN N
. . N

A DT N
sequential JJ N
treatment NN N
schedule NN N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
, , N
but CC N
studies NNS N
published VBN N
to TO N
date NN N
were VBD N
performed VBN N
in IN N
Italy NNP N
. . N

We PRP N
undertook VBD N
this DT N
study NN N
to TO N
determine VB N
whether IN N
these DT N
results NNS N
could MD N
be VB N
replicated VBN N
in IN N
India NNP N
. . N

METHODS NNP N
A NNP N
randomized JJ N
, , N
open-labeled JJ N
, , N
prospective JJ N
controlled VBN N
trial NN N
comparing VBG N
sequential JJ 3_i
vs. FW N
standard JJ 3_i
triple-drug JJ 3_i
therapy NN 3_i
was VBD N
carried VBN N
out RP N
at IN N
Lokmanya NNP N
Tilak NNP N
Municipal NNP N
General NNP N
Hospital NNP N
, , N
Mumbai NNP N
. . N

Two CD N
hundred CD N
and CC N
thirty-one JJ N
patients NNS N
with IN N
dyspepsia NNS N
were VBD N
randomized VBN N
to TO N
a DT N
10-day JJ 3_i
sequential JJ 3_i
regimen NNS 3_i
( ( N
40 CD 3_i
mg NN 3_i
of IN 3_i
pantoprazole NN 3_i
, , N
1 CD 3_i
g NN 3_i
of IN 3_i
amoxicillin NN 3_i
, , N
each DT N
administered VBN N
twice RB N
daily RB N
for IN N
the DT N
first JJ N
5 CD N
days NNS N
, , N
followed VBN N
by IN N
40 CD 3_i
mg NNS 3_i
of IN 3_i
pantoprazole NN 3_i
, , N
500 CD 3_i
mg NN 3_i
of IN 3_i
clarithromycin NN 3_i
, , N
and CC N
500 CD 3_i
mg NN 3_i
of IN 3_i
tinidazole NN 3_i
, , N
each DT N
administered VBN N
twice RB N
daily RB N
for IN N
the DT N
remaining VBG N
5 CD N
days NNS N
) ) N
or CC N
to TO N
standard VB 3_i
14-day JJ 3_i
therapy NN 3_i
( ( N
40 CD 3_i
mg NN 3_i
of IN 3_i
pantoprazole NN 3_i
, , N
500 CD 3_i
mg NN 3_i
of IN 3_i
clarithromycin NN 3_i
, , N
and CC N
1 CD 3_i
g NN 3_i
of IN 3_i
amoxicillin NN 3_i
, , N
each DT N
administered VBN N
twice RB N
daily RB N
) ) N
. . N

RESULTS VB N
The DT N
eradication NN N
rate NN N
achieved VBN N
with IN N
the DT N
sequential JJ 3_i
regimen NN 3_i
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
obtained VBN N
with IN N
the DT N
triple JJ 3_i
therapy NN 3_i
. . N

Per-protocol JJ N
eradication NN N
rate NN N
of IN N
sequential JJ 3_i
therapy NN 3_i
was VBD N
92.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
85.8-96.1 CD N
% NN N
) ) N
vs. FW N
81.8 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
73.9-87.8 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.027 CD N
) ) N
for IN N
standard JJ N
drug NN N
therapy NN N
. . N

Intention-to-treat JJ N
eradication NN N
rates NNS N
were VBD N
88.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
80.9-93.0 CD N
% NN N
) ) N
vs. FW N
79.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
71.1-85.4 CD N
% NN N
) ) N
, , N
p JJ N
= NN N
0.029 CD N
, , N
respectively RB N
. . N

The DT N
incidence NN N
of IN N
major JJ N
and CC N
minor JJ N
side NN N
effects NNS N
between IN N
therapy NN N
groups NNS N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
14.6 CD N
% NN N
in IN N
the DT N
triple JJ N
therapy NN N
group NN N
vs. FW N
23.5 CD N
% NN N
in IN N
sequential JJ N
group NN N
, , N
p VBP N
= RB N
0.12 CD N
) ) N
. . N

Follow NNP N
up RP N
was VBD N
incomplete JJ N
in IN N
3.3 CD N
% NN N
and CC N
4.7 CD N
% NN N
patients NNS N
in IN N
standard JJ N
and CC N
sequential JJ N
therapy NN N
groups NNS N
, , N
respectively RB N
. . N

Sequential JJ N
therapy NN N
includes VBZ N
one CD N
additional JJ N
antibiotic NN N
( ( N
tinidazole NN N
) ) N
that WDT N
is VBZ N
not RB N
contained VBN N
in IN N
standard JJ N
therapy NN N
. . N

CONCLUSIONS NNP N
Sequential NNP N
therapy NN N
was VBD N
significantly RB N
better JJR N
than IN N
standard JJ N
therapy NN N
for IN N
eradicating VBG N
H. NNP N
pylori JJ N
infection NN N
. . N

-DOCSTART- -X- O O

Hemolytic JJ 3_i
streptococcus NN 3_i
preparation NN 3_i
OK-432 NNP 3_i
; : N
beneficial JJ N
adjuvant NN N
therapy NN N
in IN N
recurrent NN N
gastric JJ N
carcinoma NN N
. . N

The DT N
administration NN N
of IN N
a DT N
hemolytic JJ 3_i
streptococcus NN 3_i
preparation NN 3_i
, , N
OK-432 NNP N
, , N
is VBZ N
thought VBN N
to TO N
be VB N
of IN N
therapeutic JJ N
value NN N
in IN N
the DT N
treatment NN N
of IN N
cancer NN N
patients NNS N
through IN N
a DT N
stimulatory JJ N
effect NN N
on IN N
the DT N
immune NN N
system NN N
. . N

In IN N
order NN N
to TO N
evaluate VB N
any DT N
beneficial JJ N
effect NN N
of IN N
such JJ N
an DT N
administration NN N
, , N
a DT N
group NN N
of IN N
patients NNS N
with IN N
recurrent JJ N
gastric JJ N
cancer NN N
was VBD N
studied VBN N
. . N

This DT N
group NN N
was VBD N
randomly RB N
subdivided VBN N
into IN N
3 CD N
groups NNS N
: : N
1 CD N
) ) N
Intradermal NNP N
group NN N
( ( N
ID NNP N
Group NNP N
) ) N
, , N
42 CD N
patients NNS N
given VBN N
an DT N
intradermal JJ 3_i
injections NNS 3_i
of IN 3_i
OK-432 NNP 3_i
. . N

2 CD N
) ) N
Intramuscular NNP N
group NN N
( ( N
IM NNP N
Group NNP N
) ) N
, , N
40 CD N
patients NNS N
given VBN N
an DT N
intramuscular JJ 3_i
injections NNS 3_i
of IN 3_i
OK-432 NNP 3_i
. . N

3 CD N
) ) N
Control NNP 7_i
group NN N
( ( N
C NNP N
Group NNP N
) ) N
, , N
39 CD N
patients NNS N
not RB N
given VBN N
injections NNS N
. . N

Each DT N
group NN N
was VBD N
studied VBN N
in IN N
regards NNS N
to TO N
the DT N
length NN N
of IN N
survival NN N
, , N
the DT N
host NN N
immune JJ N
response NN N
and CC N
the DT N
incidence NN N
of IN N
side NN N
effects NNS N
. . N

When WRB N
compared VBN N
to TO N
the DT N
IM NNP N
and CC N
C NNP N
Groups NNP N
, , N
the DT N
ID NNP N
Group NNP N
showed VBD N
improved JJ N
survival NN N
. . N

Accompanying VBG N
this DT N
improved JJ N
survival NN N
, , N
the DT N
ID NNP N
Group NNP N
also RB N
had VBD N
greater JJR N
white JJ N
cell NN N
and CC N
lymphocyte NN N
counts NNS N
, , N
a DT N
greater JJR N
number NN N
of IN N
T NNP N
cells NNS N
, , N
and CC N
a DT N
more RBR N
dramatic JJ N
skin NN N
reaction NN N
to TO N
the DT N
extracted VBN N
cell NN N
wall NN N
polysaccharide NN N
of IN N
hemolytic JJ N
streptococcus NN N
Su-strain NNP N
( ( N
Su-PS NNP N
) ) N
. . N

The DT N
ID NNP N
Group NNP N
, , N
following VBG N
OK-432 JJ N
injection NN N
, , N
had VBD N
a DT N
4.8 CD N
% NN N
incidence NN N
of IN N
fever NN N
and CC N
a DT N
52.4 CD N
% NN N
incidence NN N
of IN N
local JJ N
abscess NN N
formation NN N
at IN N
the DT N
injection NN N
site NN N
. . N

90 CD N
% NN N
of IN N
the DT N
IM NNP N
Group NNP N
developed VBD N
fever RB N
but CC N
abscess JJ N
formation NN N
was VBD N
absent VBN N
in IN N
all DT N
patients NNS N
. . N

From IN N
these DT N
results NNS N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
in IN N
the DT N
patients NNS N
tested VBN N
, , N
intradermal JJ N
injection NN N
of IN N
OK-432 NNP N
appears VBZ N
to TO N
be VB N
clinically RB N
superior JJ N
to TO N
intramuscular JJ N
injection NN N
. . N

-DOCSTART- -X- O O

Dose-response JJ N
effect NN N
of IN N
flecainide NN 3_i
in IN N
patients NNS N
with IN N
symptomatic JJ N
paroxysmal JJ N
atrial JJ N
fibrillation NN N
and/or NN N
flutter NN N
monitored VBD N
with IN N
trans-telephonic JJ N
electrocardiography NN N
: : N
a DT N
multicenter NN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

BACKGROUND VB N
A DT N
double-blind NN N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ 7_i
trial NN N
was VBD N
conducted VBN N
in IN N
patients NNS N
with IN N
paroxysmal JJ N
atrial JJ N
fibrillation NN N
or CC N
flutter NN N
( ( N
PAF/PAFL NNP N
) ) N
experiencing VBG N
2 CD N
or CC N
more JJR N
episodes NNS N
of IN N
symptomatic JJ N
PAF/PAFL NNP N
during IN N
a DT N
28-day JJ N
observation NN N
period NN N
to TO N
determine VB N
the DT N
dose-response JJ N
effect NN N
and CC N
safety NN N
of IN N
flecainide NN 3_i
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
143 CD N
patients NNS N
at IN N
30 CD N
centers NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
25 CD N
, , N
50 CD N
, , N
or CC N
100 CD N
mg NN N
of IN N
flecainide NN 3_i
or CC N
placebo VB 7_i
twice JJ N
daily JJ N
( ( N
BID NNP N
) ) N
. . N

In IN N
123 CD N
patients NNS N
( ( N
per IN N
protocol NN N
set NN N
) ) N
, , N
those DT N
remaining VBG N
free JJ N
from IN N
PAF/PAFL NNP N
after IN N
the DT N
treatment NN N
were VBD N
3.1 CD N
% NN N
on IN N
placebo NN 7_i
, , N
7.7 CD N
% NN N
on IN N
25 CD N
mg/BID NN N
, , N
9.4 CD N
% NN N
on IN N
50 CD N
mg/BID NN N
, , N
and CC N
39.4 CD N
% NN N
on IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN 3_i
. . N

As IN N
a DT N
whole JJ N
group NN N
, , N
a DT N
significant JJ N
linear JJ N
dose-response NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
was VBD N
observed VBN N
and CC N
a DT N
significant JJ N
difference NN N
between IN N
placebo NN N
and CC N
100 CD N
mg/BID NN N
was VBD N
observed VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
similar JJ N
dose-response NN N
between IN N
the DT N
present JJ N
study NN N
and CC N
Caucasian NNP N
study NN N
was VBD N
demonstrated VBN N
. . N

Although IN N
there EX N
were VBD N
5 CD N
patients NNS N
who WP N
needed VBD N
cardioversion NN N
or CC N
ablation NN N
because IN N
of IN N
frequent JJ N
episodes NNS N
of IN N
PAF/PAFL NNP N
( ( N
2 CD N
in IN N
25 CD N
mg/BID NN N
, , N
1 CD N
in IN N
50 CD N
mg/BID NN N
, , N
and CC N
2 CD N
in IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN 3_i
) ) N
, , N
neither CC N
death NN N
nor CC N
ventricular JJ N
proarrhythmic JJ N
event NN N
was VBD N
reported VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
indicated VBD N
that IN N
flecainide NN 3_i
exerted VBD N
a DT N
significant JJ N
dose-dependent JJ N
effect NN N
on IN N
the DT N
prevention NN N
of IN N
symptomatic JJ N
PAF/PAFL NNP N
recurrence NN N
and CC N
showed VBD N
that IN N
there EX N
was VBD N
no DT N
inter-ethnic JJ N
difference NN N
in IN N
the DT N
clinical JJ N
effect NN N
of IN N
flecainide NN 3_i
in IN N
patients NNS N
with IN N
PAF/PAFL NNP N
. . N

-DOCSTART- -X- O O

Ilioinguinal-iliohypogastric JJ N
nerve NN N
block NN N
within IN N
travenous JJ N
dexketoprofen NN 3_i
improves VBZ N
postoperative JJ N
analgesia NN N
in IN N
abdominal JJ N
hysterectomies NNS N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
In IN N
this DT N
study NN N
, , N
our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
intravenous JJ N
dexketoprofen NNS 3_i
trometamol VBP 3_i
with IN N
ilioinguinal JJ N
and CC N
iliohypogastric JJ N
nerve NN N
block NN N
on IN N
analgesic JJ N
quality NN N
and CC N
morphine NN N
consumption NN N
after IN N
total JJ N
abdominal JJ N
hysterectomy NN N
operations NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
this DT N
randomized VBN N
controlled VBD N
clinical JJ N
study NN N
on IN N
61 CD N
patients NNS N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
the DT N
operation NN N
room NN N
, , N
post-anesthesia JJ N
care NN N
unit NN N
, , N
and CC N
inpatient JJ N
clinic NN N
. . N

We PRP N
randomly RB N
grouped VBD N
the DT N
61 CD N
patients NNS N
into IN N
control NN 7_i
group NN 7_i
( ( N
group NN N
C NNP N
) ) N
, , N
block NN 3_i
group NN 3_i
( ( N
group NN N
B NNP N
) ) N
and CC N
dexketoprofen-block JJ 3_i
group NN 3_i
( ( N
group NN N
DB NNP N
) ) N
. . N

Before IN N
the DT N
skin NN N
incision NN N
performed VBD N
after IN N
anesthesia JJ N
induction NN N
, , N
we PRP N
performed VBD N
ilioinguinal JJ 3_i
iliohypogastric JJ 3_i
block NN 3_i
( ( N
group NN N
C NNP N
given VBN N
saline NN 3_i
and CC N
group NN N
P NNP N
and CC N
DB NNP 3_i
given VBN N
levobupivacaine NN 3_i
) ) N
. . N

In IN N
contrast NN N
to TO N
group NN N
C NNP N
and CC N
B NNP N
, , N
group NN N
DB NNP N
was VBD N
given VBN N
dexketoprofen RB 3_i
. . N

We PRP N
administered VBD N
morphine JJ 3_i
analgesia NN 3_i
to TO N
all DT N
patients NNS N
by IN N
patient-controlled JJ N
analgesia NN N
( ( N
PCA NNP N
) ) N
during IN N
the DT N
postoperative JJ N
24 CD N
hours NNS N
. . N

We PRP N
recorded VBD N
Visual NNP N
Analogue NNP N
Scale NNP N
( ( N
VAS NNP N
) ) N
, , N
satisfaction NN N
scores NNS N
, , N
morphine NN N
consumption NN N
and CC N
side NN N
effects NNS N
during IN N
postoperative JJ N
24 CD N
hours NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
the DT N
DB NNP N
group?s NN N
VAS NNP N
scores VBZ N
to TO N
be VB N
lower JJR N
than IN N
the DT N
control NN N
group NN N
and CC N
block NN N
group?s NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
values NNS N
at IN N
postoperative JJ N
1st CD N
, , N
2nd CD N
, , N
6th CD N
and CC N
12th CD N
hours NNS N
. . N

VAS NNP N
scores NNS N
of IN N
group NN N
C NNP N
were VBD N
higher JJR N
than IN N
of IN N
group NN N
B NNP N
at IN N
postoperative JJ N
fi NN N
rst VBD N
2 CD N
hours NNS N
. . N

Time NNP N
to TO N
fi VB N
rst JJ N
PCA NNP N
demand NN N
was VBD N
longer RBR N
, , N
morphine JJ N
consumption NN N
values NNS N
were VBD N
lower JJR N
and CC N
satisfaction NN N
scores NNS N
were VBD N
higher JJR N
in IN N
group NN N
DB NNP N
than IN N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Ilioinguinal-iliohypogastric JJ N
nerve NN N
block NN N
with IN N
IV NNP N
dexketoprofen NN N
increases NNS N
patient JJ N
satisfaction NN N
by IN N
decreasing VBG N
opioid JJ N
consumption NN N
, , N
increasing VBG N
patient JJ N
satisfaction NN N
, , N
which WDT N
suggests VBZ N
that IN N
dexketoprofen NN N
trometamol NN N
is VBZ N
an DT N
effective JJ N
non-steroidal JJ N
anti-inflammatory JJ N
analgesic NN N
in IN N
postoperative JJ N
analgesia NN N
. . N

-DOCSTART- -X- O O

Monitoring VBG N
acute JJ N
effects NNS N
on IN N
athletic JJ N
performance NN N
with IN N
mixed JJ N
linear JJ N
modeling NN N
. . N

UNLABELLED IN N
There EX N
is VBZ N
a DT N
need NN N
for IN N
a DT N
sophisticated JJ N
approach NN N
to TO N
track VB N
athletic JJ N
performance NN N
and CC N
to TO N
quantify VB N
factors NNS N
affecting VBG N
it PRP N
in IN N
practical JJ N
settings NNS N
. . N

PURPOSE NNP N
To TO N
demonstrate VB N
the DT N
application NN N
of IN N
mixed JJ N
linear JJ N
modeling VBG N
for IN N
monitoring VBG N
athletic JJ N
performance NN N
. . N

METHODS NNP N
Elite NNP N
sprint NN N
and CC N
middle-distance NN N
swimmers NNS N
( ( N
three CD N
females NNS N
and CC N
six CD N
males NNS N
; : N
aged VBN N
21-26 JJ N
yr NN N
) ) N
performed VBD N
6-13 JJ N
time NN N
trials NNS N
in IN N
training NN N
and CC N
competition NN N
in IN N
the DT N
9 CD N
wk NN N
before IN N
and CC N
including VBG N
Olympic-qualifying JJ N
trials NNS N
, , N
all DT N
in IN N
their PRP$ N
specialty NN N
event NN N
. . N

We PRP N
included VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
diet-controlled JJ 4_i
crossover NN 4_i
intervention NN 4_i
, , N
in IN N
which WDT N
the DT N
swimmers NNS N
consumed VBN N
caffeine NN 3_i
( ( N
5 CD N
mg NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
body NN N
mass NN N
) ) N
or CC N
placebo NN 7_i
. . N

The DT N
swimmers NNS N
also RB N
knowingly RB N
consumed VBD N
varying VBG N
doses NNS N
of IN N
caffeine NN 3_i
in IN N
some DT N
time NN N
trials NNS N
. . N

We PRP N
used VBD N
mixed JJ N
linear JJ N
modeling NN N
of IN N
log-transformed JJ N
swim JJ N
time NN N
to TO N
quantify VB N
effects NNS N
on IN N
performance NN N
in IN N
training VBG N
versus NN N
competition NN N
, , N
in IN N
morning NN N
versus NN N
evening NN N
swims NNS N
, , N
and CC N
with IN N
use NN N
of IN N
caffeine NN N
. . N

Predictor NN N
variables NNS N
were VBD N
coded VBN N
as IN N
0 CD N
or CC N
1 CD N
to TO N
represent VB N
absence NN N
or CC N
presence NN N
, , N
respectively RB N
, , N
of IN N
each DT N
condition NN N
and CC N
were VBD N
included VBN N
as IN N
fixed JJ N
effects NNS N
. . N

The DT N
date NN N
of IN N
each DT N
performance NN N
test NN N
was VBD N
included VBN N
as IN N
a DT N
continuous JJ N
linear JJ N
fixed VBN N
effect NN N
and CC N
interacted VBN N
with IN N
the DT N
random NN N
effect NN N
for IN N
the DT N
athlete NN N
to TO N
represent VB N
individual JJ N
differences NNS N
in IN N
linear JJ N
trends NNS N
in IN N
performance NN N
. . N

RESULTS NNP N
Most JJS N
effects NNS N
were VBD N
clear JJ N
, , N
owing VBG N
to TO N
the DT N
high JJ N
reliability NN N
of IN N
performance NN N
times NNS N
in IN N
training NN N
and CC N
competition NN N
( ( N
typical JJ N
errors NNS N
of IN N
0.9 CD N
% NN N
and CC N
0.8 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Performance NN N
time NN N
improved VBN N
linearly RB N
by IN N
0.8 CD N
% NN N
per IN N
4 CD N
wk NN N
. . N

The DT N
swimmers NNS N
performed VBD N
substantially RB N
better RBR N
in IN N
evenings NNS N
versus JJ N
mornings NNS N
and CC N
in IN N
competition NN N
versus IN N
training NN N
. . N

A DT N
100-mg JJ N
dose NN N
of IN N
caffeine NN N
enhanced VBN N
performance NN N
in IN N
training NN N
and CC N
competition NN N
by IN N
approximately RB N
1.3 CD N
% NN N
. . N

There EX N
were VBD N
substantial JJ N
but CC N
unclear JJ N
individual JJ N
responses NNS N
to TO N
training NN N
and CC N
caffeine NN N
( ( N
SD NNP N
of IN N
0.3 CD N
% NN N
and CC N
0.8 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Mixed NNP N
linear IN N
modeling VBG N
can MD N
be VB N
applied VBN N
successfully RB N
to TO N
monitor VB N
factors NNS N
affecting VBG N
performance NN N
in IN N
a DT N
squad NN N
of IN N
elite JJ N
athletes NNS N
. . N

-DOCSTART- -X- O O

Locomoting-to-reach NN 2_i
: : N
information NN N
variables NNS N
and CC N
control NN N
strategies NNS N
for IN N
nested JJ N
actions NNS N
. . N

Locomoting-to-reach NNP 2_i
is VBZ N
a DT N
basic JJ N
perception/action NN N
behavior NN N
that WDT N
requires VBZ N
visual JJ N
information NN N
for IN N
the DT N
control NN N
of IN N
both DT N
locomotion NN N
and CC N
reaching VBG N
components NNS N
. . N

We PRP N
investigated VBD N
the DT N
visual JJ N
information NN N
and CC N
the DT N
control NN N
strategies NNS N
used VBN N
to TO N
guide VB N
both PDT N
the DT N
head NN N
and CC N
the DT N
hand NN N
on IN N
approach NN N
to TO N
a DT N
target NN N
in IN N
a DT N
locomotion-to-reach JJ 2_i
task NN 2_i
. . N

In IN N
this DT N
study NN N
, , N
participants NNS N
were VBD N
required VBN N
to TO N
locomote VB N
in IN N
the DT N
dark NN N
to TO N
a DT N
lit NN N
target NN N
in IN N
three CD N
different JJ N
conditions NNS N
: : N
monocular JJ N
vision/target NN N
with IN N
image NN N
size NN N
, , N
binocular JJ N
vision/target NN N
with IN N
image NN N
size NN N
, , N
and CC N
binocular JJ N
vision/point-light JJ N
target NN N
( ( N
without IN N
image NN N
size NN N
) ) N
. . N

In IN N
task NN N
one CD N
, , N
participants NNS N
brought VBD N
their PRP$ N
eyes NNS N
to TO N
the DT N
target NN N
. . N

In IN N
task NN N
two CD N
, , N
participants NNS N
brought VBD N
their PRP$ N
outstretched JJ N
hand NN N
to TO N
the DT N
target NN N
. . N

Movement JJ N
trajectories NNS N
for IN N
both DT N
tasks NNS N
were VBD N
analyzed VBN N
. . N

Results NNP N
show VBP N
that IN N
participants NNS N
were VBD N
significantly RB N
more RBR N
accurate JJ N
when WRB N
binocular JJ N
information NN N
was VBD N
present JJ N
. . N

In IN N
both DT N
tasks NNS N
, , N
participants NNS N
were VBD N
found VBN N
to TO N
use VB N
a DT N
proportional JJ N
rate NN N
control NN N
strategy NN N
rather RB N
than IN N
a DT N
constant JJ N
? . N
strategy NN N
. . N

In IN N
the DT N
walk-to-reach NN N
task NN N
, , N
they PRP N
used VBD N
monocular JJ N
and/or NN N
binocular NN N
? . N
information NN N
to TO N
guide VB N
the DT N
head NN N
and CC N
then RB N
switched VBD N
to TO N
using VBG N
relative JJ N
disparity NN N
? . N
to TO N
guide VB N
the DT N
hand NN N
to TO N
final JJ N
target NN N
acquisition NN N
, , N
switching VBG N
when WRB N
the DT N
hand NN N
centric NN N
? . N
became VBD N
less JJR N
than IN N
the DT N
head NN N
centric JJ N
?. NNP N
Dynamical NNP N
models NNS N
of IN N
the DT N
information NN N
and CC N
control NN N
strategies NNS N
were VBD N
used VBN N
to TO N
perform VB N
simulations NNS N
that WDT N
were VBD N
found VBN N
to TO N
fit VB N
the DT N
data NN N
well RB N
. . N

The DT N
conclusion NN N
is VBZ N
that IN N
proportional JJ N
rate NN N
control NN N
is VBZ N
used VBN N
sequentially RB N
with IN N
head NN N
centric NN N
, , N
then RB N
hand-centric JJ N
?-based JJ N
information NN N
, , N
using VBG N
at IN N
each DT N
moment NN N
the DT N
? . N
with IN N
the DT N
smallest JJS N
value NN N
. . N

-DOCSTART- -X- O O

Gabapentin NNP 3_i
for IN N
the DT N
prevention NN N
of IN N
postoperative JJ N
pain NN N
after IN N
vaginal JJ N
hysterectomy NN N
. . N

Gabapentin NNP 3_i
alleviates VBZ N
and/or JJ N
prevents NNS N
acute JJ N
nociceptive JJ N
and CC N
inflammatory JJ N
pain NN N
both DT N
in IN N
animals NNS N
and CC N
volunteers NNS N
, , N
especially RB N
when WRB N
given VBN N
before IN N
trauma NN N
. . N

Gabapentin NNP 3_i
might MD N
also RB N
reduce VB N
postoperative JJ N
pain NN N
. . N

To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
gabapentin NN 3_i
reduces VBZ N
the DT N
postoperative JJ N
need NN N
for IN N
additional JJ N
pain NN N
treatment NN N
( ( N
postoperative JJ N
opioid NN N
sparing VBG N
effect NN N
of IN N
gabapentin NN 3_i
in IN N
humans NNS N
) ) N
, , N
we PRP N
gave VBD N
1200 CD N
mg NN N
of IN N
gabapentin NN 3_i
or CC N
15 CD N
mg NN N
of IN N
oxazepam NN 3_i
( ( 3_i
active JJ 7_i
placebo NN 7_i
) ) 3_i
2.5 CD N
h NN N
prior RB N
to TO N
induction NN N
of IN N
anaesthesia NN N
to TO N
patients NNS N
undergoing VBG N
elective JJ 1_i
vaginal JJ 1_i
hysterectomy NN 1_i
in IN N
an DT N
active JJ N
placebo-controlled JJ N
, , N
double JJ N
blind NN N
, , N
randomised VBD N
study NN N
. . N

Gabapentin NNP 3_i
reduced VBD N
the DT N
need NN N
for IN N
additional JJ N
postoperative JJ N
pain NN N
treatment NN N
( ( N
PCA NNP N
boluses NNS N
of IN N
50 CD N
microg NN N
of IN N
fentanyl NN N
) ) N
by IN N
40 CD N
% NN N
during IN N
the DT N
first JJ N
20 CD N
postoperative JJ N
hours NNS N
. . N

During IN N
the DT N
first JJ N
2 CD N
postoperative JJ N
hours NNS N
pain VBP N
scores NNS N
at IN N
rest NN N
and CC N
worst JJS N
pain NN N
score NN N
( ( N
VAS NNP N
0-100 NNP N
mm NN N
) ) N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
active JJ N
placebo NN 7_i
group NN N
compared VBN N
to TO N
the DT N
gabapentin-treated JJ 3_i
patients NNS N
. . N

Additionally RB N
, , N
pretreatment NN N
with IN N
gabapentin NN 3_i
reduced VBD N
the DT N
degree NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
incidence NN N
of IN N
vomiting/retching VBG N
possibly RB N
either RB N
due JJ N
to TO N
the DT N
diminished JJ N
need NN N
for IN N
postoperative JJ N
pain NN N
treatment NN N
with IN N
opioids NNS N
or CC N
because IN N
of IN N
an DT N
anti-emetic JJ N
effect NN N
of IN N
gabapentin NN 3_i
itself PRP N
. . N

No DT N
preoperative JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
encountered VBN N
with IN N
respect NN N
to TO N
the DT N
side NN N
effects NNS N
of IN N
the DT N
premedication NN N
. . N

However RB N
, , N
15 CD N
mg NN N
oxazepam NN 3_i
was VBD N
more RBR N
effective JJ N
in IN N
relieving VBG N
preoperative JJ N
anxiety NN N
than IN N
1200 CD N
mg NN N
gabapentin NN 3_i
. . N

-DOCSTART- -X- O O

Pilot NNP N
study NN N
of IN N
imiquimod JJ 3_i
5 CD 3_i
% NN 3_i
cream NN 3_i
as IN N
adjunctive JJ 3_i
therapy NN 3_i
to TO N
curettage VB 1_i
and CC N
electrodesiccation NN 2_i
for IN N
nodular JJ N
basal NN N
cell NN N
carcinoma NN N
. . N

BACKGROUND NNP N
Curettage NNP 1_i
and CC N
electrodesiccation NN 2_i
( ( N
C NNP 2_i
& CC 2_i
D NNP 2_i
) ) N
is VBZ N
a DT N
widely RB N
used VBN N
method NN N
to TO N
treat VB N
nodular JJ N
basal NN N
cell NN N
carcinoma NN N
( ( N
BCC NNP N
) ) N
. . N

However RB N
, , N
residual JJ N
tumor NN N
is VBZ N
present JJ N
immediately RB N
after IN N
the DT N
procedure NN N
in IN N
approximately RB N
20 CD N
to TO N
40 CD N
% NN N
of IN N
cases NNS N
. . N

Imiquimod NNP N
, , N
a DT N
topical JJ N
immune NN N
response NN N
modifier NN N
that WDT N
targets VBZ N
Toll-like NNP N
receptor NN N
7 CD N
, , N
is VBZ N
currently RB N
approved VBN N
for IN N
superficial JJ N
BCC NNP N
. . N

OBJECTIVE NNP N
In IN N
a DT N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
, , N
the DT N
administration NN N
of IN N
imiquimod NN 3_i
after IN N
C NNP N
& CC N
D NNP N
was VBD N
investigated VBN N
to TO N
determine VB N
if IN N
the DT N
combination NN N
regimen NNS N
would MD N
reduce VB N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
compared VBN N
with IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
alone RB N
in IN N
patients NNS N
with IN N
nodular JJ N
BCC NNP N
. . N

METHODS NNP N
Twenty NNP N
patients NNS N
received VBD N
three CD N
cycles NNS N
of IN N
C NNP 2_i
& CC 2_i
D NNP 2_i
followed VBN N
by IN N
imiquimod JJ 3_i
5 CD 3_i
% NN 3_i
or CC N
vehicle NN 3_i
cream NN 3_i
once RB 3_i
daily JJ 3_i
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ 3_i
therapy NN 3_i
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
. . N

The DT N
secondary JJ N
end NN N
points NNS N
included VBD N
the DT N
time NN N
to TO N
heal VB N
and CC N
cosmetic JJ N
appearance NN N
. . N

RESULTS NNP N
Twenty NNP N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
imiquimod NN 3_i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
vehicle NN 7_i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
treatment NN N
group NN N
. . N

At IN N
8 CD N
weeks NNS N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
residual JJ N
tumor NN N
was VBD N
substantially RB N
decreased VBN N
with IN N
imiquimod JJ 3_i
therapy NN N
( ( N
10 CD N
% NN N
) ) N
compared VBN N
with IN N
vehicle NN 7_i
( ( N
40 CD N
% NN N
) ) N
. . N

Wounds VBZ N
in IN N
the DT N
vehicle NN N
group NN N
healed VBD N
more RBR N
quickly RB N
than IN N
those DT N
in IN N
the DT N
imiquimod NN N
group NN N
, , N
although IN N
by IN N
8 CD N
weeks NNS N
, , N
all DT N
excision NN N
sites NNS N
were VBD N
healed VBN N
. . N

The DT N
majority NN N
of IN N
scars NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
atrophic JJ N
and CC N
hypopigmented VBD N
, , N
whereas IN N
most JJS N
scars NNS N
in IN N
the DT N
imiquimod NN 3_i
group NN N
were VBD N
flat JJ N
and CC N
slightly RB N
pink VBP N
. . N

CONCLUSION NNP N
Imiquimod NNP 3_i
5 CD N
% NN N
cream NN N
once RB N
daily JJ N
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ N
therapy NN N
after IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
substantially RB N
reduced VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
and CC N
improved VBD N
the DT N
cosmetic JJ N
appearance NN N
compared VBN N
with IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
alone RB N
. . N

These DT N
preliminary JJ N
results NNS N
suggest VBP N
that IN N
further JJ N
studies NNS N
to TO N
investigate VB N
imiquimod JJ 3_i
adjunctive JJ 3_i
therapy NN 3_i
are VBP N
warranted VBN N
. . N

-DOCSTART- -X- O O

Infliximab NNP 3_i
in IN N
ankylosing VBG N
spondylitis NN N
: : N
alone RB N
or CC N
in IN N
combination NN N
with IN N
methotrexate NN 3_i
? . N
A NNP N
pharmacokinetic JJ N
comparative NN N
study NN N
. . N

INTRODUCTION NNP N
Methotrexate NNP 3_i
( ( 3_i
MTX NNP 3_i
) ) 3_i
has VBZ N
been VBN N
shown VBN N
to TO N
modify VB N
infliximab JJ 3_i
pharmacokinetics NNS N
in IN N
rheumatoid JJ N
arthritis NN N
. . N

However RB N
, , N
its PRP$ N
combination NN N
with IN N
infliximab NN 3_i
in IN N
the DT N
treatment NN N
of IN N
ankylosing VBG N
spondylitis NN N
( ( N
AS IN N
) ) N
is VBZ N
not RB N
recommended VBN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
influence NN N
of IN N
MTX NNP 3_i
on IN 3_i
infliximab NN 3_i
exposure NN N
in IN N
patients NNS N
with IN N
AS NNP N
. . N

METHODS NNP N
Patients NNPS N
with IN N
AS NNP N
patients NNS N
who WP N
had VBD N
predominantly RB N
axial JJ N
symptoms NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
infliximab NN 3_i
alone RB 3_i
( ( N
infusions NNS N
of IN N
5 CD N
mg/kg NNS N
at IN N
weeks NNS N
0 CD N
, , N
2 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
18 CD N
) ) N
or CC 3_i
infliximab JJ 3_i
combined VBN 3_i
with IN 3_i
MTX NNP 3_i
( ( N
10 CD N
mg/week NN N
) ) N
. . N

Infliximab JJ 3_i
concentrations NNS N
were VBD N
measured VBN N
before IN N
and CC N
2 CD N
hours NNS N
after IN N
each DT N
infusion NN N
and CC N
at IN N
1 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
8 CD N
, , N
10 CD N
, , N
14 CD N
and CC N
18 CD N
weeks NNS N
. . N

We PRP N
estimated VBD N
individual JJ N
cumulative JJ N
area NN N
under IN N
the DT N
concentration NN N
versus NN N
time NN N
curves NNS N
( ( N
AUC NNP N
) ) N
for IN N
infliximab JJ 3_i
concentration NN N
between IN N
baseline NN N
and CC N
week NN N
18 CD N
( ( N
AUC NNP N
( ( N
0-18 NNP N
) ) N
) ) N
. . N

Clinical JJ N
and CC N
laboratory JJ N
evaluations NNS N
were VBD N
performed VBN N
at IN N
each DT N
visit NN N
. . N

The DT N
Bath NNP N
Ankylosing NNP N
Spondylitis NNP N
Disease NNP N
Activity NNP N
Index NNP N
( ( N
BASDAI NNP N
) ) N
score NN N
was VBD N
the DT N
primary JJ N
end NN N
point NN N
for IN N
clinical JJ N
response NN N
. . N

RESULTS NNP N
Twenty-six JJ N
patients NNS N
were VBD N
included VBN N
( ( N
infliximab JJ N
group NN N
: : N
n JJ N
= NN N
12 CD N
, , N
infliximab NN 3_i
+ NNP 3_i
MTX NNP 3_i
group NN N
: : N
n JJ N
= NNP N
14 CD N
) ) N
, , N
and CC N
507 CD N
serum NN N
samples NNS N
were VBD N
available JJ N
for IN N
measurement NN N
of IN N
infliximab JJ 3_i
concentration NN N
. . N

The DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
with IN N
regard NN N
to TO N
AUC NNP N
( ( N
0-18 CD N
) ) N
or CC N
evolution NN N
of IN N
BASDAI NNP N
scores NNS N
and CC N
biomarkers NNS N
of IN N
inflammation NN N
. . N

CONCLUSIONS VB N
The DT N
combination NN N
of IN N
MTX NNP 4_i
and CC 4_i
infliximab NN 4_i
does VBZ N
not RB N
increase VB N
the DT N
exposure NN N
to TO N
infliximab VB N
over RP N
infliximab JJ 4_i
alone RB N
in IN N
patients NNS N
with IN N
AS NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT00507403 NN N
. . N

-DOCSTART- -X- O O

A DT N
community-based JJ N
randomized JJ N
trial NN N
of IN N
praziquantel NN 3_i
to TO N
control VB N
schistosomiasis NN N
morbidity NN N
in IN N
schoolchildren NN N
in IN N
Zambia NNP N
. . N

A DT N
community-based JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
of IN N
praziquantel NN 3_i
was VBD N
carried VBN N
out RP N
in IN N
an DT N
area NN N
of IN N
Zambia NNP N
endemic FW N
for IN N
schistosomiasis NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
treatment NN N
on IN N
Schistosoma NNP N
mansoni NNP N
morbidity NN N
. . N

A DT N
total NN N
of IN N
377 CD N
infected JJ N
children NNS N
, , N
aged VBD N
seven CD N
to TO N
19 CD N
years NNS N
, , N
was VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
one CD N
of IN N
190 CD N
( ( N
group NN N
A NNP N
) ) N
and CC N
one CD N
of IN N
187 CD N
( ( N
group NN N
B NNP N
) ) N
. . N

All DT N
children NNS N
were VBD N
treated VBN N
with IN N
40 CD N
mg NNS N
praziquantel/kg NN 3_i
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
. . N

Six CD N
months NNS N
later RB N
, , N
the DT N
children NNS N
in IN N
group NN N
A NNP N
were VBD N
re-treated JJ N
with IN N
the DT N
same JJ N
dose NN N
of IN N
praziquantel NN 3_i
, , N
while IN N
the DT N
children NNS N
in IN N
group NN N
B NNP N
were VBD N
given VBN N
placebos NNS 7_i
. . N

All DT N
children NNS N
were VBD N
followed VBN N
up RP N
three CD N
, , N
six CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
initial JJ N
treatment NN N
, , N
morbidity NN N
being VBG N
clinically RB N
evaluated VBN N
at IN N
the DT N
six- JJ N
and CC N
12-month JJ N
follow-ups NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
, , N
in IN N
both DT N
groups NNS N
of IN N
children NNS N
, , N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
splenomegaly NN N
, , N
hepatomegaly NN N
, , N
and CC N
subjective JJ N
symptoms NNS N
of IN N
morbidity NN N
six CD N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
treatment NN N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
, , N
between IN N
the DT N
two CD N
groups NNS N
, , N
in IN N
the DT N
prevalences NNS N
of IN N
these DT N
symptoms NNS N
of IN N
morbidity NN N
. . N

It PRP N
therefore RB N
appears VBZ N
that IN N
once-yearly JJ N
treatment NN N
of IN N
children NNS N
, , N
in IN N
this DT N
and CC N
similar JJ N
endemic JJ N
areas NNS N
, , N
is VBZ N
sufficient JJ N
to TO N
reduce VB N
schistosomiasis NN N
morbidity NN N
to TO N
, , N
and CC N
maintain VB N
it PRP N
at IN N
, , N
a DT N
tolerable JJ N
level NN N
. . N

-DOCSTART- -X- O O

Methylphenidate NNP 3_i
and CC N
baseball NN N
playing NN N
in IN N
ADHD NNP N
children NNS N
: : N
who WP N
's VBZ N
on IN N
first JJ N
? . N
The DT N
effects NNS N
of IN N
0.3 CD 3_i
and CC 3_i
0.6 CD 3_i
mg/kg NN 3_i
methylphenidate NN 3_i
were VBD N
analyzed VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
, , N
cross-over JJ N
study NN N
in IN N
which WDT N
17 CD N
boys NNS N
( ( N
ages IN N
7.8-9.9 CD N
years NNS N
) ) N
with IN N
attention NN N
deficit NN N
hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
played VBD N
in IN N
baseball NN N
games NNS N
. . N

Drug JJ N
effects NNS N
were VBD N
evaluated VBN N
on IN N
children NNS N
's POS N
attention NN N
during IN N
the DT N
game NN N
, , N
as IN N
indicated VBN N
by IN N
their PRP$ N
on-task JJ N
behavior NN N
on IN N
the DT N
field NN N
and CC N
their PRP$ N
ability NN N
to TO N
answer VB N
questions NNS N
about IN N
the DT N
status NN N
of IN N
the DT N
game NN N
at IN N
all DT N
times NNS N
. . N

Judgment NN N
during IN N
batting NN N
, , N
batting VBG N
skill NN N
during IN N
the DT N
game NN N
, , N
and CC N
performance NN N
on IN N
skill NN N
drills NNS N
prior RB N
to TO N
the DT N
game NN N
were VBD N
also RB N
assessed VBN N
as IN N
a DT N
function NN N
of IN N
medication NN N
. . N

Results NNS N
revealed VBD N
that IN N
methylphenidate NN 3_i
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
attending VBG N
during IN N
the DT N
game NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
diuresis NN N
on IN N
extracorporeal NN N
shockwave VBP N
lithotripsy VBN N
treatment NN N
of IN N
ureteric JJ N
calculi NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
diuresis NN 2_i
during IN N
extracorporeal JJ 2_i
shockwave JJ 2_i
lithotripsy NN 2_i
( ( 2_i
ESWL NNP 2_i
) ) 2_i
treatment NN N
of IN N
ureteric JJ N
calculi NN N
. . N

The DT N
purpose NN N
is VBZ N
to TO N
improve VB N
stone NN N
fragmentation NN N
and CC N
clearance NN N
rates NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
One NNP N
hundred VBD N
and CC N
six CD N
consecutive JJ N
patients NNS N
with IN N
ureteric JJ N
calculi NNS N
at IN N
different JJ N
levels NNS N
were VBD N
treated VBN N
by IN N
ESWL NNP 1_i
using VBG N
Siemens NNP N
Lithostar NNP N
2 CD N
machine NN N
. . N

Patients NNS N
have VBP N
been VBN N
randomized VBN N
into IN N
two CD N
treatment NN N
groups NNS N
. . N

The DT N
first JJ N
group NN N
was VBD N
treated VBN N
by IN N
standard JJ 1_i
ESWL NNP 1_i
and CC N
included VBD N
54 CD N
patients NNS N
. . N

The DT N
second JJ N
group NN N
was VBD N
treated VBN N
by IN N
ESWL NNP 1_i
with IN 1_i
diuresis NN 1_i
during IN 1_i
the DT 1_i
ESWL NNP 1_i
session NN 1_i
. . N

Shock NNP N
waves NNS N
were VBD N
given VBN N
at IN N
a DT N
rate NN N
of IN N
90 CD N
shocks/minute NN N
with IN N
energy NN N
starting VBG N
from IN N
10 CD N
up RB N
to TO N
18 CD N
KV NNP N
. . N

During IN N
the DT N
ESWL NNP N
session NN N
the DT N
patient NN N
belonging NN N
to TO N
the DT N
second JJ N
group NN N
received VBD N
i.v RB N
. . N

infusion NN N
of IN N
500 CD N
ml NNS N
normal JJ N
saline JJ N
containing VBG N
40 CD N
mg JJ N
furosemide RB N
as IN N
a DT N
diuretic JJ N
. . N

The DT N
stone NN N
fragmentation NN N
and CC N
clearance NN N
rates NNS N
were VBD N
the DT N
two CD N
end NN N
points NNS N
for IN N
evaluation NN N
. . N

RESULTS VB N
The DT N
average JJ N
number NN N
of IN N
sessions NNS N
per IN N
stone NN N
was VBD N
1.92 CD N
and CC N
1.5 CD N
and CC N
the DT N
average JJ N
number NN N
of IN N
shocks NNS N
per IN N
stone NN N
was VBD N
6295 CD N
and CC N
5300 CD N
for IN N
the DT N
first JJ N
and CC N
second JJ N
treatment NN N
groups NNS N
respectively RB N
. . N

Stone CD N
fragmentation NN N
rate NN N
was VBD N
47/54 CD N
( ( N
87 CD N
% NN N
) ) N
and CC N
50/52 CD N
( ( N
96.2 CD N
% NN N
) ) N
and CC N
the DT N
stone NN N
clearance NN N
( ( N
success NN N
) ) N
rate NN N
was VBD N
47/54 CD N
( ( N
87 CD N
% NN N
) ) N
and CC N
48/52 CD N
( ( N
92.3 CD N
% NN N
) ) N
for IN N
the DT N
first JJ N
and CC N
the DT N
second JJ N
groups NNS N
respectively RB N
. . N

Analysis NN N
of IN N
the DT N
results NNS N
in IN N
relation NN N
to TO N
stone VB N
location NN N
showed VBD N
that IN N
the DT N
two CD N
treatment NN N
groups NNS N
were VBD N
comparable JJ N
for IN N
upper JJ N
and CC N
middle JJ N
ureteric JJ N
calculi NN N
. . N

However RB N
for IN N
distal JJ N
ureteric JJ N
stones NNS N
, , N
the DT N
addition NN N
of IN N
diuresis NN N
during IN N
ESWL NNP N
was VBD N
associated VBN N
with IN N
a DT N
lower JJR N
mean JJ N
number NN N
of IN N
ESWL NNP N
sessions NNS N
and CC N
shocks NNS N
per IN N
stone NN N
compared VBN N
with IN N
standard JJ N
ESWL NNP N
: : N
1.38 CD N
and CC N
4950 CD N
for IN N
ESWL NNP N
with IN N
diuresis NN N
compared VBN N
with IN N
2.9 CD N
and CC N
8544 CD N
for IN N
standard JJ N
ESWL NNP N
respectively RB N
. . N

The DT N
stone NN N
fragmentation NN N
and CC N
3-month JJ N
clearance NN N
( ( N
success NN N
) ) N
rates NNS N
were VBD N
clearly RB N
higher JJR N
: : N
93.8 CD N
% NN N
and CC N
87.5 CD N
% NN N
respectively RB N
for IN N
ESWL NNP N
with IN N
diuresis NN N
compared VBN N
with IN N
70.6 CD N
% NN N
( ( N
for IN N
both DT N
fragmentation NN N
and CC N
clearance NN N
) ) N
with IN N
standard JJ N
ESWL NNP N
. . N

CONCLUSIONS NNP N
Diuresis NNP N
is VBZ N
a DT N
useful JJ N
, , N
inexpensive JJ N
and CC N
safe JJ N
adjunct NN N
to TO N
ESWL NNP N
of IN N
ureteric JJ N
stones NNS N
. . N

It PRP N
markedly RB N
improves VBZ N
the DT N
results NNS N
of IN N
ESWL NNP N
treatment NN N
of IN N
distal JJ N
ureteric JJ N
stones NNS N
compared VBN N
with IN N
standard JJ N
ESWL NNP N
. . N

-DOCSTART- -X- O O

Pilot NNP N
randomized VBD N
controlled VBN N
trial NN N
of IN N
Reciprocal NNP 4_i
Imitation NNP 4_i
Training NNP 4_i
for IN N
teaching VBG N
elicited VBN N
and CC N
spontaneous JJ N
imitation NN N
to TO N
children NNS N
with IN N
autism NN N
. . N

Children NNP N
with IN N
autism NN N
exhibit NN N
significant JJ N
deficits NNS N
in IN N
imitation NN N
skills NNS N
. . N

Reciprocal JJ 4_i
Imitation NNP 4_i
Training NNP 4_i
( ( 4_i
RIT NNP 4_i
) ) 4_i
, , N
a DT N
naturalistic JJ N
imitation NN N
intervention NN N
, , N
was VBD N
developed VBN N
to TO N
teach VB N
young JJ N
children NNS N
with IN N
autism NN N
to TO N
imitate VB N
during IN N
play NN N
. . N

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
RIT NNP N
on IN N
elicited VBN N
and CC N
spontaneous JJ N
imitation NN N
skills NNS N
in IN N
21 CD N
young JJ N
children NNS N
with IN N
autism NN N
. . N

Results NNP N
found VBD N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB N
more RBR N
gains NNS N
in IN N
elicited JJ N
and CC N
spontaneous JJ N
imitation NN N
, , N
replicating VBG N
previous JJ N
single-subject JJ N
design NN N
studies NNS N
. . N

Number NNP N
of IN N
spontaneous JJ N
play NN N
acts NNS N
at IN N
pre-treatment NN N
was VBD N
related VBN N
to TO N
improvements NNS N
in IN N
imitation NN N
during IN N
the DT N
intervention NN N
, , N
suggesting VBG N
that IN N
children NNS N
with IN N
a DT N
greater JJR N
play NN N
repertoire NN N
make VBP N
greater JJR N
gains NNS N
during IN N
RIT NNP N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
a DT N
leptin JJ N
single JJ N
nucleotide NN N
polymorphism NN N
and CC N
zilpaterol NN 3_i
hydrochloride NN 3_i
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
in IN N
finishing VBG N
steers NNS N
. . N

A DT N
total NN N
of IN N
4,178 CD N
steers NNS N
( ( N
mean JJ N
initial JJ N
BW NNP N
= NN N
403.9 CD N
? . N
16.04 CD N
kg NN N
) ) N
were VBD N
used VBN N
to TO N
test VB N
the DT N
interactive JJ N
effects NNS N
, , N
if IN N
any DT N
, , N
of IN N
leptin JJ N
R25C NNP N
genotypes NNS N
( ( N
CC NNP N
, , N
CT NNP N
, , N
or CC N
TT NNP N
) ) N
and CC N
zilpaterol $ N
hydrochloride NN N
( ( N
ZH NNP N
) ) N
feeding VBG N
duration NN N
on IN N
growth NN N
performance NN N
and CC N
carcass NN N
traits NNS N
. . N

Steers NNS N
were VBD N
blocked VBN N
by IN N
arrival NN N
at IN N
the DT N
feed NN N
yard NN N
, , N
genotyped VBD N
for IN N
the DT N
leptin NN N
SNP NNP N
, , N
allotted VBD N
to TO N
genotype-specific JJ N
pens NNS N
( ( N
90 CD N
steers/pen NN N
) ) N
, , N
and CC N
assigned VBD N
randomly RB N
within IN N
genotype NN N
and CC N
block NN N
to TO N
0 CD N
or CC N
21 CD N
d NN N
of IN N
dietary JJ N
ZH NNP N
. . N

All DT N
pens NNS N
within IN N
a DT N
block NN N
were VBD N
slaughtered VBN N
on IN N
the DT N
same JJ N
day NN N
( ( N
132.1 CD N
? . N
10.9 CD N
d NN N
on IN N
feed NN N
) ) N
. . N

Final NNP N
BW NNP N
of IN N
steers NNS N
fed VBP N
ZH NNP N
was VBD N
6.0 CD N
kg NN N
heavier NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
, , N
and CC N
ZH-fed NNP N
steers NNS N
had VBD N
greater JJR N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
ADG NNP N
than IN N
steers NNS N
not RB N
fed VBN N
ZH NNP N
. . N

Feeding VBG N
ZH NNP N
decreased VBD N
DMI NNP N
in IN N
steers NNS N
with IN N
increased JJ N
frequency NN N
of IN N
the DT N
T NNP N
allele NN N
( ( N
9.67 CD N
, , N
9.53 CD N
, , N
and CC N
9.28 CD N
kg/d NN N
for IN N
CC NNP N
, , N
CT NNP N
, , N
and CC N
TT NNP N
, , N
respectively RB N
) ) N
, , N
but CC N
DMI NNP N
increased VBD N
with IN N
the DT N
frequency NN N
of IN N
the DT N
T NNP N
allele NN N
( ( N
9.68 CD N
, , N
9.90 CD N
, , N
and CC N
10.1 CD N
kg NN N
for IN N
CC NNP N
, , N
CT NNP N
, , N
and CC N
TT NNP N
, , N
respectively RB N
) ) N
when WRB N
ZH NNP N
was VBD N
not RB N
fed VBN N
( ( N
leptin JJ N
genotype NN N
? . N
ZH NNP N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

At IN N
the DT N
conclusion NN N
of IN N
the DT N
study NN N
, , N
ultrasonic JJ N
fat NN N
was VBD N
greatest JJS N
for IN N
TT NNP N
steers NNS N
( ( N
11.4 CD N
? . N
0.28 CD N
mm NN N
) ) N
and CC N
least JJS N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
for IN N
CC NNP N
steers NNS N
( ( N
11.0 CD N
? . N
0.25 CD N
mm NN N
) ) N
. . N

Regardless NNP N
of IN N
ZH-feeding NNP N
duration NN N
, , N
TT NNP N
steers NNS N
produced VBD N
a DT N
greater JJR N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
percentage NN N
of IN N
USDA NNP N
yield NN N
grade NN N
( ( N
YG NNP N
) ) N
4 CD N
or CC N
higher JJR N
carcasses NNS N
( ( N
5.4 CD N
vs. FW N
2.7 CD N
% NN N
) ) N
and CC N
a DT N
lesser JJR N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
percentage NN N
of IN N
YG NNP N
1 CD N
carcasses NNS N
( ( N
17.7 CD N
vs. FW N
26.8 CD N
% NN N
) ) N
than IN N
CC NNP N
steers NNS N
. . N

In IN N
addition NN N
, , N
ZH-fed NNP N
steers NNS N
produced VBD N
a DT N
greater JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
percentage NN N
of IN N
USDA NNP N
YG NNP N
1 CD N
carcasses NNS N
( ( N
25.9 CD N
vs. FW N
16.2 CD N
% NN N
) ) N
and CC N
a DT N
lesser JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
percentage NN N
of IN N
YG NNP N
4 CD N
or CC N
higher JJR N
carcasses NNS N
( ( N
1.6 CD N
vs. FW N
6.0 CD N
% NN N
) ) N
than IN N
steers NNS N
fed VBP N
the DT N
control NN N
diet NN N
. . N

Marbling VBG N
scores NNS N
and CC N
the DT N
percentage NN N
of IN N
carcasses NNS N
grading VBG N
USDA NNP N
Choice NNP N
and CC N
Prime NNP N
were VBD N
greater JJR N
in IN N
TT NNP N
than IN N
CC NNP N
steers NNS N
when WRB N
fed VBN N
diets NNS N
devoid VBP N
of IN N
ZH NNP N
, , N
but CC N
both DT N
marbling NN N
and CC N
quality NN N
grades NNS N
did VBD N
not RB N
differ VB N
among IN N
leptin JJ N
genotypes NNS N
when WRB N
fed VBN N
ZH NNP N
for IN N
21 CD N
d NN N
( ( N
leptin JJ N
genotype NN N
? . N
ZH NNP N
, , N
P NNP N
? . N
0.03 CD N
) ) N
. . N

The DT N
amount NN N
of IN N
HCW NNP N
gain NN N
tended VBD N
to TO N
be VB N
less JJR N
( ( N
P NNP N
= NNP N
0.095 CD N
) ) N
for IN N
steers NNS N
of IN N
the DT N
TT NNP N
genotype NN N
( ( N
12.7 CD N
kg NN N
) ) N
than IN N
either DT N
CC NNP N
( ( N
16.3 CD N
kg NN N
) ) N
or CC N
CT NNP N
( ( N
17.0 CD N
kg NN N
) ) N
genotypes NNS N
. . N

Results NNS N
indicated VBD N
that IN N
leptin NN N
R25C NNP N
genotype NN N
impacted VBD N
most RBS N
traits NNS N
associated VBN N
with IN N
fatness JJ N
whereas NNS N
feeding VBG N
ZH NNP N
for IN N
21 CD N
d NN N
affected VBD N
HCW NNP N
and CC N
ADG NNP N
positively RB N
but CC N
impacted VBD N
feed NN N
intake NN N
, , N
marbling NN N
, , N
and CC N
USDA NNP N
quality NN N
grades NNS N
negatively RB N
. . N

-DOCSTART- -X- O O

The DT N
individual JJ N
responsiveness NN N
to TO N
growth NN 3_i
hormone NN 3_i
( ( 3_i
GH NNP 3_i
) ) 3_i
treatment NN 3_i
in IN N
GH-deficient NNP N
adults NNS N
is VBZ N
dependent JJ N
on IN N
the DT N
level NN N
of IN N
GH-binding NNP N
protein NN N
, , N
body NN N
mass NN N
index NN N
, , N
age NN N
, , N
and CC N
gender NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
trial NN N
was VBD N
to TO N
study VB N
the DT N
individual JJ N
responsiveness NN N
to TO N
GH NNP 3_i
treatment NN 3_i
in IN N
terms NNS N
of IN N
body NN N
composition NN N
and CC N
to TO N
search VB N
for IN N
possible JJ N
predictors NNS N
of IN N
the DT N
response NN N
in IN N
GH-deficient NNP N
adults NNS N
. . N

Sixty-eight JJ N
patients NNS N
( ( N
44 CD N
men NNS N
and CC N
24 CD N
women NNS N
) ) N
with IN N
a DT N
mean JJ N
age NN N
of IN N
44.3 CD N
( ( N
1.2 CD N
) ) N
yr NN N
and CC N
verified VBD N
GH NNP N
deficiency NN N
participated VBD N
in IN N
a DT N
2-phase JJ N
treatment NN N
trial NN N
with IN N
an DT N
initial JJ N
randomized NN N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ 7_i
, , N
6-month JJ N
period NN N
, , N
followed VBN N
by IN N
an DT N
open JJ N
treatment NN N
period NN N
, , N
thereby RB N
ensuring VBG N
all DT N
patients NNS N
12 CD N
months NNS N
of IN N
GH NNP N
treatment NN N
. . N

Recombinant JJ 3_i
human JJ 3_i
GH NNP 3_i
was VBD N
administered VBN N
sc JJ N
daily RB N
at IN N
bedtime NN N
, , N
with IN N
a DT N
target NN N
dose NN N
of IN N
12 CD N
micrograms/kg NNS N
x JJ N
day NN N
. . N

GHBP NNP N
was VBD N
measured VBN N
by IN N
ligand-mediated JJ N
immunofunctional JJ N
assay NN N
, , N
and CC N
serum JJ N
insulin-like JJ N
growth NN N
factor NN N
I PRP N
( ( N
IGF-I NNP N
) ) N
was VBD N
determined VBN N
by IN N
RIA NNP N
after IN N
acid-ethanol JJ N
extraction NN N
, , N
using VBG N
a DT N
truncated JJ N
IGF-I JJ N
analog NN N
as IN N
the DT N
radioligand NN N
. . N

Lean JJ N
body NN N
mass NN N
( ( N
LBM NNP N
) ) N
and CC N
body NN N
fat NN N
( ( N
BF NNP N
) ) N
were VBD N
determined VBN N
by IN N
dual JJ N
energy NN N
x-ray JJ N
absorptiometry NN N
, , N
and CC N
total JJ N
body NN N
water NN N
( ( N
TBW NNP N
) ) N
was VBD N
determined VBN N
by IN N
bioelectrical JJ N
impedance NN N
. . N

During IN N
the DT N
placebo NN N
control NN N
period NN N
, , N
serum JJ N
IGF-I NNP N
, , N
LBM NNP N
, , N
and CC N
TBW NNP N
increased VBD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
BF NNP N
decreased VBD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
serum JJ N
GHBP NNP N
was VBD N
unchanged JJ N
in IN N
the DT N
group NN N
treated VBD N
with IN N
GH NNP N
compared VBN N
with IN N
the DT N
patients NNS N
treated VBN N
with IN N
placebo NN N
. . N

After IN N
12 CD N
months NNS N
of IN N
GH NNP N
treatment NN N
, , N
the DT N
individual JJ N
changes NNS N
in IN N
BF NNP N
ranged VBD N
from IN N
-12.5 NN N
to TO N
4.3 CD N
kg NNS N
and CC N
from IN N
-4.5 NNP N
to TO N
10.1 CD N
kg NNS N
in IN N
LBM NNP N
. . N

Age NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
baseline JJ N
GHBP NNP N
level NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
were VBD N
inversely RB N
correlated VBN N
with IN N
the DT N
increase NN N
in IN N
LBM NNP N
. . N

The DT N
GH-induced JJ N
increment NN N
in IN N
IGF-I NNP N
and CC N
TBW NNP N
was VBD N
greater JJR N
in IN N
men NNS N
than IN N
in IN N
women NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas IN N
the DT N
decreases NNS N
in IN N
BF NNP N
were VBD N
similar JJ N
in IN N
men NNS N
and CC N
women NNS N
. . N

This DT N
trial NN N
demonstrates VBZ N
the DT N
variability NN N
in IN N
responsiveness NN N
to TO N
GH NNP 3_i
administration NN N
in IN N
GH-deficient NNP N
adults NNS N
. . N

The DT N
best JJS N
response NN N
to TO N
GH NNP N
was VBD N
obtained VBN N
in IN N
younger JJR N
patients NNS N
with IN N
low JJ N
GHBP NNP N
levels NNS N
. . N

Furthermore RB N
, , N
men NNS N
responded VBD N
better RBR N
than IN N
women NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Diphtheria NNP N
antitoxin NN N
level NN N
2 CD N
years NNS N
after IN N
booster NN 3_i
vaccination NN 3_i
] NNP N
. . N

In IN N
a DT N
prospective JJ N
, , N
controlled VBN N
, , N
randomized VBN N
, , N
multicenter RBR N
study VBP N
the DT N
immunogenicity NN N
of IN N
a DT N
single JJ N
( ( N
day NN N
0 CD N
) ) N
and CC N
two CD N
( ( N
day NN N
0 CD N
, , N
28 CD N
) ) N
booster NN 3_i
vaccination NN 3_i
against IN 3_i
diphtheria NN 3_i
were VBD N
compared VBN N
in IN N
subjects NNS N
who WP N
had VBD N
received VBN N
their PRP$ N
last JJ N
diphtheria NN 3_i
vaccination NN 3_i
more JJR N
than IN N
10 CD N
years NNS N
ago RB N
. . N

Both DT N
short-term JJ N
and CC N
long-term JJ N
immunogenicity NN N
was VBD N
assessed VBN N
by IN N
determining VBG N
diphtheria NN 3_i
antitoxin NN 3_i
levels NNS N
four CD N
weeks NNS N
after IN N
vaccination NN N
and CC N
after IN N
one CD N
and CC N
two CD N
years NNS N
. . N

102 CD N
subjects NNS N
received VBD N
the DT N
first JJ 3_i
booster NN 3_i
vaccination NN 3_i
, , N
and CC N
83 CD N
were VBD N
vaccinated VBN 2_i
twice RB 3_i
. . N

Prior NNP N
to TO N
the DT N
first JJ N
vaccination NN N
27 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
a DT N
diphtheria NN N
antitoxin NN N
level NN N
below IN N
0.01 CD N
I.U./ml NNP N
; : N
after IN N
the DT N
first JJ N
booster NN N
only RB N
5 CD N
% NN N
were VBD N
unprotected VBN N
. . N

The DT N
second JJ N
booster NN 3_i
did VBD N
not RB N
show VB N
a DT N
significant JJ N
effect NN N
, , N
however RB N
, , N
in IN N
1 CD N
of IN N
the DT N
5 CD N
subjects NNS N
who WP N
were VBD N
still RB N
unprotected VBN N
after IN N
the DT N
first JJ N
booster NN N
the DT N
second JJ N
elicited VBD N
an DT N
antitoxin JJ N
level NN N
of IN N
more JJR N
than IN N
0.01 CD N
I.U./ml NNP N
. . N

After IN N
one CD N
and CC N
two CD N
years NNS N
7 CD N
% NN N
and CC N
8 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
diphtheria VBN N
antitoxin JJ N
level NN N
below IN N
0.01 CD N
I.U./ml NNP N
. . N

A NNP N
serological JJ N
effect NN N
of IN N
a DT N
second JJ N
booster NN 3_i
vaccination NN 3_i
four CD N
weeks NNS N
after IN N
the DT N
first JJ N
one NN N
could MD N
not RB N
be VB N
demonstrated VBN N
neither RB N
after IN N
one CD N
nor CC N
after IN N
two CD N
years NNS N
. . N

-DOCSTART- -X- O O

Intranasal NNP N
recombinant JJ N
alfa-2b JJ 3_i
interferon NN 3_i
treatment NN N
of IN N
naturally RB N
occurring VBG N
common JJ N
colds NNS N
. . N

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
, , N
patients NNS N
with IN N
naturally RB N
occurring VBG N
common JJ N
colds NNS N
of IN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
48 CD N
h NNS N
duration NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
nasal JJ N
sprays NNS N
of IN N
recombinant JJ 3_i
alfa-2b JJ 3_i
interferon NN 3_i
at IN N
10 CD N
or CC N
20 CD N
MU/day NNPS N
or CC N
placebo VB 7_i
four CD N
times NNS N
per IN N
day NN N
for IN N
5 CD N
days NNS N
. . N

The DT N
10-MU JJ N
( ( N
n JJ N
= NNP N
74 CD N
) ) N
, , N
20-MU JJ N
( ( N
n JJ N
= NNP N
74 CD N
) ) N
, , N
and CC N
placebo NN 7_i
( ( N
n JJ N
= NNP N
72 CD N
) ) N
groups NNS N
had VBD N
comparable JJ N
frequencies NNS N
of IN N
documented JJ N
rhinovirus NN N
colds NNS N
( ( N
50 CD N
to TO N
65 CD N
% NN N
) ) N
and CC N
mean JJ N
durations NNS N
of IN N
pretreatment NN N
symptoms NNS N
( ( N
26 CD N
to TO N
27 CD N
h NN N
) ) N
. . N

The DT N
median JJ N
duration NN N
of IN N
colds NNS N
tended VBD N
to TO N
be VB N
longer RBR N
in IN N
the DT N
20-MU JJ N
group NN N
( ( N
10 CD N
days NNS N
) ) N
than IN N
the DT N
10-MU JJ N
group NN N
( ( N
8 CD N
days NNS N
) ) N
or CC N
placebo VBN 7_i
group NN N
( ( N
8 CD N
days NNS N
) ) N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
. . N

In IN N
those DT N
with IN N
proven JJ N
rhinovirus NN N
colds NNS N
treated VBD N
within IN N
24 CD N
h NN N
, , N
the DT N
median JJ N
duration NN N
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
20-MU JJ N
group NN N
( ( N
9 CD N
days NNS N
) ) N
than IN N
in IN N
the DT N
placebo NN 7_i
group NN N
( ( N
6 CD N
days NNS N
) ) N
. . N

No DT N
differences NNS N
favoring VBG N
interferon NN N
treatment NN N
were VBD N
found VBN N
in IN N
respiratory JJ N
symptom JJ N
scores NNS N
or CC N
resolution NN N
of IN N
specific JJ N
symptoms NNS N
. . N

On IN N
days NNS N
5 CD N
and CC N
7 CD N
, , N
nasal JJ 2_i
washings NNS 2_i
from IN N
compliant JJ N
subjects NNS N
with IN N
proven JJ N
rhinovirus NN N
colds NNS N
yielded VBD N
rhinoviruses NNS N
more RBR N
often RB N
in IN N
placebo NN 7_i
( ( N
47 CD N
and CC N
48 CD N
% NN N
, , N
respectively RB N
) ) N
than IN N
in IN N
interferon NN 3_i
( ( N
15 CD N
and CC N
16 CD N
% NN N
, , N
respectively RB N
) ) N
recipients NNS N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
, , N
but CC N
no DT N
differences NNS N
in IN N
new JJ N
respiratory NN N
illness JJ N
occurrence NN N
were VBD N
observed VBN N
in IN N
household NN N
contacts NNS N
. . N

Interferon NNP 3_i
recipients NNS N
had VBD N
significantly RB N
higher JJR N
frequencies NNS N
of IN N
blood NN N
in IN N
nasal JJ N
mucus NN N
( ( N
16 CD N
to TO N
18 CD N
% NN N
) ) N
than IN N
did VBD N
placebo VB 7_i
recipients NNS N
( ( N
4 CD N
% NN N
) ) N
during IN N
treatment NN N
. . N

Antibiotics NNS 3_i
for IN N
presumed JJ N
secondary JJ N
infections NNS N
were VBD N
given VBN N
more RBR N
often RB N
in IN N
the DT N
20-MU JJ N
group NN N
( ( N
11 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
placebo NN 7_i
group NN N
( ( N
0 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Nasal NNP N
sprays NNS N
of IN N
recombinant JJ N
alfa-2b JJ 3_i
interferon NN 3_i
were VBD N
not RB N
an DT N
effective JJ N
treatment NN N
for IN N
natural JJ N
colds NNS N
and CC N
were VBD N
associated VBN N
with IN N
toxicity NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
L-arginine NNP 3_i
or CC N
L-citrulline JJ 3_i
oral JJ 3_i
supplementation NN 3_i
on IN N
blood NN N
pressure NN N
and CC N
right JJ N
ventricular NN N
function NN N
in IN N
heart NN N
failure NN N
patients NNS N
with IN N
preserved JJ N
ejection NN N
fraction NN N
. . N

BACKGROUND IN N
The DT N
effect NN N
of IN N
L-arginine NNP 3_i
and CC N
L-citrulline NNP 3_i
on IN N
blood NN N
pressure NN N
and CC N
right JJ N
ventricular NN N
function NN N
in IN N
heart NN N
failure NN N
patients NNS N
with IN N
preserved JJ N
ejection NN N
fraction NN N
( ( N
HFpEF NNP N
) ) N
is VBZ N
unknown JJ N
. . N

We PRP N
have VBP N
therefore RB N
evaluated VBN N
, , N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
the DT N
effect NN N
of IN N
these DT N
aminoacids NNS N
in IN N
chronic JJ N
outstanding JJ N
and CC N
stable JJ N
patients NNS N
with IN N
HFpEF NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
All NNP N
patients NNS N
underwent VBD N
an DT N
echocardiogram NN 2_i
and CC 2_i
radioisotopic NN 2_i
ventriculography NN 2_i
rest/exercise NN 2_i
, , N
and CC N
were VBD N
randomized VBN N
in IN N
a DT N
consecutive JJ N
manner NN N
to TO N
the DT N
L-arginine NNP 3_i
group NN 3_i
( ( N
n JJ N
= VBZ N
15 CD N
; : N
8 CD N
g/day NN N
) ) N
; : N
and CC N
the DT N
citrulline NN 3_i
malate NN 3_i
group NN 3_i
( ( N
n JJ N
= VBZ N
15 CD N
; : N
3 CD N
g/day NN N
) ) N
. . N

The DT N
duration NN N
of IN N
follow-up NN N
was VBD N
two CD N
months NNS N
. . N

The DT N
principal JJ N
echocardiographic JJ N
finding NN N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
pulmonary JJ N
artery NN N
pressure NN N
in IN N
the DT N
L-arginine NNP 3_i
( ( N
56.3 CD N
? . N
10 CD N
vs NN N
44 CD N
? . N
16.5 CD N
mm NN N
Hg NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
the DT N
citrulline NN N
( ( N
56.67 CD N
? . N
7.96 CD N
vs NN N
47.67 CD N
? . N
8.59 CD N
mm NN N
Hg NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
groups NNS N
. . N

Duration NN N
on IN N
treadmill NN N
and CC N
right JJ N
ventricular NN N
ejection NN N
fraction NN N
post NN N
exercise NN N
increased VBD N
, , N
while IN N
diastolic JJ N
and CC N
systolic JJ N
artery NN N
pressure NN N
decreased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
other JJ N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
L-arginine NNP N
and CC N
citrulline NN N
to TO N
patients NNS N
with IN N
HFpEF NNP N
improved VBD N
right JJ N
ventricular NN N
function NN N
by IN N
increasing VBG N
right JJ N
ventricular NN N
ejection NN N
fraction NN N
, , N
and CC N
probably RB N
decreasing VBG N
systolic JJ N
pulmonary JJ N
artery NN N
pressure NN N
. . N

-DOCSTART- -X- O O

Phase NNP N
III NNP N
trial NN N
of IN N
satraplatin NN 3_i
, , N
an DT N
oral JJ N
platinum NN 3_i
plus CC 3_i
prednisone NN 3_i
vs. FW N
prednisone NN 3_i
alone RB 3_i
in IN N
patients NNS N
with IN N
hormone-refractory JJ N
prostate NN N
cancer NN N
. . N

Satraplatin NNP 3_i
is VBZ N
a DT N
novel JJ N
oral JJ N
platinum NN 3_i
( ( N
IV NNP N
) ) N
complex VBP N
that DT N
shows VBZ N
activity NN N
against IN N
hormone-refractory JJ N
prostate NN N
cancer NN N
( ( N
HRPC NNP N
) ) N
in IN N
cisplatin-resistant JJ 3_i
human JJ N
tumor NN N
lines NNS N
in IN N
phase NN N
I PRP N
and CC N
phase VB N
II NNP N
trials NNS N
. . N

A DT N
randomized JJ N
multicenter NN N
phase NN N
III NNP N
trial NN N
with IN N
a DT N
target NN N
sample JJ N
size NN N
of IN N
380 CD N
patients NNS N
was VBD N
initiated VBN N
in IN N
men NNS N
with IN N
HRPC NNP N
. . N

After IN N
50 CD N
randomized JJ N
patients NNS N
, , N
the DT N
trial NN N
was VBD N
closed VBN N
to TO N
further RBR N
accrual JJ N
by IN N
the DT N
sponsoring VBG N
company NN N
. . N

An DT N
ad NN N
hoc NN N
analysis NN N
of IN N
all DT N
available JJ N
data NNS N
is VBZ N
reported VBN N
here RB N
. . N

Eligibility NNP N
criteria NNS N
included VBD N
pathological JJ N
proof NN N
of IN N
prostate NN N
cancer NN N
, , N
documented VBN N
progression NN N
despite IN N
prior JJ N
hormonal JJ N
manipulation NN N
, , N
WHO WP N
PS NNP N
0-2 NN N
, , N
and CC N
no DT N
daily JJ N
intake NN N
of IN N
narcotic JJ 3_i
analgesics NNS 3_i
. . N

Patients NNS N
were VBD N
randomized VBN N
between IN N
satraplatin NN 3_i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
for IN N
5 CD N
days NNS N
plus CC N
prednisone JJ 3_i
10 CD N
mg NNS N
orally RB N
BID NNP N
or CC N
prednisone VB 3_i
alone RB N
. . N

Compliance NN N
was VBD N
excellent JJ N
. . N

48/50 CD N
patients NNS N
have VBP N
progressed VBN N
and CC N
42 CD N
have VBP N
died VBN N
, , N
mostly RB N
due JJ N
to TO N
prostate VB N
cancer NN N
. . N

Median JJ N
overall JJ N
survival NN N
was VBD N
14.9 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
13.7-28.4 JJ N
) ) N
on IN N
the DT N
satraplatin NN 3_i
plus CC N
prednisone NN 3_i
arm NN N
and CC N
11.9 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
8.4-23.1 JJ N
) ) N
on IN N
prednisone NN 3_i
alone RB N
( ( N
hazard JJ N
ratio NN N
, , N
HR NNP N
= NNP N
0.84 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.46-1.55 NN N
) ) N
. . N

A DT N
> JJ N
50 CD N
% NN N
decrease NN N
in IN N
prostrate NN N
specific JJ N
antigen NN N
( ( N
PSA NNP N
) ) N
was VBD N
seen VBN N
in IN N
9/27 CD N
( ( N
33.3 CD N
% NN N
) ) N
in IN N
the DT N
satraplatin NN 3_i
plus CC 3_i
prednisone NN 3_i
arm NN N
vs. FW N
2/23 CD N
( ( N
8.7 CD N
% NN N
) ) N
on IN N
the DT N
prednisone NN 3_i
alone RB N
arm NN N
. . N

Progression-free JJ N
survival NN N
was VBD N
5.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
2.8-13.7 JJ N
) ) N
on IN N
the DT N
satraplatin NN 3_i
plus CC N
prednisone NN 3_i
arm NN N
as IN N
compared VBN N
to TO N
2.5 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
2.1- JJ N
4.7 CD N
) ) N
on IN N
the DT N
prednisone NN 3_i
alone RB N
arm NN N
( ( N
HR NNP N
= NNP N
0.50 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.28-0.92 NN N
) ) N
. . N

This DT N
difference NN N
is VBZ N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.023 CD N
) ) N
. . N

Toxicity NN N
was VBD N
generally RB N
minimal JJ N
in IN N
both DT N
arms NNS N
. . N

This DT N
randomized JJ N
comparison NN N
of IN N
a DT N
combination NN N
of IN N
satraplatin NN 3_i
and CC N
prednisone NN 3_i
versus NN N
prednisone NN N
alone RB N
supports VBZ N
the DT N
antitumor NN N
activity NN N
of IN N
the DT N
combination NN N
. . N

Its PRP$ N
role NN N
in IN N
the DT N
treatment NN N
of IN N
HPRC NNP N
remains VBZ N
to TO N
be VB N
elucidated VBN N
in IN N
an DT N
appropriate JJ N
phase NN N
III NNP N
setting NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
controlled VBN N
, , N
parallel-group JJ N
trial NN N
of IN N
routine JJ 3_i
prophylaxis NN 3_i
vs. IN N
on-demand JJ N
treatment NN N
with IN N
sucrose-formulated JJ N
recombinant JJ N
factor NN N
VIII NNP N
in IN N
adults NNS N
with IN N
severe JJ N
hemophilia NN N
A NNP N
( ( N
SPINART NNP N
) ) N
. . N

BACKGROUND IN N
The DT N
benefits NNS N
of IN N
routine JJ N
prophylaxis NN N
vs. IN N
on-demand JJ N
treatment NN N
with IN N
factor NN N
VIII NNP N
products NNS N
have VBP N
not RB N
been VBN N
evaluated VBN N
in IN N
controlled JJ N
clinical JJ N
trials NNS N
in IN N
older JJR N
patients NNS N
with IN N
hemophilia PDT N
A NNP N
. . N

OBJECTIVES NNP N
To TO N
report VB N
results NNS N
from IN N
a DT N
preplanned JJ N
analysis NN N
of IN N
data NNS N
from IN N
the DT N
first JJ N
year NN N
of IN N
the DT N
3-year JJ N
SPINART NNP N
study NN N
, , N
which WDT N
compares VBZ N
routine JJ N
prophylaxis NN N
with IN N
on-demand JJ N
treatment NN N
with IN N
sucrose-formulated JJ N
recombinant JJ N
FVIII NNP N
( ( N
rFVIII-FS NN N
) ) N
. . N

PATIENTS/METHODS NNP N
SPINART NNP N
is VBZ N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
parallel-group NN N
, , N
multinational JJ N
trial NN N
. . N

Males NNS N
aged VBN N
12-50 CD N
years NNS N
with IN N
severe JJ N
hemophilia NN N
A NNP N
, , N
? . N
150 CD N
days NNS N
of IN N
exposure NN N
to TO N
FVIII NNP N
, , N
no DT N
FVIII NNP N
inhibitors NNS N
, , N
no DT N
prophylaxis NN N
for IN N
> $ N
12 CD N
consecutive JJ N
months NNS N
in IN N
the DT N
past JJ N
5 CD N
years NNS N
and CC N
6-24 JJ N
bleeding NN N
episodes NNS N
in IN N
the DT N
preceding VBG N
6 CD N
months NNS N
were VBD N
randomized VBN N
1 CD N
: : N
1 CD N
to TO N
rFVIII-FS JJ N
prophylaxis NN N
( ( N
25 CD N
IU NNP N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
three CD N
times NNS N
weekly JJ N
) ) N
or CC N
on-demand JJ N
treatment NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
, , N
number NN N
of IN N
total JJ N
bleeding VBG N
episodes NNS N
in IN N
the DT N
intent-to-treat JJ N
population NN N
, , N
was VBD N
analyzed VBN N
after IN N
the DT N
last JJ N
patient NN N
had VBD N
completed VBN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

A DT N
negative JJ N
binomial JJ N
model NN N
was VBD N
used VBN N
for IN N
the DT N
primary JJ N
endpoint NN N
analysis NN N
; : N
analysis NN N
of IN N
variance NN N
was VBD N
used VBN N
for IN N
confirmatory JJ N
analysis NN N
of IN N
annualized JJ N
bleeding NN N
rates NNS N
. . N

RESULTS NNP N
Eighty-four JJ N
patients NNS N
were VBD N
enrolled VBN N
and CC N
analyzed VBN N
( ( N
n JJ N
= $ N
42 CD N
per IN N
group NN N
; : N
mean JJ N
age NN N
, , N
30.6 CD N
years NNS N
; : N
median JJ N
treatment NN N
duration NN N
, , N
1.7 CD N
years NNS N
) ) N
. . N

The DT N
median JJ N
number NN N
of IN N
total JJ N
bleeding NN N
episodes NNS N
and CC N
total JJ N
bleeding NN N
episodes NNS N
per IN N
year NN N
were VBD N
significantly RB N
lower JJR N
with IN N
prophylaxis NN N
than IN N
with IN N
on-demand JJ N
treatment NN N
( ( N
total JJ N
, , N
0 CD N
vs. FW N
54.5 CD N
; : N
total JJ N
per IN N
year NN N
, , N
0 CD N
vs. FW N
27.9 CD N
; : N
both DT N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

No DT N
treatment-related JJ N
adverse JJ N
events NNS N
occurred VBD N
, , N
and CC N
no DT N
patients NNS N
developed VBD N
FVIII NNP N
inhibitors NNS N
. . N

CONCLUSIONS NNP N
Routine NNP N
prophylaxis NN N
with IN N
rFVIII-FS JJ N
leads NNS N
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
bleeding VBG N
as IN N
compared VBN N
with IN N
on-demand JJ N
treatment NN N
. . N

Adverse JJ N
events NNS N
were VBD N
consistent JJ N
with IN N
the DT N
established VBN N
rFVIII-FS NN N
safety NN N
profile NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
fish-oil JJ 3_i
and CC 3_i
vegetable-oil JJ 3_i
formula NN 3_i
on IN N
aggregation NN N
and CC N
ethanolamine-containing JJ N
lysophospholipid JJ N
generation NN N
in IN N
activated JJ N
human JJ N
platelets NNS N
and CC N
on IN N
leukotriene JJ N
production NN N
in IN N
stimulated JJ N
neutrophils NNS N
. . N

The DT N
effects NNS N
of IN N
consuming VBG N
a DT N
liquid JJ 3_i
formula NN 3_i
containing VBG 3_i
either CC 3_i
fish JJ 3_i
oil NN 3_i
enriched VBN 3_i
in IN 3_i
omega-3 JJ 3_i
fatty JJ 3_i
acids NNS 3_i
or CC N
vegetable JJ 3_i
oil NN 3_i
enriched VBN 3_i
in IN 3_i
oleic JJ 3_i
acid NN 3_i
was VBD N
evaluated VBN N
in IN N
20 CD N
male JJ N
subjects NNS N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
over IN N
a DT N
42-d JJ N
period NN N
. . N

A DT N
decrease NN N
in IN N
collagen-induced JJ N
aggregation NN N
by IN N
using VBG N
washed JJ N
platelet NN N
suspensions NNS N
was VBD N
found VBN N
in IN N
both DT N
groups NNS N
after IN N
nutritional JJ N
supplementation NN N
. . N

A DT N
considerable JJ N
rise NN N
in IN N
omega-3 JJ N
and CC N
a DT N
decrease NN N
in IN N
omega-6 JJ N
fatty JJ N
acids NNS N
occurred VBD N
in IN N
the DT N
platelet NN N
phospholipid JJ N
with IN N
fish-oil JJ 3_i
consumption NN 3_i
. . N

The DT N
degree NN N
of IN N
eicosapentaenoic NN N
acid NN N
( ( N
EPA NNP N
, , N
20:5n-3 JJ N
) ) N
enrichment NN N
( ( N
fish-oil JJ N
group NN N
) ) N
was VBD N
dramatically RB N
greater JJR N
in IN N
the DT N
ether-containing JJ N
plasmenylethanolamine NN N
( ( N
13.5 CD N
mol CD N
% NN N
of IN N
fatty JJ N
acids NNS N
; : N
mol CD N
% NN N
of IN N
fatty JJ N
acids NNS N
= VBP N
moles NNS N
per IN N
100 CD N
moles NNS N
of IN N
total JJ N
fatty JJ N
acids NNS N
) ) N
than IN N
in IN N
phosphatidylethanolamine NN N
( ( N
2.8 CD N
mol CD N
% NN N
) ) N
or CC N
phosphatidylcholine NN N
( ( N
2.9 CD N
mol CD N
% NN N
) ) N
. . N

Neither CC N
treatment NN N
significantly RB N
influenced VBD N
the DT N
agonist-induced JJ N
accumulation NN N
of IN N
lysoplasmenylethanolamine NN N
as IN N
derived JJ N
via IN N
phospholipase NN N
A2 NNP N
hydrolysis NN N
of IN N
plasmenylethanolamine NN N
. . N

HPLC NNP N
measurements NNS N
of IN N
eicosanoid JJ N
production NN N
in IN N
A23187-stimulated NNP N
neutrophils NNS N
revealed VBD N
a DT N
considerable JJ N
decrease NN N
in IN N
the DT N
formation NN N
of IN N
arachidonic JJ N
acid-derived JJ N
leukotriene NN N
B4 NNP N
( ( N
LTB4 NNP N
) ) N
, , N
by IN N
41 CD N
% NN N
, , N
and CC N
5-HETE JJ N
( ( N
5-hydroxyeicosatetraenoic JJ N
acid NN N
) ) N
, , N
by IN N
30 CD N
% NN N
, , N
in IN N
the DT N
fish-oil JJ N
group NN N
along IN N
with IN N
the DT N
appearance NN N
of IN N
the DT N
corresponding JJ N
EPA-derived JJ N
products NNS N
[ JJ N
LTB5 NNP N
and CC N
5-HEPE JJ N
( ( N
5-hydroxyeicosapentaenoic JJ N
acid NN N
) ) N
] NN N
. . N

No DT N
such JJ N
alterations NNS N
in IN N
the DT N
formation NN N
of IN N
lipoxygenase NN N
products NNS N
were VBD N
found VBN N
with IN N
the DT N
vegetable JJ 3_i
oil NN 3_i
treatment NN 3_i
. . N

-DOCSTART- -X- O O

Comparative JJ N
effectiveness NN N
of IN N
exercise NN N
electrocardiography NN N
with IN N
or CC N
without IN N
myocardial JJ N
perfusion NN N
single JJ N
photon NN N
emission NN N
computed VBD N
tomography NN N
in IN N
women NNS N
with IN N
suspected JJ N
coronary JJ N
artery NN N
disease NN N
: : N
results NNS N
from IN N
the DT N
What WP N
Is VBZ N
the DT N
Optimal NNP N
Method NNP N
for IN N
Ischemia NNP N
Evaluation NNP N
in IN N
Women NNP N
( ( N
WOMEN NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
paucity NN N
of IN N
randomized JJ N
trials NNS N
regarding VBG N
diagnostic JJ N
testing NN N
in IN N
women NNS N
with IN N
suspected JJ N
coronary JJ N
artery NN N
disease NN N
( ( N
CAD NNP N
) ) N
. . N

It PRP N
remains VBZ N
unclear JJ N
whether IN N
the DT N
addition NN N
of IN N
myocardial JJ N
perfusion NN N
imaging NN N
( ( N
MPI NNP N
) ) N
to TO N
the DT N
standard JJ N
ECG NNP N
exercise NN N
treadmill NN N
test NN N
( ( N
ETT NNP N
) ) N
provides VBZ N
incremental JJ N
information NN N
to TO N
improve VB N
clinical JJ N
decision NN N
making NN N
in IN N
women NNS N
with IN N
suspected JJ N
CAD NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
randomized VBD N
symptomatic JJ N
women NNS N
with IN N
suspected JJ N
CAD NNP N
, , N
an DT N
interpretable JJ N
ECG NNP N
, , N
and CC N
?5 NNP N
metabolic JJ N
equivalents NNS N
on IN N
the DT N
Duke NNP N
Activity NNP N
Status NNP N
Index NNP N
to TO N
1 CD N
of IN N
2 CD N
diagnostic JJ N
strategies NNS N
: : N
ETT NNP N
or CC N
exercise NN N
MPI NNP N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
2-year JJ N
incidence NN N
of IN N
major JJ N
adverse JJ N
cardiac NN N
events NNS N
, , N
defined VBN N
as IN N
CAD NNP N
death NN N
or CC N
hospitalization NN N
for IN N
an DT N
acute JJ N
coronary JJ N
syndrome NN N
or CC N
heart NN N
failure NN N
. . N

A DT N
total NN N
of IN N
824 CD N
women NNS N
were VBD N
randomized VBN N
to TO N
ETT NNP N
or CC N
exercise NN N
MPI NNP N
. . N

For IN N
women NNS N
randomized VBN N
to TO N
ETT NNP N
, , N
ECG NNP N
results NNS N
were VBD N
normal JJ N
in IN N
64 CD N
% NN N
, , N
indeterminate NN N
in IN N
16 CD N
% NN N
, , N
and CC N
abnormal JJ N
in IN N
20 CD N
% NN N
. . N

By IN N
comparison NN N
, , N
the DT N
exercise NN N
MPI NNP N
results NNS N
were VBD N
normal JJ N
in IN N
91 CD N
% NN N
, , N
mildly RB N
abnormal JJ N
in IN N
3 CD N
% NN N
, , N
and CC N
moderate VB N
to TO N
severely RB N
abnormal JJ N
in IN N
6 CD N
% NN N
. . N

At IN N
2 CD N
years NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
major JJ N
adverse JJ N
cardiac NN N
events NNS N
( ( N
98.0 CD N
% NN N
for IN N
ETT NNP N
and CC N
97.7 CD N
% NN N
for IN N
MPI NNP N
; : N
P=0.59 NNP N
) ) N
. . N

Compared VBN N
with IN N
ETT NNP N
, , N
index NN N
testing VBG N
costs NNS N
were VBD N
higher JJR N
for IN N
exercise NN N
MPI NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
downstream NN N
procedural NN N
costs NNS N
were VBD N
slightly RB N
lower JJR N
( ( N
P=0.0008 NNP N
) ) N
. . N

Overall UH N
, , N
the DT N
cumulative JJ N
diagnostic JJ N
cost NN N
savings NNS N
was VBD N
48 CD N
% NN N
for IN N
ETT NNP N
compared VBN N
with IN N
exercise NN N
MPI NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
low-risk JJ N
, , N
exercising VBG N
women NNS N
, , N
a DT N
diagnostic JJ N
strategy NN N
that WDT N
uses VBZ N
ETT NNP N
versus NN N
exercise NN N
MPI NNP N
yields NNS N
similar JJ N
2-year JJ N
posttest NN N
outcomes NNS N
while IN N
providing VBG N
significant JJ N
diagnostic JJ N
cost NN N
savings NNS N
. . N

The DT N
ETT NNP N
with IN N
selective JJ N
follow-up JJ N
testing NN N
should MD N
be VB N
considered VBN N
as IN N
the DT N
initial JJ N
diagnostic JJ N
strategy NN N
in IN N
symptomatic JJ N
women NNS N
with IN N
suspected JJ N
CAD NNP N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00282711 NNP N
. . N

-DOCSTART- -X- O O

Ongoing VBG 3_i
Telmisartan NNP 3_i
Alone NNP 3_i
and CC 3_i
in IN 3_i
Combination NNP 3_i
With IN 3_i
Ramipril NNP 3_i
Global NNP 3_i
Endpoint NNP 3_i
Trial NNP 3_i
( ( 3_i
ONTARGET NNP 3_i
) ) 3_i
: : 3_i
implications NNS N
for IN N
reduced JJ N
cardiovascular JJ N
risk NN N
. . N

The DT N
recently RB N
published VBN N
Ongoing NNP 3_i
Telmisartan NNP 3_i
Alone NNP 3_i
and CC 3_i
in IN 3_i
Combination NNP 3_i
With IN 3_i
Ramipril NNP 3_i
Global NNP 3_i
Endpoint NNP 3_i
Trial NNP 3_i
( ( 3_i
ONTARGET NNP 3_i
) ) 3_i
in IN N
patients NNS N
with IN N
vascular JJ N
disease NN N
or CC N
high-risk JJ N
diabetes NNS N
, , N
as IN N
the DT N
largest JJS N
published VBN N
comparative JJ N
trial NN N
of IN N
these DT N
agent NN N
classes NNS N
, , N
provides VBZ N
further JJ N
evidence NN N
concerning VBG N
the DT N
comparison NN N
between IN N
the DT N
angiotensin-receptor NN 3_i
blockers NNS 3_i
( ( 3_i
ARBs NNP 3_i
) ) 3_i
and CC N
the DT N
angiotensin-converting JJ 3_i
enzyme NN 3_i
inhibitors NNS 3_i
( ( 3_i
ACEIs NNP 3_i
) ) 3_i
. . 3_i

In IN N
this DT N
trial NN N
, , N
telmisartan NN 3_i
( ( 3_i
an DT 3_i
ARB NNP 3_i
) ) 3_i
was VBD N
non-inferior JJ N
to TO N
ramipril VB 3_i
( ( 3_i
an DT 3_i
ACEI NNP 3_i
) ) 3_i
in IN N
reducing VBG N
fatal JJ N
and CC N
nonfatal JJ N
cardiovascular JJ N
events NNS N
. . N

Moreover RB N
, , N
ONTARGET NNP 2_i
is VBZ N
an DT N
example NN N
of IN N
a DT N
high-quality JJ N
noninferiority NN N
trial NN N
. . N

However RB N
, , N
the DT N
combination NN N
of IN N
the DT N
2 CD N
agents NNS N
was VBD N
associated VBN N
with IN N
more JJR N
adverse JJ N
effects NNS N
without IN N
an DT N
increase NN N
in IN N
benefit NN N
. . N

The DT N
study NN N
differed VBD N
from IN N
several JJ N
other JJ N
comparative JJ N
studies NNS N
in IN N
which WDT N
the DT N
dose NN N
and CC N
choice NN N
of IN N
ACEI NNP 2_i
was VBD N
left VBN N
to TO N
individual JJ N
physicians NNS N
. . N

Further NNP N
, , N
in IN N
ONTARGET NNP 3_i
, , N
the DT N
ACEI NNP 3_i
was VBD N
not RB N
titrated VBN N
to TO N
the DT N
maximum JJ N
dose NN N
and CC N
patients NNS N
with IN N
heart NN N
failure NN N
were VBD N
excluded VBN N
. . N

-DOCSTART- -X- O O

Dexamethasone NNP 3_i
effectively RB N
reduces VBZ N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
in IN N
a DT N
general JJ N
surgical JJ N
adult NN N
patient JJ N
population NN N
. . N

BACKGROUND NNP N
Postoperative NNP N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
is VBZ N
still RB N
a DT N
common JJ N
and CC N
major JJ N
complication NN N
for IN N
surgical JJ N
patients NNS N
, , N
which WDT N
may MD N
delay VB N
post-anesthetic JJ N
care NN N
unit NN N
discharge NN N
, , N
prolong JJ N
hospital NN N
stay NN N
and CC N
thus RB N
increase VB N
the DT N
cost NN N
of IN N
hospitalization NN N
. . N

It PRP N
is VBZ N
understood JJ N
that IN N
PONV NNP N
is VBZ N
a DT N
multi-factorial JJ N
outcome NN N
and CC N
occurs VBZ N
more RBR N
often RB N
with IN N
general JJ N
anesthesia NN N
than IN N
with IN N
other JJ N
anesthetic JJ N
methods NNS N
. . N

Prophylactic JJ N
administration NN N
of IN N
antihistamines NNS N
, , N
antidopaminergics NNS N
, , N
anticholinergics NNS N
, , N
phenothiazines NNS N
, , N
serotonin JJ N
antagonist NN N
, , N
steroids NNS N
and CC N
even RB N
acupuncture NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
. . N

However RB N
, , N
expenses NNS N
and CC N
side JJ N
effects NNS N
of IN N
these DT N
agents NNS N
have VBP N
also RB N
been VBN N
a DT N
concern NN N
for IN N
clinical JJ N
doctors NNS N
. . N

The DT N
aim NN N
for IN N
this DT N
prospective JJ N
study NN N
was VBD N
to TO N
find VB N
an DT N
agent NN N
that WDT N
is VBZ N
cost RBS N
effective JJ N
and CC N
side JJ N
effect NN N
free JJ N
( ( N
or CC N
at IN N
least JJS N
with IN N
a DT N
low JJ N
incidence NN N
of IN N
side JJ N
effects NNS N
) ) N
for IN N
the DT N
prevention NN N
of IN N
PONV NNP N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
700 CD N
adult NN N
surgical JJ N
patients NNS N
who WP N
planned VBD N
to TO N
have VB N
surgery NN N
under IN N
general JJ N
anesthesia NN N
were VBD N
enrolled VBN N
in IN N
this DT N
double-blinded JJ N
, , N
randomized JJ N
and CC N
placebo-controlled JJ 3_i
study NN N
. . N

Group NNP N
P NNP N
received VBD N
the DT N
placebo NN 7_i
( ( N
0.9 CD N
% NN N
normal JJ 7_i
saline JJ 7_i
2 CD N
ml NN N
) ) N
and CC N
Group NNP N
D NNP N
received VBD N
10 CD N
mg NNS N
dexamethasone RB 3_i
intravenously RB N
right JJ N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
. . N

RESULTS NNP N
We PRP N
found VBD N
that IN N
during IN N
the DT N
postoperative JJ N
period NN N
of IN N
1-8 JJ N
h NN N
, , N
patients NNS N
in IN N
Group NNP N
D NNP N
reported VBD N
a DT N
lower JJR N
incidence NN N
of IN N
PONV NNP N
( ( N
24 CD N
% NN N
) ) N
than IN N
those DT N
in IN N
Group NNP N
P NNP N
( ( N
39 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Patients NNS N
in IN N
Group NNP N
D NNP N
also RB N
requested VBD N
less JJR N
rescue JJ N
anti-emetic JJ N
( ( N
17 CD N
% NN N
) ) N
than IN N
those DT N
in IN N
Group NNP N
P NNP N
( ( N
30 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
same JJ N
phenomenon NN N
was VBD N
also RB N
noted VBN N
in IN N
the DT N
8-to-24-hour JJ N
interval NN N
( ( N
PONV NNP N
4 CD N
% NN N
vs. FW N
12 CD N
% NN N
, , N
p NN N
< VBD N
0.05 CD N
and CC N
rescue VB N
anti-emetic JJ N
3 CD N
% NN N
vs. FW N
9 CD N
% NN N
, , N
p NN N
< VBD N
0.05 CD N
in IN N
Group NNP N
D NNP N
vs. FW N
Group NNP N
P NNP N
, , N
respectively RB N
. . N

) ) N
CONCLUSIONS IN N
We PRP N
conclude VBP N
that IN N
the DT N
prophylactic JJ N
intravenous JJ N
administration NN N
of IN N
10 CD N
mg NNS N
dexamethasone VBP N
immediately RB N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
is VBZ N
effective JJ N
in IN N
preventing VBG N
PONV NNP N
in IN N
the DT N
general JJ N
surgical JJ N
adult NN N
patient JJ N
population NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
perioperative JJ N
indomethacin NN 3_i
on IN N
intracranial JJ N
pressure NN N
, , N
cerebral JJ N
blood NN N
flow NN N
, , N
and CC N
cerebral JJ N
metabolism NN N
in IN N
patients NNS N
subjected VBN N
to TO N
craniotomy VB N
for IN N
cerebral JJ N
tumors NNS N
. . N

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
perioperative JJ N
indomethacin NN N
on IN N
intracranial JJ N
pressure NN N
( ( N
ICP NNP N
) ) N
, , N
cerebral JJ N
blood NN N
flow NN N
( ( N
CBF NNP N
) ) N
, , N
and CC N
cerebral JJ N
metabolism NN N
. . N

Twenty CD N
patients NNS N
subjected VBN N
to TO N
craniotomy VB N
for IN N
supratentorial JJ N
cerebral JJ N
tumors NNS N
were VBD N
anesthetized VBN 3_i
with IN 3_i
thiopental JJ 3_i
, , 3_i
fentanyl JJ 3_i
, , 3_i
nitrous JJ 3_i
oxide NN 3_i
, , 3_i
and CC 3_i
isoflurane NN 3_i
. . 3_i

A DT N
PaCO2 NNP N
level NN N
averaging VBG N
4.8 CD N
kPa NN N
( ( N
median JJ N
) ) N
was VBD N
achieved VBN N
. . N

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
intravenous JJ 3_i
indomethacin JJ 3_i
50 CD 3_i
mg NN 3_i
or CC N
placebo NN 3_i
administrated VBN 3_i
after IN 3_i
exposure NN 3_i
of IN 3_i
the DT 3_i
dura NN 3_i
. . N

ICP NNP 2_i
was VBD 2_i
measured VBN 2_i
continuously RB 2_i
subdurally RB 2_i
with IN 2_i
a DT 2_i
22-gauge JJ 2_i
canula NN 2_i
connected VBN 2_i
to TO 2_i
a DT 2_i
transducer NN 2_i
. . N

CBF NNP N
and CC N
the DT N
arteriovenous JJ N
difference NN N
of IN N
oxygen NN N
( ( N
AVDO2 NNP N
) ) N
were VBD N
measured VBN N
twice RB N
, , N
before IN N
and CC N
after IN N
indomethacin/placebo JJ N
administration NN N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
ICP NNP N
from IN N
6.5 CD N
to TO N
1.5 CD N
mm NNS N
Hg NNP N
( ( N
median JJ N
) ) N
was VBD N
found VBN N
after IN N
indomethacin JJ N
administration NN N
. . N

This DT N
decrease NN N
was VBD N
caused VBN N
by IN N
a DT N
significant JJ N
decrease NN N
in IN N
CBF NNP N
associated VBD N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
AVDO2 NNP N
. . N

Indomethacin NNP N
did VBD N
not RB N
affect VB N
the DT N
cerebral JJ N
metabolic JJ N
rate NN N
of IN N
oxygen NN N
, , N
the DT N
arteriovenous JJ N
difference NN N
of IN N
lactate NN N
, , N
or CC N
the DT N
lactate/oxygen NN N
index NN N
, , N
suggesting VBG N
that IN N
indomethacin NN N
did VBD N
not RB N
provoke VB N
global JJ N
cerebral JJ N
ischemia NN N
. . N

In IN N
the DT N
indomethacin NN N
group NN N
, , N
dura NN N
was VBD N
sufficiently RB N
relaxed VBN N
in IN N
eight CD N
of IN N
nine CD N
patients NNS N
and CC N
dura NN N
was VBD N
opened VBN N
without IN N
the DT N
occurrence NN N
of IN N
cerebral JJ N
swelling VBG N
. . N

In IN N
one CD N
patient NN N
, , N
mannitol FW N
treatment NN N
was VBD N
necessary JJ N
to TO N
prevent VB N
dural JJ N
tightness NN N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
mannitol RB N
supplemented VBN N
with IN N
hypocapnia NN N
was VBD N
applied VBN N
in IN N
five CD N
patients NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
perioperative JJ N
treatment NN N
with IN N
indomethacin NN 3_i
is VBZ N
an DT N
excellent JJ N
treatment NN N
of IN N
intracranial JJ N
hypertension NN N
during IN N
normocapnic JJ N
isoflurane NN N
anesthesia NN N
for IN N
craniotomy NN N
. . N

-DOCSTART- -X- O O

Population NNP N
pharmacokinetic/pharmacodynamic JJ N
analysis NN N
of IN N
the DT N
DPP-4 NNP N
inhibitor NN N
linagliptin NN N
in IN N
Japanese JJ N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus RB N
. . N

OBJECTIVES NNP N
Linagliptin NNP 3_i
is VBZ N
a DT N
novel JJ N
, , N
highly RB N
selective JJ N
and CC N
long JJ N
acting VBG N
DPP-4 NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
type NN N
2 CD N
diabetes NNS N
mellitus FW N
( ( N
T2DM NNP N
) ) N
. . N

Linagliptin JJ 3_i
exhibits VBZ N
non-linear JJ N
pharmacokinetics NNS N
( ( N
PK NNP N
) ) N
due JJ N
to TO N
saturable JJ N
binding NN N
to TO N
plasma VB N
and CC N
tissue VB N
DPP-4 NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
characterize VB N
the DT N
PK NNP N
and CC N
PK/DPP-4 NNP N
inhibition NN N
relationship NN N
of IN N
linagliptin NN 3_i
in IN N
Japanese JJ N
patients NNS N
with IN N
T2DM NNP N
using VBG N
a DT N
population NN N
PK/DPP-4 NNP N
model NN N
and CC N
to TO N
support VB N
the DT N
rationale NN N
for IN N
the DT N
therapeutic JJ N
dose NN N
in IN N
Japanese JJ N
patients NNS N
by IN N
simulation NN N
. . N

METHODS NNP N
Linagliptin NNP 3_i
plasma NN N
concentration NN N
and CC N
DPP-4 NNP N
inhibition NN N
measurements NNS N
from IN N
a DT N
placebo-controlled JJ 7_i
, , N
parallel JJ N
group NN N
multiple NN N
( ( N
28 CD N
days NNS N
) ) N
dose VBP N
trial NN N
that WDT N
included VBD N
36 CD N
T2DM NNP N
patients NNS N
( ( N
18 CD N
patients NNS N
each DT N
in IN N
2.5 CD N
mg NN N
and CC N
10 CD N
mg NNS N
dose JJ N
group NN N
) ) N
were VBD N
used VBN N
for IN N
analysis NN N
. . N

Modeling NNP N
was VBD N
performed VBN N
using VBG N
FOCE NNP N
INTERACTION NNP N
estimation NN N
method NN N
implemented VBN N
in IN N
NONMEM NNP N
V. NNP N
The DT N
linagliptin JJ N
plasma JJ N
concentration- NN N
and CC N
DPP-4 NNP N
inhibition- JJ N
time NN N
profiles NNS N
were VBD N
simulated VBN N
for IN N
Japanese JJ N
patients NNS N
receiving VBG N
5 CD N
mg JJ N
linagliptin NN 3_i
once RB N
daily JJ N
by IN N
the DT N
model NN N
established VBN N
. . N

RESULTS NNP N
Nonlinear NNP N
PK NNP N
of IN N
linagliptin NN N
in IN N
T2DM NNP N
patients NNS N
were VBD N
well RB N
described VBN N
by IN N
a DT N
2-compartment JJ N
model NN N
assuming VBG N
concentration-dependent JJ N
binding NN N
to TO N
DPP-4 NNP N
in IN N
the DT N
central JJ N
and CC N
peripheral JJ N
compartment NN N
. . N

Plasma NNP N
DPP-4 NNP N
inhibition NN N
was VBD N
integrated VBN N
in IN N
the DT N
model NN N
by IN N
relating VBG N
the DT N
model-predicted JJ N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin JJ 3_i
linearly JJ N
to TO N
DPP-4 JJ N
inhibition NN N
. . N

The DT N
simulation NN N
predicted VBD N
that IN N
for IN N
the DT N
5 CD N
mg NN N
dose NN N
group NN N
the DT N
trough JJ N
DPP-4 JJ N
inhibition NN N
at IN N
steady-state NN N
was VBD N
84.2 CD N
% NN N
, , N
which WDT N
is VBZ N
higher JJR N
than IN N
the DT N
target NN N
inhibition NN N
( ( N
?80 CD N
% NN N
) ) N
for IN N
an DT N
effective JJ N
dose NN N
of IN N
DPP-4 NNP N
inhibitor NN N
. . N

In IN N
2.5 CD N
mg NNS N
dose JJ N
group NN N
, , N
steady-state JJ N
DPP-4 NNP N
inhibition NN N
of IN N
> $ N
80 CD N
% NN N
was VBD N
not RB N
maintained VBN N
over IN N
24 CD N
hours NNS N
( ( N
observed VBN N
and CC N
simulated VBN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
nonlinear JJ N
PK NNP N
of IN N
linagliptin NN N
and CC N
its PRP$ N
plasma JJ N
DPP-4 JJ N
inhibition NN N
in IN N
patients NNS N
were VBD N
well RB N
characterized VBN N
by IN N
a DT N
target-mediated JJ N
drug NN N
disposition NN N
model NN N
relating VBG N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin NN N
to TO N
DPP-4 NNP N
inhibition NN N
. . N

Simulations NNS N
of IN N
plasma JJ N
DPP-4 NNP N
inhibition NN N
suggest VBP N
that IN N
5 CD N
mg NNS N
linagliptin JJ N
once RB N
daily JJ N
is VBZ N
an DT N
appropriate JJ N
therapeutic JJ N
dose NN N
for IN N
Japanese JJ N
patients NNS N
with IN N
T2DM NNP N
. . N

-DOCSTART- -X- O O

Identifying VBG N
patients NNS N
at IN N
high JJ N
risk NN N
for IN N
neutropenic JJ N
complications NNS N
during IN N
chemotherapy NN 3_i
for IN N
metastatic JJ N
breast NN N
cancer NN N
with IN N
doxorubicin NN 3_i
or CC N
pegylated VBN 3_i
liposomal JJ 3_i
doxorubicin NN 3_i
: : N
the DT N
development NN N
of IN N
a DT N
prediction NN N
model NN N
. . N

OBJECTIVE UH N
To TO N
develop VB N
a DT N
cycle-based JJ N
risk NN N
prediction NN N
model NN N
for IN N
neutropenic JJ N
complications NNS N
( ( N
NC NNP N
) ) N
during IN N
chemotherapy NN 3_i
with IN N
doxorubicin NN 3_i
( ( N
DOX NNP N
) ) N
or CC N
a DT N
pegylated JJ 3_i
liposomal JJ 3_i
formulation NN 3_i
( ( 3_i
PLD NNP 3_i
) ) 3_i
for IN N
patients NNS N
with IN N
metastatic JJ N
breast NN N
cancer NN N
( ( N
MBC NNP N
) ) N
. . N

METHODS NNP N
Data NNP N
analyzed VBD N
was VBD N
from IN N
a DT N
phase NN N
III NNP N
, , N
randomized VBD N
clinical JJ N
trial NN N
of IN N
DOX NNP 3_i
( ( N
60 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
3 CD N
weeks NNS N
) ) N
or CC N
PLD NNP 3_i
( ( N
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
4 CD N
weeks NNS N
) ) N
for IN N
the DT N
first JJ N
line NN N
therapy NN N
for IN N
MBC NNP N
( ( N
n JJ N
= NNP N
509 CD N
) ) N
( ( N
O'Brien NNP N
et RB N
al RB N
, , N
Ann NNP N
Oncol NNP N
. . N

2004 CD N
; : N
15:440-449 JJ N
) ) N
. . N

NC NNP N
were VBD N
defined VBN N
as IN N
an DT N
absolute NN N
neutrophil NN N
count NN N
< NNP N
or CC N
=1.5 NNP N
x VBP N
10 CD N
( ( N
9 CD N
) ) N
cells/L NN N
( ( N
ie JJ N
, , N
> JJ N
or CC N
=grade JJ N
II NNP N
) ) N
before IN N
the DT N
next JJ N
cycle NN N
, , N
febrile JJ N
neutropenia NN N
or CC N
neutropenia NN N
with IN N
a DT N
documented JJ N
infection NN N
. . N

Patient NNP N
and CC N
hematologic JJ N
factors NNS N
potentially RB N
associated VBN N
with IN N
NC NNP N
were VBD N
evaluated VBN N
. . N

Factors NNS N
with IN N
a DT N
P NNP N
value NN N
of IN N
< NNP N
or CC N
=0.25 NNP N
within IN N
a DT N
cycle NN N
were VBD N
included VBN N
in IN N
a DT N
generalized JJ N
estimating NN N
equations NNS N
regression NN N
model NN N
. . N

Using VBG N
backward JJ N
elimination NN N
, , N
we PRP N
derived VBD N
a DT N
risk NN N
scoring VBG N
algorithm NN N
( ( N
range VB N
0-63 NN N
) ) N
from IN N
the DT N
final JJ N
reduced VBN N
model NN N
. . N

RESULTS NNP N
Risk NNP N
factors NNS N
retained VBD N
in IN N
the DT N
model NN N
included VBD N
poor JJ N
performance NN N
status NN N
, , N
absolute VB N
neutrophil JJ N
count NN N
< NN N
or CC N
=2.0 VB N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
cells/L NN N
in IN N
the DT N
previous JJ N
cycle NN N
, , N
the DT N
first JJ N
cycle NN N
of IN N
chemotherapy NN N
, , N
DOX NNP 3_i
versus NN N
PLD NNP 3_i
and CC N
advanced JJ N
age NN N
. . N

A DT N
precycle NN N
risk NN N
score NN N
from IN N
> NN N
or CC N
=25 NN N
to TO N
< VB N
40 CD N
for IN N
a DT N
given VBN N
patient NN N
was VBD N
identified VBN N
as IN N
being VBG N
the DT N
optimal JJ N
threshold NN N
for IN N
sensitivity NN N
( ( N
58.0 CD N
% NN N
) ) N
and CC N
specificity NN N
( ( N
78.7 CD N
% NN N
) ) N
. . N

Patients NNS N
with IN N
a DT N
score NN N
at IN N
or CC N
beyond IN N
this DT N
threshold NN N
would MD N
be VB N
considered VBN N
at IN N
high JJ N
risk NN N
for IN N
developing VBG N
NC NNP N
in IN N
later JJ N
cycles NNS N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
this DT N
model NN N
may MD N
enhance VB N
patient NN N
care NN N
by IN N
targeting VBG N
preventative JJ N
therapies NNS N
( ( N
eg NN N
, , N
granulocyte NN N
colony NN N
stimulating VBG N
factor NN N
or CC N
PLD NNP N
) ) N
to TO N
those DT N
MBC NNP N
patients NNS N
most RBS N
likely JJ N
to TO N
experience VB N
NC NNP N
during IN N
anthracycline-based JJ 3_i
chemotherapy NN 3_i
. . 3_i

-DOCSTART- -X- O O

[ JJ N
Therapeutic NNP N
efficacy NN N
of IN N
youdujing VBG 3_i
preparation NN 3_i
in IN N
treating VBG N
cervical JJ N
high-risk JJ N
human JJ N
papilloma NN N
virus NN N
infection NN N
patients NNS N
] VBP N
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanisms NN N
of IN N
Youdujing NNP 3_i
( ( 3_i
YDJ NNP 3_i
) ) 3_i
preparation NN 3_i
in IN N
treating VBG N
the DT N
cervical JJ N
high-risk JJ N
human JJ N
papilloma NN N
virus NN N
( ( N
HR-HPV NNP N
) ) N
infection NN N
. . N

METHODS NNP N
Totally RB N
HR-HPV NNP N
infection NN N
70 CD N
patients NNS N
were VBD N
assigned VBN N
to TO N
the DT N
treatment NN 7_i
group NN N
and CC N
the DT N
control NN 7_i
group NN N
using VBG N
random JJ N
single JJ N
blind NN N
method NN N
, , N
35 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

YDJ NNP 7_i
external JJ 7_i
lotion NN 7_i
and CC 7_i
YDJ NNP 7_i
cream NN 7_i
were VBD N
applied VBN N
to TO N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
, , N
while IN N
normal JJ N
saline NN N
was VBD N
applied VBN N
for IN N
those DT N
in IN N
the DT N
control NN 7_i
group NN N
. . N

HR-HPV NNP N
DNA NNP N
detection NN N
was VBD N
performed VBN N
by IN N
the DT N
end NN N
of IN N
the DT N
1st CD N
menstruation NN N
after IN N
3 CD N
menstrual JJ N
cycles NNS N
. . N

The DT N
cervical JJ N
biopsy NN N
and CC N
cervical JJ N
smear NN N
were VBD N
performed VBN N
using VBG N
vaginoscope NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

The DT N
mRNA JJ N
expression NN N
of IN N
human JJ N
telomerase NN N
reverse NN N
transcriptase NN N
( ( N
hTERT NN N
) ) N
was VBD N
detected VBN N
from IN N
fresh JJ N
tissues NNS N
of IN N
the DT N
cervical JJ N
lesion NN N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
96.6 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
, , N
higher JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
70.00 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Before IN N
treatment NN N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
pathological JJ N
results NNS N
of IN N
the DT N
cervix NN N
and CC N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
decreased VBN N
in IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Better JJR N
effects NNS N
on IN N
the DT N
pathological JJ N
results NNS N
of IN N
the DT N
cervix NN N
and CC N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
YDJ NNP 3_i
played VBD N
a DT N
role NN N
in IN N
clearing VBG N
HR-HPV NNP N
infection NN N
and CC N
reversing VBG N
the DT N
cervical JJ N
precancerous JJ N
changes NNS N
possibly RB N
through IN N
down-regulating NN N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
and CC N
lowering VBG N
the DT N
telomerase NN N
activation NN N
. . N

-DOCSTART- -X- O O

Cholesterol-lowering JJ N
effect NN N
of IN N
stanol NN 3_i
ester NN 3_i
in IN N
a DT N
US NNP N
population NN N
of IN N
mildly RB N
hypercholesterolemic JJ N
men NNS N
and CC N
women NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
stanol NN 3_i
esters NNS 3_i
in IN N
lowering VBG N
cholesterol NN N
in IN N
a DT N
US NNP N
population NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
After IN N
a DT N
run-in JJ N
phase NN N
, , N
318 CD N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
margarine-like JJ N
spreads NNS N
containing VBG N
stanol JJ 3_i
ester NN 3_i
or CC N
placebo NN 2_i
for IN N
8 CD N
weeks NNS N
: : N
EU NNP N
3 CD N
G NNP N
: : N
1 CD N
g NN N
of IN N
stanol NN 3_i
( ( 3_i
ester JJ 3_i
form NN 3_i
) ) 3_i
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
European JJ N
formula NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
US PRP N
3 CD N
G NNP N
: : N
1 CD N
g NN N
of IN N
stanol NN 3_i
( ( 3_i
ester JJ 3_i
form NN 3_i
) ) 3_i
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
US PRP N
2 CD N
G NNP N
: : N
0.67 CD N
g NN N
of IN N
stanol NN 3_i
( ( N
ester JJ N
form NN N
) ) N
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
or CC N
placebo VB 7_i
spread NN N
. . N

RESULTS JJ N
Mean JJ N
+/- JJ N
SD NNP N
baseline NN N
total NN N
cholesterol NN N
( ( N
TC NNP N
) ) N
and CC N
low-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
levels NNS N
were VBD N
233+/-20 JJ N
and CC N
153+21 CD N
mg+/-dL NN N
, , N
respectively RB N
. . N

In IN N
the DT N
US NNP N
3 CD N
G NNP N
group NN N
, , N
3 CD N
g JJ N
daily NN N
of IN N
stanol JJ 3_i
esters NNS 3_i
lowered VBD N
TC NNP N
and CC N
LDL-C NNP N
levels NNS N
by IN N
6.4 CD N
% NN N
and CC N
10.1 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
response NN N
compared VBN N
with IN N
2 CD N
g NNS N
daily RB N
( ( N
US PRP N
2 CD N
G NNP N
) ) N
. . N

Triglyceride NNP N
and CC N
high-density NN N
lipoprotein NNS N
cholesterol NN N
levels NNS N
were VBD N
unchanged JJ N
. . N

The DT N
incidence NN N
of IN N
adverse JJ N
effects NNS N
was VBD N
not RB N
different JJ N
from IN N
placebo NN 7_i
. . N

Serum NNP N
vitamin VBD N
A DT N
and CC N
25-hydroxyvitamin JJ N
D NNP N
levels NNS N
were VBD N
not RB N
affected VBN N
. . N

CONCLUSIONS NNP N
Stanol NNP 3_i
esters NNS 3_i
lowered VBD N
TC NNP N
and CC N
LDL-C NNP N
levels NNS N
in IN N
a DT N
mildly RB N
hypercholesterolemic JJ N
US NNP N
population NN N
without IN N
evidence NN N
of IN N
adverse JJ N
effects NNS N
. . N

It PRP N
may MD N
be VB N
a DT N
useful JJ N
dietary JJ N
adjunct NN N
to TO N
lower VB N
cholesterol NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
evaluation NN N
of IN N
the DT N
WOMAC NNP N
3.0 CD N
OA NNP N
Index NNP N
in IN N
numeric JJ N
rating NN N
scale NN N
format NN N
using VBG N
a DT N
computerized JJ 4_i
touch NN 4_i
screen NN 4_i
version NN 4_i
. . N

BACKGROUND IN N
The DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
( ( N
WOMAC NNP N
) ) N
Osteoarthritis NNP N
Index NNP N
is VBZ N
a DT N
previously RB N
described VBN N
self-administered JJ N
questionnaire NN N
covering VBG N
three CD N
domains NNS N
: : N
pain NN N
, , N
stiffness NN N
and CC N
function NN N
. . N

It PRP N
has VBZ N
been VBN N
validated VBN N
in IN N
patients NNS N
with IN N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
of IN N
the DT N
hip NN N
or CC N
knee NN N
in IN N
a DT N
paper-based JJ N
format NN N
. . N

AIM NNP N
To TO N
validate VB N
the DT N
WOMAC NNP N
3.0 CD N
using VBG N
a DT N
numerical JJ N
rating NN N
scale NN N
in IN N
a DT N
computerized JJ N
touch NN N
screen NN N
format NN N
allowing VBG N
immediate JJ N
evaluation NN N
of IN N
the DT N
questionnaire NN N
. . N

In IN N
the DT N
computed JJ N
version NN N
cartoons NNS N
, , N
written VBN N
and CC N
audio JJ N
instruments NNS N
were VBD N
included VBN N
in IN N
order NN N
facilitate NN N
application NN N
. . N

METHODS NNP N
Fifty NNP N
patients NNS N
, , N
demographically RB N
balanced VBN N
, , N
with IN N
radiographically RB N
proven JJ N
primary JJ N
hip NN N
or CC N
knee NN N
OA NNP N
completed VBD N
the DT N
classical JJ 4_i
paper NN 4_i
and CC N
the DT N
new JJ 4_i
computerized JJ 4_i
WOMAC NNP 4_i
version NN 4_i
. . N

Subjects NNS N
were VBD N
randomized VBN N
either RB N
to TO N
paper NN N
format NN N
or CC N
computerized JJ N
format NN N
first RB N
to TO N
balance VB N
possible JJ N
order NN N
effects NNS N
. . N

RESULTS VB N
The DT N
intra-class JJ N
correlation NN N
coefficients NNS N
for IN N
pain NN N
, , N
stiffness NN N
and CC N
function NN N
values NNS N
were VBD N
0.915 CD N
, , N
0.745 CD N
and CC N
0.940 CD N
, , N
respectively RB N
. . N

The DT N
Spearman NNP N
correlation NN N
coefficients NNS N
for IN N
pain NN N
, , N
stiffness NN N
and CC N
function NN N
were VBD N
0.88 CD N
, , N
0.77 CD N
and CC N
0.87 CD N
, , N
respectively RB N
. . N

CONCLUSION NNP N
These DT N
data NNS N
indicate VBP N
that IN N
the DT N
computerized JJ N
WOMAC NNP N
OA NNP N
index NN N
3.0 CD N
is VBZ N
comparable JJ N
to TO N
the DT N
paper NN N
WOMAC NNP N
in IN N
all DT N
three CD N
dimensions NNS N
. . N

The DT N
computerized JJ 4_i
version NN 4_i
would MD N
allow VB N
physicians NNS N
to TO N
get VB N
an DT N
immediate JJ N
result NN N
and CC N
if IN N
present JJ N
a DT N
direct JJ N
comparison NN N
with IN N
a DT N
previous JJ N
exam NN N
. . N

-DOCSTART- -X- O O

Safety NN N
and CC N
efficacy NN N
of IN N
a DT N
new JJ 3_i
3.3 CD 3_i
g NN 3_i
b.i.d NN 3_i
. . 3_i

tablet NN 3_i
formulation NN 3_i
in IN N
patients NNS N
with IN N
mild-to-moderately-active JJ N
ulcerative JJ N
colitis NN N
: : N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
new JJ N
twice-daily JJ N
balsalazide NN 3_i
disodium NN 3_i
1.1 CD 3_i
g NN 3_i
tablet NN 3_i
dosing VBG N
regimen NNS N
( ( N
6.6 CD N
g/day NN N
, , N
three CD N
tablets NNS N
twice RB N
daily RB N
) ) N
for IN N
the DT N
treatment NN N
of IN N
mild-to-moderately-active JJ N
ulcerative JJ N
colitis NN N
( ( N
UC NNP N
) ) N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
, , N
multicenter NN N
study NN N
patients NNS N
with IN N
symptoms NNS N
of IN N
acute JJ N
UC NNP N
and CC N
a DT N
baseline NN N
Modified NNP N
Mayo NNP N
Disease NNP N
Activity NNP N
Index NNP N
( ( N
MMDAI NNP N
) ) N
score NN N
between IN N
6 CD N
and CC N
10 CD N
, , N
inclusive JJ N
, , N
with IN N
a DT N
subscale JJ N
rating NN N
of IN N
> NNP N
or CC N
=2 NN N
for IN N
both DT N
rectal JJ N
bleeding NN N
and CC N
mucosal JJ N
appearance NN N
were VBD N
randomized VBN N
to TO N
receive VB N
3.3 CD N
g NN N
of IN N
balsalazide NN 3_i
or CC N
placebo NN 3_i
tablets NNS N
twice RB N
daily RB N
for IN N
8 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
achieving VBG N
clinical JJ N
improvement NN N
( ( N
> CD N
or CC N
=3 VB N
point NN N
improvement NN N
in IN N
MMDAI NNP N
) ) N
and CC N
improvement NN N
in IN N
rectal JJ N
bleeding NN N
( ( N
> CD N
or CC N
=1 VB N
point NN N
improvement NN N
) ) N
at IN N
8 CD N
weeks NNS N
. . N

Safety NN N
assessments NNS N
were VBD N
conducted VBN N
from IN N
baseline NN N
through IN N
2-weeks JJ N
post-treatment JJ N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
249 CD N
patients NNS N
( ( N
166 CD N
balsalazide NN 3_i
, , N
83 CD N
placebo NN 7_i
) ) N
received VBD N
at IN N
least JJS N
1 CD N
dose NN N
of IN N
study NN N
medication NN N
. . N

The DT N
mean JJ N
MMDAI NNP N
score NN N
at IN N
baseline NN N
was VBD N
7.9 CD N
; : N
62 CD N
% NN N
of IN N
patients NNS N
had VBD N
a DT N
score NN N
> NN N
or CC N
=8.0 NN N
( ( N
moderate JJ N
disease NN N
) ) N
. . N

A DT N
significantly RB N
larger JJR N
proportion NN N
of IN N
patients NNS N
achieved VBN N
clinical JJ N
improvement NN N
and CC N
improvement NN N
in IN N
rectal JJ N
bleeding NN N
in IN N
the DT N
balsalazide NN 3_i
group NN N
vs. FW N
the DT N
placebo NN 7_i
group NN N
( ( N
55 CD N
vs. FW N
40 CD N
% NN N
, , N
P=0.02 NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
reported VBN N
were VBD N
worsening VBG N
of IN N
UC NNP N
and CC N
headache NN N
; : N
both DT N
were VBD N
reported VBN N
more RBR N
often RB N
in IN N
the DT N
placebo NN 7_i
group NN N
. . N

CONCLUSIONS NNP N
Balsalazide NNP 3_i
disodium NN 3_i
1.1 CD N
g NN N
tablets NNS N
administered VBD N
as IN N
3.3 CD N
g JJ N
twice RB N
daily RB N
are VBP N
effective JJ N
, , N
well RB N
tolerated VBN N
and CC N
significantly RB N
better JJR N
than IN N
placebo NN 3_i
for IN N
improving VBG N
signs NNS N
and CC N
symptoms NNS N
of IN N
mild-to-moderately-active JJ N
UC NNP N
. . N

This DT N
new JJ N
formulation NN N
with IN N
a DT N
reduced VBN N
pill NN N
and CC N
dosing VBG N
burden NN N
offers VBZ N
the DT N
potential NN N
to TO N
improve VB N
convenience NN N
and CC N
compliance NN N
in IN N
patients NNS N
with IN N
active JJ N
UC NNP N
. . N

-DOCSTART- -X- O O

Plasmakinetic JJ 1_i
prostate NN 1_i
resection NN 1_i
in IN N
the DT N
treatment NN N
of IN N
benign JJ N
prostate JJ N
hyperplasia NN N
: : N
results NNS N
of IN N
1-year JJ N
follow VBP N
up RP N
. . N

AIM NNP N
In IN N
our PRP$ N
randomized JJ N
prospective JJ N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficiency NN N
of IN N
plasmakinetic JJ 1_i
resection NN 1_i
of IN 1_i
prostate NN 1_i
( ( 1_i
PKRP NNP 1_i
) ) 1_i
by IN N
comparing VBG N
the DT N
preoperative NN N
and CC N
postoperative JJ N
results NNS N
of IN N
the DT N
transurethral JJ 1_i
resection NN 1_i
of IN 1_i
prostate NN 1_i
( ( N
TURP NNP N
) ) N
and CC N
PKRP NNP N
techniques NNS N
which WDT N
we PRP N
administered VBD N
in IN N
patients NNS N
with IN N
benign JJ N
prostate NN N
hyperplasia NN N
( ( N
BPH NNP N
) ) N
in IN N
our PRP$ N
clinic NN N
. . N

METHODS NNP N
Of IN N
57 CD N
patients NNS N
for IN N
whom WP N
we PRP N
thought VBD N
an DT N
operative JJ N
intervention NN N
was VBD N
necessary JJ N
, , N
30 CD N
cases NNS N
in IN N
the DT N
first JJ N
group NN N
had VBD N
a DT N
TURP NNP 1_i
and CC N
24 CD N
cases NNS N
in IN N
the DT N
second JJ N
group NN N
had VBD N
a DT N
PKRP NNP 1_i
. . N

International NNP N
prostate JJ N
symptom NN N
scores NNS N
( ( N
I-PSS NNP N
) ) N
, , N
uroflowmetry UH N
, , N
measurement NN N
of IN N
residual JJ N
urine JJ N
amount NN N
and CC N
ultrasonography NN N
were VBD N
performed VBN N
for IN N
each DT N
patient NN N
both DT N
preoperatively RB N
and CC N
postoperatively RB N
( ( N
first JJ N
month NN N
and CC N
first JJ N
year NN N
) ) N
. . N

Operation NNP N
times NNS N
, , N
urethral JJ N
catheterization NN N
times NNS N
, , N
preoperative JJ N
and CC N
postoperative JJ N
Hb NNP N
, , N
Htc NNP N
and CC N
serum VB N
Na NNP N
values NNS N
of IN N
the DT N
patients NNS N
were VBD N
compared VBN N
and CC N
the DT N
complications NNS N
of IN N
the DT N
groups NNS N
were VBD N
also RB N
compared VBN N
. . N

RESULTS VB N
On IN N
first JJ N
month NN N
and CC N
first JJ N
year NN N
follow VBP N
up RP N
between IN N
the DT N
groups NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
statistical JJ N
difference NN N
in IN N
I-PSS NNP N
, , N
maximum JJ N
flow NN N
rate NN N
, , N
average NN N
flow NN N
, , N
residual JJ N
urine NN N
and CC N
size NN N
of IN N
the DT N
prostate NN N
. . N

The DT N
decrease NN N
in IN N
serum NN N
Na NNP N
level NN N
was VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
TURP NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
operation NN N
times NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
. . N

While IN N
the DT N
postoperative JJ N
catheterization NN N
time NN N
was VBD N
75.7 CD N
h NN N
in IN N
TURP NNP N
group NN N
, , N
it PRP N
was VBD N
found VBN N
to TO N
be VB N
42 CD N
h NN N
in IN N
PKRP NNP N
group NN N
and CC N
it PRP N
was VBD N
clear JJ N
that IN N
catheterization NN N
time NN N
was VBD N
significantly RB N
shorter JJR N
( ( N
P NNP N
< NNP N
0001 CD N
) ) N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
obvious JJ N
that IN N
PKRP NNP 1_i
is VBZ N
as RB N
efficient JJ N
as IN N
TURP NNP N
and CC N
it PRP N
has VBZ N
a DT N
similar JJ N
morbidity NN N
. . N

In IN N
our PRP$ N
opinion NN N
, , N
PKRP NNP 1_i
makes VBZ N
a DT N
promising JJ N
treatment NN N
for IN N
BPH NNP N
with IN N
its PRP$ N
advantages NNS N
, , N
such JJ N
as IN N
early JJ N
removal NN N
of IN N
postoperative JJ N
urethral JJ N
catheter NN N
, , N
a DT N
shorter JJR N
hospital NN N
stay NN N
and CC N
the DT N
absence NN N
of IN N
TUR NNP N
syndrome NN N
risk NN N
. . N

-DOCSTART- -X- O O

Bizzy NNP N
Break NNP N
! . N
The DT N
effect NN N
of IN N
a DT N
classroom-based JJ 4_i
activity NN 4_i
break NN 4_i
on IN N
in-school JJ N
physical JJ N
activity NN N
levels NNS N
of IN N
primary JJ N
school NN N
children NNS N
. . N

The DT N
school NN N
has VBZ N
been VBN N
identified VBN N
as IN N
a DT N
key JJ N
setting NN N
to TO N
promote VB N
physical JJ N
activity NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
classroom-based JJ 4_i
activity NN 4_i
break NN 4_i
on IN N
in-school JJ N
step NN N
counts NNS N
of IN N
primary JJ N
school NN N
children NNS N
. . N

Data NNP N
for IN N
90 CD N
children NNS N
( ( N
49 CD N
boys NNS N
, , N
41 CD N
girls NNS N
, , N
9.3 CD N
? . N
1.4 CD N
years NNS N
) ) N
from IN N
three CD N
Irish JJ N
primary NN N
schools NNS N
is VBZ N
presented VBN N
. . N

In IN N
each DT N
school NN N
one CD N
class NN N
was VBD N
randomly RB N
assigned VBN N
as IN N
the DT N
intervention NN N
group NN N
and CC N
another DT N
as IN N
controls NNS N
. . N

Children NNP N
's POS N
step NN N
counts NNS N
were VBD N
measured VBN N
for IN N
five CD N
consecutive JJ N
days NNS N
during IN N
school NN N
hours NNS N
at IN N
baseline NN N
and CC N
follow-up NN N
. . N

Teachers NNS N
of IN N
the DT N
intervention NN N
classes VBZ N
led VBD N
a DT N
10 CD N
min NN N
activity NN N
break NN N
in IN N
the DT N
classroom NN N
each DT N
day NN N
( ( N
Bizzy NNP N
Break NNP N
! . N
) ) N
. . N

Mean JJ N
daily JJ N
in-school JJ N
steps NNS N
for IN N
the DT N
intervention NN N
at IN N
baseline NN N
and CC N
follow-up NN N
were VBD N
5351 CD N
and CC N
5054 CD N
. . N

Corresponding VBG N
values NNS N
for IN N
the DT N
control NN N
group NN N
were VBD N
5469 CD N
and CC N
4246 CD N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
change NN N
in IN N
daily JJ N
steps NNS N
from IN N
baseline NN N
to TO N
follow-up NN N
between IN N
groups NNS N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
girls NNS N
and CC N
boys NNS N
responded VBD N
differently RB N
to TO N
the DT N
intervention NN N
( ( N
p JJ N
> NNP N
.05 NNP N
) ) N
. . N

Children NNP N
participating VBG N
in IN N
a DT N
daily JJ N
10 CD N
min JJ N
classroom-based JJ N
activity NN N
break VB N
undertake JJ N
more JJR N
physical JJ N
activity NN N
during IN N
school NN N
hours NNS N
than IN N
controls NNS N
. . N

-DOCSTART- -X- O O

Fadrozole NNP 3_i
HCL NNP 3_i
( ( 3_i
CGS-16949A NNP 3_i
) ) 3_i
versus NN N
megestrol NN 3_i
acetate VBP 3_i
treatment NN N
of IN N
postmenopausal NN N
patients NNS N
with IN N
metastatic JJ N
breast NN N
carcinoma NN N
: : N
results NNS N
of IN N
two CD N
randomized JJ N
double JJ N
blind NN N
controlled VBD N
multiinstitutional JJ N
trials NNS N
. . N

BACKGROUND NNP N
Breast NNP N
cancer NN N
patients NNS N
with IN N
prior JJ N
response NN N
to TO N
endocrine VB N
therapy NN N
achieve VB N
subsequent JJ N
benefit NN N
from IN N
additional JJ N
endocrine NN N
therapies NNS N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
an DT N
aromatase NN N
inhibitor NN N
, , N
fadrozole JJ 3_i
HCL NNP 3_i
, , N
were VBD N
compared VBN N
with IN N
megestrol NN N
acetate NN N
in IN N
post NN N
menopausal NN N
patients NNS N
who WP N
had VBD N
disease NN N
progression NN N
after IN N
receiving VBG N
antiestrogen NN N
therapy NN N
either DT N
for IN N
metastatic JJ N
disease NN N
or CC N
as IN N
adjuvant JJ N
therapy NN N
. . N

METHODS NNP N
In IN N
2 CD N
multiinstitutional JJ N
prospective JJ N
trials NNS N
, , N
683 CD N
postmenopausal NN N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
fadrozole JJ 3_i
HCL NNP 3_i
, , 3_i
1 CD 3_i
mg NN 3_i
twice RB 3_i
daily RB 3_i
, , N
or CC N
megestrol NN 3_i
acetate NN 3_i
, , 3_i
40 CD 3_i
mg NN 3_i
4 CD 3_i
times NNS 3_i
daily RB 3_i
, , N
in IN N
a DT N
double JJ N
blind NN N
fashion NN N
after IN N
progression NN N
on IN N
first-line JJ 3_i
hormonal JJ 3_i
therapy NN 3_i
. . N

Objective JJ N
response NN N
rates NNS N
, , N
time NN N
to TO N
progression NN N
, , N
survival NN N
and CC N
safety NN N
of IN N
the DT N
two CD N
regimens NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Results NNP N
of IN N
intent-to-treat JJ N
analyses NNS N
are VBP N
presented VBN N
in IN N
this DT N
study NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
detected VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
time NN N
to TO N
progression NN N
, , N
objective JJ N
response NN N
rates NNS N
, , N
duration NN N
of IN N
response NN N
, , N
and CC N
survival NN N
in IN N
either DT N
trial NN N
. . N

There EX N
were VBD N
no DT N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
experiences NNS N
, , N
except IN N
that DT N
weight NN N
gain NN N
, , N
fluid JJ N
retention NN N
, , N
and CC N
dyspnea NN N
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
megestrol NN N
acetate NN N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
fadrozole JJ N
HCL NNP N
, , N
whereas JJ N
nausea NN N
and CC N
vomiting NN N
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
fadrozole JJ N
HCL NNP N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
megestrol NN N
acetate NN N
. . N

CONCLUSIONS NNP N
Fadrozole NNP 3_i
HCL NNP 3_i
was VBD N
as RB N
efficacious JJ N
as IN N
megestrol NN N
acetate NN N
in IN N
postmenopausal NN N
patients NNS N
with IN N
metastatic JJ N
breast NN N
carcinoma NN N
after IN N
one CD N
hormonal JJ N
therapy NN N
. . N

Adverse JJ N
experiences NNS N
were VBD N
mild JJ N
with IN N
both DT N
therapies NNS N
, , N
but CC N
megestrol NN N
acetate NN N
was VBD N
associated VBN N
wiht PDT N
a DT N
higher JJR N
frequency NN N
of IN N
weight NN N
gain NN N
, , N
fluid JJ N
retention NN N
and CC N
dyspnea NN N
, , N
whereas JJ N
fadrozole NN 3_i
HCL NNP 3_i
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
frequency NN N
of IN N
nausea NN N
and CC N
vomiting NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
a DT N
spiritually RB 4_i
based VBN 4_i
and CC 4_i
non-spiritually RB 4_i
based VBN 4_i
educational JJ 4_i
intervention NN 4_i
for IN N
informed JJ N
decision NN N
making NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
among IN N
church-attending JJ N
African-American JJ N
men NNS N
. . N

INTRODUCTION NNP N
Health NNP 4_i
communication NN 4_i
interventions NNS 4_i
have VBP N
been VBN N
modestly RB N
effective JJ N
for IN N
increasing VBG N
informed JJ N
decision NN N
making NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
among IN N
African-American JJ N
men NNS N
; : N
however RB N
, , N
knowledge NN N
and CC N
informed JJ N
decision NN N
making NN N
is VBZ N
still RB N
questionable JJ N
even RB N
with IN N
screening VBG N
. . N

Church-based JJ N
programs NNS N
may MD N
be VB N
more RBR N
effective JJ N
if IN N
they PRP N
are VBP N
spiritually RB N
based VBN N
in IN N
nature NN N
. . N

OBJECTIVE CC N
The DT N
aims NNS N
of IN N
the DT N
present JJ N
study NN N
were VBD N
to TO N
implement VB N
and CC N
provide VB N
an DT N
initial JJ N
evaluation NN N
of IN N
a DT N
spiritually RB N
based VBN N
prostate NN N
cancer NN N
screening VBG N
informed JJ N
decision NN N
making VBG N
intervention NN N
for IN N
African-American JJ N
men NNS N
who WP N
attend VBP N
church NN N
, , N
and CC N
determine VB N
its PRP$ N
efficacy NN N
for IN N
increasing VBG N
informed JJ N
decision NN N
making NN N
. . N

DESIGN NNP N
AND CC N
METHOD NNP N
Churches NNP N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
the DT N
spiritually RB 4_i
based VBN 4_i
or CC 4_i
the DT 4_i
non-spiritual JJ 4_i
intervention NN 4_i
. . N

Trained NNP N
community NN N
health NN N
advisors NNS N
, , N
who WP N
were VBD N
African-American JJ N
male JJ N
church NN N
members NNS N
, , N
led VBD N
an DT N
educational JJ 4_i
session NN 4_i
and CC N
distributed VBD 4_i
educational JJ 4_i
print NN 4_i
materials NNS 4_i
. . 4_i

Participants NNS N
completed VBD N
baseline NN N
and CC N
immediate JJ N
follow-up JJ N
surveys NNS N
to TO N
assess VB N
the DT N
intervention NN N
impact NN N
on IN N
study NN N
outcomes NNS N
. . N

RESULTS VB N
The DT N
spiritually RB N
based VBN N
intervention NN N
appeared VBD N
to TO N
be VB N
more RBR N
effective JJ N
in IN N
areas NNS N
such JJ N
as IN N
knowledge NN N
, , N
and CC N
men NNS N
read VBP N
more JJR N
of IN N
their PRP$ N
materials NNS N
in IN N
the DT N
spiritually RB N
based VBN N
group NN N
than IN N
in IN N
the DT N
non-spiritual JJ N
group NN N
. . N

CONCLUSIONS NNP N
Further NNP N
examination NN N
of IN N
the DT N
efficacy NN N
of IN N
the DT N
spiritually RB N
based VBN N
approach NN N
to TO N
health NN N
communication NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Pimecrolimus NNP 3_i
cream VBZ 3_i
1 CD N
% NN N
vs. FW N
betamethasone CD 3_i
17-valerate JJ 3_i
0.1 CD N
% NN N
cream NN N
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

A DT N
randomized JJ N
open-label JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Seborrhoeic NNP N
dermatitis NN N
is VBZ N
a DT N
chronic JJ N
inflammatory NN N
disease NN N
with IN N
remissions NNS N
and CC N
exacerbations NNS N
, , N
characterized VBN N
by IN N
erythema NN N
, , N
scaling VBG N
and CC N
pruritus JJ N
primarily RB N
on IN N
the DT N
face NN N
, , N
scalp NN N
and CC N
chest NN N
. . N

Corticosteroids NNP N
and CC N
antifungals NNS N
are VBP N
the DT N
mainstay NN N
of IN N
therapy NN N
. . N

However RB N
, , N
chronic JJ N
use NN N
of IN N
corticosteroids NNS N
is VBZ N
associated VBN N
with IN N
side-effects NNS N
such JJ N
as IN N
skin JJ N
atrophy NN N
and CC N
telangiectasia NN N
. . N

Pimecrolimus NNP 3_i
, , N
an DT N
inhibitor NN N
of IN N
calcineurin NN N
, , N
has VBZ N
been VBN N
used VBN N
successfully RB N
in IN N
one CD N
patient NN N
with IN N
seborrhoeic JJ N
dermatitis NN N
. . N

OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
randomized VBN N
open-label JJ N
clinical JJ N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
pimecrolimus NN 3_i
in IN N
comparison NN N
with IN N
a DT N
potent NN N
corticosteroid NN 3_i
( ( 3_i
betamethasone CD 3_i
17-valerate NN 3_i
) ) 3_i
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

METHODS NNP N
Twenty NNP N
patients NNS N
with IN N
seborrhoeic JJ N
dermatitis NN N
were VBD N
included VBN N
in IN N
this DT N
study NN N
, , N
11 CD N
patients NNS N
in IN N
the DT N
pimecrolimus JJ 3_i
1 CD 3_i
% NN 3_i
cream NN 3_i
group NN 3_i
and CC N
nine CD N
patients NNS N
in IN N
the DT N
betamethasone NN 3_i
17-valerate JJ 3_i
0.1 CD 3_i
% NN 3_i
cream NN 3_i
group NN 3_i
. . 3_i

Patients NNS N
were VBD N
instructed VBN N
to TO N
use VB N
a DT N
thin JJ N
layer NN N
of IN N
the DT N
study NN N
products NNS N
twice RB N
daily RB N
at IN N
the DT N
lesional JJ N
area NN N
and CC N
to TO N
discontinue VB N
treatment NN N
as RB N
soon RB N
as IN N
symptoms NNS N
were VBD N
absent JJ N
. . N

Clinical JJ N
measures NNS N
assessed VBN N
were VBD N
erythema RB N
, , N
scaling VBG N
and CC N
pruritus NN N
which WDT N
were VBD N
evaluated VBN N
using VBG N
a DT N
four-point JJ N
scale NN N
( ( N
0-3 JJ N
) ) N
. . N

RESULTS NNP N
Both NNP N
pimecrolimus FW 3_i
and CC N
betamethasone NN 3_i
were VBD N
highly RB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

Betamethasone NNP 3_i
reduced VBD N
all DT N
three CD N
parameters NNS N
, , N
erythema NN N
, , N
scaling VBG N
and CC N
pruritus NN N
, , N
faster JJR N
than IN N
pimecrolimus NN 3_i
, , N
but CC N
the DT N
differences NNS N
in IN N
reduction NN N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Relapses NNS N
were VBD N
observed VBN N
more RBR N
frequently RB N
and CC N
were VBD N
more JJR N
severe JJ N
with IN N
betamethasone NN 3_i
than IN N
with IN N
pimecrolimus NN 3_i
. . N

Moreover RB N
, , N
pruritus NN N
was VBD N
not RB N
observed VBN N
after IN N
discontinuation NN N
of IN N
treatment NN N
from IN N
day NN N
15 CD N
and CC N
beyond IN N
in IN N
the DT N
pimecrolimus NN 3_i
group NN N
, , N
whereas IN N
it PRP N
was VBD N
reported VBN N
in IN N
most JJS N
patients NNS N
of IN N
the DT N
betamethasone NN 3_i
group NN N
. . N

This DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

CONCLUSIONS VB N
It PRP N
appears VBZ N
that IN N
pimecrolimus NN 3_i
, , N
a DT N
nonsteroidal JJ N
topical JJ N
treatment NN N
, , N
may MD N
be VB N
an DT N
excellent JJ N
alternative JJ N
therapeutic JJ N
modality NN N
for IN N
treating VBG N
seborrhoeic JJ N
dermatitis NN N
. . N

-DOCSTART- -X- O O

Heparin NNP 3_i
plus CC 3_i
dipyridamole NN 3_i
in IN N
childhood NN N
hemolytic-uremic JJ N
syndrome NN N
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

From IN N
1976 CD N
to TO N
1985 CD N
, , N
a DT N
total NN N
of IN N
58 CD N
infants NNS N
and CC N
children NNS N
with IN N
the DT N
hemolytic-uremic JJ N
syndrome NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
either RB N
with IN N
heparin NN 3_i
and CC 3_i
dipyridamole NN 3_i
or CC 3_i
with IN 3_i
supportive JJ 3_i
management NN 3_i
only RB 3_i
. . 3_i

In IN N
the DT N
treatment NN N
group NN N
, , N
two CD N
patients NNS N
died VBD N
in IN N
the DT N
early JJ N
weeks NNS N
of IN N
the DT N
disease NN N
. . N

Analysis NN N
of IN N
clinical JJ N
and CC N
laboratory NN N
data NNS N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
either DT N
group NN N
of IN N
patients NNS N
as IN N
to TO N
the DT N
evolution NN N
of IN N
their PRP$ N
illness NN N
except IN N
for IN N
a DT N
significantly RB N
higher JJR N
incidence NN N
of IN N
anuria NNS N
and CC N
a DT N
significantly RB N
faster RBR N
recovery NN N
from IN N
hypertension NN N
in IN N
the DT N
treated JJ N
group NN N
. . N

Renal NNP N
biopsy NN N
studies NNS N
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
incidence NN N
and CC N
severity NN N
of IN N
the DT N
histologic JJ N
lesions NNS N
. . N

The DT N
long-term JJ N
data NNS N
on IN N
blood NN N
pressure NN N
and CC N
creatinine JJ N
clearance NN N
values NNS N
in IN N
the DT N
survivors NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

This DT N
study NN N
indicates VBZ N
that IN N
treatment NN N
with IN N
heparin NN 3_i
and CC N
dipyridamole NN 3_i
has VBZ N
no DT N
benefit NN N
over IN N
symptomatic JJ 2_i
therapy NN 2_i
alone RB N
in IN N
the DT N
typical JJ N
form NN N
of IN N
childhood NN N
hemolytic-uremic JJ N
syndrome NN N
. . N

-DOCSTART- -X- O O

A DT N
controlled VBN N
study NN N
comparing VBG N
patients NNS N
with IN N
and CC N
without IN N
polycystic JJ N
ovaries NNS N
undergoing VBG N
in-vitro JJ N
fertilization NN N
. . N

The DT N
outcome NN N
of IN N
in-vitro JJ 2_i
fertilization NN 2_i
and CC 2_i
embryo NN 2_i
transfer NN 2_i
( ( 2_i
IVF-ET NNP 2_i
) ) 2_i
was VBD N
compared VBN N
in IN N
76 CD N
patients NNS N
with IN N
polycystic JJ N
ovaries NNS N
( ( N
PCO NNP N
) ) N
diagnosed VBD N
on IN N
pre-treatment JJ N
ultrasound JJ N
scan NN N
, , N
and CC N
76 CD N
control NN N
patients NNS N
who WP N
had VBD N
normal JJ N
ovaries NNS N
and CC N
were VBD N
matched VBN N
for IN N
age NN N
, , N
cause NN N
of IN N
infertility NN N
and CC N
stimulation NN N
regimen NNS N
. . N

Despite IN N
receiving VBG N
significantly RB N
less JJR N
human JJ N
menopausal NN N
gonadotrophin NN N
( ( N
HMG NNP N
) ) N
, , N
patients NNS N
with IN N
PCO NNP N
, , N
as IN N
compared VBN N
with IN N
controls NNS N
, , N
had VBD N
significantly RB N
higher JJR N
serum NN N
oestradiol NN N
levels NNS N
on IN N
the DT N
day NN N
of IN N
human JJ N
chorionic NN 2_i
gonadotrophin NN 2_i
administration NN N
( ( N
5940 CD N
+/- NN N
255 CD N
versus NN N
4370 CD N
+/- JJ N
240 CD N
pmol/l NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
developed VBD N
more JJR N
follicles NNS N
( ( N
14.9 CD N
+/- JJ N
0.7 CD N
versus NN N
9.8 CD N
+/- JJ N
0.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
produced VBD N
more JJR N
oocytes NNS N
( ( N
9.3 CD N
+/- JJ N
0.6 CD N
versus NN N
6.8 CD N
+/- JJ N
0.5 CD N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

However RB N
, , N
fertilization NN N
rates NNS N
were VBD N
reduced VBN N
in IN N
the DT N
PCO NNP N
patients NNS N
( ( N
52.8 CD N
+/- JJ N
3.4 CD N
% NN N
versus NN N
66.1 CD N
+/- JJ N
3.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
cleavage NN N
rates NNS N
. . N

The DT N
pregnancy NN N
rate/embryo NN N
transfer NN N
was VBD N
25.4 CD N
% NN N
in IN N
the DT N
PCO NNP N
group NN N
and CC N
23.0 CD N
% NN N
in IN N
the DT N
group NN N
with IN N
normal JJ N
ovaries NNS N
. . N

There EX N
were VBD N
three CD N
high JJ N
order NN N
multiple JJ N
pregnancies NNS N
in IN N
the DT N
PCO NNP N
group NN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
group NN N
with IN N
normal JJ N
ovaries NNS N
. . N

Of IN N
the DT N
PCO NNP N
patients NNS N
, , N
10.5 CD N
% NN N
developed VBD N
moderate/severe RB N
ovarian JJ N
hyperstimulation NN N
syndrome NN N
( ( N
OHSS NNP N
) ) N
compared VBN N
with IN N
none NN N
of IN N
the DT N
controls NNS N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
. . N

Patients NNS N
with IN N
and CC N
without IN N
PCO NNP N
undergoing VBG N
IVF NNP N
have VBP N
comparable JJ N
pregnancy NN N
and CC N
livebirth JJ N
rates NNS N
. . N

However RB N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
diagnose VB N
PCO NNP N
before IN N
ovarian JJ N
stimulation NN N
is VBZ N
initiated VBN N
as IN N
these DT N
patients NNS N
are VBP N
more RBR N
likely JJ N
to TO N
develop VB N
moderate JJ N
or CC N
severe JJ N
OHSS NNP N
following VBG N
IVF-ET NNP N
. . N

-DOCSTART- -X- O O

Single NNP 3_i
nucleotide JJ 3_i
polymorphism NN 3_i
in IN N
the DT N
hypoxia-inducible JJ N
factor-1alpha JJ N
gene NN N
in IN N
colorectal JJ N
carcinoma NN N
. . N

Colorectal JJ N
carcinoma NN N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
common JJ N
malignancies NNS N
in IN N
the DT N
world NN N
, , N
and CC N
its PRP$ N
incidence NN N
has VBZ N
increased VBN N
in IN N
recent JJ N
years NNS N
. . N

We PRP N
have VBP N
reported VBN N
that IN N
expression NN N
of IN N
hypoxia-inducible JJ N
factor NN N
( ( N
HIF NNP N
) ) N
-1alpha VBZ N
correlates NNS N
with IN N
expression NN N
of IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
, , N
tumor NN N
stage NN N
, , N
lymphatic JJ N
invasion NN N
, , N
venous JJ N
invasion NN N
, , N
and CC N
liver RB N
metastasis NN N
. . N

It PRP N
has VBZ N
also RB N
been VBN N
reported VBN N
that IN N
a DT N
single JJ 3_i
nucleotide NN 3_i
polymorphism NN 3_i
( ( 3_i
SNP NNP 3_i
) ) 3_i
in IN N
exon $ N
12 CD N
of IN N
HIF-1alpha NNP N
gene NN N
is VBZ N
present JJ N
in IN N
renal JJ N
cell NN N
carcinoma NN N
and CC N
head NN N
and CC N
neck NN N
squamous JJ N
cell NN N
carcinoma NN N
patients NNS N
. . N

We PRP N
investigated VBD N
the DT N
C1772T NNP 3_i
polymorphism NN 3_i
in IN N
colorectal JJ N
cancer NN N
patients NNS N
and CC N
healthy JJ N
control NN N
subjects VBZ N
to TO N
clarify VB N
the DT N
mechanism NN N
of IN N
HIF-1alpha NNP 3_i
activation NN 3_i
in IN N
colorectal JJ N
carcinoma NN N
. . N

The DT N
exon JJ N
12 CD N
genotype NN N
was VBD N
not RB N
associated VBN N
with IN N
sex NN N
or CC N
age NN N
. . N

The DT N
distribution NN N
of IN N
HIF-1alpha NNP N
genotypes NNS N
in IN N
controls NNS N
was VBD N
89 CD N
C/C NNP N
( ( N
89 CD N
% NN N
) ) N
, , N
11 CD N
C/T NNP N
( ( N
11 CD N
% NN N
) ) N
, , N
and CC N
0 CD N
T/T NNP N
( ( N
0 CD N
% NN N
) ) N
. . N

The DT N
distribution NN N
of IN N
HIF-1alpha NNP N
genotypes NNS N
in IN N
colorectal JJ N
cancer NN N
patients NNS N
was VBD N
100 CD N
C/C NNP N
( ( N
100 CD N
% NN N
) ) N
, , N
0 CD N
C/T NNP N
( ( N
0 CD N
% NN N
) ) N
, , N
and CC N
0 CD N
T/T NNP N
( ( N
0 CD N
% NN N
) ) N
. . N

The DT N
difference NN N
in IN N
genotype JJ N
distribution NN N
between IN N
patients NNS N
and CC N
control NN 7_i
subjects NNS N
was VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.0005 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
C1772T NNP 3_i
polymorphism NN N
in IN N
HIF-1alpha NNP N
is VBZ N
not RB N
involved VBN N
in IN N
progression NN N
or CC N
metastasis NN N
of IN N
colorectal JJ N
carcinoma NN N
. . N

-DOCSTART- -X- O O

The DT N
efficacy NN N
of IN N
intramammary JJ 3_i
tilmicosin NN 3_i
at IN N
drying-off NN N
, , N
and CC N
other JJ N
risk NN N
factors NNS N
for IN N
the DT N
prevention NN N
of IN N
new JJ N
intramammary JJ N
infections NNS N
during IN N
the DT N
dry JJ N
period NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
an DT N
intramammary JJ 3_i
infusion NN 3_i
, , 3_i
containing VBG 3_i
tilmicosin NN 3_i
phosphate NN 3_i
, , N
to TO N
an DT N
infusion NN 7_i
of IN 7_i
a DT 7_i
negative JJ 7_i
control NN 7_i
intramammary JJ 7_i
placebo NN 7_i
for IN N
preventing VBG N
new JJ N
intramammary JJ N
infections NNS N
( ( N
IMI NNP N
) ) N
during IN N
the DT N
dry JJ N
period NN N
. . N

Cows NNS N
were VBD N
enrolled VBN N
from IN N
24 CD N
dairy NN N
herds NNS N
from IN N
three CD N
geographical JJ N
regions NNS N
of IN N
Canada NNP N
. . N

Data NNP N
from IN N
248 CD N
cows NNS N
and CC N
938 CD N
bacteriologically RB N
negative JJ N
quarters NNS N
at IN N
drying-off NN N
are VBP N
summarized VBN N
. . N

Overall JJ N
, , N
the DT N
rate NN N
of IN N
new JJ N
IMI NNP N
during IN N
the DT N
dry JJ N
period NN N
was VBD N
16.7 CD N
% NN N
of IN N
quarters NNS N
. . N

The DT N
new JJ N
infection NN N
rates NNS N
for IN N
quarters NNS N
that WDT N
received VBD N
intramammary JJ 3_i
tilmicosin NNS 3_i
compared VBN N
with IN N
the DT N
intramammary JJ 3_i
placebo NN 3_i
were VBD N
14.4 CD N
and CC N
19.4 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
majority NN N
of IN N
new JJ N
IMI NNP N
was VBD N
caused VBN N
by IN N
coagulase-negative JJ N
staphylococci NN N
( ( N
49 CD N
% NN N
) ) N
and CC N
environmental JJ N
streptococcal JJ N
organisms NNS N
( ( N
26.8 CD N
% NN N
) ) N
. . N

The DT N
probability NN N
for IN N
quarters NNS N
to TO N
develop VB N
new JJ N
IMI NNP N
in IN N
the DT N
dry JJ N
period NN N
was VBD N
significantly RB N
increased VBN N
when WRB N
cows NNS N
had VBD N
higher JJR N
milk NN N
production NN N
before IN N
drying-off NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
when WRB N
cows NNS N
had VBD N
longer RBR N
dry JJ N
periods NNS N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
when WRB N
dry JJ N
cows NNS N
were VBD N
housed VBN N
in IN N
tie-stall JJ N
barns NNS N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Higher JJR N
parity NN N
cows NNS N
and CC N
those DT N
that WDT N
had VBD N
a DT N
linear JJ N
score NN N
somatic JJ N
cell NN N
count NN N
( ( N
SCC NNP N
) ) N
above IN N
4 CD N
on IN N
the DT N
last JJ N
DHI NNP N
test NN N
were VBD N
also RB N
at IN N
increased VBN N
risk NN N
for IN N
new JJ N
IMI NNP N
( ( N
P NNP N
< NNP N
0.10 CD N
) ) N
. . N

Administration NN N
of IN N
intramammary JJ 3_i
tilmicosin NN 3_i
appears VBZ N
to TO N
be VB N
an DT N
efficacious JJ N
therapy NN N
for IN N
prevention NN N
of IN N
new JJ N
IMI NNP N
; : N
however RB N
, , N
there EX N
is VBZ N
currently RB N
no DT N
approved VBD N
intramammary JJ N
formulation NN N
of IN N
this DT N
product NN N
available JJ N
. . N

Use NNP N
of IN N
blanket NN N
dry JJ N
cow NN N
antibiotic JJ N
therapy NN N
compared VBN N
to TO N
selective VB N
dry JJ N
cow NN N
therapy NN N
, , N
as RB N
well RB N
as IN N
the DT N
importance NN N
of IN N
identifying VBG N
risk NN N
factors NNS N
and CC N
managing VBG N
the DT N
environment NN N
of IN N
dry JJ N
cows NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
ketorolac NN 3_i
is VBZ N
associated VBN N
with IN N
decreased VBN N
pneumonia NN N
following VBG N
rib NN N
fractures NNS N
. . N

BACKGROUND IN N
The DT N
effectiveness NN N
of IN N
the DT N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
ketorolac NN 3_i
in IN N
reducing VBG N
pulmonary JJ N
morbidity NN N
after IN N
rib NN N
fractures NNS N
remains VBZ N
largely RB N
unknown JJ N
. . N

METHODS VB N
A DT N
retrospective JJ N
cohort NN N
study NN N
was VBD N
conducted VBN N
spanning VBG N
January NNP N
2003 CD N
to TO N
June NNP N
2011 CD N
assessing VBG N
pneumonia NN N
within IN N
30 CD N
days NNS N
and CC N
potential JJ N
adverse JJ N
effects NNS N
of IN N
ketorolac NN 3_i
among IN N
all DT N
patients NNS N
with IN N
rib JJ N
fractures NNS N
who WP N
received VBD N
ketorolac NN N
< $ N
4 CD N
days NNS N
after IN N
injury NN N
compared VBN N
with IN N
a DT N
random JJ N
sample NN N
of IN N
those DT N
who WP N
did VBD N
not RB N
. . N

RESULTS NNP N
Among IN N
202 CD N
patients NNS N
who WP N
received VBD N
ketorolac NN 3_i
and CC N
417 CD N
who WP N
did VBD N
not RB N
, , N
ketorolac NN N
use NN N
was VBD N
associated VBN N
with IN N
decreased VBN N
pneumonia NN N
( ( N
odds NNS N
ratio NN N
, , N
.14 NNP N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
.04 '' N
to TO N
.46 VB N
) ) N
and CC N
increased VBD N
ventilator-free JJ N
days NNS N
( ( N
difference NN N
, , N
1.8 CD N
days NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.1 CD N
to TO N
2.5 CD N
) ) N
and CC N
intensive JJ N
care NN N
unit-free JJ N
days NNS N
( ( N
difference NN N
, , N
2.1 CD N
days NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.3 CD N
to TO N
3.0 CD N
) ) N
within IN N
30 CD N
days NNS N
. . N

The DT N
rates NNS N
of IN N
acute JJ N
kidney NN N
injury NN N
, , N
gastrointestinal JJ N
hemorrhage NN N
, , N
and CC N
fracture NN N
nonunion NN N
were VBD N
not RB N
different JJ N
. . N

CONCLUSIONS NNP N
Early JJ N
administration NN N
of IN N
ketorolac NNS 3_i
to TO N
patients NNS N
with IN N
rib JJ N
fractures NNS N
is VBZ N
associated VBN N
with IN N
a DT N
decreased JJ N
likelihood NN N
of IN N
pneumonia NN N
, , N
without IN N
apparent JJ N
risks NNS N
. . N

-DOCSTART- -X- O O

Cognitive-behavioural JJ 4_i
stress NN 4_i
management NN 4_i
with IN N
HIV-positive JJ N
homosexual JJ N
men NNS N
: : N
mechanisms NNS N
of IN N
sustained JJ N
reductions NNS N
in IN N
depressive JJ N
symptoms NNS N
. . N

BACKGROUND IN N
We PRP N
examined VBD N
the DT N
sustained JJ N
efficacy NN N
of IN N
a DT N
group-based JJ 4_i
cognitive-behavioural JJ 4_i
stress NN 4_i
management NN 4_i
( ( 4_i
CBSM NNP 4_i
) ) 4_i
intervention NN 4_i
in IN N
comparison NN N
to TO N
a DT N
modified VBN N
wait-list NN 7_i
control NN 7_i
condition NN 7_i
on IN N
measures NNS N
of IN N
mood NN N
, , N
coping VBG N
and CC N
social JJ N
support NN N
in IN N
mildly RB N
symptomatic JJ N
HIV-positive JJ N
homosexual JJ N
and CC N
bisexual JJ N
men NNS N
. . N

Participants NNS N
were VBD N
recruited VBN N
largely RB N
during IN N
the DT N
era NN N
prior RB N
to TO N
highly RB N
active JJ N
antiretroviral JJ N
therapy NN N
( ( N
HAART NNP N
; : N
1992-1997 JJ N
) ) N
. . N

METHODS NNP N
Men NNPS N
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
10-week JJ N
, , N
group-based JJ N
CBSM NNP 4_i
intervention NN 4_i
( ( N
n JJ N
= NNP N
83 CD N
) ) N
or CC N
a DT N
psychoeducational JJ 7_i
seminar NN 7_i
group NN 7_i
( ( N
n JJ N
= NNP N
46 CD N
) ) N
. . N

All DT N
participants NNS N
completed VBD N
a DT N
battery NN N
of IN N
psychosocial JJ N
questionnaires NNS N
administered VBN N
by IN N
a DT N
research NN N
assistant NN N
at IN N
baseline NN N
, , N
immediately RB N
following VBG N
the DT N
10-week JJ 4_i
CBSM NNP 4_i
intervention NN 4_i
period NN N
, , N
and CC N
at IN N
a DT N
6-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Men NNP N
in IN N
the DT N
CBSM NNP N
group NN N
maintained VBD N
previously RB N
observed VBN N
effects NNS N
on IN N
depressive NN N
symptoms NNS N
and CC N
perceived VBD N
social JJ N
support NN N
. . N

These DT N
sustained JJ N
effects NNS N
of IN N
CBSM NNP N
on IN N
depressive JJ N
symptoms NNS N
were VBD N
mediated VBN N
by IN N
10-week JJ N
increases NNS N
in IN N
cognitive JJ N
coping NN N
( ( N
i.e JJ N
. . N

positive JJ N
reframing NN N
) ) N
. . N

DISCUSSION NNP N
CBSM NNP N
appears VBZ N
to TO N
be VB N
a DT N
potentially RB N
efficacious JJ N
treatment NN N
that WDT N
reduces VBZ N
and CC N
maintains NNS N
lower JJR N
levels NNS N
of IN N
depressive NN N
symptoms NNS N
and CC N
enhances VBZ N
social JJ N
support NN N
in IN N
HIV-positive JJ N
homosexual JJ N
and CC N
bisexual JJ N
men NNS N
. . N

In IN N
particular JJ N
, , N
changes NNS N
in IN N
positive JJ N
reframing NN N
during IN N
the DT N
10-week JJ N
intervention NN N
period NN N
remain VBP N
a DT N
crucial JJ N
factor NN N
contributing VBG N
to TO N
sustained VBN N
reductions NNS N
in IN N
depressive JJ N
symptoms NNS N
. . N

-DOCSTART- -X- O O

Trial JJ N
design NN N
challenges NNS N
when WRB N
combining VBG N
medication NN 3_i
and CC N
parent NN 4_i
training NN 4_i
in IN N
children NNS N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

This DT N
paper NN N
presents VBZ N
the DT N
rationale NN N
for IN N
a DT N
24-week JJ N
, , N
randomized JJ N
trial NN N
designed VBN N
to TO N
test VB N
whether IN N
risperidone NN 3_i
plus CC N
structured JJ 4_i
parent NN 4_i
training NN 4_i
would MD N
be VB N
superior JJ N
to TO N
risperidone VB 3_i
only RB 3_i
on IN N
measures NNS N
of IN N
noncompliance NN N
, , N
irritability NN N
and CC N
adaptive JJ N
functioning NN N
. . N

In IN N
this DT N
model NN N
, , N
medication NN N
reduces NNS N
tantrums NNS N
, , N
aggression NN N
and CC N
self-injury NN N
; : N
parent NN N
training NN N
promotes NNS N
improvement NN N
in IN N
noncompliance NN N
and CC N
adaptive JJ N
functioning NN N
. . N

Thus RB N
, , N
medication NN N
and CC N
parent NN N
training NN N
target NN N
related VBN N
, , N
but CC N
separate JJ N
, , N
outcomes RB N
. . N

At IN N
week NN N
24 CD N
, , N
the DT N
medication NN N
was VBD N
gradually RB N
withdrawn VBN N
to TO N
determine VB N
whether IN N
subjects NNS N
in IN N
the DT N
combined JJ N
treatment NN N
group NN N
could MD N
be VB N
managed VBN N
on IN N
a DT N
lower JJR N
dose NN N
or CC N
off IN N
medication NN N
without IN N
relapse NN N
. . N

Both DT N
symptom JJ N
reduction NN N
and CC N
functional JJ N
improvement NN N
are VBP N
important JJ N
clinical JJ N
treatment NN N
targets NNS N
. . N

Thus RB N
, , N
experimental JJ N
evidence NN N
on IN N
the DT N
beneficial JJ N
effects NNS N
of IN N
combining VBG N
pharmacotherapy NN 3_i
and CC N
exportable JJ 4_i
behavioral JJ 4_i
interventions NNS 4_i
is VBZ N
needed VBN N
to TO N
guide VB N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Efficacy NNP N
and CC N
safety NN N
of IN N
extended-release JJ N
niacin JJ 3_i
alone NN 3_i
or CC N
with IN N
atorvastatin NN 3_i
for IN N
lipid JJ N
profile JJ N
modification NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
extended-release JJ 3_i
niacin NN 3_i
( ( 3_i
niacin JJ 3_i
ER NNP 3_i
) ) 3_i
either CC N
alone RB N
or CC N
in IN N
combination NN N
with IN N
atorvastatin NN 3_i
for IN N
the DT N
lipid JJ N
profile NN N
modification NN N
in IN N
the DT N
patients NNS N
with IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
and CC N
its PRP$ N
equivalents NNS N
. . N

METHODS NNP N
One CD N
hundred CD N
and CC N
ten JJ N
patients NNS N
with IN N
CHD NNP N
and CC N
its PRP$ N
equivalents NNS N
with IN N
serum JJ N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
> VBD N
or CC N
= $ N
3.5 CD N
mmol/L NN N
were VBD N
randomly RB N
assigned VBN N
into IN N
three CD N
treatment NN N
groups NNS N
: : N
( ( N
1 CD N
) ) N
atorvastatin NN 3_i
group NN N
( ( N
n JJ N
= NNP N
38 CD N
) ) N
, , N
receiving VBG N
atorvastatin NN 3_i
10 CD N
mg/d NN N
for IN N
8 CD N
weeks NNS N
; : N
( ( N
2 CD N
) ) N
niacin NN 3_i
ER NNP 3_i
group NN N
( ( N
n JJ N
= NNP N
38 CD N
) ) N
, , N
given VBN N
niacin NNS 3_i
ER NNP 3_i
500 CD N
mg/d NN N
for IN N
4 CD N
weeks NNS N
and CC N
then RB N
1000 CD N
mg/d NN N
for IN N
4 CD N
weeks NNS N
; : N
( ( N
3 CD N
) ) N
combination NN 7_i
treatment NN 7_i
group NN N
( ( N
n JJ N
= NNP N
34 CD N
) ) N
, , N
treated VBN N
with IN N
atorvastatin NN 3_i
( ( 3_i
10 CD 3_i
mg/d NN 3_i
) ) 3_i
plus CC N
niacin JJ 3_i
ER NNP 3_i
, , N
with IN N
the DT N
dose JJ N
initiating NN N
from IN N
500 CD N
mg/d NN N
, , N
and CC N
increasing VBG N
to TO N
1000 CD N
mg/d NN N
after IN N
4 CD N
weeks NNS N
, , N
for IN N
8 CD N
weeks NNS N
. . N

The DT N
serums NNS N
lipid JJ N
profiles NNS N
and CC N
adverse JJ N
effects NNS N
were VBD N
assessed VBN N
in IN N
all PDT N
the DT N
patients NNS N
before IN N
treatment NN N
, , N
and CC N
4 CD N
and CC N
8 CD N
weeks NNS N
after IN N
treatment NN N
. . N

RESULTS NNP N
( ( N
1 CD N
) ) N
After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
serum JJ N
level NN N
of IN N
triglyceride NN N
( ( N
TG NNP N
) ) N
and CC N
high-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
were VBD N
reduced VBN N
by IN N
30 CD N
% NN N
and CC N
16 CD N
% NN N
respectively RB N
in IN N
the DT N
niacin JJ N
ER NNP N
group NN N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
8 CD N
weeks NNS N
, , N
the DT N
TC NNP N
, , N
low-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
, , N
and CC N
TG NNP N
in IN N
the DT N
atorvastatin NN N
group NN N
decreased VBN N
by IN N
19 CD N
% NN N
, , N
26 CD N
% NN N
, , N
and CC N
17 CD N
% NN N
respectively RB N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Combination NNP N
treatment NN N
decreased VBD N
the DT N
TC NNP N
, , N
LDL-C NNP N
, , N
and CC N
TG NNP N
levels NNS N
by IN N
28 CD N
% NN N
, , N
38 CD N
% NN N
, , N
and CC N
39 CD N
% NN N
respectively RB N
, , N
and CC N
increased VBD N
the DT N
HDL-C NNP N
level NN N
by IN N
23 CD N
% NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
improvement NN N
in IN N
TC NNP N
and CC N
LDL-C NNP N
achieved VBN N
by IN N
combination NN N
treatment NN N
was VBD N
superior JJ N
to TO N
treatment NN N
of IN N
atorvastatin NN N
alone RB N
and CC N
treatment NN N
of IN N
niacin JJ N
ER NNP N
alone RB N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

( ( N
2 CD N
) ) N
The DT N
rate NN N
of IN N
achieving VBG N
the DT N
LDL-C JJ N
goal NN N
of IN N
The DT N
National NNP N
Cholesterol NNP N
Education NNP N
Program NNP N
( ( N
NCEP NNP N
) ) N
in IN N
Adult NNP N
Treatment NNP N
Panel NNP N
III NNP N
( ( N
ATP NNP N
III NNP N
) ) N
in IN N
the DT N
combination NN N
therapy NN N
group NN N
was VBD N
73.5 CD N
% NN N
, , N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
the DT N
atorvastatin NN N
and CC N
niacin JJ N
groups NNS N
( ( N
47.7 CD N
% NN N
and CC N
42.1 CD N
% NN N
respectively RB N
, , N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

( ( N
3 CD N
) ) N
Adverse NNP N
effect NN N
, , N
such JJ N
as IN N
flushing NN N
( ( N
15.8 CD N
% NN N
) ) N
and CC N
gastrointestinal JJ N
symptoms NNS N
( ( N
23.7 CD N
% NN N
) ) N
were VBD N
found VBN N
in IN N
the DT N
niacin JJ N
ER NNP N
group NN N
, , N
however RB N
, , N
no DT N
more JJR N
adverse JJ N
effects NNS N
were VBD N
found VBN N
in IN N
the DT N
combination NN N
therapy NN N
group NN N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ N
events NNS N
in IN N
all DT N
groups NNS N
. . N

CONCLUSION NNP N
Niacin NNP N
ER NNP N
has VBZ N
a DT N
favorable JJ N
effect NN N
in IN N
modulating VBG N
the DT N
blood NN N
lipid JJ N
profile NN N
, , N
especially RB N
in IN N
reducing VBG N
TG NNP N
and CC N
elevating VBG N
HDL-C NNP N
. . N

Combined VBN N
statin NN N
with IN N
niacin NN N
may MD N
produce VB N
a DT N
more JJR N
global JJ N
and CC N
effective JJ N
improvement NN N
in IN N
lipid JJ N
blood NN N
levels NNS N
than IN N
monotherapy NN N
and CC N
is VBZ N
generally RB N
safe JJ N
and CC N
well RB N
tolerable JJ N
. . N

-DOCSTART- -X- O O

Pruritus NN N
in IN N
HIV-1 NNP N
disease NN N
: : N
therapy NN N
with IN N
drugs NNS N
which WDT N
may MD N
modulate VB N
the DT N
pattern NN N
of IN N
immune JJ N
dysregulation NN N
. . N

BACKGROUND NNP N
Pruritus NNP N
in IN N
HIV-1+ NNP N
patients NNS N
is VBZ N
common JJ N
and CC N
increases VBZ N
with IN N
disease NN N
progression NN N
. . N

The DT N
causes NNS N
of IN N
pruritus NN N
are VBP N
numerous JJ N
including VBG N
xerosis NN N
, , N
drug NN N
and CC N
photoeruptions NNS N
, , N
follicular JJ N
and CC N
papular JJ N
eruptions NNS N
as RB N
well RB N
as IN N
infestations NNS N
and CC N
infections NNS N
by IN N
a DT N
wide JJ N
range NN N
of IN N
organisms NNS N
. . N

One CD N
other JJ N
possible JJ N
factor NN N
contributing VBG N
to TO N
pruritus VB N
is VBZ N
the DT N
pattern NN N
of IN N
immune JJ N
dysregulation NN N
. . N

With IN N
advancing VBG N
HIV-1 JJ N
disease NN N
there EX N
is VBZ N
Th1 NNP N
to TO N
Th2 NNP N
cytokine NN N
switching VBG N
. . N

METHODS NNP N
After IN N
some DT N
positive JJ N
results NNS N
with IN N
prostaglandin JJ N
inhibitors NNS N
, , N
we PRP N
undertook VBP N
a DT N
study NN N
in IN N
which WDT N
we PRP N
randomly VBP N
placed VBN N
patients NNS N
on IN N
four CD N
different JJ N
forms NNS N
of IN N
therapy NN N
for IN N
their PRP$ N
pruritus NN N
. . N

The DT N
therapies NNS N
included VBD N
hydroxyzine NN 3_i
with IN 3_i
or CC 3_i
without IN 3_i
doxepin NN 3_i
at IN 3_i
night NN 3_i
, , N
pentoxifylline NN 3_i
, , N
indomethacin NN 3_i
and CC 3_i
topical JJ 3_i
moisturization NN 3_i
with IN 3_i
medium-strength JJ 3_i
topical JJ 3_i
steroids NNS 3_i
. . N

All DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
both DT N
subjective JJ N
relief NN N
as RB N
well RB N
as IN N
side NN N
effects NNS N
. . N

RESULTS NNP N
Patients NNPS N
placed VBD N
on IN N
indomethacin NN N
obtained VBN N
relief NN N
more RBR N
consistently RB N
and CC N
more RBR N
completely RB N
. . N

Patients NNS N
on IN N
pentoxifylline NN N
had VBD N
the DT N
fewest JJS N
side NN N
effects NNS N
of IN N
all DT N
oral JJ N
therapies NNS N
. . N

Patients NNS N
on IN N
antihistamines NNS N
with IN N
or CC N
without IN N
doxepin NN N
had VBD N
the DT N
highest JJS N
incidence NN N
of IN N
side NN N
effects NNS N
, , N
although IN N
more JJR N
of IN N
these DT N
patients NNS N
reported VBD N
a DT N
greater JJR N
degree NN N
of IN N
relief NN N
than IN N
patients NNS N
on IN N
pentoxifylline NN N
. . N

All DT N
patients NNS N
on IN N
oral JJ N
therapy NN N
overall NN N
had VBD N
greater JJR N
relief NN N
than IN N
patients NNS N
using VBG N
topical JJ N
steroids NNS N
. . N

CONCLUSION VB N
The DT N
systemic JJ N
therapies NNS N
which WDT N
may MD N
modulate VB N
the DT N
pattern NN N
of IN N
immune JJ N
dysregulation NN N
seen VBN N
in IN N
HIV-1 NNP N
disease NN N
may MD N
be VB N
beneficial JJ N
in IN N
the DT N
pruritus NN N
seen VBN N
in IN N
late-stage JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Behavioral JJ N
changes NNS N
in IN N
autistic JJ N
individuals NNS N
as IN N
a DT N
result NN N
of IN N
wearing VBG N
ambient JJ 2_i
transitional JJ 2_i
prism NN 2_i
lenses NNS 2_i
. . 4_i

A DT N
double-blind JJ N
crossover NN N
design NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
wearing VBG 2_i
ambient JJ 2_i
lenses NNS 2_i
to TO N
reduce VB N
the DT N
behavioral JJ N
symptoms NNS N
of IN N
autism NN N
. . N

Eighteen NNP N
autistic JJ N
individuals NNS N
, , N
ranging VBG N
in IN N
age NN N
from IN N
7 CD N
to TO N
18 CD N
years NNS N
, , N
participated VBD N
in IN N
the DT N
study NN N
. . N

Behavior NNP N
, , N
attention NN N
, , N
and CC N
orientation NN N
were VBD N
evaluated VBN N
at IN N
1 CD N
1/2 CD N
months NNS N
, , N
2 CD N
months NNS N
, , N
3 CD N
months NNS N
, , N
and CC N
4 CD N
months NNS N
. . N

Compared VBN N
to TO N
the DT N
placebo NN 7_i
condition NN N
, , N
the DT N
results NNS N
showed VBD N
a DT N
decrease NN N
in IN N
behavior JJ N
problems NNS N
at IN N
the DT N
1 CD N
1/2 CD N
and CC N
2 CD N
month NN N
assessment NN N
periods NNS N
and CC N
a DT N
slight JJ N
loss NN N
of IN N
these DT N
benefits NNS N
at IN N
the DT N
3 CD N
and CC N
4 CD N
month NN N
assessment NN N
periods NNS N
. . N

These DT N
findings NNS N
support VBP N
the DT N
prediction NN N
that WDT N
ambient JJ 2_i
lenses NNS 2_i
, , N
worn VBN N
without IN N
engaging VBG N
in IN N
visual-motor NN N
exercises NNS N
, , N
have VBP N
positive JJ N
effects NNS N
on IN N
autistic JJ N
individuals NNS N
. . N

-DOCSTART- -X- O O

Ambient JJ N
temperature NN N
and CC N
biomarkers NNS N
of IN N
heart NN N
failure NN N
: : N
a DT N
repeated JJ N
measures NNS N
analysis NN N
. . N

BACKGROUND NNP N
Extreme NNP N
temperatures NNS N
have VBP N
been VBN N
associated VBN N
with IN N
hospitalization NN N
and CC N
death NN N
among IN N
individuals NNS N
with IN N
heart NN N
failure NN N
, , N
but CC N
few JJ N
studies NNS N
have VBP N
explored VBN N
the DT N
underlying JJ N
mechanisms NN N
. . N

OBJECTIVES IN N
We PRP N
hypothesized VBD N
that IN N
outdoor JJ N
temperature NN N
in IN N
the DT N
Boston NNP N
, , N
Massachusetts NNP N
, , N
area NN N
( ( N
1- JJ N
to TO N
4-day JJ N
moving NN N
averages NNS N
) ) N
would MD N
be VB N
associated VBN N
with IN N
higher JJR N
levels NNS N
of IN N
biomarkers NNS N
of IN N
inflammation NN N
and CC N
myocyte JJ N
injury NN N
in IN N
a DT N
repeated-measures JJ N
study NN N
of IN N
individuals NNS N
with IN N
stable JJ N
heart NN N
failure NN N
. . N

METHODS NNP N
We PRP N
analyzed VBD N
data NNS N
from IN N
a DT N
completed VBN N
clinical JJ N
trial NN N
that WDT N
randomized VBD N
100 CD N
patients NNS N
to TO N
12 CD 4_i
weeks NNS 4_i
of IN 4_i
tai NN 4_i
chi NN 4_i
classes NNS 4_i
or CC 4_i
to TO 4_i
time-matched JJ 7_i
education NN 7_i
control NN 7_i
. . 4_i

B-type NNP N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
, , N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
and CC N
tumor NN N
necrosis NN N
factor NN N
( ( N
TNF NNP N
) ) N
were VBD N
measured VBN N
at IN N
baseline NN N
, , N
6 CD N
weeks NNS N
, , N
and CC N
12 CD N
weeks NNS N
. . N

Endothelin-1 NNP N
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
12 CD N
weeks NNS N
. . N

We PRP N
used VBD N
fixed VBN N
effects NNS N
models NNS N
to TO N
evaluate VB N
associations NNS N
with IN N
measures NNS N
of IN N
temperature NN N
that WDT N
were VBD N
adjusted VBN N
for IN N
time-varying JJ N
covariates NNS N
. . N

RESULTS NNP N
Higher NNP N
apparent JJ N
temperature NN N
was VBD N
associated VBN N
with IN N
higher JJR N
levels NNS N
of IN N
BNP NNP N
beginning VBG N
with IN N
2-day JJ N
moving VBG N
averages NNS N
and CC N
reached VBD N
statistical JJ N
significance NN N
for IN N
3- JJ N
and CC N
4-day JJ N
moving NN N
averages NNS N
. . N

CRP NNP N
results NNS N
followed VBD N
a DT N
similar JJ N
pattern NN N
but CC N
were VBD N
delayed VBN N
by IN N
1 CD N
day NN N
. . N

A DT N
5?C CD N
change NN N
in IN N
3- JJ N
and CC N
4-day JJ N
moving NN N
averages NNS N
of IN N
apparent JJ N
temperature NN N
was VBD N
associated VBN N
with IN N
11.3 CD N
% NN N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
1.1 CD N
, , N
22.5 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
and CC N
11.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.2 CD N
, , N
22.5 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
higher JJR N
BNP NNP N
. . N

A DT N
5?C CD N
change NN N
in IN N
the DT N
4-day JJ N
moving JJ N
average NN N
of IN N
apparent JJ N
temperature NN N
was VBD N
associated VBN N
with IN N
21.6 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
2.5 CD N
, , N
44.2 CD N
; : N
p NN N
= VBZ N
0.03 CD N
) ) N
higher JJR N
CRP NNP N
. . N

No DT N
clear JJ N
associations NNS N
with IN N
TNF NNP N
or CC N
endothelin-1 JJ N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Among IN N
patients NNS N
undergoing VBG N
treatment NN N
for IN N
heart NN N
failure NN N
, , N
we PRP N
observed VBD N
positive JJ N
associations NNS N
between IN N
temperature NN N
and CC N
both DT N
BNP NNP N
and CC N
CRP-predictors NNS N
of IN N
heart NN N
failure NN N
prognosis NN N
and CC N
severity NN N
. . N

-DOCSTART- -X- O O

A DT N
randomised VBN N
, , N
controlled VBD N
study NN N
of IN N
dietary JJ N
intervention NN N
in IN N
autistic JJ N
syndromes NNS N
. . N

Impaired NNP N
social JJ N
interaction NN N
, , N
communication NN N
and CC N
imaginative JJ N
skills NNS N
characterize VBP N
autistic JJ N
syndromes NNS N
. . N

In IN N
these DT N
syndromes NNS N
urinary JJ N
peptide NN N
abnormalities NNS N
, , N
derived VBN N
from IN N
gluten NN N
, , N
gliadin NN N
, , N
and CC N
casein NN N
, , N
are VBP N
reported VBN N
. . N

They PRP N
reflect VBP N
processes NNS N
with IN N
opioid JJ N
effect NN N
. . N

The DT N
aim NN N
of IN N
this DT N
single JJ N
blind NN N
study NN N
was VBD N
to TO N
evaluate VB N
effect NN N
of IN N
gluten NN N
and CC N
casein-free JJ N
diet NN N
for IN N
children NNS N
with IN N
autistic JJ N
syndromes NNS N
and CC N
urinary JJ N
peptide NN N
abnormalities NNS N
. . N

A DT N
randomly RB N
selected VBN N
diet JJ N
and CC N
control NN N
group NN N
with IN N
10 CD N
children NNS N
in IN N
each DT N
group NN N
participated VBD N
. . N

Observations NNS N
and CC N
tests NNS N
were VBD N
done VBN N
before RB N
and CC N
after IN N
a DT N
period NN N
of IN N
1 CD N
year NN N
. . N

The DT N
development NN N
for IN N
the DT N
group NN N
of IN N
children NNS N
on IN N
diet NN N
was VBD N
significantly RB N
better JJR N
than IN N
for IN N
the DT N
controls NNS 7_i
. . 7_i

-DOCSTART- -X- O O

Osteopontin NNP 3_i
is VBZ N
a DT N
prognostic JJ N
factor NN N
for IN N
survival NN N
of IN N
acute JJ N
myeloid JJ N
leukemia NN N
patients NNS N
. . N

Osteopontin NNP 3_i
( ( N
OPN NNP N
) ) N
is VBZ N
a DT N
glycoprotein NN N
that WDT N
is VBZ N
secreted VBN N
by IN N
osteoblasts NNS N
and CC N
hematopoietic JJ N
cells NNS N
. . N

OPN NNP 3_i
suppresses VBZ N
the DT N
proliferation NN N
of IN N
hematopoietic JJ N
stem NN N
cells NNS N
in IN N
vitro NN N
and CC N
may MD N
regulate VB N
the DT N
hematopoietic JJ N
stem NN N
cell NN N
pool NN N
. . N

Increased VBN N
serum NN N
OPN NNP N
concentrations NNS N
occur VBP N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
, , N
multiple JJ N
myeloma NN N
, , N
and CC N
acute JJ N
myeloid NN N
leukemia NN N
( ( N
AML NNP N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
analyzed VBD N
the DT N
prognostic JJ N
impact NN N
of IN N
OPN NNP N
in IN N
AML NNP N
by IN N
investigating VBG N
the DT N
expression NN N
and CC N
relevance NN N
of IN N
OPN NNP 3_i
in IN N
newly RB N
diagnosed VBN N
AML NNP N
patients NNS N
from IN N
2 CD N
large JJ N
study NN N
groups NNS N
( ( N
the DT N
German JJ N
AML NNP N
Cooperative NNP N
Group NNP N
and CC N
the DT N
Dutch-Belgian JJ N
Hematology NNP N
Oncology NNP N
Cooperative NNP N
group NN N
) ) N
. . N

IHC NNP N
( ( N
n JJ N
= NNP N
84 CD N
) ) N
, , N
ELISAs NNP N
of IN N
blood/BM NN N
sera NN N
( ( N
n JJ N
= NNP N
41 CD N
) ) N
, , N
and CC N
microarray NN 3_i
data NNS 3_i
for IN 3_i
mRNA NN 3_i
levels NNS 3_i
( ( N
n JJ N
= NNP N
261 CD N
) ) N
were VBD N
performed VBN N
. . N

Expression NN N
of IN N
OPN NNP 3_i
protein NN N
was VBD N
increased VBN N
in IN N
AML NNP N
patients NNS N
both DT N
in IN N
BM NNP N
blasts NNS N
( ( N
IHC NNP N
) ) N
and CC N
in IN N
BM NNP N
serum NN N
( ( N
ELISA NNP N
) ) N
compared VBN N
with IN N
healthy JJ N
controls NNS N
. . N

Patients NNS N
expressing VBG N
high JJ N
levels NNS N
of IN N
OPN NNP N
within IN N
the DT N
BM NNP N
( ( N
IHC NNP N
) ) N
experienced VBD N
shortened VBN N
overall JJ N
survival NN N
( ( N
OS NNP N
; : N
P NNP N
= NNP N
.025 NNP N
) ) N
. . N

Multivariate NNP N
analysis NN N
identified VBD N
karyotype NN N
, , N
blast JJ N
clearance NN N
( ( N
day NN N
16 CD N
) ) N
, , N
and CC N
the DT N
level NN N
of IN N
OPN NNP N
expression NN N
as IN N
independent JJ N
prognostic JJ N
factors NNS N
for IN N
OS NNP N
. . N

This DT N
prompted VBD N
us PRP N
to TO N
analyze VB N
microarray NN N
data NNS N
from IN N
261 CD N
patients NNS N
from IN N
a DT N
third JJ N
cohort NN N
. . N

The DT N
analysis NN N
confirmed VBD N
OPN NNP N
as IN N
a DT N
prognostic JJ N
marker NN N
. . N

In IN N
summary JJ N
, , N
high JJ N
OPN NNP 3_i
mRNA NN N
expression NN N
indicated VBD N
decreased JJ N
event-free JJ N
survival NN N
( ( N
P NNP N
= NNP N
.0002 NNP N
) ) N
and CC N
OS NNP N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

The DT N
prognostic JJ N
role NN N
of IN N
OPN NNP N
was VBD N
most RBS N
prominent JJ N
in IN N
intermediate-risk JJ N
AML NNP N
. . N

These DT N
data NNS N
provide VBP N
evidence NN N
that IN N
OPN NNP N
expression NN N
is VBZ N
an DT N
independent JJ N
prognostic JJ N
factor NN N
in IN N
AML NNP N
. . N

-DOCSTART- -X- O O

Final JJ N
analysis NN N
of IN N
the DT N
UKLG NNP N
LY02 NNP N
trial NN N
comparing VBG N
6-8 JJ N
cycles NNS N
of IN N
CHOP NNP 3_i
with IN N
3 CD N
cycles NNS N
of IN N
CHOP NNP 3_i
followed VBN N
by IN N
a DT N
BEAM NNP 3_i
autograft NN 3_i
in IN N
patients NNS N
< JJ N
65 CD N
years NNS N
with IN N
poor JJ N
prognosis NN N
histologically RB N
aggressive JJ N
NHL NNP N
. . N

This DT N
trial NN N
involved VBD N
457 CD N
patients NNS N
and CC N
sought VBD N
to TO N
assess VB N
the DT N
value NN N
of IN N
early JJ N
intensification NN N
with IN N
autologous JJ N
transplantation NN N
in IN N
patients NNS N
with IN N
poor JJ N
prognosis NN N
histologically RB N
aggressive JJ N
non-Hodgkin JJ N
lymphoma NN N
( ( N
NHL NNP N
) ) N
showing VBG N
a DT N
response NN N
to TO N
initial JJ N
CHOP NNP 3_i
( ( 3_i
cyclophosphamide NN 3_i
, , 3_i
doxorubicin NN 3_i
, , 3_i
vincristine NN 3_i
, , 3_i
prednisolone NN 3_i
) ) 3_i
chemotherapy NN 3_i
. . N

Randomization NN N
was VBD N
made VBN N
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
with IN N
223 CD N
assigned VBD N
to TO N
continuing VBG N
CHOP NNP 3_i
and CC N
234 CD N
to TO N
3 CD N
cycles NNS N
of IN N
CHOP NNP 3_i
followed VBN N
by IN N
a DT N
BEAM NNP 3_i
( ( 3_i
carmustine NN 3_i
, , 3_i
etoposide RB 3_i
, , 3_i
cytarabine NN 3_i
, , 3_i
melphalan NN 3_i
) ) 3_i
autograft NN 3_i
. . N

Analysis NN N
was VBD N
on IN N
an DT N
intention NN N
to TO N
treat VB N
basis NN N
. . N

After IN N
the DT N
initial JJ N
three CD N
cycles NNS N
of IN N
CHOP NNP 3_i
19 CD N
% NN N
of IN N
the DT N
whole JJ N
group NN N
were VBD N
in IN N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
and CC N
53 CD N
% NN N
in IN N
partial JJ N
remission NN N
( ( N
PR NNP N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
treatment NN N
86 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
CHOP NNP 3_i
arm NN N
had VBD N
responded VBN N
with IN N
58 CD N
% NN N
in IN N
CR NNP N
. . N

In IN N
the DT N
high-dose JJ N
therapy NN N
arm NN N
the DT N
overall JJ N
response NN N
rate NN N
was VBD N
83 CD N
% NN N
with IN N
64 CD N
% NN N
in IN N
CR NNP N
( ( N
difference NN N
between IN N
arms NNS N
not RB N
significant JJ N
) ) N
. . N

The DT N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
and CC N
overall JJ N
survival NN N
at IN N
5 CD N
years NNS N
for IN N
the DT N
continuing VBG N
CHOP NNP N
arm NN N
were VBD N
38 CD N
% NN N
and CC N
50 CD N
% NN N
respectively RB N
, , N
and CC N
for IN N
the DT N
autograft NN N
arm NN N
were VBD N
44 CD N
% NN N
and CC N
50 CD N
% NN N
( ( N
differences NNS N
not RB N
significant JJ N
) ) N
. . N

Of IN N
the DT N
patients NNS N
who WP N
attained VBD N
CR NNP N
and CC N
subsequently RB N
relapsed VBN N
, , N
there EX N
were VBD N
no DT N
long-term JJ N
survivors NNS N
in IN N
the DT N
autograft NN N
recipients NNS N
compared VBN N
to TO N
46 CD N
% NN N
of IN N
the DT N
continuing VBG N
CHOP NNP 3_i
recipients NNS N
( ( N
P NNP N
= NNP N
0.0008 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
no DT N
survival JJ N
benefit NN N
was VBD N
demonstrated VBN N
for IN N
an DT N
early JJ N
autograft NN N
in IN N
first JJ N
response NN N
. . N

-DOCSTART- -X- O O

Blind NNP 1_i
versus NN 1_i
open JJ 1_i
approach NN 1_i
to TO 1_i
laparoscopic VB 1_i
cholecystectomy NN 1_i
: : 1_i
a DT N
randomized JJ N
study NN N
. . N

Intraabdominal NNP N
structures NNS N
may MD N
be VB N
damaged VBN N
during IN N
blind JJ N
introduction NN N
of IN N
the DT N
first JJ N
trocar NN N
for IN N
laparoscopic JJ 1_i
operations NNS N
. . N

In IN N
this DT N
study NN N
, , N
150 CD N
patients NNS N
with IN N
gallbladder JJ N
lithiasis NN N
who WP N
underwent JJ N
laparoscopy NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
, , N
a DT N
blind NN N
( ( N
V NNP N
group NN N
) ) N
or CC N
an DT N
open JJ N
( ( N
H NNP N
group NN N
) ) N
, , N
in IN N
order NN N
to TO N
compare VB N
the DT N
results NNS N
and CC N
the DT N
rate NN N
of IN N
complications NNS N
. . N

No DT N
mortality NN N
was VBD N
observed VBN N
. . N

Major JJ N
complications NNS N
occurred VBD N
in IN N
3/75 CD N
( ( N
4 CD N
% NN N
) ) N
patients NNS N
of IN N
the DT N
V NNP N
group NN N
and CC N
in IN N
1/75 CD N
( ( N
1.3 CD N
% NN N
) ) N
patient NN N
of IN N
the DT N
H NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Minor JJ N
complications NNS N
occurred VBD N
in IN N
5/75 CD N
( ( N
6.7 CD N
% NN N
) ) N
patients NNS N
of IN N
either DT N
group NN N
. . N

The DT N
achievement NN N
of IN N
pneumoperitoneum NN N
required VBN N
4.5+/-0.4 JJ N
min NN N
in IN N
the DT N
V NNP N
group NN N
and CC N
3.2+/-0.2 JJ N
min NN N
in IN N
the DT N
H NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
open JJ 1_i
laparoscopic NN 1_i
technique NN 1_i
is VBZ N
safer JJR N
and CC N
faster RBR N
than IN N
the DT N
blind JJ 2_i
approach NN 2_i
; : N
therefore RB N
, , N
it PRP N
is VBZ N
proposed VBN N
that IN N
this DT N
approach NN N
be VB N
routinely RB N
used VBN N
in IN N
all DT N
laparoscopic NN N
procedures NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
supplementary JJ 3_i
antioxidant JJ 3_i
vitamin NNS 3_i
intake VBP N
on IN N
carotid NNS N
arterial JJ N
wall JJ N
intima-media JJ N
thickness NN N
in IN N
a DT N
controlled JJ N
clinical JJ N
trial NN N
of IN N
cholesterol NN N
lowering VBG N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
accumulating VBG N
experimental JJ N
, , N
epidemiological JJ N
, , N
and CC N
clinical JJ N
evidence NN N
of IN N
an DT N
association NN N
between IN N
anti-oxidant JJ 3_i
vitamin NNS 3_i
intake NN N
and CC N
reduced JJ N
risk NN N
of IN N
coronary JJ N
heart NN N
disease NN N
. . N

Using VBG N
data NNS N
from IN N
the DT N
Cholesterol NNP N
Lowering NNP N
Atherosclerosis NNP N
Study NNP N
( ( N
CLAS NNP N
) ) N
, , N
we PRP N
explored VBD N
the DT N
association NN N
of IN N
self-selected JJ N
supplementary JJ N
antioxidant NN 3_i
vitamin NNS 3_i
intake VBP N
on IN N
the DT N
rate NN N
of IN N
progression NN N
of IN N
early JJ N
preintrusive JJ N
atherosclerosis NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
CLAS NNP N
was VBD N
an DT N
arterial JJ N
imaging NN N
trial NN N
in IN N
which WDT N
nonsmoking VBG N
40- JJ N
to TO N
59-year-old JJ N
men NNS N
with IN N
previous JJ N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
were VBD N
randomized VBN N
to TO N
colestipol/niacin VB 3_i
plus JJ N
diet JJ N
or CC N
placebo JJ 7_i
plus CC 7_i
diet JJ 7_i
. . 7_i

The DT N
rate NN N
of IN N
progression NN N
of IN N
early JJ N
preintrusive JJ N
atherosclerosis NN N
was VBD N
determined VBN N
in IN N
146 CD N
subjects NNS N
using VBG N
high-resolution JJ N
B-mode NNP N
ultrasound JJ N
quantification NN N
of IN N
the DT N
distal JJ N
common JJ N
carotid NN N
artery NN N
far RB N
wall JJ N
intima-media JJ N
thickness NN N
( ( N
IMT NNP N
) ) N
. . N

From IN N
the DT N
nutritional JJ N
supplement NN N
database NN N
, , N
22 CD N
subjects NNS N
had VBD N
an DT N
on-trial JJ N
average JJ N
supplementary JJ N
vitamin NN 3_i
E NNP 3_i
intake NN N
of IN N
> NN N
or CC N
= $ N
100 CD N
IU NNP N
per IN N
day NN N
( ( N
high JJ N
users NNS N
) ) N
and CC N
29 CD N
subjects NNS N
had VBD N
an DT N
average JJ N
on-trial JJ N
supplementary JJ N
vitamin NN 3_i
C NNP 3_i
intake NN N
of IN N
> NN N
or CC N
= $ N
250 CD N
mg JJ N
per IN N
day NN N
( ( N
high JJ N
users NNS N
) ) N
. . N

Within IN N
the DT N
placebo NN 7_i
group NN N
, , N
less JJR N
carotid JJ N
IMT NNP N
progression NN N
was VBD N
found VBN N
for IN N
high JJ N
supplementary JJ N
vitamin NN 3_i
E NNP 3_i
users NNS N
when WRB N
compared VBN N
with IN N
low JJ N
vitamin NNS 3_i
E NN 3_i
users NNS N
( ( N
0.008 CD N
versus NN N
0.023 CD N
mm/y NN N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

No DT N
effect NN N
of IN N
vitamin NN 3_i
E NNP 3_i
within IN N
the DT N
drug NN N
group NN N
was VBD N
found VBN N
. . N

No DT N
effect NN N
of IN N
vitamin NN 3_i
C NNP 3_i
within IN N
the DT N
drug NN N
or CC N
placebo NN 7_i
group NN N
was VBD N
found VBN N
. . N

CONCLUSIONS NNP N
Supplementary NNP 3_i
vitamin NN 3_i
E NNP 3_i
intake NN N
appears VBZ N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
the DT N
progression NN N
of IN N
atherosclerosis NN N
in IN N
subjects NNS N
not RB N
treated VBN N
with IN N
lipid-lowering JJ 3_i
drugs NNS 3_i
while IN N
the DT N
process NN N
is VBZ N
still RB N
confined VBN N
to TO N
the DT N
arterial JJ N
wall NN N
( ( N
early JJ N
preintrusive JJ N
atherosclerosis NN N
) ) N
. . N

-DOCSTART- -X- O O

Value NNP N
of IN N
an DT N
anal JJ 2_i
dilator NN 2_i
after IN N
anal JJ N
stretch NN N
for IN N
haemorrhoids NNS N
. . N

A DT N
prospective JJ N
randomized VBN N
trial NN N
compared VBN N
anal JJ 2_i
stretch NN 2_i
with IN N
or CC N
without IN N
continued JJ 2_i
dilatation NN 2_i
for IN N
three CD N
months NNS N
in IN N
89 CD N
consecutive JJ N
patients NNS N
with IN N
haemorrhoids NNS N
. . N

Complications NNS N
of IN N
therapy NN N
occurred VBD N
in IN N
only RB N
4 CD N
patients NNS N
, , N
3 CD N
of IN N
whom WP N
had VBD N
transient JJ N
incontinence NN N
of IN N
flatus NN N
. . N

When WRB N
patients NNS N
were VBD N
reviewed VBN N
four CD N
months NNS N
after IN N
treatment NN N
, , N
only RB N
4 CD N
of IN N
44 CD N
patients NNS N
( ( N
9 CD N
% NN N
) ) N
who WP N
used VBD N
a DT N
dilator NN N
had VBD N
not RB N
been VBN N
improved VBN N
and CC N
required VBN N
additional JJ N
therapy NN N
, , N
compared VBN N
with IN N
15 CD N
of IN N
42 CD N
patients NNS N
( ( N
36 CD N
% NN N
) ) N
who WP N
had VBD N
anal JJ 2_i
stretch NN 2_i
alone RB N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
use NN N
of IN N
an DT N
anal JJ N
dilator NN N
improves VBZ N
the DT N
results NNS N
of IN N
anal JJ 2_i
stretch NN 2_i
. . N

-DOCSTART- -X- O O

A DT N
communication-based JJ 5_i
intervention NN 5_i
for IN N
nonverbal JJ N
children NNS N
with IN N
autism NN N
: : N
what WP N
changes NNS N
? . N
Who WP N
benefits NNS N
? . N
OBJECTIVE IN N
This DT N
article NN N
examines VBZ N
the DT N
form NN N
and CC N
function NN N
of IN N
spontaneous JJ N
communication NN N
and CC N
outcome NN N
predictors NNS N
in IN N
nonverbal JJ N
children NNS N
with IN N
autism NN N
following VBG N
classroom-based JJ 5_i
intervention NN 5_i
( ( 5_i
Picture NNP 5_i
Exchange NNP 5_i
Communication NNP 5_i
System NNP 5_i
[ NNP 5_i
PECS NNP 5_i
] NNP 5_i
training NN 5_i
) ) 5_i
. . N

METHOD $ N
84 CD N
children NNS N
from IN N
15 CD N
schools NNS N
participated VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
of IN N
PECS NNP N
( ( N
P. NNP N
Howlin NNP N
, , N
R. NNP N
K. NNP N
Gordon NNP N
, , N
G. NNP N
Pasco NNP N
, , N
A NNP N
. . N

Wade NNP N
, , N
& CC N
T. NNP N
Charman NNP N
, , N
2007 CD N
) ) N
. . N

They PRP N
were VBD N
aged VBN N
4-10 JJ N
years NNS N
( ( N
73 CD N
boys NNS N
) ) N
. . N

Primary JJ N
outcome JJ N
measure NN N
was VBD N
naturalistic JJ N
observation NN N
of IN N
communication NN N
in IN N
the DT N
classroom NN N
. . N

Multilevel NNP N
Poisson NNP N
regression NN N
was VBD N
used VBN N
to TO N
test VB N
for IN N
intervention NN N
effects NNS N
and CC N
outcome JJ N
predictors NNS N
. . N

RESULTS NNP N
Spontaneous JJ N
communication NN N
using VBG N
picture NN N
cards NNS N
, , N
speech NN N
, , N
or CC N
both DT N
increased VBN N
significantly RB N
following VBG N
training NN N
( ( N
rate NN N
ratio NN N
[ NNP N
RR NNP N
] NNP N
=1.90 NNP N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.46 CD N
, , N
2.48 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
; : N
RR NNP N
= VBZ N
1.77 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.35 CD N
, , N
2.32 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
; : N
RR NNP N
= VBZ N
3.74 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
2.19 CD N
, , N
6.37 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
. . N

Spontaneous JJ N
communication NN N
to TO N
request VB N
objects NNS N
significantly RB N
increased VBD N
( ( N
RR NNP N
= NNP N
2.17 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.75 CD N
, , N
2.68 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
) ) N
, , N
but CC N
spontaneous JJ N
requesting NN N
for IN N
social JJ N
purposes NNS N
did VBD N
not RB N
( ( N
RR NNP N
= NNP N
1.34 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.83 CD N
, , N
2.18 CD N
] NN N
, , N
p NN N
= NNP N
.237 NNP N
) ) N
. . N

Only RB N
the DT N
effect NN N
on IN N
spontaneous JJ N
speech NN N
persisted VBN N
by IN N
follow-up NN N
( ( N
9 CD N
months NNS N
later RB N
) ) N
. . N

Less CC N
severe JJ N
baseline NN N
autism NN N
symptomatology NN N
( ( N
lower JJR N
Autism NNP N
Diagnosis NNP N
Observation NNP N
Schedule NNP N
[ NNP N
ADOS NNP N
] NNP N
score NN N
; : N
C. NNP N
Lord NNP N
et VBZ N
al. RB N
, , N
2000 CD N
) ) N
was VBD N
associated VBN N
with IN N
greater JJR N
increase NN N
in IN N
spontaneous JJ N
speech NN N
( ( N
RR NNP N
= NNP N
0.90 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.83 CD N
, , N
0.98 CD N
] NN N
, , N
p NN N
= NNP N
.011 NNP N
) ) N
and CC N
less RBR N
severe JJ N
baseline NN N
expressive JJ N
language NN N
impairment NN N
( ( N
lower JJR N
ADOS NNP N
item NN N
A1 NNP N
score NN N
) ) N
, , N
with IN N
larger JJR N
increases NNS N
in IN N
spontaneous JJ N
use NN N
of IN N
speech NN N
and CC N
pictures VBZ N
together RB N
( ( N
RR NNP N
= NNP N
0.62 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.44 CD N
, , N
0.88 CD N
] NN N
, , N
p NN N
= NNP N
.008 NNP N
) ) N
. . N

CONCLUSION NNP N
Overall NNP N
, , N
PECS NNP N
appeared VBD N
to TO N
enhance VB N
children NNS N
's POS N
spontaneous JJ N
communication NN N
for IN N
instrumental JJ N
requesting VBG N
using VBG N
pictures NNS N
, , N
speech NN N
, , N
or CC N
a DT N
combination NN N
of IN N
both DT N
. . N

Some DT N
effects NNS N
of IN N
training NN N
were VBD N
moderated VBN N
by IN N
baseline NN N
factors NNS N
. . N

For IN N
example NN N
, , N
PECS NNP 5_i
appears VBZ N
to TO N
have VB N
increased VBN N
spontaneous JJ N
speech NN N
in IN N
children NNS N
who WP N
could MD N
talk VB N
a DT N
little JJ N
at IN N
baseline NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Acute NNP N
cardiovascular NN N
and CC N
metabolic JJ N
changes NNS N
in IN N
interval NN N
and CC N
endurance NN 2_i
training NN 2_i
in IN N
selected VBN N
patients NNS N
following VBG N
aortocoronary JJ N
bypass NN N
operation NN N
] NNP N
. . N

UNLABELLED VB N
This DT N
study NN N
compared VBN N
the DT N
acute NN N
changes NNS N
of IN N
cardiovascular NN N
and CC N
metabolic JJ N
reactions NNS N
during IN N
interval NN 2_i
and CC 2_i
continuous JJ 2_i
training NN 2_i
after IN N
coronary JJ N
bypass NN N
surgery NN N
. . N

Two CD N
groups NNS N
of IN N
9 CD N
male JJ N
patients NNS N
( ( N
age NN N
: : N
59 CD N
+/- JJ N
4 CD N
and CC N
56 CD N
+/- JJ N
6 CD N
years NNS N
, , N
resp NN N
. . N

) ) N
each DT 2_i
trained VBN 2_i
on IN 2_i
bicycle NN 2_i
ergometer JJ 2_i
start NN 2_i
on IN 2_i
post-operative JJ 2_i
days NNS 2_i
24 CD 2_i
and CC 2_i
26 CD 2_i
, , 2_i
resp NN 2_i
. . N

In IN N
both DT N
training NN N
groups NNS N
training VBG N
heart NN N
rate NN N
was VBD N
set VBN N
at IN N
86 CD N
% NN N
of IN N
individual JJ N
maximum JJ N
heart NN N
rate NN N
. . N

In IN 2_i
the DT 2_i
last JJ 2_i
week NN 2_i
of IN 2_i
training VBG 2_i
the DT 2_i
exercise NN 2_i
intensity NN 2_i
in IN 2_i
the DT 2_i
group NN 2_i
of IN 2_i
patients NNS 2_i
who WP 2_i
were VBD 2_i
trained VBN 2_i
by IN 2_i
the DT 2_i
continuous JJ 2_i
method NN 2_i
was VBD 2_i
at IN 2_i
83 CD 2_i
watts NN 2_i
, , 2_i
and CC 2_i
at IN 2_i
20:121 CD 2_i
watts NN 2_i
in IN 2_i
the DT 2_i
group NN 2_i
of IN 2_i
patients NNS 2_i
who WP 2_i
were VBD 2_i
trained VBN 2_i
by IN 2_i
interval JJ 2_i
method NN 2_i
( ( 2_i
rest NN 2_i
: : 2_i
work NN 2_i
each DT 2_i
1:1 CD 2_i
min NN 2_i
) ) 2_i
. . N

At IN N
this DT N
exercise NN N
training NN N
that WDT N
lasted VBD N
for IN N
20 CD N
min PDT N
the DT N
acute JJ N
response NN N
of IN N
heart NN N
rate NN N
, , N
blood NN N
pressure NN N
, , N
rate-pressure JJ N
product NN N
, , N
glucose JJ N
, , N
lactate JJ N
and CC N
catecholamines NNS N
was VBD N
measured VBN N
. . N

RESULTS NNP N
In IN N
both DT N
methods NNS N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
systolic JJ N
and CC N
diastolic JJ N
pressure NN N
, , N
rate-pressure JJ N
product NN N
, , N
in IN N
glucose NN N
or CC N
catecholamine NN N
levels NNS N
. . N

However RB N
, , N
there EX N
was VBD N
a DT N
significantly RB N
higher JJR N
rate NN N
of IN N
lactate NN N
in IN N
the DT N
second JJ N
10 CD N
min NN N
of IN N
the DT N
interval JJ N
training NN N
. . N

And CC N
, , N
in IN N
spite NN N
of IN N
higher JJR N
peripheral JJ N
exercise NN N
intensity NN N
by IN N
interval JJ N
training NN N
, , N
there EX N
was VBD N
no DT N
higher JJR N
cardiac NN N
work NN N
than IN N
by IN N
the DT N
continuous JJ N
training NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
interval JJ N
training NN N
strains VBZ N
the DT N
oxidative JJ N
capacity NN N
of IN N
the DT N
trained JJ N
muscles NNS N
in IN N
a DT N
more RBR N
intensive JJ N
and CC N
direct JJ N
way NN N
than IN N
does VBZ N
continuous JJ N
training NN N
. . N

-DOCSTART- -X- O O

Detection NN N
of IN N
traumatic JJ N
arthrotomy NN N
of IN N
the DT N
knee NN N
using VBG N
the DT N
saline JJ 4_i
solution NN 4_i
load NN 4_i
test NN 4_i
. . N

BACKGROUND IN N
The DT N
saline JJ 4_i
solution NN 4_i
load NN 4_i
test NN 4_i
helps VBZ N
to TO N
determine VB N
if IN N
a DT N
wound NN N
extends VBZ N
into IN N
the DT N
knee NN N
joint NN N
. . N

Little JJ N
is VBZ N
known VBN N
about IN N
the DT N
volume NN N
of IN N
injected JJ N
intra-articular JJ N
saline NN 3_i
solution NN 3_i
that WDT N
is VBZ N
needed VBN N
to TO N
effectively RB N
rule VB N
in IN N
or CC N
rule VB N
out IN N
a DT N
traumatic JJ N
arthrotomy NN N
of IN N
the DT N
knee NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
appropriate JJ N
volume NN N
and CC N
needle JJ N
location NN N
for IN N
the DT N
diagnosis NN N
of IN N
a DT N
traumatic JJ N
knee NN N
arthrotomy NN N
and CC N
to TO N
assess VB N
the DT N
effect NN N
of IN N
associated JJ N
variables NNS N
, , N
including VBG N
knee NN N
circumference NN N
, , N
body NN N
mass NN N
index NN N
, , N
and CC N
sex NN N
. . N

METHODS NNP N
Fifty-six NNP N
consecutive JJ N
patients NNS N
scheduled VBN N
for IN N
knee NN N
arthroscopy NN N
were VBD N
enrolled VBN N
. . N

A DT N
standard JJ N
inferolateral JJ N
arthroscopic NN N
portal NN N
was VBD N
made VBN N
with IN N
a DT N
single JJ 2_i
stab NN 2_i
incision NN 2_i
with IN 2_i
use NN 2_i
of IN 2_i
a DT 2_i
number-11 JJ 2_i
blade NN 2_i
. . N

Injection NN N
sites NNS N
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
superomedial NN N
or CC N
inferomedial JJ N
location NN N
. . N

The DT N
injection NN 3_i
of IN 3_i
normal JJ 3_i
saline JJ 3_i
solution NN 3_i
at IN 3_i
a DT 3_i
rate NN 3_i
of IN 3_i
5 CD 3_i
mL/sec NNS 3_i
through IN 3_i
an DT 3_i
18-gauge JJ 3_i
needle NN 3_i
was VBD N
continued VBN N
while IN N
the DT N
knee NN N
was VBD N
moved VBN N
through IN N
a DT N
range NN N
of IN N
motion NN N
until IN N
fluid NNS N
extravasated VBN N
from IN N
the DT N
iatrogenic JJ N
laceration NN N
. . N

The DT N
volume NN N
of IN N
injected JJ N
fluid NN N
was VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
study NN N
group NN N
included VBD N
thirty-one JJ N
female NN N
patients NNS N
and CC N
twenty-five JJ N
male NN N
patients NNS N
with IN N
a DT N
combined JJ N
average JJ N
age NN N
of IN N
fifty JJ N
years NNS N
and CC N
an DT N
average JJ N
body NN N
mass NN N
index NN N
of IN N
30.9 CD N
. . N

In IN N
order NN N
to TO N
effectively RB N
diagnose VB N
50 CD N
% NN N
of IN N
the DT N
arthrotomies NNS N
, , N
75 CD N
mL NN N
of IN N
injected JJ N
fluid NN N
was VBD N
needed VBN N
; : N
the DT N
volumes NNS N
that WDT N
were VBD N
needed VBN N
in IN N
order NN N
to TO N
effectively RB N
diagnose VB N
75 CD N
% NN N
, , N
90 CD N
% NN N
, , N
95 CD N
% NN N
, , N
and CC N
99 CD N
% NN N
of IN N
the DT N
arthrotomies NNS N
were VBD N
110 CD N
, , N
145 CD N
, , N
155 CD N
, , N
and CC N
175 CD N
mL NN N
, , N
respectively RB N
. . N

The DT N
mean JJ N
volumes NNS N
of IN N
injected JJ N
fluid NN N
needed VBN N
for IN N
a DT N
positive JJ N
result NN N
at IN N
the DT N
inferomedial JJ N
and CC N
superomedial JJ N
needle JJ N
locations NNS N
were VBD N
64.0 CD N
and CC N
95.2 CD N
mL NN N
, , N
respectively RB N
; : N
this DT N
difference NN N
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN N
necessary JJ N
injection NN N
volume NN N
and CC N
sex NN N
, , N
body NN N
mass NN N
index NN N
, , N
or CC N
knee VB N
circumference NN N
. . N

CONCLUSIONS NNP N
In IN N
order NN N
to TO N
detect VB N
95 CD N
% NN N
of IN N
1-cm JJ N
inferolateral JJ N
arthrotomies NNS N
of IN N
the DT N
knee NN N
with IN N
use NN N
of IN N
the DT N
saline JJ N
solution NN N
load NN N
test NN N
, , N
155 CD N
mL NN N
must MD N
be VB N
injected VBN N
. . N

An DT N
inferomedial JJ N
injection NN N
location NN N
requires VBZ N
significantly RB N
less JJR N
fluid NN N
than IN N
a DT N
superomedial JJ N
injection NN N
location NN N
does VBZ N
for IN N
the DT N
diagnosis NN N
of IN N
inferolateral JJ N
arthrotomies NNS N
of IN N
the DT N
knee NN N
. . N

-DOCSTART- -X- O O

Relief NN N
of IN N
pain NN N
by IN N
infusion NN N
of IN N
morphine NN 3_i
after IN N
operation NN N
: : N
does VBZ N
tolerance VB N
develop VB N
? . N
To TO N
see VB N
whether IN N
continuous JJ N
intravenous JJ N
infusion NN N
of IN N
opiates NNS N
provides VBZ N
more RBR N
effective JJ N
postoperative JJ N
relief NN N
of IN N
pain NN N
than IN N
conventional JJ N
intramuscular JJ N
injection NN N
these DT N
regimens NNS N
were VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
double NN N
blind IN N
trial NN N
. . N

Thirty NN N
patients NNS N
undergoing VBG N
elective JJ N
cholecystectomy NN N
were VBD N
allocated VBN N
randomly RB N
to TO N
receive VB N
an DT N
infusion NN N
of IN N
morphine NN 3_i
or CC N
an DT N
infusion NN N
of IN N
placebo NN 7_i
( ( N
control VB N
group NN N
) ) N
for IN N
24 CD N
hours NNS N
. . N

Both DT N
groups NNS N
were VBD N
allowed VBN N
supplementary JJ N
morphine NN 3_i
boluses NNS N
as IN N
requested JJ N
. . N

During IN N
the DT N
first JJ N
48 CD N
hours NNS N
after IN N
operation NN N
the DT N
degree NN N
of IN N
pain NN N
was VBD N
almost RB N
identical JJ N
between IN N
the DT N
groups NNS N
. . N

Surprisingly RB N
, , N
the DT N
group NN N
that WDT N
was VBD N
given VBN N
the DT N
infusion NN N
of IN N
morphine NN N
received VBN N
as IN N
much JJ N
supplementary JJ N
morphine NN 3_i
as IN N
the DT N
control NN N
group NN N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
and CC N
appreciably RB N
more RBR N
during IN N
the DT N
24 CD N
hours NNS N
after IN N
the DT N
infusion NN N
had VBD N
been VBN N
withdrawn VBN N
. . N

Nausea NN N
and CC N
vomiting NN N
were VBD N
more RBR N
prevalent JJ N
among IN N
the DT N
patients NNS N
given VBN N
the DT N
infusion NN N
of IN N
morphine NN 3_i
. . N

These DT N
results NNS N
suggest VBP N
that IN N
continuous JJ N
infusion NN N
of IN N
morphine NN 3_i
may MD N
be VB N
an DT N
inferior JJ N
regimen NNS N
to TO N
intermittent VB N
bolus JJ N
administration NN N
in IN N
the DT N
relief NN N
of IN N
postoperative JJ N
pain NN N
. . N

This DT N
may MD N
be VB N
explained VBN N
by IN N
the DT N
development NN N
of IN N
tolerance NN N
in IN N
patients NNS N
who WP N
received VBD N
the DT N
infusion NN N
of IN N
morphine NN 3_i
. . 3_i

-DOCSTART- -X- O O

Effects NNS N
of IN N
mild JJ 2_i
physical JJ 2_i
exercise NN 2_i
on IN N
serum NN N
lipoproteins NNS N
and CC N
metabolites NNS N
of IN N
arachidonic JJ N
acid NN N
: : N
a DT N
controlled VBN N
randomised JJ N
trial NN N
in IN N
middle JJ N
aged VBN N
men NNS N
. . N

To TO N
study VB N
the DT N
effects NNS N
of IN N
physical JJ 2_i
exercise NN 2_i
on IN N
biochemical JJ N
risk NN N
factors NNS N
for IN N
ischaemic JJ N
heart NN N
disease NN N
31 CD N
healthy JJ N
middle NNS N
aged VBN N
men NNS N
undertook IN N
regular JJ 2_i
physical JJ 2_i
exercise NN 2_i
for IN 2_i
two CD 2_i
months NNS 2_i
and CC N
29 CD N
served VBD N
as IN N
controls NNS N
in IN N
a DT N
randomised JJ N
trial NN N
. . N

In IN N
the DT N
men NNS N
taking VBG N
regular JJ N
exercise NN N
serum NN N
cholesterol NN N
concentrations NNS N
increased VBD N
26 CD N
% NN N
more JJR N
in IN N
the DT N
high JJ N
density NN N
lipoprotein VBP N
subfraction NN N
two CD N
( ( N
HDL2 NNP N
) ) N
and CC N
decreased VBD N
31 CD N
% NN N
more JJR N
in IN N
the DT N
subfraction NN N
three CD N
( ( N
HDL3 NNP N
) ) N
and CC N
9 CD N
% NN N
more JJR N
in IN N
the DT N
low JJ N
density NN N
lipoprotein NN N
fraction NN N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

A DT N
tendency NN N
towards NNS N
increased VBD N
plasma JJ N
6-keto-prostaglandin JJ N
F1 NNP N
alpha NN N
concentration NN N
and CC N
decreased VBD N
serum NN N
thromboxane NN N
B2 NNP N
concentration NN N
was VBD N
found VBN N
during IN N
the DT N
period NN N
of IN N
regular JJ N
exercise NN 2_i
, , N
but CC N
prostaglandin VBP N
E2 NNP N
concentrations NNS N
remained VBD N
unchanged JJ N
. . N

The DT N
increase NN N
in IN N
plasma JJ N
6-keto-prostaglandin JJ N
F1 NNP N
alpha NN N
concentration NN N
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
serum JJ N
HDL2 NNP N
cholesterol NN N
concentration NN N
in IN N
the DT N
group NN N
taking VBG N
regular JJ N
exercise NN 2_i
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
mild JJ 2_i
regular JJ 2_i
physical JJ 2_i
exercise NN 2_i
favourably RB N
influences VBZ N
cholesterol NN N
distribution NN N
in IN N
serum NN N
lipoproteins NNS N
in IN N
healthy JJ N
middle NN N
aged VBN N
men NNS N
and CC N
may MD N
have VB N
beneficial JJ N
effects NNS N
on IN N
circulating VBG N
metabolites NNS N
of IN N
arachidonic JJ N
acid NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
entacapone NN 3_i
, , N
a DT N
peripherally RB N
acting VBG N
catechol-O-methyltransferase NN N
inhibitor NN N
, , N
on IN N
the DT N
motor NN N
response NN N
to TO N
acute VB N
treatment NN N
with IN N
levodopa NN N
in IN N
patients NNS N
with IN N
Parkinson NNP N
's POS N
disease NN N
. . N

Catechol-O-methyltransferase NNP N
( ( N
COMT NNP N
) ) N
inhibitors NNS N
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
Parkinson NNP N
's POS N
disease NN N
by IN N
improving VBG N
the DT N
bioavailability NN N
of IN N
levodopa NN N
and CC N
by IN N
prolonging VBG N
its PRP$ N
effects NNS N
. . N

Entacapone NNP 3_i
( ( 3_i
OR-611 NNP 3_i
) ) 3_i
, , N
a DT N
novel JJ 3_i
COMT NNP 3_i
inhibitor NN 3_i
, , N
which WDT N
does VBZ N
not RB N
cross VB N
the DT N
blood NN N
brain NN N
barrier NN N
, , N
was VBD N
assessed VBN N
in IN N
12 CD N
patients NNS N
with IN N
Parkinson NNP N
's POS N
disease NN N
and CC N
motor NN N
fluctuations NNS N
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
, , N
single JJ N
dose NN N
study NN N
. . N

The DT N
magnitude NN N
and CC N
duration NN N
of IN N
the DT N
therapeutic JJ N
response NN N
to TO N
a DT N
single JJ N
dose NN N
of IN N
200 CD N
mg NNS N
levodopa/50 JJ 3_i
mg FW N
carbidopa NN 3_i
was VBD N
evaluated VBN N
after IN N
concomitant JJ N
placebo NN 7_i
, , N
or CC N
200 CD N
or CC N
800 CD N
mg NN N
entacapone NN 3_i
. . N

A DT N
significant JJ N
increase NN N
in IN N
the DT N
duration NN N
of IN N
the DT N
motor NN N
response NN N
to TO N
levodopa NN N
was VBD N
seen VBN N
when WRB N
200 CD N
mg NN N
entacapone NN N
was VBD N
given VBN N
with IN N
levodopa/carbidopa NN N
. . N

Plasma NNP N
levodopa JJ N
concentrations NNS N
were VBD N
increased VBN N
with IN N
both DT N
doses NNS N
of IN N
the DT N
COMT NNP N
inhibitor NN N
. . N

The DT N
latency NN N
to TO N
onset VB N
of IN N
motor NN N
response NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
active JJ N
drug NN N
and CC N
placebo NN N
. . N

Entacapone NN N
may MD N
prove VB N
useful JJ N
in IN N
prolonging VBG N
the DT N
duration NN N
of IN N
the DT N
benefit NN N
obtained VBN N
from IN N
individual JJ N
doses NNS N
of IN N
levodopa NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Opposing NNP N
effects NNS N
of IN N
propranolol NN 3_i
and CC N
diltiazem NN 3_i
on IN N
the DT N
angina NN N
threshold NN N
during IN N
an DT N
exercise NN N
test NN N
in IN N
patients NNS N
with IN N
syndrome JJ N
X NNP N
] NNP N
. . N

Patients NNS N
with IN N
angina JJ N
pectoris NN N
, , N
exercise NN N
induced VBN N
myocardial JJ N
ischemia NN N
, , N
normal JJ N
coronary JJ N
arteries NNS N
and CC N
no DT N
evidence NN N
of IN N
epicardial JJ N
spasm NN N
, , N
i.e NN N
. . N

patients NNS N
with IN N
syndrome JJ N
x NN N
, , N
have VBP N
been VBN N
suggested VBN N
to TO N
haven VB N
inadequate JJ N
increase NN N
in IN N
coronary JJ N
blood NN N
flow NN N
during IN N
tachycardia NN N
, , N
possibly RB N
due JJ N
to TO N
a DT N
functional JJ N
disorder NN N
of IN N
small JJ N
coronary JJ N
vessels NNS N
. . N

To TO N
evaluate VB N
the DT N
best JJS N
medical JJ N
management NN N
of IN N
this DT N
syndrome NN N
we PRP N
studied VBD N
13 CD N
patients NNS N
who WP N
showed VBD N
the DT N
above JJ N
set NN N
of IN N
findings NNS N
. . N

Patients NNS N
were VBD N
given VBN N
propranolol NNS N
( ( N
160 CD N
mg NNS N
daily RB N
) ) N
, , N
diltiazem NN 3_i
( ( N
360 CD N
mg NNS N
daily RB N
) ) N
and CC N
placebo NN 7_i
for IN N
2 CD N
weeks NNS N
, , N
using VBG N
a DT N
randomized JJ N
single JJ N
blind NN N
protocol NN N
. . N

Upright NNP 2_i
bicycle NN 2_i
ergometer NN 2_i
testing NN 2_i
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
period NN N
of IN N
treatment NN N
. . N

Compared VBN N
to TO N
placebo VB N
, , N
diltiazem VB N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
prolonged VBD N
exercise NN N
duration NN N
( ( N
x JJ N
+/- JJ N
SD NNP N
: : N
365 CD N
+/- JJ N
86 CD N
vs JJ N
303 CD N
+/- JJ N
89 CD N
sec NN N
) ) N
and CC N
time NN N
to TO N
onset VB N
of IN N
angina NN N
( ( N
358 CD N
+/- JJ N
88 CD N
vs JJ N
276 CD N
+/- JJ N
90 CD N
sec NN N
) ) N
. . N

Angina NNP N
appeared VBD N
in IN N
7 CD N
patients NNS N
with IN N
diltiazem JJ 3_i
vs NNS N
13 CD N
patients NNS N
with IN N
placebo NN 7_i
and CC N
occurred VBD N
at IN N
a DT N
higher JJR N
rate NN N
pressure NN N
product NN N
( ( N
26.3 CD N
+/- JJ N
3.5 CD N
vs JJ N
24.1 CD N
+/- JJ N
2.8 CD N
X NN N
10 CD N
( ( N
-3 NN N
) ) N
; : N
p VBZ N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

Conversely RB N
, , N
following VBG N
propranolol NN N
exercise NN N
duration NN N
and CC N
time NN N
to TO N
onset VB N
of IN N
angina NNS N
were VBD N
unchanged JJ N
and CC N
angina JJ N
appeared VBN N
in IN N
all DT N
patients NNS N
at IN N
a DT N
lower JJR N
rate NN N
pressure NN N
product NN N
( ( N
18.3 CD N
+/- JJ N
2.9 CD N
vs JJ N
24.4 CD N
+/- JJ N
3.6 CD N
X NN N
10 CD N
( ( N
-3 NN N
) ) N
; : N
p VBZ N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
most RBS N
likely JJ N
explanations NNS N
for IN N
these DT N
findings NNS N
are VBP N
: : N
propranolol JJ 3_i
counteracts NNS N
beta VBP N
2-adrenergic JJ N
receptors NNS N
, , N
thus RB N
further RB N
reducing VBG N
coronary JJ N
reserve NN N
. . N

This DT N
may MD N
lower VB N
the DT N
anginal JJ N
threshold NN N
; : N
Diltiazem NNP 3_i
reduces VBZ N
smooth JJ N
muscle NN N
tone NN N
in IN N
small JJ N
coronary JJ N
vessels NNS N
. . N

This DT N
may MD N
result VB N
in IN N
increased JJ N
coronary JJ N
reserve NN N
and CC N
exercise NN N
duration NN N
. . N

-DOCSTART- -X- O O

Tolerance NN N
and CC N
efficacy NN N
of IN N
combined JJ 3_i
diethylcarbamazine NN 3_i
and CC 3_i
albendazole NN 3_i
for IN N
treatment NN N
of IN N
Wuchereria NNP N
bancrofti NN N
and CC N
intestinal JJ N
helminth NN N
infections NNS N
in IN N
Haitian JJ N
children NNS N
. . N

This DT N
randomized JJ N
, , N
placebo-controlled JJ 7_i
trial NN N
investigated VBD N
the DT N
tolerance NN N
, , N
efficacy NN N
, , N
and CC N
nutritional JJ N
benefit NN N
of IN N
combining VBG N
chemotherapeutic JJ N
treatment NN N
of IN N
intestinal JJ N
helminths NNS N
and CC N
lymphatic JJ N
filariasis NN N
. . N

Children NNP N
were VBD N
infected VBN N
with IN N
Ascaris NNP N
( ( N
30.7 CD N
% NN N
) ) N
, , N
Trichuris NNP N
( ( N
53.4 CD N
% NN N
) ) N
, , N
and CC N
hookworm NN N
( ( N
9.7 CD N
% NN N
) ) N
with IN N
69.9 CD N
% NN N
having VBG N
more JJR N
than IN N
one CD N
of IN N
these DT N
parasites NNS N
. . N

A DT N
total NN N
of IN N
15.8 CD N
% NN N
of IN N
the DT N
children NNS N
had VBD N
Wuchereria NNP N
bancrofti NN N
microfilariae NN N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
treatment NN N
with IN N
placebo NN 7_i
, , N
albendazole NN 3_i
( ( 3_i
ALB NNP 3_i
) ) 3_i
, , N
diethylcarbamazine NN 3_i
( ( 3_i
DEC NNP 3_i
) ) 3_i
, , 3_i
or CC N
combined VBN 3_i
therapy NN 3_i
. . N

The DT N
combination NN N
of IN N
DEC/ALB NNP N
reduced VBD N
microfilarial JJ N
density NN N
compared VBN N
with IN N
placebo NN N
, , N
ALB NNP N
, , N
or CC N
DEC NNP N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.03 CD N
) ) N
. . N

Albendazole NNP 3_i
and CC N
DEC/ALB NNP 3_i
reduced VBD N
the DT N
prevalence NN N
of IN N
Ascaris NNP N
, , N
Trichuris NNP N
, , N
and CC N
hookworm RB N
more JJR N
than IN N
placebo NN N
or CC N
DEC NNP N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.03 CD N
) ) N
. . N

Among IN N
Trichuris-infected JJ N
children NNS N
, , N
those DT N
receiving VBG N
ALB NNP 3_i
and CC N
DEC/ALB NNP 3_i
demonstrated VBD N
greater JJR N
gains NNS N
in IN N
weight NN N
compared VBN N
with IN N
placebo NN 7_i
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.05 CD N
) ) N
. . N

Albendazole NNP 3_i
and CC N
DEC/ALB NNP 3_i
were VBD N
equally RB N
efficacious JJ N
in IN N
treating VBG N
intestinal JJ N
helminths NNS N
and CC N
for IN N
children NNS N
with IN N
W. NNP N
bancrofti NN N
microfilaremia NN N
, , N
DEC/ALB NNP 3_i
was VBD N
more RBR N
effective JJ N
than IN N
DEC NNP 3_i
, , N
with IN N
no DT N
increase NN N
in IN N
severity NN N
of IN N
adverse JJ N
reactions NNS N
. . N

-DOCSTART- -X- O O

Why WRB N
the DT N
prone NN 2_i
position NN 2_i
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
sudden JJ N
infant NN N
death NN N
syndrome NN N
. . N

INTRODUCTION NNP N
The DT N
laryngeal NN N
chemoreflex NN N
may MD N
explain VB N
why WRB N
prone NN N
sleeping NN N
increases VBZ N
the DT N
risk NN N
of IN N
sudden JJ N
infant NN N
death NN N
syndrome NN N
( ( N
SIDS NNP N
) ) N
. . N

Swallowing VBG N
and CC N
arousal NN N
are VBP N
crucial JJ N
to TO N
prevent VB N
laryngeal JJ N
chemoreflex JJ N
stimulation NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
examine VB N
these DT N
reflexes NNS N
and CC N
breathing VBG N
responses NNS N
in IN N
healthy JJ N
neonates NNS N
after IN N
pharyngeal JJ N
infusion NN N
of IN N
water NN N
in IN N
the DT N
supine NN N
versus IN N
the DT N
prone NN N
position NN N
, , N
controlling VBG N
for IN N
sleep JJ N
state NN N
. . N

METHODS CC N
A DT N
total NN N
of IN N
10 CD N
term NN N
infants NNS N
were VBD N
recruited VBN N
after IN N
parental JJ N
consent NN N
and CC N
ethics NNS N
approval NN N
. . N

Polygraphic JJ N
recordings NNS N
included VBD N
sleep JJ N
state NN N
( ( N
active JJ N
and CC N
quiet JJ N
sleep NN N
by IN N
electroencephalogram NN N
, , N
eye NN N
movements NNS N
, , N
breathing NN N
, , N
and CC N
behavior NN N
) ) N
, , N
cardiorespiratory JJ N
measurements NNS N
( ( N
nasal JJ N
airflow NN N
, , N
chest VBP N
wall NN N
movements NNS N
, , N
heart NN N
rate NN N
, , N
and CC N
oxygen PRP N
saturation NN N
) ) N
, , N
swallowing VBG N
, , N
and CC N
esophageal JJ N
activity NN N
( ( N
solid JJ N
state NN N
pressure NN N
catheter NN N
) ) N
. . N

Initial JJ 2_i
sleeping VBG 2_i
position NN 2_i
was VBD 2_i
assigned VBN 2_i
randomly RB 2_i
. . N

Measurements NNS N
were VBD N
made VBN N
for IN N
1 CD 2_i
minute NN 2_i
before IN 2_i
and CC 2_i
after IN 2_i
0.4 CD 2_i
mL NN 2_i
of IN 2_i
water NN 2_i
was VBD 2_i
instilled VBN 2_i
into IN 2_i
the DT 2_i
oropharynx NN 2_i
. . N

To TO N
detect VB N
a DT N
30 CD N
% NN N
decrease NN N
in IN N
swallowing NN N
, , N
power NN N
analysis NN N
indicated VBD N
that IN N
> NNP N
/=10 NNP N
babies NNS N
were VBD N
required VBN N
. . N

Analysis NN N
, , N
blinded VBD N
to TO N
position NN N
, , N
was VBD N
made VBN N
using VBG N
nonparametric JJ N
statistics NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
164 CD N
infusions NNS N
, , N
the DT N
most RBS N
commonly RB N
evoked VBD N
airway RB N
protective JJ N
responses NNS N
to TO N
pharyngeal VB N
infusion NN N
were VBD N
swallowing VBG N
( ( N
95 CD N
% NN N
) ) N
and CC N
arousal NN N
( ( N
54 CD N
% NN N
) ) N
. . N

After IN N
infusion NN N
in IN N
active JJ N
sleep NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
swallowing VBG N
and CC N
breathing VBG N
when WRB N
the DT N
prone NN N
position NN N
was VBD N
compared VBN N
with IN N
the DT N
supine JJ N
position NN N
( ( N
prone NN N
: : N
21.3 CD N
[ $ N
1.0 CD N
] NNP N
swallows/min NN N
and CC N
-9.6 NNP N
[ NNP N
2.1 CD N
] NNP N
breaths/min NN N
; : N
and CC N
supine VB N
: : N
32 CD N
( ( N
2.2 CD N
) ) N
and CC N
-2 NNP N
. . N

9 CD N
( ( N
1.5 CD N
) ) N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
occurrence NN N
of IN N
arousal NN N
after IN N
water NN N
infusion NN N
. . N

CONCLUSION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
airway NN N
protection NN N
is VBZ N
compromised VBN N
in IN N
the DT N
prone NN N
sleeping VBG N
position NN N
during IN N
active JJ N
sleep NN N
, , N
even RB N
in IN N
healthy JJ N
infants NNS N
exposed VBN N
to TO N
minute VB N
pharyngeal JJ N
fluid JJ N
volumes NNS N
of IN N
0.4 CD N
mL NN N
. . N

This DT N
is VBZ N
because IN N
swallowing VBG N
rate NN N
is VBZ N
reduced VBN N
significantly RB N
, , N
and CC N
there EX N
is VBZ N
no DT N
compensatory JJ N
increase NN N
in IN N
arousal NN N
. . N

The DT N
reduction NN N
in IN N
airway RB N
protective JJ N
reflexes NNS N
when WRB N
in IN N
the DT N
prone NN N
position NN N
and CC N
in IN N
active JJ N
sleep NN N
may MD N
be VB N
the DT N
mechanism NN N
for IN N
the DT N
increased VBN N
risk NN N
of IN N
SIDS NNP N
in IN N
the DT N
prone NN N
position NN N
. . N

-DOCSTART- -X- O O

The DT N
cognitive NN N
, , N
subjective JJ N
, , N
and CC N
physical JJ N
effects NNS N
of IN N
a DT N
ginkgo NN 3_i
biloba/panax NN 3_i
ginseng NN 3_i
combination NN 3_i
in IN N
healthy JJ N
volunteers NNS N
with IN N
neurasthenic JJ N
complaints NNS N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
a DT N
Ginkgo NNP 3_i
biloba/ginseng NN 3_i
combination NN 3_i
on IN N
cognitive JJ N
function NN N
in IN N
this DT N
90-day JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
, , N
parallel-group JJ N
study NN N
. . N

Sixty-four CD N
healthy JJ N
volunteers NNS N
( ( N
aged VBN N
40 CD N
to TO N
65 CD N
years NNS N
) ) N
, , N
selected VBN N
on IN N
the DT N
basis NN N
of IN N
fulfilling VBG N
the DT N
ICD-10 NNP N
F48.0 NNP N
criteria NNS N
for IN N
neurasthenia NN N
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
four CD N
equal JJ N
dosing NN N
groups NNS N
, , N
receiving VBG N
80 CD N
, , N
160 CD N
, , N
or CC N
320 CD N
mg NN N
of IN N
the DT N
combination NN N
b.i.d NN N
. . N

or CC N
placebo NN 7_i
. . N

Assessments NNS N
were VBD N
performed VBN N
on IN N
the DT N
day NN N
before IN N
dosing NN N
, , N
and CC N
again RB N
at IN N
Days NNP N
1 CD N
, , N
30 CD N
, , N
and CC N
90 CD N
at IN N
1 CD N
hour NN N
after IN N
the DT N
morning NN N
dose NN N
and CC N
1 CD N
hour NN N
after IN N
the DT N
afternoon NN N
dose NN N
. . N

The DT N
assessments NNS N
included VBD N
the DT N
Cognitive NNP N
Drug NNP N
Research NNP N
( ( N
CDR NNP N
) ) N
computerized VBD N
assessment NN N
system NN N
, , N
the DT N
Vienna NNP N
Determination NNP N
Unit NNP N
, , N
cycle NN N
ergometry NN N
, , N
and CC N
various JJ N
questionnaires NNS N
. . N

The DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
by IN N
all DT N
volunteers NNS N
. . N

On IN N
Day NNP N
90 CD N
at IN N
1 CD N
hour NN N
post NN N
morning NN N
dosing NN N
, , N
dose-related JJ N
improvements NNS N
were VBD N
seen VBN N
on IN N
the DT N
CDR NNP N
tests NNS N
, , N
the DT N
320 CD N
mg NN N
dose NN N
being VBG N
significantly RB N
superior JJ N
to TO N
placebo VB 7_i
. . N

These DT N
effects NNS N
, , N
however RB N
, , N
were VBD N
reversed VBN N
1 CD N
hour NN N
after IN N
the DT N
afternoon NN N
dose NN N
, , N
possibly RB N
suggesting VBG N
that IN N
a DT N
longer JJR N
inter-dosing JJ N
interval NN N
would MD N
be VB N
preferable JJ N
. . N

The DT N
80-mg JJ N
dose NN N
produced VBD N
a DT N
significant JJ N
benefit NN N
on IN N
the DT N
ergometry NN N
assessment NN N
of IN N
heart NN N
rate NN N
at IN N
maximum JJ N
load NN N
. . N

There EX N
were VBD N
also RB N
several JJ N
supporting VBG N
changes NNS N
from IN N
other JJ N
assessments NNS N
, , N
including VBG N
an DT N
advantage NN N
of IN N
320 CD N
mg NN N
over IN N
placebo NN N
on IN N
the DT N
global JJ N
score NN N
from IN N
the DT N
Symptom NNP N
Checklist-90-revised JJ N
( ( N
SCL-90-R NNP N
) ) N
at IN N
Day NNP N
90 CD N
. . N

-DOCSTART- -X- O O

Custom NNP N
tray JJ N
application NN N
of IN N
peroxide JJ 3_i
gel NN 3_i
as IN N
an DT N
adjunct NN N
to TO N
scaling NN 1_i
and CC 2_i
root NN 1_i
planing NN 1_i
in IN N
the DT N
treatment NN N
of IN N
periodontitis NN N
: : N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
after IN N
six CD N
months NNS N
. . N

OBJECTIVE NNP N
Scaling NNP 1_i
and CC 1_i
root NN 1_i
planing NN 1_i
( ( 1_i
SRP NNP 1_i
) ) 1_i
is VBZ N
the DT N
primary JJ N
non-surgical JJ N
treatment NN N
for IN N
periodontitis NN N
, , N
but CC N
its PRP$ N
effectiveness NN N
is VBZ N
limited VBN N
. . N

Consequently RB N
, , N
various JJ N
adjunctive JJ N
therapies NNS N
have VBP N
been VBN N
investigated VBN N
to TO N
improve VB N
clinical JJ N
outcome NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
clinical JJ N
effects NNS N
of IN N
one CD N
SRP NNP 1_i
procedure NN N
alone RB N
or CC N
combined VBN N
with IN N
local JJ N
administration NN N
of IN N
hydrogen NN 3_i
peroxide NN 3_i
gel NN 3_i
using VBG N
customized JJ N
trays NNS N
for IN N
the DT N
treatment NN N
of IN N
subjects NNS N
with IN N
chronic JJ N
periodontitis NN N
over IN N
a DT N
period NN N
of IN N
six CD N
months NNS N
. . N

METHODS NNP N
An DT N
examiner-blind JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
among IN N
30 CD N
subjects NNS N
with IN N
moderate JJ N
to TO N
advanced JJ N
periodontitis NN N
who WP N
were VBD N
randomized VBN N
to TO N
SRP VB 1_i
alone RB N
or CC N
SRP NNP 1_i
combined VBN 2_i
with IN N
prescription NN N
custom-tray JJ N
application NN N
( ( N
Perio NNP N
Tray NNP N
) ) N
of IN N
1.7 CD 3_i
% NN 3_i
hydrogen NN 3_i
peroxide NN 3_i
gel NN 3_i
( ( 3_i
Perio NNP 3_i
Gel NNP 3_i
) ) 3_i
for IN N
a DT N
period NN N
of IN N
three CD N
months NNS N
, , N
then RB N
extended VBD N
to TO N
six CD N
months NNS N
. . N

Following VBG N
impressions NNS N
for IN N
the DT N
test NN N
group NN N
, , N
all DT N
subjects NNS N
brushed VBN 2_i
twice RB 2_i
daily RB 2_i
with IN 2_i
a DT 2_i
regular JJ 2_i
dentifrice NN 2_i
and CC 2_i
toothbrush NN 2_i
for IN N
a DT N
four-week JJ N
acclimation NN N
phase NN N
to TO N
standardize VB N
oral JJ N
conditions NNS N
( ( N
while IN N
trays NNS N
were VBD N
fabricated VBN N
) ) N
prior RB N
to TO N
initiating VBG N
the DT N
treatment NN N
phase NN N
. . N

SRP NNP 1_i
was VBD N
performed VBN N
three CD N
weeks NNS N
after IN N
baseline NN N
, , N
and CC N
clinical JJ N
assessments NNS N
, , N
i.e. FW N
, , N
pocket NN N
probing VBG N
depth NN N
( ( N
PPD NNP N
) ) N
and CC N
bleeding VBG N
index NN N
( ( N
BI NNP N
) ) N
, , N
were VBD N
conducted VBN N
at IN N
baseline NN N
and CC N
after IN N
two CD N
, , N
five CD N
, , N
13 CD N
, , N
and CC N
26 CD N
weeks NNS N
of IN N
peroxide JJ 3_i
gel NN 3_i
applications NNS N
. . N

Clinical JJ N
variables NNS N
were VBD N
compared VBN N
by IN N
ANCOVA NNP N
and CC N
paired VBD N
t-tests NNS N
after IN N
each DT N
treatment NN N
interval NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
13 CD N
test NN N
and CC N
15 CD N
control NN N
subjects NNS N
completed VBD N
the DT N
original JJ N
three-month JJ N
trial NN N
, , N
of IN N
whom WP N
10 CD N
test NN N
and CC N
13 CD N
control NN N
subjects NNS N
finished VBD N
the DT N
three-month JJ N
extension NN N
. . N

After IN N
two CD N
weeks NNS N
of IN N
peroxide NN 3_i
gel NN 3_i
use NN N
prior RB N
to TO N
SRP NNP 1_i
, , N
mean JJ N
PPD NNP N
for IN N
the DT N
test NN N
group NN N
significantly RB N
decreased VBN N
from IN N
baseline NN N
by IN N
0.21 CD N
mm NNS N
and CC N
mean JJ N
BI NNP N
significantly RB N
dropped VBD N
by IN N
0.14 CD N
; : N
clinical JJ N
parameters NNS N
for IN N
the DT N
control NN N
group NN N
were VBD N
unchanged JJ N
. . N

Two CD N
weeks NNS N
following VBG N
SRP NNP 1_i
, , N
mean JJ N
PPD NNP N
significantly RB N
decreased VBD N
from IN N
baseline NN N
by IN N
0.65 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.17 CD N
mm NN N
for IN N
the DT N
control NN N
; : N
mean CC N
BI NNP N
significantly RB N
dropped VBD N
by IN N
0.17 CD N
for IN N
the DT N
test NN N
group NN N
and CC N
0.05 CD N
for IN N
the DT N
control NN N
. . N

Ten CD N
weeks NNS N
following VBG N
SRP NNP 1_i
, , N
mean JJ N
PPD NNP N
decreases NNS N
were VBD N
0.77 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.13 CD N
mm NN N
for IN N
the DT N
control NN N
, , N
and CC N
mean JJ N
BI NNP N
reductions NNS N
were VBD N
0.14 CD N
for IN N
the DT N
test NN N
group NN N
and CC N
0.00 CD N
for IN N
the DT N
control NN N
. . N

For IN N
subjects NNS N
who WP N
completed VBD N
the DT N
three-month JJ N
extension NN N
( ( N
i.e. JJ N
, , N
23 CD N
weeks NNS N
post-SRP NN N
) ) N
, , N
mean JJ N
PPD NNP N
decreases NNS N
were VBD N
0.72 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.13 CD N
mm NN N
for IN N
the DT N
control NN N
, , N
and CC N
mean JJ N
BI NNP N
reductions NNS N
were VBD N
0.05 CD N
for IN N
the DT N
test NN N
group NN N
and CC N
0.01 CD N
for IN N
the DT N
control NN N
. . N

Analysis NN N
of IN N
deeper JJR N
pockets NNS N
( ( N
i.e. NN N
, , N
> VBZ N
5 CD N
mm NN N
at IN N
baseline NN N
) ) N
showed VBD N
the DT N
same JJ N
relationship NN N
for IN N
PPD NNP N
, , N
but CC N
with IN N
larger JJR N
differences NNS N
between IN N
groups NNS N
. . N

For IN N
example NN N
, , N
after IN N
two CD N
weeks NNS N
of IN N
peroxide NN 3_i
gel NN 3_i
use NN N
prior RB N
to TO N
SRP NNP 1_i
, , N
mean JJ N
PPD NNP N
decreased VBN N
by IN N
0.48 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
compared VBN N
to TO N
0.04 CD N
mm NN N
for IN N
the DT N
control NN N
. . N

Two CD N
weeks NNS N
after IN N
SRP NNP 1_i
, , N
mean JJ N
PPD NNP N
decreased VBD N
from IN N
baseline NN N
by IN N
1.40 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.60 CD N
mm NN N
for IN N
the DT N
control NN N
, , N
and CC N
10 CD N
weeks NNS N
after IN N
SRP NNP N
by IN N
1.57 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.58 CD N
mm NN N
for IN N
the DT N
control NN N
. . N

After IN N
the DT N
extension NN N
( ( N
i.e. JJ N
, , N
23 CD N
weeks NNS N
post-SRP NN N
) ) N
, , N
mean JJ N
PPD NNP N
changed VBD N
from IN N
baseline NN N
by IN N
1.50 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.55 CD N
mm NN N
for IN N
the DT N
control NN N
. . N

With IN N
the DT N
exception NN N
of IN N
BI NNP N
at IN N
23 CD N
weeks NNS N
post-SRP JJ N
, , N
all DT N
reductions NNS N
cited VBN N
above IN N
for IN N
the DT N
test NN N
group NN N
were VBD N
statistically RB N
significantly RB N
different JJ N
from IN N
the DT N
control NN N
group NN N
for IN N
both DT N
PPD NNP N
and CC N
BI NNP N
for IN N
all DT N
comparisons NNS N
. . N

CONCLUSION NN N
When WRB N
compared VBN N
with IN N
SRP NNP 1_i
alone RB N
, , N
clinical JJ N
improvements NNS N
in IN N
PPD NNP N
( ( N
e.g. NN N
, , N
-1.0 NNP N
mm NN N
for IN N
pockets NNS N
> VBP N
5 CD N
mm NN N
at IN N
baseline NN N
) ) N
were VBD N
maintained VBN N
for IN N
up IN N
to TO N
six CD N
months NNS N
after IN N
SRP NNP 1_i
with IN N
adjunctive JJ N
use NN N
of IN N
1.7 CD N
% NN N
hydrogen NN 3_i
peroxide NN 3_i
gel NN 3_i
, , N
locally RB N
administered VBN N
using VBG N
prescription NN N
customized VBD N
trays NNS N
in IN N
the DT N
treatment NN N
of IN N
subjects NNS N
with IN N
moderate JJ N
to TO N
advanced JJ N
periodontitis NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
camel NN 3_i
milk NN 3_i
on IN N
thymus NN N
and CC N
activation-regulated JJ N
chemokine NN N
in IN N
autistic JJ N
children NNS N
: : N
double-blind NN N
study NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
role NN N
of IN N
the DT N
effectiveness NN N
of IN N
camel NN 3_i
milk NN 3_i
( ( 3_i
CM NNP 3_i
) ) 3_i
( ( 3_i
raw JJ 3_i
and CC 3_i
boiled VBN 3_i
) ) 3_i
on IN N
thymus NN N
and CC N
activation-regulated JJ N
chemokine NN N
( ( N
TARC NNP N
) ) N
serum NN N
levels NNS N
and CC N
childhood NN N
autism NN N
rating NN N
scale NN N
( ( N
CARS NNP N
) ) N
score NN N
in IN N
subjects NNS N
with IN N
autism NN N
and CC N
compared VBN N
to TO N
placebo VB 7_i
group NN 7_i
( ( 7_i
cow JJ 7_i
milk NN 7_i
) ) 7_i
. . N

METHODS NNP N
Forty-five JJ N
subjects NNS N
diagnosed VBN N
with IN N
autism NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
boiled VBN 3_i
CM NNP 3_i
for IN 3_i
group NN 3_i
I PRP 3_i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
, , N
raw JJ 3_i
CM NNP 3_i
for IN 3_i
group NN 3_i
II NNP 3_i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
, , N
and CC N
placebo NN 7_i
for IN 7_i
group NN 7_i
III NNP 7_i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
for IN N
2 CD N
wk NN N
. . N

Measures NNS N
included VBD N
changes NNS N
in IN N
professionally RB N
completed VBN N
CARS NNP N
score NN N
and CC N
blood NN N
samples NNS N
for IN N
TARC NNP N
serum NN N
level NN N
were VBD N
taken VBN N
before RB N
and CC N
after IN N
milk NN N
consumption NN N
of IN N
500 CD N
ml NNS N
per IN N
day NN N
in IN N
children NNS N
's POS N
regular JJ N
daily JJ N
diet NN N
. . N

RESULTS VB N
The DT N
serum NN N
levels NNS N
of IN N
TARC NNP N
decreased VBD N
significantly RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
boiled VBN N
CM NNP N
and CC N
in IN N
raw JJ N
CM NNP N
group NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
too RB N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
( ( N
P NNP N
= NNP N
0.68 CD N
) ) N
in IN N
placebo NN N
group NN N
. . N

Furthermore RB N
, , N
significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
CARS NNP N
score NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
raw JJ N
CM NNP N
group NN N
only RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
relationships NNS N
between IN N
the DT N
serum NN N
of IN N
TARC NNP N
level NN N
and CC N
the DT N
CARS NNP N
score NN N
, , N
age NN N
, , N
or CC N
gender VB N
for IN N
any DT N
group NN N
. . N

CONCLUSION NNP N
CM NNP N
administered VBD N
for IN N
2 CD N
wk NNS N
significantly RB N
improved VBN N
clinical JJ N
measurements NNS N
of IN N
autism NN N
severity NN N
and CC N
decreased VBD N
serum JJR N
level NN N
of IN N
TARC NNP N
in IN N
autistic JJ N
children NNS N
, , N
but CC N
subsequent JJ N
studies NNS N
are VBP N
recommended VBN N
. . N

-DOCSTART- -X- O O

Outcomes NNS N
in IN N
a DT N
nursing NN N
home NN N
transition NN N
case-management JJ N
program NN N
targeting VBG N
new JJ N
admissions NNS N
. . N

PURPOSE VB N
The DT N
Providing VBG 4_i
Assistance NNP 4_i
to TO 4_i
Caregivers NNPS 4_i
in IN 4_i
Transition NNP 4_i
( ( 4_i
PACT NNP 4_i
) ) 4_i
program NN 4_i
offers NNS N
nursing VBG N
home NN N
discharge NN N
planning NN N
and CC N
case NN N
management NN N
for IN N
individuals NNS N
in IN N
the DT N
transitional JJ N
period NN N
following VBG N
a DT N
return NN N
to TO N
the DT N
community NN N
. . N

The DT N
PACT NNP 6_i
program NN 6_i
targeted VBN N
individuals NNS N
newly RB N
admitted VBN N
to TO N
nursing VBG N
homes NNS N
and CC N
worked VBD N
with IN N
a DT N
family NN N
caregiver NN N
to TO N
develop VB N
and CC N
implement VB N
a DT N
nursing NN N
home NN N
discharge NN N
plan NN N
. . N

DESIGN NNP N
AND CC N
METHOD NNP N
Reported NNP N
are VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
control NN N
design NN N
evaluating VBG N
the DT N
program NN N
's POS N
effectiveness NN N
. . N

Those DT N
individuals NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
intervention NN N
group NN N
( ( N
n JJ N
= NNP N
33 CD N
) ) N
received VBN N
PACT NNP 4_i
case NN 4_i
management NN 4_i
in IN 4_i
addition NN 4_i
to TO 4_i
their PRP$ 4_i
usual JJ 4_i
medical JJ 4_i
and CC 4_i
nursing NN 4_i
home NN 4_i
care NN 4_i
. . N

The DT N
individuals NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
29 CD N
) ) N
continued VBD N
their PRP$ N
usual JJ 4_i
care NN 4_i
. . N

RESULT CC N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
in IN N
the DT N
discharge NN N
rate NN N
( ( N
84 CD N
% NN N
treatment NN N
vs RB N
76 CD N
% NN N
controls NNS N
) ) N
or CC N
in IN N
the DT N
median JJ N
length NN N
of IN N
stay NN N
( ( N
42 CD N
days NNS N
vs RB N
55 CD N
days NNS N
) ) N
between IN N
the DT N
two CD N
groups NNS N
of IN N
individuals NNS N
. . N

IMPLICATIONS NNP N
Replications NNPS N
or CC N
extensions NNS N
of IN N
a DT N
PACT-type JJ 4_i
intervention NN 4_i
might MD N
consider VB N
a DT N
broader JJR N
mix NN N
of IN N
nursing NN N
homes NNS N
, , N
working VBG N
directly RB N
with IN N
the DT N
nursing NN N
home NN N
's POS N
admission NN N
Minimum NNP N
Data NNP N
Set NNP N
coordinator NN N
in IN N
patient JJ N
selection NN N
, , N
or CC N
working VBG N
with IN N
Medicare NNP N
or CC N
Medicaid NNP N
HMO NNP N
plans VBZ N
. . N

-DOCSTART- -X- O O

Ultrasonographic JJ 2_i
tissue NN 2_i
characterisation NN 2_i
of IN N
human JJ N
Achilles NNP N
tendons NNS N
: : N
quantification NN N
of IN N
tendon NN N
structure NN N
through IN N
a DT N
novel JJ N
non-invasive JJ N
approach NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
whether IN N
three-dimensional JJ 2_i
imaging NN 2_i
of IN 2_i
the DT 2_i
Achilles NNP 2_i
tendon NN 2_i
by IN 2_i
ultrasonographic JJ 2_i
tissue NN 2_i
characterisation NN 2_i
( ( 2_i
UTC NNP 2_i
) ) 2_i
can MD N
differentiate VB N
between IN N
symptomatic JJ N
and CC N
asymptomatic JJ N
tendons NNS N
. . N

DESIGN NNP N
Case-control NNP N
study NN N
. . N

SETTING NNP N
Sports NNP N
Medical NNP N
Department NNP N
of IN N
the DT N
Hague NNP N
Medical NNP N
Centre NNP N
. . N

PATIENTS NNP N
Twenty-six JJ N
tendons NNS N
from IN N
patients NNS N
with IN N
chronic JJ N
midportion NN N
Achilles NNP N
tendinopathy NN N
were VBD N
included VBN N
. . N

The DT N
matched JJ N
control NN N
group NN N
consisted VBD N
of IN N
26 CD N
asymptomatic JJ N
tendons NNS N
. . N

INTERVENTIONS NNP N
Symptomatic NNP N
and CC N
asymptomatic JJ N
tendons NNS N
were VBD N
scanned VBN 2_i
using VBG 2_i
the DT 2_i
UTC NNP 2_i
procedure NN 2_i
. . N

One CD N
researcher NN N
performed VBD N
the DT N
ultrasonographic JJ 2_i
data NNS 2_i
collection NN 2_i
. . N

These DT N
blinded VBN N
data NNS N
were VBD N
randomised VBN N
, , N
and CC N
outcome JJ N
measures NNS N
were VBD N
determined VBN N
by IN N
two CD N
independent JJ N
observers NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASUREMENTS NNP N
The DT N
raw JJ N
ultrasonographic JJ N
images NNS N
were VBD N
analysed VBN N
with IN N
a DT N
custom-designed JJ N
algorithm NN N
that WDT N
quantifies VBZ N
the DT N
three-dimensional JJ N
stability NN N
of IN N
echo NN N
patterns NNS N
, , N
qua JJ N
intensity NN N
and CC N
distribution NN N
over IN N
contiguous JJ N
transverse JJ N
images NNS N
. . N

This DT N
three-dimensional JJ N
stability NN N
was VBD N
related VBN N
to TO N
tendon VB N
structure NN N
in IN N
previous JJ N
studies NNS N
. . N

UTC NNP N
categorises VBZ N
four CD N
different JJ N
echotypes NNS N
that WDT N
represent VBP N
( ( N
I PRP N
) ) N
highly RB N
stable JJ N
; : N
( ( N
II NNP N
) ) N
medium NN N
stable JJ N
; : N
( ( N
III NNP N
) ) N
highly RB N
variable JJ N
and CC N
( ( N
IV NNP N
) ) N
constantly RB N
low JJ N
intensity NN N
and CC N
variable JJ N
distribution NN N
. . N

The DT N
percentages NNS N
of IN N
echo-types NNS N
were VBD N
calculated VBN N
, , N
and CC N
the DT N
maximum JJ N
tendon NN N
thickness NN N
was VBD N
measured VBN N
. . N

Finally RB N
, , N
the DT N
inter-observer JJ N
reliability NN N
of IN N
UTC NNP 2_i
was VBD N
determined VBN N
. . N

RESULTS NNP N
Symptomatic JJ N
tendons NNS N
showed VBD N
less JJR N
pixels NNS N
in IN N
echo-types JJ N
I PRP N
and CC N
II NNP N
than IN N
asymptomatic JJ N
tendons NNS N
( ( N
51.5 CD N
% NN N
vs JJ N
76.6 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
thus RB N
less JJR N
three-dimensional JJ N
stability NN N
of IN N
the DT N
echo JJ N
pattern NN N
. . N

The DT N
mean JJ N
maximum JJ N
tendon NN N
thickness NN N
was VBD N
9.2 CD N
mm NN N
in IN N
the DT N
symptomatic JJ N
group NN N
and CC N
6.8 CD N
mm NN N
in IN N
the DT N
asymptomatic JJ N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
Intraclass NNP N
Correlation NNP N
Coefficient NNP N
( ( N
ICC NNP N
) ) N
for IN N
the DT N
interobserver JJ N
reliability NN N
of IN N
determining VBG N
the DT N
echo-types JJ N
I+II NNP N
was VBD N
0.95 CD N
. . N

The DT N
ICC NNP N
for IN N
tendon NN N
thickness NN N
was VBD N
0.84 CD N
. . N

CONCLUSION NNP N
UTC NNP N
can MD N
quantitatively RB N
evaluate VB N
tendon NN N
structure NN N
and CC N
thereby RB N
discriminate VB N
symptomatic JJ N
and CC N
asymptomatic JJ N
tendons NNS N
. . N

As IN N
such JJ N
, , N
UTC NNP 2_i
might MD N
be VB N
useful JJ N
to TO N
monitor VB N
treatment NN N
protocols NNS N
. . N

-DOCSTART- -X- O O

Oral JJ N
magnesium NN 3_i
supplementation NN 3_i
in IN N
children NNS N
with IN N
cystic JJ N
fibrosis NN N
improves VBZ N
clinical JJ N
and CC N
functional JJ N
variables NNS N
: : N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
. . N

BACKGROUND NNP N
Magnesium NNP N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
important JJ N
minerals NNS N
in IN N
the DT N
body NN N
. . N

Although IN N
some DT N
studies NNS N
reported VBD N
that IN N
patients NNS N
with IN N
cystic JJ N
fibrosis NN N
( ( N
CF NNP N
) ) N
lack NN N
magnesium NN N
, , N
no DT N
international JJ N
study NN N
has VBZ N
assessed VBN N
the DT N
importance NN N
of IN N
oral JJ N
magnesium NN N
supplementation NN N
in IN N
CF NNP N
patients NNS N
. . N

OBJECTIVE IN N
We PRP N
prospectively RB N
investigated VBD N
the DT N
long-term JJ N
effect NN N
of IN N
oral JJ N
magnesium NN 3_i
supplementation NN N
on IN N
respiratory JJ N
muscle NN N
strength NN N
by IN N
using VBG N
manuvacuometry NN N
and CC N
the DT N
Shwachman-Kulczycki NNP N
( ( N
SK NNP N
) ) N
score NN N
among IN N
children NNS N
and CC N
adolescents NNS N
with IN N
CF NNP N
. . N

DESIGN NNP N
This DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
included VBD N
44 CD N
CF NNP N
patients NNS N
( ( N
aged VBN N
7-19 CD N
y NN N
; : N
20 CD N
males NNS N
) ) N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
magnesium NN 3_i
( ( N
n JJ N
= VBZ N
22 CD N
; : N
300 CD N
mg/d NN N
) ) N
or CC N
placebo NN 7_i
( ( N
n JJ N
= NNP N
22 CD N
) ) N
for IN N
8 CD N
wk NN N
with IN N
a DT N
4-wk JJ N
washout NN N
period NN N
between IN N
trials NNS N
. . N

All DT N
patients NNS N
were VBD N
undergoing JJ N
conventional JJ N
treatment NN N
of IN N
CF NNP N
. . N

The DT N
experimental JJ N
protocol NN N
included VBD N
clinical JJ N
evaluation NN N
, , N
assessment NN N
of IN N
urinary JJ N
concentration NN N
of IN N
magnesium NN N
, , N
and CC N
manuvacuometric JJ N
measurements NNS N
[ VBP N
maximal JJ N
inspiratory JJ N
pressure NN N
( ( N
MIP NNP N
) ) N
and CC N
maximal JJ N
expiratory NN N
pressure NN N
( ( N
MEP NNP N
) ) N
] NN N
. . N

MIP NNP N
was VBD N
the DT N
primary JJ N
outcome NN N
. . N

RESULTS NNP N
Urinary JJ N
magnesium NN N
increased VBD N
after IN N
the DT N
administration NN N
of IN N
magnesium NN N
( ( N
change NN N
: : N
36.38 CD N
mg/d NN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.72 CD N
mg/d NNS N
after IN N
placebo NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Moreover RB N
, , N
MIP NNP N
and CC N
MEP NNP N
significantly RB N
improved VBD N
only RB N
after IN N
magnesium NN 3_i
administration NN N
( ( N
change NN N
in IN N
MIP NNP N
: : N
11 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.5 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
change NN N
in IN N
MEP NNP N
: : N
11.9 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.8 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

Magnesium NNP N
administration NN N
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
clinical JJ N
variables NNS N
assessed VBN N
by IN N
the DT N
SK NNP N
score NN N
( ( N
change NN N
: : N
4.48 CD N
points NNS N
after IN N
magnesium NN N
compared VBN N
with IN N
-1.30 NNP N
points NNS N
after IN N
placebo NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Oral NNP N
magnesium NN 3_i
supplementation NN N
helped VBD N
improve VB N
both DT N
the DT N
SK NNP N
score NN N
and CC N
respiratory JJ N
muscle NN N
strength NN N
in IN N
pediatric JJ N
patients NNS N
with IN N
CF NNP N
. . N

-DOCSTART- -X- O O

[ JJ N
Dose-effect NNP N
relationship NN N
of IN N
isosorbide NN 3_i
dinitrate NN 3_i
in IN N
the DT N
treatment NN N
of IN N
angina JJ N
pectoris NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

Fifteen JJ N
males NNS N
with IN N
angiographic JJ N
evidence NN N
of IN N
coronary JJ N
heart NN N
disease NN N
and CC N
stable JJ N
, , N
exercise-induced JJ N
angina NN N
pectoris NN N
were VBD N
given VBN N
placebo NNS 7_i
or CC N
isosorbide VB 3_i
dinitrate NN 3_i
( ( 3_i
ISDN NNP 3_i
) ) 3_i
in IN N
a DT N
dialy NN N
dose NN N
of IN N
30 CD N
mg NNS N
, , N
120 CD N
mg NN N
, , N
240 CD N
mg NN N
and CC N
480 CD N
mg NN N
in IN N
a DT N
randomized JJ N
single-blind JJ N
trial NN N
. . N

The DT N
daily JJ N
doses NNS N
were VBD N
given VBN N
as IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
5 CD N
mg NNS N
, , N
20 CD N
mg NN N
, , N
40 CD N
mg NN N
and CC N
80 CD N
mg JJ N
tablets NNS N
. . N

Each DT N
dose NN N
and CC N
placebo NN N
was VBD N
given VBN N
for IN N
seven CD N
days NNS N
. . N

On IN N
the DT N
seventh JJ N
day NN N
an DT N
exercise NN N
ECG NNP N
of IN N
standardized JJ N
level NN N
and CC N
duration NN N
of IN N
exercise NN N
was VBD N
recorded VBN N
. . N

The DT N
ischaemia NN N
response NN N
in IN N
the DT N
ECG NNP N
revealed VBD N
a DT N
dose-dependent JJ N
reduction NN N
by IN N
28 CD N
% NN N
( ( N
5 CD N
mg RB N
ISDN NNP N
) ) N
, , N
43 CD N
% NN N
( ( N
20 CD N
mg NN N
) ) N
, , N
60 CD N
% NN N
( ( N
40 CD N
mg NN N
) ) N
and CC N
73 CD N
% NN N
( ( N
80 CD N
mg NN N
) ) N
. . N

The DT N
number NN N
of IN N
anginal JJ N
attacks NNS N
similarly RB N
fell VBD N
parallel RB N
to TO N
dose VB N
. . N

Plasma NNP N
level NN N
of IN N
ISDN NNP N
and CC N
the DT N
mononitrates NNS N
, , N
measured VBD N
one CD N
and CC N
four CD N
hours NNS N
after IN N
drug NN N
intake NN N
, , N
rose VBD N
almost RB N
linearly JJ N
in IN N
relation NN N
to TO N
dose VB N
. . N

Oral NNP N
ISDN NNP N
thus RB N
has VBZ N
a DT N
dose-dependent JJ N
effect NN N
on IN N
the DT N
frequency NN N
of IN N
angina NN N
and CC N
ischaemia NN N
parameters NNS N
during IN N
ergometric JJ N
exercise NN N
. . N

The DT N
protracted JJ N
anti-anginal JJ N
effect NN N
of IN N
ISDN NNP N
is VBZ N
largely RB N
due JJ N
to TO N
its PRP$ N
metabolites NNS N
. . N

At IN N
high JJ N
doses NNS N
there EX N
is VBZ N
presumably RB N
an DT N
added JJ N
effect NN N
of IN N
the DT N
high JJ N
blood NN N
level NN N
of IN N
the DT N
basic JJ N
substance.U NN N
-DOCSTART- -X- O O

Cemented VBN 2_i
CeraOne NNP 2_i
and CC 2_i
porcelain NN 2_i
fused VBD 2_i
to TO 2_i
TiAdapt NNP 2_i
abutment JJ 2_i
single-implant JJ 2_i
crown JJ 2_i
restorations NNS 2_i
: : N
a DT N
10-year JJ N
comparative JJ N
follow-up NN N
study NN N
. . N

BACKGROUND NNP N
Long-term NNP N
data NNS N
comparing NN N
cemented VBN 2_i
and CC N
noncemented VBN 2_i
single-implant JJ 2_i
restorations NNS 2_i
has VBZ N
not RB N
been VBN N
reported VBN N
. . N

AIM NNP N
To TO N
compare VB N
clinical JJ N
and CC N
radiographic JJ N
performance NN N
of IN N
single-implant JJ 2_i
crown NN 2_i
restorations NNS 2_i
made VBN N
by IN N
either DT N
directly RB N
baked VBN 2_i
porcelain NN 2_i
to TO 2_i
custom-made JJ 2_i
TiAdapt NNP 2_i
titanium NN 2_i
abutments NNS 2_i
( ( N
Nobel NNP N
Biocare NNP N
AB NNP N
, , N
G?teborg NNP N
, , N
Sweden NNP N
) ) N
( ( N
test NN N
) ) N
or CC N
cement JJ N
crowns NNS N
onto IN N
CeraOne NNP N
( ( N
Nobel NNP N
Biocare NNP N
AB NNP N
) ) N
abutments NNS N
( ( N
control NN N
) ) N
after IN N
10 CD N
years NNS N
in IN N
function NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Altogether NNP N
, , N
35 CD N
consecutive JJ N
patients NNS N
were VBD N
provided VBN N
with IN N
41 CD N
turned VBD N
single JJ N
Br?nemark NNP N
System NNP N
implants NNS N
( ( N
Nobel NNP N
Biocare NNP N
AB NNP N
) ) N
in IN N
the DT N
partially RB N
edentulous JJ N
upper JJ N
jaw NN N
. . N

By IN N
random NN N
, , N
15 CD N
and CC N
20 CD N
patients NNS N
were VBD N
provided VBN N
with IN N
18 CD N
test NN N
and CC N
23 CD N
control NN N
implant JJ N
crowns NNS N
, , N
respectively RB N
. . N

Thereafter NNP N
, , N
clinical JJ N
and CC N
radiographic JJ N
data NNS N
were VBD N
collected VBN N
and CC N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
None NN N
of IN N
the DT N
implants NNS N
were VBD N
found VBN N
loose RB N
during IN N
the DT N
follow-up JJ N
period NN N
( ( N
100 CD N
% NN N
) ) N
. . N

Few JJ N
clinical JJ N
problems NNS N
were VBD N
observed VBN N
, , N
and CC N
the DT N
overall JJ N
average JJ N
marginal JJ N
bone NN N
loss NN N
was VBD N
0.26 CD N
mm NN N
( ( N
SD NNP N
0.64 CD N
) ) N
during IN N
10 CD N
years NNS N
in IN N
function NN N
. . N

After IN N
the DT N
final JJ N
tightening NN N
of IN N
the DT N
crowns NNS N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
test NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
> NNP N
.05 NNP N
) ) N
. . N

The DT N
head NN N
of IN N
the DT N
implants NNS N
was VBD N
placed VBN N
on IN N
an DT N
average JJ N
6.3 CD N
mm NN N
( ( N
SD NNP N
2.24 CD N
) ) N
below IN N
the DT N
cement/enamel JJ N
junction NN N
of IN N
the DT N
adjacent JJ N
teeth NN N
( ( N
range JJ N
2.5-10.0 JJ N
mm NN N
) ) N
. . N

Implants NNS N
with IN N
reported JJ N
mechanical JJ N
and/or NN N
mucosal NN N
problems NNS N
or CC N
placed VBD N
more JJR N
apically RB N
in IN N
relation NN N
to TO N
the DT N
adjacent JJ N
teeth NN N
did VBD N
not RB N
present VB N
more JJR N
bone JJ N
loss NN N
as IN N
compared VBN N
with IN N
implants NNS N
with IN N
no DT N
problems NNS N
or CC N
placed VBD N
more RBR N
coronally RB N
, , N
respectively RB N
( ( N
p JJ N
> NNP N
.05 NNP N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
seems VBZ N
to TO N
be VB N
no DT N
obvious JJ N
clinical JJ N
or CC N
radiographic JJ N
differences NNS N
between IN N
the DT N
test NN N
and CC N
control VB N
single-implant JJ N
restorations NNS N
during IN N
10 CD N
years NNS N
of IN N
follow-up JJ N
. . N

Occasionally NNP N
, , N
some DT N
restorations NNS N
presented VBD N
loose JJ N
abutment JJ N
screws NNS N
and/or VBP N
fistulas NNS N
during IN N
follow-up JJ N
. . N

This DT N
implies VBZ N
a DT N
certain JJ N
need NN N
for IN N
maintenance NN N
where WRB N
a DT N
one-piece JJ N
single-implant JJ N
protocol NN N
( ( N
test NN N
) ) N
allows VBZ N
both DT N
for IN N
a DT N
simple JJ N
clinical JJ N
procedure NN N
at IN N
placement NN N
without IN N
cementation NN N
problems NNS N
, , N
as RB N
well RB N
as IN N
for IN N
an DT N
easy JJ N
and CC N
simple JJ N
maintenance NN N
of IN N
installed JJ N
single JJ N
implant NN N
crowns NNS N
in IN N
long-term JJ N
function NN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
peer NN 4_i
counseling VBG 4_i
on IN N
smoking VBG N
cessation NN N
and CC N
reduction NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
a DT N
peer NN 4_i
counseling VBG 4_i
intervention NN 4_i
for IN N
pregnant JJ N
smokers NNS N
. . N

METHODS NNP N
One CD N
hundred VBD N
forty-two NN N
pregnant NN N
, , N
predominantly RB N
Hispanic JJ N
women NNS N
were VBD N
assigned VBN N
to TO N
a DT N
peer-led JJ 4_i
smoking NN 4_i
cessation NN 4_i
program NN 4_i
or CC 4_i
to TO 4_i
usual JJ 4_i
care NN 4_i
. . N

RESULTS NNP N
Compared VBD N
with IN N
usual JJ 4_i
care NN 4_i
, , 4_i
peer NN 4_i
counseling NN 4_i
reduced VBN N
smoking NN N
( ( N
-9.1 JJ N
versus NN N
-4.5 NNP N
cigarettes VBZ N
daily RB N
, , N
P NNP N
=.03 NNP N
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
absolute JJ N
quit NN N
rates NNS N
( ( N
24 CD N
% NN N
versus IN N
21 CD N
% NN N
) ) N
at IN N
36 CD N
weeks NNS N
' POS N
gestation NN N
. . N

Infant NNP N
birth NN N
weight VBD N
negatively RB N
correlated VBN N
with IN N
cigarettes NNS N
smoked VBN N
per IN N
day NN N
( ( N
r VB N
= NNP N
-0.29 NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
expired JJ N
carbon NN N
monoxide NN N
( ( N
r JJ N
= NNP N
-0.39 NN N
, , N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
at IN N
delivery NN N
. . N

Birth NNP N
weight VBD N
for IN N
infants NNS N
born VBN N
to TO N
women NNS N
who WP N
quit VBP N
smoking VBG N
averaged VBD N
7.2 CD N
lb JJ N
versus NN N
6.8 CD N
and CC N
6.3 CD N
lb NN N
for IN N
mothers NNS N
smoking VBG N
one CD N
to TO N
six CD N
and CC N
more JJR N
than IN N
six CD N
cigarettes NNS N
per IN N
day NN N
at IN N
delivery NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSION NNP N
Peer NNP 4_i
counseling NN 4_i
reduced VBD N
the DT N
number NN N
of IN N
cigarettes NNS N
smoked VBN N
daily RB N
but CC N
did VBD N
not RB N
increase VB N
cigarette NN N
abstinence NN N
rates NNS N
. . N

Infant NNP N
birth NN N
weight NN N
increases NNS N
with IN N
both DT N
smoking VBG N
cessation NN N
and CC N
smoking NN N
reduction NN N
, , N
suggesting VBG N
that IN N
peer NN 4_i
counseling VBG 4_i
intervention NN 4_i
programs NNS 4_i
may MD N
improve VB N
newborn JJR N
health NN N
despite IN N
their PRP$ N
failure NN N
to TO N
affect VB N
smoking VBG N
cessation NN N
. . N

-DOCSTART- -X- O O

Concomitant NNP N
, , N
sequential JJ N
, , N
and CC N
hybrid JJ N
therapy NN N
for IN N
H. NNP N
pylori JJ N
eradication NN N
: : N
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Since IN N
the DT N
efficacy NN N
of IN N
the DT N
standard JJ N
triple NN N
therapies NNS N
for IN N
Helicobacter NNP N
pylori NN N
eradication NN N
has VBZ N
decreased VBN N
, , N
novel JJ 3_i
antibiotic JJ 3_i
regimens NNS 3_i
have VBP N
been VBN N
introduced VBN N
, , N
including VBG 4_i
concomitant NN 4_i
, , 4_i
sequential JJ 4_i
, , N
and CC N
hybrid JJ 2_i
therapies NNS 2_i
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
cure NN N
rates NNS N
achieved VBN N
by IN N
these DT N
new JJ N
therapy NN N
regimens NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
open-label JJ N
, , N
pilot NN N
study NN N
enrolling VBG N
consecutive JJ N
non-ulcer JJ N
dyspepsia NN N
patients NNS N
with IN N
H. NNP N
pylori FW N
infection NN N
never RB N
previously RB N
treated VBN N
for IN N
the DT N
infection NN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( N
a DT N
) ) N
concomitant NN 2_i
therapy NN 2_i
: : 2_i
omeprazole JJ 2_i
20mg CD N
, , N
amoxicillin RB 3_i
1g CD N
, , N
clarithromycin VBD 3_i
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ 3_i
500 CD N
mg NN N
for IN N
5 CD N
days NNS N
; : N
( ( N
b NN N
) ) N
sequential JJ 2_i
therapy NN 2_i
: : 2_i
omeprazole JJ 2_i
20mg CD N
and CC N
amoxicillin $ 3_i
1g CD N
for IN N
5 CD N
days NNS N
followed VBN N
by IN N
omeprazole JJ 3_i
20mg CD N
, , N
clarithromycin VBD 3_i
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ 3_i
500 CD N
mg NN N
for IN N
5 CD N
days NNS N
; : N
( ( N
c NN N
) ) N
hybrid JJ 2_i
therapy NN 2_i
: : 2_i
omeprazole JJ 2_i
20mg CD N
, , N
and CC N
amoxicillin VBZ 3_i
1g CD N
for IN N
7 CD N
days NNS N
followed VBN N
by IN N
omeprazole JJ 3_i
20mg CD N
, , N
amoxicillin RB 3_i
1g CD N
, , N
clarithromycin VBD 3_i
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ 3_i
500 CD N
mg NN N
, , N
for IN N
7 CD N
days NNS N
. . N

All DT N
drugs NNS N
were VBD N
administered VBN N
twice RB N
daily RB N
. . N

Bacterial JJ N
eradication NN N
was VBD N
checked VBN N
6 CD N
weeks NNS N
after IN N
treatment NN N
by IN N
using VBG N
a DT N
( ( 2_i
13 CD 2_i
) ) 2_i
C-urea NNP 2_i
breath NN 2_i
test NN 2_i
. . N

A DT N
10-day JJ N
, , N
second-line JJ 2_i
therapy NN 2_i
with IN N
omeprazole JJ 3_i
20mg CD N
, , N
levofloxacin VBD 3_i
250 CD N
mg NN N
, , N
and CC N
amoxicillin RB 3_i
1g CD N
, , N
all DT N
given VBN N
twice RB N
daily RB N
, , N
was VBD N
offered VBN N
to TO N
the DT N
eradication NN N
failure NN N
patients NNS N
. . N

RESULTS NNP N
Overall NNP N
, , N
270 CD N
patients NNS N
were VBD N
enrolled VBN N
, , N
but CC N
13 CD N
patients NNS N
early RB N
interrupted VBN N
treatment NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

At IN N
intention-to-treat NN N
( ( N
ITT NNP N
) ) N
and CC N
per-protocol JJ N
analysis NN N
( ( N
PP NNP N
) ) N
, , N
the DT N
eradication NN N
rates NNS N
were VBD N
85.5 CD N
% NN N
and CC N
91.6 CD N
% NN N
with IN N
the DT N
concomitant JJ 3_i
regimen NNS 3_i
, , N
91.1 CD N
% NN N
and CC N
92.1 CD N
% NN N
with IN N
the DT N
sequential JJ 2_i
therapy NN 2_i
, , N
and CC N
80 CD N
% NN N
and CC N
85.7 CD N
% NN N
with IN N
the DT N
hybrid JJ 3_i
regimen NNS 3_i
. . N

Differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

H. NNP N
pylori JJ N
infection NN N
was VBD N
cured VBN N
in IN N
10 CD N
( ( N
55.6 CD N
% NN N
) ) N
patients NNS N
with IN N
the DT N
second-line JJ 3_i
regimen NNS 3_i
. . N

CONCLUSION NN N
In IN N
our PRP$ N
study NN N
, , N
both DT N
concomitant NN 3_i
and CC N
sequential JJ N
therapy NN N
, , N
but CC N
not RB N
hybrid JJ N
therapy NN N
, , N
reached VBN N
high JJ N
eradication NN N
rates NNS N
. . N

The DT N
success NN N
rate NN N
of IN N
second-line JJ N
levofloxacin-based JJ N
triple NN N
therapy NN N
is VBZ N
decreasing VBG N
. . N

-DOCSTART- -X- O O

Trunk NNP 2_i
exercise NN 2_i
combined VBN 2_i
with IN 2_i
spinal JJ 2_i
manipulative NN 2_i
or CC N
NSAID NNP 3_i
therapy NN 3_i
for IN N
chronic JJ N
low JJ N
back RB N
pain NN N
: : N
a DT N
randomized JJ N
, , N
observer-blinded JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
study VB N
the DT N
relative JJ N
efficacy NN N
of IN N
three CD N
different JJ N
treatment NN N
for IN N
chronic JJ N
low JJ N
back RB N
pain NN N
( ( N
CLBP NNP N
) ) N
. . N

Two CD N
preplanned JJ N
comparisons NNS N
were VBD N
made VBN N
: : N
( ( N
a DT N
) ) N
Spinal NNP 2_i
manipulative JJ 2_i
therapy NN 2_i
( ( 2_i
SMT NNP 2_i
) ) 2_i
combined VBD 2_i
with IN 2_i
trunk NN 2_i
strengthening VBG 2_i
exercises NNS 2_i
( ( 2_i
TSE NNP 2_i
) ) 2_i
vs. FW 2_i
SMT NNP 2_i
combined VBD 2_i
with IN 2_i
trunk NN 2_i
stretching VBG 2_i
exercises NNS 2_i
, , 2_i
and CC 2_i
( ( N
b NN N
) ) N
SMT NNP 2_i
combined VBN 2_i
with IN 2_i
TSE NNP 2_i
vs. FW 2_i
nonsteroidal JJ 3_i
anti-inflammatory JJ 3_i
drug NN 3_i
( ( 3_i
NSAID NNP 3_i
) ) 3_i
therapy NN 3_i
combined VBN 3_i
with IN 3_i
TSE NNP 3_i
. . N

STUDY NNP N
DESIGN NNP N
Interdisciplinary NNP N
, , N
prospective JJ N
, , N
observer-blinded JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
with IN N
a DT N
1-yr JJ N
follow-up JJ N
period NN N
. . N

The DT N
trial NN N
evaluated VBD N
therapies NNS N
in IN N
combination NN N
only RB N
and CC N
was VBD N
not RB N
designed VBN N
to TO N
test VB N
the DT N
individual JJ N
treatment NN N
components NNS N
. . N

SETTING NNP N
Primary NNP N
contact NN N
, , N
college NN N
out-patient JJ N
clinic NN N
. . N

PATIENTS NNP N
In IN N
total JJ N
, , N
174 CD N
patients NNS N
aged VBN N
20-60 JJ N
yr NNS N
were VBD N
admitted VBN N
to TO N
the DT N
study NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Patient-rated NNP N
low JJ N
back RB N
pain NN N
, , N
disability NN N
, , N
and CC N
functional JJ N
health NN N
status NN N
at IN N
5 CD N
and CC N
11 CD N
wk NN N
. . N

INTERVENTIONS NNP N
Five NNP N
weeks NNS N
of IN N
SMT NNP 2_i
or CC N
NSAID NNP 3_i
therapy NN 2_i
in IN 2_i
combination NN 2_i
with IN 2_i
supervised JJ 2_i
trunk NN 2_i
exercise NN 2_i
, , N
followed VBN N
by IN N
and CC N
additional JJ N
6 CD N
wk NN N
of IN N
supervised JJ 2_i
exercise NN 2_i
alone RB 2_i
. . 2_i

RESULTS NNP N
Individual NNP N
group NN N
comparisons NNS N
after IN N
5 CD N
and CC N
11 CD N
wk NN N
of IN N
intervention NN N
on IN N
all DT N
three CD N
main JJ N
outcome NN N
measures NNS N
did VBD N
not RB N
reveal VB N
any DT N
clear JJ N
clinically RB N
important JJ N
or CC N
statistically RB N
significant JJ N
differences NNS N
. . N

There EX N
seemed VBD N
to TO N
be VB N
a DT N
sustained JJ N
reduction NN N
in IN N
medication NN N
use NN N
at IN N
the DT N
1-yr JJ N
follow-up NN N
. . N

in IN N
the DT N
SMT/TSE NNP N
group NN N
. . N

Continuance NN N
of IN N
exercise NN N
during IN N
the DT N
follow-up JJ N
year NN N
, , N
regardless RB N
of IN N
type NN N
, , N
was VBD N
associated VBN N
with IN N
a DT N
better JJR N
outcome NN N
. . N

CONCLUSION NNP N
Each DT N
of IN N
the DT N
three CD N
therapeutic JJ N
regimens NNS N
was VBD N
associated VBN N
with IN N
similar JJ N
and CC N
clinically RB N
important JJ N
improvement NN N
over IN N
time NN N
that WDT N
was VBD N
considered VBN N
superior JJ N
to TO N
the DT N
expected JJ N
natural JJ N
history NN N
of IN N
long-standing JJ N
CLBP NNP N
. . N

For IN N
the DT N
management NN N
of IN N
CLBP NNP N
, , N
trunk NN N
exercise NN N
in IN N
combination NN N
with IN N
SMT NNP 2_i
or CC N
NSAID NNP 3_i
therapy NN 3_i
seemed VBD N
to TO N
be VB N
beneficial JJ N
and CC N
worthwhile JJ N
. . N

The DT N
magnitude NN N
of IN N
nonspecific JJ N
therapeutic JJ N
( ( 7_i
placebo NN 7_i
) ) 7_i
effects NNS N
, , N
cost-effectiveness NN N
and CC N
relative JJ N
risks NNS N
of IN N
side NN N
effects NNS N
associated VBN N
with IN N
these DT N
types NNS N
of IN N
therapy NN N
need NN N
to TO N
be VB N
addressed VBN N
in IN N
future JJ N
studies NNS N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
the DT N
effectiveness NN N
and CC N
patient JJ N
tolerance NN N
of IN N
oral JJ N
sodium NN N
phosphate NN N
, , N
castor NN N
oil NN N
, , N
and CC N
standard JJ N
electrolyte NN N
lavage NN N
for IN N
colonoscopy NN N
or CC N
sigmoidoscopy JJ N
preparation NN N
. . N

One CD N
hundred VBD N
thirteen JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ 3_i
sodium NN 3_i
phosphate NN 3_i
( ( 3_i
Fleet NNP 3_i
Phospho-Soda NNP 3_i
) ) 3_i
, , N
lemon-flavored JJ 3_i
castor NN 3_i
oil NN 3_i
( ( 3_i
Purge NNP 3_i
) ) 3_i
, , N
or CC N
standard JJ 3_i
polyethylene NN 3_i
glycol-based JJ 3_i
lavage NN 3_i
solution NN 3_i
( ( 3_i
GoLYTELY NNP 3_i
) ) 3_i
before IN N
elective JJ N
colonoscopy NN N
. . N

The DT N
study NN N
purpose NN N
was VBD N
to TO N
confirm VB N
the DT N
efficacy NN N
of IN N
oral JJ N
sodium NN 3_i
phosphate NN 3_i
and CC N
extend VB N
observations NNS N
to TO N
include VB N
castor JJ 3_i
oil NN 3_i
. . N

Overall NNP N
, , N
patients NNS N
reported VBD N
that IN N
sodium NN 3_i
phosphate NN 3_i
and CC N
castor NN 3_i
oil NN 3_i
were VBD N
easier JJR N
to TO N
complete VB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Scores NNS N
for IN N
cleansing VBG N
the DT N
entire JJ N
colon NN N
as IN N
determined VBN N
by IN N
endoscopists NNS N
who WP N
were VBD N
blinded VBN N
to TO N
the DT N
cathartic JJ N
agent NN N
were VBD N
highest JJS N
in IN N
patients NNS N
receiving VBG N
sodium NN 3_i
phosphate NN 3_i
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

Scores NNS N
of IN N
left-colon NN N
cleansing NN N
for IN N
flexible JJ N
sigmoidoscopy NN N
were VBD N
equally RB N
high JJ N
for IN N
the DT N
three CD N
methods NNS N
. . N

Scores NNS N
for IN N
taste NN N
and CC N
symptom JJ N
side NN N
effects NNS N
were VBD N
similar JJ N
for IN N
each DT N
preparation NN N
. . N

There EX N
were VBD N
no DT N
recognized VBN N
signs NNS N
or CC N
symptoms NNS N
of IN N
hypocalcemia NN N
in IN N
the DT N
sodium NN N
phosphate NN N
group NN N
. . N

Because IN N
of IN N
the DT N
low JJ N
cost NN N
of IN N
oral JJ N
sodium NN 3_i
phosphate NN 3_i
combined VBN N
with IN N
the DT N
lowest JJS N
repeat NN N
endoscopy NN N
rate NN N
for IN N
inadequate JJ N
cleansing NN N
, , N
patient JJ N
savings NNS N
were VBD N
projected VBN N
to TO N
be VB N
$ $ N
5000 CD N
per IN N
100 CD N
patients NNS N
at IN N
this DT N
center NN N
. . N

Oral JJ N
sodium NN 3_i
phosphate NN 3_i
is VBZ N
a DT N
cost-effective JJ N
colonoscopy NN N
preparation NN N
that WDT N
is VBZ N
better RBR N
tolerated VBN N
and CC N
more RBR N
effective JJ N
than IN N
the DT N
polyethylene JJ 3_i
glycol-electrolyte JJ 3_i
lavage NN 3_i
solution NN 3_i
or CC N
castor NN 3_i
oil NN 3_i
. . N

-DOCSTART- -X- O O

Different JJ N
cardiac JJ N
biomarkers NNS N
to TO N
detect VB N
peri-procedural JJ N
myocardial JJ N
infarction NN N
in IN N
contemporary JJ N
coronary JJ N
stent NN N
trials NNS N
: : N
impact NN N
on IN N
outcome NN N
reporting NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
differential JJ N
implications NNS N
of IN N
cardiac JJ N
biomarker NN N
type NN N
on IN N
peri-procedural JJ N
myocardial JJ N
infarction NN N
( ( N
PMI NNP N
) ) N
reporting NN N
. . N

SETTING CC N
The DT N
Resolute NNP N
'All-Comers NNS N
' POS N
stent JJ N
trial NN N
. . N

INTERVENTIONS NNP N
Blood NNP N
samples NNS N
for IN N
creatine NN N
kinase NN N
( ( N
CK NNP N
) ) N
, , N
CK-myoband NNP N
( ( N
CK-MB NNP N
) ) N
mass NN N
or CC N
cardiac JJ N
troponin NN N
( ( N
cTn NN N
) ) N
( ( N
optional JJ N
) ) N
were VBD N
collected VBN N
before RB N
and CC N
at IN N
6 CD N
, , N
12 CD N
and CC N
18 CD N
h NN N
after IN N
the DT N
assigned JJ N
percutaneous JJ 2_i
coronary JJ 2_i
intervention NN 2_i
or CC N
at IN N
discharge NN N
. . N

PMIs NNP N
were VBD N
adjudicated VBN N
using VBG N
either CC N
the DT N
2007 CD N
universal JJ N
definition NN N
of IN N
MI NNP N
( ( N
type-4a JJ N
) ) N
or CC N
the DT N
extended JJ N
historical JJ N
definition NN N
of IN N
MI NNP N
. . N

PATIENTS NNP N
2121/2292 CD N
patients NNS N
( ( N
92.5 CD N
% NN N
) ) N
had VBD N
an DT N
analysable JJ N
dataset NN N
for IN N
either DT N
biomarker NN N
. . N

890/2121 CD N
patients NNS N
( ( N
42 CD N
% NN N
) ) N
presented VBN N
with IN N
an DT N
acute JJ N
coronary JJ N
syndrome NN N
( ( N
ACS NNP N
) ) N
. . N

267/890 CD N
patients NNS N
( ( N
30 CD N
% NN N
) ) N
were VBD N
within IN N
24 CD N
h NN N
of IN N
an DT N
ST-segment JJ N
elevation NN N
MI NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Type-4a NNP N
MI NNP N
was VBD N
diagnosed VBN N
in IN N
208/2121 CD N
patients NNS N
( ( N
9.8 CD N
% NN N
) ) N
when WRB N
cTn NN N
was VBD N
used VBN N
( ( N
CK-MB JJ N
mass NN N
if IN N
cTn NN N
not RB N
available JJ N
) ) N
, , N
and CC N
in IN N
93/2121 CD N
of IN N
patients NNS N
( ( N
4.4 CD N
% NN N
) ) N
when WRB N
CK-MB JJ N
mass NN N
was VBD N
used VBN N
( ( N
cTn JJ N
if IN N
CK-MB NNP N
mass NN N
not RB N
available JJ N
) ) N
. . N

With IN N
the DT N
extended JJ N
historical JJ N
CK-based JJ N
definition NN N
of IN N
MI NNP N
, , N
PMI NNP N
was VBD N
diagnosed VBN N
in IN N
65/2121 CD N
patients NNS N
( ( N
3.1 CD N
% NN N
) ) N
. . N

Adjudication NN N
of IN N
type-4a JJ N
MI NNP N
in IN N
patients NNS N
with IN N
an DT N
ACS NNP N
was VBD N
problematic JJ N
with IN N
< JJ N
10 CD N
% NN N
of IN N
the DT N
potential JJ N
type-4a NN N
MI NNP N
being VBG N
confirmed VBN N
as IN N
an DT N
event NN N
, , N
as IN N
compared VBN N
with IN N
approximately RB N
95 CD N
% NN N
in IN N
stable JJ N
patients NNS N
undergoing VBG N
elective JJ N
PCI NNP N
. . N

Type-4a NNP N
MI NNP N
was VBD N
not RB N
associated VBN N
with IN N
the DT N
subsequent JJ N
hazard NN N
for IN N
cardiac JJ N
mortality NN N
( ( N
p=0.6 NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
percentage NN N
of IN N
adjudicated JJ N
PMI NNP N
events NNS N
is VBZ N
driven VBN N
by IN N
the DT N
MI-definition NNP N
criteria NNS N
and CC N
biomarker NN N
type NN N
. . N

Type-4a JJ N
MI NNP N
may MD N
not RB N
be VB N
a DT N
reliable JJ N
component NN N
of IN N
the DT N
primary JJ N
composite JJ N
end NN N
point NN N
in IN N
coronary JJ N
stent NN N
investigations NNS N
which WDT N
recruit VBP N
patients NNS N
with IN N
ACS NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
http NN N
: : N
//www.ClinicalTrials.gov NN N
; : N
Unique NNP N
identifier NN N
: : N
NCT00617084 NNP N
. . N

-DOCSTART- -X- O O

DTkid NN N
: : N
interactive JJ N
simulation NN N
software NN N
for IN N
training VBG N
tutors NNS N
of IN N
children NNS N
with IN N
autism NN N
. . N

Discrete-trial JJ 2_i
training NN 2_i
( ( N
DTT NNP N
) ) N
relies VBZ N
critically RB N
on IN N
implementation NN N
by IN N
trained JJ N
tutors NNS N
. . N

We PRP N
report VBP N
three CD N
experiments NNS N
carried VBD N
out RP N
in IN N
the DT N
development NN N
of IN N
DTkid NNP N
-- : N
interactive JJ N
computer NN N
simulation NN N
software NN N
that WDT N
presents VBZ N
SIMon NNP N
, , N
a DT N
realistic JJ N
virtual JJ N
child NN N
with IN N
whom WP N
novice JJ N
tutors NNS N
can MD N
learn VB N
and CC N
practise VB N
DTT NNP N
techniques NNS N
. . N

Experiments NNS N
1 CD N
and CC N
2 CD N
exposed JJ N
groups NNS N
of IN N
participants NNS N
either DT N
to TO N
DTkid NNP 4_i
training NN 4_i
or CC N
to TO N
a DT N
control NN 7_i
task NN 7_i
. . N

Participants NNS N
in IN N
the DT N
former JJ N
groups NNS N
demonstrated VBD N
significantly RB N
greater JJR N
procedural JJ N
and CC N
declarative JJ N
knowledge NN N
of IN N
DTT NNP N
. . N

Experiment NNP N
3 CD N
confirmed VBD N
this DT N
finding NN N
, , N
further JJ N
demonstrating NN N
that IN N
observation NN N
of IN N
DTkid NNP 2_i
training NN 2_i
trials NNS N
alone RB N
was VBD N
sufficient JJ N
to TO N
enhance VB N
participants NNS N
' POS N
declarative NN N
and CC N
procedural JJ N
knowledge NN N
of IN N
DTT NNP N
. . N

Results NNP N
indicate VBP N
that IN N
DTkid NNP N
offers VBZ N
the DT N
potential NN N
for IN N
an DT N
effective JJ N
means NNS N
of IN N
teaching VBG N
DTT NNP N
skills NNS N
to TO N
novice JJ N
tutors NNS N
of IN N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O

A DT N
stable JJ 3_i
prostacyclin NN 3_i
analogue NN 3_i
( ( 3_i
iloprost NN 3_i
) ) 3_i
in IN N
the DT N
treatment NN N
of IN N
ischaemic JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
. . N

A DT N
Scandinavian-Polish JJ N
placebo NN 7_i
controlled VBN N
, , N
randomised VBN N
multicenter NN N
study NN N
. . N

The DT N
clinical JJ N
efficacy NN N
of IN N
the DT N
prostacyclin NN 3_i
analogue NN 3_i
iloprost NN 3_i
was VBD N
studied VBN N
during IN N
a DT N
2 CD N
week NN N
treatment NN N
and CC N
6 CD N
month NN N
follow-up JJ N
period NN N
in IN N
103 CD N
patients NNS N
with IN N
ischaemic JJ N
ulcers NNS N
who WP N
were VBD N
randomised VBN N
to TO N
receive VB N
active JJ 3_i
treatment NN 3_i
or CC N
placebo NN 7_i
. . N

Responders NNS N
were VBD N
defined VBN N
as IN N
those DT N
patients NNS N
who WP N
achieved VBD N
healing NN N
of IN N
at IN N
least JJS N
one CD N
third NN N
of IN N
the DT N
ulcer JJ N
area NN N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
overall JJ N
responder NN N
rate NN N
was VBD N
41.3 CD N
% NN N
, , N
compared VBN N
with IN N
25 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.086 CD N
) ) N
. . N

Side JJ N
effects NNS N
including VBG N
flushing NN N
and CC N
headache NN N
, , N
were VBD N
common JJ N
. . N

The DT N
study NN N
population NN N
had VBD N
a DT N
mortality NN N
of IN N
23 CD N
% NN N
during IN N
the DT N
6 CD N
month NN N
period NN N
, , N
the DT N
amputation NN N
rate NN N
was VBD N
43.5 CD N
% NN N
for IN N
iloprost NN 3_i
and CC N
50 CD N
% NN N
for IN N
placebo NN 7_i
treated VBN N
patients NNS N
. . N

In IN N
this DT N
severely RB N
diseased JJ N
population NN N
of IN N
patients NNS N
a DT N
treatment NN N
period NN N
limited VBD N
to TO N
2 CD N
weeks NNS N
did VBD N
not RB N
sufficiently RB N
improve VB N
ulcer NN N
healing NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
health-promotion NN 4_i
programme NN 4_i
and CC N
its PRP$ N
effect NN N
on IN N
ADL NNP N
dependence NN N
and CC N
self-reported JJ N
health NN N
problems NNS N
for IN N
the DT N
elderly JJ N
visually RB N
impaired VBN N
. . N

BACKGROUND NNP N
Ageing VBG N
with IN N
visual JJ N
impairment NN N
is VBZ N
associated VBN N
with IN N
a DT N
high JJ N
degree NN N
of IN N
disability NN N
whereby WRB N
age-related JJ N
macular JJ N
degeneration NN N
in IN N
particular JJ N
causes NNS N
dependence NN N
in IN N
activities NNS N
of IN N
daily JJ N
living NN N
( ( N
ADL NNP N
) ) N
even RB N
at IN N
an DT N
early JJ N
stage NN N
. . N

AIMS NNP N
To TO N
compare VB N
an DT N
activity-based JJ N
, , N
health-promotion JJ 4_i
programme NN 4_i
with IN N
an DT N
individual JJ 4_i
programme NN 4_i
, , N
targeting VBG N
the DT N
elderly JJ N
with IN N
age-related JJ N
macular JJ N
degeneration NN N
concerning VBG N
the DT N
effect NN N
on IN N
the DT N
development NN N
of IN N
dependence NN N
in IN N
ADL NNP N
, , N
general JJ N
health NN N
, , N
and CC N
self-reported JJ N
health NN N
problems NNS N
. . N

METHODS VB N
A DT N
randomized NN N
controlled VBN N
study NN N
with IN N
a DT N
28-month JJ N
follow-up NN N
. . N

A DT N
total NN N
of IN N
229 CD N
persons NNS N
were VBD N
randomized VBN N
to TO N
the DT N
study NN N
and CC N
131 CD N
( ( N
57 CD N
% NN N
) ) N
were VBD N
followed VBN N
up RP N
( ( 4_i
individual JJ 7_i
intervention NN 7_i
n=69 NN N
, , N
health-promotion NN 4_i
programme NN 4_i
n=62 NN N
) ) N
at IN N
28-month JJ N
. . N

RESULTS VB N
The DT N
health-promotion NN 4_i
group NN 4_i
maintained VBD N
their PRP$ N
ADL NNP N
level NN N
despite IN N
a DT N
significant JJ N
decrease NN N
in IN N
visual JJ N
acuity NN N
, , N
while IN N
the DT N
individual JJ 4_i
intervention NN 4_i
group NN N
increased VBD N
its PRP$ N
dependence NN N
in IN N
ADL NNP N
. . N

General NNP N
health NN N
systematically RB N
dropped VBD N
to TO N
a DT N
lower JJR N
level NN N
in IN N
both DT N
groups NNS N
, , N
but CC N
participants NNS N
from IN N
the DT N
health-promotion NN 4_i
group NN 4_i
reported VBD N
fewer JJR N
health NN N
problems NNS N
. . N

There EX N
were VBD N
significantly RB N
fewer JJR N
reports NNS N
of IN N
tiredness NN N
and CC N
dizziness NN N
among IN N
the DT N
health-promotion NN 2_i
participants NNS N
. . N

CONCLUSION VB N
The DT N
health-promotion NN N
programme NN N
seems VBZ N
to TO N
have VB N
slowed VBN N
down RP N
the DT N
disablement JJ N
process NN N
among IN N
elderly JJ N
with IN N
decreased JJ N
vision NN N
by IN N
enabling VBG N
them PRP N
to TO N
maintain VB N
their PRP$ N
ADL NNP N
level NN N
and CC N
by IN N
reducing VBG N
self-reported JJ N
health NN N
problems NNS N
for IN N
at IN N
least JJS N
28 CD N
months NNS N
following VBG N
intervention NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
and CC N
prognostic JJ N
significance NN N
of IN N
serum NN N
magnesium NN N
concentration NN N
in IN N
patients NNS N
with IN N
severe JJ N
chronic JJ N
congestive JJ N
heart NN N
failure NN N
: : N
the DT N
PROMISE NNP N
Study NNP N
. . N

OBJECTIVES NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
prognostic JJ N
significance NN N
of IN N
alterations NNS N
in IN N
serum JJ N
magnesium NN N
in IN N
patients NNS N
with IN N
moderate JJ N
to TO N
severe VB N
congestive JJ N
heart NN N
failure NN N
. . N

BACKGROUND NNP N
Reductions NNPS N
in IN N
serum NN N
magnesium NN N
have VBP N
been VBN N
postulated VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
promoting VBG N
arrhythmias NN N
and CC N
to TO N
have VB N
an DT N
adverse JJ N
impact NN N
on IN N
survival NN N
in IN N
congestive JJ N
heart NN N
failure NN N
, , N
although IN N
support NN N
for IN N
this DT N
postulate NN N
is VBZ N
lacking VBG N
. . N

METHODS NNP N
Serum NNP N
magnesium NN N
levels NNS N
were VBD N
measured VBN N
in IN N
1,068 CD N
patients NNS N
enrolled VBN N
in IN N
a DT N
survival NN N
study NN N
of IN N
class NN N
III NNP N
or CC N
IV NNP N
heart NN N
failure NN N
at IN N
the DT N
time NN N
of IN N
double-blind JJ N
randomization NN N
to TO N
milrinone VB 3_i
, , N
a DT N
phosphodiesterase NN 3_i
inhibitor NN 3_i
, , N
or CC N
placebo NN 7_i
. . N

All DT N
patients NNS N
received VBD N
conventional JJ 3_i
therapy NN 3_i
with IN 3_i
digoxin NN 3_i
, , 3_i
diuretic JJ 3_i
drugs NNS 3_i
and CC 3_i
a DT 3_i
converting VBG 3_i
enzyme NN 3_i
inhibitor NN 3_i
throughout IN N
the DT N
trial NN N
. . N

The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
6.1 CD N
months NNS N
( ( N
range VB N
1 CD N
day NN N
to TO N
20 CD N
months NNS N
) ) N
. . N

RESULTS JJ N
Patients NNS N
with IN N
high JJ N
serum NN N
magnesium NN N
( ( N
defined VBN N
as IN N
> NN N
or CC N
= $ N
1.9 CD N
mEq/liter NN N
, , N
n JJ N
= NNP N
242 CD N
) ) N
were VBD N
less RBR N
likely JJ N
to TO N
survive VB N
than IN N
were VBD N
patients NNS N
with IN N
a DT N
normal JJ N
magnesium NN N
level NN N
( ( N
n JJ N
= NNP N
627 CD N
) ) N
( ( N
p JJ N
< NN N
0.05 CD N
, , N
risk NN N
ratio NN N
= NNP N
1.41 CD N
) ) N
. . N

Patients NNS N
with IN N
a DT N
low JJ N
magnesium NN N
level NN N
( ( N
defined VBN N
as IN N
< NN N
or CC N
= $ N
1.5 CD N
mEq/liter NN N
, , N
n JJ N
= NNP N
199 CD N
) ) N
had VBD N
no DT N
difference NN N
in IN N
survival NN N
compared VBN N
with IN N
the DT N
group NN N
with IN N
a DT N
normal JJ N
magnesium NN N
level NN N
( ( N
p JJ N
= NNP N
NS NNP N
, , N
risk NN N
ratio NN N
= NNP N
0.89 CD N
) ) N
. . N

At IN N
baseline NN N
, , N
the DT N
patients NNS N
in IN N
the DT N
high JJ N
magnesium NN N
group NN N
were VBD N
older JJR N
and CC N
had VBD N
more RBR N
severe JJ N
functional JJ N
and CC N
renal JJ N
impairment NN N
. . N

An DT N
analysis NN N
after IN N
adjustment NN N
for IN N
these DT N
variables NNS N
demonstrated VBD N
no DT N
difference NN N
in IN N
survival NN N
comparing VBG N
the DT N
low JJ N
, , N
normal JJ N
and CC N
high JJ N
magnesium NN N
groups NNS N
. . N

Although IN N
the DT N
three CD N
groups NNS N
had VBD N
no DT N
difference NN N
in IN N
frequency NN N
of IN N
ventricular JJ N
tachycardia NN N
, , N
length NN N
of IN N
longest JJS N
run NN N
or CC N
frequency NN N
of IN N
ventricular JJ N
premature NN N
beats NNS N
on IN N
baseline NN N
Holter NNP N
monitoring NN N
, , N
the DT N
group NN N
with IN N
hypomagnesemia NN N
had VBD N
more RBR N
frequent JJ N
ventricular JJ N
couplets NNS N
. . N

CONCLUSIONS NNP N
Serum NNP N
magnesium NN N
does VBZ N
not RB N
appear VB N
to TO N
be VB N
an DT N
independent JJ N
risk NN N
factor NN N
for IN N
either DT N
sudden JJ N
death NN N
or CC N
death NN N
due JJ N
to TO N
all DT N
causes NNS N
in IN N
patients NNS N
with IN N
moderate JJ N
to TO N
severe VB N
heart NN N
failure NN N
. . N

Hypomagnesemia NNP N
is VBZ N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
the DT N
frequency NN N
of IN N
certain JJ N
forms NNS N
of IN N
ventricular JJ N
ectopic NN N
activity NN N
, , N
but CC N
this DT N
is VBZ N
not RB N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
clinical JJ N
events NNS N
. . N

The DT N
higher JJR N
mortality NN N
rate NN N
among IN N
the DT N
patients NNS N
with IN N
hypermagnesemia NN N
is VBZ N
attributable JJ N
to TO N
older JJR N
age NN N
, , N
more RBR N
advanced JJ N
heart NN N
failure NN N
and CC N
renal JJ N
insufficiency NN N
. . N

-DOCSTART- -X- O O

Evaluating VBG N
proton NN 2_i
stereotactic JJ 2_i
body NN 2_i
radiotherapy NN 2_i
to TO N
reduce VB N
chest JJS N
wall NN N
dose NN N
in IN N
the DT N
treatment NN N
of IN N
lung NN N
cancer NN N
. . N

Stereotactic JJ 2_i
body NN 2_i
radiotherapy NN 2_i
( ( 2_i
SBRT NNP 2_i
) ) 2_i
can MD N
produce VB N
excellent JJ N
local JJ N
control NN N
of IN N
several JJ N
types NNS N
of IN N
solid JJ N
tumor NN N
; : N
however RB N
, , N
toxicity NN N
to TO N
nearby RB N
critical JJ N
structures NNS N
is VBZ N
a DT N
concern NN N
. . N

We PRP N
found VBD N
previously RB N
that IN N
in IN N
SBRT NNP 2_i
for IN N
lung NN N
cancer NN N
, , N
the DT N
chest JJS N
wall NN N
( ( N
CW NNP N
) ) N
volume NN N
receiving VBG N
20 CD 6_i
, , 6_i
30 CD 6_i
, , 6_i
or CC 6_i
40Gy CD 6_i
( ( N
V20 NNP N
, , N
V30 NNP N
, , N
or CC N
V40 NNP N
) ) N
was VBD N
linked VBN N
with IN N
the DT N
development NN N
of IN N
neuropathy NN N
. . N

Here RB N
we PRP N
sought VBD N
to TO N
determine VB N
whether IN N
the DT N
dosimetric JJ N
advantages NNS N
of IN N
protons NNS N
could MD N
produce VB N
lower JJR N
CW NNP N
doses NNS N
than IN N
traditional JJ N
photon-based JJ 2_i
SBRT NNP 2_i
. . 2_i

We PRP N
searched VBD N
an DT N
institutional JJ N
database NN N
to TO N
identify VB N
patients NNS N
treated VBN N
with IN N
photon NN 2_i
SBRT NNP 2_i
for IN N
lung NN N
cancer NN N
with IN N
tumors NNS N
within IN N
< JJ N
2.5cm CD N
of IN N
the DT N
CW NNP N
. . N

We PRP N
found VBD N
260 CD N
cases NNS N
; : N
of IN N
these DT N
, , N
chronic NN N
grade NN N
? . N
2 CD N
CW NNP N
pain NN N
was VBD N
identified VBN N
in IN N
23 CD N
patients NNS N
. . N

We PRP N
then RB N
selected VBD N
10 CD N
representative JJ N
patients NNS N
from IN N
this DT N
group NN N
and CC N
generated VBD N
proton NN N
SBRT NNP N
treatment NN N
plans NNS N
, , N
using VBG N
the DT N
identical JJ N
dose NN N
of IN N
50Gy CD N
in IN N
4 CD N
fractions NNS N
, , N
and CC N
assessed VBD N
potential JJ N
differences NNS N
in IN N
CW NNP N
dose NN N
between IN N
the DT N
2 CD N
plans NNS N
. . N

The DT N
proton NN N
SBRT NNP N
plans VBZ N
reduced VBD N
the DT N
CW NNP N
doses NNS N
at IN N
all DT N
dose JJ N
levels NNS N
measured VBN N
. . N

The DT N
median JJ N
CW NNP N
V20 NNP N
was VBD N
364.0cm CD N
( ( N
3 CD N
) ) N
and CC N
160.0cm CD N
( ( N
3 CD N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
V30 NNP N
was VBD N
144.6cm CD N
( ( N
3 CD N
) ) N
vs NN N
77.0cm CD N
( ( N
3 CD N
) ) N
( ( N
p JJ N
= NNP N
0.0012 CD N
) ) N
, , N
V35 NNP N
was VBD N
93.9cm CD N
( ( N
3 CD N
) ) N
vs NN N
57.9cm CD N
( ( N
3 CD N
) ) N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
, , N
V40 NNP N
was VBD N
66.5cm CD N
( ( N
3 CD N
) ) N
vs NN N
45.4cm CD N
( ( N
3 CD N
) ) N
( ( N
p JJ N
= NNP N
0.0112 CD N
) ) N
, , N
and CC N
mean JJ N
lung NN N
dose NN N
was VBD N
5.9Gy CD N
vs NN N
3.8Gy CD N
( ( N
p NN N
= RB N
0.0001 CD N
) ) N
for IN N
photons NNS N
and CC N
protons NNS N
, , N
respectively RB N
. . N

Coverage NN N
of IN N
the DT N
planning NN N
target NN N
volume NN N
( ( N
PTV NNP N
) ) N
was VBD N
comparable JJ N
between IN N
the DT N
2 CD N
sets NNS N
of IN N
plans NNS N
( ( N
96.4 CD N
% NN N
for IN N
photons NNS N
and CC N
97 CD N
% NN N
for IN N
protons NNS N
) ) N
. . N

From IN N
a DT N
dosimetric JJ N
standpoint NN N
, , N
proton NN N
SBRT NNP N
can MD N
achieve VB N
the DT N
same JJ N
coverage NN N
of IN N
the DT N
PTV NNP N
while IN N
significantly RB N
reducing VBG N
the DT N
dose NN N
to TO N
the DT N
CW NNP N
and CC N
lung RB N
relative JJ N
to TO N
photon VB N
SBRT NNP N
and CC N
therefore RB N
may MD N
be VB N
beneficial JJ N
for IN N
the DT N
treatment NN N
of IN N
lesions NNS N
closer VBP N
to TO N
critical JJ N
structures NNS N
. . N

-DOCSTART- -X- O O

Argatroban NNP 3_i
for IN N
elective JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
: : N
the DT N
ARG-E04 NNP N
multi-center NN N
study NN N
. . N

UNLABELLED IN N
The DT N
synthetic JJ N
arginine-derived JJ N
direct JJ N
thrombin NN N
inhibitor NN N
argatroban NN 3_i
is VBZ N
an DT N
attractive JJ N
anticoagulant NN N
for IN N
percutaneous JJ 1_i
coronary JJ 1_i
intervention NN 1_i
( ( 1_i
PCI NNP 1_i
) ) 1_i
, , N
because IN N
of IN N
its PRP$ N
rapid JJ N
onset NN N
and CC N
offset NN N
, , N
and CC N
its PRP$ N
hepatic JJ N
elimination NN N
. . N

Argatroban NNP 3_i
was VBD N
approved VBN N
for IN N
PCI NNP N
in IN N
patients NNS N
with IN N
heparin-induced JJ N
thrombocytopenia NN N
( ( N
HIT NNP N
) ) N
. . N

However RB N
, , N
there EX N
are VBP N
limited VBN N
data NNS N
about IN N
argatroban NN 3_i
in IN N
non-HIT JJ N
patients NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
open-label JJ N
, , N
multiple-dose JJ N
, , N
controlled VBD N
study NN N
was VBD N
to TO N
examine VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
argatroban NN 3_i
in IN N
patients NNS N
undergoing VBG N
elective JJ N
PCI NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Of IN N
140 CD N
patients NNS N
randomized VBN N
to TO N
three CD N
argatroban NNS 3_i
dose JJ N
groups NNS N
( ( N
ARG250 NNP 3_i
, , N
ARG300 NNP 3_i
, , N
and CC N
ARG350 NNP 3_i
with IN N
250 CD N
, , N
300 CD N
, , N
or CC N
350 CD N
?g/kg JJ N
bolus NN N
, , N
followed VBN N
by IN N
15 CD N
, , N
20 CD N
, , N
or CC N
25 CD N
?g/kg/min JJ N
infusion NN N
) ) N
and CC N
one CD N
unfractionated JJ N
heparin NN N
( ( N
UFH NNP N
) ) N
group NN N
( ( N
70-100 JJ N
IU/kg NNP N
bolus NN N
) ) N
, , N
138 CD N
patients NNS N
were VBD N
analyzed VBN N
. . N

Argatroban NNP N
dose-dependently RB N
prolonged VBD N
activated VBN N
clotting NN N
time NN N
( ( N
ACT NNP N
) ) N
with IN N
more JJR N
patients NNS N
reaching VBG N
the DT N
minimum NN N
target NN N
ACT NNP N
after IN N
the DT N
initial JJ N
bolus NN N
injection NN N
( ( N
ARG250 NNP N
: : N
86.1 CD N
% NN N
, , N
ARG300 NNP N
: : N
89.5 CD N
% NN N
, , N
and CC N
ARG350 NNP N
: : N
96.8 CD N
% NN N
) ) N
compared VBN N
to TO N
45.5 CD N
% NN N
in IN N
UFH NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
patient JJ N
proportion NN N
who WP N
did VBD N
not RB N
require VB N
additional JJ N
bolus NN N
injections NNS N
to TO N
start VB N
PCI NNP N
was VBD N
significantly RB N
higher JJR N
in IN N
argatroban NN N
than IN N
in IN N
UFH NNP N
( ( N
p VB N
? . N
0.002 CD N
) ) N
. . N

Consequently RB N
, , N
the DT N
time NN N
to TO N
start VB N
of IN N
PCI NNP N
was VBD N
shortened VBN N
in IN N
argatroban JJ N
groups NNS N
. . N

Composite NNP N
incidences NNS N
of IN N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
and CC N
urgent JJ N
revascularization NN N
until IN N
day NN N
30 CD N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
( ( N
ARG250 NNP N
: : N
2.8 CD N
% NN N
, , N
ARG300 NNP N
: : N
0.0 CD N
% NN N
, , N
ARG350 NNP N
: : N
3.2 CD N
% NN N
vs. FW N
UFH NNP N
: : N
3.0 CD N
% NN N
) ) N
. . N

Major JJ N
bleeding NN N
was VBD N
observed VBN N
only RB N
in IN N
UFH NNP N
( ( N
3.0 CD N
% NN N
) ) N
, , N
while IN N
minor JJ N
bleeding NN N
occurred VBD N
in IN N
ARG350 NNP N
( ( N
3.2 CD N
% NN N
) ) N
and CC N
UFH NNP N
( ( N
6.1 CD N
% NN N
, , N
n.s. NN N
) ) N
. . N

CONCLUSION NNP N
Argatroban NNP N
dose-dependently JJ N
increases NNS N
coagulation NN N
parameters NNS N
and CC N
, , N
compared VBN N
to TO N
UFH NNP N
, , N
demonstrates VBZ N
a DT N
superior JJ N
predictable JJ N
anticoagulant JJ N
effect NN N
in IN N
patients NNS N
undergoing VBG N
elective JJ N
PCI NNP N
. . N

-DOCSTART- -X- O O

A DT N
phase NN N
II NNP N
, , N
randomized VBD N
, , N
multicenter NN N
study NN N
evaluating VBG N
the DT N
combination NN N
of IN N
lapatinib NN N
and CC N
vinorelbine NN N
in IN N
women NNS N
with IN N
ErbB2 NNP N
overexpressing VBG N
metastatic JJ N
breast NN N
cancer NN N
. . N

Lapatinib NNP N
is VBZ N
approved VBN N
in IN N
combination NN N
with IN N
capecitabine NN N
for IN N
treatment NN N
of IN N
patients NNS N
with IN N
human JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
2 CD N
( ( N
HER2 NNP N
) ) N
-positive VBP N
metastatic JJ N
breast NN N
cancer NN N
( ( N
MBC NNP N
) ) N
who WP N
have VBP N
progressed VBN N
on IN N
prior JJ N
trastuzumab NN N
in IN N
the DT N
metastatic JJ N
setting NN N
. . N

Vinorelbine NNP N
is VBZ N
an DT N
important JJ N
chemotherapy NN N
option NN N
for IN N
MBC NNP N
. . N

We PRP N
evaluated VBD N
efficacy NN N
and CC N
safety NN N
of IN N
lapatinib JJ N
plus CC N
vinorelbine JJ N
, , N
compared VBN N
with IN N
lapatinib JJ N
plus CC N
capecitabine JJ N
, , N
in IN N
women NNS N
with IN N
HER2-positive JJ N
MBC NNP N
. . N

In IN N
this DT N
open-label JJ N
, , N
multicenter NN N
, , N
phase NN N
II NNP N
study NN N
, , N
eligible JJ N
patients NNS N
( ( N
N NNP N
= NNP N
112 CD N
) ) N
were VBD N
randomized VBN N
2:1 CD N
to TO N
lapatinib VB 3_i
plus JJ 3_i
vinorelbine NN 3_i
[ NNP N
( ( N
N NNP N
= NNP N
75 CD N
) ) N
1,250 CD N
mg NN N
orally RB N
once RB N
daily JJ N
( ( N
QD NNP N
) ) N
continuously RB N
plus CC N
20 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
intravenously RB N
] VBZ N
or CC N
lapatinib JJ 3_i
plus CC 3_i
capecitabine JJ 3_i
[ NNP N
( ( N
N NNP N
= NNP N
37 CD N
) ) N
1,250 CD N
mg NN N
orally RB N
QD NNP N
continuously RB N
plus CC N
2,000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
orally RB N
, , N
2 CD N
doses NNS N
] RB N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
. . N

Other JJ N
endpoints NNS N
included VBD N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
and CC N
safety NN N
. . N

Patients NNS N
progressing VBG N
within IN N
the DT N
study NN N
were VBD N
given VBN N
the DT N
option NN N
of IN N
crossover NN N
to TO N
the DT N
other JJ N
treatment NN N
arm NN N
; : N
time NN N
to TO N
second JJ N
progression NN N
was VBD N
an DT N
exploratory JJ N
endpoint NN N
. . N

Patient JJ N
demographics NNS N
, , N
stratification NN N
, , N
and CC N
prognostic JJ N
factors NNS N
were VBD N
well RB N
balanced VBN N
between IN N
treatments NNS N
. . N

Median JJ N
PFS NNP N
in IN N
both DT N
arms NNS N
was VBD N
6.2 CD N
months NNS N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
4.2 CD N
, , N
8.8 CD N
( ( N
lapatinib JJ N
plus CC N
vinorelbine JJ N
) ) N
; : N
4.4 CD N
, , N
8.3 CD N
( ( N
lapatinib JJ N
plus CC N
capecitabine NN N
) ) N
] NN N
. . N

Median JJ N
OS NNP N
on IN N
lapatinib JJ N
plus CC N
vinorelbine NN N
was VBD N
24.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
16.4 CD N
, , N
NE NNP N
) ) N
and CC N
19.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
16.4 CD N
, , N
27.2 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
capecitabine NN N
. . N

In IN N
total JJ N
, , N
42 CD N
patients NNS N
opted VBN N
to TO N
cross VB N
over RP N
; : N
median JJ N
PFS NNP N
was VBD N
3.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
1.7 CD N
, , N
5.1 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
vinorelbine NN N
and CC N
4.0 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
2.1 CD N
, , N
5.8 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
capecitabine NN N
. . N

Lapatinib NNP N
plus CC N
vinorelbine NN N
offers NNS N
an DT N
effective JJ N
treatment NN N
option NN N
for IN N
patients NNS N
with IN N
HER2-overexpressing NNP N
MBC NNP N
, , N
having VBG N
displayed VBN N
comparable JJ N
efficacy NN N
and CC N
tolerability NN N
rates NNS N
to TO N
lapatinib VB N
plus JJ N
capecitabine NN N
. . N

-DOCSTART- -X- O O

Advice NN N
or CC N
exercise NN N
for IN N
chronic JJ N
whiplash NN N
disorders NNS N
? . N
Design NNP N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Whiplash-associated JJ N
disorder NN N
( ( N
or CC N
whiplash NN N
) ) N
is VBZ N
a DT N
common JJ N
condition NN N
incurring VBG N
considerable JJ N
expense NN N
in IN N
social JJ N
and CC N
economic JJ N
terms NNS N
. . N

A DT N
lack NN N
of IN N
research NN N
on IN N
effective JJ N
therapy NN N
for IN N
patients NNS N
with IN N
chronic JJ N
whiplash NN N
associated VBN N
disorders NNS N
prompted VBD N
the DT N
design NN N
of IN N
the DT N
current JJ N
study NN N
. . N

The DT N
primary JJ N
aim NN N
of IN N
this DT N
randomised VBN N
controlled VBN N
trial NN N
is VBZ N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
a DT N
physical JJ N
activity NN N
program NN N
for IN N
people NNS N
with IN N
chronic JJ N
( ( N
symptoms NNS N
of IN N
> JJ N
3 CD N
months NNS N
duration NN N
) ) N
whiplash NN N
. . N

A DT N
secondary JJ N
aim NN N
is VBZ N
to TO N
determine VB N
if IN N
pain JJ N
severity NN N
, , N
level NN N
of IN N
disability NN N
and CC N
fear NN N
of IN N
movement/ NN N
( ( N
re NN N
) ) N
injury NN N
predict VBP N
response NN N
to TO N
a DT N
physical JJ N
activity NN N
program NN N
. . N

METHODS/DESIGN NNP N
This DT N
paper NN N
presents VBZ N
the DT N
rationale NN N
and CC N
design NN N
of IN N
a DT N
randomised VBN N
controlled VBN N
trial NN N
examining VBG N
the DT N
effects NNS N
of IN N
advice NN 4_i
and CC 4_i
individualized JJ 2_i
sub-maximal JJ 2_i
exercise NN 2_i
programs NNS 2_i
in IN N
the DT N
treatment NN N
of IN N
whiplash NN N
associated VBN N
disorders NNS N
. . N

DISCUSSION NNP N
This DT N
paper NN N
highlights VBZ N
the DT N
design NN N
, , N
methods NNS N
and CC N
operational JJ N
aspects NNS N
of IN N
a DT N
significant JJ N
clinical JJ N
trial NN N
in IN N
the DT N
area NN N
of IN N
whiplash NN N
and CC N
chronic JJ N
pain NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
enalapril NN 3_i
on IN N
myocardial JJ N
infarction NN N
and CC N
unstable JJ N
angina NN N
in IN N
patients NNS N
with IN N
low JJ N
ejection NN N
fractions NNS N
. . N

An DT N
association NN N
between IN N
raised VBN N
renin NN N
levels NNS N
and CC N
myocardial JJ N
infarction NN N
has VBZ N
been VBN N
reported VBN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
enalapril NN 3_i
, , N
an DT N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitor NN N
, , N
on IN N
the DT N
development NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
unstable JJ N
angina NN N
in IN N
6797 CD N
patients NNS N
with IN N
ejection NN N
fractions NNS N
< VBP N
or CC N
= VBP N
0.35 CD N
enrolled VBN N
into IN N
the DT N
two CD N
Studies NNS N
of IN N
Left NNP N
Ventricular NNP N
Dysfunction NNP N
( ( N
SOLVD NNP N
) ) N
trials NNS N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB 7_i
( ( N
n JJ N
= NN N
3401 CD N
) ) N
or CC N
enalapril $ 3_i
( ( N
n JJ N
= NN N
3396 CD N
) ) N
at IN N
doses NNS N
of IN N
2.5-20 JJ N
mg NNS N
per IN N
day NN N
in IN N
two CD N
concurrent JJ N
double-blind JJ N
trials NNS N
with IN N
the DT N
same JJ N
protocol NN N
. . N

Patients NNS N
with IN N
heart NN N
failure NN N
entered VBD N
the DT N
treatment NN N
trial NN N
( ( N
n JJ N
= NN N
2569 CD N
) ) N
and CC N
those DT N
without IN N
heart NN N
failure NN N
entered VBD N
the DT N
prevention NN N
trial NN N
( ( N
n JJ N
= NN N
4228 CD N
) ) N
. . N

Follow-up NNP N
averaged VBD N
40 CD N
months NNS N
. . N

In IN N
each DT N
trial NN N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
the DT N
number NN N
of IN N
patients NNS N
developing VBG N
myocardial JJ N
infarction NN N
( ( N
treatment NN N
trial NN N
: : N
158 CD N
placebo NN 7_i
vs NN N
127 CD N
enalapril NN 3_i
, , N
p NN N
< VBD N
0.02 CD N
; : N
prevention NN N
trial NN N
: : N
204 CD N
vs NN N
161 CD N
p NN N
< NNP N
0.01 CD N
) ) N
or CC N
unstable JJ N
angina NN N
( ( N
240 CD N
vs RB N
187 CD N
p NN N
< NN N
0.001 CD N
; : N
355 CD N
vs NN N
312 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

Combined VBN N
, , N
there EX N
were VBD N
362 CD N
placebo NNS 7_i
group NN N
patients NNS N
with IN N
myocardial JJ N
infarction NN N
compared VBN N
with IN N
288 CD N
in IN N
the DT N
enalapril NN 3_i
group NN N
( ( N
risk NN N
reduction NN N
23 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
11-34 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

595 CD N
placebo NN 7_i
group NN N
patients NNS N
developed VBD N
unstable JJ N
angina NNS N
compared VBN N
with IN N
499 CD N
in IN N
the DT N
enalapril NN 3_i
group NN N
( ( N
risk NN N
reduction NN N
20 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
9-29 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
reduction NN N
in IN N
cardiac JJ N
deaths NNS N
( ( N
711 CD N
placebo NN 7_i
, , N
615 CD N
enalapril NN 3_i
; : N
p CC N
< VB N
0.003 CD N
) ) N
, , N
so RB N
that IN N
the DT N
reduction NN N
in IN N
the DT N
combined JJ N
endpoint NN N
of IN N
deaths NNS N
, , N
myocardial JJ N
infarction NN N
, , N
and CC N
unstable JJ N
angina NN N
was VBD N
highly RB N
significant JJ N
( ( N
20 CD N
% NN N
risk NN N
reduction NN N
, , N
95 CD N
% NN N
CI NNP N
14-26 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Enalapril NNP 7_i
treatment NN N
significantly RB N
reduced VBN N
myocardial JJ N
infarction NN N
, , N
unstable JJ N
angina NN N
, , N
and CC N
cardiac JJ N
mortality NN N
in IN N
patients NNS N
with IN N
low JJ N
ejection NN N
fractions NNS N
. . N

-DOCSTART- -X- O O

B-vitamins NNS 3_i
reduce VB N
plasma NN N
levels NNS N
of IN N
beta NN N
amyloid NN N
. . N

Elevated VBN N
plasma JJ N
homocysteine NN N
( ( N
tHcy NN N
) ) N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
Alzheimer NNP N
's POS N
disease NN N
( ( N
AD NNP N
) ) N
, , N
and CC N
thus RB N
B NNP 3_i
vitamins NNS 3_i
may MD N
have VB N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
tHcy JJ N
lowering NN N
vitamins NNS N
decrease VBP N
the DT N
circulating NN N
levels NNS N
of IN N
A-beta NNP N
protein NN N
1-40 JJ N
( ( N
A NNP N
beta RB N
40 CD N
) ) N
. . N

We PRP N
randomized VBD N
299 CD N
older JJR N
men NNS N
to TO N
treatment NN N
with IN N
2mg CD 3_i
of IN 3_i
folate NN 3_i
, , N
plus CC 3_i
25mg CD 3_i
of IN 3_i
B6 NNP 3_i
and CC N
400 CD 3_i
microg NN 3_i
of IN 3_i
B12 NNP 3_i
, , N
or CC N
placebo NN 7_i
. . N

After IN N
2 CD N
years NNS N
of IN N
treatment NN N
the DT N
mean NN N
( ( N
S.E NNP N
. . N

) ) N
increase NN N
of IN N
A NNP N
beta NN N
40 CD N
was VBD N
7.0 CD N
pg/ml NN N
( ( N
8.4 CD N
) ) N
in IN N
the DT N
vitamin NN N
group NN N
( ( N
4.9 CD N
% NN N
) ) N
, , N
and CC N
26.8 CD N
pg/ml NN N
( ( N
7.7 CD N
) ) N
( ( N
18.5 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
B NNP N
vitamins NNS N
may MD N
decrease VB N
the DT N
plasma JJ N
level NN N
of IN N
A NNP N
beta NN N
40 CD N
and CC N
have VBP N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
. . N

-DOCSTART- -X- O O

Promoting VBG N
physical JJ N
activity NN N
in IN N
patients NNS N
with IN N
colon NN N
adenomas NN N
: : N
a DT N
randomized JJ N
pilot NN N
intervention NN N
trial NN N
. . N

BACKGROUND NNP N
Physical NNP N
activity NN N
decreases VBZ N
risk NN N
of IN N
colon NN N
polyps NNS N
and CC N
colon NN N
cancer NN N
and CC N
might MD N
reduce VB N
risk NN N
of IN N
colon NN N
cancer NN N
recurrence NN N
. . N

Focusing VBG N
on IN N
recent JJ N
calls NNS N
for IN N
translation NN N
of IN N
epidemiologic JJ N
evidence NN N
into IN N
clinical JJ N
care NN N
, , N
our PRP$ N
pilot NN N
study NN N
delivered VBD N
an DT N
evidence-based JJ 2_i
physical JJ 2_i
activity NN 2_i
intervention NN 2_i
in IN N
adults NNS N
with IN N
polyps NNS N
, , N
who WP N
are VBP N
thus RB N
at IN N
elevated VBN N
risk NN N
of IN N
developing VBG N
colon NN N
cancer NN N
. . N

The DT N
objective NN N
was VBD N
to TO N
evaluate VB N
change NN N
in IN N
physical JJ N
activity NN N
, , N
measured VBN N
by IN N
steps NNS N
per IN N
day NN N
and CC N
minutes NNS N
of IN N
moderate/vigorous JJ N
physical JJ N
activity NN N
. . N

METHODS NNP N
Sixteen NNP N
adults NNS N
with IN N
adenomas NN N
detected VBN N
and CC N
removed VBN N
at IN N
screening VBG 2_i
colonoscopy NN 2_i
were VBD N
recruited VBN N
to TO N
a DT N
12-week JJ N
physical JJ 2_i
activity NN 2_i
intervention NN 2_i
. . 4_i

Participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
standard NN 2_i
( ( 2_i
30 CD 2_i
minutes/day NN 2_i
) ) 2_i
or CC 2_i
high JJ 2_i
( ( 2_i
60 CD 2_i
minutes/day NN 2_i
) ) 2_i
walking VBG 2_i
program NN 2_i
. . 4_i

Physical JJ 2_i
activity NN 2_i
was VBD N
measured VBN N
via IN N
blinded VBN N
pedometer NN N
and CC N
accelerometer NN N
at IN N
baseline NN N
and CC N
follow-up NN N
. . N

Intervention NN N
messages NNS N
focused VBD N
on IN N
self-monitoring JJ N
using VBG N
pedometers NNS N
and CC N
overcoming VBG N
barriers NNS N
to TO N
engaging VBG N
in IN N
physical JJ N
activity NN N
. . N

RESULTS JJ N
Participants NNS N
in IN N
both DT N
arms NNS N
significantly RB N
increased VBD N
objectively RB N
measured VBN N
minutes NNS N
of IN N
moderate/vigorous JJ N
physical JJ N
activity NN N
over IN N
the DT N
course NN N
of IN N
the DT N
intervention NN N
. . N

Both DT N
arms NNS N
exceeded VBD N
the DT N
intervention NN N
goal NN N
, , N
but CC N
there RB N
was VBD N
not RB N
a DT N
significant JJ N
difference NN N
between IN N
arms NNS N
at IN N
follow-up JJ N
. . N

Results NNS N
were VBD N
similar JJ N
for IN N
pedometer NN N
measured VBN N
physical JJ N
activity NN N
, , N
with IN N
a DT N
significant JJ N
overall JJ N
increase NN N
in IN N
steps/day JJ N
from IN N
baseline NN N
to TO N
follow-up NN N
, , N
but CC N
no DT N
between IN N
arm NN N
difference NN N
in IN N
change NN N
. . N

CONCLUSION NNP N
Simple NNP N
interventions NNS N
of IN N
minimal JJ N
contact NN N
time NN N
focusing VBG N
on IN N
walking NN N
can MD N
significantly RB N
increase VB N
physical JJ N
activity NN N
in IN N
individuals NNS N
at IN N
increased VBN N
risk NN N
of IN N
developing VBG N
colon NN N
cancer NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT01476631 NNP N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
coronary JJ N
spasm NN N
by IN N
nicorandil NNS 3_i
: : 3_i
comparison NN N
with IN N
nifedipine NN 3_i
. . 3_i

The DT N
efficacy NN N
of IN N
nicorandil NN 3_i
was VBD N
compared VBN N
with IN N
that DT N
of IN N
nifedipine NN 3_i
in IN N
13 CD N
patients NNS N
with IN N
vasospastic JJ N
angina NNS N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 2_i
, , N
crossover NN N
study NN N
. . N

All DT N
patients NNS N
had VBD N
a DT N
coronary JJ N
spasm NN N
during IN N
coronary JJ N
arteriography NN N
, , N
either CC N
spontaneously RB N
or CC N
ergometrine-induced JJ N
. . N

During IN N
two CD N
consecutive JJ N
periods NNS N
of IN N
2 CD N
days NNS N
, , N
patients NNS N
received VBD N
active JJ 3_i
drugs NNS 3_i
or CC N
placebo NN 3_i
in IN N
a DT N
randomized JJ N
order NN N
. . N

Each DT N
patient NN N
received VBD N
single JJ N
oral JJ N
doses NNS N
of IN N
30 CD N
mg NN N
nicorandil NN 3_i
, , N
10 CD N
mg NN N
nifedipine NN 3_i
, , N
and CC N
, , N
on IN N
2 CD N
days NNS N
, , N
a DT N
placebo NN 3_i
. . N

One CD N
hour NN N
after IN N
drug NN N
intake NN N
, , N
patients NNS N
underwent VBD N
an DT N
ergometrine JJ N
test NN N
with IN N
increasing VBG N
doses NNS N
of IN N
Methergin NNP 3_i
( ( 3_i
ergometrine NN 3_i
) ) 3_i
( ( N
0.05 CD N
, , N
0.10 CD N
, , N
0.20 CD N
, , N
and CC N
0.40 CD N
mg NN N
every DT N
5 CD N
min NN N
) ) N
. . N

After IN N
placebo NN 3_i
, , N
the DT N
tests NNS N
always RB N
were VBD N
positive JJ N
, , N
and CC N
the DT N
ECG NNP N
changes NNS N
occurred VBD N
at IN N
the DT N
same JJ N
+/- JJ N
1 CD N
dose NN N
of IN N
ergometrine NN 3_i
in IN N
10 CD N
cases NNS N
, , N
showing VBG N
good JJ N
reproducibility NN N
. . N

After IN N
nicorandil NN 3_i
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
nine CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
lower JJR N
dose NN N
of IN N
ergometrine NN 3_i
in IN N
three CD N
and CC N
one CD N
patient NN N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0034 CD N
vs. FW N
placebo NN 3_i
) ) 3_i
. . N

After IN N
nifedipine NN 3_i
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
five CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
the DT N
same JJ N
dose NN N
of IN N
ergometrine NN 3_i
in IN N
four CD N
and CC N
four CD N
patients NNS N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0039 CD N
vs. FW N
placebo NN 3_i
) ) N
. . N

Nifedipine NNP 3_i
( ( N
10 CD N
mg NN N
) ) N
and CC N
nicorandil $ N
( ( N
30 CD N
mg NN N
) ) N
were VBD N
equally RB N
effective JJ N
in IN N
eight CD N
patients NNS N
; : N
in IN N
the DT N
remaining VBG N
five CD N
patients NNS N
, , N
nicorandil NNS 3_i
had VBD N
better JJR N
results NNS N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Nicorandil NNP 3_i
( ( N
30 CD N
mg NN N
) ) N
prevents VBZ N
ergometrine-induced JJ N
coronary JJ N
spasm NN N
. . N

This DT N
compound NN N
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS N
with IN N
vasospastic JJ N
angina NN N
. . N

-DOCSTART- -X- O O

Endurance NN N
training NN N
has VBZ N
little JJ N
effect NN N
on IN N
active JJ N
muscle NN N
free JJ N
fatty NN N
acid NN N
, , N
lipoprotein FW N
cholesterol NN N
, , N
or CC N
triglyceride JJ N
net JJ N
balances NNS N
. . N

We PRP N
evaluated VBD N
the DT N
hypothesis NN N
that WDT N
net JJ N
leg NN N
total JJ N
FFA NNP N
, , N
LDL-C NNP N
, , N
and CC N
TG NNP N
uptake JJ N
and CC N
HDL-C JJ N
release NN N
during IN N
moderate-intensity NN N
cycling NN N
exercise NN N
would MD N
be VB N
increased VBN N
following VBG N
endurance NN N
training NN N
. . N

Eight NNP N
sedentary JJ N
men NNS N
( ( N
26 CD N
+/- JJ N
1 CD N
yr NN N
, , N
77.4 CD N
+/- JJ N
3.7 CD N
kg NN N
) ) N
were VBD N
studied VBN N
in IN N
the DT N
postprandial JJ N
state NN N
during IN N
90 CD N
min NNS N
of IN N
rest NN N
and CC N
60 CD N
min NN N
of IN N
exercise NN N
twice NN N
before IN N
( ( N
45 CD N
% NN N
and CC N
65 CD N
% NN N
V NNP N
( ( N
O2 NNP N
peak NN N
) ) N
) ) N
and CC N
twice RB N
after IN N
9 CD N
wk NN N
of IN N
endurance NN 2_i
training NN 2_i
( ( N
55 CD N
% NN N
and CC N
65 CD N
% NN N
posttraining VBG N
V NNP N
( ( N
O2 NNP N
peak NN N
) ) N
) ) N
. . N

Measurements NNS N
across IN N
an DT N
exercising VBG N
leg NN N
were VBD N
taken VBN N
to TO N
be VB N
a DT N
surrogate NN N
for IN N
active JJ N
skeletal JJ N
muscle NN N
. . N

To TO N
determine VB N
limb NN N
lipid JJ N
exchange NN N
, , N
femoral JJ N
arterial NN N
and CC N
venous JJ N
blood NN N
samples NNS N
drawn VBP N
simultaneously RB N
at IN N
rest NN N
and CC N
during IN N
exercise NN N
were VBD N
analyzed VBN N
for IN N
total JJ N
and CC N
individual JJ N
FFA NNP N
( ( N
e.g. NN N
, , N
palmitate NN N
, , N
oleate NN N
) ) N
, , N
LDL-C NNP N
, , N
HDL-C NNP N
, , N
and CC N
TG NNP N
concentrations NNS N
, , N
and CC N
limb NN N
blood NN N
flow NN N
was VBD N
determined VBN N
by IN N
thermodilution NN N
. . N

The DT N
transition NN N
from IN N
rest NN N
to TO N
exercise VB N
resulted VBN N
in IN N
a DT N
shift NN N
from IN N
net JJ N
leg NN N
total JJ N
FFA NNP N
release NN N
( ( N
-44 JJ N
+/- JJ N
16 CD N
micromol/min NN N
) ) N
to TO N
uptake VB N
( ( N
193 CD N
+/- JJ N
49 CD N
micromol/min NN N
) ) N
that WDT N
was VBD N
unaffected VBN N
by IN N
either DT N
exercise NN N
intensity NN N
or CC N
endurance NN N
training NN N
. . N

The DT N
relative JJ N
net NN N
leg NN N
release NN N
and CC N
uptake NN N
of IN N
individual JJ N
FFA NNP N
closely RB N
resembled VBD N
their PRP$ N
relative JJ N
abundances NNS N
in IN N
the DT N
plasma NN N
with IN N
approximately RB N
21 CD N
and CC N
41 CD N
% NN N
of IN N
net JJ N
leg NN N
total JJ N
FFA NNP N
uptake NN N
during IN N
exercise NN N
accounted VBN N
for IN N
by IN N
palmitate NN N
and CC N
oleate NN N
, , N
respectively RB N
. . N

Endurance NNP 2_i
training NN 2_i
resulted VBD N
in IN N
significant JJ N
changes NNS N
in IN N
arterial JJ N
concentrations NNS N
of IN N
HDL-C NNP N
( ( N
49 CD N
+/- JJ N
5 CD N
vs. FW N
52 CD N
+/- JJ N
5 CD N
mg/dl NN N
, , N
pre NN N
vs. FW N
post NN N
) ) N
and CC N
LDL-C NNP N
( ( N
82 CD N
+/- JJ N
9 CD N
vs. FW N
76 CD N
+/- JJ N
9 CD N
mg/dl NN N
, , N
pre NN N
vs. FW N
post NN N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
net JJ N
TG NN N
or CC N
LDL-C JJ N
uptake NN N
or CC N
HDL-C JJ N
release NN N
across IN N
the DT N
resting NN N
or CC N
active JJ N
leg NN N
before IN N
or CC N
after IN N
endurance JJ N
training NN N
. . N

In IN N
conclusion NN N
, , N
endurance NN N
training NN N
favorably RB N
affects VBZ N
blood NN N
lipoprotein NN N
profiles NNS N
, , N
even RB N
in IN N
young JJ N
, , N
healthy JJ N
normolipidemic JJ N
men NNS N
, , N
but CC N
muscle NN N
contractions NNS N
per IN N
se NN N
have VBP N
little JJ N
effect NN N
on IN N
net JJ N
leg NN N
LDL-C NNP N
, , N
or CC N
TG NNP N
uptake VBP N
or CC N
HDL-C JJ N
release NN N
during IN N
moderate-intensity NN N
cycling NN N
exercise NN N
. . N

Therefore RB N
, , N
the DT N
favorable JJ N
effects NNS N
of IN N
physical JJ N
activity NN N
on IN N
the DT N
lipid JJ N
profiles NNS N
of IN N
young JJ N
, , N
healthy JJ N
normolipidemic JJ N
men NNS N
in IN N
the DT N
postprandial JJ N
state NN N
are VBP N
not RB N
attributable JJ N
to TO N
changes NNS N
in IN N
HDL-C NNP N
or CC N
LDL-C NNP N
exchange NN N
across IN N
active JJ N
skeletal JJ N
muscle NN N
. . N

-DOCSTART- -X- O O

The DT N
6 CD N
minute NN N
walk NN N
in IN N
idiopathic JJ N
pulmonary JJ N
fibrosis NN N
: : N
longitudinal JJ N
changes NNS N
and CC N
minimum JJ N
important JJ N
difference NN N
. . N

RATIONALE VB N
The DT N
response NN N
characteristics NNS N
of IN N
the DT N
6 CD 2_i
minute NN 2_i
walk NN 2_i
test NN 2_i
( ( 2_i
6MWT CD 2_i
) ) 2_i
in IN N
studies NNS N
of IN N
idiopathic JJ N
pulmonary JJ N
fibrosis NN N
( ( N
IPF NNP N
) ) N
are VBP N
only RB N
poorly RB N
understood JJ N
, , N
and CC N
the DT N
change NN N
in IN N
walk NN N
distance NN N
that WDT N
constitutes VBZ N
the DT N
minimum JJ N
important JJ N
difference NN N
( ( N
MID NNP N
) ) N
over IN N
time NN N
is VBZ N
unknown JJ N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
changes NNS N
over IN N
time NN N
in IN N
distance NN N
walked VBD N
( ( N
ie NN N
, , N
6MWD CD N
) ) N
during IN N
the DT N
6MWT CD 2_i
and CC N
to TO N
estimate VB N
the DT N
change NN N
in IN N
distance NN N
that WDT N
constitutes VBZ N
the DT N
MID NNP N
in IN N
patients NNS N
with IN N
IPF NNP N
. . N

METHODS NNP N
Data NNP N
from IN N
a DT N
recently RB N
completed VBN N
trial NN N
that WDT N
included VBD N
subjects NNS N
with IN N
IPF NNP N
who WP N
completed VBD N
the DT N
6MWT CD 2_i
, , N
Saint NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
( ( N
SGRQ NNP N
) ) N
and CC N
forced VBN N
vital JJ N
capacity NN N
( ( N
FVC NNP N
) ) N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
were VBD N
used VBN N
to TO N
examine VB N
longitudinal JJ N
changes NNS N
in IN N
6MWD CD N
. . N

Both DT N
anchor- JJ N
and CC N
distribution-based JJ N
approaches NNS N
as RB N
well RB N
as IN N
linear JJ N
regression NN N
analyses NNS N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
MID NNP N
for IN N
6MWD CD N
. . N

The DT N
SGRQ NNP N
Total NNP N
score NN N
and CC N
FVC NNP N
were VBD N
used VBN N
as IN N
clinical JJ N
anchors NNS N
. . N

MAIN NNP N
RESULTS NNP N
Among IN N
123 CD N
subjects NNS N
alive JJ N
and CC N
able JJ N
to TO N
complete VB N
the DT N
6MWT CD N
at IN N
both DT N
follow-up JJ N
time NN N
points NNS N
, , N
6MWD CD N
did VBD N
not RB N
change VB N
significantly RB N
over IN N
time NN N
( ( N
378.1 CD N
m NN N
at IN N
baseline NN N
vs NN N
376.8 CD N
m NN N
at IN N
6 CD N
months NNS N
vs RB N
361.3 CD N
m NN N
at IN N
12 CD N
months NNS N
, , N
p=0.5 NN N
) ) N
. . N

The DT N
point NN N
estimate NN N
for IN N
the DT N
6MWD CD N
MID NNP N
was VBD N
28 CD N
m NN N
with IN N
a DT N
range NN N
of IN N
10.8-58.5 JJ N
m. JJ N
CONCLUSION NNP N
In IN N
a DT N
group NN N
of IN N
patients NNS N
with IN N
IPF NNP N
with IN N
moderate JJ N
physiological JJ N
impairment NN N
, , N
for IN N
those DT N
alive JJ N
and CC N
able JJ N
to TO N
complete VB N
a DT N
6MWT CD N
, , N
6MWD CD N
does VBZ N
not RB N
change VB N
over IN N
12 CD N
months NNS N
. . N

At IN N
the DT N
population NN N
level NN N
, , N
the DT N
MID NNP N
for IN N
6MWD CD N
appears VBZ N
to TO N
be VB N
approximately RB N
28 CD N
m. NNS N
Further NNP N
investigation NN N
using VBG N
other JJ N
anchors NNS N
and CC N
derivation NN N
methods NNS N
is VBZ N
required VBN N
to TO N
refine VB N
estimates NNS N
of IN N
the DT N
MID NNP N
for IN N
6MWD CD N
in IN N
this DT N
patient JJ N
population NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
parallel NN N
study NN N
to TO N
assess VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
two CD N
different JJ N
dosing VBG N
regimens NNS N
of IN N
5 CD N
% NN N
imiquimod NN 3_i
in IN N
the DT N
treatment NN N
of IN N
superficial JJ N
basal NN N
cell NN N
carcinoma NN N
. . N

OBJECTIVES CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
two CD N
cycled VBD N
dosing VBG N
regimens NNS N
of IN N
imiquimod JJ 3_i
5 CD N
% NN N
cream NN N
for IN N
treatment NN N
of IN N
superficial JJ N
basal NN N
cell NN N
carcinoma NN N
( ( N
sBCC NN N
) ) N
. . N

METHODS JJ N
Patients NNPS N
( ( N
n JJ N
= NNP N
32 CD N
) ) N
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
two CD N
treatment NN N
regimens NNS N
: : N
8 CD 3_i
weeks NNS 3_i
of IN 3_i
treatment NN 3_i
with IN 3_i
once-daily JJ 3_i
dosing VBG 3_i
for IN 3_i
alternate JJ 3_i
weeks NNS 3_i
( ( 3_i
R1 NNP 3_i
) ) 3_i
and CC N
5 CD N
weeks NNS N
of IN N
once-daily JJ N
dosing NN N
with IN N
a DT N
1-week JJ N
interval NN N
in IN N
the DT N
middle NN N
of IN N
the DT N
course NN N
( ( N
R2 NNP N
) ) N
. . N

Efficacy NN N
measures NNS N
were VBD N
tumour JJ N
clearance NN N
at IN N
weeks NNS N
19 CD N
and CC N
52 CD N
and CC N
measures NNS N
of IN N
patients NNS N
' POS N
acceptability NN N
. . N

RESULTS NNP N
Data NNP N
from IN N
30 CD N
patients NNS N
( ( N
13 CD N
females NNS N
) ) N
, , N
14 CD N
on IN N
R1 NNP N
and CC N
16 CD N
on IN N
R2 NNP N
, , N
were VBD N
analysed VBN N
. . N

The DT N
results NNS N
revealed VBD N
an DT N
initial JJ N
clearance NN N
rate NN N
of IN N
64 CD N
% NN N
at IN N
week NN N
19 CD N
for IN N
R1 NNP N
and CC N
81 CD N
% NN N
for IN N
R2 NNP N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
: : N
-14 NN N
% NN N
to TO N
45 CD N
% NN N
, , N
p NN N
= NNP N
0.21 CD N
) ) N
. . N

However RB N
, , N
clearance NN N
rates NNS N
at IN N
week NN N
52 CD N
were VBD N
significantly RB N
different JJ N
: : N
43 CD N
% NN N
for IN N
R1 NNP N
and CC N
88 CD N
% NN N
for IN N
R2 NNP N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
: : N
11 CD N
% NN N
to TO N
68 CD N
% NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
acceptability NN N
of IN N
treatment NN N
as IN N
measured VBN N
by IN N
composite JJ N
median JJ N
visual JJ N
analogue NN N
scores NNS N
at IN N
week NN N
8 CD N
. . N

CONCLUSION NNP N
Five NNP N
weeks NNS N
of IN N
5 CD N
% NN N
imiquimod JJ 3_i
cream NN N
once RB N
daily JJ N
with IN N
a DT N
1-week JJ N
interval NN N
was VBD N
more RBR N
effective JJ N
but CC N
as RB N
well RB N
tolerated VBN N
as IN N
the DT N
8-week JJ N
alternate NN N
week NN N
regimen NNS N
for IN N
sBCC NN N
. . N

-DOCSTART- -X- O O

Development NNP N
of IN N
renal JJ N
disease NN N
in IN N
people NNS N
at IN N
high JJ N
cardiovascular JJ N
risk NN N
: : N
results NNS N
of IN N
the DT N
HOPE NNP N
randomized VBD N
study NN N
. . N

In IN N
people NNS N
with IN N
diabetes NNS N
, , N
renal JJ N
disease NN N
tends VBZ N
to TO N
progress VB N
from IN N
microalbuminuria NN N
to TO N
clinical JJ N
proteinuria NN N
to TO N
renal JJ N
insufficiency NN N
. . N

Little JJ N
evidence NN N
has VBZ N
been VBN N
published VBN N
for IN N
the DT N
nondiabetic JJ N
population NN N
. . N

This DT N
study NN N
retrospectively RB N
analyzed VBD N
changes NNS N
of IN N
proteinuria NN N
over IN N
4.5 CD N
yr NNS N
in IN N
the DT N
HOPE NNP N
( ( N
Heart NNP N
Outcomes NNP N
and CC N
Prevention NNP N
Evaluation NNP N
) ) N
study NN N
, , N
which WDT N
compared VBN N
ramipril NN 3_i
's POS 3_i
effects NNS N
to TO N
placebo VB 7_i
in IN N
9297 CD N
participants NNS N
, , N
including VBG N
3577 CD N
with IN N
diabetes NNS N
and CC N
1956 CD N
with IN N
microalbuminuria NN N
. . N

This DT N
report NN N
is VBZ N
restricted VBN N
to TO N
7674 CD N
participants NNS N
with IN N
albuminuria NNS N
data NNS N
at IN N
baseline NN N
and CC N
at IN N
follow-up JJ N
. . N

Inclusion NN N
criteria NNS N
were VBD N
known VBN N
vascular JJ N
disease NN N
or CC N
diabetes VBZ N
plus CC N
one CD N
other JJ N
cardiovascular JJ N
risk NN N
factor NN N
, , N
exclusion NN N
criteria NNS N
included VBD N
heart NN N
failure NN N
or CC N
known VBN N
impaired JJ N
left VBD N
ventricular JJ N
function NN N
, , N
dipstick-positive JJ N
proteinuria NN N
( ( N
> JJ N
1+ CD N
) ) N
, , N
and CC N
serum JJ N
creatinine NN N
> $ N
2.3 CD N
mg/dl NN N
( ( N
200 CD N
microM NN N
) ) N
. . N

Baseline NNP N
microalbuminuria NN N
predicted VBD N
subsequent JJ N
clinical JJ N
proteinuria NN N
for IN N
the DT N
study NN N
participants NNS N
overall JJ N
( ( N
adjusted VBN N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
17.5 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
12.6 CD N
to TO N
24.4 CD N
) ) N
, , N
in IN N
participants NNS N
without IN N
diabetes NNS N
( ( N
OR NNP N
, , N
16.7 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
8.6 CD N
to TO N
32.4 CD N
) ) N
, , N
and CC N
in IN N
participants NNS N
with IN N
diabetes NNS N
( ( N
OR NNP N
, , N
18.2 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
12.4 CD N
to TO N
26.7 CD N
) ) N
. . N

Any DT N
progression NN N
of IN N
albuminuria NNS N
( ( N
defined VBN N
as IN N
new JJ N
microalbuminuria NNS N
or CC N
new JJ N
clinical JJ N
proteinuria NN N
) ) N
occurred VBD N
in IN N
1859 CD N
participants NNS N
; : N
1542 CD N
developed VBD N
new JJ N
microalbuminuria NNS N
, , N
and CC N
317 CD N
participants NNS N
developed VBD N
clinical JJ N
proteinuria NN N
. . N

Ramipril NNP 3_i
reduced VBD N
the DT N
risk NN N
for IN N
any DT N
progression NN N
( ( N
OR NNP N
, , N
0.87 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.78 CD N
to TO N
0.97 CD N
; : N
P NNP N
= NNP N
0.0146 CD N
) ) N
. . N

People NNS N
without IN N
and CC N
with IN N
diabetes NNS N
who WP N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
cardiovascular JJ N
disease NN N
are VBP N
also RB N
at IN N
risk NN N
for IN N
a DT N
progressive JJ N
rise NN N
in IN N
albuminuria NN N
. . N

Microalbuminuria NNP N
itself PRP N
predicts VBZ N
clinical JJ N
proteinuria NNS N
in IN N
nondiabetic JJ N
and CC N
in IN N
diabetic JJ N
people NNS N
. . N

Ramipril JJ 3_i
prevents NNS N
or CC N
delays VBZ N
the DT N
progression NN N
of IN N
albuminuria NN N
. . N

-DOCSTART- -X- O O

Placebo-controlled JJ N
study NN N
of IN N
oral JJ 3_i
enoximone NN 3_i
in IN N
congestive JJ N
heart NN N
failure NN N
with IN N
initial JJ N
and CC N
final JJ N
intravenous JJ N
hemodynamic JJ N
evaluation NN N
. . N

Seventeen JJ N
patients NNS N
with IN N
stable JJ N
congestive JJ N
heart NN N
failure NN N
( ( N
class NN N
II NNP N
and CC N
III NNP N
New NNP N
York NNP N
Heart NNP N
Association NNP N
) ) N
received VBD N
intravenous JJ N
and CC N
oral JJ N
enoximone NN 3_i
in IN N
a DT N
2-part JJ N
study NN N
. . N

Hemodynamic NNP N
data NNS N
were VBD N
first RB N
obtained VBN N
after IN N
intravenous JJ N
administration NN N
of IN N
0.75 CD 3_i
mg/kg NN 3_i
of IN 3_i
enoximone NN 3_i
; : N
data NNS N
were VBD N
again RB N
obtained VBN N
after IN N
12 CD N
weeks NNS N
of IN N
therapy NN N
with IN N
either DT N
oral JJ 3_i
enoximone NN 3_i
( ( N
150 CD N
mg RB N
3 CD N
times NNS N
daily RB N
) ) N
or CC N
placebo NN 7_i
. . N

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ 3_i
enoximone NN 3_i
were VBD N
also RB N
studied VBN N
in IN N
a DT N
12-week JJ N
, , N
double-blind JJ N
randomized JJ N
format NN N
. . N

In IN N
the DT N
intravenous JJ N
study NN N
, , N
enoximone NN 3_i
was VBD N
delivered VBN N
over IN N
5 CD N
minutes NNS N
and CC N
hemodynamic JJ N
data NNS N
were VBD N
measured VBN N
for IN N
up RB N
to TO N
12 CD N
hours NNS N
after IN N
. . N

Cardiac NNP N
index NN N
increased VBD N
2.76 CD N
+/- JJ N
0.63 CD N
to TO N
3.42 CD N
+/- JJ N
0.72 CD N
liters/min/m2 NN N
) ) N
, , N
pulmonary JJ N
wedge NN N
pressure NN N
decreased VBN N
( ( N
19.5 CD N
+/- JJ N
8.8 CD N
to TO N
14.6 CD N
+/- JJ N
8.0 CD N
mm NN N
Hg NNP N
) ) N
as IN N
did VBD N
mean VB N
arterial JJ N
blood NN N
pressure NN N
( ( N
101 CD N
+/- JJ N
14.8 CD N
to TO N
85 CD N
+/- JJ N
13.7 CD N
mm NN N
Hg NNP N
) ) N
and CC N
systemic JJ N
vascular NN N
resistance NN N
( ( N
1,880 CD N
+/- JJ N
573 CD N
to TO N
1,254 CD N
+/- JJ N
383 CD N
dynes NNS N
s RB N
cm-5 NN N
) ) N
. . N

Heart NNP N
rate NN N
increased VBD N
slightly RB N
( ( N
82 CD N
+/- JJ N
17 CD N
to TO N
86 CD N
+/- JJ N
14 CD N
beats/min NN N
) ) N
. . N

All PDT N
these DT N
changes NNS N
were VBD N
maximal JJ N
1 CD N
to TO N
2 CD N
hours NNS N
after IN N
infusion NN N
and CC N
lasted VBD N
8 CD N
hours NNS N
at IN N
least JJS N
. . N

Patients NNS N
were VBD N
then RB N
randomized VBN N
double-blind NN N
to TO N
oral JJ N
treatment NN N
. . N

Baseline NNP N
values VBZ N
showed VBD N
that IN N
the DT N
7 CD N
patients NNS N
who WP N
received VBD N
placebo NN 7_i
had VBD N
more RBR N
severe JJ N
CHF NNP N
. . N

Therefore NNP N
, , N
comparison NN N
might MD N
be VB N
biased VBN N
. . N

Patient NNP N
overall JJ N
assessment NN N
showed VBD N
a DT N
continuous JJ N
benefit NN N
in IN N
both DT N
groups NNS N
. . N

Ejection NNP N
fraction NN N
improved VBD N
from IN N
30.1 CD N
+/- JJ N
6.8 CD N
% NN N
to TO N
33.9 CD N
+/- JJ N
9.9 CD N
% NN N
in IN N
the DT N
enoximone NN N
group NN N
while IN N
it PRP N
remained VBD N
unchanged JJ N
with IN N
placebo NN N
( ( N
23.4 CD N
+/- JJ N
6.5 CD N
% NN N
to TO N
23.4 CD N
+/- JJ N
1.5 CD N
% NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Cognitive JJ 4_i
behavioral JJ 4_i
therapy NN 4_i
for IN N
anxiety NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Children NNP N
with IN N
autism NN N
spectrum NN N
disorders NNS N
often RB N
present JJ N
with IN N
comorbid NN N
anxiety NN N
disorders NNS N
that WDT N
cause VBP N
significant JJ N
functional JJ N
impairment NN N
. . N

This DT N
study NN N
tested VBD N
a DT N
modular JJ N
cognitive JJ 4_i
behavioral JJ 4_i
therapy NN 4_i
( ( 4_i
CBT NNP 4_i
) ) 4_i
program NN N
for IN N
children NNS N
with IN N
this DT N
profile NN N
. . N

A DT N
standard JJ N
CBT NNP 4_i
program NN N
was VBD N
augmented VBN N
with IN N
multiple JJ N
treatment NN N
components NNS N
designed VBN N
to TO N
accommodate VB N
or CC N
remediate VB N
the DT N
social JJ N
and CC N
adaptive JJ N
skill NN N
deficits NNS N
of IN N
children NNS N
with IN N
ASD NNP N
that WDT N
could MD N
pose VB N
barriers NNS N
to TO N
anxiety VB N
reduction NN N
. . N

METHOD NNP N
Forty NNP N
children NNS N
( ( N
7-11 CD N
years NNS N
old JJ N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
16 CD N
sessions NNS N
of IN N
CBT NNP 4_i
or CC N
a DT N
3-month JJ 4_i
waitlist NN 4_i
( ( N
36 CD N
completed VBN N
treatment NN N
or CC N
waitlist NN N
) ) N
. . N

Therapists NNS N
worked VBD N
with IN N
individual JJ N
families NNS N
. . N

The DT N
CBT NNP 4_i
model NN N
emphasized VBD N
behavioral JJ N
experimentation NN N
, , N
parent-training NN N
, , N
and CC N
school NN N
consultation NN N
. . N

Independent JJ N
evaluators NNS N
blind VBP N
to TO N
treatment NN N
condition NN N
conducted VBN N
structured JJ N
diagnostic JJ N
interviews NNS N
and CC N
parents NNS N
and CC N
children NNS N
completed VBN N
anxiety NN N
symptom NN N
checklists NNS N
at IN N
baseline NN N
and CC N
posttreatment/postwaitlist NN N
. . N

RESULTS NNP N
In IN N
intent-to-treat JJ N
analyses NNS N
, , N
78.5 CD N
% NN N
of IN N
the DT N
CBT NNP 4_i
group NN N
met VBD N
Clinical JJ N
Global NNP N
Impressions-Improvement NNP N
scale NN N
criteria NNS N
for IN N
positive JJ N
treatment NN N
response NN N
at IN N
posttreatment NN N
, , N
as IN N
compared VBN N
to TO N
only RB N
8.7 CD N
% NN N
of IN N
the DT N
waitlist NN 4_i
group NN N
. . N

CBT NNP 4_i
also RB N
outperformed VBD N
the DT N
waitlist NN 4_i
on IN N
diagnostic JJ N
outcomes NNS N
and CC N
parent NN N
reports NNS N
of IN N
child NN N
anxiety NN N
, , N
but CC N
not RB N
children NNS N
's POS N
self-reports NNS N
. . N

Treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
CBT NNP 4_i
manual JJ N
employed VBN N
in IN N
this DT N
study NN N
is VBZ N
one CD N
of IN N
the DT N
first JJ N
adaptations NNS N
of IN N
an DT N
evidence-based JJ N
treatment NN N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Remission NN N
of IN N
anxiety NN N
disorders NNS N
appears VBZ N
to TO N
be VB N
an DT N
achievable JJ N
goal NN N
among IN N
high-functioning JJ N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O

Iron NNP 3_i
in IN N
relation NN N
to TO N
gastric JJ N
cancer NN N
in IN N
the DT N
Alpha-tocopherol NNP N
, , N
Beta-carotene NNP N
Cancer NNP N
Prevention NNP N
Study NNP N
. . N

BACKGROUND NNP N
Iron NNP 3_i
is VBZ N
an DT N
essential JJ N
micronutrient NN N
that WDT N
can MD N
have VB N
carcinogenic JJ N
effects NNS N
when WRB N
at IN N
high JJ N
or CC N
low JJ N
concentrations NNS N
. . N

Previous JJ N
studies NNS N
of IN N
iron NN N
in IN N
relation NN N
to TO N
gastric JJ N
cancer NN N
have VBP N
not RB N
assessed VBN N
subtype-specific JJ N
relationships NNS N
. . N

We PRP N
used VBD N
the DT N
prospective JJ N
Alpha-Tocopherol NNP N
, , N
Beta-Carotene NNP N
( ( N
ATBC NNP N
) ) N
Cancer NNP N
Prevention NNP N
Study NNP N
to TO N
assess VB N
whether IN N
iron NN N
metrics NNS N
were VBD N
associated VBN N
with IN N
gastric JJ N
cardia NN N
cancer NN N
( ( N
GCC NNP N
) ) N
and CC N
gastric JJ N
noncardia NN N
cancer NN N
( ( N
GNCC NNP N
) ) N
. . N

METHODS NNP N
We PRP N
selected VBD N
341 CD N
incident JJ N
gastric JJ N
cancer NN N
cases NNS N
( ( N
86 CD N
cardia NN N
, , N
172 CD N
noncardia NN N
, , N
and CC N
83 CD N
nonspecified VBN N
) ) N
, , N
accrued VBN N
during IN N
22 CD N
years NNS N
of IN N
follow-up NN N
, , N
and CC N
341 CD N
individually RB N
matched VBN N
controls NNS N
. . N

We PRP N
measured VBD N
prediagnostic JJ N
serum NN N
iron NN N
, , N
ferritin NN N
, , N
unsaturated JJ N
iron NN N
binding NN N
capacity NN N
, , N
and CC N
C-reactive JJ N
protein NN N
. . N

Total JJ N
iron-binding JJ N
capacity NN N
( ( N
TIBC NNP N
) ) N
and CC N
transferrin JJ N
saturation NN N
were VBD N
estimated VBN N
from IN N
these DT N
metrics NNS N
. . N

Dietary NNP 3_i
iron NN 3_i
exposures NNS N
were VBD N
estimated VBN N
from IN N
a DT N
food NN N
frequency NN N
questionnaire NN N
. . N

Multivariable JJ N
logistic JJ N
regression NN N
was VBD N
used VBN N
for IN N
analysis NN N
. . N

RESULTS NNP N
Serum NNP N
iron NN N
metrics NNS N
were VBD N
not RB N
associated VBN N
with IN N
GCC NNP N
, , N
except IN N
for IN N
a DT N
potential JJ N
n NN N
-shaped VBD N
relationship NN N
with IN N
TIBC NNP N
( ( N
global JJ N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

GNCC NNP N
was VBD N
inversely RB N
associated VBN N
with IN N
serum NN N
ferritin NN N
( ( N
global JJ N
P NNP N
= NNP N
0.024 CD N
) ) N
, , N
serum JJ N
iron NN N
( ( N
global JJ N
P NNP N
= NNP N
0.060 CD N
) ) N
and CC N
, , N
possibly RB N
, , N
transferrin JJ N
saturation NN N
. . N

TIBC NNP N
appeared VBD N
to TO N
share NN N
a DT N
u NN N
-shaped VBD N
relationship NN N
with IN N
GNCC NNP N
( ( N
global JJ N
P NNP N
= NNP N
0.033 CD N
) ) N
. . N

Dietary NNP N
iron NN 3_i
exposures NNS N
were VBD N
not RB N
associated VBN N
with IN N
either DT N
subsite NN N
. . N

Adjustment NN N
for IN N
Helicobacter NNP N
pylori NN N
and CC N
gastric JJ N
atrophy NN N
had VBD N
little JJ N
effect NN N
on IN N
observed JJ N
associations NNS N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
little JJ N
evidence NN N
for IN N
the DT N
involvement NN N
of IN N
iron NN 3_i
exposure NN N
in IN N
the DT N
pathogenesis NN N
of IN N
GCC NNP N
. . N

GNCC NNP N
was VBD N
associated VBN N
with IN N
an DT N
iron NN 3_i
profile NN N
similar JJ N
to TO N
that DT N
of IN N
iron NN N
deficiency NN N
. . N

IMPACT NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
inverse JJ N
associations NNS N
between IN N
iron NN N
metrics NNS N
and CC N
gastric JJ N
cancer NN N
are VBP N
driven VBN N
by IN N
associations NNS N
with IN N
GNCC NNP N
. . N

Further NNP N
elucidation NN N
of IN N
potential JJ N
mechanisms NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Anti-IgG JJ N
antibodies NNS N
during IN N
immunotherapy NN N
with IN N
purified JJ N
grass NN N
pollen NN N
extracts NNS N
. . N

In IN N
a DT N
double JJ N
blind NN N
study NN N
40 CD N
patients NNS N
were VBD N
allocated VBN N
specific JJ 3_i
immunotherapy NN 3_i
( ( 3_i
hyposensitization NN 3_i
) ) 3_i
with IN 3_i
partially RB 3_i
purified VBN 3_i
timothy JJ 3_i
extract NN 3_i
or CC 3_i
two CD 3_i
timothy JJ 3_i
major JJ 3_i
allergens NNS 3_i
19 CD 3_i
, , 3_i
25 CD 3_i
. . 3_i

All DT N
patients NNS N
had VBD N
typical JJ N
grass NN N
pollen NN N
hay NN N
fever NN N
, , N
in IN N
27 CD N
% NN N
associated VBN N
with IN N
grass NN N
pollen NN N
asthma NN N
and CC N
in IN N
13 CD N
% NN N
with IN N
birch NN N
pollen NN N
allergy NN N
. . N

Serum NNP N
IgG NNP N
anti-IgG JJ N
antibodies NNS N
were VBD N
determined VBN N
after IN N
dithiothreitol JJ N
treatment NN N
. . N

Before IN N
hyposensitization NN N
, , N
IgG NNP N
anti-IgG JJ N
titres NNS N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
9 CD N
were VBD N
demonstrated VBN N
in IN N
45 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

During IN N
hyposensitization NN N
IgG NNP N
anti-IgG NN N
titres NNS N
showed VBD N
a DT N
slight JJ N
initial JJ N
increase NN N
followed VBN N
by IN N
a DT N
decrease NN N
below IN N
pretreatment JJ N
level NN N
. . N

Neither CC N
increase VB N
nor CC N
decrease VB N
was VBD N
statistically RB N
significant JJ N
. . N

Reactions NNS N
to TO N
rabbit VB N
IgG NNP N
F NNP N
( ( N
ab IN N
' POS N
) ) N
2 CD N
fractions NNS N
were VBD N
only RB N
obtained VBN N
during IN N
hyposensitization NN N
. . N

The DT N
occurrence NN N
of IN N
anti-IgG JJ N
antibodies NNS N
did VBD N
no DT N
correlate NN N
with IN N
symptoms NNS N
, , N
side NN N
effects NNS N
, , N
or CC N
the DT N
level NN N
of IN N
allergen-specific JJ N
IgG NNP N
. . N

In IN N
a DT N
previous JJ N
study NN N
it PRP N
was VBD N
demonstrated VBN N
that IN N
patients NNS N
with IN N
multiallergy JJ N
hyposensitized VBN N
with IN N
combined JJ N
allergen NN N
extracts NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
IgG NNP N
anti-IgG JJ N
titres NNS N
during IN N
treatment NN N
. . N

The DT N
increase NN N
failed VBD N
to TO N
appear VB N
in IN N
the DT N
present JJ N
patients NNS N
allergic VBZ N
only RB N
to TO N
pollen VB N
and CC N
treated VBN N
with IN N
purified JJ N
allergen NN N
extracts NNS N
. . N

It PRP N
is VBZ N
therefore RB N
suggested VBN N
that IN N
a DT N
multiallergic JJ N
condition NN N
and CC N
the DT N
combination NN N
and/or JJ N
purification NN N
of IN N
allergen NN N
extracts NNS N
administered VBN N
during IN N
hyposensitization NN N
may MD N
influence VB N
the DT N
production NN N
of IN N
IgG NNP N
anti- JJ N
IgG NNP N
antibodies NNS N
. . N

-DOCSTART- -X- O O

Intervention NN 2_i
to TO 2_i
lower VB 2_i
household NN 2_i
wood NN 2_i
smoke NN 2_i
exposure NN 2_i
in IN N
Guatemala NNP N
reduces NNS N
ST-segment NNP N
depression NN N
on IN N
electrocardiograms NNS N
. . N

BACKGROUND VB N
A DT N
large JJ N
body NN N
of IN N
evidence NN N
suggests VBZ N
that IN N
fine JJ N
particulate NN N
matter NN N
( ( N
PM NNP N
) ) N
air NN N
pollution NN N
is VBZ N
a DT N
cause NN N
of IN N
cardiovascular JJ N
disease NN N
, , N
but CC N
little JJ N
is VBZ N
known VBN N
in IN N
particular JJ N
about IN N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
indoor JJ N
air NN N
pollution NN N
from IN N
household NN N
use NN N
of IN N
solid JJ N
fuels NNS N
in IN N
developing VBG N
countries NNS N
. . N

RESPIRE NNP N
( ( N
Randomized NNP N
Exposure NNP N
Study NNP N
of IN N
Pollution NNP N
Indoors NNP N
and CC N
Respiratory NNP N
Effects NNP N
) ) N
was VBD N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
chimney NN 2_i
woodstove NN 2_i
that WDT N
reduces VBZ N
wood NN 2_i
smoke NN 2_i
exposure NN 2_i
. . N

OBJECTIVES IN N
We PRP N
tested VBD N
the DT N
hypotheses NNS N
that IN N
the DT N
stove NN 2_i
intervention NN 2_i
, , N
compared VBN N
with IN N
open JJ 2_i
fire NN 2_i
use NN 2_i
, , N
would MD N
reduce VB N
ST-segment NNP N
depression NN N
and CC N
increase VB N
heart NN N
rate NN N
variability NN N
( ( N
HRV NNP N
) ) N
. . N

METHODS NNP N
We PRP N
used VBD N
two CD N
complementary JJ N
study NN N
designs NNS N
: : N
a DT N
) ) N
between-groups NN N
comparisons NNS N
based VBN N
on IN N
randomized JJ 2_i
stove NN 2_i
assignment NN 2_i
, , N
and CC N
b NN N
) ) N
before-and-after NN N
comparisons NNS N
within IN N
control NN N
subjects NNS N
who WP N
used VBD 2_i
open JJ 2_i
fires NNS 2_i
during IN 2_i
the DT 2_i
trial NN 2_i
and CC 2_i
received VBD 2_i
chimney NN 2_i
stoves NNS 2_i
after IN 2_i
the DT 2_i
trial NN 2_i
. . N

Electrocardiogram NNP 2_i
sessions NNS 2_i
that WDT N
lasted VBD N
20 CD N
hr NNS N
were VBD N
repeated VBN N
up RP N
to TO N
three CD N
times NNS N
among IN N
49 CD N
intervention NN N
and CC N
70 CD N
control NN N
women NNS N
38-84 CD N
years NNS N
of IN N
age NN N
, , N
and CC N
55 CD N
control NN N
subjects NNS N
were VBD N
also RB N
assessed VBN N
after IN N
receiving VBG N
stoves NNS 2_i
. . N

HRV NNP N
and CC N
ST-segment JJ N
values NNS N
were VBD N
assessed VBN N
for IN N
each DT N
30-min JJ N
period NN N
. . N

ST-segment JJ N
depression NN N
was VBD N
defined VBN N
as IN N
an DT N
average JJ N
value NN N
below IN N
-1.00 NNP N
mm NN N
. . N

Personal JJ N
fine JJ N
PM NNP N
[ NNP N
aerodynamic JJ N
diameter NN N
? . N
2.5 CD N
?m NN N
( ( N
PM?.? NNP N
] NNP N
exposures NNS N
were VBD N
measured VBN N
for IN N
24 CD N
hr NN N
before IN N
each DT N
electrocardiogram NN N
. . N

RESULTS NNP N
PM?.? NNP N
exposure NN N
means NNS N
were VBD N
266 CD N
and CC N
102 CD N
?g/m? NN N
during IN N
the DT N
trial NN N
period NN N
in IN N
the DT N
control NN N
and CC N
intervention NN N
groups NNS N
, , N
respectively RB N
. . N

During IN N
the DT N
trial NN N
, , N
the DT N
stove NN N
intervention NN N
was VBD N
associated VBN N
with IN N
an DT N
odds NNS N
ratio NN N
of IN N
0.26 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.08-0.90 NN N
) ) N
for IN N
ST-segment JJ N
depression NN N
. . N

We PRP N
found VBD N
similar JJ N
associations NNS N
with IN N
the DT N
before-and-after JJ N
comparison NN N
. . N

The DT N
intervention NN N
was VBD N
not RB N
significantly RB N
associated VBN N
with IN N
HRV NNP N
. . N

CONCLUSIONS NNP N
The DT N
stove NN N
intervention NN N
was VBD N
associated VBN N
with IN N
reduced JJ N
occurrence NN N
of IN N
nonspecific JJ N
ST-segment JJ N
depression NN N
, , N
suggesting VBG N
that IN N
household NN N
wood NN N
smoke NN N
exposures NNS N
affect VBP N
ventricular JJ N
repolarization NN N
and CC N
potentially RB N
cardiovascular JJ N
health NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
effect NN N
of IN N
fuzheng NN 3_i
yiliu NN 3_i
granule NN 3_i
on IN N
cell NN N
cycle NN N
and CC N
nuclear JJ N
transcription NN N
factor-kappa NN N
B NNP N
in IN N
tissue NN N
of IN N
esophageal-gastric JJ N
carcinoma NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
effect NN N
of IN N
Fuzheng NNP 3_i
Yiliu NNP 3_i
Granule NNP 3_i
( ( 3_i
FZYLG NNP 3_i
) ) 3_i
on IN N
cell NN N
cycle NN N
and CC N
nuclear JJ N
transcription NN N
factor-kappa NN N
B NNP N
( ( N
NF-kappa NNP N
B NNP N
) ) N
in IN N
tissue NN N
of IN N
esophageal-gastric JJ N
carcinoma NN N
. . N

METHODS NNP N
Seventy-six JJ N
patients NNS N
with IN N
esophageal JJ N
gastric JJ N
carcinoma NN N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
FZYLG NNP 3_i
group NN N
and CC N
the DT N
control NN 7_i
group NN 7_i
. . N

FZYLG NNP 3_i
was VBD N
given VBN N
to TO N
the DT N
former JJ N
for IN N
15 CD N
days NNS N
. . N

The DT N
tumor NN N
tissue NN N
in IN N
both DT N
groups NNS N
was VBD N
resected VBN N
and CC N
cell JJ N
cycle NN N
and CC N
apoptosis NN N
rate NN N
as RB N
well RB N
as IN N
NF-kappa NNP N
B NNP N
were VBD N
determined VBN N
by IN N
flowcytometry NN N
. . N

RESULTS NNP N
Level NNP N
of IN N
NF-kappa NNP N
B NNP N
in IN N
the DT N
treated JJ N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
treated JJ N
group NN N
, , N
the DT N
percentage NN N
of IN N
G0/G1 NNP N
stage NN N
cells NNS N
were VBD N
significantly RB N
increased VBN N
and CC N
that IN N
of IN N
S NNP N
stage NN N
significantly RB N
decreased VBN N
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
same JJ N
time NN N
, , N
obvious JJ N
cell NN N
apoptosis NN N
was VBD N
found VBN N
in IN N
the DT N
treated JJ N
group NN N
, , N
the DT N
apoptosis NN N
rate NN N
of IN N
which WDT N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
FZYLG NNP 3_i
can MD N
increase VB N
the DT N
NF-kappa NNP N
B NNP N
expression NN N
, , N
block VB N
the DT N
proliferation NN N
to TO N
promote VB N
the DT N
apoptosis NN N
of IN N
tumor NN N
cells NNS N
. . N

-DOCSTART- -X- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
electro-acupuncture NN 2_i
for IN N
autism NN N
spectrum NN N
disorder NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
efficacy NN N
, , N
safety NN N
, , N
and CC N
compliance NN N
of IN N
short-term JJ N
electro-acupuncture NN 2_i
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
sham-controlled JJ N
, , N
clinical JJ N
trial NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Children NNP N
with IN N
ASD NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
electro-acupuncture NN 2_i
( ( 2_i
EA NNP 2_i
) ) 2_i
group NN N
( ( N
n=30 JJ N
) ) N
or CC N
a DT N
sham JJ 7_i
electro-acupuncture NN 7_i
( ( N
SEA NNP N
) ) N
group NN N
( ( N
n=25 RB N
) ) N
matched VBN N
by IN N
age NN N
and CC N
severity NN N
of IN N
autism NN N
. . N

The DT N
EA NNP N
group NN N
received VBD N
electro-acupuncture NN N
for IN N
selected VBN N
acupoints NNS N
while IN N
the DT N
SEA NNP N
group NN N
received VBD N
sham JJ N
electro-acupuncture NN N
to TO N
sham VB N
acupoints NNS N
. . N

A DT N
total NN N
of IN N
12 CD N
EA NNP N
and CC N
SEA NNP N
sessions NNS N
over IN N
four CD N
weeks NNS N
were VBD N
given VBN N
. . N

Primary JJ N
outcome NN N
measures NNS N
included VBD N
Functional NNP N
Independence NNP N
Measure NN N
for IN N
Children NNP N
( ( N
WeeFIM NNP N
) ) N
, , N
Pediatric NNP N
Evaluation NNP N
of IN N
Disability NNP N
Inventory NNP N
( ( N
PEDI NNP N
) ) N
, , N
Leiter NNP N
International NNP N
Performance NNP N
Scale-Revised JJ N
( ( N
Leiter-R NNP N
) ) N
, , N
and CC N
Clinical JJ N
Global NNP N
Impression-Improvement NNP N
( ( N
CGI-I NNP N
) ) N
scale NN N
. . N

Secondary JJ N
outcome NN N
measures NNS N
consisted VBN N
of IN N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
, , N
Ritvo-Freeman JJ N
Real NNP N
Life NNP N
Scale NNP N
( ( N
RFRLS NNP N
) ) N
, , N
Reynell NNP N
Developmental NNP N
Language NNP N
Scale NNP N
( ( N
RDLS NNP N
) ) N
, , N
and CC N
a DT N
standardized JJ N
parental JJ N
report NN N
. . N

Data NNP N
were VBD N
analyzed VBN N
by IN N
the DT N
Mann-Whitney NNP N
test NN N
. . N

RESULTS CC N
There EX N
were VBD N
significant JJ N
improvements NNS N
in IN N
the DT N
language NN N
comprehension NN N
domain NN N
of IN N
WeeFIM NNP N
( ( N
p=0.02 NN N
) ) N
, , N
self-care JJ N
caregiver NN N
assistant NN N
domain NN N
of IN N
PEDI NNP N
( ( N
p=0.028 NN N
) ) N
, , N
and CC N
CGI-I NNP N
( ( N
p=0.003 NN N
) ) N
in IN N
the DT N
EA NNP N
group NN N
compared VBN N
to TO N
the DT N
SEA NNP N
group NN N
. . N

As IN N
for IN N
the DT N
parental JJ N
report NN N
, , N
the DT N
EA NNP N
group NN N
also RB N
showed VBD N
significantly RB N
better RBR N
social JJ N
initiation NN N
( ( N
p=0.01 NN N
) ) N
, , N
receptive JJ N
language NN N
( ( N
p=0.006 NN N
) ) N
, , N
motor NN N
skills NNS N
( ( N
p=0.034 NN N
) ) N
, , N
coordination NN N
( ( N
p=0.07 NN N
) ) N
, , N
and CC N
attention NN N
span NN N
( ( N
p=0.003 NN N
) ) N
. . N

More JJR N
than IN N
70 CD N
percent NN N
of IN N
children NNS N
with IN N
ASD NNP N
adapted VBD N
to TO N
acupuncture VB N
easily RB N
, , N
while IN N
eight CD N
percent NN N
had VBD N
poor JJ N
acupuncture NN N
compliance NN N
. . N

Mild NNP N
side JJ N
effects NNS N
of IN N
minor JJ N
superficial JJ N
bleeding NN N
or CC N
irritability NN N
during IN N
acupuncture NN N
were VBD N
observed VBN N
. . N

CONCLUSION VB N
A DT N
short JJ N
, , N
four-week JJ N
( ( N
12 CD N
sessions NNS N
) ) N
course NN N
of IN N
electro-acupuncture NN N
is VBZ N
useful JJ N
to TO N
improve VB N
specific JJ N
functions NNS N
in IN N
children NNS N
with IN N
ASD NNP N
, , N
especially RB N
for IN N
language NN N
comprehension NN N
and CC N
self-care JJ N
ability NN N
. . N

-DOCSTART- -X- O O

Collagen NNP 3_i
cross-linking NN 3_i
with IN 3_i
photoactivated JJ 3_i
riboflavin NN 3_i
( ( 3_i
PACK-CXL NNP 3_i
) ) 3_i
for IN N
the DT N
treatment NN N
of IN N
advanced JJ N
infectious JJ N
keratitis NN N
with IN N
corneal JJ N
melting NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
corneal JJ 3_i
collagen NN 3_i
cross-linking NN 3_i
( ( 3_i
CXL NNP 3_i
) ) 3_i
with IN N
photoactivated VBN 3_i
riboflavin NN 3_i
( ( 3_i
photoactivated VBN 3_i
chromophore NN 3_i
for IN 3_i
infectious JJ 3_i
keratitis NN 3_i
[ NNP 3_i
PACK NNP 3_i
] NNP 3_i
-CXL NNP 3_i
) ) 3_i
in IN N
the DT N
management NN N
of IN N
infectious JJ N
keratitis NN N
with IN N
corneal JJ N
melting VBG N
. . N

DESIGN NNP N
Prospective NNP N
clinical JJ N
trial NN N
. . N

PARTICIPANTS NNP N
Forty NNP N
eyes NNS N
from IN N
40 CD N
patients NNS N
with IN N
advanced JJ N
infectious JJ N
keratitis NN N
and CC N
coexisting VBG N
corneal NN N
melting NN N
. . N

METHODS NNP N
Twenty-one CD N
patients NNS N
( ( N
21 CD N
eyes NNS N
) ) N
underwent JJ N
PACK-CXL JJ 3_i
treatment NN 3_i
in IN 3_i
addition NN 3_i
to TO 3_i
antimicrobial JJ 3_i
therapy NN 3_i
. . 3_i

The DT N
control NN N
group NN N
consisted VBD N
of IN N
19 CD N
patients NNS N
( ( N
19 CD N
eyes NNS N
) ) N
who WP N
received VBD N
only RB 3_i
antimicrobial JJ 3_i
therapy NN 3_i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
slit-lamp JJ N
characteristics NNS N
of IN N
the DT N
corneal NN N
ulceration NN N
, , N
corrected VBN N
distance NN N
visual JJ N
acuity NN N
, , N
duration NN N
until IN N
healing VBG N
, , N
and CC N
complications NNS N
were VBD N
documented VBN N
in IN N
each DT N
group NN N
. . N

The DT N
Mann-Whitney NNP N
U NNP N
test NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

P NNP N
values VBZ N
less JJR N
than IN N
0.05 CD N
were VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS VB N
The DT N
average JJ N
time NN N
until IN N
healing VBG N
was VBD N
39.76 CD N
? . N
18.22 CD N
days NNS N
in IN N
the DT N
PACK-CXL NNP N
group NN N
and CC N
46.05 CD N
? . N
27.44 CD N
days NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.68 CD N
) ) N
. . N

After IN N
treatment NN N
and CC N
healing NN N
, , N
corrected VBN N
distance NN N
visual JJ N
acuity NN N
was VBD N
1.64 CD N
? . N
0.62 CD N
in IN N
the DT N
PACK-CXL NNP N
group NN N
and CC N
1.67 CD N
? . N
0.48 CD N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.68 CD N
) ) N
. . N

The DT N
corneal JJ N
ulceration NN N
's POS N
width NN N
and CC N
length NN N
was VBD N
significantly RB N
bigger JJR N
in IN N
the DT N
PACK-CXL NNP N
group NN N
( ( N
P NNP N
= NNP N
0.004 CD N
and CC N
P NNP N
= NNP N
0.007 CD N
) ) N
. . N

Three CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
demonstrated VBD N
corneal JJ N
perforation NN N
; : N
infection NN N
recurred VBD N
in IN N
1 CD N
of IN N
them PRP N
. . N

No DT N
serious JJ N
complications NNS N
occurred VBD N
in IN N
the DT N
PACK-CXL NNP N
group NN N
. . N

CONCLUSIONS NNP N
Corneal NNP N
CXL NNP N
with IN N
photoactivated JJ N
riboflavin NN N
did VBD N
not RB N
shorten VB N
the DT N
time NN N
to TO N
corneal VB N
healing NN N
; : N
however RB N
, , N
the DT N
complication NN N
rate NN N
was VBD N
21 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
, , N
whereas IN N
there EX N
was VBD N
no DT N
incidence NN N
of IN N
corneal JJ N
perforation NN N
or CC N
recurrence NN N
of IN N
the DT N
infection NN N
in IN N
the DT N
PACK-CXL NNP N
group NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
PACK-CXL NNP N
may MD N
be VB N
an DT N
effective JJ N
adjuvant NN N
therapy NN N
in IN N
the DT N
management NN N
of IN N
severe JJ N
infectious JJ N
keratitis NN N
associated VBN N
with IN N
corneal NN N
melting NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
and CC N
safety NN N
of IN N
two CD 2_i
different JJ 2_i
testosterone NN 2_i
undecanoate JJ 2_i
formulations NNS 2_i
in IN N
hypogonadal JJ N
men NNS N
with IN N
metabolic JJ N
syndrome NN N
. . N

AIM NNP N
To TO N
investigate VB N
efficacy NN N
and CC N
safety NN N
of IN N
two CD 2_i
different JJ 2_i
preparations NNS 2_i
of IN 2_i
testosterone NN 2_i
undecanoate NN 2_i
( ( 2_i
TU NNP 2_i
) ) 2_i
in IN N
52 CD N
hypogonadal JJ N
men NNS N
[ VBP N
mean JJ N
age NN N
57 CD N
yr NN N
and CC N
mean VB N
testosterone NN N
( ( N
T NNP N
) ) N
< VBD N
320 CD N
ng/dl JJ N
] NN N
with IN N
metabolic JJ N
syndrome NN N
( ( N
MS NNP N
) ) N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
double-dummy JJ N
study NN N
with IN N
three CD N
parallel JJ N
treatment NN N
arms NNS N
[ VBP N
oral JJ N
TU NNP N
; : N
transdermal JJ 7_i
placebo NN 7_i
gel NN 7_i
( ( N
P NNP N
) ) N
; : N
im JJ N
TU NNP 3_i
] NNP N
administration NN N
for IN N
12 CD N
months NNS N
( ( N
mo NN N
) ) N
. . N

Each DT N
subject NN N
was VBD N
randomized VBN N
( ( N
1:1:3 CD N
) ) N
to TO N
receive VB N
either DT N
oral JJ 3_i
TU NNP 3_i
( ( N
2 CD N
capsules NNS N
of IN N
40 CD N
mg/twice NNS N
per IN N
day NN N
at IN N
breakfast NN N
and CC N
dinner NN N
, , N
equalling VBG N
a DT N
total JJ N
dose NN N
of IN N
160 CD N
mg/day NN N
; : N
no.=10 CC N
) ) N
for IN N
6 CD N
mo NN N
and CC N
continued VBN N
with IN N
im JJ N
TU NNP N
for IN N
further JJ N
6 CD N
mo NN N
, , N
or CC N
P NNP 7_i
( ( N
3-4 JJ N
g/day NN N
; : N
no.=10 CC N
) ) N
and CC N
im JJ 3_i
TU NNP 3_i
( ( N
1000 CD N
mg/12 NN N
weeks NNS N
from IN N
week NN N
6 CD N
; : N
no.=32 NNS N
) ) N
for IN N
12 CD N
mo NNS N
. . N

RESULTS NNP N
After IN N
6 CD N
mo NN N
, , N
im JJ N
TU NNP 3_i
increased VBD N
T NNP N
and CC N
free- JJ N
T NNP N
levels NNS N
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
, , N
and CC N
improved VBN N
metabolic JJ N
parameters NNS N
[ VBP N
reduction NN N
in IN N
Homeostasis NNP N
Model NNP N
Assessment NNP N
( ( N
HOMA NNP N
) ) N
index NN N
, , N
p NN N
< VBD N
0.0001 CD N
; : N
waist JJ N
circumference NN N
and CC N
fat JJ N
mass NN N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
] JJ N
, , N
in IN N
International NNP N
Index NNP N
of IN N
Erectile NNP N
Function-5 NNP N
and CC N
Aging NNP N
Males NNP N
' POS N
Symptoms NNP N
scores NNS N
( ( N
p VB N
< RB N
0.01 CD N
, , N
respectively RB N
) ) N
. . N

After IN N
12 CD N
months NNS N
, , N
im JJ 3_i
TU NNP 3_i
produced VBD N
further JJ N
increases NNS N
in IN N
T NNP N
and CC N
free- JJ N
T NNP N
levels NNS N
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
and CC N
metabolic JJ N
parameters NNS N
( ( N
reduction NN N
in IN N
HOMA-index NNP N
, , N
p NN N
< VBD N
0.0001 CD N
; : N
waist JJ N
circumference NN N
p NN N
< VBZ N
0.0001 CD N
; : N
fat JJ N
mass NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
major JJ N
adverse JJ N
event NN N
due JJ N
to TO N
T NNP N
treatment NN N
occurred VBD N
. . N

CONCLUSIONS NNP N
Clinical NNP N
efficacy NN N
of IN N
T NNP N
replacement NN N
therapy NN N
in IN N
hypogonadal JJ N
men NNS N
with IN N
MS NNP N
is VBZ N
reached VBN N
when WRB N
its PRP$ N
plasmatic JJ N
levels NNS N
approach VBP N
into IN N
the DT N
medium-high JJ N
range NN N
of IN N
normality NN N
( ( N
> JJ N
5 CD N
ng/ml NN N
) ) N
, , N
although IN N
subjective JJ N
threshold JJ N
values NNS N
may MD N
be VB N
different JJ N
. . N

Administration NN N
of IN N
im JJ N
TU NNP 3_i
was VBD N
more RBR N
effective JJ N
than IN N
oral JJ N
TU NNP N
to TO N
reach VB N
the DT N
target NN N
for IN N
T NNP N
levels NNS N
and CC N
to TO N
improve VB N
MS NNP N
parameters NNS N
. . N

TU NNP N
was VBD N
safe JJ N
over IN N
12 CD N
months NNS N
and CC N
discontinuation NN N
rates NNS N
were VBD N
similar JJ N
to TO N
placebo VB 7_i
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
aromatherapy JJ 2_i
massage NN 2_i
in IN N
the DT N
management NN N
of IN N
anxiety NN N
and CC N
depression NN N
in IN N
patients NNS N
with IN N
cancer NN N
: : N
a DT N
multicenter NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
To TO N
test VB N
the DT N
effectiveness NN N
of IN N
supplementing VBG N
usual JJ N
supportive JJ N
care NN N
with IN N
aromatherapy JJ 2_i
massage NN 2_i
in IN N
the DT N
management NN N
of IN N
anxiety NN N
and CC N
depression NN N
in IN N
cancer NN N
patients NNS N
through IN N
a DT N
pragmatic JJ N
two-arm NN N
randomized VBD N
controlled JJ N
trial NN N
in IN N
four CD N
United NNP N
Kingdom NNP N
cancer NN N
centers NNS N
and CC N
a DT N
hospice NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Two CD N
hundred VBD N
eighty-eight JJ N
cancer NN N
patients NNS N
, , N
referred VBD N
to TO N
complementary JJ N
therapy NN N
services NNS N
with IN N
clinical JJ N
anxiety NN N
and/or NN N
depression NN N
, , N
were VBD N
allocated VBN N
randomly RB N
to TO N
a DT N
course NN N
of IN N
aromatherapy JJ 2_i
massage NN 2_i
or CC N
usual JJ 7_i
supportive JJ 7_i
care NN 7_i
alone RB 7_i
. . N

RESULTS JJ N
Patients NNPS N
who WP N
received VBD N
aromatherapy JJ 2_i
massage NN 2_i
had VBD N
no DT N
significant JJ N
improvement NN N
in IN N
clinical JJ N
anxiety NN N
and/or NN N
depression NN N
compared VBN N
with IN N
those DT N
receiving VBG N
usual JJ N
care NN N
at IN N
10 CD N
weeks NNS N
postrandomization NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.3 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.9 CD N
to TO N
1.7 CD N
; : N
P NNP N
= NNP N
.1 NNP N
) ) N
, , N
but CC N
did VBD N
at IN N
6 CD N
weeks NNS N
postrandomization NN N
( ( N
OR NNP N
, , N
1.4 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.1 CD N
to TO N
1.9 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Patients NNS N
receiving VBG N
aromatherapy JJ 2_i
massage NN 2_i
also RB N
described VBD N
greater JJR N
improvement NN N
in IN N
self-reported JJ N
anxiety NN N
at IN N
both DT N
6 CD N
and CC N
10 CD N
weeks NNS N
postrandomization NN N
( ( N
OR NNP N
, , N
3.4 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.2 CD N
to TO N
6.7 CD N
; : N
P NNP N
= NNP N
.04 NNP N
and CC N
OR NNP N
, , N
3.4 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.2 CD N
to TO N
6.6 CD N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
, , N
respectively RB N
. . N

CONCLUSION NNP N
Aromatherapy NNP 2_i
massage NN 2_i
does VBZ N
not RB N
appear VB N
to TO N
confer VB N
benefit NN N
on IN N
cancer NN N
patients NNS N
' POS N
anxiety NN N
and/or NN N
depression NN N
in IN N
the DT N
long-term JJ N
, , N
but CC N
is VBZ N
associated VBN N
with IN N
clinically RB N
important JJ N
benefit NN N
up IN N
to TO N
2 CD N
weeks NNS N
after IN N
the DT N
intervention NN N
. . N

-DOCSTART- -X- O O

Low-intensity NNP 2_i
exercise NN 2_i
and CC N
reduction NN N
of IN N
the DT N
risk NN N
for IN N
falls NNS N
among IN N
at-risk JJ N
elders NNS N
. . N

BACKGROUND NNP N
Among IN N
elderly JJ N
persons NNS N
, , N
falls VBZ N
account NN N
for IN N
87 CD N
% NN N
of IN N
all DT N
fractures NNS N
and CC N
are VBP N
contributing VBG N
factors NNS N
in IN N
many JJ N
nursing NN N
home NN N
admissions NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
an DT N
easily RB N
implemented VBN N
, , N
low-intensity JJ 2_i
exercise NN 2_i
program NN 2_i
on IN N
the DT N
incidence NN N
of IN N
falls NNS N
and CC N
the DT N
time NN N
to TO N
first VB N
fall NN N
among IN N
a DT N
clinically RB N
defined JJ N
population NN N
of IN N
elderly JJ N
men NNS N
and CC N
women NNS N
. . N

METHODS VB N
This DT N
community-based JJ N
, , N
randomized JJ N
trial NN N
compared VBN N
the DT N
exercise NN 2_i
intervention NN 2_i
with IN N
a DT N
no-intervention JJ 7_i
control NN 7_i
. . 7_i

The DT N
participants NNS N
were VBD N
294 CD N
men NNS N
and CC N
women NNS N
, , N
aged VBD N
60 CD N
years NNS N
or CC N
older JJR N
, , N
who WP N
had VBD N
either CC N
a DT N
hospital JJ N
admission NN N
or CC N
bed NN N
rest NN N
for IN N
2 CD N
days NNS N
or CC N
more JJR N
within IN N
the DT N
previous JJ N
month NN N
. . N

Exercise NN 2_i
participants NNS N
were VBD N
scheduled VBN N
to TO N
attend VB N
exercise NN 2_i
sessions NNS 2_i
lasting VBG N
45 CD N
minutes NNS N
, , N
including VBG N
warm-up JJ N
and CC N
cool-down JJ N
, , N
3 CD N
times NNS N
a DT N
week NN N
for IN N
8 CD N
weeks NNS N
( ( N
24 CD N
sessions NNS N
) ) N
. . N

Assessments NNS N
included VBD N
gait NN N
and CC N
balance NN N
measures NNS N
, , N
self-reported JJ N
physical JJ N
function NN N
, , N
the DT N
number NN N
of IN N
medications NNS N
being VBG N
taking VBG N
at IN N
baseline NN N
, , N
participant JJ N
age NN N
, , N
sex NN N
, , N
and CC N
history NN N
of IN N
falling VBG N
. . N

Falls NNS N
were VBD N
tracked VBN N
for IN N
1 CD N
year NN N
after IN N
each DT N
participant NN N
's POS N
baseline JJ N
assessment NN N
. . N

RESULTS VB N
29 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
reported VBD N
a DT N
fall NN N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
effect NN N
of IN N
exercise NN 2_i
in IN N
preventing VBG N
falls NNS N
varied VBN N
significantly RB N
by IN N
baseline JJ N
physical JJ N
function NN N
level NN N
( ( N
p JJ N
< NN N
or CC N
=.002 NN N
) ) N
. . N

The DT N
risk NN N
for IN N
falls NNS N
decreased VBN N
for IN N
exercise NN N
participants NNS N
with IN N
low JJ N
baseline NN N
physical JJ N
functioning NN N
( ( N
hazard JJ N
ratio NN N
, , N
.51 NN N
) ) N
but CC N
increased VBD N
for IN N
exercise NN N
participants NNS N
with IN N
high JJ N
baseline NN N
physical JJ N
functioning NN N
( ( N
hazard JJ N
ratio NN N
, , N
3.51 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
easily RB N
implemented VBN N
, , N
low-intensity JJ 2_i
exercise NN 2_i
program NN 2_i
appears VBZ N
to TO N
reduce VB N
the DT N
risk NN N
for IN N
falls NNS N
among IN N
elderly JJ N
men NNS N
and CC N
women NNS N
recovering VBG N
from IN N
recent JJ N
hospitalizations NNS N
, , N
bed VBD N
rest NN N
, , N
or CC N
both DT N
who WP N
have VBP N
low JJ N
levels NNS N
of IN N
physical JJ N
functioning NN N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
a DT N
single JJ N
intravenous JJ N
administration NN N
of IN N
nicorandil JJ 3_i
before IN N
reperfusion NN N
in IN N
patients NNS N
with IN N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
. . N

BACKGROUND NNP N
Intravenous NNP N
nicorandil NN 3_i
, , N
a DT N
hybrid JJ N
compound NN N
of IN N
ATP-sensitive JJ N
potassium NN N
channel NN N
opener NN N
and CC N
nitric JJ N
oxide NN N
donor NN N
, , N
has VBZ N
been VBN N
reported VBN N
to TO N
ameliorate VB N
early JJ N
functional NN N
and CC N
clinical JJ N
problems NNS N
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

However RB N
, , N
its PRP$ N
effects NNS N
on IN N
the DT N
late JJ N
phase NN N
remain VBP N
unclear JJ N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
This DT N
follow-up JJ N
study NN N
to TO N
5 CD N
years NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
trial NN N
was VBD N
conducted VBN N
among IN N
368 CD N
patients NNS N
with IN N
first JJ N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
undergoing VBG N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
12 CD N
mg NN N
of IN N
nicorandil NN 3_i
or CC N
a DT N
placebo NN 3_i
intravenously RB N
just RB N
before IN N
reperfusion NN N
. . N

We PRP N
analyzed VBD N
incidence NN N
of IN N
cardiovascular JJ N
death NN N
or CC N
rehospitalization NN N
for IN N
congestive JJ N
heart NN N
failure NN N
after IN N
PCI NNP N
as RB N
well RB N
as IN N
various JJ N
aspects NNS N
of IN N
epicardial JJ N
flow NN N
and CC N
microvascular JJ N
function NN N
. . N

Mean JJ N
follow-up NN N
was VBD N
2.4 CD N
years NNS N
( ( N
SD NNP N
, , N
1.4 CD N
) ) N
. . N

A DT N
total NN N
of IN N
12 CD N
( ( N
6.5 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
nicorandil JJ 3_i
and CC N
30 CD N
( ( N
16.4 CD N
% NN N
) ) N
receiving NN N
placebo NN 7_i
had VBD N
cardiovascular JJ N
death NN N
or CC N
hospital NN N
admission NN N
for IN N
congestive JJ N
heart NN N
failure NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.39 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.20 CD N
to TO N
0.76 CD N
; : N
P=0.0058 NNP N
) ) N
. . N

Postprocedural NNP N
TIMI NNP N
3 CD N
flow NN N
was VBD N
obtained VBN N
in IN N
89.7 CD N
% NN N
of IN N
the DT N
nicorandil JJ 3_i
group NN N
and CC N
in IN N
81.4 CD N
% NN N
of IN N
the DT N
placebo NN 7_i
( ( N
hazard JJ N
ratio NN N
, , N
1.99 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.09 CD N
to TO N
3.65 CD N
; : N
P=0.025 NNP N
) ) N
. . N

Corrected VBN N
TIMI NNP N
frame NN N
count NN N
was VBD N
furthermore RB N
lower JJR N
in IN N
the DT N
nicorandil NN 3_i
group NN N
( ( N
21.0+/-9.1 JJ N
versus NN N
25.1+/-14.1 CD N
; : N
P=0.0009 NNP N
) ) N
. . N

ST-segment JJ N
resolution NN N
> VBD N
50 CD N
% NN N
was VBD N
observed VBN N
in IN N
79.5 CD N
% NN N
and CC N
61.2 CD N
% NN N
of IN N
the DT N
nicorandil NN 3_i
and CC N
placebo NN 7_i
groups NNS N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
, , N
2.45 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.54 CD N
to TO N
3.90 CD N
; : N
P=0.0002 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
intravenous JJ N
nicorandil NNS 3_i
to TO N
PCI NNP N
leads VBZ N
to TO N
beneficial JJ N
clinical JJ N
outcomes NNS N
and CC N
prevents NNS N
cardiovascular JJ N
events NNS N
of IN N
long JJ N
duration NN N
and CC N
death NN N
in IN N
patients NNS N
with IN N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
physiotherapy JJ 2_i
management NN 2_i
of IN N
knee NN N
joint JJ N
osteoarthritis NN N
: : N
a DT N
randomised JJ N
, , N
double JJ N
blind NN N
, , N
placebo NN 7_i
controlled VBD N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
a DT N
multimodal JJ 2_i
physiotherapy NN 2_i
programme NN 2_i
including VBG N
taping VBG 2_i
, , N
exercises NNS 2_i
, , N
and CC N
massage NN 2_i
is VBZ N
effective JJ N
for IN N
knee NN N
osteoarthritis NN N
, , N
and CC N
if IN N
benefits NNS N
can MD N
be VB N
maintained VBN N
with IN N
self JJ N
management NN N
. . N

METHODS NNP N
Randomised VBD N
, , N
double JJ N
blind NN N
, , N
placebo NN 7_i
controlled VBD N
trial NN N
; : N
140 CD N
community NN N
volunteers NNS N
with IN N
knee NN N
osteoarthritis NN N
participated VBD N
and CC N
119 CD N
completed VBD N
the DT N
trial NN N
. . N

Physiotherapy NNP 2_i
and CC N
placebo JJ 7_i
interventions NNS N
were VBD N
applied VBN N
by IN N
10 CD N
physiotherapists NNS N
in IN N
private JJ N
practices NNS N
for IN N
12 CD N
weeks NNS N
. . N

Physiotherapy NNP 2_i
included VBD 2_i
exercise NN 2_i
, , N
massage NN 2_i
, , N
taping VBG 2_i
, , N
and CC N
mobilisation NN 2_i
, , N
followed VBN N
by IN N
12 CD N
weeks NNS N
of IN N
self JJ N
management NN N
. . N

Placebo NNP 7_i
was VBD N
sham VBN 7_i
ultrasound JJ 7_i
and CC 7_i
light JJ 7_i
application NN 7_i
of IN 7_i
a DT 7_i
non-therapeutic JJ 7_i
gel NN 7_i
, , 7_i
followed VBN 7_i
by IN 7_i
no DT 7_i
treatment NN 7_i
. . N

Primary JJ N
outcomes NNS N
were VBD N
pain RB N
measured VBN N
by IN N
visual JJ N
analogue NN N
scale NN N
and CC N
patient JJ N
global JJ N
change NN N
. . N

Secondary JJ N
measures NNS N
included VBD N
WOMAC NNP N
, , N
knee NN N
pain NN N
scale NN N
, , N
SF-36 NNP N
, , N
assessment NN N
of IN N
quality NN N
of IN N
life NN N
index NN N
, , N
quadriceps JJ N
strength NN N
, , N
and CC N
balance NN N
test NN N
. . N

RESULTS NNP N
Using VBG N
an DT N
intention NN N
to TO N
treat VB N
analysis NN N
, , N
physiotherapy NN N
and CC N
placebo NN N
groups NNS N
showed VBD N
similar JJ N
pain NN N
reductions NNS N
at IN N
12 CD N
weeks NNS N
: : N
-2.2 NN N
cm NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-2.6 NNP N
to TO N
-1.7 VB N
) ) N
and CC N
-2.0 $ N
cm NN N
( ( N
-2.5 UH N
to TO N
-1.5 VB N
) ) N
, , N
respectively RB N
. . N

At IN N
24 CD N
weeks NNS N
, , N
pain NN N
remained VBD N
reduced VBN N
from IN N
baseline NN N
in IN N
both DT N
groups NNS N
: : N
-2.1 NN N
( ( N
-2.6 UH N
to TO N
-1.6 VB N
) ) N
and CC N
-1.6 NNP N
( ( N
-2.2 UH N
to TO N
-1.0 VB N
) ) N
, , N
respectively RB N
. . N

Global JJ N
improvement NN N
was VBD N
reported VBN N
by IN N
70 CD N
% NN N
of IN N
physiotherapy NN N
participants NNS N
( ( N
51/73 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
59 CD N
% NN N
( ( N
43/73 CD N
) ) N
at IN N
24 CD N
weeks NNS N
. . N

Similarly RB N
, , N
global JJ N
improvement NN N
was VBD N
reported VBN N
by IN N
72 CD N
% NN N
of IN N
placebo NN N
participants NNS N
( ( N
48/67 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
49 CD N
% NN N
( ( N
33/67 CD N
) ) N
at IN N
24 CD N
weeks NNS N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
physiotherapy NN 2_i
programme NN 2_i
tested VBN N
in IN N
this DT N
trial NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
regular JJ N
contact NN N
with IN N
a DT N
therapist NN N
at IN N
reducing VBG N
pain NN N
and CC N
disability NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
ozone NN 2_i
application NN 2_i
on IN N
the DT N
resin-dentin JJ N
microtensile NN N
bond NN N
strength NN N
. . N

When WRB N
ozone NN N
is VBZ N
used VBN N
during IN N
caries NNS N
treatment NN N
, , N
bond NN N
strength NN N
can MD N
be VB N
compromised VBN N
by IN N
the DT N
release NN N
of IN N
oxygen NN N
. . N

The DT N
use NN N
of IN N
antioxidant JJ N
agents NNS N
neutralizes VBZ N
the DT N
free JJ N
oxygen NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
ozone NN 2_i
and CC N
sodium NN 2_i
ascorbate NN 2_i
on IN N
resin-dentin JJ N
microtensile NN N
bond NN N
strength NN N
( ( N
?TBS NN N
) ) N
. . N

Forty NNP N
human JJ N
third JJ N
molars NNS N
were VBD N
divided VBN N
into IN N
four CD N
groups NNS N
: : N
Group NNP N
1 CD N
, , N
not RB N
treated VBN N
with IN N
ozone NN N
; : N
Group NNP N
2 CD N
, , N
ozone NN N
application NN N
followed VBN N
by IN N
acid NN N
etching NN N
; : N
Group NNP N
3 CD N
, , N
acid NN N
etching VBG N
followed VBN N
by IN N
ozone NN N
application NN N
; : N
and CC N
Group NNP N
4 CD N
, , N
ozone NN N
and CC N
application NN N
of IN N
sodium NN N
ascorbate NN N
. . N

Bonded VBN N
beams NN N
( ( N
1.0 CD N
mm NN N
( ( N
2 CD N
) ) N
) ) N
were VBD N
tested VBN N
under IN N
tension NN N
( ( N
0.5 CD N
mm NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

The DT N
?TBS JJ N
values NNS N
were VBD N
analyzed VBN N
using VBG N
one-way JJ N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
and CC N
the DT N
Tukey NNP N
test NN N
( ( N
p=0.05 NN N
) ) N
. . N

All DT N
beams NNS N
that WDT N
fractured VBD N
were VBD N
analyzed VBN N
under IN N
stereomicroscopy NN N
( ( N
40? CD N
) ) N
. . N

Group NNP N
1 CD N
had VBD N
significantly RB N
higher JJR N
?TBS NN N
values NNS N
than IN N
Group NNP N
2 CD N
or CC N
3 CD N
. . N

The DT N
?TBS JJ N
values NNS N
of IN N
Groups NNP N
1 CD N
and CC N
4 CD N
were VBD N
similar JJ N
and CC N
higher JJR N
than IN N
those DT N
of IN N
Group NNP N
2 CD N
. . N

The DT N
use NN N
of IN N
ozone NN N
in IN N
Group NNP N
2 CD N
resulted VBD N
in IN N
lower JJR N
values NNS N
of IN N
?TBS NN N
in IN N
all DT N
conditions NNS N
evaluated VBN N
. . N

The DT N
predominant JJ N
failure NN N
mode NN N
was VBD N
adhesive JJ N
. . N

The DT N
application NN N
of IN N
ozone NN N
decreased VBD N
the DT N
?TBS NN N
of IN N
the DT N
dentin-composite JJ N
resin NN N
interface NN N
. . N

These DT N
values NNS N
were VBD N
reversed VBN N
when WRB N
compared VBN N
with IN N
Groups NNP N
1 CD N
and CC N
2 CD N
when WRB N
sodium NN N
ascorbate NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O

Alendronate NNP 3_i
daily RB N
, , N
weekly JJ N
in IN N
conventional JJ N
tablets NNS N
and CC N
weekly JJ N
in IN N
enteric JJ N
tablets NNS N
: : N
preliminary JJ N
study NN N
on IN N
the DT N
effects NNS N
in IN N
bone NN N
turnover NN N
markers NNS N
and CC N
incidence NN N
of IN N
side NN N
effects NNS N
. . N

Bisphosphonates NNS 3_i
are VBP N
now RB N
in IN N
the DT N
vanguard NN N
of IN N
osteoporosis NN N
treatment NN N
. . N

Frequently RB N
, , N
gastro-oesophageal JJ N
symptoms NNS N
are VBP N
associated VBN N
with IN N
these DT N
drugs NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
side JJ N
effects NNS N
and CC N
bone NN N
turnover NN N
markers NNS N
in IN N
postmenopausal JJ N
women NNS N
who WP N
had VBD N
received VBN N
alendronate JJ 3_i
daily JJ N
or CC N
weekly JJ N
in IN N
tablets NNS N
with IN N
or CC N
without IN N
enteric JJ N
coating NN N
. . N

We PRP N
conducted VBD N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
3-month JJ N
trial NN N
. . N

The DT N
trial NN N
involved VBD N
75 CD N
volunteers NNS N
, , N
aged VBD N
45-58 JJ N
with IN N
moderate JJ N
to TO N
severe VB N
osteopenia NN N
( ( N
T-score NNP N
lower JJR N
than IN N
-2 JJR N
SD NNP N
) ) N
assessed VBN N
by IN N
quantitative JJ N
ultrasound NN N
. . N

Women NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
: : N
( ( N
a DT N
) ) N
alendronate NN 3_i
10mg/day CD 3_i
: : N
( ( N
b NN N
) ) N
alendronate NN 3_i
70 CD 3_i
mg NN 3_i
once RB 3_i
a DT 3_i
week NN 3_i
: : 3_i
or CC N
( ( N
c NN N
) ) N
enteric JJ 3_i
alendronate NN 3_i
70 CD 3_i
mg NN 3_i
per IN 3_i
week NN 3_i
. . N

We PRP N
recorded VBD N
side JJ N
effects NNS N
, , N
C-telopeptide NNP N
, , N
osteocalcin NN N
and CC N
urine JJ N
hydroxyproline NN N
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
and CC N
at IN N
3 CD N
months NNS N
. . N

After IN N
3 CD N
months NNS N
, , N
pyrosis NN N
( ( N
heartburn NN N
) ) N
was VBD N
noted VBN N
by IN N
seven CD N
women NNS N
in IN N
group NN N
A NNP N
( ( N
28 CD N
% NN N
) ) N
, , N
three CD N
in IN N
group NN N
B NNP N
( ( N
12 CD N
% NN N
) ) N
and CC N
two CD N
in IN N
group NN N
C NNP N
( ( N
8 CD N
% NN N
) ) N
; : N
nausea NN N
: : N
by IN N
one CD N
woman NN N
in IN N
group NN N
B NNP N
; : N
and CC N
headache NN N
by IN N
one CD N
patient NN N
in IN N
each DT N
group NN N
. . N

C-telopeptide NNP N
( ( N
A DT N
: : N
40.7 CD N
% NN N
; : N
B NNP N
: : N
34.1 CD N
% NN N
and CC N
C NNP N
: : N
38.5 CD N
% NN N
) ) N
; : N
hydroxyproline NN N
( ( N
A DT N
: : N
31.1 CD N
% NN N
; : N
B NNP N
: : N
25.3 CD N
% NN N
and CC N
C NNP N
: : N
31.5 CD N
% NN N
) ) N
and CC N
osteocalcin $ N
( ( N
A DT N
: : N
27.0 CD N
% NN N
; : N
B NNP N
: : N
25.4 CD N
% NN N
and CC N
C NNP N
: : N
25.1 CD N
% NN N
) ) N
decreased VBD N
similarly RB N
in IN N
the DT N
three CD N
groups NNS N
. . N

Weekly JJ N
intake NN N
of IN N
alendronate NN 3_i
, , N
whether IN N
conventional JJ N
or CC N
enteric-coated JJ N
; : N
is VBZ N
associated VBN N
with IN N
less JJR N
heartburn NN N
and CC N
nausea NN N
. . N

Enteric JJ 3_i
alendronate NN 3_i
has VBZ N
a DT N
similar JJ N
action NN N
to TO N
the DT N
conventional JJ N
tablets NNS N
on IN N
biochemical JJ N
markers NNS N
. . N

-DOCSTART- -X- O O

A DT N
comparative JJ N
study NN N
of IN N
netilmicin-cefoxitin JJ 3_i
and CC N
gentamicin-cefoxitin JJ 3_i
in IN N
surgical JJ N
patients NNS N
with IN N
serious JJ N
systemic JJ N
infection NN N
. . N

A DT N
double-blind NN N
, , N
randomized VBN N
study NN N
of IN N
gentamicin NN 3_i
and CC N
netilmicin NN 3_i
, , N
each DT N
in IN N
combination NN N
with IN N
cefoxitin NN 3_i
, , N
was VBD N
done VBN N
to TO N
compare VB N
their PRP$ N
respective JJ N
efficacy NN N
and CC N
toxicity NN N
in IN N
patients NNS N
with IN N
serious JJ N
systemic JJ N
infection NN N
. . N

Thirty-seven JJ N
surgical JJ N
patients NNS N
were VBD N
evaluated VBN N
for IN N
efficacy NN N
and CC N
46 CD N
patients NNS N
were VBD N
evaluated VBN N
for IN N
toxicity NN N
. . N

The DT N
most RBS N
frequently RB N
cultured VBN N
organisms NNS N
were VBD N
Escherichia NNP N
coli NNS N
( ( N
15 CD N
) ) N
, , N
Klebsiella NNP N
sp NN N
( ( N
9 CD N
) ) N
, , N
Proteus NNP N
sp NN N
( ( N
6 CD N
) ) N
, , N
and CC N
Bacteroides NNP N
sp NN N
( ( N
4 CD N
) ) N
. . N

For IN N
23 CD N
patients NNS N
treated VBN N
with IN N
gentamicin-cefoxitin JJ 3_i
( ( N
G-C NNP N
) ) N
, , N
the DT N
clinical JJ N
response NN N
was VBD N
favorable JJ N
in IN N
20/21 CD N
( ( N
95.2 CD N
% NN N
) ) N
evaluable JJ N
cases NNS N
, , N
and CC N
elimination NN N
or CC N
marked VBN N
reduction NN N
of IN N
33/34 CD N
( ( N
97.1 CD N
% NN N
) ) N
organisms NN N
was VBD N
achieved VBN N
. . N

For IN N
14 CD N
patients NNS N
treated VBN N
with IN N
netilmicin-cefoxitin JJ 3_i
( ( N
N-C NNP N
) ) N
, , N
the DT N
clinical JJ N
response NN N
was VBD N
favorable JJ N
in IN N
13/13 CD N
( ( N
100 CD N
% NN N
) ) N
evaluable JJ N
cases NNS N
, , N
and CC N
19/20 CD N
( ( N
95 CD N
% NN N
) ) N
organisms WDT N
were VBD N
eliminated VBN N
or CC N
markedly RB N
reduced VBN N
. . N

Nephrotoxicity NNP N
was VBD N
defined VBN N
as IN N
an DT N
increase NN N
in IN N
serum JJ N
creatinine NN N
to TO N
greater JJR N
than IN N
25 CD N
% NN N
over IN N
baseline NN N
with IN N
an DT N
absolute JJ N
rise NN N
of IN N
at IN N
least JJS N
0.5 CD N
mg/100 JJ N
ml NN N
to TO N
a DT N
value NN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
1.3 CD N
mg/100 NN N
ml NN N
. . N

Based VBN N
on IN N
these DT N
criteria NNS N
, , N
nephrotoxicity NN N
was VBD N
seen VBN N
in IN N
2/27 CD N
( ( N
7.4 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
G-C NNP N
and CC N
in IN N
3/19 CD N
( ( N
15.8 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
N-C. NNP N
Ototoxicity NNP N
was VBD N
defined VBN N
as IN N
a DT N
greater JJR N
than IN N
20 CD N
dB JJ N
loss NN N
at IN N
any DT N
frequency NN N
. . N

Based VBN N
on IN N
these DT N
criteria NNS N
, , N
ototoxicity NN N
was VBD N
seen VBN N
in IN N
5/27 CD N
( ( N
18.5 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
G-C NNP N
and CC N
2/19 CD N
( ( N
10.5 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
N-C NNP N
. . N

The DT N
data NN N
show NN N
no DT N
significant JJ N
difference NN N
in IN N
toxicity NN N
and CC N
suggest VBP N
that IN N
netilmicin NN N
and CC N
gentamicin NN N
are VBP N
both DT N
highly RB N
effective JJ N
in IN N
combination NN N
with IN N
cefoxitin NN N
in IN N
patients NNS N
who WP N
have VBP N
serious JJ N
infections NNS N
after IN N
surgery NN N
. . N

-DOCSTART- -X- O O

Studies NNS N
on IN N
section NN N
2D1 CD N
monoclonal JJ N
antibodies NNS N
. . N

Monoclonal JJ N
antibodies NNS N
in IN N
Other JJ N
Blood NNP N
Groups NNP N
were VBD N
tested VBN N
with IN N
random JJ 2_i
blood NN 2_i
samples NNS 2_i
collected VBN N
from IN N
the DT N
various JJ N
ethnic JJ N
groups NNS N
in IN N
KwaZulu-Natal NNP N
, , N
South NNP N
Africa NNP N
, , N
and CC N
with IN N
samples NNS N
of IN N
selected VBN N
red JJ N
cell NN N
phenotypes NNS N
. . N

Standard NNP 2_i
red VBD 2_i
cell NN 2_i
serological JJ 2_i
techniques NNS 2_i
were VBD N
used VBN N
. . N

-DOCSTART- -X- O O

The DT N
SPEM NNP N
( ( N
Studio NNP N
Policentrico NNP N
Elettrocateteri NNP N
Membrane NNP N
) ) N
: : N
a DT N
multicenter NN N
study NN N
on IN N
membrane NN N
leads NNS N
. . N

SPEM NNP N
is VBZ N
a DT N
multicenter NN N
randomized VBN N
double-blind NN N
study NN N
performed VBD N
to TO N
test VB N
the DT N
acute NN N
and CC N
chronic JJ N
electrophysiological JJ N
behavior NN N
of IN N
three CD N
different JJ N
ventricular JJ N
leads NNS N
: : N
( ( N
1 CD N
) ) N
an DT N
ion NN 2_i
exchange NN 2_i
membrane NN 2_i
with IN 2_i
30-microgram JJ 2_i
dexamethasone NN 2_i
elution NN 2_i
in IN 2_i
a DT 2_i
contoured JJ 2_i
activated JJ 2_i
carbon NN 2_i
tip NN 2_i
lead NN 2_i
( ( N
Membrane NNP N
1400T CD N
, , N
30 CD N
patients NNS N
) ) N
; : N
( ( N
2 CD N
) ) N
the DT 4_i
same JJ 2_i
lead NN 2_i
design NN 2_i
without IN 2_i
steroid NN 2_i
( ( N
Membrane NNP N
1401T CD N
, , N
24 CD N
patients NNS N
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT 4_i
same JJ 2_i
lead NN 2_i
design NN 2_i
without IN 2_i
steroid NN 2_i
or CC 2_i
membrane NN 2_i
( ( N
control NN N
group NN N
, , N
27 CD N
patients NNS N
) ) N
. . N

Twenty-three CD N
of IN N
the DT N
81 CD N
patients NNS N
were VBD N
women NNS N
; : N
the DT N
mean JJ N
age NN N
for IN N
all DT N
patients NNS N
was VBD N
74 CD N
+/- JJ N
10 CD N
years NNS N
. . N

Parameters NNS N
are VBP N
calculated VBN N
both DT N
in IN N
uni- JJ N
and CC N
bipolar JJ N
configuration NN N
at IN N
implant JJ N
and CC N
at IN N
follow-up JJ N
after IN N
1 CD N
, , N
5 CD N
, , N
15 CD N
, , N
30 CD N
, , N
90 CD N
, , N
180 CD N
, , N
and CC N
360 CD N
days NNS N
. . N

Implant JJ N
threshold NN N
( ( N
chronaxie JJ N
= $ N
0.413 CD N
+/- JJ N
0.280 CD N
ms NN N
, , N
rheobase VB N
= JJ N
0.264 CD N
+/- JJ N
0.099 CD N
V NNP N
) ) N
, , N
signal JJ N
amplitude NN N
( ( N
13.45 CD N
+/- JJ N
5.87 CD N
mV NN N
) ) N
, , N
and CC N
slew JJ N
rate NN N
( ( N
2.05 CD N
+/- JJ N
1.38 CD N
V/s NNP N
) ) N
reveal VBP N
no DT N
significant JJ N
differences NNS N
. . N

Pacing VBG N
impedance NN N
values NNS N
both DT N
at IN N
implant NN N
( ( N
unipolar JJ N
571 CD N
+/- JJ N
165 CD N
omega NN N
; : N
bipolar JJ N
605 CD N
+/- JJ N
123 CD N
omega NN N
) ) N
and CC N
at IN N
follow-ups NNS N
( ( N
unipolar JJ N
480 CD N
+/- JJ N
72 CD N
omega NN N
; : N
bipolar JJ N
518 CD N
+/- JJ N
75 CD N
omega NN N
) ) N
are VBP N
slightly RB N
lower JJR N
in IN N
the DT N
unipolar JJ N
configuration NN N
. . N

At IN N
15 CD N
and CC N
30-day JJ N
follow-ups NNS N
, , N
control NN N
group NN N
and CC N
nonsteroid JJ N
leads VBZ N
show VB N
a DT N
higher JJR N
threshold JJ N
value NN N
growth NN N
( ( N
in IN N
unipolar NN N
from IN N
0.16 CD N
+/- JJ N
0.11 CD N
to TO N
1.19 CD N
+/- JJ N
0.85 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.18 CD N
+/- JJ N
0.13 CD N
to TO N
1.24 CD N
+/- JJ N
0.88 CD N
microJ NN N
) ) N
than IN N
the DT N
membrane NN N
steroid NN N
leads VBZ N
( ( N
in IN N
unipolar NN N
from IN N
0.13 CD N
+/- JJ N
0.11 CD N
to TO N
0.70 CD N
+/- JJ N
0.39 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.23 CD N
+/- JJ N
0.32 CD N
to TO N
0.76 CD N
+/- JJ N
0.36 CD N
microJ NN N
) ) N
; : N
the DT N
threshold NN N
of IN N
nonsteroid JJ N
leads NNS N
decreases NNS N
after IN N
1-3 JJ N
months NNS N
and CC N
it PRP N
settles VBZ N
at IN N
the DT N
same JJ N
threshold JJ N
level NN N
of IN N
the DT N
leads NNS N
with IN N
membrane NN N
and CC N
steroid NN N
( ( N
in IN N
unipolar JJ N
0.60 CD N
+/- JJ N
0.33 CD N
microJ NN N
; : N
in IN N
bipolar JJ N
0.55 CD N
+/- JJ N
0.26 CD N
microJ NN N
) ) N
, , N
which WDT N
has VBZ N
been VBN N
stable JJ N
since IN N
the DT N
first JJ N
month NN N
. . N

The DT N
ion NN 2_i
exchange NN 2_i
membrane NN 2_i
is VBZ N
effective JJ N
in IN N
reducing VBG N
the DT N
chronic JJ N
pacing NN N
threshold NN N
like IN N
acute JJ N
steroid JJ N
elution NN N
at IN N
low JJ N
doses NNS N
, , N
but CC N
membrane FW N
alone RB N
does VBZ N
not RB N
prevent VB N
an DT N
acute JJ N
pacing NN N
threshold JJ N
increase NN N
through IN N
the DT N
first JJ N
month NN N
postimplant NN N
. . N

-DOCSTART- -X- O O

Do NNP N
heavier JJR N
women NNS N
benefit VBP N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
leuprolide JJ 3_i
acetate NN 3_i
for IN N
suppression NN N
of IN N
serum NN N
estradiol NN N
? . N
OBJECTIVE UH N
To TO N
determine VB N
if IN N
heavier JJR N
women NNS N
benefit VBP N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
the DT N
gonadotropin-releasing JJ 3_i
hormone NN 3_i
analogue NN 3_i
leuprolide NN 3_i
acetate NN 3_i
( ( 3_i
LA NNP 3_i
) ) 3_i
depot NN N
in IN N
terms NNS N
of IN N
suppression NN N
of IN N
serum NN N
estradiol NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
retrospective JJ N
analysis NN N
of IN N
the DT N
effect NN N
of IN N
LA NNP 3_i
depot FW 3_i
3.75 CD N
mg NN N
and CC N
7.5 CD N
mg NN N
on IN N
serum NN 3_i
estradiol NN 3_i
from IN N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
, , N
12-week JJ N
study NN N
of IN N
women NNS N
with IN N
anemia NN N
due JJ N
to TO N
bleeding VBG N
from IN N
uterine JJ N
leiomyomata NN N
. . N

Serum NNP N
estradiol NN N
levels NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
week NN N
12 CD N
. . N

Patients NNS N
were VBD N
divided VBN N
into IN N
weight NN N
quartiles NNS N
according VBG N
to TO N
their PRP$ N
baseline NN N
weight NN N
in IN N
kilograms NNS N
: : N
46- JJ N
< NN N
64 CD N
, , N
64- JJ N
< NN N
72 CD N
, , N
72- JJ N
< NN N
89 CD N
, , N
89-159 JJ N
( ( N
pounds-102- JJ N
< NN N
140 CD N
, , N
140- JJ N
< NN N
159 CD N
, , N
159- JJ N
< NN N
196 CD N
, , N
196-350 JJ N
) ) N
. . N

RESULTS VBN N
At IN N
baseline NN N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
estradiol JJ N
level NN N
between IN N
groups NNS N
as IN N
a DT N
whole NN N
or CC N
within IN N
weight JJ N
quartiles NNS N
. . N

Within IN N
each DT N
group NN N
there EX N
was VBD N
no DT N
relationship NN N
between IN N
weight NN N
and CC N
baseline NN N
estradiol NN N
. . N

At IN N
week NN N
12 CD N
, , N
whereas NNS N
estradiol VBP N
levels NNS N
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
heavier JJR N
patients NNS N
in IN N
each DT N
of IN N
the DT N
groups NNS N
( ( N
LA NNP N
3.75 CD N
mg NN N
, , N
p NN N
= VBD N
0.044 CD N
; : N
LA NNP N
7.5 CD N
mg NN N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
estradiol NN N
between IN N
groups NNS N
as IN N
a DT N
whole NN N
or CC N
within IN N
any DT N
of IN N
the DT N
weight NN N
quartiles NNS N
. . N

Moreover RB N
, , N
at IN N
week NN N
12 CD N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
estradiol NNS N
suppressed VBN N
to TO N
the DT N
menopausal NN N
range NN N
. . N

CONCLUSION NNP N
Heavier NNP N
women NNS N
do VBP N
not RB N
benefit VB N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
LA NNP 3_i
depot NNP N
( ( N
7.5 CD N
vs. FW N
3.75 CD N
mg NN N
) ) N
for IN N
suppression NN N
of IN N
serum NN N
levels NNS N
of IN N
estradiol NN N
. . N

-DOCSTART- -X- O O

The DT N
TOM NNP 6_i
test NN 6_i
: : N
a DT N
new JJ N
instrument NN N
for IN N
assessing VBG N
theory NN N
of IN N
mind NN N
in IN N
normal JJ N
children NNS N
and CC N
children NNS N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

This DT N
article NN N
describes VBZ N
a DT N
first JJ N
attempt NN N
to TO N
investigate VB N
the DT N
reliability NN N
and CC N
validity NN N
of IN N
the DT N
TOM NNP 6_i
test NN 6_i
, , N
a DT N
new JJ N
instrument NN N
for IN N
assessing VBG N
theory NN N
of IN N
mind NN N
ability NN N
in IN N
normal JJ N
children NNS N
and CC N
children NNS N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
( ( N
PDDs NNP N
) ) N
. . N

In IN N
Study NNP N
1 CD N
, , N
TOM NNP 6_i
test NN 6_i
scores NNS N
of IN N
normal JJ N
children NNS N
( ( N
n JJ N
= NNP N
70 CD N
) ) N
correlated VBD N
positively RB N
with IN N
their PRP$ N
performance NN N
on IN N
other JJ N
theory NN N
of IN N
mind NN N
tasks NNS N
. . N

Furthermore NNP N
, , N
young JJ N
children NNS N
only RB N
succeeded VBD N
on IN N
TOM NNP N
items NNS N
that WDT N
tap VBP N
the DT N
basic JJ N
domains NNS N
of IN N
theory NN N
of IN N
mind NN N
( ( N
e.g. JJ N
, , N
emotion JJ N
recognition NN N
) ) N
, , N
whereas JJ N
older JJR N
children NNS N
also RB N
passed VBD N
items NNS N
that WDT N
measure VBP N
the DT N
more JJR N
mature JJ N
areas NNS N
of IN N
theory NN N
of IN N
mind NN N
( ( N
e.g. JJ N
, , N
understanding NN N
of IN N
humor NN N
, , N
understanding VBG N
of IN N
second-order JJ N
beliefs NNS N
) ) N
. . N

Taken VBN N
together RB N
, , N
the DT N
findings NNS N
of IN N
Study NNP N
1 CD N
suggest NN N
that IN N
the DT N
TOM NNP 6_i
test NN 6_i
is VBZ N
a DT N
valid JJ N
measure NN N
. . N

Study NNP N
2 CD N
showed VBD N
for IN N
a DT N
separate JJ N
sample NN N
of IN N
normal JJ N
children NNS N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
that IN N
the DT N
TOM NNP 6_i
test NN 6_i
possesses VBZ N
sufficient JJ N
test-retest JJ N
stability NN N
. . N

Study NNP N
3 CD N
demonstrated VBD N
for IN N
a DT N
sample NN N
of IN N
children NNS N
with IN N
PDDs NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
that IN N
the DT N
interrater NN N
reliability NN N
of IN N
the DT N
TOM NNP 6_i
test NN 6_i
is VBZ N
good JJ N
. . N

Study VB N
4 CD N
found NN N
that IN N
children NNS N
with IN N
PDDs NNP N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
had VBD N
significantly RB N
lower JJR N
TOM NNP 6_i
test NN 6_i
scores NNS N
than IN N
children NNS N
with IN N
other JJ N
psychiatric JJ N
disorders NNS N
( ( N
e.g. NN N
, , N
children NNS N
with IN N
Attention-deficit NNP N
Hyperactivity NNP N
Disorder NNP N
; : N
n CC N
= VB N
32 CD N
) ) N
, , N
a DT N
finding NN N
that WDT N
underlines VBZ N
the DT N
discriminant JJ N
validity NN N
of IN N
the DT N
TOM NNP 6_i
test NN 6_i
. . N

Furthermore RB N
, , N
Study NNP N
4 CD N
showed VBD N
that DT N
intelligence NN N
as IN N
indexed VBN N
by IN N
the DT N
Wechsler NNP N
Intelligence NNP N
Scale NNP N
for IN N
Children NNP N
was VBD N
positively RB N
associated VBN N
with IN N
TOM NNP 6_i
test NN 6_i
scores NNS N
. . N

Finally RB N
, , N
in IN N
all DT N
studies NNS N
, , N
the DT N
TOM NNP 6_i
test NN 6_i
was VBD N
found VBN N
to TO N
be VB N
reliable JJ N
in IN N
terms NNS N
of IN N
internal JJ N
consistency NN N
. . N

Altogether RB N
, , N
results NNS N
indicate VBP N
that IN N
the DT N
TOM NNP 6_i
test NN 6_i
is VBZ N
a DT N
reliable JJ N
and CC N
valid JJ N
instrument NN N
that WDT N
can MD N
be VB N
employed VBN N
to TO N
measure VB N
various JJ N
aspects NNS N
of IN N
theory NN N
of IN N
mind NN N
. . N

-DOCSTART- -X- O O

Physical JJ N
health NN N
-- : N
a DT N
cluster NN 4_i
randomized VBN 4_i
controlled VBN 4_i
lifestyle JJ 4_i
intervention NN 4_i
among IN N
persons NNS N
with IN N
a DT N
psychiatric JJ N
disability NN N
and CC N
their PRP$ N
staff NN N
. . N

The DT N
objective NN N
was VBD N
to TO N
explore VB N
the DT N
impact NN N
on IN N
physical JJ N
health NN N
of IN N
a DT N
lifestyle JJ 4_i
programme NN 4_i
among IN N
persons NNS N
with IN N
psychiatric JJ N
disabilities NNS N
, , N
and CC N
their PRP$ N
caregivers NNS N
. . N

Their PRP$ N
satisfaction NN N
with IN N
the DT N
intervention NN N
was VBD N
also RB N
assessed VBN N
. . N

Somatic JJ N
comorbidity NN N
and CC N
an DT N
increased VBN N
mortality NN N
related VBN N
to TO N
the DT N
lifestyle NN N
among IN N
persons NNS N
with IN N
psychiatric JJ N
disabilities NNS N
are VBP N
well RB N
known VBN N
. . N

Few JJ N
randomized VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
aimed VBN N
specifically RB N
at IN N
lifestyle JJ N
issues NNS N
among IN N
persons NNS N
with IN N
a DT N
psychiatric JJ N
disability NN N
. . N

This DT N
trial NN N
includes VBZ N
clients NNS N
with IN N
psychiatric JJ N
disabilities NNS N
living VBG N
in IN N
supported JJ N
housing NN N
and CC N
their PRP$ N
staff NN N
. . N

Forty-one CD N
persons NNS N
with IN N
a DT N
DSM- NNP N
? . N
V NNP N
diagnosis NN N
of IN N
severe JJ N
mental JJ N
illness NN N
from IN N
psychiatric JJ N
disability NN N
from IN N
10 CD N
supported VBD N
housing NN N
facilities NNS N
and CC N
41 CD N
of IN N
their PRP$ N
caregivers NNS N
participated VBN N
in IN N
this DT N
12-month JJ N
study NN N
during IN N
2005-2006 JJ N
in IN N
Sweden NNP N
. . N

The DT N
supported JJ N
housing NN N
facilities NNS N
with IN N
residents NNS N
and CC N
staff NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
a DT N
health NN 4_i
intervention NN 4_i
programme NN 4_i
or CC N
a DT N
control NN N
programme NN N
with IN N
an DT N
aesthetic JJ N
content NN N
. . N

The DT N
presence NN N
of IN N
metabolic JJ N
syndrome NN N
and CC N
changes NNS N
in IN N
the DT N
mean NN N
of IN N
physiological JJ N
parameters NNS N
such JJ N
as IN N
Hba1c NNP N
, , N
P-glucose NNP N
, , N
P-insulin NNP N
, , N
lipids NNS N
, , N
blood NN N
pressure NN N
, , N
physical JJ N
working NN N
capacity NN N
, , N
body NN N
mass NN N
index NN N
, , N
Heart NNP N
Score NNP N
were VBD N
investigated VBN N
and CC N
participants NNS N
' POS N
satisfaction NN N
assessed VBD N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
mean NN N
of IN N
metabolic JJ N
syndrome JJ N
criteria NNS N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
at IN N
the DT N
follow-up NN N
. . N

The DT N
participants NNS N
expressed VBD N
satisfaction NN N
with IN N
the DT N
programme NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
health NN 4_i
interventions NNS 4_i
on IN N
lifestyle JJ N
issues NNS N
when WRB N
involving VBG N
carers NNS N
are VBP N
appreciated VBN N
, , N
feasible JJ N
and CC N
could MD N
be VB N
successful JJ N
in IN N
reducing VBG N
some DT N
health-related JJ N
risk NN N
factors NNS N
among IN N
persons NNS N
with IN N
psychiatric JJ N
disabilities NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
maternal JJ N
and CC N
dietary JJ 3_i
selenium NN 3_i
( ( 3_i
Se-enriched NNP 3_i
yeast NN 3_i
) ) 3_i
on IN N
the DT N
expression NN N
of IN N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
of IN N
germ JJ N
cells NNS N
of IN N
their PRP$ N
offspring NN N
in IN N
goats NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
selenium NN 3_i
on IN N
the DT N
expression NN N
of IN N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
( ( N
two CD N
components NNS N
of IN N
MPF NNP N
regulating VBG N
cell NN N
cycle NN N
) ) N
of IN N
germ JJ N
cells NNS N
of IN N
their PRP$ N
offspring NN N
in IN N
goats NNS N
. . N

A DT N
herd NN N
of IN N
119 CD N
Taihang NNP N
Black NNP N
Goats NNP N
, , N
which WDT N
was VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
treatments NNS N
, , N
received VBD N
experimental JJ 3_i
diet JJ 3_i
with IN 3_i
different JJ 3_i
Se NNP 3_i
levels NNS 3_i
( ( N
from IN N
Se-enriched NNP N
yeast NN N
) ) N
for IN N
174d CD N
. . N

The DT N
four CD N
treatments NNS N
, , N
fed VBN N
with IN N
a DT N
basal NN N
diet JJ N
, , N
were VBD N
supplemented VBN N
with IN N
0 CD N
( ( N
control NN N
) ) N
, , N
0.5 CD N
, , N
2 CD N
and CC N
4 CD N
mgkg?? NN N
DM NNP N
Se NNP N
. . N

Testis NN N
samples NNS N
were VBD N
collected VBN N
from IN N
the DT N
young JJ N
male NN N
goats NNS N
of IN N
each DT N
treatment NN N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
30d CD N
after IN N
weaning VBG N
) ) N
for IN N
mRNA NN N
expression NN N
using VBG N
real-time JJ N
PCR NNP N
and CC N
for IN N
protein JJ N
expression NN N
by IN N
immunohistochemistry NN N
assay NN N
. . N

Results NNP N
show VBP N
that IN N
a DT N
significant JJ N
decrease NN N
was VBD N
observed VBN N
in IN N
mRNA JJ N
expression NN N
of IN N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
in IN N
the DT N
testis NN N
of IN N
Se-deficient NNP N
( ( N
Group NNP N
1 CD N
) ) N
and CC N
Se-excess NNP N
( ( N
Group NNP N
4 CD N
) ) N
animals NNS N
compared VBN N
with IN N
that DT N
in IN N
Groups NNP N
2 CD N
and CC N
3 CD N
. . N

However RB N
, , N
no DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
mRNA JJ N
expression NN N
of IN N
p34 NN N
( ( N
cdc2 NN N
) ) N
between IN N
Se-deficient NNP N
( ( N
Group NNP N
1 CD N
) ) N
and CC N
Se-excess NNP N
( ( N
Group NNP N
4 CD N
) ) N
. . N

Also RB N
the DT N
immunohistochemistry NN N
assay NN N
detected VBD N
similar JJ N
results NNS N
of IN N
protein JJ N
expression NN N
of IN N
these DT N
two CD N
genes NNS N
. . N

These DT N
results NNS N
suggest VBP N
, , N
that DT N
maternal JJ N
and CC N
dietary JJ N
Se-induced NNP N
oxidative JJ N
stress NN N
can MD N
modulate VB N
the DT N
mRNA NN N
and CC N
protein JJ N
expression NN N
of IN N
the DT N
cell NN N
cycle NN N
related VBN N
genes NNS N
( ( N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
) ) N
in IN N
the DT N
testis NN N
of IN N
their PRP$ N
offspring NN N
. . N

In IN N
addition NN N
, , N
Se NNP N
deficiency NN N
and CC N
Se NNP N
excess NN N
could MD N
prevent VB N
the DT N
completion NN N
of IN N
the DT N
cell NN N
cycle NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
augmented JJ 2_i
sensorimotor NN 2_i
input NN 2_i
on IN N
learning VBG N
verbal JJ N
and CC N
nonverbal JJ N
tasks NNS N
among IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Thirty-four JJ N
children NNS N
, , N
with IN N
autism NN N
spectrum NN N
disorders NNS N
, , N
ages VBZ N
4-14 CD N
years NNS N
, , N
were VBD N
matched VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
conditions NNS N
for IN N
learning VBG N
a DT N
novel JJ N
juice-making NN N
task NN N
and CC N
producing VBG N
two CD N
novel JJ N
words NNS N
about IN N
the DT N
event NN N
. . N

Seventeen NNP N
sighted VBD N
children NNS N
were VBD N
manually RB 2_i
guided VBN 2_i
to TO N
perform VB N
the DT N
task NN N
and CC N
tactually RB N
prompted VBD N
during IN N
imitated JJ N
productions NNS N
of IN N
novel JJ N
words NNS N
for IN N
the DT N
event NN N
. . N

Their PRP$ N
matched JJ N
controls NNS N
heard VBD N
the DT N
novel JJ N
words NNS N
and CC N
watched VBD N
the DT N
juice-making NN N
task NN N
being VBG N
performed VBN N
. . N

Performances NNS N
on IN N
four CD N
verbal NNS N
and CC N
two CD N
nonverbal JJ N
measures NNS N
right RB N
after IN N
instruction NN N
and CC N
at IN N
24-48 JJ N
h NN N
post-instruction NN N
, , N
revealed VBD N
higher JJR N
scores NNS N
for IN N
the DT N
??hands-on?? JJ N
, , N
participation NN N
than IN N
observation NN N
group NN N
on IN N
both DT N
verbal JJ N
and CC N
nonverbal JJ N
tasks NNS N
. . N

This DT N
study NN N
offers VBZ N
a DT N
paradigm NN N
for IN N
exploring VBG N
the DT N
instructional JJ N
advantage NN N
of IN N
enhanced JJ N
participatory JJ N
experience NN N
. . N

-DOCSTART- -X- O O

A DT N
drug NN N
interaction NN N
study NN N
between IN N
ticlopidine NN 3_i
and CC N
cyclosporin NN 3_i
in IN N
heart NN N
transplant NN N
recipients NNS N
. . N

OBJECTIVES NNP N
Previous NNP N
uncontrolled JJ N
studies NNS N
have VBP N
suggested VBN N
an DT N
interaction NN N
between IN N
ticlopidine NN 3_i
, , N
a DT N
major JJ N
antiplatelet NN N
agent NN N
, , N
and CC N
cyclosporin NN 3_i
in IN N
heart- JJ N
and CC N
kidney-transplant JJ N
recipients NNS N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
fashion NN N
, , N
the DT N
possible JJ N
interaction NN N
between IN N
cyclosporin NN 3_i
A NNP 3_i
and CC 3_i
ticlopidine NN 3_i
( ( N
250 CD N
mg NNS N
per IN N
day NN N
) ) N
and CC N
the DT N
tolerability NN N
of IN N
this DT N
combination NN N
in IN N
heart-transplant JJ N
recipients NNS N
. . N

METHODS NNP N
Twenty NNP N
heart-transplant JJ N
recipients NNS N
were VBD N
randomised VBN N
into IN N
either CC N
a DT N
treated JJ N
or CC N
a DT N
placebo NN 3_i
group NN N
. . N

Blood NN N
samples NNS N
were VBD N
drawn VBN N
for IN N
time-course JJ N
evaluation NN N
of IN N
cyclosporin NN N
blood NN N
levels NNS N
over IN N
a DT N
period NN N
of IN N
12 CD N
h NNS N
, , N
following VBG N
the DT N
morning NN N
intake NN N
of IN N
cyclosporin NN 3_i
and CC N
, , N
for IN N
platelet NN N
aggregation NN N
studies NNS N
, , N
before IN N
and CC N
after IN N
14 CD N
days NNS N
of IN N
ticlopidine JJ 3_i
administration NN N
. . N

Twenty CD N
four-hour JJ N
urine JJ N
samples NNS N
were VBD N
collected VBN N
for IN N
6-beta-hydroxycortisol JJ N
measurements NNS N
, , N
before IN N
and CC N
after IN N
14 CD N
days NNS N
of IN N
ticlopidine NN N
. . N

RESULTS NNP N
Although IN N
given VBN N
at IN N
half PDT N
the DT N
recommended JJ N
daily JJ N
dosage NN N
, , N
ticlopidine NN N
significantly RB N
reduced VBN N
platelet NN N
aggregation NN N
. . N

Pharmacokinetic JJ N
parameters NNS N
indicate VBP N
that IN N
the DT N
bioavailability NN N
of IN N
cyclosporin NN 3_i
A NNP 3_i
was VBD N
not RB N
significantly RB N
modified VBN N
by IN N
ticlopidine NN 3_i
. . N

However RB N
, , N
one CD N
patient NN N
in IN N
the DT N
ticlopidine NN N
group NN N
was VBD N
withdrawn VBN N
because IN N
of IN N
a DT N
major JJ N
fall NN N
in IN N
cyclosporin JJ N
blood NN N
level NN N
within IN N
3 CD N
days NNS N
of IN N
treatment NN N
. . N

Urinary JJ N
excretion NN N
of IN N
6-beta-hydroxycortisol NNP N
was VBD N
augmented VBN N
after IN N
treatment NN N
in IN N
the DT N
ticlopidine NN 3_i
group NN N
compared VBN N
with IN N
the DT N
placebo NN 3_i
group NN N
, , N
suggesting VBG N
that IN N
induction NN N
of IN N
drug NN N
metabolism NN N
might MD N
have VB N
occurred VBN N
. . N

Data NNP N
also RB N
show VBP N
quite RB N
a DT N
large JJ N
intra-individual JJ N
variability NN N
in IN N
cyclosporin JJ 3_i
bioavailability NN N
in IN N
the DT N
placebo NN 3_i
group NN N
, , N
suggesting VBG N
that IN N
poor JJ N
absorption NN N
of IN N
the DT N
drug NN N
formulation NN N
and/or IN N
poor JJ N
compliance NN N
might MD N
have VB N
contributed VBN N
to TO N
the DT N
decreased VBN N
cyclosporin NN 3_i
blood NN N
levels NNS N
in IN N
the DT N
patient JJ N
withdrawn NN N
from IN N
this DT N
study NN N
and CC N
in IN N
previous JJ N
uncontrolled JJ N
studies NNS N
. . N

CONCLUSION NNP N
Cyclosporin NNP N
bioavailability NN N
was VBD N
not RB N
clearly RB N
modified VBN N
by IN N
a DT N
half JJ N
dosage NN N
of IN N
ticlopidine NN 3_i
in IN N
this DT N
study NN N
. . N

We PRP N
, , N
however RB N
, , N
recommend VBP N
closely RB N
monitoring JJ N
cyclosporin NNS N
blood NN N
levels NNS N
when WRB N
prescribing VBG N
ticlopidine NN 3_i
. . N

Further JJ N
studies NNS N
will MD N
be VB N
needed VBN N
with IN N
new JJ N
formulations NNS N
of IN N
cyclosporin NN 3_i
or CC N
when WRB N
using VBG N
the DT N
full JJ N
dosage NN N
of IN N
ticlopidine NN 3_i
. . N

-DOCSTART- -X- O O

Cost-effectiveness NN N
of IN N
clozapine NN N
compared VBN N
with IN N
conventional JJ N
antipsychotic JJ N
medication NN N
for IN N
patients NNS N
in IN N
state NN N
hospitals NNS N
. . N

BACKGROUND NNP N
An DT N
open-label JJ N
, , N
randomized VBN N
controlled VBD N
trial NN N
compared VBN N
clozapine NN 3_i
with IN N
physicians'-choice JJ N
medications NNS N
among IN N
long-term JJ N
state NN N
hospital NN N
inpatients NNS N
in IN N
Connecticut NNP N
. . N

The DT N
goal NN N
was VBD N
to TO N
examine VB N
clozapine NN N
's POS N
cost-effectiveness NN N
in IN N
routine JJ N
practice NN N
for IN N
people NNS N
experiencing VBG N
lengthy JJ N
hospitalizations NNS N
. . N

METHODS NNP N
Long-stay JJ N
patients NNS N
with IN N
schizophrenia NN N
in IN N
a DT N
state NN N
hospital NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
begin VB N
open-label JJ N
clozapine NN 3_i
( ( N
n JJ N
= NNP N
138 CD N
) ) N
or CC N
to TO N
continue VB 7_i
receiving VBG 7_i
conventional JJ 7_i
antipsychotic JJ 7_i
medications NNS 7_i
( ( N
n JJ N
= NNP N
89 CD N
) ) N
. . N

We PRP N
interviewed VBD N
study NN N
participants NNS N
every DT N
4 CD N
months NNS N
for IN N
2 CD N
years NNS N
to TO N
assess VB N
psychiatric JJ N
symptoms NNS N
and CC N
functional JJ N
status NN N
, , N
and CC N
we PRP N
collected VBD N
continuous JJ N
measures NNS N
of IN N
prescribed JJ N
medications NNS N
, , N
service NN N
utilization NN N
, , N
and CC N
other JJ N
costs NNS N
. . N

We PRP N
used VBD N
both DT N
parametric JJ N
and CC N
nonparametric JJ N
techniques NNS N
to TO N
examine VB N
changes NNS N
in IN N
cost NN N
and CC N
parametric JJ N
analyses NNS N
to TO N
examine VB N
changes NNS N
in IN N
effectiveness NN N
. . N

We PRP N
used VBD N
bootstrap NN N
techniques NNS N
to TO N
estimate VB N
incremental JJ N
cost-effectiveness JJ N
ratios NNS N
and CC N
create VB N
cost-effectiveness JJ N
acceptability NN N
curves NNS N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
incurred VBD N
similar JJ N
costs NNS N
during IN N
the DT N
2-year JJ N
study NN N
period NN N
, , N
with IN N
a DT N
trend NN N
for IN N
clozapine NN N
to TO N
be VB N
less RBR N
costly JJ N
than IN N
usual JJ N
care NN N
in IN N
the DT N
second JJ N
study NN N
year NN N
. . N

Clozapine NNP 3_i
was VBD N
more RBR N
effective JJ N
than IN N
usual JJ N
care NN N
on IN N
many JJ N
but CC N
not RB N
all DT N
measures NNS N
. . N

With IN N
the DT N
use NN N
of IN N
effectiveness NN N
measures NNS N
that WDT N
favored VBD N
clozapine NN N
( ( N
extrapyramidal JJ N
side NN N
effects NNS N
, , N
disruptiveness NN N
) ) N
, , N
bootstrap NN N
techniques NNS N
indicated VBD N
that IN N
, , N
even RB N
when WRB N
a DT N
payer NN N
is VBZ N
unwilling JJ N
to TO N
incur VB N
any DT N
additional JJ N
cost NN N
for IN N
gains NNS N
in IN N
effectiveness NN N
, , N
the DT N
probability NN N
that IN N
clozapine NN 3_i
is VBZ N
more RBR N
cost-effective JJ N
than IN N
usual JJ N
care NN N
is VBZ N
at IN N
least JJS N
0.80 CD N
. . N

These DT N
findings NNS N
were VBD N
not RB N
as IN N
evident JJ N
when WRB N
outcomes NNS N
where WRB N
clozapine NN N
was VBD N
not RB N
clearly RB N
superior JJ N
( ( N
psychotic JJ N
symptoms NNS N
, , N
weight VBD N
gain NN N
) ) N
were VBD N
examined VBN N
. . N

CONCLUSION NNP N
Clozapine NNP 3_i
demonstrated VBD N
cost-effectiveness NN N
on IN N
some DT N
but CC N
not RB N
all DT N
measures NNS N
of IN N
effectiveness NN N
when WRB N
the DT N
alternative NN N
was VBD N
a DT N
range NN N
of IN N
conventional JJ N
antipsychotic JJ N
medications NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
clonidine NN 3_i
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
in IN N
breast NN N
cancer NN N
surgery NN N
. . N

BACKGROUND NNP N
Postoperative NNP N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
is VBZ N
still RB N
common JJ N
, , N
especially RB N
among IN N
female JJ N
patients NNS N
. . N

Our PRP$ N
hypothesis NN N
is VBZ N
that IN N
coinduction NN N
with IN N
clonidine NN 3_i
reduces VBZ N
the DT N
incidence NN N
of IN N
PONV NNP N
in IN N
adult NN N
patients NNS N
undergoing VBG N
breast NN N
cancer NN N
surgery NN N
. . N

METHODS NNP N
Sixty-eight JJ N
women NNS N
premedicated VBN N
with IN N
midazolam NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
coinduction NN N
with IN N
intravenous JJ N
clonidine NN 3_i
( ( N
group NN N
C NNP N
) ) N
or CC N
placebo NN 7_i
( ( N
group NN N
P NNP N
) ) N
in IN N
this DT N
prospective JJ N
, , N
double-blind JJ N
study NN N
. . N

Anesthesia NNP N
was VBD N
standardized VBN N
( ( N
laryngeal JJ 3_i
mask NN 3_i
airway NN 3_i
, , 3_i
fentanyl NN 3_i
, , 3_i
propofol NN 3_i
, , 3_i
sevoflurane NN 3_i
, , 3_i
nitrous JJ 3_i
oxide NN 3_i
, , 3_i
and CC 3_i
oxygen NN 3_i
) ) N
. . N

Hemodynamic JJ N
parameters NNS N
and CC N
the DT N
requirements NNS N
for IN N
propofol NN N
, , N
sevoflurane NN N
, , N
and CC N
the DT N
postoperative JJ N
need NN N
for IN N
ketobemidone NN N
were VBD N
noted VBN N
. . N

The DT N
primary JJ N
endpoints NNS N
studied VBN N
were VBD N
the DT N
number NN N
of IN N
PONV-free JJ N
patients NNS N
and CC N
patient JJ N
satisfaction NN N
with IN N
respect NN N
to TO N
PONV NNP N
. . N

RESULTS NNP N
Patients NNPS N
in IN N
group NN N
C NNP N
had VBD N
a DT N
significantly RB N
reduced VBN N
need NN N
for IN N
propofol NN N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
and CC N
sevoflurane NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
a DT N
reduced VBN N
early JJ N
need NN N
for IN N
ketobemidone NN N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

There EX N
were VBD N
significantly RB N
more RBR N
PONV-free JJ N
patients NNS N
in IN N
group NN N
C NNP N
compared VBN N
with IN N
group NN N
P NNP N
( ( N
20 CD N
and CC N
11 CD N
of IN N
30 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

The DT N
number NN N
needed VBN N
to TO N
treat VB N
was VBD N
3.3 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.8 CD N
, , N
16.9 CD N
) ) N
. . N

Intraoperative JJ N
blood NN N
pressure NN N
, , N
postoperative JJ N
heart NN N
rate NN N
, , N
and CC N
postoperative JJ N
blood NN N
pressure NN N
were VBD N
all DT N
significantly RB N
lower JJR N
in IN N
group NN N
C NNP N
compared VBN N
with IN N
group NN N
P NNP N
, , N
but CC N
were VBD N
not RB N
considered VBN N
to TO N
be VB N
of IN N
clinical JJ N
importance NN N
. . N

No DT N
negative JJ N
side NN N
effects NNS N
were VBD N
recorded VBN N
. . N

CONCLUSION NNP N
Coinduction NNP N
with IN N
clonidine NN 3_i
significantly RB N
increased VBD N
the DT N
number NN N
of IN N
PONV-free JJ N
patients NNS N
after IN N
breast NN N
cancer NN N
surgery NN N
with IN N
general JJ N
anesthesia NN N
. . N

-DOCSTART- -X- O O

[ NN N
Study NNP N
on IN N
classification NN N
and CC N
treatment NN N
of IN N
vulvovaginal JJ N
candidiasis NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
clinical JJ N
manifestations NNS N
of IN N
vulvovaginal JJ N
candidiasis NN N
( ( N
VVC NNP N
) ) N
and CC N
to TO N
study VB N
the DT N
mycologic JJ N
eradication NN N
rate NN N
of IN N
different JJ N
miconazole JJ 3_i
treatment NN N
courses NNS N
for IN N
VVC NNP N
. . N

METHODS NNP N
Three CD N
hundred VBD N
cases NNS N
of IN N
VVC NNP N
were VBD N
recruited VBN N
. . N

The DT N
Candidas NNPS N
were VBD N
cultured VBN N
. . N

A DT N
prospective JJ N
and CC N
randomized VBD N
study NN N
was VBD N
performed VBN N
to TO N
compare VB N
the DT N
treatment NN N
effect NN N
of IN N
3 CD 3_i
day NN 3_i
miconazole NN 3_i
( ( N
400 CD N
mg/d NN N
) ) N
, , N
6 CD 3_i
day NN 3_i
miconazole NN 3_i
( ( N
400 CD N
mg/d NN N
) ) N
, , N
and CC N
7 CD 3_i
day NN 3_i
miconazole NN 3_i
( ( N
200 CD N
mg/d NN N
) ) N
for IN N
uncomplicated JJ N
and CC N
complicated VBD N
VVC NNP N
. . N

RESULTS NNP N
Among IN N
300 CD N
cases NNS N
of IN N
VVC NNP N
, , N
uncomplicated VBD N
, , N
complicated VBN N
and CC N
recurrent JJ N
VVC NNP N
were VBD N
56.0 CD N
% NN N
, , N
44.0 CD N
% NN N
and CC N
9.7 CD N
% NN N
( ( N
29/300 CD N
) ) N
respectively RB N
. . N

C. NNP N
albicans NNS N
was VBD N
isolated VBN N
most JJS N
frequently RB N
90.3 CD N
% NN N
( ( N
271/300 CD N
) ) N
, , N
followed VBN N
by IN N
C. NNP N
glabrata NN N
( ( N
7.3 CD N
% NN N
) ) N
, , N
C. NNP N
tropicalis NN N
( ( N
1.3 CD N
% NN N
) ) N
, , N
C. NNP N
krusei NNP N
( ( N
0.7 CD N
% NN N
) ) N
, , N
and CC N
C. NNP N
parapsilosis NN N
( ( N
0.3 CD N
% NN N
) ) N
. . N

Mycologic JJ N
eradication NN N
rate NN N
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN 3_i
courses NNS N
for IN N
uncomplicated JJ N
VVC NNP N
at IN N
day NN N
14 CD N
was VBD N
96.0 CD N
% NN N
, , N
93.5 CD N
% NN N
and CC N
98.0 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Eradication NNP N
rate NN N
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN 3_i
courses NNS N
for IN N
complicated VBN N
VVC NNP N
at IN N
day NN N
14 CD N
was VBD N
86.7 CD N
% NN N
, , N
92.5 CD N
% NN N
, , N
and CC N
86.4 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Eradication NNP N
rate NN N
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN 3_i
courses NNS N
for IN N
uncomplicated JJ N
VVC NNP N
at IN N
day NN N
35 CD N
was VBD N
93.8 CD N
% NN N
, , N
95.3 CD N
% NN N
, , N
and CC N
89.8 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Eradication NNP N
rate NN N
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN 3_i
courses NNS N
for IN N
complicated VBN N
VVC NNP N
at IN N
day NN N
35 CD N
was VBD N
89.7 CD N
% NN N
, , N
97.3 CD N
% NN N
and CC N
86.8 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Treatment NNP N
of IN N
VVC NNP N
should MD N
be VB N
individualized VBN N
, , N
and CC N
women NNS N
with IN N
complicated JJ N
VVC NNP N
achieve VBP N
superior JJ N
mycologic JJ N
eradication NN N
by IN N
a DT N
6 CD N
day NN N
miconazole JJ 3_i
course NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
placebo-controlled JJ 7_i
trial NN N
of IN N
controlled JJ N
release NN N
melatonin NN 3_i
treatment NN 3_i
of IN N
delayed JJ N
sleep JJ N
phase NN N
syndrome NN N
and CC N
impaired JJ N
sleep JJ N
maintenance NN N
in IN N
children NNS N
with IN N
neurodevelopmental JJ N
disabilities NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
controlled-release NN N
( ( N
CR NNP N
) ) N
melatonin NN 3_i
in IN N
the DT N
treatment NN N
of IN N
delayed JJ N
sleep JJ N
phase NN N
syndrome NN N
and CC N
impaired JJ N
sleep JJ N
maintenance NN N
of IN N
children NNS N
with IN N
neurodevelopmental JJ N
disabilities NNS N
including VBG N
autistic JJ N
spectrum NN N
disorders NNS N
. . N

A DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ 7_i
crossover NN N
trial NN N
of IN N
CR NNP 3_i
melatonin NN 3_i
( ( N
5 CD N
mg NN N
) ) N
followed VBN N
by IN N
a DT N
3-month JJ N
open-label NN N
study NN N
was VBD N
conducted VBN N
during IN N
which WDT N
the DT N
dose NN N
was VBD N
gradually RB N
increased VBN N
until IN N
the DT N
therapy NN N
showed VBD N
optimal JJ N
beneficial JJ N
effects NNS N
. . N

Sleep JJ N
characteristics NNS N
were VBD N
measured VBN N
by IN N
caregiver NN N
who WP N
completed VBD N
somnologs NNS N
and CC N
wrist JJ N
actigraphs NN N
. . N

Clinician JJ N
rating NN N
of IN N
severity NN N
of IN N
the DT N
sleep JJ N
disorder NN N
and CC N
improvement NN N
from IN N
baseline NN N
, , N
along IN N
with IN N
caregiver JJ N
ratings NNS N
of IN N
global JJ N
functioning NN N
and CC N
family NN N
stress NN N
were VBD N
also RB N
obtained VBN N
. . N

Fifty-one CD N
children NNS N
( ( N
age NN N
range NN N
2-18 CD N
years NNS N
) ) N
who WP N
did VBD N
not RB N
respond VB N
to TO N
sleep VB N
hygiene NN N
intervention NN N
were VBD N
enrolled VBN N
. . N

Fifty JJ N
patients NNS N
completed VBD N
the DT N
crossover NN N
trial NN N
and CC N
47 CD N
completed VBD N
the DT N
open-label JJ N
phase NN N
. . N

Recordings NNS N
of IN N
total JJ N
night-time JJ N
sleep NN N
and CC N
sleep JJ N
latency NN N
showed VBD N
significant JJ N
improvement NN N
of IN N
approximately RB N
30 CD N
min NNS N
. . N

Similarly RB N
, , N
significant JJ N
improvement NN N
was VBD N
observed VBN N
in IN N
clinician JJ N
and CC N
parent JJ N
ratings NNS N
. . N

There EX N
was VBD N
additional JJ N
improvement NN N
in IN N
the DT N
open-label JJ N
somnolog NN N
measures NNS N
of IN N
sleep JJ N
efficiency NN N
and CC N
the DT N
longest JJS N
sleep JJ N
episode NN N
in IN N
the DT N
open-label JJ N
phase NN N
. . N

Overall UH N
, , N
the DT N
therapy NN N
improved VBD N
the DT N
sleep NN N
of IN N
47 CD N
children NNS N
and CC N
was VBD N
effective JJ N
in IN N
reducing VBG N
family NN N
stress NN N
. . N

Children NNP N
with IN N
neurodevelopmental JJ N
disabilities NNS N
, , N
who WP N
had VBD N
treatment NN N
resistant JJ N
chronic JJ N
delayed VBN N
sleep JJ N
phase NN N
syndrome NN N
and CC N
impaired JJ N
sleep JJ N
maintenance NN N
, , N
showed VBD N
improvement NN N
in IN N
melatonin NN 3_i
therapy NN 3_i
. . 3_i

-DOCSTART- -X- O O

Human NNP 2_i
recombinant JJ 2_i
GM-CSF NNP 2_i
in IN N
allogeneic JJ N
bone NN N
marrow NN N
transplantation NN N
for IN N
leukaemia NN N
: : N
double-blind JJ N
placebo NN N
controlled VBN N
trial NN N
. . N

A DT N
double-blind NN N
randomised VBN N
trial NN N
compared VBN N
20 CD N
patients NNS N
with IN N
leukaemia JJ N
receiving VBG N
human JJ 3_i
recombinant JJ 3_i
granulocyte NN 3_i
macrophage NN 3_i
colony NN 3_i
stimulating VBG 3_i
factor NN 3_i
( ( 3_i
GM NNP 3_i
CSF NNP 3_i
) ) 3_i
, , N
with IN N
20 CD N
patients NNS N
receiving VBG N
placebo NN 7_i
for IN N
14 CD N
days NNS N
after IN N
allogeneic JJ N
matched VBD N
sibling VBG N
bone NN N
marrow NN N
transplantation NN N
. . N

The DT N
median JJ N
neutrophil NN N
count NN N
at IN N
14 CD N
days NNS N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM NNP 2_i
CSF NNP 2_i
group NN N
( ( N
1.90 CD N
vs. FW N
0.46 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
) ) N
. . N

The DT N
duration NN N
of IN N
hospital NN N
stay NN N
, , N
the DT N
number NN N
of IN N
antibiotic JJ N
days NNS N
, , N
and CC N
the DT N
number NN N
of IN N
fever JJ N
days NNS N
was VBD N
the DT N
same JJ N
for IN N
both DT N
patient JJ N
groups NNS N
. . N

The DT N
lymphocyte NN N
count NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM-CSF NNP 3_i
group NN N
than IN N
in IN N
the DT N
placebo NN 7_i
group NN N
between IN N
days NNS N
10 CD N
and CC N
15 CD N
after IN N
transplantation NN N
. . N

The DT N
GM-CSF NNP 3_i
group NN N
had VBD N
lower JJR N
haemoglobin NN N
concentrations NNS N
and CC N
platelets NNS N
counts NNS N
, , N
and CC N
higher JJR N
plasma NN N
urea JJ N
creatinine NN N
and CC N
bilirubin NN N
, , N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
GM NNP 3_i
CSF NNP 3_i
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
leukaemic JJ N
relapse NN N
. . N

-DOCSTART- -X- O O

Stepwise NNP N
assessment JJ N
tool NN N
of IN N
operative JJ 2_i
skills NNS 2_i
( ( 2_i
SATOS NNP 2_i
) ) 2_i
: : N
validity NN N
testing VBG N
on IN N
a DT N
porcine JJ 4_i
training NN 4_i
model NN 4_i
of IN N
open JJ N
gastrectomy NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
study NN N
was VBD N
to TO N
evaluate VB N
and CC N
compare VB N
operative JJ N
performance NN N
and CC N
technical JJ N
improvement NN N
of IN N
surgical JJ N
trainees NNS N
learning VBG N
open JJ N
gastrectomy NN N
using VBG N
an DT N
objective JJ N
structured JJ N
stepwise NN 2_i
assessment JJ 2_i
tool NN 2_i
of IN 2_i
operative JJ 2_i
skills NNS 2_i
( ( 2_i
SATOS NNP 2_i
) ) 2_i
previously RB N
validated VBN N
for IN N
open JJ N
surgery NN N
. . N

STUDY NNP N
DESIGN NNP N
Thirty NNP N
residents NNS N
in IN N
general JJ N
surgery NN N
performed VBD N
2 CD N
open JJ 2_i
partial JJ 2_i
gastrectomy NN 2_i
training VBG 2_i
events NNS 2_i
on IN N
a DT N
porcine JJ 2_i
model NN 2_i
. . 2_i

Earlier JJR N
instruction NN N
was VBD N
provided VBN N
for IN N
the DT N
critical JJ N
operative JJ N
steps NNS N
, , N
with IN N
additional JJ N
intraoperative JJ N
instruction NN N
when WRB N
required VBN N
. . N

Performance NN N
was VBD N
assessed VBN N
by IN N
postgraduate JJ N
year NN N
( ( N
PGY NNP N
) ) N
according VBG N
to TO N
operative JJ N
time NN N
, , N
technical JJ N
skills NNS N
using VBG N
a DT N
23-step JJ N
objective NN N
structured VBD N
tool NN N
, , N
and CC N
error NN N
rate NN N
. . N

RESULTS CC N
There EX N
were VBD N
11 CD N
PGY-3 NNP N
, , N
11 CD N
PGY-4 NN N
, , N
and CC N
8 CD N
PGY-5 JJ N
residents NNS N
. . N

At IN N
the DT N
initial JJ N
assessment NN N
, , N
performance NN N
significantly RB N
differentiated VBD N
the DT N
3 CD N
PGY NNP N
grades NNS N
according VBG N
to TO N
technical JJ N
skills NNS N
and CC N
error NN N
rate NN N
. . N

At IN N
the DT N
second JJ N
assessment NN N
, , N
all DT N
3 CD N
PGY NNP N
classes NNS N
were VBD N
still RB N
significantly RB N
differentiable JJ N
by IN N
technical JJ N
skills NNS N
, , N
with IN N
no DT N
difference NN N
in IN N
error NN N
rate NN N
. . N

Comparing NNP N
performances NNS N
, , N
residents NNS N
improved VBD N
operative JJ N
time NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
technical JJ N
skills NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
error NN N
rate NN N
( ( N
p JJ N
= NNP N
0.019 CD N
) ) N
over IN N
the DT N
2 CD N
training NN N
events NNS N
. . N

CONCLUSIONS NNP N
SATOS NNP N
demonstrated VBD N
relevant JJ N
and CC N
accurate JJ N
objective JJ N
assessment NN N
of IN N
trainees NNS N
' POS N
operative JJ N
skills NNS N
and CC N
improvement NN N
for IN N
open JJ N
gastrectomy NN N
in IN N
a DT N
porcine JJ N
model NN N
. . N

This DT N
tool NN N
may MD N
be VB N
useful JJ N
to TO N
standardize VB N
instruction NN N
, , N
to TO N
expose VB N
weaknesses NNS N
of IN N
trainees NNS N
, , N
and CC N
to TO N
determine VB N
minimal JJ N
technical JJ N
standards NNS N
in IN N
residency NN N
programs NNS N
. . N

-DOCSTART- -X- O O

Interventional NNP N
study NN N
to TO N
strengthen VB N
the DT N
health NN N
promoting VBG N
behaviours NNS N
of IN N
pregnant JJ N
women NNS N
to TO N
prevent VB N
anaemia NN N
in IN N
southern JJ N
India NNP N
. . N

OBJECTIVES NNP N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
health NN 4_i
information NN 4_i
package NN 4_i
in IN N
terms NNS N
of IN N
empowering VBG N
the DT N
pregnant JJ N
women NNS N
to TO N
modify VB N
their PRP$ N
health-care JJ N
behaviour NN N
and CC N
take VB N
appropriate JJ N
action NN N
to TO N
combat VB N
anaemia NN N
in IN N
pregnancy NN N
. . N

DESIGN VB N
the DT N
study NN N
was VBD N
conceptualized VBN N
based VBN N
on IN N
Rosenstock NNP N
and CC N
Becker NNP N
's POS N
health NN N
belief NN N
model NN N
. . N

A DT N
quasi-experimental JJ N
pretest-posttest JJ N
control NN N
group NN N
design NN N
was VBD N
used VBN N
. . N

The DT N
sample NN N
consists VBZ N
of IN N
225 CD N
anaemic JJ N
pregnant JJ N
women NNS N
randomly RB N
allocated VBN N
in IN N
experimental JJ N
( ( N
n=75 JJ N
) ) N
, , N
control NN 7_i
group NN N
A NNP N
( ( N
n=75 NN N
) ) N
and CC N
control NN 7_i
group NN N
B NNP N
( ( N
n=75 NN N
) ) N
. . N

The DT N
health NN N
seeking VBG N
behaviour NN N
outcome NN N
measure NN N
included VBD N
knowledge NN N
regarding VBG N
anaemia NN N
, , N
food NN N
selection NN N
ability NN N
, , N
increase NN N
in IN N
haemoglobin JJ N
level NN N
and CC N
compliance NN N
to TO N
iron VB N
supplementation NN N
. . N

Intervention NN N
was VBD N
a DT N
validated JJ 6_i
planned JJ 6_i
educational JJ 6_i
programme NN 6_i
with IN 6_i
visual JJ 6_i
aids NNS 6_i
and CC 6_i
iron NN 6_i
supplementation NN 6_i
. . N

FINDINGS IN N
the DT N
results NNS N
show VBP N
the DT N
mean JJ N
gain NN N
of IN N
knowledge NN N
scores NNS N
of IN N
experimental JJ N
group NN N
was VBD N
comparatively RB N
higher JJR N
and CC N
control VB N
groups NNS N
A NNP N
and CC N
B NNP N
showed VBD N
that IN N
F NNP N
ratio NN N
was VBD N
( ( N
F NNP N
( ( N
2,190 CD N
) ) N
=11.910 NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
indicating NN N
that IN N
the DT N
pregnant JJ N
women NNS N
learned VBD N
more RBR N
about IN N
anaemia NN N
prevention NN N
than IN N
others NNS N
. . N

With IN N
regard NN N
to TO N
food NN N
selection NN N
ability NN N
scores NNS N
of IN N
experimental JJ N
, , N
control NN N
groups NNS N
A NNP N
and CC N
B NNP N
the DT N
F NNP N
ratio NN N
was VBD N
also RB N
significant JJ N
( ( N
F NNP N
( ( N
2,190 CD N
) ) N
=20.92 NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

Nearly RB N
61.2 CD N
% NN N
of IN N
the DT N
subjects NNS N
in IN N
experimental JJ N
group NN N
became VBD N
non-anaemic JJ N
after IN N
the DT N
intervention NN N
when WRB N
compared VBN N
to TO N
control VB N
group NN N
A NNP N
. . N

This DT N
indicated VBD N
that IN N
inspite NN N
of IN N
iron NN 3_i
supplementation NN 3_i
received VBN N
by IN N
the DT N
three CD N
groups NNS N
health NN N
education NN N
contributed VBD N
significantly RB N
in IN N
modifying VBG N
their PRP$ N
health NN N
seeking VBG N
behaviour NN N
and CC N
their PRP$ N
perception NN N
about IN N
significance NN N
of IN N
anaemia NN N
has VBZ N
a DT N
problem NN N
. . N

CONCLUSION NNP N
developing VBG N
countries NNS N
still RB N
face VBP N
the DT N
critical JJ N
problem NN N
of IN N
anaemia NN N
in IN N
pregnancy NN N
. . N

These DT N
are VBP N
the DT N
socio-cultural JJ N
priority NN N
problems NNS N
that WDT N
demand VBP N
immediate JJ N
attention NN N
by IN N
the DT N
policy NN N
makers NNS N
and CC N
health NN N
professionals NNS N
. . N

The DT N
national JJ N
anaemia NN N
control NN N
programme NN N
focuses VBZ N
on IN N
iron NN N
supplementation NN N
, , N
but CC N
nutritional JJ N
education NN N
and CC N
supervision NN N
of IN N
iron NN N
supplementation NN N
has VBZ N
failed VBN N
in IN N
different JJ N
regions NNS N
. . N

The DT N
study NN N
implies VBZ N
that IN N
economic JJ N
empowerment NN N
; : N
strengthening VBG N
health NN N
literacy NN N
through IN N
planned VBN N
educational JJ N
programs NNS N
will MD N
definitely RB N
improve VB N
the DT N
health NN N
behaviour NN N
of IN N
individual JJ N
and CC N
community NN N
at IN N
large JJ N
. . N

-DOCSTART- -X- O O

Randomized VBN N
controlled VBD N
study NN N
of IN N
chemoimmunotherapy NN 3_i
with IN 3_i
bestatin NN 3_i
of IN N
acute JJ N
nonlymphocytic JJ N
leukemia NN N
in IN N
adults NNS N
. . N

A DT N
new JJ N
immunomodulating NN 3_i
agent NN 3_i
, , 3_i
bestatin NN 3_i
( ( N
INN NNP N
: : N
Ubenimex NNP 3_i
has VBZ N
low JJ N
toxicity NN N
even RB N
after IN N
long-term JJ N
oral JJ N
administration NN N
and CC N
has VBZ N
significant JJ N
modifications NNS N
in IN N
immunological JJ N
response NN N
. . N

A DT N
cooperative JJ N
randomized NN N
controlled VBD N
study NN N
of IN N
bestatin NN 3_i
immunotherapy NN 3_i
in IN N
combination NN N
with IN N
remission NN 3_i
maintenance NN 3_i
chemotherapy NN 3_i
for IN N
adult NN N
acute JJ N
nonlymphocytic JJ N
leukemia NN N
( ( N
ANLL NNP N
) ) N
was VBD N
performed VBN N
. . N

After IN N
induction NN N
of IN N
complete JJ N
remission NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
bestatin NN 3_i
group NN 3_i
( ( N
30 CD N
mg/bw NN N
per IN N
os NN N
( ( N
po NN N
) ) N
daily RB N
) ) N
and CC N
the DT N
control NN 7_i
group NN 7_i
. . 7_i

The DT N
101 CD N
eligible JJ N
cases NNS N
( ( 3_i
bestatin NN 3_i
: : 3_i
48 CD N
, , N
control NN N
: : N
53 CD N
) ) N
were VBD N
analyzed VBN N
; : N
the DT N
bestatin NN 3_i
group NN N
achieved VBD N
longer JJR N
remission NN N
than IN N
the DT N
control NN N
group NN N
and CC N
a DT N
statistically RB N
significant JJ N
longer JJR N
survival NN N
. . N

Though IN N
this DT N
prolongation NN N
of IN N
remission NN N
was VBD N
not RB N
significant JJ N
in IN N
the DT N
bestatin NN 3_i
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
in IN N
the DT N
15-49 JJ N
yr NN N
age NN N
group NN N
, , N
in IN N
the DT N
50-65 JJ N
yr NN N
age NN N
group NN N
it PRP N
was VBD N
significantly RB N
longer JJR N
. . N

Bestatin NNP 3_i
is VBZ N
shown VBN N
to TO N
be VB N
a DT N
clinically RB N
useful JJ N
drug NN N
for IN N
immunotherapy NN 3_i
of IN N
adult NN N
ANLL NNP N
, , N
since IN N
it PRP N
has VBZ N
prolonged VBN N
survival NN N
and CC N
remission NN N
especially RB N
in IN N
elderly JJ N
patients NNS N
, , N
with IN N
few JJ N
side-effects NNS N
. . N

-DOCSTART- -X- O O

Lowering VBG N
of IN N
glucose NN N
in IN N
critical JJ N
care NN N
: : N
a DT N
randomized JJ N
pilot NN N
trial NN N
. . N

BACKGROUND NNP N
Similar NNP N
to TO N
cardiac VB N
surgery NN N
patients NNS N
, , N
medical-surgical JJ N
critically RB N
ill JJ N
patients NNS N
may MD N
benefit VB N
from IN N
intensive JJ 3_i
insulin NN 3_i
therapy NN 3_i
. . N

The DT N
objectives NNS N
of IN N
this DT N
pilot NN N
trial NN N
were VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
intensive JJ 3_i
insulin NN 3_i
therapy NN 3_i
with IN N
respect NN N
to TO N
( ( N
a DT N
) ) N
achieving VBG N
target NN N
glucose JJ N
values NNS N
in IN N
the DT N
2 CD N
ranges NNS N
of IN N
5 CD N
to TO N
7 CD N
and CC N
8 CD N
to TO N
10 CD N
mmol/L NNS N
and CC N
( ( N
b NN N
) ) N
uncovering VBG N
problems NNS N
with IN N
the DT N
protocol NN N
in IN N
anticipation NN N
of IN N
a DT N
larger JJR N
trial NN N
. . N

SETTING VB N
The DT N
trial NN N
was VBD N
conducted VBN N
in IN N
a DT N
15-bed JJ N
medical-surgical JJ N
university-affiliated JJ N
intensive JJ N
care NN N
unit NN N
( ( N
ICU NNP N
) ) N
. . N

METHODS NNP N
We PRP N
included VBD N
patients NNS N
older JJR N
than IN N
18 CD N
years NNS N
, , N
expected VBN N
to TO N
be VB N
in IN N
ICU NNP N
for IN N
more JJR N
than IN N
72 CD N
hours NNS N
, , N
with IN N
a DT N
glucose JJ N
value NN N
of IN N
more JJR N
than IN N
10 CD N
mmol/L NNS N
within IN N
48 CD N
hours NNS N
of IN N
ICU NNP N
admission NN N
. . N

Exclusion NN N
criteria NNS N
were VBD N
diabetic JJ N
ketoacidosis NN N
, , N
severe JJ N
hepatic JJ N
failure NN N
or CC N
hepatic JJ N
resection NN N
, , N
pancreatitis NN N
, , N
glucose NN N
of IN N
less JJR N
than IN N
2.2 CD N
mmol/L NN N
on IN N
admission NN N
to TO N
hospital NN N
, , N
insulin JJ N
infusion NN N
on IN N
admission NN N
to TO N
ICU NNP N
, , N
planned VBD N
withdrawal NN N
of IN N
life NN N
support NN N
, , N
and CC N
inability NN N
to TO N
obtain VB N
informed JJ N
consent NN N
. . N

Patients NNS N
underwent JJ N
concealed JJ N
random NN N
allocation NN N
to TO N
a DT N
target NN N
glucose JJ N
range NN N
of IN N
5 CD N
to TO N
7 CD N
or CC N
8 CD N
to TO N
10 CD N
mmol/L NNS N
using VBG N
pretested JJ N
algorithms NN N
of IN N
insulin NN 3_i
infusions NNS 3_i
. . N

Dedicated VBN N
glucometer JJ N
measurement NN N
of IN N
arterial JJ N
glucose NN N
values NNS N
was VBD N
calibrated VBN N
daily RB N
to TO N
values NNS N
measured VBN N
in IN N
the DT N
laboratory NN N
. . N

RESULTS NNP N
We PRP N
enrolled VBD N
20 CD N
patients NNS N
with IN N
a DT N
mean NN N
( ( N
SD NNP N
) ) N
Acute NNP N
Physiology NNP N
and CC N
Chronic NNP N
Health NNP N
Evaluation NNP N
( ( N
APACHE NNP N
) ) N
II NNP N
score NN N
of IN N
32 CD N
( ( N
10.2 CD N
) ) N
; : N
14 CD N
were VBD N
insulin-dependent JJ N
pre-ICU JJ N
, , N
and CC N
all DT N
were VBD N
medical JJ N
admissions NNS N
. . N

Mean NNP N
glucose JJ N
values NNS N
were VBD N
different JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
7.1 CD N
+/- JJ N
2.6 CD N
vs JJ N
9.4 CD N
+/- JJ N
2.1 CD N
mmol/L NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Although IN N
the DT N
intensive JJ 3_i
insulin NN 3_i
therapy NN 3_i
group NN N
had VBD N
more RBR N
glucose JJ N
measurements NNS N
performed VBN N
than IN N
the DT N
control NN N
group NN N
, , N
a DT N
similar JJ N
proportion NN N
of IN N
values NNS N
were VBD N
within IN N
the DT N
target NN N
range NN N
( ( N
682 CD N
[ RB N
42.4 CD N
% NN N
] NN N
of IN N
1607 CD N
values NNS N
in IN N
the DT N
5- JJ N
to TO N
7-mmol/L JJ N
range NN N
; : N
250 CD N
[ $ N
38.7 CD N
% NN N
] NN N
of IN N
660 CD N
values NNS N
in IN N
the DT N
8- JJ N
to TO N
10-mmol/L JJ N
range NN N
, , N
P NNP N
= NNP N
.35 NNP N
) ) N
. . N

Glucose NNP N
values NNS N
of IN N
less JJR N
than IN N
2.5 CD N
mmol/L NN N
developed VBD N
7 CD N
times NNS N
in IN N
5 CD N
patients NNS N
, , N
4 CD N
of IN N
whom WP N
were VBD N
in IN N
the DT N
intensive JJ N
insulin NN 3_i
therapy NN N
group NN N
; : N
however RB N
, , N
no DT N
adverse JJ N
consequences NNS N
were VBD N
documented VBN N
. . N

As IN N
expected VBN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
clinically RB N
important JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
pilot JJ N
trial NN N
of IN N
ICU NNP N
patients NNS N
with IN N
high JJ N
illness NN N
severity NN N
, , N
glucose JJ N
values NNS N
were VBD N
in IN N
the DT N
2 CD N
target NN N
ranges VBZ N
only RB N
40 CD N
% NN N
of IN N
the DT N
time NN N
, , N
using VBG N
well-accepted JJ N
initiation NN N
and CC N
maintenance NN N
insulin NN N
infusion NN N
algorithms NN N
. . N

A DT N
large JJ N
randomized JJ N
trial NN N
of IN N
glycemic JJ N
control NN N
is VBZ N
feasible JJ N
in IN N
this DT N
population NN N
to TO N
examine VB N
clinically RB N
important JJ N
outcomes NNS N
, , N
but CC N
will MD N
require VB N
refined JJ N
insulin NN 3_i
algorithms NN N
and CC N
more RBR N
comprehensive JJ N
behavior NN N
change NN N
strategies NNS N
to TO N
achieve VB N
target NN N
values NNS N
. . N

-DOCSTART- -X- O O

Group-based JJ N
HIV NNP N
risk NN N
reduction NN N
intervention NN N
for IN N
adolescent JJ N
girls NNS N
: : N
evidence NN N
of IN N
feasibility NN N
and CC N
efficacy NN N
. . N

The DT N
purposes NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
( ( N
a DT N
) ) N
to TO N
assess VB N
the DT N
feasibility NN N
of IN N
a DT N
community-based JJ N
, , N
small JJ N
group NN N
HIV NNP N
risk NN N
reduction NN N
intervention NN N
with IN N
adolescent JJ N
girls NNS N
, , N
and CC N
( ( N
b NN N
) ) N
to TO N
obtain VB N
preliminary JJ N
evidence NN N
of IN N
the DT N
efficacy NN N
of IN N
this DT N
theoretically-guided JJ 4_i
intervention NN 4_i
using VBG N
a DT N
controlled JJ N
design NN N
. . N

The DT N
feasibility NN N
of IN N
the DT N
intervention NN N
was VBD N
demonstrated VBN N
by IN N
successfully RB N
implementing VBG N
it PRP N
with IN N
33 CD N
sexually-active JJ N
, , N
single JJ N
girls NNS N
. . N

Preliminary JJ N
evidence NN N
of IN N
the DT N
efficacy NN N
of IN N
the DT N
intervention NN N
was VBD N
obtained VBN N
using VBG N
a DT N
randomized JJ N
trial NN N
with IN N
62 CD N
sexually-active JJ N
, , N
single JJ N
girls NNS N
. . N

Data NNS N
obtained VBD N
at IN N
a DT N
3-month JJ N
follow-up JJ N
assessment NN N
showed VBD N
that IN N
girls NNS N
who WP N
received VBD N
the DT N
HIV-related JJ N
intervention NN N
improved VBD N
their PRP$ N
HIV-related JJ N
knowledge NN N
and CC N
enhanced VBD N
their PRP$ N
motivation NN N
for IN N
risk NN N
reduction NN N
compared VBN N
to TO N
girls NNS N
who WP N
received VBD N
a DT N
control NN 7_i
( ( 7_i
health NN 7_i
promotion NN 7_i
) ) 7_i
intervention NN 7_i
. . N

Effect JJ N
sizes VBZ N
suggest VBP N
that IN N
the DT N
HIV NNP N
intervention NN N
also RB N
reduced VBD N
several JJ N
risk NN N
behaviors NNS N
( ( N
e.g. NN N
, , N
vaginal JJ N
sex NN N
without IN N
a DT N
condom NN N
, , N
giving VBG N
oral JJ N
sex NN N
, , N
and CC N
alcohol NN N
and CC N
drug NN N
use NN N
before IN N
sex NN N
) ) N
. . N

Challenges VBZ N
to TO N
implementation NN N
and CC N
suggestions NNS N
for IN N
intervention NN N
enhancement NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Intravenous JJ N
pretreatment NN N
of IN N
hypertonic JJ 3_i
saline NN 3_i
can MD N
prevent VB N
systemic JJ N
hypotension NN N
induced VBN N
by IN N
spinal JJ N
anesthesia NN N
. . N

BACKGROUND NNP N
Hypertonic NNP N
saline NN N
improves VBZ N
organ JJ N
perfusion NN N
and CC N
patient JJ N
survival NN N
during IN N
hemorrhagic NN N
shock NN N
because IN N
it PRP N
expands VBZ N
plasma JJ N
volume NN N
and CC N
increases VBZ N
tissue NN N
oxygenation NN N
. . N

Its PRP$ N
beneficial JJ N
results NNS N
have VBP N
been VBN N
reported VBN N
in IN N
patients NNS N
suffering VBG N
from IN N
hypotension NN N
during IN N
spinal JJ N
anesthesia NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
influence NN N
between IN N
prehydration NN N
with IN N
3 CD N
% NN N
hypertonic JJ 3_i
saline NN 3_i
and CC 3_i
with IN 3_i
isotonic JJ 3_i
lactated VBN 3_i
Ringer NNP 3_i
's POS 3_i
solution NN 3_i
on IN N
the DT N
hemodynamic JJ N
changes NNS N
and CC N
serum NN N
electrolyte NN N
concentrations NNS N
in IN N
patients NNS N
undergoing JJ N
spinal JJ N
anesthesia NN N
. . N

METHODS NNP N
Sixty NNP N
ASA NNP N
class NN N
I PRP N
patients NNS N
scheduled VBN N
for IN N
herniorrhapy NN 1_i
under IN N
spinal JJ N
anesthesia NN N
were VBD N
assigned VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

Group NNP N
1 CD N
= NN N
patients NNS N
were VBD N
prehydrated VBN 3_i
with IN 3_i
isotonic JJ 3_i
lactated VBN 3_i
Ringer NNP 3_i
's POS 3_i
solution NN 3_i
at IN 3_i
7 CD 3_i
mg/kg NN 3_i
( ( N
n JJ N
= NNP N
30 CD N
) ) N
; : N
Group NNP N
2 CD N
= NN N
patients NNS N
were VBD N
given VBN N
prehydration NN 3_i
with IN 3_i
3 CD 3_i
% NN 3_i
hypertonic JJ 3_i
saline NN 3_i
at IN 3_i
7 CD 3_i
ml/kg NN 3_i
( ( N
n JJ N
= NNP N
30 CD N
) ) N
. . N

Following VBG N
prehydration NN N
, , N
arterial JJ N
blood NN N
pressure NN N
and CC N
heart NN N
rate NN N
were VBD N
recorded VBN N
and CC N
serum JJ N
electrolyte NN N
concentrations NNS N
were VBD N
measured VBN N
. . N

RESULTS VB N
The DT N
incidence NN N
of IN N
hypotension NN N
was VBD N
17/30 CD N
( ( N
57 CD N
% NN N
) ) N
in IN N
the DT N
isotonic JJ N
lactated VBD N
Ringer NNP N
's POS N
solution NN N
group NN N
as IN N
against IN N
7/30 CD N
( ( N
23 CD N
% NN N
) ) N
in IN N
the DT N
hypertonic JJ N
saline NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
two CD N
groups NNS N
in IN N
relation NN N
to TO N
the DT N
level NN N
of IN N
anesthesia NN N
or CC N
maximal JJ N
heart NN N
rate NN N
, , N
and CC N
electrolyte JJ N
imbalance NN N
did VBD N
not RB N
occur VB N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS NNP N
Prior NNP N
to TO N
spinal VB N
anesthesia NN N
, , N
hydration NN N
with IN N
small JJ N
amount NN N
of IN N
hypertonic JJ 3_i
saline NN 3_i
is VBZ N
effective JJ N
to TO N
minimize VB N
hypotension NN N
associated VBN N
with IN N
spinal JJ N
anesthesia NN N
. . N

If IN N
so RB N
administered VBN N
it PRP N
would MD N
not RB N
increase VB N
bodily RB N
sodium JJ N
load NN N
and CC N
unlike IN N
isotonic JJ N
crystalloid NN N
solution NN N
it PRP N
dose VBD N
not RB N
cause JJ N
accumulation NN N
of IN N
water NN N
in IN N
the DT N
body NN N
on IN N
equipollent JJ N
basis NN N
. . N

-DOCSTART- -X- O O

Not RB N
Now RB N
! . N
Supporting VBG N
interruption NN N
management NN N
by IN N
indicating VBG N
the DT N
modality NN N
and CC N
urgency NN N
of IN N
pending VBG N
tasks NNS N
. . N

Operators NNS N
in IN N
complex JJ N
event-driven JJ N
domains NNS N
must MD N
coordinate VB N
competing VBG N
attentional JJ N
demands NNS N
in IN N
the DT N
form NN N
of IN N
multiple JJ N
tasks NNS N
and CC N
interactions NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
extent NN N
to TO N
which WDT N
this DT N
requirement NN N
can MD N
be VB N
supported VBN N
more RBR N
effectively RB N
through IN N
informative JJ N
interruption NN N
cueing NN N
( ( N
in IN N
this DT N
case NN N
, , N
partial JJ N
information NN N
about IN N
the DT N
nature NN N
of IN N
pending VBG N
tasks NNS N
) ) N
. . N

The DT N
48 CD N
participants NNS N
performed VBD N
a DT N
visually RB 6_i
demanding VBG 6_i
air NN 6_i
traffic NN 6_i
control NN 6_i
( ( 6_i
ATC NNP 6_i
) ) 6_i
task NN 6_i
. . 4_i

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
experimental JJ N
groups NNS N
that WDT N
differed VBD N
in IN N
the DT N
availability NN 4_i
of IN 4_i
information NN 4_i
( ( 4_i
not RB 4_i
available JJ 4_i
, , 4_i
available JJ 4_i
upon IN 4_i
request NN 4_i
, , 4_i
available JJ 4_i
automatically RB 4_i
) ) N
about IN N
the DT N
urgency NN N
and CC N
modality NN N
of IN N
pending VBG N
interruption NN N
tasks NNS N
. . N

Within-subject JJ N
variables NNS N
included VBD N
ATC-related JJ 6_i
workload NN 6_i
and CC N
the DT N
modality NN 6_i
, , 6_i
frequency NN 6_i
, , 6_i
and CC 6_i
priority NN 6_i
of IN 6_i
interruption NN 6_i
tasks NNS 6_i
. . N

The DT N
results NNS N
show VBP N
that IN N
advance NN N
knowledge NN N
about IN N
the DT N
nature NN N
of IN N
pending VBG N
tasks NNS N
led VBD N
participants NNS N
to TO N
delay VB N
visual JJ N
interruption NN N
tasks VBZ N
the DT N
longest JJS N
, , N
which WDT N
allowed VBD N
them PRP N
to TO N
avoid VB N
intramodal JJ N
interference NN N
and CC N
scanning NN N
costs NNS N
associated VBN N
with IN N
performing VBG N
these DT N
tasks NNS N
concurrently RB N
with IN N
ATC NNP N
tasks NNS N
. . N

The DT N
3 CD N
experimental JJ N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
their PRP$ N
interruption NN N
task NN N
performance NN N
; : N
however RB N
, , N
the DT N
group NN N
that WDT N
automatically RB N
received VBD N
task-related JJ N
information NN N
showed VBD N
better JJR N
ATC NNP N
performance NN N
, , N
thus RB N
experiencing VBG N
a DT N
net JJ N
performance NN N
gain NN N
. . N

Actual NNP N
or CC N
potential JJ N
applications NNS N
of IN N
this DT N
research NN N
include VBP N
the DT N
design NN N
of IN N
interfaces NNS N
in IN N
support NN N
of IN N
attention NN N
and CC N
interruption NN N
management NN N
in IN N
a DT N
wide JJ N
range NN N
of IN N
event-driven JJ N
environments NNS N
. . N

-DOCSTART- -X- O O

Decompressive JJ 2_i
craniectomy NN 2_i
in IN N
traumatic JJ N
brain NN N
injury NN N
: : N
the DT N
randomized JJ N
multicenter NN N
RESCUEicp NNP N
study NN N
( ( N
www.RESCUEicp.com NN N
) ) N
. . N

The DT N
RESCUEicp NNP N
( ( N
Randomized NNP N
Evaluation NNP N
of IN N
Surgery NNP N
with IN N
Craniectomy NNP N
for IN N
Uncontrollable JJ N
Elevation NN N
of IN N
intracranial JJ N
pressure NN N
) ) N
study NN N
has VBZ N
been VBN N
established VBN N
to TO N
determine VB N
whether IN N
decompressive JJ 2_i
craniectomy NN 2_i
has VBZ N
a DT N
role NN N
in IN N
the DT N
management NN N
of IN N
patients NNS N
with IN N
traumatic JJ N
brain NN N
injury NN N
and CC N
raised VBD N
intracranial JJ N
pressure NN N
that WDT N
does VBZ N
not RB N
respond VB N
to TO N
initial JJ N
treatment NN N
measures NNS N
. . N

We PRP N
describe VBP N
the DT N
concept NN N
of IN N
decompressive JJ 2_i
craniectomy NN 2_i
in IN N
traumatic JJ N
brain NN N
injury NN N
and CC N
the DT N
rationale NN N
and CC N
protocol NN N
of IN N
the DT N
RESCUEicp NNP N
study NN N
. . N

-DOCSTART- -X- O O

Scent NN N
and CC N
mood NN N
state NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
water NN 3_i
, , 3_i
lavender NN 3_i
, , 3_i
or CC 3_i
rosemary JJ 3_i
scent NN 3_i
on IN N
physiology NN N
and CC N
mood NN N
state NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

The DT N
nonsmoking JJ N
participants NNS N
, , N
ages VBZ N
18-30 CD N
years NNS N
, , N
included VBD N
42 CD N
women NNS N
and CC N
31 CD N
men NNS N
who WP N
reported VBD N
demographic JJ N
information NN N
and CC N
measures NNS N
of IN N
external JJ N
temperature NN N
and CC N
heart NN N
rate NN N
were VBD N
taken VBN N
prior RB N
to TO N
introduction NN N
of IN N
an DT N
anxiety-eliciting JJ 4_i
task NN 4_i
and CC N
exposure NN N
to TO N
lavender VB 3_i
, , 3_i
rosemary JJ 3_i
, , 3_i
or CC 3_i
water NN 3_i
scents NNS 3_i
. . N

Following VBG N
the DT N
task NN N
, , N
participants NNS N
completed VBD N
the DT N
Profile NNP N
of IN N
Mood NNP N
States NNPS N
to TO N
assess VB N
mood NN N
, , N
and CC N
temperature NN N
and CC N
heart NN N
rate NN N
were VBD N
reassessed VBN N
. . N

Participants NNS N
rated VBD N
the DT N
pleasantness NN N
of IN N
the DT N
scent NN N
received VBD N
. . N

When WRB N
pleasantness JJ N
ratings NNS N
of IN N
scent NN N
were VBD N
covaried VBN N
, , N
physiological JJ N
changes NNS N
in IN N
temperature NN N
and CC N
heart NN N
rate NN N
did VBD N
not RB N
differ VB N
based VBN N
on IN N
scent NN N
exposure NN N
, , N
but CC N
mood VBD N
ratings NNS N
differed VBN N
by IN N
scent JJ N
condition NN N
. . N

Participants NNS N
in IN N
the DT N
rosemary JJ N
condition NN N
scored VBD N
higher JJR N
on IN N
measures NNS N
of IN N
tension-anxiety NN N
and CC N
confusion-bewilderment JJ N
relative NN N
to TO N
the DT N
lavender NN N
and CC N
control NN N
conditions NNS N
. . N

The DT N
lavender NN N
and CC N
control NN N
conditions NNS N
showed VBD N
higher JJR N
mean JJ N
vigor-activity NN N
ratings NNS N
relative VBP N
to TO N
the DT N
rosemary JJ N
group NN N
, , N
while IN N
both DT N
rosemary JJ N
and CC N
lavender JJ N
scents NNS N
were VBD N
associated VBN N
with IN N
lower JJR N
mean NN N
ratings NNS N
on IN N
the DT N
fatigue-inertia JJ N
subscale NN N
, , N
relative JJ N
to TO N
the DT N
control NN N
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
, , N
when WRB N
individual JJ N
perception NN N
of IN N
scent JJ N
pleasantness NN N
is VBZ N
controlled VBN N
, , N
scent NN N
has VBZ N
the DT N
potential JJ N
to TO N
moderate VB N
different JJ N
aspects NNS N
of IN N
mood NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

-DOCSTART- -X- O O

Early RB N
clinical JJ N
outcomes NNS N
and CC N
toxicity NN N
of IN N
intensity NN N
modulated VBN N
versus IN N
conventional JJ N
pelvic JJ N
radiation NN N
therapy NN N
for IN N
locally RB N
advanced JJ N
cervix NN N
carcinoma NN N
: : N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
toxicity NN N
and CC N
clinical JJ N
outcome NN N
in IN N
patients NNS N
with IN N
locally RB N
advanced JJ N
cervical JJ N
cancer NN N
( ( N
LACC NNP N
) ) N
treated VBD N
with IN N
whole JJ 3_i
pelvic JJ 3_i
conventional JJ 3_i
radiation NN 3_i
therapy NN 3_i
( ( N
WP-CRT NNP N
) ) N
versus NN N
intensity NN 3_i
modulated VBN 3_i
radiation NN 3_i
therapy NN 3_i
( ( N
WP-IMRT NNP N
) ) N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP N
January NNP N
2010 CD N
and CC N
January NNP N
2012 CD N
, , N
44 CD N
patients NNS N
with IN N
International NNP N
Federation NNP N
of IN N
Gynecology NNP N
and CC N
Obstetrics NNP N
( ( N
FIGO NNP N
2009 CD N
) ) N
stage NN N
IIB-IIIB NNP N
squamous JJ N
cell NN N
carcinoma NN N
of IN N
the DT N
cervix NN N
were VBD N
randomized VBN N
to TO N
receive VB N
50.4 CD N
Gy NNP N
in IN N
28 CD N
fractions NNS N
delivered VBN N
via IN N
either DT N
WP-CRT JJ 2_i
or CC N
WP-IMRT JJ 2_i
with IN N
concurrent JJ N
weekly JJ N
cisplatin NN N
40 CD N
mg/m NN N
( ( N
2 CD N
) ) N
. . N

Acute NNP N
toxicity NN N
was VBD N
graded VBN N
according VBG N
to TO N
the DT N
Common NNP N
Terminology NNP N
Criteria NNP N
for IN N
Adverse NNP N
Events NNP N
, , N
version NN N
3.0 CD N
, , N
and CC N
late JJ N
toxicity NN N
was VBD N
graded VBN N
according VBG N
to TO N
the DT N
Radiation NNP N
Therapy NNP N
Oncology NNP N
Group NNP N
system NN N
. . N

The DT N
primary JJ N
and CC N
secondary JJ N
endpoints NNS N
were VBD N
acute JJ N
gastrointestinal JJ N
toxicity NN N
and CC N
disease-free JJ N
survival NN N
, , N
respectively RB N
. . N

RESULTS NNP N
Of IN N
44 CD N
patients NNS N
, , N
22 CD N
patients NNS N
received VBD N
WP-CRT NNP 3_i
and CC N
22 CD N
received VBD N
WP-IMRT NNP 3_i
. . N

In IN N
the DT N
WP-CRT JJ 3_i
arm NN N
, , N
13 CD N
patients NNS N
had VBD N
stage NN N
IIB NNP N
disease NN N
and CC N
9 CD N
had VBD N
stage NN N
IIIB NNP N
disease NN N
; : N
in IN N
the DT N
IMRT NNP 3_i
arm NN N
, , N
12 CD N
patients NNS N
had VBD N
stage NN N
IIB NNP N
disease NN N
and CC N
10 CD N
had VBD N
stage NN N
IIIB NNP N
disease NN N
. . N

The DT N
median JJ N
follow-up JJ N
time NN N
in IN N
the DT N
WP-CRT JJ N
arm NN N
was VBD N
21.7 CD N
months NNS N
( ( N
range NN N
, , N
10.7-37.4 JJ N
months NNS N
) ) N
, , N
and CC N
in IN N
the DT N
WP-IMRT JJ N
arm NN N
it PRP N
was VBD N
21.6 CD N
months NNS N
( ( N
range NN N
, , N
7.7-34.4 JJ N
months NNS N
) ) N
. . N

At IN N
27 CD N
months NNS N
, , N
disease-free JJ N
survival NN N
was VBD N
79.4 CD N
% NN N
in IN N
the DT N
WP-CRT NNP 3_i
group NN N
versus VBD N
60 CD N
% NN N
in IN N
the DT N
WP-IMRT NNP 3_i
group NN N
( ( N
P=.651 NNP N
) ) N
, , N
and CC N
overall JJ N
survival NN N
was VBD N
76 CD N
% NN N
in IN N
the DT N
WP-CRT NNP N
group NN N
versus VBD N
85.7 CD N
% NN N
in IN N
the DT N
WP-IMRT NNP N
group NN N
( ( N
P=.645 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
WP-IMRT JJ N
arm NN N
experienced VBD N
significantly RB N
fewer JJR N
grade NN N
?2 NNP N
acute VBZ N
gastrointestinal JJ N
toxicities NNS N
( ( N
31.8 CD N
% NN N
vs JJ N
63.6 CD N
% NN N
, , N
P=.034 NNP N
) ) N
and CC N
grade JJ N
?3 NNP N
gastrointestinal JJ N
toxicities NNS N
( ( N
4.5 CD N
% NN N
vs JJ N
27.3 CD N
% NN N
, , N
P=.047 NNP N
) ) N
than IN N
did VBD N
patients NNS N
receiving VBG N
WP-CRT NNP N
and CC N
had VBD N
less JJR N
chronic JJ N
gastrointestinal JJ N
toxicity NN N
( ( N
13.6 CD N
% NN N
vs JJ N
50 CD N
% NN N
, , N
P=.011 NNP N
) ) N
. . N

CONCLUSION NNP N
WP-IMRT NNP N
is VBZ N
associated VBN N
with IN N
significantly RB N
less JJR N
toxicity NN N
compared VBN N
with IN N
WP-CRT NNP N
and CC N
has VBZ N
a DT N
comparable JJ N
clinical JJ N
outcome NN N
. . N

Further JJ N
studies NNS N
with IN N
larger JJR N
sample NN N
sizes NNS N
and CC N
longer JJR N
follow-up JJ N
times NNS N
are VBP N
warranted VBN N
to TO N
justify VB N
its PRP$ N
use NN N
in IN N
routine JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

Exploring VBG N
effects NNS N
of IN N
different JJ N
treadmill NN 2_i
interventions NNS 2_i
on IN N
walking VBG N
onset NN N
and CC N
gait NN N
patterns NNS N
in IN N
infants NNS N
with IN N
Down NNP N
syndrome NN N
. . N

Two CD N
cohorts NNS N
of IN N
participants NNS N
were VBD N
included VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
different JJ N
treadmill NN 2_i
interventions NNS 2_i
on IN N
walking VBG N
onset NN N
and CC N
gait NN N
patterns NNS N
in IN N
infants NNS N
with IN N
Down NNP N
syndrome NN N
( ( N
DS NNP N
) ) N
. . N

The DT N
first JJ N
cohort NN N
included VBD N
30 CD N
infants NNS N
with IN N
DS NNP N
( ( N
17 CD N
males NNS N
, , N
13 CD N
females NNS N
; : N
mean JJ N
age NN N
10 CD N
mo NN N
[ NNP N
SD NNP N
1.9 CD N
mo NN N
] NN N
) ) N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
lower-intensity-generalized JJ 2_i
( ( 2_i
LG NNP 2_i
) ) 2_i
training VBG 2_i
group NN 2_i
, , N
or CC N
a DT N
higher-intensity-individualized JJ 2_i
( ( 2_i
HI NNP 2_i
) ) 2_i
training VBG 2_i
group NN 2_i
. . N

A DT N
control NN 7_i
( ( 7_i
C NNP 7_i
) ) 7_i
group NN N
from IN N
another DT N
study NN N
, , N
who WP N
did VBD N
not RB 2_i
receive VB 2_i
treadmill NN 2_i
training NN 2_i
, , N
served VBD N
as IN N
the DT N
control NN N
( ( N
eight CD N
males NNS N
, , N
seven CD N
females NNS N
; : N
mean JJ N
age NN N
10.4 CD N
mo NN N
[ NNP N
SD NNP N
2.2 CD N
mo NN N
] NN N
) ) N
. . N

Mean JJ N
age NN N
at IN N
walking VBG N
onset NN N
was VBD N
19.2 CD N
, , N
21.4 CD N
, , N
and CC N
23.9 CD N
months NNS N
for IN N
the DT N
HI NNP N
, , N
LG NNP N
, , N
and CC N
C NNP N
groups NNS N
respectively RB N
. . N

At IN N
walking VBG N
onset RP N
the DT N
HI NNP N
group NN N
was VBD N
significantly RB N
younger JJR N
than IN N
the DT N
C NNP N
group NN N
( ( N
p=0.011 NN N
) ) N
. . N

At IN N
the DT N
gait NN N
follow-up NN N
that WDT N
was VBD N
conducted VBN N
between IN N
1 CD N
and CC N
3 CD N
months NNS N
after IN N
walking VBG N
onset NN N
, , N
three CD N
groups NNS N
significantly RB N
different JJ N
in IN N
overall JJ N
gait NN N
patterns NNS N
( ( N
p=0.037 NN N
) ) N
were VBD N
examined VBN N
by IN N
six CD N
basic JJ N
gait NN N
parameters NNS N
including VBG N
average JJ N
velocity NN N
, , N
stride JJ N
length NN N
, , N
step NN N
width NN N
, , N
stride JJ N
time NN N
, , N
stance NN N
time NN N
, , N
and CC N
dynamic JJ N
base NN N
. . N

Post-hoc JJ N
analyses NNS N
demonstrated VBD N
that IN N
stride JJ N
length NN N
was VBD N
the DT N
gait NN N
parameter NN N
largely RB N
contributing VBG N
to TO N
this DT N
overall JJ N
group NN N
difference NN N
( ( N
p=0.033 NN N
) ) N
, , N
and CC N
the DT N
HI NNP N
group NN N
produced VBD N
a DT N
significantly RB N
longer RBR N
stride JJ N
length NN N
than IN N
the DT N
C NNP N
group NN N
( ( N
p=0.030 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
HI NNP N
treadmill NN N
intervention NN N
significantly RB N
promoted VBN N
earlier RBR N
walking JJ N
onset NN N
and CC N
elicited VBD N
more RBR N
advanced JJ N
gait NN N
patterns NNS N
( ( N
particularly RB N
in IN N
stride JJ N
length NN N
) ) N
in IN N
infants NNS N
with IN N
DS NNP N
. . N

-DOCSTART- -X- O O

Caries NNS N
preventive JJ N
effects NNS N
of IN N
toothpastes NNS N
containing VBG N
monofluorophosphate NN 3_i
and CC N
trimetaphosphate NN 3_i
: : N
a DT N
3-year JJ N
clinical JJ N
trial NN N
. . N

The DT N
caries-preventive JJ N
effects NNS N
of IN N
two CD N
toothpastes NNS N
were VBD N
tested VBN N
in IN N
a DT N
3-year JJ N
clinical JJ N
trial NN N
involving VBG N
1319 CD N
children NNS N
aged VBN N
11-13 CD N
years NNS N
. . N

The DT N
test NN N
toothpastes NNS N
were VBD N
: : N
1 CD N
) ) N
a DT 3_i
low JJ 3_i
abrasion NN 3_i
paste NN 3_i
containing VBG 3_i
0.8 CD 3_i
% NN 3_i
sodium NN 3_i
monofluorophosphate NN 3_i
( ( 3_i
MFP NNP 3_i
) ) 3_i
, , N
and CC N
2 CD N
) ) N
a DT 3_i
paste NN 3_i
containing VBG 3_i
3 CD 3_i
% NN 3_i
sodium NN 3_i
trimetaphosphate NN 3_i
( ( 3_i
TMP NNP 3_i
) ) 3_i
. . N

The DT N
control NN N
toothpaste NN N
was VBD N
a DT N
conventional JJ 3_i
, , 3_i
moderately RB 3_i
abrasive JJ 3_i
paste NN 3_i
containing VBG 3_i
0.8 CD 3_i
% NN 3_i
sodium NN 3_i
monofluorophosphate NN 3_i
. . N

The DT N
children NNS N
were VBD N
examined VBN N
clinically RB N
and CC N
radiologically RB N
each DT N
year NN N
. . N

Toothpaste NN N
was VBD N
supplied VBN N
to TO N
the DT N
children NNS N
's POS N
homes NNS N
, , N
and CC N
its PRP$ N
use NN N
was VBD N
unsupervised JJ N
. . N

Caries NNS N
increments NNS N
after IN N
3 CD N
years NNS N
, , N
in IN N
terms NNS N
of IN N
DMF NNP N
teeth NNS N
and CC N
DMF NNP N
surfaces NNS N
, , N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
MFP NNP 3_i
test NN 3_i
group NN N
( ( N
444 CD N
children NNS N
) ) N
and CC N
the DT N
MFP NNP 7_i
control NN 7_i
group NN N
( ( N
450 CD N
children NNS N
) ) N
. . N

However RB N
, , N
the DT N
TMP NNP 3_i
test NN N
group NN N
( ( N
425 CD N
children NNS N
) ) N
had VBD N
significantly RB N
higher JJR N
caries NNS N
increments NNS N
than IN N
the DT N
MFP NNP 7_i
control NN 7_i
group NN N
. . N

All DT N
three CD N
groups NNS N
of IN N
children NNS N
showed VBD N
some DT N
improvement NN N
in IN N
oral JJ N
hygiene NN N
and CC N
in IN N
gingival JJ N
health NN N
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

-DOCSTART- -X- O O

Transitions NNS N
during IN N
effective JJ N
treatment NN N
for IN N
cocaine-abusing JJ N
homeless JJ N
persons NNS N
: : N
establishing VBG N
abstinence NN N
, , N
lapse NN N
, , N
and CC N
relapse NN N
, , N
and CC N
reestablishing VBG N
abstinence NN N
. . N

Data NNS N
are VBP N
reported VBN N
on IN N
drug NN N
use NN N
among IN N
cocaine-dependent JJ N
homeless NN N
persons NNS N
who WP N
participated VBD N
in IN N
a DT N
clinical JJ N
trial NN N
that WDT N
compared VBN N
day NN 7_i
treatment NN 7_i
only RB 7_i
( ( N
DT NNP N
, , N
n JJ N
= NNP N
69 CD N
) ) N
with IN N
day NN 7_i
treatment NN 7_i
plus CC N
abstinent-contingent JJ 7_i
housing NN 7_i
and CC 7_i
work NN 7_i
( ( N
DT+ NNP N
, , N
n JJ N
= NNP N
72 CD N
) ) N
. . N

Drug NNP N
use NN N
was VBD N
measured VBN N
with IN N
multiple JJ N
weekly JJ N
urine NN N
toxicologies NNS N
. . N

Compared VBN N
with IN N
DT NNP N
participants NNS N
, , N
more JJR N
DT+ JJ N
participants NNS N
established VBN N
abstinence NN 4_i
, , N
maintained VBD N
abstinence NN N
for IN N
longer JJR N
durations NNS N
, , N
were VBD N
marginally RB N
significantly RB N
more RBR N
likely JJ N
to TO N
lapse VB N
, , N
and CC N
significantly RB N
less RBR N
likely JJ N
to TO N
relapse VB N
. . N

Of IN N
all DT N
participants NNS N
who WP N
established VBD N
abstinence NN N
and CC N
then RB N
relapsed VBD N
, , N
DT+ NNP N
participants NNS N
relapsed VBD N
later RB N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
reestablish VB N
abstinence NN N
. . N

These DT N
analyses NNS N
yield VBP N
information NN N
on IN N
the DT N
processes NNS N
involved VBN N
in IN N
the DT N
manner NN N
in IN N
which WDT N
drug NN N
use NN N
changes NNS N
as IN N
a DT N
result NN N
of IN N
abstinent-contingent JJ 4_i
housing NN 4_i
and CC 4_i
work NN 4_i
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
rectal JJ 2_i
distension NN 2_i
on IN N
bladder NN N
function NN N
in IN N
patients NNS N
with IN N
overactive JJ N
bladder NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
rectal JJ 2_i
distension NN 2_i
on IN N
bladder NN N
sensation NN N
volumes NNS N
and CC N
the DT N
number NN N
of IN N
detrusor NN N
contractions NNS N
in IN N
patients NNS N
with IN N
overactive JJ N
bladder NN N
( ( N
OAB NNP N
) ) N
symptoms NNS N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
study NN N
included VBD N
patients NNS N
with IN N
OAB NNP N
symptoms NNS N
. . N

Multichannel NNP N
urodynamic JJ N
studies NNS N
were VBD N
completed VBN N
with IN 2_i
and CC 2_i
without IN 2_i
rectal JJ 2_i
balloon NN 2_i
distension NN 2_i
. . 2_i

Bladder NNP N
sensation NN N
volumes NNS N
and CC N
detrusor NN N
contractions NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Twenty-six JJ N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

The DT N
mean JJ N
age NN N
was VBD N
67 CD N
years NNS N
and CC N
mean JJ N
BMI NNP N
was VBD N
28.3 CD N
kg/m NN N
( ( N
2 CD N
) ) N
. . N

Bladder NNP N
sensation NN N
volumes NNS N
were VBD N
lower JJR N
with IN N
rectal JJ N
distention NN N
as IN N
follows VBZ N
: : N
normal JJ N
desire NN N
to TO N
void VB N
( ( N
139 CD N
ml NN N
SD NNP N
, , N
?114 NNP N
vs. FW N
197 CD N
ml NN N
SD NNP N
?150 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
strong JJ N
desire NN N
to TO N
void VB N
( ( N
260 CD N
ml NN N
SD NNP N
?171 NNP N
vs. IN N
330 CD N
ml NNS N
SD NNP N
?172 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
maximum JJ N
cystometric JJ N
capacity NN N
( ( N
326 CD N
ml NN N
SD NNP N
?183 NNP N
vs. IN N
403 CD N
ml NNS N
SD NNP N
?180 NNP N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
detrusor JJ N
contractions NNS N
or CC N
the DT N
bladder NN N
volume NN N
at IN N
which WDT N
the DT N
first JJ N
detrusor NN N
contraction NN N
had VBD N
occurred VBN N
with IN N
and CC N
without IN N
rectal JJ N
distension NN N
. . N

CONCLUSION NNP N
Rectal NNP N
distention NN N
in IN N
patients NNS N
with IN N
OAB NNP N
symptoms NNS N
significantly RB N
lowered VBD N
bladder JJR N
sensation NN N
volumes NNS N
( ( N
normal JJ N
desire NN N
, , N
strong JJ N
desire NN N
, , N
and CC N
maximal JJ N
capacity NN N
) ) N
. . N

-DOCSTART- -X- O O

Combination NNP N
hydrocodone NN 3_i
and CC 3_i
ibuprofen JJ 3_i
versus NN N
combination NN N
codeine NN 3_i
and CC 3_i
acetaminophen NN 3_i
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
pain NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
combination NN N
hydrocodone NN 3_i
7.5 CD N
mg NN N
and CC N
ibuprofen $ 3_i
200 CD N
mg NN N
with IN N
that DT N
of IN N
combination NN N
codeine NN 3_i
30 CD N
mg NN N
and CC N
acetaminophen $ 3_i
300 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
pain NN N
. . N

BACKGROUND NNP N
Hydrocodone NNP 3_i
7.5 CD N
mg NN N
with IN N
ibuprofen JJ 3_i
200 CD N
mg NN N
is VBZ N
the DT N
only JJ N
approved VBD N
fixed-dose JJ N
combination NN N
analgesic IN N
containing VBG N
an DT N
opioid NN N
and CC N
ibuprofen NN N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
repeated-dose JJ N
, , N
active-comparator JJ N
, , N
4-week JJ N
, , N
multicenter NN N
study NN N
, , N
469 CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
1-tablet JJ N
( ( N
n JJ N
= NNP N
156 CD N
) ) N
or CC N
2-tablet JJ N
( ( N
n JJ N
= NNP N
153 CD N
) ) N
dose NN N
of IN N
combination NN 3_i
hydrocodone NN 3_i
7.5 CD 3_i
mg NN 3_i
and CC 3_i
ibuprofen $ 3_i
200 CD 3_i
mg NN 3_i
( ( N
HI1 NNP N
and CC N
HI2 NNP N
, , N
respectively RB N
) ) N
or CC N
a DT N
2-tablet JJ N
dose NN N
of IN N
combination NN N
codeine NN 3_i
30 CD 3_i
mg NN 3_i
and CC 3_i
acetaminophen $ 3_i
300 CD 3_i
mg NN 3_i
( ( N
CA NNP N
, , N
n RB N
= VBZ N
160 CD N
) ) N
, , N
the DT N
active JJ N
comparator NN N
, , N
every DT N
6 CD N
to TO N
8 CD N
hours NNS N
as IN N
needed VBN N
for IN N
pain NN N
. . N

Efficacy NN N
was VBD N
measured VBN N
through IN N
pain NN N
relief NN N
scores NNS N
, , N
number NN N
of IN N
daily JJ N
doses NNS N
of IN N
study NN N
medication NN N
, , N
number NN N
of IN N
daily JJ N
doses NNS N
of IN N
supplemental JJ N
analgesics NNS N
, , N
number NN N
of IN N
patients NNS N
who WP N
discontinued VBD N
therapy NN N
due JJ N
to TO N
an DT N
unsatisfactory JJ N
analgesic JJ N
response NN N
, , N
and CC N
global JJ N
assessment NN N
scores NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
469 CD N
patients NNS N
, , N
255 CD N
( ( N
54.4 CD N
% NN N
) ) N
were VBD N
female JJ N
and CC N
214 CD N
( ( N
45.6 CD N
% NN N
) ) N
were VBD N
male JJ N
. . N

The DT N
mean JJ N
age NN N
was VBD N
51.1 CD N
years NNS N
. . N

Types NNS N
of IN N
chronic NN N
pain NN N
included VBD N
back RB N
( ( N
214 CD N
; : N
45.6 CD N
% NN N
) ) N
, , N
arthritic JJ N
( ( N
145 CD N
; : N
30.9 CD N
% NN N
) ) N
, , N
other JJ N
musculoskeletal NN N
( ( N
65 CD N
; : N
13.9 CD N
% NN N
) ) N
, , N
cancer NN N
( ( N
6 CD N
; : N
1.3 CD N
% NN N
) ) N
, , N
diabetic JJ N
neuropathic NN N
( ( N
3 CD N
; : N
0.6 CD N
% NN N
) ) N
, , N
postherpetic JJ N
neuralgic NN N
( ( N
5 CD N
; : N
1.1 CD N
% NN N
) ) N
, , N
other JJ N
neurologic NN N
( ( N
21 CD N
; : N
4.5 CD N
% NN N
) ) N
, , N
and CC N
other JJ N
unclassified JJ N
chronic JJ N
pain NN N
( ( N
10 CD N
; : N
2.1 CD N
% NN N
) ) N
. . N

During IN N
the DT N
48 CD N
hours NNS N
prior RB N
to TO N
the DT N
study NN N
, , N
351 CD N
( ( N
74.8 CD N
% NN N
) ) N
patients NNS N
had VBD N
been VBN N
treated VBN N
with IN N
opioid JJ N
or CC N
opioid-nonopioid JJ N
combination NN N
analgesics NNS N
. . N

The DT N
overall JJ N
mean JJ N
daily JJ N
pain NN N
relief NN N
score NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2.25+/-0.89 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
1.98+/-0.87 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
or CC N
the DT N
CA NNP N
group NN N
( ( N
1.85+/-0.96 JJ N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
overall JJ N
mean JJ N
number NN N
of IN N
daily JJ N
doses NNS N
of IN N
study NN N
medication NN N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2.94+/-0.99 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
3.23+/-0.76 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
or CC N
the DT N
CA NNP N
group NN N
( ( N
3.26+/-0.75 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

The DT N
overall JJ N
mean JJ N
number NN N
of IN N
daily JJ N
doses NNS N
of IN N
supplemental JJ N
analgesics NNS N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
0.24+/-0.49 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
0.34+/-0.58 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.021 CD N
) ) N
or CC N
CA NNP N
group NN N
( ( N
0.49+/-0.85 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

The DT N
number NN N
of IN N
patients NNS N
who WP N
discontinued VBD N
treatment NN N
due JJ N
to TO N
an DT N
unsatisfactory JJ N
analgesic JJ N
response NN N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2 CD N
; : N
1.3 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
CA NNP N
group NN N
( ( N
12 CD N
; : N
7.5 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

HI2 NNP N
was VBD N
more RBR N
effective JJ N
than IN N
HI1 NNP N
and CC N
CA NNP N
as IN N
measured VBN N
by IN N
pain NN N
relief NN N
scores NNS N
for IN N
week NN N
1 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
and CC N
week NN N
3 CD N
( ( N
P NNP N
= VBZ N
0.008 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ N
doses NNS N
of IN N
study NN N
medication NN N
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.019 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.011 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ N
doses NNS N
of IN N
supplemental JJ N
analgesics NNS N
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.010 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
; : N
and CC N
global JJ N
assessment NN N
scores NNS N
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.018 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
= VBZ N
0.005 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
and CC N
week NN N
4 CD N
( ( N
P NNP N
= VBZ N
0.013 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.023 CD N
vs NN N
CA NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
HI1 NNP N
and CC N
CA NNP N
in IN N
any DT N
efficacy NN N
variable JJ N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN N
of IN N
patients NNS N
experiencing VBG N
adverse JJ N
events NNS N
in IN N
the DT N
HI2 NNP N
( ( N
127 CD N
; : N
83 CD N
% NN N
) ) N
, , N
HI1 NNP N
( ( N
124 CD N
; : N
79.5 CD N
% NN N
) ) N
, , N
and CC N
CA NNP N
( ( N
129 CD N
; : N
80.6 CD N
% NN N
) ) N
groups NNS N
. . N

However RB N
, , N
the DT N
mean JJ N
number NN N
of IN N
patients NNS N
who WP N
discontinued VBD N
treatment NN N
due JJ N
to TO N
adverse JJ N
events NNS N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
40 CD N
; : N
26.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
23 CD N
; : N
14.7 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
hydrocodone NN 3_i
7.5 CD N
mg NN N
and CC N
ibuprofen $ 3_i
200 CD N
mg NN N
may MD N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
1-tablet JJ N
doses NNS N
of IN N
this DT N
combination NN N
or CC N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN 3_i
30 CD N
mg NN N
and CC N
acetaminophen $ 3_i
300 CD N
mg NN N
. . N

Moreover RB N
, , N
1-tablet JJ N
doses NNS N
of IN N
combination NN 3_i
hydrocodone NN 3_i
7.5 CD 3_i
mg NN 3_i
and CC 3_i
ibuprofen $ 3_i
200 CD N
mg NN N
may MD N
be VB N
as RB N
effective JJ N
as IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN 3_i
30 CD N
mg NN N
and CC N
acetaminophen $ 3_i
300 CD N
mg NN N
. . N

-DOCSTART- -X- O O

Registration NNP N
accuracy NN N
of IN N
153Gd CD N
transmission NN N
images NNS N
of IN N
the DT N
brain NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
accuracy NN N
of IN N
non-rigid JJ N
nine-parameter JJ N
image NN N
registrations NNS N
based VBN N
on IN N
153Gd CD 2_i
transmission NN 2_i
computed VBN 2_i
tomography NN 2_i
( ( N
TCT NNP N
) ) N
images VBZ N
as IN N
compared VBN N
with IN N
those DT N
based VBN N
on IN N
99mTc-ethyl JJ 2_i
cysteinate NN 2_i
dimer NN 2_i
( ( 2_i
ECD NNP 2_i
) ) 2_i
images NNS 2_i
and CC N
to TO N
assess VB N
whether IN N
normalised JJ N
mutual JJ N
information NN N
( ( N
NMI NNP N
) ) N
or CC N
count NN N
difference NN N
( ( N
CD NN N
) ) N
should MD N
be VB N
used VBN N
. . N

METHODS NNP N
TCT NNP N
and CC N
ECD NNP N
data NNS N
were VBD N
acquired VBN N
in IN N
25 CD N
randomly RB N
selected VBN N
patients NNS N
. . N

Emission NN N
images NNS N
were VBD N
registered VBN N
to TO N
an DT N
ECD NNP 2_i
template NN N
with IN N
a DT N
CD NN N
cost NN N
function NN N
. . N

The DT N
same JJ N
registration NN N
parameters NNS N
were VBD N
applied VBN N
to TO N
the DT N
transmission NN N
images VBZ N
to TO N
create VB N
a DT N
TCT NNP N
template NN N
. . N

All DT N
TCT NNP N
images NNS N
were VBD N
registered VBN N
to TO N
the DT N
TCT NNP 2_i
template NN N
and CC N
the DT N
same JJ N
registration NN N
parameters NNS N
were VBD N
applied VBN N
to TO N
the DT N
ECD NNP 2_i
images NNS N
. . N

The DT N
procedure NN N
was VBD N
repeated VBN N
with IN N
NMI NNP N
as IN N
cost NN N
function NN N
. . N

Accuracy NN N
of IN N
both DT N
ECD-based JJ 2_i
and CC N
TCT-based JJ 2_i
registrations NNS N
was VBD N
assessed VBN N
by IN N
comparing VBG N
the DT N
normalisation NN N
parameter NN N
values NNS N
and CC N
regional JJ N
activities NNS N
in IN N
the DT N
spatially RB N
normalised JJ N
ECD NNP N
images NNS N
, , N
using VBG N
a DT N
mixed-model JJ N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
. . N

Scheffe NNP N
post NN N
hoc NN N
tests NNS N
were VBD N
performed VBN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
ECD/CD NNP 2_i
, , N
ECD/NMI NNP 2_i
and CC N
TCT/CD NNP 2_i
, , N
suggesting VBG N
that IN N
ECD NNP N
registration NN N
can MD N
be VB N
done VBN N
with IN N
either DT N
CD NN N
or CC N
NMI NNP N
, , N
and CC N
that IN N
TCT NNP N
registration NN N
using VBG N
CD NN N
is VBZ N
equally RB N
as RB N
accurate JJ N
as IN N
ECD NNP N
registration NN N
. . N

The DT N
accuracy NN N
of IN N
TCT NNP N
registration NN N
with IN N
NMI NNP N
was VBD N
lower JJR N
, , N
with IN N
discrepancies NNS N
occurring VBG N
in IN N
the DT N
frontal JJ N
inferior JJ N
region NN N
and CC N
the DT N
cerebellum NN N
. . N

The DT N
analysis NN N
of IN N
normalisation NN N
parameters NNS N
indicated VBD N
that IN N
z-scaling NN N
is VBZ N
underestimated JJ N
and CC N
yz-rotation NN N
overestimated VBN N
with IN N
TCT/NMI NNP N
registration NN N
. . N

CONCLUSION NNP N
We PRP N
conclude VBP N
that IN N
ECD NNP 2_i
registrations NNS N
with IN N
CD NN 2_i
or CC N
NMI NNP 2_i
are VBP N
as RB N
accurate JJ N
as IN N
TCT NNP 2_i
registrations NNS N
with IN N
CD NN N
and CC N
that DT N
TCT NNP 2_i
registrations NNS N
with IN N
NMI NNP N
should MD N
be VB N
avoided VBN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
the DT N
ophthalmic JJ 2_i
insert NN 2_i
Mydriasert NNP 2_i
in IN N
patients NNS N
undergoing JJ N
retinal JJ N
angiography NN N
. . N

PURPOSE NNP N
To TO N
verify VB N
the DT N
efficacy NN N
to TO N
obtain VB N
mydriasis NN N
and CC N
cardiovascular JJ N
safety NN N
of IN N
Mydriasert NNP N
( ( N
ophthalmic JJ N
insert NN N
containing VBG N
tropicamide NN N
and CC N
phenylephrine NN N
) ) N
in IN N
diabetic JJ N
and CC N
nondiabetic JJ N
patients NNS N
undergoing VBG N
retinal JJ N
angiography NN N
by IN N
comparing VBG N
it PRP N
with IN N
usually RB N
administered VBN N
eyedrops NNS N
( ( 3_i
tropicamide VB 3_i
1 CD 3_i
% NN 3_i
and CC 3_i
phenylephrine VB 3_i
10 CD 3_i
% NN 3_i
) ) 3_i
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

A DT N
total NN N
of IN N
154 CD N
eyes NNS N
of IN N
77 CD N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
2 CD N
groups NNS N
: : N
group NN N
1 CD N
consisted VBD N
of IN N
78 CD N
eyes NNS N
, , N
group NN N
2 CD N
consisted VBD N
of IN N
76 CD N
eyes NNS N
, , N
and CC N
the DT N
patients NNS N
were VBD N
monitored VBN N
for IN N
pupillary JJ N
dilation NN N
, , N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
and CC N
possible JJ N
adverse JJ N
effects NNS N
at IN N
0 CD N
, , N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
minutes NNS N
. . N

RESULTS NNP N
No NNP N
severe JJ N
adverse JJ N
effects NNS N
were VBD N
observed VBN N
in IN N
either DT N
group NN N
. . N

In IN N
the DT N
entire JJ N
sample NN N
studied VBD N
, , N
the DT N
mean JJ N
pupillary JJ N
diameter NN N
was VBD N
greater JJR N
in IN N
the DT N
eyedrops NNS N
group NN N
after IN N
20 CD N
and CC N
40 CD N
minutes NNS N
, , N
while IN N
mydriasis NN N
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
after IN N
60 CD N
minutes NNS N
. . N

The DT N
diabetic JJ N
patients NNS N
treated VBN N
with IN N
Mydriasert NNP 3_i
had VBD N
less JJR N
mydriasis NN N
than IN N
those DT N
treated VBN N
with IN N
eyedrops NNS N
after IN N
20 CD N
and CC N
40 CD N
minutes NNS N
, , N
and CC N
diabetic JJ N
patients NNS N
showed VBD N
less JJR N
mydriasis NN N
than IN N
the DT N
nondiabetic JJ N
patients NNS N
after IN N
60 CD N
and CC N
90 CD N
minutes NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
between-group JJ N
difference NN N
in IN N
mean JJ N
heart NN N
rate NN N
or CC N
systolic NN N
and CC N
diastolic JJ N
blood NN N
pressure NN N
at IN N
any DT N
of IN N
the DT N
time NN N
points NNS N
. . N

CONCLUSIONS NNP N
Mydriasert NNP 3_i
assures VBZ N
an DT N
adequate JJ N
degree NN N
of IN N
mydriasis NN N
for IN N
retinal JJ N
angiography NN N
in IN N
both DT N
diabetic JJ N
and CC N
nondiabetic JJ N
patients NNS N
. . N

There EX N
are VBP N
no DT N
differences NNS N
in IN N
efficacy NN N
or CC N
safety NN N
between IN N
the DT N
insert NN N
and CC N
the DT N
usually RB N
administered VBN N
eyedrops NNS N
, , N
but CC N
the DT N
low JJ N
total JJ N
drug NN N
dose NN N
administered VBN N
with IN N
the DT N
insert NN N
reduces VBZ N
the DT N
risk NN N
of IN N
cardiovascular JJ N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O

Fixed-dose JJ N
manidipine/delapril NN 3_i
versus NN N
losartan/hydrochlorothiazide NN 3_i
in IN N
hypertensive JJ N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
and CC N
microalbuminuria NNS N
. . N

INTRODUCTION NNP N
Patients NNPS N
with IN N
diabetes NNS N
complicated VBN N
by IN N
hypertension NN N
and CC N
microalbuminuria NNS N
have VBP N
elevated VBN N
cardiovascular JJ N
risk NN N
, , N
and CC N
controlling VBG N
blood NN N
pressure NN N
in IN N
these DT N
patients NNS N
is VBZ N
an DT N
urgent JJ N
clinical JJ N
priority NN N
. . N

The DT N
present JJ N
study NN N
aimed VBN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
a DT N
fixed-dose JJ N
combination NN N
of IN N
antihypertensives NNS N
on IN N
blood NN N
pressure NN N
and CC N
microalbuminuria NN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
type JJ N
2 CD N
diabetes NNS N
, , N
mild-to-moderate JJ N
hypertension NN N
( ( N
diastolic JJ N
blood NN N
pressure NN N
85-105 JJ N
mmHg NN N
, , N
systolic JJ N
blood NN N
pressure NN N
< VBZ N
160 CD N
mmHg NN N
, , N
and CC N
24-hour JJ N
mean JJ N
systolic JJ N
blood NN N
pressure NN N
> VBZ N
130 CD N
mmHg NN N
) ) N
, , N
and CC N
microalbuminuria NNS N
were VBD N
randomized VBN N
to TO N
1 CD N
year NN N
of IN N
doubleblind NN N
treatment NN N
with IN N
fixed-dose JJ 3_i
manidipine/delapril NN 3_i
( ( N
n=54 JJ N
) ) N
or CC N
losartan/hydrochlorothiazide JJ 3_i
( ( 3_i
HCTZ NNP 3_i
) ) 3_i
( ( N
n=56 JJ N
) ) N
. . N

RESULTS NNP N
Blood NNP N
pressure NN N
was VBD N
significantly RB N
reduced VBN N
at IN N
1 CD N
year NN N
in IN N
both DT N
groups NNS N
( ( N
-22.2/-14.6 JJ N
mmHg NN N
and CC N
-19.5/-14.3 NNP N
mmHg NN N
, , N
for IN N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
respectively RB N
, , N
P NNP N
< VBZ N
0.001 CD N
for IN N
each DT N
) ) N
, , N
with IN N
no DT N
significant JJ N
between-group JJ N
difference NN N
. . N

Reductions NNS N
in IN N
microalbuminuria NN N
occurred VBN N
in IN N
both DT N
groups NNS N
, , N
with IN N
mean JJ N
changes NNS N
at IN N
1 CD N
year NN N
of IN N
-3.9 NNP N
mg/mmol FW N
creatinine NN N
( ( N
95 CD N
% NN N
CI NNP N
-5.3 NNP N
, , N
-2.5 NNP N
) ) N
for IN N
manidipine/delapril NN 3_i
( ( N
P NNP N
< VBZ N
0.001 CD N
vs. FW N
baseline NN N
) ) N
and CC N
-2.7 $ N
mg/mmol FW N
creatinine NN N
( ( N
95 CD N
% NN N
CI NNP N
-4.0 NNP N
, , N
-1.3 NNP N
) ) N
for IN N
losartan/HCTZ NN 3_i
( ( N
P NNP N
< VBZ N
0.001 CD N
vs. NN N
baseline NN N
and CC N
P=0.199 NNP N
between IN N
groups NNS N
) ) N
. . N

Glycemia NNP N
over IN N
the DT N
1-year JJ N
study NN N
was VBD N
largely RB N
unaffected JJ N
; : N
the DT N
blood NN N
glucose JJ N
concentration NN N
was VBD N
reduced VBN N
from IN N
baseline NN N
with IN N
manidipine/delapril NN 3_i
, , N
although IN N
not RB N
statistically RB N
significant JJ N
( ( N
mean JJ N
change NN N
-0.2 NNP N
mmol/L NN N
, , N
P=0.064 NNP N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
, , N
with IN N
discontinuation NN N
for IN N
adverse JJ N
events NNS N
for IN N
one CD N
( ( N
1.9 CD N
% NN N
) ) N
patient NN N
in IN N
the DT N
manidipine/delapril NN 3_i
group NN N
and CC N
two CD N
( ( N
3.6 CD N
% NN N
) ) N
in IN N
the DT N
losartan/HCTZ NN 3_i
group NN N
. . N

CONCLUSIONS VB N
A DT N
fixed-dose JJ N
manidipine/delapril NN 3_i
combination NN N
represents VBZ N
a DT N
useful JJ N
addition NN N
to TO N
the DT N
treatment NN N
options NNS N
available JJ N
to TO N
control VB N
hypertension NN N
complicated VBN N
by IN N
diabetes NNS N
and CC N
microalbuminuria NNS N
. . N

-DOCSTART- -X- O O

Validation NN N
of IN N
an DT N
FFQ NNP N
for IN N
evaluation NN N
of IN N
EPA NNP N
and CC N
DHA NNP N
intake VBP N
. . N

OBJECTIVE NNP N
To TO N
validate VB N
an DT N
FFQ NNP N
for IN N
the DT N
assessment NN N
of IN N
dietary JJ N
EPA NNP 3_i
and CC N
DHA NNP 3_i
against IN N
their PRP$ N
relative JJ N
concentrations NNS N
in IN N
red JJ N
blood NN N
cells NNS N
( ( N
RBC NNP N
) ) N
. . N

DESIGN NNP N
Cross-sectional JJ N
analysis NN N
of IN N
baseline NN N
data NNS N
. . N

Intakes NNS N
of IN N
marine NN 2_i
food NN 2_i
products NNS 2_i
and CC N
EPA NNP 3_i
and CC N
DHA NNP 3_i
were VBD N
estimated VBN N
by IN N
FFQ NNP N
on IN N
the DT N
basis NN N
of IN N
consumption NN N
of IN N
marine NN 3_i
food NN 3_i
products NNS 3_i
in IN N
the DT N
last JJ N
month NN N
. . N

Fatty NNP N
acid JJ N
composition NN N
of IN N
RBC NNP N
membranes NNS N
was VBD N
quantified VBN N
by IN N
GC NNP N
. . N

SETTING NNP N
Saint-Fran?ois JJ N
d'Assise NN N
Hospital NNP N
, , N
Qu?bec NNP N
, , N
Canada NNP N
. . N

SUBJECTS NNP N
A NNP N
total NN N
of IN N
sixty-five JJ N
middle-aged JJ N
women NNS N
who WP N
participated VBD N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

RESULTS NNP N
Spearman NNP N
's POS N
correlation NN N
coefficient NN N
between IN N
intake NN N
of IN N
EPA NNP N
, , N
DHA NNP N
and CC N
EPA NNP N
+ NNP N
DHA NNP N
and CC N
their PRP$ N
corresponding JJ N
concentration NN N
in IN N
RBC NNP N
was VBD N
0.46 CD N
, , N
0.40 CD N
and CC N
0.42 CD N
, , N
respectively RB N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Multiple JJ N
regression NN N
analysis NN N
of IN N
EPA+DHA NNP N
intake NN N
and CC N
RBC NNP N
EPA NNP N
+ NNP N
DHA NNP N
concentration NN N
indicated VBD N
positive JJ N
and CC N
significant JJ N
correlations NNS N
for IN N
oily RB N
fish JJ N
( ( N
beta JJ N
= NN N
0.44 CD N
, , N
95 CD N
% NN N
CI NNP N
0.16 CD N
, , N
0.72 CD N
, , N
P NNP N
= NNP N
0.0027 CD N
) ) N
, , N
total JJ N
fish NN N
( ( N
beta JJ N
= NN N
0.42 CD N
, , N
95 CD N
% NN N
CI NNP N
0.19 CD N
, , N
0.64 CD N
, , N
P NNP N
= NNP N
0.0005 CD N
) ) N
and CC N
marine VB N
food NN N
products NNS N
( ( N
beta NN N
= RB N
0.42 CD N
, , N
95 CD N
% NN N
CI NNP N
0.20 CD N
, , N
0.64 CD N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

No UH N
other JJ N
marine VB N
food NN N
products NNS N
significantly RB N
predicted VBD N
RBC NNP N
EPA NNP N
+ NNP N
DHA NNP N
concentration NN N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
present JJ N
validation NN N
study NN N
was VBD N
undertaken VBN N
among IN N
middle-aged JJ N
women NNS N
with IN N
low JJ N
consumption NN N
of IN N
marine NN N
food NN N
products NNS N
( ( N
< $ N
3 CD N
servings/week NN N
) ) N
, , N
our PRP$ N
FFQ NNP N
provided VBD N
estimates NNS N
of IN N
EPA NNP N
and CC N
DHA NNP N
intakes NNS N
that WDT N
correlated VBD N
fairly RB N
well RB N
with IN N
their PRP$ N
RBC NNP N
concentrations NNS N
. . N

However RB N
, , N
the DT N
absence NN N
of IN N
correlations NNS N
between IN N
EPA NNP N
+ NNP N
DHA NNP N
intakes NNS N
from IN N
different JJ N
marine NN N
species NNS N
suggests VBZ N
that IN N
a DT N
minimum JJ N
EPA NNP N
+ NNP N
DHA NNP N
intake NN N
is VBZ N
necessary JJ N
to TO N
observe VB N
a DT N
relationship NN N
with IN N
RBC NNP N
EPA NNP N
+ NNP N
DHA NNP N
concentrations NNS N
. . N

-DOCSTART- -X- O O

Conscious JJ N
analgesia/sedation NN N
with IN N
remifentanil NN 3_i
and CC N
propofol NN 3_i
versus NN N
total JJ 3_i
intravenous JJ 3_i
anesthesia NN 3_i
with IN 3_i
fentanyl NN 3_i
, , 3_i
midazolam NN 3_i
, , 3_i
and CC 3_i
propofol NN 3_i
for IN N
outpatient JJ N
colonoscopy NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that WDT N
, , N
for IN N
colonoscopy NN N
, , N
analgesia/sedation NN N
with IN N
remifentanil NN 3_i
and CC N
propofol NN 3_i
might MD N
be VB N
more RBR N
effective JJ N
compared VBN N
with IN N
anesthesia NN N
by IN N
intravenous JJ N
administration NN N
of IN N
midazolam NN 3_i
, , 3_i
fentanyl NN 3_i
, , 3_i
and CC 3_i
propofol NN 3_i
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
100 CD N
adult NN N
patients NNS N
received VBD N
either RB N
conscious JJ N
analgesia/sedation NN 3_i
( ( 3_i
Sedation NNP 3_i
group NN 3_i
) ) 3_i
or CC N
total JJ 3_i
intravenous JJ 3_i
anesthesia NN 3_i
( ( 3_i
TIVA NNP 3_i
group NN 3_i
) ) 3_i
. . N

Analgesia/sedation NN 3_i
was VBD N
achieved VBN N
by IN N
infusion NN N
of IN N
remifentanil NN 3_i
( ( N
0.20 CD N
to TO N
0.25 CD N
microg/kg/min NN N
) ) N
and CC N
propofol NN 3_i
in IN N
titrated JJ N
doses NNS N
. . N

TIVA NNP N
was VBD N
induced VBN N
by IN N
intravenous JJ N
administration NN N
of IN N
fentanyl NN 3_i
( ( 3_i
2 CD 3_i
microg/kg NN 3_i
) ) 3_i
, , 3_i
midazolam FW 3_i
( ( 3_i
0.05 CD 3_i
mg/kg NN 3_i
) ) 3_i
and CC 3_i
propofol NN 3_i
( ( N
dosage NN N
titrated VBN N
) ) N
. . N

Cardiorespiratory JJ N
parameters NNS N
and CC N
bispectral JJ N
index NN N
were VBD N
monitored VBN N
and CC N
recorded VBN N
. . N

The DT N
quality NN N
of IN N
the DT N
analgesia NN N
was VBD N
assessed VBN N
with IN N
a DT N
Numerical JJ N
Pain NN N
Rating NNP N
Scale NNP N
( ( N
NRS NNP N
) ) N
; : N
recovery NN N
level NN N
and CC N
return NN N
of IN N
psychomotor NN N
efficiency NN N
were VBD N
evaluated VBN N
with IN N
, , N
respectively RB N
, , N
the DT N
Aldrete NNP N
scale NN N
and CC N
a DT N
Modified NNP N
Post NNP N
Anesthesia NNP N
Discharge NNP N
Scoring NNP N
( ( N
MPADS NNP N
) ) N
system NN N
. . N

RESULTS VB N
Both DT N
groups NNS N
of IN N
50 CD N
patients NNS N
were VBD N
comparable JJ N
with IN N
respect NN N
to TO N
demographic VB N
data NNS N
, , N
initial JJ N
parameters NNS N
, , N
and CC N
duration NN N
of IN N
colonoscopy NN N
. . N

All DT N
patients NNS N
in IN N
the DT N
TIVA NNP 3_i
group NN N
found VBD N
the DT N
colonoscopy NN N
painless NN N
( ( N
NRS NNP N
score RB N
0 CD N
) ) N
. . N

In IN N
the DT N
Sedation NNP N
group NN N
, , N
the DT N
average JJ N
pain NN N
intensity NN N
score NN N
was VBD N
0.4 CD N
( ( N
0.8 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
marked JJ N
difference NN N
between IN N
the DT N
Sedation NNP 3_i
and CC N
TIVA NNP 3_i
groups NNS N
with IN N
respect NN N
to TO N
the DT N
time NN N
from IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
until IN N
the DT N
maximum JJ N
MPADS NNP N
score NN N
was VBD N
reached VBN N
: : N
respectively RB N
, , N
-6.9 NNP N
( ( N
4.0 CD N
) ) N
versus NN N
25.7 CD N
( ( N
8.4 CD N
) ) N
minutes NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
the DT N
TIVA NNP 3_i
group NN N
, , N
changes NNS N
in IN N
mean JJ N
arterial JJ N
pressure NN N
and CC N
heart NN N
rate NN N
and CC N
signs NNS N
of IN N
respiratory NN N
depression NN N
were VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Combined NNP N
administration NN N
of IN N
remifentanil NN 3_i
and CC N
propofol NN 3_i
for IN N
colonoscopy NN N
provides VBZ N
sufficient JJ N
analgesia NN N
, , N
satisfactory JJ N
hemodynamic JJ N
stability NN N
, , N
minor JJ N
respiratory NN N
depression NN N
, , N
and CC N
rapid JJ N
recovery NN N
, , N
and CC N
allows VBZ N
patients NNS N
to TO N
be VB N
discharged VBN N
approximately RB N
15 CD N
minutes NNS N
after IN N
the DT N
procedure NN N
. . N

-DOCSTART- -X- O O

Intravenous JJ N
levosimendan NN 3_i
treatment NN N
is VBZ N
cost-effective JJ N
compared VBN N
with IN N
dobutamine NN 3_i
in IN N
severe JJ N
low-output JJ N
heart NN N
failure NN N
: : N
an DT N
analysis NN N
based VBN N
on IN N
the DT N
international JJ N
LIDO NNP N
trial NN N
. . N

BACKGROUND NNP N
Levosimendan NNP 3_i
, , N
a DT N
novel JJ N
calcium NN N
sensitiser NN N
, , N
improves VBZ N
cardiac JJ N
performance NN N
and CC N
symptoms NNS N
without IN N
increasing VBG N
oxygen NN N
consumption NN N
, , N
and CC N
decreases VBZ N
the DT N
mortality NN N
of IN N
patients NNS N
with IN N
low-output JJ N
heart NN N
failure NN N
. . N

AIMS NNP N
To TO N
estimate VB N
the DT N
cost-effectiveness NN N
of IN N
intravenous JJ N
treatment NN N
with IN N
levosimendan NNS 3_i
compared VBN N
with IN N
dobutamine NN 3_i
in IN N
patients NNS N
with IN N
severe JJ N
low-output JJ N
heart NN N
failure NN N
. . N

METHODS NNP N
This DT N
economic JJ N
evaluation NN N
was VBD N
based VBN N
on IN N
a DT N
European JJ N
clinical JJ N
trial NN N
( ( N
LIDO NNP N
) ) N
, , N
in IN N
which WDT N
203 CD N
patients NNS N
with IN N
severe JJ N
heart NN N
failure NN N
randomly RB N
received VBD N
a DT N
24 CD N
h NN N
infusion NN N
with IN N
either DT N
levosimendan NN 3_i
or CC N
dobutamine NN 3_i
. . N

Survival NNP N
and CC N
resource VB N
utilisation NN N
data NNS N
were VBD N
collected VBN N
for IN N
6 CD N
months NNS N
; : N
survival NN N
was VBD N
extrapolated VBN N
assuming VBG N
a DT N
mean JJ N
additional JJ N
lifetime NN N
of IN N
3 CD N
years NNS N
based VBN N
on IN N
data NNS N
from IN N
the DT N
Cooperative NNP N
North NNP N
Scandinavian JJ N
Enalapril NNP N
Survival NNP N
Study NNP N
trial NN N
. . N

Costs NNS N
were VBD N
based VBN N
on IN N
study JJ N
drug NN N
usage NN N
and CC N
hospitalisation NN N
in IN N
the DT N
6-month JJ N
follow-up NN N
. . N

A DT N
sensitivity NN N
analysis NN N
on IN N
dosage NN N
of IN N
drug NN N
and CC N
duration NN N
of IN N
survival NN N
was VBD N
performed VBN N
. . N

RESULTS VB N
The DT N
mean JJ N
survival NN N
over IN N
6 CD N
months NNS N
was VBD N
157+/-52 JJ N
days NNS N
in IN N
the DT N
levosimendan NN 3_i
group NN N
and CC N
139+/-64 JJ N
days NNS N
in IN N
the DT N
dobutamine NN 3_i
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

When WRB N
extrapolated VBD N
up RB N
to TO N
3 CD N
years NNS N
, , N
the DT N
gain NN N
in IN N
life NN N
expectancy NN N
was VBD N
estimated VBN N
at IN N
0.35 CD N
years NNS N
( ( N
discounted VBN N
at IN N
3 CD N
% NN N
) ) N
. . N

Levosimendan NNP 3_i
increased VBD N
the DT N
mean NN N
cost NN N
per IN N
patient NN N
by IN N
1108 CD N
, , N
which WDT N
was VBD N
entirely RB N
due JJ N
to TO N
the DT N
cost NN N
of IN N
the DT N
study NN N
drug NN N
. . N

The DT N
incremental JJ N
cost NN N
per IN N
life-year JJ N
saved NN N
( ( N
LYS NNP N
) ) N
was VBD N
3205 CD N
at IN N
the DT N
European NNP N
level NN N
; : N
in IN N
the DT N
individual JJ N
countries NNS N
the DT N
cost NN N
per IN N
LYS NNP N
ranged VBD N
between IN N
3091 CD N
and CC N
3331 CD N
. . N

The DT N
result NN N
was VBD N
robust JJ N
in IN N
the DT N
sensitivity NN N
analysis NN N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
patients NNS N
in IN N
the DT N
levosimendan NN N
group NN N
were VBD N
alive JJ N
for IN N
more JJR N
days NNS N
and CC N
thus RB N
at IN N
risk NN N
of IN N
hospitalisation NN N
for IN N
longer JJR N
, , N
there EX N
was VBD N
no DT N
increase NN N
in IN N
hospitalisation NN N
or CC N
hospitalisation NN N
costs NNS N
with IN N
levosimendan JJ 3_i
treatment NN N
. . N

The DT N
cost NN N
per IN N
LYS NNP N
using VBG N
levosimendan JJ 3_i
compares NNS N
favourably RB N
with IN N
other JJ N
cost-effectiveness JJ N
analyses NNS N
in IN N
cardiology NN N
. . N

-DOCSTART- -X- O O

The DT N
use NN N
of IN N
transvaginal JJ 1_i
synthetic JJ 1_i
mesh NN 1_i
for IN N
anterior JJ N
vaginal JJ N
wall NN N
prolapse NN N
repair NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

INTRODUCTION NNP N
AND CC N
HYPOTHESIS NNP N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
transvaginal JJ 1_i
trocar-guided JJ 1_i
polypropylene NN 1_i
mesh JJ 1_i
insertion NN 1_i
with IN 1_i
traditional JJ 1_i
colporrhaphy NN 1_i
for IN N
treatment NN N
of IN N
anterior JJ N
vaginal JJ N
wall NN N
prolapse NN N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
randomized JJ N
controlled JJ N
trial NN N
in IN N
which WDT N
women NNS N
with IN N
advanced JJ N
anterior JJ N
vaginal NN N
wall NN N
prolapse NN N
, , N
at IN N
least JJS N
stage NN N
II NNP N
with IN N
Ba NNP N
? . N
+1 NN N
cm NN N
according VBG N
to TO N
the DT N
Pelvic NNP N
Organ NNP N
Prolapse NNP N
Quantification NNP N
( ( N
POP-Q NNP N
) ) N
classification NN N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
either DT N
anterior JJ N
colporrhaphy NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
or CC N
repair NN N
using VBG N
trocar-guided JJ N
transvaginal JJ N
mesh NN N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
objective JJ N
cure NN N
rate NN N
of IN N
the DT N
anterior JJ N
compartment NN N
( ( N
point NN N
Ba NNP N
) ) N
assessed VBD N
at IN N
the DT N
12-month JJ N
follow-up JJ N
visit NN N
, , N
with IN N
stages NNS N
0 CD N
and CC N
I PRP N
defined VBD N
as IN N
anatomical JJ N
success NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
quantification NN N
of IN N
other JJ N
vaginal JJ N
compartments NNS N
( ( N
POP-Q NNP N
points NNS N
) ) N
, , N
comparison NN N
of IN N
quality NN N
of IN N
life NN N
by IN N
the DT N
prolapse NN N
quality NN N
of IN N
life NN N
( ( N
P-QOL NNP N
) ) N
questionnaire NN N
, , N
and CC N
complication NN N
rate NN N
between IN N
the DT N
groups NNS N
after IN N
1 CD N
year NN N
. . N

Study NNP N
power NN N
was VBD N
fixed VBN N
as IN N
80 CD N
% NN N
with IN N
5 CD N
% NN N
cutoff NN N
point NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
statistical JJ N
significance NN N
. . N

RESULTS VB N
The DT N
groups NNS N
were VBD N
similar JJ N
regarding VBG N
demographic JJ N
and CC N
clinical JJ N
preoperative NN N
parameters NNS N
. . N

Anatomical JJ N
success NN N
rates NNS N
for IN N
colporrhaphy NN N
and CC N
repair NN N
with IN N
mesh JJ N
placement NN N
groups NNS N
were VBD N
56.4 CD N
vs JJ N
82.5 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
0.068-0.54 NN N
) ) N
, , N
respectively RB N
, , N
and CC N
the DT N
difference NN N
between IN N
the DT N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.018 CD N
) ) N
. . N

Similar JJ N
total JJ N
complication NN N
rates NNS N
were VBD N
observed VBN N
in IN N
both DT N
groups NNS N
, , N
with IN N
tape NN N
exposure NN N
observed VBN N
in IN N
5 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
all DT N
P-QOL NNP N
domains NNS N
as IN N
a DT N
result NN N
of IN N
both DT N
procedures NNS N
( ( N
p VB N
< RB N
0.001 CD N
) ) N
, , N
but CC N
they PRP N
were VBD N
not RB N
distinct JJ N
between IN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Trocar-guided JJ N
transvaginal JJ N
synthetic JJ N
mesh NN N
for IN N
advanced JJ N
anterior JJ N
POP NNP N
repair NN N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR N
anatomical JJ N
success NN N
rate NN N
for IN N
the DT N
anterior JJ N
compartment NN N
compared VBN N
with IN N
traditional JJ N
colporrhaphy NN N
. . N

Quality NN N
of IN N
life NN N
equally RB N
improved VBN N
after IN N
both DT N
techniques NNS N
. . N

However RB N
, , N
the DT N
trial NN N
failed VBD N
to TO N
detect VB N
differences NNS N
in IN N
P-QOL NNP N
scores NNS N
and CC N
complication NN N
rates NNS N
between IN N
the DT N
groups NNS N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
bladder NN N
cancer NN N
with IN N
intravesical JJ N
instillation NN N
of IN N
adriamycin NN 3_i
. . N

Intravesical JJ N
treatment NN N
with IN N
adriamycin NN 3_i
has VBZ N
been VBN N
extensively RB N
employed VBN N
in IN N
the DT N
last JJ N
decade NN N
. . N

In IN N
the DT N
treatment NN N
of IN N
carcinoma NN N
in IN N
situ JJ N
complete JJ N
responses NNS N
have VBP N
been VBN N
reported VBN N
in IN N
about RB N
60 CD N
% NN N
of IN N
cases NNS N
. . N

Its PRP$ N
efficacy NN N
is VBZ N
probably RB N
lower RBR N
in IN N
the DT N
therapy NN N
of IN N
multiple JJ N
or CC N
diffuse NN N
low JJ N
stage NN N
transitional JJ N
cell NN N
carcinoma NN N
that WDT N
is VBZ N
too RB N
extensive JJ N
to TO N
be VB N
completely RB N
resected VBN N
by IN N
conventional JJ N
transurethral JJ N
surgery NN N
. . N

In IN N
such JJ N
circumstances NNS N
, , N
including VBG N
cancer NN N
in IN N
situ NN N
, , N
adriamycin JJ 3_i
compares VBZ N
favorably RB N
with IN N
other JJ N
local JJ N
forms NNS N
of IN N
treatment NN N
. . N

The DT N
prophylactic JJ N
use NN N
of IN N
intravesical JJ N
instillation NN N
of IN N
Adriamycin NNP 3_i
has VBZ N
been VBN N
studied VBN N
more RBR N
extensively RB N
. . N

Preliminary JJ N
results NNS N
of IN N
controlled JJ N
randomized JJ N
trials NNS N
implemented VBN N
from IN N
the DT N
EORTC NNP N
Urological NNP N
Group NNP N
show VBP N
that IN N
adriamycin JJ 3_i
instillations NNS N
significantly RB N
reduce VB N
recurrence NN N
rate NN N
after IN N
TUR NNP N
. . N

The DT N
treatment NN N
is VBZ N
well RB N
tolerated VBN N
. . N

Systemic JJ N
absorption NN N
is VBZ N
virtually RB N
absent JJ N
, , N
and CC N
no DT N
severe JJ N
drug-related JJ N
side NN N
effects NNS N
have VBP N
ever RB N
been VBN N
reported VBN N
. . N

Chemical NNP N
cystitis NN N
is VBZ N
occasionally RB N
observed VBN N
, , N
especially RB N
if IN N
multiple JJ N
instillations NNS N
are VBP N
started VBN N
immediately RB N
after IN N
TUR NNP N
, , N
or CC N
in IN N
the DT N
presence NN N
of IN N
additional JJ N
inflammatory NN N
conditions NNS N
, , N
such JJ N
as IN N
previous JJ N
irradiation NN N
or CC N
bacterial JJ N
cystitis NN N
. . N

-DOCSTART- -X- O O

Psoriasis NN N
of IN N
the DT N
scalp NN N
treated VBD N
with IN N
Grenz NNP 2_i
rays NNS 2_i
or CC N
topical JJ 2_i
corticosteroid NN 2_i
combined VBN 2_i
with IN 2_i
Grenz NNP 2_i
rays NNS 2_i
. . 2_i

A DT N
comparative JJ N
randomized VBN N
trial NN N
. . N

To TO N
investigate VB N
the DT N
effect NN N
of IN N
Grenz NNP 2_i
ray NN 2_i
therapy NN 2_i
alone RB N
compared VBN N
with IN N
Grenz NNP 3_i
rays NNS 3_i
combined VBN 3_i
with IN 3_i
a DT 3_i
topical JJ 3_i
corticosteroid NN 3_i
( ( 3_i
betamethasone JJ 3_i
dipropionate NN 3_i
) ) 2_i
in IN N
psoriasis NN N
of IN N
the DT N
scalp NN N
, , N
40 CD N
patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
4 CD N
Gy NNP 2_i
of IN 2_i
Grenz NNP 2_i
rays NNS 2_i
administered VBD N
on IN N
six CD N
occasions NNS N
at IN N
intervals NNS N
of IN N
1 CD N
week NN N
and CC N
the DT N
other JJ N
group NN N
was VBD N
given VBN N
the DT N
same JJ N
Grenz NNP 2_i
ray NN 2_i
treatment NN 2_i
plus CC 2_i
topical JJ 2_i
corticosteroid NN 2_i
. . 2_i

The DT N
patients NNS N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
Grenz NNP N
ray NN N
therapy NN N
and CC N
were VBD N
followed-up NNS N
for IN N
6 CD N
months NNS N
. . N

Of IN N
the DT N
37 CD N
patients NNS N
who WP N
completed VBD N
the DT N
trial NN N
16 CD N
out IN N
of IN N
19 CD N
( ( N
84 CD N
% NN N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
Grenz NNP 2_i
ray NN 2_i
group NN N
, , N
and CC N
13 CD N
out IN N
of IN N
18 CD N
( ( N
72 CD N
% NN N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
combination NN N
group NN N
healed VBD N
. . N

The DT N
remission NN N
time NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

Of IN N
the DT N
patients NNS N
who WP N
healed VBD N
, , N
5 CD N
of IN N
16 CD N
patients NNS N
in IN N
the DT N
Grenz NNP 2_i
ray NN 2_i
only RB N
group NN N
and CC N
4 CD N
of IN N
13 CD N
patients NNS N
in IN N
the DT N
combination NN N
group NN N
remained VBD N
healed VBN N
at IN N
6 CD N
months NNS N
. . N

We PRP N
conclude VBP N
that IN N
Grenz NNP 2_i
ray NN 2_i
therapy NN 2_i
is VBZ N
a DT N
useful JJ N
treatment NN N
modality NN N
for IN N
scalp JJ N
psoriasis NN N
, , N
but CC N
that IN N
the DT N
addition NN N
of IN N
a DT N
topical JJ N
corticosteroid NN 2_i
has VBZ N
only RB N
a DT N
minor JJ N
effect NN N
. . N

-DOCSTART- -X- O O

Contingency NNP 4_i
management NN 4_i
for IN N
the DT N
treatment NN N
of IN N
antipsychotic-induced JJ N
weight JJ N
gain NN N
: : N
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
Weight NNP N
gain NN N
is VBZ N
common JJ N
for IN N
individuals NNS N
with IN N
serious JJ N
mental JJ N
illness NN N
( ( N
SMI NNP N
) ) N
receiving VBG N
antipsychotic JJ N
drug NN N
therapy NN N
. . N

Contingency NNP 4_i
management NN 4_i
( ( 4_i
CM NNP 4_i
) ) 4_i
is VBZ N
a DT N
behavioral JJ N
intervention NN N
that IN N
rewards NNS N
positive JJ N
performance NN N
and CC N
has VBZ N
demonstrated VBN N
effectiveness NN N
in IN N
reducing VBG N
drug NN N
use NN N
in IN N
SMI NNP N
populations NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
feasibility NN N
of IN N
using VBG N
CM NNP 4_i
to TO N
promote VB N
weight JJ N
loss NN N
in IN N
individuals NNS N
with IN N
SMI NNP N
over IN N
8 CD N
weeks NNS N
. . N

METHOD NNP N
30 CD N
individuals NNS N
( ( N
BMI NNP N
? . N
28 CD N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
: : N
i NN N
) ) N
The DT N
combination NN N
of IN N
a DT N
standardized JJ N
lifestyle NN N
modification NN N
( ( N
LM NNP N
) ) N
program NN N
for IN N
individuals NNS N
with IN N
SMI NNP N
and CC N
payment NN N
for IN N
group NN N
attendance NN N
( ( N
CM NNP N
( ( N
attendance NN N
) ) N
) ) N
, , N
ii NN N
) ) N
The DT N
combination NN N
of IN N
LM NNP N
and CC N
payment NN N
for IN N
weight JJ N
loss NN N
( ( N
CM NNP N
( ( N
weight NN N
) ) N
) ) N
, , N
and CC N
iii NN N
) ) N
waitlist NN N
control NN N
( ( N
CON NNP N
) ) N
. . N

After IN N
the DT N
waitlist JJ N
period NN N
, , N
those DT N
participants NNS N
joined VBD N
a DT N
LM NNP N
group NN N
and CC N
received VBD N
payment NN N
for IN N
behavioral JJ N
change NN N
( ( N
CM NNP N
( ( N
behavior NN N
) ) N
) ) N
. . N

RESULTS JJ N
Subjects NNPS N
in IN N
the DT N
CM NNP N
( ( N
attendance NN N
) ) N
and CC N
in IN N
the DT N
CM NNP N
( ( N
weight NN N
) ) N
group NN N
lost VBD N
a DT N
mean NN N
of IN N
1.16 CD N
kg NNS N
and CC N
1.23 CD N
kg NN N
, , N
respectively RB N
, , N
while IN N
subjects NNS N
in IN N
the DT N
CON NNP N
gained VBD N
a DT N
mean NN N
of IN N
0.68 CD N
kg NNS N
. . N

Subjects NNS N
receiving VBG N
CM NNP N
( ( N
behavior NN N
) ) N
, , N
lost VBD N
a DT N
mean NN N
of IN N
2.54 CD N
kg NNS N
, , N
which WDT N
was VBD N
a DT N
significant JJ N
weight NN N
loss NN N
compared VBN N
to TO N
the DT N
control NN N
period NN N
. . N

CONCLUSION NNP N
LM NNP N
supplemented VBD N
with IN N
CM NNP N
may MD N
facilitate VB N
weight NN N
loss NN N
in IN N
patients NNS N
taking VBG N
antipsychotic JJ N
medications NNS N
; : N
financial JJ N
reimbursement NN N
for IN N
behavioral JJ N
change NN N
may MD N
be VB N
particularly RB N
effective JJ N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -X- O O

Studies NNS N
on IN N
leptin NN N
and CC N
leptin NN N
receptor NN N
gene NN N
expression NN N
in IN N
myometrium NN N
and CC N
uterine JJ N
myomas NN N
of IN N
gnRH JJ 2_i
analogue-treated JJ 2_i
women NNS N
. . N

AIM NNP N
To TO N
test VB N
if IN N
treatment NN N
with IN N
GnRH NNP 3_i
analogue NN 3_i
, , N
which WDT N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
myoma NN N
volume NN N
, , N
changes NNS N
expression NN N
of IN N
leptin NN N
genes NNS N
and CC N
gene NN N
coding VBG N
leptin JJ N
receptor NN N
isoforms NNS N
in IN N
uterine JJ N
myomas NN N
and CC N
in IN N
the DT N
surrounding NN N
unaltered JJ N
myometrium NN N
. . N

METHODS NNP N
Using VBG N
RT-PCR NNP N
, , N
expression NN N
of IN N
leptin NN N
genes NNS N
and CC N
leptin NN N
receptor NN N
genes NNS N
was VBD N
studied VBN N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
in IN N
women NNS N
with IN N
uterine JJ N
myomas NN N
, , N
untreated VBD N
or CC N
treated VBN N
with IN N
GnRH NNP 3_i
analogue NN 3_i
. . N

In IN N
the DT N
randomly RB N
selected VBN N
cases NNS N
presence NN N
of IN N
leptin NN N
protein NN N
and CC N
of IN N
leptin JJ N
receptor NN N
proteins NNS N
was VBD N
examined VBN N
also RB N
by IN N
Western JJ N
blotting NN N
. . N

RESULTS NNP N
Expression NNP N
of IN N
leptin NN N
genes NNS N
was VBD N
demonstrated VBN N
both DT N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
, , N
and CC N
a DT N
similar JJ N
pattern NN N
of IN N
expression NN N
was VBD N
found VBN N
for IN N
leptin JJ N
receptor NN N
isoforms NNS N
. . N

The DT N
results NNS N
of IN N
RT-PCR NNP N
were VBD N
confirmed VBN N
by IN N
Western JJ N
blotting NN N
, , N
which WDT N
documented VBD N
the DT N
identical JJ N
distribution NN N
of IN N
leptin NN N
proteins NNS N
and CC N
leptin JJ N
receptor NN N
proteins NNS N
in IN N
studied JJ N
tissues NNS N
. . N

Treatment NN N
with IN N
GnRH NNP 3_i
analogue NN 3_i
had VBD N
no DT N
effect NN N
on IN N
the DT N
expression NN N
pattern NN N
of IN N
studied VBN N
genes NNS N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
on IN N
the DT N
administration NN N
of IN N
GnRH NNP 3_i
analogue NN 3_i
to TO N
females NNS N
with IN N
myomas NN N
suggest VBP N
that IN N
no DT N
direct JJ N
or CC N
immediate JJ N
inter-relationship JJ N
exists NNS N
between IN N
expression NN N
of IN N
leptin NN N
genes NNS N
in IN N
uterine JJ N
myomas NN N
on IN N
one CD N
hand NN N
and CC N
estrogen NN N
, , N
progesterone NN N
and CC N
leptin NN N
levels NNS N
in IN N
the DT N
blood NN N
on IN N
the DT N
other JJ N
. . N

Expression NN N
seems VBZ N
to TO N
be VB N
of IN N
a DT N
more RBR N
durable JJ N
nature NN N
but CC N
factors NNS N
that WDT N
induce VBP N
such JJ N
expression NN N
remain VBP N
unknown JJ N
. . N

-DOCSTART- -X- O O

Improved VBN N
intraoperative JJ N
management NN N
of IN N
anastomotic JJ N
bleeding NN N
during IN N
aortic JJ N
reconstruction NN N
: : N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
the DT N
effectiveness NN N
of IN N
a DT N
polymeric JJ 1_i
surgical JJ 1_i
sealant NN 1_i
( ( 1_i
CoSeal NNP 1_i
) ) 1_i
was VBD N
compared VBN N
to TO N
Gelfoam/thrombin NNP 1_i
for IN N
managing VBG N
anastomotic JJ N
bleeding NN N
after IN N
implantation NN 2_i
of IN 1_i
Dacron NNP 1_i
grafts NNS 1_i
during IN 1_i
aortic JJ 1_i
reconstruction NN 1_i
for IN 1_i
nonruptured JJ 1_i
aneurysms NNS 1_i
. . N

Each DT 1_i
treatment NN 1_i
was VBD 1_i
directly RB 1_i
applied VBN 1_i
to TO 1_i
the DT 1_i
suture NN 1_i
line NN 1_i
after IN 1_i
confirmation NN 1_i
of IN 1_i
anastomotic JJ 1_i
bleeding NN 1_i
. . 1_i

The DT N
proportion NN N
of IN N
suture NN N
line NN N
sites VBZ N
that IN N
achieved VBD N
immediate JJ N
sealing NN N
and CC N
the DT N
proportion NN N
sealed VBD N
within IN N
5 CD N
minutes NNS N
were VBD N
determined VBN N
among IN N
37 CD N
experimental JJ N
( ( N
59 CD N
sites NNS N
) ) N
and CC N
17 CD N
control NN N
subjects NNS N
( ( N
27 CD N
sites NNS N
) ) N
. . N

A DT N
significantly RB N
greater JJR N
proportion NN N
of IN N
bleeding VBG N
suture NN N
line NN N
sites NNS N
treated VBD N
with IN N
the DT N
polymeric JJ 1_i
sealant NN 1_i
achieved VBN N
immediate JJ N
sealing NN N
following VBG N
reestablishment NN N
of IN N
blood NN N
flow NN N
compared VBN N
with IN N
control-treated JJ N
sites NNS N
[ VBP N
48 CD N
of IN N
59 CD N
( ( N
81 CD N
% NN N
) ) N
vs VBZ N
10 CD N
of IN N
27 CD N
( ( N
37 CD N
% NN N
) ) N
; : N
P NNP N
= VBD N
0.002 CD N
] NN N
. . N

The DT N
difference NN N
between IN N
treatment NN N
groups NNS N
was VBD N
maintained VBN N
after IN N
5 CD N
minutes NNS N
with IN N
approximately RB N
85 CD N
per IN N
cent NN N
( ( N
50 CD N
of IN N
59 CD N
) ) N
of IN N
CoSeal NNP 1_i
sites NNS N
compared VBN N
to TO N
just RB N
over IN N
one-half JJ N
( ( N
14 CD N
of IN N
27 CD N
) ) N
of IN N
control NN N
sites VBZ N
demonstrating VBG N
ultimate JJ N
sealing NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
adverse JJ N
events NNS N
related VBN N
to TO N
the DT N
use NN N
of IN N
the DT N
polymeric JJ 1_i
sealant NN 1_i
in IN N
this DT N
study NN N
. . N

These DT N
results NNS N
support VBP N
the DT N
use NN N
of IN N
this DT N
novel JJ N
sealant NN N
for IN N
the DT N
intraoperative JJ N
management NN N
of IN N
anastomotic JJ N
bleeding NN N
during IN N
aortic JJ N
reconstruction NN N
procedures NNS N
. . N

-DOCSTART- -X- O O

Why WRB N
are VBP N
there RB N
sometimes RB N
concreteness JJ N
effects NNS N
in IN N
memory NN N
for IN N
prose NN N
? . N
Four CD N
experiments NNS N
explored VBD N
on-line JJ N
encoding NN N
strategies NNS N
and CC N
memory NN N
for IN N
high JJ N
imagery NN N
and CC N
low JJ N
imagery NN N
texts NN N
. . N

Results NNP N
consistently RB N
indicated VBD N
that IN N
concreteness NN N
effects NNS N
in IN N
memory NN N
for IN N
text JJ N
depend NN N
on IN N
how WRB N
materials NNS N
are VBP N
presented VBN N
in IN N
several JJ N
different JJ N
respects NNS N
. . N

Most JJS N
importantly RB N
, , N
the DT N
experiments NNS N
clarified VBD N
apparently RB N
contradictory JJ N
results NNS N
of IN N
previous JJ N
studies NNS N
by IN N
indicating VBG N
that IN N
concreteness NN N
effects NNS N
generally RB N
do VBP N
not RB N
occur VB N
in IN N
memory NN N
for IN N
prose NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
between-subjects NNS N
, , N
and CC N
that IN N
their PRP$ N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
of IN N
presentation NN N
. . N

In IN N
addition NN N
, , N
moving VBG N
window JJ N
analyses NNS N
of IN N
text JJ 4_i
processing NN 4_i
strategies NNS 4_i
indicated VBD N
that IN N
differential JJ N
strategies NNS N
observed VBN N
in IN N
previous JJ N
studies NNS N
when WRB N
subjects NNS N
listened VBD N
to TO N
high JJ N
vs NN N
low JJ N
imagery NN N
text NN N
do VBP N
not RB N
generalize VB N
to TO N
reading NN N
of IN N
the DT N
same JJ N
materials NNS N
. . N

Potential JJ N
explanations NNS N
for IN N
the DT N
pattern NN N
of IN N
results NNS N
are VBP N
evaluated VBN N
, , N
and CC N
implications NNS N
for IN N
theories NNS N
of IN N
mental JJ N
imagery NN N
and CC N
memory NN N
are VBP N
considered VBN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
vitamin JJ 3_i
A-fortified NNP 3_i
coconut NN 3_i
cooking VBG 3_i
oil NN 3_i
on IN N
the DT N
serum NN N
retinol JJ N
concentration NN N
of IN N
Filipino NNP N
children NNS N
4-7 CD N
years NNS N
old JJ N
. . N

A DT N
6-month JJ N
intervention NN N
trial NN N
was VBD N
conducted VBN N
among IN N
542 CD N
Filipino NNP N
children NNS N
aged VBD N
4 CD N
to TO N
7 CD N
years NNS N
to TO N
determine VB N
the DT N
effect NN N
of IN N
vitamin JJ 3_i
A-fortified NNP 3_i
coconut NN 3_i
cooking VBG 3_i
oil NN 3_i
intake NN N
on IN N
their PRP$ N
vitamin NN N
A DT N
status NN N
and CC N
to TO N
identify VB N
factors NNS N
that WDT N
influence NN N
this DT N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
vitamin JJ 3_i
A-fortified JJ 3_i
cooking NN 3_i
oil NN 3_i
ration NN N
; : N
to TO N
Control-1 NNP N
group NN N
with IN N
unfortified JJ 3_i
cooking NN 3_i
oil NN 3_i
ration NN 3_i
; : N
and CC N
to TO N
Control-2 NNP N
group NN N
without IN 7_i
cooking VBG 7_i
oil NN 7_i
ration NN 7_i
. . N

In IN N
all DT N
groups NNS N
, , N
children NNS N
's POS N
serum NN N
retinol NN N
concentration NN N
improved VBN N
. . N

Relative JJ N
change NN N
in IN N
serum NN N
retinol NN N
concentration NN N
was VBD N
significantly RB N
higher JJR N
among IN N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
one-third NN N
of IN N
total JJ N
vitamin FW N
A DT N
intake NN N
coming VBG N
from IN N
vitamin JJ 3_i
A-fortified JJ 3_i
cooking NN 3_i
oil NN 3_i
intake NN N
, , N
than IN N
in IN N
the DT N
Control NNP N
groups NNS N
, , N
with IN N
more JJR N
than IN N
half NN N
of IN N
intake NN N
from IN N
other JJ N
vitamin JJ N
A-rich JJ N
foods NNS N
. . N

Determinants NNS N
of IN N
post-intervention NN N
serum NN N
retinol NN N
concentration NN N
included VBD N
baseline JJ N
serum NN N
retinol NN N
concentration NN N
, , N
caregiver NN N
's POS N
education NN N
, , N
receipt NN N
of IN N
high-dose JJ N
vitamin NN N
A NNP N
capsule NN N
, , N
interaction NN N
between IN N
consumption NN N
of IN N
vitamin JJ N
A-fortified JJ N
cooking NN N
oil NN N
and CC N
of IN N
other JJ N
vitamin JJ N
A-rich NNP N
foods NNS N
, , N
and CC N
between IN N
households NNS N
purchasing VBG N
cooking JJ N
oil NN N
and CC N
food NN N
expenditure NN N
. . N

Intake NNP N
of IN N
vitamin JJ 3_i
A-fortified JJ 3_i
cooking NN 3_i
oil NN 3_i
combined VBN N
with IN N
vitamin JJ N
A-rich NNP N
foods NNS N
was VBD N
necessary JJ N
to TO N
increase VB N
serum NN N
retinol JJ N
concentration NN N
. . N

It PRP N
is VBZ N
recommended VBN N
to TO N
vigorously RB N
promote VB N
the DT N
consumption NN N
of IN N
vitamin JJ 3_i
A-fortified JJ 3_i
cooking NN 3_i
oil NN 3_i
together RB N
with IN N
other JJ N
vitamin JJ N
A-rich JJ N
sources NNS N
to TO N
sustain VB N
the DT N
prevention NN N
and CC N
control NN N
of IN N
vitamin FW N
A DT N
deficiency NN N
. . N

-DOCSTART- -X- O O

Behavior NNP N
in IN N
children NNS N
with IN N
Down NNP N
syndrome NN N
. . N

OBJECTIVE UH N
To TO N
highlight VB N
the DT N
differences NNS N
in IN N
behaviors NNS N
in IN N
children NNS N
with IN N
diagnosis NN N
of IN N
Down NNP N
syndrome NN N
. . N

METHOD NNP N
Eight NNP N
children NNS N
with IN N
Down NNP N
syndrome NN N
who WP N
displayed VBD N
autistic JJ N
features NNS N
were VBD N
compared VBN N
with IN N
eight CD N
Down NNP N
syndrome NN N
children NNS N
without IN N
autistic JJ N
features NNS N
. . N

These DT N
children NNS N
were VBD N
randomly RB N
selected VBN N
and CC N
were VBD N
matched VBN N
for IN N
age NN N
and CC N
level NN N
of IN N
retardation NN N
. . N

Standardized JJ 5_i
Psychological JJ 5_i
tests NNS 5_i
were VBD N
administered VBN N
to TO N
tap VB N
the DT N
behavioral JJ N
differences NNS N
. . N

Mann-Whitney NNP 5_i
U NNP 5_i
test NN 5_i
was VBD N
used VBN N
for IN N
significance NN N
of IN N
difference NN N
between IN N
both CC N
the DT N
groups NNS N
. . N

RESULTS NNP N
Down NNP N
syndrome JJ N
children NNS N
without IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
had VBD N
better JJR N
communication NN N
and CC N
socialization NN N
skills NNS N
than IN N
children NNS N
with IN N
Down NNP N
syndrome NN N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
. . N

Down NNP N
syndrome JJ N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
displayed VBD N
more RBR N
restricted JJ N
repetitive NN N
and CC N
stereotyped VBD N
patterns NNS N
of IN N
behaviors NNS N
, , N
interests NNS N
and CC N
activities NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
manifests VBZ N
as IN N
a DT N
distinct JJ N
behavioral JJ N
phenomenon NN N
in IN N
Down NNP N
syndrome NN N
. . N

Hence NN N
it PRP N
is VBZ N
important JJ N
for IN N
professionals NNS N
to TO N
consider VB N
the DT N
possibility NN N
of IN N
a DT N
dual JJ N
diagnosis NN N
which WDT N
will MD N
entitle VB N
the DT N
child NN N
to TO N
a DT N
more JJR N
specialized JJ N
and CC N
effective JJ N
educational JJ N
and CC N
intervention NN N
services NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
long-term JJ N
vitamin NN 3_i
D NNP 3_i
and CC N
calcium NN 3_i
supplementation NN 3_i
on IN N
falls NNS N
and CC N
parameters NNS N
of IN N
muscle NN N
function NN N
in IN N
community-dwelling JJ N
older NN N
individuals NNS N
. . N

UNLABELLED NN N
In IN N
242 CD N
community-dwelling JJ N
seniors NNS N
, , N
supplementation NN N
with IN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN 3_i
or CC N
1000 CD N
mg NN N
of IN N
calcium NN 3_i
plus CC 3_i
vitamin NN 3_i
D NNP 3_i
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS N
with IN N
first JJ N
falls NNS N
of IN N
27 CD N
% NN N
at IN N
month NN N
12 CD N
and CC N
39 CD N
% NN N
at IN N
month NN N
20 CD N
. . N

Additionally RB N
, , N
parameters NNS N
of IN N
muscle NN N
function NN N
improved VBD N
significantly RB N
. . N

INTRODUCTION NNP N
The DT N
efficacy NN N
of IN N
vitamin NN 3_i
D NNP 3_i
and CC N
calcium NN 3_i
supplementation NN N
on IN N
risk NN N
of IN N
falling VBG N
in IN N
the DT N
elderly JJ N
is VBZ N
discussed VBN N
controversially RB N
. . N

Randomized NNP N
controlled VBD N
trials NNS N
using VBG N
falls NNS N
as IN N
primary JJ N
outcome NN N
are VBP N
needed VBN N
. . N

We PRP N
investigated VBD N
long-term JJ N
effects NNS N
of IN N
calcium NN 3_i
and CC N
vitamin NN 3_i
D NNP 3_i
on IN N
falls NNS N
and CC N
parameters NNS N
of IN N
muscle NN N
function NN N
in IN N
community-dwelling JJ N
elderly JJ N
women NNS N
and CC N
men NNS N
. . N

METHODS NNP N
Our PRP$ N
study NN N
population NN N
consisted VBD N
of IN N
242 CD N
individuals NNS N
recruited VBN N
by IN N
advertisements NNS N
and CC N
mailing VBG N
lists NNS N
( ( N
mean JJ N
[ NNP N
+/- NN N
SD NNP N
] NNP N
age NN N
, , N
77 CD N
+/- JJ N
4 CD N
years NNS N
) ) N
. . N

All DT N
serum JJ N
25-hydroxyvitamin JJ N
D NNP N
( ( N
25 CD N
[ NNP N
OH NNP N
] NNP N
D NNP N
) ) N
levels NNS N
were VBD N
below IN N
78 CD N
nmol/l NN N
. . N

Individuals NNS N
received VBD N
in IN N
a DT N
double JJ N
blinded JJ N
fashion NN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN 3_i
or CC N
1000 CD N
mg NN N
of IN N
calcium NN 3_i
plus CC N
800 CD N
IU NNP N
of IN N
vitamin NNP 3_i
D NNP 3_i
per IN N
day NN N
over IN N
a DT N
treatment NN N
period NN N
of IN N
12 CD N
months NNS N
, , N
which WDT N
was VBD N
followed VBN N
by IN N
a DT N
treatment-free JJ N
but CC N
still RB N
blinded VBD N
observation JJ N
period NN N
of IN N
8 CD N
months NNS N
. . N

Falls NNP N
were VBD N
documented VBN N
using VBG N
diaries NNS N
. . N

The DT N
study NN N
took VBD N
place NN N
in IN N
Bad NNP N
Pyrmont NNP N
, , N
Germany NNP N
( ( N
latitude VBP N
52 CD N
degrees NNS N
) ) N
and CC N
Graz NNP N
, , N
Austria NNP N
( ( N
latitude VBP N
46 CD N
degrees NNS N
) ) N
. . N

RESULTS $ N
Compared VBD N
to TO N
calcium VB N
mono NN N
, , N
supplementation NN N
with IN N
calcium NN N
plus CC N
vitamin NN 3_i
D NNP 3_i
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS N
with IN N
first JJ N
falls NNS N
of IN N
27 CD N
% NN N
at IN N
month NN N
12 CD N
( ( N
RR NNP N
= NNP N
0.73 CD N
; : N
CI NNP N
= NNP N
0.54-0.96 NN N
) ) N
and CC N
39 CD N
% NN N
at IN N
month NN N
20 CD N
( ( N
RR NNP N
= NNP N
0.61 CD N
; : N
CI NNP N
= NNP N
0.34-0.76 NN N
) ) N
. . N

Concerning VBG N
secondary JJ N
endpoints NNS N
, , N
we PRP N
observed VBD N
significant JJ N
improvements NNS N
in IN N
quadriceps JJ N
strength NN N
of IN N
8 CD N
% NN N
, , N
a DT N
decrease NN N
in IN N
body NN N
sway NN N
of IN N
28 CD N
% NN N
, , N
and CC N
a DT N
decrease NN N
in IN N
time NN N
needed VBN N
to TO N
perform VB N
the DT N
TUG NNP N
test NN N
of IN N
11 CD N
% NN N
. . N

DISCUSSION NNP N
Combined NNP N
calcium NN 3_i
and CC N
vitamin NN 3_i
D NNP 3_i
supplementation NN N
proved VBD N
superior JJ N
to TO N
calcium VB N
alone RB N
in IN N
reducing VBG N
the DT N
number NN N
of IN N
falls NNS N
and CC N
improving VBG N
muscle NN N
function NN N
in IN N
community-dwelling JJ N
older NN N
individuals NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
skin-to-skin JJ 2_i
contact NN 2_i
on IN N
autonomic JJ N
pain NN N
responses NNS N
in IN N
preterm JJ N
infants NNS N
. . N

UNLABELLED IN N
The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
crossover NN N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
on IN N
autonomic JJ N
responses NNS N
in IN N
preterm JJ N
infants NNS N
of IN N
longer JJR N
Kangaroo NNP 2_i
Care NNP 2_i
( ( N
30 CD N
minutes NNS N
, , N
KC30 NNP 2_i
) ) N
and CC N
shorter JJR N
KC NNP 4_i
( ( N
15 CD N
minutes NNS N
, , N
KC15 NNP 2_i
) ) N
before IN N
and CC N
throughout IN N
heel NN N
stick NNS N
compared VBN N
with IN N
incubator NN 2_i
care NN 2_i
( ( 2_i
IC NNP 2_i
) ) 4_i
. . N

Beat-to-beat JJ N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
and CC N
spectral JJ N
power NN N
analysis NN N
of IN N
heart NN N
rate NN N
variability NN N
, , N
low JJ N
frequency NN N
power NN N
( ( N
LF NNP N
) ) N
, , N
high JJ N
frequency NN N
power NN N
( ( N
HF NNP N
) ) N
, , N
and CC N
LF/HF NNP N
ratio NN N
were VBD N
measured VBN N
in IN N
26 CD N
infants NNS N
. . N

HR NNP N
changes NNS N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
were VBD N
significantly RB N
less RBR N
in IN N
KC30 NNP N
and CC N
KC15 NNP N
than IN N
in IN N
IC NNP N
, , N
and CC N
more JJR N
infants NNS N
had VBD N
HR NNP N
decrease NN N
in IN N
IC NNP N
than IN N
in IN N
2 CD N
KC NNP N
conditions NNS N
. . N

In IN N
IC NNP N
, , N
LF NNP N
and CC N
HF NNP N
significantly RB N
increased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
dropped VBD N
from IN N
Heel NNP N
Stick NNP N
to TO N
Recovery NNP N
; : N
in IN N
2 CD N
KC NNP N
conditions NNS N
, , N
no DT N
changes NNS N
across IN N
study NN N
phases NNS N
were VBD N
found VBN N
. . N

During IN N
Heel NNP N
Stick NNP N
, , N
LF NNP N
and CC N
HF NNP N
were VBD N
significantly RB N
higher JJR N
in IN N
IC NNP N
than IN N
in IN N
KC30 NNP 2_i
. . N

In IN N
all DT N
3 CD N
conditions NNS N
, , N
LF/HF NNP N
ratio NN N
decreased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
increased VBD N
to TO N
Recovery NNP N
; : N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
IC NNP 2_i
and CC N
two CD N
KC NNP 4_i
conditions NNS N
. . N

Both NNP N
longer JJR N
and CC N
shorter JJR N
KC NNP 4_i
before IN N
and CC N
throughout IN N
heel NN N
stick NN N
can MD N
stabilize VB N
HR NNP N
response NN N
in IN N
preterm JJ N
infants NNS N
, , N
and CC N
longer JJR N
KC NNP 2_i
significantly RB N
affected VBD N
infants NNS N
' POS N
sympathetic JJ N
and CC N
parasympathetic JJ N
responses NNS N
during IN N
heel NN N
stick NNS N
compared VBN N
with IN N
incubator NN 2_i
care NN 2_i
. . N

PERSPECTIVE VB N
This DT N
study NN N
showed VBD N
that IN N
KC NNP 4_i
has VBZ N
a DT N
significant JJ N
effect NN N
on IN N
reducing VBG N
autonomic JJ N
pain NN N
responses NNS N
in IN N
preterm JJ N
infants NNS N
. . N

The DT N
findings NNS N
support NN N
that IN N
KC NNP 4_i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
pain NN N
intervention NN N
in IN N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
. . N

-DOCSTART- -X- O O

Bacteremia NNP N
due JJ N
to TO N
Bacteroides NNP N
fragilis NN N
after IN N
elective JJ N
appendectomy NN N
in IN N
renal JJ N
transplant NN N
recipients NNS N
. . N

Bacteremia NNP N
caused VBN N
by IN N
Bacteroides NNP N
fragilis NN N
occurred VBD N
in IN N
four CD N
of IN N
75 CD N
children NNS N
after IN N
renal JJ N
transplantation NN N
, , N
and CC N
B. NNP N
fragilis NN N
was VBD N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
postoperative JJ N
bacteremia NN N
. . N

Bacteroides NNP N
bacteremia NN N
was VBD N
significantly RB N
associated VBN N
with IN N
performance NN N
of IN N
elective JJ 2_i
appendectomy NN 2_i
at IN N
the DT N
time NN N
of IN N
transplantation NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
with IN N
profound JJ N
lymphocytopenia NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

No DT N
patient NN N
received VBD N
antibiotics NNS 3_i
at IN N
the DT N
time NN N
of IN N
surgery NN N
or CC N
prior RB N
to TO N
the DT N
first JJ N
positive JJ N
blood NN N
culture NN N
, , N
yet RB N
B. NNP N
fragilis NN N
was VBD N
the DT N
single JJ N
organism NN N
isolated VBN N
from IN N
blood NN N
and CC N
abscesses NNS N
in IN N
these DT N
patients NNS N
. . N

A DT N
role NN N
for IN N
lymphocytes NNS N
in IN N
containment NN N
of IN N
B. NNP N
fragilis NN N
has VBZ N
not RB N
been VBN N
suggested VBN N
previously RB N
, , N
although IN N
unexplained JJ N
occurrence NN N
of IN N
bacteroides NNS N
bacteremia VBP N
in IN N
immunocompromised JJ N
patients NNS N
has VBZ N
occasionally RB N
been VBN N
reported VBN N
. . N

Lymphocytes VBZ N
themselves PRP N
may MD N
be VB N
important JJ N
in IN N
this DT N
host-bacterium JJ N
interaction NN N
, , N
or CC N
lymphocytopenia NN N
may MD N
be VB N
the DT N
marker NN N
for IN N
a DT N
more RBR N
generalized JJ N
deficiency NN N
in IN N
host NN N
defenses NNS N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
activated JJ N
charcoal NN N
in IN N
a DT N
simulated JJ N
poisoning NN N
with IN N
acetaminophen NN N
: : N
a DT N
new JJ N
loading NN N
dose NN N
for IN N
N-acetylcysteine NNP 3_i
? . N
STUDY NNP N
OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
ability NN N
of IN N
a DT N
supranormal JJ N
dose NN N
of IN N
N-acetylcysteine NNP 3_i
to TO N
overcome VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
N-acetylcysteine NNP N
bioavailability NN N
and CC N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
serum NN N
acetaminophen NN N
levels NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Ten NNP N
healthy JJ N
adult NN N
volunteers NNS N
participated VBD N
in IN N
a DT N
controlled JJ N
cross-over JJ N
experiment NN N
. . N

During IN N
phase NN N
I PRP N
( ( N
control NN N
) ) N
, , N
subjects VBZ N
ingested JJ N
3 CD N
g NN N
acetaminophen NN 3_i
, , N
followed VBD N
one CD N
hour NN N
later RB N
by IN N
the DT N
normal JJ N
loading VBG N
dose NN N
of IN N
N-acetylcysteine NNP 3_i
( ( N
140 CD N
mg/kg NN N
) ) N
. . N

During IN N
phase NN N
II NNP N
( ( N
charcoal NN N
) ) N
, , N
subjects VBZ N
ingested JJ N
3 CD N
g NN N
acetaminophen NN 3_i
, , N
followed VBD N
one CD N
hour NN N
later RB N
by IN N
60 CD N
g NNS N
activated VBN 3_i
charcoal NN 3_i
and CC N
a DT N
supranormal JJ 3_i
loading NN 3_i
dose NN 3_i
of IN 3_i
N-acetylcysteine NNP 3_i
( ( N
235 CD N
mg/kg NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Serum NNP N
levels NNS N
of IN N
N-acetylcysteine NNP 3_i
were VBD N
measured VBN N
every DT N
30 CD N
minutes NNS N
for IN N
six CD N
hours NNS N
. . N

A DT N
serum NN N
acetaminophen NN N
level NN N
was VBD N
measured VBN N
at IN N
four CD N
hours NNS N
. . N

RESULTS VB N
The DT N
area NN N
under IN N
the DT N
curve NN N
for IN N
N-acetylcysteine NNP 3_i
was VBD N
significantly RB N
higher JJR N
for IN N
phase NN N
II NNP N
than IN N
phase NN N
I PRP N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
two-tailed JJ N
paired VBD N
t-test NN N
) ) N
. . N

Peak VB N
N-acetylcysteine JJ N
and CC N
time NN N
to TO N
peak VB N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
four-hour JJ N
serum NN N
acetaminophen NN N
level NN N
was VBD N
significantly RB N
lower JJR N
for IN N
phase NN N
II NNP N
than IN N
phase NN N
I PRP N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
two-tailed JJ N
paired VBD N
t-test NN N
) ) N
. . N

Diarrhea NNP N
occurred VBD N
during IN N
both DT N
phases NNS N
, , N
but CC N
N-acetylcysteine NNP 3_i
was VBD N
otherwise RB N
well RB N
tolerated VBN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
activated JJ N
charcoal NN N
can MD N
be VB N
used VBN N
safely RB N
for IN N
victims NNS N
of IN N
acetaminophen NN N
overdose NN N
. . N

A DT N
beneficial JJ N
effect NN N
in IN N
preventing VBG N
acetaminophen JJ N
absorption NN N
can MD N
be VB N
expected VBN N
if IN N
it PRP N
is VBZ N
given VBN N
within IN N
one CD N
hour NN N
after IN N
ingestion NN N
. . N

If IN N
N-acetylcysteine NNP 3_i
is VBZ N
needed VBN N
because IN N
of IN N
a DT N
toxic JJ N
serum NN N
acetaminophen NN N
level NN N
, , N
bioavailability NN N
can MD N
be VB N
ensured VBN N
by IN N
increasing VBG N
the DT N
N-acetylcysteine JJ 3_i
loading NN N
dose NN N
from IN N
140 CD N
mg/kg NNS N
to TO N
235 CD N
mg/kg NNS N
. . N

-DOCSTART- -X- O O

Long JJ N
term NN N
response NN N
to TO N
therapy NN N
of IN N
chronic JJ N
anti-HBe-positive JJ N
hepatitis NN N
B NNP N
is VBZ N
poor JJ N
independent JJ N
of IN N
type NN N
and CC N
schedule NN N
of IN N
interferon NN N
. . N

OBJECTIVE CC N
The DT N
response NN N
rate NN N
to TO N
alpha VB 3_i
interferon NN 3_i
( ( 3_i
IFN NNP 3_i
) ) 3_i
of IN N
chronic JJ N
anti-HBe-positive JJ N
hepatitis NN N
B NNP N
is VBZ N
variable JJ N
. . N

We PRP N
studied VBD N
whether IN N
type NN N
, , N
dose NN N
, , N
and CC N
schedule NN N
of IN N
IFN NNP 3_i
, , N
and CC N
type NN N
and CC N
frequency NN N
of IN N
posttreatment NN N
monitoring NN N
, , N
influence VB N
the DT N
response NN N
rate NN N
. . N

METHODS NNP N
Seventy-two JJ N
consecutive JJ N
anti-HBe-positive JJ N
chronic NN N
hepatitis NN N
B NNP N
patients NNS N
( ( N
59 CD N
male NN N
and CC N
13 CD N
female NN N
, , N
median JJ N
age NN N
41 CD N
yr NN N
) ) N
stratified VBN N
by IN N
sex NN N
and CC N
histology NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
treatment NN N
arms NNS N
. . N

Twenty-seven JJ N
patients NNS N
( ( N
A DT N
) ) N
received VBD N
10 CD N
million CD N
units NNS N
alpha-N1 JJ 3_i
IFN NNP 3_i
i.m NN 3_i
. . 3_i

t.w NN N
. . N

for IN N
24 CD N
wk NN N
( ( N
total JJ N
dose NN N
: : N
720 CD N
million CD N
units NNS N
) ) N
; : N
21 CD N
( ( N
B NNP N
) ) N
received VBD N
9 CD N
million CD N
units NNS N
alpha-2a JJ 3_i
IFN NNP 3_i
i.m NN 3_i
. . 3_i

t.w NN N
. . N

for IN N
4 CD N
wk NN N
, , N
followed VBN N
by IN N
18 CD N
million CD N
units NNS N
for IN N
12 CD N
wk NN N
and CC N
9 CD N
million CD N
units NNS N
for IN N
8 CD N
wk NN N
( ( N
972 CD N
million CD N
units NNS N
) ) N
; : N
24 CD N
( ( N
C NNP N
) ) N
received VBD N
2 CD 3_i
alpha-2a JJ 3_i
IFN NNP 3_i
courses NNS N
( ( N
9 CD N
million CD N
units NNS N
i.m RB N
. . N

t.w NN N
. . N

for IN N
16 CD N
and CC N
12 CD N
wk NN N
separated VBN N
by IN N
a DT N
6-month JJ N
interval NN N
[ $ N
756 CD N
million CD N
units NNS N
] NNP N
) ) N
. . N

Primary JJ N
response NN N
was VBD N
defined VBN N
by IN N
normal JJ N
ALT NNP N
and CC N
serum VB N
HBV-DNA NNP N
levels NNS N
below IN N
10 CD N
pg/ml NN N
at IN N
the DT N
end NN N
of IN N
therapy NN N
and CC N
sustained VBN N
response NN N
by IN N
normal JJ N
ALT NNP N
( ( N
tested VBN N
monthly RB N
) ) N
, , N
undetectable JJ N
HBV-DNA NN N
and CC N
IgM NNP N
anti-HBc NN N
( ( N
< JJ N
7 CD N
I.U NNP N
. . N

Paul NNP N
Ehrlich NNP N
Institute NNP N
) ) N
( ( N
tested VBN N
every DT N
3 CD N
months NNS N
) ) N
during IN N
the DT N
posttreatment JJ N
follow-up NN N
. . N

RESULTS NNP N
At IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
12 CD N
, , N
8 CD N
, , N
and CC N
13 CD N
patients NNS N
from IN N
groups NNS N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
, , N
respectively RB N
, , N
were VBD N
responders NNS N
. . N

At IN N
the DT N
18-month JJ N
follow-up JJ N
, , N
two CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
only RB N
one CD N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
maintained VBD N
the DT N
response NN N
. . N

Overall NNP N
, , N
after IN N
34 CD N
months NNS N
( ( N
median JJ N
posttreatment NN N
follow-up NN N
) ) N
, , N
three CD N
patients NNS N
were VBD N
long JJ N
term NN N
responders NNS N
, , N
whereas NNS N
three CD N
showed VBD N
a DT N
sustained VBN N
remission NN N
after IN N
relapse NN N
. . N

CONCLUSIONS VB N
The DT N
rate NN N
of IN N
long JJ N
term NN N
response NN N
to TO N
interferon VB N
of IN N
anti-HBe-positive JJ N
chronic JJ N
hepatitis NN N
B NNP N
is VBZ N
poor JJ N
, , N
independent JJ N
of IN N
IFN NNP N
type NN N
, , N
dose VB N
, , N
or CC N
schedule NN N
; : N
the DT N
more RBR N
stringent JJ N
the DT N
monitoring NN N
, , N
the DT N
higher JJR N
the DT N
relapse NN N
rate NN N
. . N

-DOCSTART- -X- O O

Standardized NNP N
preoperative JJ N
corticosteroid NN 3_i
treatment NN N
in IN N
neonates NNS N
undergoing VBG N
cardiac JJ N
surgery NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE CC N
A DT N
heightened JJ N
inflammatory NN N
response NN N
occurs VBZ N
after IN N
cardiac JJ N
surgery NN N
. . N

The DT N
perioperative JJ N
use NN N
of IN N
glucocorticoids NNS N
has VBZ N
been VBN N
advocated VBN N
as IN N
a DT N
method NN N
to TO N
improve VB N
postoperative JJ N
outcomes NNS N
. . N

Randomized VBN N
prospective JJ N
studies NNS N
to TO N
quantify VB N
the DT N
effect NN N
of IN N
methylprednisolone NN 3_i
on IN N
perioperative JJ N
outcomes NNS N
in IN N
neonatal JJ N
cardiac NN N
surgery NN N
have VBP N
not RB N
been VBN N
performed VBN N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
preoperative JJ N
methylprednisolone NN N
would MD N
improve VB N
postoperative JJ N
recovery NN N
in IN N
neonates NNS N
requiring VBG N
cardiac JJ N
surgery NN N
. . N

METHODS NNP N
Neonates NNP N
scheduled VBD N
for IN N
cardiac JJ N
surgery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
2-dose JJ N
( ( N
8 CD N
hours NNS N
preoperatively RB N
and CC N
operatively RB N
, , N
n JJ N
= NNP N
39 CD N
) ) N
or CC N
single-dose JJ N
( ( N
operatively RB N
, , N
n JJ N
= NNP N
37 CD N
) ) N
methylprednisolone NN N
( ( N
30 CD N
mg/kg NN N
per IN N
dose NN N
) ) N
in IN N
a DT N
prospective JJ N
double-blind JJ N
trial NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
incidence NN N
of IN N
low JJ N
cardiac JJ N
output NN N
syndrome NN N
( ( N
standardized VBN N
score NN N
) ) N
or CC N
death NN N
36 CD N
hours NNS N
postoperatively RB N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
death NN N
at IN N
30 CD N
days NNS N
, , N
interleukin-6 JJ N
levels NNS N
, , N
inotropic NN N
score NN N
, , N
fluid NN N
balance NN N
, , N
serum JJ N
creatinine NN N
, , N
and CC N
intensive JJ N
care NN N
unit NN N
and CC N
hospital NN N
stay NN N
. . N

RESULTS NNP N
Preoperative NNP N
plasma NN N
levels NNS N
of IN N
the DT N
inflammatory JJ N
cytokine JJ N
interleukin-6 NN N
were VBD N
reduced VBN N
by IN N
2-fold JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
2-dose JJ N
methylprednisolone NN N
group NN N
, , N
consistent NN N
with IN N
the DT N
anti-inflammatory JJ N
effects NNS N
of IN N
methylprednisolone NN N
. . N

However RB N
, , N
the DT N
incidence NN N
of IN N
low JJ N
cardiac JJ N
output NN N
syndrome NN N
was VBD N
46 CD N
% NN N
( ( N
17/37 CD N
) ) N
in IN N
the DT N
single-dose JJ N
and CC N
38 CD N
% NN N
( ( N
15/39 CD N
) ) N
in IN N
the DT N
2-dose JJ N
methylprednisolone NN N
groups NNS N
( ( N
P NNP N
= NNP N
.51 NNP N
) ) N
. . N

Two-dose JJ N
methylprednisolone NN N
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
serum NN N
creatinine NN N
( ( N
0.61 CD N
? . N
0.18 CD N
mg/dL NN N
vs NN N
0.53 CD N
? . N
0.12 CD N
mg/dL NN N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC N
poorer $ N
postoperative JJ N
diuresis NN N
( ( N
-96 VB N
? . N
49 CD N
mL NN N
, , N
P NNP N
= NNP N
.05 NNP N
) ) N
. . N

Inotropic NNP N
requirement NN N
, , N
duration NN N
of IN N
mechanical JJ N
ventilation NN N
, , N
intensive JJ N
care NN N
unit NN N
, , N
and CC N
hospital JJ N
stay NN N
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Combined NNP N
preoperative NN N
and CC N
intraoperative JJ N
use NN N
of IN N
glucocorticoids NNS N
in IN N
neonatal JJ N
cardiac JJ N
surgery NN N
does VBZ N
not RB N
favorably RB N
affect VBP N
early JJ N
clinical JJ N
outcomes NNS N
and CC N
may MD N
exacerbate VB N
perioperative JJ N
renal JJ N
dysfunction NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
clinical JJ N
context NN N
on IN N
simulator-based JJ N
assessment NN N
of IN N
blood NN N
pressure NN N
taking VBG N
- : N
a DT N
pilot NN N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Blood NNP N
pressure NN N
measurement NN N
is VBZ N
an DT N
essential JJ N
clinical JJ N
skill NN N
that WDT N
can MD N
readily RB N
be VB N
assessed VBN N
in IN N
objective JJ N
structured JJ N
clinical JJ N
examination NN N
( ( N
OSCE NNP N
) ) N
. . N

While IN N
the DT N
use NN N
of IN N
simulators NNS 6_i
can MD N
enhance VB N
test NN N
validity NN N
and CC N
reliability NN N
, , N
the DT N
given VBN N
clinical JJ N
context NN N
may MD N
also RB N
affect VB N
student NN N
performance NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
variations NNS N
in IN N
clinical JJ N
context NN N
on IN N
blood NN N
pressure NN N
measurement NN N
in IN N
a DT N
simulator-based JJ 6_i
OSCE NNP 6_i
. . N

METHOD NNP N
We PRP N
randomized VBD N
162 CD N
first-year JJ N
medical JJ N
students NNS N
into IN N
four CD N
groups NNS N
that WDT N
received VBD N
different JJ N
lead-in JJ N
statements NNS N
before IN N
measuring VBG N
blood NN N
pressure NN N
on IN N
a DT N
manikin JJ 6_i
simulator NN 6_i
. . N

These DT N
statements NNS N
described VBD N
hypothetical JJ N
patients NNS N
with IN N
different JJ N
likelihoods NNS N
of IN N
having VBG N
systemic JJ N
hypertension NN N
. . N

RESULTS VB N
The DT N
lead-in JJ N
that WDT N
described VBD N
the DT N
highest JJS N
likelihood NN N
of IN N
hypertension NN N
was VBD N
associated VBN N
with IN N
significantly RB N
higher JJR N
reported VBD N
readings NNS N
and CC N
lower JJR N
accuracy NN N
. . N

The DT N
lead-in NN N
that WDT N
suggested VBD N
normality NN N
yielded VBN N
the DT N
best JJS N
performance NN N
. . N

CONCLUSION NNP N
Student NNP N
performance NN N
in IN N
simulator-based JJ 6_i
OSCE NNP 6_i
may MD N
be VB N
affected VBN N
by IN N
the DT N
clinical JJ N
context NN N
provided VBN N
. . N

However RB N
, , N
we PRP N
argue VBP N
that IN N
construct NN N
validity NN N
should MD N
be VB N
viewed VBN N
in IN N
light NN N
of IN N
the DT N
application NN N
of IN N
a DT N
test NN N
, , N
in IN N
that DT N
patients NNS N
may MD N
also RB N
present VB N
with IN N
different JJ N
cues NNS N
and CC N
likelihoods NNS N
of IN N
having VBG N
hypertension NN N
. . N

Variations NNS N
in IN N
construct NN N
design NN N
should MD N
be VB N
further RB N
explored VBN N
to TO N
enhance VB N
the DT N
training NN N
and CC N
assessment NN N
of IN N
clinical JJ N
competence NN N
that WDT N
reflects VBZ N
the DT N
unpredictability NN N
encountered VBN N
in IN N
daily JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

Soluble JJ 3_i
intercellular JJ 3_i
adhesion NN 3_i
molecule-1 NN 3_i
in IN N
primary JJ N
biliary JJ N
cirrhosis NN N
: : N
effect NN N
of IN N
ursodeoxycholic JJ 3_i
acid NN 3_i
and CC N
immunosuppressive JJ 3_i
therapy NN 3_i
. . N

OBJECTIVES NNP N
Soluble JJ N
intercellular JJ N
adhesion NN N
molecule-1 NN N
( ( N
sICAM-1 JJ N
) ) N
is VBZ N
thought VBN N
to TO N
be VB N
released VBN N
by IN N
a DT N
variety NN N
of IN N
cells NNS N
at IN N
sites NNS N
of IN N
inflammation NN N
, , N
and CC N
their PRP$ N
serum NN N
levels NNS N
have VBP N
been VBN N
used VBN N
as IN N
markers NNS N
of IN N
inflammatory NN N
and CC N
immune JJ N
activity NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
therapy NN N
with IN N
ursodeoxycholic JJ 3_i
acid NN 3_i
alone RB 3_i
and CC N
in IN N
combination NN N
with IN N
azathioprine NN 3_i
and CC 3_i
prednisone NN 3_i
on IN N
serum JJ N
sICAM-1 JJ N
levels NNS N
in IN N
primary JJ N
biliary JJ N
cirrhosis NN N
. . N

DESIGN/METHODS NNP N
Twenty-four JJ N
patients NNS N
with IN N
primary JJ N
biliary JJ N
cirrhosis NN N
and CC N
17 CD N
healthy JJ N
subjects NNS N
were VBD N
studied VBN N
. . N

Primary JJ N
biliary JJ N
cirrhosis NN N
patients NNS N
received VBD N
ursodeoxycholic JJ 3_i
acid NN 3_i
for IN N
12 CD N
months NNS N
and CC N
were VBD N
then RB N
randomized VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
to TO N
receive VB N
prednisone NN 3_i
and CC 3_i
azathioprine NN 3_i
, , N
or CC N
placebo NN 7_i
in IN N
addition NN N
to TO N
ursodeoxycholic JJ 3_i
acid NN 3_i
. . N

RESULTS NNP N
sICAM-1 JJ N
levels NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
primary JJ N
biliary JJ N
cirrhosis NN N
patients NNS N
than IN N
healthy JJ N
subjects NNS N
and CC N
fell VBD N
by IN N
a DT N
median NN N
of IN N
20 CD N
% NN N
after IN N
12 CD N
months NNS N
' POS N
therapy NN N
with IN N
ursodeoxycholic JJ 3_i
acid NN 3_i
( ( N
P NNP N
< NNP N
0.0004 CD N
) ) N
. . N

Addition NN N
of IN N
azathioprine NN 3_i
and CC 3_i
prednisone NN 3_i
to TO N
ursodeoxycholic JJ 3_i
acid NN 3_i
resulted VBD N
in IN N
a DT N
further JJ N
reduction NN N
of IN N
sICAM-1 JJ N
levels NNS N
by IN N
a DT N
median NN N
of IN N
25 CD N
% NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Reductions NNPS N
in IN N
sICAM-1 JJ N
were VBD N
accompanied VBN N
by IN N
improvement NN N
in IN N
liver JJ N
function NN N
tests NNS N
but CC N
not RB N
in IN N
the DT N
lymphocyte JJ N
activation NN N
marker NN N
, , N
soluble JJ N
interleukin-2 JJ N
receptor NN N
. . N

CONCLUSION NNP N
sICAM-1 JJ N
levels NNS N
in IN N
primary JJ N
biliary JJ N
cirrhosis NN N
are VBP N
reduced VBN N
by IN N
ursodeoxycholic JJ 3_i
acid NN 3_i
. . N

Further JJ N
reductions NNS N
were VBD N
achieved VBN N
by IN N
adding VBG N
prednisone NN 3_i
and CC 3_i
azathioprine NN 3_i
. . N

These DT N
reductions NNS N
probably RB N
reflect VBP N
an DT N
improvement NN N
in IN N
hepatobiliary JJ N
excretion NN N
and CC N
a DT N
reduction NN N
in IN N
cellular JJ N
production NN N
of IN N
sICAM-1 NN N
. . N

-DOCSTART- -X- O O

Vancomycin NNP 3_i
added VBD N
to TO N
empirical JJ N
combination NN N
antibiotic JJ N
therapy NN N
for IN N
fever NN N
in IN N
granulocytopenic JJ N
cancer NN N
patients NNS N
. . N

European JJ N
Organization NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
( ( N
EORTC NNP N
) ) N
International NNP N
Antimicrobial NNP N
Therapy NNP N
Cooperative NNP N
Group NNP N
and CC N
the DT N
National NNP N
Cancer NNP N
Institute NNP N
of IN N
Canada-Clinical NNP N
Trials NNP N
Group NNP N
. . N

A NNP N
total NN N
of IN N
747 CD N
febrile JJ N
granulocytopenic JJ N
patients NNS N
with IN N
cancer NN N
were VBD N
randomized VBN N
to TO N
receive VB N
ceftazidime NN 3_i
plus CC 3_i
amikacin NN 3_i
( ( 3_i
CA NNP 3_i
) ) 3_i
with IN 3_i
or CC 3_i
without IN 3_i
vancomycin NN 3_i
( ( 3_i
V NNP 3_i
) ) 3_i
as IN N
initial JJ N
empirical JJ N
therapy NN N
. . N

Single NNP N
gram-positive JJ N
bacteremias NN N
responded VBD N
in IN N
29 CD N
( ( N
43 CD N
% NN N
) ) N
of IN N
68 CD N
patients NNS N
treated VBN N
with IN N
CA NNP N
and CC N
in IN N
48 CD N
( ( N
72 CD N
% NN N
) ) N
of IN N
67 CD N
treated JJ N
with IN N
CAV NNP N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

For IN N
single JJ N
gram-negative JJ N
bacteremias NN N
and CC N
clinically RB N
documented VBN N
and CC N
possible JJ N
infections NNS N
the DT N
response NN N
rates NNS N
of IN N
CA NNP N
and CC N
CAV NNP N
were VBD N
80 CD N
% NN N
and CC N
63 CD N
% NN N
( ( N
P NNP N
= NNP N
.17 NNP N
) ) N
, , N
55 CD N
% NN N
and CC N
75 CD N
% NN N
( ( N
P NNP N
= NNP N
.009 NNP N
) ) N
, , N
and CC N
74 CD N
% NN N
and CC N
81 CD N
% NN N
( ( N
P NNP N
= NNP N
.16 NNP N
) ) N
, , N
respectively RB N
. . N

However RB N
, , N
for IN N
patients NNS N
with IN N
gram-positive JJ N
bacteremia NN N
and CC N
for IN N
all DT N
other JJ N
patients NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
by IN N
treatment NN N
regimens NNS N
in IN N
the DT N
proportion NN N
of IN N
febrile JJ N
patients NNS N
on IN N
each DT N
trial NN N
day NN N
( ( N
P NNP N
= NNP N
.85 NNP N
, , N
P NNP N
= NNP N
.82 NNP N
, , N
respectively RB N
) ) N
or CC N
in IN N
the DT N
duration NN N
of IN N
fever NN N
( ( N
P NNP N
= NNP N
.22 NNP N
, , N
P NNP N
= NNP N
.93 NNP N
, , N
respectively RB N
) ) N
. . N

Moreover RB N
, , N
no DT N
patient NN N
with IN N
gram-positive JJ N
bacteremia NN N
died VBD N
during IN N
the DT N
first JJ N
3 CD N
days NNS N
of IN N
true JJ N
empirical JJ N
therapy NN N
. . N

Antibiotic-associated JJ N
nephrotoxicity NN N
was VBD N
more RBR N
frequent JJ N
in IN N
patients NNS N
treated VBN N
with IN N
vancomycin NN N
( ( N
6 CD N
% NN N
vs. FW N
2 CD N
% NN N
, , N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

These DT N
results NNS N
do VBP N
not RB N
support VB N
the DT N
empirical JJ N
addition NN N
of IN N
vancomycin NN N
to TO N
initial JJ N
antibiotic JJ N
therapy NN N
in IN N
cancer NN N
patients NNS N
with IN N
fever NN N
and CC N
granulocytopenia NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
tailored JJ N
skin NN N
cancer NN N
prevention NN N
messages NNS N
for IN N
adults NNS N
: : N
Project NN N
SCAPE NNP N
. . N

OBJECTIVES NNP N
We PRP N
evaluated VBD N
the DT N
impact NN N
of IN N
a DT N
mailed VBN 4_i
, , 4_i
tailored VBN 4_i
intervention NN 4_i
on IN N
skin JJ N
cancer NN N
prevention NN N
and CC N
skin JJ N
self-examination NN N
behaviors NNS N
of IN N
adults NNS N
at IN N
moderate JJ N
and CC N
high JJ N
risk NN N
for IN N
skin JJ N
cancer NN N
. . N

METHODS NNP N
Adults NNP N
at IN N
moderate NNP N
and CC N
high JJ N
risk NN N
for IN N
skin JJ N
cancer NN N
were VBD N
recruited VBN N
in IN N
primary JJ N
health NN N
care NN N
settings NNS N
in IN N
Honolulu NNP N
, , N
HI NNP N
, , N
and CC N
Long NNP N
Island NNP N
, , N
NY NNP N
. . N

After IN N
completing VBG N
a DT N
baseline NN N
survey NN N
, , N
participants NNS N
were VBD N
randomized VBN N
to TO N
2 CD N
groups NNS N
. . N

The DT N
treatment NN N
group NN N
received VBD N
tailored JJ 4_i
materials NNS 4_i
, , 4_i
including VBG 4_i
personalized VBN 4_i
risk NN 4_i
feedback NN 4_i
, , N
and CC N
the DT N
control NN N
group NN N
received VBD N
general JJ 4_i
educational JJ 4_i
materials NNS 4_i
. . N

Multivariate NNP N
analyses NNS N
compared VBN N
sun JJ N
protection NN N
and CC N
skin VB N
self-examination NN N
between IN N
groups NNS N
, , N
controlling VBG N
for IN N
location NN N
, , N
risk NN N
level NN N
, , N
gender NN N
, , N
and CC N
age NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
596 CD N
adults NNS N
completed VBD N
the DT N
trial NN N
. . N

The DT N
tailored JJ N
materials NNS N
had VBD N
a DT N
significant JJ N
effect NN N
on IN N
overall JJ N
sun-protection NN N
habits NNS N
, , N
the DT N
use NN N
of IN N
hats NNS N
, , N
the DT N
use NN N
of IN N
sunglasses NNS N
, , N
and CC N
the DT N
recency NN N
of IN N
skin JJ N
self-examination NN N
. . N

Some DT N
effects NNS N
were VBD N
moderated VBN N
by IN N
location NN N
and CC N
risk NN N
level NN N
. . N

CONCLUSIONS NNP N
Tailored NNP 4_i
communications NNS 4_i
including VBG N
personalized VBN N
risk NN N
feedback NN N
can MD N
improve VB N
sun-protection NN N
behaviors NNS N
and CC N
skin JJ N
self-examination NN N
among IN N
adults NNS N
at IN N
increased VBN N
risk NN N
for IN N
skin JJ N
cancer NN N
. . N

These DT N
convenient NN N
, , N
low-cost JJ N
interventions NNS N
can MD N
be VB N
implemented VBN N
in IN N
a DT N
variety NN N
of IN N
settings NNS N
and CC N
should MD N
be VB N
tested VBN N
further JJ N
to TO N
assess VB N
their PRP$ N
long-term JJ N
effectiveness NN N
. . N

-DOCSTART- -X- O O

Safety NN N
, , N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
GS-9620 NNP 3_i
, , N
an DT N
oral JJ N
Toll-like NNP N
receptor NN N
7 CD N
agonist NN N
. . N

BACKGROUND NNP N
GS-9620 NNP 3_i
is VBZ N
a DT N
novel JJ N
oral JJ N
agonist NN N
of IN N
Toll-like NNP N
receptor NN N
7 CD N
( ( N
TLR7 NNP N
) ) N
in IN N
development NN N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
viral JJ N
hepatitis NN N
. . N

TLR7 NNP N
is VBZ N
a DT N
highly RB N
conserved JJ N
innate NN N
immune NN N
receptor NN N
expressed VBD N
primarily RB N
on IN N
plasmacytoid JJ N
dendritic JJ N
cells NNS N
and CC N
B NNP N
lymphocytes NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
, , N
single JJ N
ascending-dose JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
safety NN N
, , N
tolerability NN N
, , N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
GS-9620 NNP 3_i
in IN N
healthy JJ N
volunteers NNS N
. . N

METHODS NNP N
In IN N
total JJ N
, , N
75 CD N
healthy JJ N
volunteers NNS N
( ( N
8 CD N
subjects NNS N
in IN N
each DT N
of IN N
the DT N
10 CD N
cohorts NNS N
; : N
5 CD N
subjects NNS N
participated VBN N
in IN N
two CD N
cohorts NNS N
) ) N
were VBD N
randomized VBN N
( ( N
6:2 CD N
) ) N
to TO N
receive VB N
a DT N
single JJ 3_i
dose NN 3_i
of IN 3_i
GS-9620 NNP 3_i
( ( 3_i
0.3 CD 3_i
, , 3_i
1 CD 3_i
, , 3_i
2 CD 3_i
, , 3_i
4 CD 3_i
, , 3_i
6 CD 3_i
, , 3_i
8 CD 3_i
or CC 3_i
12 CD 3_i
mg NN 3_i
) ) 3_i
or CC N
placebo NN 7_i
. . N

RESULTS NNP N
GS-9620 NNP 3_i
was VBD N
well-absorbed JJ N
and CC N
well-tolerated JJ N
in IN N
oral JJ N
doses NNS N
up RB N
to TO N
12 CD N
mg NN N
. . N

Minimal JJ N
treatment-related JJ N
adverse JJ N
events NNS N
were VBD N
seen VBN N
at IN N
doses NNS N
up RB N
to TO N
8 CD N
mg. NNS N
Serum NNP N
interferon NN N
( ( N
IFN NNP N
) ) N
-? NN N
was VBD N
only RB N
detected VBN N
in IN N
subjects NNS N
who WP N
received VBD N
8 CD N
or CC N
12 CD N
mg NN N
doses NNS N
, , N
and CC N
the DT N
adverse JJ N
event NN N
profile NN N
at IN N
8 CD N
and CC N
12 CD N
mg NN N
doses NNS N
was VBD N
generally RB N
consistent JJ N
with IN N
that DT N
associated VBN N
with IN N
IFN-? NNP N
exposure NN N
( ( N
flu-like JJ N
symptoms NNS N
) ) N
, , N
consistent JJ N
with IN N
the DT N
mechanism NN N
of IN N
TLR7 NNP N
agonism NN N
. . N

All DT N
adverse JJ N
events NNS N
resolved VBD N
within IN N
72 CD N
h. JJ N
Induction NNP N
of IN N
chemokines/cytokines NNS N
and CC N
IFN-stimulated JJ N
genes NNS N
were VBD N
seen VBN N
at IN N
GS-9620 NNP N
doses NNS N
? . N
2 CD N
mg NN N
, , N
well RB N
below IN N
doses NNS N
that WDT N
induced VBD N
serum JJ N
IFN-? NNP N
or CC N
led VBN N
to TO N
clinical JJ N
adverse JJ N
events NNS N
. . N

CONCLUSIONS NNP N
GS-9620 NNP N
demonstrates VBZ N
safety NN N
and CC N
pharmacodynamic JJ N
activity NN N
at IN N
doses VBZ N
up RB N
to TO N
12 CD N
mg. NNS N
Pharmacodynamic NNP N
activity NN N
is VBZ N
seen VBN N
before IN N
adverse JJ N
events NNS N
, , N
suggesting VBG N
the DT N
potential NN N
for IN N
induction NN N
of IN N
an DT N
antiviral JJ N
response NN N
without IN N
systemic JJ N
adverse JJ N
events NNS N
in IN N
subjects NNS N
with IN N
chronic JJ N
viral JJ N
hepatitis NN N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
adult NN 4_i
intervention NN 4_i
on IN N
infants NNS N
' POS N
level NN N
of IN N
attention NN N
. . N

The DT N
effects NNS N
of IN N
adult NN 4_i
intervention NN 4_i
on IN N
infants NNS N
' POS N
level NN N
of IN N
attention NN N
to TO N
objects NNS N
were VBD N
studied VBN N
with IN N
10-month-old JJ N
infants NNS N
. . N

After IN N
a DT N
baseline JJ N
measure NN N
of IN N
spontaneous JJ N
attention NN N
was VBD N
obtained VBN N
, , N
infants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
conditions NNS N
( ( N
low JJ 4_i
, , 4_i
medium NN 4_i
, , 4_i
high JJ 4_i
intervention NN 4_i
, , N
or CC N
no-intervention JJ 2_i
control NN N
) ) N
. . N

Level NN N
of IN N
intervention NN N
was VBD N
controlled VBN N
by IN N
systematically RB N
varying VBG N
the DT N
manner NN 4_i
and CC 4_i
frequency NN 4_i
with IN 4_i
which WDT 4_i
objects NNS 4_i
were VBD 4_i
presented VBN 4_i
, , N
the DT N
extent NN 4_i
to TO 4_i
which WDT 4_i
the DT 4_i
experimenter NN 4_i
talked VBD 4_i
to TO 4_i
the DT 4_i
infant NN 4_i
, , N
and CC N
physical JJ 4_i
proximity NN 4_i
. . N

Infant JJ N
attention NN N
was VBD N
defined VBN N
as IN N
duration NN N
of IN N
time NN N
spent VBN N
examining VBG N
objects NNS N
. . N

The DT N
overall JJ N
duration NN N
of IN N
infant JJ N
attention NN N
increased VBD N
during IN N
medium NN N
intervention NN N
when WRB N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Baseline NNP N
attention NN N
was VBD N
then RB N
used VBN N
to TO N
separate VB N
low JJ N
and CC N
high JJ N
attenders NNS N
. . N

Low JJ N
attending VBG N
infants NNS N
attended VBD N
more RBR N
in IN N
medium NN N
and CC N
high JJ N
intervention NN N
than IN N
in IN N
the DT N
low JJ N
condition NN N
, , N
while IN N
high JJ N
attending VBG N
infants NNS N
were VBD N
unaffected VBN N
by IN N
intervention NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
level NN N
of IN N
intervention NN 4_i
interacts NNS N
with IN N
the DT N
child NN N
's POS N
spontaneous JJ N
tendency NN N
to TO N
focus VB N
attention NN N
on IN N
objects NNS N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
amantadine NN 3_i
on IN N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
treated VBD N
with IN N
interferon-alpha JJ 3_i
and CC 3_i
ribavirin NN 3_i
: : N
results NNS N
from IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ 7_i
, , N
double-blind JJ N
trial NN N
. . N

AIM VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
amantadine JJ N
reduces NNS N
deterioration NN N
of IN N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
during IN N
and CC N
after IN N
treatment NN N
with IN N
interferon-alpha JJ N
( ( N
IFN-alpha NNP N
) ) N
and CC N
ribavirin NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
, , N
prospective JJ N
, , N
placebo-controlled JJ 7_i
, , N
multicenter JJ N
trial NN N
, , N
previously RB N
untreated JJ N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
were VBD N
treated VBN N
with IN N
IFN-alpha NNP 3_i
plus CC 3_i
ribavirin JJ 3_i
[ NN 3_i
17 CD 3_i
] NN 3_i
and CC N
randomized VBN N
for IN N
treatment NN N
with IN N
amantadine NN 3_i
( ( N
200 CD N
mg/day NN N
, , N
orally RB N
, , N
n=136 NN N
) ) N
or CC N
placebo NN 7_i
( ( N
n=131 JJ N
) ) N
. . N

Quality NN N
of IN N
life NN N
was VBD N
assessed VBN N
with IN N
the DT N
'Profile NN N
of IN N
Mood NNP N
States NNPS N
' POS N
scale NN N
and CC N
the DT N
'Everyday JJ N
Life NNP N
' POS N
questionnaire NN N
at IN N
baseline NN N
, , N
treatment NN N
week NN N
( ( N
TW NNP N
) ) N
8 CD N
, , N
TW24 NNP N
, , N
TW48 NNP N
, , N
and CC N
at IN N
follow-up JJ N
. . N

RESULTS VB N
Early JJ N
during IN N
treatment NN N
at IN N
TW8 NNP N
, , N
quality NN N
of IN N
life NN N
was VBD N
not RB N
different JJ N
between IN N
patients NNS N
in IN N
the DT N
control NN N
and CC N
the DT N
amantadine NN N
group NN N
. . N

At IN N
TW24 NNP N
, , N
the DT N
control NN N
group NN N
but CC N
not RB N
the DT N
amantadine NN 3_i
group NN N
, , N
however RB N
, , N
showed VBD N
significant JJ N
deterioration NN N
of IN N
the DT N
modalities NNS N
depression NN N
, , N
fatigue NN N
, , N
and CC N
vigor NN N
compared VBN N
with IN N
baseline NN N
. . N

Especially RB N
, , N
nonresponders NNS N
in IN N
the DT N
amantadine NN N
group NN N
showed VBD N
significantly RB N
lower JJR N
deterioration NN N
of IN N
depression NN N
, , N
anger NN N
, , N
mind NN N
function NN N
, , N
everyday JJ N
life NN N
, , N
and CC N
zest JJS N
for IN N
life NN N
than IN N
those DT N
in IN N
the DT N
placebo NN 7_i
group NN N
. . N

After IN N
treatment NN N
, , N
the DT N
beneficial JJ N
effects NNS N
of IN N
amantadine NN N
disappeared VBN N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
amantadine NN 3_i
to TO N
IFN-alpha NNP 3_i
plus CC 3_i
ribavirin JJ 3_i
combination NN N
therapy NN N
may MD N
reduce VB N
deterioration NN N
of IN N
depression NN N
, , N
fatigue NN N
, , N
and CC N
vigor NN N
during IN N
treatment NN N
but CC N
does VBZ N
not RB N
affect JJ N
quality NN N
of IN N
life NN N
after IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Tomato NNP 3_i
paste NN 3_i
rich JJ 3_i
in IN 3_i
lycopene JJ 3_i
protects NNS N
against IN N
cutaneous JJ N
photodamage NN N
in IN N
humans NNS N
in IN N
vivo NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Previous NNP N
epidemiological JJ N
, , N
animal JJ N
and CC N
human JJ N
data NNS N
report NN N
that IN N
lycopene NN N
has VBZ N
a DT N
protective JJ N
effect NN N
against IN N
ultraviolet NN N
radiation NN N
( ( N
UVR NNP N
) ) N
-induced VBD N
erythema NN N
. . N

OBJECTIVES IN N
We PRP N
examined VBD N
whether IN N
tomato NN 3_i
paste NN 3_i
-- : 3_i
rich JJ 3_i
in IN 3_i
lycopene NN 3_i
, , N
a DT N
powerful JJ N
antioxidant NN N
-- : N
can MD N
protect VB N
human JJ N
skin NN N
against IN N
UVR-induced JJ N
effects NNS N
partially RB N
mediated VBN N
by IN N
oxidative JJ N
stress NN N
, , N
i.e NN N
. . N

erythema NN N
, , N
matrix NN N
changes NNS N
and CC N
mitochondrial JJ N
DNA NNP N
( ( N
mtDNA NN N
) ) N
damage NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
study NN N
, , N
20 CD N
healthy JJ N
women NNS N
( ( N
median JJ N
age NN N
33 CD N
years NNS N
, , N
range VBP N
21-47 JJ N
; : N
phototype JJ N
I/II NNP N
) ) N
ingested VBD N
55 CD 2_i
g NN 2_i
tomato NN 2_i
paste NN 2_i
( ( 2_i
16 CD 2_i
mg RB 2_i
lycopene NN 2_i
) ) 2_i
in IN 2_i
olive JJ 2_i
oil NN 2_i
, , 2_i
or CC 2_i
olive JJ 2_i
oil NN 2_i
alone RB 2_i
, , 2_i
daily JJ 2_i
for IN 2_i
12 CD 2_i
weeks NNS 2_i
. . 2_i

Pre- NNP N
and CC N
postsupplementation NN N
, , N
UVR NNP N
erythemal JJ N
sensitivity NN N
was VBD N
assessed VBN N
visually RB N
as IN N
the DT N
minimal JJ N
erythema NN N
dose NN N
( ( N
MED NNP N
) ) N
and CC N
quantified VBN N
with IN N
a DT N
reflectance NN N
instrument NN N
. . N

Biopsies NNS N
were VBD N
taken VBN N
from IN N
unexposed JJ N
and CC N
UVR-exposed JJ N
( ( N
3 CD N
? . N
MED NNP N
24 CD N
h NN N
earlier RBR N
) ) N
buttock NN N
skin JJ N
pre- NN N
and CC N
postsupplementation NN N
, , N
and CC N
analysed VBD N
immunohistochemically RB N
for IN N
procollagen NN N
( ( N
pC NN N
) ) N
I PRP N
, , N
fibrillin-1 JJ N
and CC N
matrix JJ N
metalloproteinase NN N
( ( N
MMP NNP N
) ) N
-1 NN N
, , N
and CC N
by IN N
quantitative JJ N
polymerase NN N
chain NN N
reaction NN N
for IN N
mtDNA JJ N
3895-bp JJ N
deletion NN N
. . N

RESULTS VB N
Mean NNP N
? . N
SD NNP N
erythemal JJ N
D NNP N
( ( N
30 CD N
) ) N
was VBD N
significantly RB N
higher JJR N
following VBG N
tomato JJ N
paste NN N
vs. FW N
control NN N
( ( N
baseline NN N
, , N
26?5 CD N
? . N
7?5 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
control NN N
, , N
23 CD N
? . N
6?6 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
tomato CC N
paste NN N
, , N
36?6 CD N
? . N
14?7 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
P NNP N
= NNP N
0?03 CD N
) ) N
, , N
while IN N
the DT N
MED NNP N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
( ( N
baseline NN N
, , N
35?1 CD N
? . N
9?9 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
control NN N
, , N
32?6 CD N
? . N
9?6 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
tomato CC N
paste NN N
, , N
42?2 CD N
? . N
11?3 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
) ) N
. . N

Presupplementation NN N
, , N
UVR NNP N
induced VBD N
an DT N
increase NN N
in IN N
MMP-1 NNP N
( ( N
P NNP N
= NNP N
0?01 CD N
) ) N
and CC N
a DT N
reduction NN N
in IN N
fibrillin-1 NN N
( ( N
P NNP N
= NNP N
0?03 CD N
) ) N
. . N

Postsupplementation NN N
, , N
UVR-induced JJ N
MMP-1 NNP N
was VBD N
reduced VBN N
in IN N
the DT N
tomato NN N
paste NN N
vs. FW N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0?04 CD N
) ) N
, , N
while IN N
the DT N
UVR-induced JJ N
reduction NN N
in IN N
fibrillin-1 NN N
was VBD N
similarly RB N
abrogated VBN N
in IN N
both DT N
groups NNS N
, , N
and CC N
an DT N
increase NN N
in IN N
pCI JJ N
deposition NN N
was VBD N
seen VBN N
following VBG N
tomato JJ N
paste NN N
( ( N
P NNP N
= NNP N
0?05 CD N
) ) N
. . N

mtDNA JJ N
3895-bp JJ N
deletion NN N
following VBG N
3 CD N
? . N
MED NNP N
UVR NNP N
was VBD N
significantly RB N
reduced VBN N
postsupplementation NN N
with IN N
tomato JJ N
paste NN N
( ( N
P NNP N
= NNP N
0?01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Tomato NNP N
paste NN N
containing VBG N
lycopene NNP N
provides VBZ N
protection NN N
against IN N
acute NN N
and CC N
potentially RB N
longer-term JJ N
aspects NNS N
of IN N
photodamage NN N
. . N

-DOCSTART- -X- O O

Visual JJ N
field NN N
progression NN N
in IN N
the DT N
Collaborative NNP N
Initial NNP N
Glaucoma NNP N
Treatment NNP N
Study NNP N
the DT N
impact NN N
of IN N
treatment NN N
and CC N
other JJ N
baseline NN N
factors NNS N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
factors NNS N
associated VBN N
with IN N
visual JJ N
field NN N
( ( N
VF NNP N
) ) N
progression NN N
, , N
using VBG N
all DT N
available JJ N
follow-up NNS N
through IN N
9 CD N
years NNS N
after IN N
treatment NN N
initiation NN N
, , N
in IN N
the DT N
Collaborative NNP N
Initial NNP N
Glaucoma NNP N
Treatment NNP N
Study NNP N
( ( N
CIGTS NNP N
) ) N
. . N

DESIGN NNP N
Longitudinal NNP N
follow-up NN N
of IN N
participants NNS N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

PARTICIPANTS NNP N
Six NNP N
hundred VBD N
seven CD N
newly RB N
diagnosed VBN N
glaucoma NN N
patients NNS N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
607 CD N
subjects NNS N
with IN N
newly RB N
diagnosed VBN N
open-angle JJ N
glaucoma NN N
initially RB N
were VBD N
treated VBN 3_i
with IN 3_i
either DT 3_i
medication NN 3_i
or CC 3_i
trabeculectomy NN 3_i
. . N

After IN N
treatment NN N
initiation NN N
and CC N
early JJ N
follow-up NN N
, , N
subjects NNS N
were VBD N
evaluated VBN N
clinically RB N
at IN N
6-month JJ N
intervals NNS N
. . N

Study NNP N
participants NNS N
in IN N
both DT N
arms NNS N
of IN N
the DT N
CIGTS NNP N
were VBD N
treated VBN 2_i
aggressively RB 2_i
in IN 2_i
an DT 2_i
effort NN 2_i
to TO 2_i
reduce VB 2_i
intraocular JJ 2_i
pressure NN 2_i
( ( 2_i
IOP NNP 2_i
) ) 2_i
to TO 2_i
a DT 2_i
level NN 2_i
at IN 2_i
or CC 2_i
below IN 2_i
a DT 2_i
predetermined JJ 2_i
, , 2_i
eye-specific JJ 2_i
target NN 2_i
pressure NN 2_i
. . 2_i

Visual JJ 2_i
field NN 2_i
progression NN 2_i
was VBD 2_i
analyzed VBN 2_i
using VBG 2_i
repeated JJ 2_i
measures NNS 2_i
models NNS 2_i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Visual NNP N
field NN N
progression NN N
, , N
measured VBN N
by IN N
Humphrey NNP N
24-2 JJ N
full-threshold JJ N
testing NN N
and CC N
assessed VBN N
by IN N
the DT N
change NN N
in IN N
the DT N
mean JJ N
deviation NN N
( ( N
MD NNP N
) ) N
, , N
and CC N
an DT N
indicator NN N
of IN N
substantial JJ N
worsening NN N
of IN N
the DT N
VF NNP N
( ( N
MD NNP N
decrease NN N
of IN N
> NN N
or CC N
=3 JJ N
dB NN N
from IN N
baseline NN N
) ) N
, , N
assessed VBN N
at IN N
each DT N
follow-up JJ N
visit NN N
. . N

RESULTS NNP N
Follow-up NNP N
indicated VBD N
minimal JJ N
change NN N
from IN N
baseline NN N
in IN N
each DT N
initial JJ N
treatment NN N
group NN N
's POS N
average JJ N
MD NNP N
. . N

However RB N
, , N
at IN N
the DT N
8-year JJ N
follow-up JJ N
examination NN N
, , N
substantial JJ N
worsening NN N
( ( N
> CD N
or CC N
=3 VB N
dB NN N
) ) N
of IN N
MD NNP N
from IN N
baseline NN N
was VBD N
found VBN N
in IN N
21.3 CD N
% NN N
and CC N
25.5 CD N
% NN N
of IN N
the DT N
initial JJ N
surgery NN N
and CC N
initial JJ N
medicine NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
effect NN N
of IN N
initial JJ N
treatment NN N
on IN N
subsequent JJ N
VF NNP N
loss NN N
was VBD N
modified VBN N
by IN N
time NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
baseline JJ N
MD NNP N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
diabetes NNS N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

Initial JJ 1_i
surgery NN 1_i
led VBD N
to TO N
less RBR N
VF NNP N
progression NN N
than IN N
initial JJ 3_i
medicine NN 3_i
in IN N
subjects NNS N
with IN N
advanced JJ N
VF NNP N
loss NN N
at IN N
baseline NN N
, , N
whereas JJ N
subjects NNS N
with IN N
diabetes NNS N
had VBD N
more RBR N
VF JJ N
loss NN N
over IN N
time NN N
if IN N
treated VBN N
initially RB N
with IN N
surgery NN N
. . N

CONCLUSIONS VB N
The DT N
CIGTS NNP N
intervention NN N
protocol NN N
led VBD N
to TO N
a DT N
lowering NN N
of IN N
IOP NNP N
that WDT N
persisted VBD N
over IN N
time NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Progression NN N
in IN N
VF NNP N
loss NN N
was VBD N
seen VBN N
in IN N
a DT N
subset NN N
, , N
increasing VBG N
to TO N
more JJR N
than IN N
20 CD N
% NN N
of IN N
the DT N
subjects NNS N
. . N

The DT N
findings NNS N
regarding VBG N
initial JJ N
surgery NN N
being VBG N
beneficial JJ N
for IN N
subjects NNS N
with IN N
more RBR N
advanced JJ N
VF NNP N
loss NN N
at IN N
presentation NN N
, , N
but CC N
detrimental JJ N
for IN N
patients NNS N
with IN N
diabetes NNS N
, , N
are VBP N
noteworthy JJ N
and CC N
warrant JJ N
independent JJ N
confirmation NN N
. . N

FINANCIAL NNP N
DISCLOSURE NNP N
( ( N
S NNP N
) ) N
The DT N
author NN N
( ( N
s PRP N
) ) N
have VBP N
no DT N
proprietary JJ N
or CC N
commercial JJ N
interest NN N
in IN N
any DT N
materials NNS N
discussed VBN N
in IN N
this DT N
article NN N
. . N

-DOCSTART- -X- O O

Validity NNP N
and CC N
reliability NN N
assessment NN N
of IN N
the DT N
Siriraj NNP 6_i
Asthma NNP 6_i
Control NNP 6_i
Questionnaire NNP 6_i
. . N

OBJECTIVE CC N
The DT N
present JJ N
study NN N
assessed VBD N
the DT N
validity NN N
and CC N
reliability NN N
of IN N
the DT N
Siriraj NNP 6_i
Asthma NNP 6_i
Control NNP 6_i
Questionnaire NNP 6_i
in IN N
Asthma NNP N
Clinic NNP N
, , N
Siriraj NNP N
Hospital NNP N
. . N

MATERIAL NNP N
AND CC N
METHOD NNP N
The DT N
data NN N
of IN N
the DT N
questionnaire NN N
responses NNS N
and CC N
spirometric JJ N
results NNS N
from IN N
20 CD N
randomized JJ N
asthmatic JJ N
patients NNS N
in IN N
the DT N
clinic NN N
including VBG N
the DT N
record NN N
of IN N
3 CD N
visits NNS N
for IN N
each DT N
subject NN N
. . N

The DT N
validation NN N
was VBD N
performed VBN N
by IN N
Kruskal-Wallis NNP 6_i
test NN 6_i
comparing VBG N
the DT N
scores NNS N
with IN N
the DT N
level NN N
of IN N
asthma NNS N
control NN N
determined VBN N
by IN N
physicians NNS N
according VBG N
to TO N
GINA NNP N
guideline NN N
. . N

Internal NNP N
consistency NN N
reliability NN N
was VBD N
analyzed VBN N
by IN N
Cronbach NNP N
's POS N
alpha NN N
. . N

RESULTS NNP N
Sixty NNP N
questionnaires VBZ N
from IN N
20 CD N
patients NNS N
with IN N
age NN N
29-73 CD N
years NNS N
were VBD N
analyzed VBN N
. . N

There EX N
were VBD N
40 CD N
controlled VBN N
, , N
7 CD N
partly RB N
controlled VBN N
and CC N
13 CD N
uncontrolled JJ N
visits NNS N
. . N

The DT N
scores NNS N
from IN N
5-items JJ N
questionnaires NNS N
and CC N
6-items JJ N
clinical JJ N
score NN N
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
physician-diagnosed JJ N
groups NNS N
( ( N
i.e. FW N
, , N
controlled VBD N
, , N
partly RB N
controlled VBN N
and CC N
uncontrolled JJ N
groups NNS N
) ) N
. . N

Median JJ N
scores NNS N
( ( N
min NN N
, , N
max NN N
) ) N
were VBD N
0 CD N
( ( N
0 CD N
, , N
5 CD N
) ) N
, , N
2 CD N
( ( N
0 CD N
, , N
6 CD N
) ) N
, , N
4 CD N
( ( N
0 CD N
, , N
12 CD N
) ) N
respectively RB N
, , N
( ( N
5-items CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
and CC N
2 CD N
( ( N
0 CD N
, , N
7 CD N
) ) N
, , N
3 CD N
( ( N
1 CD N
, , N
7 CD N
) ) N
, , N
6 CD N
( ( N
2,15 CD N
) ) N
respectively RB N
, , N
( ( N
6-items CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
. . N

Internal NNP N
consistency NN N
reliability NN N
of IN N
both DT N
5-items JJ N
questionnaire NN N
and CC N
6-items JJ N
clinical JJ N
score NN N
were VBD N
within IN N
the DT N
acceptable JJ N
range NN N
( ( N
0.829 CD N
and CC N
0.708 CD N
respectively RB N
) ) N
. . N

5-items JJ N
questionnaire NN N
is VBZ N
more RBR N
associated JJ N
with IN N
the DT N
physician NN N
diagnosed VBN N
group NN N
and CC N
more JJR N
consistent JJ N
than IN N
6-items JJ N
clinical JJ N
score NN N
. . N

Further JJ N
analysis NN N
revealed VBD N
cutoff NN N
point NN N
at IN N
2.5 CD N
to TO N
separate VB N
uncontrolled JJ N
from IN N
controlled VBN N
or CC N
partly RB N
controlled VBN N
patient NN N
with IN N
sensitivity NN N
76.9 CD N
% NN N
and CC N
specificity NN N
89.4 CD N
% NN N
and CC N
cutoff NN N
point NN N
at IN N
1.5 CD N
to TO N
separate VB N
uncontrolled JJ N
or CC N
partly RB N
controlled VBN N
from IN N
controlled VBN N
patient NN N
with IN N
sensitivity NN N
70.0 CD N
% NN N
and CC N
specificity NN N
85.0 CD N
% NN N
. . N

CONCLUSION NNP N
The DT N
validity NN N
and CC N
reliability NN N
of IN N
Siriraj NNP 6_i
Asthma NNP 6_i
Control NNP 6_i
Questionnaire NNP 6_i
is VBZ N
acceptable JJ N
and CC N
might MD N
be VB N
used VBN N
in IN N
the DT N
clinical JJ N
practice NN N
and CC N
research NN N
in IN N
Thai NNP N
asthmatic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Intermittent NNP 2_i
recombinant JJ 2_i
growth NN 2_i
hormone NN 2_i
treatment NN 2_i
in IN N
short JJ N
children NNS N
born VBP N
small JJ N
for IN N
gestational JJ N
age NN N
: : N
four-year JJ N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
different JJ N
treatment NN N
regimens NNS N
. . N

BACKGROUND NNP N
Treatment NNP N
of IN N
short JJ N
children NNS N
born VBP N
small JJ N
for IN N
gestational JJ N
age NN N
SGA NNP N
with IN N
recombinant JJ 3_i
human JJ 3_i
growth NN 3_i
hormone VBD 3_i
r-hGH JJ 3_i
increases NNS N
growth NN N
velocity NN N
during IN N
childhood NN N
. . N

As IN N
in IN N
other JJ N
indications NNS N
, , N
the DT N
growth NN N
velocity NN N
in IN N
these DT N
patients NNS N
is VBZ N
more JJR N
marked JJ N
during IN N
the DT N
first JJ N
year NN N
of IN N
treatment NN N
and CC N
then RB N
decreases VBZ N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
different JJ N
r-hGH JJ N
treatment NN N
schedules NNS N
( ( N
67 CD N
microg/kg/day NN N
in IN N
a DT N
discontinuous JJ N
or CC N
continuous JJ N
regimen NNS N
) ) N
during IN N
the DT N
second JJ N
year NN N
of IN N
r-hGH JJ N
treatment NN N
by IN N
comparing VBG N
height JJ N
velocity NN N
changes NNS N
and CC N
total JJ N
gain NN N
of IN N
height NN N
over IN N
a DT N
4-year JJ N
period NN N
. . N

METHODS $ N
58 CD N
growth-retarded JJ N
SGA NNP N
children NNS N
aged VBN N
2-5 CD N
years NNS N
were VBD N
randomized VBN N
to TO N
a DT N
TOTO NNP 3_i
regimen NN 3_i
( ( N
4 CD N
years NNS N
alternating VBG N
treatment NN N
( ( N
T NNP N
) ) N
and CC N
observation NN N
( ( N
O NNP N
) ) N
, , N
n JJ N
= NNP N
30 CD N
) ) N
or CC N
a DT N
TTOO JJ N
regimen NN N
( ( N
2 CD N
years NNS N
' POS N
treatment NN N
, , N
followed VBN N
by IN N
2 CD N
years NNS N
' POS N
observation NN N
, , N
n JJ N
= NNP N
28 CD N
) ) N
. . N

Height NNP N
velocity NN N
HV NNP N
and CC N
total JJ N
height NN N
gain NN N
were VBD N
assessed VBN N
during IN N
the DT N
4-year JJ N
study NN N
. . N

RESULTS NNP N
In IN N
both DT N
groups NNS N
, , N
HV NNP N
and CC N
HV NNP N
standard JJ N
deviation NN N
score VBD N
HV-SDSCA NNP N
increased VBD N
during IN N
treatment NN N
and CC N
decreased VBD N
during IN N
observation NN N
periods NNS N
. . N

Interruption NN N
of IN N
treatment NN N
in IN N
the DT N
TOTO NNP N
group NN N
did VBD N
not RB N
result VB N
in IN N
a DT N
better JJR N
gain NN N
in IN N
height JJ N
standard NN N
deviation NN N
score VBD N
H-SDSCA NNP N
when WRB N
compared VBN N
with IN N
the DT N
TTOO NNP N
group NN N
. . N

After IN N
4 CD N
years NNS N
of IN N
study NN N
, , N
the DT N
gain NN N
in IN N
H-SDSCA NNP N
was VBD N
1.4 CD N
+ NN N
or CC N
- : N
01 CD N
in IN N
the DT N
TOTO NNP N
group NN N
and CC N
1.6 CD N
+ NN N
or CC N
- : N
0.2 CD N
in IN N
the DT N
TTOO NNP N
group NN N
leading VBG N
to TO N
a DT N
mean JJ N
height NN N
of IN N
-2.0 NNP N
+ NNP N
or CC N
- : N
1.0 CD N
SDS NNP N
and CC N
-2.0 NNP N
+ NNP N
or CC N
- : N
0.8 CD N
SDS NNP N
, , N
respectively RB N
. . N

The DT N
rate NN N
of IN N
bone NN N
maturation NN N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
short JJ N
SGA NNP N
children NNS N
, , N
TOTO NNP 3_i
and CC N
TTOO NNP 3_i
regimens NNS N
produced VBD N
significant JJ N
improvements NNS N
in IN N
growth NN N
during IN N
r-hGH JJ 2_i
treatment NN 2_i
. . N

However RB N
, , N
treatment NN N
interruption NN N
after IN N
1 CD N
year NN N
did VBD N
not RB N
influence VB N
the DT N
overall JJ N
gain NN N
in IN N
height NN N
SDS NNP N
when WRB N
compared VBN N
with IN N
2 CD N
years NNS N
' POS N
continuous JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Dacarbazine NNP 3_i
versus NN N
dacarbazine-vindesine NN 3_i
in IN N
disseminated JJ N
malignant JJ N
melanoma NN N
: : N
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
. . N

In IN N
a DT N
phase NN N
II NNP N
study NN N
119 CD N
patients NNS N
with IN N
disseminated JJ N
malignant JJ N
melanoma NN N
were VBD N
randomized VBN N
to TO N
receive VB N
treatment NN N
with IN N
dacarbazine JJ 3_i
alone NN N
or CC N
in IN N
combination NN N
with IN N
vindesine NN N
. . N

The DT N
study NN N
was VBD N
designed VBN N
to TO N
reveal VB N
an DT N
additive JJ N
response NN N
rate NN N
when WRB N
the DT N
drugs NNS N
were VBD N
combined VBN N
. . N

Dacarbazine NNP 3_i
was VBD 3_i
given VBN 3_i
i.v NN 3_i
. . N

at IN N
250 CD N
mg JJ N
m-2 JJ N
per IN N
day NN N
X NNP N
V NNP N
every DT N
4 CD N
weeks NNS N
. . N

In IN N
the DT N
combination NN N
regimen NNS N
vindesine VB 3_i
given VBN N
at IN N
3 CD N
mg JJ N
m-2 JJ N
per IN N
week NN N
was VBD N
included VBN N
. . N

One CD N
hundred CD N
and CC N
ten JJ N
patients NNS N
were VBD N
available JJ N
for IN N
evaluation NN N
of IN N
response NN N
. . N

With IN N
dacarbazine JJ 3_i
4/51 CD N
patients NNS N
obtained VBD N
a DT N
complete JJ N
remission NN N
( ( N
8 CD N
% NN N
) ) N
and CC N
5/51 CD N
patients NNS N
a DT N
partial JJ N
remission NN N
( ( N
10 CD N
% NN N
) ) N
. . N

Overall JJ N
response NN N
rate NN N
was VBD N
18 CD N
% NN N
. . N

With IN N
dacarbazine-vindesine JJ 3_i
8/59 CD N
patients NNS N
obtained VBD N
a DT N
complete JJ N
remission NN N
( ( N
13 CD N
% NN N
) ) N
and CC N
7/59 CD N
patients NNS N
a DT N
partial JJ N
remission NN N
( ( N
12 CD N
% NN N
) ) N
. . N

Overall JJ N
response NN N
rate NN N
was VBD N
25 CD N
% NN N
. . N

The DT N
difference NN N
in IN N
response NN N
rates NNS N
observed VBD N
between IN N
the DT N
treatment NN N
arms NNS N
is VBZ N
not RB N
statistically RB N
significant JJ N
. . N

Median JJ N
response NN N
duration NN N
was VBD N
123 CD N
days NNS N
for IN N
dacarbazine JJ N
patients NNS N
and CC N
171 CD N
days NNS N
for IN N
patients NNS N
receiving VBG N
dacarbazine-vindesine NN N
( ( N
difference NN N
not RB N
statistically RB N
significant JJ N
) ) N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
enflurane NN 3_i
and CC N
isoflurane NN 3_i
on IN N
splanchnic JJ N
oxygenation NN N
in IN N
humans NNS N
. . N

STUDY NNP N
OBJECTIVES NNP N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
enflurane NN 3_i
and CC N
isoflurane NN 3_i
on IN N
hepatic JJ N
venous JJ N
oxygen NN N
saturation NN N
( ( N
ShvO2 NNP N
) ) N
and CC N
splanchnic JJ N
oxygen NN N
( ( N
O2 NNP N
) ) N
extraction NN N
. . N

To TO N
measure VB N
hemodynamic JJ N
parameters NNS N
and CC N
ShvO2 NNP N
, , N
mixed JJ N
venous JJ N
, , N
and CC N
arterial JJ N
lactate NN N
concentrations NNS N
during IN N
enflurane NN 3_i
and CC N
isoflurane NN 3_i
anesthesia NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
prospective JJ N
study NN N
. . N

SETTING NNP N
University NNP N
hospital NN N
. . N

PATIENTS CC N
20 CD N
ASA NNP N
physical JJ N
status NN N
I PRP N
, , N
II NNP N
, , N
and CC N
III NNP N
adults NNS N
, , N
who WP N
underwent VBD N
major JJ N
abdominal JJ N
surgery NN N
requiring VBG N
mechanical JJ N
ventilation NN N
a DT N
few JJ N
hours NNS N
postoperatively RB N
. . N

INTERVENTIONS NNP N
After IN N
placement NN N
of IN N
catheters NNS N
in IN N
the DT N
pulmonary JJ N
artery NN N
, , N
radial JJ N
artery NN N
, , N
peripheral JJ N
and CC N
right JJ N
hepatic JJ N
vein NN N
, , N
one CD N
hour NN N
postoperatively RB N
either CC N
enflurane NN 3_i
or CC N
isoflurane NN 3_i
was VBD N
applied VBN N
at IN N
different JJ N
minimum JJ N
alveolar JJ N
concentration NN N
( ( N
MAC NNP N
) ) N
of IN N
0.5 CD N
, , N
1.0 CD N
, , N
and CC N
1.5 CD N
in IN N
a DT N
randomized JJ N
order NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Before NNP N
and CC N
10 CD N
minutes NNS N
after IN N
administration NN N
of IN N
each DT N
desired VBN N
end-expiratory JJ N
anesthetic JJ N
concentration NN N
, , N
the DT N
following JJ N
parameters NNS N
were VBD N
determined VBN N
: : N
hemodynamic JJ N
parameters NNS N
, , N
arterial JJ N
( ( N
SaO2 NNP N
) ) N
, , N
mixed JJ N
venous JJ N
( ( N
SvO2 NNP N
) ) N
, , N
and CC N
hepatic JJ N
venous JJ N
oxygen NN N
saturations NNS N
, , N
systemic JJ N
and CC N
splanchnic JJ N
O2 NNP N
extraction NN N
, , N
arterial JJ N
, , N
mixed JJ N
venous JJ N
, , N
and CC N
hepatic JJ N
venous JJ N
lactate NN N
concentrations NNS N
. . N

Cardiac NNP N
output NN N
( ( N
CO NNP N
) ) N
and CC N
mean JJ N
arterial JJ N
pressure NN N
( ( N
MAP NNP N
) ) N
decreased VBD N
in IN N
a DT N
dose JJ N
dependent JJ N
manner NN N
. . N

SaO2 NNP N
, , N
SvO2 NNP N
, , N
and CC N
systemic JJ N
O2 NNP N
extraction NN N
remained VBD N
unchanged JJ N
with IN N
enflurane NN N
and CC N
isoflurane NN N
anesthesia NN N
. . N

In IN N
the DT N
enflurane NN 3_i
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
isoflurane NN N
group NN N
, , N
ShvO2 NNP N
decreased VBD N
with IN N
increasing VBG N
inhalational JJ N
concentrations NNS N
. . N

This DT N
decrease NN N
in IN N
ShvO2 NNP N
reflected VBD N
an DT N
increase NN N
in IN N
splanchnic JJ N
O2 NNP N
extraction NN N
with IN N
enflurane NN 3_i
; : N
in IN N
contrast NN N
to TO N
isoflurane VB 3_i
. . N

CONCLUSIONS NNP N
Enflurane NNP 3_i
causes VBZ N
a DT N
decrease NN N
in IN N
ShvO2 NNP N
, , N
which WDT N
indicates VBZ N
an DT N
impairment NN N
of IN N
splanchnic JJ N
perfusion NN N
corresponding VBG N
to TO N
the DT N
reduction NN N
in IN N
CO NNP N
and CC N
MAP NNP N
in IN N
a DT N
dose-dependent JJ N
manner NN N
. . N

Isoflurane NNP 3_i
maintains VBZ N
splanchnic JJ N
perfusion NN N
in IN N
contrast NN N
to TO N
enflurane VB 3_i
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
hormonal JJ 3_i
contraceptives NNS 3_i
and CC N
risk NN N
of IN N
HIV-1 NNP N
transmission NN N
: : N
a DT N
prospective JJ N
cohort NN N
study NN N
. . N

BACKGROUND NNP N
Hormonal NNP 3_i
contraceptives NNS 3_i
are VBP N
used VBN N
widely RB N
but CC N
their PRP$ N
effects NNS N
on IN N
HIV-1 NNP N
risk NN N
are VBP N
unclear JJ N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
association NN N
between IN N
hormonal JJ 3_i
contraceptive NN 3_i
use NN N
and CC N
risk NN N
of IN N
HIV-1 NNP N
acquisition NN N
by IN N
women NNS N
and CC N
HIV-1 JJ N
transmission NN N
from IN N
HIV-1-infected JJ N
women NNS N
to TO N
their PRP$ N
male JJ N
partners NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
study NN N
, , N
we PRP N
followed VBD N
up RP N
3790 CD N
heterosexual JJ N
HIV-1-serodiscordant JJ N
couples NNS N
participating VBG N
in IN N
two CD N
longitudinal JJ N
studies NNS N
of IN N
HIV-1 NNP N
incidence NN N
in IN N
seven CD N
African JJ N
countries NNS N
. . N

Among IN N
injectable JJ N
and CC N
oral JJ N
hormonal JJ 3_i
contraceptive NN 3_i
users NNS N
and CC N
non-users NNS N
, , N
we PRP N
compared VBN N
rates NNS N
of IN N
HIV-1 NNP N
acquisition NN N
by IN N
women NNS N
and CC N
HIV-1 JJ N
transmission NN N
from IN N
women NNS N
to TO N
men NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
HIV-1 JJ N
seroconversion NN N
. . N

We PRP N
used VBD N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
and CC N
marginal JJ N
structural JJ N
modelling NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
contraceptive NN N
use NN N
on IN N
HIV-1 NNP N
risk NN N
. . N

FINDINGS NNP N
Among IN N
1314 CD N
couples NNS N
in IN N
which WDT N
the DT N
HIV-1-seronegative JJ N
partner NN N
was VBD N
female JJ N
( ( N
median JJ N
follow-up NN N
18?0 CD N
[ JJ N
IQR NNP N
12?6-24?2 JJ N
] NNP N
months NNS N
) ) N
, , N
rates NNS N
of IN N
HIV-1 NNP N
acquisition NN N
were VBD N
6?61 CD N
per IN N
100 CD N
person-years NNS N
in IN N
women NNS N
who WP N
used VBD N
hormonal JJ N
contraception NN N
and CC N
3?78 CD N
per IN N
100 CD N
person-years NNS N
in IN N
those DT N
who WP N
did VBD N
not RB N
( ( N
adjusted VBN N
hazard RB N
ratio JJ N
1?98 CD N
, , N
95 CD N
% NN N
CI NNP N
1?06-3?68 CD N
, , N
p=0?03 NN N
) ) N
. . N

Among IN N
2476 CD N
couples NNS N
in IN N
which WDT N
the DT N
HIV-1-seronegative JJ N
partner NN N
was VBD N
male JJ N
( ( N
median JJ N
follow-up NN N
18?7 CD N
[ JJ N
IQR NNP N
12?8-24?2 JJ N
] NNP N
months NNS N
) ) N
, , N
rates NNS N
of IN N
HIV-1 NNP N
transmission NN N
from IN N
women NNS N
to TO N
men NNS N
were VBD N
2?61 CD N
per IN N
100 CD N
person-years NNS N
in IN N
couples NNS N
in IN N
which WDT N
women NNS N
used VBD N
hormonal JJ N
contraception NN N
and CC N
1?51 CD N
per IN N
100 CD N
person-years NNS N
in IN N
couples NNS N
in IN N
which WDT N
women NNS N
did VBD N
not RB N
use VB N
hormonal JJ N
contraception NN N
( ( N
adjusted VBN N
hazard RB N
ratio JJ N
1?97 CD N
, , N
95 CD N
% NN N
CI NNP N
1?12-3?45 CD N
, , N
p=0?02 NN N
) ) N
. . N

Marginal JJ N
structural JJ N
model NN N
analyses NNS N
generated VBD N
much RB N
the DT N
same JJ N
results NNS N
to TO N
the DT N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
. . N

INTERPRETATION NNP N
Women NNP N
should MD N
be VB N
counselled VBN N
about IN N
potentially RB N
increased VBN N
risk NN N
of IN N
HIV-1 NNP N
acquisition NN N
and CC N
transmission NN N
with IN N
hormonal JJ N
contraception NN N
, , N
especially RB N
injectable JJ N
methods NNS N
, , N
and CC N
about IN N
the DT N
importance NN N
of IN N
dual JJ N
protection NN N
with IN N
condoms NNS N
to TO N
decrease VB N
HIV-1 NNP N
risk NN N
. . N

Non-hormonal JJ N
or CC N
low-dose JJ N
hormonal JJ N
contraceptive NN N
methods NNS N
should MD N
be VB N
considered VBN N
for IN N
women NNS N
with IN N
or CC N
at-risk JJ N
for IN N
HIV-1 NNP N
. . N

FUNDING NNP N
US NNP N
National NNP N
Institutes NNP N
of IN N
Health NNP N
and CC N
the DT N
Bill NNP N
& CC N
Melinda NNP N
Gates NNP N
Foundation NNP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
iron NN 3_i
in IN N
formula NN N
milk NN N
after IN N
6 CD N
months NNS N
of IN N
age NN N
. . N

Ninety NNP N
two CD N
normal JJ N
birthweight JJ N
infants NNS N
aged VBD N
6 CD N
months NNS N
entered VBD N
a DT N
double JJ N
blind NN N
controlled VBD N
trial NN N
which WDT N
compared VBN N
a DT N
follow NN N
on IN N
formula NN 7_i
milk NN 7_i
with IN 7_i
no DT 7_i
added JJ 7_i
iron NN 7_i
against IN N
the DT N
same JJ 3_i
formula NN 3_i
milk NN 3_i
containing VBG 3_i
1.2 CD 3_i
mg NN 3_i
of IN 3_i
iron NN 3_i
per IN 3_i
100 CD 3_i
ml NN 3_i
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
social JJ N
class NN N
or CC N
demographic JJ N
characteristics NNS N
of IN N
the DT N
two CD N
treatment NN N
groups NNS N
or CC N
in IN N
the DT N
proportion NN N
of IN N
each DT N
group NN N
completing VBG N
the DT N
trial NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
quantity NN N
of IN N
milk NN N
taken VBN N
but CC N
the DT N
amounts NNS N
taken VBN N
lessened VBD N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
mean VB N
haemoglobin NN N
and CC N
median JJ N
serum NN N
ferritin NN N
at IN N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
15 CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

Very RB N
few JJ N
infants NNS N
developed VBD N
iron NN N
deficiency NN N
anaemia NN N
in IN N
either CC N
group NN N
but CC N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
serum NN N
ferritin NN N
levels NNS N
to TO N
fall VB N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
iron NN 3_i
added VBD N
to TO N
follow VB N
on IN N
milk NN N
was VBD N
not RB N
an DT N
important JJ N
source NN N
of IN N
dietary JJ N
iron NN 3_i
in IN N
the DT N
infants NNS N
studied VBN N
. . N

-DOCSTART- -X- O O

Argon NNP 2_i
laser NN 2_i
trabeculoplasty NN 2_i
in IN N
primary JJ N
open-angle JJ N
glaucoma NN N
-- : N
results NNS N
in IN N
black JJ N
Jamaican JJ N
population NN N
. . N

A DT N
controlled JJ N
, , N
randomised VBD N
, , N
prospective JJ N
trial NN N
of IN N
Argon NNP 1_i
laser NN 1_i
trabeculoplasty NN 1_i
( ( 1_i
ALT NNP 1_i
) ) 1_i
was VBD N
carried VBN N
out RP N
on IN N
48 CD N
eyes NNS N
of IN N
30 CD N
black JJ N
Jamaican JJ N
patients NNS N
with IN N
primary JJ N
open-angle JJ N
glaucoma NN N
. . N

All DT N
eyes NNS N
had VBD N
uncontrolled VBN N
intra-ocular JJ N
pressures NNS N
( ( N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
22 CD N
mm NNS N
Hg NNP N
) ) N
despite IN N
medical JJ N
therapy NN N
. . N

Treatment NN N
was VBD N
successful JJ N
in IN N
controlling VBG N
intraocular JJ N
pressure NN N
in IN N
68 CD N
% NN N
of IN N
eyes NNS N
after IN N
12 CD N
months NNS N
follow-up JJ N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
average JJ N
drop NN N
in IN N
intraocular JJ N
pressure NN N
attributable JJ N
to TO N
ALT NNP 2_i
was VBD N
6.6 CD N
mmHg NN N
. . N

Argon NNP 2_i
laser NN 2_i
trabeculoplasty NN 2_i
is VBZ N
an DT N
effective JJ N
adjunct NN N
in IN N
managing VBG N
to TO N
control VB N
intraocular JJ N
pressure NN N
in IN N
black JJ N
Jamaican NNP N
glaucoma NN N
patients NNS N
. . N

-DOCSTART- -X- O O

Primary JJ 2_i
vitrectomy NN 2_i
for IN N
combined VBN N
rhegmatogenous JJ N
retinal JJ N
detachment NN N
and CC N
choroidal JJ N
detachment NN N
with IN 3_i
or CC 3_i
without IN 3_i
oral JJ 3_i
corticosteroids NNS 3_i
: : N
a DT N
pilot NN N
study NN N
. . N

PURPOSE VB N
The DT N
occurrence NN N
of IN N
choroidal JJ N
detachment NN N
( ( N
CD NN N
) ) N
in IN N
eyes NNS N
with IN N
primary JJ N
rhegmatogenous JJ N
retinal JJ N
detachment NN N
( ( N
RRD NNP N
) ) N
is VBZ N
relatively RB N
uncommon JJ N
( ( N
2 CD N
% NN N
-4.5 NNP N
% NN N
) ) N
. . N

Recent JJ N
reports NNS N
suggest VBP N
that IN N
primary JJ N
vitrectomy NN N
yields NNS N
better RBR N
anatomic JJ N
success NN N
than IN N
scleral JJ N
buckling NN N
. . N

However RB N
, , N
for IN N
these DT N
inflamed JJ N
eyes NNS N
with IN N
low JJ N
intraocular JJ N
pressure NN N
, , N
the DT N
influence NN N
of IN N
preoperative JJ N
oral JJ N
steroids NNS N
on IN N
reattachment NN N
rates NNS N
has VBZ N
not RB N
been VBN N
elucidated VBN N
yet RB N
. . N

METHODS NNP N
Twenty NNP N
eyes NNS N
with IN N
combined JJ N
RRD NNP N
and CC N
CD NNP N
that WDT N
underwent JJ 2_i
primary JJ 2_i
vitrectomy NN 2_i
were VBD N
randomized VBN N
to TO N
receive VB 1_i
oral JJ 1_i
steroids NNS 1_i
( ( 1_i
for IN 1_i
1 CD 1_i
week NN 1_i
) ) 1_i
or CC 1_i
no DT 1_i
oral JJ 1_i
steroids NNS 1_i
before IN 1_i
surgery NN 1_i
. . N

RESULTS NNP N
Preoperative NNP N
clinical JJ N
data NNS N
such JJ N
as IN N
mean JJ N
age NN N
, , N
lens VBZ N
status NN N
, , N
Snellen NNP N
visual JJ N
acuity NN N
, , N
duration NN N
of IN N
macular JJ N
detachment NN N
, , N
CD NNP N
( ( N
size NN N
and CC N
extent NN N
) ) N
, , N
and CC N
retinal JJ N
detachment NN N
characteristics NNS N
( ( N
e.g. NN N
, , N
extent NN N
, , N
number NN N
of IN N
retinal JJ N
breaks NNS N
, , N
atrophic JJ N
or CC N
tractional JJ N
retinal JJ N
break NN N
, , N
size NN N
of IN N
retinal JJ N
break NN N
, , N
and CC N
location NN N
of IN N
retinal JJ N
break NN N
) ) N
were VBD N
similarly RB N
distributed VBN N
in IN N
both DT N
groups NNS N
. . N

Single-operation NNP N
anatomic JJ N
success NN N
was VBD N
81.8 CD N
% NN N
( ( N
9/11 CD N
) ) N
among IN N
those DT N
patients NNS N
who WP N
received VBD N
preoperative JJ N
oral JJ N
steroids NNS 3_i
and CC N
was VBD N
66.7 CD N
% NN N
( ( N
6/9 CD N
) ) N
among IN N
those DT N
who WP N
did VBD N
not RB N
receive VB N
preoperative JJ N
oral JJ N
steroids NNS 3_i
. . N

After IN N
reoperation NN N
, , N
anatomic JJ N
success NN N
was VBD N
100 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
mean JJ N
follow-up NN N
was VBD N
20.1 CD N
months NNS N
. . N

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
administration NN N
of IN N
oral JJ N
steroids NNS N
before IN N
primary JJ N
vitrectomy NN N
in IN N
eyes NNS N
with IN N
combined JJ N
RRD NNP N
and CC N
CD NNP N
improves VBZ N
reattachment JJ N
rates NNS N
. . N

-DOCSTART- -X- O O

Does NNS N
waiting VBG N
matter NN N
? . N
A DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
new JJ N
non-urgent JJ N
rheumatology NN N
out-patient JJ N
referrals NNS N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
waiting VBG N
times NNS N
on IN N
the DT N
health NN N
status NN N
of IN N
patients NNS N
referred VBN N
for IN N
a DT N
non-urgent JJ N
rheumatology NN N
opinion NN N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
randomized VBN N
controlled VBN N
clinical JJ N
study NN N
evaluating VBG N
a DT N
'fast JJ 6_i
track NN 6_i
' POS 6_i
appointment NN 6_i
with IN 6_i
a DT 6_i
6-week JJ 6_i
target NN 6_i
waiting VBG 6_i
time NN 6_i
against IN N
an DT N
'ordinary JJ 7_i
' POS 7_i
appointment NN 7_i
in IN N
the DT N
main JJ N
city NN N
out-patient JJ N
clinic NN N
of IN N
the DT N
rheumatology NN N
service NN N
for IN N
the DT N
Lothian JJ N
and CC N
Borders NNPS N
region NN N
( ( N
population NN N
approximately RB N
1 CD N
million CD N
) ) N
. . N

Health NNP N
status NN N
was VBD N
measured VBN N
using VBG N
the DT N
SF12 NNP N
physical JJ N
and CC N
mental JJ N
summary JJ N
component NN N
T-scores NNS N
and CC N
pain NN N
was VBD N
measured VBN N
with IN N
a DT N
100 CD N
mm NN N
visual JJ N
analogue NN N
pain NN N
scale NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
health NN N
utility NN N
and CC N
perceived VBD N
health NN N
both DT N
measured VBN N
with IN N
the DT N
EuroQol NNP N
instrument NN N
, , N
mental JJ N
health NN N
measured VBN N
with IN N
the DT N
Hospital NNP N
Anxiety NNP N
and CC N
Depression NNP N
scale NN N
, , N
disability NN N
with IN N
the DT N
modified JJ N
Health NNP N
Assessment NNP N
Questionnaire NNP N
and CC N
economic JJ N
costs NNS N
measured VBN N
from IN N
a DT N
societal JJ N
perspective NN N
. . N

RESULTS JJ N
Mean NNP N
waiting VBG N
times NNS N
were VBD N
43 CD N
days NNS N
( ( N
sigma JJ N
= NNP N
+/-16 NN N
) ) N
and CC N
105 CD N
days NNS N
( ( N
sigma JJ N
= NNP N
+/-51 NN N
) ) N
for IN N
'fast $ N
track NN N
' '' N
and CC N
'ordinary NNP N
' POS N
appointments NNS N
, , N
respectively RB N
. . N

Both DT N
groups NNS N
showed VBD N
significant JJ N
improvements NNS N
in IN N
mean JJ N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
] NN N
scores NNS N
for IN N
pain NN N
: : N
11 CD N
( ( N
7 CD N
, , N
16 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
physical JJ N
health NN N
status NN N
: : N
4 CD N
( ( N
2 CD N
, , N
5 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
mental JJ N
health NN N
status NN N
: : N
2 CD N
( ( N
0.1 CD N
, , N
4 CD N
) ) N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
; : N
and CC N
health NN N
utility NN N
: : N
0.11 CD N
( ( N
0.07 CD N
, , N
0.16 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
by IN N
the DT N
end NN N
of IN N
the DT N
15-month JJ N
period NN N
of IN N
the DT N
study NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
either DT N
arm NN N
of IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
Rationing NNP N
by IN N
delay NN N
was VBD N
not RB N
detrimental JJ N
to TO N
either DT N
mental JJ N
or CC N
physical JJ N
health NN N
and CC N
patients NNS N
in IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
showed VBD N
significant JJ N
and CC N
similar JJ N
improvement NN N
in IN N
health NN N
by IN N
15 CD N
months NNS N
. . N

Expenditure NN N
of IN N
resources NNS N
on IN N
waiting VBG N
times NNS N
without IN N
regard NN N
to TO N
clinical JJ N
outcomes NNS N
is VBZ N
likely JJ N
to TO N
be VB N
wasteful JJ N
and CC N
additional JJ N
resources NNS N
should MD N
be VB N
directed VBN N
at IN N
achieving VBG N
the DT N
greatest JJS N
clinical JJ N
benefit NN N
. . N

More JJR N
research NN N
into IN N
effective JJ N
methods NNS N
of IN N
controlling VBG N
demand NN N
and CC N
better JJR N
identification NN N
of IN N
those DT N
who WP N
would MD N
benefit VB N
from IN N
access NN N
to TO N
specialist VB N
care NN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
prostate-specific JJ 3_i
antigen NN 3_i
corrected VBN 3_i
for IN 3_i
total JJ 3_i
prostate NN 3_i
volume NN 3_i
and CC N
transition NN 3_i
zone NN 3_i
volume NN 3_i
in IN N
a DT N
population-based JJ N
screening NN N
study NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
discriminatory JJ N
potential NN N
between IN N
prostate NN N
cancer NN N
and CC N
benign JJ N
conditions NNS N
of IN N
the DT N
prostate NN N
in IN N
a DT N
population-based JJ N
screening NN N
study NN N
, , N
of IN N
serum JJ N
prostate-specific JJ N
antigen NN N
levels NNS N
( ( N
PSA NNP N
) ) N
and CC N
PSA NNP N
corrected VBD N
for IN N
both DT N
the DT N
total JJ N
prostate NN N
volume NN N
( ( N
PSA-D NNP N
) ) N
and CC N
the DT N
transition NN N
zone NN N
volume NN N
( ( N
PSA-T NNP N
) ) N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
population-based JJ N
screening NN N
study NN N
( ( N
Rotterdam NNP N
section NN N
of IN N
the DT N
European NNP N
Randomized NNP N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP N
Cancer NNP N
) ) N
, , N
in IN N
which WDT N
10,865 CD N
men NNS N
have VBP N
been VBN N
screened VBN N
, , N
the DT N
biopsy NN 2_i
results NNS N
of IN N
1202 CD N
men NNS N
with IN N
PSA NNP N
levels NNS N
of IN N
4 CD N
ng/mL NNS N
or CC N
more JJR N
were VBD N
evaluated VBN N
. . N

Planimetric NNP 2_i
and CC 2_i
prolate VB 2_i
ellipsoid JJ 2_i
volumes NNS 2_i
of IN 2_i
the DT 2_i
total JJ 2_i
prostate NN 2_i
as RB 2_i
well RB 2_i
as IN 2_i
of IN 2_i
the DT 2_i
transition NN 2_i
zone NN 2_i
were VBD N
measured VBN N
. . N

The DT N
measured JJ N
volumes NNS N
were VBD N
compared VBN N
with IN N
the DT N
volumes NNS 2_i
of IN 2_i
57 CD 2_i
radical JJ 2_i
prostatectomy NN 2_i
specimens NNS 2_i
through IN N
Spearman NNP N
's POS N
rank NN N
correlation NN N
coefficient NN N
and CC N
agreement NN N
tests NNS N
. . N

A DT N
receiver NN N
operating VBG N
characteristic JJ N
( ( N
ROC NNP N
) ) N
curve VBP N
analysis NN N
was VBD N
done VBN N
of IN N
sensitivity NN N
and CC N
specificity NN N
of IN N
biopsy NN N
indications NNS N
through IN N
PSA NNP N
and CC N
PSA NNP N
corrected VBD N
for IN N
the DT N
volumes NNS N
measured VBN N
with IN N
transrectal JJ N
ultrasound NN N
. . N

RESULTS NNP N
In IN N
the DT N
1202 CD N
men NNS N
studied VBD N
, , N
361 CD N
cases NNS N
of IN N
prostate NN N
cancer NN N
were VBD N
diagnosed VBN N
. . N

Both DT N
PSA-D NNP N
and CC N
PSA-T NNP N
showed VBD N
a DT N
significantly RB N
higher JJR N
area NN N
under IN N
the DT N
ROC NNP N
curve NN N
( ( N
0.77 CD N
and CC N
0.79 CD N
, , N
respectively RB N
) ) N
than IN N
PSA NNP N
alone RB N
( ( N
area NN N
0.65 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
PSA-D NNP N
and CC N
PSA-T NNP N
. . N

The DT N
use NN N
of IN N
a DT N
PSA-D NNP N
threshold JJ N
value NN N
of IN N
0 CD N
. . N

10 CD N
ng/mL/cc NN N
would MD N
have VB N
avoided VBN N
28 CD N
% NN N
of IN N
biopsies NNS N
at IN N
the DT N
cost NN N
of IN N
10 CD N
% NN N
of IN N
detectable JJ N
cancers NNS N
. . N

A DT N
PSA-D JJ N
threshold NN N
of IN N
0.15 CD N
ng/mL/cc NNS N
would MD N
have VB N
avoided VBN N
73.8 CD N
% NN N
of IN N
biopsies NNS N
at IN N
the DT N
cost NN N
of IN N
not RB N
diagnosing VBG N
43.8 CD N
% NN N
of IN N
detectable JJ N
cancers NNS N
. . N

CONCLUSIONS VB N
The DT N
planimetrically RB N
obtained JJ N
prostate NN N
volume NN N
showed VBD N
a DT N
more RBR N
favorable JJ N
agreement NN N
with IN N
the DT N
radical JJ N
prostatectomy NN N
volume NN N
than IN N
the DT N
prolate JJ N
ellipsoid NN N
volume NN N
. . N

The DT N
discriminatory JJ N
potential NN N
of IN N
the DT N
corrected VBN N
PSA NNP N
value NN N
is VBZ N
better JJR N
at IN N
predicting VBG N
the DT N
results NNS N
of IN N
needle JJ N
biopsy NN N
of IN N
the DT N
prostate NN N
when WRB N
compared VBN N
with IN N
PSA NNP N
alone RB N
. . N

The DT N
use NN N
of IN N
the DT N
transition NN 2_i
zone NN 2_i
volume NN 2_i
for IN N
this DT N
correction NN N
results NNS N
in IN N
a DT N
higher JJR N
discriminatory JJ N
potential NN N
when WRB N
compared VBN N
to TO N
the DT N
use NN N
of IN N
the DT N
total JJ 2_i
prostate NN 2_i
volume NN 2_i
; : N
however RB N
, , N
the DT N
observed JJ N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -X- O O

Functional JJ N
modification NN N
of IN N
agonist-antagonist JJ N
electromyographic JJ N
activity NN N
for IN N
rapid JJ N
movement NN N
inhibition NN N
. . N

Subjects NNS N
made VBD N
a DT N
fast JJ N
elbow NN N
extension NN N
movement NN N
to TO N
designated VBN N
target NN N
in IN N
response NN N
to TO N
a DT N
go JJ 2_i
signal NN 2_i
. . N

In IN N
45 CD N
% NN N
of IN N
trials NNS N
a DT N
stop JJ N
signal NN N
was VBD N
presented VBN N
after IN N
the DT N
go JJ N
signal NN N
, , N
to TO N
which WDT N
subjects NNS N
were VBD N
asked VBN N
to TO N
stop VB N
the DT N
movement NN N
as RB N
rapidly RB N
as IN N
possible JJ N
. . N

The DT N
interstimulus JJ 2_i
interval NN 2_i
( ( 2_i
ISI NNP 2_i
) ) 2_i
, , N
or CC N
time NN 2_i
interval NN 2_i
between IN 2_i
the DT 2_i
go NN 2_i
and CC 2_i
stop NN 2_i
signals NNS 2_i
, , N
was VBD N
randomly RB N
varied VBN N
between IN N
0 CD N
and CC N
200 CD N
ms. NN N
Electromyographic NNP 2_i
( ( 2_i
EMG NNP 2_i
) ) 2_i
activity NN N
was VBD N
recorded VBN N
from IN N
biceps NNS N
brachii NNS N
and CC N
triceps NNS N
brachii NN N
. . N

Subjects NNS N
could MD N
sometimes RB N
completely RB N
inhibit JJ N
initiation NN N
of IN N
the DT N
movements NNS N
when WRB N
the DT N
ISI NNP N
was VBD N
0 CD N
ms NN N
, , N
but CC N
could MD N
rarely RB N
do VB N
so RB N
when WRB N
the DT N
ISI NNP N
exceeded VBD N
100 CD N
ms. NN N
For IN N
responses NNS N
that WDT N
were VBD N
initiated VBN N
but CC N
stopped VBN N
on IN N
the DT N
way NN N
, , N
the DT N
amplitude NN N
of IN N
the DT N
movement NN N
decreased VBD N
linearly RB N
as IN N
the DT N
time NN N
interval NN N
( ( N
=modification JJ N
time NN N
) ) N
from IN N
the DT N
stop JJ N
signal NN N
to TO N
EMG NNP N
onset NN N
increased VBD N
. . N

The DT N
peak JJ N
velocity NN N
increased VBD N
linearly RB N
as IN N
the DT N
movement NN N
amplitude NN N
increased VBD N
. . N

This DT N
tendency NN N
was VBD N
similar JJ N
to TO N
those DT N
previously RB N
reported VBN N
in IN N
step-tracking JJ N
movements NNS N
with IN N
various JJ N
amplitudes NNS N
. . N

In IN N
spite NN N
of IN N
the DT N
similarity NN N
in IN N
the DT N
kinematics NNS N
of IN N
the DT N
movement NN N
, , N
the DT N
EMG NNP N
pattern NN N
was VBD N
different JJ N
from IN N
that DT N
of IN N
step-tracking JJ N
movement NN N
. . N

While IN N
the DT N
initial JJ N
agonist NN N
burst NN N
( ( N
AG1 NNP N
) ) N
decreased VBD N
linearly RB N
after IN N
the DT N
modification NN N
time NN N
exceeded VBD N
100 CD N
ms NN N
, , N
the DT N
antagonist NN N
burst NN N
( ( N
ANT NNP N
) ) N
increased VBD N
compared VBN N
with IN N
the DT N
go JJ N
trial NN N
for IN N
the DT N
modification NN N
time NN N
from IN N
0 CD N
to TO N
200 CD N
ms NNS N
and CC N
decreased VBN N
after IN N
the DT N
modification NN N
time NN N
exceeded VBD N
300 CD N
ms NN N
. . N

This DT N
change NN N
of IN N
activation NN N
is VBZ N
analogous JJ N
to TO N
functional JJ N
modification NN N
of IN N
middle-latency NN N
reflex NN N
EMG NNP N
response NN N
to TO N
load VB N
, , N
or CC N
cutaneous JJ N
perturbation NN N
. . N

In IN N
conclusion NN N
, , N
it PRP N
is VBZ N
suggested VBN N
that IN N
adaptive JJ N
mechanisms NNS N
, , N
which WDT N
would MD N
functionally RB N
modify VB N
the DT N
reflex NN N
responses NNS N
, , N
are VBP N
also RB N
continuously RB N
working VBG N
during IN N
voluntary JJ N
movements NNS N
in IN N
response NN N
to TO N
sudden JJ N
changes NNS N
in IN N
environmental JJ N
information NN N
. . N

-DOCSTART- -X- O O

The DT N
UKEP NNP N
study NN N
: : N
multicentre JJ N
clinical JJ N
trial NN N
on IN N
two CD N
local JJ N
regimens NNS N
of IN N
urokinase NN 3_i
in IN N
massive JJ N
pulmonary JJ N
embolism NN N
. . N

The DT N
UKEP NNP N
Study NNP N
Research NNP N
Group NNP N
. . N

A NNP N
multicentre JJ N
trial NN N
( ( N
10 CD N
centres NNS N
) ) N
of IN N
urokinase NN 3_i
( ( 3_i
UK NNP 3_i
) ) 3_i
was VBD N
performed VBN N
in IN N
patients NNS N
with IN N
acute NN N
severe JJ N
pulmonary JJ N
embolism NN N
( ( N
PE NNP N
) ) N
. . N

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
, , N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
two CD 3_i
doses NNS 3_i
of IN 3_i
UK NNP 3_i
administered VBD N
via IN N
a DT N
catheter NN N
in IN N
the DT N
pulmonary JJ N
artery NN N
: : N
2000 CD N
IU NNP N
kg-1 JJ N
h-1 NN N
for IN N
24 CD 3_i
hours NNS 3_i
( ( 3_i
UK IN 3_i
2000 CD 3_i
) ) 3_i
in IN 3_i
conjunction NN 3_i
with IN 3_i
heparin NN 3_i
versus NN N
4400 CD 3_i
IU NNP 3_i
kg-1 JJ 3_i
h-1 JJ 3_i
UK NNP 3_i
alone RB 3_i
for IN 3_i
12 CD 3_i
hours NNS 3_i
( ( 3_i
UK IN 3_i
4400 CD 3_i
) ) 3_i
followed VBN 3_i
by IN 3_i
heparin NN 3_i
. . N

PE NNP N
was VBD N
less JJR N
than IN N
5 CD N
days NNS N
old JJ N
and CC N
the DT N
clinical JJ N
diagnosis NN N
was VBD N
confirmed VBN N
by IN N
pulmonary JJ N
angiograms NNS N
demonstrating VBG N
a DT N
vascular JJ N
obstruction NN N
of IN N
more JJR N
than IN N
30 CD N
% NN N
( ( N
Miller NNP N
's POS N
index NN N
greater JJR N
than IN N
11 CD N
) ) N
. . N

The DT N
efficacy NN N
of IN N
treatment NN N
was VBD N
evaluated VBN N
by IN N
the DT N
degree NN N
of IN N
early JJ N
revascularization NN N
( ( N
pulmonary JJ N
angiograms NNS N
were VBD N
performed VBN N
30 CD N
to TO N
48 CD N
hours NNS N
after IN N
initiation NN N
of IN N
thrombolytic JJ 3_i
treatment NN 3_i
and CC N
analysed VBN N
blindly RB N
by IN N
four CD N
independent JJ N
vascular JJ N
radiologists NNS N
) ) N
. . N

133 CD N
patients NNS N
were VBD N
included VBN N
in IN N
this DT N
trial NN N
: : N
two CD N
patients NNS N
died VBD N
before IN N
treatment NN N
and CC N
two CD N
were VBD N
excluded VBN N
retrospectively RB N
, , N
leaving VBG N
129 CD N
patients NNS N
for IN N
final JJ N
analysis NN N
( ( N
67 CD N
: : N
UK NN N
2000 CD N
+ NNP N
heparin NN N
; : N
62 CD N
: : N
UK JJ N
4400 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
had VBD N
similar JJ N
pretreatment NN N
clinical JJ N
, , N
haemodynamic JJ N
and CC N
angiographic JJ N
characteristics NNS N
: : N
the DT N
Miller NNP N
angiographic JJ N
index NN N
of IN N
severity NN N
averaged VBD N
22.6 CD N
+/- JJ N
3.7 CD N
for IN N
patients NNS N
in IN N
the DT N
UK NNP N
2000 CD N
group NN N
, , N
and CC N
22.6 CD N
+/- JJ N
3.4 CD N
for IN N
patients NNS N
in IN N
the DT N
UK NNP N
4400 CD N
group NN N
( ( N
average JJ N
filling VBG N
defect NN N
of IN N
66 CD N
% NN N
on IN N
pulmonary JJ N
angiograms NNS N
) ) N
. . N

There EX N
was VBD N
a DT N
similar JJ N
and CC N
significant JJ N
degree NN N
of IN N
resolution NN N
in IN N
the DT N
two CD N
groups NNS N
: : N
26 CD N
% NN N
and CC N
20 CD N
% NN N
, , N
respectively RB N
. . N

Minor NNP N
and CC N
major JJ N
bleeding NN N
problems NNS N
were VBD N
observed VBN N
with IN N
equal JJ N
frequency NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
24 CD N
% NN N
and CC N
29 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

These DT N
bleeding VBG N
complications NNS N
were VBD N
severe RB N
in IN N
only RB N
4.5 CD N
% NN N
and CC N
3 CD N
% NN N
, , N
respectively RB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Validation NN N
of IN N
a DT N
novel JJ N
satisfaction NN 4_i
questionnaire NN 4_i
for IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
receiving VBG N
outpatient JJ N
clinical JJ N
nurse NN N
specialist NN N
care NN N
, , N
inpatient NN N
care NN N
, , N
or CC N
day NN N
patient JJ N
team NN N
care NN N
. . N

OBJECTIVES NNP N
To TO N
develop VB N
and CC N
validate VB N
a DT N
questionnaire NN N
for IN N
measuring VBG N
satisfaction NN N
with IN N
different JJ N
forms NNS N
of IN N
complex JJ N
multidisciplinary JJ N
care NN N
in IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

METHODS PDT N
The DT N
satisfaction NN 4_i
questionnaire NN 4_i
( ( N
score JJ N
range NN N
0-100 NN N
) ) N
comprised VBD N
28 CD N
items NNS N
covering VBG N
11 CD N
domains NNS N
. . N

Together RB N
with IN N
a DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
, , N
range VB N
0-100 NNP N
) ) N
on IN N
overall JJ N
satisfaction NN N
, , N
the DT N
questionnaire NN 4_i
was VBD N
applied VBN N
in IN N
210 CD N
RA NNP N
patients NNS N
who WP N
participated VBD N
in IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
3 CD N
types NNS N
of IN N
multidisciplinary JJ N
care NN N
. . N

RESULTS VB N
The DT N
questionnaire NN N
was VBD N
returned VBN N
by IN N
174 CD N
patients NNS N
( ( N
83 CD N
% NN N
) ) N
. . N

The DT N
questionnaire NN N
and CC N
VAS NNP N
scores NNS N
in IN N
the DT N
total JJ N
group NN N
were VBD N
75 CD N
( ( N
SD NNP N
12 CD N
) ) N
and CC N
83 CD N
( ( N
SD NNP N
20 CD N
) ) N
, , N
respectively RB N
. . N

Reliability NNP N
analysis NN N
showed VBD N
Cronbach NNP N
's POS N
alpha NN N
of IN N
the DT N
questionnaire NN N
was VBD N
0.91 CD N
. . N

Spearman NNP N
's POS N
correlation NN N
coefficient NN N
between IN N
the DT N
satisfaction NN N
questionnaire NN N
score NN N
and CC N
VAS NNP N
score NN N
was VBD N
0.58 CD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Mean JJ N
total JJ N
satisfaction NN N
questionnaire NN N
scores NNS N
were VBD N
72 CD N
( ( N
SD NNP N
9 CD N
) ) N
, , N
76 CD N
( ( N
SD NNP N
14 CD N
) ) N
, , N
and CC N
78 CD N
( ( N
SD NNP N
11 CD N
) ) N
, , N
in IN N
the DT N
nurse JJ N
specialist NN N
, , N
inpatient JJ N
and CC N
day NN N
patient NN N
groups NNS N
, , N
respectively RB N
( ( N
nurse JJ N
specialist NN N
versus IN N
day NN N
patient NN N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

Significant JJ N
differences NNS N
between IN N
nurse JJ N
specialist NN N
and CC N
day NN N
patients NNS N
were VBD N
seen VBN N
in IN N
the DT N
following JJ N
domains NNS N
: : N
waiting VBG N
time NN N
during IN N
the DT N
treatment NN N
, , N
autonomy NN N
, , N
coordination NN N
, , N
non-financial JJ N
access NN N
, , N
and CC N
quality NN N
of IN N
general JJ N
information NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Overall NNP N
, , N
patients NNS N
were VBD N
highly RB N
satisfied VBN N
with IN N
the DT N
multidisciplinary JJ N
care NN N
they PRP N
received VBD N
. . N

Major JJ N
differences NNS N
regarding VBG N
the DT N
organization NN N
of IN N
care NN N
were VBD N
reflected VBN N
in IN N
the DT N
results NNS N
of IN N
the DT N
questionnaire NN N
scores NNS N
. . N

The DT N
satisfaction NN N
questionnaire NN N
appears VBZ N
to TO N
be VB N
a DT N
useful JJ N
instrument NN N
for IN N
measuring VBG N
satisfaction NN N
with IN N
complex JJ N
multidisciplinary NN N
care NN N
in IN N
RA NNP N
patients NNS N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
subsequent JJ N
exercise-induced JJ N
periinfarct NN N
ischemia NN N
by IN N
emergency NN 2_i
coronary JJ 2_i
angioplasty NN 2_i
in IN N
acute JJ N
myocardial JJ N
infarction NN N
: : N
comparison NN N
with IN N
intracoronary JJ 2_i
streptokinase NN 2_i
. . N

To TO N
compare VB N
the DT N
efficacy NN N
of IN N
emergency NN 1_i
percutaneous JJ 1_i
transluminal JJ 1_i
coronary NN 1_i
angioplasty NN 1_i
and CC N
intracoronary JJ 2_i
streptokinase NN 2_i
in IN N
preventing VBG N
exercise-induced JJ N
periinfarct NN N
ischemia NN N
, , N
28 CD N
patients NNS N
presenting VBG N
within IN N
12 CD N
hours NNS N
of IN N
the DT N
onset NN N
of IN N
symptoms NNS N
of IN N
acute JJ N
myocardial JJ N
infarction NN N
were VBD N
prospectively RB N
randomized VBN N
. . N

Of IN N
these DT N
, , N
14 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
emergency NN 2_i
angioplasty NN 2_i
and CC N
14 CD N
patients NNS N
received VBD N
intracoronary JJ 2_i
streptokinase NN 2_i
. . N

Recatheterization NN 2_i
and CC 2_i
submaximal JJ 2_i
exercise NN 2_i
thallium-201 JJ 2_i
single JJ 2_i
photon NN 2_i
emission NN 2_i
computed VBD 2_i
tomography NN 2_i
were VBD N
performed VBN N
before IN N
hospital JJ N
discharge NN N
. . N

Periinfarct NNP N
ischemia NN N
was VBD N
defined VBN N
as IN N
a DT N
reversible JJ N
thallium NN N
defect NN N
adjacent NN N
to TO N
a DT N
fixed VBN N
defect NN N
assessed VBN N
qualitatively RB N
. . N

Successful JJ N
reperfusion NN N
was VBD N
achieved VBN N
in IN N
86 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
emergency NN 2_i
angioplasty NN 2_i
and CC N
86 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
intracoronary JJ N
streptokinase NN 2_i
( ( N
p JJ N
= NNP N
NS NNP N
) ) N
. . N

Residual JJ N
stenosis NN N
of IN N
the DT N
infarct-related JJ N
coronary JJ N
artery NN N
shown VBN N
at IN N
predischarge NN N
angiography NN N
was VBD N
43.8 CD N
+/- JJ N
31.4 CD N
% NN N
for IN N
the DT N
angioplasty JJ N
group NN N
and CC N
75.0 CD N
+/- JJ N
15.6 CD N
% NN N
for IN N
the DT N
streptokinase NN N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Of IN N
the DT N
angioplasty JJ N
group NN N
, , N
9 CD N
% NN N
developed VBD N
exercise-induced JJ N
periinfarct NN N
ischemia NN N
compared VBN N
with IN N
60 CD N
% NN N
of IN N
the DT N
streptokinase NN N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Thus RB N
, , N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
treated VBN N
with IN N
emergency NN N
angioplasty NN N
had VBD N
significantly RB N
less RBR N
severe JJ N
residual JJ N
coronary JJ N
stenosis NN N
and CC N
exercise-induced JJ N
periinfarct NN N
ischemia NN N
than IN N
did VBD N
those DT N
treated VBN N
with IN N
intracoronary JJ N
streptokinase NN 2_i
. . N

These DT N
results NNS N
suggest VBP N
further JJ N
application NN N
of IN N
coronary JJ 2_i
angioplasty NN 2_i
in IN N
the DT N
management NN N
of IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O

The DT N
utility NN N
of IN N
laparoscopy NN N
in IN N
the DT N
diagnosis NN N
of IN N
acute JJ N
appendicitis NN N
in IN N
women NNS N
of IN N
reproductive JJ N
age NN N
. . N

AIM NNP N
To TO N
see VB N
whether IN N
laparoscopy NN 2_i
improves VBZ N
the DT N
accuracy NN N
of IN N
a DT N
clinical JJ N
diagnosis NN N
of IN N
acute JJ N
appendicitis NN N
in IN N
women NNS N
of IN N
reproductive JJ N
age NN N
, , N
and CC N
to TO N
determine VB N
what WP N
the DT N
long-term JJ N
sequelae NN N
are VBP N
of IN N
not RB N
removing VBG N
an DT N
appendix NN N
deemed VBN N
at IN N
laparoscopy NN N
to TO N
be VB N
normal JJ N
. . N

METHOD NNP N
The DT N
initial JJ N
part NN N
of IN N
the DT N
study NN N
was VBD N
undertaken VBN N
during IN N
1991-1992 JJ N
. . N

Female JJ N
patients NNS N
between IN N
16 CD N
and CC N
45 CD N
years NNS N
were VBD N
eligible JJ N
for IN N
inclusion NN N
once RB N
a DT N
clinical JJ N
decision NN N
had VBD N
been VBN N
made VBN N
to TO N
perform VB N
an DT N
appendicectomy NN N
for IN N
suspected JJ N
acute JJ N
appendicitis NN N
. . N

Following VBG N
consent NN N
, , N
patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
. . N

One CD N
group NN N
had VBD N
open JJ 1_i
appendicectomy NN 1_i
, , N
as IN N
planned VBN N
. . N

The DT N
other JJ N
group NN N
had VBD N
laparoscopy VBN 2_i
, , N
followed VBN N
by IN N
open JJ 1_i
appendicectomy NN 1_i
only RB N
if IN N
the DT N
appendix NN N
was VBD N
seen VBN N
to TO N
be VB N
inflamed VBN N
or CC N
was VBD N
not RB N
visualized VBN N
. . N

The DT N
end NN N
points NNS N
for IN N
the DT N
study NN N
were VBD N
the DT N
clinical JJ N
outcomes NNS N
of IN N
all DT N
patients NNS N
, , N
and CC N
the DT N
results NNS N
of IN N
histology NN N
, , N
where WRB N
appropriate NN N
. . N

An DT N
attempt NN N
was VBD N
made VBN N
to TO N
contact VB N
all DT N
patients NNS N
at IN N
10 CD N
years NNS N
to TO N
determine VB N
whether IN N
they PRP N
had VBD N
had VBN N
a DT N
subsequent JJ N
appendicectomy NN N
, , N
or CC N
had VBD N
been VBN N
diagnosed VBN N
with IN N
another DT N
abdominal JJ N
condition NN N
that WDT N
might MD N
be VB N
relevant JJ N
to TO N
the DT N
initial JJ N
presentation NN N
in IN N
1991-1992 JJ N
. . N

RESULTS NNP N
Laparoscopic NNP N
assessment NN N
was VBD N
correct JJ N
in IN N
all DT N
cases NNS N
in IN N
which WDT N
the DT N
appendix NN N
was VBD N
visualized VBN N
. . N

Diagnostic JJ N
accuracy NN N
was VBD N
improved VBN N
from IN N
75 CD N
% NN N
to TO N
97 CD N
% NN N
. . N

Laparoscopy NNP N
was VBD N
associated VBN N
with IN N
no DT N
added JJ N
complications NNS N
, , N
no DT N
increase NN N
in IN N
hospital JJ N
stay NN N
in IN N
patients NNS N
who WP N
went VBD N
on IN N
to TO N
appendicectomy VB N
, , N
and CC N
a DT N
reduction NN N
in IN N
hospital NN N
stay NN N
for IN N
those DT N
who WP N
underwent JJ N
laparoscopy NN N
alone RB N
. . N

No UH N
patients NNS N
developed VBD N
a DT N
problem NN N
over IN N
the DT N
10-year JJ N
follow-up JJ N
period NN N
from IN N
having VBG N
a DT N
normal-looking JJ N
appendix NN N
not RB N
removed VBN N
at IN N
laparoscopy NN N
. . N

CONCLUSION NNP N
Laparoscopic NNP N
assessment NN N
of IN N
the DT N
appendix NN N
is VBZ N
reliable JJ N
, , N
and CC N
to TO N
leave VB N
a DT N
normal-looking JJ N
appendix NN N
at IN N
laparoscopy NN N
does VBZ N
not RB N
appear VB N
to TO N
cause VB N
any DT N
long-term JJ N
problems NNS N
. . N

-DOCSTART- -X- O O

Prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
diclofenac NN 3_i
and CC N
ketorolac NN N
after IN N
refractive JJ N
surgery NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
effectiveness NN N
of IN N
diclofenac NN 3_i
and CC N
ketorolac NN 3_i
in IN N
relieving VBG N
corneal NN N
pain NN N
after IN N
refractive JJ N
surgery NN N
, , N
and CC N
determine VB N
if IN N
there EX N
is VBZ N
a DT N
difference NN N
in IN N
stinging VBG N
on IN N
instillation NN N
. . N

METHODS NNP N
Thirty NNP N
patients NNS N
were VBD N
randomized VBN N
prospectively RB N
to TO N
postoperative VB 3_i
diclofenac NN 3_i
in IN N
one CD N
eye NN N
and CC N
ketorolac NN 3_i
in IN 3_i
the DT 3_i
other JJ 3_i
. . N

Patients NNS N
and CC N
surgeon NN N
did VBD N
not RB N
know VB N
which WDT N
medications NNS N
were VBD N
used VBN N
. . N

Ocular JJ N
postoperative JJ N
pain NN N
and CC N
discomfort NN N
on IN N
instillation NN N
of IN N
medication NN N
were VBD N
measured VBN N
after IN N
radial JJ N
keratotomy NN N
with IN N
a DT N
visual JJ N
analog NN N
scale NN N
and CC N
a DT N
questionnaire NN N
. . N

RESULTS NNP N
Both NNP N
medications NNS N
were VBD N
highly RB N
effective JJ N
in IN N
relieving VBG N
pain NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pain NN N
relief NN N
, , N
or CC N
stinging VBG N
on IN N
instillation NN N
( ( N
P NNP N
= NNP N
.29 NNP N
) ) N
. . N

CONCLUSION NNP N
There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
effectiveness NN N
of IN N
the DT N
medications NNS N
on IN N
pain NN N
relief NN N
, , N
or CC N
in IN N
stinging VBG N
on IN N
instillation NN N
. . N

-DOCSTART- -X- O O

Schizophrenia NNP N
. . N

A DT N
follow-up JJ N
study NN N
of IN N
the DT N
results NNS N
of IN N
five CD N
forms NNS N
of IN N
treatment NN N
. . N

Two CD N
hundred VBD N
twenty-eight JJ N
first-admission NN N
schizophrenic JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
following VBG N
five CD N
treatments NNS N
: : N
psychotherapy NN 5_i
alone RB 5_i
, , N
drug NN 3_i
alone RB 3_i
, , N
psychotherapy JJ 5_i
plus CC 5_i
drug NN 5_i
, , N
electroconvulsive JJ 2_i
therapy NN 2_i
( ( 2_i
ECT NNP 2_i
, , 2_i
and CC 2_i
milieu NN 2_i
. . N

A DT N
there- JJ N
to TO N
five-year JJ N
follow-up NN N
examined VBD N
their PRP$ N
course NN N
after IN N
release NN N
from IN N
the DT N
hospital NN N
. . N

The DT N
drug NN N
alone RB N
and CC N
ECT NNP N
groups NNS N
tended VBD N
to TO N
have VB N
the DT N
best JJS N
outcome NN N
and CC N
the DT N
psychotherapy NN N
alone RB N
group NN N
the DT N
worst JJS N
. . N

The DT N
positive JJ N
effect NN N
from IN N
prior JJ N
drug NN N
treatment NN N
began VBD N
to TO N
dissipate VB N
after IN N
three CD N
years NNS N
postadmission NN N
. . N

For IN N
the DT N
in-hospital JJ N
treatment NN N
successes NNS N
, , N
the DT N
advantage NN N
from IN N
drug NN N
treatment NN N
and CC N
the DT N
disadvantage NN N
from IN N
psychotherapy NN N
were VBD N
less JJR N
apparent JJ N
. . N

Overall JJ N
, , N
the DT N
follow-up JJ N
outcome NN N
is VBZ N
far RB N
from IN N
reassuring VBG N
, , N
whatever WP N
the DT N
type NN N
of IN N
treatment NN N
. . N

Even RB N
though IN N
a DT N
few JJ N
patients NNS N
may MD N
do VB N
well RB N
, , N
much JJ N
remains VBZ N
to TO N
be VB N
done VBN N
in IN N
and CC N
out IN N
of IN N
the DT N
hospital NN N
. . N

-DOCSTART- -X- O O

Prognostic JJ N
significance NN N
of IN N
the DT N
dobutamine NN N
echocardiography NN N
test NN N
in IN N
idiopathic JJ N
dilated VBN N
cardiomyopathy NN N
. . N

Dobutamine NNP 2_i
stress NN 2_i
echo NN 2_i
provides VBZ N
potentially RB N
useful JJ N
information NN N
on IN N
idiopathic JJ 1_i
dilated VBN 1_i
cardiomyopathy NN 1_i
( ( N
IDC NNP N
) ) N
. . N

From IN N
February NNP N
1 CD N
, , N
1997 CD N
, , N
to TO N
October NNP N
1 CD N
, , N
1999 CD N
, , N
186 CD N
patients NNS N
( ( N
131 CD N
men NNS N
and CC N
55 CD N
women NNS N
, , N
mean JJ N
age NN N
56 CD N
+/- JJ N
12 CD N
years NNS N
) ) N
with IN N
IDC NNP N
, , N
ejection NN N
fraction NN N
< VBD N
35 CD N
% NN N
, , N
and CC N
angiographically RB N
normal JJ N
coronary JJ N
arteries NNS N
were VBD N
studied VBN N
by IN N
high-dose NN N
( ( N
up IN N
to TO N
40 CD N
micro/kg/min NN N
) ) N
dobutamine NN 2_i
echo NN 2_i
in IN N
6 CD N
centers NNS N
, , N
all DT N
quality NN N
controlled VBN N
for IN N
stress NN N
echo NN N
reading NN N
. . N

In IN N
all DT N
patients NNS N
, , N
wall JJ N
motion NN N
score NN N
index NN N
( ( N
WMSI NNP N
) ) N
( ( N
from IN N
1 CD N
= NNS N
normal JJ N
to TO N
4 CD N
= NNP N
dyskinetic NN N
in IN N
a DT N
16- JJ N
segment NN N
model NN N
of IN N
the DT N
left JJ N
ventricle NN N
) ) N
was VBD N
evaluated VBN N
by IN N
echo NN N
at IN N
baseline NN N
and CC N
peak JJ N
dobutamine NN N
. . N

One CD N
hundred VBD N
eighty-four JJ N
patients NNS N
were VBD N
followed VBN N
up RP N
( ( N
mean JJ N
15 CD N
+/- JJ N
13 CD N
months NNS N
) ) N
and CC N
only RB N
cardiac JJ N
death NN N
was VBD N
considered VBN N
as IN N
an DT N
end NN N
point NN N
. . N

There EX N
were VBD N
29 CD N
cardiac JJ N
deaths NNS N
. . N

Significant JJ N
parameters NNS N
for IN N
survival JJ N
prediction NN N
at IN N
univariate JJ N
analysis NN N
are VBP N
: : N
DeltaWMSI NNP N
( ( N
chi-square JJ N
20.1 CD N
; : N
p NN N
< VBZ N
0.0000 CD N
) ) N
, , N
New NNP N
York NNP N
Heart NNP N
Association NNP N
( ( N
NYHA NNP N
) ) N
class NN N
( ( N
chi-square JJ N
17.57 CD N
; : N
p NN N
< VBZ N
0.0000 CD N
) ) N
, , N
rest JJS N
ejection NN N
fraction NN N
( ( N
chi-square JJ N
10.41 CD N
; : N
p NN N
= VBZ N
0.0013 CD N
) ) N
, , N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
( ( N
chi-square JJ N
8.23 CD N
; : N
p NN N
= VBZ N
0.0041 CD N
) ) N
, , N
and CC N
hypertension NN N
( ( N
chi-square JJ N
8.08 CD N
, , N
p NN N
= NNP N
0.0045 CD N
) ) N
. . N

In IN N
the DT N
multivariate NN N
stepwise NN N
analysis NN N
only RB N
DeltaWMSI NNP N
and CC N
NYHA NNP N
were VBD N
independent JJ N
predictors NNS N
of IN N
outcome NN N
( ( N
DeltaWMSI NNP N
= NNP N
hazard VBD N
ratio NN N
0.02 CD N
, , N
p NN N
< VBD N
0.0000 CD N
; : N
NYHA NNP N
class NN N
= NNP N
hazard NN N
ratio NN N
3.83 CD N
, , N
p NN N
< NNP N
0.0000 CD N
) ) N
. . N

Kaplan-Meier NNP N
survival NN N
estimates NNS N
showed VBD N
a DT N
better JJR N
outcome NN N
for IN N
patients NNS N
with IN N
a DT N
large JJ N
inotropic NN N
response NN N
( ( N
DeltaWMSI NNP N
> NNP N
or CC N
=0.44 NNP N
, , N
a DT N
cutoff NN N
identified VBN N
by IN N
receiver-operating JJ N
characteristic JJ N
curves NNS N
analysis NN N
) ) N
than IN N
for IN N
those DT N
with IN N
a DT N
small JJ N
or CC N
no DT N
myocardial JJ N
inotropic NN N
response NN N
to TO N
dobutamine VB N
( ( N
93.6 CD N
% NN N
vs JJ N
69.4 CD N
% NN N
, , N
p NN N
= NNP N
0.00033 CD N
) ) N
. . N

Thus RB N
, , N
in IN N
patients NNS N
with IN N
IDC NNP N
, , N
an DT N
extensive JJ N
contractile NN N
reserve NN N
identified VBN N
by IN N
high-dose JJ N
dobutamine NN N
stress NN N
echocardiography NN N
is VBZ N
associated VBN N
with IN N
a DT N
better JJR N
survival NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
prophylactic JJ 3_i
calcium NN 3_i
and CC 3_i
magnesium NN 3_i
infusions NNS 3_i
on IN N
the DT N
incidence NN N
of IN N
neurotoxicity NN N
and CC N
clinical JJ N
outcome NN N
of IN N
oxaliplatin-based JJ N
systemic JJ N
treatment NN N
in IN N
advanced JJ N
colorectal JJ N
cancer NN N
patients NNS N
. . N

BACKGROUND NNP N
Peripheral NNP N
sensory JJ N
neurotoxicity NN N
is VBZ N
a DT N
frequent JJ N
and CC N
potentially RB N
debilitating JJ N
side NN N
effect NN N
of IN N
oxaliplatin NN N
treatment NN N
. . N

Calcium NN N
and CC N
magnesium NN N
( ( N
Ca/Mg NNP N
) ) N
infusions NNS N
are VBP N
frequently RB N
used VBN N
to TO N
prevent VB N
this DT N
toxicity NN N
. . N

However RB N
, , N
concerns NNS N
about IN N
a DT N
negative JJ N
impact NN N
of IN N
Ca/Mg NNP N
infusions NNS N
on IN N
outcome NN N
have VBP N
been VBN N
raised VBN N
. . N

We PRP N
retrospectively RB N
assessed VBD N
the DT N
effect NN N
of IN N
Ca/Mg NNP N
infusions NNS N
on IN N
the DT N
incidence NN N
of IN N
neurotoxicity NN N
and CC N
on IN N
clinical JJ N
outcome NN N
in IN N
advanced JJ N
colorectal JJ N
cancer NN N
( ( N
ACC NNP N
) ) N
patients NNS N
treated VBN N
in IN N
the DT N
phase NN N
III NNP N
CAIRO2 NNP N
study NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Seven NNP N
hundred VBD N
and CC N
fifty JJ N
five CD N
previously RB N
untreated JJ N
ACC NNP N
patients NNS N
were VBD N
randomised VBN N
between IN N
treatment NN 3_i
with IN 3_i
capecitabine NN 3_i
, , 3_i
oxaliplatin NN 3_i
and CC 3_i
bevacizumab NN 3_i
or CC N
the DT N
same JJ 3_i
combination NN 3_i
with IN 3_i
the DT 3_i
addition NN 3_i
of IN 3_i
cetuximab NN 3_i
. . N

Patients NNS N
were VBD N
retrospectively RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
patients NNS N
in IN N
the DT N
Ca/Mg NNP 3_i
( ( 3_i
+ NNP 3_i
) ) 3_i
group NN 3_i
received VBD N
Ca/Mg NNP 2_i
at IN N
least JJS N
during IN N
their PRP$ N
first JJ N
treatment NN N
cycle NN N
, , N
and CC N
patients NNS N
in IN N
the DT N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
did VBD N
not RB N
. . N

RESULTS VB N
Seven NNP N
hundred CD N
and CC N
thirty VB N
two CD N
patients NNS N
were VBD N
evaluable JJ N
for IN N
this DT N
analysis NN N
. . N

The DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
group NN N
consisted VBD N
of IN N
551 CD N
patients NNS N
, , N
the DT N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
consisted VBD N
of IN N
181 CD N
patients NNS N
. . N

The DT N
incidence NN N
of IN N
all DT N
grade JJ N
neurotoxicity NN N
in IN N
the DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
group NN N
and CC N
the DT N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
was VBD N
85 CD N
% NN N
and CC N
92 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
the DT N
incidence NN N
of IN N
grade NN N
? . N
2 CD N
neurotoxicity NN N
was VBD N
40 CD N
% NN N
and CC N
45 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.22 CD N
) ) N
. . N

The DT N
median JJ N
PFS NNP N
in IN N
the DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
versus NN N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
was VBD N
10.1 CD N
versus NN N
10.7 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.92 CD N
) ) N
, , N
the DT N
median JJ N
OS NNP N
was VBD N
19.8 CD N
versus NN N
20.7 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
, , N
and CC N
the DT N
response NN N
rate NN N
was VBD N
43.1 CD N
% NN N
versus IN N
50 CD N
% NN N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
largest JJS N
retrospective JJ N
analysis NN N
to TO N
date NN N
we PRP N
observed VBD N
that IN N
Ca/Mg NNP N
infusions NNS N
significantly RB N
reduced VBD N
all DT N
grade JJ N
oxaliplatin-related JJ N
neurotoxicity NN N
. . N

Ca/Mg NNP N
infusions NNS N
did VBD N
not RB N
affect VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
food NN 3_i
on IN N
the DT N
antiviral JJ N
activity NN N
of IN N
didanosine JJ 3_i
enteric-coated JJ 3_i
capsules NNS 3_i
: : N
a DT N
pilot NN N
comparative NN N
study NN N
. . N

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
effect NN N
of IN N
food NN 3_i
on IN N
the DT N
antiviral JJ N
activity NN N
of IN N
enteric-coated JJ 3_i
( ( 3_i
EC NNP 3_i
) ) 3_i
capsules NNS 3_i
of IN 3_i
didanosine NN 3_i
( ( 3_i
ddI NN 3_i
) ) 3_i
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
pilot NN N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
of IN N
28-day JJ N
ddI-EC JJ 3_i
capsules NNS 3_i
monotherapy-administered VBN 3_i
in IN N
a DT N
fasted JJ 4_i
state NN 4_i
( ( N
group NN N
1 CD N
, , N
n=11 NN N
) ) N
or CC N
with IN 3_i
food NN 3_i
( ( N
group NN N
2 CD N
, , N
n=10 RB N
) ) N
to TO N
treatment-na?ve JJ N
chronically RB N
HIV-1-infected JJ N
individuals NNS N
. . N

To TO N
assess VB N
the DT N
antiviral JJ N
efficacy NN N
, , N
HIV-1 NNP N
RNA NNP N
was VBD N
determined VBN N
at IN N
baseline NN N
, , N
day NN N
3 CD N
, , N
day NN N
7 CD N
and CC N
weekly JJ N
thereafter NN N
. . N

The DT N
area NN N
under IN N
the DT N
HIV-1 NNP N
RNA NNP N
curve NN N
minus NN N
baseline NN N
weighted VBN N
by IN N
time NN N
( ( N
AUCMB/day NNP N
) ) N
was VBD N
calculated VBN N
. . N

RESULTS JJ N
Mean JJ N
baseline JJ N
HIV-1 NNP N
RNA NNP N
was VBD N
4.2 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
in IN N
group NN N
1 CD N
and CC N
3.8 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
in IN N
group NN N
2 CD N
. . N

After IN N
28 CD N
days NNS N
, , N
the DT N
mean JJ N
HIV-1 NNP N
RNA NNP N
reduction NN N
was VBD N
0.99 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
[ $ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.45-1.53 CD N
] NN N
for IN N
group NN N
1 CD N
and CC N
0.89 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.38-1.40 NN N
) ) N
for IN N
group NN N
2 CD N
. . N

AUCMB/day JJ N
values NNS N
were VBD N
0.775 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.33-1.22 NN N
) ) N
and CC N
0.774 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.48-1.07 NN N
) ) N
, , N
respectively RB N
, , N
showing VBG N
no DT N
difference NN N
in IN N
the DT N
rate NN N
of IN N
decrease NN N
of IN N
HIV-1 NNP N
RNA NNP N
( ( N
P=0.995 NNP N
) ) N
. . N

Mean NNP N
ddI JJ N
plasma NN N
levels NNS N
at IN N
day NN N
28 CD N
were VBD N
0.0234 CD N
mg/L NN N
for IN N
group NN N
1 CD N
and CC N
0.0227 CD N
mg/L NN N
for IN N
group NN N
2 CD N
( ( N
P=0.96 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
pilot NN N
study NN N
, , N
the DT N
administration NN N
of IN N
food NN N
did VBD N
not RB N
have VB N
any DT N
significant JJ N
effect NN N
on IN N
the DT N
antiviral JJ N
activity NN N
of IN N
ddI-EC JJ N
capsules NNS N
. . N

-DOCSTART- -X- O O

Postoperative JJ N
analgesia NN N
by IN N
D-myo-inositol-1,2,6-trisphosphate NNP 3_i
in IN N
patients NNS N
undergoing VBG N
cholecystectomy NN N
. . N

UNLABELLED JJ N
D-myo-inositol-1,2,6-trisphosphate NNP 3_i
( ( 3_i
1,2,6-IP3 CD 3_i
) ) 3_i
possesses VBZ N
antiinflammatory JJ N
properties NNS N
, , N
such JJ N
as IN N
reduced JJ N
eicosanoid JJ N
synthesis NN N
and CC N
inhibition NN N
of IN N
inflammation-induced JJ N
edema NN N
. . N

These DT N
properties NNS N
suggest VBP N
possible JJ N
analgesic JJ N
effects NNS N
. . N

The DT N
analgesic JJ N
effect NN N
of IN N
1,2,6-IP3 NN N
was VBD N
evaluated VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
study NN N
in IN N
24 CD N
patients NNS N
undergoing JJ N
cholecystectomy NN 1_i
. . N

Ten CD N
patients NNS N
received VBD N
1,2,6-IP3 JJ 3_i
as IN N
an DT N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
bolus IN N
dose NN N
of IN N
240 CD N
mg NN N
, , N
followed VBN N
by IN N
a DT N
continuous JJ N
i.v NN N
. . N

infusion NN N
at IN N
90 CD N
mg/h NN N
for IN N
24 CD N
h. PDT N
The DT N
placebo NN 7_i
group NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
received VBD N
corresponding VBG N
volumes NNS N
of IN N
isotonic JJ 3_i
saline NN 3_i
. . N

Postoperative JJ N
pain NN N
( ( N
visual JJ N
analog NN N
pain VBP N
scale NN N
; : N
VAS NNP N
) ) N
and CC N
opiate JJ N
analgesic JJ N
requirements NNS N
( ( N
ketobemidon NN 3_i
) ) N
were VBD N
evaluated VBN N
during IN N
five CD N
postoperative JJ N
days NNS N
. . N

Results NNS N
showed VBD N
significantly RB N
reduced VBN N
pain NN N
during IN N
the DT N
first JJ N
five CD N
postoperative JJ N
days NNS N
in IN N
patients NNS N
treated VBN N
with IN N
1,2,6-IP3 JJ N
, , N
as IN N
measured VBN N
by IN N
using VBG N
a DT N
VAS NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
requirements NNS N
of IN N
opioid JJ N
analgesics NNS N
were VBD N
significantly RB N
reduced VBN N
during IN N
the DT N
first JJ N
three CD N
postoperative JJ N
days NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
drug-related JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
. . N

Results NNS N
of IN N
the DT N
present JJ N
study NN N
demonstrate VB N
a DT N
potent NN N
and CC N
long-lasting JJ N
analgesic JJ N
effect NN N
of IN N
1,2,6-IP3 JJ N
, , N
possibly RB N
related VBN N
to TO N
its PRP$ N
antiinflammatory NN N
properties NNS N
. . N

IMPLICATIONS VB N
A DT N
new JJ N
antiinflammatory JJ N
drug NN N
under IN N
investigation NN N
, , N
inositol-1,2,6-trisphosphate JJ 3_i
, , N
was VBD N
evaluated VBN N
as IN N
a DT N
possible JJ N
analgesic NN N
in IN N
a DT N
pilot NN N
study NN N
during IN N
the DT N
postoperative JJ N
period NN N
in IN N
cholecystectomized JJ N
patients NNS N
. . N

Results NNS N
showed VBD N
significantly RB N
lower JJR N
pain NN N
assessment NN N
and CC N
opioid JJ N
consumption NN N
, , N
which WDT N
should MD N
encourage VB N
further JJ N
studies NNS N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
an DT N
aquatics NNS 4_i
programme NN 4_i
on IN N
fitness NN N
parameters NNS N
of IN N
individuals NNS N
with IN N
a DT N
brain NN N
injury NN N
. . N

The DT N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
an DT N
aquatic JJ 4_i
exercise NN 4_i
programme NN 4_i
on IN N
the DT N
physical JJ N
fitness NN N
of IN N
people NNS N
with IN N
a DT N
brain NN N
injury NN N
. . N

A DT N
pre-test-post-test JJ N
randomized-groups JJ N
design NN N
was VBD N
conducted VBN N
. . N

Sixteen JJ N
outpatients NNS N
with IN N
a DT N
brain NN N
injury NN N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Eight CD N
participants NNS N
were VBD N
assigned VBN N
to TO N
an DT N
aquatic JJ 4_i
exercise NN 4_i
group NN 4_i
and CC 4_i
eight CD 4_i
to TO 4_i
a DT 4_i
control NN 4_i
group NN 4_i
. . N

The DT N
components NNS N
of IN N
physical JJ N
fitness NN N
measured VBD N
included VBD N
cardiovascular JJ N
endurance NN N
, , N
body NN N
composition NN N
, , N
muscular JJ N
strength NN N
and CC N
endurance NN N
and CC N
flexibility NN N
. . N

Measurements NNS N
were VBD N
taken VBN N
pre- JJ N
and CC N
post-programme JJ N
. . N

Results NNP N
indicated VBD N
an DT N
increase NN N
in IN N
components NNS N
of IN N
physical JJ N
fitness NN N
for IN N
the DT N
experimental JJ N
group NN N
but CC N
not RB N
the DT N
control NN N
group NN N
. . N

Increases VBZ N
in IN N
fitness NN N
were VBD N
reported VBN N
as IN N
having VBG N
a DT N
positive JJ N
impact NN N
on IN N
the DT N
functional JJ N
capacity NN N
of IN N
individuals NNS N
in IN N
the DT N
exercise NN N
group NN N
as RB N
well RB N
as IN N
enhancing VBG N
the DT N
individual NN N
's POS N
ability NN N
to TO N
complete VB N
activities NNS N
of IN N
daily JJ N
living VBG N
successfully RB N
. . N

Results VB N
indicate JJ N
that IN N
aquatic JJ N
exercise NN N
may MD N
positively RB N
impact VB N
the DT N
primary JJ N
and CC N
secondary JJ N
physical JJ N
injuries NNS N
caused VBN N
by IN N
a DT N
brain NN N
injury NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
effect NN N
of IN N
transcatheter NN 1_i
arterial JJ 1_i
chemoembolization NN 1_i
combined VBN N
with IN N
high JJ 1_i
intensity NN 1_i
focused VBD 1_i
ultrasound JJ 1_i
ablation NN 1_i
in IN N
treatment NN N
of IN N
large JJ N
hepatocellular JJ N
carcinoma NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
clinical JJ N
effect NN N
of IN N
transcatheter NN 1_i
arterial JJ 1_i
chemoembolization NN 1_i
( ( 1_i
TACE NNP 1_i
) ) 1_i
combined VBN N
with IN N
high JJ 1_i
intensity NN 1_i
focused VBN 1_i
ultrasound NN 1_i
( ( 1_i
HIFU NNP 1_i
) ) 1_i
ablation NN N
in IN N
treatment NN N
of IN N
large JJ N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
. . N

METHODS NNP N
Sixty-eight JJ N
patients NNS N
with IN N
unresectable JJ N
HCC NNP N
were VBD N
randomized VBN N
into IN N
2 CD 2_i
age NN 2_i
, , 2_i
tumor NN 2_i
size NN 2_i
, , 2_i
TNM NNP 2_i
stages VBZ 2_i
, , N
and CC N
liver JJ 2_i
function NN 2_i
grade-matched JJ 2_i
groups NNS 2_i
: : N
TACE NNP 1_i
group NN 2_i
( ( 2_i
n=30 RB 2_i
) ) 2_i
undergoing VBG 2_i
TACE NNP 1_i
and CC N
TACE+HIFU NNP 1_i
group NN 2_i
( ( 2_i
n=38 RB 2_i
) ) 2_i
undergoing VBG 2_i
2-3 JJ 2_i
weeks NNS 2_i
after IN 2_i
TACE NNP 2_i
. . N

A NNP N
total NN N
of IN N
88 CD N
tumors NNS N
( ( N
9.3+/-3.2 CD N
) ) N
( ( N
5.0-14.5 JJ N
) ) N
cm NN N
in IN N
diameter NN N
were VBD N
detected VBN N
, , N
and CC N
the DT N
largest JJS N
tumor NN N
in IN N
a DT N
specific JJ N
patients NNS N
with IN N
multiple JJ N
lesions NNS N
was VBD N
selected VBN N
for IN N
observation NN N
. . N

Follow-up NNP N
was VBD N
conducted VBN N
for IN N
( ( N
13+/-7 JJ N
) ) N
( ( N
3-24 JJ N
) ) N
months NNS N
to TO N
observe VB N
the DT N
necrosis NN N
of IN N
tumor NN N
, , N
size NN N
of IN N
tumor NN N
, , N
local JJ N
recurrence NN N
, , N
and CC N
survival NN N
of IN N
patient NN N
. . N

RESULTS VB N
The DT N
clinical JJ N
symptom JJ N
remission NN N
rate NN N
was VBD N
90.6 CD N
% NN N
( ( N
29/32 CD N
) ) N
in IN N
the DT N
TACE+HIFU NNP 1_i
group NN N
and CC N
70.8 CD N
% NN N
( ( N
28/38 CD N
) ) N
in IN N
the DT N
TACE NNP N
group NN N
. . N

The DT N
tumor NN N
necrosis NN N
and CC N
minification NN N
rates NNS N
of IN N
the DT N
TACE+HIFU NNP 1_i
and CC N
TACE NNP 1_i
groups NNS N
were VBD N
73.7 CD N
% NN N
and CC N
68.4 CD N
% NN N
respectively RB N
, , N
both DT N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
TACE NNP 1_i
group NN N
( ( N
26.7 CD N
% NN N
and CC N
33.3 CD N
% NN N
respectively RB N
, , N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
tumor NN N
local JJ N
recurrence NN N
rate NN N
of IN N
the DT N
TACE+HIFU NNP 1_i
group NN N
was VBD N
21.1 CD N
% NN N
, , N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
the DT N
TACE NNP 1_i
group NN N
( ( N
33.3 CD N
% NN N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
median JJ N
survival NN N
duration NN N
of IN N
the DT N
TACE+HIFU NNP 1_i
group NN N
was VBD N
18 CD N
months NNS N
, , N
significantly RB N
longer JJR N
than IN N
that DT N
of IN N
the DT N
TACE NNP 1_i
group NN N
( ( N
10 CD N
months NNS N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
the DT N
TACE NNP 1_i
therapy NN N
alone RB N
, , N
the DT N
combination NN N
therapy NN N
improves VBZ N
the DT N
tumor NN N
necrosis NN N
rate NN N
and CC N
prolongs VBZ N
the DT N
patients NNS N
' POS N
survival JJ N
duration NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
esmolol NN 3_i
, , N
a DT N
short-acting JJ N
beta NN N
blocker NN N
, , N
with IN N
placebo NN 7_i
in IN N
the DT N
treatment NN N
of IN N
supraventricular JJ N
tachyarrhythmias NN N
. . N

The DT N
Esmolol NNP 3_i
vs NN N
Placebo NNP 3_i
Multicenter NNP N
Study NNP N
Group NNP N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
esmolol NN 3_i
, , N
a DT N
short-acting JJ N
intravenous JJ N
beta-adrenergic-blocking JJ N
agent NN N
, , N
and CC N
placebo NN 7_i
were VBD N
compared VBN N
in IN N
patients NNS N
with IN N
supraventricular JJ N
tachyarrhythmias NN N
( ( N
heart NN N
rate NN N
greater JJR N
than IN N
120 CD N
bpm NN N
) ) N
in IN N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
partial-crossover JJ N
study NN N
. . N

Seventy-one CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
esmolol NN 3_i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
or CC N
placebo NN 7_i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
as IN N
initial JJ N
treatment NN N
. . N

Therapeutic JJ N
failures NNS N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
other JJ N
study NN N
medication NN N
. . N

Therapeutic JJ N
response NN N
was VBD N
defined VBN N
as IN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
20 CD N
% NN N
reduction NN N
in IN N
heart NN N
rate NN N
, , N
heart NN N
rate NN N
less JJR N
than IN N
100 CD N
bpm NN N
, , N
or CC N
conversion NN N
to TO N
normal JJ N
sinus NN N
rhythm NN N
. . N

The DT N
therapeutic JJ N
response NN N
to TO N
esmolol VB 3_i
during IN N
the DT N
initial JJ N
treatment NN N
period NN N
( ( N
72 CD N
% NN N
) ) N
was VBD N
similar JJ N
to TO N
that DT N
obtained VBN N
when WRB N
esmolol NN N
was VBD N
given VBN N
as IN N
a DT N
second JJ N
agent NN N
. . N

The DT N
average JJ N
esmolol JJ N
dosage NN N
producing VBG N
a DT N
therapeutic JJ N
response NN N
was VBD N
97.5 CD N
micrograms/kg/min NN N
. . N

Four CD N
patients NNS N
( ( N
6 CD N
% NN N
) ) N
converted VBD N
to TO N
normal JJ N
sinus JJ N
rhythm NN N
during IN N
esmolol JJ N
infusion NN N
. . N

In IN N
the DT N
majority NN N
of IN N
patients NNS N
( ( N
80 CD N
% NN N
) ) N
, , N
therapeutic JJ N
response NN N
was VBD N
lost VBN N
within IN N
30 CD N
minutes NNS N
following VBG N
discontinuation NN N
of IN N
esmolol JJ 3_i
infusion NN N
, , N
a DT N
finding JJ N
indicative NN N
of IN N
rapid JJ N
reversal NN N
of IN N
beta-adrenoceptor NN N
blockade NN N
. . N

The DT N
most RBS N
prevalent JJ N
adverse JJ N
effect NN N
during IN N
esmolol JJ 3_i
infusion NN N
was VBD N
hypotension NN N
which WDT N
occurred VBD N
in IN N
eight CD N
patients NNS N
( ( N
12 CD N
% NN N
) ) N
. . N

Hypotension NN N
and CC N
associated VBN N
symptoms NNS N
resolved VBD N
within IN N
30 CD N
minutes NNS N
after IN N
discontinuation NN N
of IN N
esmolol JJ 3_i
infusion NN N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
the DT N
short JJ N
duration NN N
of IN N
action NN N
of IN N
esmolol NN 3_i
( ( N
elimination JJ N
half-life NN N
of IN N
9.2 CD N
minutes NNS N
) ) N
. . N

-DOCSTART- -X- O O

Acute NNP N
and CC N
long-term JJ N
safety NN N
and CC N
tolerability NN N
of IN N
risperidone NN 3_i
in IN N
children NNS N
with IN N
autism NN N
. . N

Treatment-emergent JJ N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
were VBD N
monitored VBN N
during IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
trial NN N
of IN N
risperidone NN 3_i
( ( N
0.5-3.5 JJ N
mg/day NN N
) ) N
in IN N
101 CD N
children NNS N
and CC N
adolescents NNS N
with IN N
a DT N
lifetime JJ N
diagnosis NN N
of IN N
autistic JJ N
disorder NN N
. . N

In IN N
addition NN N
, , N
37 CD N
placebo NN N
nonresponders NNS N
received VBD N
open-label JJ N
risperidone NN 3_i
for IN N
another DT N
8 CD N
weeks NNS N
. . N

Of IN N
all PDT N
the DT N
risperidone NN 3_i
responders NNS N
( ( N
n=65 NN N
) ) N
, , N
63 CD N
entered VBD N
an DT N
open JJ N
extension NN N
of IN N
another DT N
16 CD N
weeks NNS N
( ( N
6 CD N
months NNS N
total JJ N
risperidone NN 3_i
exposure NN N
) ) N
, , N
and CC N
32 CD N
of IN N
them PRP N
were VBD N
rerandomized VBN N
to TO N
either DT N
continued VBN N
risperidone NN 3_i
therapy NN N
( ( N
n=16 JJ N
) ) N
or CC N
gradual JJ N
replacement NN N
with IN N
placebo NN 3_i
( ( N
n=16 JJ N
) ) N
over IN N
8 CD N
weeks NNS N
. . N

We PRP N
collected VBD N
the DT N
following JJ N
measures NNS N
of IN N
safety NN N
and CC N
tolerability NN N
: : N
( ( N
1 CD N
) ) N
laboratory NN N
blood NN N
assessments NNS N
( ( N
CBC NNP N
with IN N
differential JJ N
, , N
electrolytes NNS N
, , N
and CC N
liver JJ N
function NN N
tests NNS N
) ) N
and CC N
urinalyses NNS N
, , N
( ( N
2 CD N
) ) N
vital NN N
signs NNS N
, , N
( ( N
3 CD N
) ) N
Side NNP N
Effects NNP N
Review NNP N
of IN N
AEs NNP N
thought VBD N
to TO N
be VB N
associated VBN N
with IN N
risperidone NN N
, , N
( ( N
4 CD N
) ) N
sleep NN N
records NNS N
, , N
( ( N
5 CD N
) ) N
Simpson NNP N
Angus NNP N
Neurological NNP N
Rating NNP N
Scale NNP N
( ( N
SARS NNP N
) ) N
, , N
( ( N
6 CD N
) ) N
Abnormal NNP N
Involuntary NNP N
Movement NNP N
Scale NNP N
( ( N
AIMS NNP N
) ) N
, , N
and CC N
( ( N
7 CD N
) ) N
height NN N
and CC N
weight NN N
. . N

No DT N
clinically RB N
significant JJ N
changes NNS N
were VBD N
found VBN N
on IN N
the DT N
lab NN N
tests NNS N
. . N

During IN N
the DT N
8-week JJ N
acute JJ N
trial NN N
, , N
the DT N
most RBS N
common JJ N
AEs NNP N
on IN N
the DT N
Side NNP N
Effects NNP N
Review NNP N
, , N
scored VBD N
as IN N
moderate JJ N
or CC N
higher JJR N
, , N
were VBD N
as IN N
follows VBZ N
( ( N
placebo NN N
and CC N
risperidone NN N
, , N
respectively RB N
) ) N
: : N
Somnolence NN N
( ( N
12 CD N
% NN N
and CC N
37 CD N
% NN N
) ) N
, , N
enuresis NN N
( ( N
29 CD N
% NN N
and CC N
33 CD N
% NN N
) ) N
, , N
excessive JJ N
appetite NN N
( ( N
10 CD N
% NN N
and CC N
33 CD N
% NN N
) ) N
, , N
rhinitis NN N
( ( N
8 CD N
% NN N
and CC N
16 CD N
% NN N
) ) N
, , N
difficulty NN N
waking NN N
( ( N
8 CD N
% NN N
and CC N
12 CD N
% NN N
) ) N
, , N
and CC N
constipation NN N
( ( N
12 CD N
% NN N
and CC N
10 CD N
% NN N
) ) N
. . N

Difficulty NN N
falling VBG N
asleep JJ N
and CC N
anxiety NN N
actually RB N
favored VBD N
the DT N
risperidone NN N
condition NN N
at IN N
statistically RB N
significant JJ N
levels NNS N
. . N

The DT N
same JJ N
AEs NNP N
tended VBD N
to TO N
recur VB N
through IN N
6 CD N
months NNS N
of IN N
treatment NN N
, , N
although IN N
often RB N
at IN N
reduced VBN N
levels NNS N
. . N

Using VBG N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
( ( N
CDC NNP N
) ) N
standardized VBD N
scores NNS N
, , N
both DT N
weight NN N
and CC N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
increased VBD N
with IN N
risperidone NN 3_i
during IN N
the DT N
acute JJ N
trial NN N
( ( N
0.5 CD N
and CC N
0.6 CD N
SDs NNP N
, , N
respectively RB N
, , N
for IN N
risperidone NN 3_i
; : 3_i
0.0 CD N
and CC N
0.1 CD N
SDs NNP N
, , N
respectively RB N
, , N
for IN N
placebo NN N
) ) N
and CC N
into IN N
open-label JJ N
extension NN N
( ( N
0.19 CD N
and CC N
0.16 CD N
SDs NNP N
, , N
respectively RB N
) ) N
, , N
although IN N
the DT N
amount NN N
of IN N
gain NN N
decelerated VBN N
with IN N
time NN N
. . N

Extrapyramidal NNP N
symptoms NNS N
, , N
as IN N
assessed VBN N
by IN N
the DT N
SARS NNP N
, , N
were VBD N
no DT N
more RBR N
common JJ N
for IN N
drug NN N
than IN N
placebo NN N
, , N
although IN N
drooling NN N
was VBD N
reported VBN N
more RBR N
often RB N
in IN N
the DT N
risperidone NN 3_i
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
groups NNS N
on IN N
the DT N
AIMS NNP N
. . N

Two CD N
subjects NNS N
had VBD N
seizures NNS N
( ( N
one CD N
taking VBG N
placebo NN N
) ) N
, , N
but CC N
these DT N
were VBD N
considered VBN N
unrelated JJ N
to TO N
active JJ N
drug NN N
. . N

Most JJS N
AEs NNPS N
were VBD N
mild JJ N
to TO N
moderate VB N
and CC N
failed VBD N
to TO N
interfere VB N
with IN N
therapeutic JJ N
changes NNS N
; : N
there EX N
were VBD N
no DT N
unanticipated JJ N
AEs NNP N
. . N

The DT N
side NN N
effects NNS N
of IN N
most JJS N
concern NN N
were VBD N
somnolence NN N
and CC N
weight JJ N
gain NN N
. . N

-DOCSTART- -X- O O

Risperidone-induced JJ N
prolactin NN N
elevation NN N
in IN N
a DT N
prospective JJ N
study NN N
of IN N
children NNS N
, , N
adolescents NNS N
, , N
and CC N
adults NNS N
with IN N
mental JJ N
retardation NN N
and CC N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

OBJECTIVE NNP N
Risperidone NNP N
is VBZ N
widely RB N
prescribed VBN N
for IN N
aggression NN N
and CC N
self-injury NN N
in IN N
children NNS N
, , N
adolescents NNS N
, , N
and CC N
adults NNS N
with IN N
mental JJ N
retardation NN N
( ( N
MR NNP N
) ) N
and CC N
pervasive JJ N
developmental NN N
disorders NNS N
( ( N
PDD NNP N
) ) N
. . N

Risperidone NNP N
elevates VBZ N
prolactin RB N
more JJR N
than IN N
other JJ N
atypical JJ N
antipsychotic JJ N
medications NNS N
. . N

Females NNS N
may MD N
show VB N
greater JJR N
prolactin NN N
elevation NN N
than IN N
males NNS N
. . N

METHOD NNP N
In IN N
this DT N
relatively RB N
long-term JJ N
study NN N
of IN N
risperidone NN 3_i
efficacy NN N
and CC N
safety NN N
for IN N
aggression NN N
and CC N
self-injury NN N
in IN N
children NNS N
, , N
adolescents NNS N
, , N
and CC N
adults NNS N
with IN N
MR NNP N
and CC N
PDDs NNP N
, , N
serum NN N
prolactin NN N
was VBD N
measured VBN N
in IN N
a DT N
21-subject JJ N
subset NN N
during IN N
the DT N
course NN N
of IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
trial NN N
. . N

Prolactin NNP 3_i
was VBD N
measured VBN N
in IN N
ng/mL NN N
at IN N
baseline NN N
, , N
once RB N
during IN N
acute JJ N
treatment NN N
, , N
and CC N
once RB N
during IN N
maintenance NN N
. . N

RESULTS NNP N
In IN N
children NNS N
and CC N
adolescents NNS N
( ( N
n=10 NN N
) ) N
, , N
mean JJ N
age NN N
of IN N
12.5 CD N
years NNS N
, , N
prolactin NN N
increased VBD N
from IN N
mean JJ N
13.2+/-8.6 CD N
at IN N
baseline NN N
to TO N
31.0+/-11.6 JJ N
acutely RB N
and CC N
remained VBD N
elevated VBN N
at IN N
37.9+/-10.4 JJ N
in IN N
maintenance NN N
. . N

In IN N
adults NNS N
, , N
mean JJ N
age NN N
of IN N
35.3 CD N
years NNS N
, , N
prolactin NN N
increased VBD N
more JJR N
markedly RB N
from IN N
11.6+/-7.4 JJ N
baseline NN N
( ( N
n=11 JJ N
) ) N
to TO N
93.3+/-54.2 CD N
acutely RB N
but CC N
decreased VBD N
to TO N
67.8+/-62.9 JJ N
in IN N
maintenance NN N
( ( N
n=7 JJ N
) ) N
. . N

Prolactin NNP N
remained VBD N
significantly RB N
elevated VBN N
above IN N
normal JJ N
in IN N
all DT N
subjects NNS N
for IN N
at IN N
least JJS N
26 CD N
weeks NNS N
. . N

Mean NNP N
prolactin NN N
of IN N
adult NN N
females NNS N
, , N
while IN N
similar JJ N
to TO N
that DT N
of IN N
adult NN N
males NNS N
at IN N
baseline NN N
, , N
was VBD N
2.2 CD N
times NNS N
male JJ N
levels NNS N
acutely RB N
and CC N
3.7 CD N
times NNS N
greater JJR N
in IN N
maintenance NN N
. . N

CONCLUSION NN N
In IN N
this DT N
small JJ N
subset NN N
, , N
mean JJ N
prolactin NN N
elevation NN N
persisted VBD N
for IN N
at IN N
least JJS N
26 CD N
weeks NNS N
. . N

In IN N
adults NNS N
, , N
females NNS N
showed VBD N
significantly RB N
greater JJR N
elevations NNS N
than IN N
males NNS N
. . N

-DOCSTART- -X- O O

Parenteral JJ N
nutrition NN N
and CC N
protein NN N
sparing NN N
after IN N
surgery NN 1_i
: : N
do VBP N
we PRP N
need VB N
glucose RB 3_i
? . N
Although IN N
capable JJ N
of IN N
inducing VBG N
an DT N
anabolic JJ N
state NN N
after IN N
surgery NN N
, , N
parenteral JJ 3_i
nutrition NN 3_i
, , N
including VBG N
glucose NN 3_i
, , N
leads VBZ N
to TO N
hyperglycemia VB N
. . N

Even RB N
moderate JJ N
increases NNS N
in IN N
blood NN N
glucose NN N
are VBP N
associated VBN N
with IN N
poor JJ N
surgical JJ N
outcome NN N
. . N

We PRP N
examined VBD N
the DT N
hypothesis NN N
that WDT N
amino NN 3_i
acids NNS 3_i
, , N
in IN N
the DT N
absence NN N
of IN N
glucose JJ 3_i
supply NN N
, , N
spare JJ N
protein NN N
while IN N
preventing VBG N
hyperglycemia NN N
. . N

In IN N
this DT N
prospective JJ N
study NN N
, , N
14 CD N
patients NNS N
with IN N
colonic JJ N
cancer NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
a DT N
6-hour JJ N
stable JJ N
isotope NN 3_i
infusion NN 3_i
study NN N
( ( N
3 CD N
hours NNS N
of IN N
fasting VBG 2_i
followed VBN N
by IN N
3-hour JJ N
infusions NNS N
of IN N
amino NN 3_i
acids NNS 3_i
, , N
Travasol NNP N
[ NNP N
Baxter NNP N
, , N
Montreal NNP N
, , N
Canada NNP N
] VBD N
10 CD N
% NN N
at IN N
0.02 CD N
mL.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
, , N
with IN 3_i
or CC 3_i
without IN 3_i
glucose JJ 3_i
at IN N
4 CD N
mg.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
) ) N
on IN N
the DT N
second JJ N
day NN N
after IN N
colorectal JJ N
surgery NN N
. . N

Protein NNP N
breakdown NN N
, , N
protein JJ N
oxidation NN N
, , N
protein JJ N
balance NN N
, , N
and CC N
glucose JJ N
production NN N
were VBD N
assessed VBN N
by IN N
stable JJ N
isotope NN N
tracer NN N
kinetics NNS N
using VBG N
l- JJ N
[ JJ N
1- JJ N
( ( N
13 CD N
) ) N
C NNP N
] NNP N
leucine NN N
and CC N
[ JJ N
6,6- JJ N
( ( N
2 CD N
) ) N
H2 NNP N
] NNP N
glucose NN N
. . N

Circulating VBG N
concentrations NNS N
of IN N
glucose NN N
, , N
cortisol NN N
, , N
insulin NN N
, , N
and CC N
glucagon NN N
were VBD N
determined VBN N
. . N

The DT N
administration NN N
of IN N
amino JJ 3_i
acids NNS 3_i
increased VBD N
protein JJ N
balance NN N
from IN N
-16+/-4 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
in IN N
the DT N
fasted JJ N
state NN N
to TO N
16+/-3 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
. . N

Combined VBN N
infusion NN N
of IN N
amino JJ N
acids NNS N
and CC N
glucose VB N
increased JJ N
protein NN N
balance NN N
from IN N
-17+/-7 JJ N
to TO N
7+/-5 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
. . N

The DT N
increase NN N
in IN N
protein JJ N
balance NN N
during IN N
nutrition NN N
was VBD N
comparable JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
P=.07 NNP N
) ) N
. . N

Combined VBN N
administration NN N
of IN N
amino JJ 3_i
acids NNS 3_i
and CC N
glucose VB 3_i
decreased VBN N
endogenous JJ N
glucose JJ N
production NN N
( ( N
P=.001 NNP N
) ) N
and CC N
stimulated VBN N
insulin NN N
secretion NN N
( ( N
P=.001 NNP N
) ) N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
the DT N
administration NN N
of IN N
amino JJ 3_i
acids NNS 3_i
alone RB N
. . N

Hyperglycemia NNP N
( ( N
blood NN N
glucose NN N
, , N
10.1+/-1.9 JJ N
micromol/L NN N
) ) N
occurred VBD N
only RB N
in IN N
the DT N
presence NN N
of IN N
glucose JJ 3_i
infusion NN N
. . N

In IN N
summary JJ N
, , N
excluding VBG N
glucose NN 3_i
from IN N
a DT N
short-term JJ N
feeding NN N
protocol NN N
does VBZ N
not RB N
diminish VB N
the DT N
protein-sparing JJ N
effect NN N
of IN N
amino NN 3_i
acids NNS 3_i
and CC N
avoids NNS N
hyperglycemia NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Observation NNP N
on IN N
therapeutic JJ N
effect NN N
of IN N
acupuncture NN 2_i
on IN N
early JJ N
peripheral JJ N
facial JJ N
paralysis NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
observe VB N
therapeutic JJ N
effects NNS N
of IN N
acupuncture NN 2_i
at IN N
different JJ N
opportunities NNS N
on IN N
peripheral JJ N
facial JJ N
paralysis NN N
. . N

METHODS NNP N
Fifty-two JJ N
cases NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
treatment NN N
group NN N
( ( N
n=28 CC N
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
n=24 RB N
) ) N
. . N

The DT N
treatment NN N
group NN N
at IN N
the DT N
acute JJ N
stage NN N
( ( N
1-10 JJ N
days NNS N
) ) N
were VBD N
treated VBN N
with IN N
acupuncture NN 3_i
at IN 3_i
Dicang NNP 3_i
( ( 3_i
ST NNP 3_i
4 CD 3_i
) ) 3_i
, , N
Jiache NNP 3_i
( ( 3_i
ST NNP 3_i
6 CD 3_i
) ) 3_i
, , N
Yangbai NNP 3_i
( ( 3_i
GB NNP 3_i
14 CD 3_i
) ) 3_i
, , N
etc. FW N
, , N
with IN 7_i
less JJR 7_i
than IN 7_i
4 CD 7_i
points NNS 7_i
selected VBN 7_i
on IN 7_i
the DT 7_i
face NN 7_i
and CC 7_i
with IN 7_i
shallow JJ 7_i
puncture NN 7_i
, , 7_i
and CC 7_i
10 CD 7_i
days NNS 7_i
later RB 7_i
electroacupuncture VBP 7_i
were VBD 7_i
added VBN 7_i
at IN 7_i
acupoints NNS 7_i
selected VBN 7_i
routinely RB 7_i
; : 7_i
the DT 7_i
control NN 7_i
group NN 7_i
were VBD 7_i
treated VBN 7_i
with IN 7_i
the DT 7_i
same JJ 7_i
methods NNS 7_i
as IN 7_i
the DT 7_i
treatment NN 7_i
group NN 7_i
but CC 7_i
acupuncture NN 7_i
was VBD 7_i
not RB 7_i
given VBN 7_i
at IN 7_i
the DT 7_i
acute JJ 7_i
stage NN 7_i
. . N

RESULTS VB N
The DT N
cured JJ N
rate NN N
of IN N
78.6 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
50.0 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Early JJ N
acupuncture NN 2_i
is VBZ N
a DT N
key NN N
for IN N
achieving VBG N
the DT N
best JJS N
therapeutic JJ N
effect NN N
on IN N
facial JJ N
paralysis NN N
. . N

-DOCSTART- -X- O O

The DT N
Relaxation NNP N
Inventory NN N
: : N
self-report JJ N
scales NNS N
of IN N
relaxation NN 2_i
training NN 2_i
effects NNS 2_i
. . N

The DT N
development NN N
of IN N
a DT N
self-report JJ N
measure NN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
relaxation NN N
training NN N
was VBD N
examined VBN N
. . N

A DT N
rigorous JJ N
statistical JJ N
method NN N
of IN N
scale JJ N
construction NN N
consisting NN N
of IN N
a DT N
modification NN N
of IN N
the DT N
scale JJ N
discrimination NN N
technique NN N
was VBD N
employed VBN N
, , N
resulting VBG N
in IN N
a DT N
45-item JJ 4_i
questionnaire NN 4_i
representing VBG N
three CD N
orthogonally RB N
derived VBN N
scales NNS N
. . N

The DT N
three CD N
scales NNS N
, , N
Physiological NNP N
Tension NNP N
, , N
Physical NNP N
Assessment NNP N
, , N
and CC N
Cognitive NNP N
Tension NNP N
, , N
demonstrated VBD N
adequate JJ N
internal JJ N
consistency NN N
with IN N
KR20 NNP N
reliability NN N
coefficients NNS N
of IN N
.89 NNP N
, , N
.95 NNP N
, , N
and CC N
.81 NNP N
, , N
respectively RB N
. . N

In IN N
a DT N
second JJ N
study NN N
of IN N
predictive JJ N
validity NN N
, , N
40 CD N
individuals NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
conditions NNS N
: : N
relaxation NN 5_i
training NN 5_i
, , N
tension NN 5_i
inducement NN 5_i
, , N
pre-postcontrol NN 5_i
, , 5_i
or CC 5_i
postcontrol NN 5_i
. . N

Univariate NNP N
analysis NN N
of IN N
variance NN N
indicated VBN N
significant JJ N
findings NNS N
for IN N
each DT N
of IN N
the DT N
three CD N
dimensions NNS N
of IN N
the DT N
inventory NN N
. . N

The DT N
Physiological JJ N
Tension NNP N
Scale NNP N
detected VBD N
significant JJ N
increases NNS N
in IN N
tension NN N
following VBG N
tension NN N
inducement NN N
, , N
whereas IN N
the DT N
Physical NNP N
Assessment NNP N
Scale NNP N
and CC N
Cognitive NNP N
Tension NNP N
Scale NNP N
detected VBD N
increases NNS N
in IN N
relaxation NN N
following VBG N
relaxation NN 5_i
training NN 5_i
. . N

Recommendations NNS N
were VBD N
made VBN N
for IN N
future JJ N
research NN N
on IN N
the DT N
inventory NN N
. . N

-DOCSTART- -X- O O

Should MD N
snacks NNS 2_i
be VB N
recommended VBN N
in IN N
obesity NN N
treatment NN N
? . N
A DT N
1-year JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
to TO N
recommend VB N
no DT 2_i
snacks NNS 2_i
vs VBP N
three CD 2_i
snacks NNS 2_i
per IN N
day NN N
on IN N
1-year JJ N
weight JJ N
loss NN N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
it PRP N
is VBZ N
easier JJR N
to TO N
control VB N
energy NN N
intake NN N
and CC N
lose VB N
weight NN N
if IN N
snacks NNS N
in IN N
between IN N
meals NNS N
are VBP N
omitted VBN N
. . N

SUBJECTS/METHOD NNP N
In IN N
total JJ N
140 CD N
patients NNS N
( ( N
36 CD N
men NNS N
, , N
104 CD N
women NNS N
) ) N
, , N
aged VBN N
18-60 CD N
years NNS N
and CC N
body NN N
mass NN N
index NN N
> VBD N
30 CD N
kg/m NN N
( ( N
2 CD N
) ) N
were VBD N
randomized VBN N
and CC N
93 CD N
patients NNS N
( ( N
27 CD N
men NNS N
, , N
66 CD N
women NNS N
) ) N
completed VBD N
the DT N
study NN N
. . N

A DT N
1-year JJ N
randomized JJ N
intervention NN N
trial NN N
was VBD N
conducted VBN N
with IN N
two CD N
treatment NN N
arms NNS N
with IN N
different JJ N
eating VBG N
frequencies NNS N
; : N
3 CD 2_i
meals/day NN 2_i
( ( 2_i
3M CD 2_i
) ) 2_i
or CC N
3 CD 2_i
meals NNS 2_i
and CC 2_i
3 CD 2_i
snacks/day NN 2_i
( ( N
3+3M CD N
) ) N
. . N

The DT N
patients NNS N
received VBD N
regular JJ N
and CC N
individualized JJ N
counseling NN N
by IN N
dieticians NNS N
. . N

Information NN N
on IN N
eating NN N
patterns NNS N
, , N
dietary JJ N
intake NN N
, , N
weight NN N
and CC N
metabolic JJ N
variables NNS N
was VBD N
collected VBN N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
year NN N
. . N

RESULTS NNP N
Over IN N
1 CD N
year NN N
the DT N
3M CD 3_i
group NN N
reported VBD N
a DT N
decrease NN N
in IN N
the DT N
number NN N
of IN N
snacks NNS N
whereas VBP N
the DT N
3+3M CD 3_i
group NN N
reported VBD N
an DT N
increase NN N
( ( N
-1.1 JJ N
vs NN N
+0.4 NN N
snacks/day NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Both DT N
groups NNS N
decreased VBD N
energy NN N
intake NN N
and CC N
E NNP N
% NN N
( ( N
energy NN N
percent NN N
) ) N
fat NN N
and CC N
increased VBD N
E NNP N
% NN N
protein NN N
and CC N
fiber VB N
intake NN N
but CC N
there EX N
was VBD N
no DT N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Both DT N
groups NNS N
lost VBD N
weight NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
weight JJ N
loss NN N
after IN N
1 CD N
year NN N
of IN N
treatment NN N
( ( N
3M CD 3_i
vs RB N
3+3M=-4.1+/-6.1 JJ 3_i
vs NN N
-5.9+/-9.4 NNP N
kg NN N
; : N
P=0.31 NNP N
) ) N
. . N

Changes NNS N
in IN N
metabolic JJ N
variables NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
, , N
except IN N
for IN N
high-density NN N
lipoprotein NN N
that WDT N
increased VBD N
in IN N
the DT N
3M CD 3_i
group NN N
but CC N
not RB N
in IN N
3+3M CD 3_i
group NN N
( ( N
P NNP N
< VBZ N
0.033 CD N
for IN N
group NN N
difference NN N
) ) N
. . N

CONCLUSION NNP N
Recommending VBG N
snacks NNS N
or CC N
not RB N
between IN N
meals NNS N
does VBZ N
not RB N
influence VB N
1-year JJ N
weight NN N
loss NN N
. . N

-DOCSTART- -X- O O

Anecortave NNP 3_i
acetate NN 3_i
treatment NN 3_i
for IN N
retinal JJ N
angiomatous JJ N
proliferation NN N
: : N
a DT N
pilot NN N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
anecortave JJ 3_i
acetate JJ 3_i
treatment NN 3_i
of IN N
retinal JJ N
angiomatous JJ N
proliferation NN N
( ( N
RAP NNP N
) ) N
, , N
a DT N
neovascular JJ N
form NN N
of IN N
age-related JJ N
macular JJ N
degeneration NN N
, , N
with IN N
specific JJ N
regard NN N
to TO N
inhibition NN N
of IN N
neovascularization NN N
and CC N
maintenance NN N
of IN N
vision NN N
. . N

METHODS NNP N
Thirty-four JJ N
patients NNS N
with IN N
RAP NNP N
with IN N
any DT N
stage NN N
of IN N
neovascularization NN N
were VBD N
randomized VBN N
1:1:1 CD N
for IN N
treatment NN N
with IN N
three CD N
different JJ N
quantities NNS N
( ( N
30 CD N
mg NN N
, , N
15 CD N
mg NN N
, , N
3 CD N
mg NN N
) ) N
of IN N
anecortave NN 3_i
acetate NN 3_i
sterile JJ 3_i
suspension NN 3_i
for IN 3_i
juxtascleral JJ 3_i
administration NN 3_i
. . N

Best-corrected JJ N
visual JJ N
acuity NN N
( ( N
Early JJ N
Treatment NNP N
Diabetic NNP N
Retinopathy NNP N
Study NNP N
chart NN N
) ) N
, , N
intraocular JJ N
pressure NN N
measurement NN N
, , N
biomicroscopy NN N
, , N
funduscopy NN N
, , N
digital JJ N
fluorescein NN N
, , N
and CC N
indocyanine NN N
green JJ N
angiography NN N
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
at IN N
3 CD N
months NNS N
. . N

A DT N
6-month JJ N
retreatment NN N
interval NN N
was VBD N
established VBN N
for IN N
this DT N
study NN N
with IN N
a DT N
follow-up NN N
of IN N
12 CD N
months NNS N
. . N

In IN N
selected JJ N
patients NNS N
optical JJ N
coherence NN N
tomography NN N
was VBD N
performed VBN N
. . N

The DT N
outcomes NNS N
were VBD N
mean JJ N
changes NNS N
in IN N
visual JJ N
acuity NN N
and CC N
lesion NN N
size NN N
at IN N
1 CD N
year NN N
. . N

RESULTS VB N
The DT N
detachment NN N
of IN N
the DT N
neurosensory JJ N
retina NN N
and CC N
retinal JJ N
pigment NN N
epithelium NN N
improved VBN N
in IN N
all DT N
eyes NNS N
, , N
but CC N
all DT N
neovascular JJ N
lesions NNS N
increased VBD N
in IN N
size NN N
. . N

Vision NNP N
loss NN N
occurred VBD N
in IN N
the DT N
majority NN N
of IN N
study NN N
eyes NNS N
( ( N
22 CD N
out IN N
of IN N
34 CD N
eyes NNS N
, , N
64.7 CD N
% NN N
) ) N
independent JJ N
of IN N
the DT N
concentration NN N
administered VBD N
. . N

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
a DT N
posterior JJ N
juxtascleral JJ N
injection NN N
of IN N
anecortave JJ 3_i
acetate NN 3_i
reduces NNS N
capillary JJ N
permeability NN N
in IN N
patients NNS N
with IN N
RAP NNP N
. . N

However RB N
, , N
in IN N
spite NN N
of IN N
improvement NN N
of IN N
the DT N
exudation NN N
there EX N
is VBZ N
a DT N
progression NN N
of IN N
neovascularization NN N
and CC N
a DT N
significant JJ N
loss NN N
of IN N
vision NN N
in IN N
all PDT N
these DT N
patients NNS N
. . N

Like IN N
other JJ N
monotherapeutic JJ N
methods NNS N
used VBN N
to TO N
treat VB N
this DT N
variant NN N
of IN N
neovascular JJ N
age-related JJ N
macular JJ N
degeneration NN N
, , N
anecortave VBP 3_i
acetate JJ 3_i
alone RB N
does VBZ N
not RB N
appear VB N
to TO N
benefit VB N
these DT N
patients NNS N
. . N

Future JJ N
studies NNS N
should MD N
investigate VB N
a DT N
combination NN N
form NN N
of IN N
therapy NN N
. . N

-DOCSTART- -X- O O

Timing NN N
of IN N
death NN N
and CC N
myocardial JJ N
infarction NN N
in IN N
patients NNS N
with IN N
non-ST JJ N
elevation NN N
acute NN N
coronary JJ N
syndromes NNS N
: : N
insights NNS N
from IN N
randomized VBN N
clinical JJ N
trials NNS N
. . N

BACKGROUND NNP N
Adverse NNP N
events NNS N
occur VBP N
following VBG N
non-ST JJ N
elevation NN N
acute NN N
coronary JJ N
syndromes NNS N
( ( N
NSTE NNP N
ACS NNP N
) ) N
. . N

However RB N
, , N
the DT N
timing NN N
of IN N
these DT N
events NNS N
in IN N
relation NN N
to TO N
index NN N
event NN N
is VBZ N
less RBR N
clear JJ N
. . N

METHODS NNP N
Accordingly RB N
, , N
we PRP N
evaluated VBD N
26,466 CD N
NSTE NNP N
ACS NNP N
patients NNS N
from IN N
the DT N
Global NNP N
Use NNP N
of IN N
Strategies NNPS N
to TO N
Open VB N
Occluded NNP N
Arteries NNPS N
in IN N
Acute NNP N
Coronary NNP N
Syndromes NNP N
( ( N
GUSTO-IIb NNP N
) ) N
, , N
Platelet NNP 3_i
Glycoprotein NNP 3_i
IIb/IIIa NNP 3_i
in IN N
Unstable JJ N
Angina NNP N
: : N
Receptor NNP 3_i
Suppression NNP 3_i
Using NNP 3_i
Integrilin NNP 3_i
Therapy NNP 3_i
( ( N
PURSUIT NNP N
) ) N
, , N
and CC N
Platelet NNP 3_i
IIb/IIIa NNP 3_i
Antagonism NNP 3_i
for IN N
the DT N
Reduction NNP N
of IN N
Acute NNP N
Coronary NNP N
Syndrome NNP N
Events NNP N
in IN N
a DT N
Global NNP N
Organization NNP N
Network NNP N
( ( N
PARAGON NNP N
) ) N
A NNP N
and CC N
B NNP N
trials NNS N
to TO N
ascertain VB N
the DT N
timing NN N
of IN N
adverse JJ N
events NNS N
. . N

Outcomes NNS N
of IN N
interest NN N
were VBD N
death NN N
, , N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
, , N
and CC N
death NN N
or CC N
MI NNP N
at IN N
180 CD N
days NNS N
. . N

Logistic JJ 4_i
regression NN 4_i
modeling VBG 4_i
for IN N
death NN N
was VBD N
used VBN N
to TO N
categorize VB N
patients NNS N
into IN N
low- JJ N
, , N
medium- JJ N
, , N
and CC N
high-risk JJ N
groups NNS N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
6.2 CD N
% NN N
of IN N
patients NNS N
died VBD N
, , N
12.1 CD N
% NN N
had VBD N
MI NNP N
, , N
and CC N
15.7 CD N
% NN N
suffered VBD N
death NN N
or CC N
MI NNP N
. . N

From IN N
15 CD N
% NN N
to TO N
40 CD N
% NN N
of IN N
these DT N
events NNS N
occurred VBD N
beyond IN N
30 CD N
days NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
3 CD N
% NN N
, , N
4 CD N
% NN N
, , N
and CC N
13 CD N
% NN N
of IN N
patients NNS N
died VBN N
in IN N
low- JJ N
, , N
medium- JJ N
, , N
and CC N
high-risk JJ N
groups NNS N
, , N
respectively RB N
. . N

However RB N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
dying VBG N
beyond IN N
30 CD N
days NNS N
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
( ( N
44 CD N
% NN N
, , N
43 CD N
% NN N
, , N
and CC N
41 CD N
% NN N
of IN N
death NN N
, , N
respectively RB N
) ) N
. . N

Similarly RB N
, , N
whereas JJ N
death NN N
or CC N
MI NNP N
increased VBD N
with IN N
higher JJR N
risk NN N
( ( N
11 CD N
% NN N
, , N
14 CD N
% NN N
, , N
and CC N
23 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
this DT N
event NN N
beyond IN N
30 CD N
days NNS N
did VBD N
not RB N
differ VB N
in IN N
the DT N
three CD N
strata NNS N
( ( N
22 CD N
% NN N
, , N
20 CD N
% NN N
, , N
and CC N
25 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
provides VBZ N
important JJ N
insights NNS N
into IN N
the DT N
timing NN N
of IN N
adverse JJ N
events NNS N
and CC N
suggests VBZ N
that IN N
the DT N
substantial JJ N
proportion NN N
of IN N
patients NNS N
suffer VBP N
subsequent JJ N
adverse JJ N
events NNS N
after IN N
their PRP$ N
index NN N
NSTE NNP N
ACS NNP N
. . N

Thus RB N
, , N
these DT N
data NNS N
call NN N
for IN N
continuous JJ N
surveillance NN N
for IN N
these DT N
events NNS N
and CC N
efforts NNS N
beyond IN N
the DT N
acute JJ N
phase NN N
at IN N
increasing VBG N
adherence NN N
to TO N
evidence-based JJ N
therapies NNS N
to TO N
improve VB N
the DT N
outcomes NNS N
of IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Efficacy NN N
and CC N
safety NN N
of IN N
diclofenac JJ 3_i
diethylamine JJ 3_i
1.16 CD N
% NN N
gel NN N
in IN N
acute JJ N
neck NN N
pain NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

BACKGROUND NNP N
Neck NNP N
pain NN N
( ( N
NP NNP N
) ) N
is VBZ N
a DT N
common JJ N
musculoskeletal JJ N
disorder NN N
in IN N
primary JJ N
care NN N
that WDT N
frequently RB N
causes VBZ N
discomfort NN N
. . N

Non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
( ( N
NSAIDs NNP N
) ) N
may MD N
be VB N
used VBN N
to TO N
reduce VB N
neck NN N
pain NN N
and CC N
associated VBN N
inflammation NN N
and CC N
facilitate NN N
earlier RBR N
recovery NN N
. . N

Topical JJ 3_i
diclofenac NN 3_i
diethylamine NN 3_i
( ( 3_i
DDEA NNP 3_i
) ) 3_i
1.16 CD 3_i
% NN 3_i
gel NN 3_i
is VBZ N
clinically RB N
proven VBN N
to TO N
be VB N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
acute NN N
and CC N
chronic JJ N
musculoskeletal NN N
conditions NNS N
, , N
but CC N
until IN N
now RB N
no DT N
clinical JJ N
data NNS N
existed VBD N
for IN N
its PRP$ N
use NN N
in IN N
acute JJ N
NP NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
compared VBN N
with IN N
placebo NN 3_i
gel NN 3_i
in IN N
acute JJ N
NP NNP N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
, , N
patients NNS N
with IN N
acute JJ N
NP NNP N
( ( N
n JJ N
= NNP N
72 CD N
) ) N
were VBD N
treated VBN N
with IN N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
( ( N
2 CD N
g NN N
, , N
4x/day CD N
, , N
for IN N
5 CD N
days NNS N
) ) N
or CC N
placebo NN N
. . N

Efficacy NN N
assessments NNS N
included VBD N
pain-on-movement NN N
( ( N
POM NNP N
) ) N
, , N
pain-at-rest JJ N
( ( N
PAR NNP N
) ) N
, , N
functional JJ N
neck NN N
disability NN N
index NN N
( ( N
NDI NNP N
) ) N
and CC N
response NN N
to TO N
treatment NN N
( ( N
decrease NN N
in IN N
POM NNP N
by IN N
50 CD N
% NN N
after IN N
48 CD N
h NN N
) ) N
. . N

Adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
were VBD N
recorded VBN N
throughout IN N
the DT N
study NN N
. . N

RESULTS VB N
The DT N
primary JJ N
outcome NN N
, , N
POM NNP N
at IN N
48 CD N
h NN N
, , N
was VBD N
statistically RB N
significantly RB N
lower JJR N
with IN N
DDEA NNP N
gel NN N
( ( N
19.5 CD N
mm NN N
) ) N
vs. FW N
placebo NN N
( ( N
56.9 CD N
mm NN N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
representing VBG N
a DT N
clinically RB N
relevant JJ N
decrease NN N
from IN N
baseline NN N
( ( N
75 CD N
% NN N
vs. FW N
23 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

All DT N
POM NNP N
scores NNS N
were VBD N
significantly RB N
lower JJR N
with IN N
DDEA NNP N
gel NN N
vs. FW N
placebo NN N
from IN N
1 CD N
h NN N
, , N
as IN N
were VBD N
PAR NNP N
and CC N
NDI NNP N
scores NNS N
from IN N
first JJ N
assessment NN N
( ( N
24 CD N
h NN N
) ) N
onwards NNS N
( ( N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
. . N

Response NNP N
to TO N
treatment NN N
was VBD N
significantly RB N
higher JJR N
with IN N
DDEA NNP N
gel NN N
( ( N
94.4 CD N
% NN N
) ) N
vs. FW N
placebo NN N
( ( N
8.3 CD N
% NN N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
AEs NNP N
with IN N
DDEA NNP N
gel NN N
. . N

CONCLUSIONS NNP N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
, , N
which WDT N
is VBZ N
available JJ N
over-the-counter JJ N
, , N
was VBD N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
neck NN N
pain NN N
. . N

The DT N
tools NNS N
used VBD N
to TO N
assess VB N
efficacy NN N
suggest VBP N
that IN N
it PRP N
quickly RB N
reduced VBD N
neck NN N
pain NN N
and CC N
improved VBN N
neck NN N
function NN N
. . N

However RB N
, , N
questions NNS N
remain VBP N
regarding VBG N
the DT N
comparability NN N
and CC N
validity NN N
of IN N
such JJ N
tools NNS N
. . N

Further JJ N
studies NNS N
will MD N
help VB N
ascertain VB N
whether IN N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
offers VBZ N
an DT N
alternative JJ N
treatment NN N
option NN N
in IN N
this DT N
common JJ N
, , N
often RB N
debilitating VBG N
condition NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT01335724 NNP N
. . N

-DOCSTART- -X- O O

End-expiratory JJ N
lung NN N
volume NN N
recovers NNS N
more RBR N
slowly RB N
after IN N
closed JJ 2_i
endotracheal NN 2_i
suctioning VBG 2_i
than IN N
after IN N
open JJ 2_i
suctioning NN 2_i
: : 2_i
a DT N
randomized VBN N
crossover NN N
study NN N
. . N

PURPOSE NNP N
Endotracheal NNP N
suctioning VBG N
causes NNS N
significant JJ N
lung JJ N
derecruitment NN N
. . N

Closed VBN 2_i
suction NN 2_i
( ( 2_i
CS NNP 2_i
) ) 2_i
minimizes VBZ N
lung JJ N
volume NN N
loss NN N
during IN N
suction NN N
, , N
and CC N
therefore RB N
, , N
volumes NNS N
are VBP N
presumed VBN N
to TO N
recover VB N
more RBR N
quickly RB N
postsuctioning VBG N
. . N

Conflicting VBG N
evidence NN N
exists VBZ N
regarding VBG N
this DT N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
open JJ 2_i
suction NN 2_i
( ( 2_i
OS NNP 2_i
) ) 2_i
and CC N
CS NNP 2_i
on IN N
lung NN N
volume NN N
loss NN N
during IN N
suctioning NN 2_i
, , N
and CC N
recovery NN N
of IN N
end-expiratory JJ N
lung NN N
volume NN N
( ( N
EELV NNP N
) ) N
up RB N
to TO N
30 CD N
minutes NNS N
postsuction NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Randomized NNP N
crossover NN N
study NN N
examining VBG N
20 CD N
patients NNS N
postcardiac JJ N
surgery NN N
. . N

CS NNP 2_i
and CC N
OS NNP 2_i
were VBD N
performed VBN N
in IN N
random JJ N
order NN N
, , N
30 CD N
minutes NNS N
apart RB N
. . N

Lung NNP N
impedance NN N
was VBD N
measured VBN N
during IN N
suction NN N
, , N
and CC N
end-expiratory JJ N
lung NN N
impedance NN N
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
postsuctioning VBG N
using VBG N
electrical JJ N
impedance NN N
tomography NN N
. . N

Oximetry NNP N
, , N
partial JJ N
pressure NN N
of IN N
oxygen NN N
in IN N
the DT N
alveoli/fraction NN N
of IN N
inspired JJ N
oxygen NN N
ratio NN N
and CC N
compliance NN N
were VBD N
collected VBN N
. . N

RESULTS JJ N
Reductions NNPS N
in IN N
lung NN N
impedance NN N
during IN N
suctioning VBG N
were VBD N
less JJR N
for IN N
CS NNP 2_i
than IN N
for IN N
OS NNP 2_i
( ( N
mean JJ N
difference NN N
, , N
-905 JJ N
impedance NN N
units NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
-1234 NNP N
to TO N
-587 VB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

However RB N
, , N
at IN N
all DT N
points NNS N
postsuctioning VBG N
, , N
EELV NNP N
recovered VBD N
more RBR N
slowly RB N
after IN N
CS NNP 2_i
than IN N
after IN N
OS NNP 2_i
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
other JJ N
respiratory NN N
parameters NNS N
. . N

CONCLUSIONS NNP N
Closed VBD 2_i
suctioning VBG 2_i
minimized VBN N
lung NN N
volume NN N
loss NN N
during IN N
suctioning VBG N
but CC N
, , N
counterintuitively RB N
, , N
resulted VBD N
in IN N
slower JJR N
recovery NN N
of IN N
EELV NNP N
postsuction NN N
compared VBN N
with IN N
OS NNP 2_i
. . N

Therefore NNP N
, , N
the DT N
use NN N
of IN N
CS NNP 2_i
can MD N
not RB N
be VB N
assumed VBN N
to TO N
be VB N
protective JJ N
of IN N
lung NN N
volumes NNS N
postsuctioning VBG N
. . N

Consideration NN N
should MD N
be VB N
given VBN N
to TO N
restoring VBG N
EELV NNP N
after IN N
either DT N
suction NN N
method NN N
via IN N
a DT N
recruitment JJ N
maneuver NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
transcranial JJ 2_i
electrostimulation NN 2_i
on IN N
clinical JJ N
and CC N
laboratory JJ N
characteristics NNS N
in IN N
patients NNS N
with IN N
gastric JJ N
ulcer JJ N
] NN N
. . N

The DT N
study NN N
included VBD N
100 CD N
patients NNS N
with IN N
gastric JJ N
ulcer NNS N
aged VBN N
from IN N
16 CD N
to TO N
60 CD N
years NNS N
. . N

In IN N
58 CD N
patients NNS N
, , N
traditional JJ 3_i
treatment NN 3_i
was VBD N
supplemented VBN N
by IN N
transcranial JJ 2_i
electrotherapy NN 2_i
using VBG N
a DT N
TRANSAIR-02 JJ N
apparatus NN N
. . N

Laboratory NNP N
studies NNS N
included VBD N
measurements NNS N
of IN N
lactoferrin NN N
( ( N
LF NNP N
) ) N
and CC N
tumour JJ N
necrosis NN N
factor-alpha NN N
( ( N
TNF-alpha NNP N
) ) N
, , N
besides VBZ N
standard JJ N
analyses NNS N
. . N

Combined VBN 3_i
treatment NN 3_i
( ( 3_i
traditional JJ 3_i
therapy NN 3_i
plus CC 3_i
electrostimulation NN 2_i
) ) N
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
duration NN N
of IN N
the DT N
main JJ N
symptoms NNS N
of IN N
the DT N
gastric JJ N
ulcer NN N
depending VBG N
on IN N
the DT N
severity NN N
of IN N
ulceration NN N
process NN N
, , N
patients NNS N
' POS N
age NN N
and CC N
sex NN N
. . N

Moreover RB N
, , N
it PRP N
facilitated VBD N
ulcer JJ N
scarring NN N
and CC N
had VBD N
beneficial JJ N
effect NN N
on IN N
dynamics NNS N
of IN N
serum NN N
LF NNP N
and CC N
TNF-alpha NNP N
levels NNS N
. . N

-DOCSTART- -X- O O

The DT N
relationship NN N
of IN N
alexithymia NN N
to TO N
emotional JJ N
dysregulation NN N
within IN N
an DT N
alcohol NN N
dependent JJ N
treatment NN N
sample NN N
. . N

Difficulties NNS N
regulating VBG N
emotions NNS N
have VBP N
implications NNS N
for IN N
the DT N
development NN N
, , N
maintenance NN N
, , N
and CC N
recovery NN N
from IN N
alcohol NN N
problems NNS N
. . N

One CD N
construct NN N
thought NN N
to TO N
impede VB N
the DT N
regulation NN N
of IN N
emotion NN N
is VBZ N
alexithymia JJ N
. . N

Alexithymia NNP N
is VBZ N
characterized VBN N
by IN N
difficulties NNS N
identifying VBG N
, , N
differentiating VBG N
and CC N
expressing VBG N
feelings NNS N
, , N
a DT N
limited JJ N
imagination NN N
and CC N
fantasy JJ N
life NN N
, , N
and CC N
an DT N
externally-oriented JJ N
thinking NN N
style NN N
( ( N
e.g. UH N
, , N
prefer VBP N
talking VBG N
about IN N
daily JJ N
activities NNS N
rather RB N
than IN N
feelings NNS N
) ) N
. . N

Given VBN N
that IN N
poor JJ N
emotion NN N
regulation NN N
skills NNS N
have VBP N
been VBN N
found VBN N
to TO N
predict VB N
posttreatment NN N
levels NNS N
of IN N
alcohol NN N
use NN N
, , N
and CC N
that IN N
several JJ N
defining VBG N
characteristics NNS N
of IN N
alexithymia JJ N
bear JJ N
similarity NN N
to TO N
deficits NNS N
in IN N
emotion NN N
regulation NN N
skills NNS N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
alexithymia NN N
may MD N
predict VB N
poorer JJR N
alcohol NN N
treatment NN N
outcomes NNS N
. . N

Thus RB N
, , N
the DT N
present JJ N
study NN N
first RB N
examined VBD N
the DT N
relationship NN N
of IN N
alexithymia NN 6_i
to TO N
several JJ N
other JJ N
emotion NN 5_i
regulation NN 5_i
measures NNS 5_i
and CC N
then RB N
investigated VBD N
the DT N
impact NN N
of IN N
alexithymia NN 6_i
on IN N
attrition NN N
and CC N
alcohol NN N
treatment NN N
outcomes NNS N
in IN N
men NNS N
and CC N
women NNS N
( ( N
N=77 NNP N
) ) N
enrolled VBD N
in IN N
a DT N
12-week JJ 5_i
cognitive-behavioral JJ 5_i
intervention NN 5_i
for IN 5_i
alcohol NN 5_i
dependence NN 5_i
. . N

At IN N
baseline NN N
, , N
higher JJR N
scores NNS N
on IN N
alexithymia NN N
were VBD N
associated VBN N
poorer JJR N
emotion NN N
regulation NN N
skills NNS N
, , N
fewer JJR N
percent NN N
days NNS N
abstinent NN N
, , N
greater JJR N
alcohol NN N
dependence NN N
severity NN N
, , N
and CC N
several JJ N
high-risk JJ N
drinking NN N
situations NNS N
. . N

Alexithymia NNP N
was VBD N
unrelated JJ N
to TO N
attrition NN N
and CC N
to TO N
level NN N
of IN N
alcohol NN N
consumption NN N
at IN N
posttreatment NN N
. . N

Overall UH N
, , N
the DT N
construct NN N
of IN N
alexithymia NN N
is VBZ N
shown VBN N
to TO N
be VB N
related VBN N
to TO N
several JJ N
theoretically-related JJ N
constructs NNS N
( ( N
e.g. NN N
, , N
emotion NN N
regulation NN N
, , N
mindfulness NN N
) ) N
but CC N
demonstrated VBD N
a DT N
limited JJ N
relationship NN N
to TO N
drinking VBG N
outcomes NNS N
in IN N
those DT N
seeking VBG N
treatment NN N
for IN N
alcohol NN N
dependence NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
and CC N
safety NN N
of IN N
a DT N
fixed JJ N
low-dose JJ N
perindopril/indapamide NN 3_i
combination NN 3_i
in IN N
essential JJ N
hypertension NN N
. . N

A DT N
randomised JJ N
controlled VBN N
study NN N
. . N

This DT N
multicenter NN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
the DT N
safety NN N
of IN N
fixed JJ N
low JJ 3_i
dose NN 3_i
combination NN 3_i
perindopril VBD 3_i
2 CD 3_i
mg/indapamide RB 3_i
0.625 CD N
mg NN N
( ( N
Per/Ind NNP N
) ) N
versus NN N
atenolol $ 3_i
50 CD N
mg NN N
( ( N
Ate NNP N
) ) N
. . N

After IN N
a DT N
4-week JJ N
placebo NN N
run-in NN N
, , N
446 CD N
hypertensive JJ N
patients NNS N
( ( N
mean JJ N
age NN N
: : N
55.8 CD N
+/- JJ N
11.0 CD N
years NNS N
) ) N
were VBD N
randomised VBN N
to TO N
receive VB N
Per/Ind NNP 3_i
or CC N
Ate NNP 3_i
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
changes NNS N
in IN N
trough JJ N
supine NN N
systolic NN N
and CC N
diastolic JJ N
blood NN N
pressure NN N
( ( N
sSBP NN N
, , N
sDBP NN N
) ) N
between IN N
baseline NN N
and CC N
the DT N
last JJ N
observation NN N
. . N

Equivalence NN N
was VBD N
assessed VBN N
in IN N
an DT N
intention-to-treat JJ N
analysis NN N
using VBG N
a DT N
two CD N
one-sided JJ N
tests NNS N
procedure NN N
. . N

Per/Ind NNP N
and CC N
Ate NNP N
decreased VBD N
sSBP NN N
by IN N
-20.5 NNP N
mmHg NN N
and CC N
-20.1 NNP N
mmHg NN N
, , N
respectively RB N
; : N
the DT N
90 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
-2.3 NNP N
; : N
1.5 CD N
] NN N
of IN N
the DT N
intertreatment NN N
difference NN N
( ( N
-0.4 JJ N
mmHg NN N
) ) N
fell VBD N
within IN N
the DT N
predefined JJ N
equivalence NN N
interval NN N
[ NNP N
-8 NNP N
; : N
+8 NNP N
mmHg FW N
] NNP N
. . N

Similarly RB N
, , N
the DT N
sDBP NN N
decreased VBN N
by IN N
-15.1 NNP N
mmHg NN N
( ( N
Per/Ind NNP N
) ) N
and CC N
-16.2 $ N
mmHg NN N
( ( N
Ate NNP N
) ) N
with IN N
an DT N
intertreatment JJ N
difference NN N
of IN N
1.1 CD N
mmHg NNS N
whose WP$ N
90 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
-0.1 NNP N
; : N
2.2 CD N
mmHg NN N
] NN N
fell VBD N
within IN N
the DT N
predefined JJ N
equivalence NN N
interval NN N
[ NNP N
-4 NNP N
; : N
+4 NNP N
mmHg VBZ N
] NNP N
; : N
thus RB N
antihypertensive JJ N
efficacy NN N
of IN N
Per/Ind NNP N
and CC N
Ate NNP N
were VBD N
equivalent JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS N
older JJR N
than IN N
65 CD N
, , N
Per/Ind NNP N
induces VBZ N
a DT N
statistically RB N
greater JJR N
decrease NN N
in IN N
sSBP NN N
than IN N
Ate NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Per/Ind NNP N
was VBD N
well RB N
tolerated VBN N
. . N

Further RBR N
controlled JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
confirm VB N
these DT N
results NNS N
on IN N
a DT N
long-term JJ N
period NN N
. . N

-DOCSTART- -X- O O

Necessary NNP N
but CC N
not RB N
sufficient JJ N
: : N
the DT N
effect NN N
of IN N
screening NN 4_i
and CC 4_i
feedback NN 4_i
on IN N
outcomes NNS N
of IN N
primary JJ N
care NN N
patients NNS N
with IN N
untreated JJ N
anxiety NN N
. . N

OBJECTIVE UH N
To TO N
consider VB N
the DT N
impact NN N
on IN N
primary JJ N
care NN N
patient JJ N
outcomes NNS N
of IN N
using VBG N
both DT N
a DT N
screener NN N
to TO N
determine VB N
elevated VBN N
anxiety NN N
levels NNS N
among IN N
patients NNS N
with IN N
previously RB N
undetected VBN N
anxiety NN N
and CC N
a DT N
physician JJ N
intervention NN N
to TO N
inform VB N
physicians NNS N
of IN N
their PRP$ N
patients NNS N
' POS N
conditions NNS N
. . N

DESIGN NNP N
Participating VBG N
physicians NNS N
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
demonstration NN 4_i
or CC N
the DT N
control NN N
arm NN N
, , N
and CC N
patients NNS N
were VBD N
assigned VBN N
to TO N
a DT N
study NN N
arm NN N
based VBN N
on IN N
the DT N
randomization NN N
of IN N
their PRP$ N
physicians NNS N
. . N

The DT N
patients NNS N
were VBD N
followed VBN N
for IN N
change NN N
in IN N
outcome JJ N
measures NNS N
during IN N
the DT N
five-month JJ N
study NN N
period NN N
. . N

SETTING VB N
A DT N
mixed-model JJ N
health NN N
maintenance NN N
organization NN N
serving VBG N
approximately RB N
110,000 CD N
enrollees NNS N
in IN N
central JJ N
Colorado NNP N
. . N

PATIENTS/PARTICIPANTS NNP N
573 CD N
patients NNS N
who WP N
had VBD N
unrecognized VBN N
and CC N
untreated JJ N
anxiety NN N
identified VBN N
from IN N
the DT N
approximately RB N
8,000 CD N
patients NNS N
who WP N
completed VBD N
the DT N
waiting VBG 4_i
room NN 4_i
screening NN 4_i
questionnaire NN 4_i
. . N

INTERVENTIONS VBZ N
A DT N
physician JJ 4_i
intervention NN 4_i
served VBD N
the DT N
dual JJ N
function NN N
of IN N
1 CD N
) ) N
providing VBG 4_i
an DT 4_i
educational JJ 4_i
demonstration NN 4_i
of IN 4_i
anxiety NN 4_i
in IN 4_i
the DT 4_i
primary JJ 4_i
care NN 4_i
setting VBG 4_i
and CC N
2 CD N
) ) N
providing VBG 4_i
a DT 4_i
reporting NN 4_i
system NN 4_i
for IN 4_i
summarizing VBG 4_i
the DT 4_i
anxiety NN 4_i
symptom NN 4_i
levels NNS 4_i
and CC 4_i
functioning VBG 4_i
status NN 4_i
of IN 4_i
the DT 4_i
patients NNS 4_i
enrolled VBN 4_i
in IN 4_i
the DT 4_i
study NN 4_i
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Patient NNP N
outcomes NNS N
were VBD N
measured VBN N
as IN N
changes NNS N
in IN N
global JJ N
anxiety NN N
scores NNS N
, , N
functioning VBG N
and CC N
well-being JJ N
, , N
and CC N
patients NNS N
' POS N
reports NNS N
of IN N
global JJ N
improvements NNS N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
indicate VBP N
that IN N
this DT N
method NN N
of IN N
reporting VBG N
symptoms NNS N
and CC N
functioning VBG N
status NN N
to TO N
primary VB N
care NN N
physicians NNS N
did VBD N
not RB N
significantly RB N
change VBP N
patient JJ N
outcomes NNS N
. . N

Improvement NN N
in IN N
outcomes NNS N
appeared VBD N
to TO N
be VB N
more RBR N
closely RB N
associated VBN N
with IN N
the DT N
patient NN N
's POS N
severity NN N
of IN N
psychological JJ N
distress NN N
. . N

-DOCSTART- -X- O O

A DT N
preliminary JJ N
trial NN N
of IN N
ascorbic JJ 3_i
acid NN 3_i
as IN N
supplemental JJ N
therapy NN N
for IN N
autism NN N
. . N

1 CD N
. . N

This DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
30-week JJ N
double-blind NN N
, , N
placebo-controlled JJ 7_i
trial NN N
exploring VBG N
the DT N
effectiveness NN N
of IN N
ascorbic JJ 3_i
acid NN 3_i
( ( N
8g/70kg/day CD N
) ) N
as IN N
a DT N
supplemental JJ N
pharmacological JJ N
treatment NN N
for IN N
autistic JJ N
children NNS N
in IN N
residential JJ N
treatment NN N
. . N

2 CD N
. . N

Residential JJ N
school NN N
children NNS N
( ( N
N NNP N
= NNP N
18 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
ascorbate-ascorbate-placebo JJ 3_i
treatment NN 3_i
order NN 3_i
group NN 3_i
or CC N
ascorbate-placebo-ascorbate JJ 3_i
treatment NN 3_i
order NN N
group NN N
. . N

Each DT N
treatment NN N
phase NN N
lasted VBD N
10 CD N
weeks NNS N
and CC N
behaviors NNS N
were VBD N
rated VBN N
weekly JJ N
using VBG N
the DT N
Ritvo-Freeman NNP N
scale NN N
. . N

3 CD N
. . N

Significant JJ N
group NN N
by IN N
phase NN N
interactions NNS N
were VBD N
found VBN N
for IN N
total JJ N
scores NNS N
and CC N
also RB N
sensory JJ N
motor NN N
scores NNS N
indicating VBG N
a DT N
reduction NN N
in IN N
symptom JJ N
severity NN N
associated VBN N
with IN N
the DT N
ascorbic JJ 3_i
acid NN 3_i
treatment NN 3_i
. . N

4 CD N
. . N

These DT N
results NNS N
were VBD N
consistent JJ N
with IN N
a DT N
hypothesized VBN N
dopaminergic NN N
mechanism NN N
of IN N
action NN N
of IN N
ascorbic JJ 3_i
acid NN 3_i
. . N

-DOCSTART- -X- O O

Social NNP N
skills NNS N
improvement NN N
in IN N
children NNS N
with IN N
high-functioning JJ N
autism NN N
: : N
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

High-functioning JJ N
autism NN N
( ( N
HFA NNP N
) ) N
is VBZ N
characterized VBN N
by IN N
persistent JJ N
impairment NN N
in IN N
social JJ N
interaction NN N
despite IN N
the DT N
absence NN N
of IN N
mental JJ N
retardation NN N
. . N

Although IN N
an DT N
increasing VBG N
number NN N
of IN N
group-based JJ N
programs NNS N
for IN N
the DT N
improvement NN N
of IN N
social JJ N
skills NNS N
have VBP N
been VBN N
described VBN N
, , N
randomized VBN N
controlled VBN N
trials NNS N
are VBP N
needed VBN N
to TO N
evaluate VB N
their PRP$ N
efficacy NN N
. . N

To TO N
compare VB N
the DT N
effect NN N
of IN N
a DT N
Social NNP 4_i
Skills NNP 4_i
Training NNP 4_i
Group-based JJ 4_i
Program NNP 4_i
( ( 4_i
SST-GP NNP 4_i
) ) 4_i
and CC N
a DT N
Leisure NN 4_i
Activities VBZ 4_i
Group-based JJ 4_i
Program NNP 4_i
( ( 4_i
LA-GP NNP 4_i
) ) 4_i
on IN N
the DT N
perception NN N
of IN N
facial JJ N
emotions NNS N
and CC N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
in IN N
young JJ N
people NNS N
with IN N
HFA NNP N
. . N

Eligible JJ N
patients NNS N
were VBD N
children NNS N
and CC N
adolescents NNS N
with IN N
HFA NNP N
. . N

Participants NNS N
were VBD N
randomized VBN N
to TO N
the DT N
SST NNP 4_i
or CC N
LA NNP 4_i
group NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
an DT N
improvement NN N
of IN N
2 CD N
points NNS N
in IN N
error NN N
rates NNS N
for IN N
facial JJ N
emotion NN N
labeling NN N
( ( N
DANVA2 NNP N
) ) N
from IN N
baseline NN N
. . N

After IN N
the DT N
6-month JJ N
training NN N
period NN N
, , N
the DT N
SST NNP 4_i
Group NNP N
made VBD N
fewer JJR N
errors NNS N
in IN N
labeling VBG N
anger NN N
on IN N
adult NN N
faces VBZ N
, , N
whereas JJ N
error NN N
rates NNS N
in IN N
the DT N
LA NNP 4_i
Group NNP N
remained VBD N
stable JJ N
. . N

Progress NN N
in IN N
the DT N
ability NN N
to TO N
recognize VB N
anger NN N
in IN N
the DT N
SST NNP 4_i
Group NNP N
was VBD N
due JJ N
to TO N
better JJR N
recognition NN N
of IN N
low JJ N
intensity NN N
stimuli NN N
on IN N
adult NN N
faces VBZ N
. . N

QoL NNP N
increased VBD N
in IN N
the DT N
SST NNP 4_i
Group NNP N
in IN N
the DT N
dimension NN N
of IN N
school NN N
environment NN N
, , N
as IN N
a DT N
marker NN N
of IN N
the DT N
transfer NN N
of IN N
skills NNS N
acquired VBN N
in IN N
the DT N
treatment NN N
setting VBG N
to TO N
their PRP$ N
use NN N
in IN N
the DT N
community NN N
. . N

The DT N
SST-GP NNP 4_i
had VBD N
higher JJR N
efficacy NN N
than IN N
the DT N
LA-GP NNP 4_i
. . N

Data NNP N
justify NN N
replication NN N
using VBG N
larger JJR N
samples NNS N
. . N

-DOCSTART- -X- O O

Risperidone NNP 3_i
treatment NN N
of IN N
autistic JJ N
disorder NN N
: : N
longer-term JJ N
benefits NNS N
and CC N
blinded VBD N
discontinuation NN N
after IN N
6 CD N
months NNS N
. . N

OBJECTIVE NNP N
Risperidone NNP 3_i
is VBZ N
effective JJ N
for IN N
short-term JJ N
treatment NN N
of IN N
aggression NN N
, , N
temper JJ N
outbursts NNS N
, , N
and CC N
self-injurious JJ N
behavior NN N
in IN N
children NNS N
with IN N
autism NN N
. . N

Because IN N
these DT N
behaviors NNS N
may MD N
be VB N
chronic JJ N
, , N
there EX N
is VBZ N
a DT N
need NN N
to TO N
establish VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
longer-term JJ N
treatment NN N
with IN N
this DT N
agent NN N
. . N

METHOD NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
multisite NN N
, , N
two-part JJ N
study NN N
of IN N
risperidone NN 3_i
in IN N
children NNS N
ages NNS N
5 CD N
to TO N
17 CD N
years NNS N
with IN N
autism NN N
accompanied VBN N
by IN N
severe JJ N
tantrums NNS N
, , N
aggression NN N
, , N
and/or JJ N
self-injurious JJ N
behavior NN N
who WP N
showed VBD N
a DT N
positive JJ N
response NN N
in IN N
an DT N
earlier JJR N
8-week JJ N
trial NN N
. . N

Part NN N
I PRP N
consisted VBD N
of IN N
4-month JJ N
open-label JJ N
treatment NN N
with IN N
risperidone NN 3_i
, , N
starting VBG N
at IN N
the DT N
established VBN N
optimal JJ N
dose NN N
; : N
part NN N
II NNP N
was VBD N
an DT N
8-week JJ N
randomized NN N
, , N
double-blind JJ N
, , N
placebo-substitution JJ 7_i
study NN N
of IN N
risperidone NN 3_i
withdrawal NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
irritability NN N
subscale NN N
and CC N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
improvement NN N
scale NN N
. . N

RESULTS NNP N
Part NNP N
I PRP N
included VBD N
63 CD N
children NNS N
. . N

The DT N
mean JJ N
risperidone NN 3_i
dose NN N
was VBD N
1.96 CD N
mg/day NN N
at IN N
entry NN N
and CC N
remained VBD N
stable JJ N
over IN N
16 CD N
weeks NNS N
of IN N
open JJ N
treatment NN N
. . N

The DT N
change NN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
irritability NN N
subscale NN N
was VBD N
small JJ N
and CC N
clinically JJ N
insignificant NN N
. . N

Reasons NNS N
for IN N
discontinuation NN N
of IN N
part NN N
I PRP N
included VBD N
loss NN N
of IN N
efficacy NN N
( ( N
N=5 NNP N
) ) N
and CC N
adverse JJ N
effects NNS N
( ( N
N=1 NNP N
) ) N
. . N

The DT N
subjects NNS N
gained VBD N
an DT N
average NN N
of IN N
5.1 CD N
kg NNS N
. . N

Part NNP N
II NNP N
included VBD N
32 CD N
patients NNS N
. . N

The DT N
relapse NN N
rates NNS N
were VBD N
62.5 CD N
% NN N
for IN N
gradual JJ N
placebo NN N
substitution NN N
and CC N
12.5 CD N
% NN N
for IN N
continued JJ N
risperidone NN 3_i
; : 3_i
this DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

CONCLUSIONS NNP N
Risperidone NNP 3_i
showed VBD N
persistent JJ N
efficacy NN N
and CC N
good JJ N
tolerability NN N
for IN N
intermediate-length JJ N
treatment NN N
of IN N
children NNS N
with IN N
autism NN N
characterized VBN N
by IN N
tantrums NNS N
, , N
aggression NN N
, , N
and/or JJ N
self-injurious JJ N
behavior NN N
. . N

Discontinuation NN N
after IN N
6 CD N
months NNS N
was VBD N
associated VBN N
with IN N
a DT N
rapid JJ N
return NN N
of IN N
disruptive JJ N
and CC N
aggressive JJ N
behavior NN N
in IN N
most JJS N
subjects NNS N
. . N

-DOCSTART- -X- O O

Penetration NN N
of IN N
ofloxacin NN 3_i
and CC N
ciprofloxacin NN 3_i
into IN N
the DT N
aqueous JJ N
humor NN N
of IN N
eyes NNS N
with IN N
functioning VBG N
filtering VBG N
blebs NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
concentrations NNS N
of IN N
ofloxacin NN N
and CC N
ciprofloxacin NN N
hydrochloride NN N
in IN N
aqueous JJ N
humor NN N
after IN N
topical JJ N
or CC N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
in IN N
eyes NNS N
with IN N
filtering VBG N
blebs NN N
. . N

DESIGN VB N
A DT N
prospective JJ N
, , N
investigator-masked JJ N
, , N
randomized VBN N
, , N
controlled VBD N
comparative JJ N
study NN N
involving VBG N
36 CD N
eyes NNS N
of IN N
34 CD N
patients NNS N
with IN N
functioning VBG N
filtering VBG N
blebs NNS N
who WP N
were VBD N
to TO N
undergo VB N
cataract NN N
surgery NN N
. . N

Treatment NN N
groups NNS N
received VBD N
either RB N
topical JJ 3_i
ofloxacin NN 3_i
or CC N
topical JJ 3_i
ciprofloxacin NN 3_i
( ( N
instillation NN N
of IN N
0.3 CD N
% NN N
ophthalmic JJ N
solution NN N
every DT N
30 CD N
minutes NNS N
for IN N
4 CD N
hours NNS N
before IN N
surgery NN 1_i
) ) N
, , N
or CC N
a DT N
combined JJ N
topical JJ N
plus CC N
oral JJ N
regimen NNS N
( ( 3_i
ciprofloxacin JJ 3_i
hydrochloride NN 3_i
, , 3_i
four CD 3_i
100-mg JJ 3_i
tablets NNS 3_i
, , N
or CC N
ofloxacin RB 3_i
, , 3_i
one CD 3_i
400-mg JJ 3_i
tablet NN 3_i
, , N
administered VBN N
24-26 JJ N
, , N
12-14 JJ N
, , N
and CC N
2 CD N
hours NNS N
preceding VBG N
surgery NN 1_i
) ) N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
antibiotic JJ N
concentration NN N
measured VBN N
by IN N
chromatographic JJ N
separation NN N
and CC N
mass NN N
spectrometry NN N
of IN N
aqueous JJ N
samples NNS N
obtained VBN N
during IN N
surgery NN N
. . N

RESULTS NNP N
Topical NNP N
antibiotic JJ N
treatment NN N
yielded VBN N
mean JJ N
concentrations NNS N
of IN N
ofloxacin NN 3_i
, , N
0.75 CD N
microg/mL NN N
, , N
and CC N
ciprofloxacin NN 3_i
, , N
0.21 CD N
microg/mL NN N
, , N
in IN N
aqueous JJ N
. . N

With IN N
combined JJ N
topical JJ N
and CC N
oral JJ N
therapy NN N
, , N
significantly RB N
more JJR N
ofloxacin NN N
was VBD N
measured VBN N
than IN N
ciprofloxacin NN N
( ( N
3.84 CD N
microg/mL NN N
vs NN N
0.35 CD N
microg/mL NN N
[ NNP N
P NNP N
< NNP N
.001 NNP N
] NNP N
) ) N
. . N

The DT N
combination NN N
regimen NNS N
produced VBD N
significantly RB N
greater JJR N
ofloxacin NN N
levels NNS N
than IN N
did VBD N
topical JJ N
therapy NN N
alone RB N
( ( N
P NNP N
=.007 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Ofloxacin NNP N
penetrates VBZ N
better JJR N
than IN N
ciprofloxacin NN N
into IN N
the DT N
aqueous JJ N
of IN N
eyes NNS N
with IN N
filtering VBG N
blebs NNS N
, , N
particularly RB N
after IN N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
, , N
by IN N
which WDT N
ofloxacin NN N
reaches VBZ N
more JJR N
than IN N
a DT N
10-fold JJ N
greater JJR N
concentration NN N
than IN N
does VBZ N
ciprofloxacin VB N
. . N

Combined VBN N
topical JJ 3_i
and CC 3_i
oral JJ 3_i
therapy NN 3_i
with IN 3_i
ofloxacin NN 3_i
may MD N
be VB N
beneficial JJ N
in IN N
the DT N
treatment NN N
of IN N
bleb-associated JJ N
infections NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
a DT N
high-protein JJ 3_i
, , 3_i
energy-restricted JJ 3_i
diet NN 3_i
on IN N
weight JJ N
loss NN N
and CC N
energy NN N
expenditure NN N
after IN N
weight JJ N
stabilization NN N
in IN N
hyperinsulinemic JJ N
subjects NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effect NN N
of IN N
replacing VBG N
some DT N
dietary JJ N
carbohydrate NN N
with IN N
protein NN N
, , N
during IN N
energy NN N
restriction NN N
, , N
on IN N
weight JJ N
loss NN N
, , N
total JJ N
energy NN N
expenditure NN N
( ( N
TEE NNP N
) ) N
, , N
resting VBG N
energy NN N
expenditure NN N
( ( N
REE NNP N
) ) N
, , N
respiratory JJ N
quotient NN N
( ( N
RQ NNP N
) ) N
, , N
and CC N
the DT N
thermic JJ N
effect NN N
of IN N
feeding NN N
( ( N
TEF NNP N
) ) N
in IN N
subjects NNS N
with IN N
hyperinsulinemia NN N
. . N

DESIGN NNP N
Parallel NNP N
, , N
clinical JJ N
intervention NN N
study NN N
of IN N
12 CD N
weeks NNS N
energy NN 6_i
restriction NN 6_i
( ( N
6.5 CD N
MJ/day NNP N
) ) N
and CC N
4 CD N
weeks NNS N
energy NN 6_i
balance NN 6_i
( ( N
8.2 CD N
MJ/day NNP N
) ) N
in IN N
two CD N
groups NNS N
of IN N
subjects NNS N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
high-protein NN 3_i
( ( 3_i
HP NNP 3_i
) ) 3_i
diet NN 3_i
( ( N
27 CD N
% NN N
of IN N
energy NN N
( ( N
% NN N
E NNP N
) ) N
as IN N
protein NN N
, , N
45 CD N
% NN N
E NNP N
as IN N
carbohydrate NN N
) ) N
or CC N
a DT N
lower-protein JJ 3_i
( ( 3_i
LP NNP 3_i
) ) 3_i
diet NN 3_i
( ( N
16 CD N
% NN N
E NNP N
as IN N
protein NN N
, , N
57 CD N
% NN N
E NNP N
as IN N
carbohydrate NN N
) ) N
. . N

SUBJECTS VB N
A DT N
total NN N
of IN N
36 CD N
obese JJ N
nondiabetic JJ N
volunteers NNS N
with IN N
hyperinsulinemia NN N
( ( N
10 CD N
males/26 NN N
females NNS N
, , N
aged VBD N
34-65 JJ N
y NN N
, , N
BMI NNP N
28-43 CD N
kg/m NN N
( ( N
2 CD N
) ) N
, , N
fasting VBG N
insulin JJ N
12-45 JJ N
mU/l NN N
) ) N
. . N

MEASUREMENTS NNP N
Body NNP N
weight VBD N
and CC N
composition NN N
, , N
TEE NNP N
, , N
REE NNP N
, , N
and CC N
RQ NNP N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
at IN N
week NN N
16 CD N
. . N

In IN N
addition NN N
, , N
the DT N
TEF NNP N
to TO N
an DT N
HP NNP 6_i
or CC N
LP NNP 6_i
meal NN N
was VBD N
determined VBN N
for IN N
3 CD N
h NN N
, , N
at IN N
baseline NN N
and CC N
at IN N
week NN N
16 CD N
. . N

RESULTS NN N
After IN N
16 CD N
weeks NNS N
, , N
weight JJ N
loss NN N
was VBD N
similar JJ N
in IN N
response NN N
to TO N
each DT N
diet NN N
; : N
the DT N
overall JJ N
decrease NN N
was VBD N
7.9+/-0.6 JJ N
kg NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
of IN N
which WDT N
6.8+/-0.5 JJ N
kg NN N
was VBD N
fat JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

REE NNP N
fell VBD N
similarly RB N
with IN N
each DT N
diet NN N
; : N
the DT N
overall JJ N
decrease NN N
was VBD N
719+/-106 JJ N
kJ/day NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
TEF NNP N
was VBD N
2 CD N
% NN N
greater JJR N
after IN N
the DT N
HP NNP 2_i
than IN N
after IN N
the DT N
LP NNP 2_i
meal NN N
at IN N
baseline NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
0.8 CD N
% NN N
greater JJR N
at IN N
week NN N
16 CD N
( ( N
P=0.35 NNP N
) ) N
. . N

After IN N
16 CD N
weeks NNS N
, , N
the DT N
TEF NNP N
was VBD N
not RB N
reduced VBN N
in IN N
either DT N
dietary JJ N
group NN N
. . N

There EX N
was VBD N
no DT N
change NN N
in IN N
TEE NNP N
after IN N
16 CD N
weeks NNS N
. . N

CONCLUSION NNP N
In IN N
subjects NNS N
with IN N
hyperinsulinemia PDT N
an DT N
energy-restrictive JJ N
diet NN N
containing VBG N
an DT N
increased VBN N
protein-to-carbohydrate NN N
ratio NN N
does VBZ N
not RB N
enhance VB N
weight JJ N
loss NN N
or CC N
significantly RB N
affect JJ N
energy NN N
expenditure NN N
. . N

Caloric NNP N
restriction NN N
, , N
rather RB N
than IN N
the DT N
macronutrient JJ N
composition NN N
of IN N
the DT N
diet NN N
, , N
is VBZ N
the DT N
most RBS N
important JJ N
determinant NN N
of IN N
weight JJ N
loss NN N
. . N

-DOCSTART- -X- O O

Protocol NN N
for IN N
the DT N
Multicenter NNP N
Acute NNP N
Stroke NNP N
Trial NNP N
-- : N
thrombolysis NN N
study NN N
. . N

The DT N
rationale NN N
for IN N
the DT N
Multicenter NNP N
Acute NNP N
Stroke NNP N
Trial NNP N
( ( N
MAST NNP N
) ) N
is VBZ N
presented VBN N
in IN N
a DT N
companion NN N
article NN N
appearing VBG N
in IN N
this DT N
issue NN N
. . N

Acute NNP N
ischaemic JJ N
stroke NN N
is VBZ N
the DT N
third JJ N
major JJ N
cause NN N
of IN N
death NN N
in IN N
developed JJ N
countries NNS N
, , N
and CC N
a DT N
major JJ N
cause NN N
of IN N
disability NN N
. . N

Despite IN N
a DT N
very RB N
poor JJ N
prognosis NN N
, , N
no DT N
treatment NN N
has VBZ N
demonstrated VBN N
an DT N
efficacy NN N
in IN N
lowering VBG N
the DT N
mortality NN N
and CC N
disability NN N
resulting VBG N
from IN N
stroke NN N
events NNS N
. . N

Thrombolysis NN 3_i
has VBZ N
been VBN N
proven VBN N
to TO N
reduce VB N
mortality NN N
in IN N
myocardial JJ N
infarction NN N
, , N
and CC N
it PRP N
has VBZ N
been VBN N
shown VBN N
able JJ N
to TO N
induce VB N
recanalisation NN N
when WRB N
administered VBN N
to TO N
acute VB N
stroke NN N
patients NNS N
. . N

A DT N
recent JJ N
meta NN N
analysis NN N
of IN N
small-sized JJ N
studies NNS N
suggests VBZ N
that IN N
thrombolysis NN 3_i
could MD N
offer VB N
some DT N
benefit NN N
to TO N
stroke VB N
patients NNS N
, , N
by IN N
reducing VBG N
the DT N
mortality NN N
and CC N
severe JJ N
invalidity NN N
by IN N
56 CD N
% NN N
; : N
these DT N
results NNS N
need VBP N
to TO N
be VB N
confirmed VBN N
in IN N
adequately RB N
designed VBN N
and CC N
sized VBN N
studies NNS N
. . N

-DOCSTART- -X- O O

The DT N
interobserver JJ N
variability NN N
of IN N
digital JJ 2_i
rectal JJ 2_i
examination NN 2_i
in IN N
a DT N
large JJ N
randomized JJ N
trial NN N
for IN N
the DT N
screening NN N
of IN N
prostate NN N
cancer NN N
. . N

BACKGROUND NNP N
To TO N
analyze VB N
to TO N
what WP N
extent VB N
the DT N
percentage NN N
of IN N
suspicious JJ N
digital JJ 2_i
rectal JJ 2_i
examination NN 2_i
( ( 2_i
DRE NNP 2_i
) ) 2_i
findings NNS N
vary VBP N
between IN N
examiners NNS N
and CC N
to TO N
what WP N
extent VB N
the DT N
percentage NN N
of IN N
prostate NN N
cancers NNS N
( ( N
PCs NNS N
) ) N
detected VBN N
in IN N
men NNS N
with IN N
these DT N
suspicious JJ N
findings NNS N
varies NNS N
between IN N
examiners NNS N
. . N

METHODS NNP N
In IN N
the DT N
first JJ N
screening NN N
round NN N
of IN N
the DT N
European NNP N
Randomized NNP N
study NN N
of IN N
Screening VBG N
for IN N
PC NN N
( ( N
ERSPC NNP N
) ) N
Rotterdam NNP N
, , N
7,280 CD N
men NNS N
underwent VBD N
a DT N
PSA-determination NN 2_i
and CC 2_i
DRE NNP 2_i
of IN 2_i
whom WP 2_i
2,102 CD 2_i
underwent JJ 2_i
prostate NN 2_i
biopsy NN 2_i
( ( N
biopsy JJ N
indication NN N
PSA NNP N
> NNP N
or CC N
= $ N
4.0 CD N
ng/ml JJ N
and/or RB N
suspicious JJ N
DRE NNP N
and/or NN N
TRUS NNP N
) ) N
. . N

Descriptive JJ N
statistics NNS N
of IN N
DRE-outcome NNP N
per IN N
PSA-range NNP N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
observer JJ N
variability NN N
of IN N
six CD N
examiners NNS N
. . N

Because IN N
this DT N
analysis NN N
did VBD N
not RB N
correct VB N
properly RB N
for IN N
other JJ N
predictors NNS N
of IN N
a DT N
suspicious JJ N
DRE NNP N
( ( N
PSA-level NNP N
, , N
biopsy NN N
indication NN N
, , N
TRUS-outcome NNP N
, , N
prostate NN N
volume NN N
and CC N
age NN N
) ) N
, , N
a DT N
logistic JJ N
regression NN N
analysis NN N
controlling VBG N
for IN N
these DT N
explanatory JJ N
variables NNS N
was VBD N
performed VBN N
as RB N
well RB N
. . N

RESULTS NNP N
In IN N
2,102 CD N
men NNS N
biopsied VBD N
, , N
443 CD N
PCs NNS N
were VBD N
detected VBN N
( ( N
PPV NNP N
= RB N
21 CD N
% NN N
) ) N
. . N

For IN N
all DT N
PSA NNP N
levels NNS N
the DT N
percentage NN N
suspicious JJ N
DRE NNP N
varied VBD N
between IN N
examiners NNS N
from IN N
4 CD N
% NN N
to TO N
28 CD N
% NN N
and CC N
percentage NN N
PC NN N
detected VBN N
in IN N
men NNS N
with IN N
a DT N
suspicious JJ N
DRE NNP N
varied VBD N
from IN N
18 CD N
% NN N
to TO N
36 CD N
% NN N
. . N

Logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
three CD N
of IN N
six CD N
examiners NNS N
considered VBN N
DRE NNP 2_i
significantly RB N
more RBR N
often RB N
abnormal JJ N
than IN N
others NNS N
( ( N
ORs NNP N
3.48 CD N
, , N
2.80 CD N
, , N
2.47 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
all DT N
examiners NNS N
the DT N
odds NNS N
to TO N
have VB N
PC NN N
was VBD N
statistically RB N
significantly RB N
higher JJR N
in IN N
case NN N
of IN N
a DT N
suspicious JJ N
DRE NNP N
( ( N
ORs NNP N
2.21-5.96 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

This DT N
increased VBD N
chance NN N
to TO N
find VB N
PC NN N
was VBD N
not RB N
significantly RB N
observer-dependent JJ N
. . N

CONCLUSIONS NNP N
Three CD N
of IN N
six CD N
examiners NNS N
considered VBN N
DRE NNP 2_i
significantly RB N
more RBR N
often RB N
suspicious JJ N
than IN N
the DT N
others NNS N
. . N

However RB N
, , N
under IN N
equal JJ N
circumstances NNS N
a DT N
suspicious JJ N
DRE NNP N
executed VBN N
by IN N
each DT N
examiner NN N
increased VBD N
the DT N
chance NN N
of IN N
the DT N
presence NN N
of IN N
PC NNP N
similarly RB N
. . N

-DOCSTART- -X- O O

Pharmacokinetic- JJ N
pharmacodynamic JJ N
analysis NN N
of IN N
the DT N
role NN N
of IN N
CYP2C19 NNP N
genotypes NNS N
in IN N
short-term JJ N
rabeprazole-based JJ 3_i
triple JJ 3_i
therapy NN 3_i
against IN N
Helicobacter NNP N
pylori NN N
. . N

AIMS IN N
The DT N
aim NN N
was VBD N
to TO N
explore VB N
the DT N
role NN N
of IN N
CYP2C19 NNP N
polymorphism NN N
in IN N
short-term JJ N
rabeprazole-based JJ 3_i
triple JJ 3_i
therapy NN 3_i
against IN N
Helicobacter NNP N
pylori JJ N
infection NN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
H. NNP N
pylori FW N
infection NN N
were VBD N
tested VBN N
for IN N
CYP2C19 NNP N
genotype NN N
as IN N
poor JJ N
metabolizers NNS N
( ( N
PMs NNP N
) ) N
or CC N
extensive JJ N
metabolizers NNS N
( ( N
EMs NNP N
, , N
homozygous JJ N
EM NNP N
or CC N
heterozygous JJ N
EM NNP N
) ) N
and CC N
given VBN N
rabeprazole NN 3_i
for IN N
7 CD N
days NNS N
. . N

Antibiotics NNS 3_i
( ( N
clarithromycin NN 3_i
and CC 3_i
amoxicillin NN 3_i
) ) N
were VBD N
given VBN N
on IN N
days NNS N
1-4 CD N
, , N
days NNS N
4-7 CD N
, , N
or CC N
days NNS N
1-7 RB N
. . N

A DT N
direct JJ N
link NN N
model NN N
with IN N
an DT N
effect NN N
compartment NN N
was VBD N
used VBN N
in IN N
the DT N
population NN N
pharmacokinetic-pharmacodynamic JJ N
analysis NN N
. . N

The DT N
status NN N
of IN N
H. NNP N
pylori FW N
infection NN N
was VBD N
evaluated VBN N
. . N

RESULTS NNP N
Rabeprazole NNP 3_i
clearance NN N
was VBD N
lower JJR N
in IN N
CYP2C19 NNP N
PMs NNP N
than IN N
in IN N
EMs NNP N
( ( N
with IN N
average NN N
values NNS N
of IN N
10.7 CD N
vs. FW N
16.8 CD N
l NN N
h NN N
( ( N
-1 NNP N
) ) N
in IN N
PMs NNP N
and CC N
EMs NNP N
, , N
respectively RB N
) ) N
, , N
resulting VBG N
in IN N
higher JJR N
plasma NN N
levels NNS N
in IN N
the DT N
former JJ N
group NN N
. . N

The DT N
values NNS N
of IN N
EC NNP N
( ( N
50 CD N
) ) N
and CC N
k $ N
( ( N
eo NN N
) ) N
of IN N
gastrin JJ N
response NN N
increased VBD N
with IN N
multiple JJ N
doses NNS N
of IN N
rabeprazole NN 3_i
. . N

The DT N
k NN N
( ( N
eo NN N
) ) N
values NNS N
were VBD N
lower JJR N
in IN N
CYP2C19 NNP N
PMs NNP N
than IN N
in IN N
EMs NNP N
on IN N
day NN N
1 CD N
( ( N
0.012 CD N
vs. FW N
0.017 CD N
x $ N
10 CD N
( ( N
-4 NN N
) ) N
l NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
and CC N
higher JJR N
than IN N
in IN N
EMs NNP N
on IN N
day NN N
4 CD N
( ( N
0.804 CD N
vs. FW N
0.169 CD N
x $ N
10 CD N
( ( N
-4 NN N
) ) N
l NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
of IN N
rabeprazole NN 3_i
treatment NN N
. . N

The DT N
predicted JJ N
gastrin-time NN N
profile NN N
showed VBD N
a DT N
higher JJR N
response NN N
in IN N
CYP2C19 NNP N
PMs NNP N
than IN N
in IN N
EMs NNP N
on IN N
days NNS N
4 CD N
and CC N
7 CD N
. . N

Helicobacter NNP N
pylori NN N
was VBD N
eradicated VBN N
in IN N
all DT N
CYP2C19 NNP N
PMs NNP N
except IN N
in IN N
one CD N
patient NN N
infected VBN N
by IN N
a DT N
resistant JJ N
strain NN N
. . N

In IN N
contrast NN N
, , N
in IN N
CYP2C19 NNP N
EMs NNP N
the DT N
eradication NN N
rates NNS N
ranged VBD N
from IN N
58 CD N
to TO N
85 CD N
% NN N
. . N

CONCLUSIONS NNP N
CYP2C19 NNP N
genotypes VBZ N
play VB N
a DT N
role NN N
in IN N
H. NNP N
pylori FW N
eradication NN N
therapy NN N
. . N

Rabeprazole-based JJ 3_i
short-term JJ 3_i
triple JJ 3_i
therapy NN 3_i
may MD N
be VB N
applicable JJ N
in IN N
CYP2C19 NNP N
PMs NNP N
for IN N
H. NNP N
pylori JJ N
eradication NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
comparing VBG N
standard NN 4_i
wound NN 4_i
care NN 4_i
with IN N
adjunctive JJ 2_i
hyperbaric JJ 2_i
oxygen NN 2_i
therapy NN 2_i
( ( 2_i
HBOT NNP 2_i
) ) 2_i
to TO N
standard VB N
wound NN N
care NN N
only RB N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
, , N
non-healing JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
in IN N
patients NNS N
with IN N
diabetes NNS N
mellitus NNS N
: : N
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
the DT N
use NN N
of IN N
adjunctive JJ 2_i
hyperbaric JJ 2_i
oxygen NN 2_i
therapy NN 2_i
improves VBZ N
the DT N
healing NN N
of IN N
diabetic JJ N
foot NN N
ulcers NNS N
, , N
and CC N
decreases VBZ N
the DT N
risk NN N
of IN N
lower JJR N
extremity NN N
amputations NNS N
. . N

A DT N
limited JJ N
number NN N
of IN N
studies NNS N
have VBP N
used VBN N
a DT N
double JJ N
blind NN N
approach NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ 2_i
oxygen NN 2_i
therapy NN 2_i
in IN N
the DT N
treatment NN N
of IN N
diabetic JJ N
ulcers NNS N
. . N

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ 2_i
oxygen NN 2_i
therapy NN 2_i
plus CC 2_i
standard NN 2_i
wound NN 2_i
care NN 2_i
compared VBN N
with IN N
standard NN 2_i
wound NN 2_i
care NN 2_i
alone RB N
in IN N
preventing VBG N
the DT N
need NN N
for IN N
major JJ N
amputation NN N
in IN N
patients NNS N
with IN N
diabetes NNS N
mellitus NNS N
and CC N
chronic JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
. . N

METHODS/DESIGN NNP N
One CD N
hundred CD N
and CC N
eighteen JJ N
( ( N
59 CD N
patients NNS N
per IN N
arm NN N
) ) N
patients NNS N
with IN N
non-healing JJ N
diabetic JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
, , N
referred VBD N
to TO N
the DT N
Judy NNP N
Dan NNP N
Research NNP N
and CC N
Treatment NNP N
Centre NNP N
are VBP N
being VBG N
recruited VBN N
if IN N
they PRP N
are VBP N
at IN N
least JJS N
18 CD N
years NNS N
of IN N
age NN N
, , N
have VBP N
either DT N
Type NNP N
1 CD N
or CC N
2 CD N
diabetes NNS N
with IN N
a DT N
Wagner NNP N
grading NN N
of IN N
foot NN N
lesions NNS N
2 CD N
, , N
3 CD N
or CC N
4 CD N
on IN N
lower JJR N
limb NN N
not RB N
healing VBG N
for IN N
at IN N
least JJS N
4 CD N
weeks NNS N
. . N

Patients NNS N
receive JJ N
hyperbaric JJ 2_i
oxygen NN 2_i
therapy NN 2_i
every DT N
day NN N
for IN N
6 CD N
weeks NNS N
during IN N
the DT N
treatment NN N
phase NN N
and CC N
are VBP N
provided VBN N
ongoing VBG 4_i
wound NN 4_i
care NN 4_i
and CC N
weekly JJ N
assessments NNS N
. . N

Patients NNS N
are VBP N
required VBN N
to TO N
return VB N
to TO N
the DT N
study NN N
centre NN N
every DT N
week NN N
for IN N
an DT N
additional JJ N
6 CD N
weeks NNS N
of IN N
follow-up NN N
for IN N
wound JJ N
evaluation NN N
and CC N
management NN N
. . N

The DT N
primary JJ N
outcome NN N
is VBZ N
freedom RB N
from IN N
having VBG N
, , N
or CC N
meeting VBG N
the DT N
criteria NN N
for IN N
, , N
a DT N
major JJ N
amputation NN N
( ( N
below IN N
knee NN N
amputation NN N
, , N
or CC N
metatarsal VB N
level NN N
) ) N
up RB N
to TO N
12 CD N
weeks NNS N
after IN N
randomization NN N
. . N

The DT N
decision NN N
to TO N
amputate VB N
is VBZ N
made VBN N
by IN N
a DT N
vascular JJ N
surgeon NN N
. . N

Other JJ N
outcomes NNS N
include VBP N
wound IN N
healing NN N
, , N
effectiveness NN N
, , N
safety NN N
, , N
healthcare JJ N
resource NN N
utilization NN N
, , N
quality NN N
of IN N
life NN N
, , N
and CC N
cost-effectiveness NN N
. . N

The DT N
study NN N
will MD N
run VB N
for IN N
a DT N
total NN N
of IN N
about IN N
3 CD N
years NNS N
. . N

DISCUSSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
will MD N
provide VB N
detailed JJ N
information NN N
on IN N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
non-healing JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
. . N

This DT N
will MD N
be VB N
the DT N
first JJ N
double-blind JJ N
randomized VBN N
controlled JJ N
trial NN N
for IN N
this DT N
health NN N
technology NN N
which WDT N
evaluates VBZ N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
in IN N
prevention NN N
of IN N
amputations NNS N
in IN N
diabetic JJ N
patients NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
Identifier NNP N
: : N
NCT00621608 NN N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
disease NN N
severity NN N
on IN N
outcome NN N
of IN N
antiviral JJ 3_i
therapy NN 3_i
for IN N
chronic JJ N
hepatitis NN N
C NNP N
: : N
Lessons NNS N
from IN N
the DT N
HALT-C NNP N
trial NN N
. . N

In IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
, , N
advanced VBD N
fibrosis NN N
and CC N
cirrhosis NN N
are VBP N
associated VBN N
with IN N
lower JJR N
rates NNS N
of IN N
sustained JJ N
virologic JJ N
response NN N
( ( N
SVR NNP N
) ) N
to TO N
interferon VB N
( ( N
IFN NNP N
) ) N
-based VBD N
therapy NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
assessed VBD N
virologic JJ N
response NN N
to TO N
retreatment VB N
with IN N
peginterferon JJ 3_i
alfa-2a JJ 3_i
and CC N
ribavirin NN 3_i
( ( 3_i
RBV NNP 3_i
) ) 3_i
, , N
as IN N
a DT N
function NN N
of IN N
the DT N
baseline NN N
fibrosis NN N
score NN N
( ( N
Ishak NNP N
staging VBG N
) ) N
and CC N
platelet NN N
count NN N
, , N
in IN N
1,046 CD N
patients NNS N
enrolled VBN N
in IN N
the DT N
Hepatitis NNP N
C NNP N
Antiviral NNP N
Long-term NNP N
Treatment NNP N
against IN N
Cirrhosis NNP N
( ( N
HALT-C NNP N
) ) N
Trial NNP N
. . N

All DT N
patients NNS N
had VBD N
failed VBN N
prior RB N
treatment NN N
with IN N
IFN NNP 3_i
or CC N
peginterferon VB 3_i
+/- JJ 3_i
RBV NNP 3_i
and CC N
had VBD N
Ishak NNP N
fibrosis NN N
scores VBZ N
> CD N
or CC N
= VB N
3 CD N
. . N

Four CD N
groups NNS N
of IN N
patients NNS N
with IN N
increasingly RB N
severe JJ N
liver NN N
disease NN N
were VBD N
compared VBN N
: : N
( ( N
A DT N
) ) N
bridging NN N
fibrosis NN N
( ( N
Ishak NNP N
3 CD N
and CC N
4 CD N
) ) N
with IN N
platelet NN N
counts NNS N
> VBP N
125,000/mm3 CD N
( ( N
n JJ N
= NNP N
559 CD N
) ) N
; : N
( ( N
B NNP N
) ) N
bridging VBG N
fibrosis NN N
with IN N
platelet NN N
counts NNS N
< VBP N
or CC N
=125,000/mm3 NNP N
( ( N
n JJ N
= NNP N
96 CD N
) ) N
; : N
( ( N
C NNP N
) ) N
cirrhosis NN N
( ( N
Ishak NNP N
5 CD N
and CC N
6 CD N
) ) N
with IN N
platelet NN N
counts NNS N
> VBP N
125,000/mm3 CD N
( ( N
n JJ N
= NNP N
198 CD N
) ) N
; : N
and CC N
( ( N
D NNP N
) ) N
cirrhosis NN N
with IN N
platelet NN N
counts NNS N
< VBP N
or CC N
=125,000/mm3 NNP N
( ( N
n JJ N
= NNP N
193 CD N
) ) N
. . N

SVR JJ N
rates NNS N
were VBD N
23 CD N
% NN N
, , N
17 CD N
% NN N
, , N
10 CD N
% NN N
, , N
and CC N
9 CD N
% NN N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
, , N
C NNP N
, , N
and CC N
D NNP N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
.0001 NNP N
for IN N
trend NN N
) ) N
. . N

Reduction NN N
in IN N
SVR NNP N
as IN N
a DT N
function NN N
of IN N
increasingly RB N
severe JJ N
disease NN N
was VBD N
independent JJ N
of IN N
age NN N
, , N
percent JJ N
African JJ N
American NNP N
, , N
HCV NNP N
genotype NN N
, , N
HCV NNP N
level NN N
, , N
and CC N
type NN N
of IN N
prior JJ N
therapy NN N
. . N

Dose NNP N
reduction NN N
lowered VBD N
SVR NNP N
frequencies NNS N
, , N
but CC N
to TO N
a DT N
lesser JJR N
extent NN N
than IN N
disease NN N
severity NN N
. . N

By IN N
logistic JJ N
regression NN N
, , N
cirrhosis NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
was VBD N
the DT N
major JJ N
determinant NN N
that WDT N
impaired VBD N
virologic JJ N
response NN N
, , N
independent JJ N
of IN N
dose JJ N
reduction NN N
or CC N
platelet NN N
count NN N
. . N

In IN N
conclusion NN N
, , N
disease NN N
severity NN N
is VBZ N
a DT N
major JJ N
independent JJ N
determinant NN N
of IN N
rate NN N
of IN N
SVR NNP N
in IN N
patients NNS N
with IN N
advanced JJ N
chronic JJ N
hepatitis NN N
C. NNP N
New NNP N
strategies NNS N
are VBP N
needed VBN N
to TO N
optimize VB N
antiviral JJ N
therapy NN N
in IN N
these DT N
difficult-to-cure JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Induction NNP 3_i
versus NN N
noninduction NN 3_i
in IN N
renal JJ N
transplant NN N
recipients NNS N
with IN N
tacrolimus-based JJ N
immunosuppression NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
induction NN N
treatment NN N
with IN N
antithymocyte NN 3_i
globulins NNS 3_i
( ( 3_i
ATG NNP 3_i
) ) 3_i
followed VBN N
by IN N
tacrolimus JJ 3_i
therapy NN N
with IN N
immediate JJ N
tacrolimus NNS N
therapy NN N
in IN N
renal JJ N
transplant NN N
recipients NNS N
. . N

METHODS NNP N
This DT N
12-month JJ N
, , N
open JJ N
, , N
prospective JJ N
study NN N
was VBD N
conducted VBN N
in IN N
15 CD N
centers NNS N
in IN N
France NNP N
and CC N
1 CD N
center NN N
in IN N
Belgium NNP N
; : N
309 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
induction NN 3_i
therapy NN 3_i
with IN 3_i
ATG NNP 3_i
( ( N
n=151 NN N
) ) N
followed VBN N
by IN N
initiation NN N
of IN N
tacrolimus NN 3_i
on IN N
day NN N
9 CD N
or CC N
immediate JJ N
tacrolimus-based JJ 3_i
triple NN 3_i
therapy NN 3_i
( ( N
n=158 JJ N
) ) N
. . N

In IN N
both DT N
study NN N
arms NNS N
, , N
the DT N
initial JJ N
daily JJ N
tacrolimus NN 3_i
dose NN N
was VBD N
0.2 CD N
mg/kg NN N
. . N

Steroid JJ 3_i
boluses NNS 3_i
were VBD N
given VBN N
in IN N
the DT N
first JJ N
2 CD N
days NNS N
and CC N
tapered JJ N
thereafter NN N
from IN N
20 CD N
mg/day NN N
to TO N
5 CD N
mg/day NN N
. . N

Azathioprine NNP 3_i
was VBD N
administered VBN N
at IN N
1-2 JJ N
mg/kg NNS N
per IN N
day NN N
. . N

RESULTS NNP N
At IN N
month NN N
12 CD N
, , N
biopsy-confirmed JJ N
acute NN N
rejections NNS N
were VBD N
reported VBN N
for IN N
15.2 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
30.4 CD N
% NN N
( ( N
noninduction NN N
) ) N
of IN N
patients NNS N
( ( N
P=0.001 NNP N
) ) N
. . N

The DT N
incidence NN N
of IN N
steroid-sensitive JJ N
acute JJ N
rejections NNS N
was VBD N
7.9 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
22.2 CD N
% NN N
( ( N
noninduction NN N
) ) N
( ( N
P=0.001 NNP N
) ) N
. . N

Steroid-resistant JJ N
acute JJ N
rejections NNS N
were VBD N
reported VBN N
for IN N
8.6 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
8.9 CD N
% NN N
( ( N
noninduction NN N
) ) N
of IN N
patients NNS N
. . N

A DT N
total NN N
of IN N
nine CD N
patients NNS N
died VBD N
. . N

Patient NNP N
survival NN N
and CC N
graft NN N
survival NN N
at IN N
month NN N
12 CD N
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
( ( N
97.4 CD N
% NN N
vs. FW N
96.8 CD N
% NN N
and CC N
92.1 CD N
% NN N
vs. FW N
91.1 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Statistically NNP N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
were VBD N
found VBN N
for IN N
cytomegalovirus NN N
( ( N
CMV NNP N
) ) N
infection NN N
( ( N
induction NN N
, , N
32.5 CD N
% NN N
vs. FW N
noninduction NN N
, , N
19.0 CD N
% NN N
, , N
P=0.009 NNP N
) ) N
, , N
leukopenia NN N
( ( N
37.3 CD N
% NN N
vs. FW N
9.5 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
fever RB N
( ( N
25.2 CD N
% NN N
vs. FW N
10.1 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
herpes VBZ N
simplex JJ N
( ( N
17.9 CD N
% NN N
vs. FW N
5.7 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
and CC N
thrombocytopenia NN N
( ( N
11.3 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
, , N
P=0.007 NNP N
) ) N
. . N

In IN N
the DT N
induction NN N
group NN N
, , N
serum NN N
sickness NN N
was VBD N
observed VBN N
in IN N
10.6 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
incidence NN N
of IN N
new JJ N
onset NN N
diabetes NNS N
mellitus NN N
was VBD N
3.4 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
4.5 CD N
% NN N
( ( N
noninduction NN N
) ) N
. . N

CONCLUSION NNP N
Low NNP N
incidences NNS N
of IN N
acute JJ N
rejection NN N
were VBD N
found VBN N
in IN N
both DT N
treatment NN N
arms NNS N
. . N

Induction NNP N
treatment NN N
with IN N
ATG NNP 3_i
has VBZ N
the DT N
advantage NN N
of IN N
a DT N
lower JJR N
incidence NN N
of IN N
acute JJ N
rejection NN N
, , N
but CC N
it PRP N
significantly RB N
increases VBZ N
adverse JJ N
events NNS N
, , N
particularly RB N
CMV NNP N
infection NN N
. . N

-DOCSTART- -X- O O

Low-dose JJ N
naltrexone NN 3_i
effects NNS N
on IN N
plasma NN N
chemistries NNS N
and CC N
clinical JJ N
symptoms NNS N
in IN N
autism NN N
: : N
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
effect NN N
of IN N
month-long JJ N
naltrexone NN 3_i
( ( 3_i
NTX NNP 3_i
) ) 3_i
treatment NN N
at IN N
a DT N
daily JJ N
oral JJ N
dose NN N
of IN N
0.5 CD N
mg/kg/day NN N
was VBD N
contrasted VBN N
with IN N
placebo NN 7_i
( ( N
PLC NNP N
) ) N
in IN N
a DT N
double-blind NN N
study NN N
with IN N
conjoint NN N
clinical JJ N
and CC N
biochemical JJ N
evaluations NNS N
of IN N
therapeutic JJ N
effects NNS N
. . N

Modest NNP N
clinical JJ N
benefits NNS N
were VBD N
achieved VBN N
with IN N
both DT N
PLC NNP 3_i
and CC N
NTX NNP 3_i
, , N
with IN N
marginally RB N
better JJR N
overall JJ N
results NNS N
following VBG N
NTX NNP N
, , N
and CC N
degree NN N
of IN N
improvement NN N
appeared VBD N
to TO N
be VB N
related VBN N
to TO N
plasma VB N
chemical JJ N
profiles NNS N
. . N

Massively RB N
elevated JJ N
levels NNS N
of IN N
beta-endorphin NN N
were VBD N
observed VBN N
in IN N
all DT N
children NNS N
with IN N
assays NNS N
using VBG N
C-terminal JJ N
antibody NN N
but CC N
not RB N
with IN N
an DT N
N-terminal JJ N
antibody NN N
assay NN N
. . N

In IN N
addition NN N
, , N
70 CD N
% NN N
of IN N
the DT N
children NNS N
exhibited VBD N
abnormally RB N
low JJ N
levels NNS N
of IN N
adrenocorticotropic NN N
hormone NN N
, , N
and CC N
smaller JJR N
subsets NNS N
exhibited VBD N
elevated JJ N
norepinephrine NN N
( ( N
60 CD N
% NN N
) ) N
, , N
arginine-vasopressin JJ N
( ( N
50 CD N
% NN N
) ) N
, , N
and CC N
serotonin NN N
( ( N
20 CD N
% NN N
) ) N
. . N

The DT N
best JJS N
clinical JJ N
responders NNS N
exhibited VBD N
the DT N
clearest JJS N
normalization NN N
of IN N
the DT N
elevated JJ N
plasma NN N
chemistries NNS N
, , N
especially RB N
in IN N
C-terminal-beta-endorphin NNP N
and CC N
serotonin NN N
. . N

There EX N
was VBD N
some DT N
evidence NN N
of IN N
therapeutic JJ N
carry-over JJ N
effects NNS N
in IN N
both DT N
clinical JJ N
and CC N
biochemical JJ N
measures NNS N
in IN N
those DT N
children NNS N
who WP N
received VBD N
NTX NNP 3_i
before IN N
PLC NNP 3_i
. . 3_i

The DT N
results NNS N
suggest VBP N
that IN N
NTX NNP 3_i
only RB N
benefits NNS N
a DT N
subgroup NN N
of IN N
autistic JJ N
children NNS N
, , N
who WP N
may MD N
be VB N
identified VBN N
by IN N
the DT N
presence NN N
of IN N
certain JJ N
plasma JJ N
abnormalities NNS N
. . N

These DT N
results NNS N
suggest VBP N
a DT N
possible JJ N
linkage NN N
between IN N
abnormal JJ N
plasma NN N
chemistries NNS N
, , N
especially RB N
those DT N
related VBN N
to TO N
the DT N
pro-opiomelanocortin JJ N
system NN N
, , N
and CC N
autistic JJ N
symptoms NNS N
. . N

-DOCSTART- -X- O O

Prospective JJ N
study NN N
of IN N
C-reactive NNP N
protein NN N
, , N
homocysteine NN N
, , N
and CC N
plasma VB N
lipid JJ N
levels NNS N
as IN N
predictors NNS N
of IN N
sudden JJ N
cardiac JJ N
death NN N
. . N

BACKGROUND NNP N
Sudden NNP N
cardiac JJ N
death NN N
( ( N
SCD NNP N
) ) N
is VBZ N
an DT N
important JJ N
cause NN N
of IN N
mortality NN N
even RB N
among IN N
apparently RB N
healthy JJ N
populations NNS N
. . N

However RB N
, , N
our PRP$ N
ability NN N
to TO N
identify VB N
those DT N
at IN N
risk NN N
for IN N
SCD NNP N
in IN N
the DT N
general JJ N
population NN N
is VBZ N
poor JJ N
, , N
and CC N
more RBR N
specific JJ N
markers NNS N
are VBP N
needed VBN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
To TO N
compare VB N
and CC N
contrast VB N
the DT N
relative JJ N
importance NN N
of IN N
C-reactive JJ 3_i
protein NN 3_i
( ( 3_i
CRP NNP 3_i
) ) 3_i
, , N
homocysteine NN 3_i
, , N
and CC N
lipids NNS 3_i
as IN N
long-term JJ N
predictors NNS N
of IN N
SCD NNP N
, , N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
nested JJ N
, , N
case-control JJ N
analysis NN N
involving VBG N
97 CD N
cases NNS N
of IN N
SCD NNP N
among IN N
apparently RB N
healthy JJ N
men NNS N
enrolled VBN N
in IN N
the DT N
Physician NNP N
's POS N
Health NNP N
Study NNP N
. . N

Of IN N
these DT N
plasma JJ N
markers NNS N
measured VBD N
, , N
only RB N
baseline JJ N
CRP NNP N
levels NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
SCD NNP N
over IN N
the DT N
ensuing VBG N
17 CD N
years NNS N
of IN N
follow-up NN N
( ( N
P NNP N
for IN N
trend=0.001 NN N
) ) N
. . N

The DT N
increase NN N
in IN N
risk NN N
associated VBN N
with IN N
CRP NNP 3_i
levels NNS N
was VBD N
primarily RB N
seen VBN N
among IN N
men NNS N
in IN N
the DT N
highest JJS N
quartile NN N
, , N
who WP N
were VBD N
at IN N
a DT N
2.78-fold JJ N
increased JJ N
risk NN N
of IN N
SCD NNP N
( ( N
95 CD N
% NN N
CI NNP N
1.35 CD N
to TO N
5.72 CD N
) ) N
compared VBN N
with IN N
men NNS N
in IN N
the DT N
lowest JJS N
quartile NN N
. . N

These DT N
results NNS N
were VBD N
not RB N
significantly RB N
altered VBN N
in IN N
analyses NNS N
that WDT N
( ( N
in IN N
addition NN N
to TO N
the DT N
matching JJ N
variables NNS N
of IN N
age NN N
and CC N
smoking NN N
status NN N
) ) N
controlled VBD N
for IN N
lipid JJ N
parameters NNS N
, , N
homocysteine NN N
, , N
and CC N
multiple JJ N
cardiac JJ N
risk NN N
factors NNS N
( ( N
relative JJ N
risk NN N
for IN N
highest JJS N
versus NN N
lowest JJS N
quartile NN N
2.65 CD N
, , N
95 CD N
% NN N
CI NNP N
0.79 CD N
to TO N
8.83 CD N
; : N
P NNP N
for IN N
trend=0.03 NN N
) ) N
. . N

In IN N
contrast NN N
to TO N
the DT N
positive JJ N
relationship NN N
observed VBD N
for IN N
CRP NNP 3_i
, , N
neither DT N
homocysteine NN N
nor CC N
lipid JJ N
levels NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
risk NN N
of IN N
SCD NNP N
. . N

CONCLUSIONS NNP N
These DT N
prospective JJ N
data NNS N
suggest VBP N
that IN N
CRP NNP N
levels NNS N
may MD N
be VB N
useful JJ N
in IN N
identifying VBG N
apparently RB N
healthy JJ N
men NNS N
who WP N
are VBP N
at IN N
an DT N
increased VBN N
long-term JJ N
risk NN N
of IN N
SCD NNP N
. . N

-DOCSTART- -X- O O

Mass NNP N
inoculation NN N
in IN N
a DT N
community NN N
: : N
the DT N
effect NN N
of IN N
primary JJ N
prevention NN N
of IN N
stress JJ N
reactions NNS N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effectiveness NN N
of IN N
a DT N
brief JJ N
, , N
situation-specific JJ N
, , N
group-administered JJ N
preparatory NN N
intervention NN N
in IN N
a DT N
nonclient JJ N
school NN N
population NN N
undergoing VBG N
mass NN 2_i
inoculation NN 2_i
against IN 2_i
rubella NN 2_i
. . N

Fifty-one CD N
girls NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
practice NN 2_i
, , 2_i
no-practice JJ 2_i
, , 2_i
or CC 2_i
control NN 7_i
groups NNS 7_i
. . N

Both CC N
the DT N
practice NN N
and CC N
the DT N
no-practice JJ N
groups NNS N
received VBD N
information NN N
that IN N
described VBD N
the DT N
inoculation NN N
procedure NN N
and CC N
how WRB N
to TO N
cope VB N
with IN N
it PRP N
by IN N
using VBG N
cognitive-behavioral JJ N
coping NN N
skills NNS N
. . N

The DT N
practice NN N
group NN N
was VBD N
encouraged VBN N
to TO N
perform VB N
coping VBG N
techniques NNS N
of IN N
this DT N
type NN N
, , N
whereas IN N
the DT N
no-practice JJ N
group NN N
was VBD N
told VBN N
only RB N
that IN N
the DT N
intervention NN N
would MD N
help VB N
them PRP N
during IN N
the DT N
inoculation NN N
. . N

Subjects NNS N
in IN N
both DT N
practice NN N
and CC N
no-practice JJ N
groups NNS N
reported VBD N
less JJR N
anxiety NN N
and CC N
exhibited VBD N
more RBR N
cooperative JJ N
behavior NN N
during IN N
inoculation NN N
than IN N
subjects NNS N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
those DT N
who WP N
were VBD N
guided VBN N
and CC N
prompted VBN N
to TO N
actively RB N
practice NN N
derived VBD N
greater JJR N
benefit NN N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
a DT N
controlled VBN 2_i
heated VBN 2_i
breathing VBG 2_i
tube NN 2_i
humidifier NN 2_i
on IN N
sleep JJ N
quality NN N
during IN N
CPAP NNP 2_i
therapy NN 2_i
in IN N
a DT N
cool JJ N
sleeping NN N
environment NN N
. . N

There EX N
are VBP N
conflicting VBG N
data NNS N
on IN N
the DT N
effect NN N
of IN N
adding VBG N
a DT N
heated VBN 2_i
humidifier NN 2_i
to TO N
nasal RB N
continuous JJ 2_i
positive JJ 2_i
airway NN 2_i
pressure NN 2_i
( ( 2_i
CPAP NNP 2_i
) ) 2_i
therapy NN 2_i
for IN N
patients NNS N
with IN N
obstructive JJ N
sleep JJ N
apnoea NN N
syndrome NN N
( ( N
OSAS NNP N
) ) N
. . N

The DT N
effects NNS N
of IN N
heated JJ N
humidification NN N
on IN N
sleep JJ N
quality NN N
and CC N
treatment NN N
side-effects NNS N
for IN N
patients NNS N
who WP N
prefer VBP N
a DT N
cold JJ N
bedroom NN N
environment NN N
have VBP N
not RB N
been VBN N
studied VBN N
. . N

A DT N
randomised JJ N
, , N
controlled VBD N
crossover RB N
trial NN N
involving VBG N
19 CD N
patients NNS N
with IN N
a DT N
first-ever JJ N
diagnosis NN N
of IN N
OSAS NNP N
measured VBD N
the DT N
effect NN N
of IN N
conventional JJ 2_i
heated JJ 2_i
humidification NN 2_i
added VBD 2_i
to TO 2_i
CPAP NNP 2_i
compared VBN N
with IN N
a DT N
controlled VBN 2_i
heated VBN 2_i
breathing VBG 2_i
tube NN 2_i
humidifier NN 2_i
( ( 2_i
ThermoSmart NNP 2_i
( ( 2_i
R NNP 2_i
) ) 2_i
; : 2_i
Fisher NNP N
and CC N
Paykel NNP N
Healthcare NNP N
, , N
Auckland NNP N
, , N
New NNP N
Zealand NNP N
) ) N
on IN N
sleep JJ N
quality NN N
. . N

During IN N
the DT N
night NN N
in IN N
the DT N
sleep JJ N
laboratory NN N
at IN N
a DT N
mean JJ N
room NN N
temperature NN N
of IN N
14 CD N
degrees NNS N
C NNP N
, , N
less JJR N
condensation NN N
formed VBN N
with IN N
the DT N
controlled VBN 2_i
heated VBD 2_i
breathing VBG 2_i
tube NN 2_i
humidifier NN 2_i
( ( N
1.9 CD N
mL NN N
versus NN N
35.3 CD N
mL NN N
) ) N
in IN N
the DT N
delivery NN N
system NN N
. . N

In IN N
addition NN N
, , N
the DT N
total JJ N
sleep JJ N
time NN N
, , N
time NN N
spent VBN N
in IN N
sleep JJ N
stages NNS N
3 CD N
and CC N
4 CD N
, , N
and CC N
rapid JJ N
eye NN N
movement NN N
sleep JJ N
phases NNS N
were VBD N
significantly RB N
longer RBR N
and CC N
the DT N
overall JJ N
side-effect JJ N
score NN N
was VBD N
lower JJR N
than IN N
with IN N
conventional JJ N
heated JJ N
humidification NN N
. . N

Patients NNS N
on IN N
nasal JJ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
desiring VBG N
a DT N
cool JJ N
bedroom NN N
temperature NN N
could MD N
benefit VB N
from IN N
controlled VBN 2_i
heated VBN 2_i
breathing VBG 2_i
tube JJ 2_i
humidification NN 2_i
technology NN 2_i
( ( N
with IN N
inputs NNS N
from IN N
ambient JJ N
temperature NN N
, , N
set VBN N
pressure NN N
and CC N
flow NN N
) ) N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
two CD N
combined JJ N
hormonal JJ 3_i
contraceptives NNS 3_i
with IN N
the DT N
same JJ N
composition NN N
and CC N
different JJ N
doses NNS N
on IN N
female JJ N
sexual JJ N
function NN N
and CC N
plasma NN N
androgen NN N
levels NNS N
. . N

BACKGROUND NNP N
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
two CD N
contraceptive JJ 3_i
pills NNS 3_i
with IN N
different JJ N
doses NNS N
of IN N
the DT N
same JJ N
components NNS N
, , N
on IN N
plasma JJ N
androgen NN N
levels NNS N
and CC N
female JJ N
sexual JJ N
function NN N
among IN N
women NNS N
without IN N
previous JJ N
sexual JJ N
dysfunction NN N
. . N

STUDY NNP N
DESIGN NNP N
The DT N
participants NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
to TO N
receive VB N
pills NNS N
containing VBG N
ethynylestradiol NN 3_i
( ( 3_i
EE NNP 3_i
) ) 3_i
30 CD 3_i
mcg NN 3_i
and CC 3_i
levonorgestrel NN 3_i
( ( 3_i
LNG NNP 3_i
) ) 3_i
150 CD 3_i
mcg NN 3_i
or CC 3_i
EE NNP 3_i
20 CD 3_i
mcg NN 3_i
and CC 3_i
LNG NNP 3_i
100 CD 3_i
mcg NN 3_i
, , N
for IN N
six CD N
cycles NNS N
. . N

Sexual JJ N
function NN N
was VBD N
assessed VBN N
using VBG N
a DT N
standardized JJ N
questionnaire NN N
[ NNP N
Female NNP N
Sexual NNP N
Function NNP N
Index NNP N
( ( N
FSFI NNP N
) ) N
] NN N
. . N

Hormone NNP N
assays NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
sixth JJ N
cycle NN N
. . N

RESULTS NNP N
Forty-nine JJ N
women NNS N
were VBD N
included VBN N
in IN N
the DT N
EE30/LNG150 NNP 3_i
group NN N
and CC N
48 CD N
in IN N
the DT N
EE20/LNG100 NNP 3_i
group NN N
. . N

EE30/LNG150 NNP 3_i
group NN N
presented VBD N
54 CD N
% NN N
and CC N
67 CD N
% NN N
decreases NNS N
of IN N
total JJ N
testosterone NN N
and CC N
free JJ N
androgen NN N
index NN N
, , N
respectively RB N
, , N
with IN N
statistical JJ N
significance NN N
. . N

EE20/LNG100 NNP 3_i
presented VBD N
reductions NNS N
of IN N
20 CD N
% NN N
and CC N
42 CD N
% NN N
, , N
respectively RB N
, , N
but CC N
without IN N
statistical JJ N
significance NN N
. . N

Both DT N
groups NNS N
showed VBD N
improvements NNS N
in IN N
the DT N
FSFI NNP N
desire NN N
score NN N
, , N
but CC N
with IN N
statistical JJ N
significance NN N
only RB N
for IN N
EE20/LNG100 NNP 3_i
group NN N
. . N

CONCLUSIONS NNP N
EE30/LNG150 NNP 3_i
decreased VBD N
plasma JJ N
androgen NN N
levels NNS N
, , N
but CC N
there EX N
was VBD N
no DT N
impairment NN N
in IN N
sexual JJ N
desire NN N
, , N
on IN N
the DT N
other JJ N
hand NN N
, , N
sexual JJ N
desire NN N
score NN N
increased VBD N
with IN N
EE20/LNG100 NNP 3_i
formulation NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
once RB N
and CC N
twice RB N
daily JJ N
atenolol NN 3_i
for IN N
angina JJ N
pectoris NN N
. . N

We PRP N
have VBP N
studied VBN N
the DT N
effects NNS N
of IN N
four CD N
doses NNS N
of IN N
atenolol NN 3_i
in IN N
11 CD N
patients NNS N
with IN N
stable JJ N
angina NNS N
pectoris VBP N
using VBG N
a DT N
symptom-limited JJ N
exercise NN N
test NN N
and CC N
angina NN N
diaries NNS N
. . N

The DT N
doses NNS N
100 CD N
mg JJ N
twice RB N
daily RB N
and CC N
50 CD N
mg NN N
, , N
100 CD N
mg NN N
and CC N
200 CD N
mg NN N
once RB N
daily JJ N
were VBD N
given VBN N
double-blind NNS N
and CC N
randomised VBD N
within IN N
patients NNS N
following VBG N
run-in NN N
on IN N
placebo NN 7_i
. . N

Measurements NNS N
were VBD N
made VBN N
12 CD N
hours NNS N
after IN N
the DT N
last JJ N
twice JJ N
daily RB N
dose JJ N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
last JJ N
once JJ N
daily JJ N
dose NN N
. . N

Exercise NN N
tolerance NN N
was VBD N
improved VBN N
by IN N
40-74 JJ N
% NN N
and CC N
exercise NN N
duration NN N
before IN N
the DT N
onset NN N
of IN N
angina NN N
by IN N
61-94 JJ N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Maximal JJ N
heart NN N
rate NN N
was VBD N
reduced VBN N
further RB N
by IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
200 CD N
mg NNS N
than IN N
by IN N
lower JJR N
doses NNS N
, , N
but CC N
no DT N
extra JJ N
benefit NN N
was VBD N
derived VBN N
by IN N
giving VBG N
the DT N
drug NN N
twice RB N
daily RB N
. . N

The DT N
largest JJS N
increase NN N
in IN N
exercise NN N
tolerance NN N
was VBD N
obtained VBN N
during IN N
treatment NN N
with IN N
50 CD N
mg NNS N
once RB N
daily RB N
. . N

Atenolol NNP 3_i
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ N
anti-anginal JJ N
agent NN N
when WRB N
given VBN N
once RB N
daily JJ N
, , N
and CC N
there EX N
were VBD N
no DT N
major JJ N
differences NNS N
between IN N
the DT N
doses NNS N
studied VBN N
. . N

-DOCSTART- -X- O O

Cryoprobe NNP 1_i
biopsy NN 1_i
increases VBZ N
the DT N
diagnostic JJ N
yield NN N
in IN N
endobronchial JJ N
tumor NN N
lesions NNS N
. . N

OBJECTIVE NNP N
Forceps NNP 1_i
biopsy NN 1_i
is VBZ N
the DT N
standard JJ N
method NN N
to TO N
obtain VB N
specimens NNS N
in IN N
endoscopically RB N
visible JJ N
lesions NNS N
. . N

It PRP N
is VBZ N
common JJ N
to TO N
combine VB N
forceps NNS 1_i
biopsy VB 1_i
with IN 1_i
cytology NN 1_i
methods NNS 1_i
to TO N
increase VB N
the DT N
diagnostic JJ N
yield NN N
. . N

Although IN N
the DT N
flexible JJ N
cryoprobe NN 1_i
has VBZ N
been VBN N
established VBN N
for IN N
bronchoscopic NN N
interventions NNS N
in IN N
malignant JJ N
stenosis NN N
, , N
the DT N
obtained JJ N
biopsies NNS N
, , N
called VBN N
cryobiopsies NNS N
, , N
have VBP N
not RB N
been VBN N
investigated VBN N
in IN N
a DT N
large JJ N
cohort NN N
of IN N
patients NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
feasibility NN N
study NN N
was VBD N
to TO N
prospectively RB N
evaluate VB N
the DT N
diagnostic JJ N
yield NN N
and CC N
safety NN N
of IN N
cryobiopsy NN 1_i
and CC N
forceps JJ 1_i
biopsy NN 1_i
. . N

METHODS NNP N
During IN N
a DT N
6-year JJ N
period NN N
, , N
296 CD N
patients NNS N
with IN N
visible JJ N
endoluminal JJ N
tumor NN N
lesions NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
at IN N
the DT N
bronchoscopy NN N
unit NN N
of IN N
a DT N
university NN N
hospital NN N
. . N

In IN N
the DT N
first JJ N
consecutively RB N
conducted VBN N
55 CD N
cases NNS N
, , N
both DT N
techniques NNS N
, , N
forceps NNS 1_i
biopsy NN 1_i
and CC N
cryobiopsy NN 1_i
, , N
were VBD N
applied VBN N
simultaneously RB N
. . N

Pathologic NNP N
and CC N
quantitative JJ N
image NN N
analyses NNS N
were VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
size NN N
and CC N
quality NN N
of IN N
the DT N
obtained VBN N
specimens NNS N
. . N

We PRP N
evaluated VBD N
the DT N
safety NN N
and CC N
diagnostic JJ N
yield NN N
to TO N
describe VB N
the DT N
feasibility NN N
of IN N
cryobiopsy NN 1_i
. . N

RESULTS NNP N
Comparative JJ N
analysis NN N
of IN N
the DT N
first JJ N
conducted VBN N
and CC N
randomly RB N
assigned VBD N
55 CD N
cases NNS N
revealed VBD N
a DT N
significantly RB N
higher RBR N
diagnostic JJ N
yield NN N
for IN N
cryobiopsy NN 1_i
compared VBN N
with IN N
forceps NNS 1_i
biopsy NNS 1_i
( ( N
89.1 CD N
% NN N
vs JJ N
65.5 CD N
% NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

In IN N
this DT N
cohort NN N
, , N
quantitative JJ N
image NN N
analysis NN N
showed VBD N
significantly RB N
larger JJR N
biopsies NNS N
regarding VBG N
size NN N
and CC N
artifact-free JJ N
tissue NN N
sections NNS N
for IN N
cryobiopsy NN 1_i
compared VBN N
with IN N
forceps NNS 1_i
biopsy NN 1_i
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

The DT N
overall JJ N
diagnostic JJ N
yield NN N
of IN N
cryobiopsy NN 1_i
was VBD N
89.5 CD N
% NN N
. . N

Mild NNP N
bleeding VBG N
occurred VBD N
in IN N
11 CD N
cases NNS N
( ( N
3.7 CD N
% NN N
) ) N
, , N
moderate JJ N
bleeding NN N
occurred VBD N
in IN N
3 CD N
cases NNS N
( ( N
1.0 CD N
% NN N
) ) N
, , N
and CC N
severe JJ N
bleeding NN N
occurred VBD N
in IN N
1 CD N
case NN N
( ( N
0.3 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Cryobiopsy NNP 1_i
is VBZ N
safe JJ N
and CC N
increases VBZ N
the DT N
diagnostic JJ N
yield NN N
in IN N
endobronchial JJ N
tumor NN N
lesions NNS N
. . N

The DT N
method NN N
also RB N
is VBZ N
feasible JJ N
under IN N
routine JJ N
conditions NNS N
. . N

-DOCSTART- -X- O O

Tactile NNP N
feedback NN N
is VBZ N
present JJ N
during IN N
minimally RB 1_i
invasive JJ 1_i
surgery NN 1_i
. . N

BACKGROUND IN N
The DT N
applications NNS N
of IN N
minimally RB 1_i
invasive JJ 1_i
surgery NN 1_i
( ( 1_i
MIS NNP 1_i
) ) 1_i
and CC N
laparoscopy $ 1_i
are VBP N
rapidly RB N
expanding VBG N
. . N

Despite IN N
this DT N
expansion NN N
, , N
our PRP$ N
understanding NN N
of IN N
the DT N
importance NN N
of IN N
haptic JJ N
feedback NN N
during IN N
laparoscopic NN 1_i
surgery NN 1_i
is VBZ N
incomplete JJ N
. . N

Although IN N
many JJ N
surgeons NNS N
believe VBP N
that IN N
the DT N
use NN N
of IN N
minimally RB 1_i
invasive JJ 1_i
techniques NNS 1_i
eliminates VBZ N
force VBP N
feedback NN N
and CC N
tactile JJ N
sensation NN N
( ( N
haptics NNS N
) ) N
, , N
the DT N
importance NN N
of IN N
haptics NNS N
in IN N
MIS NNP N
has VBZ N
not RB N
been VBN N
fully RB N
evaluated VBN N
. . N

There EX N
is VBZ N
considerable JJ N
interest NN N
in IN N
the DT N
development NN N
of IN N
simulators NNS N
for IN N
MIS NNP N
even RB N
though IN N
the DT N
importance NN N
of IN N
force NN N
feedback NN N
remains VBZ N
poorly RB N
understood JJ N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
ability NN N
of IN N
experienced JJ N
surgeons NNS N
to TO N
interpret VB N
haptic JJ N
feedback NN N
with IN N
respect NN N
to TO N
texture NN N
, , N
shape NN N
, , N
and CC N
consistency NN N
of IN N
an DT N
object NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized JJ N
, , N
single-blinded JJ N
study NN N
was VBD N
designed VBN N
. . N

Twenty CD N
surgeons NNS N
were VBD N
presented VBN N
objects NNS N
in IN N
a DT N
random NN N
order NN N
, , N
with IN N
participants NNS N
blinded VBN N
as IN N
to TO N
their PRP$ N
identity NN N
. . N

Inspection NN 2_i
by IN 2_i
direct JJ 2_i
palpation NN 2_i
, , N
conventional JJ 2_i
instruments NNS 2_i
, , N
and CC N
laparoscopic JJ 2_i
instruments NNS 2_i
was VBD N
performed VBN N
on IN N
all DT N
objects NNS N
. . N

Statistic JJ N
analysis NN N
of IN N
the DT N
data NN N
was VBD N
performed VBN N
using VBG N
chi-square JJ N
analysis NN N
and CC N
, , N
when WRB N
appropriate NN N
, , N
a DT N
Fischer NNP N
exact JJ N
probability NN N
test NN N
. . N

RESULTS NNP N
Direct NNP N
palpation NN N
was VBD N
associated VBN N
with IN N
the DT N
highest JJS N
accuracy NN N
for IN N
shape NN N
identification NN N
and CC N
was VBD N
superior VBN N
to TO N
both DT N
conventional JJ N
instruments NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
laparoscopic JJ N
instruments NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Fine JJ N
texture NN N
analysis NN N
with IN N
either CC N
a DT N
conventional JJ 2_i
instrument NN 2_i
or CC N
a DT N
laparoscopic JJ 2_i
instrument NN 2_i
was VBD N
superior JJ N
to TO N
direct JJ N
palpation NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Finally RB N
, , N
the DT N
three CD N
methods NNS N
of IN N
analysis NN N
were VBD N
comparable JJ N
for IN N
consistency NN N
analysis NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
indicate VBP N
that IN N
laparoscopic NN N
instruments NNS N
do VBP N
, , N
in IN N
fact NN N
, , N
provide VB N
surgeons NNS N
with IN N
haptic JJ N
feedback NN N
. . N

Interpretation NN N
of IN N
the DT N
texture NN N
, , N
shape NN N
, , N
and CC N
consistency NN N
of IN N
objects NNS N
can MD N
be VB N
performed VBN N
. . N

In IN N
some DT N
situations NNS N
, , N
laparoscopic JJ 1_i
instruments NNS 1_i
appear VBP N
to TO N
amplify VB N
the DT N
haptic JJ N
information NN N
available JJ N
. . N

Our PRP$ N
ongoing JJ N
work NN N
is VBZ N
directed VBN N
at IN N
further JJ N
defining VBG N
force NN N
interactions NNS N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
amantadine NN N
and CC N
pemoline NN N
on IN N
cognitive JJ N
functioning NN N
in IN N
multiple JJ N
sclerosis NN N
. . N

BACKGROUND NNP N
Amantadine NNP 3_i
hydrochloride NN 3_i
and CC N
pemoline NN N
, , N
both DT N
frequently RB N
used VBN N
to TO N
treat VB N
the DT N
fatigue NN N
of IN N
multiple JJ N
sclerosis NN N
( ( N
MS NNP N
) ) N
, , N
may MD N
also RB N
improve VB N
attention NN N
and CC N
other JJ N
cognitive JJ N
functions NNS N
in IN N
MS. NNP N
To TO N
our PRP$ N
knowledge NN N
, , N
these DT N
agents NNS N
have VBP N
never RB N
been VBN N
compared VBN N
in IN N
a DT N
placebo-controlled JJ N
trial NN N
of IN N
patients NNS N
with IN N
MS NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
amantadine NN 3_i
and CC 3_i
pemoline NN 3_i
on IN N
cognitive JJ N
functioning NN N
in IN N
MS. NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
45 CD N
ambulatory JJ N
patients NNS N
with IN N
MS NNP N
and CC N
severe JJ N
fatigue NN N
were VBD N
treated VBN N
for IN N
6 CD N
weeks NNS N
with IN N
amantadine NN N
, , N
pemoline NN N
, , N
or CC N
placebo NN 7_i
using VBG N
a DT N
parallel JJ N
group NN N
design NN N
. . N

They PRP N
underwent VBD N
comprehensive JJ N
neuropsychological JJ N
testing NN N
to TO N
determine VB N
treatment NN N
effects NNS N
on IN N
cognitive JJ N
functioning NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
tests NNS N
of IN N
attention NN N
( ( N
Digit NNP N
Span NNP N
, , N
Trail NNP N
Making NNP N
Test NNP N
, , N
and CC N
Symbol NNP N
Digit NNP N
Modalities NNP N
Test NNP N
) ) N
, , N
verbal JJ N
memory NN N
( ( N
Selective JJ N
Reminding NNP N
Test NNP N
) ) N
, , N
nonverbal JJ N
memory NN N
( ( N
Benton NNP N
Visual NNP N
Retention NNP N
Test NNP N
) ) N
, , N
and CC N
motor NN N
speed NN N
( ( N
Finger NNP N
Tapping NNP N
Test NNP N
) ) N
. . N

RESULTS NNP N
Fatigue NNP N
did VBD N
not RB N
significantly RB N
correlate VB N
with IN N
any DT N
of IN N
the DT N
neuropsychological JJ N
outcome NN N
measures NNS N
at IN N
baseline NN N
or CC N
after IN N
treatment NN N
. . N

All DT N
three CD N
treatment NN N
groups NNS N
improved VBN N
on IN N
tests NNS N
of IN N
attention NN N
( ( N
P NNP N
< NNP N
.003 NNP N
) ) N
, , N
verbal JJ N
memory NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
motor NN N
speed NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
amantadine NN N
, , N
pemoline NN N
, , N
and CC N
placebo NN N
. . N

CONCLUSIONS NNP N
Cognitive NNP N
functioning NN N
in IN N
MS NNP N
is VBZ N
independent JJ N
of IN N
fatigue NN N
. . N

Neither CC N
amantadine JJ 3_i
nor CC N
pemoline JJ 3_i
enhances NNS N
cognitive JJ N
performance NN N
in IN N
MS NNP N
compared VBN N
with IN N
placebo NN 7_i
. . 7_i

-DOCSTART- -X- O O

Direct JJ N
renin NN N
inhibition NN N
improves VBZ N
parasympathetic JJ N
function NN N
in IN N
diabetes NNS N
. . N

AIM VB N
The DT N
renin-angiotensin-aldosterone NN N
system NN N
( ( N
RAAS NNP N
) ) N
and CC N
autonomic JJ N
nervous JJ N
system NN N
regulate VB N
the DT N
cardiovascular JJ N
system NN N
. . N

Blockade NN N
of IN N
the DT N
RAAS NNP N
may MD N
slow VB N
the DT N
progression NN N
of IN N
end-organ JJ N
damage NN N
. . N

Direct JJ N
renin NN N
inhibition NN N
offers VBZ N
a DT N
means NN N
for IN N
blocking VBG N
the DT N
RAAS NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
direct JJ N
renin NN N
inhibition NN N
on IN N
cardiovascular JJ N
autonomic JJ N
function NN N
. . N

METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ 7_i
trial NN N
, , N
60 CD N
individuals NNS N
with IN N
diabetes NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
300 CD N
mg NN N
of IN N
aliskiren NN 3_i
or CC N
placebo NN 3_i
once RB N
daily JJ N
for IN N
6 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
a DT N
change NN N
in IN N
tests NNS N
of IN N
cardiovascular JJ N
autonomic JJ N
function NN N
. . N

Autonomic NNP N
function NN N
was VBD N
assessed VBN N
by IN N
power NN N
spectral JJ N
analysis NN N
and CC N
RR-variation NNP N
during IN N
deep JJ N
breathing NN N
[ JJ N
i.e NN N
. . N

mean VB N
circular JJ N
resultant NN N
( ( N
MCR NNP N
) ) N
, , N
expiration/inspiration NN N
( ( N
E/I NNP N
) ) N
ratio NN N
] NN N
. . N

The DT N
MCR NNP N
and CC N
E/I NNP N
ratio NN N
assess NN N
parasympathetic JJ N
function NN N
. . N

Secondary JJ N
measures NNS N
included VBD N
change NN N
in IN N
biochemical JJ N
parameters NNS N
[ VBP N
e.g NN N
. . N

plasma JJ N
renin NN N
activity NN N
, , N
leptin NN N
and CC N
interleukin-6 JJ N
] NN N
. . N

Change NN N
in IN N
cardiovascular JJ N
autonomic JJ N
function NN N
and CC N
blood NN N
analytes NNS N
were VBD N
analysed VBN N
by IN N
a DT N
mixed JJ N
effects NNS N
model NN N
for IN N
repeated JJ N
measures NNS N
. . N

RESULTS NNP N
Baseline NNP N
characteristics NNS N
were VBD N
similar JJ N
between IN N
treatment NN N
groups NNS N
. . N

In IN N
response NN N
to TO N
aliskiren NNS 3_i
compared VBN N
with IN N
placebo NN 7_i
, , N
blood NN N
pressure NN N
was VBD N
reduced VBN N
as RB N
well RB N
as IN N
plasma JJ N
renin NN N
activity NN N
[ VBP N
from IN N
2.4 CD N
? . N
3.8 CD N
( ( N
mean VB N
? . N
standard JJ N
deviation NN N
) ) N
to TO N
0.5 CD N
? . N
0.4 CD N
?g/l/h NN N
, , N
p NN N
< VBD N
0.001 CD N
] NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
( ( N
aliskiren VB N
? . N
visit NN N
) ) N
for IN N
MCR NNP N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
E/I NNP N
ratio NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
indicating VBG N
improvement NN N
in IN N
MCR NNP N
and CC N
E/I NNP N
ratio NN N
for IN N
those DT N
on IN N
aliskiren NNS N
. . N

MCR NNP N
means VBZ N
, , N
baseline VB N
vs. IN N
follow-up JJ N
, , N
were VBD N
41.8 CD N
? . N
19.7 CD N
vs. IN N
50.8 CD N
? . N
26.1 CD N
( ( N
aliskiren NN N
) ) N
and CC N
38.2 CD N
? . N
23.6 CD N
vs. IN N
37.5 CD N
? . N
24.1 CD N
( ( N
placebo NN N
) ) N
. . N

CONCLUSIONS NNP N
Parasympathetic NNP N
function NN N
( ( N
i.e JJ N
. . N

MCR NNP N
and CC N
E/I NNP N
ratio NN N
) ) N
was VBD N
enhanced VBN N
by IN N
downregulation NN N
of IN N
the DT N
RAAS NNP N
. . N

-DOCSTART- -X- O O

[ IN N
The DT N
efficacy NN N
of IN N
psychotherapy NN 2_i
with IN 2_i
biofeedback NN 2_i
in IN N
the DT N
rehabilitation NN N
of IN N
hypertension NN N
patients NNS N
] VBP N
. . N

85 CD N
females NNS N
with IN N
borderline JJ N
mental JJ N
disorders NNS N
in IN N
essential JJ N
hypertension NN N
were VBD N
followed VBN N
up RP N
for IN N
a DT N
month NN N
and CC N
6 CD N
months NNS N
after IN N
the DT N
treatment NN N
( ( N
hypotensive JJ 5_i
drugs NNS 5_i
+ VBP 5_i
psychotherapy NN 5_i
with IN 5_i
biofeedback NN 5_i
or CC 5_i
hypotensive JJ 5_i
drugs NNS 5_i
only RB 5_i
-- : 3_i
45 CD 3_i
patients NNS N
and CC N
40 CD N
controls NNS 7_i
, , N
respectively RB N
) ) N
. . N

The DT N
addition NN N
of IN N
psychotherapy NN N
to TO N
hypotensive VB N
drugs NNS N
contributed VBD N
to TO N
a DT N
higher JJR N
hypotensive JJ N
effect NN N
, , N
long-term JJ N
improvement NN N
of IN N
psychic JJ N
condition NN N
, , N
more RBR N
active JJ N
attitude NN N
to TO N
the DT N
treatment NN N
process NN N
and CC N
psychic JJ N
adaptation NN N
. . N

Better NNP N
quality NN N
of IN N
life NN N
was VBD N
achieved VBN N
. . N

-DOCSTART- -X- O O

Principal JJ N
results NNS N
of IN N
the DT N
Japanese JJ N
trial NN N
to TO N
assess VB N
optimal JJ N
systolic JJ N
blood NN N
pressure NN N
in IN N
elderly JJ N
hypertensive JJ N
patients NNS N
( ( N
JATOS NNP N
) ) N
. . N

The DT N
benefits NNS N
of IN N
lowering VBG N
a DT N
systolic JJ N
blood NN N
pressure NN N
below IN N
140 CD N
mmHg NN N
in IN N
elderly JJ N
hypertension NN N
remain VBP N
controversial JJ N
. . N

This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
with IN N
blinded JJ N
assessment NN N
of IN N
endpoints NNS N
to TO N
compare VB N
the DT N
2-year JJ N
effect NN N
of IN N
strict JJ 2_i
treatment NN 2_i
to TO 2_i
maintain VB 2_i
systolic JJ 2_i
blood NN 2_i
pressure NN 2_i
below IN N
140 CD N
mmHg NN N
with IN N
that DT N
of IN N
mild JJ 2_i
treatment NN 2_i
to TO 2_i
maintain VB 2_i
systolic JJ 2_i
blood NN 2_i
pressure NN 2_i
below IN N
160 CD N
but CC N
at IN N
or CC N
above IN N
140 CD N
mmHg NN N
in IN N
elderly JJ N
hypertensive JJ N
patients NNS N
. . N

Patients NNS N
with IN N
essential JJ N
hypertension NN N
( ( N
65-85 CD N
years NNS N
old JJ N
, , N
with IN N
a DT N
pretreatment JJ N
systolic JJ N
blood NN N
pressure NN N
of IN N
above IN N
160 CD N
mmHg NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
strict JJ 2_i
treatment NN 2_i
( ( N
n=2,212 JJ N
) ) N
or CC N
mild JJ 2_i
treatment NN 2_i
( ( N
n=2,206 JJ N
) ) N
. . N

The DT N
baseline JJ N
drug NN N
was VBD N
efonidipine JJ 2_i
hydrochloride NN 2_i
, , N
a DT N
long-acting JJ N
calcium NN N
antagonist NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
combined JJ N
incidence NN N
of IN N
cardiovascular JJ N
disease NN N
and CC N
renal JJ N
failure NN N
, , N
and CC N
the DT N
secondary JJ N
endpoints NNS N
were VBD N
total JJ N
deaths NNS N
and CC N
any DT N
safety NN N
problems NNS N
. . N

Although IN N
final JJ N
blood NN N
pressures NNS N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
strict-treatment JJ N
group NN N
compared VBN N
with IN N
the DT N
mild-treatment JJ N
group NN N
( ( N
135.9/74.8 CD N
vs. FW N
145.6/78.1 CD N
mmHg NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
, , N
the DT N
incidence NN N
of IN N
the DT N
primary JJ N
endpoint NN N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
86 CD N
patients NNS N
in IN N
each DT N
group NN N
; : N
p=0.99 NN N
) ) N
. . N

Total JJ N
deaths NNS N
were VBD N
54 CD N
in IN N
the DT N
strict-treatment JJ N
group NN N
vs. FW N
42 CD N
in IN N
the DT N
mild-treatment JJ N
group NN N
( ( N
p=0.22 NN N
) ) N
, , N
and CC N
treatment NN N
was VBD N
withdrawn VBN N
because IN N
of IN N
adverse JJ N
events NNS N
in IN N
36 CD N
patients NNS N
in IN N
each DT N
group NN N
( ( N
p=0.99 NN N
) ) N
. . N

An DT N
interaction NN N
between IN N
age NN N
and CC N
treatment NN N
for IN N
the DT N
primary JJ N
endpoints NNS N
( ( N
p=0.03 NN N
) ) N
was VBD N
seen VBN N
. . N

Complex NNP N
clinical JJ N
features NNS N
associated VBN N
with IN N
aging VBG N
seem VBP N
to TO N
have VB N
obscured VBN N
the DT N
difference NN N
in IN N
effect NN N
between IN N
the DT N
two CD N
treatments NNS N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
assess VB N
the DT N
optimal JJ N
treatment NN N
strategy NN N
for IN N
hypertension NN N
in IN N
the DT N
elderly JJ N
. . N

-DOCSTART- -X- O O

Beneficial JJ N
effect NN N
of IN N
etidronate NN 3_i
therapy NN 3_i
in IN N
chronically RB N
hospitalized VBN N
, , N
disabled JJ N
patients NNS N
with IN N
stroke NN N
. . N

Incidence NN N
of IN N
hip NN N
fractures NNS N
is VBZ N
high JJ N
in IN N
chronically RB N
hospitalized VBN N
, , N
disabled VBD N
, , N
elderly JJ N
patients NNS N
after IN N
stroke NN N
. . N

Duration NN N
of IN N
hospitalization NN N
was VBD N
more JJR N
than IN N
1 CD N
year NN N
because IN N
of IN N
insufficiency NN N
of IN N
nursing NN N
homes NNS N
. . N

Our PRP$ N
study NN N
showed VBD N
that IN N
immobilization-induced JJ N
hypercalcemia NN N
and CC N
25-hydroxyvitamin JJ N
D NNP N
deficiency NN N
contribute NN N
to TO N
reduced VB N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
address VB N
the DT N
possibility NN N
that WDT N
treatment NN N
with IN N
etidronate NN 3_i
may MD N
reduce VB N
the DT N
bone NN N
resorption NN N
and CC N
lower JJR N
the DT N
incidence NN N
of IN N
fractures NNS N
in IN N
elderly JJ N
patients NNS N
who WP N
are VBP N
chronically RB N
hospitalized VBN N
and CC N
disabled VBN N
as IN N
a DT N
result NN N
of IN N
hemiparesis NN N
after IN N
stroke NN N
. . N

Patients NNS N
with IN N
stroke NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
daily VB N
treatment NN N
with IN N
400 CD N
mg NNS N
of IN N
etidronate NN 3_i
( ( N
n JJ N
= NNP N
40 CD N
) ) N
or CC N
a DT N
placebo NN 7_i
( ( N
n JJ N
= NNP N
40 CD N
) ) N
, , N
and CC N
followed VBD N
up RB N
for IN N
2 CD N
years NNS N
. . N

At IN N
baseline NN N
, , N
both DT N
groups NNS N
had VBD N
low JJ N
BMD NNP N
with IN N
high JJ N
levels NNS N
of IN N
serum NN N
ionized VBN N
calcium NN N
and CC N
urinary JJ N
deoxypyridinoline NN N
. . N

In IN N
the DT N
etidronate NN 3_i
group NN N
, , N
serum NN N
calcium NN N
and CC N
urinary JJ N
deoxypyridinoline NN N
levels NNS N
decreased VBN N
significantly RB N
during IN N
the DT N
study NN N
period NN N
, , N
whereas IN N
the DT N
levels NNS N
in IN N
the DT N
placebo NN 7_i
group NN N
were VBD N
increased VBN N
. . N

BMD NNP N
on IN N
the DT N
hemiplegic JJ N
side NN N
increased VBN N
by IN N
1.4 CD N
% NN N
in IN N
the DT N
etidronate NN N
group NN N
and CC N
decreased VBN N
by IN N
2.2 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Two CD N
patients NNS N
sustained VBD N
hip JJ N
fractures NNS N
in IN N
the DT N
placebo NN 7_i
group NN N
, , N
and CC N
no DT N
hip NN N
fracture NN N
occurred VBD N
in IN N
the DT N
etidronate NN 3_i
group NN N
. . N

Treatment NN N
with IN N
etidronate NN 3_i
increases NNS N
BMD NNP N
in IN N
chronically RB N
hospitalized VBN N
patients NNS N
poststroke VBD N
, , N
and CC N
may MD N
prevent VB N
hip NN N
fracture NN N
. . N

-DOCSTART- -X- O O

Sulfadoxine/pyrimethamine NNP 3_i
alone RB 3_i
or CC 3_i
with IN 3_i
amodiaquine JJ 3_i
or CC 3_i
artesunate NN 3_i
for IN N
treatment NN N
of IN N
uncomplicated JJ N
malaria NNS N
: : N
a DT N
longitudinal JJ N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
New NNP N
antimalarial JJ N
treatments NNS N
are VBP N
urgently RB N
needed VBN N
in IN N
sub-Saharan JJ N
Africa NNP N
. . N

Improved NNP N
therapies NNS N
should MD N
decrease VB N
failure NN N
rates NNS N
in IN N
the DT N
short JJ N
term NN N
, , N
but CC N
their PRP$ N
effect NN N
on IN N
incidence NN N
of IN N
subsequent JJ N
episodes NNS N
of IN N
malaria NN N
is VBZ N
little JJ N
studied JJ N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
short-term JJ N
and CC N
long-term JJ N
effectiveness NN N
of IN N
three CD N
antimalarial JJ N
regimens NNS N
in IN N
children NNS N
from IN N
Kampala NNP N
, , N
Uganda NNP N
. . N

METHODS NNP N
We PRP N
randomly RB N
allocated VBD N
healthy JJ N
children NNS N
aged VBD N
6 CD N
months NNS N
to TO N
5 CD N
years NNS N
to TO N
receive VB N
25 CD 3_i
mg/kg JJ 3_i
sulfadoxine NN 3_i
and CC 3_i
1.25 CD 3_i
mg/kg NN 3_i
pyrimethamine NN 3_i
plus CC 3_i
either DT 3_i
placebo NN 3_i
, , 3_i
25 CD 3_i
mg/kg NN 3_i
amodiaquine NN 3_i
, , 3_i
or CC 3_i
12 CD 3_i
mg/kg JJ 3_i
artesunate NN 3_i
. . 3_i

Participants NNS N
were VBD N
followed VBN N
up RP N
for IN N
1 CD N
year NN N
and CC N
received VBD N
the DT N
same JJ N
preassigned JJ N
treatment NN N
for IN N
every DT N
new JJ N
episode NN N
of IN N
uncomplicated JJ N
malaria NNS N
diagnosed VBN N
during IN N
follow-up JJ N
. . N

Recrudescent NNP N
and CC N
new JJ N
infections NNS N
were VBD N
distinguished VBN N
by IN N
comparison NN N
of IN N
polymorphisms NNS N
in IN N
merozoite JJ N
surface NN N
protein NN N
2 CD N
( ( N
MSP2 NNP N
) ) N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
the DT N
total JJ N
number NN N
of IN N
treatments NNS N
for IN N
malaria NNS N
per IN N
time NN N
at IN N
risk NN N
. . N

Analyses NNS N
were VBD N
done VBN N
per IN N
protocol NN N
. . N

FINDINGS $ N
183 CD N
( ( N
61 CD N
% NN N
) ) N
of IN N
316 CD N
participants NNS N
were VBD N
diagnosed VBN N
with IN N
at IN N
least JJS N
one CD N
episode NN N
of IN N
uncomplicated JJ N
malaria NN N
. . N

A DT N
total NN N
of IN N
577 CD N
episodes NNS N
of IN N
uncomplicated JJ N
Plasmodium NNP N
falciparum NN N
malaria NNS N
were VBD N
treated VBN N
with IN N
study NN N
drugs NNS N
; : N
all DT N
regimens NNS N
were VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

Clinical JJ N
treatment NN N
failure NN N
after IN N
14 CD N
days NNS N
was VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
the DT N
sulfadoxine/pyrimethamine NN N
group NN N
( ( N
38 CD N
of IN N
215 CD N
, , N
18 CD N
% NN N
) ) N
compared VBN N
with IN N
either CC N
the DT N
sulfadoxine/pyrimethamine NN N
plus CC N
amodiaquine JJ N
group NN N
( ( N
two CD N
of IN N
164 CD N
, , N
1 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
or CC N
sulfadoxine/pyrimethamine JJ N
plus CC N
artesunate JJ N
group NN N
( ( N
one CD N
of IN N
198 CD N
, , N
1 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

After IN N
28 CD N
and CC N
42 CD N
days NNS N
, , N
patients NNS N
in IN N
the DT N
sulfadoxine/pyrimethamine NN N
plus CC N
amodiaquine JJ N
group NN N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
develop VB N
malaria NNS N
than IN N
were VBD N
those DT N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Overall NNP N
, , N
sulfadoxine/pyrimethamine NN N
plus CC N
amodiaquine NN N
reduced VBD N
the DT N
rate NN N
of IN N
subsequent JJ N
treatments NNS N
for IN N
malaria NN N
by IN N
54 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
36-66 CD N
, , N
p VBZ N
< NNP N
0.0001 CD N
) ) N
compared VBN N
with IN N
sulfadoxine/ JJ N
pyrimethamine NN N
alone RB N
and CC N
by IN N
37 CD N
% NN N
( ( N
12-54 JJ N
, , N
p=0.007 NN N
) ) N
compared VBN N
with IN N
sulfadoxine/pyrimethamine JJ N
plus JJ N
artesunate NN N
. . N

INTERPRETATION NNP N
Sulfadoxine/pyrimethamine NNP N
plus CC N
amodiaquine NN N
could MD N
be VB N
used VBN N
as IN N
an DT N
inexpensive JJ N
regimen NNS N
to TO N
decrease VB N
the DT N
rate NN N
of IN N
subsequent JJ N
episodes NNS N
of IN N
malaria NN N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
progressive JJ 4_i
muscle NN 4_i
relaxation NN 4_i
training NN 4_i
of IN N
patients NNS N
after IN N
stoma NN N
surgery NN N
. . N

Eighteen JJ N
patients NNS N
who WP N
had VBD N
undergone JJ N
stoma NN N
surgery NN N
were VBD N
assessed VBN N
with IN N
respect NN N
to TO N
their PRP$ N
anxiety NN N
level NN N
and CC N
self-reported JJ N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
on IN N
three CD N
occasions NNS N
; : N
namely RB N
, , N
immediately RB N
after IN N
surgery NN N
, , N
5 CD N
weeks NNS N
after IN N
surgery NN N
, , N
and CC N
10 CD N
weeks NNS N
after IN N
surgery NN N
. . N

The DT N
patients NNS N
were VBD N
randomised VBN N
into IN N
a DT N
control NN 4_i
group NN 4_i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
and CC N
an DT N
experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
. . N

A DT N
20-min JJ 4_i
set NN 4_i
of IN 4_i
audiotaped JJ 4_i
instructions NNS 4_i
on IN 4_i
progressive JJ 4_i
muscle NN 4_i
relaxation NN 4_i
training NN 4_i
( ( 4_i
PMRT NNP 4_i
) ) 4_i
was VBD N
given VBN N
to TO N
the DT N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
for IN N
home NN N
practice NN N
. . N

Assessment NNP N
instructions NNS N
included VBD N
the DT N
Chinese JJ N
State-Trait NNP N
Anxiety NNP N
Inventory NNP N
( ( N
C-STAI NNP N
) ) N
, , N
the DT N
Quality NN N
of IN N
Life NNP N
Index NNP N
for IN N
Colostomy NNP N
( ( N
QoL-Colostomy NNP N
) ) N
and CC N
the DT N
Hong NNP N
Kong NNP N
Chinese JJ N
version NN N
of IN N
the DT N
World NNP N
Health NNP N
Organisation NNP N
Quality NNP N
of IN N
Life NNP N
Scale NNP N
( ( N
WHOQoL NNP N
) ) N
. . N

Results NNS N
indicated VBD N
that IN N
there EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
both DT N
the DT N
C-STAI NNP N
score NN N
( ( N
F NNP N
= NNP N
4.66 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
the DT N
WHOQoL NNP N
score NN N
( ( N
F NNP N
= NNP N
4.74 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
. . N

Among IN N
the DT N
domains NNS N
of IN N
WHOQoL NNP N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
shown VBN N
in IN N
physical JJ N
health/independence NN N
and CC N
general JJ N
perception NN N
of IN N
QoL NNP N
, , N
with IN N
the DT N
experimental JJ N
group NN N
demonstrating VBG N
better JJR N
functioning NN N
. . N

For IN N
the DT N
QoL-Colostomy NNP N
, , N
however RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
control NN N
and CC N
experimental JJ N
groups NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
PMRT NNP 4_i
could MD N
enhance VB N
quality NN N
of IN N
life NN N
and CC N
decrease NN N
state NN N
anxiety NN N
in IN N
patients NNS N
after IN N
stoma NN N
surgery NN N
. . N

-DOCSTART- -X- O O

Mortality NN N
in IN N
patients NNS N
with IN N
small JJ N
choroidal NNS N
melanoma NN N
. . N

COMS NNP N
report NN N
no DT N
. . N

4 CD N
. . N

The DT N
Collaborative JJ N
Ocular NNP N
Melanoma NNP N
Study NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
describe VB N
the DT N
clinical JJ N
characteristics NNS N
and CC N
survival JJ N
experience NN N
of IN N
a DT N
prospectively RB N
followed VBN N
up RP N
group NN N
of IN N
patients NNS N
with IN N
small JJ N
choroidal NNS N
melanoma NN N
. . N

METHODS NNP N
The DT N
Collaborative NNP N
Ocular NNP N
Melanoma NNP N
Study NNP N
( ( N
COMS NNP N
) ) N
is VBZ N
a DT N
set NN N
of IN N
clinical JJ N
trials NNS N
designed VBN N
to TO N
compare VB N
the DT N
role NN N
of IN N
radiotherapy NN 2_i
and CC N
enucleation NN 2_i
in IN N
the DT N
treatment NN N
of IN N
medium NN N
and CC N
large-size JJ N
choroidal NN N
melanoma NN N
. . N

From IN N
December NNP N
1986 CD N
to TO N
August NNP N
1989 CD N
, , N
patients NNS N
with IN N
small JJ N
choroidal NN N
melanoma NN N
, , N
not RB N
large JJ N
enough RB N
to TO N
be VB N
eligible JJ N
for IN N
the DT N
COMS NNP N
clinical JJ N
trials NNS N
, , N
were VBD N
offered VBN N
participation NN N
in IN N
a DT N
nonrandomized JJ N
prospective JJ N
follow-up NN N
study NN N
. . N

Small NNP N
choroidal JJ N
melanomas NN N
were VBD N
defined VBN N
as IN N
1.0 CD N
to TO N
3.0 CD N
mm NNS N
in IN N
apical JJ N
height NN N
and CC N
at IN N
least JJS N
5.0 CD N
mm NN N
in IN N
basal NN N
diameter NN N
. . N

A DT N
total NN N
of IN N
204 CD N
patients NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

Patients NNS N
were VBD N
followed VBN N
up RP N
annually RB N
through IN N
August NNP N
1989 CD N
. . N

Two CD N
additional JJ N
assessments NNS N
of IN N
treatment NN N
status NN N
and CC N
mortality NN N
were VBD N
conducted VBN N
in IN N
1993-1994 JJ N
and CC N
1995-1996 JJ N
. . N

The DT N
median JJ N
length NN N
of IN N
follow-up NN N
was VBD N
92 CD N
months NNS N
. . N

Eight NNP N
percent NN N
of IN N
patients NNS N
were VBD N
treated VBN N
at IN N
the DT N
time NN N
of IN N
study NN N
enrollment NN N
and CC N
an DT N
additional JJ N
33 CD N
% NN N
were VBD N
treated VBN N
during IN N
follow-up JJ N
. . N

RESULTS JJ N
Twenty-seven JJ N
patients NNS N
have VBP N
died VBN N
; : N
6 CD N
deaths NNS N
were VBD N
reported VBN N
by IN N
the DT N
clinical JJ N
center NN N
as IN N
due JJ N
to TO N
metastatic JJ N
melanoma NN N
. . N

The DT N
Kaplan-Meier NNP N
estimate NN N
of IN N
5-year JJ N
all-cause JJ N
mortality NN N
was VBD N
6.0 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
2.7 CD N
% NN N
-9.3 NNP N
% NN N
) ) N
and CC N
8-year JJ N
all-cause NN N
mortality NN N
was VBD N
14.9 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
9.6 CD N
% NN N
-20.2 NNP N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Otherwise NNP N
healthy JJ N
patients NNS N
, , N
average JJ N
age NN N
of IN N
60 CD N
years NNS N
, , N
without IN N
a DT N
previous JJ N
diagnosis NN N
of IN N
malignant JJ N
disease NN N
who WP N
have VBP N
small JJ N
choroidal JJ N
lesions NNS N
judged VBD N
to TO N
be VB N
melanoma VBN N
have VBP N
a DT N
low JJ N
risk NN N
of IN N
dying VBG N
within IN N
5 CD N
years NNS N
. . N

-DOCSTART- -X- O O

Ropivacaine NNP 3_i
versus NN N
lidocaine NN 3_i
in IN N
digital JJ N
nerve NN N
blocks NNS N
: : N
a DT N
prospective JJ N
study NN N
. . N

BACKGROUND NNP N
Ropivacaine NNP 3_i
is VBZ N
a DT N
relatively RB N
new JJ N
long-acting JJ N
amide JJ N
local JJ N
anesthetic NN N
. . N

Since IN N
its PRP$ N
introduction NN N
in IN N
1996 CD N
, , N
it PRP N
has VBZ N
been VBN N
used VBN N
for IN N
subcutaneous JJ N
infiltration NN N
; : N
epidural JJ N
, , N
intrathecal JJ N
, , N
and CC N
peripheral JJ N
nerve NN N
block NN N
surgery NN N
; : N
and CC N
postoperative JJ N
analgesia NN N
. . N

However RB N
, , N
it PRP N
has VBZ N
never RB N
been VBN N
used VBN N
for IN N
digital JJ N
blocks NNS N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
compares VBZ N
the DT N
digital JJ N
block NN N
results NNS N
following VBG N
the DT N
administration NN N
of IN N
2.5 CD 3_i
ml NN 3_i
of IN 3_i
0.75 CD 3_i
% NN 3_i
ropivacaine JJ 3_i
solution NN 3_i
and CC N
2.5 CD 3_i
ml NN 3_i
of IN 3_i
2 CD 3_i
% NN 3_i
lidocaine JJ 3_i
solution NN 3_i
. . N

METHODS NN N
From IN N
March NNP N
of IN N
1999 CD N
to TO N
March NNP N
of IN N
2001 CD N
, , N
70 CD N
adult NN N
patients NNS N
who WP N
underwent VBP N
immediate JJ N
reconstruction NN 1_i
for IN 1_i
traumatic JJ 1_i
injuries NNS 1_i
of IN 1_i
the DT 1_i
digits NNS 1_i
were VBD N
prospectively RB N
randomized VBN N
into IN N
two CD N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
received VBD N
2.5 CD N
ml NNS N
0.75 CD N
% NN N
ropivacaine NN 3_i
and CC N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
received VBD N
2.5 CD N
ml NN N
of IN N
2 CD N
% NN N
lidocaine NN 3_i
for IN N
digital JJ N
anesthesia NN N
. . N

Onset NNP N
time NN N
of IN N
anesthetic JJ N
action NN N
, , N
duration NN N
of IN N
anesthesia NN N
, , N
time NN N
until IN N
first JJ N
postoperative JJ N
requirement NN N
for IN N
pain NN N
medication NN N
, , N
and CC N
digital-brachial JJ N
artery NN N
systolic JJ N
blood NN N
pressure NN N
index NN N
were VBD N
recorded VBN N
and CC N
evaluated VBN N
. . N

Local JJ N
vascular JJ N
effects NNS N
were VBD N
observed VBN N
visually RB N
. . N

RESULTS NNP N
No NNP N
side JJ N
effects NNS N
were VBD N
observed VBN N
. . N

Lidocaine NNP 3_i
had VBD N
the DT N
quickest JJS N
onset NN N
of IN N
anesthesia NN N
, , N
with IN N
a DT N
mean JJ N
time NN N
of IN N
1.3 CD N
minutes NNS N
( ( N
range NN N
, , N
1 CD N
to TO N
2.7 CD N
minutes NNS N
) ) N
. . N

Ropivacaine NNP 3_i
had VBD N
a DT N
mean JJ N
onset NN N
time NN N
of IN N
4.5 CD N
minutes NNS N
( ( N
range NN N
, , N
3.5 CD N
to TO N
5.5 CD N
minutes NNS N
) ) N
. . N

The DT N
mean JJ N
duration NN N
of IN N
postoperative JJ N
anesthesia NN N
for IN N
lidocaine NN 3_i
was VBD N
2.4 CD N
hours NNS N
( ( N
range NN N
, , N
1.4 CD N
to TO N
4 CD N
hours NNS N
) ) N
, , N
compared VBN N
with IN N
21.5 CD N
hours NNS N
for IN N
ropivacaine NN 3_i
and CC N
less RBR N
requirement NN N
for IN N
analgesics NNS N
during IN N
the DT N
first JJ N
24 CD N
postoperative JJ N
hours NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
( ( N
range NN N
, , N
19 CD N
to TO N
23 CD N
hours NNS N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
digital-brachial JJ N
artery NN N
systolic JJ N
blood NN N
pressure NN N
index NN N
of IN N
group NN N
A NNP N
compared VBN N
with IN N
group NN N
B NNP N
. . N

CONCLUSIONS NNP N
Ropivacaine NNP 3_i
can MD N
be VB N
used VBN N
effectively RB N
as IN N
a DT N
local JJ N
anesthetic NN N
for IN N
digital JJ N
nerve NN N
blocks NNS N
. . N

It PRP N
can MD N
be VB N
used VBN N
for IN N
prolonged JJ N
operations NNS N
( ( N
> $ N
1.5 CD N
hours NNS N
) ) N
without IN N
additional JJ N
injections NNS N
and CC N
can MD N
provide VB N
long-lasting JJ N
postoperative JJ N
analgesia NN N
. . N

-DOCSTART- -X- O O

Improvement NN N
in IN N
sensory JJ N
impairment NN N
and CC N
social JJ N
interaction NN N
in IN N
young JJ N
children NNS N
with IN N
autism NN N
following VBG N
treatment NN N
with IN N
an DT N
original JJ 6_i
Qigong NNP 6_i
massage NN 6_i
methodology NN 6_i
. . N

In IN N
clinical JJ N
research NN N
, , N
sensory JJ N
impairment NN N
is VBZ N
considered VBN N
one CD N
of IN N
the DT N
core NN N
deficits NNS N
in IN N
autism NN N
and CC N
is VBZ N
associated VBN N
with IN N
impaired JJ N
socialization NN N
, , N
behavioral JJ N
disturbances NNS N
and CC N
bowel NN N
and CC N
sleep JJ N
problems NNS N
. . N

The DT N
effectiveness NN N
of IN N
the DT N
Cignolini NNP 6_i
methodology NN 6_i
, , 2_i
an DT 2_i
original JJ 6_i
Qigong NNP 6_i
massage NN 6_i
methodology NN 6_i
, , N
in IN N
treating VBG N
sensory JJ N
impairment NN N
in IN N
young JJ N
children NNS N
with IN N
autism NN N
was VBD N
evaluated VBN N
in IN N
a DT N
small JJ N
, , N
controlled VBN N
study NN N
. . N

Thirteen NNP N
children NNS N
with IN N
autism NN N
between IN N
the DT N
ages NNS N
of IN N
three CD N
and CC N
six CD N
received VBD N
daily JJ N
treatment NN N
according VBG N
to TO N
the DT N
methodology NN N
for IN N
5 CD N
months NNS N
. . N

Compared VBN N
with IN N
untreated JJ N
children NNS N
, , N
treated VBD N
children NNS N
experienced VBD N
significant JJ N
improvement NN N
of IN N
their PRP$ N
sensory JJ N
impairment NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
demonstrated VBD N
increased VBN N
social JJ N
skills NNS N
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
and CC N
basic JJ N
living NN N
skills NNS N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
on IN N
standardized JJ N
measures NNS N
. . N

In IN N
addition NN N
, , N
all DT N
of IN N
the DT N
children NNS N
with IN N
bowel NN N
and CC N
sleep JJ N
abnormalities NNS N
demonstrated VBD N
improvement NN N
after IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Recurrent NNP N
ulcer NN N
after IN N
successful JJ N
treatment NN N
with IN N
cimetidine NN 3_i
or CC N
antacid NN 3_i
. . 3_i

This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
rates NNS N
of IN N
duodenal JJ N
ulcer NN N
healing NN N
and CC N
recurrence NN N
after IN N
treatment NN N
with IN N
cimetidine NN 3_i
or CC N
antacid NN 3_i
. . N

Patients NNS N
with IN N
endoscopically RB N
documented VBN N
duodenal JJ N
ulcer NN N
received VBD N
cimetidine NN 3_i
, , N
1200 CD N
mg NN N
daily RB N
, , N
or CC N
Mylanta NNP 3_i
II NNP 3_i
, , N
7 CD N
oz JJ N
daily RB N
, , N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
. . N

For IN N
the DT N
69 CD N
patients NNS N
in IN N
each DT N
group NN N
who WP N
completed VBD N
the DT N
healing VBG N
phase NN N
of IN N
the DT N
trial NN N
, , N
endoscopic JJ N
ulcer NN N
healing NN N
was VBD N
almost RB N
identical JJ N
. . N

At IN N
2 CD N
, , N
4 CD N
, , N
and CC N
6 CD N
wk NN N
, , N
the DT N
cumulative JJ N
percent NN N
healed VBD N
on IN N
antacid NN 3_i
was VBD N
33 CD N
% NN N
, , N
64 CD N
% NN N
, , N
and CC N
80 CD N
% NN N
, , N
and CC N
on IN N
cimetidine NN 3_i
it PRP N
was VBD N
25 CD N
% NN N
, , N
62 CD N
% NN N
, , N
and CC N
86 CD N
% NN N
. . N

The DT N
114 CD N
patients NNS N
with IN N
healed JJ N
ulcer NN N
were VBD N
observed VBN N
on IN N
no DT N
therapy NN N
and CC N
underwent JJ N
additional JJ N
endoscopy NN N
to TO N
detect VB N
recurrences NNS N
when WRB N
symptomatic JJ N
or CC N
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
mo NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
frequency NN N
of IN N
recurrences NNS N
between IN N
treatments NNS N
. . N

At IN N
3 CD N
and CC N
6 CD N
mo NN N
, , N
the DT N
cumulative JJ N
percentages NNS N
of IN N
patients NNS N
with IN N
recurrence NN N
were VBD N
29 CD N
% NN N
and CC N
56 CD N
% NN N
after IN N
antacid JJ 2_i
therapy NN N
and CC N
36 CD N
% NN N
and CC N
55 CD N
% NN N
after IN N
cimetidine JJ 3_i
therapy NN N
. . N

Some DT N
patient JJ N
variables NNS N
were VBD N
associated VBN N
with IN N
delayed JJ N
ulcer NN N
healing NN N
or CC N
ulcer JJ N
recurrence NN N
. . N

These DT N
included VBD N
sex NN N
, , N
pain NN N
frequency NN N
, , N
smoking NN N
, , N
disease NN N
duration NN N
, , N
and CC N
acid JJ N
secretion NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
double-blind NN N
study NN N
of IN N
atomoxetine JJ 3_i
versus NN N
placebo NN 7_i
for IN N
attention-deficit/hyperactivity NN N
disorder NN N
symptoms NNS N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

OBJECTIVE CC N
The DT N
efficacy NN N
of IN N
atomoxetine NN 3_i
as IN N
treatment NN N
of IN N
symptoms NNS N
of IN N
attention-deficit/hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
in IN N
patients NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
has VBZ N
not RB N
been VBN N
established VBN N
. . N

METHOD NNP N
In IN N
this DT N
study NN N
, , N
97 CD N
patients NNS N
aged VBD N
6 CD N
to TO N
17 CD N
years NNS N
with IN N
ADHD NNP N
and CC N
ASD NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
double-blind VB N
treatment NN N
with IN N
1.2 CD N
mg/kg/day JJ N
atomoxetine NN 3_i
or CC N
placebo NN 7_i
for IN N
8 CD N
weeks NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
ADHD NNP N
Rating NNP N
Scale NNP N
( ( N
ADHD-RS NNP N
) ) N
score NN N
; : N
secondary JJ N
endpoints NNS N
were VBD N
the DT N
Clinical JJ N
Global NNP N
Impression NNP N
of IN N
ADHD-Improvement NNP N
( ( N
CGI-I NNP N
) ) N
and CC N
the DT N
Conners NNP N
Teacher NNP N
Rating VBG N
Scale-Revised JJ N
: : N
Short JJ N
Form NNP N
( ( N
CTRS-R JJ N
: : N
S NN N
) ) N
score NN N
. . N

RESULTS NNP N
Baseline NNP N
mean JJ N
ADHD-RS NNP N
scores NNS N
for IN N
atomoxetine JJ 3_i
versus NN N
placebo NN 7_i
were VBD N
40.7 CD N
and CC N
38.6 CD N
; : N
after IN N
8 CD N
weeks NNS N
, , N
mixed-effect JJ N
model NN N
repeated-measure NN N
means NNS N
were VBD N
31.6 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
29.2-33.9 JJ N
) ) N
and CC N
38.3 CD N
( ( N
36.0-40.6 CD N
) ) N
, , N
respectively RB N
, , N
with IN N
a DT N
difference NN N
in IN N
least JJS N
square JJ N
means NNS N
of IN N
-6.7 NNP N
( ( N
-10.0 UH N
to TO N
-3.4 VB N
; : N
p CC N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
CTRS-R JJ N
: : N
S NNP N
Hyperactivity NNP N
subscore NN N
also RB N
improved VBN N
significantly RB N
for IN N
atomoxetine NN 3_i
compared VBN N
with IN N
placebo NN 7_i
, , N
but CC N
not RB N
the DT N
other JJ N
CTRS-R JJ N
: : N
S JJ N
subscores NNS N
. . N

However RB N
, , N
there EX N
were VBD N
not RB N
significantly RB N
more RBR N
patients NNS N
on IN N
atomoxetine NN 3_i
( ( N
20.9 CD N
% NN N
) ) N
who WP N
improved VBD N
much RB N
, , N
or CC N
very RB N
much JJ N
according VBG N
to TO N
the DT N
CGI-I NNP N
, , N
than IN N
on IN N
placebo NN 7_i
( ( N
8.7 CD N
% NN N
; : N
p CC N
= VB N
0.14 CD N
) ) N
. . N

Adverse JJ N
events NNS N
( ( N
mostly RB N
nausea RB N
, , N
decrease NN N
in IN N
appetite NN N
, , N
fatigue NN N
, , N
and CC N
early JJ N
morning NN N
awakening VBG N
) ) N
were VBD N
reported VBN N
in IN N
81.3 CD N
% NN N
of IN N
atomoxetine JJ 3_i
patients NNS N
and CC N
65.3 CD N
% NN N
of IN N
placebo NN N
patients NNS N
( ( N
p JJ N
> NNP N
.1 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ N
events NNS N
. . N

CONCLUSIONS NNP N
Atomoxetine NNP 3_i
moderately RB N
improved VBD N
ADHD NNP N
symptoms NNS N
in IN N
patients NNS N
with IN N
ASD NNP N
and CC N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

Adverse JJ N
events NNS N
in IN N
this DT N
study NN N
were VBD N
similar JJ N
to TO N
those DT N
in IN N
other JJ N
studies NNS N
with IN N
ADHD NNP N
patients NNS N
without IN N
ASD NNP N
. . N

Clinical JJ N
trial NN N
registration NN N
information-A JJ N
Randomized NNP N
Double-Blind NNP N
Study NNP N
of IN N
Atomoxetine NNP 3_i
Versus NNP N
Placebo NNP N
for IN N
ADHD NNP N
Symptoms NNP N
in IN N
Children NNP N
with IN N
ASD NNP N
; : N
www.clinicaltrials.gov NN N
; : N
NCT00380692 NNP N
. . N

-DOCSTART- -X- O O

Comparative JJ N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
metronidazole JJ 3_i
application NN N
in IN N
adult NN N
periodontitis NN N
; : N
12-months JJ N
results NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
application NN N
of IN N
25 CD N
% NN N
metronidazole JJ 3_i
dental JJ 3_i
gel NN 3_i
as IN N
an DT N
adjunct NN N
to TO N
scaling NN 2_i
and CC 2_i
root NN 2_i
planing NN 2_i
( ( 2_i
SRP NNP 2_i
) ) 2_i
in IN N
the DT N
treatment NN N
of IN N
adult NN N
periodontitis NN N
. . N

Eighty NNP N
teeth VBZ N
in IN N
18 CD N
patients NNS N
were VBD N
evaluated VBN N
using VBG N
a DT N
split NN N
mouth NN N
design NN N
. . N

The DT N
test NN N
teeth NN N
received VBD N
SRP NNP 2_i
and CC N
a DT N
25 CD N
% NN N
metronidazole JJ 3_i
gel NN 3_i
applied VBN N
subgingivally RB N
on IN N
days NNS N
0 CD N
and CC N
7 CD N
. . N

The DT N
control NN N
teeth VBZ N
received VBN N
SRP NNP 7_i
only RB 7_i
. . N

Clinical JJ N
and CC N
microbiological JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
treatment NN N
and CC N
on IN N
weeks NNS N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
13 CD N
, , N
26 CD N
, , N
38 CD N
and CC N
52 CD N
of IN N
the DT N
experimental JJ N
period NN N
. . N

Colony NNP N
forming VBG N
units NNS N
of IN N
Porphyromonas NNP N
gingivalis NN N
and CC N
Prevotella NNP N
intermedia VBP N
/ NNP N
Prevotella NNP N
nigrescens NNS N
were VBD N
determined VBN N
. . N

Both DT N
treatments NNS N
provided VBD N
significant JJ N
improvements NNS N
in IN N
all PDT N
the DT N
clinical JJ N
and CC N
microbiological JJ N
parameters NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
none NN N
of IN N
the DT N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
were VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

As IN N
a DT N
conclusion NN N
, , N
the DT N
present JJ N
study NN N
does VBZ N
not RB N
provide VB N
evidence NN N
in IN N
favour NN N
of IN N
the DT N
routine JJ N
use NN N
of IN N
adjunctive JJ N
metronidazole JJ N
dental NN N
gel NN N
in IN N
the DT N
treatment NN N
of IN N
adult NN N
periodontitis NN N
. . N

-DOCSTART- -X- O O

Analgesic JJ N
efficacy NN N
of IN N
piroxicam NN 3_i
in IN N
the DT N
treatment NN N
of IN N
postoperative JJ N
pain NN N
. . N

Two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
single-dose JJ N
studies NNS N
were VBD N
conducted VBN N
to TO N
assess VB N
the DT N
analgesic JJ N
efficacy NN N
and CC N
safety NN N
of IN N
piroxicam NN 3_i
for IN N
the DT N
treatment NN N
of IN N
moderate JJ N
or CC N
severe JJ N
postoperative JJ N
pain NN N
. . N

Study NNP N
1 CD N
evaluated VBD N
the DT N
analgesic JJ N
efficacy NN N
of IN N
piroxicam NN 3_i
20 CD N
mg NN N
compared VBN N
with IN N
that DT N
of IN N
codeine NN 3_i
sulfate NN 3_i
60 CD N
mg NN N
and CC N
placebo NN 7_i
. . N

A DT N
final JJ N
patient NN N
population NN N
of IN N
149 CD N
subjects NNS N
rated VBN N
pain JJ N
intensity NN N
and CC N
pain NN N
relief NN N
at IN N
one CD N
half NN N
hour NN N
and CC N
one CD N
hour NN N
following VBG N
treatment NN N
and CC N
then RB N
hourly RB N
for IN N
six CD N
hours NNS N
, , N
with IN N
a DT N
global JJ N
assessment NN N
made VBN N
at IN N
the DT N
completion NN N
of IN N
24 CD N
hours NNS N
. . N

Piroxicam NNP 3_i
20 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
efficacious JJ N
than IN N
placebo NN 7_i
for IN N
all DT N
analgesic JJ N
variables NNS N
, , N
including VBG N
the DT N
sum NN N
of IN N
the DT N
pain NN N
intensity NN N
differences NNS N
( ( N
SPID NNP N
) ) N
, , N
total JJ N
pain NN N
relief NN N
( ( N
TOTAL NNP N
) ) N
, , N
percent JJ N
SPID NNP N
, , N
duration NN N
of IN N
effect NN N
, , N
and CC N
time NN N
to TO N
remedication NN N
. . N

Codeine VB 3_i
60 CD N
mg NN N
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB N
for IN N
percent NN N
SPID NNP N
and CC N
some DT N
hourly JJ N
measures NNS N
. . N

Piroxicam NNP 3_i
20 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
codeine VBP 3_i
60 CD N
mg NN N
for IN N
percent NN N
SPID NNP N
and CC N
a DT N
few JJ N
hourly JJ N
measures NNS N
including VBG N
time NN N
to TO N
remedication NN N
. . N

Study NNP N
2 CD N
assessed VBD N
the DT N
efficacy NN N
of IN N
piroxicam NN 3_i
20 CD N
mg NN N
or CC N
40 CD N
mg NNS N
compared VBN N
with IN N
aspirin JJ 3_i
648 CD N
mg NN N
and CC N
placebo NN N
. . N

Sixty CD N
patients NNS N
rated VBN N
their PRP$ N
pain NN N
intensity NN N
and CC N
relief NN N
hourly RB N
for IN N
12 CD N
hours NNS N
and CC N
at IN N
24 CD N
hours NNS N
after IN N
administration NN N
of IN N
study JJ N
medication NN N
. . N

Both DT N
doses NNS N
of IN N
piroxicam NN 3_i
were VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN N
from IN N
Hours $ N
2 CD N
to TO N
12 CD N
for IN N
pain NN N
intensity NN N
difference NN N
( ( N
PID NNP N
) ) N
and CC N
relief NN N
scores NNS N
, , N
as RB N
well RB N
as IN N
for IN N
SPID NNP N
and CC N
TOTAL NNP N
. . N

Aspirin NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN N
from IN N
Hours $ N
2 CD N
to TO N
8 CD N
for IN N
relief NN N
and CC N
Hours $ N
2 CD N
to TO N
10 CD N
for IN N
PID NNP N
as RB N
well RB N
as IN N
SPID NNP N
and CC N
TOTAL NNP N
. . N

Piroxicam NNP 3_i
40 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
aspirin RB 3_i
648 CD N
mg NN N
for IN N
SPID NNP N
, , N
TOTAL NNP N
, , N
and CC N
hourly RB N
measures NNS N
beginning VBG N
with IN N
Hour NNP N
6 CD N
through IN N
Hour NNP N
12 CD N
. . N

Piroxicam VB 3_i
20 CD N
mg NN N
was VBD N
significantly RB N
better JJR N
than IN N
aspirin NN 3_i
for IN N
a DT N
few JJ N
hourly JJ N
measures NNS N
: : N
Hours $ N
7 CD N
to TO N
9 CD N
for IN N
relief NN N
and CC N
Hour $ N
7 CD N
for IN N
PID NNP N
. . N

In IN N
addition NN N
, , N
effects NNS N
of IN N
piroxicam NN N
20 CD N
mg NN N
had VBD N
a DT N
significantly RB N
longer JJR N
duration NN N
than IN N
aspirin NN N
. . N

Similarly RB N
, , N
piroxicam VBD 3_i
20 CD N
mg NN N
had VBD N
a DT N
significantly RB N
longer JJR N
time NN N
to TO N
remedication VB N
compared VBN N
with IN N
aspirin NN 3_i
and CC N
placebo NN N
. . N

The DT N
results NNS N
of IN N
these DT N
studies NNS N
provide VBP N
evidence NN N
in IN N
support NN N
of IN N
the DT N
longer JJR N
duration NN N
of IN N
analgesic JJ N
efficacy NN N
of IN N
piroxicam NNS 3_i
compared VBN N
with IN N
codeine NN 3_i
or CC N
aspirin NN 3_i
in IN N
patients NNS N
with IN N
postoperative JJ N
pain NN N
. . N

-DOCSTART- -X- O O

Activation NN N
of IN N
the DT N
carotid NN N
chemoreflex JJ N
secondary JJ N
to TO N
muscle VB N
metaboreflex JJ N
stimulation NN N
in IN N
men NNS N
. . N

Recent JJ N
work NN N
has VBZ N
shown VBN N
that IN N
the DT N
carotid NN N
chemoreceptor NN N
( ( N
CC NNP N
) ) N
contributes VBZ N
to TO N
sympathetic VB N
control NN N
of IN N
cardiovascular JJ N
function NN N
during IN N
exercise NN N
, , N
despite IN N
no DT N
evidence NN N
of IN N
increased JJ N
circulating VBG N
CC NNP N
stimuli NN N
, , N
suggesting VBG N
enhanced VBN N
CC NNP N
activity/sensitivity NN N
. . N

As IN N
interactions NNS N
between IN N
metaboreceptors NNS N
and CC N
chemoreceptors NNS N
have VBP N
been VBN N
previously RB N
observed VBN N
, , N
the DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
isolate VB N
the DT N
metaboreflex NN N
while IN N
acutely RB N
stimulating VBG N
or CC N
inhibiting VBG N
the DT N
CC NNP N
to TO N
determine VB N
whether IN N
the DT N
metaboreflex NN N
increased VBD N
CC NNP N
activity/sensitivity NN N
. . N

Fourteen NNP N
young JJ N
healthy JJ N
men NNS N
( ( N
height NN N
: : N
177.0 CD N
? . N
2.1 CD N
cm NN N
, , N
weight NN N
: : N
85.8 CD N
? . N
5.5 CD N
kg NN N
, , N
age NN N
: : N
24.6 CD N
? . N
1.1 CD N
yr NN N
) ) N
performed VBD N
three CD N
trials NNS N
of IN N
40 CD N
% NN N
maximal JJ N
voluntary JJ N
contraction NN N
handgrip NN N
for IN N
2 CD N
min NN N
, , N
followed VBN N
by IN N
3 CD N
min NN N
of IN N
postexercise NN N
circulatory NN N
occlusion NN N
( ( N
PECO NNP N
) ) N
to TO N
stimulate VB N
the DT N
metaboreflex NN N
. . N

In IN N
random JJ N
order NN N
, , N
subjects VBZ N
either CC N
breathed JJ N
room NN N
air NN N
, , N
hypoxia NN N
( ( N
target VB N
SPo2 NNP N
= NNP N
85 CD N
% NN N
) ) N
, , N
or CC N
hyperoxia NN N
( ( N
FiO2 NNP N
= NNP N
1.0 CD N
) ) N
during IN N
the DT N
PECO NNP N
to TO N
modulate VB N
the DT N
chemoreflex NN N
. . N

After IN N
these DT N
trials NNS N
, , N
a DT N
resting VBG N
hypoxia JJ N
trial NN N
was VBD N
conducted VBN N
without IN N
handgrip NN N
or CC N
PECO NNP N
. . N

Ventilation NNP N
( ( N
Ve NNP N
) ) N
, , N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
, , N
blood NN N
pressure NN N
, , N
and CC N
muscle NN N
sympathetic JJ N
nervous JJ N
activity NN N
( ( N
MSNA NNP N
) ) N
data NNS N
were VBD N
continuously RB N
obtained VBN N
. . N

Relative JJ N
to TO N
normoxic JJ N
PECO NNP N
, , N
inhibition NN N
of IN N
the DT N
CC NNP N
during IN N
hyperoxic JJ N
PECO NNP N
resulted VBD N
in IN N
lower JJR N
MSNA NNP N
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
and CC N
HR NNP N
( ( N
P NNP N
= NNP N
0.021 CD N
) ) N
. . N

Relative JJ N
to TO N
normoxic JJ N
PECO NNP N
, , N
stimulation NN N
of IN N
the DT N
CC NNP N
during IN N
hypoxic JJ N
PECO NNP N
resulted VBD N
in IN N
higher JJR N
HR NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
Ve NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
ventilatory NN N
and CC N
MSNA NNP N
responses NNS N
to TO N
hypoxic VB N
PECO NNP N
were VBD N
not RB N
greater JJR N
than IN N
the DT N
sum NN N
of IN N
the DT N
responses NNS N
to TO N
hypoxia VB N
and CC N
PECO NNP N
individually RB N
, , N
indicating VBG N
that IN N
the DT N
CC NNP N
are VBP N
not RB N
sensitized VBN N
during IN N
metaboreflex JJ N
activation NN N
. . N

These DT N
results NNS N
demonstrate VBP N
that IN N
stimulation NN N
of IN N
the DT N
metaboreflex NN N
activates VBZ N
, , N
but CC N
does VBZ N
not RB N
sensitize VB N
the DT N
CC NNP N
, , N
and CC N
help NN N
explain VB N
the DT N
enhanced JJ N
CC NNP N
activity NN N
with IN N
exercise NN N
. . N

-DOCSTART- -X- O O

Befriending NNP 4_i
as IN N
an DT N
intervention NN N
for IN N
chronic JJ N
depression NN N
among IN N
women NNS N
in IN N
an DT N
inner JJ N
city NN N
. . N

2 CD N
: : N
Role NN N
of IN N
fresh-start JJ N
experiences NNS N
and CC N
baseline JJ N
psychosocial JJ N
factors NNS N
in IN N
remission NN N
from IN N
depression NN N
. . N

BACKGROUND NNP N
Volunteer NNP 4_i
befriending NN 4_i
promoted VBD N
remission NN N
of IN N
chronic JJ N
depression NN N
when WRB N
clinical JJ N
and CC N
other JJ N
treatment NN N
variables NNS N
were VBD N
controlled VBN N
. . N

AIMS NNP N
To TO N
examine VB N
the DT N
role NN N
of IN N
other JJ N
psychosocial JJ N
factors NNS N
relevant VBP N
for IN N
outcome NN N
. . N

METHOD NNP N
Factors NNPS N
measured VBD N
at IN N
baseline NN N
interview NN N
were VBD N
examined VBN N
in IN N
multivariate NN N
analyses NNS N
along IN N
with IN N
psychosocial JJ N
factors NNS N
occurring VBG N
during IN N
follow-up JJ N
, , N
such JJ N
as IN N
'fresh-start JJ 4_i
' POS 4_i
experiences NNS 4_i
and CC N
new JJ N
severe JJ N
events NNS N
and CC N
difficulties NNS N
. . N

RESULTS NNP N
Fresh-start JJ N
experiences NNS N
and CC N
a DT N
standard JJ N
attachment NN N
style NN N
were VBD N
found VBN N
to TO N
enhance VB N
chances NNS N
of IN N
remission NN N
, , N
with IN N
new JJ N
severe JJ N
stressors NNS N
and CC N
markedly RB N
poor JJ N
coping VBG N
strategies NNS N
liable JJ N
to TO N
prevent VB N
it PRP N
, , N
with IN N
volunteer NN N
befriending VBG 4_i
continuing VBG N
to TO N
play VB N
a DT N
role NN N
. . N

CONCLUSIONS VB N
The DT N
positive JJ N
result NN N
reported VBN N
in IN N
the DT N
preceding JJ N
paper NN N
is VBZ N
unlikely JJ N
to TO N
be VB N
an DT N
artefact NN N
. . N

However RB N
, , N
fresh-start JJ N
experiences NNS N
, , N
absence NN N
of IN N
new JJ N
severe JJ N
stressors NNS N
and CC N
standard JJ N
attachment NN N
style NN N
were VBD N
more RBR N
important JJ N
predictors NNS N
of IN N
remission NN N
. . N

This DT N
knowledge NN N
might MD N
profitably RB N
be VB N
incorporated VBN N
into IN N
the DT N
evaluation NN N
of IN N
existing VBG N
treatments NNS N
. . N

-DOCSTART- -X- O O

Lengthening VBG N
the DT N
moment NN N
arm NN N
of IN N
the DT N
patella NN N
confers NNS N
enhanced VBD N
extensor NN N
mechanism NN N
power NN N
following VBG N
total JJ N
knee JJ N
arthroplasty NN N
. . N

We PRP N
investigated VBD N
whether IN N
a DT N
postulated JJ N
biomechanical JJ N
advantage NN N
conferred VBD N
to TO N
the DT N
extensor NN N
mechanism NN N
by IN N
a DT N
change NN N
in IN N
knee NN N
implant JJ N
design NN N
was VBD N
detectable JJ N
in IN N
patients NNS N
by IN N
direct JJ N
physical JJ N
testing NN N
. . N

212 CD N
TKA JJ N
patients NNS N
were VBD N
enrolled VBN N
in IN N
a DT N
double JJ N
blind NN N
randomized VBD N
controlled VBN N
trial NN N
to TO N
receive VB N
either CC N
a DT N
traditional JJ 2_i
implant NN 2_i
or CC 2_i
one CD 2_i
which WDT 2_i
incorporated VBD 2_i
new JJ 2_i
design NN 2_i
features NNS 2_i
. . N

Extensor NNP N
mechanism NN N
power NN N
output NN N
and CC N
physical JJ N
performance NN N
on IN N
a DT N
battery NN N
of IN N
timed JJ N
functional JJ N
activities NNS N
was VBD N
assessed VBN N
pre-operatively RB N
and CC N
then RB N
at IN N
6 CD N
, , N
26 CD N
, , N
and CC N
52 CD N
weeks NNS N
post-operatively RB N
. . N

Significantly RB N
enhanced JJ N
power NN N
output NN N
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
post-arthroplasty VBP N
; : N
however RB N
, , N
the DT N
new JJ 2_i
design NN 2_i
implant JJ 2_i
group NN N
demonstrated VBD N
a DT N
greater JJR N
change NN N
in IN N
power NN N
output NN N
than IN N
the DT N
traditional JJ 2_i
implant NN 2_i
group NN N
. . N

Posthoc NNP N
testing VBG N
of IN N
between IN N
group NN N
differences NNS N
highlighted VBD N
greater JJR N
improvement NN N
at IN N
all DT N
post-operative JJ N
assessments NNS N
. . N

At IN N
52 CD N
weeks NNS N
, , N
patients NNS N
receiving VBG N
the DT N
implant NN N
with IN N
the DT N
postulated JJ N
biomechanical JJ N
advantage NN N
achieved VBD N
116 CD N
% NN N
of IN N
the DT N
power NN N
output NN N
of IN N
their PRP$ N
contralateral JJ N
limb NN N
, , N
whereas JJ N
patients NNS N
with IN N
the DT N
traditional JJ N
design NN N
achieved VBD N
90 CD N
% NN N
. . N

No DT N
between IN N
group NN N
difference NN N
was VBD N
detected VBN N
in IN N
the DT N
patient NN N
's POS N
time NN N
to TO N
complete VB N
functional JJ N
tasks NNS N
. . N

Thus RB N
, , N
patients NNS N
receiving VBG N
a DT N
knee NN 2_i
implant NN 2_i
of IN 2_i
a DT 2_i
modern JJ 2_i
design NN 2_i
( ( N
theoretically RB N
able JJ N
to TO N
confer VB N
a DT N
mechanical JJ N
advantage NN N
to TO N
the DT N
extensor NN N
mechanism NN N
) ) N
were VBD N
found VBN N
to TO N
generate VB N
significantly RB N
greater JJR N
extensor NN N
power NN N
than IN N
those DT N
receiving VBG N
a DT N
traditional JJ 2_i
implant NN 2_i
without IN N
the DT N
postulated JJ N
mechanical JJ N
advantage NN N
. . N

-DOCSTART- -X- O O

Combined VBN N
therapy NN N
for IN N
obese JJ N
type NN N
2 CD N
diabetes NNS N
: : N
suppertime NN 3_i
mixed JJ 3_i
insulin NN 3_i
with IN 3_i
daytime JJ 3_i
sulfonylurea NN 3_i
. . N

Combined VBN 3_i
insulin NN 3_i
and CC 3_i
sulfonylurea JJ 3_i
therapy NN 3_i
for IN N
type NN N
2 CD N
diabetes NNS N
may MD N
improve VB N
the DT N
effectiveness NN N
of IN N
a DT N
single JJ N
injection NN 3_i
of IN 3_i
insulin NN 3_i
, , N
thereby RB N
postponing VBG N
the DT N
need NN N
for IN N
multiple JJ N
injections NNS N
. . N

This DT N
concept NN N
was VBD N
tested VBN N
in IN N
21 CD N
obese JJ N
subjects NNS N
imperfectly RB N
controlled VBN N
by IN N
20 CD 3_i
mg NNS 3_i
of IN 3_i
glyburide JJ 3_i
daily JJ 3_i
in IN N
a DT N
double JJ N
masked VBN N
, , N
placebo-controlled JJ 7_i
, , N
parallel JJ N
design NN N
, , N
16-week JJ N
protocol NN N
. . N

Premixed CC N
70 CD N
% NN N
NPH/30 NNP N
% NN N
Regular NNP 3_i
insulin NN 3_i
was VBD N
taken VBN N
before RB N
supper JJ N
, , N
and CC N
the DT N
dosage NN N
was VBD N
adjusted VBN N
weekly RB N
by IN N
an DT N
algorithm NN N
seeking VBG N
nearly RB N
normal JJ N
fasting VBG N
glycemia NN N
. . N

Eleven JJ N
subjects NNS N
using VBG N
insulin NN 3_i
plus CC 3_i
10 CD N
mg NNS N
glyburide NN 3_i
before IN N
breakfast NN N
had VBD N
lower JJR N
mean NN N
fasting VBG N
glucose NN N
at IN N
10-16 JJ N
weeks NNS N
than IN N
10 CD N
subjects NNS N
using VBG N
insulin NN N
with IN N
placebo NN 7_i
( ( N
mean JJ N
+/- JJ N
SEM NNP N
; : N
5.9 CD N
+/- JJ N
0.3 CD N
versus NN N
7.5 CD N
+/- JJ N
0.7 CD N
mmol/L NN N
; : N
p CC N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
and CC N
had VBD N
a DT N
greater JJR N
decrement NN N
of IN N
glycosylated JJ N
hemoglobin NN N
from IN N
baseline NN N
values NNS N
( ( N
1.3 CD N
+/- JJ N
0.1 CD N
versus NN N
0.8 CD N
+/- JJ N
0.2 CD N
% NN N
A1 NNP N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

After IN N
16 CD N
weeks NNS N
the DT N
combined JJ N
therapy NN N
group NN N
used VBD N
half NN N
as IN N
much JJ N
insulin NN N
as IN N
the DT N
insulin-only JJ N
group NN N
( ( N
50 CD N
+/- JJ N
5 CD N
versus NN N
101 CD N
+/- JJ N
13 CD N
units/d NN N
; : N
p CC N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Fasting VBG N
serum JJ N
free JJ N
insulin NN N
values NNS N
increased VBD N
58 CD N
% NN N
from IN N
baseline NN N
after IN N
insulin NN N
therapy NN N
in IN N
the DT N
insulin-only JJ N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.05 CD N
) ) N
but CC N
did VBD N
not RB N
increase VB N
with IN N
combined JJ N
therapy NN N
. . N

Weight NNP N
gain NN N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

These DT N
data NNS N
support NN N
this DT N
form NN N
of IN N
combined JJ N
therapy NN N
as IN N
one CD N
option NN N
for IN N
treating VBG N
obese JJ N
persons NNS N
with IN N
type JJ N
2 CD N
diabetes VBZ N
no RB N
longer RBR N
responsive VB N
to TO N
oral JJ N
therapy NN N
alone RB N
. . N

-DOCSTART- -X- O O

[ JJ N
Pharmacological NNP N
correction NN N
of IN N
free JJ N
radical JJ N
disturbances NNS N
and CC N
endotoxicosis NN N
in IN N
patients NNS N
with IN N
diffuse NN N
peritonitis NN N
at IN N
the DT N
postoperative JJ N
period NN N
] NNP N
. . N

The DT N
examination NN N
and CC N
treatment NN N
of IN N
64 CD N
patients NNS N
have VBP N
shown VBN N
that IN N
inclusion NN N
of IN N
complex JJ 3_i
antioxidant NN 3_i
cytoflavin NN 3_i
in IN N
intensive JJ N
therapy NN N
at IN N
the DT N
postoperative JJ N
period NN N
of IN N
diffuse NN N
peritonitis NN N
allows VBZ N
the DT N
hypoxia NN N
degree NN N
to TO N
be VB N
decreased VBN N
that IN N
in IN N
its PRP$ N
turn NN N
results NNS N
in IN N
quicker JJ N
recovery NN N
of IN N
the DT N
antioxidant JJ N
system NN N
and CC N
decreased JJ N
activity NN N
of IN N
peroxidation NN N
and CC N
endotoxicosis NN N
level NN N
. . N

The DT N
clinical JJ N
course NN N
of IN N
the DT N
postoperative JJ N
period NN N
of IN N
diffuse NN N
peritonitis NN N
with IN N
cytoflavin NN 3_i
included VBN N
in IN N
intensive JJ N
therapy NN N
is VBZ N
characterized VBN N
by IN N
shorter JJR N
terms NNS N
of IN N
artificial JJ N
lung NN N
ventilation NN N
, , N
shorter JJR N
time NN N
of IN N
staying VBG N
in IN N
critical JJ N
condition NN N
, , N
more RBR N
favorable JJ N
course NN N
of IN N
complications NNS N
. . N

-DOCSTART- -X- O O

Learning VBG N
curve NN N
in IN N
multidetector NN 2_i
CT NNP 2_i
coronary JJ 2_i
angiography NN 2_i
( ( N
MDCT-CA NNP N
) ) N
. . N

PURPOSE NNP N
Coronary NNP 2_i
angiography NN 2_i
using VBG 2_i
multidetector NN 2_i
computed VBD 2_i
tomography NN 2_i
( ( 2_i
MDCT-CA NNP 2_i
) ) 2_i
is VBZ N
a DT N
recent JJ N
technique NN N
for IN N
the DT N
nonivasive JJ N
study NN N
of IN N
coronary JJ N
arteries NNS N
. . N

This DT N
study NN N
assessed VBD N
the DT N
diagnostic JJ N
accuracy NN N
of IN N
coronary JJ N
artery NN N
stenosis NN N
evaluation NN N
obtained VBN N
by IN N
three CD N
readers NNS N
at IN N
different JJ N
levels NNS N
of IN N
training NN N
or CC N
at IN N
different JJ N
points NNS N
of IN N
the DT N
learning VBG N
curve NN N
proposed VBN N
by IN N
the DT N
international JJ N
guidelines NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Three NNP N
radiologists VBZ N
in IN N
training VBG N
with IN N
different JJ N
levels NNS N
of IN N
experience NN N
in IN N
MDCT-CA NNP N
scored VBD N
50 CD N
cases NNS N
at IN N
various JJ N
time NN N
points NNS N
of IN N
the DT N
learning VBG N
curve NN N
: : N
baseline NN N
, , N
4 CD N
weeks NNS N
, , N
8 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
. . N

The DT N
trainee NN N
radiologists VBZ N
evaluated VBD N
the DT N
degree NN N
of IN N
stenosis NN N
on IN N
each DT N
coronary JJ N
segment NN N
, , N
and CC N
overall JJ N
accuracy NN N
was VBD N
calculated VBN N
on IN N
a DT N
per-segment JJ N
, , N
pervessel JJ N
and CC N
per-patient JJ N
basis NN N
. . N

RESULTS NNP N
All NNP N
readers NNS N
improved VBD N
analysis NN N
accuracy NN N
per IN N
segment NN N
( ( N
range NN N
, , N
73-90 CD N
% NN N
) ) N
; : N
sensitivity NN N
reached VBD N
45 CD N
% NN N
per IN N
segment NN N
, , N
84 CD N
% NN N
per IN N
vessel NN N
and CC N
93 CD N
% NN N
per IN N
patient NN N
; : N
specificity NN N
was VBD N
99 CD N
% NN N
per IN N
segment NN N
and CC N
vessel NN N
and CC N
98 CD N
% NN N
per IN N
patient NN N
. . N

Positive JJ N
and CC N
negative JJ N
predictive JJ N
values NNS N
increased VBD N
to TO N
94 CD N
% NN N
and CC N
92 CD N
% NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Although IN N
all DT N
readers NNS N
improved VBN N
in IN N
diagnostic JJ N
performance NN N
with IN N
growing VBG N
experience NN N
with IN N
MDCT-CA NNP N
, , N
a DT N
longer RBR 4_i
training JJ 4_i
period NN 4_i
may MD N
be VB N
necessary JJ N
to TO N
achieve VB N
adequate JJ N
levels NNS N
of IN N
expertise NN N
in IN N
MDCT-CA NNP N
to TO N
be VB N
able JJ N
to TO N
perform VB N
as IN N
independent JJ N
readers NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
conjugated JJ 3_i
linoleic JJ 3_i
acid NN 3_i
supplementation NN 3_i
and CC N
exercise NN 4_i
on IN N
post-heparin JJ N
lipoprotein NN N
lipase NN N
, , N
butyrylcholinesterase NN N
, , N
blood NN N
lipid JJ N
profile NN N
and CC N
glucose JJ N
metabolism NN N
in IN N
young JJ N
men NNS N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
conjugated JJ 3_i
linoleic JJ 3_i
acid NN 3_i
( ( 3_i
CLA NNP 3_i
) ) 3_i
supplementation NN 3_i
and CC N
endurance NN 4_i
exercise NN 4_i
training-induced JJ N
changes NNS N
on IN N
post-heparin JJ N
lipoprotein NN N
lipase NN N
( ( N
PH-LPL NNP N
) ) N
and CC N
butyrylcholinesterase NN N
( ( N
BChE NNP N
) ) N
activities NNS N
along IN N
with IN N
leptin NN N
, , N
insulin NN N
and CC N
lipid JJ N
levels NNS N
in IN N
plasma NN N
by IN N
a DT N
randomized JJ N
double JJ N
blind NN N
experiment NN N
. . N

Eighteen NNP N
sedentary JJ N
male NN N
volunteers NNS N
were VBD N
randomly RB 4_i
divided VBN N
into IN N
CLA NNP 3_i
and CC N
Placebo NNP 7_i
( ( 7_i
PLC NNP 7_i
) ) 7_i
supplementation NN N
groups NNS N
. . N

Both DT N
groups NNS N
underwent JJ N
daily JJ N
supplementation NN N
of IN N
either CC N
3g CD N
CLA NNP 3_i
or CC N
3g CD N
placebo NN 7_i
for IN N
30 CD N
days NNS N
, , N
respectively RB N
, , N
and CC N
performed VBD 2_i
exercise NN 2_i
on IN 2_i
a DT 2_i
bicycle NN 2_i
ergometer NN 2_i
3 CD 2_i
times NNS 2_i
per IN 2_i
week NN 2_i
for IN 2_i
30-40 JJ 2_i
min NN 2_i
at IN 2_i
50 CD 2_i
% NN 2_i
VO2 NNP 2_i
peak NN 2_i
workload NN 2_i
. . N

For IN N
plasma NN N
glucose NN N
, , N
insulin NN N
and CC N
leptin NN N
levels NNS N
and CC N
BChE NNP N
activity NN N
fasting VBG N
blood NN N
was VBD N
used VBN N
. . N

For IN N
PH-LPL JJ N
measurements NNS N
, , N
blood NN N
was VBD N
collected VBN N
15 CD N
min NNS N
after IN N
50 CD N
IU/kg NNP N
iv NN N
heparin NN N
injection NN N
. . N

In IN N
all DT N
groups NNS N
, , N
there EX N
is VBZ N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
BChE NNP N
( ( N
p JJ N
= NN N
0.03 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
and CC N
leptin $ N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
, , N
insulin JJ N
and CC N
HOMA-IR JJ N
levels NNS N
( ( N
p VB N
= RB N
0.02 CD N
) ) N
. . N

Exercise NN N
with IN N
or CC N
without IN N
CLA NNP 3_i
supplementation NN N
decreased VBD N
insulin NN N
levels NNS N
and CC N
increased VBD N
insulin NN N
sensitivity NN N
. . N

PH-LPL JJ N
activity NN N
was VBD N
increased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
displaying VBG N
increased VBN N
fatty JJ N
acid JJ N
mobilization NN N
. . N

We PRP N
conclude VBP N
that IN N
though IN N
CLA NNP 3_i
supplementation NN N
and CC N
exercise NN N
can MD N
affect VB N
these DT N
parameters NNS N
, , N
CLA NNP 3_i
is VBZ N
not RB N
more RBR N
effective JJ N
than IN N
exercise NN N
alone RB N
. . N

Hence NNP N
, , N
a DT N
prolonged JJ N
supplementation NN N
regime NN N
may MD N
be VB N
more RBR N
effective JJ N
. . N

Taken VB N
together RB N
in IN N
our PRP$ N
small JJ N
study NN N
group NN N
, , N
our PRP$ N
findings NNS N
display VBP N
that IN N
BChE NNP N
is VBZ N
a DT N
potential JJ N
marker NN N
for IN N
synthetic JJ N
function NN N
of IN N
liver NN N
, , N
fat JJ N
metabolism NN N
, , N
an DT N
obesity NN N
marker NN N
, , N
a DT N
function NN N
long RB N
overlooked VBD N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
prophylactic JJ 4_i
management NN 4_i
and CC 4_i
therapeutics NNS 4_i
on IN N
hypertensive JJ N
disease NN N
in IN N
pregnancy NN N
: : N
preliminary JJ N
studies NNS N
. . N

A DT N
controlled JJ N
prospective JJ N
evaluation NN N
of IN N
pregnancy NN N
complicated VBN N
by IN N
chronic JJ N
hypertension NN N
is VBZ N
proposed VBN N
and CC N
preliminary JJ N
data NNS N
on IN N
population NN N
selection NN N
and CC N
pregnancy NN N
outcome NN N
are VBP N
presented VBN N
. . N

Sixty-three JJ N
women NNS N
with IN N
evidence NN N
of IN N
underlying VBG N
hypertensive JJ N
disease NN N
were VBD N
followed VBN N
prospectively RB N
throughout IN N
pregnancy NN N
. . N

Twenty-three JJ N
patients NNS N
were VBD N
followed VBN N
in IN N
a DT N
protocol NN N
of IN N
intensified JJ N
prenatal JJ N
care NN N
and CC N
randomized JJ N
assignment NN N
of IN N
antihypertensive JJ 3_i
agents NNS 3_i
: : 3_i
placebo NN 3_i
, , 3_i
hydralazine NN 3_i
, , 3_i
or CC 3_i
methyldopa NN 3_i
. . N

Forty CD N
patients NNS N
were VBD N
followed VBN N
in IN N
the DT N
high-risk JJ N
pregnancy NN N
clinics NNS N
at IN N
Duke NNP N
University NNP N
. . N

The DT N
incidence NN N
of IN N
preeclampsia NN N
in IN N
the DT N
randomized JJ N
prophylactic JJ N
antihypertensive JJ N
group NN N
was VBD N
statistically RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
nonrandomized JJ N
group NN N
( ( N
8.7 CD N
versus RB N
32.5 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
other JJ N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

The DT N
63 CD N
hypertensive JJ N
women NNS N
had VBD N
a DT N
high JJ N
incidence NN N
of IN N
diabetes NNS N
mellitus NNS N
diagnosed VBD N
during IN N
pregnancy NN N
( ( N
49.2 CD N
% NN N
) ) N
as IN N
compared VBN N
to TO N
the DT N
authors NNS N
' POS N
general JJ N
obstetric JJ N
population NN N
( ( N
8.1 CD N
% NN N
) ) N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
knee NN 2_i
position NN 2_i
on IN N
blood NN N
loss NN N
and CC N
range NN N
of IN N
motion NN N
following VBG N
total JJ N
knee JJ N
arthroplasty NN N
. . N

PURPOSE VB N
This DT N
study NN N
prospectively RB N
assessed VBD N
the DT N
effects NNS N
of IN N
knee JJ 2_i
position NN 2_i
on IN N
blood NN N
loss NN N
and CC N
range NN N
of IN N
motion NN N
after IN N
primary JJ N
total JJ N
knee NN N
arthroplasty NN N
( ( N
TKA NNP N
) ) N
. . N

METHODS NNP N
One CD N
hundred CD N
and CC N
ten VB N
consecutive JJ N
TKA NNP N
patients NNS N
were VBD N
randomized VBN N
into IN N
flexion NN N
group NN N
and CC N
extension NN N
group NN N
. . N

Both DT N
groups NNS N
had VBD N
the DT N
leg NN N
elevated VBD N
30? CD N
at IN N
the DT N
hip NN N
over IN N
an DT N
inactive JJ N
CPM NNP N
for IN N
72 CD N
h NN N
postoperatively RB N
. . N

The DT N
flexion NN N
group NN N
had VBD N
the DT N
knee NN N
flexed VBD N
to TO N
30? CD N
during IN N
this DT N
period NN N
. . N

The DT N
extension NN N
group NN N
had VBD N
the DT N
knee NN N
extended VBD N
fully RB N
. . N

Perioperative JJ N
blood NN N
loss NN N
, , N
hidden JJ N
blood NN N
loss NN N
, , N
knee NN N
swelling NN N
, , N
ecchymosis NN N
, , N
analgesia NN N
requirements NNS N
, , N
range NN N
of IN N
motion NN N
( ( N
ROM NNP N
) ) N
, , N
fixed VBN N
flexion NN N
deformity NN N
( ( N
FFD NNP N
) ) N
, , N
straight-leg JJ N
raising VBG N
action NN N
, , N
and CC N
postoperative JJ N
complications NNS N
within IN N
6 CD N
weeks NNS N
of IN N
surgery NN N
were VBD N
measured VBN N
for IN N
evaluation NN N
and CC N
comparison NN N
. . N

RESULTS VB N
The DT N
postoperative JJ N
hidden JJ N
blood NN N
loss NN N
, , N
knee NN N
swelling NN N
, , N
and CC N
scope NN N
of IN N
ecchymosis NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
flexion NN N
group NN N
than IN N
in IN N
the DT N
extension NN N
group NN N
, , N
and CC N
ROM NNP N
and CC N
straight-leg JJ N
raising VBG N
action NN N
were VBD N
significantly RB N
higher JJR N
during IN N
the DT N
early JJ N
period NN N
after IN N
operation NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
perioperative JJ N
blood NN N
loss NN N
, , N
the DT N
amount NN N
of IN N
morphine NN N
used VBN N
, , N
or CC N
FFD NNP N
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
or CC N
in IN N
ROM NNP N
and CC N
FFD NNP N
at IN N
6 CD N
weeks NNS N
postoperatively RB N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
flexion NN N
of IN N
the DT N
knee NN N
to TO N
30? CD N
with IN N
the DT N
leg NN N
elevated VBD N
30? CD N
at IN N
the DT N
hip NN N
after IN N
total JJ N
knee NN N
arthroplasty NN N
may MD N
mitigate VB N
knee NN N
swelling VBG N
and CC N
provide VB N
other JJ N
beneficial JJ N
results NNS N
during IN N
the DT N
early JJ N
rehabilitation NN N
following VBG N
TKA NNP N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
Prospective NNP N
comparative NN N
study NN N
, , N
Level NNP N
I PRP N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
intranasal NN 3_i
oxytocin NN 3_i
on IN N
the DT N
neural JJ N
basis NN N
of IN N
face NN N
processing NN N
in IN N
autism NN N
spectrum NN N
disorder NN N
. . N

BACKGROUND NNP N
Autism NNP N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
is VBZ N
associated VBN N
with IN N
altered JJ N
face NN N
processing NN N
and CC N
decreased JJ N
activity NN N
in IN N
brain NN N
regions NNS N
involved VBN N
in IN N
face NN N
processing NN N
. . N

The DT N
neuropeptide JJ 3_i
oxytocin NN 3_i
has VBZ N
been VBN N
shown VBN N
to TO N
promote VB N
face NN N
processing NN N
and CC N
modulate NN N
brain NN N
activity NN N
in IN N
healthy JJ N
adults NNS N
. . N

The DT N
present JJ N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
oxytocin NN 3_i
on IN N
the DT N
neural JJ N
basis NN N
of IN N
face NN N
processing NN N
in IN N
adults NNS N
with IN N
Asperger NNP N
syndrome NN N
( ( N
AS IN N
) ) N
. . N

METHODS NNP N
A NNP N
group NN N
of IN N
14 CD N
individuals NNS N
with IN N
AS NNP N
and CC N
a DT N
group NN N
of IN N
14 CD N
neurotypical JJ N
control NN N
participants NNS N
performed VBD N
a DT N
face-matching JJ N
and CC N
a DT N
house-matching JJ N
task NN N
during IN N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
. . N

The DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
24 CD N
IU NNP N
intranasally RB N
administered VBD N
oxytocin NNS 3_i
were VBD N
tested VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 7_i
, , N
within-subject JJ N
, , N
cross-over JJ N
design NN N
. . N

RESULTS NNP N
Under IN N
placebo NN 7_i
, , N
the DT N
AS NNP N
group NN N
showed VBD N
decreased JJ N
activity NN N
in IN N
the DT N
right JJ N
amygdala NN N
, , N
fusiform NN N
gyrus NN N
, , N
and CC N
inferior JJ N
occipital JJ N
gyrus NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
during IN N
face NN N
processing NN N
. . N

After IN N
oxytocin JJ N
treatment NN N
, , N
right JJ N
amygdala NN N
activity NN N
to TO N
facial JJ N
stimuli NNS N
increased VBN N
in IN N
the DT N
AS NNP N
group NN N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
oxytocin NN N
increases VBZ N
the DT N
saliency NN N
of IN N
social JJ N
stimuli NNS N
and CC N
in IN N
ASD NNP N
and CC N
suggest VBP N
that IN N
oxytocin NN 3_i
might MD N
promote VB N
face NN N
processing NN N
and CC N
eye NN N
contact NN N
in IN N
individuals NNS N
with IN N
ASD NNP N
as IN N
prerequisites NNS N
for IN N
neurotypical JJ N
social JJ N
interaction NN N
. . N

-DOCSTART- -X- O O

A DT N
program NN N
of IN N
screening VBG N
and CC N
prompting VBG N
improves NNS N
short-term JJ N
physician JJ N
counseling NN N
of IN N
dependent NN N
and CC N
nondependent JJ N
harmful JJ N
drinkers NNS N
. . N

BACKGROUND NNP N
Physicians NNPS N
in IN N
the DT N
general JJ N
medical JJ N
setting VBG N
commonly RB N
encounter RB N
but CC N
rarely RB N
counsel NN N
patients NNS N
with IN N
dependent JJ N
or CC N
harmful JJ N
drinking NN N
behaviors NNS N
. . N

We PRP N
tested VBD N
whether IN N
providing VBG N
physicians NNS N
with IN N
their PRP$ N
patients NNS N
' POS N
results NNS N
on IN N
the DT N
alcohol NN N
module NN N
of IN N
the DT N
Diagnostic NNP N
Interview NNP N
Schedule NNP N
and CC N
counseling VBG N
directives NNS N
would MD N
prompt VB N
them PRP N
to TO N
counsel NN N
these DT N
patients NNS N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBN N
83 CD N
first- JJ N
, , N
second- JJ N
, , N
and CC N
third-year JJ N
medical JJ N
residents NNS N
to TO N
receive VB 4_i
or CC 4_i
not RB 4_i
to TO 4_i
receive VB 4_i
diagnostic JJ 4_i
information NN 4_i
and CC 4_i
counseling VBG 4_i
directives NNS 4_i
on IN 4_i
214 CD N
patients NNS N
who WP N
reported VBD N
at IN N
least JJS N
one CD N
symptom NN N
of IN N
alcohol NN N
impairment NN N
as IN N
defined VBN N
in IN N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Third NNP N
Edition NNP N
. . N

Using VBG N
binary JJ 4_i
logistic JJ 4_i
regression NN 4_i
, , N
we PRP N
examined VBD N
the DT N
effect NN N
of IN N
specific JJ N
covariables NNS N
on IN N
rates NNS N
of IN N
physician JJ N
counseling NN N
. . N

These DT N
variables NNS N
included VBD N
physician JJ N
information NN N
status NN N
, , N
patient JJ N
gender NN N
, , N
and CC N
drinking VBG N
disorder NN N
severity NN N
and CC N
recency NN N
. . N

We PRP N
also RB N
examined VBD N
the DT N
effect NN N
of IN N
physician JJ N
prompting VBG N
on IN N
counseling NN N
of IN N
female JJ N
patients NNS N
, , N
patients NNS N
with IN N
inactive JJ N
disorders NNS N
, , N
and CC N
nondependent NN N
but CC N
harmful JJ N
drinkers NNS N
. . N

We PRP N
determined VBD N
counseling VBG N
by IN N
post-visit JJ N
patient JJ N
interviews NNS N
. . N

RESULTS NNP N
Physician JJ N
prompting NN N
, , N
dependent JJ N
drinking NN N
, , N
and CC N
recent JJ N
disorder NN N
activity NN N
were VBD N
significant JJ N
correlates NNS N
of IN N
physician JJ N
counseling NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
while IN N
male JJ N
gender NN N
was VBD N
a DT N
marginally RB N
significant JJ N
correlate NN N
( ( N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

Informed VBN N
physicians NNS N
counseled VBD N
female JJ N
patients NNS N
, , N
harmful JJ N
but CC N
nondependent JJ N
drinkers NNS N
, , N
and CC N
patients NNS N
with IN N
inactive JJ N
disorders NNS N
more RBR N
often RB N
than IN N
their PRP$ N
uninformed JJ N
colleagues NNS N
, , N
although IN N
only RB N
the DT N
last JJ N
variable JJ N
achieved VBD N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
Providing VBG N
physicians NNS N
with IN N
the DT N
results NNS N
of IN N
the DT N
Diagnostic NNP N
Interview NNP N
Schedule NNP N
and CC N
counseling VBG N
directives NNS N
resulted VBD N
in IN N
short-term JJ N
improvement NN N
in IN N
their PRP$ N
rates NNS N
of IN N
counseling VBG N
patients NNS N
with IN N
a DT N
history NN N
of IN N
dependent NN N
or CC N
nondependent NN N
but CC N
harmful JJ N
drinking NN N
. . N

Further NNP N
research NN N
is VBZ N
necessary JJ N
to TO N
determine VB N
long-term JJ N
gains NNS N
in IN N
rates NNS N
of IN N
physician JJ 4_i
counseling NN 4_i
and CC 4_i
improvements NNS 4_i
in IN N
the DT N
course NN N
of IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Translucency NN N
of IN N
zirconia NN N
copings NNS N
made VBN N
with IN N
different JJ N
CAD/CAM NNP N
systems NNS N
. . N

STATEMENT NNP N
OF IN N
PROBLEM NNP N
Zirconia NNP N
cores NNS N
are VBP N
reported VBN N
to TO N
be VB N
less RBR N
translucent JJ N
than IN N
glass NN N
, , N
lithium NN N
disilicate NN N
, , N
or CC N
alumina JJ N
cores NNS N
. . N

This DT N
could MD N
affect VB N
the DT N
esthetic JJ N
appearance NN N
and CC N
the DT N
clinical JJ N
choices NNS N
made VBD N
when WRB N
using VBG N
zirconia-based JJ N
restorations NNS N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
in IN N
vitro NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
translucency NN N
of IN N
zirconia NN 3_i
copings NNS 3_i
for IN N
single JJ N
crowns NNS N
fabricated VBN N
using VBG N
different JJ N
CAD/CAM NNP N
systems NNS N
, , N
using VBG N
lithium NN 3_i
disilicate NN 3_i
glass NN 3_i
ceramic NN 3_i
as IN N
a DT N
control NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Using NNP N
impressions NNS N
made VBD N
from IN N
a DT N
stainless JJ N
steel NN N
complete-crown JJ N
master NN N
die NN N
, , N
9 CD N
stone NN N
cast NN N
replicas NN N
were VBD N
fabricated VBN N
, , N
numbered VBN N
, , N
and CC N
distributed VBD N
into IN N
8 CD N
ceramic JJ N
ZrO NNP N
( ( N
2 CD N
) ) N
CAD/CAM NNP N
system NN N
groups NNS N
( ( N
Lava NNP N
Frame NNP N
0.3 CD N
and CC N
0.5 CD N
, , N
IPS NNP N
e.max VBZ N
ZirCAD NNP N
, , N
VITA NNP N
YZ NNP N
, , N
Procera NNP N
AllZircon NNP N
, , N
Digizon NNP N
, , N
DC NNP N
Zircon NNP N
, , N
and CC N
Cercon NNP N
Base NNP N
) ) N
and CC N
to TO N
a DT N
lithium NN N
disilicate JJ N
glass-ceramic JJ N
control NN N
group NN N
( ( N
IPS NNP N
e.max RB N
Press NNP N
) ) N
using VBG N
a DT N
simple JJ N
computer-generated JJ N
randomization NN N
method NN N
. . N

From IN N
each DT N
die NN N
, , N
the DT N
manufacturer NN N
's POS N
authorized JJ N
milling NN N
centers NNS N
supplied VBD N
5 CD N
copings NNS N
per IN N
group NN N
without IN N
applying VBG N
any DT N
dying VBG N
technique NN N
to TO N
the DT N
ceramic JJ N
base NN N
material NN N
. . N

The DT N
copings NNS N
were VBD N
prepared VBN N
to TO N
allow VB N
for IN N
a DT N
40-mum JJ N
cement NN N
layer NN N
and CC N
were VBD N
of IN N
different JJ N
thicknesses NNS N
according VBG N
to TO N
system NN N
specifications NNS N
. . N

Translucency NN N
was VBD N
measured VBN N
by IN N
the DT N
direct JJ N
transmission NN N
method NN N
with IN N
a DT N
digital JJ N
photoradiometer NN N
mounted VBN N
in IN N
a DT N
dark JJ N
chamber NN N
. . N

The DT N
light JJ N
source NN N
was VBD N
a DT N
150-W JJ N
halogen NN N
lamp NN N
beam NN N
. . N

Measurements NNS N
were VBD N
repeated VBN N
3 CD N
times NNS N
for IN N
each DT N
specimen NNS N
. . N

Data NNS N
obtained VBN N
were VBD N
analyzed VBN N
using VBG N
1-way JJ N
ANOVA NNP N
and CC N
the DT N
Bonferroni NNP N
multiple NN N
comparison NN N
test NN N
( ( N
alpha=.05 NN N
) ) N
. . N

RESULTS NNP N
Among IN N
ZrO NNP N
( ( N
2 CD N
) ) N
copings NNS N
, , N
Lava NNP N
( ( N
0.3 CD N
mm NN N
and CC N
0.5 CD N
mm NNS N
thick NN N
) ) N
showed VBD N
the DT N
highest JJS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
values NNS N
of IN N
translucency NN N
measured VBN N
as IN N
light JJ N
flow JJ N
units NNS N
( ( N
3.572 CD N
+ NN N
or CC N
- : N
018 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
lx NN N
and CC N
3.181 CD N
+ NN N
or CC N
- : N
0.13 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
lx NN N
, , N
respectively RB N
) ) N
. . N

These DT N
values NNS N
represent VBP N
71.7 CD N
% NN N
and CC N
63.9 CD N
% NN N
, , N
respectively RB N
, , N
of IN N
the DT N
glass-ceramic JJ N
control NN N
group NN N
( ( N
4.98 CD N
x RB N
10 CD N
( ( N
3 CD N
) ) N
lx NN N
) ) N
. . N

CONCLUSIONS NNP N
All NNP N
ZrO NNP N
( ( N
2 CD N
) ) N
copings NNS N
demonstrated VBN N
different JJ N
levels NNS N
of IN N
light JJ N
transmission NN N
, , N
with IN N
the DT N
2 CD N
Lava NNP N
specimens NNS N
showing VBG N
the DT N
highest JJS N
values NNS N
. . N

Translucency NN N
of IN N
zirconia NN N
copings NNS N
was VBD N
significantly RB N
lower JJR N
( ( N
P=.001 NNP N
) ) N
than IN N
that DT N
of IN N
the DT N
lithium NN N
disilicate JJ N
glass-ceramic JJ N
control NN N
. . N

-DOCSTART- -X- O O

A DT N
novel JJ N
methodology NN N
for IN N
generating VBG N
3D CD 6_i
finite JJ 6_i
element NN 6_i
models NNS 6_i
of IN N
the DT N
hip NN N
from IN N
2D CD 2_i
radiographs NN 2_i
. . N

Finite NNP 6_i
element NN 6_i
( ( 6_i
FE NNP 6_i
) ) 6_i
modelling NN 6_i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
tool NN N
for IN N
estimating VBG N
fracture NN N
risk NN N
and CC N
patient-specific JJ 6_i
FE NNP 6_i
models NNS 6_i
are VBP N
commonly RB N
based VBN N
on IN N
computed JJ 6_i
tomography NN 6_i
( ( N
CT NNP N
) ) N
. . N

Here RB N
, , N
we PRP N
present VBP N
a DT N
novel JJ N
method NN N
to TO N
automatically RB N
create VB 6_i
personalised VBD 6_i
3D CD 6_i
models NNS 6_i
from IN 6_i
standard JJ 6_i
2D CD 6_i
hip NN 6_i
radiographs NN 6_i
. . N

A DT N
set NN N
of IN N
geometrical JJ N
parameters NNS N
of IN N
the DT N
femur NN N
were VBD N
determined VBN N
from IN N
seven CD N
a-p JJ 2_i
hip NN 2_i
radiographs NN 2_i
and CC N
compared VBN N
to TO N
the DT N
3D CD 2_i
femoral JJ 2_i
shape NN 2_i
obtained VBN 2_i
from IN 2_i
CT NNP 2_i
as IN N
training VBG N
material NN N
; : N
the DT N
error NN N
in IN N
reconstructing VBG N
the DT N
3D CD N
model NN N
from IN N
the DT N
2D CD N
radiographs NN N
was VBD N
assessed VBN N
. . N

Using VBG N
the DT N
geometry NN N
parameters NNS N
as IN N
the DT N
input NN N
, , N
the DT N
3D CD N
shape NN N
of IN N
another DT N
21 CD N
femora NN N
was VBD N
built VBN N
and CC N
meshed VBN N
, , N
separating VBG N
a DT N
cortical JJ N
and CC N
trabecular JJ N
compartment NN N
. . N

The DT N
material NN N
properties NNS N
were VBD N
derived VBN N
from IN N
the DT N
homogeneity NN N
index NN N
assessed VBN N
by IN N
texture NN N
analysis NN N
of IN N
the DT N
radiographs NN N
, , N
with IN N
focus NN N
on IN N
the DT N
principal NN N
tensile NN N
and CC N
compressive JJ N
trabecular JJ N
systems NNS N
. . N

The DT N
ability NN N
of IN N
these DT N
FE NNP 6_i
models NNS 6_i
to TO N
predict VB N
failure NN N
load NN N
as IN N
determined VBN N
by IN N
experimental JJ N
biomechanical JJ N
testing NN N
was VBD N
evaluated VBN N
and CC N
compared VBN N
to TO N
the DT N
predictive JJ N
ability NN N
of IN N
DXA NNP N
. . N

The DT N
average JJ N
reconstruction NN N
error NN N
of IN N
the DT N
3D CD N
models NNS N
was VBD N
1.77 CD N
mm NN N
( ( N
?1.17 NNP N
mm NN N
) ) N
, , N
with IN N
the DT N
error NN N
being VBG N
smallest JJS N
in IN N
the DT N
femoral JJ N
head NN N
and CC N
neck NN N
, , N
and CC N
greatest JJS N
in IN N
the DT N
trochanter NN N
. . N

The DT N
correlation NN N
of IN N
the DT N
FE NNP N
predicted VBD N
failure NN N
load NN N
with IN N
the DT N
experimental JJ N
failure NN N
load NN N
was VBD N
r NN N
( ( N
2 CD N
) ) N
=64 CD N
% NN N
for IN N
the DT N
reconstruction NN N
FE NNP N
model NN N
, , N
which WDT N
was VBD N
significantly RB N
better JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
than IN N
that DT N
for IN N
DXA NNP N
( ( N
r NN N
( ( N
2 CD N
) ) N
=24 CD N
% NN N
) ) N
. . N

This DT N
novel JJ N
method NN N
for IN N
automatically RB N
constructing VBG N
a DT N
patient-specific JJ N
3D CD N
finite JJ N
element NN N
model NN N
from IN N
standard JJ N
2D CD N
radiographs NN N
shows NNS N
encouraging VBG N
results NNS N
in IN N
estimating VBG N
patient-specific JJ N
failure NN N
loads NNS N
. . N

-DOCSTART- -X- O O

Breast NNP 1_i
reduction NN 1_i
alleviates VBZ N
depression NN N
and CC N
anxiety NN N
and CC N
restores VBZ N
self-esteem NNS N
: : N
a DT N
prospective JJ N
randomised JJ N
clinical JJ N
trial NN N
. . N

Of IN N
women NNS N
who WP N
seek VBP N
reduction NN N
mammaplasty NN N
, , N
up RB N
to TO N
a DT N
third JJ N
have VBP N
pathological JJ N
degrees NNS N
of IN N
anxiety NN N
or CC N
depression NN N
, , N
or CC N
both DT N
. . N

The DT N
psychological JJ N
aspect NN N
of IN N
reduction NN 1_i
mammaplasty NN 1_i
is VBZ N
therefore RB N
an DT N
important JJ N
consideration NN N
. . N

We PRP N
did VBD N
a DT N
prospective NN N
randomised VBN N
clinical JJ N
trial NN N
to TO N
see VB N
how WRB N
reduction NN 1_i
mammaplasty RB 1_i
affected VBD N
macromastia JJ N
patients NNS N
' POS N
depression NN N
, , N
anxiety NN N
, , N
and CC N
self-esteem JJ N
. . N

Eighty-two JJ N
patients NNS N
were VBD N
randomised VBN N
, , N
40 CD N
to TO N
have VB N
the DT N
operation NN N
, , N
and CC N
42 CD N
patients NNS N
to TO N
conservative JJ N
treatment NN N
. . N

Both DT N
groups NNS N
were VBD N
followed VBN N
for IN N
six CD N
months NNS N
. . N

The DT N
patients NNS N
completed VBD N
the DT N
RBDI NNP N
questionnaire NN N
( ( N
Raitasalo NNP N
's POS N
modification NN N
of IN N
the DT N
short JJ N
form NN N
of IN N
the DT N
Beck NNP N
Depression NNP N
Inventory NNP N
) ) N
. . N

Twenty-nine JJ N
patients NNS N
in IN N
the DT N
operated JJ N
group NN N
and CC N
35 CD N
patients NNS N
in IN N
the DT N
conservative JJ N
group NN N
completed VBD N
the DT N
study NN N
. . N

At IN N
the DT N
second JJ N
examination NN N
, , N
the DT N
patients NNS N
who WP N
had VBD N
been VBN N
operated VBN N
on IN N
, , N
had VBD N
significantly RB N
less JJR N
depression NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
better JJR N
self-esteem NN N
( ( N
p=0.03 NN N
) ) N
than IN N
the DT N
conservative JJ N
group NN N
. . N

The DT N
proportions NNS N
of IN N
depressed JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
anxious JJ N
( ( N
p=0.04 NN N
) ) N
patients NNS N
were VBD N
also RB N
smaller JJR N
in IN N
the DT N
group NN N
who WP N
were VBD N
operated VBN N
on IN N
. . N

There EX N
is VBZ N
significantly RB N
less JJR N
depression NN N
and CC N
anxiety NN N
after IN N
reduction NN N
mammaplasty NN 1_i
, , N
and CC N
patients NNS N
' POS N
self-esteem NN N
is VBZ N
restored VBN N
. . N

-DOCSTART- -X- O O

Oscillatory NN N
potentials NNS N
, , N
retinopathy NN N
, , N
and CC N
long-term JJ N
glucose NN N
control NN N
in IN N
insulin-dependent JJ N
diabetes NNS N
. . N

The DT N
main JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess JJ N
effects NNS N
of IN N
long-term JJ N
lowering NN N
of IN N
glucosylated JJ 2_i
hemoglobin NN 2_i
( ( 2_i
HbA1 NNP 2_i
% NN 2_i
) ) 2_i
on IN N
neurosensory JJ N
function NN N
in IN N
insulin-dependent JJ N
diabetes NNS N
. . N

Individual NNP N
( ( N
OP-1 NNP N
, , N
OP-2 NNP N
, , N
OP-3 NNP N
) ) N
and CC N
summed VBN N
( ( N
OP-sum NNP N
) ) N
amplitudes NNS N
of IN N
oscillatory JJ N
potentials NNS N
( ( N
OPs NNP N
) ) N
of IN N
electroretinography NN 2_i
were VBD N
recorded VBN N
at IN N
study JJ N
start NN N
and CC N
7-years NNS N
later RB N
in IN N
45 CD N
patients NNS N
( ( N
the DT N
Oslo NNP N
study NN N
) ) N
. . N

As IN N
an DT N
overall JJ N
7-year JJ N
change NN N
, , N
amplitudes NNS N
of IN N
OP-2 NNP N
, , N
OP-3 NNP N
and CC N
OP-sum NNP N
were VBD N
reduced VBN N
( ( N
p JJ N
< NNP N
0.0001-0.01 NN N
) ) N
, , N
retinopathy JJ N
worsened VBD N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
, , N
intraocular JJ N
pressure NN N
decreased VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
systolic JJ N
blood NN N
pressure NN N
increased VBD N
( ( N
p JJ N
< NNP N
0.0002 CD N
) ) N
, , N
and CC N
glycemic JJ N
control NN N
improved VBN N
from IN N
HbA1 NNP N
of IN N
11.2 CD N
+/- JJ N
2.2 CD N
% NN N
at IN N
study JJ N
start NN N
to TO N
a DT N
7-year JJ N
cumulative JJ N
mean NN N
of IN N
9.5 CD N
+/- JJ N
1.5 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Multiple JJ N
regression NN N
analysis NN N
did VBD N
not RB N
identify VB N
any DT N
independent JJ N
relations NNS N
between IN N
change NN N
in IN N
OP-1 NNP N
, , N
OP-2 NNP N
, , N
OP-3 NNP N
, , N
OP-sum NNP N
and CC N
change NN N
in IN N
glycemic JJ N
control NN N
or CC N
background NN N
variables NNS N
, , N
including VBG N
change NN N
in IN N
age NN N
and CC N
duration NN N
of IN N
diabetes NNS N
. . N

However RB N
, , N
cross-sectional JJ N
observations NNS N
at IN N
7 CD N
years NNS N
showed VBD N
negative JJ N
correlations NNS N
between IN N
all DT N
OPs NNP N
and CC N
age NN N
( ( N
p JJ N
< NNP N
0.0001-0.003 NN N
) ) N
, , N
and CC N
between IN N
OP-3 NNP N
and CC N
duration NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
counts NNS N
of IN N
microaneurysms NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
data NN N
suggest NN N
that IN N
various JJ N
clinical JJ N
background NN N
variables NNS N
may MD N
influence VB N
individual JJ N
and CC N
summed VBD N
amplitudes NNS N
of IN N
OPs NNP N
differently RB N
. . N

Reduced NNP N
neurosensory JJ N
retinal JJ N
function NN N
( ( N
OPs NNP N
) ) N
seemed VBD N
to TO N
appear VB N
after IN N
7-years NNS N
, , N
independently RB N
of IN N
vascular JJ N
defects NNS N
of IN N
retinopathy JJ N
and CC N
long-term JJ N
improvement NN N
in IN N
glucose JJ N
control NN N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
bone NN N
loss NN N
in IN N
survivors NNS N
of IN N
breast NN N
cancer NN N
: : N
A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Few NNP N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
once-weekly JJ N
oral JJ N
bisphosphonate NN 3_i
therapy NN 3_i
in IN N
breast NN N
cancer NN N
survivors NNS N
. . N

OBJECTIVE NNP N
Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
risedronate NN 3_i
, , N
35 CD N
mg JJ N
weekly JJ N
, , N
is VBZ N
efficacious JJ N
and CC N
safe JJ N
in IN N
preventing VBG N
bone NN N
loss NN N
associated VBN N
with IN N
chemotherapy-induced JJ N
menopause NN N
. . N

DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
clinical JJ N
trial NN N
over IN N
12 CD N
months NNS N
. . N

SETTING NN N
AND CC N
PARTICIPANTS NNP N
Participants NNP N
included VBD N
87 CD N
newly RB N
postmenopausal JJ N
women NNS N
with IN N
status NN N
post NN N
chemotherapy NN N
, , N
recruited VBN N
from IN N
a DT N
breast NN N
cancer NN N
clinic NN N
in IN N
an DT N
academic JJ N
medical JJ N
center NN N
. . N

INTERVENTION JJ N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
risedronate NN 3_i
35 CD N
mg/wk NN N
or CC N
placebo NN 7_i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcomes NNS N
were VBD N
the DT N
12-month JJ N
changes NNS N
in IN N
spine NN N
and CC N
hip NN N
bone NN N
mineral JJ N
density NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
changes NNS N
in IN N
markers NNS N
of IN N
bone NN N
resorption NN N
( ( N
urine JJ N
N-telopeptide NNP N
cross-linked JJ N
collagen NN N
type NN N
I PRP N
) ) N
and CC N
formation NN N
( ( N
osteocalcin JJ N
, , N
N-terminal JJ N
propeptide NN N
of IN N
type NN N
I PRP N
procollagen VBP N
, , N
and CC N
bone-specific JJ N
alkaline NN N
phosphatase NN N
) ) N
. . N

RESULTS NNP N
After IN N
12 CD N
months NNS N
, , N
bone JJ N
mineral JJ N
density NN N
increased VBN N
by IN N
1.2 CD N
% NN N
at IN N
the DT N
spine NN N
and CC N
1.3 CD N
% NN N
at IN N
the DT N
hip NN N
in IN N
women NNS N
on IN N
risedronate NN 3_i
vs. FW N
significant JJ N
decreases NNS N
for IN N
women NNS N
in IN N
the DT N
placebo NN N
group NN N
of IN N
0.9 CD N
% NN N
at IN N
the DT N
spine NN N
and CC N
0.8 CD N
% NN N
at IN N
the DT N
hip NN N
( ( N
P NNP N
< NNP N
0.01 CD N
, , N
difference NN N
between IN N
groups NNS N
) ) N
. . N

N-telopeptide JJ N
cross-linked JJ N
collagen NN N
type NN N
I PRP N
, , N
a DT N
marker NN N
of IN N
bone NN N
resorption NN N
, , N
decreased VBN N
by IN N
19.3 CD N
% NN N
, , N
and CC N
N-terminal JJ N
propeptide NN N
of IN N
type NN N
I PRP N
procollagen VBP N
, , N
a DT N
marker NN N
of IN N
bone NN N
formation NN N
, , N
decreased VBN N
by IN N
26.6 CD N
% NN N
in IN N
participants NNS N
on IN N
active JJ N
therapy NN N
compared VBN N
with IN N
increases NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Risedronate NNP 3_i
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
the DT N
retention NN N
rate NN N
was VBD N
95 CD N
% NN N
at IN N
1 CD N
yr NN N
. . N

CONCLUSIONS NNP N
Risedronate NNP 3_i
once RB N
weekly RB N
prevented VBD N
bone JJ N
loss NN N
and CC N
reduced JJ N
bone NN N
turnover NN N
in IN N
women NNS N
with IN N
breast NN N
cancer NN N
treated VBN N
with IN N
chemotherapy NN N
. . N

Early JJ N
measures NNS N
to TO N
prevent VB N
bone JJ N
loss NN N
should MD N
be VB N
considered VBN N
in IN N
this DT N
cohort NN N
of IN N
breast NN N
cancer NN N
survivors NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
endocrine NN 3_i
and CC N
radiation NN 2_i
therapy NN 2_i
in IN N
locally RB N
advanced JJ N
prostatic JJ N
cancer NN N
. . N

151 CD N
patients NNS N
with IN N
locally RB N
advanced JJ N
prostatic JJ N
cancer NN N
( ( N
T3-4 NNP N
M0 NNP N
) ) N
, , N
representing VBG N
38 CD N
% NN N
of IN N
the DT N
404 CD N
cancer NN N
patients NNS N
in IN N
a DT N
Finnish JJ N
multicenter NN N
study NN N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
arms NNS N
: : N
orchiectomy NN 1_i
, , N
estrogens VBZ 3_i
or CC N
radiotherapy NN 2_i
. . N

During IN N
the DT N
4-year JJ N
follow-up JJ N
period NN N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
progression NN N
rates NNS N
( ( N
appearance NN N
of IN N
metastases NNS N
in IN N
bone NN N
scan NN N
) ) N
between IN N
the DT N
therapy NN N
groups NNS N
. . N

The DT N
frequency NN N
of IN N
thromboembolic JJ N
and CC N
other JJ N
cardiovascular JJ N
complications NNS N
was VBD N
highest JJS N
in IN N
the DT N
estrogen NN N
group NN N
( ( N
13/50 CD N
patients NNS N
) ) N
. . N

In IN N
the DT N
radiotherapy NN N
group NN N
, , N
19 CD N
of IN N
45 CD N
patients NNS N
had VBD N
bowel NN N
or CC N
bladder NN N
complications NNS N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
orchiectomy NN N
has VBZ N
few JJ N
, , N
if IN N
any DT N
, , N
complications NNS N
. . N

The DT N
high JJ N
risk NN N
of IN N
complications NNS N
associated VBN N
with IN N
estrogens NNS N
and CC N
radiotherapy NN N
has VBZ N
to TO N
be VB N
taken VBN N
into IN N
consideration NN N
in IN N
the DT N
selection NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Stage NN N
II NNP N
carcinoma NN N
of IN N
the DT N
ovary JJ N
: : N
an DT N
analysis NN N
of IN N
survival NN N
after IN N
comprehensive JJ N
surgical JJ 1_i
staging NN 1_i
and CC N
adjuvant JJ 2_i
therapy NN 2_i
. . N

Ninety-three JJ N
women NNS N
with IN N
FIGO NNP N
stage NN N
II NNP N
epithelial JJ N
ovarian JJ N
carcinoma NN N
underwent JJ N
comprehensive JJ N
surgical JJ N
staging NN N
and CC N
were VBD N
randomized VBN N
prospectively RB N
to TO N
therapy VB N
consisting NN N
of IN N
either DT N
intraperitoneal JJ 3_i
radioactive JJ 3_i
phosphorus NN 3_i
or CC N
oral JJ 3_i
melphalan NN 3_i
. . N

No DT N
patient NN N
had VBD N
gross JJ N
residual JJ N
disease NN N
at IN N
the DT N
time NN N
of IN N
randomization NN N
. . N

Ten CD N
of IN N
the DT N
forty-five JJ N
women NNS N
treated VBN N
with IN N
melphalan NN 3_i
experienced VBN N
severe JJ N
bone NN N
marrow NN N
depression NN N
at IN N
some DT N
time NN N
during IN N
therapy NN N
and CC N
two CD N
women NNS N
expired VBD N
from IN N
leukemia NN N
. . N

Four CD N
of IN N
the DT N
forty-eight JJ N
women NNS N
treated VBN N
with IN N
intraperitoneal JJ 3_i
phosphorus NN 3_i
required VBN N
surgical JJ N
reexploration NN N
for IN N
intestinal JJ N
obstruction NN N
or CC N
bowel NN N
injury NN N
. . N

Twenty-one JJ N
women NNS N
died VBD N
of IN N
their PRP$ N
disease NN N
. . N

Survival NNP N
was VBD N
not RB N
statistically RB N
different JJ N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
. . N

The DT N
5-year JJ N
actuarial JJ N
survival NN N
was VBD N
78 CD N
% NN N
. . N

-DOCSTART- -X- O O

The DT N
use NN N
of IN N
adrenocorticotrophic JJ 3_i
hormone NN 3_i
( ( 3_i
4-9 JJ 3_i
) ) 3_i
analog NN 3_i
ORG NNP 3_i
2766 CD 3_i
in IN N
autistic JJ N
children NNS N
: : N
effects NNS N
on IN N
the DT N
organization NN N
of IN N
behavior NN N
. . N

In IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
trial NN N
, , N
14 CD N
autistic JJ N
children NNS N
were VBD N
treated VBN N
with IN N
the DT N
neuropeptide NN 3_i
ORG NNP 3_i
2766 CD 3_i
, , N
a DT N
synthetic JJ N
analog NN N
of IN N
adrenocorticotrophic JJ N
hormone NN N
( ( N
ACTH NNP N
) ) N
( ( N
4-9 JJ N
) ) N
. . N

ORG JJ 3_i
2766 CD 3_i
treatment NN 3_i
( ( N
20 CD N
mg NNS N
per IN N
day NN N
during IN N
4 CD N
weeks NNS N
) ) N
was VBD N
associated VBN N
with IN N
an DT N
increased JJ N
amount NN N
and CC N
an DT N
improved JJ N
quality NN N
of IN N
the DT N
social JJ N
interaction NN N
of IN N
the DT N
autistic JJ N
children NNS N
with IN N
a DT N
familiar JJ N
experimenter NN N
. . N

These DT N
changes NNS N
in IN N
interaction NN N
were VBD N
clinically RB N
relevant JJ N
. . N

Following VBG N
treatment NN N
with IN N
ORG NNP 3_i
2766 CD 3_i
gaze NN N
and CC N
smile JJ N
behaviors NNS N
of IN N
child NN N
and CC N
experimenter NN N
showed VBD N
stronger JJR N
temporal JJ N
contingencies NNS N
. . N

Further NNP N
, , N
after IN N
ORG NNP 3_i
2766 CD 3_i
, , N
stereotypies NNS N
were VBD N
temporally RB N
disconnected VBN N
from IN N
verbal JJ N
initiatives NNS N
. . N

The DT N
data NN N
supported VBD N
the DT N
notion NN N
of IN N
a DT N
stimulating JJ N
effect NN N
of IN N
ORG NNP 3_i
2766 CD 3_i
on IN N
social JJ N
interaction NN N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
for IN N
the DT N
endogenous JJ N
opioid JJ N
theory NN N
of IN N
autism NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Virtual JJ 5_i
reality NN 5_i
hypnosis NN 5_i
for IN N
pain NN N
associated VBN N
with IN N
recovery NN N
from IN N
physical JJ N
trauma NN N
. . N

Pain VB N
following VBG N
traumatic JJ N
injuries NNS N
is VBZ N
common JJ N
, , N
can MD N
impair VB N
injury JJ N
recovery NN N
and CC N
is VBZ N
often RB N
inadequately RB N
treated VBN N
. . N

In IN N
particular JJ N
, , N
the DT N
role NN N
of IN N
adjunctive JJ N
nonpharmacologic JJ 4_i
analgesic JJ 4_i
techniques NNS 4_i
is VBZ N
unclear JJ N
. . N

The DT N
authors NNS N
report VBP N
a DT N
randomized VBN N
, , N
controlled VBD N
study NN N
of IN N
21 CD N
hospitalized JJ N
trauma NN N
patients NNS N
to TO N
assess VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
virtual JJ 5_i
reality NN 5_i
hypnosis NN 5_i
( ( 5_i
VRH NNP 5_i
) ) 5_i
-hypnotic JJ 5_i
induction NN 5_i
and CC N
analgesic JJ N
suggestion NN N
delivered VBN N
by IN N
customized JJ N
virtual JJ N
reality NN N
( ( N
VR NNP N
) ) N
hardware/software NN N
. . N

Subjective JJ N
pain NN N
ratings NNS N
were VBD N
obtained VBN N
immediately RB N
and CC N
8 CD N
hours NNS N
after IN N
VRH NNP N
( ( N
used VBN N
as IN N
an DT N
adjunct NN N
to TO N
standard VB N
analgesic JJ N
care NN N
) ) N
and CC N
compared VBN N
to TO N
both DT N
adjunctive JJ N
VR NNP N
without IN N
hypnosis NN N
and CC N
standard JJ N
care NN N
alone RB N
. . N

VRH JJ N
patients NNS N
reported VBD N
less RBR N
pain JJ N
intensity NN N
and CC N
less JJR N
pain NN N
unpleasantness JJ N
compared VBN N
to TO N
control VB N
groups NNS N
. . N

These DT N
preliminary JJ N
findings NNS N
suggest VBP N
that IN N
VRH NNP 5_i
analgesia NN N
is VBZ N
a DT N
novel JJ N
technology NN N
worthy NN N
of IN N
further JJ N
study NN N
, , N
both DT N
to TO N
improve VB N
pain NN N
management NN N
and CC N
to TO N
increase VB N
availability NN N
of IN N
hypnotic JJ N
analgesia NN N
to TO N
populations NNS N
without IN N
access NN N
to TO N
therapist-provided JJ N
hypnosis NN N
and CC N
suggestion NN N
. . N

-DOCSTART- -X- O O

The DT N
treatment NN N
of IN N
senile JJ N
dementia NN N
associated VBN N
with IN N
cerebrovascular JJ N
insufficiency NN N
: : N
a DT N
comparative JJ N
study NN N
of IN N
buflomedil NN 3_i
and CC N
dihydrogenated VBD 3_i
ergot JJ 3_i
alkaloids NNS 3_i
. . N

Seventy-six JJ N
patients NNS N
took VBD N
part NN N
in IN N
a DT N
randomized JJ N
, , N
comparative JJ N
study NN N
of IN N
the DT N
efficacy NN N
of IN N
buflomedil NN 3_i
hydrochloride NN 3_i
and CC N
dihydrogenated VBD 3_i
ergot JJ 3_i
alkaloids NNS 3_i
in IN N
the DT N
treatment NN N
of IN N
senile JJ N
dementia NN N
associated VBN N
with IN N
cerebrovascular JJ N
insufficiency NN N
. . N

Efficacy NN N
was VBD N
assessed VBN N
by IN N
the DT N
patients NNS N
' POS N
performance NN N
in IN N
four CD N
psychometric JJ N
tests NNS N
. . N

The DT N
results NNS N
showed VBD N
that IN N
a DT N
trend NN N
in IN N
favour NN N
of IN N
the DT N
buflomedil NN N
group NN N
in IN N
three CD N
of IN N
the DT N
tests NNS N
became VBD N
statistically RB N
significant JJ N
in IN N
the DT N
fourth JJ N
. . N

Both DT N
drugs NNS N
appeared VBD N
to TO N
be VB N
safe JJ N
, , N
causing VBG N
no DT N
marked JJ N
adverse JJ N
reactions NNS N
. . N

In IN N
conclusion NN N
, , N
buflomedil NN N
is VBZ N
as IN N
effective JJ N
or CC N
more RBR N
effective JJ N
than IN N
dihydrogenated VBN N
ergot JJ N
alkaloids NNS N
in IN N
the DT N
treatment NN N
of IN N
senile JJ N
dementia NN N
associated VBN N
with IN N
cerebrovascular JJ N
insufficiency NN N
and CC N
could MD N
prove VB N
a DT N
valuable JJ N
addition NN N
to TO N
long-term JJ N
therapy NN N
if IN N
further JJ N
studies NNS N
support VBP N
the DT N
trend NN N
shown VBN N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
effectiveness NN N
of IN N
oral JJ N
diazepam NN 3_i
and CC 3_i
midazolam NN 3_i
for IN N
the DT N
sedation NN N
of IN N
autistic JJ N
patients NNS N
during IN N
dental JJ N
treatment NN N
. . N

PURPOSE VB N
This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
oral JJ N
diazepam NN 3_i
and CC 3_i
midazolam NN 3_i
in IN N
sedating VBG N
autistic JJ N
patients NNS N
during IN N
dental JJ N
treatment NN N
. . N

METHODS NNP N
The DT N
treatment NN N
regimen NNS N
consisted VBD N
of IN N
nitrous JJ 3_i
oxide/oxygen NN 3_i
inhalation NN 3_i
in IN N
conjunction NN N
with IN N
oral JJ 3_i
administration NN 3_i
of IN 3_i
either DT 3_i
diazepam NN 3_i
0.3 CD 3_i
mg/kg NN 3_i
or CC 3_i
midazolam VB 3_i
0.5 CD 3_i
mg/kg NN 3_i
in IN N
a DT N
cross-over JJ N
design NN N
study NN N
of IN N
13 CD N
subjects NNS N
aged VBD N
5.8 CD N
to TO N
14.7 CD N
years NNS N
. . N

A DT N
drug NN N
was VBD N
classified VBN N
as IN N
being VBG N
effective JJ N
when WRB N
over RB N
70 CD N
% NN N
of IN N
the DT N
patients NNS N
taking VBG N
the DT N
drug NN N
were VBD N
judged VBN N
as IN N
success NN N
in IN N
all DT N
3 CD N
behavioral JJ N
criteria NNS N
: : N
( ( N
1 CD N
) ) N
sleeping NN N
; : N
( ( N
2 CD N
) ) N
body NN N
movement NN N
; : N
and CC N
( ( N
3 CD N
) ) N
crying NN N
behaviors NNS N
. . N

The DT N
study NN N
was VBD N
observed VBN N
by IN N
an DT N
independent JJ N
clinician NN N
with IN N
an DT N
intraexaminer NN N
reliability NN N
of IN N
88 CD N
% NN N
. . N

RESULTS NNP N
For IN N
sleeping VBG N
behavior NN N
, , N
midazolam NN N
was VBD N
found VBN N
to TO N
be VB N
significantly RB N
more RBR N
effective JJ N
than IN N
diazepam RB N
as IN N
the DT N
duration NN N
of IN N
stimulation NN N
increased VBN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

For IN N
the DT N
movement NN N
and CC N
crying NN N
behaviors NNS N
, , N
midazolam NN N
also RB N
proved VBD N
to TO N
be VB N
significantly RB N
more RBR N
effective JJ N
from IN N
the DT N
start NN N
of IN N
treatment NN N
through IN N
the DT N
35- JJ N
and CC N
40-min JJ N
markers NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

For IN N
the DT N
remainder NN N
of IN N
treatment NN N
, , N
however RB N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
these DT N
behaviors NNS N
between IN N
the DT N
trials NNS N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
. . N

Diazepam NNP N
and CC N
midazolam NNS N
were VBD N
rated VBN N
as IN N
77 CD N
% NN N
and CC N
100 CD N
% NN N
successful JJ N
, , N
according VBG N
to TO N
the DT N
overall JJ N
behavior NN N
evaluation NN N
criteria NNS N
( ( N
P=.02 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Both NNP N
diazepam NN N
and CC N
midazolam NN N
were VBD N
shown VBN N
to TO N
be VB N
effective JJ N
sedative JJ N
agents NNS N
, , N
successfully RB N
and CC N
safely RB N
used VBN N
to TO N
sedate VB N
autistic JJ N
patients NNS N
for IN N
dental JJ N
treatment NN N
. . N

Midazolam NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
diazepam NN N
in IN N
those DT N
portions NNS N
of IN N
the DT N
procedure NN N
with IN N
increased JJ N
stimulation NN N
. . N

-DOCSTART- -X- O O

Bevacizumab NNP 3_i
plus CC 3_i
irinotecan JJ 3_i
, , 3_i
fluorouracil NN 3_i
, , 3_i
and CC 3_i
leucovorin NN 3_i
for IN N
metastatic JJ N
colorectal JJ N
cancer NN N
. . N

BACKGROUND NNP N
Bevacizumab NNP 3_i
, , N
a DT N
monoclonal JJ N
antibody NN N
against IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
, , N
has VBZ N
shown VBN N
promising JJ N
preclinical JJ N
and CC N
clinical JJ N
activity NN N
against IN N
metastatic JJ N
colorectal JJ N
cancer NN N
, , N
particularly RB N
in IN N
combination NN N
with IN N
chemotherapy NN N
. . N

METHODS NNP N
Of IN N
813 CD N
patients NNS N
with IN N
previously RB N
untreated VBN N
metastatic JJ N
colorectal NN N
cancer NN N
, , N
we PRP N
randomly VBP N
assigned VBD N
402 CD N
to TO N
receive VB N
irinotecan JJ 3_i
, , 3_i
bolus JJ 3_i
fluorouracil NN 3_i
, , 3_i
and CC 3_i
leucovorin NN 3_i
( ( 3_i
IFL NNP 3_i
) ) 3_i
plus CC 3_i
bevacizumab NN 3_i
( ( N
5 CD N
mg NN N
per IN N
kilogram NN N
of IN N
body NN N
weight JJ N
every DT N
two CD N
weeks NNS N
) ) N
and CC N
411 CD N
to TO N
receive VB N
IFL NNP 7_i
plus CC 7_i
placebo NN 7_i
. . 7_i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ N
survival NN N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ N
survival NN N
, , N
the DT N
response NN N
rate NN N
, , N
the DT N
duration NN N
of IN N
the DT N
response NN N
, , N
safety NN N
, , N
and CC N
the DT N
quality NN N
of IN N
life NN N
. . N

RESULTS VB N
The DT N
median JJ N
duration NN N
of IN N
survival NN N
was VBD N
20.3 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP 3_i
plus CC 3_i
bevacizumab NN 3_i
, , N
as IN N
compared VBN N
with IN N
15.6 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP 7_i
plus CC 7_i
placebo NN 7_i
, , N
corresponding VBG N
to TO N
a DT N
hazard NN N
ratio NN N
for IN N
death NN N
of IN N
0.66 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
median JJ N
duration NN N
of IN N
progression-free JJ N
survival NN N
was VBD N
10.6 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP 3_i
plus CC 3_i
bevacizumab NN 3_i
, , N
as IN N
compared VBN N
with IN N
6.2 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP 7_i
plus CC 7_i
placebo NN 7_i
( ( N
hazard JJ N
ratio NN N
for IN N
disease NN N
progression NN N
, , N
0.54 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
the DT N
corresponding JJ N
rates NNS N
of IN N
response NN N
were VBD N
44.8 CD N
percent NN N
and CC N
34.8 CD N
percent NN N
( ( N
P=0.004 NNP N
) ) N
. . N

The DT N
median JJ N
duration NN N
of IN N
the DT N
response NN N
was VBD N
10.4 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP 3_i
plus CC 3_i
bevacizumab NN 3_i
, , N
as IN N
compared VBN N
with IN N
7.1 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP 7_i
plus CC 7_i
placebo NN 7_i
( ( N
hazard JJ N
ratio NN N
for IN N
progression NN N
, , N
0.62 CD N
; : N
P=0.001 NNP N
) ) N
. . N

Grade $ N
3 CD N
hypertension NN N
was VBD N
more RBR N
common JJ N
during IN N
treatment NN N
with IN N
IFL NNP 3_i
plus CC 3_i
bevacizumab NN 3_i
than IN N
with IN N
IFL NNP 7_i
plus CC 7_i
placebo NN 7_i
( ( N
11.0 CD N
percent NN N
vs. FW N
2.3 CD N
percent NN N
) ) N
but CC N
was VBD N
easily RB N
managed VBN N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
bevacizumab NN 3_i
to TO N
fluorouracil-based JJ 3_i
combination NN 3_i
chemotherapy NN 3_i
results NNS N
in IN N
statistically RB N
significant JJ N
and CC N
clinically RB N
meaningful JJ N
improvement NN N
in IN N
survival NN N
among IN N
patients NNS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
, , N
phase VB N
II NNP N
trial NN N
of IN N
two CD N
dose JJ N
schedules NNS N
of IN N
carboplatin/paclitaxel/cetuximab NN 3_i
in IN N
stage NN N
IIIB/IV NNP N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
. . N

BACKGROUND NNP N
This DT N
trial NN N
investigated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
weekly JJ N
cetuximab NN 3_i
combined VBN 3_i
with IN 3_i
two CD 3_i
different JJ 3_i
schedules NNS 3_i
of IN 3_i
paclitaxel/carboplatin NN 3_i
for IN N
stage NN N
IIIB/IV NNP N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
. . N

METHODS CC N
A DT N
total NN N
of IN N
168 CD N
patients NNS N
with IN N
previously RB N
untreated VBN N
stage NN N
IIIB/IV NNP N
NSCLC NNP N
were VBD N
randomized VBN N
to TO N
arm VB N
A NNP N
, , N
cetuximab NN 3_i
( ( N
400 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1 CD N
followed VBN N
by IN N
weekly JJ N
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
+ FW N
paclitaxel NN 3_i
( ( N
Taxol NNP N
) ) N
( ( N
225 CD N
mg/m NN 3_i
( ( 3_i
2 CD 3_i
) ) 3_i
) ) 3_i
/carboplatin NN 3_i
( ( 3_i
AUC6 NNP 3_i
) ) 3_i
day NN N
1 CD N
every DT N
3 CD N
weeks NNS N
or CC N
arm NN N
B NNP N
, , N
same JJ N
cetuximab NN 3_i
regimen NNS 3_i
plus CC 3_i
paclitaxel NN 3_i
( ( N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
days NNS N
1 CD N
, , N
8 CD N
, , N
and CC N
15 CD N
every DT N
3 CD N
weeks NNS N
and CC 3_i
carboplatin NN 3_i
( ( N
AUC6 NNP N
) ) N
day NN N
1 CD N
every DT N
4 CD N
weeks NNS N
. . N

Treatment NNP N
continued VBD N
for IN N
a DT N
four-cycle JJ N
maximum NN N
. . N

Patients NNS N
with IN N
a DT N
complete JJ N
response NN N
, , N
partial JJ N
response NN N
, , N
or CC N
stable JJ N
disease NN N
after IN N
four CD N
cycles NNS N
could MD N
receive VB N
cetuximab NN 3_i
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/week NN N
until IN N
disease JJ N
progression NN N
or CC N
unacceptable JJ N
toxicity NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
to TO N
evaluate VB N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
. . N

RESULTS NNP N
Median JJ N
PFS NNP N
was VBD N
4.7 CD N
and CC N
4.3 CD N
months NNS N
for IN N
arms NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
6-month JJ N
PFS NNP N
, , N
27.3 CD N
% NN N
versus IN N
30.9 CD N
% NN N
) ) N
. . N

Median JJ N
overall JJ N
survival NN N
was VBD N
11.4 CD N
versus NN N
9.8 CD N
months NNS N
for IN N
arms NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
; : N
estimated VBN N
1-year JJ N
survival NN N
, , N
47.7 CD N
% NN N
versus IN N
39.3 CD N
% NN N
; : N
and CC N
objective JJ N
response NN N
rate NN N
, , N
29.6 CD N
% NN N
versus IN N
25 CD N
% NN N
. . N

The DT N
regimen NN N
was VBD N
well RB N
tolerated VBN N
with IN N
rash NN N
and CC N
hematologic JJ N
toxicity NN N
being VBG N
most RBS N
common JJ N
. . N

CONCLUSIONS VB N
This DT N
study NN N
did VBD N
not RB N
meet VB N
the DT N
prespecified JJ N
benchmark NN N
of IN N
35 CD N
% NN N
6-month JJ N
PFS NNP N
rate NN N
; : N
both DT N
combination NN N
schedules NNS N
of IN N
cetuximab NN 3_i
plus CC 3_i
paclitaxel/carboplatin NN 3_i
were VBD N
feasible JJ N
and CC N
equivalent JJ N
for IN N
treating VBG N
advanced JJ N
NSCLC NNP N
. . N

-DOCSTART- -X- O O

The DT N
management NN N
of IN N
dermoid JJ N
cysts NNS N
-- : N
a DT N
comparative JJ N
study NN N
of IN N
laparoscopy NN 1_i
and CC N
laparotomy NN 1_i
. . N

The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
compare VB N
laparoscopy NN 1_i
with IN N
laparotomy NN 1_i
for IN N
the DT N
removal NN N
of IN N
ovarian JJ N
dermoid NN N
cysts NNS N
. . N

Thirty-eight JJ N
women NNS N
with IN N
benign JJ N
ovarian JJ N
dermoid NN N
cyst NN N
were VBD N
allocated VBN N
for IN N
either DT N
laparoscopy NN 1_i
( ( N
18 CD N
patients NNS N
) ) N
or CC N
laparotomy NN 1_i
( ( N
20 CD N
patients NNS N
) ) N
. . N

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
for IN N
operative JJ N
and CC N
hospitalization NN N
times NNS N
and CC N
postoperative JJ N
course NN N
. . N

Operating NN N
time NN N
was VBD N
longer RB N
( ( N
93.6 CD N
+/- JJ N
23.8 CD N
min NN N
) ) N
and CC N
hospitalization NN N
time NN N
significantly RB N
shorter JJR N
( ( N
22.4 CD N
+/- JJ N
6.6 CD N
h NN N
) ) N
in IN N
the DT N
laparoscopy NN N
group NN N
. . N

No DT N
complications NNS N
were VBD N
reported VBN N
in IN N
either DT N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
operative JJ 1_i
laparoscopy NN 1_i
is VBZ N
a DT N
safe JJ N
procedure NN N
for IN N
the DT N
removal NN N
of IN N
dermoid JJ N
ovarian JJ N
cysts NNS N
and CC N
is VBZ N
as RB N
effective JJ N
as IN N
laparotomy NN 1_i
. . N

-DOCSTART- -X- O O

Beta NNP 2_i
radiation NN 2_i
as IN N
an DT N
adjunct JJ N
to TO N
low-risk JJ N
trabeculectomy NN N
. . N

PURPOSE NNP N
To TO N
assess VB N
a DT N
single JJ N
dose NN N
of IN N
intraoperative JJ 2_i
beta NN 2_i
radiation NN 2_i
used VBN N
to TO N
enhance VB N
the DT N
success NN N
rate NN N
of IN N
trabeculectomy NN N
in IN N
a DT N
population NN N
of IN N
low-risk JJ N
glaucoma NN N
patients NNS N
in IN N
whom WP N
antimetabolites NNS N
might MD N
not RB N
be VB N
indicated VBN N
. . N

METHODS VB N
A DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
65 CD N
eyes NNS N
was VBD N
designed VBN N
, , N
with IN N
31 CD N
eyes NNS N
receiving VBG N
750 CD 2_i
rads NNS 2_i
of IN 2_i
intraoperative JJ 2_i
beta NN 2_i
radiation NN 2_i
( ( N
group NN N
1 CD N
) ) N
, , N
and CC N
34 CD N
eyes NNS N
receiving VBG 7_i
no DT 7_i
supplementation NN 7_i
( ( N
group NN N
2 CD N
) ) N
. . N

RESULTS JJ N
Mean JJ N
follow-up JJ N
time NN N
was VBD N
24 CD N
months NNS N
. . N

Mean NNP N
postoperative JJ N
intraocular JJ N
pressure NN N
was VBD N
12.2 CD N
mmHg NN N
in IN N
group NN N
1 CD N
, , N
and CC N
13.7 CD N
mmHg NN N
in IN N
group NN N
2 CD N
( ( N
P NNP N
= NNP N
0.16 CD N
) ) N
. . N

Mean JJ N
decrease NN N
in IN N
intraocular JJ N
pressure NN N
was VBD N
10.3 CD N
mmHg NN N
in IN N
group NN N
1 CD N
, , N
and CC N
9.3 CD N
mmHg NN N
in IN N
group NN N
2 CD N
( ( N
P NNP N
= NNP N
0.49 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
in IN N
terms NNS N
of IN N
surgical JJ N
complications NNS N
. . N

CONCLUSION NN N
For IN N
this DT N
population NN N
of IN N
low-risk JJ N
patients NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
outcome NN N
after IN N
applications NNS N
of IN N
a DT N
single JJ N
intraoperative JJ N
dose NN N
of IN N
beta NN 2_i
radiation NN 2_i
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
diagnosis NN N
of IN N
deep JJ N
venous JJ N
thrombosis NN N
after IN N
hip NN N
replacement NN N
surgery NN N
] NN N
. . N

Hip NNP N
replacement NN N
surgery NN N
is VBZ N
associated VBN N
with IN N
a DT N
high JJ N
frequency NN N
of IN N
postoperative JJ N
deep JJ N
vein NN N
thrombosis NN N
. . N

This DT N
prospective JJ N
study NN N
was VBD N
performed VBN N
in IN N
order NN N
to TO N
investigate VB N
if IN N
routine JJ 5_i
bedside NN 5_i
questioning VBG 5_i
and CC 5_i
examination NN 5_i
by IN 5_i
the DT 5_i
visiting NN 5_i
doctor NN 5_i
could MD N
reveal VB N
deep JJ N
vein NN N
thrombosis NN N
in IN N
the DT N
legs NN N
of IN N
patients NNS N
who WP N
had VBD N
received VBN N
a DT N
hip NN N
replacement NN N
. . N

258 CD N
patients NNS N
were VBD N
evaluated VBN N
. . N

Thromboprophylaxis NNP 3_i
( ( 3_i
dextran-70 JJ 3_i
, , 3_i
low JJ 3_i
molecular JJ 3_i
weight NN 3_i
heparin NN 3_i
and CC 3_i
graded VBD 2_i
elastic JJ 2_i
stockings NNS 2_i
) ) 3_i
was VBD N
given VBN N
during IN N
the DT N
first JJ N
week NN N
after IN N
operation NN N
. . N

Bilateral NNP 2_i
venography NN 2_i
was VBD N
performed VBN N
in IN N
all DT N
patients NNS N
on IN N
day NN N
seven CD N
after IN N
operation NN N
, , N
and CC N
showed VBD N
an DT N
overall JJ N
deep JJ N
vein NN N
thrombosis NN N
incidence NN N
of IN N
16 CD N
% NN N
. . N

The DT N
visiting NN N
doctors NNS N
had VBD N
not RB N
suspected VBN N
deep JJ N
vein NN N
thrombosis NN N
in IN N
any DT N
of IN N
the DT N
patients NNS N
. . N

This DT N
may MD N
have VB N
been VBN N
because RB N
postoperative JJ N
painful NN N
and CC N
swollen JJ N
legs NNS N
effectively RB N
masked VBD N
any DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
deep JJ N
vein NN N
thrombosis NN N
. . N

Our PRP$ N
results NNS N
show VBP N
that IN N
deep JJ N
vein NN N
thrombosis NN N
during IN N
the DT N
first JJ N
week NN N
after IN N
hip NN N
replacement NN N
surgery NN N
can MD N
not RB N
be VB N
discovered VBN N
by IN N
clinical JJ N
diagnostics NNS N
. . N

The DT N
high JJ N
subclinical JJ N
frequency NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
indicates VBZ N
the DT N
importance NN N
of IN N
improving VBG N
thromboprophylaxis NN N
in IN N
order NN N
to TO N
further RBR N
minimise VB N
the DT N
occurrence NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
and CC N
the DT N
risk NN N
of IN N
thromboembolic JJ N
complications NNS N
. . N

-DOCSTART- -X- O O

Bronchodilator NNP N
effect NN N
of IN N
fenoterol NN 3_i
and CC 3_i
ipratropium NN 3_i
bromide NN 3_i
in IN N
infants NNS N
with IN N
acute JJ N
wheezing NN N
: : N
use NN N
of IN N
MDI NNP N
with IN N
a DT N
spacer NN N
device NN N
. . N

Twenty-eight JJ N
infants NNS N
admitted VBN N
to TO N
Exequiel NNP N
Gonz?lez NNP N
Cortes NNP N
Children NNP N
's POS N
Hospital NNP N
because IN N
of IN N
acute NN N
wheezing NN N
( ( N
AW NNP N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
study NN N
groups NNS N
. . N

Fenoterol NNP N
( ( N
FNT NNP N
) ) N
, , N
ipratropium JJ 3_i
bromide NN 3_i
( ( 3_i
IB NNP 3_i
) ) 3_i
, , N
and CC N
placebo NN 7_i
were VBD N
administered VBN N
respectively RB N
to TO N
children NNS N
in IN N
the DT N
different JJ N
groups NNS N
by IN N
means NNS N
of IN N
metered VBN N
dose JJ N
inhalers NNS N
( ( N
MDI NNP N
) ) N
with IN N
spacers NNS N
, , N
using VBG N
doses NNS N
of IN N
3 CD N
puffs NNS N
every DT N
hour NN N
, , N
for IN N
4 CD N
hours NNS N
. . N

The DT N
degree NN N
of IN N
bronchial JJ N
obstruction NN N
was VBD N
assessed VBN N
clinically RB N
and CC N
scored VBN N
with IN N
the DT N
single-blind JJ N
method NN N
every DT N
hour NN N
prior RB N
to TO N
each DT N
treatment NN N
. . N

The DT N
criterion NN N
of IN N
a DT N
bronchodilator NN N
effect NN N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
degree NN N
of IN N
bronchial JJ N
obstruction NN N
at IN N
subsequent JJ N
scorings NNS N
. . N

The DT N
scores NNS N
of IN N
the DT N
three CD N
groups NNS N
were VBD N
compared VBN N
using VBG N
the DT N
Student NN N
's POS N
t JJ N
test NN N
for IN N
matched JJ N
samples NNS N
. . N

The DT N
same JJ N
test NN N
was VBD N
also RB N
applied VBN N
to TO N
the DT N
independent JJ N
samples NNS N
for IN N
determining VBG N
the DT N
superiority NN N
of IN N
one CD N
treatment NN N
, , N
FNT NNP N
or CC N
IB NNP N
, , N
over IN N
the DT N
other JJ N
. . N

The DT N
results NNS N
indicated VBD N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
scores NNS N
of IN N
the DT N
groups NNS N
receiving VBG N
FNT NNP N
and CC N
IB NNP N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
; : N
this DT N
did VBD N
not RB N
occur VB N
in IN N
the DT N
group NN N
in IN N
which WDT N
placebo NN N
was VBD N
used VBN N
. . N

FNT NNP N
produced VBD N
a DT N
more RBR N
rapid JJ N
and CC N
sustained VBD N
effect NN N
than IN N
IB NNP N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Significant JJ N
bronchodilator NN N
effect NN N
was VBD N
obtained VBN N
in IN N
infants NNS N
with IN N
AW NNP N
when WRB N
repeated VBN N
doses NNS N
of IN N
FNT NNP N
or CC N
IB NNP N
were VBD N
administered VBN N
with IN N
MDI NNP N
and CC N
spacers NNS N
. . N

This DT N
effect NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
group NN N
treated VBD N
with IN N
FNT NNP N
. . N

-DOCSTART- -X- O O

Continuous JJ N
low-level JJ N
heatwrap NN N
therapy NN N
for IN N
treating VBG N
acute JJ N
nonspecific NN N
low JJ N
back RB N
pain NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
8 CD N
hours NNS N
of IN N
continuous JJ 2_i
low-level JJ 2_i
heatwrap NN 2_i
therapy NN 2_i
for IN N
the DT N
treatment NN N
of IN N
acute JJ N
nonspecific NN N
low JJ N
back RB N
pain NN N
( ( N
LBP NNP N
) ) N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
parallel JJ N
, , N
single-blind JJ N
( ( N
investigator NN N
) ) N
, , N
placebo-controlled JJ 7_i
, , N
multicenter JJ N
clinical JJ N
trial NN N
. . N

SETTING NN N
Five CD N
community-based JJ N
research NN N
facilities NNS N
. . N

PARTICIPANTS VB N
Two-hundred JJ N
nineteen JJ N
subjects NNS N
, , N
aged VBD N
18 CD N
to TO N
55 CD N
years NNS N
, , N
with IN N
acute JJ N
nonspecific JJ N
LBP NNP N
. . N

INTERVENTION NNP N
Subjects NNPS N
were VBD N
stratified VBN N
by IN N
baseline NN N
pain NN N
intensity NN N
and CC N
gender NN N
and CC N
randomized VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
groups NNS N
: : N
evaluation NN N
of IN N
efficacy NN N
( ( N
heatwrap NN 2_i
, , 2_i
n=95 RB 2_i
; : 2_i
oral JJ 2_i
placebo NN 2_i
, , 2_i
n=96 NN 2_i
) ) 2_i
and CC N
blinding VBG 7_i
( ( 7_i
oral JJ 7_i
ibuprofen NN 7_i
, , 7_i
n=12 RB 7_i
; : 7_i
unheated VBN 7_i
back RB 7_i
, , 7_i
wrap NN 7_i
n=16 NN 7_i
) ) 7_i
. . N

All DT N
treatments NNS N
were VBD N
administered VBN N
for IN N
3 CD N
consecutive JJ N
days NNS N
with IN N
2 CD N
days NNS N
of IN N
follow-up JJ N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
: : N
day NN N
1 CD N
mean NN N
pain NN N
relief NN N
( ( N
0- JJ N
to TO N
5-point JJ N
verbal JJ N
response NN N
scale NN N
) ) N
. . N

Secondary JJ N
: : N
muscle NN N
stiffness NN N
( ( N
101-point JJ N
numeric NN N
rating NN N
scale NN N
) ) N
, , N
lateral JJ N
trunk NN N
flexibility NN N
( ( N
fingertip-floor JJ N
distance NN N
) ) N
, , N
and CC N
Roland-Morris NNP N
Disability NNP N
Questionnaire NNP N
over IN N
3 CD N
days NNS N
of IN N
treatment NN N
and CC N
2 CD N
days NNS N
of IN N
follow-up JJ N
. . N

RESULTS NNP N
Heatwrap NNP 2_i
therapy NN 2_i
was VBD N
shown VBN N
to TO N
provide VB N
significant JJ N
therapeutic JJ N
benefits NNS N
when WRB N
compared VBN N
with IN N
placebo NN 7_i
during IN N
both CC N
the DT N
treatment NN N
and CC N
follow-up JJ N
period NN N
. . N

On IN N
day NN N
1 CD N
, , N
the DT N
heatwrap NN 2_i
group NN N
had VBD N
greater JJR N
pain NN N
relief NN N
( ( N
1.76+/-.10 JJ N
vs NN N
1.05+/-.11 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
less JJR N
muscle NN N
stiffness NN N
( ( N
43.1+/-1.21 JJ N
vs NN N
47.6+/-1.21 CD N
, , N
P=.008 NNP N
) ) N
, , N
and CC N
increased VBD N
flexibility NN N
( ( N
18.6+/-.44 JJ N
cm NN N
vs IN N
16.5+/-.45 JJ N
cm NN N
, , N
P=.001 NNP N
) ) N
compared VBN N
with IN N
placebo NN 7_i
. . N

Disability NN N
was VBD N
also RB N
reduced VBN N
in IN N
the DT N
heatwrap NN 2_i
group NN N
( ( N
5.3 CD N
vs NN N
7.4 CD N
, , N
P=.0002 NNP N
) ) N
. . N

Adverse JJ N
events NNS N
were VBD N
mild JJ N
and CC N
infrequent JJ N
. . N

CONCLUSION NNP N
Continuous NNP N
low-level JJ N
heatwrap NN 2_i
therapy NN 2_i
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
for IN N
the DT N
treatment NN N
of IN N
acute NN N
, , N
nonspecific JJ N
LBP NNP N
. . N

-DOCSTART- -X- O O

Microbial JJ N
protein NN N
synthesis NN N
, , N
nitrogen JJ N
capture NN N
efficiency NN N
and CC N
nutrient JJ N
utilisation NN N
in IN N
sheep JJ N
fed NN N
on IN N
finger NN 3_i
millet NN 3_i
straw NN 3_i
( ( 3_i
Eleucine NNP 3_i
coracana NN 3_i
) ) 3_i
-based VBD 3_i
diet JJ N
with IN N
different JJ N
rumen-degradable JJ N
nitrogen NN N
levels NNS N
. . N

BACKGROUND NNP N
Microbial NNP N
protein NN N
synthesised VBD N
in IN N
the DT N
rumen NNS N
is VBZ N
a DT N
very RB N
important JJ N
protein NN N
source NN N
for IN N
ruminants NNS N
. . N

It PRP N
is VBZ N
essential JJ N
to TO N
provide VB N
an DT N
adequate JJ N
amount NN N
of IN N
rumen-degradable JJ N
nitrogen NN N
( ( N
RDN NNP N
) ) N
for IN N
optimum JJ N
microbial JJ N
protein NN N
synthesis NN N
in IN N
the DT N
rumen NNS N
on IN N
straw-based JJ N
diets NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
RDN NNP N
requirement NN N
for IN N
optimum JJ N
microbial JJ N
protein NN N
synthesis NN N
( ( N
MPS NNP N
) ) N
, , N
nitrogen JJ N
capture NN N
efficiency NN N
( ( N
NCE NNP N
) ) N
and CC N
nutrient JJ N
utilisation NN N
in IN N
Nellore NNP N
rams NNS N
fed VBP N
on IN N
a DT N
finger NN 3_i
millet NN 3_i
straw NN 3_i
( ( 3_i
FMS NNP 3_i
) ) 3_i
-based VBD 3_i
diet JJ 3_i
. . N

RESULTS VB N
Thirty-six JJ N
Nellore NNP N
sheep NN N
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
of IN N
nine CD N
animals NNS N
each DT N
using VBG N
a DT N
balanced VBN N
, , N
completely RB N
randomised JJ N
design NN N
. . N

The DT N
animals NNS N
in IN N
group NN N
1 CD N
( ( N
RDN0 NNP N
) ) N
were VBD N
fed VBN N
with IN N
ad NN 3_i
libitum NN 3_i
FMS NNP 3_i
. . N

Those DT N
in IN N
groups NNS N
2 CD N
, , N
3 CD N
and CC N
4 CD N
( ( N
RDN1 NNP N
, , N
RDN2 NNP N
and CC N
RDN3 NNP N
) ) N
were VBD N
supplemented VBN N
with IN N
groundnut NNS 3_i
cake VBP 3_i
to TO N
provide VB N
RDN NNP N
levels NNS N
of IN N
14 CD N
, , N
18 CD N
and CC N
23 CD N
g NN N
RDN NNP N
kg?? NNP N
digestible JJ N
organic JJ N
matter NN N
intake NN N
( ( N
DOMI NNP N
) ) N
or CC N
21 CD N
, , N
27 CD N
and CC N
35 CD N
g NN N
RDN NNP N
kg?? NNP N
digestible JJ N
organic JJ N
matter NN N
apparently RB N
digested VBN N
in IN N
the DT N
rumen NNS N
( ( N
DOMR NNP N
) ) N
respectively RB N
along IN N
with IN N
FMS NNP N
. . N

The DT N
digestibility NN N
coefficients NNS N
of IN N
all DT N
nutrients NNS N
and CC N
MPS NNP N
increased VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
quadratically RB N
with IN N
increasing VBG N
level NN N
of IN N
RDN NNP N
supplementation NN N
. . N

NCE NNP N
decreased VBD N
linearly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
the DT N
level NN N
of IN N
RDN NNP N
increased VBD N
. . N

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
12 CD N
g NNS N
RDN NNP N
kg?? VBP N
DOMI NNP N
or CC N
19 CD N
g NNS N
RDN NNP N
kg?? VBD N
DOMR NNP N
may MD N
be VB N
adequate JJ N
for IN N
optimum JJ N
MPS NNP N
, , N
NCE NNP N
and CC N
digestibility NN N
of IN N
nutrients NNS N
in IN N
sheep JJ N
fed NN N
on IN N
an DT N
FMS-based JJ N
diet NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
misoprostol NN 3_i
on IN N
human JJ N
circulation NN N
. . N

Prostaglandins NNP N
( ( N
PGs NNP N
) ) N
of IN N
the DT N
E-type NNP N
are VBP N
potent JJ N
vasodilators NNS N
in IN N
most JJS N
species NNS N
and CC N
in IN N
most JJS N
vascular JJ N
beds NNS N
. . N

However RB N
, , N
vasoconstrictor JJ N
effects NNS N
of IN N
PGEs NNP N
have VBP N
also RB N
been VBN N
noted VBN N
at IN N
selected VBN N
sites NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
misoprostol NN 3_i
, , N
a DT N
PGE1 NNP N
analog NN N
with IN N
antiulcer NN N
activity NN N
, , N
on IN N
the DT N
human JJ N
cardiovascular NN N
system NN N
. . N

Twenty NNP N
healthy JJ N
subjects NNS N
participated VBN N
in IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
. . N

Following VBG N
a DT N
12 CD N
hour NN N
fast NN N
, , N
heart NN N
rate NN N
, , N
arterial JJ N
blood NN N
pressure NN N
, , N
light JJ N
reflex JJ N
plethysmography NN N
of IN N
the DT N
finger NN N
, , N
resting VBG N
blood NN N
flow NN N
volume NN N
in IN N
the DT N
lower JJR N
arm NN N
and CC N
leg NN N
and CC N
peripheral JJ N
vascular JJ N
resistance NN N
were VBD N
measured VBN N
at IN N
10 CD N
min NN N
. . N

intervals NNS N
for IN N
1 CD N
hour NN N
prior RB N
to TO N
drug NN N
administration NN N
, , N
to TO N
permit VB N
calculating VBG N
baseline NN N
values NNS N
. . N

Misoprostol NNP 3_i
( ( N
400 CD N
mcg NN N
) ) N
or CC N
its PRP$ N
matching JJ N
placebo NN 7_i
were VBD N
administered VBN N
orally RB N
, , N
and CC N
the DT N
measurements NNS N
were VBD N
repeated VBN N
at IN N
10 CD N
min NN N
. . N

intervals NNS N
over IN N
the DT N
next JJ N
2 CD N
hours NNS N
. . N

A DT N
decrease NN N
in IN N
leg NN N
blood NN N
flow NN N
volume NN N
and CC N
a DT N
corresponding JJ N
increase NN N
in IN N
leg JJ N
peripheral JJ N
vascular JJ N
resistance NN N
were VBD N
noted VBN N
in IN N
the DT N
misoprostol NN 3_i
group NN N
. . N

A DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
heart NN N
rate NN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
was VBD N
also RB N
noted VBN N
. . N

These DT N
small JJ N
changes NNS N
were VBD N
not RB N
considered VBN N
to TO N
be VB N
of IN N
clinical JJ N
importance NN N
. . N

No DT N
adverse JJ N
experiences NNS N
were VBD N
reported VBN N
. . N

In IN N
conclusion NN N
, , N
a DT N
single JJ N
dose NN N
of IN N
misoprostol NN 3_i
( ( N
400 CD N
mcg NN N
) ) N
has VBZ N
no DT N
clinically RB N
significant JJ N
vasoconstrictive JJ N
or CC N
vasodilative JJ N
properties NNS N
in IN N
man NN N
. . N

-DOCSTART- -X- O O

A DT N
six-month JJ N
crossover NN N
chemoprevention NN N
clinical JJ N
trial NN N
of IN N
tea NN 2_i
in IN N
smokers NNS N
and CC N
non-smokers NNS N
: : N
methodological JJ N
issues NNS N
in IN N
a DT N
feasibility NN N
study NN N
. . N

BACKGROUND NNP N
Chemoprevention NNP N
crossover NN N
trials NNS N
of IN N
tea NN N
can MD N
be VB N
more RBR N
efficient JJ N
than IN N
parallel JJ N
designs NNS N
but CC N
the DT N
attrition NN N
and CC N
compliance NN N
rates NNS N
with IN N
such JJ N
trials NNS N
are VBP N
unknown JJ N
. . N

METHODS NNP N
Attrition NNP N
( ( N
dropouts NNS N
) ) N
and CC N
compliance NN N
with IN N
treatment NN N
were VBD N
assessed VBN N
in IN N
a DT N
25-week JJ N
randomized NN N
, , N
placebo NN N
controlled VBD N
, , N
crossover NN N
, , N
feasibility NN N
clinical JJ N
trial NN N
of IN N
four CD 2_i
tea NN 2_i
treatments NNS 2_i
to TO N
investigate VB N
the DT N
effect NN N
of IN N
tea NN N
on IN N
oral JJ N
cancer NN N
biomarkers NNS N
. . N

Each DT N
treatment NN N
lasted VBD N
4 CD N
weeks NNS N
with IN N
2 CD N
weeks NNS N
of IN N
washout NN N
in IN N
between IN N
. . N

Participants NNS N
were VBD N
32 CD N
smokers NNS N
and CC N
33 CD N
non-smokers NNS N
without IN N
any DT N
evidence NN N
of IN N
premalignant JJ N
oral JJ N
lesions NNS N
. . N

The DT N
interventions NNS N
consisted VBD N
of IN N
packets NNS N
of IN N
green JJ N
tea NN N
, , N
black JJ N
tea NN N
, , N
caffeinated JJ N
water NN N
, , N
or CC N
placebo NN N
. . N

Participants NNS N
were VBD N
assigned VBN N
to TO N
each DT N
treatment NN N
for IN N
four CD N
weeks NNS N
, , N
and CC N
were VBD N
instructed VBN N
to TO N
drink VB N
five CD N
packets NNS N
per IN N
day NN N
while IN N
on IN N
the DT N
treatment NN N
. . N

Dropout IN N
from IN N
the DT N
trial NN N
and CC N
compliance NN N
( ( N
consumption NN N
of IN N
?85 NNP N
% NN N
of IN N
the DT N
prescribed JJ N
treatment NN N
packets NNS N
) ) N
are VBP N
the DT N
main JJ N
outcome NN N
measures NNS N
reported VBN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
high JJ N
rate NN N
of IN N
dropout NN N
( ( N
51 CD N
% NN N
) ) N
from IN N
the DT N
study NN N
, , N
and CC N
the DT N
rates NNS N
were VBD N
significantly RB N
higher JJR N
among IN N
smokers NNS N
( ( N
64 CD N
% NN N
) ) N
than IN N
non-smokers NNS N
( ( N
36 CD N
% NN N
) ) N
. . N

Among IN N
participants NNS N
who WP N
completed VBD N
the DT N
study NN N
the DT N
rate NN N
of IN N
compliance NN N
was VBD N
72 CD N
% NN N
. . N

The DT N
highest JJS N
rates NNS N
of IN N
dropouts NNS N
occurred VBD N
between IN N
the DT N
first JJ N
and CC N
second JJ N
treatment NN N
visits NNS N
in IN N
both DT N
smokers NNS N
( ( N
38 CD N
% NN N
dropout NN N
) ) N
and CC N
non-smokers NNS N
( ( N
18 CD N
% NN N
dropout NN N
) ) N
. . N

Throughout IN N
the DT N
study NN N
smokers NNS N
were VBD N
more RBR N
likely JJ N
to TO N
dropout VB N
than IN N
non-smokers NNS N
. . N

Black NNP N
tea NN N
treatment NN N
was VBD N
associated VBN N
with IN N
the DT N
highest JJS N
rates NNS N
of IN N
dropout NN N
among IN N
smokers NNS N
( ( N
37 CD N
% NN N
) ) N
, , N
but CC N
was VBD N
associated VBN N
with IN N
the DT N
lowest JJS N
rate NN N
of IN N
dropout NN N
among IN N
non-smokers NNS N
( ( N
4 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
a DT N
study NN N
conducted VBN N
to TO N
test VB N
the DT N
feasibility NN N
of IN N
a DT N
four-treatment JJ N
crossover NN N
tea NN N
trial NN N
, , N
a DT N
high JJ N
rate NN N
of IN N
dropout NN N
among IN N
smokers NNS N
and CC N
non-smokers NNS N
was VBD N
observed VBN N
. . N

Multi-arm JJ N
crossover NN N
tea NN N
trials NNS N
might MD N
pose VB N
a DT N
higher JJR N
burden NN N
on IN N
participants NNS N
and CC N
research NN N
is VBZ N
needed VBN N
to TO N
improve VB N
adherence NN N
and CC N
treatment NN N
compliance NN N
in IN N
such JJ N
trials NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN70410203 NNP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
reinforcement NN N
or CC N
stimulus NN N
control NN N
to TO N
reduce VB N
sedentary JJ N
behavior NN N
in IN N
the DT N
treatment NN N
of IN N
pediatric JJ N
obesity NN N
. . N

Obese JJ N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
family-based JJ 4_i
behavioral JJ 4_i
treatment NN 4_i
that WDT N
included VBD N
either DT N
stimulus NN N
control NN N
or CC N
reinforcement NN N
to TO N
reduce VB N
sedentary JJ N
behaviors NNS N
. . N

Significant NNP N
and CC N
equivalent JJ N
decreases NNS N
in IN N
sedentary JJ N
behavior NN N
and CC N
high JJ N
energy NN N
density NN N
foods NNS N
, , N
increases NNS N
in IN N
physical JJ N
activity NN N
and CC N
fruits NNS N
and CC N
vegetables NNS N
, , N
and CC N
decreases NNS N
in IN N
standardized JJ N
body NN N
mass NN N
index NN N
( ( N
z-BMI NN N
) ) N
were VBD N
observed VBN N
. . N

Children NNP N
who WP N
substituted VBD N
active JJ N
for IN N
sedentary JJ N
behaviors NNS N
had VBD N
significantly RB N
greater JJR N
z-BMI JJ N
changes NNS N
at IN N
6 CD N
( ( N
-1.21 NNP N
vs. IN N
-0.76 NNP N
) ) N
and CC N
12 CD N
( ( N
-1.05 NNP N
vs. IN N
-0.51 NNP N
) ) N
months NNS N
, , N
respectively RB N
. . N

Substitution NN N
of IN N
physically RB N
active JJ N
for IN N
sedentary JJ N
behaviors NNS N
and CC N
changes NNS N
in IN N
activity NN N
level NN N
predicted VBD N
6- CD N
and CC N
12-month JJ N
z-BMI NN N
changes NNS N
. . N

Results NNS N
suggest VBP N
stimulus JJ N
control NN N
and CC N
reinforcing VBG N
reduced VBN N
sedentary JJ N
behaviors NNS N
are VBP N
equivalent JJ N
ways NNS N
to TO N
decrease VB N
sedentary JJ N
behaviors NNS N
, , N
and CC N
behavioral JJ N
economic JJ N
relationships NNS N
in IN N
eating NN N
and CC N
activity NN N
may MD N
mediate VB N
the DT N
effects NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Comparative NNP N
study NN N
for IN N
the DT N
effect NN N
of IN N
photodynamic JJ 3_i
therapy NN 3_i
, , N
imiquimod JJ 3_i
immunotherapy NN 3_i
and CC N
combination NN 3_i
of IN 3_i
both DT 3_i
therapies NNS 3_i
on IN N
40 CD N
lesions NNS N
of IN N
actinic JJ N
keratosis NN N
in IN N
Japanese JJ N
patients NNS N
. . N

We PRP N
treated VBD N
12 CD N
, , N
15 CD N
and CC N
13 CD N
Japanese JJ N
actinic JJ N
keratosis NN N
( ( N
AK NNP N
) ) N
lesions NNS N
with IN N
5-aminolevulinic JJ 3_i
acid JJ 3_i
photodynamic JJ 3_i
therapy NN 3_i
( ( 3_i
PDT NNP 3_i
) ) 3_i
, , N
5 CD 3_i
% NN 3_i
imiquimod JJ 3_i
cream NN 3_i
and CC N
combination NN 3_i
of IN 3_i
both DT 3_i
therapies NNS 3_i
, , N
respectively RB N
, , N
and CC N
compared VBN N
the DT N
effects NNS N
. . N

Patients NNS N
underwent VBD N
the DT N
second JJ N
course NN N
, , N
when WRB N
AK NNP N
lesions NNS N
remained VBD N
after IN N
the DT N
first JJ N
course NN N
. . N

Efficacy NNP N
was VBD N
evaluated VBN N
1 CD N
month NN N
after IN N
each DT N
treatment NN N
. . N

Combination NNP N
therapy NN N
cleared VBD N
all DT N
AK NNP N
lesions NNS N
only RB N
after IN N
the DT N
first JJ N
course NN N
, , N
while IN N
PDT NNP N
and CC N
imiquimod JJ N
therapy NN N
cleared VBD N
41.7 CD N
% NN N
and CC N
66.7 CD N
% NN N
of IN N
AK NNP N
lesions NNS N
after IN N
the DT N
first JJ N
course NN N
, , N
respectively RB N
. . N

All DT N
residual JJ N
AK NNP N
lesions NNS N
after IN N
the DT N
first JJ N
course NN N
were VBD N
cleared VBN N
by IN N
the DT N
second JJ N
courses NNS N
of IN N
PDT NNP N
or CC N
imiquimod JJ N
therapy NN N
. . N

During IN N
the DT N
course NN N
, , N
erosion NN N
and CC N
crust NN N
developed VBD N
significantly RB N
more RBR N
frequently RB N
in IN N
combination NN N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Most JJS N
Japanese JJ N
AK NNP N
lesions NNS N
can MD N
be VB N
satisfactorily RB N
treated VBN N
with IN N
either DT N
PDT NNP N
or CC N
imiquimod JJ N
monotherapy NN N
. . N

However RB N
, , N
only RB N
severe JJ N
cases NNS N
may MD N
better RB N
be VB N
treated VBN N
with IN N
combination NN N
therapy NN N
, , N
which WDT N
show VBP N
higher JJR N
efficacy NN N
even RB N
though IN N
adverse JJ N
events NNS N
occur VBP N
frequently RB N
. . N

-DOCSTART- -X- O O

Naltrexone NN 3_i
in IN N
autistic JJ N
children NNS N
: : N
behavioral NN N
symptoms NNS N
and CC N
attentional JJ N
learning NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
critically RB N
the DT N
short-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
naltrexone NN 3_i
in IN N
autistic JJ N
children NNS N
and CC N
its PRP$ N
effects NNS N
on IN N
discrimination NN N
learning NN N
in IN N
the DT N
laboratory NN N
. . N

METHOD NNP N
A NNP N
parallel JJ N
group NN N
design NN N
was VBD N
employed VBN N
. . N

After IN N
a DT N
2-week JJ N
placebo NN N
baseline NN N
period NN N
, , N
children NNS N
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
naltrexone CD 3_i
or CC N
to TO N
placebo VB 7_i
for IN N
a DT N
period NN N
of IN N
3 CD N
weeks NNS N
followed VBN N
by IN N
a DT N
one-week JJ N
posttreatment NN N
placebo NN N
period NN N
. . N

Multiple JJ N
raters NNS N
and CC N
rating NN N
scales NNS N
were VBD N
employed VBN N
in IN N
a DT N
variety NN N
of IN N
conditions NNS N
. . N

Forty-one CD N
children NNS N
, , N
all DT N
inpatients NNS N
, , N
ages VBZ N
2.9 CD N
to TO N
7.8 CD N
years NNS N
, , N
completed VBD N
the DT N
study NN N
. . N

Naltrexone NNP 3_i
reduced VBD N
hyperactivity NN N
and CC N
had VBD N
no DT N
effect NN N
on IN N
discrimination NN N
learning NN N
in IN N
the DT N
laboratory NN N
. . N

There EX N
was VBD N
a DT N
suggestion NN N
that IN N
it PRP N
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
decreasing VBG N
self-injurious JJ N
behavior NN N
. . N

Untoward JJ N
effects NNS N
were VBD N
mild JJ N
and CC N
transient NN N
. . N

CONCLUSION NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
naltrexone RB N
significantly RB N
reduced VBN N
only RB N
hyperactivity NN N
, , N
and CC N
no DT N
serious JJ N
untoward JJ N
effects NNS N
were VBD N
observed VBN N
. . N

The DT N
effectiveness NN N
of IN N
naltrexone NN 3_i
in IN N
the DT N
treatment NN N
of IN N
autism NN N
and CC N
self-injurious JJ N
behavior NN N
requires VBZ N
additional JJ N
assessment NN N
in IN N
a DT N
sample NN N
of IN N
children NNS N
with IN N
moderate JJ N
to TO N
severe VB N
self-injurious JJ N
behavior NN N
. . N

-DOCSTART- -X- O O

5 CD N
FU NNP N
infusion NN N
with IN N
mitomycin-C JJ 3_i
vs. FW 3_i
5 CD 3_i
FU NNP 3_i
infusion NN 3_i
with IN 3_i
methyl-CCNU NN 3_i
in IN N
the DT N
treatment NN N
of IN N
advanced JJ N
upper JJ N
gastrointestinal JJ N
cancer NN N
: : N
a DT N
Southwest NNP N
Oncology NNP N
Group NNP N
Study NNP N
. . N

A NNP N
randomized JJ N
trial NN N
was VBD N
conducted VBN N
by IN N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
( ( N
SWOG NNP N
) ) N
in IN N
advanced JJ N
carcinoma NN N
of IN N
the DT N
stomach NN N
and CC N
pancreas NNS N
. . N

Patients NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
monthly JJ N
5-fluorouracil JJ 3_i
96-hour CD 3_i
continuous JJ 3_i
infusions NNS 3_i
with IN N
either DT N
bolus JJ 3_i
mitomycin-C NN 3_i
or CC 3_i
oral JJ 3_i
methyl-CCNU JJ 3_i
. . N

Mitomycin-C JJ 3_i
and CC 3_i
methyl-CCNU JJ 3_i
were VBD N
administered VBN N
every DT N
eight CD N
weeks NNS N
. . N

The DT N
5 CD 3_i
FU-mitomycin JJ 3_i
combination NN 3_i
produced VBD N
a DT N
14 CD N
% NN N
and CC N
22 CD N
% NN N
response NN N
rate NN N
in IN N
disseminated VBN N
stomach NN N
and CC N
pancreatic JJ N
carcinoma NN N
, , N
respectively RB N
. . N

The DT N
combination NN 3_i
of IN 3_i
infusion NN 3_i
5 CD 3_i
FU NNP 3_i
and CC 3_i
methyl-CCNU JJ 3_i
achieved JJ N
responses NNS N
in IN N
9 CD N
% NN N
and CC N
5 CD N
% NN N
of IN N
stomach NN N
and CC N
pancreatic JJ N
tumors NNS N
, , N
respectively RB N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
survival NN N
between IN N
limbs NNS N
for IN N
either DT N
tumor NN N
. . N

Median JJ N
survival NN N
in IN N
gastric JJ N
carcinoma NN N
on IN N
the DT N
5 CD 3_i
FU-mitomycin JJ 3_i
regimen NNS N
was VBD N
25 CD N
weeks NNS N
vs. RB N
18 CD N
weeks NNS N
on IN N
the DT N
5 CD 3_i
FU-METHYL-CCNU JJ 3_i
arm NN N
. . N

In IN N
pancreatic JJ N
carcinoma NN N
median JJ N
survival NN N
on IN N
the DT N
mitomycin NN N
limb NN N
was VBD N
19 CD N
weeks NNS N
as RB N
compared VBN N
to TO N
17 CD N
weeks NNS N
on IN N
the DT N
methyl-CCNU JJ 3_i
program NN N
. . N

Leukopenia NNP N
was VBD N
greater JJR N
for IN N
the DT N
first JJ N
course NN N
on IN N
the DT N
mitomycin NN 3_i
limb NN N
. . N

Regression NNP N
analysis NN N
demonstrated VBD N
that IN N
performance NN N
status NN N
was VBD N
the DT N
most RBS N
important JJ N
pretreatment NN N
characteristic NN N
for IN N
predicting VBG N
survival NN N
in IN N
both DT N
tumors NNS N
. . N

Neither CC N
5 CD 3_i
FU NNP 3_i
infusion NN 3_i
combination NN N
appears VBZ N
to TO N
significantly RB N
alter VB N
the DT N
dismal JJ N
prognosis NN N
of IN N
advanced JJ N
upper JJ N
gastrointestinal JJ N
neoplasms NNS N
. . N

-DOCSTART- -X- O O

Combining VBG N
afferent JJ 2_i
stimulation NN 2_i
and CC N
mirror NN 2_i
therapy NN 2_i
for IN N
rehabilitating VBG N
motor NN N
function NN N
, , N
motor NN N
control NN N
, , N
ambulation NN N
, , N
and CC N
daily JJ N
functions NNS N
after IN N
stroke NN N
. . N

BACKGROUND NNP N
Mirror NNP 2_i
therapy NN 2_i
( ( 2_i
MT NNP 2_i
) ) 2_i
and CC N
mesh JJ 2_i
glove NN 2_i
( ( 2_i
MG NNP 2_i
) ) 2_i
afferent NN 2_i
stimulation NN 2_i
may MD N
be VB N
effective JJ N
in IN N
reducing VBG N
motor NN N
impairment NN N
after IN N
stroke NN N
. . N

A DT N
hybrid JJ N
intervention NN N
of IN N
MT NNP 2_i
combined VBD 2_i
with IN 2_i
MG NNP 2_i
( ( 2_i
MT NNP 2_i
+ NNP 2_i
MG NNP 2_i
) ) 2_i
may MD N
broaden VB N
aspects NNS N
of IN N
treatment NN N
benefits NNS N
. . N

OBJECTIVE NNP N
To TO N
demonstrate VB N
the DT N
comparative JJ N
effects NNS N
of IN N
MG NNP 2_i
+ NNP 2_i
MT NNP 2_i
, , 2_i
MT NNP 2_i
, , N
and CC N
a DT N
control NN 7_i
treatment NN 7_i
( ( 7_i
CT NNP 7_i
) ) 7_i
on IN N
the DT N
outcomes NNS N
of IN N
motor NN N
impairments NNS N
, , N
manual JJ N
dexterity NN N
, , N
ambulation NN N
function NN N
, , N
motor NN N
control NN N
, , N
and CC N
daily JJ N
function NN N
. . N

METHODS NNP N
Forty-three JJ N
chronic JJ N
stroke NN N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
upper JJ N
extremity NN N
impairment NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
MT NNP 2_i
+ NNP 2_i
MG NNP 2_i
, , N
MT NNP 2_i
, , N
or CC N
CT NNP 7_i
for IN N
1.5 CD N
hours/day NN N
, , N
5 CD N
days/week NN N
for IN N
4 CD N
weeks NNS N
. . N

Outcome NNP N
measures NNS N
were VBD N
the DT N
Fugl-Meyer NNP N
Assessment NNP N
( ( N
FMA NNP N
) ) N
and CC N
muscle NN N
tone NN N
measured VBN N
by IN N
Myoton-3 NNP N
for IN N
motor NN N
impairment NN N
and CC N
the DT N
Box NNP N
and CC N
Block NNP N
Test NNP N
( ( N
BBT NNP N
) ) N
and CC N
10-Meter JJ N
Walk NNP N
Test NNP N
( ( N
10 CD N
MWT NNP N
) ) N
for IN N
motor NN N
function NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
kinematic JJ N
parameters NNS N
for IN N
motor NN N
control NN N
and CC N
the DT N
Motor NNP N
Activity NNP N
Log NNP N
and CC N
ABILHAND NNP N
Questionnaire NNP N
for IN N
daily JJ N
function NN N
. . N

RESULTS NNP N
FMA NNP N
total JJ N
scores NNS N
were VBD N
significantly RB N
higher JJR N
and CC N
synergistic JJ N
shoulder NN N
abduction NN N
during IN N
reach NN N
was VBD N
less RBR N
in IN N
the DT N
MT NNP 2_i
+ NNP 2_i
MG NNP 2_i
and CC N
MT NNP 2_i
groups NNS N
compared VBN N
with IN N
the DT N
CT NNP 7_i
group NN N
. . N

Performance NN N
on IN N
the DT N
BBT NNP N
and CC N
the DT N
10 CD N
MWT NNP N
( ( N
velocity NN N
and CC N
stride JJ N
length NN N
in IN N
self-paced JJ N
task NN N
and CC N
velocity NN N
in IN N
as-quickly-as-possible JJ N
task NN N
) ) N
were VBD N
improved VBN N
after IN N
MT NNP 2_i
+ NNP 2_i
MG NNP 2_i
compared VBN N
with IN N
MT NNP 2_i
. . N

CONCLUSIONS NNP N
MT NNP 2_i
+ NNP 2_i
MG NNP 2_i
improved VBD N
manual JJ N
dexterity NN N
and CC N
ambulation NN N
. . N

MT NNP 2_i
+ NNP 2_i
MG NNP 2_i
and CC N
MT NNP 2_i
reduced VBD N
motor NN N
impairment NN N
and CC N
synergistic JJ N
shoulder NN N
abduction NN N
more JJR N
than IN N
CT. NNP 7_i
Future NNP N
studies NNS N
may MD N
integrate VB N
functional JJ N
task NN N
practice NN N
into IN N
treatments NNS N
to TO N
enhance VB N
functional JJ N
outcomes NNS N
in IN N
patients NNS N
with IN N
various JJ N
levels NNS N
of IN N
motor NN N
severity NN N
. . N

The DT N
long-term JJ N
effects NNS N
of IN N
MG NNP 2_i
+ NNP 2_i
MT NNP 2_i
remain VBP N
to TO N
be VB N
evaluated VBN N
. . N

-DOCSTART- -X- O O

Cost NNP N
effectiveness NN N
of IN N
training VBG N
incontinent JJ N
elderly RB N
in IN N
nursing VBG N
homes NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
clinical JJ N
trial NN N
with IN N
133 CD N
incontinent JJ N
elderly RB N
in IN N
seven CD N
nursing NN N
homes NNS N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
behavioral JJ 5_i
training NN 5_i
therapy NN 5_i
and CC N
its PRP$ N
cost NN N
implications NNS N
. . N

The DT N
training NN N
program NN N
lasted VBD N
three CD N
months NNS N
, , N
and CC N
a DT N
22-week JJ N
follow-up JJ N
period NN N
examined VBD N
the DT N
durability NN N
of IN N
the DT N
treatment NN N
effect NN N
. . N

The DT N
therapy NN N
became VBD N
effective JJ N
after IN N
six CD N
weeks NNS N
of IN N
training NN N
. . N

By IN N
the DT N
final JJ N
months NNS N
of IN N
training NN N
, , N
the DT N
treatment NN N
participants NNS N
' POS N
wet NN N
episodes NNS N
had VBD N
been VBN N
reduced VBN N
by IN N
0.6 CD N
episode NNS N
per IN N
day NN N
, , N
or CC N
a DT N
26 CD N
percent NN N
reduction NN N
over IN N
baseline NN N
, , N
and CC N
improvement NN N
was VBD N
maintained VBN N
during IN N
the DT N
follow-up JJ N
period NN N
. . N

Trainees NNS N
with IN N
a DT N
high JJ N
frequency NN N
of IN N
incontinence NN N
during IN N
baseline NN N
, , N
relatively RB N
more RBR N
cognitive JJ N
residents NNS N
, , N
and CC N
residents NNS N
with IN N
a DT N
normal JJ N
bladder NN N
capacity NN N
responded VBD N
better JJR N
to TO N
this DT N
behavioral JJ 4_i
program NN 4_i
. . N

The DT N
cost NN N
of IN N
training NN N
was VBD N
the DT N
equivalent NN N
of IN N
about IN N
one CD N
hour NN N
of IN N
nursing VBG N
aide JJ N
time NN N
per IN N
patient JJ N
day NN N
. . N

The DT N
reduction NN N
in IN N
incontinence NN N
during IN N
the DT N
follow-up JJ N
period NN N
resulted VBD N
in IN N
some DT N
small JJ N
savings NNS N
in IN N
laundry NN N
costs NNS N
and CC N
supplies NNS N
used VBN N
, , N
and CC N
some DT N
quantitatively RB N
unmeasurable JJ N
but CC N
detectable JJ N
improvement NN N
in IN N
psychosocial JJ N
well-being NN N
among IN N
the DT N
trainees NNS N
. . N

Since IN N
the DT N
central JJ N
figure NN N
in IN N
implementing VBG N
this DT N
training NN N
protocol NN N
is VBZ N
the DT N
nursing NN N
aide NN N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
find VB N
an DT N
organizational JJ N
management NN N
scheme NN N
that WDT N
will MD N
stimulate VB N
nursing NN N
aides NNS N
to TO N
reduce VB N
incontinence NN N
among IN N
nursing JJ N
home NN N
residents NNS N
. . N

-DOCSTART- -X- O O

Infrared NNP 2_i
LED NNP 2_i
irradiation NN 2_i
applied VBD N
during IN N
high-intensity NN N
treadmill NN N
training VBG N
improves NNS N
maximal JJ N
exercise NN N
tolerance NN N
in IN N
postmenopausal JJ N
women NNS N
: : N
a DT N
6-month JJ N
longitudinal JJ N
study NN N
. . N

Reduced NNP N
aerobic JJ N
fitness NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
diseases NNS N
among IN N
the DT N
older JJR N
population NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
LED NNP 2_i
irradiation NN 2_i
( ( N
850 CD N
nm RB N
) ) N
applied VBD N
during IN N
treadmill JJ N
training VBG N
on IN N
the DT N
maximal JJ N
exercise NN N
tolerance NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

At IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
, , N
45 CD N
postmenopausal JJ N
women NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
three CD N
groups NNS N
, , N
and CC N
30 CD N
women NNS N
completed VBD N
the DT N
entire JJ N
6 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

The DT N
groups NNS N
were VBD N
: : N
( ( N
1 CD N
) ) N
the DT N
LED NNP N
group NN N
( ( N
treadmill IN N
training VBG N
associated VBN N
with IN N
phototherapy NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
( ( N
2 CD N
) ) N
the DT N
exercise NN N
group NN N
( ( N
treadmill IN N
training NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
and CC N
( ( N
3 CD N
) ) N
the DT N
sedentary JJ N
group NN N
( ( N
neither DT N
physical JJ N
training NN N
nor CC N
phototherapy NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
. . N

The DT N
training NN N
was VBD N
performed VBN N
for IN N
45 CD N
min NN N
twice RB N
a DT N
week NN N
for IN N
6 CD N
months NNS N
at IN N
intensities NNS N
between IN N
85 CD N
% NN N
and CC N
90 CD N
% NN N
maximal JJ N
heart NN N
rate NN N
( ( N
HRmax NNP N
) ) N
. . N

The DT N
irradiation NN N
parameters NNS N
were VBD N
39 CD N
mW/cm NN N
( ( N
2 CD N
) ) N
, , N
45 CD N
min NN N
and CC N
108 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
. . N

The DT N
cardiovascular JJ N
parameters NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

As IN N
expected VBN N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
sedentary JJ N
group NN N
( ( N
p VB N
? . N
0.05 CD N
) ) N
. . N

The DT N
maximal JJ N
time NN N
of IN N
tolerance NN N
( ( N
Tlim NNP N
) ) N
, , N
metabolic JJ N
equivalents NNS N
( ( N
METs NNP N
) ) N
and CC N
Bruce NNP N
stage NN N
reached VBD N
significantly RB N
higher JJR N
values NNS N
in IN N
the DT N
LED NNP N
group NN N
and CC N
the DT N
exercise NN N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Furthermore UH N
, , N
the DT N
HR NNP N
, , N
double JJ N
product NN N
and CC N
Borg NNP N
score NN N
at IN N
isotime NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
LED NNP N
group NN N
and CC N
in IN N
the DT N
exercise NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
the DT N
time NN N
of IN N
recovery NN N
showed VBD N
a DT N
significant JJ N
decrease NN N
only RB N
in IN N
the DT N
LED NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Moreover RB N
, , N
the DT N
differences NNS N
between IN N
before IN N
and CC N
after IN N
training NN N
( ( N
delta JJ N
values NNS N
) ) N
for IN N
the DT N
Tlim NNP N
, , N
METs NNP N
and CC N
HR NNP N
at IN N
isotime NN N
were VBD N
greater JJR N
in IN N
the DT N
LED NNP N
group NN N
than IN N
in IN N
the DT N
exercise NN N
group NN N
with IN N
a DT N
significant JJ N
intergroup NN N
difference NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Therefore RB N
, , N
the DT N
infrared JJ N
LED NNP N
irradiation NN N
during IN N
treadmill JJ N
training NN N
can MD N
improve VB N
maximal JJ N
performance NN N
and CC N
post-exercise JJ N
recovery NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

-DOCSTART- -X- O O

Serum NNP N
selenium NN 3_i
concentration NN N
and CC N
antioxidant JJ N
activity NN N
in IN N
cervical JJ N
cancer NN N
patients NNS N
before IN N
and CC N
after IN N
treatment NN N
. . N

AIM NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
the DT N
effect NN N
of IN N
chemo NN N
and CC N
radio NN N
therapies NNS N
on IN N
serum NN N
trace NN N
elements NNS N
content NN N
and CC N
antioxidant JJ N
activity NN N
in IN N
blood NN N
serum NN N
of IN N
cervical JJ N
cancer NN N
patients NNS N
was VBD N
evaluated VBN N
. . N

METHODS NNP N
Among IN N
104 CD N
cervical JJ N
cancer NN N
patients NNS N
selected VBN N
for IN N
the DT N
present JJ N
study NN N
, , N
54 CD N
and CC N
50 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
chemo- JJ 2_i
and CC 2_i
radiotherapy NN 2_i
respectively RB N
. . N

Plasma NNP N
Se NNP N
, , N
Zn NNP N
, , N
Cu NNP N
and CC N
some DT N
enzymatic JJ N
antioxidants NNS N
activities NNS N
were VBD N
estimated VBN N
in IN N
serum NN N
before IN N
and CC N
after IN N
the DT N
treatment NN N
. . N

RESULTS VB N
The DT N
decreased JJ N
levels NNS N
of IN N
serum NN N
trace NN N
elements NNS N
, , N
glutathione NN N
peroxidase NN N
activity NN N
and CC N
total JJ N
antioxidant JJ N
capacity NN N
, , N
and CC N
increased VBD N
malondialdehyde NN N
, , N
glutathion NN N
reductase NN N
was VBD N
observed VBN N
in IN N
cervical JJ N
cancer NN N
patients NNS N
when WRB N
compared VBN N
to TO N
healthy JJ N
controls NNS N
. . N

The DT N
increased JJ N
concentration NN N
of IN N
serum NN N
Se NNP N
, , N
Zn NNP N
was VBD N
observed VBN N
in IN N
patients NNS N
treated VBN N
with IN N
chemotherapy NN 3_i
. . N

Simultaneously RB N
there EX N
was VBD N
a DT N
significant JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
increase NN N
in IN N
glutathione JJ N
peroxidase NN N
and CC N
total JJ N
antioxidant JJ N
capacity NN N
, , N
and CC N
significant JJ N
decrease NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
malondialdehyde NN N
and CC N
glutathion NN N
reductase NN N
levels NNS N
in IN N
the DT N
serum NN N
of IN N
patients NNS N
treated VBN N
with IN N
chemotherapy NN 3_i
compared VBN N
to TO N
the DT N
patients NNS N
treated VBN N
with IN N
radiotherapy NN 2_i
. . N

CONCLUSION VB N
The DT N
results NNS N
demonstrated VBD N
that IN N
chemotherapy NN 3_i
but CC N
not RB N
radiotherapy JJ 2_i
results NNS N
in IN N
significant JJ N
increase NN N
in IN N
the DT N
trace NN N
elements NNS N
levels NNS N
and CC N
antioxidant JJ N
activities NNS N
in IN N
blood NN N
serum NN N
of IN N
cervical JJ N
cancer NN N
patients NNS N
. . N

-DOCSTART- -X- O O

Long JJ N
term NN N
follow VBP N
up IN N
of IN N
patients NNS N
treated VBN N
for IN N
Helicobacter NNP N
pylori JJ N
infection NN N
. . N

BACKGROUND NNP N
Helicobacter NNP N
pylori POS N
infection NN N
induces NNS N
progressive JJ N
inflammatory JJ N
changes NNS N
in IN N
the DT N
gastric JJ N
mucosa NN N
that WDT N
may MD N
lead VB N
to TO N
gastric JJ N
cancer NN N
. . N

Understanding VBG N
long JJ N
term NN N
effects NNS N
resulting VBG N
from IN N
the DT N
cure NN N
of IN N
this DT N
infection NN N
is VBZ N
needed VBN N
to TO N
design VB N
cancer NN N
prevention NN N
strategies NNS N
. . N

METHODS NNP N
A NNP N
cohort NN N
of IN N
795 CD N
adults NNS N
with IN N
preneoplastic JJ N
gastric JJ N
lesions NNS N
was VBD N
randomised VBN N
to TO N
receive VB 3_i
anti-H JJ 3_i
pylori NN 3_i
treatment NN 3_i
and/or JJ 3_i
antioxidants NNS 3_i
. . 3_i

At IN N
the DT N
end NN N
of IN N
six CD N
years NNS N
of IN N
intervention NN N
, , N
those DT N
who WP N
did VBD N
not RB N
receive VB N
anti-H JJ N
pylori NN N
treatment NN N
were VBD N
offered VBN N
it PRP N
. . N

Gastric JJ N
biopsies NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
and CC N
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
years NNS N
. . N

A DT N
histopathology NN N
score NN N
was VBD N
utilised VBN N
to TO N
document VB N
changes NNS N
in IN N
gastric JJ N
lesions NNS N
. . N

Non-linear JJ N
mixed JJ N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
cumulative JJ N
effect NN N
of IN N
H NNP N
pylori JJ N
clearance NN N
on IN N
histopathology NN N
scores NNS N
adjusted VBN N
for IN N
follow VB N
up RP N
time NN N
, , N
interventions NNS N
, , N
and CC N
confounders NNS N
. . N

RESULTS NNP N
Ninety NNP N
seven CD N
per IN N
cent NN N
of IN N
subjects NNS N
were VBD N
H NNP N
pylori JJ N
positive JJ N
at IN N
baseline NN N
, , N
and CC N
53 CD N
% NN N
were VBD N
positive JJ N
at IN N
12 CD N
years NNS N
. . N

Subjects NNS N
accumulated JJ N
1703 CD N
person NN N
years NNS N
free JJ N
of IN N
infection NN N
. . N

A DT N
multivariate NN N
model NN N
showed VBD N
a DT N
significant JJ N
regression NN N
in IN N
histopathology NN N
score NN N
as IN N
a DT N
function NN N
of IN N
the DT N
square NN N
of IN N
H NNP N
pylori FW N
negative JJ N
time NN N
. . N

Subjects NNS N
who WP N
were VBD N
H NNP N
pylori JJ N
negative JJ N
had VBD N
14.8 CD N
% NN N
more JJR N
regression NN N
and CC N
13.7 CD N
% NN N
less JJR N
progression NN N
than IN N
patients NNS N
who WP N
were VBD N
positive JJ N
at IN N
12 CD N
years NNS N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
rate NN N
of IN N
healing NN N
of IN N
gastric JJ N
lesions NNS N
occurred VBD N
more RBR N
rapidly RB N
as IN N
years NNS N
free JJ N
of IN N
infection NN N
accumulated VBN N
, , N
and CC N
was VBD N
more RBR N
pronounced JJ N
in IN N
less RBR N
advanced JJ N
lesions NNS N
. . N

CONCLUSIONS NNP N
Preneoplastic NNP N
gastric JJ N
lesions NNS N
regress NN N
at IN N
a DT N
rate NN N
equal JJ N
to TO N
the DT N
square NN N
of IN N
time NN N
in IN N
patients NNS N
rendered JJ N
free JJ N
of IN N
H NNP N
pylori JJ N
infection NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
patients NNS N
with IN N
preneoplastic JJ N
gastric JJ N
lesions NNS N
should MD N
be VB N
treated VBN N
and CC N
cured VBN N
of IN N
their PRP$ N
H NNP N
pylori NN N
infection NN N
. . N

-DOCSTART- -X- O O

Review NN N
of IN N
the DT N
Multicenter NNP N
Trial NNP N
Committee NNP N
report NN N
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
on IN N
the DT N
prophylaxis NN N
of IN N
postoperative JJ N
deep JJ N
venous JJ N
thrombosis NN N
. . N

The DT N
etiology NN N
of IN N
postoperative JJ N
deep JJ N
venous JJ N
thrombosis NN N
( ( N
DVT NNP N
) ) N
is VBZ N
thought VBN N
to TO N
be VB N
due JJ N
to TO N
a DT N
combination NN N
of IN N
factors NNS N
including VBG N
stasis NN N
, , N
a DT N
hypercoagulable JJ N
state NN N
and CC N
venous JJ N
endothelial JJ N
damage NN N
. . N

Methods NNS N
of IN N
prophylaxis NN N
are VBP N
directed VBN N
toward IN N
correcting VBG N
one CD N
or CC N
more JJR N
of IN N
these DT N
pathologic JJ N
events NNS N
. . N

Methods NNS N
counteracting VBG N
more JJR N
than IN N
one CD N
of IN N
these DT N
factors NNS N
can MD N
be VB N
expected VBN N
to TO N
be VB N
even RB N
more RBR N
effective JJ N
. . N

The DT N
combination NN N
of IN N
dihydroergotamine NN 3_i
( ( 3_i
DHE NNP 3_i
) ) 3_i
and CC N
heparin NN 3_i
was VBD N
anticipated VBN N
to TO N
minimize VB N
stasis NN N
and CC N
the DT N
hypercoagulable JJ N
state NN N
respectively RB N
. . N

Based VBN N
upon IN N
current JJ N
experimental JJ N
evidence NN N
and CC N
current JJ N
theory NN N
, , N
an DT N
additional JJ N
benefit NN N
might MD N
include VB N
minimizing VBG N
venous JJ N
endothelial JJ N
injury NN N
by IN N
controlling VBG N
venomotor NN N
tone NN N
. . N

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicenter JJ N
trial NN N
was VBD N
designed VBN N
and CC N
performed VBN N
in IN N
the DT N
United NNP N
States NNPS N
evaluating VBG N
the DT N
prophylactic JJ N
efficacy NN N
of IN N
DHE NNP 3_i
0.5 CD 3_i
mg NN 3_i
plus CC 3_i
heparin JJ 3_i
5000 CD 3_i
U NNP 3_i
, , 3_i
DHE NNP 3_i
0.5 CD 3_i
mg NN 3_i
plus CC 3_i
heparin JJ 3_i
2500 CD 3_i
U NNP 3_i
, , 3_i
heparin NN 3_i
5000 CD 3_i
U NNP 3_i
, , N
and CC N
DHE NNP 3_i
0.5 CD 3_i
mg NN 3_i
versus NN N
placebo NN 7_i
. . N

General NNP N
surgical JJ N
patients NNS N
including VBG N
those DT N
undergoing JJ N
noncardiac JJ N
thoracic NN N
and CC N
pelvic JJ N
operations NNS N
who WP N
were VBD N
identified VBN N
at IN N
moderate JJ N
to TO N
high JJ N
risk NN N
for IN N
postop JJ N
DVT NNP N
were VBD N
included VBN N
. . N

Study NNP N
medications NNS N
were VBD N
injected VBN N
subcutaneously RB N
two CD N
hours NNS N
preoperatively RB N
and CC N
every DT N
12 CD N
hours NNS N
postoperatively RB N
for IN N
5-7 JJ N
days NNS N
or CC N
until IN N
the DT N
125I-fibrinogen-uptake JJ N
test NN N
( ( N
RFUT NNP N
) ) N
became VBD N
positive JJ N
. . N

Eight NNP N
hundred VBD N
and CC N
eighty JJ N
eight CD N
patients NNS N
were VBD N
entered VBN N
into IN N
this DT N
trial NN N
and CC N
744 CD N
( ( N
85 CD N
% NN N
) ) N
completed VBD N
the DT N
study NN N
. . N

Results NNP N
showed VBD N
a DT N
statistically RB N
significant JJ N
benefit NN N
from IN N
DHE/Hep NNP 3_i
5000 CD N
compared VBN N
to TO N
placebo VB 7_i
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
compared VBN N
to TO N
other JJ N
active JJ N
agents NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

None NN N
of IN N
the DT N
other JJ N
active JJ N
agents NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
prophylactic JJ N
benefit NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Cholesterol-lowering JJ 2_i
therapy NN 2_i
may MD N
retard VB N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN N
. . N

There EX N
is VBZ N
experimental JJ N
evidence NN N
to TO N
suggest VB N
that IN N
hypercholesterolaemia NN N
may MD N
play VB N
a DT N
pathogenetic JJ N
role NN N
in IN N
progressive JJ N
glomerular JJ N
injury NN N
. . N

We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
cholesterol-lowering JJ N
therapy NN N
on IN N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN N
in IN N
34 CD N
patients NNS N
with IN N
non-insulin-dependent JJ N
diabetes NNS N
mellitus NNS N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
single-blind JJ N
fashion NN N
to TO N
treatment NN N
with IN N
either DT N
lovastatin NN 3_i
, , 3_i
an DT 3_i
HMG NNP 3_i
CoA NNP 3_i
reductase NN 3_i
inhibitor NN 3_i
( ( N
n JJ N
= VBZ N
16 CD N
; : N
mean VB N
dose JJ N
30.0 CD N
+/- JJ N
12.6 CD N
mg/day NN N
) ) N
or CC N
placebo NN 7_i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
for IN N
2 CD N
years NNS N
. . N

Renal JJ N
function NN N
was VBD N
assessed VBN N
by IN N
serially RB N
measuring VBG N
the DT N
serum NN N
creatinine NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
( ( N
using VBG N
Cr51-EDTA NNP N
) ) N
, , N
and CC N
24-h JJ N
urinary JJ N
protein NN N
excretion NN N
. . N

Lovastatin NNP 3_i
treatment NN N
was VBD N
associated VBN N
with IN N
significant JJ N
reductions NNS N
in IN N
total JJ N
cholesterol NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
LDL-cholesterol NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
apo JJ N
B NNP N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
the DT N
reductions NNS N
at IN N
24 CD N
months NNS N
being VBG N
26 CD N
, , N
30 CD N
and CC N
18 CD N
% NN N
, , N
respectively RB N
. . N

Beneficial JJ N
effects NNS N
on IN N
serum NN N
triglyceride NN N
, , N
HDL-cholesterol NNP N
and CC N
apo VB N
A1 NNP N
levels NNS N
were VBD N
also RB N
observed VBN N
. . N

Lp NNP N
( ( N
a DT N
) ) N
showed VBD N
no DT N
significant JJ N
change NN N
in IN N
both DT N
groups NNS N
. . N

Glomerular JJ N
filtration NN N
rate NN N
deteriorated VBN N
significantly RB N
in IN N
the DT N
placebo NN N
group NN N
after IN N
24 CD N
months NNS N
( ( N
p JJ N
< NNP N
0.025 CD N
) ) N
but CC N
showed VBD N
no DT N
significant JJ N
change NN N
in IN N
the DT N
lovastatin-treated JJ 3_i
patients NNS N
. . N

The DT N
increase NN N
in IN N
serum JJ N
creatinine NN N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
in IN N
placebo-treated JJ N
patients NNS N
at IN N
12 CD N
and CC N
24 CD N
months NNS N
, , N
and CC N
in IN N
the DT N
lovastatin NN 3_i
group NN N
after IN N
24 CD N
months NNS N
. . N

Twenty-four CD N
hour NN N
urinary JJ N
protein NN N
excretion NN N
increased VBN N
in IN N
both DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Lovastatin NNP 3_i
treatment NN N
was VBD N
not RB N
associated VBN N
with IN N
significant JJ N
elevations NNS N
in IN N
liver NN N
or CC N
muscle NN N
enzymes NNS N
. . N

We PRP N
conclude VBP N
that IN N
effective JJ N
normalisation NN N
of IN N
hypercholesterolaemia NN N
may MD N
retard VB N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
postoperative JJ N
hypocalcemia NN N
with IN N
routine JJ N
oral JJ N
calcium NN 3_i
and CC N
vitamin NN 3_i
D NNP 3_i
supplements NNS 3_i
in IN N
patients NNS N
with IN N
differentiated JJ N
papillary JJ N
thyroid NN N
carcinoma NN N
undergoing JJ N
total JJ N
thyroidectomy NN N
plus CC N
central JJ N
neck NN N
dissection NN N
. . N

BACKGROUND NNP N
Routine NNP N
oral JJ 3_i
calcium NN 3_i
and CC N
vitamin NN 3_i
D NNP 3_i
supplementation NN 3_i
may MD N
prevent VB N
hypocalcemic JJ N
crisis NN N
, , N
but CC N
its PRP$ N
efficacy NN N
has VBZ N
not RB N
been VBN N
studied VBN N
in IN N
patients NNS N
undergoing VBG N
thyroidectomy JJ N
plus JJ N
central JJ N
neck NN N
dissection NN N
( ( N
CND NNP N
) ) N
. . N

The DT N
authors NNS N
therefore VBP N
prospectively RB N
evaluated VBN N
the DT N
clinical JJ N
usefulness NN N
of IN N
routine JJ N
oral JJ N
calcium NN N
and CC N
vitamin NN N
D NNP N
supplementation NN N
for IN N
prevention NN N
of IN N
hypocalcemia NN N
after IN N
total JJ N
thyroidectomy NN N
and CC N
CND NNP N
. . N

METHODS NNP N
Of IN N
197 CD N
patients NNS N
with IN N
differentiated JJ N
papillary JJ N
thyroid NN N
carcinoma NN N
, , N
49 CD N
underwent JJ N
total JJ N
thyroidectomy NN N
alone RB N
, , N
and CC N
148 CD N
underwent JJ N
total JJ 3_i
thyroidectomy NN 3_i
plus CC 3_i
CND NNP 3_i
. . N

The DT N
latter JJ N
were VBD N
randomized VBN N
to TO N
oral JJ 3_i
calcium NN 3_i
( ( N
3 CD N
g/day NN N
) ) N
plus CC N
vitamin JJ 3_i
D NNP 3_i
( ( N
1 CD N
mg/day NN N
) ) N
( ( N
Group NNP N
A NNP N
, , N
n=49 NN N
) ) N
, , N
calcium NN 3_i
alone RB 3_i
( ( N
Group NNP N
B NNP N
, , N
n=49 NN N
) ) N
, , N
or CC N
no DT 3_i
supplements NNS 3_i
( ( N
Group NNP N
C NNP N
, , N
n=50 RB N
) ) N
. . N

Hypocalcemic NNP N
symptoms NNS N
, , N
serum JJ N
calcium NN N
, , N
and CC N
parathyroid VB N
hormone NN N
( ( N
PTH NNP N
) ) N
levels NNS N
were VBD N
compared VBN N
among IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
Group NNP N
C NNP N
had VBD N
significantly RB N
higher JJR N
incidences NNS N
of IN N
symptomatic JJ N
( ( N
26.0 CD N
% NN N
vs JJ N
6.1 CD N
% NN N
; : N
P NNP N
< NNP N
.015 NNP N
) ) N
and CC N
laboratory NN N
( ( N
44.0 CD N
% NN N
vs JJ N
14.3 CD N
% NN N
; : N
P NNP N
< NNP N
.015 NNP N
) ) N
hypocalcemia NN N
than IN N
the DT N
group NN N
without IN N
CND NNP N
. . N

The DT N
incidences NNS N
of IN N
symptomatic JJ N
and CC N
laboratory JJ N
hypocalcemia NN N
were VBD N
significantly RB N
decreased VBN N
in IN N
Groups NNP N
A NNP N
( ( N
2.0 CD N
% NN N
and CC N
8.2 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
B NNP N
( ( N
12.2 CD N
% NN N
and CC N
24.5 CD N
% NN N
, , N
respectively RB N
) ) N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Serum NNP N
calcium NN N
levels NNS N
decreased VBN N
in IN N
most JJS N
patients NNS N
after IN N
surgery NN N
, , N
but CC N
recovered VBD N
earliest JJS N
in IN N
Group NNP N
A. NNP N
Hypercalcemia NNP N
and CC N
PTH NNP N
inhibition NN N
did VBD N
not RB N
occur VB N
in IN N
gs NN N
A NNP N
and CC N
B NNP N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
total JJ N
thyroidectomy NN N
alone RB N
, , N
CND NNP N
significantly RB N
increases VBZ N
the DT N
rate NN N
of IN N
postoperative JJ N
hypocalcemia NN N
, , N
which WDT N
can MD N
be VB N
prevented VBN N
by IN N
routine JJ N
postoperative JJ N
supplementation NN N
with IN N
oral JJ N
calcium NN N
and CC N
vitamin NN N
D NNP N
. . N

-DOCSTART- -X- O O

Delayed VBN N
alloimmunization NN N
using VBG N
random JJ 2_i
single JJ 2_i
donor NN 2_i
platelet NN 2_i
transfusions NNS 2_i
: : N
a DT N
prospective JJ N
study NN N
in IN N
thrombocytopenic JJ N
patients NNS N
with IN N
acute JJ N
leukemia NN N
. . N

A DT N
randomized JJ N
study NN N
was VBD N
performed VBN N
in IN N
54 CD N
thrombocytopenic JJ N
patients NNS N
with IN N
acute JJ N
leukemia NN N
. . N

Alloimmunization NN N
of IN N
recipients NNS N
of IN N
random JJ N
multiple-donor JJ 3_i
platelet NN 3_i
concentrates NNS 3_i
( ( N
MD NNP N
group NN N
) ) N
was VBD N
compared VBN N
to TO N
that DT N
of IN N
patients NNS N
receiving VBG N
random JJ 2_i
single-donor JJ 2_i
platelets NNS 2_i
( ( N
SD NNP N
group NN N
) ) N
. . N

In IN N
the DT N
SD NNP N
patients NNS N
, , N
formation NN N
of IN N
alloantibodies NNS N
( ( N
mostly RB N
anti-HLA RB N
) ) N
occurred VBD N
less RBR N
frequently RB N
( ( N
p NN N
less JJR N
than IN N
0.002 CD N
) ) N
, , N
after IN N
a DT N
longer JJR N
time NN N
period NN N
( ( N
p NN N
less JJR N
than IN N
0.002 CD N
) ) N
, , N
and CC N
after IN N
a DT N
higher JJR N
number NN N
of IN N
transfusions NNS N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
as IN N
compared VBN N
to TO N
MD NNP N
patients NNS N
. . N

SD NNP N
patients NNS N
also RB N
became VBD N
refractory JJ N
to TO N
random VB N
platelets NNS N
less RBR N
frequently RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
, , N
after IN N
a DT N
longer JJR N
time NN N
period NN N
, , N
and CC N
after IN N
a DT N
higher JJR N
number NN N
of IN N
transfusions NNS N
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

In IN N
SD NNP N
patients NNS N
, , N
the DT N
increments NNS N
after IN N
the DT N
first JJ N
and CC N
the DT N
last JJ N
transfusion NN N
were VBD N
in IN N
the DT N
same JJ N
range NN N
, , N
whereas NNS N
in IN N
MD NNP N
patients NNS N
, , N
the DT N
1-hr JJ N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
the DT N
24-hr JJ N
( ( N
p NN N
less JJR N
than IN N
0.025 CD N
) ) N
increments NNS N
decreased VBN N
from IN N
the DT N
first JJ N
to TO N
the DT N
last JJ N
transfusion NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
random NN 2_i
SD NNP 2_i
platelet NN 2_i
transfusions NNS 2_i
postponed VBD N
alloimmunization NN N
. . N

-DOCSTART- -X- O O

Prognostic JJ N
value NN N
of IN N
postoperative JJ 1_i
CEA NNP 1_i
clearance NN 1_i
in IN N
rectal JJ N
cancer NN N
patients NNS N
with IN N
high JJ N
preoperative JJ N
CEA NNP N
levels NNS N
. . N

PURPOSE NNP N
We PRP N
determined VBD N
the DT N
prognostic JJ N
value NN N
of IN N
carcinoembryonic JJ N
antigen NN N
( ( N
CEA NNP N
) ) N
clearance NN N
after IN N
tumor NN 1_i
resection NN 1_i
with IN N
serial JJ N
evaluation NN N
of IN N
postoperative JJ N
CEA NNP N
levels NNS N
in IN N
rectal JJ N
cancer NN N
. . N

METHODS NNP N
Between NNP N
1994 CD N
and CC N
2004 CD N
, , N
we PRP N
retrospectively RB N
reviewed VBD N
122 CD N
patients NNS N
with IN N
rectal JJ N
cancer NN N
whose WP$ N
serum JJ N
CEA NNP N
levels NNS N
were VBD N
measured VBN N
on IN N
the DT N
preoperative JJ N
day NN N
and CC N
postoperative JJ N
days NNS N
7 CD N
and CC N
30 CD N
. . N

Patients NNS N
with IN N
preoperative JJ N
CEA NNP N
levels NNS N
< VBP N
5.0 CD N
ng/ml NNS N
were VBD N
excluded VBN N
. . N

An DT N
exponential JJ N
trend NN N
line NN N
was VBD N
drawn VBN N
using VBG N
the DT N
three CD N
CEA NNP N
values NNS N
. . N

Patients NNS N
were VBD N
categorized VBN N
into IN N
three CD N
groups NNS N
based VBN N
on IN N
R NNP N
( ( N
2 CD N
) ) N
values NNS N
calculated VBN N
through IN N
trend NN N
line NN N
, , N
which WDT N
indicates VBZ N
the DT N
correlation NN N
coefficient NN N
between IN N
exponential JJ N
graph NN N
and CC N
measured VBD N
CEA NNP N
values NNS N
: : N
exponential JJ N
decrease NN N
group NN N
( ( N
group NN N
1 CD N
: : N
0.9 CD N
< NN N
R NNP N
( ( N
2 CD N
) ) N
< NN N
or CC N
= VB N
1.0 CD N
) ) N
, , N
nearly RB N
exponential JJ N
decrease NN N
group NN N
( ( N
group NN N
2 CD N
: : N
0.5 CD N
< NN N
R NNP N
( ( N
2 CD N
) ) N
< NN N
or CC N
= VB N
0.9 CD N
) ) N
, , N
and CC N
randomized JJ N
clearance NN N
group NN N
( ( N
group NN N
3 CD N
: : N
0.5 CD N
< NN N
or CC N
= VB N
R NNP N
( ( N
2 CD N
) ) N
) ) N
. . N

We PRP N
then RB N
analyzed VBD N
the DT N
CEA NNP N
clearance NN N
pattern NN N
as IN N
a DT N
prognostic JJ N
indicator NN N
. . N

RESULTS NNP N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
57 CD N
months NNS N
, , N
the DT N
5-year JJ N
overall JJ N
survival NN N
was VBD N
62.3 CD N
% NN N
vs. FW N
48.1 CD N
% NN N
vs. FW N
25 CD N
% NN N
and CC N
the DT N
5-year JJ N
disease-free JJ N
survival NN N
was VBD N
58.6 CD N
% NN N
vs. FW N
52.7 CD N
% NN N
vs. FW N
25 CD N
% NN N
among IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
( ( N
P NNP N
= NNP N
0.014 CD N
, , N
P NNP N
= NNP N
0.027 CD N
, , N
respectively RB N
) ) N
in IN N
patients NNS N
with IN N
stage NN N
III NNP N
rectal JJ N
cancer NN N
. . N

For IN N
those DT N
with IN N
stage NN N
II NNP N
rectal NN N
cancer NN N
, , N
the DT N
5-year JJ N
overall JJ N
survival NN N
rate NN N
of IN N
group NN N
1 CD N
was VBD N
significantly RB N
better JJR N
than IN N
groups NNS N
2 CD N
and CC N
3 CD N
( ( N
88.8 CD N
% NN N
vs. FW N
74.1 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
0.021 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
postoperative JJ 1_i
pattern NN 1_i
of IN 1_i
CEA NNP 1_i
clearance NN 1_i
is VBZ N
a DT N
useful JJ N
prognostic JJ N
determinant NN N
in IN N
patients NNS N
with IN N
rectal JJ N
cancer NN N
. . N

Patients NNS N
with IN N
a DT N
randomized JJ N
pattern NN N
of IN N
CEA NNP N
clearance NN N
after IN N
tumor NN N
resection NN N
should MD N
be VB N
regarded VBN N
as IN N
having VBG N
the DT N
possibility NN N
of IN N
a DT N
persistent JJ N
CEA NNP N
source NN N
and CC N
may MD N
require VB N
consideration NN N
of IN N
intensive JJ N
follow-up NN N
or CC N
adjuvant JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

[ JJ 3_i
Afala NNP 3_i
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
BPH NNP N
: : N
efficacy NN N
and CC N
safety NN N
] NN N
. . N

The DT N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
, , N
randomized JJ N
clinical JJ N
trial NN N
involving VBG N
94 CD N
patients NNS N
has VBZ N
evaluated VBN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
domestic JJ N
preparation NN N
afala NN 3_i
in IN N
patients NNS N
with IN N
symptoms NNS N
of IN N
I-II NNP N
stages NNS N
benign VBP N
prostatic JJ N
hyperplasia NN N
( ( N
BPH NNP N
) ) N
. . N

It PRP N
was VBD N
shown VBN N
that IN N
a DT N
6-month JJ N
course NN N
of IN N
treatment NN N
with IN N
afala NN 3_i
at IN 3_i
a DT 3_i
dose NN 3_i
of IN 3_i
2 CD 3_i
tablets NNS 3_i
4 CD 3_i
times NNS 3_i
a DT 3_i
day NN 3_i
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
severity NN N
of IN N
urinary JJ N
disorders NNS N
, , N
estimated VBN N
by IN N
total JJ N
IPSS NNP N
score NN N
, , N
relative JJ N
to TO N
baseline VB N
values NNS N
and CC N
compared VBN N
to TO N
placebo VB 7_i
therapy NN N
. . N

The DT N
most RBS N
pronounced JJ N
therapeutic JJ N
effects NNS N
of IN N
the DT N
drug NN N
were VBD N
registered VBN N
in IN N
respect NN N
of IN N
irritative JJ N
symptoms NNS N
of IN N
BPH NNP N
. . N

According VBG N
uroflowmetry NN N
, , N
peak JJ N
flow NN N
rate NN N
after IN N
6 CD N
months NNS N
of IN N
treatment NN N
was VBD N
increased VBN N
by IN N
more JJR N
than IN N
50 CD N
% NN N
. . N

Significant JJ N
clinical JJ N
benefit NN N
persisted VBD N
not RB N
only RB N
within IN N
the DT N
6-month JJ N
course NN N
of IN N
therapy NN N
, , N
but CC N
3 CD N
months NNS N
after IN N
. . N

Long-term JJ N
therapy NN N
had VBD N
no DT N
effect NN N
on IN N
the DT N
concentration NN N
of IN N
total JJ N
, , N
free JJ N
and CC N
complex JJ N
PSA NNP N
, , N
testosterone NN N
( ( N
total JJ N
and CC N
free JJ N
) ) N
, , N
dihydrotestosterone NN N
, , N
and CC N
prolactin NN N
in IN N
the DT N
blood NN N
. . N

Absence NN N
of IN N
adverse JJ N
effects NNS N
, , N
biochemical JJ N
abnormalities NNS N
, , N
changes NNS N
in IN N
clinical JJ N
blood NN N
and CC N
urine NN N
confirmed VBD N
the DT N
safety NN N
of IN N
6-month JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

Randomised VBN N
, , N
parallel-group JJ N
, , N
multicentre NN N
, , N
multinational JJ N
phase NN N
2 CD N
study NN N
comparing VBG N
edoxaban NN 3_i
, , N
an DT N
oral JJ N
factor NN N
Xa NNP N
inhibitor NN N
, , N
with IN N
warfarin NN 3_i
for IN N
stroke NN N
prevention NN N
in IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
. . N

The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
safety NN N
of IN N
four CD N
fixed-dose JJ N
regimens NNS N
of IN N
edoxaban NN 3_i
with IN 3_i
warfarin NN 3_i
in IN N
patients NNS N
with IN N
non-valvular JJ N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
. . N

In IN N
this DT N
12-week JJ N
, , N
parallel-group JJ N
, , N
multicentre NN N
, , N
multinational JJ N
study NN N
, , N
1,146 CD N
patients NNS N
with IN N
AF NNP N
and CC N
risk NN N
of IN N
stroke NN N
were VBD N
randomised VBN N
to TO N
edoxaban VB 3_i
30 CD N
mg NN N
qd NN N
, , N
30 CD N
mg NN N
bid NN N
, , N
60 CD N
mg NN N
qd NN N
, , N
or CC N
60 CD N
mg JJ N
bid NN N
or CC 3_i
warfarin VB 3_i
dose-adjusted JJ N
to TO N
a DT N
target NN N
international JJ N
normalised JJ N
ratio NN N
of IN N
2.0-3.0 JJ N
. . N

The DT N
study NN N
was VBD N
double-blind JJ N
to TO N
edoxaban VB 3_i
dose JJ N
, , N
but CC N
open-label JJ N
to TO N
warfarin VB 3_i
. . 3_i

Primary JJ N
outcomes NNS N
were VBD N
occurrence NN N
of IN N
major JJ N
and/or NNS N
clinically RB N
relevant JJ N
non-major JJ N
bleeding NN N
and CC N
elevated VBD N
hepatic JJ N
enzymes NNS N
and/or VBP N
bilirubin NN N
. . N

Mean NNP N
age NN N
was VBD N
65 CD N
+/- JJ N
8.7 CD N
years NNS N
and CC N
64.4 CD N
% NN N
were VBD N
warfarin-na?ve JJ N
. . N

Whereas IN N
major JJ N
plus CC N
clinically JJ N
relevant JJ N
non-major JJ N
bleeding NN N
occurred VBD N
in IN N
3.2 CD N
% NN N
of IN N
patients NNS N
randomised VBN N
to TO N
warfarin VB N
, , N
the DT N
incidence NN N
of IN N
bleeding NN N
was VBD N
significantly RB N
higher JJR N
with IN N
the DT N
edoxaban NN N
60 CD N
mg NN N
bid NN N
( ( N
10.6 CD N
% NN N
; : N
p=0.002 CC N
) ) N
and CC N
30 CD N
mg NNS N
bid NN N
regimens VBZ N
( ( N
7.8 CD N
% NN N
; : N
p=0.029 NN N
) ) N
, , N
but CC N
not RB N
with IN N
the DT N
edoxaban NN N
60 CD N
mg NN N
qd NN N
( ( N
3.8 CD N
% NN N
) ) N
or CC N
30 CD N
mg NNS N
qd JJ N
regimens NNS N
( ( N
3.0 CD N
% NN N
) ) N
. . N

For IN N
the DT N
same JJ N
total JJ N
daily JJ N
dose NN N
of IN N
60 CD N
mg NN N
, , N
both DT N
bleeding VBG N
frequency NN N
and CC N
trough JJ N
edoxaban NN N
concentrations NNS N
were VBD N
higher JJR N
in IN N
the DT N
30-mg JJ N
bid NN N
group NN N
than IN N
in IN N
the DT N
60-mg JJ N
qd NN N
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
hepatic JJ N
enzyme NN N
elevations NNS N
or CC N
bilirubin JJ N
values NNS N
among IN N
the DT N
groups NNS N
. . N

The DT N
safety NN N
profiles NNS N
of IN N
edoxaban JJ N
30 CD N
and CC N
60 CD N
mg NN N
qd NN N
in IN N
patients NNS N
with IN N
AF NNP N
were VBD N
similar JJ N
to TO N
warfarin VB N
. . N

In IN N
contrast NN N
, , N
the DT N
edoxaban JJ N
bid NN N
regimens NNS N
were VBD N
associated VBN N
with IN N
more RBR N
bleeding NN N
than IN N
warfarin NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
in IN N
this DT N
three-month JJ N
study NN N
, , N
edoxaban VBP N
30 CD N
or CC N
60 CD N
mg NNS N
qd NNS N
are VBP N
safe JJ N
and CC N
well-tolerated JJ N
. . N

-DOCSTART- -X- O O

Longitudinal JJ N
follow-up NN N
of IN N
children NNS N
with IN N
autism NN N
receiving VBG N
targeted VBN N
interventions NNS N
on IN N
joint JJ 4_i
attention NN 4_i
and CC N
play NN 4_i
. . N

OBJECTIVE CC N
This DT N
study NN N
examines VBZ N
the DT N
cognitive NN N
and CC N
language NN N
outcomes NNS N
of IN N
children NNS N
with IN N
an DT N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
over IN N
a DT N
5-year JJ N
period NN N
after IN N
receiving VBG N
targeted VBD 4_i
early JJ 4_i
interventions NNS 4_i
that WDT 4_i
focused VBD 4_i
on IN 4_i
joint JJ 4_i
attention NN 4_i
and CC 4_i
play NN 4_i
skills NNS 4_i
. . 4_i

METHOD NNP N
Forty NNP N
children NNS N
from IN N
the DT N
original JJ N
study NN N
( ( N
n JJ N
= NNP N
58 CD N
) ) N
had VBD N
complete JJ N
data NNS N
at IN N
the DT N
5-year JJ N
follow-up NN N
. . N

RESULTS NNP N
In IN N
all DT N
, , N
80 CD N
% NN N
of IN N
children NNS N
had VBD N
achieved VBN N
functional JJ N
use NN N
of IN N
spoken JJ N
language NN N
with IN N
baseline JJ N
play NN N
level NN N
predicting VBG N
spoken JJ N
language NN N
at IN N
the DT N
5-year JJ N
follow-up NN N
. . N

Of IN N
children NNS N
who WP N
were VBD N
using VBG N
spoken JJ N
language NN N
at IN N
age NN N
8 CD N
years NNS N
, , N
several JJ N
baseline NN N
behaviors NNS N
predicted VBD N
their PRP$ N
later JJ N
ability NN N
, , N
including VBG N
earlier JJR N
age NN N
of IN N
entry NN N
into IN N
the DT N
study NN N
, , N
initiating VBG N
joint JJ N
attention NN N
skill NN N
, , N
play VB N
level NN N
, , N
and CC N
assignment NN N
to TO N
either VB N
the DT N
joint JJ 4_i
attention NN 4_i
or CC 4_i
symbolic JJ 4_i
play NN 4_i
intervention NN N
group NN N
. . N

Only RB N
baseline JJ N
play NN N
diversity NN N
predicted VBD N
cognitive JJ N
scores NNS N
at IN N
age NN N
8 CD N
years NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
is VBZ N
one CD N
of IN N
the DT N
only JJ N
long-term JJ N
follow-up JJ N
studies NNS N
of IN N
children NNS N
who WP N
participated VBD N
in IN N
preschool NN N
early JJ N
interventions NNS N
aimed VBN N
at IN N
targeting VBG N
core NN N
developmental NN N
difficulties NNS N
. . N

The DT N
study NN N
findings NNS N
suggest VBP N
that IN N
focusing VBG N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
skills NNS N
in IN N
comprehensive JJ N
treatment NN N
models NNS N
is VBZ N
important JJ N
for IN N
long-term JJ N
spoken JJ N
language NN N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
extended JJ N
release NN N
methylphenidate NN 3_i
treatment NN 3_i
on IN N
ratings NNS N
of IN N
attention-deficit/hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
and CC N
associated VBN N
behavior NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
and CC N
ADHD NNP N
symptoms NNS N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
behavioral JJ N
effects NNS N
of IN N
four CD N
doses NNS N
of IN N
psychostimulant JJ N
medication NN N
, , N
combining VBG N
extended-release JJ 3_i
methylphenidate NN 3_i
( ( 3_i
MPH NNP 3_i
) ) 3_i
in IN 3_i
the DT 3_i
morning NN 3_i
with IN N
immediate-release JJ 3_i
MPH NNP 3_i
in IN 3_i
the DT 3_i
afternoon NN 3_i
. . N

METHOD NNP N
The DT N
sample NN N
comprised VBD N
24 CD N
children NNS N
( ( N
19 CD N
boys NNS N
; : N
5 CD N
girls NNS N
) ) N
who WP N
met VBD N
American NNP N
Psychiatric NNP N
Association NNP N
, , N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
4th CD N
ed NN N
. . N

( ( N
DSM-IV-TR NNP N
) ) N
criteria NN N
for IN N
an DT N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
on IN N
the DT N
Autism NNP N
Diagnostic NNP N
Interview-Revised JJ N
( ( N
ADI-R NNP N
) ) N
and CC N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
, , N
and CC N
had VBD N
significant JJ N
symptoms NNS N
of IN N
attention-deficit/hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
. . N

This DT N
sample NN N
consisted VBD N
of IN N
elementary JJ N
school-age NN N
, , N
community-based JJ N
children NNS N
( ( N
mean JJ N
chronological JJ N
age=8.8 NN N
years NNS N
, , N
SD=1.7 NNP N
; : N
mean JJ N
intelligence NN N
quotient NN N
[ NNP N
IQ NNP N
] NNP N
=85 NNP N
; : N
SD=16.8 NNP N
) ) N
. . N

Effects NNS N
of IN N
four CD N
dose NN N
levels NNS N
of IN N
MPH NNP 3_i
on IN N
parent NN N
and CC N
teacher RB N
behavioral JJ N
ratings NNS N
were VBD N
investigated VBN N
using VBG N
a DT N
within-subject JJ N
, , N
crossover NN N
, , N
placebo-controlled JJ N
design NN N
. . N

RESULTS NNP N
MPH NNP 3_i
treatment NN N
was VBD N
associated VBN N
with IN N
significant JJ N
declines NNS N
in IN N
hyperactive JJ N
and CC N
impulsive JJ N
behavior NN N
at IN N
both DT N
home NN N
and CC N
school NN N
. . N

Parents NNS N
noted VBD N
significant JJ N
declines NNS N
in IN N
inattentive JJ N
and CC N
oppositional JJ N
behavior NN N
, , N
and CC N
improvements NNS N
in IN N
social JJ N
skills NNS N
. . N

No DT N
exacerbation NN N
of IN N
stereotypies NNS N
was VBD N
noted VBN N
, , N
and CC N
side JJ N
effects NNS N
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
in IN N
typically RB N
developing VBG N
children NNS N
with IN N
ADHD NNP N
. . N

Dose NNP N
response NN N
was VBD N
primarily RB N
linear JJ N
in IN N
the DT N
dose JJ N
range NN N
studied VBN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
MPH NNP N
formulations NNS N
are VBP N
efficacious JJ N
and CC N
well-tolerated JJ N
for IN N
children NNS N
with IN N
ASD NNP N
and CC N
significant JJ N
ADHD NNP N
symptoms NNS N
. . N

-DOCSTART- -X- O O

Efficacy NN N
and CC N
safety NN N
of IN N
timolol/pilocarpine JJ 3_i
combination NN N
drops NNS N
in IN N
glaucoma NN N
patients NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
randomized VBN N
, , N
double-blind JJ N
study NN N
with IN N
two CD N
parallel JJ N
groups NNS N
was VBD N
to TO N
examine VB N
the DT N
safety NN N
, , N
efficacy NN N
and CC N
tolerability NN N
of IN N
two CD N
combination NN N
eye NN N
drops VBZ N
containing VBG N
0.5 CD N
% NN N
timolol NN 3_i
and CC N
2 CD N
% NN N
pilocarpine NN 3_i
( ( N
Fotil NNP N
, , N
Leiras NNP N
, , N
Finland NNP N
, , N
and CC N
Timpilo NNP N
, , N
MSD NNP N
, , N
USA NNP N
) ) N
in IN N
patients NNS N
with IN N
glaucoma NN N
or CC N
ocular JJ N
hypertension NN N
. . N

Efficacy NN N
was VBD N
determined VBN N
based VBN N
on IN N
daytime JJ N
intraocular JJ N
pressure NN N
curve NN N
and CC N
safety NN N
by IN N
examining VBG N
visual JJ N
fields NNS N
, , N
visual JJ N
acuity NN N
, , N
optic JJ N
discs NN N
, , N
by IN N
determining VBG N
blood NN N
pressure NN N
and CC N
pulse JJ N
rate NN N
, , N
and CC N
by IN N
performing VBG N
Schirmer NNP N
and CC N
fluorescein JJ N
tests NNS N
. . N

A DT N
total NN N
of IN N
89 CD N
patients NNS N
were VBD N
enrolled VBN N
, , N
and CC N
71 CD N
completed VBD N
the DT N
10-week JJ N
treatment NN N
period NN N
. . N

This DT N
study NN N
showed VBD N
that IN N
the DT N
two CD N
combinations NNS N
of IN N
0.5 CD N
% NN N
timolol JJ 3_i
maleate NN 3_i
and CC N
2 CD N
% NN N
pilocarpine NN 3_i
HCl NNP 3_i
compared VBN N
in IN N
this DT N
study NN N
were VBD N
equally RB N
effective JJ N
in IN N
reducing VBG N
intraocular JJ N
pressure NN N
. . N

The DT N
decrease NN N
in IN N
mean JJ N
daily JJ N
intraocular JJ N
pressure NN N
from IN N
0 CD N
to TO N
10 CD N
weeks NNS N
was VBD N
7.48 CD N
mmHg NN N
for IN N
Fotil NNP N
, , N
and CC N
6.31 CD N
for IN N
Timpilo NNP N
. . N

The DT N
mean JJ N
decrease NN N
in IN N
mean JJ N
daily JJ N
intraocular JJ N
pressure NN N
was VBD N
29.3 CD N
% NN N
for IN N
Fotil NNP N
, , N
and CC N
26.0 CD N
% NN N
for IN N
Timpilo NNP N
. . N

No NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
. . N

Adverse JJ N
event NN N
were VBD N
reported VBN N
by IN N
70 CD N
out IN N
of IN N
89 CD N
patients NNS N
by IN N
the DT N
end NN N
of IN N
2 CD N
weeks NNS N
, , N
but CC N
were VBD N
severe RB N
enough RB N
only RB N
in IN N
11 CD N
for IN N
the DT N
treatment NN N
to TO N
be VB N
discontinued VBN N
. . N

In IN N
all DT N
others NNS N
, , N
adverse JJ N
events NNS N
were VBD N
of IN N
transient JJ N
nature NN N
and CC N
considered VBN N
mild NN N
. . N

In IN N
general JJ N
, , N
adverse JJ N
events NNS N
were VBD N
similar JJ N
in IN N
both DT N
study NN N
groups NNS N
. . N

However RB N
, , N
burning VBG N
was VBD N
more RBR N
common JJ N
in IN N
patients NNS N
on IN N
Fotil NNP N
, , N
and CC N
blurring NN N
of IN N
vision NN N
and CC N
light JJ N
sensitivity NN N
were VBD N
more JJR N
common JJ N
in IN N
patients NNS N
on IN N
Timpilo NNP N
. . N

In IN N
patients NNS N
with IN N
no DT N
contraindication NN N
to TO N
beta-blockers NNS N
, , N
these DT N
drugs NNS N
appeared VBD N
to TO N
be VB N
safe JJ N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Clonidine NNP 3_i
in IN N
patients NNS N
undergoing JJ N
noncardiac JJ N
surgery NN N
. . N

BACKGROUND NNP N
Marked NNP N
activation NN N
of IN N
the DT N
sympathetic JJ N
nervous JJ N
system NN N
occurs VBZ N
during IN N
and CC N
after IN N
noncardiac JJ N
surgery NN N
. . N

Low-dose JJ N
clonidine NN N
, , N
which WDT N
blunts VBZ N
central JJ N
sympathetic JJ N
outflow NN N
, , N
may MD N
prevent VB N
perioperative JJ N
myocardial JJ N
infarction NN N
and CC N
death NN N
without IN N
inducing VBG N
hemodynamic JJ N
instability NN N
. . N

METHODS NNP N
We PRP N
performed VBD N
a DT N
blinded VBN N
, , N
randomized VBN N
trial NN N
with IN N
a DT N
2-by-2 JJ N
factorial JJ N
design NN N
to TO N
allow VB N
separate JJ N
evaluation NN N
of IN N
low-dose JJ 3_i
clonidine NN 3_i
versus NN 3_i
placebo NN 7_i
and CC 3_i
low-dose JJ 3_i
aspirin NN 3_i
versus NN 3_i
placebo NN 3_i
in IN N
patients NNS N
with IN N
, , N
or CC N
at IN N
risk NN N
for IN N
, , N
atherosclerotic JJ N
disease NN N
who WP N
were VBD N
undergoing VBG N
noncardiac JJ N
surgery NN N
. . N

A DT N
total NN N
of IN N
10,010 CD N
patients NNS N
at IN N
135 CD N
centers NNS N
in IN N
23 CD N
countries NNS N
were VBD N
enrolled VBN N
. . N

For IN N
the DT N
comparison NN N
of IN N
clonidine NN 3_i
with IN 3_i
placebo NN 3_i
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
clonidine NN N
( ( N
0.2 CD N
mg NNS N
per IN N
day NN N
) ) N
or CC N
placebo VB N
just RB N
before RB N
surgery NN N
, , N
with IN N
the DT N
study NN N
drug NN N
continued VBD N
until IN N
72 CD N
hours NNS N
after IN N
surgery NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
composite JJ N
of IN N
death NN N
or CC N
nonfatal JJ N
myocardial JJ N
infarction NN N
at IN N
30 CD N
days NNS N
. . N

RESULTS NNP N
Clonidine NNP N
, , N
as IN N
compared VBN N
with IN N
placebo NN N
, , N
did VBD N
not RB N
reduce VB N
the DT N
number NN N
of IN N
primary-outcome JJ N
events NNS N
( ( N
367 CD N
and CC N
339 CD N
, , N
respectively RB N
; : N
hazard PRP$ N
ratio NN N
with IN N
clonidine NN N
, , N
1.08 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.93 CD N
to TO N
1.26 CD N
; : N
P=0.29 NNP N
) ) N
. . N

Myocardial JJ N
infarction NN N
occurred VBD N
in IN N
329 CD N
patients NNS N
( ( N
6.6 CD N
% NN N
) ) N
assigned VBD N
to TO N
clonidine VB N
and CC N
in IN N
295 CD N
patients NNS N
( ( N
5.9 CD N
% NN N
) ) N
assigned VBD N
to TO N
placebo VB N
( ( N
hazard NN N
ratio NN N
, , N
1.11 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.95 CD N
to TO N
1.30 CD N
; : N
P=0.18 NNP N
) ) N
. . N

Significantly RB N
more JJR N
patients NNS N
in IN N
the DT N
clonidine NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
had VBD N
clinically RB N
important JJ N
hypotension NN N
( ( N
2385 CD N
patients NNS N
[ JJ N
47.6 CD N
% NN N
] NN N
vs. FW N
1854 CD N
patients NNS N
[ JJ N
37.1 CD N
% NN N
] NN N
; : N
hazard CC N
ratio VB N
1.32 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.24 CD N
to TO N
1.40 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Clonidine NNP N
, , N
as IN N
compared VBN N
with IN N
placebo NN N
, , N
was VBD N
associated VBN N
with IN N
an DT N
increased JJ N
rate NN N
of IN N
nonfatal JJ N
cardiac JJ N
arrest NN N
( ( N
0.3 CD N
% NN N
[ JJ N
16 CD N
patients NNS N
] JJ N
vs. FW N
0.1 CD N
% NN N
[ JJ N
5 CD N
patients NNS N
] VBP N
; : N
hazard NN N
ratio NN N
, , N
3.20 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.17 CD N
to TO N
8.73 CD N
; : N
P=0.02 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
low-dose JJ N
clonidine NN N
in IN N
patients NNS N
undergoing JJ N
noncardiac JJ N
surgery NN N
did VBD N
not RB N
reduce VB N
the DT N
rate NN N
of IN N
the DT N
composite JJ N
outcome NN N
of IN N
death NN N
or CC N
nonfatal JJ N
myocardial JJ N
infarction NN N
; : N
it PRP N
did VBD N
, , N
however RB N
, , N
increase VB N
the DT N
risk NN N
of IN N
clinically RB N
important JJ N
hypotension NN N
and CC N
nonfatal JJ N
cardiac JJ N
arrest NN N
. . N

( ( N
Funded VBN N
by IN N
the DT N
Canadian NNP N
Institutes NNPS N
of IN N
Health NNP N
Research NNP N
and CC N
others NNS N
; : N
POISE-2 NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT01082874 NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O

Clinical JJ N
outcome NN N
of IN N
postoperative JJ N
adjuvant JJ N
immunochemotherapy NN N
with IN N
sizofiran NN 3_i
for IN N
patients NNS N
with IN N
resectable JJ N
gastric JJ N
cancer NN N
: : N
a DT N
randomised VBN N
controlled VBN N
study NN N
. . N

Adjuvant NNP 3_i
immunochemotherapy NN 3_i
using VBG 3_i
the DT 3_i
antitumour JJ 3_i
polysaccharide NN 3_i
sizofiran NN 3_i
( ( 3_i
SPG NNP 3_i
) ) 3_i
, , N
an DT N
extract NN N
from IN N
the DT N
culture NN N
broth NN N
of IN N
Schizophyllum NNP N
commune NN N
Fries NNS N
, , N
was VBD N
prescribed VBN N
randomly RB N
for IN N
386 CD N
Japanese JJ N
patients NNS N
with IN N
resectable JJ N
gastric JJ N
cancer NN N
. . N

Although IN N
the DT N
overall JJ N
survival NN N
probability NN N
for IN N
5 CD N
years NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
SPG NNP N
and CC N
control NN N
groups NNS N
, , N
in IN N
264 CD N
patients NNS N
with IN N
curatively RB N
resected VBN N
cancer NN N
, , N
the DT N
probability NN N
to TO N
5 CD N
year NN N
survival NN N
and CC N
to TO N
recurrence VB N
in IN N
the DT N
sizofiran-administered JJ N
patients NNS N
was VBD N
better JJR N
than IN N
in IN N
the DT N
controls NNS N
. . N

In IN N
the DT N
multivariate NN N
analysis NN N
, , N
four CD N
of IN N
six CD N
prognostic JJ N
factors NNS N
correlated VBD N
with IN N
the DT N
prognosis NN N
of IN N
the DT N
264 CD N
patients NNS N
who WP N
underwent VBP N
curative JJ N
surgery NN N
, , N
that WDT N
is VBZ N
, , N
nodal JJ N
involvement NN N
( ( N
chi JJ N
2 CD N
= JJ N
21.426 CD N
, , N
P NNP N
= NNP N
less JJR N
than IN N
0.0001 CD N
) ) N
, , N
age NN N
distribution NN N
( ( N
chi JJ N
2 CD N
= JJ N
9.262 CD N
, , N
P NNP N
= NNP N
0.010 CD N
) ) N
, , N
sizofiran JJ N
administration NN N
( ( N
chi JJ N
2 CD N
= JJ N
6.507 CD N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
, , N
and CC N
primary JJ N
tumour NN N
size NN N
( ( N
chi JJ N
2 CD N
= JJ N
9.345 CD N
, , N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

Thus RB N
, , N
patients NNS N
with IN N
a DT N
curatively RB N
resected VBN N
gastric JJ N
cancer NN N
had VBD N
a DT N
better JJR N
prognosis NN N
when WRB N
sizofiran NN 3_i
was VBD N
prescribed VBN N
in IN N
combination NN N
with IN N
antitumour JJ N
drugs NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
efficacy NN N
of IN N
fluoxetine NN 3_i
alone RB 3_i
vs. FW N
fluoxetine JJ 3_i
plus CC N
local JJ 3_i
lidocaine NN 3_i
ointment NN 3_i
in IN N
the DT N
treatment NN N
of IN N
premature JJ N
ejaculation NN N
. . N

OBJECTIVE CC N
The DT N
present JJ N
study NN N
compares VBZ N
the DT N
efficacy NN N
and CC N
side JJ N
effects NNS N
of IN N
fluoxetine NN 3_i
alone RB 3_i
vs. FW N
fluoxetine JJ 3_i
plus CC N
local JJ 3_i
lidocaine NN 3_i
ointment NN 3_i
in IN N
the DT N
treatment NN N
of IN N
premature JJ N
ejaculation NN N
. . N

METHODS NNP N
Forty-three JJ N
patients NNS N
suffering VBG N
from IN N
premature JJ N
ejaculation NN N
were VBD N
studied VBN N
. . N

The DT N
exclusion NN N
criteria NNS N
were VBD N
erectile JJ N
dysfunction NN N
, , N
loss NN N
of IN N
libido NN N
, , N
alcohol NN N
and CC N
substance NN N
abuse NN N
, , N
mental JJ N
retardation NN N
, , N
diabetes VBZ N
mellitus NN N
, , N
thyroid JJ N
disease NN N
, , N
hypotension NN N
, , N
previous JJ N
use NN N
of IN N
these DT N
drugs NNS N
and CC N
urogenital JJ N
infections NNS N
. . N

The DT N
patients NNS N
' POS N
ages NNS N
ranged VBD N
from IN N
19 CD N
to TO N
48 CD N
years NNS N
( ( N
mean JJ N
age NN N
28 CD N
+/- JJ N
1.6 CD N
) ) N
. . N

They PRP N
had VBD N
regular JJ N
sexual JJ N
lives NNS N
. . N

They PRP N
had VBD N
normal JJ N
psychiatric JJ N
consultation NN N
and CC N
the DT N
Glombock NNP N
Rast NNP N
Sexual NNP N
Satisfactory NNP N
Test NNP N
( ( N
GRISS NNP N
) ) N
psychiatric JJ N
test NN N
were VBD N
in IN N
accordance NN N
with IN N
premature JJ N
ejaculation NN N
. . N

RESULTS VB N
The DT N
patients NNS N
were VBD N
assigned VBN N
to TO N
two CD N
groups NNS N
. . N

Twenty-six JJ N
patients NNS N
, , N
aged VBD N
21 CD N
to TO N
36 CD N
years NNS N
( ( N
mean JJ N
age NN N
27 CD N
) ) N
, , N
received VBD N
only RB N
fluoxetine JJ 3_i
20 CD N
mg/day NN N
( ( N
1 CD N
capsule NN N
) ) N
for IN N
a DT N
week NN N
which WDT N
was VBD N
later RBR N
increased VBN N
to TO N
40 CD N
mg/day NN N
( ( N
2 CD N
capsules NNS N
) ) N
. . N

Seventeen JJ N
patients NNS N
, , N
aged VBD N
19 CD N
to TO N
48 CD N
years NNS N
( ( N
mean JJ N
age NN N
31 CD N
) ) N
, , N
were VBD N
given VBN N
fluoxetine JJ 3_i
20 CD N
mg/day JJ N
plus CC N
local JJ N
application NN N
of IN N
lidocaine JJ 3_i
ointment NN 3_i
. . N

The DT N
patients NNS N
and CC N
partners NNS N
were VBD N
re-evaluated JJ N
8 CD N
weeks NNS N
after IN N
the DT N
treatment NN N
. . N

The DT N
results NNS N
were VBD N
classified VBN N
as IN N
unsuccessful JJ N
, , N
improvement NN N
and CC N
cure NN N
. . N

The DT N
chi-square JJ N
test NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

In IN N
the DT N
fluoxetine NN N
group NN N
, , N
8 CD N
( ( N
30.8 CD N
% NN N
) ) N
patients NNS N
cured VBD N
, , N
11 CD N
( ( N
42.2 CD N
% NN N
) ) N
showed VBD N
improvement NN N
and CC N
there EX N
were VBD N
7 CD N
failures NNS N
( ( N
26.9 CD N
% NN N
) ) N
. . N

In IN N
the DT N
combination NN N
treatment NN N
group NN N
, , N
9 CD N
( ( N
52.9 CD N
% NN N
) ) N
patients NNS N
cured VBN N
, , N
improvement NN N
was VBD N
observed VBN N
in IN N
5 CD N
( ( N
29.4 CD N
% NN N
) ) N
and CC N
failure NN N
in IN N
3 CD N
( ( N
17.6 CD N
% NN N
) ) N
. . N

Side JJ N
effects NNS N
in IN N
group NN N
I PRP N
were VBD N
observed VBN N
in IN N
6 CD N
patients NNS N
( ( N
23 CD N
% NN N
) ) N
and CC N
in IN N
5 CD N
( ( N
29.4 CD N
% NN N
) ) N
in IN N
group NN N
II NNP N
. . N

There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
according VBG N
to TO N
the DT N
side NN N
effects NNS N
( ( N
p JJ N
> NNP N
0.01 CD N
) ) N
. . N

No UH N
patients NNS N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

CONCLUSION VB N
The DT N
combination NN N
of IN N
fluoxetine JJ 3_i
plus CC N
local JJ N
application NN N
of IN N
lidocaine JJ 3_i
ointment NN N
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
fluoxetine VB 3_i
alone RB N
in IN N
the DT N
treatment NN N
of IN N
premature JJ N
ejaculation NN N
. . N

However RB N
, , N
the DT N
results NNS N
should MD N
be VB N
confirmed VBN N
in IN N
further JJ N
studies NNS N
with IN N
a DT N
placebo NN N
group NN N
to TO N
rule VB N
out IN N
the DT N
placebo NN N
effect NN N
. . N

-DOCSTART- -X- O O

Development NNP N
of IN N
the DT N
WAIS-III NNP N
general JJ N
ability NN N
index NN N
estimate NN N
( ( N
GAI-E NNP N
) ) N
. . N

The DT N
WAIS-III JJ N
General NNP N
Ability NNP N
Index NNP N
( ( N
GAI NNP N
; : N
Tulsky NNP N
, , N
Saklofske NNP N
, , N
Wilkins NNP N
, , N
& CC N
Weiss NNP N
, , N
2001 CD N
) ) N
is VBZ N
a DT N
recently RB N
developed VBN N
, , N
6-subtest JJ N
measure NN N
of IN N
global JJ N
intellectual JJ N
functioning NN N
. . N

However RB N
, , N
clinical JJ N
use NN N
of IN N
the DT N
GAI NNP N
is VBZ N
currently RB N
limited VBN N
by IN N
the DT N
absence NN N
of IN N
a DT N
method NN N
to TO N
estimate VB N
premorbid NN N
functioning VBG N
as IN N
measured VBN N
by IN N
this DT N
index NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
regression NN N
equations NNS N
to TO N
estimate VB N
GAI NNP N
scores NNS N
from IN N
demographic JJ N
variables NNS N
and CC N
WAIS-III JJ N
subtest NN N
performance NN N
. . N

Participants NNS N
consisted VBD N
of IN N
those DT N
subjects NNS N
in IN N
the DT N
WAIS-III JJ N
standardization NN N
sample NN N
that WDT N
has VBZ N
complete JJ N
demographic JJ N
data NNS N
( ( N
N=2,401 NNP N
) ) N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

The DT N
first JJ N
group NN N
( ( N
n=1,200 RB N
) ) N
was VBD N
used VBN N
to TO N
develop VB 6_i
the DT 6_i
formulas NN 4_i
( ( N
i.e. FW N
, , N
Development NNP N
group NN N
) ) N
and CC N
the DT N
second JJ N
( ( N
n=1,201 JJ N
) ) N
group NN N
was VBD N
used VBN N
to TO N
validate VB 6_i
the DT 6_i
prediction NN 4_i
algorithms NN 4_i
( ( N
i.e. FW N
, , N
Validation NNP N
group NN N
) ) N
. . N

Demographic JJ N
variables NNS N
included VBD N
age NN N
, , N
education NN N
, , N
ethnicity NN N
, , N
gender NN N
and CC N
region NN N
of IN N
country NN N
. . N

Subtest NNP N
variables NNS N
included VBD N
vocabulary JJ N
, , N
information NN N
, , N
picture NN N
completion NN N
, , N
and CC N
matrix NN N
reasoning VBG N
raw JJ N
scores NNS N
. . N

Ten CD N
regression NN N
algorithms NNS N
were VBD N
generated VBN N
designed VBN N
to TO N
estimate VB N
GAI NNP N
. . N

The DT N
GAI-Estimate NNP N
( ( N
GAI-E NNP N
) ) N
algorithms NN N
accounted VBD N
for IN N
58 CD N
% NN N
to TO N
82 CD N
% NN N
of IN N
the DT N
variance NN N
. . N

The DT N
standard JJ N
error NN N
of IN N
estimate NN N
ranged VBN N
from IN N
6.44 CD N
to TO N
9.57 CD N
. . N

The DT N
correlations NNS N
between IN N
actual JJ N
and CC N
estimated JJ N
GAI NNP N
ranged VBD N
from IN N
r=.76 NN N
to TO N
r=.90 VB N
. . N

These DT N
algorithms NNS N
provided VBD N
accurate JJ N
estimates NNS N
of IN N
GAI NNP N
in IN N
the DT N
WAIS-III JJ N
standardization NN N
sample NN N
. . N

Implications NNS N
for IN N
estimating VBG N
GAI NNP N
in IN N
patients NNS N
with IN N
known VBN N
or CC N
suspected VBN N
neurological JJ N
dysfunction NN N
is VBZ N
discussed VBN N
and CC N
future JJ N
research NN N
is VBZ N
proposed VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN 3_i
treatment NN N
on IN N
prolactin NN N
levels NNS N
in IN N
children NNS N
with IN N
autism NN N
. . N

BACKGROUND IN N
The DT N
effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN 3_i
treatment NN N
on IN N
serum NN N
prolactin NN N
were VBD N
assessed VBN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
autism NN N
( ( N
N NNP N
= NNP N
101 CD N
, , N
5-17 CD N
years NNS N
of IN N
age NN N
) ) N
were VBD N
randomized VBN N
to TO N
an DT N
8-week JJ N
trial NN N
of IN N
risperidone NN 3_i
or CC N
placebo NN 7_i
and CC N
63 CD N
then RB N
took VBD N
part NN N
in IN N
a DT N
4-month JJ N
open-label JJ N
follow-up JJ N
phase NN N
. . N

Serum NNP N
samples NNS N
were VBD N
obtained VBN N
at IN N
Baseline NNP N
and CC N
Week-8 NNP N
( ( N
N NNP N
= NNP N
78 CD N
) ) N
, , N
and CC N
at IN N
6-month JJ N
( ( N
N NNP N
= NNP N
43 CD N
) ) N
and CC N
22-month JJ N
( ( N
N NNP N
= NNP N
30 CD N
) ) N
follow-up NN N
. . N

Serum NNP N
prolactin NN N
was VBD N
determined VBN N
by IN N
immunoradiometric JJ N
assay NN N
; : N
dopamine JJ N
type-2 JJ N
receptor NN N
( ( N
DRD2 NNP N
) ) N
polymorphisms NNS N
were VBD N
genotyped VBN N
. . N

RESULTS NNP N
Baseline NNP N
prolactin NN N
levels NNS N
were VBD N
similar JJ N
in IN N
the DT N
risperidone NN 3_i
( ( N
N NNP N
= NNP N
42 CD N
) ) N
and CC N
placebo NN 7_i
( ( N
N NNP N
= NNP N
36 CD N
) ) N
groups NNS N
( ( N
9.3 CD N
+/- JJ N
7.5 CD N
and CC N
9.3 CD N
+/- JJ N
7.6 CD N
ng/ml NN N
, , N
respectively RB N
) ) N
. . N

After IN N
8 CD N
weeks NNS N
of IN N
risperidone NN 3_i
, , N
prolactin NN N
increased VBD N
to TO N
39.0 CD N
+/- JJ N
19.2 CD N
ng/ml NN N
, , N
compared VBN N
with IN N
10.1 CD N
+/- JJ N
8.8 CD N
ng/ml NN N
for IN N
placebo NN N
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
. . N

Prolactin NN N
levels NNS N
were VBD N
also RB N
significantly RB N
increased VBN N
at IN N
6 CD N
months NNS N
( ( N
32.4 CD N
+/- JJ N
17.8 CD N
ng/ml NN N
; : N
N NNP N
= VBZ N
43 CD N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
and CC N
at IN N
22 CD N
months NNS N
( ( N
N NNP N
= NNP N
30 CD N
, , N
25.3 CD N
+/- JJ N
15.6 CD N
ng/ml NN N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
. . N

Prolactin NN N
levels NNS N
were VBD N
not RB N
associated VBN N
with IN N
adverse JJ N
effects NNS N
and CC N
DRD2 NNP N
alleles NNS N
( ( N
Taq1A NNP N
, , N
-141C NNP N
Ins/Del NNP N
, , N
C957T NNP N
) ) N
did VBD N
not RB N
significantly RB N
influence VB N
baseline NN N
levels NNS N
or CC N
risperidone-induced JJ N
increases NNS N
in IN N
prolactin NN N
. . N

CONCLUSIONS NNP N
Risperidone NNP 3_i
treatment NN N
was VBD N
associated VBN N
with IN N
two- JJ N
to TO N
four-fold JJ N
mean NN N
increases NNS N
in IN N
serum NN N
prolactin NN N
in IN N
children NNS N
with IN N
autism NN N
. . N

Although IN N
risperidone-induced JJ N
increases NNS N
tended VBD N
to TO N
diminish VB N
with IN N
time NN N
, , N
further JJ N
research NN N
on IN N
the DT N
consequences NNS N
of IN N
long-term JJ N
prolactin NN N
elevations NNS N
in IN N
children NNS N
and CC N
adolescents NNS N
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- O O

[ NN N
Specific NNP N
T NNP N
cell NN N
immune NN N
response NN N
in IN N
chronic JJ N
hepatitis NN N
B NNP N
patients NNS N
treated VBD N
with IN N
different JJ N
doses NNS N
of IN N
recombinant JJ 3_i
hepatitis NN 3_i
B NNP 3_i
vaccine NN 3_i
] NN 3_i
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
specific JJ N
cellular JJ N
immunoresponse NN N
of IN N
peripheral JJ N
blood NN N
lymphocytes NNS N
in IN N
the DT N
chronic JJ N
hepatitis NN N
B NNP N
patients NNS N
treated VBD N
with IN N
different JJ N
doses NNS N
of IN N
recombinant JJ 3_i
hepatitis NN 3_i
B NNP 3_i
vaccine NN 3_i
. . N

METHODS NNP N
Seventy-two NNP N
chronic JJ N
hepatitis NN N
B NNP N
patients NNS N
who WP N
did VBD N
not RB N
use VB N
any DT N
anti-HBV JJ N
drugs NNS N
within IN N
6 CD N
months NNS N
were VBD N
randomized VBN N
into IN N
3 CD N
groups NNS N
( ( N
90 CD N
micrograms NNS N
, , N
60 CD N
micrograms NNS N
, , N
and CC N
placebo NN 7_i
) ) 7_i
in IN N
a DT N
ratio NN N
of IN N
1:1:1 CD N
. . N

The DT N
patients NNS N
in IN N
different JJ N
groups NNS N
were VBD N
treated VBN N
with IN N
different JJ 3_i
doses NNS 3_i
of IN 3_i
recombinant JJ 3_i
hepatitis NN 3_i
B NNP 3_i
vaccine NN 3_i
in IN 3_i
combination NN 3_i
with IN 3_i
IFN NNP 3_i
alpha VBP 3_i
1b CD 3_i
50 CD 3_i
micrograms NNS 3_i
with IN 3_i
3 CD 3_i
times NNS 3_i
a DT 3_i
week NN 3_i
for IN 3_i
24 CD 3_i
weeks NNS 3_i
. . N

All DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
24 CD N
weeks NNS N
( ( N
W24 NNP N
) ) N
. . N

HBV NNP N
DNA NNP N
, , N
HBeAg NNP N
and CC N
liver JJ N
functions NNS N
were VBD N
detected VBN N
at IN N
different JJ N
time NN N
points NNS N
, , N
and CC N
the DT N
number NN N
of IN N
cells NNS N
that WDT N
secrete VBP N
IFN-gamma NNP N
were VBD N
detected VBN N
by IN N
ELISPOT NNP N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
difference NN N
in IN N
ELISPOT NNP N
positive JJ N
ratio NN N
among IN N
the DT N
3 CD N
groups NNS N
on IN N
baseline JJ N
detection NN N
. . N

At IN N
W24 NNP N
, , N
12 CD N
cases NNS N
, , N
12 CD N
cases NNS N
, , N
and CC N
7 CD N
cases NNS N
showed VBD N
ELISPOT NNP N
positive JJ N
in IN N
the DT N
group NN N
of IN N
90 CD N
micrograms NNS N
, , N
60 CD N
micrograms NNS N
, , N
and CC N
placebo NN N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
who WP N
were VBD N
ELISPOT NNP N
positive JJ N
was VBD N
higher RBR N
in IN N
the DT N
groups NNS N
treated VBD N
with IN N
recombinant JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
including VBG N
the DT N
dose NN N
of IN N
90 CD N
micrograms NNS N
and CC N
60 CD N
micrograms NNS N
) ) N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P=0.0446 NNP N
) ) N
. . N

HBV NNP N
DNA NNP N
turned VBD N
negative JJ N
in IN N
6/24 CD N
of IN N
the DT N
patients NNS N
treated VBD N
with IN N
recombinant JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
at IN N
both DT N
the DT N
doses NNS N
of IN N
90 CD N
micrograms NNS N
and CC N
60 CD N
micrograms NNS N
) ) N
, , N
and CC N
HBeAg/Anti-HBe NNP N
seroconversion NN N
or CC N
HBeAg NNP N
became VBD N
negative JJ N
in IN N
7/24 CD N
of IN N
them PRP N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
none NN N
of IN N
the DT N
patients NNS N
showed VBD N
undetectable JJ N
HBV NNP N
DNA NNP N
, , N
HBeAg/Anti-HBe NNP N
seroconversion NN N
or CC N
HBeAg NNP N
disappearance NN N
. . N

At IN N
the DT N
24W CD N
of IN N
follow NN N
up RB N
, , N
in IN N
the DT N
patients NNS N
who WP N
were VBD N
ELISPOT NNP N
positive JJ N
, , N
HBV NNP N
DNA NNP N
became VBD N
undetectable JJ N
in IN N
4 CD N
of IN N
the DT N
patients NNS N
treated VBD N
with IN N
recombinant JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
at IN N
doses NNS N
of IN N
90 CD N
micrograms NNS N
and CC N
60 CD N
micrograms NNS N
) ) N
, , N
and CC N
HBeAg/Anti-HBe NNP N
seroconversion NN N
or CC N
HBeAg NNP N
disappearance NN N
were VBD N
found VBN N
in IN N
9 CD N
of IN N
the DT N
cases NNS N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
none NN N
of IN N
the DT N
cases NNS N
showed VBD N
undetectable JJ N
HBV NNP N
DNA NNP N
, , N
and CC N
only RB N
1 CD N
case NN N
had VBD N
HBeAg/Anti-HBe NNP N
seroconversion NN N
. . N

CONCLUSION VB N
The DT N
recombinant JJ 3_i
hepatitis NN 3_i
B NNP 3_i
vaccine NN 3_i
may MD N
increase VB N
the DT N
function NN N
of IN N
specific JJ N
T NNP N
lymphocytes NNS N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
B NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
patients NNS N
treated VBN N
with IN N
the DT N
dose NN N
of IN N
90 CD N
micrograms NNS N
and CC N
60 CD N
micrograms NNS N
hepatitis NN N
B NNP N
vaccine NN N
. . N

-DOCSTART- -X- O O

Association NNP N
between IN N
frequency NN N
of IN N
ready-to-eat JJ N
cereal NN N
consumption NN N
, , N
nutrient JJ N
intakes NNS N
, , N
and CC N
body NN N
mass NN N
index NN N
in IN N
fourth- JJ N
to TO N
sixth-grade JJ N
low-income JJ N
minority NN N
children NNS N
. . N

BACKGROUND IN N
The DT N
consumption NN N
of IN N
non-ready-to-eat JJ N
cereal NN N
and CC N
ready-to-eat NN 6_i
cereal NN 6_i
( ( 6_i
RTEC NNP 6_i
) ) 6_i
breakfasts NNS N
have VBP N
been VBN N
associated VBN N
with IN N
increased JJ N
nutrient NN N
intakes NNS N
and CC N
lower JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

These DT N
relationships NNS N
have VBP N
not RB N
been VBN N
examined VBN N
in IN N
low-income JJ N
minority NN N
children NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
, , N
in IN N
low-income JJ N
minority NN N
children NNS N
, , N
whether IN N
there EX N
is VBZ N
a DT N
relationship NN N
among IN N
the DT N
frequency NN N
of IN N
RTEC NNP 4_i
consumption NN N
and CC N
nutrient JJ N
intakes NNS N
measured VBN N
at IN N
baseline NN N
, , N
and CC N
whether IN N
there EX N
is VBZ N
a DT N
relationship NN N
between IN N
the DT N
frequency NN N
of IN N
RTEC NNP 4_i
and CC N
BMI NNP N
controlling VBG N
for IN N
age NN N
, , N
sex NN N
, , N
ethnicity NN N
, , N
and CC N
energy NN N
intake NN N
. . N

DESIGN VB N
A DT N
longitudinal JJ N
study NN N
design NN N
where WRB N
a DT N
cohort NN N
was VBD N
followed VBN N
for IN N
3 CD N
years NNS N
. . N

SUBJECTS/SETTING NN N
Participants NNS N
were VBD N
625 CD N
fourth- JJ N
through IN N
sixth-grade JJ N
, , N
low-income JJ N
children NNS N
living VBG N
in IN N
San NNP N
Antonio NNP N
, , N
Texas NNP N
, , N
and CC N
enrolled VBD N
in IN N
the DT N
control NN N
arm NN N
of IN N
the DT N
Bienestar NNP N
Diabetes NNP N
Prevention NNP N
Program NNP N
's POS N
cluster NN N
randomized VBD N
trial NN N
. . N

Three CD N
multiple-pass JJ N
24-hour JJ N
dietary JJ N
recalls NNS N
were VBD N
collected VBN N
at IN N
the DT N
beginning NN N
of IN N
their PRP$ N
fourth-grade JJ N
year NN N
and CC N
at IN N
the DT N
end NN N
of IN N
their PRP$ N
fifth- JJ N
and CC N
sixth-grade JJ N
years NNS N
. . N

Children NNP N
's POS N
age NN N
, , N
sex NN N
, , N
ethnicity NN N
, , N
and CC N
height NN N
and CC N
weight NN N
( ( N
used VBN N
to TO N
calculate VB N
BMI NNP N
) ) N
were VBD N
collected VBN N
between IN N
August NNP N
2001 CD N
and CC N
May NNP N
2004 CD N
. . N

STATISTICAL JJ N
ANALYSES NNP N
PERFORMED NNP N
Descriptive NNP N
and CC N
inferential JJ N
statistical JJ N
analyses NNS N
were VBD N
performed VBN N
. . N

The DT N
frequency NN N
of IN N
breakfast NN N
consumption NN N
was VBD N
examined VBN N
using VBG N
a DT N
6?4 CD N
cross-tabulation NN N
table NN N
with IN N
? . N
( ( N
2 CD N
) ) N
test NN N
to TO N
establish VB N
categorical JJ N
differences NNS N
. . N

The DT N
degree NN N
of IN N
association NN N
between IN N
BMI NNP N
percentile NN N
and CC N
frequency NN N
of IN N
RTEC NNP N
consumption NN N
adjusted VBD N
for IN N
age NN N
, , N
sex NN N
, , N
ethnicity NN N
, , N
and CC N
nutrition-related JJ N
parameters NNS N
were VBD N
calculated VBN N
using VBG N
a DT N
partial JJ N
correlation NN N
multivariate NN N
linear JJ N
model NN N
analysis NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
positive JJ N
relationship NN N
between IN N
the DT N
frequency NN N
of IN N
RTEC NNP N
consumption NN N
and CC N
nutrient JJ N
intakes NNS N
measured VBN N
at IN N
baseline NN N
. . N

There EX N
was VBD N
also RB N
a DT N
significant JJ N
inverse NN N
relationship NN N
between IN N
frequency NN N
of IN N
RTEC NNP N
consumption NN N
and CC N
BMI NNP N
percentile NN N
over IN N
the DT N
cumulative JJ N
3-year JJ N
period NN N
controlling VBG N
for IN N
age NN N
, , N
sex NN N
, , N
ethnicity NN N
, , N
and CC N
energy NN N
intake NN N
. . N

CONCLUSIONS NNP N
Children NNP N
who WP N
frequently RB N
consumed VBD N
RTEC NNP N
had VBD N
greater JJR N
intakes NNS N
of IN N
essential JJ N
nutrients NNS N
at IN N
baseline NN N
and CC N
significantly RB N
lower JJR N
BMI NNP N
over IN N
a DT N
3-year JJ N
period NN N
. . N

-DOCSTART- -X- O O

Equivalence NNP N
study NN N
of IN N
a DT N
topical JJ 3_i
diclofenac NN 3_i
solution NN 3_i
( ( 3_i
pennsaid NN 3_i
) ) 3_i
compared VBN N
with IN N
oral JJ 3_i
diclofenac NN 3_i
in IN N
symptomatic JJ N
treatment NN N
of IN N
osteoarthritis NN N
of IN N
the DT N
knee NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NNP N
. . N

To TO N
compare VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
topical JJ 3_i
diclofenac NN 3_i
solution NN 3_i
versus IN N
oral JJ 3_i
diclofenac NN 3_i
in IN N
relieving VBG N
the DT N
symptoms NNS N
of IN N
primary JJ N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
of IN N
the DT N
knee NN N
, , N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
equivalence NN N
trial NN N
. . N

METHODS VB N
A DT N
total NN N
of IN N
622 CD N
men NNS N
and CC N
women NNS N
with IN N
radiological JJ N
evidence NN N
of IN N
primary JJ N
knee NN N
OA NNP N
and CC N
mild VB N
to TO N
severe VB N
symptoms NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
a DT N
topical JJ 3_i
diclofenac NN 3_i
solution NN 3_i
plus CC N
placebo JJ 7_i
oral JJ 7_i
capsules NNS 7_i
, , N
or CC N
placebo VB 7_i
topical JJ 7_i
solution NN 7_i
plus CC N
oral JJ 3_i
diclofenac NN 3_i
( ( N
50 CD N
mg NN N
) ) N
capsules NNS N
. . N

Patients NNS N
applied VBD N
50 CD N
drops NNS N
of IN N
study NN N
solution NN N
and CC N
took VBD N
1 CD N
study NN N
capsule NN N
3 CD N
times NNS N
daily RB N
for IN N
12 CD N
weeks NNS N
. . N

Efficacy NN N
variables NNS N
were VBD N
pain NN N
and CC N
physical JJ N
function NN N
, , N
measured VBN N
by IN N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
( ( N
WOMAC NNP N
) ) N
VA NNP N
3.1 CD N
OA NNP N
Index NNP N
, , N
and CC N
patient JJ N
global JJ N
assessment NN N
( ( N
PGA NNP N
) ) N
. . N

Equivalence NN N
in IN N
the DT N
per-protocol JJ N
group NN N
was VBD N
based VBN N
on IN N
previously RB N
defined VBN N
ranges NNS N
of IN N
clinically RB N
significant JJ N
difference NN N
. . N

Safety NN N
was VBD N
assessed VBN N
by IN N
evaluation NN N
of IN N
adverse JJ N
events NNS N
, , N
vital JJ N
signs NNS N
, , N
and CC N
laboratory NN N
data NNS N
. . N

RESULTS VB N
The DT N
difference NN N
in IN N
mean NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
change NN N
scores NNS N
( ( N
final JJ N
minus NN N
baseline NN N
) ) N
between IN N
treatments NNS N
was VBD N
13.3 CD N
mm NN N
( ( N
-8.6 UH N
to TO N
35.2 CD N
) ) N
for IN N
pain NN N
( ( N
total JJ N
scale NN N
500 CD N
mm NN N
) ) N
, , N
71.0 CD N
mm NN N
( ( N
-2.4 UH N
to TO N
144.5 CD N
) ) N
for IN N
physical JJ N
function NN N
( ( N
total JJ N
scale NN N
1700 CD N
mm NN N
) ) N
, , N
and CC N
4.3 CD N
mm NN N
( ( N
-1.2 UH N
to TO N
9.8 CD N
) ) N
for IN N
PGA NNP N
( ( N
total JJ N
scale NN N
100 CD N
mm NN N
) ) N
. . N

The DT N
CI NNP N
for IN N
each DT N
efficacy NN N
variable NN N
fell VBD N
within IN N
the DT N
predefined JJ N
equivalence NN N
ranges NNS N
( ( N
pain NN N
, , N
+/- JJ N
75 CD N
mm NN N
; : N
physical JJ N
function NN N
, , N
+/- JJ N
255 CD N
mm NN N
; : N
PGA NNP N
, , N
+/- JJ N
20 CD N
mm NN N
) ) N
, , N
indicating VBG N
that IN N
no DT N
clinically RB N
relevant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
2 CD N
treatment NN N
arms NNS N
. . N

Safety NN N
analyses NNS N
of IN N
patients NNS N
applying VBG N
topical JJ N
diclofenac NN 3_i
solution NN 3_i
revealed VBD N
some DT N
minor JJ N
skin NN N
irritation NN N
at IN N
the DT N
application NN N
site NN N
-- : N
mostly RB N
skin JJ N
dryness NN N
in IN N
83/311 CD N
( ( N
27 CD N
% NN N
) ) N
patients NNS N
-- : N
but CC N
a DT N
significantly RB N
reduced VBN N
incidence NN N
, , N
relative JJ N
to TO N
oral JJ N
diclofenac NN N
, , N
of IN N
total JJ N
and CC N
severe JJ N
gastrointestinal NN N
( ( N
GI NNP N
) ) N
adverse JJ N
events NNS N
, , N
including VBG N
dyspepsia NN N
, , N
abdominal JJ N
pain NN N
, , N
diarrhea NN N
, , N
and CC N
nausea NN N
. . N

The DT N
number NN N
of IN N
patients NNS N
developing VBG N
abnormal JJ N
liver NN N
function NN N
tests NNS N
( ( N
including VBG N
clinically RB N
significant JJ N
elevation NN N
) ) N
, , N
hemoglobin UH N
, , N
and CC N
creatinine JJ N
clearance NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
oral JJ 3_i
diclofenac NN 3_i
group NN N
. . N

CONCLUSION NNP N
Application NNP N
of IN N
this DT N
topical JJ 3_i
diclofenac NN 3_i
solution NN 3_i
to TO N
the DT N
knee NN N
of IN N
patients NNS N
with IN N
OA NNP N
produced VBD N
relief NN N
of IN N
symptoms NNS N
equivalent JJ N
to TO N
oral JJ 3_i
diclofenac NN 3_i
, , N
with IN N
minor JJ N
local JJ N
skin NN N
irritation NN N
, , N
but CC N
significantly RB N
reduced VBD N
incidence NN N
of IN N
diclofenac-related JJ N
GI NNP N
complaints NNS N
and CC N
abnormal JJ N
laboratory NN N
values NNS N
. . N

-DOCSTART- -X- O O

Central JJ N
neuronal JJ N
mechanisms NNS N
of IN N
gastric JJ 2_i
electrical JJ 2_i
stimulation NN 2_i
in IN N
diabetic JJ N
gastroparesis NN N
. . N

OBJECTIVE CC N
The DT N
mechanisms NNS N
underlying VBG N
symptom JJ N
improvement NN N
in IN N
gastric JJ 1_i
electrical JJ 1_i
stimulation NN 1_i
( ( 1_i
GES NNP 1_i
) ) 1_i
are VBP N
not RB N
fully RB N
understood JJ N
. . N

Modulation NN N
of IN N
the DT N
central JJ N
nervous JJ N
system NN N
excitability NN N
may MD N
be VB N
involved VBN N
. . N

The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
central JJ N
effects NNS N
of IN N
GES NNP 1_i
, , N
including VBG N
the DT N
possible JJ N
modulation NN N
of IN N
the DT N
visceral JJ N
sensory NN N
nervous JJ N
system NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP N
gastric JJ 1_i
electrical JJ 1_i
stimulator NN 1_i
was VBD N
implanted VBN N
in IN N
seven CD N
diabetic JJ N
patients NNS N
with IN N
medically RB N
refractory JJ N
gastroparesis NN 1_i
. . N

A DT N
double-blinded JJ N
protocol NN N
was VBD N
used VBN N
to TO N
investigate VB N
the DT N
patients NNS N
at IN N
baseline NN N
and CC N
one CD N
month NN N
after IN N
recovery NN N
with IN N
the DT N
stimulator NN N
turned VBD N
on IN N
and CC N
off IN N
( ( N
1-month JJ N
periods NNS N
) ) N
. . N

The DT N
following JJ N
assessments NNS N
were VBD N
carried VBN N
out IN N
: : N
mechanical JJ N
, , N
thermal JJ N
and CC N
electrical JJ N
stimulations NNS N
with IN N
sensory JJ N
recordings NNS N
in IN N
the DT N
esophagus NN N
and CC N
duodenum NN N
, , N
and CC N
standardized VBD N
, , N
self-administered JJ N
, , N
daily JJ N
symptom NN N
questionnaires NNS N
. . N

RESULTS NNP N
No NNP N
difference NN N
was VBD N
found VBN N
between IN N
baseline NN N
and CC N
the DT N
on- JJ N
and CC N
off RP N
periods NNS N
in IN N
overall JJ N
gut NN N
pain NN N
thresholds NNS N
across IN N
all DT N
stimulus NN N
modalities NNS N
in IN N
the DT N
esophagus NN N
( ( N
p=0.63 NN N
) ) N
, , N
duodenum NN N
( ( N
p=0.19 NN N
) ) N
or CC N
esophagus JJ N
and CC N
duodenum NN N
combined VBN N
( ( N
p=0.76 NN N
) ) N
. . N

No DT N
difference NN N
in IN N
the DT N
sensory JJ N
response NN N
to TO N
mechanical JJ N
stimulation NN N
was VBD N
found VBN N
in IN N
the DT N
esophagus NN N
before IN N
( ( N
all DT N
p VBP N
> $ N
0.31 CD N
) ) N
and CC N
after IN N
( ( N
all DT N
p VBP N
> $ N
0.43 CD N
) ) N
smooth FW N
muscle NN N
relaxation NN N
with IN N
butylscopolamine NN 3_i
. . N

Similar JJ N
findings NNS N
were VBD N
observed VBN N
in IN N
the DT N
duodenum NN N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
in IN N
thermal JJ N
sensitivity NN N
( ( N
esophagus JJ N
( ( N
p=0.67 NN N
) ) N
and CC N
duodenum NN N
( ( N
p=0.17 NN N
) ) N
) ) N
, , N
sensory JJ N
response NN N
to TO N
electrical JJ N
stimulation NN N
( ( N
esophagus JJ N
( ( N
p=0.57 NN N
) ) N
and CC N
duodenum NN N
( ( N
p=0.52 NN N
) ) N
) ) N
or CC N
induced VBN N
somatic JJ N
referred VBD N
pain NN N
areas NNS N
( ( N
esophagus NN N
( ( N
p=0.75 NN N
) ) N
and CC N
duodenum NN N
( ( N
p=0.51 NN N
) ) N
) ) N
. . N

No DT N
difference NN N
was VBD N
seen VBN N
in IN N
the DT N
induced JJ N
somatic JJ N
referred VBD N
pain JJ N
areas NNS N
or CC N
self-reported JJ N
symptoms NNS N
. . N

CONCLUSIONS NNP N
No NNP N
evidence NN N
was VBD N
found VBN N
for IN N
GES-induced NNP 1_i
modulation NN N
of IN N
the DT N
visceral JJ N
sensory NN N
system NN N
and CC N
central JJ N
excitability NN N
. . N

However RB N
, , N
GES NNP 1_i
has VBZ N
been VBN N
proven VBN N
to TO N
modulate VB N
the DT N
central JJ N
nervous JJ N
system NN N
in IN N
animal JJ N
studies NNS N
, , N
necessitating VBG N
further JJ N
human JJ N
experiments NNS N
in IN N
order NN N
unambiguously RB N
to TO N
establish VB N
the DT N
possible JJ N
central JJ N
effects NNS N
of IN N
GES NNP 1_i
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
regimens NNS N
of IN N
amphotericin NN 3_i
B NNP 3_i
deoxycholate NN 3_i
in IN N
kala-azar NN N
. . N

A DT N
total NN N
of IN N
288 CD N
parasitologically RB N
proved JJ N
patients NNS N
of IN N
kala-azar NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
treatment NN N
groups NNS N
. . N

Patients NNS N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
received VBD N
amphotericin JJ 3_i
B NNP 3_i
( ( 3_i
AMB NNP 3_i
) ) 3_i
in IN N
a DT N
dose NN N
of IN N
1 CD N
mg/kg NNS N
body NN N
weight NN N
( ( N
bw NN N
) ) N
/day NN N
, , N
0.75 CD N
mg/kg NN N
bw/day NN N
and CC N
0.5 CD N
mg/kg NNS N
bw/day NN N
for IN N
20 CD N
days NNS N
respectively RB N
. . N

Apparent JJ N
cure NN N
( ( N
afebrile NN N
at IN N
the DT N
end NN N
of IN N
therapy NN N
) ) N
occurred VBD N
in IN N
all DT N
patients NNS N
and CC N
parasitological JJ N
cure NN N
in IN N
96 CD N
( ( N
100 CD N
% NN N
) ) N
, , N
92 CD N
( ( N
96 CD N
% NN N
) ) N
and CC N
84 CD N
( ( N
88 CD N
% NN N
) ) N
patients NNS N
respectively RB N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C. NNP N
Ultimate NNP N
cure NN N
( ( N
no DT N
relapse NN N
in IN N
six CD N
months NNS N
of IN N
follow VBP N
up RP N
) ) N
occurred VBD N
in IN N
95 CD N
( ( N
99 CD N
% NN N
) ) N
, , N
87 CD N
( ( N
91 CD N
% NN N
) ) N
and CC N
79 CD N
( ( N
82 CD N
% NN N
) ) N
patients NNS N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
respectively RB N
. . N

The DT N
difference NN N
between IN N
the DT N
ultimate JJ N
cure NN N
in IN N
the DT N
three CD N
groups NNS N
was VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
( ( N
rise NN N
in IN N
serum JJ N
creatinine NN N
and CC N
fall NN N
in IN N
serum JJ N
potassium NN N
, , N
loss NN N
of IN N
appetite NN N
and CC N
shivering NN N
, , N
rigor NN N
and CC N
fever NN N
during IN N
infusion NN N
indicative NN N
of IN N
renal JJ N
, , N
GIT NNP N
and CC N
infusion NN N
related JJ N
toxicities NNS N
respectively RB N
) ) N
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

This DT N
study NN N
showed VBD N
that IN N
amphotericin NN 3_i
B NNP 3_i
should MD N
be VB N
given VBN N
at IN N
a DT N
dosage NN N
of IN N
1 CD N
mg/kg NNS N
bw/day NN N
for IN N
20 CD N
days NNS N
for IN N
Indian JJ N
kala-azar JJ N
patients NNS N
to TO N
minimise VB N
relapses NNS N
and CC N
prevent NN N
development NN N
of IN N
drug NN N
unresponsiveness NN N
. . N

-DOCSTART- -X- O O

Targeting VBG N
alpha-7 JJ 3_i
nicotinic JJ 3_i
neurotransmission NN 3_i
in IN N
schizophrenia NN N
: : N
a DT N
novel JJ N
agonist NN N
strategy NN N
. . N

Alpha7 NNP N
nicotinic JJ N
acetylcholine NN N
receptor NN N
( ( N
?7 NNP N
nAChR RB N
) ) N
agonists NNS N
may MD N
be VB N
valuable JJ N
treatments NNS N
for IN N
negative JJ N
symptoms NNS N
and CC N
cognitive JJ N
impairment NN N
in IN N
schizophrenia NN N
. . N

Unfortunately RB N
, , N
chronic JJ N
exposure NN N
to TO N
an DT N
agonist NN N
may MD N
reduce VB N
the DT N
receptor NN N
's POS N
sensitivity NN N
. . N

Therefore RB N
, , N
we PRP N
combined VBD N
CDP-choline NNP N
, , N
a DT N
dietary JJ N
source NN N
of IN N
the DT N
direct JJ N
agonist NN N
choline NN N
, , N
with IN N
galantamine NN N
, , N
a DT N
positive JJ N
allosteric JJ N
modulator NN N
( ( N
PAM NNP N
) ) N
of IN N
nicotinic JJ N
acetylcholine NN N
receptors NNS N
, , N
to TO N
improve VB N
the DT N
efficiency NN N
of IN N
transducing VBG N
the DT N
choline JJ N
signal NN N
and CC N
, , N
possibly RB N
, , N
preserve VB N
the DT N
receptor NN N
in IN N
a DT N
sensitive JJ N
state NN N
. . N

We PRP N
conducted VBD N
a DT N
single-site JJ N
, , N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG N
galantamine/CDP-choline NN N
to TO N
placebos VB N
in IN N
schizophrenia NN N
patients NNS N
with IN N
negative JJ N
symptoms NNS N
who WP N
were VBD N
receiving VBG N
second JJ N
generation NN N
antipsychotics NNS N
. . N

Forty-three JJ N
subjects NNS N
received VBN N
galantamine JJ N
and CC N
CDP-choline JJ N
or CC N
matching JJ N
placebos NNS N
for IN N
16weeks CD N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
5-item JJ N
Marder NNP N
negative-symptoms JJ N
factor NN N
of IN N
the DT N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
( ( N
PANSS NNP N
) ) N
. . N

Cognition NN N
and CC N
functioning NN N
were VBD N
also RB N
assessed VBN N
. . N

Trial JJ N
completion NN N
was VBD N
high JJ N
; : N
79 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
treatment NN N
effect NN N
on IN N
negative JJ N
symptoms NNS N
, , N
other JJ N
PANSS NNP N
symptom NN N
factors NNS N
, , N
or CC N
the DT N
MATRICS NNP N
Cognitive NNP N
Consensus NNP N
Battery NNP N
. . N

There EX N
were VBD N
significant JJ N
treatment NN N
effects NNS N
in IN N
overall JJ N
functioning NN N
and CC N
a DT N
test NN N
of IN N
free JJ N
verbal JJ N
recall NN N
. . N

Three CD N
subjects NNS N
discontinued VBN N
treatment NN N
in IN N
the DT N
active JJ N
treatment NN N
group NN N
for IN N
gastro-intestinal JJ N
adverse JJ N
events NNS N
( ( N
AE NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
AE NNP N
for IN N
galantamine/CDP-choline NN N
was VBD N
abdominal JJ N
pain NN N
; : N
for IN N
placebo NN N
it PRP N
was VBD N
headache NN N
and CC N
sweating NN N
. . N

Although IN N
there EX N
was VBD N
no DT N
significant JJ N
treatment NN N
effect NN N
on IN N
negative JJ N
symptoms NNS N
, , N
the DT N
direction NN N
of IN N
effect NN N
mirrored VBD N
the DT N
effects NNS N
on IN N
a DT N
cognitive JJ N
measure NN N
and CC N
overall JJ N
functioning NN N
. . N

Further NNP N
study NN N
of IN N
?7 NNP N
nAChR JJ N
agonist/PAMs NN N
is VBZ N
warranted VBN N
in IN N
larger JJR N
studies NNS N
that WDT N
will MD N
have VB N
greater JJR N
power NN N
. . N

-DOCSTART- -X- O O

Promoting VBG 6_i
social JJ 6_i
skill NN 6_i
development NN 6_i
in IN N
children NNS N
with IN N
pervasive JJ N
developmental JJ N
disorders NNS N
: : N
a DT N
feasibility NN N
and CC N
efficacy NN N
study NN N
. . N

A DT N
randomized JJ N
controlled JJ N
design NN N
was VBD N
employed VBN N
to TO N
evaluate VB N
a DT N
social JJ 4_i
skills NNS 4_i
intervention NN 4_i
for IN N
children NNS N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

Aims NNP N
included VBD N
evaluating VBG N
the DT N
acceptability NN N
of IN N
the DT N
program NN N
and CC N
gathering VBG N
preliminary JJ N
evidence NN N
on IN N
efficacy NN N
. . N

Forty-four JJ N
children NNS N
, , N
ages VBZ N
8-11 CD N
years NNS N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN 5_i
or CC N
wait JJ 6_i
list NN 6_i
. . N

Treatment NNP N
consisted VBD N
of IN N
a DT N
16-week JJ N
group NN 4_i
intervention NN 4_i
designed VBN 4_i
to TO 4_i
teach VB 4_i
appropriate JJ 4_i
social JJ 4_i
behavior NN 4_i
. . N

Between NNP N
group NN N
comparisons NNS N
showed VBD N
that IN N
children NNS N
in IN N
treatment NN N
were VBD N
rated VBN N
as IN N
improved VBN N
on IN N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
( ( N
unblinded JJ N
parent NN N
report NN N
) ) N
, , N
but CC N
not RB N
on IN N
the DT N
secondary JJ N
outcome NN N
measure NN N
, , N
a DT N
parent NN N
questionnaire NN N
. . N

Parents NNS N
reported VBD N
a DT N
high JJ N
level NN N
of IN N
satisfaction NN N
with IN N
the DT N
intervention NN N
. . N

The DT N
study NN N
supports VBZ N
the DT N
feasibility NN N
of IN N
this DT N
intervention NN N
to TO N
families NNS N
and CC N
highlights NNS N
challenges NNS N
for IN N
future JJ N
research NN N
in IN N
social JJ 4_i
skills NNS 4_i
intervention NN 4_i
. . 4_i

-DOCSTART- -X- O O

Cardiovascular JJ N
effects NNS N
of IN N
non-depolarizing JJ 3_i
neuromuscular JJ 3_i
blockers NNS 3_i
in IN N
patients NNS N
with IN N
aortic JJ N
valve NN N
disease NN N
. . N

To TO N
compare VB N
haemodynamic JJ N
responses NNS N
associated VBN N
with IN N
equipotent JJ N
doses NNS N
of IN N
neuromuscular JJ 3_i
blockers NNS 3_i
and CC N
high-dose JJ N
fentanyl NN 3_i
( ( N
50 CD N
micrograms.kg-1 NN N
) ) N
, , N
40 CD N
patients NNS N
with IN N
aortic JJ N
valve NNS N
stenosis NN N
( ( N
AS IN N
) ) N
and CC N
20 CD N
patients NNS N
with IN N
aortic JJ N
insufficiency NN N
( ( N
AI NNP N
) ) N
were VBD N
randomized VBN N
to TO N
four CD N
study NN N
groups NNS N
to TO N
receive VB N
the DT N
following NN N
: : N
( ( N
1 CD N
) ) N
pancuronium NN 3_i
0.12 CD 3_i
mg.kg-1 NN 3_i
, , 3_i
( ( 3_i
2 CD 3_i
) ) 3_i
vecuronium NN 3_i
0.12 CD 3_i
mg.kg-1 NN 3_i
, , N
( ( 3_i
3 CD 3_i
) ) 3_i
atracurium NN 3_i
0.4 CD 3_i
mg.kg-1 NN 3_i
, , N
or CC N
( ( 3_i
4 CD 3_i
) ) 3_i
pancuronium-metocurine NN 3_i
mixture NN 3_i
( ( N
0.4 CD N
mg NN N
+ VBD N
1.6 CD N
mg/ml NN N
) ) N
: : N
1 CD N
ml/10 NNS N
kg NN N
) ) N
. . N

Neuromuscular JJ 3_i
blockers NNS 3_i
were VBD N
injected VBN N
at IN N
the DT N
same JJ N
time NN N
with IN N
the DT N
fentanyl NN 3_i
; : N
haemodynamics NNS N
were VBD N
recorded VBN N
with IN N
the DT N
patients NNS N
awake VBP N
( ( N
baseline NN N
) ) N
, , N
at IN N
two CD N
minutes NNS N
post-induction NN N
, , N
and CC N
at IN N
two CD N
and CC N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

In IN N
patients NNS N
with IN N
AS NNP N
, , N
pancuronium NN 3_i
increased VBD N
heart NN N
rate NN N
more JJR N
than IN N
vecuronium NN 3_i
or CC N
atracurium NN 3_i
; : N
heart NN N
rates NNS N
were VBD N
also RB N
higher JJR N
with IN N
the DT N
pancuronium-metocurine JJ 3_i
mixture NN 3_i
than IN N
with IN N
vecuronium NN 3_i
. . N

Although IN N
there EX N
were VBD N
no DT N
ECG NNP N
signs NNS N
of IN N
ischaemia NN N
, , N
one CD N
patient NN N
given VBN N
pancuronium NN N
developed VBD N
severe JJ N
hypotension NN N
associated VBN N
with IN N
tachycardia NN N
. . N

Reductions NNS N
in IN N
SVR NNP N
after IN N
atracurium NN N
allowed VBD N
small JJ N
but CC N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
decreases NNS N
in IN N
MAP NNP N
which WDT N
were VBD N
well RB N
tolerated VBN N
; : N
one CD N
patient NN N
, , N
however RB N
, , N
did VBD N
develop VB N
severe JJ N
hypotension NN N
. . N

Intubation NNP N
resulted VBD N
in IN N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
increases NNS N
in IN N
MAP NNP N
in IN N
the DT N
pancuronium-metocurine JJ 3_i
mixture NN N
group NN N
. . N

Vecuronium NNP 3_i
permitted VBD N
the DT N
most RBS N
stable JJ N
overall JJ N
haemodynamic JJ N
course NN N
at IN N
all DT N
measurement JJ N
times NNS N
. . N

In IN N
contrast NN N
, , N
patients NNS N
with IN N
AI NNP N
showed VBD N
stable JJ N
haemodynamics NNS N
after IN N
vecuronium NN 3_i
, , N
pancuronium NN 3_i
and CC N
the DT N
pancuronium-metocurine JJ 3_i
mixture NN 3_i
; : N
one CD N
patient NN N
became VBD N
tachycardic JJ N
following VBG N
vecuronium NN 3_i
. . N

Atracurium NNP 3_i
caused VBD N
unexplained JJ N
elevations NNS N
in IN N
diastolic JJ N
and CC N
mean JJ N
arterial NN N
pressures NNS N
which WDT N
were VBD N
significant JJ N
when WRB N
compared VBN N
to TO N
vecuronium VB 3_i
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

These DT N
results NNS N
in IN N
increases NNS N
in IN N
PCWP NNP N
; : N
mean JJ N
PA NNP N
pressures NNS N
and CC N
CVP NNP N
were VBD N
also RB N
increased VBN N
. . N

These DT N
effects NNS N
of IN N
atracurium NN 3_i
inpatients NNS N
with IN N
Al NNP N
need VBP N
further JJ N
evaluation NN N
. . N

-DOCSTART- -X- O O

Risperidone NNP 3_i
versus NN N
haloperidol NN 3_i
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
AD NNP N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
double-blind JJ N
trial NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
safety NN N
, , N
efficacy NN N
and CC N
tolerability NN N
of IN N
risperidone NN 3_i
with IN N
haloperidol NN 3_i
in IN N
the DT N
treatment NN N
of IN N
Autistic JJ N
Disorder NNP N
( ( N
AD NNP N
) ) N
. . N

METHOD NNP N
This DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
double-blind NN N
, , N
prospective JJ N
, , N
for IN N
a DT N
12-week JJ N
period NN N
. . N

A DT N
total NN N
of IN N
30 CD N
subjects NNS N
, , N
between IN N
the DT N
ages NNS N
of IN N
8 CD N
and CC N
18 CD N
with IN N
AD NNP N
based VBN N
on IN N
DSM NNP N
IV NNP N
criteria NNS N
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Behavioral NNP N
Rating VBG N
Scales NNS N
were VBD N
performed VBN N
by IN N
the DT N
investigators NNS N
and CC N
the DT N
parents NNS N
. . N

Safety NNP N
assessment NN N
included VBD N
vital JJ N
signs NNS N
, , N
electrocardiogram NN 2_i
, , N
electroencephalogram NN 2_i
, , N
adverse JJ N
events NNS N
, , N
laboratory NN N
tests NNS N
, , N
extrapyramidal NN N
symptoms NNS N
and CC N
the DT N
side NN N
effects NNS N
. . N

Both DT N
treatments NNS N
were VBD N
applied VBN N
in IN N
a DT N
once RB N
daily JJ N
dosage NN N
regimen NNS N
of IN N
0.01-0.08 JJ N
mg/kg/day NN N
. . N

RESULTS VB N
The DT N
reduction NN N
from IN N
baseline NN N
in IN N
Ritvo-Freeman NNP N
Real NNP N
Life NNP N
Rating NNP N
Scale NNP N
( ( N
RF-RLRS NNP N
) ) N
, , N
sensory JJ N
motor NN N
( ( N
subscale JJ N
I PRP N
) ) N
and CC N
language NN N
( ( N
subscale JJ N
V NNP N
) ) N
scores NNS N
were VBD N
significant JJ N
in IN N
risperidone NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Compared VBN N
to TO N
haloperidol VB N
, , N
risperidone NN N
led VBD N
to TO N
a DT N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
and CC N
Turgay NNP N
DSM-IV NNP N
Pervasive NNP N
Developmental NNP N
Disorder NNP N
( ( N
PDD NNP N
) ) N
scale NN N
scores NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
greater JJR N
increase NN N
of IN N
prolactin NN N
in IN N
the DT N
risperidone NN N
group NN N
, , N
while IN N
alanine JJ N
amino NN N
transferase NN N
( ( N
ALT NNP N
) ) N
had VBD N
further RBR N
increased VBN N
in IN N
the DT N
haloperidol NN N
group NN N
. . N

Sensory NNP N
motor NN N
behaviors NNS N
( ( N
subscale JJ N
I PRP N
) ) N
and CC N
language NN N
at IN N
the DT N
end NN N
of IN N
the DT N
12th CD N
week NN N
, , N
RF-RLRS NNP N
sensory NN N
motor NN N
and CC N
language NN N
subscale JJ N
scores NNS N
decreased VBN N
in IN N
the DT N
risperidone NN N
group NN N
further RBR N
than IN N
the DT N
other JJ N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Risperidone NNP N
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
haloperidol NN N
in IN N
the DT N
treatment NN N
of IN N
behavioral JJ N
symptoms NNS N
, , N
impulsivity NN N
, , N
language NN N
skills NNS N
, , N
and CC N
impaired JJ N
social JJ N
relations NNS N
in IN N
children NNS N
with IN N
AD NNP N
. . N

These DT N
results NNS N
demonstrated VBD N
that IN N
both DT N
drugs NNS N
were VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
AD NNP N
. . N

-DOCSTART- -X- O O

Low-dose JJ N
mifepristone NN 3_i
for IN N
uterine JJ N
leiomyomata NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
5 CD N
and CC N
10 CD N
mg NN N
of IN N
mifepristone NN 3_i
on IN N
uterine JJ N
leiomyoma NN N
size NN N
and CC N
symptoms NNS N
, , N
and CC N
to TO N
measure VB N
side JJ N
effects NNS N
. . N

METHODS NNP N
Forty NNP N
premenopausal JJ N
women NNS N
with IN N
large JJ N
, , N
symptomatic JJ N
leiomyomata NNS N
were VBD N
randomized VBN N
to TO N
receive VB 3_i
either RB 3_i
5 CD 3_i
or CC 3_i
10 CD 3_i
mg NN 3_i
of IN 3_i
mifepristone JJ 3_i
daily JJ 3_i
for IN 3_i
6 CD 3_i
months NNS 3_i
in IN 3_i
an DT 3_i
open-label JJ 3_i
study NN 3_i
. . 3_i

Uterine NNP N
volume NN N
was VBD N
measured VBN N
at IN N
bimonthly JJ N
intervals NNS N
by IN N
sonography NN N
. . N

Serum NNP N
concentrations NNS N
of IN N
hemoglobin NN N
levels NNS N
, , N
follicle-stimulating JJ N
hormone NN N
, , N
and CC N
liver RB N
enzymes NNS N
were VBD N
obtained VBN N
, , N
and CC N
endometrial JJ N
samples NNS N
, , N
symptoms NNS N
, , N
and CC N
menstrual JJ N
bleeding NN N
were VBD N
also RB N
assessed VBN N
. . N

RESULTS NNP N
Nineteen NNP N
of IN N
20 CD N
subjects NNS N
taking VBG N
5 CD N
mg NN N
and CC N
all DT N
20 CD N
subjects NNS N
taking VBG N
10 CD N
mg NN N
completed VBD N
all DT N
6 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

Mean NNP N
uterine JJ N
volume NN N
shrank NN N
by IN N
48 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
5-mg JJ N
group NN N
and CC N
49 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
10-mg JJ N
group NN N
, , N
a DT N
nonsignificant JJ N
difference NN N
. . N

Leiomyoma-related JJ N
symptoms NNS N
were VBD N
comparably RB N
reduced VBN N
in IN N
both DT N
groups NNS N
. . N

Amenorrhea NNP N
occurred VBD N
in IN N
60-65 CD N
% NN N
of IN N
both DT N
groups NNS N
. . N

Hemoglobin NNP N
levels NNS N
increased VBN N
by IN N
2.5 CD N
g/dL NNS N
in IN N
anemic JJ N
subjects NNS N
. . N

The DT N
incidence NN N
of IN N
hot JJ N
flashes NNS N
increased VBD N
significantly RB N
over IN N
baseline NN N
in IN N
the DT N
10-mg JJ N
group NN N
but CC N
not RB N
in IN N
the DT N
5-mg JJ N
group NN N
. . N

Simple NNP N
endometrial JJ N
hyperplasia NN N
occurred VBD N
in IN N
28 CD N
% NN N
of IN N
all DT N
subjects NNS N
, , N
with IN N
no DT N
difference NN N
between IN N
groups NNS N
. . N

No DT N
atypical JJ N
hyperplasia NN N
was VBD N
noted VBN N
. . N

CONCLUSION NNP N
Mifepristone NNP 3_i
in IN N
doses NNS N
of IN N
5 CD N
mg NNS N
or CC N
10 CD N
mg JJ N
results NNS N
in IN N
comparable JJ N
leiomyoma NN N
regression NN N
, , N
improvement NN N
in IN N
symptoms NNS N
, , N
and CC N
few JJ N
side NN N
effects NNS N
. . N

Further NNP N
study NN N
is VBZ N
needed VBN N
to TO N
assess VB N
the DT N
long-term JJ N
safety NN N
and CC N
efficacy NN N
of IN N
low-dose JJ N
mifepristone NN 3_i
. . N

-DOCSTART- -X- O O

Improvement NN N
of IN N
pain NN N
related VBN N
self JJ N
management NN N
for IN N
oncologic JJ N
patients NNS N
through IN N
a DT N
trans JJ N
institutional JJ N
modular JJ N
nursing NN N
intervention NN N
: : N
protocol NN N
of IN N
a DT N
cluster NN N
randomized VBN N
multicenter RB N
trial NN N
. . N

BACKGROUND NNP N
Pain NNP N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
frequent JJ N
and CC N
distressing VBG N
symptoms NNS N
in IN N
cancer NN N
patients NNS N
. . N

For IN N
the DT N
majority NN N
of IN N
the DT N
patients NNS N
, , N
sufficient JJ N
pain NN N
relief NN N
can MD N
be VB N
obtained VBN N
if IN N
adequate JJ N
treatment NN N
is VBZ N
provided VBN N
. . N

However RB N
, , N
pain NN N
remains NNS N
often RB N
undertreated VBD N
due JJ N
to TO N
institutional JJ N
, , N
health NN N
care NN N
professional JJ N
and CC N
patient JJ N
related JJ N
barriers NNS N
. . N

Patients NNS N
self JJ N
management NN N
skills NNS N
are VBP N
affected VBN N
by IN N
the DT N
patients NNS N
' POS N
knowledge NN N
, , N
activities NNS N
and CC N
attitude NN N
to TO N
pain VB N
management NN N
. . N

This DT N
trial NN N
protocol NN N
is VBZ N
aimed VBN N
to TO N
test VB N
the DT N
SCION-PAIN JJ N
program NN N
, , N
a DT N
multi NN N
modular NN N
structured VBD N
intervention NN N
to TO N
improve VB N
self NN N
management NN N
in IN N
cancer NN N
patients NNS N
with IN N
pain NN N
. . N

METHODS NNP N
240 CD N
patients NNS N
with IN N
diagnosed JJ N
malignancy NN N
and CC N
pain NN N
> VBP N
3 CD N
days NNS N
and CC N
average JJ N
pain NN N
> JJ N
or= NN N
3/10 CD N
will MD N
participate VB N
in IN N
a DT N
cluster NN N
randomized VBN N
trial NN N
on IN N
18 CD N
wards NNS N
in IN N
2 CD N
German JJ N
university NN N
hospitals NNS N
. . N

Patients NNS N
from IN N
the DT N
intervention NN N
wards NNS N
will MD N
receive VB N
, , N
additionally RB N
to TO N
standard VB 7_i
pain NN 7_i
treatment NN 7_i
, , N
the DT 2_i
SCION-PAIN JJ 2_i
program NN 2_i
consisting NN 2_i
of IN 2_i
3 CD 2_i
modules NNS 2_i
: : 2_i
pharmacologic NN 2_i
pain NN 2_i
management NN 2_i
, , 2_i
nonpharmacologic RB 2_i
pain JJ 2_i
management NN 2_i
and CC 2_i
discharge NN 2_i
management NN 2_i
. . N

The DT N
intervention NN N
will MD N
be VB N
conducted VBN N
by IN N
specially RB N
trained JJ N
oncology NN N
nurses NNS N
and CC N
includes VBZ N
components NNS N
of IN N
patient JJ 4_i
education NN 4_i
, , 4_i
skills NNS 4_i
training NN 4_i
and CC 4_i
counseling NN 4_i
to TO 4_i
improve VB 4_i
self PRP 4_i
care VB 4_i
regarding VBG 4_i
pain JJ 4_i
management NN 4_i
beginning VBG 4_i
with IN 4_i
admission NN 4_i
followed VBN 4_i
by IN 4_i
booster NN 4_i
session NN 4_i
every DT 4_i
3rd CD 4_i
day NN 4_i
and CC 4_i
one CD 4_i
follow VBP 4_i
up RP 4_i
telephone NN 4_i
counseling NN 4_i
within IN 4_i
2 CD 4_i
to TO 4_i
3 CD 4_i
days NNS 4_i
after IN 4_i
discharge NN 4_i
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
will MD N
receive VB N
standard NN N
care NN N
. . N

Primary JJ N
endpoint NN N
is VBZ N
the DT N
group NN N
difference NN N
in IN N
patient NN N
related JJ N
barriers NNS N
to TO N
management NN N
of IN N
cancer NN N
pain NN N
( ( N
BQII NNP N
) ) N
, , N
7 CD N
days NNS N
after IN N
discharge NN N
. . N

Secondary JJ N
endpoints NNS N
are VBP N
: : N
pain NN N
intensity NN N
& CC N
interference NN N
, , N
adherence NN N
, , N
coping VBG N
and CC N
HRQoL NNP N
. . N

DISCUSSION NNP N
The DT N
study NN N
will MD N
determine VB N
if IN N
the DT N
acquired VBN N
self NN N
management NN N
skills NNS N
of IN N
the DT N
patients NNS N
continue VBP N
to TO N
be VB N
used VBN N
after IN N
discharge NN N
from IN N
hospital NN N
. . N

It PRP N
is VBZ N
hypothesized VBN N
that IN N
patients NNS N
who WP N
receive VBP N
the DT N
multi NN N
modular NN N
structured VBN N
intervention NN N
will MD N
have VB N
less RBR N
patient JJ N
related JJ N
barriers NNS N
and CC N
a DT N
better JJR N
self JJ N
management NN N
of IN N
cancer NN N
pain NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials NNP N
NCT00779597 NNP N
. . N

-DOCSTART- -X- O O

Stress NNP N
reduction NN N
and CC N
analgesia NN N
in IN N
patients NNS N
exposed VBN N
to TO N
calming VBG N
music NN N
postoperatively RB N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
, , N
first RB N
, , N
whether IN N
intra- JJ N
or CC N
postoperative JJ N
music NN N
therapy NN N
could MD N
influence VB N
stress NN N
and CC N
immune JJ N
response NN N
during IN N
and CC N
after IN N
general JJ N
anaesthesia NN N
and CC N
second JJ N
, , N
if IN N
there EX N
was VBD N
a DT N
different JJ N
response NN N
between IN N
patients NNS N
exposed VBN N
to TO N
music NN N
intra- NN N
or CC N
postoperatively RB N
. . N

METHOD NNP N
Seventy-five JJ N
patients NNS N
undergoing VBG N
open JJ N
hernia NN N
repair NN N
as IN N
day NN N
care NN N
surgery NN N
were VBD N
randomly RB 4_i
allocated VBN 4_i
to TO 4_i
three CD 4_i
groups NNS 4_i
: : 4_i
intraoperative JJ 4_i
music NN 4_i
, , 4_i
postoperative JJ 4_i
music NN 4_i
and CC 4_i
silence NN 7_i
( ( 4_i
control VB 4_i
group NN 4_i
) ) 4_i
. . N

Anaesthesia NNP 2_i
and CC 2_i
postoperative JJ 2_i
analgesia NN 2_i
were VBD 2_i
standardized VBN 2_i
and CC N
the DT N
same JJ N
surgeon NN 1_i
performed VBD 1_i
all PDT 1_i
the DT 1_i
operations NNS 1_i
. . N

Stress NNP N
response NN N
was VBD N
assessed VBN N
during IN N
and CC N
after IN N
surgery NN N
by IN N
determining VBG N
the DT N
plasma NN 1_i
cortisol NN 1_i
and CC N
blood NN 1_i
glucose NN 1_i
levels NNS 1_i
. . N

Immune NNP N
function NN N
was VBD N
evaluated VBN N
by IN N
studying VBG N
immunoglobulin NN 2_i
A NNP 2_i
( ( 2_i
IgA NNP 2_i
) ) 2_i
levels NNS 2_i
. . N

Patients NNS N
' POS N
postoperative JJ N
pain NN 5_i
, , N
anxiety NN 5_i
, , N
blood NN 2_i
pressure NN 2_i
( ( 2_i
BP NNP 2_i
) ) 2_i
, , N
heart NN 2_i
rate NN 2_i
( ( 2_i
HR NNP 2_i
) ) 2_i
and CC N
oxygen JJ 2_i
saturation NN 2_i
were VBD N
also RB N
studied VBN N
as IN N
stress NN N
markers NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significantly RB N
greater JJR N
decrease NN N
in IN N
the DT N
level NN N
of IN N
cortisol NN N
in IN N
the DT N
postoperative JJ N
music NN N
group NN N
vs. IN N
the DT N
control NN N
group NN N
( ( N
206 CD N
and CC N
72 CD N
mmol NN N
L NNP N
( ( N
-1 NNP N
) ) N
decreases VBZ N
, , N
respectively RB N
) ) N
after IN N
2 CD N
h NN N
in IN N
the DT N
post NN N
anaesthesia NN N
care NN N
unit NN N
. . N

The DT N
postoperative JJ N
music NN N
group NN N
had VBD N
less JJR N
anxiety NN N
and CC N
pain NN N
and CC N
required VBD N
less JJR N
morphine NN N
after IN N
1 CD N
h NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
postoperative JJ N
music NN N
group NN N
the DT N
total JJ N
requirement NN N
of IN N
morphine NN N
was VBD N
significantly RB N
lower JJR N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
intraoperative JJ N
music NN N
group NN N
reported VBD N
less JJR N
pain NN N
after IN N
1 CD N
h NN N
in IN N
the DT N
post NN N
anaesthesia NN N
care NN N
unit NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
IgA NNP N
, , N
blood NN N
glucose NN N
, , N
BP NNP N
, , N
HR NNP N
and CC N
oxygen NN N
saturation NN N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
This DT N
study NN N
suggests VBZ N
that IN N
intraoperative JJ N
music NN N
may MD N
decrease VB N
postoperative JJ N
pain NN N
, , N
and CC N
that IN N
postoperative JJ N
music NN N
therapy NN N
may MD N
reduce VB N
anxiety NN N
, , N
pain NN N
and CC N
morphine NN N
consumption NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
entecavir NN 3_i
prophylaxis NN 3_i
for IN N
rituximab-associated JJ N
hepatitis NN N
B NNP N
virus NN N
reactivation NN N
in IN N
patients NNS N
with IN N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
. . N

PURPOSE NNP N
The DT N
role NN N
of IN N
antiviral JJ 3_i
prophylaxis NN 3_i
in IN N
preventing VBG N
hepatitis NN N
B NNP N
virus NN N
( ( N
HBV NNP N
) ) N
reactivation NN N
before IN N
rituximab-based JJ 3_i
chemotherapy NN 3_i
in IN N
patients NNS N
with IN N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
is VBZ N
unclear JJ N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Eighty NNP N
patients NNS N
with IN N
CD20 NNP N
( ( N
+ NNP N
) ) N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
prophylactic JJ 3_i
entecavir NN 3_i
( ( 3_i
ETV NNP 3_i
) ) 2_i
before IN 2_i
chemotherapy NN 3_i
to TO 2_i
3 CD 2_i
months NNS 2_i
after IN 2_i
completing VBG 2_i
chemotherapy NN 3_i
( ( 2_i
ETV NNP 2_i
prophylactic JJ 2_i
group NN 2_i
, , 2_i
n RB 2_i
= VBZ 2_i
41 CD 2_i
) ) 2_i
or CC N
to TO N
receive VB 2_i
therapeutic JJ 2_i
ETV NNP 2_i
at IN 2_i
the DT 2_i
time NN 2_i
of IN 2_i
HBV NNP 2_i
reactivation NN 2_i
and CC 2_i
hepatitis NN 2_i
B NNP 2_i
surface NN 2_i
antigen NN 2_i
( ( 2_i
HBsAg NNP 2_i
) ) 2_i
reverse NN 2_i
seroconversion NN 2_i
since IN 2_i
chemotherapy NN 2_i
( ( 2_i
control NN 2_i
group NN 2_i
, , 2_i
n RB 2_i
= VBZ 2_i
39 CD 2_i
) ) 2_i
. . N

RESULTS JJ N
Fifty-eight JJ N
patients NNS N
( ( N
72.5 CD N
% NN N
) ) N
were VBD N
positive JJ N
for IN N
hepatitis NN N
B NNP N
surface NN N
antibody NN N
, , N
and CC N
HBV NNP N
DNA NNP N
was VBD N
undetectable JJ N
in IN N
50 CD N
patients NNS N
( ( N
62.5 CD N
% NN N
) ) N
. . N

During IN N
a DT N
mean JJ N
18-month JJ N
follow-up JJ N
period NN N
, , N
one CD N
patient NN N
( ( N
2.4 CD N
% NN N
) ) N
in IN N
the DT N
ETV NNP 2_i
prophylactic JJ N
group NN N
and CC N
seven CD N
patients NNS N
( ( N
17.9 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
developed VBD N
HBV NNP N
reactivation NN N
( ( N
P NNP N
= NNP N
.027 NNP N
) ) N
. . N

The DT N
cumulative JJ N
HBV NNP N
reactivation NN N
rates NNS N
at IN N
months NNS N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
after IN N
chemotherapy NN N
were VBD N
8 CD N
% NN N
, , N
11.2 CD N
% NN N
, , N
and CC N
25.9 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
0 CD N
% NN N
, , N
0 CD N
% NN N
, , N
and CC N
4.3 CD N
% NN N
in IN N
the DT N
ETV NNP N
prophylactic JJ N
group NN N
( ( N
P NNP N
= NNP N
.019 NNP N
) ) N
. . N

Four CD N
patients NNS N
( ( N
50 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
had VBD N
HBsAg NNP N
reverse NN N
seroconversion NN N
after IN N
HBV NNP N
reactivation NN N
. . N

The DT N
cumulative JJ N
HBsAg NNP N
reverse NN N
seroconversion NN N
rates NNS N
at IN N
months NNS N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
since IN N
chemotherapy NN N
were VBD N
0 CD N
% NN N
, , N
6.4 CD N
% NN N
, , N
and CC N
16.3 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
, , N
respectively RB N
, , N
which WDT N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
ETV NNP N
prophylactic JJ N
group NN N
( ( N
P NNP N
= NNP N
.032 NNP N
) ) N
. . N

Patients NNS N
with IN N
detectable JJ N
or CC N
undetectable JJ N
viral JJ N
load NN N
could MD N
develop VB N
HBV NNP N
reactivation NN N
and CC N
HBsAg NNP N
reverse NN N
seroconversion NN N
. . N

CONCLUSION NNP N
Undetectable JJ N
HBV NNP N
viral JJ N
load NN N
before IN N
chemotherapy NN N
did VBD N
not RB N
confer VB N
reactivation-free JJ N
status NN N
. . N

Antiviral NNP 3_i
prophylaxis NN 3_i
can MD N
potentially RB N
prevent VB N
rituximab-associated JJ N
HBV NNP N
reactivation NN N
in IN N
patients NNS N
with IN N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
. . N

-DOCSTART- -X- O O

Single-dose JJ N
tranexamic JJ 3_i
acid NN 3_i
reduces NNS N
postoperative VBP N
bleeding NN N
after IN N
coronary JJ 1_i
surgery NN 1_i
in IN N
patients NNS N
treated VBN N
with IN N
aspirin NN 3_i
until IN N
surgery NN N
. . N

UNLABELLED NNP N
Tranexamic NNP 3_i
acid NN 3_i
reduces NNS N
postoperative VBP N
bleeding NN N
after IN N
coronary JJ 1_i
artery NN 1_i
bypass NN 1_i
grafting VBG 1_i
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
tranexamic JJ 3_i
acid NN 3_i
given VBN N
immediately RB N
before IN N
cardiopulmonary JJ 1_i
bypass NN 1_i
( ( 1_i
CPB NNP 1_i
) ) 1_i
in IN N
patients NNS N
treated VBN N
with IN N
aspirin NN 3_i
until IN N
the DT N
day NN N
before IN N
surgery NN N
. . N

The DT N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ 7_i
, , N
parallel-group JJ N
trial NN N
. . N

Eighty JJ N
patients NNS N
were VBD N
included VBN N
and CC N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
one CD N
group NN N
received VBD N
tranexamic JJ 3_i
acid NN 3_i
30 CD 3_i
mg/kg NN 3_i
, , 3_i
and CC N
one CD N
group NN N
received VBD N
placebo NN 7_i
( ( N
0.9 CD N
% NN N
NaCl NNP N
) ) N
as IN N
a DT N
bolus JJ N
injection NN N
before IN N
CPB NNP 1_i
. . N

Postoperative NNP N
blood NN N
loss NN N
was VBD N
recorded VBN N
for IN N
16 CD N
h. JJ N
Transfusions NNS 3_i
of IN N
blood NN N
products NNS N
were VBD N
recorded VBN N
for IN N
the DT N
whole JJ N
hospital NN N
stay NN N
. . N

Transfusions NNS N
of IN N
packed JJ N
red JJ N
cells NNS N
were VBD N
given VBN N
when WRB N
the DT N
hematocrit NN N
value NN N
was VBD N
less JJR N
than IN N
20 CD N
% NN N
during IN N
CPB NNP N
and CC N
less JJR N
than IN N
25 CD N
% NN N
after IN N
surgery NN N
. . N

The DT N
patients NNS N
in IN N
the DT N
tranexamic JJ 3_i
acid NN 3_i
group NN N
had VBD N
significantly RB N
less RBR N
postoperative JJ N
bleeding NN N
compared VBN N
with IN N
the DT N
patients NNS N
in IN N
the DT N
placebo NN 7_i
group NN N
( ( N
mean JJ N
[ NNP N
SD NNP N
] NNP N
) ) N
( ( N
475 CD N
[ RB N
274 CD N
] JJ N
mL NN N
versus NN N
713 CD N
[ NN N
243 CD N
] NNP N
mL NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

An DT N
effective JJ N
inhibition NN N
of IN N
fibrinolysis NN N
was VBD N
found VBN N
in IN N
patients NNS N
receiving VBG N
tranexamic JJ 3_i
acid NN 3_i
. . 3_i

Tranexamic NNP 3_i
acid NN 3_i
reduces NNS N
postoperative VBP N
bleeding NN N
in IN N
coronary JJ 1_i
artery NN 1_i
bypass NN 1_i
grafting VBG 1_i
patients NNS N
treated VBN N
with IN N
aspirin NN N
until IN N
the DT N
day NN N
before IN N
surgery NN N
. . N

IMPLICATIONS NNP N
Continuation NNP N
of IN N
aspirin JJ 3_i
medication NN N
until IN N
the DT N
day NN N
before IN N
coronary JJ 1_i
artery NN 1_i
bypass NN 1_i
grafting NN 1_i
may MD N
increase VB N
postoperative JJ N
bleeding NN N
. . N

The DT N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
tranexamic JJ 3_i
acid NN 3_i
( ( N
30 CD N
mg/kg NN N
) ) N
immediately RB N
before IN N
cardiopulmonary JJ N
bypass NN N
significantly RB N
reduced VBD N
postoperative JJ N
bleeding NN N
and CC N
inhibited JJ N
fibrinolysis NN N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Perispinal JJ N
analgesia NN N
for IN N
labour NN N
followed VBN N
by IN N
patient-controlled JJ N
infusion NN N
with IN N
bupivacaine NN 3_i
and CC N
sufentanil NN 3_i
: : N
combined VBN N
spinal-epidural JJ 3_i
vs. FW 3_i
epidural JJ 3_i
analgesia NN N
alone RB N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Combined NNP N
spinal-epidural JJ N
is VBZ N
an DT N
alternative JJ N
technique NN N
to TO N
epidural JJ N
analgesia NN N
for IN N
labour NN N
, , N
but CC N
its PRP$ N
benefits NNS N
are VBP N
not RB N
clearly RB N
identified VBN N
. . N

METHODS VB N
A DT N
prospective JJ N
, , N
blinded VBD N
, , N
randomized VBD N
study NN N
was VBD N
undertaken JJ N
involving VBG N
113 CD N
women NNS N
attending VBG N
a DT N
university NN N
hospital NN N
obstetric JJ N
department NN N
. . N

Analgesia NNP N
was VBD N
initiated VBN N
with IN N
intrathecal JJ N
bupivacaine NN 3_i
0.25 CD 3_i
% NN 3_i
1 CD 3_i
mL NN 3_i
+ NNP N
sufentanil VBD 3_i
5 CD 3_i
microg NN 3_i
in IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
( ( N
n JJ N
= NNP N
54 CD N
) ) N
, , N
and CC N
with IN N
bupivacaine JJ 3_i
0.125 CD 3_i
% NN 3_i
+ JJ N
epinephrine NN 3_i
2.5 CD 3_i
microg NN 3_i
mL NN 3_i
( ( 3_i
-1 NNP 3_i
) ) 3_i
+ VBD N
sufentanil $ 3_i
7.5 CD 3_i
microg NN 3_i
in IN N
the DT N
epidural JJ N
group NN N
( ( N
n JJ N
= NNP N
59 CD N
) ) N
. . N

In IN 3_i
both DT 3_i
cases NNS 3_i
this DT 3_i
was VBD 3_i
followed VBN 3_i
by IN 3_i
patient-controlled JJ 3_i
epidural JJ 3_i
analgesia NN 3_i
with IN 3_i
bupivacaine JJ 3_i
0.125 CD 3_i
% NN 3_i
( ( N
+ JJ N
sufentanil NN 3_i
0.25 CD 3_i
microg NN 3_i
mL NN 3_i
( ( 3_i
-1 NNP 3_i
) ) 3_i
) ) 3_i
. . N

Duration NN N
of IN N
labour NN N
, , N
quality NN N
of IN N
analgesia NN N
and CC N
side-effects NNS N
were VBD N
compared VBN N
between IN N
groups NNS N
. . N

RESULTS NNP N
In IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
the DT N
onset NN N
of IN N
analgesia NN N
was VBD N
faster RBR N
( ( N
5 CD N
vs. FW N
15 CD N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
the DT N
consumption NN N
of IN N
bupivacaine NN 3_i
was VBD N
lower JJR N
( ( N
7.5 CD N
vs. FW N
11.3 CD N
mg NN N
h NN N
( ( N
-1 NNP N
) ) N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
and CC N
there EX N
was VBD N
less JJR N
unilateral JJ N
analgesia NN N
( ( N
14.8 CD N
% NN N
vs. FW N
40.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
than IN N
in IN N
the DT N
epidural JJ N
group NN N
. . N

The DT N
characteristics NNS N
of IN N
labour NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
in IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
there EX N
was VBD N
a DT N
higher JJR N
incidence NN N
of IN N
posterior JJ N
presentation NN N
( ( N
25.9 CD N
% NN N
vs. FW N
10 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
pruritus NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
hypotension NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
somnolence NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
nausea NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
one CD N
case NN N
of IN N
meningitis NN N
. . N

CONCLUSIONS VB N
The DT N
combined JJ N
spinal-epidural JJ N
technique NN N
provided VBD N
more RBR N
effective JJ N
analgesia NN N
during IN N
labour JJR N
than IN N
epidural JJ N
analgesia NN N
alone RB N
but CC N
offered VBN N
no DT N
other JJ N
advantage NN N
. . N

It PRP N
induced VBD N
more RBR N
adverse JJ N
effects NNS N
and CC N
this DT N
should MD N
be VB N
considered VBN N
before IN N
routinely RB N
using VBG N
the DT N
combined JJ N
spinal-epidural JJ N
technique NN N
. . N

-DOCSTART- -X- O O

Preliminary JJ N
findings NNS N
of IN N
the DT N
minimally-invasive JJ 1_i
surgery NN 1_i
plus CC 1_i
rtPA NN 1_i
for IN N
intracerebral JJ N
hemorrhage NN N
evacuation NN N
( ( N
MISTIE NNP N
) ) N
clinical JJ N
trial NN N
. . N

INTRODUCTION NNP N
Compared VBD N
to TO N
ischemic VB N
stroke NN N
, , N
intracerebral JJ N
hemorrhage NN N
( ( N
ICH NNP N
) ) N
is VBZ N
easily RB N
and CC N
rapidly RB N
identified VBN N
, , N
occurs VBZ N
in IN N
younger JJR N
patients NNS N
, , N
and CC N
produces VBZ N
relatively RB N
small JJ N
initial JJ N
injury NN N
to TO N
cerebral JJ N
tissues NNS N
-- : N
all DT N
factors NNS N
suggesting VBG N
that IN N
interventional JJ N
amelioration NN N
is VBZ N
possible JJ N
. . N

Investigations NNS N
from IN N
the DT N
last JJ N
decade NN N
established VBD N
that IN N
extent NN N
of IN N
ICH-mediated NNP N
brain NN N
injury NN N
relates VBZ N
directly RB N
to TO N
blood VB N
clot NN N
volume NN N
and CC N
duration NN N
of IN N
blood NN N
exposure NN N
to TO N
brain NN N
tissue NN N
. . N

Using VBG N
minimally-invasive JJ 1_i
surgery NN 1_i
plus CC 1_i
recombinant JJ 1_i
tissue NN 1_i
plasminogen NN 1_i
activator NN 1_i
( ( 1_i
rtPA NN 1_i
) ) 1_i
, , N
MISTIE NNP N
investigators NNS N
explored VBD N
aggressive JJ N
avenues NNS N
to TO N
treat VB N
ICH NNP N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
difference NN N
between IN N
surgical JJ 1_i
intervention NN 1_i
plus CC 1_i
rtPA NN 1_i
and CC N
standard JJ N
medical JJ N
management NN N
for IN N
ICH NNP N
. . N

Subjects NNS N
in IN N
both DT N
groups NNS N
were VBD N
medically RB N
managed VBN N
according VBG N
to TO N
standard JJ N
ICU NNP N
protocols NNS N
. . N

Subjects NNS N
randomized VBD N
to TO N
surgery VB N
underwent JJ N
stereotactic JJ 1_i
catheter NN 1_i
placement NN 1_i
and CC 1_i
clot NN 1_i
aspiration NN 1_i
. . N

Injections NNS 3_i
of IN 3_i
rtPA NN 3_i
were VBD N
then RB N
given VBN N
through IN N
hematoma NN N
catheter NN N
every DT N
8 CD N
h NN N
, , N
up RB N
to TO N
9 CD N
doses NNS N
, , N
or CC N
until IN N
a DT N
clot-reduction JJ N
endpoint NN N
. . N

After IN N
each DT N
injection NN N
the DT N
system NN N
was VBD N
flushed VBN N
with IN N
sterile JJ 3_i
saline NN 3_i
and CC N
closed VBD N
for IN N
60 CD N
min NN N
before IN N
opening VBG N
to TO N
spontaneous JJ N
drainage NN N
. . N

RESULTS JJ N
Average JJ N
aspiration NN N
of IN N
clots NNS N
for IN N
all DT N
patients NNS N
randomized VBN N
to TO N
surgery VB N
plus CC N
rtPA VB N
was VBD N
20 CD N
% NN N
of IN N
mean JJ N
initial JJ N
clot NN N
size NN N
. . N

After IN N
acute JJ N
treatment NN N
phase NN N
( ( N
aspiration NN N
plus CC N
rtPA NN N
) ) N
, , N
clot NN N
was VBD N
reduced VBN N
an DT N
average NN N
of IN N
46 CD N
% NN N
. . N

Recorded VBN N
adverse JJ N
events NNS N
were VBD N
within IN N
safety NN N
limits NNS N
, , N
including VBG N
30-day JJ N
mortality NN N
, , N
8 CD N
% NN N
; : N
symptomatic JJ N
re-bleeding NN N
, , N
8 CD N
% NN N
; : N
and CC N
bacterial JJ N
ventriculitis NN N
, , N
0 CD N
% NN N
. . N

Patients NNS N
randomized VBD N
to TO N
medical JJ N
management NN N
showed VBD N
4 CD N
% NN N
clot NN N
resolution NN N
in IN N
a DT N
similar JJ N
time NN N
window NN N
. . N

Preliminary JJ N
analysis NN N
indicates VBZ N
that IN N
clot NN N
resolution NN N
rates NNS N
are VBP N
greatly RB N
dependent JJ N
on IN N
catheter NN N
placement NN N
. . N

Location NN N
of IN N
ICH NNP N
also RB N
affects VBZ N
efficacy NN N
of IN N
aggressive JJ N
treatment NN N
of IN N
ICH NNP N
. . N

CONCLUSION NNP N
There EX N
is VBZ N
tentative JJ N
indication NN N
that IN N
minimally-invasive JJ N
surgery NN N
plus CC N
rtPA NN N
shows NNS N
greater JJR N
clot NN N
resolution NN N
than IN N
traditional JJ N
medical JJ N
management NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
guided JJ 5_i
imagery NN 5_i
with IN 5_i
relaxation NN 5_i
training NN 5_i
on IN N
anxiety NN N
and CC N
quality NN N
of IN N
life NN N
among IN N
patients NNS N
with IN N
inflammatory JJ N
bowel NN N
disease NN N
. . N

BACKGROUND NNP N
Inflammatory NNP N
Bowel NNP N
Disease NNP N
( ( N
IBD NNP N
) ) N
impacts VBZ N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
. . N

Psychological JJ N
factors NNS N
influence VBP N
the DT N
course NN N
of IN N
the DT N
disease NN N
and CC N
should MD N
be VB N
targeted VBN N
for IN N
intervention NN N
. . N

METHODS NNP N
Our PRP$ N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomised VBD N
control NN N
trial NN N
. . N

Fifty-six JJ N
outpatients NNS N
were VBD N
randomly RB N
chosen VBN N
and CC N
allocated VBN N
to TO N
a DT N
treatment NN 2_i
group NN N
or CC N
a DT N
waiting-list JJ N
control NN 7_i
group NN N
. . N

Treatment NNP N
group NN N
patients NNS N
attended VBD N
three CD 4_i
relaxation-training JJ 4_i
sessions NNS 4_i
and CC 4_i
received VBD 4_i
an DT 4_i
audio JJ 4_i
disc NN 4_i
for IN 4_i
home NN 4_i
practice NN 4_i
. . 4_i

Evaluations NNS N
performed VBD N
pre JJ N
and CC N
post-treatment JJ N
: : N
state NN N
anxiety NN N
was VBD N
assessed VBN N
with IN N
the DT N
State-Trait NNP N
Anxiety NNP N
Inventory NNP N
, , N
QoL NNP N
with IN N
the DT N
IBD NNP N
Questionnaire NNP N
. . N

The DT N
Visual NNP N
Analogue NNP N
Scale NNP N
assessed VBD N
pain NN N
, , N
depression NN N
, , N
stress NN N
and CC N
mood NN N
. . N

Patients NNS N
completed VBD N
a DT N
symptom JJ N
monitoring NN N
diary NN N
. . N

The DT N
control NN N
group NN N
's POS N
symptoms NNS N
were VBD N
monitored VBN N
without IN N
study-related JJ N
treatment NN N
. . N

RESULTS NNP N
Thirty-nine JJ N
subjects NNS N
completed VBD N
the DT N
study NN N
and CC N
were VBD N
included VBN N
in IN N
the DT N
data NN N
analysis NN N
. . N

Following VBG N
the DT N
relaxation-training JJ N
intervention NN N
, , N
the DT N
treatment NN N
group NN N
's POS N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
measured VBN N
results NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
improvement NN N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
21 CD N
) ) N
( ( N
time NN N
by IN N
treatment NN N
interaction NN N
) ) N
: : N
anxiety NN N
levels NNS N
decreased VBN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
QoL NNP N
and CC N
mood NN N
improved VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
while IN N
levels NNS N
of IN N
pain NN N
and CC N
stress NN N
decreased VBN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Findings NNP N
indicate VBP N
IBD NNP N
patients NNS N
may MD N
benefit VB N
from IN N
relaxation NN N
training NN N
in IN N
their PRP$ N
holistic JJ N
care NN N
. . N

New NNP N
studies NNS N
as RB N
well RB N
as IN N
further JJ N
investigation NN N
of IN N
the DT N
subject NN N
are VBP N
warranted VBN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
a DT N
biopsychosocial JJ 5_i
therapy NN 5_i
( ( 5_i
BT NNP 5_i
) ) 5_i
with IN N
a DT N
conventional JJ 3_i
biomedical JJ 3_i
therapy NN 3_i
( ( 3_i
MT NNP 3_i
) ) 3_i
of IN N
subacute NN N
low JJ N
back RB N
pain NN N
in IN N
the DT N
first JJ N
episode NN N
of IN N
sick JJ N
leave NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

This DT N
randomized VBD N
controlled JJ N
clinical JJ N
trial NN N
compares VBZ N
the DT N
effectiveness NN N
of IN N
a DT N
biopsychosocial JJ 3_i
treatment NN 3_i
with IN 3_i
a DT 3_i
solely JJ 3_i
conventional JJ 3_i
biomedical JJ 3_i
therapy NN 3_i
in IN N
patients NNS N
with IN N
subacute JJ N
low JJ N
back RB N
pain NN N
using VBG N
parameters NNS N
for IN N
pain NN N
intensity NN N
, , N
functional JJ N
status NN N
, , N
depressive JJ N
dysfunction NN N
and CC N
work NN N
performance NN N
. . N

Sixty-four JJ N
patients NNS N
with IN N
a DT N
first-time JJ N
sick NN N
leave VBP N
between IN N
3 CD N
and CC N
12 CD N
weeks NNS N
due JJ N
to TO N
low VB N
back RB N
pain NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
conventional JJ 3_i
biomedical JJ 3_i
therapy NN 3_i
( ( N
MT NNP N
; : N
n=33 CC N
) ) N
group NN N
, , N
or CC N
a DT N
biopsychosocial JJ 5_i
therapy NN 5_i
( ( N
BT NNP N
; : N
n=31 CC N
) ) N
group NN N
including VBG N
a DT N
psychotherapeutic JJ N
module NN N
; : N
both DT N
in IN N
accordance NN N
with IN N
a DT N
standardized JJ N
3 CD N
weeks NNS N
inpatient JJ N
treatment NN N
. . N

Pain NNP N
intensity NN N
, , N
functional JJ N
back RB N
capacity NN N
, , N
clinical JJ N
parameters NNS N
and CC N
depressive JJ N
dysfunction NN N
revealed VBD N
significant JJ N
improvement NN N
in IN N
both DT N
treatment NN N
groups NNS N
at IN N
end NN N
of IN N
3 CD N
weeks NNS N
therapy NN N
( ( N
T1 NNP N
) ) N
. . N

However RB N
, , N
at IN N
6 CD N
months NNS N
( ( N
T2 NNP N
) ) N
, , N
analysis NN N
revealed VBD N
significant JJ N
better JJR N
results NNS N
for IN N
nearly RB N
all DT N
parameters NNS N
in IN N
the DT N
BT NNP N
group NN N
that WDT N
showed VBD N
further JJ N
improvement NN N
from IN N
T1 NNP N
to TO N
T2 NNP N
, , N
whereas IN N
the DT N
values NNS N
in IN N
the DT N
MT NNP N
group NN N
deteriorated VBD N
from IN N
T1 NNP N
back RB N
to TO N
the DT N
baseline NN N
values NNS N
. . N

During IN N
the DT N
2-year JJ N
period NN N
after IN N
therapy NN N
, , N
10 CD N
% NN N
in IN N
MT NNP N
and CC N
59 CD N
% NN N
in IN N
BT NNP N
required VBD N
no DT N
further JJ N
sick NN N
leave VBP N
due JJ N
to TO N
low VB N
back RB N
pain NN N
. . N

The DT N
results NNS N
of IN N
the DT N
study NN N
indicate VBP N
that IN N
a DT N
psychotherapeutic JJ N
element NN N
in IN N
the DT N
treatment NN N
of IN N
low JJ N
back RB N
pain NN N
appears VBZ N
to TO N
positively RB N
influence VB N
pain NN N
, , N
functional JJ N
status NN N
and CC N
work NN N
performance NN N
when WRB N
conducted VBN N
at IN N
an DT N
early JJ N
stage NN N
of IN N
chronification NN N
and CC N
helps VBZ N
in IN N
the DT N
achievement NN N
of IN N
a DT N
better JJR N
outcome NN N
. . N

-DOCSTART- -X- O O

Adjuvant NNP N
subcutaneous JJ N
interleukin-2 NN 3_i
in IN N
patients NNS N
with IN N
resected JJ N
renal JJ N
cell NN N
carcinoma NN N
: : N
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
A NNP N
pilot NN N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
toxicity NN N
and CC N
tolerance NN N
to TO N
low-dose JJ N
subcutaneous JJ 3_i
interleukin-2 NN 3_i
( ( 3_i
IL-2 NNP 3_i
) ) 3_i
for IN N
patients NNS N
with IN N
resected JJ N
renal JJ N
cell NN N
carcinoma NN N
( ( N
RCC NNP N
) ) N
at IN N
high JJ N
risk NN N
for IN N
recurrent JJ N
disease NN N
( ( N
TNM NNP N
stages VBZ N
III NNP N
and CC N
IV NNP N
resected VBD N
distant JJ N
metastases NNS N
) ) N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
surgically RB N
resected VBN N
locally RB N
advanced JJ N
( ( N
T3-4 CD N
or CC N
N1-2 NNP N
) ) N
or CC N
metastatic JJ N
RCC NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
treatment NN N
groups NNS N
that WDT N
received VBD N
different JJ N
dose NN N
levels NNS N
and CC N
schedules NNS N
of IN N
subcutaneous JJ N
IL-2 NNP 3_i
as IN N
follows VBZ N
: : N
dose JJ N
level NN N
1 CD N
, , N
4 CD N
MIU/m2 NNP N
per IN N
day NN N
, , N
every DT N
other JJ N
week NN N
for IN N
24 CD N
weeks NNS N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
; : N
dose JJ N
level NN N
2 CD N
, , N
8 CD N
MIU/m2 NNP N
per IN N
day NN N
, , N
every DT N
other JJ N
week NN N
for IN N
24 CD N
weeks NNS N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
; : N
dose JJ N
level NN N
3 CD N
, , N
4 CD N
MIU/m2 NNP N
per IN N
day NN N
, , N
weeks NNS N
1-4 CD N
, , N
9-12 CD N
, , N
and CC N
17-20 JJ N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
; : N
and CC N
dose VB N
level NN N
4 CD N
, , N
8 CD N
MIU/m2 NNP N
per IN N
day NN N
, , N
weeks NNS N
1-4 CD N
, , N
9-12 CD N
, , N
and CC N
17-20 JJ N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
. . N

Interleukin-2 NN 3_i
was VBD N
administered VBN N
in IN N
2 CD N
daily JJ N
doses NNS N
on IN N
days NNS N
1-5 CD N
of IN N
each DT N
week NN N
indicated VBN N
. . N

A DT N
dose JJ N
level NN N
was VBD N
considered VBN N
tolerable JJ N
if IN N
no DT N
more JJR N
than IN N
2 CD N
patients NNS N
experienced VBD N
grade JJ N
3/4 CD N
toxicity NN N
. . N

RESULTS JJ N
Forty-one JJ N
patients NNS N
were VBD N
entered VBN N
in IN N
the DT N
study NN N
and CC N
40 CD N
were VBD N
evaluable JJ N
for IN N
toxicity NN N
. . N

Therapy NN N
was VBD N
well RB N
tolerated VBN N
at IN N
all DT N
dose JJ N
levels NNS N
and CC N
schedules NNS N
, , N
with IN N
most JJS N
patients NNS N
( ( N
98 CD N
% NN N
) ) N
experiencing VBG N
mild-to-moderate JJ N
constitutional JJ N
symptoms NNS N
. . N

Grade VB N
3/4 CD N
toxicity NN N
was VBD N
seen VBN N
in IN N
8 CD N
patients NNS N
( ( N
20 CD N
% NN N
) ) N
. . N

Interleukin-2 NNP 3_i
dose JJ N
reductions NNS N
were VBD N
required VBN N
in IN N
7 CD N
patients NNS N
, , N
and CC N
no DT N
patient NN N
discontinued VBN N
therapy RB N
secondary JJ N
to TO N
toxicity NN N
. . N

Of IN N
39 CD N
patients NNS N
evaluable JJ N
for IN N
efficacy NN N
, , N
31 CD N
have VBP N
experienced VBN N
relapse NN N
( ( N
79 CD N
% NN N
) ) N
, , N
and CC N
15 CD N
have VBP N
died VBN N
( ( N
38 CD N
% NN N
) ) N
. . N

Median JJ N
survival NN N
was VBD N
1.4 CD N
years NNS N
, , N
and CC N
the DT N
3-year JJ N
disease-free JJ N
survival NN N
rate NN N
was VBD N
33 CD N
% NN N
. . N

Median JJ N
overall JJ N
survival NN N
has VBZ N
not RB N
been VBN N
reached VBN N
; : N
however RB N
, , N
the DT N
3-year JJ N
survival NN N
rate NN N
was VBD N
70 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
any DT N
of IN N
the DT N
treatment NN N
arms NNS N
with IN N
respect NN N
to TO N
disease-free JJ N
survival NN N
or CC N
3-year JJ N
survival NN N
( ( N
P NNP N
> NNP N
0.54 CD N
and CC N
P NNP N
> NNP N
or= VBZ N
0.09 CD N
for IN N
all DT N
pairwise NN N
comparisons NNS N
) ) N
, , N
schedules NNS N
( ( N
dose VB N
level NN N
1/2 CD N
vs. IN N
3/4 CD N
; : N
P NNP N
= VBZ N
0.46 CD N
and CC N
P NNP N
= NNP N
0.5 CD N
) ) N
, , N
or CC N
dose NN N
of IN N
IL-2 NNP N
administered VBD N
( ( N
dose JJ N
level NN N
1/3 CD N
vs. IN N
2/4 CD N
; : N
P NNP N
= VBZ N
0.99 CD N
and CC N
P NNP N
= NNP N
0.1 CD N
) ) N
. . N

CONCLUSION NNP N
Subcutaneous NNP 3_i
IL-2 NNP 3_i
was VBD N
well RB N
tolerated VBN N
for IN N
6 CD N
months NNS N
in IN N
patients NNS N
with IN N
surgically RB N
resected VBN N
RCC NNP N
at IN N
high JJ N
risk NN N
of IN N
recurrence NN N
. . N

Future NNP N
adjuvant JJ N
trials NNS N
in IN N
this DT N
setting NN N
are VBP N
not RB N
likely JJ N
to TO N
include VB N
IL-2 NNP 3_i
in IN N
view NN N
of IN N
the DT N
clinical JJ N
efficacy NN N
and CC N
favorable JJ N
toxicity NN N
profiles NNS N
of IN N
selected VBN N
multitargeted JJ N
kinase NN N
inhibitors NNS N
. . N

-DOCSTART- -X- O O

Neurophysiological JJ N
double-blind JJ N
trial NN N
of IN N
a DT N
botulinum NN 3_i
neurotoxin NN 3_i
type IN 3_i
a DT 3_i
free JJ N
of IN N
complexing VBG N
proteins NNS N
. . N

OBJECTIVE NNP N
Safety NNP N
and CC N
efficacy NN N
of IN N
botulinum NN 3_i
neurotoxin NN 3_i
type NN 3_i
A DT 3_i
preparation NN 3_i
NT NNP 3_i
201 CD 3_i
( ( N
Xeomin NNP N
, , N
Merz NNP N
Pharmaceuticals NNP N
GmbH NNP N
, , N
Frankfurt NNP N
am VBP N
Main NNP N
, , N
Germany NNP N
) ) N
were VBD N
investigated VBN N
over IN N
52 CD N
weeks NNS N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
trial NN N
with IN N
32 CD N
male JJ N
volunteers NNS N
. . N

METHODS NNP N
Electroneurographic JJ N
assessments NNS N
with IN N
surface NN N
electrodes NNS N
were VBD N
performed VBN N
after IN N
single JJ 3_i
injections NNS 3_i
of IN 3_i
NT NNP 3_i
201 CD 3_i
( ( N
2 CD N
, , N
4 CD N
, , N
16 CD N
, , N
or CC N
32 CD N
units NNS N
) ) N
into IN N
the DT N
extensor NN 3_i
digitorum NN 3_i
brevis NN 3_i
( ( N
EDB NNP N
) ) N
muscle NN N
and CC N
the DT N
same JJ 3_i
dose NN 3_i
( ( N
Botox NNP N
; : N
Allergan NNP N
Pharmaceuticals NNP N
( ( N
Ireland NNP N
) ) N
Ltd. NNP N
Westport NNP N
, , N
Ireland NNP N
) ) N
into IN 3_i
the DT 3_i
contralateral JJ 3_i
EDB NNP 3_i
. . N

RESULTS NNP N
All NNP N
NT NNP 3_i
201 CD 3_i
and CC 3_i
BTXCo NNP 3_i
doses VBZ N
achieved VBD N
a DT N
statistically RB N
significant JJ N
reduction NN N
of IN N
the DT N
compound NN N
muscle NN N
action NN N
potential JJ N
M-wave NNP N
amplitude NN N
in IN N
the DT N
EDB NNP N
muscle NN N
. . N

At IN N
week NN N
4 CD N
, , N
the DT N
highest JJS N
dose NN N
was VBD N
statistically RB N
significantly RB N
more RBR N
effective JJ N
than IN N
the DT N
lowest JJS N
dose NN N
( ( N
NT NNP N
201 CD N
, , N
P NNP N
= NNP N
0.019 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.195-1.370 JJ N
; : N
and CC N
BTXCo NNP N
, , N
P NNP N
= NNP N
0.002 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.309-1.167 JJ N
) ) N
. . N

Duration NN N
of IN N
effect NN N
was VBD N
dose JJ N
dependent NN N
. . N

The DT N
mean JJ N
values NNS N
of IN N
compound NN N
muscle NN N
action NN N
potential JJ N
M-wave NNP N
amplitudes NNS N
in IN N
the DT N
adjacent JJ N
muscles NNS N
( ( N
abductor NN N
digiti NN N
quinti NN N
and CC N
abductor NN N
hallucis NN N
) ) N
were VBD N
above IN N
the DT N
predefined JJ N
threshold NN N
of IN N
effect NN N
, , N
indicating VBG N
that IN N
there EX N
was VBD N
no DT N
relevant JJ N
diffusion-induced JJ N
reduction NN N
of IN N
muscle NN N
activity NN N
. . N

NT CC 3_i
201 CD 3_i
and CC N
BTXCo NNP 3_i
were VBD N
well RB N
tolerated VBN N
. . N

CONCLUSIONS NNP N
NT NNP 3_i
201 CD 3_i
is VBZ N
effective JJ N
and CC N
safe JJ N
in IN N
inducing VBG N
the DT N
desired VBN N
paretic JJ N
effect NN N
. . N

-DOCSTART- -X- O O

Oxidative JJ N
DNA NNP N
damage NN N
measured VBD N
in IN N
human JJ N
lymphocytes NNS N
: : N
large JJ N
differences NNS N
between IN N
sexes NNS N
and CC N
between IN N
countries NNS N
, , N
and CC N
correlations NNS N
with IN N
heart NN N
disease NN N
mortality NN N
rates NNS N
. . N

The DT N
'antioxidant JJ N
hypothesis NN N
' POS N
proposes NNS N
that IN N
vitamin NN N
C NNP N
, , N
vitamin NN N
E NNP N
, , N
carotenoids NNS N
, , N
and CC N
other JJ N
antioxidants NNS 3_i
occurring VBG N
in IN N
fruit NN N
and CC N
vegetables NNS N
afford VBP N
protection NN N
against IN N
heart NN N
disease NN N
and CC N
cancer NN N
by IN N
preventing VBG N
oxidative JJ N
damage NN N
to TO N
lipids NNS N
and CC N
to TO N
DNA NNP N
, , N
respectively RB N
. . N

To TO N
test VB N
elements NNS N
of IN N
this DT N
hypothesis NN N
, , N
we PRP N
have VBP N
measured VBN N
blood NN N
levels NNS N
of IN N
dietary JJ N
antioxidants NNS N
, , N
and CC N
8-oxodeoxyguanosine JJ 3_i
( ( N
8-oxo-dG JJ N
) ) N
concentrations NNS N
in IN N
lymphocyte NN 3_i
DNA NN 3_i
, , N
in IN N
healthy JJ N
men NNS N
and CC N
women NNS N
from IN N
five CD N
European JJ N
countries NNS N
: : N
France NNP N
, , N
Ireland NNP N
, , N
The DT N
Netherlands NNP N
, , N
Spain NNP N
, , N
and CC N
the DT N
U.K NNP N
. . N

Volunteers NNS N
, , N
aged VBD N
25 CD N
45 CD N
, , N
all DT N
nonsmokers NNS N
, , N
gave VBD N
blood NN N
samples NNS N
before IN N
and CC N
after IN N
a DT N
12-wk JJ 2_i
carotenoid NN 2_i
supplementation NN 2_i
regime NN 2_i
. . 2_i

Vitamin NNP N
C NNP N
was VBD N
measured VBN N
in IN N
plasma NN N
and CC N
vitamin NN N
E NNP N
and CC N
carotenoids NNS N
were VBD N
measured VBN N
in IN N
serum NN N
by IN N
high-performance NN N
liquid NN 3_i
chromatography NN 3_i
( ( N
HPLC NNP N
) ) N
. . N

8-oxo-dG CD N
was VBD N
assayed VBN N
by IN N
HPLC NNP N
( ( N
with IN N
coulometric JJ N
detection NN N
) ) N
in IN N
DNA NNP N
isolated VBD N
from IN N
lymphocytes NNS N
from IN N
the DT N
same JJ N
blood NN N
samples NNS N
. . N

Mean JJ N
values NNS N
were VBD N
calculated VBN N
for IN N
groups NNS N
of IN N
volunteers NNS N
at IN N
each DT N
sampling NN N
time NN N
according VBG N
to TO N
country NN N
, , N
sex NN N
, , N
and CC N
supplementation NN N
( ( N
between IN N
9 CD N
and CC N
24 CD N
individual JJ N
samples NNS N
contributing VBG N
to TO N
each DT N
mean NN N
) ) N
. . N

We PRP N
found VBD N
that IN N
8-oxo-dG JJ N
levels NNS N
in IN N
lymphocyte NN N
DNA NNP N
vary NN N
significantly RB N
according VBG N
to TO N
sex NN N
and CC N
country NN N
. . N

A DT N
low JJ N
mean JJ N
8-oxo-dG JJ N
concentration NN N
is VBZ N
seen VBN N
in IN N
DNA NNP N
of IN N
women NNS N
from IN N
all DT N
five CD N
countries NNS N
, , N
and CC N
of IN N
men NNS N
from IN N
France NNP N
and CC N
Spain NNP N
. . N

8-oxo-dG NN N
is VBZ N
significantly RB N
higher JJR N
( ( N
up IN N
to TO N
about IN N
threefold NN N
) ) N
in IN N
lymphocyte NN N
DNA NN N
from IN N
men NNS N
in IN N
Ireland NNP N
and CC N
the DT N
U.K. NNP N
Oxidative NNP N
DNA NNP N
damage NN N
is VBZ N
not RB N
significantly RB N
affected VBN N
by IN N
carotenoid JJ N
supplementation NN N
; : N
nor CC N
is VBZ N
there EX N
any DT N
association NN N
with IN N
mean JJ N
baseline NN N
levels NNS N
of IN N
antioxidants NNS N
, , N
which WDT N
are VBP N
generally RB N
similar JJ N
in IN N
the DT N
five CD N
countries NNS N
. . N

The DT N
five CD N
countries NNS N
sampled VBN N
lie NN N
on IN N
an DT N
axis NN N
from IN N
northern JJ N
to TO N
southern JJ N
Europe NNP N
with IN N
a DT N
steep JJ N
gradient NN N
in IN N
terms NNS N
of IN N
premature JJ N
heart NN N
disease NN N
. . N

There EX N
is VBZ N
a DT N
strong JJ N
association NN N
between IN N
premature NN N
coronary JJ N
heart NN N
disease NN N
mortality NN N
in IN N
men NNS N
and CC N
the DT N
mean JJ N
levels NNS N
of IN N
8-oxo-dG NN N
for IN N
the DT N
five CD N
countries NNS N
( ( N
r NN N
= VBZ N
0.95 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Women NNS N
have VBP N
low JJ N
coronary JJ N
heart NN N
disease NN N
mortality NN N
rates NNS N
, , N
which WDT N
do VBP N
not RB N
correlate VB N
with IN N
8-oxo-dG JJ N
. . N

In IN N
terms NNS N
of IN N
cancer NN N
deaths NNS N
, , N
only RB N
colorectal JJ N
cancer NN N
in IN N
men NNS N
shows VBZ N
a DT N
significant JJ N
positive JJ N
correlation NN N
( ( N
r JJ N
= NN N
0.91 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
stomach NN N
cancer NN N
in IN N
women NNS N
is VBZ N
negatively RB N
correlated VBN N
with IN N
DNA NNP N
oxidation NN N
( ( N
r JJ N
= NNP N
-0.92 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

-DOCSTART- -X- O O

Pharmacokinetics NNS N
and CC N
relative JJ N
bioavailability NN N
of IN N
prajmalium NN 3_i
bitartrate NN 3_i
after IN N
single JJ N
oral JJ N
dosing NN N
. . N

Pharmacokinetics NNS N
and CC N
relative JJ N
bioavailability NN N
of IN N
the DT N
marketed JJ N
prajmalium NN 3_i
bitartrate NN 3_i
tablet NN 3_i
( ( N
Neo-Gilurytmal JJ 3_i
, , 3_i
CAS NNP 3_i
2589-47-1 CD 3_i
) ) N
compared VBN N
to TO N
an DT N
oral JJ 3_i
solution NN 3_i
were VBD N
investigated VBN N
in IN N
an DT N
open JJ N
, , N
randomized VBN N
, , N
single-dose JJ N
two-fold JJ N
crossover NN N
study NN N
in IN N
20 CD N
healthy JJ N
male NN N
volunteers NNS N
. . N

One CD N
subject NN N
was VBD N
identified VBN N
to TO N
be VB N
a DT N
poor JJ N
metabolizer NN N
. . N

In IN N
the DT N
study NN N
population NN N
with IN N
normal JJ N
metabolic JJ N
status NN N
the DT N
two CD N
oral JJ N
formulations NNS N
proved VBD N
to TO N
be VB N
bioequivalent JJ N
with IN N
regard NN N
to TO N
the DT N
pharmacokinetic JJ N
parameters NNS N
Cmax NNP N
, , N
AUC NNP N
( ( N
0-Tlast NN N
) ) N
, , N
AUC NNP N
( ( N
0-infinity NN N
) ) N
and CC N
Ae NNP N
( ( N
24h CD N
) ) N
. . N

tmax NN N
was VBD N
prolonged VBN N
after IN N
administration NN N
of IN N
the DT N
tablets NNS N
. . N

The DT N
relative JJ N
bioavailability NN N
of IN N
prajmalium NN N
bitartrate NN N
from IN N
the DT N
tablet NN N
amounted VBD N
to TO N
112 CD N
% NN N
. . N

The DT N
poor JJ N
metabolizer NN N
demonstrated VBN N
in IN N
both DT N
oral JJ N
formulations NNS N
high JJ N
plasma NN N
concentrations NNS N
, , N
increased VBD N
AUCs NNP N
and CC N
prolonged VBD N
terminal JJ N
half-lives NNS N
as RB N
well RB N
as IN N
increased VBN N
renal JJ N
excretion NN N
of IN N
prajmalium NN N
bitartrate NN N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
heart NN N
rate NN N
and CC N
forearm NN N
blood NN N
flow NN N
following VBG N
intravenous JJ N
boluses NNS N
of IN N
isoprenaline NN 3_i
in IN N
the DT N
presence NN N
of IN N
practolol NN N
and CC N
propranolol NN N
. . N

1 CD N
Increases NNS N
in IN N
heart NN N
rate NN N
and CC N
forearm NN N
blood NN N
flow NN N
following VBG N
graded VBD N
intravenous JJ N
bolus JJ N
injections NNS N
of IN N
isoprenaline JJ 3_i
sulphate NN 3_i
, , N
were VBD N
measured VBN N
in IN N
a DT N
double-blind NN N
randomised VBN N
study NN N
of IN N
six CD N
subjects NNS N
who WP N
received VBD N
either DT N
placebo NN 7_i
, , N
practolol VBP 3_i
50 CD N
mg NN N
, , N
practolol VBP 3_i
200 CD N
mg NN N
, , N
propranolol VBP 3_i
10 CD N
mg NN N
or CC N
propranolol VB 3_i
40 CD N
mg. NN N
2 CD N
Dose NNP N
related JJ N
increases NNS N
in IN N
forearm NN N
blood NN N
flow NN N
were VBD N
produced VBN N
by IN N
the DT N
graded JJ N
boluses NNS N
of IN N
isoprenaline JJ 3_i
sulphate NN 3_i
. . N

3 CD N
Practolol NNP 3_i
50 CD N
mg NN N
attenuated VBD N
the DT N
heart NN N
rate NN N
response NN N
to TO N
isoprenaline VB N
but CC N
did VBD N
not RB N
significantly RB N
affect VB N
the DT N
changes NNS N
in IN N
forearm NN N
blood NN N
flow NN N
. . N

Practolol CC 3_i
200 CD N
mg NN N
further RB N
attenuated VBD N
the DT N
heart NN N
rate NN N
responses NNS N
but CC N
also RB N
decreased VBD N
the DT N
forearm NN N
blood NN N
flow NN N
responses NNS N
. . N

4 CD N
Propranolol NNP 3_i
10 CD N
mg NN N
and CC N
propranolol NN N
40 CD N
mg NN N
significantly RB N
attenuated VBD N
both DT N
the DT N
heart NN N
rate NN N
and CC N
forearm NN N
blood NN N
flow NN N
responses NNS N
. . N

The DT N
effect NN N
on IN N
forearm NN N
blood NN N
flow NN N
tended VBD N
to TO N
be VB N
greater JJR N
than IN N
the DT N
effect NN N
on IN N
heart NN N
rate NN N
. . N

5 CD N
Practolol NNP 3_i
200 CD N
mg NN N
had VBD N
the DT N
same JJ N
effect NN N
on IN N
heart NN N
rate NN N
responses NNS N
as IN N
propranolol NN 3_i
10 CD N
mg NN N
but CC N
a DT N
significantly RB N
smaller JJR N
effect NN N
on IN N
the DT N
forearm NN N
blood NN N
flow NN N
responses NNS N
. . N

6 CD N
The DT N
measurement NN N
of IN N
forearm NN N
blood NN N
flow NN N
following VBG N
intravenous JJ N
bolus JJ N
injections NNS N
of IN N
isoprenaline NN N
provides VBZ N
useful JJ N
information NN N
about IN N
the DT N
beta NN N
2-adrenoceptor JJ N
antagonism NN N
of IN N
propranolol NN 3_i
and CC N
practolol NN 3_i
. . N

However RB N
, , N
application NN N
of IN N
the DT N
technique NN N
may MD N
be VB N
limited VBN N
by IN N
the DT N
magnitude NN N
of IN N
the DT N
heart NN N
rate NN N
response NN N
and CC N
by IN N
the DT N
short-lived JJ N
nature NN N
of IN N
the DT N
increase NN N
in IN N
forearm JJ N
blood NN N
flow NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
ursodeoxycholic JJ 3_i
acid NN 3_i
on IN N
serum NN N
liver NN N
enzymes NNS N
in IN N
patients NNS N
with IN N
hepatitis JJ N
C NNP N
virus-related JJ N
chronic JJ N
liver NN N
disease NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
ursodeoxycholic JJ 3_i
acid NN 3_i
( ( 3_i
UDCA NNP 3_i
) ) 3_i
on IN N
serum NN N
liver NN N
enzyme NN N
levels NNS N
[ VBP N
alanine JJ N
aminotransferase NN N
( ( N
ALT NNP N
) ) N
and CC N
gamma-glutamyl JJ N
transferase NN N
( ( N
GGT NNP N
) ) N
] VBP N
in IN N
101 CD N
patients NNS N
with IN N
hepatitis JJ N
C NNP N
virus-related JJ N
chronic JJ N
liver NN N
disease NN N
. . N

METHODS NNP N
Forty-nine JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
UDCA NNP 3_i
( ( N
450 CD N
mg/day NN N
) ) N
over IN N
a DT N
period NN N
of IN N
6 CD N
months NNS N
and CC N
52 CD N
to TO N
receive VB N
no DT 7_i
treatment NN 7_i
. . N

RESULTS NNP N
In IN N
the DT N
UDCA NNP 3_i
group NN N
, , N
serum NN N
ALT NNP N
and CC N
GGT NNP N
levels NNS N
significantly RB N
improved VBN N
. . N

ALT NNP N
values NNS N
decreased VBN N
from IN N
pre-treatment JJ N
levels NNS N
of IN N
157.0 CD N
+/- JJ N
62.6 CD N
IU/l NNP N
to TO N
82.5 CD N
+/- JJ N
46.4 CD N
IU/l NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
GGT NNP N
fell VBD N
from IN N
141.3 CD N
+/- JJ N
86.2 CD N
IU/l NNP N
to TO N
66.0 CD N
+/- JJ N
49.5 CD N
IU/l NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
change NN N
occurred VBD N
in IN N
the DT N
mean JJ N
ALT NNP N
and CC N
GGT NNP N
levels NNS N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
Although IN N
our PRP$ N
encouraging JJ N
preliminary JJ N
results NNS N
must MD N
be VB N
validated VBN N
by IN N
double-blind JJ N
histological JJ N
trials NNS N
, , N
UDCA NNP 3_i
may MD N
be VB N
an DT N
alternative JJ N
treatment NN N
for IN N
patients NNS N
who WP N
fail VBP N
to TO N
respond VB N
to TO N
interferon VB 3_i
therapy NN 3_i
. . N

-DOCSTART- -X- O O

Antioxidant JJ 3_i
supplementation NN N
and CC N
exercise-induced JJ N
oxidative JJ N
stress NN N
in IN N
the DT N
60-year-old JJ N
as IN N
measured VBN N
by IN N
antipyrine NN N
hydroxylates NNS N
. . N

The DT N
effects NNS N
of IN N
12 CD N
weeks NNS N
of IN N
antioxidant JJ 3_i
supplementation NN 3_i
on IN N
exercise-induced JJ N
oxidative JJ N
stress NN N
were VBD N
investigated VBN N
in IN N
older JJR N
adults NNS N
( ( N
60 CD N
( ( N
SE NNP N
1 CD N
) ) N
years NNS N
; : N
BMI NNP N
26 CD N
( ( N
SE NNP N
1 CD N
) ) N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
. . N

Subjects NNS N
were VBD N
randomly RB N
divided VBN N
in IN N
two CD N
groups NNS N
: : N
supplementation NN 3_i
( ( N
n JJ N
11 CD N
) ) N
with IN N
100 CD N
mg NNS N
dl-alpha-tocopheryl JJ 3_i
acetate NN 3_i
, , N
200 CD N
mg NN N
ascorbic JJ 3_i
acid NN 3_i
, , N
and CC N
2 CD N
mg NN N
beta-carotene NN 3_i
, , N
and CC N
placebo NN 7_i
( ( N
n JJ N
9 CD N
) ) N
. . N

Before IN N
and CC N
after IN N
the DT N
12 CD N
week NN N
supplementation NN N
period NN N
, , N
subjects NNS N
cycled VBD N
for IN N
45 CD N
min NN N
at IN N
submaximal JJ N
intensity NN N
( ( N
50 CD N
% NN N
maximal JJ N
workload NN N
capacity NN N
) ) N
. . N

Antipyrine NNP 3_i
was VBD N
used VBN N
as IN N
marker NN N
for IN N
oxidative JJ N
stress NN N
. . N

Antipyrine NNP N
reacts VBZ N
quickly RB N
with IN N
hydroxyl JJ N
radicals NNS N
to TO N
form VB N
para- JJ N
and CC N
ortho-hydroxyantipyrine JJ N
. . N

The DT N
latter JJ N
metabolite NN N
is VBZ N
not RB N
formed VBN N
in IN N
man NN N
through IN N
the DT N
mono-oxygenase JJ N
pathway NN N
of IN N
cytochrome JJ N
P450 NNP N
. . N

Daily NNP N
supplementation NN 3_i
significantly RB N
increased VBD N
plasma JJ N
concentrations NNS N
of IN N
alpha-tocopherol NN N
and CC N
beta-carotene NN N
in IN N
the DT N
supplemented VBN N
group NN N
( ( N
Delta NNP N
14.4 CD N
( ( N
SE NNP N
3.2 CD N
) ) N
and CC N
0.4 CD N
( ( N
se VB N
0.1 CD N
) ) N
micromol/l NN N
; : N
P NNP N
< VBZ N
0.001 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
, , N
within IN N
and CC N
between IN N
groups NNS N
, , N
were VBD N
observed VBN N
in IN N
the DT N
exercise-induced JJ N
increase NN N
in IN N
the DT N
ratios NNS N
para- JJ N
and CC N
ortho-hydroxyantipyrine JJ N
to TO N
antipyrine VB N
. . N

In IN N
addition NN N
, , N
supplementation NN 3_i
did VBD N
not RB N
affect VB N
the DT N
exercise-induced JJ N
increase NN N
in IN N
thiobarbituric JJ N
acid NN N
reactive JJ N
substances NNS N
in IN N
plasma NN N
. . N

In IN N
conclusion NN N
, , N
in IN N
60-year-old JJ N
subjects NNS N
antioxidant JJ 3_i
supplementation NN 3_i
had VBD N
no DT N
effect NN N
on IN N
the DT N
exercise-induced JJ N
increase NN N
in IN N
oxidative JJ N
stress NN N
as IN N
measured VBN N
by IN N
free JJ N
radical JJ N
products NNS N
of IN N
antipyrine NN N
. . N

-DOCSTART- -X- O O

Propofol NNP 3_i
sedation NN N
with IN N
bispectral JJ N
index NN N
monitoring NN N
is VBZ N
useful JJ N
for IN N
endoscopic NN N
submucosal JJ N
dissection NN N
: : N
a DT N
randomized JJ N
prospective JJ N
phase NN N
II NNP N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
Endoscopic NNP N
submucosal NN N
dissection NN N
( ( N
ESD NNP N
) ) N
has VBZ N
become VBN N
a DT N
standard JJ N
treatment NN N
. . N

However RB N
, , N
the DT N
treatment NN N
time NN N
tends VBZ N
to TO N
be VB N
relatively RB N
long JJ N
and CC N
insufflation NN N
and CC N
manipulation NN N
of IN N
the DT N
endoscope NN N
can MD N
increase VB N
pain NN N
and CC N
discomfort NN N
. . N

We PRP N
aimed VBD N
to TO N
find VB N
an DT N
optimal JJ N
method NN N
for IN N
sedation NN N
during IN N
ESD NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP N
scheduled VBD N
to TO N
undergo VB N
ESD NNP N
for IN N
early JJ N
gastric JJ N
cancer NN N
or CC N
adenoma NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
sedation NN N
with IN N
midazolam NN 3_i
or CC 3_i
propofol NN 3_i
, , N
and CC N
consciousness JJ N
level NN N
was VBD N
evaluated VBN N
by IN N
bispectral JJ N
index NN N
( ( N
BIS NNP N
) ) N
monitoring NN N
. . N

Primary JJ N
end NN N
points NNS N
of IN N
effectiveness NN N
( ( N
three CD N
parameters NNS N
) ) N
and CC N
secondary JJ N
end NN N
points NNS N
of IN N
safety NN N
during IN N
ESD NNP N
and CC N
after IN N
return NN N
to TO N
the DT N
ward NN N
were VBD N
compared VBN N
between IN N
the DT N
groups NNS N
. . N

Study NNP N
registration NN N
was VBD N
in IN N
the DT N
UMIN NNP N
Clinical NNP N
Trial NNP N
Registry NNP N
( ( N
UMIN NNP N
000001497 CD N
) ) N
, , N
and CC N
the DT N
institutional JJ N
trial NN N
number NN N
was VBD N
KDOG NNP N
0801 CD N
. . N

RESULTS VBN N
From IN N
June NNP N
2008 CD N
through IN N
June NNP N
2009 CD N
, , N
we PRP N
enrolled VBD N
178 CD N
patients NNS N
( ( N
90 CD N
midazolam NN N
, , N
88 CD N
propofol NN N
) ) N
. . N

Regarding VBG N
safety NN N
after IN N
ESD NNP N
, , N
recovery NN N
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
propofol NN N
group NN N
immediately RB N
after IN N
and CC N
at IN N
1 CD N
hour NN N
and CC N
2 CD N
hours NNS N
after IN N
return NN N
to TO N
the DT N
ward NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
number NN N
of IN N
patients NNS N
who WP N
required VBD N
a DT N
continuous JJ N
supply NN N
of IN N
oxygen NN N
2 CD N
hours NNS N
after IN N
returning VBG N
to TO N
the DT N
ward NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
propofol NN N
group NN N
( ( N
midazolam JJ N
18 CD N
; : N
propofol CC N
6 CD N
; : N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

Though IN N
propofol NN N
seemed VBD N
to TO N
be VB N
better JJR N
for IN N
effectiveness NN N
and CC N
safety NN N
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
for IN N
all DT N
three CD N
primary JJ N
end NN N
points NNS N
and CC N
the DT N
safety NN N
parameters NNS N
( ( N
hypotension NN N
, , N
hypoxia NN N
, , N
bradycardia NN N
) ) N
. . N

CONCLUSIONS NNP N
Propofol NNP 3_i
with IN N
BIS NNP N
monitoring VBG N
improved JJ N
recovery NN N
of IN N
patients NNS N
after IN N
ESD NNP N
, , N
though IN N
this DT N
study NN N
was VBD N
underpowered VBN N
to TO N
prove VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
propofol NN N
. . N

-DOCSTART- -X- O O

A DT N
randomised JJ N
trial NN N
comparing VBG N
holmium NN 1_i
laser NN 1_i
enucleation NN 1_i
versus IN N
transurethral JJ 1_i
resection NN 1_i
in IN N
the DT N
treatment NN N
of IN N
prostates NNS N
larger JJR N
than IN N
40 CD N
grams NNS N
: : N
results NNS N
at IN N
2 CD N
years NNS N
. . N

OBJECTIVE NN N
To TO N
compare VB N
holmium NN 1_i
laser JJR 1_i
enucleation NN 1_i
of IN 1_i
the DT 1_i
prostate NN 1_i
( ( 1_i
HoLEP NNP 1_i
) ) 1_i
with IN N
transurethral JJ 1_i
resection NN 1_i
of IN 1_i
the DT 1_i
prostate NN 1_i
( ( 1_i
TURP NNP 1_i
) ) 1_i
for IN N
treatment NN N
of IN N
men NNS N
with IN N
bladder NN N
outflow JJ N
obstruction NN N
( ( N
BOO NNP N
) ) N
secondary VBP N
to TO N
benign VB N
prostatic JJ N
hyperplasia NN N
with IN N
a DT N
minimum NN N
of IN N
24-month JJ N
follow-up JJ N
. . N

PATIENTS NNPS N
AND CC N
METHODS NNP N
Sixty-one CD N
patients NNS N
were VBD N
randomised VBN N
to TO N
either DT N
HoLEP NNP 1_i
or CC N
TURP NNP 1_i
. . 1_i

All DT N
patients NNS N
had VBD N
BOO NNP N
proven RB N
on IN N
urodynamic JJ N
studies NNS N
pre-operatively RB N
( ( N
prostate JJ N
size NN N
40-200 JJ N
g NN N
) ) N
. . N

One CD N
patient NN N
died VBD N
before IN N
treatment NN N
, , N
which WDT N
left VBD N
30 CD N
patients NNS N
in IN N
each DT N
group NN N
. . N

Perioperative NNP N
data NN N
, , N
as RB N
well RB N
as IN N
symptom NN N
scores NNS N
, , N
Quality NNP N
of IN N
Life NNP N
( ( N
QoL NNP N
) ) N
scores VBZ N
, , N
and CC N
maximum JJ N
urinary JJ N
flow NN N
rates NNS N
( ( N
Qmax NNP N
) ) N
were VBD N
obtained VBN N
at IN N
one CD N
, , N
three CD N
, , N
six,12 NN N
, , N
and CC N
24 CD N
months NNS N
. . N

Post-void JJ N
residual JJ N
volumes NNS N
, , N
transrectal JJ N
ultrasound NN N
( ( N
TRUS NNP N
) ) N
volumes NNS N
, , N
and CC N
pressure NN N
flow NN N
studies NNS N
were VBD N
obtained VBN N
six CD N
months NNS N
post-operatively RB N
. . N

Continence NN N
and CC N
potency NN N
data NNS N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
surgical JJ N
groups NNS N
pre-operatively RB N
. . N

Mean JJ N
pre-operative JJ N
TRUS NNP N
volume NN N
was VBD N
77.8+/-5.6 JJ N
g NN N
( ( N
42-152 JJ N
) ) N
in IN N
the DT N
HoLEP NNP N
group NN N
and CC N
70.0+/-5.0 JJ N
g NN N
( ( N
46-156 JJ N
) ) N
in IN N
the DT N
TURP NNP 2_i
group NN N
. . N

Patients NNS N
in IN N
the DT N
HoLEP NNP 2_i
group NN N
had VBD N
shorter JJR N
catheter NN N
times NNS N
and CC N
hospital NN N
stays NNS N
. . N

More JJR N
prostate JJ N
tissue NN N
was VBD N
retrieved VBN N
in IN N
the DT N
HoLEP NNP 2_i
group NN N
. . N

At IN N
six CD N
months NNS N
, , N
HoLEP NNP 2_i
was VBD N
urodynamically RB N
superior JJ N
to TO N
TURP NNP 2_i
in IN N
relieving VBG N
BOO NNP N
. . N

At IN N
24 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
surgical JJ N
groups NNS N
with IN N
respect NN N
to TO N
American NNP N
Urology NNP N
Association NNP N
scores NNS N
, , N
QoL NNP N
scores VBZ N
, , N
or CC N
Qmax NNP N
values NNS N
; : N
however RB N
, , N
two CD N
patients NNS N
in IN N
the DT N
TURP NNP N
group NN N
required VBD N
re-operation NN N
. . N

CONCLUSIONS NNP N
HoLEP NNP 2_i
has VBZ N
less RBR N
perioperative JJ N
morbidity NN N
and CC N
produces VBZ N
superior JJ N
urodynamic JJ N
outcomes NNS N
than IN N
TURP NNP 2_i
, , N
when WRB N
treating VBG N
prostates NNS N
> VBP N
40 CD N
g. NN N
At IN N
24 CD N
months NNS N
of IN N
follow-up NN N
, , N
HoLEP NNP 2_i
is VBZ N
equivalent JJ N
to TO N
TURP NNP 2_i
. . N

-DOCSTART- -X- O O

Amiprilose NNP 3_i
hydrochloride NN 3_i
for IN N
rheumatoid JJ N
arthritis NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
assess VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
amiprilose JJ 3_i
hydrochloride NN 3_i
( ( 3_i
HCl NNP 3_i
) ) 3_i
, , N
a DT N
novel JJ N
synthetic JJ N
carbohydrate NN N
with IN N
anti-inflammatory JJ N
and CC N
immunomodulatory JJ N
properties NNS N
, , N
in IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
parallel JJ N
group NN N
, , N
double-blind JJ N
placebo-controlled JJ N
12-week JJ N
trial NN N
. . N

PATIENTS VB N
Two CD N
hundred CD N
and CC N
one CD N
functional JJ N
class NN N
I PRP N
and CC N
II NNP N
patients NNS N
with IN N
definite JJ N
or CC N
classic JJ N
rheumatoid NN N
arthritis NN N
, , N
previously RB N
untreated VBN N
with IN N
disease NN N
modifying VBG N
antirheumatic JJ N
drugs NNS N
. . N

INTERVENTIONS NN N
Patients NNPS N
were VBD N
withdrawn VBN N
from IN N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
therapy NN N
. . N

Those DT N
who WP N
flared VBD N
were VBD N
randomly RB N
assigned VBN N
to TO N
amiprilose VB 3_i
HCl NNP 3_i
, , 3_i
6 CD 3_i
g/d NN 3_i
, , N
or CC N
placebo NN N
for IN N
12 CD N
weeks NNS N
. . N

No DT N
concomitant JJ N
anti-inflammatory NN N
or CC N
antirheumatic JJ N
drug NN N
therapy NN N
was VBD N
permitted VBN N
during IN N
the DT N
study NN N
. . N

Combination NNP N
acetaminophen NN N
and CC N
propoxyphene NN N
napsylate NN N
was VBD N
the DT N
only JJ N
supplemental JJ N
analgesic JJ N
medication NN N
allowed VBN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
number NN N
of IN N
painful JJ N
joints NNS N
and CC N
swollen JJ N
joints NNS N
, , N
joint JJ N
pain NN N
and CC N
joint JJ N
swelling NN N
indices NNS N
, , N
left VBD N
and CC N
right JJ N
grip NN N
strength NN N
, , N
investigator NN N
global JJ N
assessment NN N
, , N
and CC N
patient JJ N
global JJ N
assessment NN N
returned VBD N
to TO N
baseline VB N
for IN N
the DT N
amiprilose JJ 3_i
group NN N
and CC N
showed VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
differences NNS N
from IN N
the DT N
placebo NN 7_i
group NN N
within IN N
4 CD N
to TO N
6 CD N
weeks NNS N
. . N

The DT N
protocol NN N
criteria NNS N
for IN N
overall JJ N
therapeutic JJ N
response NN N
were VBD N
satisfied VBN N
by IN N
41 CD N
% NN N
of IN N
the DT N
amiprilose JJ 3_i
patients NNS N
, , N
compared VBN N
with IN N
21 CD N
% NN N
of IN N
the DT N
placebo NN 7_i
group NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

Approximately RB N
0.5 CD N
tablet NNS N
per IN N
day NN N
less CC N
analgesic JJ N
medication NN N
was VBD N
taken VBN N
by IN N
the DT N
amiprilose JJ N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
at IN N
weeks NNS N
6 CD N
and CC N
12 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
morning NN N
stiffness NN N
, , N
walking VBG N
time NN N
, , N
erythrocyte JJ N
sedimentation NN N
rate NN N
, , N
C-reactive JJ N
protein NN N
, , N
or CC N
rheumatoid VB N
factor NN N
between IN N
the DT N
groups NNS N
. . N

A DT N
similar JJ N
number NN N
of IN N
adverse JJ N
experiences NNS N
were VBD N
reported VBN N
by IN N
the DT N
patients NNS N
on IN N
amiprilose JJ 3_i
( ( N
67 CD N
% NN N
) ) N
and CC N
on IN N
placebo NN 7_i
( ( N
63 CD N
% NN N
) ) N
. . N

One CD N
patient NN N
on IN N
amiprilose NN 3_i
developed VBN N
thrombocytopenia NN N
of IN N
unknown JJ N
cause NN N
; : N
no DT N
other JJ N
reported VBD N
adverse JJ N
effects NNS N
were VBD N
serious JJ N
. . N

CONCLUSIONS NNP N
Amiprilose NNP 3_i
HCl NNP 3_i
has VBZ N
significant JJ N
anti-inflammatory JJ N
activity NN N
and CC N
a DT N
favorable JJ N
safety NN N
profile NN N
when WRB N
used VBN N
as IN N
the DT N
sole JJ N
antirheumatic JJ N
therapy NN N
in IN N
patients NNS N
with IN N
active JJ N
rheumatoid NN N
arthritis NN N
. . N

Synthetic JJ N
carbohydrates NNS N
may MD N
represent VB N
an DT N
important JJ N
new JJ N
class NN N
of IN N
drugs NNS N
for IN N
the DT N
treatment NN N
of IN N
inflammatory NN N
, , N
autoimmune JJ N
diseases NNS N
. . N

-DOCSTART- -X- O O

The DT N
effectiveness NN N
of IN N
physical JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
-- : N
a DT N
research NN N
protocol NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
( ( N
CoAct NNP N
) ) N
. . N

BACKGROUND IN N
The DT N
CoAct NNP N
( ( N
Cocreating NNP N
Activity NNP N
) ) N
study NN N
is VBZ N
investigating VBG N
a DT N
novel JJ N
lifestyle JJ 4_i
intervention NN 4_i
, , N
aimed VBN N
at IN N
the DT N
working VBG N
population NN N
, , N
with IN N
daily JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
via IN N
telephone NN N
and CC N
secure NN N
web NN N
messages NNS N
. . N

The DT N
main JJ N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
lifestyle JJ N
counselling VBG N
on IN N
the DT N
level NN N
of IN N
physical JJ N
activity NN N
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
. . N

The DT N
purposes NNS N
include VBP N
also RB N
analysing VBG N
the DT N
potential JJ N
effects NNS N
of IN N
changes NNS N
in IN N
physical JJ N
activity NN N
on IN N
productivity NN N
at IN N
work NN N
and CC N
sickness JJ N
absence NN N
, , N
and CC N
healthcare NN N
costs NNS N
. . N

This DT N
article NN N
describes VBZ N
the DT N
design NN N
of IN N
the DT N
study NN N
and CC N
the DT N
participant NN N
flow NN N
until IN N
and CC N
including VBG N
randomization NN N
. . N

METHODS/DESIGN NNP N
CoAct NNP N
is VBZ N
a DT N
randomised JJ N
controlled VBN N
trial NN N
with IN N
two CD N
arms NNS N
: : N
a DT N
control NN 7_i
group NN N
and CC N
intervention NN N
group NN N
with IN N
daily JJ 4_i
activity NN 4_i
monitoring NN 4_i
and CC 4_i
distance NN 4_i
counselling NN 4_i
. . 4_i

The DT N
intervention NN N
focuses VBZ N
on IN N
lifestyle JJ N
modification NN N
and CC N
takes VBZ N
12 CD N
months NNS N
. . N

The DT N
study NN N
population NN N
consists VBZ N
of IN N
volunteers NNS N
from IN N
1100 CD N
eligible JJ N
employees NNS N
of IN N
a DT N
Finnish JJ N
insurance NN N
company NN N
. . N

The DT N
primary JJ N
outcomes NNS N
of IN N
this DT N
study NN N
are VBP N
change NN N
in IN N
physical JJ N
activity NN N
measured VBN N
in IN N
MET NNP N
minutes NNS N
per IN N
week NN N
, , N
work NN N
productivity NN N
and CC N
sickness NN N
absence NN N
, , N
and CC N
healthcare JJ N
utilisation NN N
. . N

Secondary JJ N
outcomes NNS N
include VBP N
various JJ N
physiological JJ N
measures NNS N
. . N

Cost-effectiveness JJ N
analysis NN N
will MD N
also RB N
be VB N
performed VBN N
. . N

The DT N
outcomes NNS N
will MD N
be VB N
measured VBN N
by IN N
questionnaires NNS N
at IN N
baseline NN N
, , N
after IN N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
months NNS N
, , N
and CC N
sickness JJ N
absence NN N
will MD N
be VB N
obtained VBN N
from IN N
the DT N
employer NN N
's POS N
registers NNS N
. . N

DISCUSSION NNP N
No NNP N
trials NNS N
are VBP N
yet RB N
available JJ N
that WDT N
have VBP N
evaluated VBN N
the DT N
effectiveness NN N
of IN N
daily JJ N
physical JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
over IN N
a DT N
12 CD N
month NN N
period NN N
and CC N
no DT N
data NN N
on IN N
cost-effectiveness NN N
of IN N
such JJ N
intervention NN N
are VBP N
available JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00994565 NNP N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
a DT N
stage-of-change NN 4_i
oriented VBN 4_i
smoking VBG 4_i
cessation NN 4_i
intervention NN 4_i
in IN N
infertile NN N
and CC N
pregnant JJ N
women NNS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
a DT N
stage-of-change NN 4_i
oriented VBN 4_i
smoking VBG 4_i
cessation NN 4_i
intervention NN 4_i
for IN N
infertile NN N
and CC N
pregnant JJ N
women NNS N
, , N
compared VBN N
with IN N
standard NN N
of IN N
care NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Three CD N
university NN N
teaching VBG N
hospitals NNS N
in IN N
Hamilton NNP N
, , N
Ontario NNP N
, , N
Canada NNP N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
Infertile NNP N
women NNS N
at IN N
their PRP$ N
first JJ N
visit NN N
to TO N
a DT N
tertiary JJ N
referral JJ N
infertility NN N
clinic NN N
( ( N
n JJ N
= NNP N
94 CD N
) ) N
and CC N
new JJ N
patients NNS N
seeking VBG N
pre-natal JJ N
care NN N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
who WP N
had VBD N
smoked VBN N
> NNP N
/= $ N
3 CD N
cigarettes NNS N
in IN N
the DT N
past JJ N
six CD N
months NNS N
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
A NNP N
three CD 4_i
to TO 4_i
five CD 4_i
minute NN 4_i
scripted VBN 4_i
intervention NN 4_i
and CC 4_i
booklet NN 4_i
specific NN 4_i
to TO 4_i
the DT 4_i
woman NN 4_i
's POS 4_i
stage-of-change NN 4_i
in IN 4_i
the DT 4_i
smoking NN 4_i
continuum NN 4_i
, , 4_i
versus JJ 4_i
standard NN 6_i
of IN 6_i
care NN 6_i
. . N

Exhaled VBN 2_i
carbon-monoxide NN 2_i
( ( 2_i
CO NNP 2_i
) ) 2_i
monitoring NN N
was VBD N
used VBN N
to TO N
validate VB N
exposure NN N
in IN N
both DT N
groups NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Delta NNP N
stage-of-change NN N
and CC N
rate NN N
of IN N
maintained VBN N
cessation NN N
at IN N
12 CD N
months NNS N
post VBN N
follow-up JJ N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Intervention NNP N
and CC N
control NN N
were VBD N
similarly RB N
effective JJ N
for IN N
infertile JJ N
women NNS N
: : N
the DT N
rate NN N
of IN N
maintained VBN N
cessation NN N
rose VBD N
significantly RB N
from IN N
4 CD N
% NN N
to TO N
24 CD N
% NN N
over IN N
twelve JJ N
months NNS N
, , N
with IN N
a DT N
mean JJ N
delta NN N
stage-of-change NN N
0.28 CD N
. . N

In IN N
prenatal JJ N
women NNS N
, , N
neither CC N
approach NN N
was VBD N
effective JJ N
. . N

Maintained VBN N
cessation NN N
did VBD N
not RB N
significantly RB N
change VBP N
from IN N
0 CD N
to TO N
12 CD N
months NNS N
( ( N
19 CD N
% NN N
to TO N
18 CD N
% NN N
) ) N
. . N

Mean JJ N
delta JJ N
stage-of-change NN N
declined VBN N
by IN N
-0.62 NNP N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
For IN N
infertile JJ N
women NNS N
, , N
basic JJ N
information NN N
describing VBG N
the DT N
impact NN N
of IN N
smoking VBG N
on IN N
fertility NN N
, , N
along IN N
with IN N
exhaled JJ N
CO NNP N
monitoring NN N
and CC N
a DT N
more RBR N
intensive JJ N
intervention NN N
were VBD N
both DT N
highly RB N
effective JJ N
. . N

In IN N
pregnant JJ N
women NNS N
neither CC N
approach NN N
was VBD N
beneficial JJ N
, , N
with IN N
some DT N
evidence NN N
of IN N
post-partum JJ N
relapse NN N
. . N

-DOCSTART- -X- O O

Ketorolac NNP 3_i
versus NN 3_i
fentanyl NN 3_i
for IN N
gynaecological JJ N
day-case NN N
surgery NN N
. . N

The DT N
effectiveness NN N
of IN N
fentanyl NN 3_i
and CC N
ketorolac NN 3_i
in IN N
providing VBG N
analgesia NN N
for IN N
day-case JJ N
gynaecological JJ N
procedures NNS N
was VBD N
evaluated VBN N
in IN N
55 CD N
healthy JJ N
volunteers NNS N
in IN N
a DT N
single JJ N
blinded JJ N
fashion NN N
. . N

Fentanyl NNP 3_i
( ( N
1 CD N
mcg/kg RB N
iv NN N
) ) N
and CC N
ketorolac NN 3_i
( ( N
30 CD N
mg RB N
im NN N
) ) N
were VBD N
administered VBN N
immediately RB N
following VBG N
induction NN N
of IN N
anaesthesia NN N
. . N

Anaesthesia NNP N
was VBD N
standardized VBN N
with IN N
propofol NN 3_i
, , N
nitrous JJ 3_i
oxide NN 3_i
and CC N
enflurane NN 3_i
. . N

Outcome NNP N
variables NNS N
assessed VBN N
were VBD N
pain RB N
, , N
additional JJ N
analgesic NN N
requirements NNS N
, , N
and CC N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
. . N

All DT N
variables NNS N
were VBD N
recorded VBN N
at IN N
15 CD N
minutes NNS N
, , N
2 CD N
hours NNS N
and CC N
24 CD N
hours NNS N
postoperatively RB N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
with IN N
respect NN N
to TO N
any DT N
of IN N
the DT N
measured JJ N
variables NNS N
. . N

Both DT N
drugs NNS N
were VBD N
ineffective JJ N
as IN N
sole JJ N
analgesic JJ N
agents NNS N
in IN N
half NN N
of IN N
their PRP$ N
respective JJ N
groups NNS N
. . N

It PRP N
may MD N
be VB N
that IN N
a DT N
combination NN N
of IN N
these DT N
drugs NNS N
, , N
providing VBG N
a DT N
multireceptor NN N
approach NN N
to TO N
analgesia VB N
, , N
will MD N
prove VB N
to TO N
be VB N
more RBR N
effective JJ N
. . N

-DOCSTART- -X- O O

Short-term JJ N
pulmonary JJ N
effects NNS N
of IN N
total JJ 2_i
parenteral JJ 2_i
nutrition NN 2_i
in IN N
children NNS N
with IN N
cystic JJ N
fibrosis NN N
. . N

Indices NNS N
of IN N
respiratory JJ N
muscle NN N
strength NN N
, , N
pulmonary JJ N
function NN N
, , N
and CC N
pulmonary JJ N
diffusing NN N
capacity NN N
were VBD N
measured VBN N
in IN N
11 CD N
malnourished JJ N
children NNS N
( ( N
age NN N
10 CD N
to TO N
17 CD N
years NNS N
) ) N
with IN N
cystic JJ N
fibrosis NN N
, , N
before IN N
and CC N
after IN N
improvement NN N
of IN N
nutritional JJ N
status NN N
with IN N
supplemental JJ 2_i
parenteral JJ 2_i
nutrients NNS 2_i
for IN N
1 CD N
month NN N
. . N

During IN N
this DT N
time NN N
, , N
the DT N
children NNS N
received VBD N
120 CD N
% NN N
of IN N
estimated VBN N
energy NN N
requirements NNS N
( ( N
either CC N
3.75 CD N
% NN N
or CC N
22.5 CD N
% NN N
as IN N
lipid NN 3_i
) ) N
and CC N
amino JJ 3_i
acids NNS 3_i
2.5 CD N
gm/120 JJ N
kcal JJ N
by IN N
central JJ N
venous JJ N
catheter NN N
, , N
plus CC N
as IN N
much JJ N
of IN N
their PRP$ N
usual JJ N
diet NN N
as IN N
desired VBN N
. . N

With IN N
nutritional JJ N
supplementation NN N
, , N
body NN N
weight NN N
, , N
triceps NNS N
skinfold VBD N
thickness NN N
, , N
and CC N
mid-arm JJ N
muscle NN N
circumference NN N
increased VBD N
( ( N
mean JJ N
15 CD N
% NN N
, , N
62 CD N
% NN N
, , N
and CC N
95 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Maximum JJ N
inspiratory JJ N
airway NN N
pressure NN N
also RB N
increased VBD N
( ( N
mean JJ N
29 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
suggesting VBG N
improvement NN N
in IN N
respiratory JJ N
muscle NN N
strength NN N
. . N

However RB N
, , N
none NN N
of IN N
the DT N
indices NNS N
of IN N
pulmonary JJ N
function NN N
improved VBN N
. . N

Pulmonary JJ N
diffusing VBG N
capacity NN N
did VBD N
not RB N
change VB N
during IN N
parenteral JJ N
nutrition NN N
regardless NN N
of IN N
the DT N
amount NN N
of IN N
parenteral JJ N
energy NN N
intake NN N
supplied VBN N
by IN N
lipid JJ N
, , N
but CC N
arterial JJ N
oxygen NN N
saturation NN N
decreased VBN N
( ( N
mean NN N
of IN N
93.5 CD N
% NN N
to TO N
91.5 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
0.005 CD N
) ) N
. . N

During IN N
the DT N
month NN N
following VBG N
parenteral JJ N
nutrition NN N
, , N
weight NN N
, , N
skinfold JJ N
thickness NN N
, , N
and CC N
mid-arm JJ N
muscle NN N
circumference NN N
, , N
but CC N
not RB N
MIP NNP N
, , N
decreased VBD N
and CC N
arterial JJ N
oxygen NN N
saturation NN N
returned VBD N
to TO N
the DT N
initial JJ N
value NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

-DOCSTART- -X- O O

Acute NNP N
and CC N
late JJ N
toxicity NN N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
conventional JJ 3_i
versus NN N
hypofractionated VBD 2_i
three-dimensional JJ 2_i
conformal JJ 2_i
radiotherapy NN 2_i
for IN N
prostate NN N
cancer NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
toxicity NN N
between IN N
hypofractionation NN 3_i
vs. FW N
conventional JJ 3_i
fractionation NN 3_i
schedules NNS N
in IN N
patients NNS N
with IN N
high-risk JJ N
prostate NN N
cancer NN N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP N
January NNP N
2003 CD N
and CC N
December NNP N
2007 CD N
, , N
168 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
hypofractionated VBN 2_i
( ( N
62 CD N
Gy NNP N
in IN N
20 CD N
fractions NNS N
within IN N
5 CD N
weeks NNS N
, , N
4 CD N
fractions/wk NN N
) ) N
or CC N
conventionally RB 3_i
fractionated VBN 3_i
( ( N
80 CD N
Gy NNP N
in IN N
40 CD N
fractions NNS N
within IN N
8 CD N
weeks NNS N
) ) N
three-dimensional JJ 3_i
conformal JJ 3_i
radiotherapy NN 3_i
to TO N
the DT N
prostate NN N
and CC N
seminal JJ N
vesicles NNS N
. . N

All DT N
patients NNS N
had VBD N
undergone RP N
a DT N
9-month JJ N
course NN N
of IN N
total JJ N
androgen NN N
deprivation NN N
, , N
with IN N
radiotherapy NN N
starting VBG N
2 CD N
months NNS N
after IN N
initiation NN N
of IN N
the DT N
total JJ N
androgen NN N
deprivation NN N
. . N

RESULTS VB N
The DT N
median JJ N
follow-up NN N
was VBD N
32 CD N
and CC N
35 CD N
months NNS N
in IN N
the DT N
hypofractionation NN N
and CC N
conventional JJ N
fractionation NN N
arms NNS N
, , N
respectively RB N
. . N

For IN N
the DT N
patients NNS N
developing VBG N
acute JJ N
toxicity NN N
, , N
no DT N
difference NN N
between IN N
the DT N
two CD N
fractionation NN N
groups NNS N
was VBD N
found VBN N
in IN N
either DT N
severity NN N
or CC N
duration NN N
of IN N
gastrointestinal JJ N
or CC N
genitourinary JJ N
toxicity NN N
. . N

Also RB N
, , N
no DT N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
late JJ N
gastrointestinal NN N
and CC N
genitourinary JJ N
toxicity NN N
between IN N
the DT N
two CD N
treatment NN N
schedules NNS N
, , N
with IN N
a DT N
3-year JJ N
rate NN N
of IN N
Grade NNP N
2 CD N
or CC N
greater JJR N
toxicity NN N
of IN N
17 CD N
% NN N
and CC N
16 CD N
% NN N
for IN N
the DT N
hypofractionation NN N
arm NN N
and CC N
14 CD N
% NN N
and CC N
11 CD N
% NN N
for IN N
the DT N
conventional JJ N
fractionation NN N
arm NN N
, , N
respectively RB N
. . N

A DT N
statistically RB N
significant JJ N
correlation NN N
between IN N
acute NN N
and CC N
late JJ N
gastrointestinal JJ N
toxicity NN N
was VBD N
found VBN N
only RB N
in IN N
the DT N
conventional JJ N
fractionation NN N
group NN N
. . N

CONCLUSION NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
the DT N
hypofractionation NN 2_i
regimen NNS N
used VBN N
in IN N
our PRP$ N
study NN N
is VBZ N
safe JJ N
, , N
with IN N
only RB N
a DT N
slight NN N
, , N
nonsignificant JJ N
increase NN N
in IN N
tolerable JJ N
and CC N
temporary JJ N
acute NN N
toxicity NN N
compared VBN N
with IN N
the DT N
conventional JJ N
fractionation NN N
schedule NN N
. . N

The DT N
severity NN N
and CC N
frequency NN N
of IN N
late JJ N
complications NNS N
was VBD N
equivalent JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

-DOCSTART- -X- O O

Differential JJ N
effects NNS N
of IN N
two CD N
dihydropyridine JJ 3_i
calcium NN 3_i
antagonists NNS 3_i
in IN N
humans NNS N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
after IN N
single JJ N
doses NNS N
of IN N
niguldipine NN 3_i
( ( N
0.3 CD N
, , N
0.6 CD N
, , N
and CC N
0.9 CD N
mg NN N
intravenously RB N
; : N
8 CD N
and CC N
16 CD N
mg NNS N
orally RB N
) ) N
and CC N
nifedipine JJ 3_i
( ( N
2 CD N
mg NN N
intravenously RB N
; : N
20 CD N
mg NNS N
orally RB N
) ) N
in IN N
healthy JJ N
male NN N
volunteers NNS N
in IN N
randomized JJ N
placebo-controlled JJ 7_i
experiments NNS N
. . N

Total JJ N
peripheral JJ N
resistance NN N
( ( N
TPR NNP N
) ) N
, , N
heart NN N
rate-corrected JJ N
electromechanical JJ N
systole NN N
( ( N
QS2c NNP N
) ) N
, , N
and CC N
preejection NN N
period NN N
( ( N
PEPc NNP N
) ) N
were VBD N
assessed VBN N
noninvasively RB N
. . N

Both DT N
drugs NNS N
induced VBD N
a DT N
similar JJ N
pronounced NN N
decreased VBD N
in IN N
TRP NNP N
, , N
indicating VBG N
peripheral JJ N
vasodilation NN N
, , N
followed VBN N
by IN N
increasing VBG N
heart NN N
rate NN N
and CC N
cardiac JJ N
output NN N
, , N
a DT N
decrease NN N
in IN N
diastolic JJ N
blood NN N
pressure NN N
, , N
and CC N
a DT N
shortening NN N
of IN N
the DT N
PEPc NNP N
. . N

QS2c NNP N
was VBD N
unchanged JJ N
after IN N
niguldipine NN N
. . N

The DT N
prolongation NN N
of IN N
QS2c NNP N
after IN N
oral JJ N
nifedipine NN 3_i
is VBZ N
suggestive JJ N
of IN N
a DT N
negative JJ N
inotropic NN N
effect NN N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
vasodilatory JJ N
effects NNS N
of IN N
dihydropyridines NNS 3_i
may MD N
( ( N
as IN N
for IN N
nifedipine NN 3_i
) ) N
or CC N
may MD N
not RB N
( ( N
as IN N
for IN N
niguldipine NN 3_i
) ) N
be VB N
associated VBN N
with IN N
changes NNS N
that WDT N
are VBP N
suggestive JJ N
of IN N
negative JJ N
inotropic NN N
effects NNS N
, , N
and CC N
that IN N
this DT N
difference NN N
is VBZ N
detectable JJ N
by IN N
noninvasive JJ N
methods NNS N
in IN N
healthy JJ N
subjects NNS N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
pentoxifylline NN 3_i
on IN N
platelet NN N
function NN N
profiles NNS N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus NN N
and CC N
coronary JJ N
artery NN N
disease NN N
on IN N
dual JJ N
antiplatelet NN N
therapy NN N
with IN N
aspirin NN N
and CC N
clopidogrel NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
the DT N
phosphodiesterase NN 3_i
( ( 3_i
PDE NNP 3_i
) ) 3_i
inhibitor NN 3_i
pentoxifylline NN 3_i
on IN N
platelet NN N
function NN N
profiles NNS N
in IN N
patients NNS N
receiving VBG N
dual JJ N
antiplatelet NN N
therapy NN N
( ( N
DAPT NNP N
) ) N
. . N

BACKGROUND NNP N
Previous NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
, , N
in IN N
patients NNS N
receiving VBG N
DAPT NNP N
, , N
the DT N
adjunctive JJ N
use NN N
of IN N
a DT N
PDE NNP 3_i
inhibitor NN 3_i
enhances NNS N
platelet NN N
inhibition NN N
, , N
particularly RB N
in IN N
those DT N
presenting VBG N
with IN N
diabetes NNS N
mellitus NNS N
( ( N
DM NNP N
) ) N
. . N

However RB N
, , N
the DT N
pharmacodynamic NN N
( ( N
PD NNP N
) ) N
effects NNS N
of IN N
the DT N
PDE NNP 3_i
inhibitor NN 3_i
pentoxifylline NN 3_i
on IN N
platelet NN N
function NN N
profiles NNS N
in IN N
DM NNP N
patients NNS N
receiving VBG N
DAPT NNP N
are VBP N
unknown JJ N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel JJ N
design NN N
study NN N
conducted VBN N
in IN N
DM NNP N
patients NNS N
with IN N
stable JJ N
coronary JJ N
artery NN N
disease NN N
receiving VBG N
DAPT NNP N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
pentoxifylline NN 3_i
400 CD 3_i
mg NN 3_i
or CC N
placebo NN 3_i
3 CD N
times NNS N
daily RB N
for IN N
14 CD N
days NNS N
. . N

The DT N
PD NNP N
effects NNS N
were VBD N
assessed VBN N
by IN N
vasodilator-stimulated JJ N
phosphoprotein NN N
phosphorylation NN N
assay NN N
, , N
light JJ N
transmittance NN N
aggregometry NN N
, , N
VerifyNow NNP N
P2Y12 NNP N
assay NN N
( ( N
Accumetric NNP N
, , N
Inc. NNP N
, , N
San NNP N
Diego NNP N
, , N
California NNP N
) ) N
, , N
and CC N
multiple JJ N
electrode NN N
aggregometry NN N
at IN N
baseline NN N
and CC N
14 CD N
days NNS N
. . N

The DT N
PD NNP N
effects NNS N
were VBD N
also RB N
assessed VBN N
according VBG N
the DT N
presence NN N
or CC N
absence NN N
of IN N
high JJ N
on-treatment JJ N
platelet NN N
reactivity NN N
status NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
40 CD N
patients NNS N
were VBD N
available JJ N
for IN N
analysis NN N
. . N

At IN N
14 CD N
days NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
P2Y NNP N
( ( N
12 CD N
) ) N
reactivity NN N
index NN N
as IN N
assessed VBN N
by IN N
vasodilator-stimulated JJ N
phosphoprotein NN N
phosphorylation NN N
between IN N
treatment NN N
groups NNS N
( ( N
primary JJ N
endpoint NN N
; : N
p CC N
= VB N
0.93 CD N
) ) N
. . N

Intra-group JJ N
comparisons NNS N
also RB N
failed VBD N
to TO N
show VB N
any DT N
differences NNS N
between IN N
baseline NN N
and CC N
14-day JJ N
P2Y NNP N
( ( N
12 CD N
) ) N
reactivity NN N
index NN N
assessment NN N
in IN N
the DT N
placebo NN 7_i
and CC N
pentoxifylline NN 3_i
arms NNS N
( ( N
p JJ N
= NNP N
0.61 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
inter- JJ N
and CC N
intra-group JJ N
differences NNS N
in IN N
all DT N
other JJ N
PD NNP N
measures NNS N
. . N

The DT N
PD NNP N
effects NNS N
did VBD N
not RB N
vary JJ N
according VBG N
the DT N
presence NN N
or CC N
absence NN N
of IN N
high JJ N
on-treatment JJ N
platelet NN N
reactivity NN N
. . N

CONCLUSIONS NNP N
Adjunctive NNP N
treatment NN N
with IN N
pentoxifylline NN 3_i
is VBZ N
not RB N
associated VBN N
with IN N
increased JJ N
platelet NN N
inhibitory NN N
effects NNS N
in IN N
DM NNP N
patients NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
receiving VBG N
DAPT NNP N
. . N

-DOCSTART- -X- O O

Safety NN N
and CC N
immunogenicity NN N
of IN N
IMVAMUNE NNP 3_i
, , N
a DT N
promising JJ N
candidate NN N
as IN N
a DT N
third JJ N
generation NN N
smallpox NN N
vaccine NN N
. . N

A DT N
Phase NN N
I PRP N
trial NN N
was VBD N
performed VBN N
to TO N
investigate VB N
the DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
the DT N
third JJ 3_i
generation NN 3_i
smallpox VBD 3_i
vaccine JJ 3_i
MVA-BN NNP 3_i
( ( 3_i
IMVAMUNE NNP 3_i
) ) 3_i
, , N
a DT N
highly RB N
attenuated VBN N
clone NN N
derived VBN N
from IN N
the DT N
Modified NNP N
Vaccinia NNP N
Virus NNP N
Ankara NNP N
strain NN N
571 CD N
, , N
in IN N
naive JJ N
and CC N
pre-immunized JJ N
subjects NNS N
. . N

A DT N
total NN N
of IN N
86 CD N
healthy JJ N
subjects NNS N
received VBD N
the DT N
vaccine NN 3_i
in IN N
five CD N
groups NNS N
using VBG N
different JJ N
doses NNS N
and CC N
routes NNS N
of IN N
administration NN N
. . N

All DT N
38 CD N
subjects NNS N
seroconverted VBN N
in IN N
the DT N
groups NNS N
receiving VBG N
the DT N
highest JJS N
dose NN N
( ( N
10 CD N
( ( N
8 CD N
) ) N
TCID50 NN N
) ) N
. . N

All DT N
vaccinations NNS N
were VBD N
well RB N
tolerated VBN N
with IN N
mainly RB N
mild NN N
or CC N
moderate JJ N
pain NN N
at IN N
the DT N
injection NN N
site NN N
being VBG N
the DT N
most RBS N
frequent JJ N
symptom NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
MVA-BN NNP N
has VBZ N
the DT N
potential JJ N
to TO N
be VB N
developed VBN N
as IN N
an DT N
efficient NN N
and CC N
safe JJ N
alternative NN N
to TO N
the DT N
conventional JJ N
smallpox JJ N
vaccines NNS N
such JJ N
as IN N
Lister-Elstree NNP 3_i
or CC N
Dryvax NNP 3_i
. . N

Unique NNP N
attributes VBZ N
render VBP N
it PRP N
a DT N
promising JJ N
candidate NN N
for IN N
prophylactic JJ N
mass NN N
immunization NN N
, , N
even RB N
in IN N
subjects NNS N
for IN N
whom WP N
conventional JJ N
smallpox NN N
vaccines NNS N
are VBP N
contraindicated VBN N
. . N

-DOCSTART- -X- O O

Take VB N
a DT N
walk NN N
in IN N
the DT N
park NN N
? . N
A DT N
cross-over NN N
pilot NN N
trial NN N
comparing VBG N
brisk JJ 2_i
walking VBG 2_i
in IN 2_i
two CD 2_i
different JJ 2_i
environments NNS 2_i
: : 2_i
park NN N
and CC N
urban JJ N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
differences NNS N
exist VBP N
between IN N
a DT N
30 CD 2_i
minute NN 2_i
brisk NN 2_i
walk VBP 2_i
taken VBN N
in IN N
two CD N
different JJ N
environments NNS N
in IN N
order NN N
to TO N
determine VB N
which WDT N
environment NN N
best JJS N
facilitates NNS N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
: : N
park NN N
or CC N
urban JJ N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
cross-over NN N
pilot NN N
study NN N
, , N
participants NNS N
performed VBD N
a DT N
self-timed JJ 2_i
30 CD 2_i
minute NN 2_i
brisk NN 2_i
walk VBP 2_i
in IN 2_i
two CD 2_i
different JJ 2_i
environments NNS 2_i
, , 2_i
park NN 2_i
and CC 2_i
urban JJ 2_i
, , N
in IN N
Glasgow NNP N
, , N
Scotland NNP N
( ( N
October NNP N
2009 CD N
to TO N
January NNP N
2010 CD N
) ) N
. . N

Cadence NN N
, , N
recorded VBD N
using VBG N
the DT N
activPAL? NN N
activity NN N
monitor NN N
, , N
was VBD N
used VBN N
to TO N
measure VB N
intensity NN N
. . N

Outcome CC N
measures NNS N
were VBD N
: : N
mean JJ N
cadence NN N
; : N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
time NN N
accumulated VBN N
in IN N
bouts NNS N
lasting VBG N
? . N
10 CD N
min NN N
; : N
number NN N
of IN N
walking VBG N
breaks NNS N
; : N
and CC N
duration NN N
. . N

RESULTS VB N
A DT N
convenience NN N
sample NN N
of IN N
40 CD N
healthy JJ N
adults NNS N
was VBD N
recruited VBN N
: : N
16 CD N
males NNS N
, , N
24 CD N
females NNS N
, , N
mean JJ N
age NN N
22.9 CD N
( ( N
5.5 CD N
) ) N
years NNS N
. . N

The DT N
mean JJ N
cadence NN N
for IN N
the DT N
whole JJ N
walk NN N
was VBD N
higher RBR N
in IN N
the DT N
park NN N
: : N
119.3 CD N
( ( N
8.3 CD N
) ) N
vs. FW N
110.9 CD N
( ( N
8.9 CD N
) ) N
steps/min NN N
. . N

Participants NNS N
accumulated VBD N
more RBR N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
in IN N
? . N
10 CD N
minute NN N
bouts NNS N
during IN N
park JJ N
walks NNS N
: : N
25.5 CD N
( ( N
9.6 CD N
) ) N
[ NN N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
] VBZ N
vs. FW N
14.0 CD N
( ( N
20.3 CD N
) ) N
min NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
self-timed JJ N
duration NN N
between IN N
locations NNS N
. . N

CONCLUSION NNP N
Participants NNPS N
accumulated VBD N
more RBR N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
in IN N
bouts NNS N
? . N
10 CD N
min NN N
in IN N
duration NN N
on IN N
park NN N
walks NNS N
due JJ N
to TO N
the DT N
lack NN N
of IN N
interruptions NNS N
in IN N
walking VBG N
. . N

Hence NNP N
the DT N
park NN N
environment NN N
better RBR N
facilitated VBD N
the DT N
achievement NN N
of IN N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
. . N

Further JJ N
research NN N
involving VBG N
a DT N
larger JJR N
, , N
more RBR N
heterogeneous JJ N
sample NN N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- O O

Promoting VBG N
question-asking NN 4_i
in IN N
school-aged JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
: : N
effectiveness NN N
of IN N
a DT N
robot NN 4_i
intervention NN 4_i
compared VBN N
to TO N
a DT N
human-trainer JJ 4_i
intervention NN 4_i
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
an DT N
applied JJ 4_i
behaviour NN 4_i
analysis NN 4_i
( ( 4_i
ABA NNP 4_i
) ) 4_i
-based VBD 4_i
intervention NN 4_i
conducted VBN 4_i
by IN 4_i
a DT 4_i
robot NN 4_i
compared VBN 4_i
to TO 4_i
an DT 4_i
ABA-based JJ 4_i
intervention NN 4_i
conducted VBN 4_i
by IN 4_i
a DT 4_i
human JJ 4_i
trainer NN 4_i
in IN N
promoting VBG N
self-initiated JJ N
questions NNS N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

METHODS NNP N
Data NNP N
were VBD N
collected VBN N
in IN N
a DT N
combined JJ N
crossover NN N
multiple JJ N
baseline NN N
design NN N
across IN N
participants NNS N
. . N

Six CD N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
experimental JJ N
groups NNS N
. . N

RESULTS NNP N
Results NNP N
revealed VBD N
that IN N
the DT N
number NN N
of IN N
self-initiated JJ N
questions NNS N
for IN N
both DT N
experimental JJ N
groups NNS N
increased VBD N
between IN N
baseline NN N
and CC N
the DT N
first JJ N
intervention NN N
and CC N
was VBD N
maintained VBN N
during IN N
follow-up NN N
. . N

The DT N
high JJ N
number NN N
of IN N
self-initiated JJ N
questions NNS N
during IN N
follow-up JJ N
indicates NNS N
that IN N
both DT N
groups NNS N
maintained VBD N
this DT N
skill NN N
. . N

CONCLUSIONS VB N
The DT N
interventions NNS 4_i
conducted VBN 4_i
by IN 4_i
a DT 4_i
robot NN 4_i
and CC 4_i
a DT 4_i
human JJ 4_i
trainer NN 4_i
were VBD N
both DT N
effective JJ N
in IN N
promoting VBG N
self-initiated JJ N
questions NNS N
in IN N
children NNS N
with IN N
ASD NNP N
. . N

No DT N
conclusion NN N
with IN N
regard NN N
to TO N
the DT N
differential JJ N
effectiveness NN N
of IN N
both DT N
interventions NNS N
could MD N
be VB N
drawn VBN N
. . N

Implications NNS N
of IN N
the DT N
results NNS N
and CC N
directions NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
neurocognitive JJ N
functioning NN N
in IN N
children NNS N
previously RB N
randomly RB N
assigned VBN N
to TO N
intrathecal JJ 3_i
methotrexate NN 3_i
compared VBN N
with IN N
triple JJ 3_i
intrathecal JJ 3_i
therapy NN 3_i
for IN N
the DT N
treatment NN N
of IN N
childhood NN N
acute NN N
lymphoblastic JJ N
leukemia NN N
. . N

PURPOSE NNP N
For IN N
the DT N
majority NN N
of IN N
children NNS N
with IN N
acute JJ N
lymphoblastic JJ N
leukemia NN N
( ( N
ALL NNP N
) ) N
, , N
CNS NNP N
prophylaxis NN N
consists VBZ N
of IN N
either DT N
intrathecal JJ 3_i
( ( 3_i
IT NNP 3_i
) ) 3_i
methotrexate NN 3_i
or CC N
triple VB 3_i
IT NNP 3_i
therapy NN 3_i
( ( 3_i
ie JJ 3_i
, , 3_i
methotrexate NN 3_i
with IN 3_i
both DT 3_i
cytarabine NN 3_i
and CC 3_i
hydrocortisone NN 3_i
) ) N
. . N

The DT N
long-term JJ N
neurotoxicities NNS N
of IN N
these DT N
two CD N
IT NNP N
strategies NNS N
have VBP N
not RB N
yet RB N
been VBN N
directly RB N
compared VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
multisite NN N
study NN N
, , N
171 CD N
children NNS N
with IN N
standard-risk JJ N
ALL NNP N
, , N
age NN N
1 CD N
to TO N
9.99 CD N
years NNS N
at IN N
diagnosis NN N
, , N
previously RB N
randomly RB N
assigned VBN N
to TO N
IT NNP 3_i
methotrexate NNP 3_i
( ( N
n JJ N
= NNP N
82 CD N
) ) N
or CC N
to TO N
triple VB 3_i
IT NNP 3_i
therapy NN 3_i
( ( N
n JJ N
= NNP N
89 CD N
) ) N
on IN N
CCG NNP N
1952 CD N
, , N
underwent JJ N
neurocognitive JJ N
evaluation NN N
by IN N
a DT N
licensed JJ N
psychologist NN N
at IN N
a DT N
mean NN N
of IN N
5.9 CD N
years NNS N
after IN N
random JJ N
assignment NN N
. . N

RESULTS JJ N
Patients NNPS N
who WP N
received VBD N
IT NNP 3_i
methotrexate NNP 3_i
had VBD N
a DT N
mean JJ N
Processing NNP N
Speed NNP N
Index NNP N
that WDT N
was VBD N
3.6 CD N
points NNS N
lower JJR N
, , N
about IN N
one CD N
fourth JJ N
of IN N
a DT N
standard JJ N
deviation NN N
, , N
than IN N
those DT N
who WP N
received VBD N
triple JJ 3_i
IT NNP 3_i
therapy NN 3_i
( ( N
P NNP N
= NNP N
.04 NNP N
) ) N
after IN N
analysis NN N
was VBD N
adjusted VBN N
for IN N
age NN N
, , N
sex NN N
, , N
and CC N
time NN N
since IN N
diagnosis NN N
. . N

Likewise NNP N
, , N
19.5 CD N
% NN N
of IN N
children NNS N
in IN N
the DT N
IT NNP 3_i
methotrexate NNP 3_i
group NN N
had VBD N
a DT N
Processing NNP N
Speed NNP N
Index NNP N
score NN N
in IN N
the DT N
below-average NN N
range NN N
compared VBN N
with IN N
6.9 CD N
% NN N
in IN N
the DT N
triple NN 3_i
IT NNP 3_i
therapy NN 3_i
group NN 3_i
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Otherwise UH N
, , N
the DT N
groups NNS N
performed VBD N
similarly RB N
on IN N
tests NNS N
of IN N
full-scale JJ N
intelligence NN N
quotient NN N
, , N
academic JJ N
achievement NN N
, , N
attention/concentration NN N
, , N
memory NN N
, , N
and CC N
visual JJ N
motor NN N
integration NN N
. . N

The DT N
association NN N
of IN N
treatment NN N
with IN N
measures NNS N
of IN N
cognitive JJ N
functioning NN N
was VBD N
not RB N
modified VBN N
by IN N
sex NN N
or CC N
age NN N
at IN N
diagnosis NN N
. . N

In IN N
the DT N
post-therapy JJ N
period NN N
, , N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
in IN N
special JJ N
education NN N
services NNS N
, , N
neurologic JJ N
events NNS N
, , N
or CC N
use NN N
of IN N
psychotropic NN N
medications NNS N
. . N

CONCLUSION NNP N
This DT N
study NN N
did VBD N
not RB N
show VB N
any DT N
clinically RB N
meaningful JJ N
differences NNS N
in IN N
neurocognitive JJ N
functioning NN N
between IN N
patients NNS N
previously RB N
randomly RB N
assigned VBN N
to TO N
IT NNP 3_i
methotrexate NN 3_i
or CC N
triple VB 3_i
IT NNP 3_i
therapy NN 3_i
except IN N
for IN N
a DT N
small JJ N
difference NN N
in IN N
processing VBG N
speed NN N
in IN N
the DT N
IT NNP 3_i
methotrexate NNP 3_i
group NN 3_i
. . 3_i

-DOCSTART- -X- O O

Local JJ 2_i
immunotherapy NN 2_i
by IN 2_i
inhalation NN 2_i
of IN 2_i
a DT 2_i
powder NN 2_i
extract NN 2_i
in IN N
asthma NN N
due JJ N
to TO N
house NN N
dust NN N
mite NN N
Dermatophagoides NNP N
pteronyssinus NN N
: : N
a DT N
double-blind JJ N
comparison NN N
with IN N
parenteral JJ N
immunotherapy NN N
. . N

To TO N
verify VB N
the DT N
efficacy NN N
and CC N
the DT N
tolerability NN N
of IN N
local JJ 3_i
immunotherapy NN 3_i
( ( 3_i
LI NNP 3_i
) ) 3_i
by IN 3_i
inhalation NN 3_i
of IN 3_i
a DT 3_i
powder NN 3_i
extract NN 3_i
of IN 3_i
house NN 3_i
dust NN 3_i
mite NN 3_i
( ( 3_i
HDM NNP 3_i
) ) 3_i
, , N
in IN N
comparison NN N
with IN N
parenteral JJ 3_i
immunotherapy NN 3_i
( ( 3_i
PI NNP 3_i
) ) 3_i
by IN 3_i
injection NN 3_i
, , N
10 CD N
patients NNS N
with IN N
asthma NNS N
due JJ N
to TO N
HDM NNP N
were VBD N
studied VBN N
in IN N
a DT N
blind JJ N
fashion NN N
. . N

5 CD N
patients NNS N
( ( N
Group NNP N
A NNP N
) ) N
underwent NN N
LI NNP N
and CC N
subcutaneous JJ N
injections NNS N
of IN N
placebo NN 7_i
, , N
5 CD N
patients NNS N
( ( N
Group NNP N
B NNP N
) ) N
underwent NN N
PI NNP 2_i
and CC 2_i
inhalation NN 3_i
of IN 3_i
lactose NN 3_i
for IN N
6 CD N
months NNS N
. . N

In IN N
both DT N
groups NNS N
each DT N
inhalation NN N
was VBD N
preceded VBN N
by IN N
premedication NN N
with IN N
disodium NN 3_i
cromoglycate NN 3_i
( ( 3_i
DSCG NNP 3_i
) ) 3_i
( ( N
40 CD N
mg NN N
) ) N
. . N

In IN N
Group NNP N
A NNP N
a DT N
significant JJ N
decrease NN N
in IN N
symptoms NNS N
score NN N
and CC N
in IN N
peak JJ N
expiratory NN N
flow NN N
( ( N
PEF NNP N
) ) N
-derived VBD N
parameters NNS N
was VBD N
observed VBN N
already RB N
after IN N
3 CD N
months NNS N
of IN N
treatment NN N
, , N
and CC N
2 CD N
patients NNS N
lost VBD N
the DT N
late JJ N
component NN N
of IN N
the DT N
bronchial JJ N
response NN N
to TO N
the DT N
challenge NN N
with IN N
HDM NNP N
. . N

No NNP N
significant JJ N
variation NN N
was VBD N
found VBN N
in IN N
bronchial JJ N
responsiveness NN N
to TO N
methacholine VB N
and CC N
ultrasonically RB N
nebulized VBN N
distilled JJ N
water NN N
( ( N
UNDW NNP N
) ) N
and CC N
in IN N
immunologic JJ N
humoral JJ N
and CC N
cellular JJ N
parameters NNS N
in IN N
peripheral JJ N
blood NN N
after IN N
treatment NN N
in IN N
either DT N
group NN N
. . N

No DT N
local JJ N
important JJ N
adverse JJ N
reactions NNS N
were VBD N
observed VBN N
in IN N
Group NNP N
A NNP N
and CC N
no DT N
systemic JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
in IN N
either DT N
group NN N
. . N

We PRP N
conclude VBP N
that DT N
LI NNP 2_i
is VBZ N
as RB N
effective JJ N
as IN N
PI NNP 2_i
, , N
but CC N
more RBR N
rapid JJ N
in IN N
its PRP$ N
action NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
asthma NNS N
due JJ N
to TO N
HDM NNP N
. . N

Moreover RB N
, , N
LI NNP N
is VBZ N
locally RB N
well RB N
tolerated VBN N
, , N
providing VBG N
DSCG NNP N
is VBZ N
inhaled VBN N
before IN N
each DT N
therapeutic JJ N
inhalation NN N
, , N
and CC N
does VBZ N
not RB N
induce VB N
systemic JJ N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O

The DT N
impact NN N
of IN N
different JJ N
doses NNS N
of IN N
medroxyprogesterone NN 3_i
acetate NN 3_i
on IN N
mood NN N
symptoms NNS N
in IN N
sequential JJ 3_i
hormonal JJ 3_i
therapy NN 3_i
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
adverse JJ N
mood NN N
effects NNS N
of IN N
two CD N
different JJ N
doses NNS N
of IN N
medroxyprogesterone NN 3_i
acetate NN 3_i
( ( 3_i
MPA NNP 3_i
) ) 3_i
during IN N
postmenopausal NN N
hormone CD N
replacement NN N
therapy NN N
( ( N
HRT NNP N
) ) N
in IN N
women NNS N
with IN N
and CC N
without IN N
a DT N
history NN N
of IN N
premenstrual JJ N
syndrome NN N
( ( N
PMS NNP N
) ) N
. . N

The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
randomized JJ N
double-blind JJ N
cross-over NN N
study NN N
and CC N
included VBD N
36 CD N
postmenopausal JJ N
women NNS N
at IN N
three CD N
health NN N
care NN N
areas NNS N
in IN N
northern JJ N
Sweden NNP N
. . N

The DT N
women NNS N
received VBD N
2 CD 3_i
mg NNS 3_i
estradiol RB 3_i
continuously RB N
during IN N
five CD N
28-day JJ N
cycles NNS N
and CC N
10 CD N
mg NN N
or CC N
20 CD N
mg NNS N
MPA NNP N
sequentially RB N
for IN N
12 CD N
days NNS N
during IN N
each DT N
cycle NN N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
mood NN N
and CC N
physical JJ N
symptoms NNS N
noted VBD N
on IN N
a DT N
daily JJ N
rating NN N
scale NN N
. . N

We PRP N
found VBD N
that IN N
physical JJ N
symptoms NNS N
did VBD N
not RB N
differ VB N
between IN N
10 CD N
and CC N
20 CD N
mg NN N
MPA NNP N
. . N

Both DT N
women NNS N
with IN N
a DT N
history NN N
of IN N
PMS NNP N
and CC N
women NNS N
without IN N
responded VBD N
with IN N
more RBR N
negative JJ N
mood NN N
symptoms NNS N
with IN N
the DT N
lower JJR N
dose NN N
of IN N
MPA NNP N
. . N

In IN N
women NNS N
with IN N
previous JJ N
PMS NNP N
the DT N
higher JJR N
dose NN N
of IN N
MPA NNP N
enhanced VBD N
positive JJ N
mood NN N
symptoms NNS N
. . N

With IN N
respect NN N
to TO N
mood NN N
and CC N
physical JJ N
symptoms NNS N
, , N
the DT N
aim NN N
to TO N
lower VB N
MPA NNP N
doses NNS N
in IN N
HRT NNP N
is VBZ N
unwarranted JJ N
. . N

-DOCSTART- -X- O O

[ RB N
Preoperative NNP N
chemotherapy NN 3_i
of IN N
esophageal JJ N
cancer NN N
] NNP N
. . N

A NNP N
series NN N
of IN N
25 CD N
patients NNS N
with IN N
advanced JJ N
esophageal NN N
cancer NN N
treated VBN N
from IN N
Mar NNP N
. . N

1981 CD N
to TO N
Sep. VB N
1982 CD N
by IN N
preoperative JJ 3_i
chemotherapy NN 3_i
plus CC N
surgery NN 1_i
is VBZ N
reported VBN N
. . N

All PDT N
the DT N
patients NNS N
came VBD N
from IN N
the DT N
hospitals NNS N
of IN N
the DT N
cooperative JJ N
research NN N
group NN N
and CC N
were VBD N
randomized VBN N
into IN N
chemotherapy NN 3_i
and CC N
control NN 7_i
groups NNS N
. . N

They PRP N
were VBD N
proved VBN N
by IN N
X-ray NNP N
, , N
cytology NN N
and CC N
histopathology NN N
prior RB N
to TO N
treatment NN N
. . N

By IN N
histology NN N
, , N
22 CD N
cases NNS N
were VBD N
squamous JJ N
cell NN N
carcinoma NN N
, , N
1 CD N
adenocarcinoma NN N
and CC N
2 CD N
squamous JJ N
adenocarcinoma NN N
. . N

The DT N
COF NNP N
chemotherapy NN 3_i
consisted VBD N
of IN N
Vincristine NNP 3_i
1 CD N
mg NN N
, , N
cyclophosphamide RB 3_i
600 CD N
mg NNS N
and CC N
5-fluorouracil JJ 3_i
500 CD N
mg NN N
IV NNP N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
with IN N
or CC N
without IN N
the DT N
addition NN N
of IN N
Pingyangmycin NNP 3_i
, , N
a DT N
drug NN N
equivalent NN N
to TO N
Bleomycin NNP 3_i
A5 NNP 3_i
, , N
at IN N
the DT N
dose NN N
of IN N
10 CD N
mg NNS N
IM NNP N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
6 CD N
and CC N
8 CD N
. . N

The DT N
interval NN N
between IN N
the DT N
ending VBG N
of IN N
chemotherapy NN 3_i
and CC N
the DT N
surgical JJ 1_i
resection NN 1_i
was VBD N
5-6 JJ N
days NNS N
. . N

The DT N
results NNS N
showed VBD N
that IN N
preoperative JJ N
chemotherapy NN N
caused VBD N
no DT N
myelosuppression NN N
, , N
but CC N
merely RB N
mild JJ N
gastrointestinal JJ N
symptoms NNS N
. . N

All DT N
patients NNS N
were VBD N
operated VBN N
and CC N
resected VBN N
without IN N
difficulty NN N
. . N

The DT N
subjective JJ N
improvement NN N
in IN N
various JJ N
degrees NNS N
and CC N
the DT N
shrinkage NN N
of IN N
tumor NN N
in IN N
the DT N
X-ray JJ N
films NNS N
were VBD N
present JJ N
in IN N
5/25 CD N
cases NNS N
who WP N
received VBD N
preoperative JJ N
chemotherapy NN 3_i
. . N

The DT N
histopathological JJ N
changes NNS N
in IN N
the DT N
chemotherapy NN N
and CC N
control NN N
groups NNS N
( ( N
16 CD N
specimens NNS N
) ) N
were VBD N
different JJ N
. . N

In IN N
the DT N
chemotherapy NN N
group NN N
, , N
excessive JJ N
keratinization NN N
in IN N
the DT N
squamous JJ N
component NN N
of IN N
the DT N
esophageal NN N
cancerous JJ N
tissue NN N
appeared VBD N
in IN N
the DT N
resected JJ N
specimens NNS N
. . N

The DT N
incidence NN N
of IN N
degeneration NN N
and CC N
necrosis NN N
in IN N
the DT N
squamous JJ N
epithelium NN N
adjacent NN N
to TO N
carcinoma VB N
was VBD N
higher RBR N
in IN N
the DT N
chemotherapy NN 3_i
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
results NNS N
suggested VBD N
that IN N
such JJ N
combined JJ N
modality NN N
is VBZ N
worth IN N
further JJ N
study NN N
. . N

-DOCSTART- -X- O O

Relationship NN N
between IN N
subjective JJ N
effects NNS N
and CC N
drug NN N
preferences NNS N
: : N
ethanol NN 3_i
and CC N
diazepam NN 3_i
. . N

The DT N
relationship NN N
between IN N
subjective JJ N
effects NNS N
and CC N
drug NN N
preferences NNS N
in IN N
normal JJ N
volunteers NNS N
was VBD N
explored VBN N
in IN N
a DT N
meta-analysis NN N
of IN N
several JJ N
previously RB N
published VBN N
studies NNS N
. . N

Subjective JJ N
effects NNS N
of IN N
, , N
and CC N
preference NN N
for IN N
, , N
ethanol NN 3_i
and CC N
diazepam NN 3_i
vs. FW N
placebo NN 7_i
were VBD N
measured VBN N
using VBG N
a DT N
choice NN N
procedure NN N
. . N

Subjects NNS N
were VBD N
grouped VBN N
according VBG N
to TO N
their PRP$ N
drug NN N
choices NNS N
: : N
'non-choosers NNS N
' POS N
never RB N
chose JJ N
drug NN N
, , N
whereas IN N
'choosers NNS N
' POS N
always RB N
chose JJ N
drug NN N
. . N

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
on IN N
their PRP$ N
subjective JJ N
responses NNS N
to TO N
drug NN N
and CC N
on IN N
demographic JJ N
variables NNS N
. . N

Ethanol NNP 3_i
decreased VBD N
Arousal NNP N
, , N
Elation NNP N
, , N
Positive NNP N
Mood NNP N
and CC N
Vigor NNP N
, , N
and CC N
increased VBD N
Anxiety NNP N
, , N
Depression NNP N
and CC N
Fatigue NNP N
in IN N
the DT N
non-choosers NNS N
, , N
whereas IN N
it PRP N
increased VBD N
Arousal NNP N
and CC N
Vigor NNP N
in IN N
the DT N
choosers NNS N
. . N

Ethanol JJ 3_i
choosers NNS N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
be VB N
males NNS N
and/or IN N
full-time JJ N
students NNS N
than IN N
non-choosers NNS N
. . N

Diazepam NNP 3_i
produced VBD N
sedative-like JJ N
effects NNS N
in IN N
both DT N
choosers NNS N
and CC N
non-choosers NNS N
, , N
but CC N
markedly RB N
decreased VBD N
Anxiety NNP N
and CC N
increased VBD N
Friendliness NNP N
in IN N
choosers NNS N
only RB N
. . N

Diazepam NNP 3_i
choice NN N
was VBD N
also RB N
associated VBN N
with IN N
more RBR N
frequent JJ N
recreational JJ N
use NN N
of IN N
marijuana NN N
and CC N
stimulants NNS N
. . N

Thus RB N
, , N
both DT N
demographic JJ N
variables NNS N
and CC N
subjective JJ N
drug NN N
effects NNS N
were VBD N
related VBN N
to TO N
drug NN N
preference NN N
. . N

-DOCSTART- -X- O O

Nebulized VBN N
racemic JJ 3_i
epinephrine NN 3_i
by IN N
IPPB NNP N
for IN N
the DT N
treatment NN N
of IN N
croup NN N
: : N
a DT N
double-blind NN N
study NN N
. . N

Racemic NNP 3_i
epinephrine NN 3_i
has VBZ N
been VBN N
advocated VBN N
for IN N
the DT N
treatment NN N
of IN N
croup NN N
, , N
but CC N
controlled VBD N
studies NNS N
have VBP N
not RB N
proved VBN N
it PRP N
more RBR N
effective JJ N
than IN N
saline NN N
. . N

Twenty CD N
patients NNS N
( ( N
aged VBN N
4 CD N
months NNS N
to TO N
5 CD N
years NNS N
) ) N
hospitalized VBD N
with IN N
acute JJ N
croup NN N
and CC N
persistent JJ N
inspiratory NN N
stridor NN N
at IN N
rest NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
saline NN 3_i
or CC 3_i
racemic JJ 3_i
epinephrine NN 3_i
, , N
both DT N
nebulized JJ N
and CC N
delivered VBN N
by IN N
intermittent NN N
positive JJ N
pressure NN N
breathing NN N
. . N

Clinical JJ N
scores NNS N
were VBD N
significantly RB N
improved VBN N
( ( N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
at IN N
ten NN N
and CC N
30 CD N
minutes NNS N
following VBG N
the DT N
treatment NN N
with IN N
racemic JJ 3_i
epinephrine NN 3_i
but CC N
not RB N
at IN N
120 CD N
minutes NNS N
. . N

Racemic NNP 3_i
epinephrine NN 3_i
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
saline NN N
at IN N
10 CD N
( ( N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
and CC N
30 CD N
minutes NNS N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
) ) N
but CC N
not RB N
at IN N
120 CD N
minutes NNS N
after IN N
the DT N
treatment NN N
. . N

We PRP N
conclude VBP N
that IN N
nebulized JJ N
racemic JJ 3_i
epinephrine NN 3_i
is VBZ N
effective JJ N
treatment NN N
for IN N
the DT N
acute JJ N
signs NNS N
of IN N
croup NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
TENS NNP N
on IN N
pain NN N
, , N
medications NNS N
, , N
and CC N
pulmonary JJ N
function NN N
following VBG N
coronary JJ N
artery JJ N
bypass NN N
graft NN N
surgery NN N
. . N

The DT N
efficacy NN N
of IN N
transcutaneous JJ 2_i
electrical JJ 2_i
nerve NN 2_i
stimulation NN 2_i
( ( 2_i
TENS NNP 2_i
) ) 2_i
as IN N
an DT N
adjunct NN N
to TO N
narcotic JJ N
medications NNS N
for IN N
the DT N
management NN N
of IN N
postoperative JJ N
pain NN N
was VBD N
assessed VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
study NN N
of IN N
patients NNS N
following VBG N
coronary JJ N
artery JJ N
bypass NN N
graft NN N
( ( N
CABG NNP N
) ) N
surgery NN N
with IN N
the DT N
right NN N
or CC N
left VBD N
internal JJ N
thoracic NN N
artery NN N
( ( N
ITA NNP N
) ) N
. . N

Forty-five JJ N
male JJ N
patients NNS N
( ( N
mean JJ N
age NN N
, , N
57 CD N
+/- JJ N
6 CD N
years NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
( ( N
1 CD N
) ) N
TENS NN 2_i
, , N
( ( N
2 CD N
) ) N
placebo NN 7_i
TENS NNP 7_i
, , N
or CC N
( ( N
3 CD N
) ) N
control NN 7_i
treatments NNS 7_i
( ( N
n JJ N
= RB N
15 CD N
each DT N
) ) N
, , N
following VBG N
extubation NN N
and CC N
during IN N
the DT N
24- JJ N
to TO N
72-h JJ N
postoperative JJ N
period NN N
. . N

Two-way JJ N
analysis NN N
of IN N
variance NN N
tests NNS N
indicated VBD N
no DT N
significant JJ N
differences NNS N
among IN N
treatment NN N
groups NNS N
for IN N
( ( N
1 CD N
) ) N
pain NN N
with IN N
cough NN N
, , N
( ( N
2 CD N
) ) N
narcotic JJ N
medication NN N
intake NN N
, , N
( ( N
3 CD N
) ) N
FVC NNP N
, , N
( ( N
4 CD N
) ) N
FEV1 NNP N
, , N
and CC N
( ( N
5 CD N
) ) N
PEFR NNP N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
pain VBP N
at IN N
rest NN N
reported VBN N
by IN N
the DT N
TENS NNP N
group NN N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
reported VBN N
by IN N
the DT N
control NN N
group NN N
( ( N
treatment NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.04 CD N
) ) N
, , N
although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
TENS NNP N
and CC N
placebo NN N
or CC N
between IN N
the DT N
placebo NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

All DT N
six CD N
criterion NN N
measures NNS N
were VBD N
characterized VBN N
by IN N
significant JJ N
changes NNS N
over IN N
time NN N
for IN N
the DT N
entire JJ N
group NN N
( ( N
n JJ N
= VBZ N
45 CD N
; : N
time NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
, , N
as IN N
follows VBZ N
: : N
pain NN N
and CC N
medication NN N
intake NN N
were VBD N
similar JJ N
on IN N
days NNS N
1 CD N
and CC N
2 CD N
, , N
but CC N
were VBD N
significantly RB N
less JJR N
on IN N
day NN N
3 CD N
, , N
and CC N
pulmonary JJ N
functions NNS N
were VBD N
significantly RB N
lower JJR N
than IN N
preoperatively RB N
on IN N
day NN N
1 CD N
, , N
decreased VBD N
further RBR N
on IN N
day NN N
2 CD N
, , N
and CC N
despite IN N
an DT N
improvement NN N
on IN N
day NN N
3 CD N
, , N
remained VBD N
significantly RB N
lower JJR N
than IN N
preoperative JJ N
values NNS N
( ( N
p VB N
< RB N
0.01 CD N
) ) N
. . N

This DT N
study NN N
suggests VBZ N
that IN N
the DT N
addition NN N
of IN N
TENS NNP 2_i
, , N
applied VBD N
continuously RB N
during IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
following VBG N
CABG NNP N
with IN N
ITA NNP N
, , N
may MD N
not RB N
be VB N
advantageous JJ N
in IN N
pain NN N
management NN N
or CC N
the DT N
prevention NN N
of IN N
pulmonary JJ N
dysfunction NN N
. . N

-DOCSTART- -X- O O

Is VBZ N
anti-Pseudomonas JJ N
therapy NN N
warranted VBN N
in IN N
acute JJ N
respiratory NN N
exacerbations NNS N
in IN N
children NNS N
with IN N
cystic JJ N
fibrosis NN N
? . N
A DT N
controlled JJ N
study NN N
was VBD N
designed VBN N
to TO N
clarify VB N
the DT N
indications NNS N
for IN N
antibiotic JJ N
therapy NN N
in IN N
children NNS N
with IN N
advanced JJ N
cystic JJ N
fibrosis NN N
hospitalized VBN N
with IN N
respiratory JJ N
exacerbations NNS N
. . N

Twenty-two JJ N
children NNS N
with IN N
severe JJ N
CF NNP N
and CC N
signs NNS N
of IN N
acute NN N
lower JJR N
respiratory NN N
infection NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
cloxacillin NN 3_i
or CC N
carbenicillin NN 3_i
plus CC 3_i
gentamicin NN 3_i
administered VBD N
intravenously RB N
for IN N
ten JJ N
days NNS N
. . N

Other JJ N
aspects NNS N
of IN N
therapy NN N
were VBD N
constant JJ N
. . N

The DT N
groups NNS N
were VBD N
comparable JJ N
in IN N
all DT N
respects NNS N
and CC N
Pseudomonas NNP N
aeruginosa NN N
was VBD N
the DT N
predominant JJ N
sputum NN N
pathogen NN N
in IN N
most JJS N
patients NNS N
. . N

Clinical JJ N
improvement NN N
, , N
chest VBP N
radiograph NN N
changes NNS N
, , N
evidence NN N
of IN N
airway JJ N
obstruction NN N
, , N
and CC N
bacteriologic JJ N
flora NNS N
of IN N
sputum NN N
were VBD N
no DT N
different JJ N
regardless NN N
of IN N
the DT N
regimen NNS N
used VBN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
anti-Pseudomonas JJ N
medication NN N
in IN N
these DT N
children NNS N
may MD N
not RB N
always RB N
be VB N
necessary JJ N
. . N

These DT N
observations NNS N
need VBP N
to TO N
be VB N
confirmed VBN N
by IN N
blind-controlled JJ N
studies NNS N
in IN N
larger JJR N
numbers NNS N
of IN N
patients NNS N
with IN N
mild JJ N
as RB N
well RB N
as IN N
severe JJ N
respiratory NN N
involvement NN N
. . N

-DOCSTART- -X- O O

Economic JJ N
evaluation NN N
of IN N
a DT N
nursing-led JJ 6_i
inpatient JJ 6_i
unit NN 6_i
: : N
the DT N
impact NN N
of IN N
findings NNS N
on IN N
management NN N
decisions NNS N
of IN N
service NN N
utility NN N
and CC N
sustainability NN N
. . N

AIMS IN N
The DT N
nursing-led JJ 6_i
inpatient NN 6_i
unit NN 6_i
is VBZ N
designed VBN N
to TO N
substitute VB N
for IN N
a DT N
period NN N
of IN N
care NN N
in IN N
acute JJ N
hospital NN N
wards NNS N
and CC N
to TO N
improve VB N
patient NN N
outcome NN N
prior RB N
to TO N
discharge VB N
to TO N
the DT N
community NN N
. . N

This DT N
paper NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
cost NN N
, , N
from IN N
the DT N
UK NNP N
National NNP N
Health NNP N
Service NNP N
perspective NN N
, , N
of IN N
transfer NN N
to TO N
a DT N
nursing-led JJ N
inpatient NN N
unit NN N
for IN N
intermediate JJ N
care NN N
and CC N
to TO N
discuss VB N
the DT N
impact NN N
of IN N
these DT N
findings NNS N
to TO N
the DT N
future NN N
development NN N
and CC N
sustainability NN N
of IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
. . N

BACKGROUND NNP N
Recent NNP N
economic JJ N
analyses NNS N
have VBP N
showed VBN N
that IN N
nursing-led JJ N
inpatient JJ N
units NNS N
are VBP N
associated VBN N
with IN N
increased JJ N
costs NNS N
of IN N
care NN N
with IN N
length NN N
of IN N
stay NN N
as IN N
the DT N
main JJ N
driver NN N
of IN N
inpatient NN N
costs NNS N
. . N

METHOD VB N
The DT N
cost-effectiveness JJ N
analysis NN N
was VBD N
part NN N
of IN N
a DT N
randomized-controlled JJ N
trial NN N
with IN N
a DT N
sample JJ N
size NN N
of IN N
175 CD N
, , N
of IN N
which WDT N
89 CD N
were VBD N
in IN N
the DT N
nursing-led JJ 6_i
inpatient NN 6_i
unit NN 6_i
arm NN 6_i
and CC 6_i
86 CD N
in IN N
the DT 6_i
control NN 6_i
arm NN 6_i
. . N

Resource NNP N
use NN N
data NNS N
included VBD N
length NN N
of IN N
stay NN N
, , N
investigations NNS N
performed VBD N
, , N
multiprofessional JJ N
input NN N
and CC N
nursing NN N
input NN N
. . N

Clinical JJ N
outcome NN N
was VBD N
measured VBN N
using VBG N
Barthel NNP N
Index NNP N
, , N
a DT N
functional JJ N
status NN N
measure NN N
. . N

RESULTS NNP N
Cost NNP N
per IN N
day NN N
was VBD N
lower JJR N
on IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
although IN N
cost NN N
per IN N
hospital NN N
stay NN N
was VBD N
higher JJR N
due JJ N
to TO N
significantly RB N
increased JJ N
length NN N
of IN N
stay NN N
. . N

Postdischarge NNP N
community NN N
care NN N
costs NNS N
were VBD N
lower JJR N
. . N

The DT N
incremental JJ N
cost-effectiveness JJ N
ratio NN N
of IN N
the DT N
treatment NN N
was VBD N
1044 CD N
pounds NNS N
sterling JJ N
per IN N
point NN N
improvement NN N
of IN N
the DT N
Barthel NNP N
Index NNP N
. . N

CONCLUSIONS VB N
The DT 6_i
nursing-led JJ 6_i
inpatient NN 6_i
unit NN 6_i
was VBD N
associated VBN N
with IN N
higher JJR N
costs NNS N
however RB N
, , N
the DT N
question NN N
of IN N
whether IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
is VBZ N
cost-effective JJ N
has VBZ N
not RB N
been VBN N
clearly RB N
answered VBN N
because IN N
of IN N
the DT N
limited JJ N
follow-up JJ N
period NN N
of IN N
the DT N
study NN N
. . N

The DT N
increased JJ N
cost NN N
of IN N
care NN N
on IN N
the DT N
nursing-led JJ 6_i
inpatient NN 6_i
unit NN 6_i
was VBD N
not RB N
a DT N
major JJ N
factor NN N
in IN N
local JJ N
management NN N
decisions NNS N
about IN N
the DT N
future NN N
of IN N
the DT N
unit NN N
. . N

The DT N
changes NNS N
in IN N
the DT N
context NN N
of IN N
service NN N
provision NN N
within IN N
which WDT N
the DT N
nursing-led JJ 6_i
inpatient NN 6_i
unit NN 6_i
operated VBD N
as IN N
a DT N
result NN N
of IN N
substantial JJ N
investment NN N
in IN N
intermediate JJ N
care NN N
did VBD N
have VB N
a DT N
major JJ N
impact NN N
. . N

-DOCSTART- -X- O O

Weight-adjusted JJ N
dalteparin NN 3_i
for IN N
prevention NN N
of IN N
vascular JJ N
thromboembolism NN N
in IN N
advanced JJ N
pancreatic JJ N
cancer NN N
patients NNS N
decreases VBZ N
serum JJ N
tissue NN N
factor NN N
and CC N
serum-mediated JJ N
induction NN N
of IN N
cancer NN N
cell NN N
invasion NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
role NN N
of IN N
tissue NN N
factor NN N
and CC N
serum-induced JJ N
cell NN N
invasion NN N
in IN N
patients NNS N
with IN N
advanced JJ N
pancreatic JJ N
cancer NN N
( ( N
APC NNP N
) ) N
. . N

A DT N
cohort NN N
of IN N
39 CD N
patients NNS N
with IN N
APC NNP N
, , N
without IN N
thrombosis NN N
, , N
receiving VBG N
chemotherapy NN 3_i
, , N
were VBD N
entered VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
ISRCTN NNP N
= NNP N
76464767 CD N
) ) N
of IN N
thromboprevention NN 3_i
with IN 3_i
weight-adjusted JJ 3_i
dalteparin NN 3_i
( ( N
WAD NNP N
) ) N
. . N

A DT N
total NN N
of IN N
19 CD N
patients NNS N
received VBD N
WAD NNP 3_i
, , N
the DT N
remaining VBG N
20 CD N
acting VBG N
as IN N
a DT N
control NN 7_i
group NN 7_i
. . N

Serum NNP N
from IN N
baseline NN N
and CC N
week NN N
8 CD N
was VBD N
analysed VBN N
for IN N
circulating-tissue JJ N
factor NN N
antigen NN N
using VBG N
ELISA NNP N
. . N

Circulating-tissue NNP N
factor NN N
antigen NN N
rose VBD N
from IN N
324 CD N
pg/ml NN N
, , N
[ NNP N
interquartile NN N
range NN N
( ( N
IQR NNP N
) ) N
282-347 CD N
pg/ml NN N
] NN N
to TO N
356 CD N
pg/ml NN N
, , N
( ( N
IQR NNP N
319-431 NNP N
pg/ml NN N
) ) N
in IN N
controls NNS N
( ( N
C NNP N
) ) N
, , N
and CC N
decreased VBN N
in IN N
the DT N
dalteparin-treated JJ N
group NN N
( ( N
D NNP N
) ) N
from IN N
336 CD N
pg/ml NN N
( ( N
IQR NNP N
281-346 CD N
pg/ml NN N
) ) N
to TO N
303 CD N
pg/ml NN N
( ( N
IQR NNP N
274-339 CD N
pg/ml NN N
) ) N
. . N

The DT N
difference NN N
in IN N
median JJ N
percentage NN N
change NN N
between IN N
D NNP N
and CC N
C NNP N
was VBD N
statistically RB N
significant JJ N
[ JJ N
-4.0 NN N
( ( N
D NNP N
) ) N
vs. FW N
4.7 CD N
( ( N
C NNP N
) ) N
; : N
P NNP N
= VBZ N
0.005 CD N
, , N
n RB N
= VBZ N
39 CD N
] NN N
. . N

Serum-induced JJ N
cellular JJ N
invasion NN N
of IN N
MIA-Paca-2 NNP N
cells NNS N
in IN N
response NN N
to TO N
patient VB N
serum NN N
was VBD N
studied VBN N
using VBG N
a DT N
Boyden NNP N
chamber NN N
assay NN N
in IN N
30 CD N
patients NNS N
( ( N
14 CD N
WAD NNP N
and CC N
16 CD N
C NNP N
) ) N
. . N

The DT N
median JJ N
percentage NN N
change NN N
between IN N
C NNP N
and CC N
D NNP N
was VBD N
significant JJ N
[ JJ N
+54.9 NN N
( ( N
C NNP N
) ) N
vs. FW N
-21.9 FW N
( ( N
D NNP N
) ) N
P NNP N
= $ N
0.025 CD N
, , N
n RB N
= VBZ N
30 CD N
] NN N
. . N

There EX N
was VBD N
a DT N
weak JJ N
correlation NN N
between IN N
BB-tissue NNP N
factor NN N
reduction NN N
and CC N
cellular JJ N
invasion NN N
reduction NN N
( ( N
Spearman NNP N
) ) N
[ VBZ N
0.384 CD N
( ( N
P NNP N
= NNP N
0.037 CD N
, , N
n RB N
= VBZ N
30 CD N
) ) N
] NN N
. . N

APC NNP N
patients NNS N
treated VBD N
with IN N
WAD NNP N
have VBP N
lower JJR N
tissue NN N
factor NN N
antigen NN N
levels NNS N
and CC N
attenuated JJ N
induction NN N
of IN N
cellular JJ N
invasion NN N
in IN N
their PRP$ N
blood NN N
. . N

These DT N
assays NNS N
may MD N
provide VB N
useful JJ N
markers NNS N
to TO N
guide VB N
appropriate JJ N
dalteparin NN N
( ( N
and CC N
other JJ N
low-molecular JJ N
weight NN N
heparin NN N
) ) N
dosing VBG N
schedules NNS N
to TO N
optimize VB N
anticancer JJ N
effects NNS N
of IN N
dalteparin NN N
in IN N
APC NNP N
. . N

-DOCSTART- -X- O O

[ JJ N
Prophylactic NNP 2_i
intraaortic JJ 2_i
balloon NN 2_i
pumping VBG 2_i
in IN N
high-risk JJ N
cardiac JJ N
surgery NN N
patients NNS N
] VBP N
. . N

BACKGROUND NNP N
We PRP N
examined VBD N
the DT N
impact NN N
of IN N
prophylactic JJ 2_i
IABP NNP 2_i
insertion NN 2_i
in IN N
EuroSCORE-stratified JJ N
high-risk JJ N
cardiac NN N
surgery NN N
patients NNS N
with IN N
a DT N
score NN N
?8 NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP N
randomized JJ N
trial NN N
with IN N
104 CD N
patients NNS N
either CC N
without IN N
prophylactic JJ N
IABP NNP N
insertion NN N
( ( N
group NN N
A NNP N
, , N
n=52 NN N
) ) N
or CC N
with IN N
IABP NNP N
( ( N
group NN N
B NNP N
, , N
n=52 NN N
) ) N
was VBD N
conducted VBN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
30-day JJ N
mortality NN N
. . N

RESULTS VB N
The DT N
median JJ N
age NN N
of IN N
the DT N
patients NNS N
was VBD N
74 CD N
years NNS N
and CC N
43 CD N
% NN N
of IN N
participants NNS N
were VBD N
females NNS N
. . N

The DT N
30-day JJ N
mortality NN N
did VBD N
not RB N
differ VB N
between IN N
group NN N
A NNP N
( ( N
17.3 CD N
% NN N
) ) N
and CC N
group NN N
B NNP N
( ( N
13.4 CD N
% NN N
; : N
p=0.78 NN N
) ) N
. . N

The DT N
median JJ N
hospital NN N
stay NN N
was VBD N
14 CD N
days NNS N
in IN N
both DT N
groups NNS N
. . N

Intra- NNP N
and CC N
postoperative JJ N
IABP NNP N
support NN N
was VBD N
required VBN N
by IN N
13 CD N
patients NNS N
( ( N
21 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
. . N

The DT N
median JJ N
ventilation NN N
time NN N
( ( N
14 CD N
hours NNS N
versus VBD N
13 CD N
hours NNS N
) ) N
, , N
median JJ N
catecholamine NN N
dose NN N
, , N
frequency NN N
of IN N
dialysis-dependent JJ N
acute JJ N
renal JJ N
failure NN N
( ( N
28 CD N
% NN N
versus IN N
18 CD N
% NN N
) ) N
, , N
cardiac JJ N
indices NNS N
, , N
and CC N
frequency NN N
of IN N
a DT N
low JJ N
cardiac JJ N
output NN N
syndrome NN N
( ( N
26 CD N
% NN N
versus IN N
25 CD N
% NN N
) ) N
did VBD N
not RB N
significantly RB N
differ VBP N
between IN N
groups NNS N
. . N

CONCLUSION NNP N
Prophylactic NNP N
preoperative JJ N
IABP NNP N
insertion NN N
in IN N
EuroSCORE-stratified JJ N
high-risk JJ N
patients NNS N
is VBZ N
not RB N
associated VBN N
with IN N
decreased JJ N
30-day JJ N
mortality NN N
. . N

-DOCSTART- -X- O O

Peritoneovenous JJ 2_i
shunting VBG 2_i
as IN N
compared VBN N
with IN N
medical JJ 3_i
treatment NN 3_i
in IN N
patients NNS N
with IN N
alcoholic JJ N
cirrhosis NN N
and CC N
massive JJ N
ascites NNS N
. . N

Veterans NNPS N
Administration NNP N
Cooperative NNP N
Study NNP N
on IN N
Treatment NNP N
of IN N
Alcoholic NNP N
Cirrhosis NNP N
with IN N
Ascites NNP N
. . N

The DT N
optimal JJ N
management NN N
of IN N
severe JJ N
ascites NNS N
in IN N
patients NNS N
with IN N
alcoholic JJ N
cirrhosis NN N
has VBZ N
not RB N
been VBN N
defined VBN N
. . N

in IN N
a DT N
5 CD N
1/2-year JJ N
study NN N
, , N
we PRP N
randomly VBP N
assigned VBN N
299 CD N
men NNS N
with IN N
alcoholic JJ N
cirrhosis NN N
, , N
who WP N
had VBD N
persistent NN N
or CC N
recurrent NN N
severe JJ N
ascites VBZ N
despite IN N
a DT N
standard JJ N
medical JJ N
regimen NNS N
, , N
to TO N
receive VB N
either RB N
intensive JJ 3_i
medical JJ 3_i
treatment NN 3_i
or CC N
peritoneovenous JJ 1_i
( ( 1_i
LeVeen NNP 1_i
) ) 1_i
shunting VBG 1_i
. . N

We PRP N
identified VBD N
three CD N
risk NN N
groups NNS N
: : N
Group NNP N
1 CD N
had VBD N
normal JJ N
or CC N
mildly RB N
abnormal JJ N
results NNS N
on IN N
liver-function NN N
tests NNS N
, , N
Group NNP N
2 CD N
had VBD N
more RBR N
severe JJ N
liver NN N
dysfunction NN N
or CC N
previous JJ N
complications NNS N
, , N
and CC N
Group NNP N
3 CD N
had VBD N
severe JJ N
prerenal JJ N
azotemia NN N
without IN N
kidney NN N
disease NN N
. . N

For IN N
the DT N
patients NNS N
who WP N
received VBD N
the DT N
medical JJ N
treatment NN N
and CC N
those DT N
who WP N
received VBD N
the DT N
surgical JJ N
treatment NN N
combined VBN N
, , N
the DT N
median JJ N
survival NN N
times NNS N
were VBD N
1093 CD N
days NNS N
in IN N
Group NNP N
1 CD N
, , N
222 CD N
days NNS N
in IN N
Group NNP N
2 CD N
, , N
and CC N
37 CD N
days NNS N
in IN N
Group NNP N
3 CD N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.01 CD N
) ) N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

For IN N
all PDT N
the DT N
groups NNS N
combined VBN N
, , N
the DT N
median JJ N
time NN N
to TO N
the DT N
resolution NN N
of IN N
ascites NNS N
was VBD N
5.4 CD N
weeks NNS N
for IN N
medical JJ N
patients NNS N
and CC N
3.0 CD N
weeks NNS N
for IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Within IN N
each DT N
risk NN N
group NN N
, , N
mortality NN N
during IN N
the DT N
initial JJ N
hospitalization NN N
and CC N
median JJ N
long-term JJ N
survival NN N
were VBD N
similar JJ N
among IN N
patients NNS N
receiving VBG N
either DT N
treatment NN N
. . N

However RB N
, , N
the DT N
median JJ N
time NN N
to TO N
the DT N
recurrence NN N
of IN N
ascites NNS N
in IN N
Group NNP N
1 CD N
was VBD N
4 CD N
months NNS N
in IN N
medical JJ N
patients NNS N
, , N
as IN N
compared VBN N
with IN N
18 CD N
months NNS N
in IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
; : N
in IN N
Group NNP N
2 CD N
it PRP N
was VBD N
3 CD N
months NNS N
in IN N
medical JJ N
patients NNS N
as IN N
compared VBN N
with IN N
12 CD N
months NNS N
in IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
median JJ N
duration NN N
of IN N
hospitalization NN N
was VBD N
longer RBR N
in IN N
medical JJ N
patients NNS N
than IN N
in IN N
surgical JJ N
patients NNS N
( ( N
6.1 CD N
vs. RB N
2.4 CD N
weeks NNS N
in IN N
Group NNP N
1 CD N
[ NNP N
P NNP N
less JJR N
than IN N
0.001 CD N
] NNS N
and CC N
5.0 CD N
vs. FW N
3.1 CD N
weeks NNS N
in IN N
Group NNP N
2 CD N
[ NNP N
P NNP N
less JJR N
than IN N
0.01 CD N
] NN N
) ) N
. . N

Group NNP N
3 CD N
was VBD N
too RB N
small JJ N
to TO N
permit VB N
a DT N
meaningful JJ N
comparison NN N
. . N

During IN N
the DT N
initial JJ N
hospitalization NN N
, , N
the DT N
incidence NN N
of IN N
infections NNS N
, , N
gastrointestinal JJ N
bleeding NN N
, , N
and CC N
encephalopathy NN N
was VBD N
similar JJ N
among IN N
the DT N
medical JJ N
and CC N
surgical JJ N
patients NNS N
. . N

We PRP N
conclude VBP N
that DT N
peritoneovenous JJ N
shunting NN N
alleviated VBD N
disabling VBG N
ascites NNS N
more RBR N
rapidly RB N
than IN N
medical JJ N
management NN N
. . N

However RB N
, , N
survival NN N
was VBD N
closely RB N
related VBN N
to TO N
the DT N
severity NN N
of IN N
the DT N
illness NN N
at IN N
the DT N
time NN N
of IN N
randomization NN N
and CC N
was VBD N
not RB N
altered VBN N
by IN N
shunting VBG N
. . N

-DOCSTART- -X- O O

Dose-response JJ N
and CC N
concentration-response JJ N
relation NN N
of IN N
rocuronium NN 3_i
infusion NN 3_i
during IN N
propofol-nitrous JJ 3_i
oxide NN 3_i
and CC N
isoflurane-nitrous JJ 3_i
oxide NN 3_i
anaesthesia NN 3_i
. . N

The DT N
dose-response JJ N
and CC N
concentration-response JJ N
relation NN N
of IN N
rocuronium NN 3_i
infusion NN 3_i
was VBD N
studied VBN N
in IN N
20 CD N
adult NN N
surgical JJ N
patients NNS N
during IN N
propofol-nitrous JJ 3_i
oxide NN 3_i
and CC N
isoflurane NN 3_i
( ( 3_i
1 CD 3_i
MAC NNP 3_i
) ) 3_i
-nitrous JJ 3_i
oxide JJ 3_i
anaesthesia NN 3_i
. . N

Neuromuscular JJ N
block NN N
was VBD N
kept VBN N
constant JJ N
, , N
initially RB N
at IN N
90 CD N
% NN N
and CC N
then RB N
at IN N
50 CD N
% NN N
with IN N
a DT N
closed-loop JJ 2_i
feedback NN 2_i
controller NN 2_i
. . N

At IN N
90 CD N
% NN N
block NN N
the DT N
steady-state JJ 3_i
infusion NN 3_i
of IN 3_i
rocuronium NN 3_i
was VBD N
0.55 CD N
+/- JJ N
0.16 CD N
mg JJ N
kg-1 JJ N
h-1 NN N
and CC N
the DT N
corresponding JJ N
concentration NN N
1714 CD N
+/- JJ N
281 CD N
ng JJ N
mL-1 NN N
in IN N
patients NNS N
receiving VBG N
propofol NN 3_i
. . N

At IN N
50 CD N
% NN N
block NN N
the DT N
corresponding JJ N
infusion NN N
rate NN N
was VBD N
0.27 CD N
+/- JJ N
0.11 CD N
mg JJ N
kg-1 JJ N
h-1 NN N
and CC N
the DT N
concentration NN N
1077 CD N
+/- JJ N
244 CD N
ng JJ N
mL-1 NN N
, , N
respectively RB N
. . N

At IN N
50 CD N
% NN N
block NN N
isoflurane NN 3_i
reduced VBD N
the DT N
rate NN N
of IN N
infusion NN N
by IN N
52 CD N
% NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
and CC N
the DT N
concentration NN N
by IN N
59 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
at IN N
90 CD N
% NN N
block NN N
both CC N
the DT N
mean JJ N
infusion NN N
rate NN N
and CC N
the DT N
concentration NN N
of IN N
rocuronium NN 3_i
were VBD N
reduced VBN N
by IN N
35 CD N
% NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

The DT N
mean JJ N
rocuronium NN 3_i
clearance NN N
at IN N
50 CD N
% NN N
block NN N
was VBD N
unaffected VBN N
by IN N
the DT N
type NN N
of IN N
anaesthesia NN 3_i
; : N
it PRP N
was VBD N
4.1 CD N
+/- JJ N
1.6 CD N
and CC N
4.9 CD N
+/- JJ N
2.7 CD N
mL JJ N
kg-1 JJ N
min-1 NN N
in IN N
the DT N
groups NNS N
receiving VBG N
propofol NN 3_i
and CC N
isoflurane NN 3_i
anaesthesia NN 3_i
, , N
respectively RB N
. . N

We PRP N
conclude VBP N
that IN N
isoflurane NN N
reduces VBZ N
the DT N
infusion NN N
requirements NNS N
of IN N
rocuronium NN 3_i
by IN N
changing VBG N
the DT N
pharmacodynamic JJ N
behaviour NN N
. . N

-DOCSTART- -X- O O

Multi-institutional JJ N
phase NN N
2 CD N
clinical JJ N
and CC N
pharmacogenomic JJ N
trial NN N
of IN N
tipifarnib JJ 3_i
plus CC 3_i
etoposide JJ 3_i
for IN N
elderly JJ N
adults NNS N
with IN N
newly RB N
diagnosed VBN N
acute RB N
myelogenous JJ N
leukemia NN N
. . N

Tipifarnib NNP N
( ( N
T NNP N
) ) N
exhibits VBZ N
modest JJ N
activity NN N
in IN N
elderly JJ N
adults NNS N
with IN N
newly RB N
diagnosed VBN N
acute RB N
myelogenous JJ N
leukemia NN N
( ( N
AML NNP N
) ) N
. . N

Based VBN N
on IN N
preclinical JJ N
synergy NN N
, , N
a DT N
phase NN N
1 CD N
trial NN N
of IN N
T NNP N
plus CC N
etoposide NN N
( ( N
E NNP N
) ) N
yielded VBD N
25 CD N
% NN N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
. . N

We PRP N
selected VBD N
2 CD N
comparable JJ N
dose NN N
levels NNS N
for IN N
a DT N
randomized JJ N
phase NN N
2 CD N
trial NN N
in IN N
84 CD N
adults NNS N
( ( N
age NN N
range NN N
, , N
70-90 JJ N
years NNS N
; : N
median JJ N
, , N
76 CD N
years NNS N
) ) N
who WP N
were VBD N
not RB N
candidates NNS N
for IN N
conventional JJ N
chemotherapy NN N
. . N

Arm VB N
A NNP N
( ( N
T NNP N
600 CD N
mg NN N
twice RB N
a DT N
day NN N
? . N
14 CD N
days NNS N
, , N
E NNP N
100 CD N
mg NN N
days NNS N
1-3 CD N
and CC N
8-10 JJ N
) ) N
and CC N
arm NN N
B NNP N
( ( N
T NNP N
400 CD N
mg NN N
twice RB N
a DT N
day NN N
? . N
14 CD N
days NNS N
, , N
E NNP N
200 CD N
mg NN N
days NNS N
1-3 CD N
and CC N
8-10 CD N
) ) N
yielded VBD N
similar JJ N
CR NNP N
, , N
but CC N
arm NN N
B NNP N
had VBD N
greater JJR N
toxicity NN N
. . N

Total JJ N
CR NNP N
was VBD N
25 CD N
% NN N
, , N
day NN N
30 CD N
death NN N
rate NN N
7 CD N
% NN N
. . N

A DT N
2-gene JJ N
signature NN N
of IN N
high JJ N
RASGRP1 NNP N
and CC N
low JJ N
aprataxin NN N
( ( N
APTX NNP N
) ) N
expression NN N
previously RB N
predicted VBN N
for IN N
T NNP N
response NN N
. . N

Assays NNS N
using VBG N
blasts NNS N
from IN N
a DT N
subset NN N
of IN N
40 CD N
patients NNS N
treated VBN N
with IN N
T NNP N
plus CC N
E NNP N
on IN N
this DT N
study NN N
showed VBD N
that IN N
AMLs NNP N
with IN N
a DT N
RASGRP1/APTX NNP N
ratio NN N
of IN N
more JJR N
than IN N
5.2 CD N
had VBD N
a DT N
78 CD N
% NN N
CR NNP N
rate NN N
and CC N
negative JJ N
predictive JJ N
value NN N
87 CD N
% NN N
. . N

This DT N
ratio NN N
did VBD N
not RB N
correlate VB N
with IN N
outcome NN N
in IN N
41 CD N
patients NNS N
treated VBN N
with IN N
conventional JJ N
chemotherapies NNS N
. . N

The DT N
next JJ N
T-based JJ N
clinical JJ N
trials NNS N
will MD N
test VB N
the DT N
ability NN N
of IN N
the DT N
2-gene JJ N
signature NN N
to TO N
enrich VB N
for IN N
T NNP N
responders NNS N
prospectively RB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00602771 NNP N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
recombinant JJ N
human JJ N
thyrotropin NN N
and CC N
thyroid VB N
hormone NN N
withdrawal NN N
for IN N
the DT N
detection NN N
of IN N
thyroid JJ N
remnant NN N
or CC N
cancer NN N
. . N

Recombinant NNP 3_i
human JJ 3_i
TSH NNP 3_i
has VBZ N
been VBN N
developed VBN N
to TO N
facilitate VB N
monitoring NN N
for IN N
thyroid JJ N
carcinoma NN N
recurrence NN N
or CC N
persistence NN N
without IN N
the DT N
attendant JJ N
morbidity NN N
of IN N
hypothyroidism NN N
seen VBN N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
administered VBN 3_i
recombinant JJ 3_i
human JJ 3_i
TSH NN 3_i
with IN N
thyroid JJ N
hormone NN N
withdrawal NN N
on IN N
the DT N
results NNS N
of IN N
radioiodine JJ N
whole JJ N
body NN N
scanning VBG N
( ( N
WBS NNP N
) ) N
and CC N
serum JJ N
thyroglobulin NN N
( ( N
Tg NNP N
) ) N
levels NNS N
. . N

Two CD N
hundred CD N
and CC N
twenty-nine JJ N
adult NN N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancer NN N
requiring VBG N
radioiodine NN N
WBS NNP N
were VBD N
studied VBN N
. . N

Radioiodine NNP 3_i
WBS NNP 3_i
and CC N
serum VB N
Tg NNP N
measurements NNS N
were VBD N
performed VBN N
after IN N
administration NN N
of IN N
recombinant JJ 3_i
human JJ 3_i
TSH NNP 3_i
and CC N
again RB N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
in IN N
each DT N
patient NN N
. . N

Radioiodine NNP N
whole JJ N
body NN N
scans NNS N
were VBD N
concordant JJ N
between IN N
the DT N
recombinant JJ 3_i
TSH-stimulated JJ 3_i
and CC N
thyroid JJ N
hormone NN N
withdrawal NN N
phases NNS N
in IN N
195 CD N
of IN N
220 CD N
( ( N
89 CD N
% NN N
) ) N
patients NNS N
. . N

Of IN N
the DT N
discordant NN N
scans NNS N
, , N
8 CD N
( ( N
4 CD N
% NN N
) ) N
had VBD N
superior JJ N
scans NNS N
after IN N
recombinant JJ 3_i
human JJ 3_i
TSH NNP 3_i
administration NN 3_i
, , N
and CC N
17 CD N
( ( N
8 CD N
% NN N
) ) N
had VBD N
superior JJ N
scans NNS N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
( ( N
P NNP N
= NNP N
0.108 CD N
) ) N
. . N

Based VBN N
on IN N
a DT N
serum NN N
Tg NNP N
level NN N
of IN N
2 CD N
ng/mL NNS N
or CC N
more JJR N
, , N
thyroid JJ N
tissue NN N
or CC N
cancer NN N
was VBD N
detected VBN N
during IN N
thyroid JJ 3_i
hormone NN 3_i
therapy NN 3_i
in IN N
22 CD N
% NN N
, , N
after IN N
recombinant JJ 3_i
human JJ 3_i
TSH NNP 3_i
stimulation NN N
in IN N
52 CD N
% NN N
, , N
and CC N
after IN N
thyroid JJ 3_i
hormone NN 3_i
withdrawal NN 3_i
in IN N
56 CD N
% NN N
of IN N
patients NNS N
with IN N
disease NN N
or CC N
tissue NN N
limited VBN N
to TO N
the DT N
thyroid NN N
bed NN N
and CC N
in IN N
80 CD N
% NN N
, , N
100 CD N
% NN N
, , N
and CC N
100 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
, , N
with IN N
metastatic JJ N
disease NN N
. . N

A DT N
combination NN N
of IN N
radioiodine NN N
WBS NNP N
and CC N
serum NN N
Tg NNP N
after IN N
recombinant JJ N
human JJ N
TSH NNP N
stimulation NN N
detected VBD N
thyroid JJ N
tissue NN N
or CC N
cancer NN N
in IN N
93 CD N
% NN N
of IN N
patients NNS N
with IN N
disease NN N
or CC N
tissue NN N
limited VBN N
to TO N
the DT N
thyroid NN N
bed NN N
and CC N
100 CD N
% NN N
of IN N
patients NNS N
with IN N
metastatic JJ N
disease NN N
. . N

In IN N
conclusion NN N
, , N
recombinant JJ 3_i
human JJ 3_i
TSH NNP 3_i
administration NN 3_i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
means NNS N
of IN N
stimulating VBG N
radioiodine JJ N
uptake NN N
and CC N
serum NN N
Tg NNP N
levels NNS N
in IN N
patients NNS N
undergoing JJ N
evaluation NN N
for IN N
thyroid JJ N
cancer NN N
persistence NN N
and CC N
recurrence NN N
. . N

-DOCSTART- -X- O O

Oral NNP N
amoxicillin NN 3_i
vs. FW N
oral JJ N
erythromycin NN 3_i
in IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
Bamako NNP N
, , N
Mali NNP N
: : N
an DT N
open JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Pyoderma NNP N
( ( N
bacterial JJ N
superficial NN N
skin NN N
infection NN N
) ) N
is VBZ N
an DT N
extremely RB N
common JJ N
disorder NN N
in IN N
tropical JJ N
developing VBG N
countries NNS N
. . N

In IN N
these DT N
settings NNS N
, , N
Streptococcus NNP N
pyogenes NNS N
is VBZ N
considered VBN N
to TO N
be VB N
the DT N
main JJ N
etiological JJ N
agent NN N
. . N

Apart RB N
from IN N
epidemics NNS N
of IN N
poststreptococcal JJ N
glomerulonephritis NN N
where WRB N
mass NN N
treatment NN N
with IN N
intramuscular JJ N
benzathine-penicillin NN 3_i
is VBZ N
recommended VBN N
, , N
no DT N
recommendation NN N
exists VBZ N
for IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
this DT N
setting NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
oral JJ N
amoxicillin NN 3_i
in IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
Mali NNP N
, , N
by IN N
comparison NN N
with IN N
oral JJ N
erythromycin NN 3_i
. . 3_i

METHODS NNP N
In IN N
Bamako NNP N
, , N
132 CD N
patients NNS N
with IN N
pyoderma NN N
, , N
diagnosed VBN N
and CC N
graded VBN N
as IN N
severe JJ N
on IN N
clinical JJ N
grounds NNS N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
oral JJ N
treatment NN N
by IN N
either DT N
amoxicillin NN 3_i
( ( N
50 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
or CC N
erythromycin $ 3_i
; : 3_i
infections NNS N
of IN N
the DT N
follicular JJ N
appendage NN N
were VBD N
excluded VBN N
. . N

Both DT N
drugs NNS N
were VBD N
associated VBN N
with IN N
the DT N
topical JJ N
application NN N
of IN N
povidone NN N
iodine NN N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
openly RB N
at IN N
the DT N
seventh JJ N
day NN N
of IN N
treatment NN N
for IN N
cure NN N
or CC N
marked JJ N
improvement NN N
of IN N
the DT N
clinical JJ N
features NNS N
, , N
indicating VBG N
successful JJ N
treatment NN N
. . N

RESULTS NNP N
Three CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up JJ N
. . N

Treatment NN N
was VBD N
successful JJ N
in IN N
57 CD N
of IN N
64 CD N
patients NNS N
treated VBN N
with IN N
amoxicillin NN N
vs. FW N
58 CD N
of IN N
65 CD N
patients NNS N
treated VBN N
with IN N
erythromycin NN N
( ( N
P NNP N
= NNP N
0.00 CD N
) ) N
. . N

CONCLUSIONS NNP N
Amoxicillin NNP N
was VBD N
as RB N
efficacious JJ N
as IN N
erythromycin NN N
in IN N
the DT N
treatment NN N
of IN N
severe JJ N
pyoderma NN N
in IN N
Mali NNP N
. . N

Owing VBG N
to TO N
its PRP$ N
efficacy NN N
, , N
added VBD N
to TO N
high JJ N
availability NN N
and CC N
low JJ N
cost NN N
, , N
this DT N
compound NN N
should MD N
be VB N
considered VBN N
a DT N
first-line JJ N
treatment NN N
of IN N
this DT N
disorder NN N
in IN N
this DT N
country NN N
, , N
and CC N
perhaps RB N
in IN N
other JJ N
countries NNS N
where WRB N
this DT N
condition NN N
presents VBZ N
in IN N
a DT N
similar JJ N
way NN N
. . N

-DOCSTART- -X- O O

Fondaparinux NNP 3_i
combined VBD 3_i
with IN 3_i
intermittent JJ 3_i
pneumatic JJ 3_i
compression NN 3_i
vs. FW N
intermittent JJ 2_i
pneumatic JJ 2_i
compression NN 2_i
alone RB 2_i
for IN N
prevention NN N
of IN N
venous JJ N
thromboembolism NN N
after IN N
abdominal JJ N
surgery NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
comparison NN N
. . N

BACKGROUND VB N
The DT N
benefit NN N
of IN N
combined JJ N
mechanical JJ N
and CC N
pharmacologic JJ N
methods NNS N
for IN N
venous JJ N
thromboembolism NN N
prevention NN N
after IN N
abdominal JJ N
surgery NN N
has VBZ N
not RB N
been VBN N
clearly RB N
established VBN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
fondaparinux NN 3_i
in IN 3_i
conjunction NN 3_i
with IN 3_i
intermittent JJ 3_i
pneumatic JJ 3_i
compression NN 3_i
vs. FW N
intermittent JJ 2_i
pneumatic JJ 2_i
compression NN 2_i
alone RB 2_i
in IN N
this DT N
context NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 7_i
superiority NN N
trial NN N
. . N

Patients NNS N
aged VBN N
at IN N
least JJS N
40 CD N
years NNS N
undergoing JJ N
abdominal JJ N
surgery NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
fondaparinux JJ 3_i
2.5 CD N
mg NN N
or CC N
placebo NN 7_i
s.c. NN N
for IN N
5-9 JJ N
days NNS N
, , N
starting VBG N
6-8 JJ N
h NN N
postoperatively RB N
. . N

All DT N
patients NNS N
received VBD N
intermittent JJ 2_i
pneumatic JJ 2_i
compression NN 2_i
. . 2_i

The DT N
primary JJ N
efficacy NN N
outcome NN N
was VBD N
venous JJ N
thromboembolism NN N
up RB N
to TO N
day NN N
10 CD N
. . N

The DT N
main JJ N
safety NN N
outcomes NNS N
were VBD N
major JJ N
bleeding NN N
and CC N
all-cause JJ N
mortality NN N
. . N

Follow-up NNP N
lasted VBD N
32 CD N
days NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
1309 CD N
patients NNS N
randomized VBN N
, , N
842 CD N
( ( N
64.3 CD N
% NN N
) ) N
were VBD N
evaluable JJ N
for IN N
efficacy NN N
. . N

The DT N
venous JJ N
thromboembolism NN N
rate NN N
was VBD N
1.7 CD N
% NN N
( ( N
7/424 CD N
) ) N
in IN N
the DT N
fondaparinux-treated JJ 3_i
patients NNS N
and CC N
5.3 CD N
% NN N
( ( N
22/418 CD N
) ) N
in IN N
the DT N
placebo-treated JJ 7_i
patients NNS N
( ( N
odds NNS N
ratio VBP N
reduction NN N
69.8 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
27.9-87.3 JJ N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

Fondaparinux NNP 3_i
significantly RB N
reduced VBD N
the DT N
proximal JJ N
deep JJ N
vein NN N
thrombosis NN N
rate NN N
from IN N
1.7 CD N
% NN N
( ( N
7/417 CD N
) ) N
to TO N
0.2 CD N
% NN N
( ( N
1/424 CD N
; : N
P NNP N
= NNP N
0.037 CD N
) ) N
. . N

Major JJ N
bleeds NNS N
occurred VBD N
in IN N
1.6 CD N
% NN N
( ( N
10/635 CD N
) ) N
and CC N
0.2 CD N
% NN N
( ( N
1/650 CD N
) ) N
of IN N
fondaparinux-treated JJ 3_i
and CC N
placebo-treated JJ 7_i
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
none NN N
being VBG N
fatal JJ N
or CC N
involving VBG N
a DT N
critical JJ N
organ NN N
. . N

By IN N
day NN N
32 CD N
, , N
eight CD N
patients NNS N
( ( N
1.3 CD N
% NN N
) ) N
receiving NN N
fondaparinux NN 3_i
and CC N
five CD N
( ( N
0.8 CD N
% NN N
) ) N
receiving NN N
placebo NN 7_i
had VBD N
died VBN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
undergoing JJ N
abdominal JJ N
surgery NN N
and CC N
receiving VBG N
intermittent JJ 3_i
pneumatic JJ 3_i
compression NN 3_i
, , 3_i
fondaparinux VBP 3_i
2.5 CD N
mg NN N
reduced VBD N
the DT N
venous JJ N
thromboembolism NN N
rate NN N
by IN N
69.8 CD N
% NN N
as IN N
compared VBN N
to TO N
pneumatic JJ 2_i
compression NN 2_i
alone RB 2_i
, , N
with IN N
a DT N
low JJ N
bleeding NN N
risk NN N
as IN N
compared VBN N
to TO N
placebo VB 7_i
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
isotonic JJ 3_i
and CC N
hypertonic JJ 3_i
saline NN 3_i
solutions NNS 3_i
on IN N
mucociliary JJ N
activity NN N
in IN N
various JJ N
nasal JJ N
pathologies NNS N
: : N
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
nasal JJ N
irrigation NN N
with IN N
isotonic JJ 3_i
or CC N
hypertonic JJ 3_i
sodium NN 3_i
chloride JJ 3_i
solution NN 3_i
on IN N
mucociliary JJ N
clearance NN N
time NN N
in IN N
patients NNS N
with IN N
allergic JJ N
rhinitis NN N
, , N
acute JJ N
sinusitis NN N
and CC N
chronic JJ N
sinusitis NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Mucociliary NNP N
clearance NN N
time NN N
was VBD N
measured VBN N
using VBG N
the DT N
saccharine JJ N
clearance NN N
test NN N
on IN N
132 CD N
adults NNS N
before IN N
and CC N
after IN N
10 CD N
days NNS N
' POS N
application NN 3_i
of IN 3_i
intranasal NN 3_i
isotonic NN 3_i
or CC N
hypertonic JJ 3_i
saline NN 3_i
. . N

Patient JJ N
numbers NNS N
were VBD N
as IN N
follows VBZ N
: : N
controls NNS N
, , N
45 CD N
; : N
allergic JJ N
rhinitis NN N
, , N
21 CD N
; : N
acute JJ N
sinusitis NN N
, , N
24 CD N
; : N
and CC N
chronic JJ N
sinusitis NN N
, , N
42 CD N
. . N

The DT N
results NNS N
before IN N
and CC N
after IN N
irrigation NN N
were VBD N
compared VBN N
using VBG N
the DT N
Wilcoxon NNP N
t-test NN N
. . N

RESULTS NNP N
Before IN N
application NN N
of IN N
saline JJ 3_i
solutions NNS 3_i
, , N
mucociliary JJ N
clearance NN N
times NNS N
in IN N
the DT N
three CD N
patient NN N
treatment NN N
groups NNS N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
delayed VBN N
, , N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Irrigation NN N
with IN N
hypertonic JJ 3_i
saline NN 3_i
restored VBN N
impaired JJ N
mucociliary JJ N
clearance NN N
in IN N
chronic JJ N
sinusitis NN N
patients NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
while IN N
isotonic JJ 3_i
saline NN 3_i
improved VBD N
mucociliary JJ N
clearance NN N
times NNS N
significantly RB N
in IN N
allergic JJ N
rhinitis NN N
and CC N
acute JJ N
sinusitis NN N
patients NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Nasal NNP N
irrigation NN N
with IN N
isotonic JJ 3_i
or CC N
hypertonic JJ 3_i
saline NN 3_i
can MD N
improve VB N
mucociliary JJ N
clearance NN N
time NN N
in IN N
various JJ N
nasal JJ N
pathologies NNS N
. . N

However RB N
, , N
these DT N
solutions NNS N
should MD N
be VB N
selectively RB N
prescribed IN N
rather RB N
than IN N
used VBN N
based VBN N
on IN N
anecdotal JJ N
evidence NN N
. . N

Further JJ N
studies NNS N
should MD N
be VB N
conducted VBN N
to TO N
develop VB N
a DT N
protocol NN N
for IN N
standardised VBN N
use NN N
of IN N
saline JJ 3_i
solution NN 3_i
irrigation NN 3_i
in IN N
various JJ N
nasal JJ N
pathologies NNS N
. . N

-DOCSTART- -X- O O

Intravenous JJ 3_i
flecainide NN 3_i
versus NN N
verapamil NN 3_i
for IN N
acute JJ N
conversion NN N
of IN N
paroxysmal JJ N
atrial JJ N
fibrillation NN N
or CC N
flutter NN N
to TO N
sinus VB N
rhythm NN N
. . N

In IN N
a DT N
single-blind JJ N
randomized NN N
study NN N
, , N
the DT N
efficacy NN N
of IN N
intravenous JJ 3_i
flecainide NN 3_i
( ( N
2 CD N
mg/kg/10 NN N
minutes NNS N
) ) N
versus VBP N
verapamil NN 3_i
( ( N
10 CD N
mg/1 RB N
minute NN N
) ) N
was VBD N
assessed VBN N
in IN N
40 CD N
patients NNS N
with IN N
paroxysmal JJ N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
or CC N
atrial JJ N
flutter NN N
( ( N
AFI NNP N
) ) N
. . N

The DT N
treatment NN N
was VBD N
considered VBN N
successful JJ N
if IN N
sinus JJ N
rhythm NN N
occurred VBD N
within IN N
1 CD N
hour NN N
. . N

Of IN N
20 CD N
patients NNS N
receiving VBG N
flecainide RB 3_i
, , N
14 CD N
of IN N
17 CD N
( ( N
82 CD N
% NN N
) ) N
with IN N
AF NNP N
converted VBD N
to TO N
sinus VB N
rhythm NN N
, , N
but CC N
in IN N
3 CD N
patients NNS N
with IN N
AFI NNP N
flecainide NN 3_i
failed VBD N
. . N

All DT N
patients NNS N
treated VBN N
with IN N
verapamil NN 3_i
( ( N
17 CD N
AF NNP N
, , N
3 CD N
AFI NNP N
) ) N
showed VBD N
lower JJR N
ventricular NN N
rates NNS N
after IN N
1 CD N
hour NN N
; : N
however RB N
, , N
only RB N
1 CD N
( ( N
6 CD N
% NN N
) ) N
with IN N
AF NNP N
converted VBD N
to TO N
sinus VB N
rhythm NN N
and CC N
1 CD N
( ( N
6 CD N
% NN N
) ) N
converted VBD N
to TO N
AFI NNP N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
convert VB N
to TO N
sinus VB N
rhythm NN N
after IN N
treatment NN N
with IN N
verapamil NNS 3_i
were VBD N
treated VBN N
with IN N
flecainide NN 3_i
and CC N
observed VBD N
for IN N
another DT N
hour NN N
. . N

After IN N
the DT N
change NN N
to TO N
flecainide VB N
, , N
9 CD N
of IN N
15 CD N
patients NNS N
( ( N
60 CD N
% NN N
) ) N
with IN N
AF NNP N
still RB N
converted VBD N
. . N

Thus NNP N
, , N
23 CD N
of IN N
32 CD N
patients NNS N
( ( N
72 CD N
% NN N
) ) N
with IN N
AF NNP N
and CC N
none NN N
of IN N
7 CD N
with IN N
AFI NNP N
converted VBD N
to TO N
sinus VB N
rhythm NN N
after IN N
treatment NN N
with IN N
flecainide NN N
. . N

Conversion NN N
to TO N
sinus VB N
rhythm NN N
was VBD N
achieved VBN N
in IN N
19 CD N
of IN N
22 CD N
patients NNS N
( ( N
86 CD N
% NN N
) ) N
when WRB N
AF NNP N
lasted VBD N
less JJR N
than IN N
24 CD N
hours NNS N
and CC N
in IN N
4 CD N
of IN N
10 CD N
( ( N
40 CD N
% NN N
) ) N
when WRB N
the DT N
arrhythmia NN N
lasted VBD N
greater JJR N
than IN N
24 CD N
hours NNS N
. . N

Transient JJ N
adverse JJ N
effects NNS N
were VBD N
noted VBN N
in IN N
10 CD N
patients NNS N
( ( N
26 CD N
% NN N
) ) N
after IN N
flecainide NN N
. . N

In IN N
summary JJ N
, , N
flecainide EX 3_i
is VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
drug NN N
for IN N
conversion NN N
of IN N
paroxysmal JJ N
AF NNP N
to TO N
sinus VB N
rhythm NN N
, , N
but CC N
ineffective JJ N
for IN N
AFI NNP N
. . N

Verapamil NNP 3_i
appears VBZ N
to TO N
be VB N
of IN N
no DT N
use NN N
for IN N
conversion NN N
of IN N
AF NNP N
or CC N
AFI NNP N
to TO N
sinus VB N
rhythm NN N
. . N

-DOCSTART- -X- O O

A DT N
phase NN N
III NNP N
study NN N
of IN N
laparoscopy-assisted JJ 2_i
versus NN N
open JJ 1_i
distal JJ 2_i
gastrectomy NN 2_i
with IN N
nodal JJ N
dissection NN N
for IN N
clinical JJ N
stage NN N
IA/IB NNP N
gastric JJ N
Cancer NNP N
( ( N
JCOG0912 NNP N
) ) N
. . N

A DT N
Phase NNP N
III NNP N
study NN N
was VBD N
started VBN N
in IN N
Japan NNP N
to TO N
evaluate VB N
the DT N
non-inferiority NN N
of IN N
overall JJ N
survival NN N
of IN N
laparoscopy-assisted JJ 1_i
distal JJ 1_i
gastrectomy NN 1_i
with IN N
open JJ 1_i
distal JJ 1_i
gastrectomy NN 1_i
in IN N
patients NNS N
with IN N
clinical JJ N
IA NNP N
( ( N
T1N0 NNP N
) ) N
or CC N
IB NNP N
[ NNP N
T1N1 NNP N
or CC N
T2 NNP N
( ( N
MP NNP N
) ) N
N0 NNP N
] NNP N
gastric JJ N
cancer NN N
. . N

This DT N
study NN N
followed VBD N
the DT N
previous JJ N
Phase NNP N
II NNP N
study NN N
to TO N
confirm VB N
the DT N
safety NN N
of IN N
laparoscopy-assisted JJ 1_i
distal JJ 1_i
gastrectomy NN 1_i
( ( N
JCOG0703 NNP N
) ) N
and CC N
began VBD N
in IN N
March NNP N
2010 CD N
. . N

A DT N
total NN N
of IN N
920 CD N
patients NNS N
will MD N
be VB N
accrued VBN N
from IN N
33 CD N
institutions NNS N
within IN N
5 CD N
years NNS N
. . N

The DT N
primary JJ N
endpoint NN N
is VBZ N
overall JJ N
survival NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
are VBP N
relapse-free JJ N
survival NN N
, , N
proportion NN N
of IN N
laparoscopy-assisted JJ 1_i
distal JJ 1_i
gastrectomy NN 1_i
completion NN N
, , N
proportion NN N
of IN N
conversion NN N
to TO N
open VB N
surgery NN N
, , N
adverse JJ N
events NNS N
, , N
short-term JJ N
clinical JJ N
outcomes NNS N
, , N
postoperative JJ N
quality NN N
of IN N
life NN N
. . N

Only RB N
a DT N
credentialed JJ N
surgeon NN N
can MD N
be VB N
responsible JJ N
for IN N
both DT N
open JJ 1_i
distal NN 1_i
gastrectomy NN 1_i
and CC N
laparoscopy-assisted JJ 1_i
distal JJ 1_i
gastrectomy NN 1_i
. . N

-DOCSTART- -X- O O

Weight NNP N
and CC N
leptin JJ N
changes NNS N
among IN N
risperidone-treated JJ 3_i
youths NNS N
with IN N
autism NN N
: : N
6-month JJ N
prospective JJ N
data NNS N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
examined VBD N
the DT N
developmental JJ N
impact NN N
and CC N
temporal JJ N
characteristics NNS N
of IN N
risperidone-associated JJ 3_i
weight NN N
change NN N
. . N

METHOD NNP N
Weight NNP N
change NN N
was VBD N
measured VBN N
for IN N
63 CD N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
treated VBN N
with IN N
risperidone NN 3_i
for IN N
6 CD N
months NNS N
. . N

Change NNP N
in IN N
serum NN N
leptin NN N
levels NNS N
after IN N
2 CD N
months NNS N
was VBD N
examined VBN N
as IN N
a DT N
predictor NN N
of IN N
final JJ N
weight NN N
gain NN N
in IN N
mixed JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
site NN N
, , N
gender NN N
, , N
age NN N
, , N
and CC N
risperidone NN 3_i
dose NN N
. . N

RESULTS NNP N
Age- JJ N
and CC N
gender-standardized JJ N
weight NN N
increased VBD N
after IN N
6 CD N
months NNS N
of IN N
treatment NN N
( ( N
gross JJ N
: : N
mean=5.6 NN N
kg NN N
[ NNP N
SD=3.9 NNP N
] NNP N
; : N
standardized VBN N
: : N
mean=0.6 NN N
z NN N
[ NNP N
SD=0.5 NNP N
] NNP N
) ) N
and CC N
was VBD N
positively RB N
correlated VBN N
with IN N
weight NN N
gained VBN N
after IN N
1 CD N
month NN N
. . N

Change NN N
in IN N
leptin NN N
levels NNS N
after IN N
2 CD N
months NNS N
of IN N
treatment NN N
( ( N
mean=-0.3 JJ N
ng/ml NN N
, , N
SD=6.2 NNP N
) ) N
( ( N
N=48 NNP N
) ) N
did VBD N
not RB N
predict JJ N
final JJ N
weight NN N
gain NN N
. . N

CONCLUSIONS NNP N
Chronic NNP N
risperidone NN 3_i
exposure NN N
in IN N
children NNS N
with IN N
autism NN N
causes NNS N
weight VBD N
gain NN N
in IN N
excess NN N
of IN N
developmentally RB N
expected VBN N
norms NNS N
that WDT N
follows VBZ N
a DT N
curvilinear JJ N
trajectory NN N
and CC N
decelerates VBZ N
over IN N
time NN N
. . N

Serum NNP N
leptin JJ N
change NN N
does VBZ N
not RB N
reliably VB N
predict JJ N
risperidone-associated JJ N
weight NN N
gain NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
clear JJ N
liquids NNS N
versus IN N
low-fat JJ N
solid JJ N
diet NN N
as IN N
the DT N
initial JJ N
meal NN N
in IN N
mild JJ N
acute JJ N
pancreatitis NN N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
Patients NNPS N
recovering VBG N
from IN N
mild JJ N
acute JJ N
pancreatitis NN N
typically RB N
receive VBP N
a DT N
clear JJ 2_i
liquid NN 2_i
diet NN 2_i
( ( 2_i
CLD NNP 2_i
) ) 2_i
when WRB N
ready JJ N
to TO N
initiate VB N
oral JJ N
nutrition NN N
. . N

Patient NNP N
discharge NN N
then RB N
depends VBZ N
on IN N
their PRP$ N
successful JJ N
advancement NN N
to TO N
solid VB N
food NN N
. . N

We PRP N
hypothesized VBD N
that IN N
initiating VBG N
oral JJ 2_i
nutrition NN 2_i
with IN 2_i
a DT 2_i
low-fat JJ 2_i
solid JJ 2_i
diet NN 2_i
( ( 2_i
LFSD NNP 2_i
) ) 2_i
after IN N
mild JJ N
pancreatitis NN N
would MD N
be VB N
well RB N
tolerated VBN N
and CC N
would MD N
result VB N
in IN N
a DT N
shorter JJR N
length NN N
of IN N
hospitalization NN N
( ( N
LOH NNP N
) ) N
. . N

METHODS JJ N
Patients NNS N
with IN N
mild JJ N
pancreatitis NNS N
were VBD N
randomized VBN N
to TO N
a DT N
CLD NNP 2_i
or CC N
LFSD NNP 2_i
when WRB N
they PRP N
were VBD N
ready JJ N
to TO N
resume VB N
oral JJ N
nutrition NN N
. . N

Decisions NNS N
about IN N
diet JJ N
advancement NN N
and CC N
hospital NN N
discharge NN N
were VBD N
at IN N
the DT N
discretion NN N
of IN N
the DT N
medical JJ N
team NN N
, , N
without IN N
input NN N
from IN N
study NN N
team NN N
members NNS N
. . N

Patients NNS N
were VBD N
monitored VBN N
daily RB N
for IN N
recurrence NN N
of IN N
pain NN N
, , N
need VBP N
to TO N
stop VB N
feeding NN N
, , N
post-refeeding JJ N
LOH NNP N
( ( N
primary JJ N
end NN N
point NN N
) ) N
, , N
and CC N
for IN N
28 CD N
days NNS N
post-refeeding JJ N
to TO N
capture VB N
re-admission NN N
rates NNS N
. . N

RESULTS NNP N
We PRP N
randomized VBD N
121 CD N
patients NNS N
: : N
66 CD N
to TO N
CLD NNP N
and CC N
55 CD N
to TO N
LFSD NNP N
. . N

The DT N
number NN N
of IN N
patients NNS N
requiring VBG N
cessation NN N
of IN N
feeding VBG N
because IN N
of IN N
pain NN N
or CC N
nausea NN N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
6 CD N
% NN N
for IN N
CLD NNP N
, , N
11 CD N
% NN N
for IN N
LFSD NNP N
; : N
P NNP N
= NNP N
.51 NNP N
) ) N
. . N

The DT N
median JJ N
LOH NNP N
after IN N
refeeding VBG N
was VBD N
identical JJ N
in IN N
both DT N
groups NNS N
( ( N
1-day JJ N
interquartile NN N
range NN N
, , N
1-2 JJ N
; : N
P NNP N
= NNP N
.77 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
LFSD NNP N
arm NN N
consumed VBD N
significantly RB N
more JJR N
calories NNS N
and CC N
grams NNS N
of IN N
fat NN N
than IN N
those DT N
in IN N
the DT N
CLD NNP N
arm NN N
during IN N
their PRP$ N
first JJ N
meal NN N
and CC N
on IN N
study NN N
day NN N
1 CD N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
28-day JJ N
re-admission NN N
rates NNS N
between IN N
the DT N
2 CD N
arms NNS N
. . N

CONCLUSIONS NNP N
Initiating NNP N
oral JJ N
nutrition NN N
after IN N
mild JJ N
acute JJ N
pancreatitis NN N
with IN N
an DT N
LFSD NNP N
appeared VBD N
safe JJ N
and CC N
provided VBD N
more JJR N
calories NNS N
than IN N
a DT N
CLD NNP N
, , N
but CC N
did VBD N
not RB N
result VB N
in IN N
a DT N
shorter NN N
LOH NNP N
. . N

